PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Meisel, A; Smith, CJ				Meisel, Andreas; Smith, Craig J.			Prevention of stroke-associated pneumonia: where next?	LANCET			English	Editorial Material							DIAGNOSIS		[Meisel, Andreas] Charite, NeuroCure Clin Res Ctr, Ctr Stroke Res Berlin, Dept Neurol, D-10117 Berlin, Germany; [Smith, Craig J.] Salford Royal Hosp NHS Fdn Trust, Ctr Stroke & Vasc Res, Salford, Lancs, England	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Salford Royal NHS Foundation Trust; Salford Royal Hospital	Meisel, A (corresponding author), Charite, NeuroCure Clin Res Ctr, Ctr Stroke Res Berlin, Dept Neurol, D-10117 Berlin, Germany.	andreas.meisel@charite.de		Smith, Craig James/0000-0002-9078-9919; Meisel, Andreas/0000-0001-7233-5342				Chamorro A, 2012, NAT REV NEUROL, V8, P401, DOI 10.1038/nrneurol.2012.98; Emsley HC, 2008, LANCET NEUROL, V7, P341, DOI 10.1016/S1474-4422(08)70061-9; Harms H, 2012, J NEUROL NEUROSUR PS, V83, P1225, DOI 10.1136/jnnp-2012-302194; Hetze S, 2013, J CEREBR BLOOD F MET, V33, P846, DOI 10.1038/jcbfm.2013.6; Kalra L, 2015, LANCET, V386, P1835, DOI 10.1016/S0140-6736(15)00126-9; Khaja AM, 2007, LANCET, V369, P319, DOI 10.1016/S0140-6736(07)60154-8; Kishore AK, 2015, STROKE, V46, P1202, DOI 10.1161/STROKEAHA.114.007843; Kumar S, 2010, LANCET NEUROL, V9, P105, DOI 10.1016/S1474-4422(09)70266-2; Marik PE, 2001, NEW ENGL J MED, V344, P665, DOI 10.1056/NEJM200103013440908; Meisel C, 2011, NEW ENGL J MED, V365, P2134, DOI 10.1056/NEJMcibr1112454; Osler W, 1998, PRINCIPLES PRACTICE, P109; Smith CJ, 2015, STROKE, V46, P2335, DOI 10.1161/STROKEAHA.115.009617; Westendorp WF, 2015, LANCET, V385, P1519, DOI 10.1016/S0140-6736(14)62456-9; Westendorp WF, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008530.pub2	14	14	16	2	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 7	2015	386	10006					1802	1804		10.1016/S0140-6736(15)00127-0	http://dx.doi.org/10.1016/S0140-6736(15)00127-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CV3VO	26343837				2023-01-03	WOS:000364194700011
J	Visweswaran, GRR; Gholizadeh, S; Ruiters, MHJ; Molema, G; Kok, RJ; Kamps, JAAM				Visweswaran, Ganesh Ram R.; Gholizadeh, Shima; Ruiters, Marcel H. J.; Molema, Grietje; Kok, Robbert J.; Kamps, Jan. A. A. M.			Targeting Rapamycin to Podocytes Using a Vascular Cell Adhesion Molecule-1 (VCAM-1)-Harnessed SAINT-Based Lipid Carrier System	PLOS ONE			English	Article							ENDOTHELIAL-CELLS; IN-VIVO; O-SOMES; EXPRESSION; DELIVERY; SIRNA; CYTOSKELETON; INFLAMMATION; ANTI-VCAM-1; INHIBITION	Together with mesangial cells, glomerular endothelial cells and the basement membrane, podocytes constitute the glomerular filtration barrier (GFB) of the kidney. Podocytes play a pivotal role in the progression of various kidney-related diseases such as glomerular sclerosis and glomerulonephritis that finally lead to chronic end-stage renal disease. During podocytopathies, the slit-diaphragm connecting the adjacent podocytes are detached leading to severe loss of proteins in the urine. The pathophysiology of podocytopathies makes podocytes a potential and challenging target for nanomedicine development, though there is a lack of known molecular targets for cell selective drug delivery. To identify VCAM-1 as a cell-surface receptor that is suitable for binding and internalization of nanomedicine carrier systems by podocytes, we investigated its expression in the immortalized podocyte cell lines AB8/13 and MPC-5, and in primary podocytes. Gene and protein expression analyses revealed that VCAM-1 expression is increased by podocytes upon TNF alpha-activation for up to 24 h. This was paralleled by anti-VCAM-1 antibody binding to the TNF alpha-activated cells, which can be employed as a ligand to facilitate the uptake of nanocarriers under inflammatory conditions. Hence, we next explored the possibilities of using VCAM-1 as a cell-surface receptor to deliver the potent immunosuppressant rapamycin to TNF alpha-activated podocytes using the lipid-based nanocarrier system Saint-O-Somes. Anti-VCAM-1-rapamycin-SAINT-O-Somes more effectively inhibited the cell migration of AB8/13 cells than free rapamycin and non-targeted rapamycin-SAINT-O-Somes indicating the potential of VCAM-1 targeted drug delivery to podocytes.	[Visweswaran, Ganesh Ram R.; Ruiters, Marcel H. J.; Molema, Grietje; Kamps, Jan. A. A. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Med Biol Sect, Groningen, Netherlands; [Gholizadeh, Shima; Kok, Robbert J.] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, Utrecht, Netherlands	University of Groningen; Utrecht University	Kamps, JAAM (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Med Biol Sect, Groningen, Netherlands.	j.a.a.m.kamps@umcg.nl	Kok, Robbert/AAX-9863-2020; Kok, Robbert/I-9579-2016	Kok, Robbert/0000-0003-4933-3968; Kok, Robbert/0000-0003-4933-3968; Molema, Grietje/0000-0002-4147-6676	NanoNextNL, a micro and nanotechnology consortium of the Government of the Netherlands;  [03D.07]	NanoNextNL, a micro and nanotechnology consortium of the Government of the Netherlands; 	Funding: This work is supported by NanoNextNL, a micro and nanotechnology consortium of the Government of the Netherlands and 130 partners (Grant number: project 03D.07), http://www.nanonextnl.nl/.	Adrian JE, 2010, J CONTROL RELEASE, V144, P341, DOI 10.1016/j.jconrel.2010.03.003; Asgeirdottir SA, 2008, AM J PHYSIOL-RENAL, V294, pF554, DOI 10.1152/ajprenal.00391.2007; Asgeirsdottir SA, 2012, AM J PHYSIOL-RENAL, V302, pF1630, DOI 10.1152/ajprenal.00400.2011; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; Canaud G, 2013, NAT MED, V19, P1288, DOI 10.1038/nm.3313; Chiang WC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011837; Fogo AB, 2011, J CLIN INVEST, V121, P2142, DOI 10.1172/JCI57935; Gao HX, 2009, CYTOKINE, V46, P24, DOI 10.1016/j.cyto.2008.12.001; Haraldsson B, 2009, CURR OPIN NEPHROL HY, V18, P331, DOI 10.1097/MNH.0b013e32832c9dba; Hauser PV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009463; Jin EJ, 2009, BLOOD, V114, P5557, DOI 10.1182/blood-2009-05-220434; Khattree N, 2013, J CELL SCI, V126, P4659, DOI 10.1242/jcs.126888; Kowalski PS, 2014, J CONTROL RELEASE, V176, P64, DOI 10.1016/j.jconrel.2013.12.029; Kowalski PS, 2013, MOL PHARMACEUT, V10, P3033, DOI 10.1021/mp4001124; Kuldo JM, 2013, J CONTROL RELEASE, V166, P57, DOI 10.1016/j.jconrel.2012.12.016; Leeuwis JW, 2010, ADV DRUG DELIVER REV, V62, P1325, DOI 10.1016/j.addr.2010.08.012; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; Ricard I, 1998, EUR J IMMUNOL, V28, P1708, DOI 10.1002/(SICI)1521-4141(199805)28:05<1708::AID-IMMU1708>3.0.CO;2-Y; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Saleem MA, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133630; Sapra P, 2002, CANCER RES, V62, P7190; Siddiqi FS, 2013, DIABETES, V62, P3647, DOI 10.2337/db13-0795; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Vollenbroker B, 2009, AM J PHYSIOL-RENAL, V296, pF418, DOI 10.1152/ajprenal.90319.2008	24	23	23	4	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2015	10	9							e0138870	10.1371/journal.pone.0138870	http://dx.doi.org/10.1371/journal.pone.0138870			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS1CR	26407295	Green Submitted, Green Published, gold			2023-01-03	WOS:000361800700106
J	Qian, XY; Qin, J; Pan, SD; Li, X; Pan, YL; Ma, SL				Qian, Xinyu; Qin, Jing; Pan, Songdan; Li, Xin; Pan, Yuelong; Ma, Shenglin			Maintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-Analysis	PLOS ONE			English	Article							PHASE-II TRIAL; 1ST-LINE TREATMENT; RANDOMIZED-TRIAL; DOUBLE-BLIND; CARBOPLATIN; PACLITAXEL; CHEMOTHERAPY; BEVACIZUMAB; COMBINATION; SORAFENIB	Background Maintenance therapy with targeted agents for prolonging remission for ovarian cancer patients remains controversial. As a result, a meta-analysis was conducted to assess the effectiveness and safety of using maintenance therapy with targeted agents for the treatment of ovarian cancer. Methods From inception to January 2015, we searched for randomized, controlled trials (RCTs) using the following databases: PubMed, ScienceDirect, the Cochrane Library, Clinicaltrials. gov and EBSCO. Eligible trials included RCTs that evaluated standard chemotherapy which was either followed or not followed by targeted maintenance in patients with ovarian cancer who had been previously receiving adjunctive treatments, such as cytoreductive surgery and standard chemotherapy. The outcome measures included progression-free survival (PFS), overall survival (OS) and incidence of adverse events. Results A total of 13 RCTs, which were published between 2006 and 2014, were found to be in accordance with our inclusion criteria. The primary meta-analysis indicated that both PFS and OS were statistically and significantly improved in the targeted maintenance therapy group as compared to the control group (PFS: HR = 0.84, 95%CI: 0.75 to 0.95, p = 0.001; OS: HR = 0.91, 95%CI: 0.84 to 0.98, p = 0.02). When taking safety into consideration, the use of targeted agents was significantly correlated with increased risks of fatigue, diarrhea, nausea, vomiting, and hypertension. However, no significant differences were found in incidence rates of abdominal pain, constipation or joint pain. Conclusions Our results indicate that targeted maintenance therapy clearly improves the survival of ovarian cancer patients but may also increase the incidence of adverse events. Additional randomized, double-blind, placebo-controlled, multicenter investigations will be required on a larger cohort of patients to verify our findings.	[Qian, Xinyu; Pan, Songdan; Li, Xin; Pan, Yuelong; Ma, Shenglin] Hangzhou Canc Hosp, Hangzhou Peoples Hosp 1, Dept Chemotherapy, Hangzhou, Zhejiang, Peoples R China; [Qin, Jing] Zhejiang Canc Hosp, Dept Chemotherapy, Hangzhou, Zhejiang, Peoples R China	Zhejiang Cancer Hospital	Ma, SL (corresponding author), Hangzhou Canc Hosp, Hangzhou Peoples Hosp 1, Dept Chemotherapy, Hangzhou, Zhejiang, Peoples R China.	hzsyzlkp@sina.com; hzmasl@163.com			Projects of Hangzhou Science and Technology Development Program [20130633B07]; Science and Technology Department of Zhejiang Province [2014C33119]	Projects of Hangzhou Science and Technology Development Program; Science and Technology Department of Zhejiang Province	Projects of Hangzhou Science and Technology Development Program 20130633B07. Science and Technology Department of Zhejiang Province social welfare technology research development projects 2014C33119. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Cancer Society, 2011, GLOB CANC FACTS FIG; [Anonymous], 2012, REV MAN REVMAN COMP; Barakat R.R., 2009, PRINCIPLES PRACTICE, V5th ed.; Berek J, 2009, J CLIN ONCOL, V27, P418, DOI 10.1200/JCO.2008.17.8400; Bolis G, 2006, INT J GYNECOL CANCER, V16, P74, DOI 10.1111/j.1525-1438.2006.00313.x; Bookman MA, 2013, J GYNECOL ONCOL, V24, P105, DOI 10.3802/jgo.2013.24.2.105; Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390; du Bois A, 2014, J CLIN ONCOL, V32, P3374, DOI 10.1200/JCO.2014.55.7348; Gaitskell K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007930.pub2; Gonzalez-Martin A, 2014, DRUGS, V74, P879, DOI 10.1007/s40265-014-0221-9; Herzog TJ, 2013, GYNECOL ONCOL, V130, P25, DOI 10.1016/j.ygyno.2013.04.011; Higgins J., 2009, COCHRANE HDB SYSTEMA; Hirte H, 2006, GYNECOL ONCOL, V102, P300, DOI 10.1016/j.ygyno.2005.12.020; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022; Karlan BY, 2012, J CLIN ONCOL, V30, P362, DOI 10.1200/JCO.2010.34.3178; Kaye SB, 2012, CLIN CANCER RES, V18, P6509, DOI 10.1158/1078-0432.CCR-12-1796; Lambert HE, 1997, ANN ONCOL, V8, P327, DOI 10.1023/A:1008256431090; Ledermann J, 2012, NEW ENGL J MED, V366, P1382, DOI 10.1056/NEJMoa1105535; Ledermann JA, 2011, J CLIN ONCOL, V29, P3798, DOI 10.1200/JCO.2010.33.5208; Meier W, 2012, GYNECOL ONCOL, V126, P236, DOI 10.1016/j.ygyno.2012.04.050; Ozols RF, 2006, SEMIN ONCOL, V33, pS3, DOI 10.1053/j.seminoncol.2006.03.011; Pecorelli S, 2009, J CLIN ONCOL, V27, P4642, DOI 10.1200/JCO.2009.21.9691; Pfisterer J, 2006, JNCI-J NATL CANCER I, V98, P1036, DOI 10.1093/jnci/djj296; Polcher M, 2010, CANCER CHEMOTH PHARM, V66, P203, DOI 10.1007/s00280-010-1276-2; Sabbatini P, 2013, J CLIN ONCOLOGY, V31; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Thigpen T, 2004, CANCER INVEST, V22, P21, DOI 10.1081/CNV-200030115; Vergote IB, 2014, J CLIN ONCOL, V32, P320, DOI 10.1200/JCO.2013.50.5669; Vergote IB, 2013, J CLIN ONCOL, V31, P3127, DOI 10.1200/JCO.2012.44.9116; Ye Q, 2013, ARCH GYNECOL OBSTET, V288, P655, DOI 10.1007/s00404-013-2820-1; Zhou MY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081858	32	12	12	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2015	10	9							e0139026	10.1371/journal.pone.0139026	http://dx.doi.org/10.1371/journal.pone.0139026			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS1BS	26402447	Green Published, Green Submitted, gold			2023-01-03	WOS:000361798100052
J	Ramesh, A; Blanchet, K; Ensink, JHJ; Roberts, B				Ramesh, Anita; Blanchet, Karl; Ensink, Jeroen H. J.; Roberts, Bayard			Evidence on the Effectiveness of Water, Sanitation, and Hygiene (WASH) Interventions on Health Outcomes in Humanitarian Crises: A Systematic Review	PLOS ONE			English	Article							SAFE STORAGE; AFFECTED COMMUNITIES; DIARRHEA PREVENTION; REFUGEE CAMP; IMPACT; QUALITY; DISEASES; CONTAMINATION; DISINFECTION; OUTBREAK	Background Water, sanitation, and hygiene (WASH) interventions are amongst the most crucial in humanitarian crises, although the impact of the different WASH interventions on health outcomes remains unclear. Aim To examine the quantity and quality of evidence on WASH interventions on health outcomes in humanitarian crises, as well as evaluate current evidence on their effectiveness against health outcomes in these contexts. Methods A systematic literature review was conducted of primary and grey quantitative literature on WASH interventions measured against health outcomes in humanitarian crises occurring from 1980-2014. Populations of interest were those in resident in humanitarian settings, with a focus on acute crisis and early recovery stages of humanitarian crises in low and middle-income countries. Interventions of interest were WASH-related, while outcomes of interest were health-related. Study quality was assessed via STROBE/CONSORT criteria. Results were analyzed descriptively, and PRISMA reporting was followed. Results Of 3963 studies initially retrieved, only 6 published studies measured a statistically significant change in health outcome as a result of a WASH intervention. All 6 studies employed point-of-use (POU) water quality interventions, with 50% using safe water storage (SWS) and 35% using household water treatment (HWT). All 6 studies used self-reported diarrhea outcomes, 2 studies also reported laboratory confirmed outcomes, and 2 studies reported health treatment outcomes (e.g. clinical admissions). 1 study measured WASH intervention success in relation to both health and water quality outcomes; 1 study recorded uptake (use of soap) as well as health outcomes. 2 studies were unblinded randomized-controlled trials, while 4 were uncontrolled longitudinal studies. 2 studies were graded as providing high quality evidence; 3 studies provided moderate and 1 study low quality evidence. Conclusion The current evidence base on the impact of WASH interventions on health outcomes in humanitarian crises is extremely limited, and numerous methodological limitations limit the ability to determine associative, let alone causal, relationships.	[Ramesh, Anita; Blanchet, Karl] London Sch Hyg & Trop Med, Dept Clin Res, Fac Infect Trop Dis, London WC1, England; [Ensink, Jeroen H. J.] London Sch Hyg & Trop Med, Dept Dis Control, Fac Infect Trop Dis, London WC1, England; [Roberts, Bayard] London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, Fac Publ Hlth & Policy, London WC1, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Ramesh, A (corresponding author), London Sch Hyg & Trop Med, Dept Clin Res, Fac Infect Trop Dis, London WC1, England.	anita.ramesh@lshtm.ac.uk		Blanchet, Karl/0000-0003-0498-8020; Roberts, Bayard/0000-0003-4482-5859	Department for International Development (DFID); Wellcome Trust [ITCRZD06]	Department for International Development (DFID); Wellcome Trust(Wellcome Trust)	Commissioned by Enhancing Learning and Research for Humanitarian Assistance (ELRHA) and funded by The Department for International Development (DFID) and the Wellcome Trust: ITCRZD06. The funders of this research have been consulted about the study design and decision to publish, but not about the data collection, analysis, or preparation of the manuscript.	[Anonymous], 1995, Lancet, V345, P339; Aunger R, 2010, SOC SCI MED, V70, P383, DOI 10.1016/j.socscimed.2009.10.038; Bartram J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000367; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Blanchet K., 2013, EVIDENCE REV RES HLT; BLUM D, 1983, INT J EPIDEMIOL, V12, P357, DOI 10.1093/ije/12.3.357; Cairncross S, 2010, INT J EPIDEMIOL, V39, P193, DOI 10.1093/ije/dyq035; Casanova LM, 2012, TROP MED INT HEALTH, V17, P1361, DOI 10.1111/j.1365-3156.2012.03082.x; Casanova LM, 2010, AM J TROP MED HYG, V83, P133; Churchill A, 1987, RURAL WATER SUPPLY S; Clasen T, 2006, WATER PRACT TECHNOL, V1, DOI 10.2166/WPT.2006031; Clasen T, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004794.pub2; Clasen T, 2007, BMJ-BRIT MED J, V334, P782, DOI 10.1136/bmj.39118.489931.BE; Clasen TF, 2010, ENVIRON SCI TECHNOL, V44, P7357, DOI 10.1021/es1018674; Clasen TF, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007180.pub2; Colindres RE, 2007, J WATER HEALTH, V5, P367, DOI 10.2166/wh.2007.032; Connolly MA, 2004, LANCET, V364, P1974, DOI 10.1016/S0140-6736(04)17481-3; Cronin AA, 2009, J WATER HEALTH, V7, P557, DOI 10.2166/wh.2009.089; Curtis V, 2003, LANCET INFECT DIS, V3, P275, DOI 10.1016/S1473-3099(03)00606-6; Davis J, 2011, AM J TROP MED HYG, V84, P184, DOI 10.4269/ajtmh.2011.10-0126; Department for International Development (DfID), 2013, WAT SAN HYG; Doocy S, 2006, TROP MED INT HEALTH, V11, P1542, DOI 10.1111/j.1365-3156.2006.01704.x; Dunston C, 2001, AM J PUBLIC HEALTH, V91, P1574, DOI 10.2105/AJPH.91.10.1574; Elsanousi S, 2009, J WATER HEALTH, V7, P478, DOI 10.2166/wh.2009.050; ESREY SA, 1991, B WORLD HEALTH ORGAN, V69, P609; Fewtrell L, 2005, LANCET INFECT DIS, V5, P42, DOI 10.1016/S1473-3099(04)01253-8; Gruber JS, 2013, AM J TROP MED HYG, V89, P238, DOI 10.4269/ajtmh.13-0017; Hunter PR, 2009, ENVIRON SCI TECHNOL, V43, P8991, DOI 10.1021/es9028217; Kouadio IK, 2012, EXPERT REV ANTI-INFE, V10, P95, DOI [10.1586/eri.11.155, 10.1586/ERI.11.155]; Lantagne D, 2013, AM J TROP MED HYG, V89, P426, DOI 10.4269/ajtmh.13-0179; Lantagne DS, 2012, ENVIRON SCI TECHNOL, V46, P11352, DOI 10.1021/es301842u; Luby S, 2006, J APPL MICROBIOL, V100, P1154, DOI 10.1111/j.1365-2672.2006.02940.x; Luby SP, 2008, J APPL MICROBIOL, V105, P1002, DOI 10.1111/j.1365-2672.2008.03826.x; Lule JR, 2005, AM J TROP MED HYG, V73, P926, DOI 10.4269/ajtmh.2005.73.926; Migele J, 2007, AM J TROP MED HYG, V76, P351, DOI 10.4269/ajtmh.2007.76.351; Mintz E, 2001, AM J PUBLIC HEALTH, V91, P1565, DOI 10.2105/AJPH.91.10.1565; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Moll DM, 2007, J WATER HEALTH, V5, P51, DOI 10.2166/wh.2006.047; Mong Y, 2001, AM J PUBLIC HEALTH, V91, P1577, DOI 10.2105/AJPH.91.10.1577; O'Connor KA, 2011, EMERG INFECT DIS, V17, P2136, DOI 10.3201/eid1711.110810; Ogutu P, 2001, AM J PUBLIC HEALTH, V91, P1610, DOI 10.2105/AJPH.91.10.1610; Peterson EA, 1998, INT J EPIDEMIOL, V27, P520, DOI 10.1093/ije/27.3.520; Quick RE, 2002, AM J TROP MED HYG, V66, P584, DOI 10.4269/ajtmh.2002.66.584; Ram PK, 2007, AM J PUBLIC HEALTH, V97, P398, DOI 10.2105/AJPH.2005.073460; Reller ME, 2001, AM J PUBLIC HEALTH, V91, P1608, DOI 10.2105/AJPH.91.10.1608; Roberts L, 2001, B WORLD HEALTH ORGAN, V79, P280; Schmidt WP, 2007, EPIDEMIOLOGY, V18, P537, DOI 10.1097/EDE.0b013e318093f3ce; Schmidt WP, 2014, TROP MED INT HEALTH, V19, P522, DOI 10.1111/tmi.12286; Schmidt WP, 2011, INT J EPIDEMIOL, V40, P1678, DOI 10.1093/ije/dyr152; Schmidt WP, 2009, ENVIRON SCI TECHNOL, V43, P986, DOI 10.1021/es802232w; SHARE Research Consortium, 2012, EV REV RES PRIOR WAT; Shultz A, 2009, AM J TROP MED HYG, V80, P640, DOI 10.4269/ajtmh.2009.80.640; Stauber CE, 2009, AM J TROP MED HYG, V80, P286, DOI 10.4269/ajtmh.2009.80.286; Steele A, 2008, J WATER HEALTH, V6, P559, DOI 10.2166/wh.2008.072; Tappero JW, 2011, EMERG INFECT DIS, V17, P2087, DOI 10.3201/eid1711.110827; The Sphere Project, 2011, SPHER HDB HUM CHART; Thomson K, 2013, MMWR-MORBID MORTAL W, V62, P581; Tillett HE, 1998, EPIDEMIOL INFECT, V120, P37, DOI 10.1017/S0950268897008431; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Walden VM, 2005, DISASTERS, V29, P213, DOI 10.1111/j.0361-3666.2005.00287.x; World Health Organization, 2007, COMB WAT DIS HOUS LE	62	58	58	1	50	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2015	10	9							e0124688	10.1371/journal.pone.0124688	http://dx.doi.org/10.1371/journal.pone.0124688			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CS1BM	26398228	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000361797500001
J	Kyaw, NTT; Harries, AD; Chinnakali, P; Antierens, A; Soe, KP; Woodman, M; Das, M; Shetty, S; Zuu, MKL; Htwe, PS; Fernandez, M				Kyaw, Nang Thu Thu; Harries, Anthony D.; Chinnakali, Palanivel; Antierens, Annick; Soe, Kyi Pyar; Woodman, Mike; Das, Mrinalini; Shetty, Sharmila; Zuu, Moe Khine Lwin; Htwe, Pyae Sone; Fernandez, Marcelo			Low Incidence of Renal Dysfunction among HIV-Infected Patients on a Tenofovir-Based First Line Antiretroviral Treatment Regimen in Myanmar	PLOS ONE			English	Article							DISOPROXIL FUMARATE; METAANALYSIS; SAFETY; RISK	Background Since 2004, Medecins Sans Frontieres-Switzerland has provided treatment and care for people living with HIV in Dawei, Myanmar. Renal function is routinely monitored in patients on tenofovir (TDF)-based antiretroviral treatment (ART), and this provides an opportunity to measure incidence and risk factors for renal dysfunction. Methods We used routinely collected program data on all patients aged >= 15 years starting first-line TDF-based ART between January 2012 and December 2013. Creatinine clearance (CrCl) was assessed at base line and six-monthly, with renal dysfunction defined as CrCl < 50ml/min/1.73m(2). We calculated incidence of renal dysfunction and used Cox regression analysis to identify associated risk factors. Results There were 1391 patients, of whom 1372 had normal renal function at baseline. Of these, 86 (6.3%) developed renal dysfunction during a median time of follow-up 1.14 years with an incidence rate of 5.4 per 100 person-years: 78 had CrCl between 30-50ml/min/1.73m(2) and were maintained on TDF-based ART, but 5 were changed to another regimen: 4 because of CrCl <30ml/min/1.73m(2). Risk factors for renal dysfunction included age >= 45 years, diagnosed diabetes, underlying renal disease, underweight and CD4 count <200cells/mm(3). There were 19 patients with baseline renal dysfunction and all continued on TDF-based ART: CrCl stayed between 30-49 ml/qmin/q1.73m(2) in five patients while the remainder regained normal renal function. Conclusions In a resource-poor country like Myanmar, the low incidence of renal toxicity in our patient cohort suggests that routine assessment of CrCl may not be needed and could be targeted to high risk groups if resources permit.	[Kyaw, Nang Thu Thu; Soe, Kyi Pyar; Shetty, Sharmila; Zuu, Moe Khine Lwin; Htwe, Pyae Sone; Fernandez, Marcelo] Med Sans Frontieres Switzerland, Yangon, Myanmar; [Harries, Anthony D.] Int Union TB & Lung Dis, Paris, France; [Harries, Anthony D.] London Sch Hyg & Trop Med, London WC1, England; [Chinnakali, Palanivel] JIPMER, Pondicherry, India; [Antierens, Annick] Med Sans Frontieres, Brussels, Belgium; [Woodman, Mike] Med Sans Frontieres, Geneva, Switzerland; [Das, Mrinalini] Med Sans Frontieres Doctors Borders, New Delhi, India	University of London; London School of Hygiene & Tropical Medicine; Jawaharlal Institute of Postgraduate Medical Education & Research; Doctors Without Borders; Doctors Without Borders	Kyaw, NTT (corresponding author), Med Sans Frontieres Switzerland, Yangon, Myanmar.	nangthu82@gmail.com	Chinnakali, Palanivel/AAV-7708-2020	Chinnakali, Palanivel/0000-0001-8320-1016	The Union, MSF, The Department for International Development (DFID), UK; World Health Organization	The Union, MSF, The Department for International Development (DFID), UK; World Health Organization(World Health Organization)	The programme was funded by The Union, MSF, The Department for International Development (DFID), UK and the World Health Organization. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2014, GLOB UPD HLTH SECT R; Barraclough K, 2009, NEPHRON CLIN PRACT, V111, pC39, DOI 10.1159/000178978; Bor J, 2013, SCIENCE, V339, P961, DOI 10.1126/science.1230413; Bygrave H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017609; Chua AC, 2012, AIDS RES THER, V9, DOI 10.1186/1742-6405-9-19; Cooper RD, 2010, CLIN INFECT DIS, V51, P496, DOI 10.1086/655681; Edginton M, 2012, PUBLIC HEALTH ACTION, V2, P21, DOI [10.5588/pha.12.0001, 10.5588/pha.12.0028]; EpiData, EPIDATA COMP PROGR; Gervasoni C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080242; Government of Myanmar, 2017, 2014 MYANM POP HOUS; Hall AM, 2013, PEDIATR NEPHROL, V28, P1011, DOI 10.1007/s00467-012-2269-7; Kalyesubula R, 2011, AIDS RES TREAT, V2011, DOI 10.1155/2011/562790; McManus H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048839; Mizushima D, 2014, J INFECT CHEMOTHER, V20, P784, DOI 10.1016/j.jiac.2014.08.015; Mulenga L, 2014, CLIN INFECT DIS, V58, P1473, DOI 10.1093/cid/ciu117; National AIDS Programme, 2011, GUID CLIN MAN HIV IN; National AIDS Programme, 2014, GLOB AIDS RESP PROGR; National AIDS Programme, 2012, HIV SENT SER SURV SU; Nishijima T, 2014, AIDS, V28, P1903, DOI 10.1097/QAD.0000000000000347; Poizot-Martin I, 2013, JAIDS-J ACQ IMM DEF, V62, P375, DOI 10.1097/QAI.0b013e31827ce4ee; Pujari SN, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-173; Scherzer R, 2012, AIDS, V26, P867, DOI 10.1097/QAD.0b013e328351f68f; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Winston J, 2014, HIV CLIN TRIALS, V15, P231, DOI 10.1310/hct1506-231; World Health Organization, 2016, CONSOLIDATED GUIDELI, V2nd ed; World Health Organization, 2010, ANT THER HIV INF AD	26	12	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2015	10	8							e0135188	10.1371/journal.pone.0135188	http://dx.doi.org/10.1371/journal.pone.0135188			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP5VA	26301416	Green Published, gold, Green Accepted, Green Submitted			2023-01-03	WOS:000359951900014
J	Di Luccia, B; Crescenzo, R; Mazzoli, A; Cigliano, L; Venditti, P; Walser, JC; Widmer, A; Baccigalupi, L; Ricca, E; Iossa, S				Di Luccia, Blanda; Crescenzo, Raffaella; Mazzoli, Arianna; Cigliano, Luisa; Venditti, Paola; Walser, Jean-Claude; Widmer, Alex; Baccigalupi, Loredana; Ricca, Ezio; Iossa, Susanna			Rescue of Fructose-Induced Metabolic Syndrome by Antibiotics or Faecal Transplantation in a Rat Model of Obesity	PLOS ONE			English	Article							GUT MICROBIOTA; INSULIN-RESISTANCE; DIET; ENDOTOXEMIA; CONSUMPTION; MODULATION; SEQUENCES; EPIDEMIC	A fructose-rich diet can induce metabolic syndrome, a combination of health disorders that increases the risk of diabetes and cardiovascular diseases. Diet is also known to alter the microbial composition of the gut, although it is not clear whether such alteration contributes to the development of metabolic syndrome. The aim of this work was to assess the possible link between the gut microbiota and the development of diet-induced metabolic syndrome in a rat model of obesity. Rats were fed either a standard or high-fructose diet. Groups of fructose- fed rats were treated with either antibiotics or faecal samples from control rats by oral gavage. Body composition, plasma metabolic parameters and markers of tissue oxidative stress were measured in all groups. A 16S DNA-sequencing approach was used to evaluate the bacterial composition of the gut of animals under different diets. The fructose-rich diet induced markers of metabolic syndrome, inflammation and oxidative stress, that were all significantly reduced when the animals were treated with antibiotic or faecal samples. The number of members of two bacterial genera, Coprococcus and Ruminococcus, was increased by the fructose-rich diet and reduced by both antibiotic and faecal treatments, pointing to a correlation between their abundance and the development of the metabolic syndrome. Our data indicate that in rats fed a fructose-rich diet the development of metabolic syndrome is directly correlated with variations of the gut content of specific bacterial taxa.	[Di Luccia, Blanda; Crescenzo, Raffaella; Mazzoli, Arianna; Cigliano, Luisa; Venditti, Paola; Baccigalupi, Loredana; Ricca, Ezio; Iossa, Susanna] Univ Naples Federico II, Dept Biol, Naples, Italy; [Walser, Jean-Claude] ETH, Genet Div Ctr, Zurich, Switzerland; [Widmer, Alex] ETH, Inst Integrat Biol IBZ, Zurich, Switzerland	University of Naples Federico II; Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Iossa, S (corresponding author), Univ Naples Federico II, Dept Biol, Naples, Italy.	susiossa@unina.it	iossa, susanna/O-1625-2016; Widmer, Alex/B-6841-2009; Cigliano, Luisa/AEL-3260-2022; Ricca, Ezio/AAG-2998-2020	iossa, susanna/0000-0001-6103-718X; Widmer, Alex/0000-0001-8253-5137; Ricca, Ezio/0000-0002-7355-0332; Baccigalupi, Loredana/0000-0003-3070-161X; mazzoli, arianna/0000-0003-4096-443X; Walser, Jean-Claude/0000-0003-1513-0783	Universita Federico II di napoli, Project FARO	Universita Federico II di napoli, Project FARO	This work was supported by the Universita Federico II di napoli, Project FARO. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bergheim I, 2008, J HEPATOL, V48, P983, DOI 10.1016/j.jhep.2008.01.035; Bray GA, 2004, AM J CLIN NUTR, V79, P537; Buettner R, 2007, OBESITY, V15, P798, DOI 10.1038/oby.2007.608; Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Caporaso JG, 2010, BIOINFORMATICS, V26, P266, DOI 10.1093/bioinformatics/btp636; Carvalho BM, 2012, DIABETOLOGIA, V55, P2823, DOI 10.1007/s00125-012-2648-4; Crescenzo R, 2014, EUR J NUTR, V53, P413, DOI 10.1007/s00394-013-0538-2; Crescenzo R, 2013, BRIT J NUTR, V110, P1996, DOI 10.1017/S0007114513001566; Crescenzo R, 2013, EUR J NUTR, V52, P537, DOI 10.1007/s00394-012-0356-y; Crescenzo R, 2008, OBESITY, V16, P958, DOI 10.1038/oby.2008.10; Daniel H, 2014, ISME J, V8, P295, DOI 10.1038/ismej.2013.155; David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Faith JJ, 2011, SCIENCE, V333, P101, DOI 10.1126/science.1206025; Ferrier L, 2006, AM J PATHOL, V168, P1148, DOI 10.2353/ajpath.2006.050617; FOLCH J, 1957, J BIOL CHEM, V226, P497; Hakansson A, 2011, NUTRIENTS, V3, P637, DOI 10.3390/nu3060637; HEATH RL, 1976, ANAL BIOCHEM, V76, P184, DOI 10.1016/0003-2697(76)90277-3; Hsieh FC, 2013, NUTR METAB, V10, DOI 10.1186/1743-7075-10-35; Johnson RJ, 2007, AM J CLIN NUTR, V86, P899; Johnson RJ, 2013, J EQUINE VET SCI, V33, P120, DOI 10.1016/j.jevs.2012.05.004; Karpe F, 2011, DIABETES, V60, P2441, DOI 10.2337/db11-0425; Kavanagh K, 2013, AM J CLIN NUTR, V98, P349, DOI 10.3945/ajcn.112.057331; Li SY, 2008, OBESITY, V16, P811, DOI 10.1038/oby.2007.116; Liang HY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0063983, 10.1371/journal.pone.0074121]; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507; Manichanh C, 2010, GENOME RES, V20, P1411, DOI 10.1101/gr.107987.110; Marriott BP, 2009, J NUTR, V139, pS1228, DOI 10.3945/jn.108.098277; McNulty NP, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001637; Membrez M, 2008, FASEB J, V22, P2416, DOI 10.1096/fj.07-102723; Nishio K, 2013, REDOX BIOL, V1, P97, DOI 10.1016/j.redox.2012.10.002; Payne AN, 2012, OBES REV, V13, P799, DOI 10.1111/j.1467-789X.2012.01009.x; Piya MK, 2013, CURR OPIN LIPIDOL, V24, P78, DOI 10.1097/MOL.0b013e32835b4431; Price MN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009490; REZNICK AZ, 1994, METHOD ENZYMOL, V233, P357; Stump CS, 2006, ANN MED, V38, P389, DOI 10.1080/07853890600888413; Tappy L, 2010, NUTRITION, V26, P1044, DOI 10.1016/j.nut.2010.02.014; Tilg H, 2009, GASTROENTEROLOGY, V136, P1476, DOI 10.1053/j.gastro.2009.03.030; van de Woestijne AP, 2011, OBES REV, V12, P829, DOI 10.1111/j.1467-789X.2011.00900.x; Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031; Walker AW, 2011, ISME J, V5, P220, DOI 10.1038/ISMEJ.2010.118; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Wang Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007401	46	109	113	1	51	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2015	10	8							e0134893	10.1371/journal.pone.0134893	http://dx.doi.org/10.1371/journal.pone.0134893			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO3MH	26244577	Green Published, gold, Green Submitted			2023-01-03	WOS:000359061400124
J	Kittappa, S; Cui, MC; Ramalingam, M; Ibrahim, S; Khim, J; Yoon, Y; Snyder, SA; Jang, M				Kittappa, Shanmuga; Cui, Mingcan; Ramalingam, Malarvili; Ibrahim, Shaliza; Khim, Jeehyeong; Yoon, Yeomin; Snyder, Shane A.; Jang, Min			Synthesis Mechanism and Thermal Optimization of an Economical Mesoporous Material Using Silica: Implications for the Effective Removal or Delivery of Ibuprofen	PLOS ONE			English	Article							DRUG-DELIVERY; ACTIVATED CARBONS; PHARMACEUTICAL COMPOUNDS; SURFACE-CHEMISTRY; MOLECULAR-SIEVES; ADSORPTION; SBA-15; MCM-41; NANOPARTICLES; COPOLYMER	Mesoporous silica materials (MSMs) were synthesized economically using silica (SiO2) as a precursor via a modified alkaline fusion method. The MSM prepared at 500 degrees C (MSM-500) had the highest surface area, pore size, and volume, and the results of isotherms and the kinetics of ibuprofen (IBP) removal indicated that MSM-500 had the highest sorption capacity and fastest removal speed vs. SBA-15 and zeolite. Compared with commercial granular activated carbon (GAC), MSM-500 had a similar to 100 times higher sorption rate at neutral pH. IBP uptake by MSM-500 was thermodynamically favorable at room temperature, which was interpreted as indicating relatively weak bonding because the entropy (Delta(adsS), -0.07 J mol(-1) K-1) was much smaller. Five times recycling tests revealed that MSM-500 had 83-87% recovery efficiencies and slower uptake speeds due to slight deformation of the outer pore structure. In the IBP delivery test, MSM-500 drug loading was 41%, higher than the reported value of SBA-15 (31%). The in vitro release of IBP was faster, almost 100%, reaching equilibrium within a few hours, indicating its effective loading and unloading characteristics. A cost analysis study revealed that the MSM was similar to 10-70 times cheaper than any other mesoporous silica material for the removal or delivery of IBP.	[Kittappa, Shanmuga; Ibrahim, Shaliza; Jang, Min] Univ Malaya, Fac Engn, Dept Civil Engn, Kuala Lumpur, Malaysia; [Cui, Mingcan; Khim, Jeehyeong] Korea Univ, Sch Civil Environm & Architectural Engn, Seoul, South Korea; [Yoon, Yeomin] Univ S Carolina, Dept Civil & Environm Engn, Columbia, SC 29208 USA; [Snyder, Shane A.] Univ Arizona, Dept Chem & Environm Engn, Tucson, AZ USA; [Jang, Min] Univ Malaya, Nanotechnol & Catalysis Res Ctr NANOCAT, Kuala Lumpur, Malaysia	Universiti Malaya; Korea University; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of Arizona; Universiti Malaya	Jang, M (corresponding author), Univ Malaya, Fac Engn, Dept Civil Engn, Kuala Lumpur, Malaysia.	minjang@um.edu.my	Ibrahim, Shaliza/A-5854-2010; Park, Jeonghyuk/AAE-3814-2020; Snyder, Shane A/AAE-8252-2021; Yoon, Yeomin/C-3331-2012; Cui, Mingcan/K-2890-2013; Jang, Min/M-6690-2018; Snyder, Shane/A-3302-2011	Ibrahim, Shaliza/0000-0001-9413-957X; Cui, Mingcan/0000-0001-9619-154X; Jang, Min/0000-0003-2700-7256; Jang, Min/0000-0002-5900-0991; Snyder, Shane/0000-0003-2709-9840	Malaysian Government Ministry of Higher Education through the High Impact Research Grant [D000062-16001]; National Research Foundation of Korea (NRF) grant - Korea government (MEST) [KRF-2009-0092799]	Malaysian Government Ministry of Higher Education through the High Impact Research Grant; National Research Foundation of Korea (NRF) grant - Korea government (MEST)	This research was funded by the Malaysian Government Ministry of Higher Education through the High Impact Research Grant (D000062-16001), and partly supported by the Basic Science Research Program through a National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST, No. KRF-2009-0092799). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Khateeb LA, 2014, J IND ENG CHEM, V20, P916, DOI 10.1016/j.jiec.2013.06.023; Alyoshina NA, 2013, J SOLID STATE CHEM, V205, P211, DOI 10.1016/j.jssc.2013.03.044; Andersson J, 2004, CHEM MATER, V16, P4160, DOI 10.1021/cm0401490; Attia TMS, 2013, CHEMOSPHERE, V93, P2076, DOI 10.1016/j.chemosphere.2013.07.046; Babonneau F, 2003, MRS P; Baccar R, 2012, CHEM ENG J, V211, P310, DOI 10.1016/j.cej.2012.09.099; Bui TX, 2009, J HAZARD MATER, V168, P602, DOI 10.1016/j.jhazmat.2009.02.072; Doadrio AL, 2004, J CONTROL RELEASE, V97, P125, DOI 10.1016/j.jconrel.2004.03.005; Foo KY, 2010, CHEM ENG J, V156, P2, DOI 10.1016/j.cej.2009.09.013; Guedidi H, 2013, CARBON, V54, P432, DOI 10.1016/j.carbon.2012.11.059; Jaroniec M., 2006, ACCESS NANOPOROUS MA, V188, P255, DOI [10.1007/0-306-47066-7_17., DOI 10.1007/0-306-47066-7_17]; Kamarudin NHN, 2014, J COLLOID INTERF SCI, V421, P6, DOI 10.1016/j.jcis.2014.01.034; Katiyar A, 2006, J CHROMATOGR A, V1122, P13, DOI 10.1016/j.chroma.2006.04.055; Kim SS, 2001, CHEM COMMUN, P2418, DOI 10.1039/b107896h; Kim Y, 2014, CHEM ENG J, V256, P475, DOI 10.1016/j.cej.2014.06.100; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Kruk M, 1997, LANGMUIR, V13, P6267, DOI 10.1021/la970776m; Kwon M, 2015, CHEM ENG J, V269, P379, DOI 10.1016/j.cej.2015.01.125; Lim MH, 1999, CHEM MATER, V11, P3285, DOI 10.1021/cm990369r; Liu TH, 2013, J RADIOANAL NUCL CH, V297, P119, DOI 10.1007/s10967-012-2316-7; Liu Y, 2008, SEP PURIF TECHNOL, V61, P229, DOI 10.1016/j.seppur.2007.10.002; Margolese D, 2000, CHEM MATER, V12, P2448, DOI 10.1021/cm0010304; Mestre AS, 2007, CARBON, V45, P1979, DOI 10.1016/j.carbon.2007.06.005; Mestre AS, 2014, CHEM ENG J, V253, P408, DOI 10.1016/j.cej.2014.05.051; Mestre AS, 2009, BIORESOURCE TECHNOL, V100, P1720, DOI 10.1016/j.biortech.2008.09.039; Munoz B, 2003, CHEM MATER, V15, P500, DOI 10.1021/cm021217q; NAKASHIMA H, 1994, ARCH TOXICOL, V68, P277, DOI 10.1007/s002040050069; Neng NR, 2011, J CHROMATOGR A, V1218, P6263, DOI 10.1016/j.chroma.2011.07.025; Park J, 2012, J NANOMATER, V2012, DOI 10.1155/2012/528174; Reijenga JC, 1997, J CHROMATOGR A, V792, P371, DOI 10.1016/S0021-9673(97)00644-4; Sadecka J, 2001, J PHARMACEUT BIOMED, V25, P881, DOI 10.1016/S0731-7085(01)00374-0; Slowing II, 2007, ADV FUNCT MATER, V17, P1225, DOI 10.1002/adfm.200601191; Son SJ, 2006, J CONTROL RELEASE, V114, P143, DOI 10.1016/j.jconrel.2006.06.004; Song SW, 2005, LANGMUIR, V21, P9568, DOI 10.1021/la051167e; Thommes M, 2010, CHEM-ING-TECH, V82, P1059, DOI 10.1002/cite.201000064; Vallet-Regi M, 2001, CHEM MATER, V13, P308, DOI 10.1021/cm0011559; Vallet-Regi M, 2007, ANGEW CHEM INT EDIT, V46, P7548, DOI 10.1002/anie.200604488; Walas S.M., 1985, PHASE EQUILIBRIA CHE, DOI 10.1016/C2013-0-04304-6; Wang XF, 2011, MICROPOR MESOPOR MAT, V142, P334, DOI 10.1016/j.micromeso.2010.12.018; Yang PP, 2007, INORG CHEM, V46, P3203, DOI 10.1021/ic0622959; Yang PP, 2012, CHEM SOC REV, V41, P3679, DOI 10.1039/c2cs15308d; Zhang L, 2013, SEP PURIF TECHNOL, V116, P145, DOI 10.1016/j.seppur.2013.05.036; Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548; Zhao DY, 1998, J AM CHEM SOC, V120, P6024, DOI 10.1021/ja974025i; Zhao XS, 1997, J PHYS CHEM B, V101, P6525, DOI 10.1021/jp971366+; Zhu YF, 2005, MICROPOR MESOPOR MAT, V85, P75, DOI 10.1016/j.micromeso.2005.06.015	46	6	6	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2015	10	7							e0130253	10.1371/journal.pone.0130253	http://dx.doi.org/10.1371/journal.pone.0130253			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1FD	26161510	Green Published, gold, Green Submitted			2023-01-03	WOS:000358162300016
J	Zengin, E; Bickel, C; Schnabel, RB; Zeller, T; Lackner, KJ; Rupprecht, HJ; Blankenberg, S; Westermann, D				Zengin, Elvin; Bickel, Christoph; Schnabel, Renate B.; Zeller, Tanja; Lackner, Karl-J.; Rupprecht, Hans-J.; Blankenberg, Stefan; Westermann, Dirk		Christoph Sinning AtheroGene-Study	Risk Factors of Coronary Artery Disease in Secondary Prevention-Results from the AtheroGene-Study	PLOS ONE			English	Article							C-REACTIVE PROTEIN; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; HEART-DISEASE; MULTIFACTORIAL INTERVENTION; MYOCARDIAL-INFARCTION; LOWER TARGETS; MORTALITY; EVENTS; PREDICTION	Background Risk factors are important in cardiovascular (CV) medicine for risk stratification of patients. We aimed to compare the traditional risk factors to clinical variables for the prediction of secondary cardiovascular events. Methods and Results For this study, 3229 patients with known coronary artery disease (CAD) were included. We calculated whether the traditional risk factors, diabetes mellitus, increased LDL/HDL ratio, arterial hypertension and smoking alone and in combination with the clinical variables, ejection fraction, creatinine clearance, multi-vessel disease and CRP concentration predict the outcome cardiovascular death or non-fatal myocardial infarction (N = 432) during the mean follow-up time of 4.2 +/- 2.0 years. In this cohort diabetes mellitus was the risk factor with the strongest influence regarding occurrence of secondary events (hazard ratio; HR: 1.70, confidence interval; CI 95%: 1.36-2.11; P<0.0001), followed by LDL/HDL ratio and smoking. However, risk stratification is further improved by using additional clinical variables like ejection fraction (HR:3.30 CI 95%: 2.51-4.33; P>0.0001) or calculated creatinine clearence (Cockroft-Gault formula) (HR:2.26 CI 95%: 1.78-2.89; P<0.0001). Further ameliorating risk stratification from the clinical variables were CRP and multi-vessel disease. The most precise risk prediction was achieved when all clinical variables were added to the CV risk factors. Conclusion Diabetes mellitus has the strongest influence to predict secondary cardiovascular events in patients with known CAD. Risk stratification can further be improved by adding CV risk factors and clinical variables together. Control of risk factors is of paramount importance in patients with known CAD, while clinical variables can further enhance prediction of events.	[Zengin, Elvin; Schnabel, Renate B.; Zeller, Tanja; Blankenberg, Stefan; Westermann, Dirk; Christoph Sinning AtheroGene-Study] Univ Heart Ctr Hamburg, Dept Gen & Intervent Cardiol, Hamburg, Germany; [Bickel, Christoph] Fed Armed Forces Cent Hosp Koblenz, Dept Med, Koblenz, Germany; [Lackner, Karl-J.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Clin Chem & Lab Med, D-55122 Mainz, Germany; [Rupprecht, Hans-J.] GPR Klinikum Ruesselsheim, Dept Med 2, Russelsheim, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; Johannes Gutenberg University of Mainz	Bickel, C (corresponding author), Fed Armed Forces Cent Hosp Koblenz, Dept Med, Koblenz, Germany.	cbickel@t-online.de	Westermann, Dirk/D-1344-2011; Schnabel, Renate B/ABE-6668-2021	Schnabel, Renate B/0000-0001-7170-9509; Westermann, Dirk/0000-0002-7542-1956; Zeller, Tanja/0000-0003-3379-2641	"Stiftung Rheinland-Pfalz fur Innovation," Ministry of Science and Education, Mainz [AZ 15202-386261/545]; MAIFOR grant of the Johannes Gutenberg-University Mainz, Germany; Fondation de France [2002004994]; French Ministry of Research [ACIIMPBIO 032619]; Institut National de la Sante et de la Recherche Medicale (Programme National de Recherches sur les Maladies Cardiovasculaires) [A04052DS]	"Stiftung Rheinland-Pfalz fur Innovation," Ministry of Science and Education, Mainz; MAIFOR grant of the Johannes Gutenberg-University Mainz, Germany; Fondation de France(Fondation de France); French Ministry of Research(Ministry of Research, FranceEuropean Commission); Institut National de la Sante et de la Recherche Medicale (Programme National de Recherches sur les Maladies Cardiovasculaires)	The AtheroGene study is supported by a grant of the "Stiftung Rheinland-Pfalz fur Innovation," Ministry of Science and Education (AZ 15202-386261/545), Mainz, by the MAIFOR grant 2001 of the Johannes Gutenberg-University Mainz, Germany, and by grants from the Fondation de France (no. 2002004994), the French Ministry of Research (ACIIMPBIO 032619) and the Institut National de la Sante et de la Recherche Medicale (Programme National de Recherches sur les Maladies Cardiovasculaires A04052DS).	Bangalore S, 2011, CIRCULATION, V123, P2799, DOI 10.1161/CIRCULATIONAHA.110.016337; Bhatt DL, 2006, JAMA-J AM MED ASSOC, V295, P180, DOI 10.1001/jama.295.2.180; Blankenberg S, 2006, CIRCULATION, V114, P201, DOI 10.1161/CIRCULATIONAHA.105.590927; Bowker TJ, 1996, HEART, V75, P334, DOI 10.1136/hrt.75.4.334; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Coresh J, 2006, CURR OPIN NEPHROL HY, V15, P276, DOI 10.1097/01.mnh.0000222695.84464.61; Cushman WC, 2010, NEW ENGL J MED, V362, P1575, DOI 10.1056/NEJMoa1001286; Fried LP, 1998, JAMA-J AM MED ASSOC, V279, P585, DOI 10.1001/jama.279.8.585; Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778; Gaede P, 2008, NEW ENGL J MED, V358, P580, DOI 10.1056/NEJMoa0706245; Germano G, 2012, EUR HEART J, V33, P137; Giannuzzi P, 2008, ARCH INTERN MED, V168, P2194, DOI 10.1001/archinte.168.20.2194; Greenland P, 2003, JAMA-J AM MED ASSOC, V290, P891, DOI 10.1001/jama.290.7.891; Howard BV, 2008, JAMA-J AM MED ASSOC, V299, P1678, DOI 10.1001/jama.299.14.1678; Kaplan RC, 2002, J CLIN EPIDEMIOL, V55, P654, DOI 10.1016/S0895-4356(02)00405-5; Keller T, 2009, EUR HEART J, V30, P314, DOI 10.1093/eurheartj/ehn598; Kotseva K, 2001, EUR HEART J, V22, P554, DOI 10.1053/euhj.2001.2610; Kotseva K, 2016, EUR J PREV CARDIOL, V23, P636, DOI 10.1177/2047487315569401; Kotseva K, 2009, EUR J CARDIOV PREV R, V16, P121, DOI 10.1097/HJR.0b013e3283294b1d; LaRosa JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMoa050461; Leander K, 2007, EUR J CARDIOV PREV R, V14, P532, DOI 10.1097/HJR.0b013e328012e3cc; Liu Jing, 2009, Zhonghua Yi Xue Za Zhi, V89, P1676; Mehta RH, 2008, EUR HEART J, V29, P3052, DOI 10.1093/eurheartj/ehn478; Mielniczuk LM, 2008, AM HEART J, V155, P725, DOI 10.1016/j.ahj.2007.11.031; Miura K, 2001, ARCH INTERN MED, V161, P1501, DOI 10.1001/archinte.161.12.1501; Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Preis SR, 2009, CIRCULATION, V120, P212, DOI 10.1161/CIRCULATIONAHA.108.846519; Prugger C, 2008, EUR J EPIDEMIOL, V23, P731, DOI 10.1007/s10654-008-9291-x; Rosvall M, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-189; Russell M, 2006, AM HEART J, V152, P867, DOI 10.1016/j.ahj.2006.05.021; Sabatine MS, 2007, CIRCULATION, V115, P1528, DOI 10.1161/CIRCULATIONAHA.106.649939; Sinning C, 2013, CLIN RES CARDIOL, V102, P495, DOI 10.1007/s00392-013-0555-4; The sixth report of the Joint National Committee, 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005; Turnbull F, 2003, LANCET, V362, P1527; Volzke H, 2007, INT J CARDIOL, V116, P46, DOI 10.1016/j.ijcard.2006.02.008; Wood D, 1997, EUR HEART J, V18, P1569; Wood D, 2001, ATHEROSCLEROSIS SUPP, V2, P3, DOI 10.1016/S1567-5688(00)00003-9; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	42	21	21	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2015	10	7							e0131434	10.1371/journal.pone.0131434	http://dx.doi.org/10.1371/journal.pone.0131434			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1EJ	26154343	gold, Green Published, Green Submitted			2023-01-03	WOS:000358159700062
J	Guo, R; Tang, LL; Mao, YP; Zhou, GQ; Qi, ZY; Liu, LZ; Lin, AH; Liu, MZ; Ma, J; Sun, Y				Guo, Rui; Tang, Ling-Long; Mao, Yan-Ping; Zhou, Guan-Qun; Qi, Zhen-Yu; Liu, Li-Zhi; Lin, Ai-Hua; Liu, Meng-Zhong; Ma, Jun; Sun, Ying			Clinical Outcomes of Volume-Modulated Arc Therapy in 205 Patients with Nasopharyngeal Carcinoma: An Analysis of Survival and Treatment Toxicities	PLOS ONE			English	Article							RADIATION-THERAPY; NECK CANCER; RADIOTHERAPY; RISK; HEAD; UPDATE; IMRT	Background To investigate the clinical efficacy and treatment toxicity of volume-modulated arc therapy (VMAT) for nasopharyngeal carcinoma (NPC). Material and Methods 205 VMAT-treated NPC patients from our cancer center were prospectively entrolled. All patients received 68-70 Gy irradiation based on the planning target volume of the primary gross tumor volume. Acute and late toxicities were graded according to the Common Terminology Criteria for Adverse Events v3.0 and Radiation Therapy Oncology Group Late Radiation Morbidity Scoring Criteria. Results The median follow-up period was 37.3 months (range, 6.3-45.1 months). The 3-year estimated local failure-free survival, regional failure-free survival, locoregional failure-free survival, distant metastasis-free survival, disease-free survival and overall survival were 95.5%, 97.0%, 94.0%, 92.1%, 86.8% and 97.0%, respectively. Cox regression analysis showed primary gross tumor volume, N stage and EBV-DNA to be independent predictors of VMAT outcomes (P < 0.05). The most common acute and late side effects were grade 2-3 mucositis (78%) and xerostomia (83%, 61%, 34%, and 9% at 3, 6, 12 and 24 months after VMAT), respectively. Conclusions VMAT for the primary treatment of NPC achieved very high locoregional control with a favorable toxicity profile. The time-saving benefit of VMAT will enable more patients to receive precision radiotherapy.	[Guo, Rui; Tang, Ling-Long; Mao, Yan-Ping; Zhou, Guan-Qun; Qi, Zhen-Yu; Liu, Meng-Zhong; Ma, Jun; Sun, Ying] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol Southern China, Dept Radiat Oncol,Collaborat Innovat Ctr Canc Med, Guangzhou 510275, Guangdong, Peoples R China; [Liu, Li-Zhi] Sun Yat Sen Univ, Ctr Canc, Imaging Diag & Intervent Ctr, Guangzhou 510275, Guangdong, Peoples R China; [Liu, Li-Zhi] Collaborat Innovat Ctr Canc Med, State Key Lab Oncol Southern China, Guangzhou, Guangdong, Peoples R China; [Lin, Ai-Hua] Sun Yat Sen Univ, Sch Publ Hlth, Dept Med Stat & Epidemiol, Guangzhou 510275, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University	Guo, R (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol Southern China, Dept Radiat Oncol,Collaborat Innovat Ctr Canc Med, Guangzhou 510275, Guangdong, Peoples R China.	drjunma@hotmail.com; sunying@sysucc.org.cn			Health & Medical Collaborative Innovation Project of Guangzhou City, China [201400000001]; National Science & Technology Pillar Program during the Twelfth Five-year Plan Period [2014BAI09B10]; Innovation Team Development Plan of the Ministry of Education [IRT1297]; National Natural Science Foundation of China [81372409]; Natural Science Foundation of Guangdong Province [S2013010012220]; Science and Technology Project of Guangzhou City, China [132000507]	Health & Medical Collaborative Innovation Project of Guangzhou City, China; National Science & Technology Pillar Program during the Twelfth Five-year Plan Period; Innovation Team Development Plan of the Ministry of Education; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Science and Technology Project of Guangzhou City, China	This work was supported by grants from the Health & Medical Collaborative Innovation Project of Guangzhou City, China (201400000001), the National Science & Technology Pillar Program during the Twelfth Five-year Plan Period (2014BAI09B10), the Innovation Team Development Plan of the Ministry of Education (No. IRT1297), the National Natural Science Foundation of China (No. 81372409), the Natural Science Foundation of Guangdong Province (No. S2013010012220), and the Science and Technology Project of Guangzhou City, China (No. 132000507).	Bakst RL, 2011, INT J RADIAT ONCOL, V80, P148, DOI 10.1016/j.ijrobp.2010.01.026; Bertelsen A, 2010, RADIOTHER ONCOL, V95, P142, DOI 10.1016/j.radonc.2010.01.011; Dijkema T, 2010, INT J RADIAT ONCOL, V78, P449, DOI 10.1016/j.ijrobp.2009.07.1708; Doornaert P, 2011, INT J RADIAT ONCOL, V79, P429, DOI 10.1016/j.ijrobp.2009.11.014; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Guo R, 2012, RADIOTHER ONCOL, V104, P294, DOI 10.1016/j.radonc.2012.09.001; Hall EJ, 2003, INT J RADIAT ONCOL, V56, P83, DOI 10.1016/S0360-3016(03)00073-7; Hall EJ, 2006, INT J RADIAT ONCOL, V65, P1, DOI 10.1016/j.ijrobp.2006.01.027; Hoogeman MS, 2008, INT J RADIAT ONCOL, V70, P609, DOI 10.1016/j.ijrobp.2007.08.066; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Johnston M, 2011, CLIN ONCOL-UK, V23, P503, DOI 10.1016/j.clon.2011.02.002; Kam MKM, 2004, INT J RADIAT ONCOL, V60, P1440, DOI 10.1016/j.ijrobp.2004.05.022; Lee N, 2002, INT J RADIAT ONCOL, V53, P12, DOI 10.1016/S0360-3016(02)02724-4; Liang SB, 2009, INT J RADIAT ONCOL, V75, P742, DOI 10.1016/j.ijrobp.2008.11.053; Lin SJ, 2009, INT J RADIAT ONCOL, V75, P1071, DOI 10.1016/j.ijrobp.2008.12.015; Ng WT, 2011, INT J RADIAT ONCOL, V79, P420, DOI 10.1016/j.ijrobp.2009.11.024; Patil VM, 2010, J CANCER RES THER, V6, P442, DOI 10.4103/0973-1482.77082; Pow EHN, 2006, INT J RADIAT ONCOL, V66, P981, DOI 10.1016/j.ijrobp.2006.06.013; Su SF, 2012, INT J RADIAT ONCOL, V82, P327, DOI 10.1016/j.ijrobp.2010.09.011; Sun Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075304; Tham IWK, 2009, INT J RADIAT ONCOL, V75, P1481, DOI 10.1016/j.ijrobp.2009.01.018; Verbakel WFAR, 2009, INT J RADIAT ONCOL, V74, P252, DOI 10.1016/j.ijrobp.2008.12.033; Wang WY, 2013, CANCER-AM CANCER SOC, V119, P963, DOI 10.1002/cncr.27853; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; Wolden SL, 2006, INT J RADIAT ONCOL, V64, P57, DOI 10.1016/j.ijrobp.2005.03.057; Wong FCS, 2010, INT J RADIAT ONCOL, V76, P138, DOI 10.1016/j.ijrobp.2009.01.084; YU CX, 1995, PHYS MED BIOL, V40, P1435, DOI 10.1088/0031-9155/40/9/004; Zeng L, 2014, BRIT J CANCER, V110, P49, DOI 10.1038/bjc.2013.720; Zhou GQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067488	29	18	20	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2015	10	7							e0129679	10.1371/journal.pone.0129679	http://dx.doi.org/10.1371/journal.pone.0129679			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1DQ	26146828	Green Published, Green Submitted, gold			2023-01-03	WOS:000358157600023
J	Kowalski, R; Baj, T; Kowalska, G; Pankiewicz, U				Kowalski, Radoslaw; Baj, Tomasz; Kowalska, Grazyna; Pankiewicz, Urszula			Estimation of Potential Availability of Essential Oil in Some Brands of Herbal Teas and Herbal Dietary Supplements	PLOS ONE			English	Article							MENTHA-PIPERITA L.; CHROMATOGRAPHY	Introduction The aim of the study was to estimate potential availability of essential oil in some brands of herbal products. Methods A comparison was performed on the basis of the essential oil yield in the unprocessed raw materials such as leaves of peppermint and lemon balm and inflorescence of chamomile as well as herbal tea bags and in dietary supplements. The yield of essential oil was determined by distillation. Essential oil was analyzed by GC-FID and GC-MS. Results It was found that the average potential availability of essential oils in the products such as dietary supplements for the doses recommended by the producers is lower than in the corresponding tea infusions: for peppermint formulations approximately 6-fold lower, for the formulations with lemon balm about 4-fold lower, and for the chamomile preparations about 3-fold lower. It was found that essential oils extracted from herbal teas have a similar chemical profile with characteristic deviations in the amount of individual components, which arise from the origin of the raw material. Discussion In contrast to homogenous pharmaceutical herbal mixtures consistent with, the Pharmacopoeia requirements, herbal teas (available in grocery stores) and dietary supplements are often out of control in terms of the yield and composition of the essential oil, which is primarily responsible for the health benefits and aromatic qualities of these products. Analysis of the composition of the dietary supplements showed that they contain on average significantly lower amounts of plant material compared to the herbal teas.	[Kowalski, Radoslaw; Pankiewicz, Urszula] Univ Life Sci Lublin, Dept Anal & Evaluat Food Qual, Lublin, Poland; [Kowalski, Radoslaw] Polish Acad Sci, Inst Agrophys, PL-20236 Lublin, Poland; [Baj, Tomasz] Med Univ Lublin, Dept Pharmacognosy Med Plant Unit, Lublin, Poland; [Kowalska, Grazyna] Univ Life Sci Lublin, Cent Lab Agroecol, Lublin, Poland	University of Life Sciences in Lublin; Polish Academy of Sciences; Bohdan Dobrzanski Institute of Agrophysics of the Polish Academy of Sciences; Medical University of Lublin; University of Life Sciences in Lublin	Kowalski, R (corresponding author), Univ Life Sci Lublin, Dept Anal & Evaluat Food Qual, Lublin, Poland.	radoslaw.kowalski@up.lublin.pl	Kowalski, Radosław/AAB-1166-2019; Baj, Tomasz/S-8374-2018; Baj, Tomasz/M-5642-2019; Kowalska, Grażyna/U-6025-2018	Kowalski, Radosław/0000-0003-3063-8710; Baj, Tomasz/0000-0001-7543-6771; Kowalska, Grażyna/0000-0002-1872-2381; Pankiewicz, Urszula/0000-0003-1477-5598				Adams R.P, 2007, IDENTIFICATION ESSEN, V207, P811; [Anonymous], 2003, ESCOP MON EUR SCI CO, P337; [Anonymous], 2008, POL PHARM, VVIII; [Anonymous], 2002, POL PHARM, VVI; [Anonymous], 1990, LIST GERMAN COMMISSI; Bakkali F, 2008, FOOD CHEM TOXICOL, V46, P446, DOI 10.1016/j.fct.2007.09.106; Basta A, 2005, FLAVOUR FRAG J, V20, P642, DOI 10.1002/ffj.1518; Chawla S, 2013, INT J PHARM RES DEV, V5, P73; Corby-Edwards AK, 2013, REGULATION DIETARY S, P1; ESCOP, 2003, ESCOP MON, P324; ESCOP Monographs, 2003, ESCOP MON, P312; Euromonitor International, 2010, VIT DIET SUPPL; Evaluation of Medicines for Human Use. Committee on Herbal Medicinal Products (HMPC), 2008, COMM HERB MON MENTH; Gora J., 2005, MOST VALUABLE ESSENT; Heuskin S, 2009, J CHROMATOGR A, V1216, P2768, DOI 10.1016/j.chroma.2008.09.109; HMPC, 2007, COMM HERB MON MEL OF; Joulain D., 1998, ATLAS SPECTRAL DATA; Konieczka P, 2009, ANAL CHEM SER, P1; Kowalski R, 2009, FLAVOUR FRAG J, V24, P31, DOI 10.1002/ffj.1914; Krasnowska G, 2011, ZYWN-NAUK TECHNOL JA, V18, P5; Mckay DL, 2006, PHYTOTHER RES, V20, P619, DOI 10.1002/ptr.1936; NIST/EPA, 2005, MASS SPECTR LIB SEAR; Orzeszko-Rywka A., 2011, Journal of Research and Applications in Agricultural Engineering, V56, P52; Patora Jolanta, 2003, Acta Pol Pharm, V60, P395; Raut JS, 2014, IND CROP PROD, V62, P250, DOI 10.1016/j.indcrop.2014.05.055; REVERCHON E, 1994, J AGR FOOD CHEM, V42, P154, DOI 10.1021/jf00037a027; Reyes-Jurado F, 2015, FOOD ENG REV, V7, P275, DOI 10.1007/s12393-014-9099-2; Strzelecka H., 2000, ENCY HERBALISM HERBA; U.S. Government Accountability Office, 2009, GAO09250; VANDENDOOL H, 1963, J CHROMATOGR, V11, P463, DOI 10.1016/S0021-9673(01)80947-X	30	6	6	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2015	10	6							e0130714	10.1371/journal.pone.0130714	http://dx.doi.org/10.1371/journal.pone.0130714			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL4OY	26110869	Green Published, gold, Green Submitted			2023-01-03	WOS:000356933800076
J	Li, R; Qu, SL; Zhang, P; Chattopadhyay, S; Gregg, EW; Albright, A; Hopkins, D; Pronk, NP				Li, Rui; Qu, Shuli; Zhang, Ping; Chattopadhyay, Sajal; Gregg, Edward W.; Albright, Ann; Hopkins, David; Pronk, Nicolaas P.			Economic Evaluation of Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Review							LIFE-STYLE INTERVENTION; IMPAIRED GLUCOSE-TOLERANCE; COST-EFFECTIVENESS; CARDIOVASCULAR-DISEASE; STRATEGIES; METFORMIN; MELLITUS; PEOPLE; TRANSLATION; OUTCOMES	Background: Diabetes is a highly prevalent and costly disease. Studies indicate that combined diet and physical activity promotion programs can prevent type 2 diabetes among persons at increased risk. Purpose: To systematically evaluate the evidence on cost, cost-effectiveness, and cost-benefit estimates of diet and physical activity promotion programs. Data Sources: Cochrane Library, EMBASE, MEDLINE, PsycINFO, Sociological Abstracts, Web of Science, EconLit, and CINAHL through 7 April 2015. Study Selection: English-language studies from high-income countries that provided data on cost, cost-effectiveness, or cost-benefit ratios of diet and physical activity promotion programs with at least 2 sessions over at least 3 months delivered to persons at increased risk for type 2 diabetes. Data Extraction: Dual abstraction and assessment of relevant study details. Data Synthesis: Twenty-eight studies were included. Costs were expressed in 2013 U.S. dollars. The median program cost per participant was $653. Costs were lower for group-based pro-grams (median, $417) and programs implemented in community or primary care settings (median, $424) than for the U.S. DPP (Diabetes Prevention Program) trial and the DPP Outcomes Study ($5881). Twenty-two studies assessed the incremental cost-effectiveness ratios (ICERs) of the programs. From a health system perspective, 16 studies reported a median ICER of $13 761 per quality-adjusted life-year (QALY) saved. Group-based programs were more cost-effective (median, $1819 per QALY) than those that used individual sessions (median, $15 846 per QALY). No cost-benefit studies were identified. Limitation: Information on recruitment costs and cost-effectiveness of translational programs implemented in community and primary care settings was limited. Conclusion: Diet and physical activity promotion programs to prevent type 2 diabetes are cost-effective among persons at increased risk. Costs are lower when programs are delivered to groups in community or primary care settings.	[Li, Rui; Qu, Shuli; Zhang, Ping; Chattopadhyay, Sajal; Gregg, Edward W.; Albright, Ann; Hopkins, David] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA; [Pronk, Nicolaas P.] HealthPartners Res Fdn, Minneapolis, MN 55425 USA	Centers for Disease Control & Prevention - USA; HealthPartners Institute for Education & Research	Li, R (corresponding author), Ctr Dis Control & Prevent, Div Diabet Translat, 4770 Buford Highway Northeast,MS F-75, Atlanta, GA 30341 USA.	eok8@cdc.gov	Qu, Shuli/HJG-7560-2022; Chattopadhyay, Sajal/GWU-8667-2022	Chattopadhyay, Sajal/0000-0002-7245-1631; Gregg, Edward/0000-0003-2381-6822	Intramural CDC HHS [CC999999] Funding Source: Medline	Intramural CDC HHS		Ackermann RT, 2006, DIABETES CARE, V29, P1237, DOI 10.2337/dc05-1709; Albright AL, 2013, AM J PREV MED, V44, pS346, DOI 10.1016/j.amepre.2012.12.009; Alderson P, 2004, COHRANE REV HDB 4 2; Ali MK, 2012, HEALTH AFFAIR, V31, P67, DOI 10.1377/hlthaff.2011.1009; Amer Diabet Assoc, 2013, DIABETES CARE, V36, P1033, DOI 10.2337/dc12-2625; [Anonymous], 2014, DIAB PREV CONTR COMB; Balk EM, 2015, ANN INTERN MED, V163, P437, DOI 10.7326/M15-0452; Bertram MY, 2010, DIABETOLOGIA, V53, P875, DOI 10.1007/s00125-010-1661-8; Board of Governors of the Federal Reserve System, 2015, FOR EXCH RAT; Boyle JP, 2010, POPUL HEALTH METR, V8, DOI 10.1186/1478-7954-8-29; Bureau of Labor Statistics, 2014, CONS PRIC IND ALL UR; Caro JJ, 2004, DIABETIC MED, V21, P1229, DOI 10.1111/j.1464-5491.2004.01330.x; Centers for Disease Control and Prevention, 2014, NAT DIAB STAT REP; Centers for Medicare and Medicaid Services, 2014, PHYS FEE SCHEDULE; Cohen JT, 2008, NEW ENGL J MED, V358, P661, DOI 10.1056/NEJMp0708558; Colagiuri S, 2008, HEALTH AFFAIR, V27, P256, DOI 10.1377/hlthaff.27.1.256; Diabet Prevention Program Res Grp, 2003, DIABETES CARE, V26, P2518, DOI 10.2337/diacare.26.9.2518; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; Eddy DM, 2005, ANN INTERN MED, V143, P251, DOI 10.7326/0003-4819-143-4-200508160-00006; Feldman Inna, 2013, Cost Eff Resour Alloc, V11, P19, DOI 10.1186/1478-7547-11-19; Gillies CL, 2008, BMJ-BRIT MED J, V336, P1180, DOI 10.1136/bmj.39545.585289.25; Grosse Scott D, 2008, Expert Rev Pharmacoecon Outcomes Res, V8, P165, DOI 10.1586/14737167.8.2.165; Herman WH, 2005, ANN INTERN MED, V142, P323, DOI 10.7326/0003-4819-142-5-200503010-00007; Herman WH, 2012, DIABETES CARE, V35, P723, DOI 10.2337/dc11-1468; Hoerger TJ, 2007, DIABETES CARE, V30, P2874, DOI 10.2337/dc07-0885; Irvine L, 2011, INT J TECHNOL ASSESS, V27, P275, DOI 10.1017/S0266462311000365; Jacobs-van der Bruggen MAM, 2007, DIABETES CARE, V30, P128, DOI 10.2337/dc06-0690; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kramer MK, 2011, DIABETES EDUCATOR, V37, P659, DOI 10.1177/0145721711411930; Kramer MK, 2009, AM J PREV MED, V37, P505, DOI 10.1016/j.amepre.2009.07.020; Krukowski RA, 2013, PREV MED, V57, P400, DOI 10.1016/j.ypmed.2013.06.027; Lawlor MS, 2013, AM J PREV MED, V44, pS381, DOI 10.1016/j.amepre.2012.12.016; Li R, 2010, DIABETES CARE, V33, P1872, DOI 10.2337/dc10-0843; Li YF, 2013, MMWR-MORBID MORTAL W, V62, P209; Lin J.S., 2014, AHRQ PUBLICATION; Lindgren P, 2007, INT J TECHNOL ASSESS, V23, P177, DOI 10.1017/S0266462307070286; Lindstrom J, 2003, DIABETES CARE, V26, P3230, DOI 10.2337/diacare.26.12.3230; Neumann Anne, 2011, Cost Eff Resour Alloc, V9, P17, DOI 10.1186/1478-7547-9-17; Ockene IS, 2012, AM J PUBLIC HEALTH, V102, P336, DOI 10.2105/AJPH.2011.300357; Palmer AJ, 2012, PRIM CARE DIABETES, V6, P109, DOI 10.1016/j.pcd.2011.10.006; Palmer AJ, 2004, CLIN THER, V26, P304, DOI 10.1016/S0149-2918(04)90029-X; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; Png ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107225; Radl K, 2013, EPIDEMOLOGY BIOSTATI, V10, P8; Ramachandran A, 2006, DIABETOLOGIA, V49, P289, DOI 10.1007/s00125-005-0097-z; Sagarra R, 2014, REV CLIN ESP, V214, P59, DOI 10.1016/j.rce.2013.10.005; Segal L, 1998, HEALTH PROMOT INT, V13, P197, DOI 10.1093/heapro/13.3.197; Smith KJ, 2010, PREV CHRONIC DIS, V7; The World Bank, 2021, GDP CAPITA CURRENT U; Vadheim LM, 2010, J RURAL HEALTH, V26, P266, DOI 10.1111/j.1748-0361.2010.00288.x; Vijgen SMC, 2006, PHARMACOECONOMICS, V24, P425, DOI 10.2165/00019053-200624050-00002; WHO, 2001, MACR HLTH INV HLTH E; Wylie-Rosett J, 2006, CURR OPIN LIPIDOL, V17, P37, DOI 10.1097/01.mol.0000203890.27267.eb; Zhuo XH, 2012, HEALTH AFFAIR, V31, P50, DOI 10.1377/hlthaff.2011.1115	54	85	87	2	42	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	2015	163	6					452	+		10.7326/M15-0469	http://dx.doi.org/10.7326/M15-0469			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CR5FL	26167962	Green Accepted			2023-01-03	WOS:000361365900019
J	Moutardier, G; Gereva, S; Mills, SC; Adjeroud, M; Beldade, R; Ham, J; Kaku, R; Dumas, P				Moutardier, Gregoire; Gereva, Sompert; Mills, Suzanne C.; Adjeroud, Mehdi; Beldade, Ricardo; Ham, Jayven; Kaku, Rocky; Dumas, Pascal			Lime Juice and Vinegar Injections as a Cheap and Natural Alternative to Control COTS Outbreaks	PLOS ONE			English	Article							OF-THORNS STARFISH; GREAT-BARRIER-REEF; LYSOSOMAL MEMBRANE DAMAGE; RED RETENTION ASSAY; ACANTHASTER-PLANCI; CORAL-REEFS; SEA STAR; MYTILUS-GALLOPROVINCIALIS; POPULATION OUTBREAKS; EXTRACELLULAR PH	Outbreaks of the corallivorous crown-of-thorns seastar Acanthaster planci (COTS) represent one of the greatest disturbances to coral reef ecosystems in the Indo-Pacific, affecting not only coral reefs but also the coastal communities which rely on their resources. While injection approaches are increasingly used in an attempt to control COTS densities, most of them display severe drawbacks including logistical challenges, high residual environmental impacts or low cost-effectiveness. We tested a new alternative control method based upon acidic injections of cheap, 100% natural products. We investigated the lethal doses, intra- and inter-specific disease transmission and immune responses of COTS when injected with fresh lime juice (extracted from local Citrus arantifolia) and white spirit vinegar. High COTS mortality was achieved with small volumes: 10-20 ml per seastar induced death in 89%/97% of injected specimens after an average 34.3 h/29.8 h for lime juice and vinegar respectively. Highest efficiency was reached for both solutions with double shots of (2 x 10 ml) in two different areas on the body: 100% mortality occurred within 12-24 h, which is similar or faster compared with other current injection methods. Multiple immune measures suggested that death was very likely caused by pH stress from the acidic solutions rather than a bacterial infection. Contagion to either conspecifics or a variety of other reef species was not observed, even at COTS densities 15 times higher than the highest naturally reported. 10 to 20 I lime juice/vinegar could kill up to a thousand COTS at a cost of less than 0.05 USD per specimen; no permits or special handling procedures are required. We conclude that injections of lime juice and vinegar offer great advantages when compared to current best practises and constitute a cheap and natural option for all reefs affected by COTS.	[Moutardier, Gregoire; Dumas, Pascal] IRD, UMR ENTROPIE 9220, Noumea, New Caledonia; [Moutardier, Gregoire; Gereva, Sompert; Ham, Jayven; Kaku, Rocky; Dumas, Pascal] Fisheries Dept Vanuatu, Port Vila, Vanuatu; [Mills, Suzanne C.; Adjeroud, Mehdi; Beldade, Ricardo; Dumas, Pascal] Lab Excellence Corail, F-66860 Perpignan, France; [Mills, Suzanne C.; Beldade, Ricardo] UPVD, CRIOBE, USR 3278, CNRS,EPHE, F-66860 Perpignan, France; [Beldade, Ricardo] Univ Lisbon, Fac Ciencias, MARE Marine & Environm Sci Ctr, P-1749016 Lisbon, Portugal; [Adjeroud, Mehdi] Univ Perpignan, IRD, UMR ENTROPIE 9220, F-66860 Perpignan, France	Institut de Recherche pour le Developpement (IRD); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Universidade de Lisboa; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Institut de Recherche pour le Developpement (IRD); Universite Perpignan Via Domitia	Dumas, P (corresponding author), IRD, UMR ENTROPIE 9220, BP A5, Noumea, New Caledonia.	pascal-paul.dumas@ird.fr	Beldade, Ricardo/B-3724-2012; Mills, Suzanne/K-5538-2012; Adjeroud, Mehdi/J-6411-2016	Beldade, Ricardo/0000-0003-1911-0122; Mills, Suzanne/0000-0001-8948-3384; Adjeroud, Mehdi/0000-0002-6825-8759; Dumas, Pascal/0000-0001-7369-8989	Fisheries Department of Vanuatu [COT012]; Government of New Caledonia; LabEx Corail; Agence Nationale de la Recherche [ANR-11-JSV7-012-01]; Fundacao para a Ciencia e Tecnologia [SFRH/BPD/26901/2006]	Fisheries Department of Vanuatu; Government of New Caledonia; LabEx Corail; Agence Nationale de la Recherche(French National Research Agency (ANR)); Fundacao para a Ciencia e Tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission)	This project was funded by grants from the Fisheries Department of Vanuatu (www.fisheries.gov.vu), grant #COT012. This was the main grant for this work, which covered fieldwork (Vanuatu) and functioning costs (hatchery and aquaculture facilities, technical staff, laboratory materials) of the study. Support was also provided by grants from the Government of New Caledonia (www.gouv.nc/portal/page/portal/gouv/), grant for project MANAO_2015, covered the hosting of Gregoire Moutardier at the Fisheries Department of Vanuatu during his MSc. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Support was also provided by grants from the LabEx Corail (www.labex-corail.fr/), grant for project DYNACANTH-2015, covered the field trip of Dr. Suzanne Mills in Vanuatu during the project. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Support was also provided by grants from the Agence Nationale de la Recherche (ANR-11-JSV7-012-01 "Live and Let Die", Suzanne C. Mills) and the Fundacao para a Ciencia e Tecnologia (SFRH/BPD/26901/2006, Ricardo Beldade) provided additional support. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adjeroud M, 2009, CORAL REEFS, V28, P775, DOI 10.1007/s00338-009-0515-7; Antonova OA, 2009, BIOCHEMISTRY-MOSCOW+, V74, P605, DOI 10.1134/S0006297909060030; BAINTON DF, 1973, J CELL BIOL, V58, P249, DOI 10.1083/jcb.58.2.249; BARHAM EG, 1973, FISH B-NOAA, V71, P927; Bekri K, 2004, AQUAT TOXICOL, V66, P39, DOI 10.1016/j.aquatox.2003.07.001; Bellwood DR, 2004, NATURE, V429, P827, DOI 10.1038/nature02691; BIRKELAND C, 1990, MAJOR MANAGEMENT PRO; Bos AR, 2013, OCEAN COAST MANAGE, V71, P116, DOI 10.1016/j.ocecoaman.2012.09.011; BRANHAM JM, 1971, SCIENCE, V172, P1155, DOI 10.1126/science.172.3988.1155; Brodie J, 2005, MAR POLLUT BULL, V51, P266, DOI 10.1016/j.marpolbul.2004.10.035; Bruno JF, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000711; CAMERON AM, 1991, MAR ECOL PROG SER, V75, P251, DOI 10.3354/meps075251; Celliers Louis, 2006, Western Indian Ocean Journal of Marine Science, V5, P105; CHENEY D P, 1973, Micronesica, V9, P171; Chesher RH., 1969, ACANTHASTER PLANCI I; Ciacci C, 2009, COMP BIOCHEM PHYS B, V153, P365, DOI 10.1016/j.cbpb.2009.04.007; Coteur G, 2002, FISH SHELLFISH IMMUN, V12, P187, DOI 10.1006/fsim.2001.0366; De Dios Homer Hermes Y., 2015, Galaxea - Tokyo, V17, P23; De'ath G, 2012, P NATL ACAD SCI USA, V109, P17995, DOI 10.1073/pnas.1208909109; Dumas P, 2015, SPC FISHERIES NEWSLE, V146, P47; Dumas P, 2014, COMMUNITY BASED MANA; Fabricius KE, 2010, CORAL REEFS, V29, P593, DOI 10.1007/s00338-010-0628-z; Fraser N, 2000, BEST PRACTICES GUIDE; Friedman KJ, 2008, VANUATU COUNTRY REPO; GLYNN PW, 1984, B MAR SCI, V35, P54; Glynn PW., 1981, INT COR REEF S MAN P; Great Barrier Reef Marine Park Authority, 2004, CROWN OF THORNS STAR; Greenberg SS, 1989, IMMUNITY SURVIVAL; Hauton C, 1998, COMP BIOCHEM PHYS B, V119, P619, DOI 10.1016/S0305-0491(98)00036-4; Hoey J, 2004, STATE GREAT BARRIER; Johansson AC, 2010, APOPTOSIS, V15, P527, DOI 10.1007/s10495-009-0452-5; JOHNSON DB, 1990, CORAL REEFS, V9, P167, DOI 10.1007/BF00258231; Kanayama RK, 1970, ALOHA AINA DEP LAND, V1, P16; Kayal M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047363; Kayal M, 2011, CORAL REEFS, V30, P827, DOI 10.1007/s00338-011-0763-1; KOBAYASHI TOSHIKAZU, 1963, JAPAN JOUR BACTERIOL, V18, P387; Koonjul MS, 2003, MAUR ANN M AGR SCI, P333; Kuroshio Biological Research Foundation, 2012, CROWN OF THORNS SEAS; Leray M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035456; LOWE DM, 1994, AQUAT TOXICOL, V30, P357, DOI 10.1016/0166-445X(94)00045-X; LOWE DM, 1992, MAR ECOL PROG SER, V91, P135, DOI 10.3354/meps091135; LOWE DM, 1995, AQUAT TOXICOL, V33, P105, DOI 10.1016/0166-445X(95)00015-V; Lowe DM, 1995, MAR ECOL PROG SER, V129, P189, DOI 10.3354/meps129189; MCCALL CE, 1969, J EXP MED, V129, P267, DOI 10.1084/jem.129.2.267; Mendonca VM, 2010, ZOOL STUD, V49, P108; Mills S, 2012, CORAL REEFS, V31, P603, DOI 10.1007/s00338-012-0883-2; Naviti W, 2000, REG S COR REEF PAC S; OHKUMA S, 1982, P NATL ACAD SCI-BIOL, V79, P2758, DOI 10.1073/pnas.79.9.2758; Ormond R.F.G., 1974, Proceedings int Coral Reef Symp, V2, P595; PEARSON RG, 1981, MAR ECOL PROG SER, V4, P105, DOI 10.3354/meps004105; Phillips RM, 2001, ANTICANCER RES, V21, P1795; Pratchett MS, 2014, OCEANOGR MAR BIOL, V52, P133; Pratchett MS, 1999, CORAL REEFS, V18, P272, DOI 10.1007/s003380050192; Rivera-Posada JA, 2011, DIS AQUAT ORGAN, V97, P85, DOI 10.3354/dao02401; Rivera-Posada J, 2013, MAR POLLUT BULL, V75, P133, DOI 10.1016/j.marpolbul.2013.07.053; Rivera-Posada J, 2012, J EXP MAR BIOL ECOL, V429, P1, DOI 10.1016/j.jembe.2012.06.008; ROMAN MR, 1993, LIMNOL OCEANOGR, V38, P1603, DOI 10.4319/lo.1993.38.8.1603; Sano M, 2000, MAR ECOL PROG SER, V198, P121, DOI 10.3354/meps198121; Schleyer M.H., 2003, Zoologische Verhandelingen (Leiden), V345, P387; Song L, 2007, J SHELLFISH RES, V26, P493, DOI 10.2983/0730-8000(2007)26[493:TAONRR]2.0.CO;2; SONG YL, 1994, DEV COMP IMMUNOL, V18, P201, DOI 10.1016/0145-305X(94)90012-4; Wang WN, 2009, COMP BIOCHEM PHYS C, V150, P428, DOI 10.1016/j.cbpc.2009.06.010; Wang WN, 2002, AQUAT TOXICOL, V60, P75, DOI 10.1016/S0166-445X(01)00271-5; Wilson SK, 2006, GLOBAL CHANGE BIOL, V12, P2220, DOI 10.1111/j.1365-2486.2006.01252.x; Yamamoto T., 2013, NATURALISTAE, V17, P63; Yanong RP, 2010, USE COPPER MARINE AQ; Zhou J, 2008, AQUACULTURE, V275, P356, DOI 10.1016/j.aquaculture.2007.12.005	67	12	13	2	55	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2015	10	9							e0137605	10.1371/journal.pone.0137605	http://dx.doi.org/10.1371/journal.pone.0137605			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ9WL	26356840	Green Published, Green Submitted, gold			2023-01-03	WOS:000360965800069
J	Maixenchs, M; Boene, H; Anselmo, R; Mindu, C; Alonso, P; Menendez, C; Macete, E; Pool, R; Letang, E; Naniche, D; Munguambe, K				Maixenchs, Maria; Boene, Helena; Anselmo, Rui; Mindu, Carolina; Alonso, Pedro; Menendez, Clara; Macete, Eusebio; Pool, Robert; Letang, Emilio; Naniche, Denise; Munguambe, Khatia			Post-ART Symptoms Were Not the Problem: A Qualitative Study on Adherence to ART in HIV-Infected Patients in a Mozambican Rural Hospital	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; ANTIRETROVIRAL THERAPY; SOUTH-AFRICA; BARRIERS; TANZANIA; METAANALYSIS; CHALLENGES; SERVICES; DISTRICT; DISEASE	Objective The objective of this qualitative study was to explore how clinical symptoms may affect adherence to antiretroviral therapy (ART) in HIV patients, and to explore factors, perceptions and attitudes related to adherence to therapy. Design A qualitative study was carried out in the context of the prospective cohort study "Evaluation of Immune Reconstitution Following Initiation of Highly Active Antiretroviral Treatment in Manhica, Mozambique". In-depth Interviews were conducted twice in a sub-sample of the study cohort (51 participants), at six-month intervals. Results Most participants (73%) knew that AIDS is a chronic disease and that ART does not cure it. Nine participants (18%) were non-adherent at some point and two (4%) abandoned ART. All participants but five reported having symptoms after starting ART, mainly attributed to pills needing time to act and body's reaction to the treatment. In spite of the perceived severity of the symptoms, only two people reported they discontinued the treatment due to symptoms. Almost all participants reported feeling comfortable with the HIV clinic organization and procedures, but afraid of staff being hostile if they did not follow the rules or if the health worker visited their home. Family was one of the most important source of support according participants. Almost all participants with children said that a decisive factor to follow the treatment was the desire to be able to look after them. Conclusions Experiencing symptoms after starting treatment was not a barrier to adherence to ART. Factors related to adherence included control measures set up by the health facility (exhaustive follow up, support, information) and family and community support. Indirect ART-related expenses did jeopardise adherence.	[Maixenchs, Maria; Boene, Helena; Anselmo, Rui; Mindu, Carolina; Macete, Eusebio; Munguambe, Khatia] CISM, Manhica, Mozambique; [Maixenchs, Maria; Alonso, Pedro; Menendez, Clara; Pool, Robert; Letang, Emilio; Naniche, Denise] Univ Barcelona, Hosp Clin, Barcelona Ctr Int Hlth Res CRESIB, ISGlobal, Barcelona, Spain; [Munguambe, Khatia] Eduardo Mondlane Univ, Fac Med, Maputo, Mozambique; [Pool, Robert] Univ Amsterdam, Ctr Social Sci & Global Hlth, Amsterdam, Netherlands; [Letang, Emilio] Swiss Trop & Publ Hlth Inst, Basel, Switzerland	Centro de Investigacao em Saude de Manhica; ISGlobal; CRESIB; University of Barcelona; Hospital Clinic de Barcelona; Eduardo Mondlane University; University of Amsterdam; University of Basel; Swiss Tropical & Public Health Institute	Maixenchs, M (corresponding author), CISM, Manhica, Mozambique.	maria.maixenchs@manhica.net	Alonso, Pedro L/AAZ-3645-2020; Naniche, Denise S/S-1814-2018; Menéndez, Clara/Q-3446-2016	Alonso, Pedro L/0000-0003-3292-3443; Naniche, Denise S/0000-0002-4495-6325; Menéndez, Clara/0000-0002-2641-6907; Maixenchs, Maria/0000-0002-5782-8197	Fundacio "la Caixa''; Agencia Catalana de Cooperacio al Desenvolupament (ACCD); Spanish Agency for International Cooperation and Development; Spanish Ministry of Education and Science (Ramon y Cajal)	Fundacio "la Caixa''(La Caixa FoundationEuropean Commission); Agencia Catalana de Cooperacio al Desenvolupament (ACCD); Spanish Agency for International Cooperation and Development(Spanish Government); Spanish Ministry of Education and Science (Ramon y Cajal)(Spanish Government)	Financial support was received from the Fundacio "la Caixa'' and the Agencia Catalana de Cooperacio al Desenvolupament (ACCD). The Centro de Investigacao em Saude de Manhica receives core funding from the Spanish Agency for International Cooperation and Development. DN was supported by a grant from the Spanish Ministry of Education and Science (Ramon y Cajal). Funders played no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Dakkak I, 2013, AIDS CARE, V25, P400, DOI 10.1080/09540121.2012.712667; [Anonymous], EP FACT SHEETS HIV A; [Anonymous], 2003, ADHERENCE LONG TERM; Audu B, 2014, AIDS CARE, V26, P270, DOI 10.1080/09540121.2013.819410; Baranoski AS, 2014, AIDS CARE, V26, P26, DOI 10.1080/09540121.2013.802282; Barfod TS, 2006, HIV MED, V7, P285, DOI 10.1111/j.1468-1293.2006.00387.x; Bezabhe WM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097353; French MA, 2004, AIDS, V18, P1615, DOI 10.1097/01.aids.0000131375.21070.06; Gonzalez R, 2012, HIV MED, V13, P581, DOI 10.1111/j.1468-1293.2012.01018.x; Gonzalez R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132053; Grant E, 2008, AIDS CARE, V20, P1155, DOI 10.1080/09540120701854634; Hardon A., 2006, ACCESS ADHERENCE CHA; Hardon AP, 2007, AIDS CARE, V19, P658, DOI 10.1080/09540120701244943; Instituto Nacional de Estadistica, 2007, TERC REC GER POP HAB; Letang E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016946; Letang E, 2010, JAIDS-J ACQ IMM DEF, V53, P589, DOI 10.1097/QAI.0b013e3181bc476f; Lyimo RA, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-716; Merten S, 2010, TROP MED INT HEALTH, V15, P16, DOI 10.1111/j.1365-3156.2010.02510.x; Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679; Murray LK, 2009, AIDS CARE, V21, P78, DOI 10.1080/09540120802032643; Nachega JB, 2012, PATIENT PREFER ADHER, V6, P887, DOI 10.2147/PPA.S38897; National AIDS Council-Republic of Mozambique, 2012, GLOB AIDS RESP PROGR; Ncama BP, 2008, INT J NURS STUD, V45, P1757, DOI 10.1016/j.ijnurstu.2008.06.006; Nhacolo AQ, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-291; Nyanzi-Wakholi B, 2012, AIDS CARE, V24, P137, DOI 10.1080/09540121.2011.596518; Olowookere SA, 2008, J INFECT DEV COUNTR, V2, P369; Orrell C, 2003, AIDS, V17, P1369, DOI 10.1097/00002030-200306130-00011; Ortego C, 2011, AIDS BEHAV, V15, P1381, DOI 10.1007/s10461-011-9942-x; Rasschaert F, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-364; Republica de Mozambique, 2008, ROND VIG EP HIV 2007; Roura M, 2009, AIDS PATIENT CARE ST, V23, P203, DOI 10.1089/apc.2008.0129; Sacoor C, 2013, INT J EPIDEMIOL, V42, P1309, DOI 10.1093/ije/dyt148; Tomori C, 2014, AIDS CARE, V26, P907, DOI 10.1080/09540121.2013.861574; *UNAIDS WHO, 2008, REP GLOB AIDS EP; UNAIDS-WHO, 2014, GAP REP; UNGASS, 2010, UN GEN ASS SPEC SESS; Vervoort SCJM, 2007, AIDS, V21, P271, DOI 10.1097/QAD.0b013e328011cb20; Ware NC, 2009, PLOS MED, V6, P39, DOI 10.1371/journal.pmed.1000011; Watt MH, 2009, SOC SCI MED, V68, P1793, DOI 10.1016/j.socscimed.2009.02.037; Zaidi J, 2012, AIDS, V29, P997	40	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2015	10	9							e0137336	10.1371/journal.pone.0137336	http://dx.doi.org/10.1371/journal.pone.0137336			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CQ4ZT	26332680	Green Published, gold, Green Submitted			2023-01-03	WOS:000360613800123
J	Hung, YC; Tseng, YJ; Hu, WL; Chen, HJ; Li, TC; Tsai, PY; Chen, HP; Huang, MH; Su, FY				Hung, Yu-Chiang; Tseng, Ying-Jung; Hu, Wen-Long; Chen, Hsuan-Ju; Li, Tsai-Chung; Tsai, Pei-Yuan; Chen, Hsin-Ping; Huang, Meng-Hsuan; Su, Fang-Yen			Demographic and Prescribing Patterns of Chinese Herbal Products for Individualized Therapy for Ischemic Heart Disease in Taiwan: Population-Based Study	PLOS ONE			English	Article							GEGEN DECOCTION PROTECTS; SMOOTH-MUSCLE-CELLS; SALVIA-MILTIORRHIZA; CARDIOVASCULAR-DISEASE; PUERARIA-LOBATA; DANSHEN; MEDICINE; FORMULA; RADIX; PHARMACOLOGY	Objective Combinations of Chinese herbal products (CHPs) are widely used for ischemic heart disease (IHD) in Taiwan. We analyzed the usage and frequency of CHPs prescribed for patients with IHD. Methods A nationwide population-based cross-sectional study was conducted, 53531 patients from a random sample of one million in the National Health Insurance Research Database (NHIRD) from 2000 to 2010 were enrolled. Descriptive statistics, the multiple logistic regression method and Poisson regression analysis were employed to estimate the adjusted odds ratios (aORs) and adjusted risk ratios (aRRs) for utilization of CHPs. Results The mean age of traditional Chinese medicine (TCM) nonusers was significantly higher than that of TCM users. Zhi-Gan-Cao-Tang (24.85%) was the most commonly prescribed formula CHPs, followed by Xue-Fu-Zhu-Yu-Tang (16.53%) and Sheng-Mai-San (16.00%). The most commonly prescribed single CHPs were Dan Shen (29.30%), Yu Jin (7.44%), and Ge Gen (6.03%). After multivariate adjustment, patients with IHD younger than 29 years had 2.62 times higher odds to use TCM than those 60 years or older. Residents living in Central Taiwan, having hyperlipidemia or cardiac dysrhythmias also have higher odds to use TCM. On the contrary, those who were males, who had diabetes mellitus (DM), hypertension, stroke, myocardial infarction (MI) were less likely to use TCM. Conclusions Zhi-Gan-Cao-Tang and Dan Shen are the most commonly prescribed CHPs for IHD in Taiwan. Our results should be taken into account by physicians when devising individualized therapy for IHD. Further large-scale, randomized clinical trials are warranted in order to determine the effectiveness and safety of these herbal medicines.	[Hung, Yu-Chiang; Tseng, Ying-Jung; Hu, Wen-Long; Tsai, Pei-Yuan; Chen, Hsin-Ping; Huang, Meng-Hsuan; Su, Fang-Yen] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Dept Chinese Med, Kaohsiung 833, Taiwan; [Hung, Yu-Chiang; Tseng, Ying-Jung; Hu, Wen-Long; Tsai, Pei-Yuan; Chen, Hsin-Ping; Huang, Meng-Hsuan; Su, Fang-Yen] Chang Gung Univ, Coll Med, Sch Tradit Chinese Med, Kaohsiung 833, Taiwan; [Hung, Yu-Chiang] I Shou Univ, Sch Chinese Med Post Baccalaureate, Kaohsiung 84001, Taiwan; [Hu, Wen-Long] Fooyin Univ, Coll Nursing, Kaohsiung 831, Taiwan; [Hu, Wen-Long] Kaohsiung Med Univ, Coll Med, Kaohsiung 807, Taiwan; [Chen, Hsuan-Ju] China Med Univ Hosp, Management Off Hlth Data, Taichung 40447, Taiwan; [Chen, Hsuan-Ju] China Med Univ, Coll Med, Taichung 40402, Taiwan; [Li, Tsai-Chung] China Med Univ, Coll Publ Hlth, Grad Inst Biostat, Taichung 40402, Taiwan; [Li, Tsai-Chung] Asia Univ, Coll Hlth Sci, Dept Healthcare Adm, Taichung 41354, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; I Shou University; Fooyin University; Kaohsiung Medical University; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan; Asia University Taiwan	Hung, YC (corresponding author), Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Dept Chinese Med, 123 Dapi Rd, Kaohsiung 833, Taiwan.	e120845@cgmh.org.tw; tcli@mail.cmu.edu.tw	Li, Tsai-Chung/P-2052-2015; Hung, yu-chiang/ABE-7636-2020; Hu, Wen-Long/N-1660-2014	Li, Tsai-Chung/0000-0002-3346-7462; Hu, Wen-Long/0000-0001-9549-6202	Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence [MOHW104-TDU-B-212-113002]; Academia Sinica Taiwan Biobank, Stroke Biosignature Project [BM104010092]; NRPB Stroke Clinical Trial Consortium [MOST 103-2325-B-039-006]; Tseng-Lien Lin Foundation, Taichung, Taiwan; Taiwan Brain Disease Foundation, Taipei, Taiwan; Katsuzo and Kiyo Aoshima Memorial Funds, Japan; Ministry of Science and Technology of Taiwan (National Science Council) [NSC101-2632-B-039-001-MY3]; China Medical University Hospital	Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence; Academia Sinica Taiwan Biobank, Stroke Biosignature Project; NRPB Stroke Clinical Trial Consortium; Tseng-Lien Lin Foundation, Taichung, Taiwan; Taiwan Brain Disease Foundation, Taipei, Taiwan; Katsuzo and Kiyo Aoshima Memorial Funds, Japan; Ministry of Science and Technology of Taiwan (National Science Council); China Medical University Hospital	The use of National Health Insurance Research Database (NHIRD) was supported by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW104-TDU-B-212-113002), China Medical University Hospital, Academia Sinica Taiwan Biobank, Stroke Biosignature Project (BM104010092), NRPB Stroke Clinical Trial Consortium (MOST 103-2325-B-039-006), Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, Katsuzo and Kiyo Aoshima Memorial Funds, Japan, and the Ministry of Science and Technology of Taiwan (National Science Council) (NSC101-2632-B-039-001-MY3). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2008, TAIWAN J CLIN CHINES, V14, P308; Cai RL, 2011, J ETHNOPHARMACOL, V133, P177, DOI 10.1016/j.jep.2010.09.013; Chang LC, 2008, J CLIN PHARM THER, V33, P243, DOI 10.1111/j.1365-2710.2008.00911.x; Chen HY, 2011, J ETHNOPHARMACOL, V137, P1261, DOI 10.1016/j.jep.2011.07.053; Chiu PY, 2012, PHYTOMEDICINE, V19, P99, DOI 10.1016/j.phymed.2011.07.002; Chiu PY, 2011, PHYTOMEDICINE, V18, P916, DOI 10.1016/j.phymed.2011.03.006; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Hu F, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-249; Hu F, 2012, PHYTOMEDICINE, V19, P1051, DOI 10.1016/j.phymed.2012.07.007; Hu SS, 2012, BIOMED ENVIRON SCI, V25, P251, DOI 10.3967/0895-3988.2012.03.001; Hung YC, 2010, BBA-PROTEINS PROTEOM, V1804, P1310, DOI 10.1016/j.bbapap.2010.02.001; Hung YC, 2009, J ETHNOPHARMACOL, V124, P463, DOI 10.1016/j.jep.2009.05.020; Kankeu HT, 2013, HEALTH RES POLICY SY, V11, DOI 10.1186/1478-4505-11-31; Koon CM, 2011, J ETHNOPHARMACOL, V138, P175, DOI 10.1016/j.jep.2011.08.073; Kuukasjarvi P, 2006, INT J TECHNOL ASSESS, V22, P219, DOI 10.1017/S026646230605104X; Liao Yueh-Hsiang, 2013, Evid Based Complement Alternat Med, V2013, P984876, DOI 10.1155/2013/984876; Liao YH, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-146; Liu HX, 2011, J TRADIT CHIN MED, V31, P269, DOI 10.1016/S0254-6272(12)60002-8; Liu L, 2004, CHEM PHARM BULL, V52, P1295, DOI 10.1248/cpb.52.1295; Ministry of Health and Welfare (MOHW), 2014, 2013 STAT CAUS DEATH; MOHW, 2014, 2012 STAT CAUS DEATH; Ng CF, 2011, J ETHNOPHARMACOL, V137, P1366, DOI 10.1016/j.jep.2011.08.006; Pratt C, 2010, PRIMARY CARE, V37, P325, DOI 10.1016/j.pop.2010.02.009; Tam WY, 2009, J ALTERN COMPLEM MED, V15, P415, DOI 10.1089/acm.2008.0400; Tao WY, 2013, J ETHNOPHARMACOL, V145, P1, DOI 10.1016/j.jep.2012.09.051; Wan AKS, 2008, J NAT PROD, V71, P1825, DOI 10.1021/np800119k; Wang NY, 2001, AM J CHINESE MED, V29, P367, DOI 10.1142/S0192415X01000381; Wang XY, 2011, J ETHNOPHARMACOL, V135, P662, DOI 10.1016/j.jep.2011.03.070; Wang YQ, 2013, PHARM BIOL, V51, P1219, DOI 10.3109/13880209.2013.784920; World Health Organization (WHO), 2014, CARD DIS CVDS; Wu L, 2010, J PHARMACEUT BIOMED, V52, P438, DOI 10.1016/j.jpba.2010.01.021; Yao K, 2012, WORLD J INTEGRATED T, V2012, P1029; Zhang YA, 2010, FOOD CHEM TOXICOL, V48, P2656, DOI 10.1016/j.fct.2010.06.036; Zhou LM, 2005, J CLIN PHARMACOL, V45, P1345, DOI 10.1177/0091270005282630	34	30	32	2	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2015	10	8							e0137058	10.1371/journal.pone.0137058	http://dx.doi.org/10.1371/journal.pone.0137058			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ2MT	26322893	Green Published, gold, Green Submitted			2023-01-03	WOS:000360435500062
J	Stecklov, G; Weinreb, AA; Sana, M				Stecklov, Guy; Weinreb, Alexander A.; Sana, Mariano			Family Planning for Strangers: An Experiment on the Validity of Reported Contraceptive Use	PLOS ONE			English	Article							SEXUAL-BEHAVIOR; SENSITIVE BEHAVIOR; EXPENDITURE DATA; ADOLESCENTS; QUALITY; INTERVIEWERS; FERTILITY; SOCIOLOGY; KNOWLEDGE; COUNTRIES	Sterilization levels reported in the Dominican Republic appear well above what we would normally expect given prevailing patterns in the region. We suspect that the use of strangers as interviewers-the normative approach in data collection in both developed and developing country settings-may be partly responsible for this result, and may underlie a long history of bias in family planning data. We present findings from a field experiment conducted in a Dominican town in 2010, where interviewer assignment was randomized by level of preexisting level of familiarity between interviewer and respondent. In our data, sterilization use is higher when the interviewer is an outsider, as opposed to someone known to the respondent or from the same community. In addition, high sterilization use is correlated with a propensity of respondents to present themselves in a positive light to interviewers. These results call into question the routine use of strangers and outsiders as interviewers in demographic and health surveys.	[Stecklov, Guy] Hebrew Univ Jerusalem, Dept Sociol & Anthropol, Jerusalem, Israel; [Weinreb, Alexander A.] Univ Texas Austin, Dept Sociol, Austin, TX 78712 USA; [Weinreb, Alexander A.] Univ Texas Austin, Populat Res Ctr, Austin, TX 78712 USA; [Sana, Mariano] Vanderbilt Univ, Dept Sociol, Nashville, TN 37235 USA	Hebrew University of Jerusalem; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Vanderbilt University	Stecklov, G (corresponding author), Hebrew Univ Jerusalem, Dept Sociol & Anthropol, Jerusalem, Israel.	Stecklov@huji.ac.il	Weinreb, Alex/L-3187-2018		NIH [1R21HD054731-01A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R24HD042849] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R21HD054731] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by NIH Grant 1R21HD054731-01A1.	Agar M., 1980, PROFESSIONAL STRANGE; Ali MM, 2005, SOC SCI MED, V60, P1175, DOI 10.1016/j.socscimed.2004.07.002; AXINN WG, 1991, SOCIOL METHOD RES, V20, P187, DOI 10.1177/0049124191020002001; Becker S, 2001, STUD FAMILY PLANN, V32, P111, DOI 10.1111/j.1728-4465.2001.00111.x; BECKER S, 1995, STUD FAMILY PLANN, V26, P233, DOI 10.2307/2137848; Biemer PP, 1991, MEASUREMENT ERROR SU; Blanc AK, 1998, STUD FAMILY PLANN, V29, P106, DOI 10.2307/172153; Blanc AK, 2002, STUD FAMILY PLANN, V33, P127, DOI 10.1111/j.1728-4465.2002.00127.x; Bollen K. A., 1989, STRUCTURAL EQUATIONS, DOI 10.1002/9781118619179; Bollen KA, 2002, POP STUD-J DEMOG, V56, P81, DOI 10.1080/00324720213796; Brea JA, 2003, POPULATION DYNAMICS; Cameron AC, 2008, REV ECON STAT, V90, P414, DOI 10.1162/rest.90.3.414; Chen K-H, 1976, CULTURE NATALITY FAM, P241; CLELAND J, 1973, STUD FAMILY PLANN, V4, P42, DOI 10.2307/1964829; Cleland J, 2006, LANCET, V368, P1810, DOI 10.1016/S0140-6736(06)69480-4; Cleland J, 2013, LANCET, V381, P1604, DOI 10.1016/S0140-6736(13)60588-7; CRESSEY PG, 1983, URBAN LIFE, V12, P102, DOI 10.1177/0098303983012001007; EVERHART RB, 1977, AM EDUC RES J, V14, P1; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292; Frye M, 2012, AM J SOCIOL, V117, P1565, DOI 10.1086/664542; Giddens A., 1990, CONSEQUENCES MODERNI; Gill GJ.O.K, 1993, MED ANTHR Q; GREEN EC, 1988, STUD FAMILY PLANN, V19, P109, DOI 10.2307/1966495; Greene WH, 2003, ECONOMETRIC ANAL; Hox JJ, 1991, MEASUREMENT ERROR SU; Jansen SC, 1980, QUALITATIVE SOCIOLOG, V2, P22; Johnson-Hanks J, 2005, CURR ANTHROPOL, V46, P363, DOI 10.1086/428799; Launiala A, 2009, ANTHR MATTERS; Levy MJ, 1972, MODERNIZATION LATECO; Lind Amy, 2010, DEV SEXUAL RIGHTS GL; LOAIZA E, 1995, STUD FAMILY PLANN, V26, P39, DOI 10.2307/2138050; Luke N, 2011, DEMOGRAPHY, P1; Marcus G, 1992, REREADING CULTURAL A; MASSEY DS, 1987, INT MIGR REV, V21, P1498, DOI 10.2307/2546522; Mayoni JR, 1983, ANTHROPOLOGICA, V25, P221; Meijer E, 2000, ECON LETT, V69, P277, DOI 10.1016/S0165-1765(00)00328-1; Mensch BS, 2008, INT FAM PLAN PERSPEC, V34, P169, DOI 10.1363/ifpp.34.169.08; Mensch BS, 2003, DEMOGRAPHY, V40, P247, DOI 10.1353/dem.2003.0017; NASH D, 1963, SOUTHWEST J ANTHROP, V19, P149, DOI 10.1086/soutjanth.19.2.3629165; O'Barr WM, 1973, SURVEY RES AFRICA; O'Muircheartaigh C, 1998, J ROY STAT SOC A STA, V161, P63, DOI 10.1111/1467-985X.00090; Paulhus DL, 2003, J PERS SOC PSYCHOL, V84, P890, DOI 10.1037/0022-3514.84.4.890; Plummer ML, 2004, SEX TRANSM INFECT, V80, P49, DOI 10.1136/sti.2004.011924; Plummer ML, 2004, TROP MED INT HEALTH, V9, P737, DOI 10.1111/j.1365-3156.2004.01254.x; Potter JE, 8675020 AG INT DEV; Poulin M, 2010, DEMOGR RES, V22, P237, DOI 10.4054/DemRes.2010.22.11; Powdermaker Hortense, 1966, STRANGER FRIEND WAY; Rodriguez LA, 2015, FIELD METHOD, V27, P163, DOI 10.1177/1525822X14549315; Rogers EM, 1999, COMMUN THEOR, V9, P58, DOI 10.1111/j.1468-2885.1999.tb00162.x; Sana M, POPULATION IN PRESS; Sana M, 2008, SOCIOL METHOD RES, V36, P515, DOI 10.1177/0049124107313857; Silverman, 2004, QUALITATIVE RES THEO, P141; Simmel G., 1950, SOCIOLOGY G SIMMEL; Simmel G, 1906, AM J SOCIOL, V11, P441, DOI 10.1086/211418; STONE L, 1984, HUM ORGAN, V43, P27, DOI 10.17730/humo.43.1.6wl5k01724878166; SUDMAN S, 1974, J MARKETING RES, V11, P128, DOI 10.2307/3150549; Sullivan TM, 2006, J BIOSOC SCI, V38, P501, DOI 10.1017/S0021932005026647; Tourangeau Roger, 2000, PSYCHOL SURVEY RESPO; Vaessen M, 2005, HOUSEHOLD SAMPLE SUR; Weinreb AA, 2011, RESULTS METHODOLOGIC; Weinreb AA, 2006, AM SOCIOL REV, V71, P1014, DOI 10.1177/000312240607100607; Westoff C. F., 1988, International Family Planning Perspectives, V14, P45, DOI 10.2307/2947679; Yoder PS, 1997, MED ANTHROPOL Q, V11, P131, DOI 10.1525/maq.1997.11.2.131; Zimmerman L, 2015, AFRICAN POPULATION S, V29, P1699, DOI 10.11564/29-1-719	64	9	9	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2015	10	8							e0136972	10.1371/journal.pone.0136972	http://dx.doi.org/10.1371/journal.pone.0136972			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CQ2MT	26322898	Green Submitted, gold, Green Published			2023-01-03	WOS:000360435500056
J	Tsai, CF; Lee, YT; Lee, WJ; Hwang, JP; Wang, SJ; Fuh, JL				Tsai, Chia-Fen; Lee, Yao-Tung; Lee, Wei-Ju; Hwang, Jen-Ping; Wang, Shuu-Jiun; Fuh, Jong-Ling			Depression of Family Caregivers Is Associated with Disagreements on Life-Sustaining Preferences for Treating Patients with Dementia	PLOS ONE			English	Article							DECISION-MAKING; CARE; CONCORDANCE; AGREEMENT; ATTITUDES; VERSION; BURDEN; STATE	Background Family caregivers may not agree with patients with dementia regarding attitudes toward end-of-life preferences, and the effects of this type of disagreement are not well understood. This study sought to identify such a disagreement and its predictors. Methods A cross-sectional sample of 84 family caregivers and patients with dementia was recruited from memory clinics. We used the Mini-Mental State Examination, Neuropsychiatric Inventory, Clinical Dementia Rating, and Katz index of independence in activities of daily living to assess patient symptoms, functions, and severity of dementia. Caregivers completed questionnaires on perceived patient end-of-life care preferences, caregiver end-of-life care preferences for patients, Zarit Burden Interview (ZBI), Center for Epidemiological Studies-Depression Scale (CES-D), and knowledge of clinical complications of advanced dementia. Results The self-disclosure rates of patient preferences were 34.5% for tube feeding, 39.3% for cardiopulmonary resuscitation, and 45.2% for mechanical ventilation. For patients who had disclosed preferences, the disagreement rate between them and their caregivers was 48.3% for tube feeding, 48.5% for cardiopulmonary resuscitation, and 60.3% for mechanical ventilation. Caregiver depression (i.e., CES-D >= 16) was associated with disagreements on cardiopulmonary resuscitation (adjusted odds ratio (aOR) = 6.6, 95% CI = 1.4-31.1, P = 0.01) and mechanical ventilation (aOR = 14, 95% CI = 2.2-87.2, P = 0.005) preferences. Conclusion The preferences of end-of-life issues differed greatly between dementia patients and their caregivers. Depression in caregivers is associated with such discrepancy.	[Tsai, Chia-Fen; Hwang, Jen-Ping] Vet Gen Hosp, Neurol Inst, Dept Psychiat, Taipei, Taiwan; [Wang, Shuu-Jiun; Fuh, Jong-Ling] Taipei Vet Gen Hosp, Neurol Inst, Dept Neurol, Taipei, Taiwan; [Tsai, Chia-Fen] Natl Yang Ming Univ, Sch Med, Inst Brain Sci, Taipei 112, Taiwan; [Lee, Wei-Ju] Natl Yang Ming Univ, Sch Med, Inst Clin Med, Taipei 112, Taiwan; [Tsai, Chia-Fen; Lee, Wei-Ju; Hwang, Jen-Ping; Wang, Shuu-Jiun; Fuh, Jong-Ling] Natl Yang Ming Univ, Sch Med, Fac Med, Taipei 112, Taiwan; [Lee, Wei-Ju] Taichung Vet Gen Hosp, Dept Neurol, Taichung, Taiwan; [Lee, Yao-Tung] Taipei Med Univ, Shuang Ho Hosp, Dept Psychiat, Taipei, Taiwan	Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taichung Veterans General Hospital; Taipei Medical University; Shuang Ho Hospital	Fuh, JL (corresponding author), 201 Sec 2,Shipai Rd, Taipei 112, Taiwan.	jlfuh@vghtpe.gov.tw		Lee, Wei-Ju/0000-0002-3720-4539	Ministry of Science and Technology of Taiwan [NSC 101-2314-B-075-037-MY2, 101-2314-B-075A-013, 102-2321-B-010-030]; Taipei Veterans General Hospital [V103E9-006, V103E3-005, V103C-083]; Ministry of Science and Technology support for the Centre for Dynamical Biomarkers and Translational Medicine, National Central University, Taiwan [NSC 102-2911-I-008-001]; Brain Research Center, National Yang-Ming University; Ministry of Education, Aim for the Top University Plan	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); Taipei Veterans General Hospital(Taipei Veterans General Hospital); Ministry of Science and Technology support for the Centre for Dynamical Biomarkers and Translational Medicine, National Central University, Taiwan; Brain Research Center, National Yang-Ming University; Ministry of Education, Aim for the Top University Plan(Ministry of Education, Taiwan)	This study was supported by the Ministry of Science and Technology of Taiwan (NSC 101-2314-B-075-037-MY2, 101-2314-B-075A-013, 102-2321-B-010-030), Taipei Veterans General Hospital (V103E9-006, V103E3-005, V103C-083), Ministry of Science and Technology support for the Centre for Dynamical Biomarkers and Translational Medicine, National Central University, Taiwan (NSC 102-2911-I-008-001), Brain Research Center, National Yang-Ming University and a grant from Ministry of Education, Aim for the Top University Plan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Psychiatric Association, 1994, DIAGNOSTIC STAT MANU; Ayalon L, 2012, INT PSYCHOGERIATR, V24, P1798, DOI 10.1017/S1041610212000877; Bambauer Kara Zivin, 2007, Am J Hosp Palliat Care, V24, P185; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Borum ML, 2000, J AM GERIATR SOC, V48, pS194, DOI 10.1111/j.1532-5415.2000.tb03132.x; Di Giulio P, 2008, J PALLIAT MED, V11, P1023, DOI 10.1089/jpm.2008.0020; Fagerlin A, 2001, HEALTH PSYCHOL, V20, P166, DOI 10.1037/0278-6133.20.3.166; FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P543, DOI 10.1016/0895-4356(90)90158-L; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fuh JL, 2001, INT PSYCHOGERIATR, V13, P121, DOI 10.1017/S1041610201007517; Jennings B, 2003, HASTINGS CENT REP, V33, pS24; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; Kim SYH, 2002, AM J GERIAT PSYCHIAT, V10, P151, DOI 10.1176/appi.ajgp.10.2.151; Ko KT, 2008, AM J GERIAT PSYCHIAT, V16, P513, DOI 10.1097/JGP.0b013e318167ae5b; Kwok T, 2007, J ADV NURS, V58, P256, DOI 10.1111/j.1365-2648.2007.04230.x; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Luchins DJ, 1997, J AM GERIATR SOC, V45, P1054, DOI 10.1111/j.1532-5415.1997.tb05966.x; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Meuser TM, 2001, GERONTOLOGIST, V41, P658, DOI 10.1093/geront/41.5.658; Mitchell SL, 2007, J AM GERIATR SOC, V55, P432, DOI 10.1111/j.1532-5415.2007.01086.x; Mitchell Susan L, 2009, N Engl J Med, V361, P1529, DOI 10.1056/NEJMoa0902234; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Neale R, 2001, INT J EPIDEMIOL, V30, P1383, DOI 10.1093/ije/30.6.1383; Pinquart M, 2003, J GERONTOL B-PSYCHOL, V58, pP112, DOI 10.1093/geronb/58.2.P112; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Reamy AM, 2013, GERONTOLOGIST, V53, P293, DOI 10.1093/geront/gns078; Rurup ML, 2006, PATIENT EDUC COUNS, V61, P372, DOI 10.1016/j.pec.2005.04.016; Shalowitz DI, 2006, ARCH INTERN MED, V166, P493, DOI 10.1001/archinte.166.5.493; Siminoff LA, 2006, PSYCHO-ONCOLOGY, V15, P528, DOI 10.1002/pon.989; Speice J, 2000, PSYCHO-ONCOL, V9, P101, DOI 10.1002/(SICI)1099-1611(200003/04)9:2<101::AID-PON435>3.0.CO;2-D; Swails P., 2009, DEMENTIA, V8, P117; Tang ST, 2005, J PAIN SYMPTOM MANAG, V30, P510, DOI 10.1016/j.jpainsymman.2005.05.019; Winter L, 2007, SOC SCI MED, V65, P1695, DOI 10.1016/j.socscimed.2007.06.012; Wu YT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066252	34	16	16	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2015	10	7							e0133711	10.1371/journal.pone.0133711	http://dx.doi.org/10.1371/journal.pone.0133711			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CO0JY	26230958	Green Submitted, Green Published, gold			2023-01-03	WOS:000358838400052
J	de Sonneville-Koedoot, C; Stolk, E; Rietveld, T; Franken, MC				de Sonneville-Koedoot, Caroline; Stolk, Elly; Rietveld, Toni; Franken, Marie-Christine			Direct versus Indirect Treatment for Preschool Children who Stutter: The RESTART Randomized Trial	PLOS ONE			English	Article							LIDCOMBE PROGRAM; SPEECH; ADOLESCENTS; ETIOLOGY; ADULTS; MODEL; TWIN; AGE	Objective Stuttering is a common childhood disorder. There is limited high quality evidence regarding options for best treatment. The aim of the study was to compare the effectiveness of direct treatment with indirect treatment in preschool children who stutter. Methods In this multicenter randomized controlled trial with an 18 month follow-up, preschool children who stutter who were referred for treatment were randomized to direct treatment (Lidcombe Program; n = 99) or indirect treatment (RESTART-DCM treatment; n = 100). Main inclusion criteria were age 3-6 years, >= 3% syllables stuttered (%SS), and time since onset >= 6 months. The primary outcome was the percentage of non-stuttering children at 18 months. Secondary outcomes included stuttering frequency (%SS), stuttering severity ratings by the parents and therapist, severity rating by the child, health-related quality of life, emotional and behavioral problems, and speech attitude. Results Percentage of non-stuttering children for direct treatment was 76.5% (65/85) versus 71.4% (65/91) for indirect treatment (Odds Ratio (OR), 0.6; 95% CI, 0.1-2.4, p = .42). At 3 months, children treated by direct treatment showed a greater decline in % SS (significant interaction time x therapy: beta = -1.89; t(282.82) = -2.807, p = .005). At 18 months, stuttering frequency was 1.2% (SD 2.1) for direct treatment and 1.5% (SD 2.1) for indirect treatment. Direct treatment had slightly better scores on most other secondary outcome measures, but no differences between treatment approaches were significant. Conclusions Direct treatment decreased stuttering more quickly during the first three months of treatment. At 18 months, however, clinical outcomes for direct and indirect treatment were comparable. These results imply that at 18 months post treatment onset, both treatments are roughly equal in treating developmental stuttering in ways that surpass expectations of natural recovery. Follow-up data are needed to confirm these findings in the longer term.	[de Sonneville-Koedoot, Caroline; Stolk, Elly] Erasmus Univ, Inst Hlth Policy & Management, Rotterdam, Netherlands; [de Sonneville-Koedoot, Caroline; Franken, Marie-Christine] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Speech & Hearing Ctr,Dept Otorhinolaryngol, Rotterdam, Netherlands; [Rietveld, Toni] Radboud Univ Nijmegen, Dept Linguist, NL-6525 ED Nijmegen, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Radboud University Nijmegen	de Sonneville-Koedoot, C (corresponding author), Erasmus Univ, Inst Hlth Policy & Management, Rotterdam, Netherlands.	desonneville@bmg.eur.nl			Netherlands Organization for Health Research and Development (ZonMw) NWO-Health Care Efficiency Research Program [945-07-417]	Netherlands Organization for Health Research and Development (ZonMw) NWO-Health Care Efficiency Research Program	The RESTART-study was funded by The Netherlands Organization for Health Research and Development (ZonMw; http://www.zonmw.nl/en/) NWO-Health Care Efficiency Research Program (Grant number 945-07-417). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achenbach T, 2000, ACHENBACH SYSTEM EMP; Altman DG, 1991, PRACTICAL STAT MED R, P396; Bernstein Ratner N., 2006, CURRENT ISSUES STUTT; BOBERG E, 1994, J SPEECH HEAR RES, V37, P1050, DOI 10.1044/jshr.3705.1050; Chang SE, 2013, BRAIN; Chang SE, 2008, NEUROIMAGE, V39, P1333, DOI 10.1016/j.neuroimage.2007.09.067; Clark CE, 2013, J FLUENCY DISORD, V38, P325, DOI 10.1016/j.jfludis.2013.09.004; Conture EG, 1996, J SPEECH HEAR RES, V39, pS18, DOI 10.1044/jshr.3905.s18; Craig A, 2009, J FLUENCY DISORD, V34, P61, DOI 10.1016/j.jfludis.2009.05.002; Cykowski MD, 2010, NEUROIMAGE, V52, P1495, DOI 10.1016/j.neuroimage.2010.05.011; Donaghy M, 2015, INT J SPEECH-LANG PA, P1; EuroQol Group, 2009, EQ 5D US GUID BAS IN; Evans S, MINIM ALLOCATION MIN; Felsenfeld S, 2000, BEHAV GENET, V30, P359, DOI 10.1023/A:1002765620208; Franken MC, 2014, RESTART DCM METHOD T; Gore K., 2015, AUSTR BUDGET LIDCOMB; Guitar B, 2013, PUBLICATION STUTTERI, V0023; Hayes AF, 2013, SPSS MACRO CALCULATI; Hayes AF, 2007, COMMUN METHODS MEAS, V1, P77, DOI 10.1080/19312450709336664; Hayhow R, 2011, INT J LANG COMM DIS, V46, P155, DOI 10.3109/13682822.2010.490572; HOLM S, 1979, SCAND J STAT, V6, P65; Imel Z.E., 2008, HDB COUNSELING PSYCH, P249; Ingham JC, 1998, J SPEECH LANG HEAR R, V41, P753, DOI 10.1044/jslhr.4104.753; Ingham RJ, 1998, AM J SPEECH-LANG PAT, V7, P10, DOI 10.1044/1058-0360.0703.10; Jones M, 2005, BMJ-BRIT MED J, V331, P659, DOI 10.1136/bmj.38520.451840.E0; Jones M, 2008, INT J LANG COMM DIS, V43, P649, DOI 10.1080/13682820801895599; Kang C, 2010, NEW ENGL J MED, V362, P677, DOI 10.1056/NEJMoa0902630; Koedoot C, 2011, J COMMUN DISORD 0327; LUBORSKY L, 1975, ARCH GEN PSYCHIAT, V32, P995; Mansson H, 2000, J FLUENCY DISORD, V25, P47, DOI 10.1016/S0094-730X(99)00023-6; Menzies RG, 2009, J FLUENCY DISORD, V34, P187, DOI 10.1016/j.jfludis.2009.09.002; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; Nye C, 2013, J SPEECH LANG HEAR R, V56, P921, DOI 10.1044/1092-4388(2012/12-0036); O'Brian S, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d3742; O'Callaghan CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110761; Onslow M, 2001, BEHAV MODIF, V25, P116, DOI 10.1177/0145445501251007; Onslow M, 2003, LIDCOMBE PROGRAM EAR; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Ratner NB, 2005, J FLUENCY DISORD, V30, P163, DOI 10.1016/j.jfludis.2005.04.002; Rautakoski P, 2012, J FLUENCY DISORD, V37, P202, DOI 10.1016/j.jfludis.2011.12.003; Reilly S, 2013, PEDIATRICS, V132, P460, DOI 10.1542/peds.2012-3067; Riley G., 1994, STUTTERING SEVERITY; Robey RR, 2004, J COMMUN DISORD, V37, P401, DOI 10.1016/j.jcomdis.2004.04.003; SANDER E K, 1961, J Speech Hear Disord, V(Suppl 7), P21; Sawyer J, 2006, AM J SPEECH-LANG PAT, V15, P36, DOI 10.1044/1058-0360(2006/005); Sommer M, 2002, LANCET, V360, P380, DOI 10.1016/S0140-6736(02)09610-1; Starkweather CW, 2002, J FLUENCY DISORD, V27, P269, DOI 10.1016/S0094-730X(02)00144-4; STARKWEATHER CW, 1990, J FLUENCY DISORD, V15, P143, DOI 10.1016/0094-730X(90)90015-K; Vanryckeghem M, 2005, J FLUENCY DISORD, V30, P307, DOI 10.1016/j.jfludis.2005.09.003; Wilson EB, 1927, J AM STAT ASSOC, V22, P209, DOI 10.2307/2276774; Yairi E, 1996, J COMMUN DISORD, V29, P51, DOI 10.1016/0021-9924(95)00051-8; Yairi E., 2005, EARLY CHILDHOOD STUT, V1st; Yairi E, 2013, J FLUENCY DISORD, V38, P66, DOI 10.1016/j.jfludis.2012.11.002; Yaruss JS, 2000, J FLUENCY DISORD, V25, P305, DOI 10.1016/S0094-730X(00)00088-7	54	67	67	2	56	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2015	10	7							e0133758	10.1371/journal.pone.0133758	http://dx.doi.org/10.1371/journal.pone.0133758			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CN7ED	26218228	Green Published, Green Submitted, gold			2023-01-03	WOS:000358595900046
J	Hansen, CM; Kragholm, K; Pearson, DA; Tyson, C; Monk, L; Myers, B; Nelson, D; Dupre, ME; Fosbol, EL; Jollis, JG; Strauss, B; Anderson, ML; McNally, B; Granger, CB				Hansen, Carolina Malta; Kragholm, Kristian; Pearson, David A.; Tyson, Clark; Monk, Lisa; Myers, Brent; Nelson, Darrell; Dupre, Matthew E.; Fosbol, Emil L.; Jollis, James G.; Strauss, Benjamin; Anderson, Monique L.; McNally, Bryan; Granger, Christopher B.			Association of Bystander and First-Responder Intervention With Survival After Out-of-Hospital Cardiac Arrest in North Carolina, 2010-2013	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ASSISTED CARDIOPULMONARY-RESUSCITATION; AUTOMATED EXTERNAL DEFIBRILLATORS; PUBLIC-ACCESS DEFIBRILLATION; MULTIPLE IMPUTATION; UNITED-STATES; LAY RESCUERS; COMMUNITY; HEART; IMPLEMENTATION; PROGRAM	IMPORTANCE Out-of-hospital cardiac arrest is associated with low survival, but early cardiopulmonary resuscitation (CPR) and defibrillation can improve outcomes if more widely adopted. OBJECTIVE To examine temporal changes in bystander and first-responder resuscitation efforts before arrival of the emergency medical services (EMS) following statewide initiatives to improve bystander and first-responder efforts in North Carolina from 2010-2013 and to examine the association between bystander and first-responder resuscitation efforts and survival and neurological outcome. DESIGN, SETTINGS, AND PARTICIPANTS We studied 4961 patients with out-of-hospital cardiac arrest for whom resuscitation was attempted and who were identified through the Cardiac Arrest Registry to Enhance Survival (2010-2013). First responders were dispatched police officers, firefighters, rescue squad, or life-saving crew trained to perform basic life support until arrival of the EMS. EXPOSURES Statewide initiatives to improve bystander and first-responder interventions included training members of the general population in CPR and in use of automated external defibrillators (AEDs), training first responders in team-based CPR including AED use and high-performance CPR, and training dispatch centers in recognition of cardiac arrest. MAIN OUTCOMES AND MEASURES The proportion of bystander and first-responder resuscitation efforts, including the combination of efforts between bystanders and first responders, from 2010 through 2013 and the association between these resuscitation efforts and survival and neurological outcome. RESULTS The combination of bystander CPR and first-responder defibrillation increased from 14.1% (51 of 362; 95% CI, 10.9%-18.1%) in 2010 to 23.1%(104 of 451; 95% CI, 19.4%-27.2%) in 2013 (P < .01). Survival with favorable neurological outcome increased from 7.1%(82 of 1149; 95% CI, 5.8%-8.8%) in 2010 to 9.7%(129 of 1334; 95% CI, 8.2%-11.4%) in 2013(P = .02) and was associated with by stander-initiated CPR. Adjusting for age and sex, bystander and first-responder interventions were associated with higher survival to hospital discharge. Survival following EMS-initiated CPR and defibrillation was 15.2%(30 of 198; 95% CI, 10.8%-20.9%) compared with 33.6%(38 of 113; 95% CI, 25.5%-42.9%) following bystander-initiated CPR and defibrillation (odds ratio [OR], 3.12; 95% CI, 1.78-5.46); 24.2%(83 of 343; 95% CI, 20.0%-29.0%) following bystander CPR and first-responder defibrillation (OR, 1.70; 95% CI, 1.06-2.71); and 25.2%(109 of 432; 95% CI, 21.4%-29.6%) following first-responder CPR and defibrillation (OR, 1.77; 95% CI, 1.13-2.77). CONCLUSIONS AND RELEVANCE Following a statewide educational intervention on rescusitation training, the proportion of patients receiving bystander-initiated CPR and defibrillation by first responders increased and was associated with greater likelihood of survival. Bystander-initiated CPR was associated with greater likelihood of survival with favorable neurological outcome.	[Hansen, Carolina Malta; Kragholm, Kristian; Tyson, Clark; Monk, Lisa; Dupre, Matthew E.; Fosbol, Emil L.; Jollis, James G.; Anderson, Monique L.; Granger, Christopher B.] Duke Clin Res Inst, Durham, NC 27705 USA; [Pearson, David A.] Carolinas Med Ctr, Charlotte, NC 28203 USA; [Tyson, Clark] Ctr Educ Excellence, Durham, NC USA; [Myers, Brent] Wake Cty EMS, Raleigh, NC USA; [Nelson, Darrell] WFU Hlth Sci, Winston Salem, NC USA; [Dupre, Matthew E.] Duke Univ, Dept Community & Family Med, Durham, NC USA; [Fosbol, Emil L.] Rigshosp, Univ Copenhagen Hosp, Ctr Heart, Copenhagen, Denmark; [Strauss, Benjamin] Duke Univ, Nicholas Sch Environm, Durham, NC 27708 USA; [McNally, Bryan] Emory Univ, Sch Med, Atlanta, GA USA; [McNally, Bryan] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA	Duke University; Carolinas Medical Center; Duke University; Rigshospitalet; University of Copenhagen; Duke University; Emory University; Emory University; Rollins School Public Health	Hansen, CM (corresponding author), Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA.	carolina.hansen@duke.edu	Dupre, Matthew/ABG-6728-2021; McNally, Bryan/AAE-9332-2020	Dupre, Matthew/0000-0002-0976-4715; Kragholm, Kristian/0000-0001-9629-8670; Fosbol, Emil/0000-0002-2048-4167				Anderson ML, 2014, JAMA INTERN MED, V174, P194, DOI 10.1001/jamainternmed.2013.11320; Blom MT, 2014, CIRCULATION, V130, P1868, DOI 10.1161/CIRCULATIONAHA.114.010905; Bobrow BJ, 2010, JAMA-J AM MED ASSOC, V304, P1447, DOI 10.1001/jama.2010.1392; Chan PS, 2014, CIRCULATION, V130, P1876, DOI 10.1161/CIRCULATIONAHA.114.009711; Hallstrom AP, 2004, NEW ENGL J MED, V351, P637; Hansen CM, 2014, CIRCULATION, V130, P1859, DOI 10.1161/CIRCULATIONAHA.114.008850; He YL, 2010, CIRC-CARDIOVASC QUAL, V3, P98, DOI 10.1161/CIRCOUTCOMES.109.875658; Hollenberg J, 2008, CIRCULATION, V118, P389, DOI 10.1161/CIRCULATIONAHA.107.734137; Iwami T, 2009, CIRCULATION, V119, P728, DOI 10.1161/CIRCULATIONAHA.108.802058; JENNETT B, 1975, LANCET, V1, P480; Kitamura T, 2012, CIRCULATION, V126, P2834, DOI 10.1161/CIRCULATIONAHA.112.109496; Lee KJ, 2010, AM J EPIDEMIOL, V171, P624, DOI 10.1093/aje/kwp425; Lewis M, 2013, CIRCULATION, V128, P1522, DOI 10.1161/CIRCULATIONAHA.113.002627; Lindner TW, 2011, RESUSCITATION, V82, P1508, DOI 10.1016/j.resuscitation.2011.06.016; McNally B, CARDIAC ARREST REGIS; McNally Bryan, 2011, Morbidity and Mortality Weekly Report, V60, P1; McNally B, 2009, ANN EMERG MED, V54, P674, DOI 10.1016/j.annemergmed.2009.03.018; Merchant RM, 2013, CIRC-CARDIOVASC QUAL, V6, P229, DOI 10.1161/CIRCOUTCOMES.113.000140; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Myerburg RJ, 2002, CIRCULATION, V106, P1058, DOI 10.1161/01.CIR.0000028147.92190.A7; Neumar RW, 2011, CIRCULATION, V123, P2898, DOI 10.1161/CIR.0b013e31821d79f3; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Nielsen AM, 2013, RESUSCITATION, V84, P430, DOI 10.1016/j.resuscitation.2012.11.008; Nielsen AM, 2012, RESUSCITATION, V83, P1067, DOI 10.1016/j.resuscitation.2012.04.012; Perkins GD, 2014, CIRCULATION; RACE Heart Rescue Project, OPT CARD ARR SYST SP; Rea TD, 2001, CIRCULATION, V104, P2513, DOI 10.1161/hc4601.099468; Rea TD, 2006, CIRCULATION, V114, P2760, DOI 10.1161/CIRCULATIONAHA.106.654715; Rea TD, 2010, CIRCULATION, V121, P1134, DOI 10.1161/CIRCULATIONAHA.109.899799; Sasson C, 2012, NEW ENGL J MED, V367, P1607, DOI 10.1056/NEJMoa1110700; Stiell IG, 1999, JAMA-J AM MED ASSOC, V281, P1175, DOI 10.1001/jama.281.13.1175; Stromsoe A, 2010, RESUSCITATION, V81, P211, DOI 10.1016/j.resuscitation.2009.10.014; van Buuren S, 2007, STAT METHODS MED RES, V16, P219, DOI 10.1177/0962280206074463; van Diepen S, 2013, AM HEART J, V166, P647, DOI 10.1016/j.ahj.2013.05.022; Weisfeldt ML, 2010, J AM COLL CARDIOL, V55, P1712, DOI 10.1016/j.jacc.2009.11.077; White RD, 2005, RESUSCITATION, V65, P279, DOI 10.1016/j.resuscitation.2004.10.018; Wissenberg M, 2013, JAMA-J AM MED ASSOC, V310, P1377, DOI 10.1001/jama.2013.278483; Zijlstra JA, 2014, RESUSCITATION, V85, P1444, DOI 10.1016/j.resuscitation.2014.07.020	39	263	263	2	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	2015	314	3					255	264		10.1001/jama.2015.7938	http://dx.doi.org/10.1001/jama.2015.7938			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CN2CM	26197186	Bronze			2023-01-03	WOS:000358228000020
J	Hamasaki, H; Kawashima, Y; Tamada, Y; Furuta, M; Katsuyama, H; Sako, A; Yanai, H				Hamasaki, Hidetaka; Kawashima, Yu; Tamada, Yoshiki; Furuta, Masashi; Katsuyama, Hisayuki; Sako, Akahito; Yanai, Hidekatsu			Associations of Low-Intensity Resistance Training with Body Composition and Lipid Profile in Obese Patients with Type 2 Diabetes	PLOS ONE			English	Article							LIPOPROTEIN(A) LEVELS; SARCOPENIC OBESITY; INSULIN-RESISTANCE; PHYSICAL-EXERCISE; OLDER-ADULTS; MUSCLE; METABOLISM; STRENGTH; MEN	Resistance training to increase muscle mass and functional capacity is an integral part of diet and exercise programs for the management of obesity and type 2 diabetes. Low-intensity resistance training with slow movement and tonic force generation (LST) may be a practical and safe regimen for elderly obese individuals but the health benefits are uncertain. This study investigated the effects of LST on body composition and metabolic parameters in obese patients with type 2 diabetes. Twenty-six obese patients with type 2 diabetes engaged in LST training during hospitalization and were advised to maintain this regimen for 12 weeks after discharge. We compared lipid profile, arterial stiffness, and body composition before and after LST training. After 12 weeks of LST training, the ratio of lower extremity muscle mass to body weight increased significantly (0.176 +/- 0.028 to 0.184 +/- 0.023, mean +/- SD), while body fat mass and body fat percentage decreased significantly (36.2 +/- 10.9 kg to 34.3 +/- 9.4 kg and 41.2 +/- 8.6% to 40.1 +/- 7.7%, respectively). Moreover, high-density lipoprotein cholesterol was significantly increased (42.2 +/- 14 mg/dl to 46.3 +/- 12.4 mg/dl) and both free fatty acids and lipoprotein(a) were decreased (665.2 +/- 212.1 mu Eq/l to 525.4 +/- 231.3 mu Eq/l and 15.4 +/- 18 mg/dl to 13.8 +/- 18 mg/dl, respectively). No significant change was observed in arterial stiffness. Although this study was a non-controlled investigation and some confounding factors including dietary intake, medication and compliance with training might affect the study result, a brief (12-week) LST training program may be a safe and effective strategy for the management of obesity and type 2 diabetes.	[Hamasaki, Hidetaka; Kawashima, Yu; Katsuyama, Hisayuki; Sako, Akahito; Yanai, Hidekatsu] Kohnodai Hosp, Natl Ctr Global Hlth & Med, Dept Internal Med, Chiba, Japan; [Hamasaki, Hidetaka] Jichi Med Univ, Grad Sch, Community Healthcare Studies, Gen Internal Med, Shimotsuke, Tochigi, Japan; [Tamada, Yoshiki] Kohnodai Hosp, Natl Ctr Global Hlth & Med, Dept Rehabil, Chiba, Japan; [Furuta, Masashi] Kohnodai Hosp, Natl Ctr Global Hlth & Med, Dept Nutr, Chiba, Japan	National Center for Global Health & Medicine - Japan; Jichi Medical University; National Center for Global Health & Medicine - Japan; National Center for Global Health & Medicine - Japan	Hamasaki, H (corresponding author), Kohnodai Hosp, Natl Ctr Global Hlth & Med, Dept Internal Med, Chiba, Japan.	hhamasaki78@gmail.com	Hamasaki, Hidetaka/H-2928-2016; Yanai, Hidekatsu/AFN-9517-2022	Hamasaki, Hidetaka/0000-0002-0124-597X; Sako, Akahito/0000-0002-2555-1293	National Center for Global Health and Medicine [26A-201]	National Center for Global Health and Medicine(National Center for Global Health & Medicine - Japan)	This study was supported in part by a Grant-in-Aid for Research from the National Center for Global Health and Medicine (26A-201). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alley DE, 2007, JAMA-J AM MED ASSOC, V298, P2020, DOI 10.1001/jama.298.17.2020; Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS11, DOI 10.2337/dc13-S011; Anderson LJ, 2012, NUTR RES, V32, P479, DOI 10.1016/j.nutres.2012.05.009; AUSTIN A, 1993, DIABETES CARE, V16, P421, DOI 10.2337/diacare.16.2.421; Braith RW, 2006, CIRCULATION, V113, P2642, DOI 10.1161/CIRCULATIONAHA.105.584060; Castaneda C, 2002, DIABETES CARE, V25, P2335, DOI 10.2337/diacare.25.12.2335; Coyle D, 2012, INT J TECHNOL ASSESS, V28, P228, DOI 10.1017/S0266462312000256; Durstine JL, 1996, MED SCI SPORT EXER, V28, P1277, DOI 10.1097/00005768-199610000-00011; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Goodpaster BH, 2000, METABOLISM, V49, P467, DOI 10.1016/S0026-0495(00)80010-4; HELLSTEN G, 1989, ATHEROSCLEROSIS, V75, P93, DOI 10.1016/0021-9150(89)90211-6; Hills AP, 2010, OBES REV, V11, P740, DOI 10.1111/j.1467-789X.2009.00692.x; Hubinger L, 1997, MED SCI SPORT EXER, V29, P436, DOI 10.1097/00005768-199704000-00003; Hubinger L, 1996, MED SCI SPORT EXER, V28, P757, DOI 10.1097/00005768-199606000-00015; Hulver MW, 2003, AM J PHYSIOL-ENDOC M, V284, pE741, DOI 10.1152/ajpendo.00514.2002; Hurley BF, 2011, SPORTS MED, V41, P289, DOI 10.2165/11585920-000000000-00000; Jensen MD, 2003, ACTA PHYSIOL SCAND, V178, P385, DOI 10.1046/j.1365-201X.2003.01167.x; Karelis AD, 2004, J CLIN ENDOCR METAB, V89, P2569, DOI 10.1210/jc.2004-0165; KARVONEN MJ, 1957, ANN MED EXP BIOL FEN, V35, P307; Kelley DE, 1999, AM J PHYSIOL-ENDOC M, V277, pE1130; Kuh D, 2005, J GERONTOL A-BIOL, V60, P224, DOI 10.1093/gerona/60.2.224; Matsuzawa Y, 2002, CIRC J, V66, P987, DOI 10.1253/circj.66.987; Mavros Y, 2013, DIABETES CARE, V36, P2372, DOI 10.2337/dc12-2196; Misra A, 2008, DIABETES CARE, V31, P1282, DOI 10.2337/dc07-2316; Miyachi M, 2013, BRIT J SPORT MED, V47, P393, DOI 10.1136/bjsports-2012-090488; MULS E, 1993, INT J OBESITY, V17, P711; Phillips SM, 1996, J APPL PHYSIOL, V81, P2182, DOI 10.1152/jappl.1996.81.5.2182; PONJEE GAE, 1995, ANN CLIN BIOCHEM, V32, P181, DOI 10.1177/000456329503200208; Prado CMM, 2012, CLIN NUTR, V31, P583, DOI 10.1016/j.clnu.2012.06.010; Rigla M, 2000, METABOLISM, V49, P640, DOI 10.1016/S0026-0495(00)80041-4; Sierra-Johnson J, 2009, EUR HEART J, V30, P710, DOI [10.1093/eurheartj/ehn347, 10.1093/eurheartj/ehp487]; Strasser B, 2010, SPORTS MED, V40, P397, DOI 10.2165/11531380-000000000-00000; Subramanian S, 2012, BBA-MOL CELL BIOL L, V1821, P819, DOI 10.1016/j.bbalip.2011.10.003; Tanimoto M, 2006, J APPL PHYSIOL, V100, P1150, DOI 10.1152/japplphysiol.00741.2005; Tarnopolsky MA, 2007, AM J PHYSIOL-REG I, V292, pR1271, DOI 10.1152/ajpregu.00472.2006; Tuttle Lori J, 2012, J Aging Res, V2012, P172957, DOI 10.1155/2012/172957; Yagi S, 2014, DIABETOL METAB SYNDR, V6, DOI 10.1186/1758-5996-6-27; Zamboni M, 2008, NUTR METAB CARDIOVAS, V18, P388, DOI 10.1016/j.numecd.2007.10.002	38	13	13	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2015	10	7							e0132959	10.1371/journal.pone.0132959	http://dx.doi.org/10.1371/journal.pone.0132959			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RL	26176700	gold, Green Published, Green Submitted			2023-01-03	WOS:000358197600188
J	Boger, E; Ellis, J; Latter, S; Foster, C; Kennedy, A; Jones, F; Fenerty, V; Kellar, I; Demain, S				Boger, Emma; Ellis, Jaimie; Latter, Sue; Foster, Claire; Kennedy, Anne; Jones, Fiona; Fenerty, Vicky; Kellar, Ian; Demain, Sara			Self-Management and Self-Management Support Outcomes: A Systematic Review and Mixed Research Synthesis of Stakeholder Views	PLOS ONE			English	Article							LONG-TERM CONDITIONS; CHRONIC ILLNESS; COLORECTAL-CANCER; STRUCTURED EDUCATION; FOCUS GROUPS; CARE; STROKE; INTERVENTIONS; EXPERIENCES; PROGRAM	Introduction Self-management has received growing attention as an effective approach for long-term condition management. Little is known about which outcomes of supported self-management are valued by patients, their families, health professionals and those who commission self-management services. This study systematically reviewed published empirical evidence in accordance with PRISMA guidelines to determine the outcomes of self-management valued by these key stakeholder groups, using three prominent exemplar conditions: colorectal cancer, diabetes and stroke. Aim To systematically review the literature to identify which generic outcomes of self-management have been targeted and are considered important using three exemplar conditions (colorectal cancer, diabetes and stroke), which collectively have a range of features that are likely to be representative of generic self-management issues. Methods Systematic searching of nine electronic databases was conducted in addition to hand searches of review articles. Abstracts were identified against inclusion criteria and appraised independently by two reviewers, using a critical appraisal tool. Synthesis of findings was conducted using mixed research synthesis. Results Over 20,536 abstracts were screened. 41 studies which met the review criteria were fully retrieved and appraised. The majority of evidence related to diabetes. Few studies directly focussed on stakeholders' views concerning desired self-management outcomes; the majority of evidence was derived from studies focusing upon the experience of self-management. The views of health care commissioners were absent from the literature. We identified that self-management outcomes embrace a range of indicators, from knowledge, skills, and bio-psychosocial markers of health through to positive social networks. Conclusions Patients', families', health professionals' and commissioners' views regarding which outcomes of self-management are important have not been clearly elicited. The extent to which bio-psychosocial indicators relate to successful self-management from the perspectives of all groups of stakeholders is unknown. Further investigation regarding which self-management outcomes are considered important by all stakeholders is necessary to guide the commissioning and design of future self-management services.	[Boger, Emma; Ellis, Jaimie; Latter, Sue; Foster, Claire; Kennedy, Anne; Fenerty, Vicky; Demain, Sara] Univ Southampton, Fac Hlth Sci, Southampton, Hants, England; [Jones, Fiona] St Georges & Kingston Univ London, Dept Social Care & Educ, London, England; [Kellar, Ian] Univ Leeds, Inst Psychol Sci, Leeds, W Yorkshire, England	University of Southampton; University of Leeds	Boger, E (corresponding author), Univ Southampton, Fac Hlth Sci, Southampton, Hants, England.	e.j.boger@soton.ac.uk	Foster, Claire/N-6223-2016; Fenerty, Vicky/AAN-3129-2020; Fenerty, Vicky/AAM-7173-2020; Kellar, Ian/F-5536-2015	Foster, Claire/0000-0002-4703-8378; Kellar, Ian/0000-0003-1608-5216; Fenerty, Victoria/0000-0002-1712-5614; Jones, Fiona/0000-0002-1452-3895; Latter, Susan/0000-0003-0973-0512	Health Foundation Insight award; National Institute for Health Research [PDF-2011-04-016] Funding Source: researchfish	Health Foundation Insight award; National Institute for Health Research(National Institute for Health Research (NIHR))	This work was funded by The Health Foundation Insight award, www.health.org.uk Funding was awarded to EB, SD, SL, AK, CF, FJ and IK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adjaye-Gbewonyo K, 2013, TRANSL BEHAV MED, V3, P72, DOI 10.1007/s13142-012-0187-7; Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS14, DOI 10.2337/dc14-S014; Anderson AS, 2013, SUPPORT CARE CANCER, V21, P35, DOI 10.1007/s00520-012-1487-7; [Anonymous], 2012, NVIVO 10 SOFTWARE; Balfe M, 2009, J ADV NURS, V65, P2367, DOI 10.1111/j.1365-2648.2009.05098.x; Bandura A., 1997, SELF EFFICACY EXERCI; Barlow JH, 2002, HLTH ED J, V61, P365, DOI DOI 10.1177/001789690206100408; Boger EJ, 2013, DISABIL REHABIL, V35, P1415, DOI 10.3109/09638288.2012.737080; Bury Mike, 2005, Health Serv J, V115, P18; Bycroft J, 2006, NEW ZEALAND FAMILY P, V33; Cadilhac DA, 2011, STROKE, V42, P1673, DOI 10.1161/STROKEAHA.110.601997; Campbell NC, 2007, BMJ-BRIT MED J, V334, P455, DOI 10.1136/bmj.39108.379965.BE; Carbone ET, 2007, PATIENT EDUC COUNS, V66, P202, DOI 10.1016/j.pec.2006.12.003; Centre for Reviews and Dissemination, 2009, SYST REV CRDS GUID U; Chang H, 2005, PREV MED, V40, P249; Collins A, 2014, MEASURING REALLY MAT; Collins MM, 2009, BMC ENDOCR DISORD, V9, DOI 10.1186/1472-6823-9-6; Corcoran KJ, 2013, AUST HEALTH REV, V37, P19, DOI 10.1071/AH11092; Coster S, 2009, INT J NURS STUD, V46, P508, DOI 10.1016/j.ijnurstu.2008.09.009; de Silva D., 2011, HELPING PEOPLE HELP; Demain S, PLOS ONE; Department of Health, 2012, LONG TERM CONDITIONS, Vthird; Department of Health, 2013, NHS OUTCOMES FRAMEWO; Department of Health, 2012, QUALITY OUTCOMES FRA; Dixon A, 2011, IMPACT QUALITY OUT C; Docherty A, 2004, PATIENT EXPERIENCE C; Dyson PA, 2010, J HUM NUTR DIET, V23, P353, DOI 10.1111/j.1365-277X.2010.01077.x; Funnell MM, 2011, DIABETES CARE, V34, pS89, DOI 10.2337/dc11-S089; Funnell MM, 2010, PRACTICAL DIABETES I, V27, P222; Gallant MP, 2003, HEALTH EDUC BEHAV, V30, P170, DOI 10.1177/1090198102251030; Gao WJ, 2011, INT NURS REV, V58, P288, DOI 10.1111/j.1466-7657.2011.00907.x; Goodwin J, 2006, GERIATRIC MED, P17; Grant L, 2013, DIABETIC MED, V30, P724, DOI 10.1111/dme.12164; Grund J, 2012, J PRIM CARE COMMUNIT, V3, P230, DOI 10.1177/2150131911435263; Gucciardi E, 2013, BMC ENDOCR DISORD, V13, DOI 10.1186/1472-6823-13-46; Hargraves JL, 2012, J AMBUL CARE MANAG, V35, P15, DOI 10.1097/JAC.0b013e31822cbe35; Heisler M, 2009, AM J PREV MED, V37, pS270, DOI 10.1016/j.amepre.2009.08.016; Howard L M, 2012, Educ Health (Abingdon), V25, P66; Huang ES, 2005, J AM GERIATR SOC, V53, P306, DOI 10.1111/j.1532-5415.2005.53119.x; Hunt LM, 1998, WESTERN J NURS RES, V20, P656, DOI 10.1177/019394599802000602; Johnston M, 2007, DISABIL REHABIL, V29, P1117, DOI 10.1080/03323310600950411; Jones F, 2006, DISABIL REHABIL, V28, P841, DOI 10.1080/09638280500534952; Jones F, 2013, PHYSIOTHER RES INT, V18, P91, DOI 10.1002/pri.1531; Jones F, 2009, CLIN REHABIL, V23, P522, DOI 10.1177/0269215508101749; Jones MC, 2011, J NURSING HEALTHCARE, V10, P174; Kendall E, 2007, SOC SCI MED, V64, P735, DOI 10.1016/j.socscimed.2006.09.012; Kennedy A, 2007, J EPIDEMIOL COMMUN H, V61, P254, DOI 10.1136/jech.2006.053538; Kidd L, 2008, J ADV NURS, V64, P469, DOI 10.1111/j.1365-2648.2008.04796.x; Kidd L, 2009, J CLIN NURS, V18, P2292, DOI 10.1111/j.1365-2702.2009.02802.x; Kralik D, 2004, J CLIN NURS, V13, P259, DOI 10.1046/j.1365-2702.2003.00826.x; Lasch KE, 2010, QUAL LIFE RES, V19, P1087, DOI 10.1007/s11136-010-9677-6; Lin CC, 2008, J CLIN NURS, V17, P34, DOI 10.1111/j.1365-2702.2007.01962.x; Lorig K R, 2001, Eff Clin Pract, V4, P256; Lorig KR, 2006, MED CARE, V44, P964, DOI 10.1097/01.mlr.0000233678.80203.c1; Lundberg PC, 2012, J ADV NURS, V68, P550, DOI 10.1111/j.1365-2648.2011.05756.x; Lynch EB, 2012, HEALTH EDUC RES, V27, P814, DOI 10.1093/her/cys058; Maillet NA, 1996, DIABETES EDUCATOR, V22, P39, DOI 10.1177/014572179602200106; Mathers CD, 2006, GLOBAL BURDEN OF DISEASE AND RISK FACTORS, P399; May C, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2803; McCorkle R, 2011, CA-CANCER J CLIN, V61, P50, DOI 10.3322/caac.20093; Minet LKR, 2011, QUAL HEALTH RES, V21, P1115, DOI 10.1177/1049732311405066; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Morrow AS, 2008, PATIENT EDUC COUNS, V72, P418, DOI 10.1016/j.pec.2008.05.017; Murphy K, 2011, J CLIN NURS, V20, P1282, DOI 10.1111/j.1365-2702.2010.03564.x; Naik AD, 2011, PATIENT EDUC COUNS, V85, P383, DOI 10.1016/j.pec.2011.01.010; National Institute for Health and Care Excellence, 2014, TYPE 1 DIABETES DIAG; New N, 2010, J AM ACAD NURSE PRAC, V22, P316, DOI 10.1111/j.1745-7599.2010.00514.x; Nolte S, 2013, QUAL LIFE RES, V22, P1805, DOI 10.1007/s11136-012-0302-8; Norris M, 2014, DISABIL REHABIL, V36, P32, DOI 10.3109/09638288.2013.776645; Palmer NRA, 2013, PALLIAT SUPPORT CARE, V11, P101, DOI 10.1017/S1478951512000788; Paterson B, 2010, TRANSLATING CHRONIC; Paul GM, 2007, BMC FAM PRACT, V8, DOI 10.1186/1471-2296-8-45; Peel E, 2004, BRIT J GEN PRACT, V54, P183; Pierce Linda L, 2004, Rehabil Nurs, V29, P14; Porter LS, 2008, PAIN, V137, P306, DOI 10.1016/j.pain.2007.09.010; Puder JJ, 2006, SWISS MED WKLY, V136, P574; Quandt SA, 2013, J APPL GERONTOL, V32, P783, DOI 10.1177/0733464811435506; Rasmussen B, 2011, J CLIN NURS, V20, P1981, DOI 10.1111/j.1365-2702.2010.03657.x; Rees R, 2009, CHILDRENS VIEWS OBES; Reeves D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098340; Renders CM, 2001, DIABETES CARE, V24, P1821, DOI 10.2337/diacare.24.10.1821; Rise MB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064009; Rygg LO, 2010, SCAND J PUBLIC HEALT, V38, P788, DOI 10.1177/1403494810382475; Sandelowski Margarete, 2006, Res Sch, V13, P29; Satink T, 2014, DISABILITY REHABILIT, P1; Schabert J, 2013, PATIENT, V6, P1, DOI 10.1007/s40271-012-0001-0; Shakibazadeh E, 2011, IRAN J PUBLIC HEALTH, V40, P146; Singh D, 2008, WHO REGIONAL OFFICE; Sprague MA, 2006, FAM COMMUNITY HEALTH, V29, P245, DOI 10.1097/00003727-200610000-00003; Steed L, 2003, PATIENT EDUC COUNS, V51, P5, DOI 10.1016/S0738-3991(02)00213-6; Sturt J, 2005, PRIM HEALTH CARE RES, V6, P291; Thoolen B, 2007, DIABETES CARE, V30, P2832, DOI 10.2337/dc07-0777; Thorne SE, 2001, PATIENT EDUC COUNS, V42, P81, DOI 10.1016/S0738-3991(00)00095-1; van der Wulp I, 2012, DIABETIC MED, V29, pe390, DOI 10.1111/j.1464-5491.2012.03629.x; Vassilev I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059723; Veg A, 2007, DIABETIC MED, V24, P408, DOI 10.1111/j.1464-5491.2006.02064.x; Vincent D, 2006, DIABETES EDUCATOR, V32, P89, DOI 10.1177/0145721705284372; Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64; Wilkinson A, 2009, INT J NURS STUD, V46, P1143, DOI 10.1016/j.ijnurstu.2008.12.011; Wilson PM, 2006, INT J NURS STUD, V43, P803, DOI 10.1016/j.ijnurstu.2005.10.011; Woodman P, 2014, DISABIL REHABIL, V36, P2031, DOI 10.3109/09638288.2014.887796; World Health Organization, 2005, PREVENTING CHRONIC D	102	92	92	3	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2015	10	7							e0130990	10.1371/journal.pone.0130990	http://dx.doi.org/10.1371/journal.pone.0130990			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CN1FD	26162086	Green Published, gold, Green Accepted, Green Submitted			2023-01-03	WOS:000358162300027
J	Rutter, P				Rutter, Paul			PERSONAL VIEW End pharmacists' monopoly on selling certain drugs	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Wolverhampton Univ, Sch Pharm, Wolverhampton WV1 1SB, England	University of Wolverhampton	Rutter, P (corresponding author), Wolverhampton Univ, Sch Pharm, Wolverhampton WV1 1SB, England.	paul.rutter@wlv.ac.uk	rutter, paul/AAG-7043-2019	Rutter, Paul/0000-0003-4106-1515				Akhtar S, 2015, RES SOC ADMIN PHARM, V11, P472, DOI 10.1016/j.sapharm.2014.09.003; [Anonymous], 2008, WHICH PHARM GET TEST; Driesen Annelies, 2009, Int J Pharm Pract, V17, P215; Medicines and Healthcare Products Regulatory Agency, 2015, OR DICL PRES LEG STA; Paudyal V, 2014, RES SOC ADMIN PHARM, V10, P88, DOI 10.1016/j.sapharm.2013.04.007; Paudyal V, 2011, HEALTH POLICY, V101, P253, DOI 10.1016/j.healthpol.2011.05.010; Pillay N, 2010, SELFCARE, V1, P105; Rutter PM, 2013, SELF CARE, V4, P125; Tisman A., 2010, RISING TIDE OTC EURO; World Self Medication Industry, 2014, RESP SELF CAR SELF M; World Self Medication Industry, 2009, SWITCH PRESCR NONPR	11	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	2015	351								h3415	10.1136/bmj.h3415	http://dx.doi.org/10.1136/bmj.h3415			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CM3TQ	26136348	Green Accepted			2023-01-03	WOS:000357607800004
J	Hadinegoro, SR; Arredondo-Garcia, JL; Capeding, MR; Deseda, C; Chotpitayasunondh, T; Dietze, R; Ismail, HIHM; Reynales, H; Limkittikul, K; Rivera-Medina, DM; Tran, HN; Bouckenooghe, A; Chansinghakul, D; Cortes, M; Fanouillere, K; Forrat, R; Frago, C; Gailhardou, S; Jackson, N; Noriega, F; Plennevaux, E; Wartel, TA; Zambrano, B; Saville, M				Hadinegoro, S. R.; Arredondo-Garcia, J. L.; Capeding, M. R.; Deseda, C.; Chotpitayasunondh, T.; Dietze, R.; Ismail, H. I. Hj Muhammad; Reynales, H.; Limkittikul, K.; Rivera-Medina, D. M.; Tran, H. N.; Bouckenooghe, A.; Chansinghakul, D.; Cortes, M.; Fanouillere, K.; Forrat, R.; Frago, C.; Gailhardou, S.; Jackson, N.; Noriega, F.; Plennevaux, E.; Wartel, T. A.; Zambrano, B.; Saville, M.		CYD-TDV Dengue Vaccine Working Grp	Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHILDREN; AMERICA	BACKGROUND A candidate tetravalent dengue vaccine is being assessed in three clinical trials involving more than 35,000 children between the ages of 2 and 16 years in Asian-Pacific and Latin American countries. We report the results of long-term follow-up interim analyses and integrated efficacy analyses. METHODS We are assessing the incidence of hospitalization for virologically confirmed dengue as a surrogate safety end point during follow-up in years 3 to 6 of two phase 3 trials, CYD14 and CYD15, and a phase 2b trial, CYD23/57. We estimated vaccine efficacy using pooled data from the first 25 months of CYD14 and CYD15. RESULTS Follow-up data were available for 10,165 of 10,275 participants (99%) in CYD14 and 19,898 of 20,869 participants (95%) in CYD15. Data were available for 3203 of the 4002 participants (80%) in the CYD23 trial included in CYD57. During year 3 in the CYD14, CYD15, and CYD57 trials combined, hospitalization for virologically confirmed dengue occurred in 65 of 22,177 participants in the vaccine group and 39 of 11,089 participants in the control group. Pooled relative risks of hospitalization for dengue were 0.84 (95% confidence interval [CI], 0.56 to 1.24) among all participants, 1.58 (95% CI, 0.83 to 3.02) among those under the age of 9 years, and 0.50 (95% CI, 0.29 to 0.86) among those 9 years of age or older. During year 3, hospitalization for severe dengue, as defined by the independent data monitoring committee criteria, occurred in 18 of 22,177 participants in the vaccine group and 6 of 11,089 participants in the control group. Pooled rates of efficacy for symptomatic dengue during the first 25 months were 60.3% (95% CI, 55.7 to 64.5) for all participants, 65.6% (95% CI, 60.7 to 69.9) for those 9 years of age or older, and 44.6% (95% CI, 31.6 to 55.0) for those younger than 9 years of age. CONCLUSIONS Although the unexplained higher incidence of hospitalization for dengue in year 3 among children younger than 9 years of age needs to be carefully monitored during long-term follow-up, the risk among children 2 to 16 years of age was lower in the vaccine group than in the control group. (Funded by Sanofi Pasteur; ClinicalTrials.gov numbers, NCT00842530, NCT01983553, NCT01373281, and NCT01374516.)	[Hadinegoro, S. R.] Univ Indonesia, Cipto Mangunkusumo Hosp, Jakarta, Indonesia; [Arredondo-Garcia, J. L.] Inst Nacl Pediat, Mexico City, DF, Mexico; [Capeding, M. R.] Res Inst Trop Med, Muntinlupa, Philippines; [Deseda, C.] Caribbean Travel Med Clin, San Juan, PR USA; [Chotpitayasunondh, T.] Queen Sirikit Natl Inst Child Hlth, Bangkok, Thailand; [Limkittikul, K.] Mahidol Univ, Fac Trop Med, Bangkok, Thailand; [Chansinghakul, D.] Sanofi Pasteur, Bangkok, Thailand; [Dietze, R.] Univ Fed Espirito Santo, Nucleo Doencas Infecciosas, Vitoria, ES, Spain; [Ismail, H. I. Hj Muhammad] Hosp Kuala Lumpur, Kuala Lumpur, Malaysia; [Reynales, H.] Ctr Atenc & Invest Med SAS CAIMED, Bogota, Colombia; [Cortes, M.] Sanofi Pasteur, Bogota, Colombia; [Rivera-Medina, D. M.] Org Desarrollo & Invest Salud Honduras ODIS, Tegucigalpa, Honduras; [Tran, H. N.] Pasteur Inst Ho Chi Minh City, Ho Chi Minh City, Vietnam; [Bouckenooghe, A.; Frago, C.; Wartel, T. A.] Sanofi Pasteur, Singapore, Singapore; [Fanouillere, K.] Sanofi R&D, Chilly Mazarin, France; [Forrat, R.; Plennevaux, E.] Sanofi R&D, Marcy Letoile, France; [Gailhardou, S.; Jackson, N.; Saville, M.] Sanofi R&D, Lyon, France; [Noriega, F.] Sanofi Pasteur, Swiftwater, PA USA; [Zambrano, B.] Sanofi Pasteur, Montevideo, Uruguay	University of Indonesia; Research Institute for Tropical Medicine - Philippines; Mahidol University; Sanofi-Aventis; Sanofi-Aventis; Sanofi-Aventis; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi-Aventis; Sanofi-Aventis; Sanofi-Aventis	Saville, M (corresponding author), Sanofi Pasteur, 2 Ave Pont Pasteur, F-69367 Lyon 07, France.	melanie.saville@sanofipasteur.com		Vigne, Claire/0000-0003-3417-9814; Dietze, Reynaldo/0000-0002-6995-8001; Arredondo-Garcia, Jose Luis/0000-0001-6560-046X	Sanofi Pasteur	Sanofi Pasteur	Funded by Sanofi Pasteur	Anders KL, 2011, AM J TROP MED HYG, V84, P127, DOI 10.4269/ajtmh.2011.10-0476; Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6; Committee for Proprietary Medicinal Products (CPMP), 2001, POINTS CONS APPL 1 M; Gamble J, 2000, CLIN SCI, V98, P211, DOI 10.1042/CS19990296; Hanna-Wakim R, 2009, J INFECT DIS, V200, P1921, DOI 10.1086/648375; Initiative for Vaccine Research Department of Immunization Vaccines and Biologicals, 2008, GUID CLIN EV DENG VA; L'Azou M, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003235; San Martin JL, 2010, AM J TROP MED HYG, V82, P128, DOI 10.4269/ajtmh.2010.09-0346; Mizumoto K, 2014, J VECTOR DIS, V51, P153; Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7; Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037; World Health Organization, 2011, GUID QUAL SAF EFF DE	12	681	698	0	67	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 24	2015	373	13					1195	1206		10.1056/NEJMoa1506223	http://dx.doi.org/10.1056/NEJMoa1506223			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CR8WP	26214039				2023-01-03	WOS:000361635200005
J	Schmidt-Hansen, M; Bennett, MI; Hilgart, J				Schmidt-Hansen, Mia; Bennett, Michael I.; Hilgart, Jennifer			Oxycodone for Cancer Pain in Adult Patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Schmidt-Hansen, Mia] Natl Collaborating Ctr Canc, Cardiff CF10 3AF, S Glam, Wales; [Bennett, Michael I.] Univ Leeds, Leeds Inst Hlth Sci, Leeds, W Yorkshire, England; [Hilgart, Jennifer] Univ South Wales, Welsh Inst Hlth & Social Care, Swansea, W Glam, Wales	University of Leeds; University of South Wales	Schmidt-Hansen, M (corresponding author), Natl Collaborating Ctr Canc, Pk House,Greyfriars Rd, Cardiff CF10 3AF, S Glam, Wales.	mia.schmidt-hansen@wales.nhs.uk	Bennett, Michael I/A-1620-2009; Hilgart, Jennifer/AAD-8659-2020	Bennett, Michael I/0000-0002-8369-8349; Hilgart, Jennifer/0000-0001-9688-5429				ARKINSTALL WW, 1989, CAN MED ASSOC J, V140, P653; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Cohen J., 2013, STAT POWER ANAL BEHA; National Institute for Health and Care Excellence, OP PALL CAR CG140; Portenoy RK, 2014, J CLIN ONCOL, V32, P1662, DOI 10.1200/JCO.2013.52.5188; Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233; Schmidt-Hansen M, 2015, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD003870	7	8	9	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	2015	314	12					1282	1283		10.1001/jama.2015.8556	http://dx.doi.org/10.1001/jama.2015.8556			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CS5IE	26393852	Green Published			2023-01-03	WOS:000362110700018
J	Huang, SY; Lin, HH; Yao, M; Tang, JL; Wu, SJ; Hou, HA; Chou, WC; Chou, SC; Hsu, SC; Ko, BS; Lu, HY; Tsay, W; Tien, HF				Huang, Shang-Yi; Lin, Hsiu-Hsia; Yao, Ming; Tang, Jih-Luh; Wu, Shang-Ju; Hou, Hsin-An; Chou, Wen-Chien; Chou, Sheng-Chieh; Hsu, Szu-Chun; Ko, Bor-Sheng; Lu, Hsiao-Yun; Tsay, Woei; Tien, Hwei-Fang			Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study	PLOS ONE			English	Article							MULTIPLE-MYELOMA; EXTRACELLULAR-MATRIX; PROTEOGLYCANS; INHIBITION; DEFICIENCY	The growth of myeloma cells depends on bone marrow (BM) stroma consisting of stromal cells, secreted cytokines and the extracellular matrix (ECM). Decorin, a small leucine-rich proteoglycan in the ECM, is a signaling ligand and native anti-tumor agent. However, the role of decorin in patients with myeloma is not clear. We evaluated the correlation between the decorin levels measured by enzyme-linked immunosorbent assay in BM plasma from 121 patients with newly diagnosed myeloma based on their clinical features and treatment response. The median decorin levels in the patients and the normal control group were 12.31 ng/mL [standard deviation (SD), 7.50 ng/mL; range, 2.45 to 44.46 ng/mL] and 10.31 ng/mL (SD, 2.42 ng/mL; range, 4.85-15.14 ng/mL), respectively (P <0.001). Using 15.15 ng/mL as a cut-off, 46 patients (38%) exhibited higher decorin levels (H-DCN), whereas the other patients exhibited normal to lower decorin levels (NL-DCN). Except for the median age, which was significantly younger in the H-DCN than in the NL-DCN group (60.6 14.0 vs. 65.8 12.2 years, respectively; P = 0.034), there were no differences between the two groups. However, in 79 patients who had received novel agent-based induction, the overall response rate was significantly better in the H-DCN than in the NL-DCN (97 vs. 63%, respectively; P < 0.001), as was the depth of responses (P = 0.008), which were not observed in those who had received chemotherapeutic agents alone. Progression-free survival (PFS) was significantly longer in H-DCN than NL-DCN (not reached vs. 19.5 mo, respectively; P = 0.0003). Multivariate analyses indicated that H-DCN, as a significantly independent factor, was associated with better treatment response (odds ratio, 20.014; 95% Cl, 2.187-183.150; P = 0.008) and longer PFS (hazard ratio, 0.135; 95% Cl, 0.051 0.361; P < 0.001). These findings disclose the potential role of decorin in myeloma and provide a basis for further study on possible synergistic anti-myeloma effects between decorin and the novel agents that target BM stroma.	[Huang, Shang-Yi; Lin, Hsiu-Hsia; Yao, Ming; Tang, Jih-Luh; Wu, Shang-Ju; Hou, Hsin-An; Chou, Sheng-Chieh; Ko, Bor-Sheng; Lu, Hsiao-Yun; Tsay, Woei; Tien, Hwei-Fang] Natl Taiwan Univ, Dept Internal Med, Med Coll & Hosp, Taipei, Taiwan; [Chou, Wen-Chien; Hsu, Szu-Chun] Natl Taiwan Univ, Dept Lab Med, Med Coll & Hosp, Taipei 10764, Taiwan	National Taiwan University; National Taiwan University	Huang, SY (corresponding author), Natl Taiwan Univ, Dept Internal Med, Med Coll & Hosp, Taipei, Taiwan.	syhuang55@ntuh.gov.tw		YAO, MING/0000-0003-2932-0019; HOU, HSIN-AN/0000-0003-2780-4845; KO, BOR-SHENG/0000-0002-7965-7579; CHOU, WEN-CHIEN/0000-0003-2967-698X; TIEN, HWEI-FANG/0000-0002-1384-5593; TANG, JIH-LUH/0000-0003-4021-3281; Huang, Shang-Yi/0000-0001-5688-3410; CHOU, SHENG-CHIEH/0000-0002-4121-019X	National Science Council [NSC97-2314-B-002-036-MY3, NSC101-2314-B-002-086, NSC102-2628-B-002-052-MY3]; National Taiwan University Hospital [NTUH 99-S1031, 100-S1659, 101-S1801, 102-S2161, 103-S2435, 104-S2720]	National Science Council(Ministry of Science and Technology, Taiwan); National Taiwan University Hospital(National Taiwan University)	Shang-Yi Huang received funding from National Science Council (NSC97-2314-B-002-036-MY3; NSC101-2314-B-002-086; NSC102-2628-B-002-052-MY3) and National Taiwan University Hospital (NTUH 99-S1031, 100-S1659, 101-S1801, 102-S2161, 103-S2435, 104-S2720). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; Anderson KC, 2011, CLIN CANCER RES, V17, P1225, DOI 10.1158/1078-0432.CCR-10-3366; Bi XL, 2008, CARCINOGENESIS, V29, P1435, DOI 10.1093/carcin/bgn141; Bi YM, 2005, J BIOL CHEM, V280, P30481, DOI 10.1074/jbc.M500573200; Bird JM, 2011, BRIT J HAEMATOL, V154, P32, DOI 10.1111/j.1365-2141.2011.08573.x; Bozoky B, 2014, CANCER MED-US, V3, P485, DOI 10.1002/cam4.231; Buraschi Simone, 2010, J Biol Chem, V285, P42075, DOI 10.1074/jbc.M110.172841; Chen SJ, 2013, AM J PATHOL, V183, P247, DOI 10.1016/j.ajpath.2013.04.001; Feugaing DDS, 2013, EUR J CELL BIOL, V92, P1, DOI 10.1016/j.ejcb.2012.08.004; Horvath Z, 2014, MATRIX BIOL, V35, P194, DOI 10.1016/j.matbio.2013.11.004; HOSMER DW, 2000, WILEY PS TX, P1; Huang SY, 2005, ANN ONCOL, V16, P1530, DOI 10.1093/annonc/mdi273; Huang SY, 2004, AM J PATHOL, V164, P747, DOI 10.1016/S0002-9440(10)63162-8; Iozzo RV, 2011, J CELL MOL MED, V15, P1013, DOI 10.1111/j.1582-4934.2010.01236.x; Iozzo RV, 1999, P NATL ACAD SCI USA, V96, P3092, DOI 10.1073/pnas.96.6.3092; Kristensen IB, 2013, EUR J HAEMATOL, V91, P196, DOI 10.1111/ejh.12125; Kumar SK, 2008, BLOOD, V111, P2516, DOI 10.1182/blood-2007-10-116129; Kwan P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123054; Kyle RA, 2003, BRIT J HAEMATOL, V121, P749; Li X, 2008, BLOOD, V112, P159, DOI 10.1182/blood-2007-11-124164; Li X, 2012, J BONE MINER RES, V27, P1635, DOI 10.1002/jbmr.1620; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Ludwig H, 2013, J CLIN ONCOL, V31, P247, DOI 10.1200/JCO.2011.39.5137; Mahindra A, 2012, NAT REV CLIN ONCOL, V9, P135, DOI 10.1038/nrclinonc.2012.15; Manier S, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/157496; Moreth K, 2012, CELL CYCLE, V11, P2084, DOI 10.4161/cc.20316; Munshi NC, 2011, BLOOD, V117, P4696, DOI 10.1182/blood-2010-10-300970; Munz C, 1999, EUR J IMMUNOL, V29, P1032; Nash MA, 1999, CANCER RES, V59, P6192; Neill T, 2012, AM J PATHOL, V181, P380, DOI 10.1016/j.ajpath.2012.04.029; Neill T, 2012, J BIOL CHEM, V287, P5492, DOI 10.1074/jbc.M111.283499; Nemani N, 2015, J BONE MINER RES, V30, P533, DOI 10.1002/jbmr.2371; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; Patel CG, 2014, CLIN CANCER RES, V20, P3955, DOI 10.1158/1078-0432.CCR-14-0434; Pennisi A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015233; Rajkumar SV, 2011, BLOOD, V117, P4691, DOI 10.1182/blood-2010-10-299487; Shintani K, 2008, ONCOL REP, V19, P1533; Todoerti K, 2010, EXP HEMATOL, V38, P141, DOI 10.1016/j.exphem.2009.11.009	38	9	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2015	10	9							e0137552	10.1371/journal.pone.0137552	http://dx.doi.org/10.1371/journal.pone.0137552			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS0RH	26379028	Green Submitted, Green Published, gold			2023-01-03	WOS:000361769400016
J	Fu, ZD; Cui, JY; Klaassen, CD				Fu, Zidong Donna; Cui, Julia Yue; Klaassen, Curtis D.			The Role of Sirt1 in Bile Acid Regulation during Calorie Restriction in Mice	PLOS ONE			English	Article							NUCLEAR RECEPTOR; STEROL 12-ALPHA-HYDROXYLASE; DIETARY RESTRICTION; X-RECEPTOR; LIFE-SPAN; METABOLISM; CHOLESTEROL; PROTECTS; EXPRESSION; DELETION	Sirtuin 1 (Sirt1) is an NAD(+)-dependent protein deacetylase that is proposed to mediate many health-promoting effects of calorie restriction (CR). We recently reported that short-term CR increased the bile acid (BA) pool size in mice, likely due to increased BA synthesis in liver. Given the important role of Sirt1 in the regulation of glucose, lipid, as well as BA metabolism, we hypothesized that the CR-induced increase in BAs is Sirt1-dependent. To address this, the present study utilized genetically-modified mice that were Sirt1 loss of function (liver knockout, LKO) or Sirt1 gain of function (whole body-transgenic, TG). Three genotypes of mice (Sirt1-LKO, wild-type, and Sirt1-TG) were each randomly divided into ad libitum or 40% CR feeding for one month. BAs were extracted from various compartments of the enterohepatic circulation, followed by BA profiling by UPLC-MS/MS. CR increased the BA pool size and total BAs in serum, gallbladder, and small intestine. The CR-induced increase in BA pool size correlated with the tendency of increase in the expression of the rate-limiting BA-synthetic enzyme Cyp7a1. However, in contrast to the hypothesis, the CR-induced increase in BA pool size and Cyp7a1 expression was still observed with ablated expression of Sirt1 in liver, and completely suppressed with whole-body overexpression of Sirt1. Furthermore, in terms of BA composition, CR increased the ratio of 12 alpha-hydroxylated BAs regardless of Sirt1 genotypes. In conclusion, the CR-induced alterations in BA pool size, BA profiles, and expression of BA-related genes do not appear to be dependent on Sirt1.	[Fu, Zidong Donna] Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, Kansas City, KS 66103 USA; [Fu, Zidong Donna] Harbin Med Univ, Dept Pharmacol, Harbin 150081, Heilongjiang Pr, Peoples R China; [Cui, Julia Yue] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA; [Klaassen, Curtis D.] Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66103 USA	University of Kansas; University of Kansas Medical Center; Harbin Medical University; University of Washington; University of Washington Seattle; University of Kansas; University of Kansas Medical Center	Klaassen, CD (corresponding author), Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66103 USA.	curtisklaassenphd@gmail.com	Fu, Zidong/A-2703-2017		National Institutes of Health [ES-019487, ES-025708]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES025708, R01ES019487] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Funded by the National Institutes of Health [Grants ES-019487 and ES-025708].	Banks AS, 2008, CELL METAB, V8, P333, DOI 10.1016/j.cmet.2008.08.014; Barger JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002264; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; Bordone L, 2007, AGING CELL, V6, P759, DOI 10.1111/j.1474-9726.2007.00335.x; Canto C, 2012, CELL METAB, V15, P838, DOI 10.1016/j.cmet.2012.04.022; Escola-Gil JC, 2013, TRANSL RES, V161, P110, DOI 10.1016/j.trsl.2012.10.008; Chen D, 2008, GENE DEV, V22, P1753, DOI 10.1101/gad.1650608; Chen YR, 2010, BIOCHEM CELL BIOL, V88, P715, DOI 10.1139/O10-010; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Chiang JYL, 2013, COMPR PHYSIOL, V3, P1191, DOI 10.1002/cphy.c120023; Chiang JYL, 2009, J LIPID RES, V50, P1955, DOI 10.1194/jlr.R900010-JLR200; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Fu ZD, 2013, TOXICOL APPL PHARM, V273, P680, DOI 10.1016/j.taap.2013.10.020; Geng YQ, 2011, J CELL BIOCHEM, V112, P3755, DOI 10.1002/jcb.23315; Gomes AP, 2013, CELL, V155, P1624, DOI 10.1016/j.cell.2013.11.037; Haeusler RA, 2012, CELL METAB, V15, P65, DOI 10.1016/j.cmet.2011.11.010; Herranz D, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1001; Hofmann AF, 2014, J LIPID RES; Inagaki T, 2005, CELL METAB, V2, P217, DOI 10.1016/j.cmet.2005.09.001; Kawamata Y, 2003, J BIOL CHEM, V278, P9435, DOI 10.1074/jbc.M209706200; Kazgan N, 2014, GASTROENTEROLOGY, V146, P1006, DOI 10.1053/j.gastro.2013.12.029; Kemper JK, 2013, VITAM HORM, V91, P385, DOI 10.1016/B978-0-12-407766-9.00016-X; Kim I, 2007, J LIPID RES, V48, P2664, DOI 10.1194/jlr.M700330-JLR200; Kir S, 2012, J BIOL CHEM, V287, P41334, DOI 10.1074/jbc.M112.421834; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lettieri Barbato Daniele, 2012, Int J Cell Biol, V2012, P759583, DOI 10.1155/2012/759583; Li TG, 2012, J LIPIDS, V2012, DOI 10.1155/2012/754067; Li X, 2007, MOL CELL, V28, P91, DOI 10.1016/j.molcel.2007.07.032; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261; Mitchell SJ, 2014, CELL REP, V6, P836, DOI 10.1016/j.celrep.2014.01.031; Moynihan KA, 2005, CELL METAB, V2, P105, DOI 10.1016/j.cmet.2005.07.001; Omodei D, 2011, FEBS LETT, V585, P1537, DOI 10.1016/j.febslet.2011.03.015; Pandak WM, 2001, GASTROENTEROLOGY, V120, P1801, DOI 10.1053/gast.2001.24833; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011; Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105; Purushotham A, 2012, MOL CELL BIOL, V32, P1226, DOI 10.1128/MCB.05988-11; Purushotham A, 2009, CELL METAB, V9, P327, DOI 10.1016/j.cmet.2009.02.006; Qiang L, 2012, CELL, V150, P620, DOI 10.1016/j.cell.2012.06.027; Rodgers JT, 2008, FEBS LETT, V582, P46, DOI 10.1016/j.febslet.2007.11.034; Rodgers JT, 2007, P NATL ACAD SCI USA, V104, P12861, DOI 10.1073/pnas.0702509104; Schwarz M, 2001, J LIPID RES, V42, P1594; Shin DJ, 2008, J BIOL CHEM, V283, P15089, DOI 10.1074/jbc.M710452200; Thomas C, 2008, NAT REV DRUG DISCOV, V7, P678, DOI 10.1038/nrd2619; Timmers S, 2011, CELL METAB, V14, P612, DOI 10.1016/j.cmet.2011.10.002; TUCHWEBER B, 1987, LIFE SCI, V41, P2091, DOI 10.1016/0024-3205(87)90526-1; Vlahcevic ZR, 2000, GASTROENTEROLOGY, V118, P599, DOI 10.1016/S0016-5085(00)70267-8; Wang DQH, 2003, AM J PHYSIOL-GASTR L, V285, pG494, DOI 10.1152/ajpgi.00156.2003; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Yu W, 2014, MOL MED REP, V9, P1218, DOI 10.3892/mmr.2014.1944; Zhang YC, 2012, LIVER INT, V32, P58, DOI 10.1111/j.1478-3231.2011.02662.x; Zhang YC, 2010, J LIPID RES, V51, P3230, DOI 10.1194/jlr.M007641	57	7	7	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2015	10	9							e0138307	10.1371/journal.pone.0138307	http://dx.doi.org/10.1371/journal.pone.0138307			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR8LR	26372644	Green Submitted, Green Published, gold			2023-01-03	WOS:000361604400064
J	Littman, DR				Littman, Dan R.			Releasing the Brakes on Cancer Immunotherapy	CELL			English	Editorial Material							T-CELLS; ANTI-PD-1 ANTIBODY; IN-VITRO; CTLA-4; CD28; VIVO	This year's Lasker similar to DeBakey Clinical Research Award goes to James Allison for discovering that antibody blockade of the T cell molecule CTLA-4 unleashes the body's immune response against malignant tumors. This has led to development of multiple "immune checkpoint therapies'' that are prolonging and saving the lives of thousands of cancer patients.	[Littman, Dan R.] NYU, Sch Med, Mol Pathogenesis Program, Kimmel Ctr Biol & Med,Skirball Inst, New York, NY 10016 USA; [Littman, Dan R.] Howard Hughes Med Inst, Chevy Chase, MD USA	New York University; Howard Hughes Medical Institute	Littman, DR (corresponding author), NYU, Sch Med, Mol Pathogenesis Program, Kimmel Ctr Biol & Med,Skirball Inst, New York, NY 10016 USA.	dan.littman@med.nyu.edu						HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoos A, 2007, J IMMUNOTHER, V30, P1, DOI 10.1097/01.cji.0000211341.88835.ae; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; JENKINS MK, 1991, J IMMUNOL, V147, P2461; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Pauken KE, 2015, TRENDS IMMUNOL, V36, P265, DOI 10.1016/j.it.2015.02.008; Selby MJ, 2013, CANCER IMMUNOL RES, V1, P32, DOI 10.1158/2326-6066.CIR-13-0013; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Wang CY, 2014, CANCER IMMUNOL RES, V2, P846, DOI 10.1158/2326-6066.CIR-14-0040; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624	14	80	84	2	36	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 10	2015	162	6					1186	1190		10.1016/j.cell.2015.08.038	http://dx.doi.org/10.1016/j.cell.2015.08.038			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	CR3QL	26359975	Bronze			2023-01-03	WOS:000361247900004
J	Morrison, C				Morrison, Chris			'Financial toxicity' looms as cancer combinations proliferate	NATURE BIOTECHNOLOGY			English	News Item																			0	7	7	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2015	33	8					783	784		10.1038/nbt0815-783	http://dx.doi.org/10.1038/nbt0815-783			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	CO6OB	26252117				2023-01-03	WOS:000359274900002
J	Ratner, M				Ratner, Mark			Microbial cocktails join fecal transplants in IBD treatment trials	NATURE BIOTECHNOLOGY			English	News Item																		2014, NAT BIOTECHNOL, V32, P401; 2015, GASTROENTEROL, V149, P102; 2015, NAT BIOTECHNOL, V33, P228	3	22	23	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2015	33	8					787	788		10.1038/nbt0815-787	http://dx.doi.org/10.1038/nbt0815-787			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	CO6OB	26252119				2023-01-03	WOS:000359274900004
J	Jones, BE; Sauer, B; Jones, MM; Campo, J; Damal, K; He, T; Ying, J; Greene, T; Goetz, MB; Neuhauser, MM; Hicks, LA; Samore, MH				Jones, Barbara Ellen; Sauer, Brian; Jones, Makoto M.; Campo, Jose; Damal, Kavitha; He, Tao; Ying, Jian; Greene, Tom; Goetz, Matthew Bidwell; Neuhauser, Melinda M.; Hicks, Lauri A.; Samore, Matthew H.			Variation in Outpatient Antibiotic Prescribing for Acute Respiratory Infections in the Veteran Population A Cross-sectional Study	ANNALS OF INTERNAL MEDICINE			English	Article							UNITED-STATES; TRACT INFECTIONS; DISEASES SOCIETY; ACUTE BRONCHITIS; AMBULATORY-CARE; ADULTS; AMERICA; TRENDS; RATES	Background: Despite efforts to reduce antibiotic prescribing for acute respiratory infections (ARIs), information on factors that drive prescribing is limited. Objective: To examine trends in antibiotic prescribing in the Veterans Affairs population over an 8-year period and to identify patient, provider, and setting sources of variation. Design: Retrospective, cross-sectional study. Setting: All emergency departments and primary and urgent care clinics in the Veterans Affairs health system. Participants: All patient visits between 2005 and 2012 with primary diagnoses of ARIs that typically had low proportions of bacterial infection. Patients with infections or comorbid conditions that indicated antibiotic use were excluded. Measurements: Overall antibiotic prescription; macrolide prescription; and patient, provider, and setting characteristics extracted from the electronic health record. Results: The proportion of 1 million visits with ARI diagnoses that resulted in antibiotic prescriptions increased from 67.5% in 2005 to 69.2% in 2012 (P < 0.001). The proportion of macrolide antibiotics prescribed increased from 36.8% to 47.0% (P < 0.001). Antibiotic prescribing was highest for sinusitis (adjusted proportion, 86%) and bronchitis (85%) and varied little according to fever, age, setting, or comorbid conditions. Substantial variation was identified in prescribing at the provider level: The 10% of providers who prescribed the most antibiotics did so during at least 95% of their ARI visits, and the 10% who prescribed the least did so during 40% or fewer of their ARI visits. Limitation: Some clinical data that may have influenced the prescribing decision were missing. Conclusion: Veterans with ARIs commonly receive antibiotics, regardless of patient, provider, or setting characteristics. Macrolide use has increased, and substantial variation was identified in antibiotic prescribing at the provider level.	Vet Affairs Salt Lake City Hlth Care Syst, Salt Lake City, UT USA; Univ Utah, Salt Lake City, UT 84112 USA; Vet Affairs Kansas City Hlth Care Syst, Kansas City, MO USA; Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; US Dept Vet Affairs, Hines, IL USA; Ctr Dis Control & Prevent, Atlanta, GA USA	US Department of Veterans Affairs; Utah System of Higher Education; University of Utah; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Centers for Disease Control & Prevention - USA	Jones, BE (corresponding author), George E Wahlen Dept Vet Affairs Med Ctr, Decision Enhancement & Analyt Sci Ctr, 500 Foothill Blvd,Mail Code 182, Salt Lake City, UT 84148 USA.	barbara.jones@hsc.utah.edu	Goetz, Matthew Bidwell/GPX-4090-2022; Sauer, Brian C./AAC-4416-2020; Sauer, Brian C/C-2548-2014	Sauer, Brian C./0000-0002-3546-3051; Sauer, Brian C/0000-0002-3546-3051; Goetz, Matthew/0000-0003-4542-992X; Greene, Tom/0000-0002-3706-7570	U.S. Department of Veterans Affairs, Centers for Disease Control and Prevention	U.S. Department of Veterans Affairs, Centers for Disease Control and Prevention	U.S. Department of Veterans Affairs, Centers for Disease Control and Prevention.	Ackerman S, 2012, ANN INTERN MED, V157, P211, DOI 10.7326/0003-4819-157-3-201208070-00013; Agency for Healthcare Research and Quality, 2012, CLIN CLASS SOFTW CCS; Aspinall SL, 2005, CLIN THER, V27, P258, DOI 10.1016/j.clinthera.2005.02.002; Barnett ML, 2014, JAMA-J AM MED ASSOC, V311, P2020, DOI 10.1001/jama.2013.286141; Barnett ML, 2014, JAMA INTERN MED, V174, P138, DOI 10.1001/jamainternmed.2013.11673; Boyko EJ, 2000, AM J EPIDEMIOL, V151, P307, DOI 10.1093/oxfordjournals.aje.a010207; Centers for Disease Control and Prevention, 2015, GET SMART KNOW ANT W; Dellit TH, 2007, CLIN INFECT DIS, V44, P159, DOI 10.1086/510393; Bui DDA, 2014, J AM MED INFORM ASSN, V21, P850, DOI 10.1136/amiajnl-2013-002411; Fairlie T, 2012, ARCH INTERN MED, V172, P1513, DOI 10.1001/archinternmed.2012.4089; Franck AJ, 2010, J AM PHARM ASSOC, V50, P726, DOI 10.1331/JAPhA.2010.09103; Gonzales R, 2001, ANN INTERN MED, V134, P479, DOI 10.7326/0003-4819-134-6-200103200-00013; Gonzales R, 1998, J GEN INTERN MED, V13, P541, DOI 10.1046/j.1525-1497.1998.00165.x; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; Grijalva CG, 2009, JAMA-J AM MED ASSOC, V302, P758, DOI 10.1001/jama.2009.1163; Hicks LA, 2013, NEW ENGL J MED, V368, P1461, DOI 10.1056/NEJMc1212055; Ivers N, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000259.pub3; Jenkins SG, 2009, EMERG INFECT DIS, V15, P1260, DOI 10.3201/eid1508.081187; Lee GC, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-96; McCaig Linda E., 2011, Morbidity and Mortality Weekly Report, V60, P1153; McCarthy M, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5649; MCCULLOCH CE, 2005, ENCY BIOSTATISTICS, P2085; Muller CJ, 2014, INT J EPIDEMIOL, V43, P962, DOI 10.1093/ije/dyu029; Office of Quality Safety and Value, 2012, 2012 VHA FAC QUAL SA; Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMc1207269; Roumie CL, 2005, J GEN INTERN MED, V20, P697, DOI 10.1111/j.1525-1497.2005.0148.x; Shapiro DJ, 2014, J ANTIMICROB CHEMOTH, V69, P234, DOI 10.1093/jac/dkt301; Spellberg B, 2008, CLIN INFECT DIS, V46, P155, DOI 10.1086/524891; Steinman MA, 2003, JAMA-J AM MED ASSOC, V289, P719, DOI 10.1001/jama.289.6.719; Steinman MA, 2009, AM J MANAG CARE, V15, P861; US Department of Veterans Affairs, 2015, VA INF COMP INFR VIN; Zhang YT, 2012, ARCH INTERN MED, V172, P1465, DOI 10.1001/archinternmed.2012.3717	32	73	75	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 21	2015	163	2					73	+		10.7326/M14-1933	http://dx.doi.org/10.7326/M14-1933			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CN4NS	26192562				2023-01-03	WOS:000358407500014
J	Rostoker, G; Griuncelli, M; Loridon, C; Magna, T; Machado, G; Drahi, G; Dahan, H; Janklewicz, P; Cohen, Y				Rostoker, Guy; Griuncelli, Mireille; Loridon, Christelle; Magna, Theophile; Machado, Gabrielle; Drahi, Gilles; Dahan, Herve; Janklewicz, Philippe; Cohen, Yves			Reassessment of Iron Biomarkers for Prediction of Dialysis Iron Overload: An MRI Study	PLOS ONE			English	Article							BONE-MARROW IRON; CHRONIC KIDNEY-DISEASE; SERUM FERRITIN LEVELS; HEMODIALYSIS-PATIENTS; ANEMIA MANAGEMENT; RENAL-FAILURE; DEFICIENCY; STORES; DIAGNOSIS; EFFICACY	Background and Objectives Iron overload among hemodialysis patients was previously considered rare but is now an increasingly recognized clinical situation. We analyzed correlations between iron biomarkers and the liver iron concentration (LIC) measured by magnetic resonance imaging (MRI), and examined their diagnostic accuracy for iron overload. Design, Setting, Participants and Measurements We performed a prospective cross-sectional study from 31 January 2005 to 31 August 2013 in the dialysis centre of a French community-based private hospital. A cohort of 212 hemodialysis patients free of overt inflammation or malnutrition, were treated for anemia with parenteral iron-sucrose and an erythropoesis-stimulating agent, in keeping with current clinical guidelines. Blinded measurements of hepatic iron stores were performed by T1 and T2* contrast MRI, and relationships were analysed using Spearman's coefficient, logistic regression and receiver-operator characteristic (ROC) curves. Results Among the biological markers, only serum ferritin showed a strong correlation with LIC (rho= 0.52, 95% CI: 0.41-0.61, p< 0.0001, Spearman test). In logistic analysis, only serum ferritin correctly classified the overall cohort into patients with normal liver iron stores (LIC <= 50 mu mol/g) and those with elevated liver iron stores (LIC > 50 mu mol/g) (odds ratio 1.007; 95% CI: 1.004-1.010). Serum ferritin was the iron biomarker with the best discriminatory capacity in ROC curves analysis (area under the curve (AUC) = 0.767; 95% CI: 0.698-0.835). The optimal serum ferritin cutoffs were 160 mu g/L for LIC > 50 mu mol/g (mild iron overload) and 290 mu g/L for LIC > 200 mu mol/g (severe iron overload). Conclusions For clinical purposes, serum ferritin correctly reflects liver iron stores, as assessed by MRI, in hemodialysis patients without overt inflammation or malnutrition. These results strongly suggest that current ferritin target values should be lowered to avoid iron overload.	[Rostoker, Guy; Griuncelli, Mireille; Loridon, Christelle; Magna, Theophile] Hop Prive Claude Galien, Div Nephrol & Dialysis, Ramsay Gen Sante, Quincy Sous Senart, France; [Machado, Gabrielle] Hop Prive Claude Galien, Dept Biochem, Ramsay Gen Sante, Quincy Sous Senart, France; [Drahi, Gilles; Dahan, Herve; Janklewicz, Philippe; Cohen, Yves] Hop Prive Claude Galien, Div Radiol, Ramsay Gen Sante, Quincy Sous Senart, France		Rostoker, G (corresponding author), Hop Prive Claude Galien, Div Nephrol & Dialysis, Ramsay Gen Sante, Quincy Sous Senart, France.	rostotom@orange.fr	Rostoker, Guy/K-1432-2019	Rostoker, Guy/0000-0002-4383-3825	Association Quincy Recherche Clinique et Therapeutique (QRCT)	Association Quincy Recherche Clinique et Therapeutique (QRCT)	The authors received a grant from the non-for-profit Association Quincy Recherche Clinique et Therapeutique (QRCT).	ALI M, 1982, LANCET, V1, P652; ANASTASSIADES EG, 1993, NEPHROL DIAL TRANSPL, V8, P846; Anemia Work Group, 2012, KIDNEY INT, V2, P279, DOI [DOI 10.1038/kisup.2012.37, DOI 10.1093/NDT/GFT033.13]; [Anonymous], 2014, KDIGO CONTR C IR MAN; Bailie GR, 2015, KIDNEY INT, V87, P162, DOI 10.1038/ki.2014.275; Barton JC., 2010, HDB IRON OVERLOAD DI; BELL JD, 1980, KIDNEY INT, V17, P237, DOI 10.1038/ki.1980.27; Bohning D, 2008, STAT METHODS MED RES, V17, P543, DOI 10.1177/0962280207081867; BRITTENHAM GM, 1994, NEW ENGL J MED, V331, P567, DOI 10.1056/NEJM199409013310902; Canavese C, 2004, KIDNEY INT, V65, P1091, DOI 10.1111/j.1523-1755.2004.00480.x; CECCHIN E, 1990, KIDNEY INT, V37, P943, DOI 10.1038/ki.1990.69; Fernandez-Rodriguez AM, 1999, AM J KIDNEY DIS, V34, P508, DOI 10.1016/S0272-6386(99)70079-X; Ferrari P, 2011, CLIN J AM SOC NEPHRO, V6, P77, DOI 10.2215/CJN.04190510; Fishbane S, 2014, NEPHROL DIAL TRANSPL, V29, P255, DOI 10.1093/ndt/gft269; Gandon Y, 2004, LANCET, V363, P357, DOI 10.1016/S0140-6736(04)15436-6; Ghoti H, 2012, EUR J HAEMATOL, V89, P87, DOI 10.1111/j.1600-0609.2012.01783.x; GOKAL R, 1979, Q J MED, V48, P393; Harmatz P, 2000, BLOOD, V96, P76, DOI 10.1182/blood.V96.1.76.013k22_76_79; Herbert V, 1997, STEM CELLS, V15, P291, DOI 10.1002/stem.150291; HUSSEIN S, 1975, BRIT MED J, V1, P546, DOI 10.1136/bmj.1.5957.546; Kalantar-Zadeh K, 2006, CLIN J AM SOC NEPHRO, V1, pS9, DOI 10.2215/CJN.01390406; KALANTARZADEH K, 1995, AM J KIDNEY DIS, V26, P292, DOI 10.1016/0272-6386(95)90649-5; KDOQI, 2006, Am J Kidney Dis, V47, pS16; Kohgo Y, 2008, INT J HEMATOL, V88, P7, DOI 10.1007/s12185-008-0120-5; Kuo KL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050295; Kuragano T, 2014, KIDNEY INT, V86, P845, DOI 10.1038/ki.2014.114; Locatelli F, 2013, NEPHROL DIAL TRANSPL, V28, P1346, DOI 10.1093/ndt/gft033; Locatelli F, 2009, NEPHROL DIAL TRANSPL, V24, P348, DOI 10.1093/ndt/gfn653; MILMAN N, 1980, ACTA MED SCAND, V207, P201; MIRAHMADI KS, 1977, JAMA-J AM MED ASSOC, V238, P601, DOI 10.1001/jama.238.7.601; Motulsky H., 2014, INTUITIVE BIOSTATIST, P203; Rostoker G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115096; Rostoker G, 2012, AM J MED, V125, P991, DOI 10.1016/j.amjmed.2012.01.015; Sheskin D. J., 2007, HDB PARAMETRIC NONPA; Skikne BS, 2008, AM J HEMATOL, V83, P872, DOI 10.1002/ajh.21279; VANWYCK DB, 1989, SEMIN NEPHROL, V9, P21; Vaziri ND, 2013, AM J KIDNEY DIS, V61, P992, DOI 10.1053/j.ajkd.2012.10.027; Vaziri ND, 2012, AM J MED, V125, P951, DOI 10.1016/j.amjmed.2012.02.009	38	32	35	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2015	10	7							e0132006	10.1371/journal.pone.0132006	http://dx.doi.org/10.1371/journal.pone.0132006			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RQ	26182077	Green Submitted, Green Published, gold			2023-01-03	WOS:000358198200013
J	Reiling, J				Reiling, Jennifer			Reinforcements in the Pure Food Crusade	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint																		REILING J, 1905, JAMA-J AM MED ASSOC, V45, P198	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	2015	314	2					190	190		10.1001/jama.2014.11860	http://dx.doi.org/10.1001/jama.2014.11860			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CM7JI	26172908				2023-01-03	WOS:000357867500028
J	Qin, DJ; Tang, CX; Yang, L; Lei, H; Wei, W; Wang, YY; Ma, CM; Gao, FH; Xu, HZ; Wu, YL				Qin, Dong-Jun; Tang, Cai-Xia; Yang, Li; Lei, Hu; Wei, Wei; Wang, Ying-Ying; Ma, Chun-Min; Gao, Feng-Hou; Xu, Han-Zhang; Wu, Ying-Li			Hsp90 Is a Novel Target Molecule of CDDO-Me in Inhibiting Proliferation of Ovarian Cancer Cells	PLOS ONE			English	Article							SHOCK-PROTEIN 90; TRITERPENOID CDDO; SYNTHETIC TRITERPENOIDS; BARDOXOLONE METHYL; APOPTOSIS; EXPRESSION; PREVENTION; ESTER	Synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9(11)-dien-28-oate (CDDO-Me) has been shown as a promising agent against ovarian cancer. However, the underlying mechanism is not well understood. Here, we demonstrate that CDDO-Me directly interacts with Hsp90 in cells by cellular thermal shift assay. CDDO-Me treatment leads to upregulation of Hsp70 and degradation of Hsp90 clients (ErbB2 and Akt), indicating the inhibition of Hsp90 by CDDO-Me in cells. Knockdown of Hsp90 significantly inhibits cell proliferation and enhances the anti-proliferation effect of CDDO-Me in H08910 ovarian cancer cells. Dithiothreitol inhibits the interaction of CDDO-Me with Hsp90 in cells and abrogates CDDOMe induced upregulation of Hsp70, degradation of Akt and cell proliferation inhibition. This suggests the anti-ovarian cancer effect of CDDO-Me is possibly mediated by the formation of Michael adducts between CDDO-Me and reactive nucleophiles on Hsp90. This study identifies Hsp90 as a novel target protein of CDDO-Me, and provides a novel insight into the mechanism of action of CDDO-Me in ovarian cancer cells.	[Qin, Dong-Jun; Tang, Cai-Xia; Yang, Li; Lei, Hu; Wei, Wei; Wang, Ying-Ying; Ma, Chun-Min; Xu, Han-Zhang; Wu, Ying-Li] Shanghai Jiao Tong Univ, Shanghai Tongren Hosp,Chinese Minist Educ, Fac Basic Med,Key Lab Cell Differentiat & Apoptos, Sch Med,Hongqiao Int Inst Med,Chem Biol Div Shang, Shanghai 200030, Peoples R China; [Gao, Feng-Hou] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Sch Med, Inst Oncol, Shanghai 200030, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Xu, HZ (corresponding author), Shanghai Jiao Tong Univ, Shanghai Tongren Hosp,Chinese Minist Educ, Fac Basic Med,Key Lab Cell Differentiat & Apoptos, Sch Med,Hongqiao Int Inst Med,Chem Biol Div Shang, Shanghai 200030, Peoples R China.	smollyxu@126.com; wuyingli@shsmu.edu.cn	Wei, Weijun/AAZ-3551-2021; Lei, Hu/AAR-7795-2021	Lei, Hu/0000-0003-3288-5205	National Basic Research Program of China (973 Program) [2015CB910403, 2013CB910903]; National Natural Science Foundation of China [91313303, 31100980, 81272886]; Science and Technology Committee of Shanghai [11JC1406500, 13431900501, 13ZR1456900]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Committee of Shanghai(Shanghai Science & Technology Committee)	National Basic Research Program of China (973 Program) (NO. 2015CB910403, 2013CB910903), National Natural Science Foundation of China (91313303, 31100980, 81272886), Science and Technology Committee of Shanghai (11JC1406500, 13431900501, 13ZR1456900).	Banerjee S, 2013, CLIN CANCER RES, V19, P961, DOI 10.1158/1078-0432.CCR-12-2243; Banerji U, 2005, J CLIN ONCOL, V23, P4152, DOI 10.1200/JCO.2005.00.612; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Bernstein SH, 2012, BLOOD, V119, P3321, DOI 10.1182/blood-2011-02-340075; Cheng JC, 2013, BIOCHEM BIOPH RES CO, V434, P81, DOI 10.1016/j.bbrc.2013.03.062; Chu SH, 2013, MOL BIOL REP, V40, P1, DOI 10.1007/s11033-012-1930-3; Citri A, 2006, J BIOL CHEM, V281, P14361, DOI 10.1074/jbc.M512613200; Deeb D, 2013, MOLECULES, V18, P3250, DOI 10.3390/molecules18033250; Deeb D, 2012, BIOCHEM BIOPH RES CO, V422, P561, DOI 10.1016/j.bbrc.2012.05.024; Duan ZF, 2009, CANCER CHEMOTH PHARM, V63, P681, DOI 10.1007/s00280-008-0785-8; Elstrand MB, 2012, HUM PATHOL, V43, P529, DOI 10.1016/j.humpath.2011.05.022; Gao XH, 2011, ANTICANCER RES, V31, P3673; Gritsina G, 2015, MOL CANCER THER, V14, P1035, DOI 10.1158/1535-7163.MCT-14-0800; Hong DS, 2012, CLIN CANCER RES, V18, P3396, DOI 10.1158/1078-0432.CCR-11-2703; Hyer ML, 2008, CANCER RES, V68, P2927, DOI 10.1158/0008-5472.CAN-07-5759; Jafari R, 2014, NAT PROTOC, V9, P2100, DOI 10.1038/nprot.2014.138; Jiao YS, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-125; Kim EH, 2012, CANCER PREV RES, V5, P89, DOI 10.1158/1940-6207.CAPR-11-0359; Konopleva M, 2002, BLOOD, V99, P326, DOI 10.1182/blood.V99.1.326; Leu JIJ, 2011, MOL CANCER RES, V9, P936, DOI 10.1158/1541-7786.MCR-11-0019; Liby K, 2007, CANCER RES, V67, P2414, DOI 10.1158/0008-5472.CAN-06-4534; Liu HQ, 2013, CLIN CANCER RES, V19, P5053, DOI 10.1158/1078-0432.CCR-13-1115; Minnnaugh EG, 2004, MOL CANCER THER, V3, P551; Molina DM, 2013, SCIENCE, V341, P84, DOI 10.1126/science.1233606; Murphy ME, 2013, CARCINOGENESIS, V34, P1181, DOI 10.1093/carcin/bgt111; Nagaraj S, 2010, CLIN CANCER RES, V16, P1812, DOI 10.1158/1078-0432.CCR-09-3272; Shanmugam MK, 2014, CANCER LETT, V346, P206, DOI 10.1016/j.canlet.2014.01.016; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Wang YY, 2014, DRUG DES DEV THER, V8, P2075, DOI 10.2147/DDDT.S68872; Wang YY, 2014, MOL CANCER, V13, DOI [10.1186/1476-4598-13-30, 10.1186/s12934-014-0151-y]; Wang Y, 2015, FUTURE MED CHEM, V7, P87, DOI [10.4155/FMC.14.154, 10.4155/fmc.14.154]; Zhao RM, 2005, BIOCHEM CELL BIOL, V83, P703, DOI 10.1139/O05-158	33	22	24	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2015	10	7							e0132337	10.1371/journal.pone.0132337	http://dx.doi.org/10.1371/journal.pone.0132337			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1CS	26134508	Green Submitted, Green Published, gold			2023-01-03	WOS:000358154400112
J	Somma, F; D'Angelo, R; Serra, N; Gatta, G; Grassi, R; Fiore, F				Somma, Francesco; D'Angelo, Roberto; Serra, Nicola; Gatta, Gianluca; Grassi, Roberto; Fiore, Francesco			Use of Ethanol in the Trans-Arterial Lipiodol Embolization (TAELE) of Intermediated-Stage HCC: Is This Safer than Conventional Trans-Arterial Chemo-Embolization (c-TACE)?	PLOS ONE			English	Article							UNRESECTABLE HEPATOCELLULAR-CARCINOMA; TRANSARTERIAL CHEMOEMBOLIZATION; TRANSCATHETER; SURVIVAL; ABLATION; MIXTURE; EFFICACY; THERAPY; LOBAR; TERM	Purpose To evaluate safety and efficacy of Trans-Arterial Ethanol-Lipiodol Embolization (TAELE) compared with conventional Trans-Arterial Chemo-Embolization (cTACE) in the treatment of small intermediate-HCC (BCLC-Stage B). Materials and Methods A random sample of 87 patients (37.93% male; 62.07% female; age range, 36-86 years) with documented small intermediate-HCC and treated with TAELE (mixture 1: 1 of Ethanol and Lipiodol) or cTACE (mixture of 50mg-Epirubicin and 5cc-Lipiodol) were retrospectively studied in an institutional review board approved protocol. The two procedures were compared with chi(2)-test, chi(2)-test with Yates correction, McNemar's exact test, ANOVA test and log-rank test. Results TAELE and cTACE therapies were performed in 45 and 42 patients, respectively. Thirty days after the procedure, a Multi-Detector Computed Tomography (MDCT) showed no significant difference in the number of patients with partial and complete response between the two groups (p-value = 0.958), according to mRECIST. Contrary, significant differences were found in tumor-devascularization, lesion-reduction and post-embolization syndrome occurrence (p-value = 0.0004, p-value = 0.0003 and p-value = 0.009, respectively). Similar survival was observed during 36-month follow-up (p-value = 0.884). Conclusion Compared to cTACE, TAELE showed a better toxicity profile with similar 36-month survival and similar one-month anti-tumor effects, which makes it better tolerated by patients, especially in case of more than one treatment.	[Somma, Francesco; Serra, Nicola; Gatta, Gianluca; Grassi, Roberto] SUN, Sect Radiol, Dept Med & Surg Magrassi & Lanzara, Naples, Italy; [D'Angelo, Roberto; Fiore, Francesco] Natl Canc Inst Naples Fdn Pascale, Dept Intervent Radiol, Naples, Italy	Universita della Campania Vanvitelli	Somma, F (corresponding author), SUN, Sect Radiol, Dept Med & Surg Magrassi & Lanzara, Naples, Italy.	fra1585@hotmail.it	Grassi, Roberto/AAL-5045-2020; Somma, Francesco/AAA-9462-2021	Grassi, Roberto/0000-0002-3587-474X; GATTA, Gianluca/0000-0003-0874-8294; Serra, Nicola/0000-0001-8086-6362; Somma, Francesco/0000-0002-8193-3050				BREEDIS C, 1954, AM J PATHOL, V30, P969; Bruix J, 2004, GASTROENTEROLOGY, V127, pS179, DOI 10.1053/j.gastro.2004.09.032; BRUIX J, 1994, HEPATOLOGY, V20, P643, DOI 10.1002/hep.1840200315; Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933; Bruix J, 2001, J HEPATOL, V35, P421, DOI 10.1016/S0168-8278(01)00130-1; Bruix J, 2009, LANCET, V373, P614, DOI 10.1016/S0140-6736(09)60381-0; Buijs M, 2008, RADIOLOGY, V249, P346, DOI 10.1148/radiol.2483071902; Camma C, 2002, RADIOLOGY, V224, P47, DOI 10.1148/radiol.2241011262; Cheng YF, 2000, WORLD J SURG, V24, P844, DOI 10.1007/s002680010135; Cheung YC, 2005, WORLD J GASTROENTERO, V11, P2792, DOI 10.3748/wjg.v11.i18.2792; Choi JY, 2011, ONCOLOGY-BASEL, V81, P141, DOI 10.1159/000333277; Chung JW, 1996, RADIOLOGY, V198, P33, DOI 10.1148/radiology.198.1.8539401; Clayton D, 1993, STAT MODELS EPIDEMIO, p[27, 146]; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI 10.1016/j.ejca.2011.12.021; FARMER DG, 1994, ANN SURG, V219, P236, DOI 10.1097/00000658-199403000-00003; Fiore F, 2014, ENDOCRINE; Forner A, 2010, SEMIN LIVER DIS, V30, P61, DOI 10.1055/s-0030-1247133; Gu YK, 2010, WORLD J GASTROENTERO, V16, P5766, DOI 10.3748/wjg.v16.i45.5766; Hogg RV., 1987, ENG STAT; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lencioni R, 2010, SEMIN LIVER DIS, V30, P52, DOI 10.1055/s-0030-1247132; Leung DA, 2001, J VASC INTERV RADIOL, V12, P321, DOI 10.1016/S1051-0443(07)61911-3; Lewandowski RJ, 2009, AM J TRANSPLANT, V9, P1920, DOI 10.1111/j.1600-6143.2009.02695.x; Lewandowski RJ, 2010, RADIOLOGY, V255, P955, DOI 10.1148/radiol.10091473; Liapi E, 2007, J CLIN ONCOL, V25, P978, DOI 10.1200/JCO.2006.09.8657; Llovet JM, 2005, J GASTROENTEROL, V40, P225, DOI 10.1007/s00535-005-1566-3; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X; Marelli L, 2007, CARDIOVASC INTER RAD, V30, P6, DOI 10.1007/s00270-006-0062-3; McNemar Q, 1947, PSYCHOMETRIKA, V12, P153, DOI 10.1007/BF02295996; Oliveri RS, 2011, CAMPBELL SYSTEMATIC, V3, P1; Omata M, 2010, HEPATOL INT, V4, P439, DOI 10.1007/s12072-010-9165-7; Park J H, 1993, J Vasc Interv Radiol, V4, P333; Parkin DM, 2005, CA CANC J CLIN, V55, P74; Sangiovanni A, 2004, GASTROENTEROLOGY, V126, P1005, DOI 10.1053/j.gastro.2003.12.049; Sokal RR, 1994, BIOMETRY PRINCIPLES; Syha R, 2012, EUR J GASTROEN HEPAT, V24, P1325, DOI 10.1097/MEG.0b013e32835724bc; Varela M, 2003, CANCER TREAT REV, V29, P99, DOI 10.1016/S0305-7372(02)00123-8; Wigmore SJ, 2003, BRIT J CANCER, V89, P1423, DOI 10.1038/sj.bjc.6601329; Yu SCH, 2009, J VASC INTERV RADIOL, V20, P352, DOI 10.1016/j.jvir.2008.12.407	41	10	10	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2015	10	6							e0129573	10.1371/journal.pone.0129573	http://dx.doi.org/10.1371/journal.pone.0129573			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL4OY	26110810	Green Published, gold, Green Submitted			2023-01-03	WOS:000356933800027
J	McCormack, S; Dunn, DT; Desai, M; Dolling, DI; Gafos, M; Gilson, R; Sullivan, AK; Clarke, A; Reeves, I; Schembri, G; Mackie, N; Bowman, C; Lacey, CJ; Apea, V; Brady, M; Fox, J; Taylor, S; Antonucci, S; Khoo, SH; Rooney, J; Nardone, A; Fisher, M; McOwan, A; Phillips, AN; Johnson, AM; Gazzard, B; Gill, ON				McCormack, Sheena; Dunn, David T.; Desai, Monica; Dolling, David I.; Gafos, Mitzy; Gilson, Richard; Sullivan, Ann K.; Clarke, Amanda; Reeves, Iain; Schembri, Gabriel; Mackie, Nicola; Bowman, Christine; Lacey, Charles J.; Apea, Vanessa; Brady, Michael; Fox, Julie; Taylor, Stephen; Antonucci, Simone; Khoo, Saye H.; Rooney, James; Nardone, Anthony; Fisher, Martin; McOwan, Alan; Phillips, Andrew N.; Johnson, Anne M.; Gazzard, Brian; Gill, Owen N.			Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial	LANCET			English	Article							ANTIRETROVIRAL PROPHYLAXIS; AFRICAN WOMEN; TRANSMISSION; TENOFOVIR; MEN; UK	Background Randomised placebo-controlled trials have shown that daily oral pre-exposure prophylaxis (PrEP) with tenofovir-emtricitabine reduces the risk of HIV infection. However, this benefit could be counteracted by risk compensation in users of PrEP. We did the PROUD study to assess this effect. Methods PROUD is an open-label randomised trial done at 13 sexual health clinics in England. We enrolled HIV-negative gay and other men who have sex with men who had had anal intercourse without a condom in the previous 90 days. Participants were randomly assigned (1: 1) to receive daily combined tenofovir disoproxil fumarate (245 mg) and emtricitabine (200 mg) either immediately or after a deferral period of 1 year. Randomisation was done via web-based access to a central computer-generated list with variable block sizes (stratified by clinical site). Follow-up was quarterly. The primary outcomes for the pilot phase were time to accrue 500 participants and retention; secondary outcomes included incident HIV infection during the deferral period, safety, adherence, and risk compensation. The trial is registered with ISRCTN (number ISRCTN94465371) and ClinicalTrials.gov (NCT02065986). Findings We enrolled 544 participants (275 in the immediate group, 269 in the deferred group) between Nov 29, 2012, and April 30, 2014. Based on early evidence of effectiveness, the trial steering committee recommended on Oct 13, 2014, that all deferred participants be offered PrEP. Follow-up for HIV incidence was complete for 243 (94%) of 259 patient-years in the immediate group versus 222 (90%) of 245 patient-years in the deferred group. Three HIV infections occurred in the immediate group (1.2/100 person-years) versus 20 in the deferred group (9.0/100 person-years) despite 174 prescriptions of post-exposure prophylaxis in the deferred group (relative reduction 86%, 90% CI 64-96, p=0.0001; absolute difference 7.8/100 person-years, 90% CI 4.3-11.3). 13 men (90% CI 9-23) in a similar population would need access to 1 year of PrEP to avert one HIV infection. We recorded no serious adverse drug reactions; 28 adverse events, most commonly nausea, headache, and arthralgia, resulted in interruption of PrEp. We detected no difference in the occurrence of sexually transmitted infections, including rectal gonorrhoea and chlamydia, between groups, despite a suggestion of risk compensation among some PrEP recipients. Interpretation In this high incidence population, daily tenofovir-emtricitabine conferred even higher protection against HIV than in placebo-controlled trials, refuting concerns that effectiveness would be less in a real-world setting. There was no evidence of an increase in other sexually transmitted infections. Our findings strongly support the addition of PrEP to the standard of prevention for men who have sex with men at risk of HIV infection. Copyright (C) McCormack et al. Open Access article distributed under the terms of CC BY.	[McCormack, Sheena; Dunn, David T.; Desai, Monica; Dolling, David I.; Gafos, Mitzy] UCL, MRC Clin Trials Unit, London WC2B 6NH, England; [Desai, Monica; Nardone, Anthony; Gill, Owen N.] Publ Hlth England Ctr Infect Dis Surveillance & C, HIV & STI Dept, London, England; [Gilson, Richard] Cent & NorthWest London NHS Fdn Trust, Mortimer Market Ctr, London, England; [Sullivan, Ann K.; Gazzard, Brian] Chelsea & Westminster Healthcare NHS Fdn Trust, St Stephens Ctr, London, England; [Clarke, Amanda; Fisher, Martin] Brighton & Sussex Univ Hosp NHS Trust, Royal Sussex Cty Hosp, Claude Nicol Ctr, Brighton, E Sussex, England; [Reeves, Iain] Homerton Univ Hosp NHS Fdn Trust, London, England; [Schembri, Gabriel] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Ctr Sexual Hlth, Manchester, Lancs, England; [Mackie, Nicola] Imperial Coll Healthcare NHS Fdn Trust, St Marys Hosp, London, England; [Bowman, Christine] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England; [Lacey, Charles J.] Univ York, York Teaching Hosp, York YO10 5DD, N Yorkshire, England; [Lacey, Charles J.] Univ York, Hull York Med Sch, York YO10 5DD, N Yorkshire, England; [Apea, Vanessa] Barts Hlth NHS Trust, Ambrose King Ctr, London, England; [Apea, Vanessa] Barts Hlth NHS Trust, Sexual Hlth Ctr, London, England; [Brady, Michael] Kings Coll Hosp NHS Fdn Trust, London, England; [Fox, Julie] Guys & St Thomas NHS Fdn Trust, London, England; [Taylor, Stephen] Heart England NHS Fdn Trust, Birmingham Heartlands Hosp, Birmingham, W Midlands, England; [McCormack, Sheena; Antonucci, Simone; McOwan, Alan] Chelsea & Westminster Hosp NHS Fdn Trust, London, England; [Rooney, James] Gilead Sci Foster City, Foster City, CA USA; [Khoo, Saye H.] Univ Liverpool, Liverpool L69 3BX, Merseyside, England; [Gilson, Richard; Phillips, Andrew N.; Johnson, Anne M.] UCL, Res Dept Infect & Populat Hlth, London, England	Medical Research Council Clinical Trials Unit; University of London; University College London; Public Health England; Brighton and Sussex University Hospitals NHS Trust; University of Brighton; University of Manchester; Imperial College London; University of Sheffield; University of York - UK; University of Hull; University of York - UK; Barts Health NHS Trust; Barts Health NHS Trust; King's College Hospital NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; Heart of England NHS Foundation Trust; University of Birmingham; Imperial College London; Gilead Sciences; University of Liverpool; University of London; University College London	McCormack, S (corresponding author), UCL, MRC Clin Trials Unit, Aviat House, London WC2B 6NH, England.	s.mccormack@ucl.ac.uk	Phillips, Andrew N/B-4427-2008	Phillips, Andrew N/0000-0003-2384-4807; Taylor, stephen/0000-0001-5496-6482; Gafos, Mitzy/0000-0002-7894-1498; Nardone, Anthony/0000-0003-1138-0937; Johnson, Anne/0000-0003-1330-7100; fox, Julie/0000-0002-0583-8019; Dunn, David/0000-0003-1836-4446	MRC Clinical Trials Unit at University College London; Public Health England; UK National Institute of Health Research Clinical Research Network; Gilead Sciences; MRC [MC_U122861322, MC_UU_12023/1] Funding Source: UKRI; Medical Research Council [MC_UU_12023/1, MC_U122861322, MC_UU_12023/23] Funding Source: researchfish; National Institute for Health Research [ACF-2008-20-002] Funding Source: researchfish	MRC Clinical Trials Unit at University College London(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Public Health England; UK National Institute of Health Research Clinical Research Network; Gilead Sciences(Gilead Sciences); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	We dedicate this paper to the late Professor Martin Fisher, who championed treatment and prevention in the UK for two decades, and whose leadership and companionship we miss. The study was supported by ad hoc funding from the MRC Clinical Trials Unit at University College London and an innovations grant from Public Health England, and most clinics received support through the UK National Institute of Health Research Clinical Research Network. Gilead Sciences provided Truvada, distributed drug to clinics, and awarded a grant for the additional diagnostic tests including drug concentrations in plasma. We thank the PROUD participants who recognised the need for the study design, the dedication of the clinic teams, and the oversight that the governance committees provided as the study evolved, including the community engagement group who helped to boost recruitment and advised us on dissemination. A full list of contributors is given in the appendix.	Aghaizu A, 2015, BASHH SPRING C 2015; Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006; [Anonymous], 2014, PREEXP PROPH PREV HI; Antonucci S, 2014, 20 INT AIDS C JUL 20; Asboe D, 2012, HIV MED, V13, P1, DOI 10.1111/j.1468-1293.2011.00971.x; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Brown AE, 2014, AIDS, V28, P281, DOI 10.1097/QAD.0000000000000137; Browne OT, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e2339; Buchbinder SP, 2014, LANCET INFECT DIS, V14, P468, DOI 10.1016/S1473-3099(14)70025-8; Cambiano V, 2015, BASHH SPRING C 2015; Cassell MM, 2006, BMJ-BRIT MED J, V332, P605, DOI 10.1136/bmj.332.7541.605; Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7; European Centre for Disease Prevention and Control, 2012, EV HIV TREATM PREV E; European Medicines Agency, 2012, EMA1712642012; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Kataria, 2016, SAUDI J SPORTS MED, V16, P139; Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269; McCormack S, 2012, INT J STD AIDS, V23, P1, DOI 10.1258/ijsa.2011.051211; Molina JM, 2015, C RETR OPP INF FEB 2; Nakagawa F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125018; Phillips AN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055312; Public Health England, 2014, HIV UK 2014 REP; Sellier PO, 2011, NEW ENGL J MED, V364, P1373, DOI 10.1056/NEJMc1101504; Standards Unit Microbiology Services Public Health England, 2013, UK STAND MICR INV SE; Sterne JAC, 2001, BMJ-BRIT MED J, V322, P226, DOI 10.1136/bmj.322.7280.226; Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711; Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614; van de Vijver DAMC, 2013, AIDS, V27, P2943, DOI 10.1097/01.aids.0000433237.63560.20; Wilson DP, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001231	29	1129	1140	5	128	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 2	2016	387	10013					53	60		10.1016/S0140-6736(15)00056-2	http://dx.doi.org/10.1016/S0140-6736(15)00056-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CZ9ZU	26364263	hybrid, Green Accepted, Green Published			2023-01-03	WOS:000367457300027
J	Jarantow, SW; Bushey, BS; Pardinas, JR; Boakye, K; Lacy, ER; Sanders, R; Sepulveda, MA; Moores, SL; Chiu, ML				Jarantow, Stephen W.; Bushey, Barbara S.; Pardinas, Jose R.; Boakye, Ken; Lacy, Eilyn R.; Sanders, Renouard; Sepulveda, Manuel A.; Moores, Sheri L.; Chiu, Mark L.			Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor x c-MET Bispecific Antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUANTITATIVE FLOW-CYTOMETRY; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACQUIRED-RESISTANCE; DENSITY; AFFINITY; HETEROGENEITY; CYTOTOXICITY; QUANTIFICATION; PERFORMANCE; PRECURSORS	The efficacy of engaging multiple drug targets using bispecific antibodies (BsAbs) is affected by the relative cell-surface protein levels of the respective targets. In this work, the receptor density values were correlated to the in vitro activity of a BsAb (JNJ-61186372) targeting epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-MET). Simultaneous binding of the BsAb to both receptors was confirmed in vitro. By using controlled Fab-arm exchange, a set of BsAbs targeting EGFR and c-MET was generated to establish an accurate receptor quantitation of a panel of lung and gastric cancer cell lines expressing heterogeneous levels of EGFR and c-MET. EGFR and c-MET receptor density levels were correlated to the respective gene expression levels as well as to the respective receptor phosphorylation inhibition values. We observed a bias in BsAb binding toward the more highly expressed of the two receptors, EGFR or c-MET, which resulted in the enhanced in vitro potency of JNJ-61186372 against the less highly expressed target. On the basis of these observations, we propose an avidity model of how JNJ-61186372 engages EGFR and c-MET with potentially broad implications for bispecific drug efficacy and design.	[Jarantow, Stephen W.; Bushey, Barbara S.; Pardinas, Jose R.; Boakye, Ken; Lacy, Eilyn R.; Sepulveda, Manuel A.; Moores, Sheri L.; Chiu, Mark L.] Janssen Res & Dev LLC, Spring House, PA 19477 USA; [Sanders, Renouard] Janssen Res & Dev, Janssen Diagnost, Huntingdon Valley, PA 19104 USA	Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc	Chiu, ML (corresponding author), Janssen R&D LLC, Dept Biol Res, 1400 McKean Rd,POB 776, Spring House, PA 19477 USA.	MChiu@its.jnj.com	chiu, mark/AAK-2756-2021	Chiu, Mark/0000-0001-6300-404X				Bai H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054170; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Beers SA, 2010, BLOOD, V115, P5191, DOI 10.1182/blood-2010-01-263533; BENE MC, 1995, LEUKEMIA, V9, P1783; Bikoue A, 1996, CYTOMETRY, V26, P137, DOI 10.1002/(SICI)1097-0320(19960615)26:2<137::AID-CYTO7>3.3.CO;2-E; Castoldi R, 2013, ONCOGENE, V32, P5593, DOI 10.1038/onc.2013.245; Davis KA, 1998, CYTOMETRY, V33, P197, DOI 10.1002/(SICI)1097-0320(19981001)33:2<197::AID-CYTO14>3.0.CO;2-P; Derer S, 2012, J IMMUNOL, V189, P5230, DOI 10.4049/jimmunol.1202037; DRACH J, 1992, CYTOMETRY, V13, P893, DOI 10.1002/cyto.990130813; Engelberts PJ, 2013, J IMMUNOL METHODS, V388, P8, DOI 10.1016/j.jim.2012.11.007; Ferrand VL, 1996, CYTOMETRY, V23, P120, DOI 10.1002/(SICI)1097-0320(19960201)23:2<120::AID-CYTO5>3.0.CO;2-O; Ginaldi L, 1998, J CLIN PATHOL, V51, P364, DOI 10.1136/jcp.51.5.364; Gratama JW, 1998, CYTOMETRY, V33, P166, DOI 10.1002/(SICI)1097-0320(19981001)33:2<166::AID-CYTO11>3.0.CO;2-S; Hsi ED, 2003, BRIT J HAEMATOL, V120, P1017, DOI 10.1046/j.1365-2141.2003.04213.x; Iyer SB, 1998, CYTOMETRY, V33, P206, DOI 10.1002/(SICI)1097-0320(19981001)33:2<206::AID-CYTO15>3.0.CO;2-Y; Janku F, 2014, THER ADV MED ONCOL, V6, P43, DOI 10.1177/1758834013517414; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Karamouzis MV, 2009, LANCET ONCOL, V10, P709, DOI 10.1016/S1470-2045(09)70137-8; KORNILOVA ES, 1992, ONCOGENE, V7, P511; Labrijn AF, 2013, P NATL ACAD SCI USA, V110, P5145, DOI 10.1073/pnas.1220145110; LANGLEY KE, 1975, P NATL ACAD SCI USA, V72, P1254, DOI 10.1073/pnas.72.4.1254; Laurent S, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-108; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Maher K. J., 2005, CLIN APPL IMMUNOL RE, V5, P353, DOI DOI 10.1016/j.cair.2005.10.001; Nguyen KSH, 2009, CLIN LUNG CANCER, V10, P281, DOI 10.3816/CLC.2009.n.039; Panke C, 2013, PROTEIN ENG DES SEL, V26, P645, DOI 10.1093/protein/gzt035; Pannu KK, 2001, CYTOMETRY, V45, P250, DOI 10.1002/1097-0320(20011201)45:4<250::AID-CYTO10021>3.0.CO;2-T; PONCELET P, 1991, RES IMMUNOL, V142, P291, DOI 10.1016/0923-2494(91)90078-W; Puri Neelu, 2008, J Carcinog, V7, P9; Rego EM, 2001, BRAZ J MED BIOL RES, V34, P183, DOI 10.1590/S0100-879X2001000200005; Rossmann ED, 2007, CYTOM PART B-CLIN CY, V72B, P450, DOI 10.1002/cyto.b.20359; Rudnick SI, 2009, CANCER BIOTHER RADIO, V24, P155, DOI 10.1089/cbr.2009.0627; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Tang Y, 2007, J IMMUNOL, V179, P2815, DOI 10.4049/jimmunol.179.5.2815; Turner NC, 2012, LANCET ONCOL, V13, pE178, DOI 10.1016/S1470-2045(11)70335-7; Velders MP, 1998, BRIT J CANCER, V78, P478, DOI 10.1038/bjc.1998.518; Wang L, 2007, CYTOM PART B-CLIN CY, V72B, P442, DOI 10.1002/cyto.b.20354; Wang LL, 2012, CYTOM PART A, V81A, P567, DOI 10.1002/cyto.a.22060; Wehrman TS, 2006, NAT METHODS, V3, P295, DOI 10.1038/NMETH868; Zenger VE, 1998, CYTOMETRY, V33, P138, DOI 10.1002/(SICI)1097-0320(19981001)33:2<138::AID-CYTO8>3.0.CO;2-F; Zuckier LS, 2000, CANCER RES, V60, P7008	43	30	33	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 9	2015	290	41					24689	24704		10.1074/jbc.M115.651653	http://dx.doi.org/10.1074/jbc.M115.651653			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CT1YF	26260789	Green Published, hybrid			2023-01-03	WOS:000362598300006
J	Wachtel, MS; Yang, SP; Dissanaike, S; Margenthaler, JA				Wachtel, Mitchell S.; Yang, Shengping; Dissanaike, Sharmila; Margenthaler, Julie A.			Hormone Replacement Therapy, Likely Neither Angel Nor Demon	PLOS ONE			English	Article							BREAST-CANCER CHEMOPREVENTION; POSTMENOPAUSAL WOMEN; RANDOMIZED-TRIAL; IN-SITU; TAMOXIFEN; PREVENTION; RALOXIFENE; CARCINOMA; LETROZOLE; ESTROGEN	Purpose A decline in breast cancer incidence has been attributed to the reduction in hormone replacement therapy (HRT) prescriptions since the publication of the landmark WHIT paper in 2003. Concurrently, a relationship between HRT and cerebrovascular disease incidence has also been suggested. No generalized analysis of HRT prescription rates and breast cancer incidence rates that included more than seven years of data. We hypothesized that detailed analysis of SEER data would clarify the relationship between HRT use and breast cancer incidence. Given the large decline in HRT prescription rates uncovered, analyses of potential complications were also conducted, with the understanding that a small effect or one limited to a subpopulation, such as a single race, might not be detected. Methods Incidence rates (per 100,000 women) and standard errors for ductal and lobular breast carcinomas, and endometrioid/endometrial carcinomas in women over 50 years were obtained from the Surveillance, Epidemiology, and End Results (SEER) database 1992-2012. From the Medical Expenditure Panel Survey 1996-2012 weighted counts and standard errors of hormone replacement therapy (HRT) prescriptions for women over 50 years were obtained. Using the National Hospital Discharge Survey (NHDS), 1996-2010 weighted counts and standard errors of femoral neck fractures, total hip replacements, acute myocardial infarctions, and cerebral infarctions were obtained for 50+ year men and women. Weighted counts and standard errors were divided by US census figures and multiplied by 100,000. Joinpoint regression was used to analyze rates. Main Results Beginning 2001, HRT prescription rates dropped dramatically, 2001-2012 AAPC -14.9 (95% CI -17.4, -12.4). Breast cancer rates, which began to decline in 1999, increased after 2003; 2012 rates were similar to those seen in 2001 for both ductal, AAPC 0.1 (-0.4, 0.6) and lobular, AAPC 0.5 (-0.4, 1.5), carcinoma. Endometrial carcinoma rates increased, 2001-2012 AAPC 3.5 (3.1, 3.8), arguing against a negative effect of HRT discontinuation of endometrial carcinoma. Tests for parallelism failed to detect APC differences among genders for femoral neck fractures (P = 0.24), for total hip replacements (P = 0.11), for myocardial infarctions (P = 0.10), or for cerebral infarctions (P = 0.19), precluding any assignment of general effect on these disorders by HRT. Conclusions Using SEER data, we demonstrated that changes in breast cancer rates cannot be explained by HRT prescription rate changes.	[Wachtel, Mitchell S.; Yang, Shengping] Texas Tech Univ, Hlth Sci Ctr, Dept Pathol, Lubbock, TX 79430 USA; [Dissanaike, Sharmila] Texas Tech Univ, Hlth Sci Ctr, Dept Surg, Lubbock, TX 79430 USA; [Margenthaler, Julie A.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Washington University (WUSTL)	Wachtel, MS (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Pathol, Lubbock, TX 79430 USA.	mitchell.wachtel@ttuhsc.edu						Agency for Healthcare Research and Quality, 2014, HOUSEHOLD COMPONENT; [Anonymous], 2014, SURVEILLANCE RESEARC; [Anonymous], 2014, OVERVIEW OF THE SEER; [Anonymous], 2015, SURVEILLANCE EPIDEMI; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Bluming AZ, 2007, NEW ENGL J MED, V357, P509; Buerger H, 2000, J CLIN PATHOL-MOL PA, V53, P118, DOI 10.1136/mp.53.3.118; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Chlebowski RT, 2015, JAMA ONCOLOGY; Elfenbein GJ, 2007, NEW ENGL J MED, V357, P509; Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508; Fentiman IS, 2006, LANCET, V367, P595, DOI 10.1016/S0140-6736(06)68226-3; Goss PE, 2011, NEW ENGL J MED, V364, P2381, DOI 10.1056/NEJMoa1103507; Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312; Goss PE, 2005, JNCI-J NATL CANCER I, V97, P1262, DOI 10.1093/jnci/dji250; Howell A, 2012, LANCET ONCOL, V13, P437, DOI 10.1016/S1470-2045(12)70110-9; Kliewer EV, 2007, NEW ENGL J MED, V357, P509; LaCroix AZ, 2011, JAMA-J AM MED ASSOC, V305, P1305, DOI 10.1001/jama.2011.382; R Core Team, 2014, R A LANGUAGE AND ENV; Ravdin PM, 2007, NEW ENGL J MED, V356, P1670, DOI 10.1056/NEJMsr070105; Stagnitti M, 2011, AGENCY FOR HEALTHCAR; Statistical Methodology and Applications Branch, 2013, MARYLAND SURVEILLANC; Statistics. NCfH, 2014, MICRODATA; Visvanathan K, 2013, J CLIN ONCOL, V31, P2942, DOI 10.1200/JCO.2013.49.3122; Wachtel MS, 2011, J SURG RES, V166, P19, DOI 10.1016/j.jss.2010.05.016; Waters EA, 2012, BREAST CANCER RES TR, V134, P875, DOI 10.1007/s10549-012-2089-2; Waters EA, 2010, CANCER EPIDEM BIOMAR, V19, P443, DOI 10.1158/1055-9965.EPI-09-0930; Wickerham DL, 2009, RECENT RESULTS CANC, V181, P113	28	10	11	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2015	10	9							e0138556	10.1371/journal.pone.0138556	http://dx.doi.org/10.1371/journal.pone.0138556			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS0ZE	26384022	Green Published, gold, Green Submitted			2023-01-03	WOS:000361790200127
J	Silvestri, A; Palumbo, F; Rasi, I; Posca, D; Pavlidou, T; Paoluzi, S; Castagnoli, L; Cesareni, G				Silvestri, Alessandra; Palumbo, Francesco; Rasi, Ignazio; Posca, Daniela; Pavlidou, Theodora; Paoluzi, Serena; Castagnoli, Luisa; Cesareni, Giovanni			Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in Breast Cancer Cells Only When Grown in Nutrient-Poor Conditions	PLOS ONE			English	Article							PROTEIN-KINASE; DIABETIC-PATIENTS; TUMOR-CELLS; COMPLEX I; INHIBITION; METAANALYSIS; METABOLISM; INITIATION; EXPRESSION; THERAPY	Introduction Metformin is proposed as adjuvant therapy in cancer treatment because of its ability to limit cancer incidence by negatively modulating the PI3K/AKT/mTOR pathway. In vitro, in addition to inhibiting cancer cell proliferation, metformin can also induce apoptosis. The molecular mechanism underlying this second effect is still poorly characterized and published data are often contrasting. We investigated how nutrient availability can modulate metformin-induced apoptosis in three breast cancer cell lines. Material and Methods MCF7, SKBR3 and MDA-MB-231 cells were plated in MEM medium supplemented with increasing glucose concentrations or in DMEM medium and treated with 10 mM metformin. Cell viability was monitored by Trypan Blue assay and treatment effects on Akt/mTOR pathway and on apoptosis were analysed by Western Blot. Moreover, we determined the level of expression of pyruvate kinase M2 (PKM2), a well-known glycolytic enzyme expressed in cancer cells. Results Our results showed that metformin can induce apoptosis in breast cancer cells when cultured at physiological glucose concentrations and that the pro-apoptotic effect was completely abolished when cells were grown in high glucose/high amino acid medium. Induction of apoptosis was found to be dependent on AMPK activation but, at least partially, independent of TORC1 inactivation. Finally, we showed that, in nutrient-poor conditions, metformin was able to modulate the intracellular glycolytic equilibrium by downregulating PKM2 expression and that this mechanism was mediated by AMPK activation. Conclusion We demonstrated that metformin induces breast cancer cell apoptosis and PKM2 downregulation only in nutrient-poor conditions. Not only glucose levels but also amino acid concentration can influence the observed metformin inhibitory effect on the mTOR pathway as well as its pro-apoptotic effect. These data demonstrate that the reduction of nutrient supply in tumors can increase metformin efficacy and that modulation of PKM2 expression/activity could be a promising strategy to boost metformin anti-cancer effect.	[Silvestri, Alessandra; Palumbo, Francesco; Rasi, Ignazio; Posca, Daniela; Pavlidou, Theodora; Paoluzi, Serena; Castagnoli, Luisa; Cesareni, Giovanni] Univ Roma Tor Vergata, Dept Biol, Mol Genet Lab, I-00173 Rome, Italy; [Cesareni, Giovanni] Fdn Santa Lucia, IRCCS, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Rome Tor Vergata; IRCCS Santa Lucia	Silvestri, A (corresponding author), Cpo Cellular Phen & Oncol GmbH, Berlin, Germany.	silvestri.alessandra@gmail.com	Cesareni, Gianni/AAW-1382-2020; Palumbo, Francesco/ABH-9395-2020	Castagnoli, Luisa/0000-0001-5283-8671; Palumbo, Francesco/0000-0002-5352-6773; Silvestri, Alessandra/0000-0003-4891-1826	Ministry of Education, Italy [RBAP11LP2W]	Ministry of Education, Italy(Ministry of Education, Universities and Research (MIUR))	Funding provided by Ministry of Education, Italy; Grant Number: RBAP11LP2W; Grant Recipient: GC.	Adler AI, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1668; Alimova IN, 2009, CELL CYCLE, V8, P909, DOI 10.4161/cc.8.6.7933; Bailey CJ, 2008, CARDIOVASC DRUG THER, V22, P215, DOI 10.1007/s10557-008-6092-0; Berstein LM, 2011, MED ONCOL, V28, P1260, DOI 10.1007/s12032-010-9572-6; Blandino G, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1859; BRINCK U, 1994, VIRCHOWS ARCH, V424, P177; Brunmair B, 2004, DIABETES, V53, P1052, DOI 10.2337/diabetes.53.4.1052; Chen GX, 2015, AM J CANCER RES, V5, P1423; Cheong JH, 2011, MOL CANCER THER, V10, P2350, DOI 10.1158/1535-7163.MCT-11-0497; Cossor FI, 2013, CANCER EPIDEMIOL, V37, P742, DOI 10.1016/j.canep.2013.04.015; DeCensi A, 2010, CANCER PREV RES, V3, P1451, DOI 10.1158/1940-6207.CAPR-10-0157; Deng XS, 2012, CELL CYCLE, V11, P367, DOI 10.4161/cc.11.2.18813; Dowling RJO, 2007, CANCER RES, V67, P10804, DOI 10.1158/0008-5472.CAN-07-2310; Dowling RJO, 2012, J MOL ENDOCRINOL, V48, pR31, DOI 10.1530/JME-12-0007; El-Mir MY, 2000, J BIOL CHEM, V275, P223, DOI 10.1074/jbc.275.1.223; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Goldberg MS, 2012, J EXP MED, V209, P217, DOI 10.1084/jem.20111487; Gupta V, 2010, PROTEIN SCI, V19, P2031, DOI 10.1002/pro.505; Hwang YP, 2010, BRIT J PHARMACOL, V160, P1195, DOI 10.1111/j.1476-5381.2010.00762.x; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Israelsen WJ, 2013, CELL, V155, P397, DOI 10.1016/j.cell.2013.09.025; Janzer A, 2014, P NATL ACAD SCI USA, V111, P10574, DOI 10.1073/pnas.1409844111; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kalinsky K, 2014, CANCER INVEST, V32, P150, DOI 10.3109/07357907.2014.889706; Liu BL, 2009, CELL CYCLE, V8, P2031, DOI 10.4161/cc.8.13.8814; Lord JM, 2003, BRIT MED J, V327, P951, DOI 10.1136/bmj.327.7421.951; Malki A, 2011, ONCOL RES, V19, P275, DOI 10.3727/096504011X13021877989838; Marini C, 2013, CELL CYCLE, V12, P3490, DOI 10.4161/cc.26461; Meiers P, 2010, SAN ANTONIO BREAST S, V70; Menendez JA, 2012, CELL CYCLE, V11, P2782, DOI 10.4161/cc.20948; Nathan DM, 2009, DIABETES CARE, V32, P193, DOI 10.2337/dc08-9025; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; REINACHER M, 1981, VIRCHOWS ARCH B, V37, P79, DOI 10.1007/BF02892557; Steinberg P, 1999, VIRCHOWS ARCH, V434, P213, DOI 10.1007/s004280050330; Viollet B, 2012, CLIN SCI, V122, P253, DOI 10.1042/CS20110386; Wahdan-Alaswad R, 2013, CELL CYCLE, V12, P3759, DOI 10.4161/cc.26641; Zakikhani M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049513; Zakikhani M, 2010, BREAST CANCER RES TR, V123, P271, DOI 10.1007/s10549-010-0763-9; Zhuang YX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108444; Zhuang YX, 2011, MOL CANCER RES, V9, P603, DOI 10.1158/1541-7786.MCR-10-0343; Zordoky BNM, 2014, BBA-GEN SUBJECTS, V1840, P1943, DOI 10.1016/j.bbagen.2014.01.023	42	37	39	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2015	10	8							e0136250	10.1371/journal.pone.0136250	http://dx.doi.org/10.1371/journal.pone.0136250			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP5KH	26291325	Green Published, gold, Green Submitted			2023-01-03	WOS:000359919900070
J	Hurley, R				Hurley, Richard			ASSISTED DYING A doctor who chose an assisted death	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																		Chambaere K, 2015, NEW ENGL J MED, V372, P1179, DOI 10.1056/NEJMc1414527; Commission Federale de Controle et d'Evaluation de l'Euthanasie, 2014, 6 COMM FED CONTR EV; Dierickx S, 2015, JAMA INTERN MED, V175, P1703, DOI 10.1001/jamainternmed.2015.3982; Portail des Services Publics Belges, EUTH DROIT STRICT RE	4	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 19	2015	351								h4385	10.1136/bmj.h4385	http://dx.doi.org/10.1136/bmj.h4385			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CP7PU	26289051				2023-01-03	WOS:000360081100004
J	Yan, H; Li, HH; Li, Q; Zhao, PF; Wang, W; Cao, BW				Yan, Han; Li, Huihui; Li, Qin; Zhao, Pengfei; Wang, Wei; Cao, Bangwei			The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis	PLOS ONE			English	Article							CELL LUNG-CANCER; PHASE-III TRIAL; GEFITINIB; ERLOTINIB; GROWTH; GEMCITABINE; HEAD; NECK; CARBOPLATIN; PACLITAXEL	Background The combination of chemotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) currently has become the hotspot issue in the treatment of non-small lung cancer (NSCLC). This systematic review was conducted to compare the efficacy and safety of the synchronous combination of these two treatments with EGFR TKIs or chemotherapy alone in advanced NSCLC. Methods EMBASE, PubMed, the Central Registry of Controlled Trials in the Cochrane Library (CENTRAL), Chinese biomedical literature database (CNKI) and meeting summaries were searched. The Phase II/III randomized controlled trials were selected by which patients with advanced NSCLC were randomized to receive a combination of EGFR TKIs and chemotherapy by synchronous mode vs. EGFR TKIs or chemotherapy alone. Results A total of six randomized controlled trials (RCTs) including 4675 patients were enrolled in the systematic review. The meta-analysis demonstrated that the synchronous combination group of chemotherapy and EGFR TKIs did not reach satisfactory results; there was no significant difference in overall survival (OS), time to progression (TTP) and objective response rate (ORR), compared with monotherapy (OS: HR = 1.05, 95% CI = 0.98-1.12; TTP: HR = 0.94, 95% CI = 0.89-1.00; ORR: RR = 1.07, 95% CI = 0.98-1.17), and no significant difference in OS and progression-free survival (PFS), compared with EGFR TKIs alone (OS: HR = 1.10, 95% CI = 0.83-1.46; PFS: HR = 0.86, 95% CI = 0.67-1.10). The patients who received synchronous combined therapy presented with increased incidences of grade 3/4 anemia (RR = 1.40, 95% CI = 1.10-1.79) and rash (RR = 7.43, 95% CI = 4.56-12.09), compared with chemotherapy, grade 3/4 anemia (RR = 6.71, 95% CI = 1.25-35.93) and fatigue (RR = 9.60, 95% CI = 2.28-40.86) compared with EGFR TKI monotherapy. Conclusions The synchronous combination of chemotherapy and TKIs is not superior to chemotherapy or EGFR TKIs alone for the first-line treatment of NSCLC.	[Yan, Han; Li, Huihui; Li, Qin; Zhao, Pengfei; Cao, Bangwei] Capital Med Univ, Beijing Friendship Hosp, Dept Oncol, Beijing, Peoples R China; [Wang, Wei] Capital Med Univ, Beijing Friendship Hosp, Med Healthcare Ctr, Beijing, Peoples R China	Capital Medical University; Capital Medical University	Cao, BW (corresponding author), Capital Med Univ, Beijing Friendship Hosp, Dept Oncol, Beijing, Peoples R China.	oncology@ccmu.edu.cn			Natural Science Foundation of China [81272615]; Beijing Municipal Health System High-level Health Person Foundation Project [2011-3-007]; Beijing Municipal "Ten, Hundred, thousand" Person Foundation Project	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Municipal Health System High-level Health Person Foundation Project; Beijing Municipal "Ten, Hundred, thousand" Person Foundation Project	This work was supported by Grants No. 81272615 from the Natural Science Foundation of China (to Bangwei Cao), by Grants from Beijing Municipal Health System High-level Health Person Foundation Project, No. 2011-3-007 (to Bangwei Cao), and by Grants from Beijing Municipal "Ten, Hundred, thousand" Person Foundation Project (2011-2013 to Bangwei Cao). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Argiris A, 2013, J CLIN ONCOL, V31, P1405, DOI 10.1200/JCO.2012.45.4272; Argiris A, 2011, CLIN CANCER RES, V17, P5755, DOI 10.1158/1078-0432.CCR-11-0861; Chen P, 2011, EUR J CLIN PHARMACOL, V67, P235, DOI 10.1007/s00228-010-0965-4; Chen YM, 2011, J THORAC ONCOL, V6, P1110, DOI 10.1097/JTO.0b013e3182121c09; Chun PY, 2006, CANCER RES, V66, P981, DOI 10.1158/0008-5472.CAN-05-2665; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; Curtis VF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054916; Davies AM, 2006, CLIN LUNG CANCER, V7, P385, DOI 10.3816/CLC.2006.n.021; Fukuoka M, 2011, J CLIN ONCOL, V29, P2866, DOI 10.1200/JCO.2010.33.4235; Gatzemeier U, 2007, J CLIN ONCOL, V25, P1545, DOI 10.1200/JCO.2005.05.1474; Giaccone G, 2004, J CLIN ONCOL, V22, P777, DOI 10.1200/JCO.2004.08.001; Herbst RS, 2004, J CLIN ONCOL, V22, P785, DOI 10.1200/JCO.2004.07.215; Herbst RS, 2005, J CLIN ONCOL, V23, P5892, DOI 10.1200/JCO.2005.02.840; Higgins B, 2004, ANTI-CANCER DRUG, V15, P503, DOI 10.1097/01.cad.0000127664.66472.60; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Janne PA, 2012, J CLIN ONCOL, V30, P2063, DOI 10.1200/JCO.2011.40.1315; Kataki A, 2002, J LAB CLIN MED, V140, P320, DOI 10.1067/mlc.2002.128317; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Martins RG, 2013, J CLIN ONCOL, V31, P1415, DOI 10.1200/JCO.2012.46.3299; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Moher D, 2009, PHYS THER, V89, P873, DOI 10.1093/ptj/89.9.873; MORIKAWA K, 1988, CANCER RES, V48, P6863; Moyer JD, 1997, CANCER RES, V57, P4838; Nyati MK, 2006, NAT REV CANCER, V6, P876, DOI 10.1038/nrc1953; Santoro A, 2008, ANN ONCOL, V19, P1888, DOI 10.1093/annonc/mdn401; Sirotnak FM, 2000, CLIN CANCER RES, V6, P4885; Solit DB, 2005, CLIN CANCER RES, V11, P1983, DOI 10.1158/1078-0432.CCR-04-1347; Stinchcombe TE, 2011, J THORAC ONCOL, V6, P1569, DOI 10.1097/JTO.0b013e3182210430; Xiao YY, 2013, EUR J CLIN PHARMACOL, V69, P151, DOI 10.1007/s00228-012-1333-3; Yang ZY, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009948.pub2; Zhang YL, 2013, ONCOTARGETS THER, V6, P1771, DOI 10.2147/OTT.S54502	31	14	14	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 18	2015	10	8							e0135829	10.1371/journal.pone.0135829	http://dx.doi.org/10.1371/journal.pone.0135829			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP1VY	26285137	gold, Green Submitted, Green Published			2023-01-03	WOS:000359666100070
J	Rasubala, L; Pernapati, L; Velasquez, X; Burk, J; Ren, YF				Rasubala, Linda; Pernapati, Lavanya; Velasquez, Ximena; Burk, James; Ren, Yan-Fang			Impact of a Mandatory Prescription Drug Monitoring Program on Prescription of Opioid Analgesics by Dentists	PLOS ONE			English	Article							DENTAL PAIN; ACETAMINOPHEN; ABUSE	Prescription Drug Monitoring Programs (PDMP) are statewide databases that collect data on prescription of controlled substances. New York State mandates prescribers to consult the PDMP registry before prescribing a controlled substance such as opioid analgesics. The effect of mandatory PDMP on opioid drug prescriptions by dentists is not known. This study investigates the impact of mandatory PDMP on frequency and quantity of opioid prescriptions by dentists in a dental urgent care center. Based on the sample size estimate, we collected patient records of a 3-month period before and two consecutive 3-month periods after the mandatory PDMP implementation and analyzed the data on number of visits, treatment types and drug prescriptions using Chi-square tests. For patients who were prescribed pain medications, 452 (30.6%), 190 (14.1%), and 140 (9.6%) received opioid analgesics in the three study periods respectively, signifying a statistically significant reduction in the number of opioid prescriptions after implementation of the mandatory PDMP (p<0.05). Total numbers of prescribed opioid pills in a 3-month period decreased from 5096 to 1120, signifying a 78% reduction in absolute quantity. Prescriptions for non-opioid analgesics acetaminophen increased during the same periods (p<0.05). We conclude that the mandatory PDMP significantly affected the prescription pattern for pain medications by dentists. Such change in prescription pattern represents a shift towards the evidence-based prescription practices for acute postoperative pain.	[Rasubala, Linda; Pernapati, Lavanya; Velasquez, Ximena; Burk, James; Ren, Yan-Fang] Univ Rochester, Eastman Inst Oral Hlth, Dept Gen Dent, Rochester, NY 14620 USA	University of Rochester	Ren, YF (corresponding author), Univ Rochester, Eastman Inst Oral Hlth, Dept Gen Dent, 625 Elmwood Ave, Rochester, NY 14620 USA.	yanfang_ren@urmc.rochester.edu	Ren, Yan-Fang/N-9369-2019	Ren, Yan-Fang/0000-0001-6428-2252				Becker Daniel E, 2010, Anesth Prog, V57, P67, DOI 10.2344/0003-3006-57.2.67; Brushwood DB, 2003, J LAW MED ETHICS, V31, P41, DOI 10.1111/j.1748-720X.2003.tb00058.x; Denisco RC, 2011, J AM DENT ASSOC, V142, P800, DOI 10.14219/jada.archive.2011.0268; Derry C, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001548.pub2; Derry CJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010210.pub2; Fox TR, 2013, ANN EMERG MED, V62, P237, DOI 10.1016/j.annemergmed.2012.11.020; FRICKE J, 1993, CLIN THER, V15, P500; Gaskell H, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002763.pub2; Goodin A, 2012, PAIN PHYSICIAN, V15, pES169; Haffajee RL, 2015, JAMA-J AM MED ASSOC, V313, P891, DOI 10.1001/jama.2014.18514; Hersh Elliot V, 2011, Compend Contin Educ Dent, V32, P24; Hersh EV, 2011, COMPENDIUM CONTINUIN, V32, P1; Hersh EV, 2011, COMPENDIUM CONTINUIN, V32, P4; Hildebran C, 2014, PAIN MED, V15, P1179, DOI 10.1111/pme.12469; Irvine JM, 2014, J PAIN, V15, P747, DOI 10.1016/j.jpain.2014.04.003; Jeske Arthur H, 2005, Tex Dent J, V122, P622; Johnson D, 2008, EUR J PROSTHODONT RE, V16, P181; Litkowski LJ, 2005, CLIN THER, V27, P418, DOI 10.1016/j.clinthera.2005.04.010; Ma M, 2004, ANN EMERG MED, V44, P323, DOI 10.1016/j.annemergmed.2004.04.016; McCabe SE, 2013, PAIN, V154, P708, DOI 10.1016/j.pain.2013.01.011; Moore Paul A, 2006, Gen Dent, V54, P201; Moore PA, 2013, J AM DENT ASSOC, V144, P898, DOI 10.14219/jada.archive.2013.0207; Mutlu I, 2013, J ORAL MAXIL SURG, V71, P1500, DOI 10.1016/j.joms.2013.04.031; National Institute on Drug Abuse, 2011, TOP BRIEF PRESCR DRU; New York State Department of Health, 2015, I STOP PMP INT SYST; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Prescription Drug Monitoring Program Center of Excellence at Brandeis, 2014, MAND PDMP PART MED P; Reece AS, 2007, AUST DENT J, V52, P144, DOI 10.1111/j.1834-7819.2007.tb00480.x; Reifler LM, 2012, PAIN MED, V13, P434, DOI 10.1111/j.1526-4637.2012.01327.x; Richards D, 2004, EVID BASED DENT, V5, P22, DOI DOI 10.1038/SJ.EBD.6400237; Toms L, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004602.pub2; Toms L, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001547.pub2; Volkow ND, 2011, JAMA-J AM MED ASSOC, V305, P1346, DOI 10.1001/jama.2011.369; Weiner SG, 2013, ANN EMERG MED, V62, P281, DOI 10.1016/j.annemergmed.2013.05.025	34	76	78	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2015	10	8							e0135957	10.1371/journal.pone.0135957	http://dx.doi.org/10.1371/journal.pone.0135957			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO9KD	26274819	Green Submitted, gold, Green Published			2023-01-03	WOS:000359493600136
J	Brouns, SHA; Stassen, PM; Lambooij, SLE; Dieleman, J; Vanderfeesten, ITP; Haak, HR				Brouns, Steffie H. A.; Stassen, Patricia M.; Lambooij, Suze L. E.; Dieleman, Jeanne; Vanderfeesten, Irene T. P.; Haak, Harm R.			Organisational Factors Induce Prolonged Emergency Department Length of Stay in Elderly Patients - A Retrospective Cohort Study	PLOS ONE			English	Article							ADVERSE OUTCOMES; OLDER-ADULTS; PATIENTS SPEND; CARE; TIME; MORTALITY; TARGET; MEDICINE; NETHERLANDS; VALIDATION	Study objective To assess the association of patient and organisational factors with emergency department length of stay (ED-LOS) in elderly ED patients (226565 years old) and in younger patients (<65 years old). Methods A retrospective cohort study of internal medicine patients visiting the emergency department between September 1st 2010 and August 31st 2011 was performed. All emergency department visits by internal medicine patients 226565 years old and a random sample of internal medicine patients <65 years old were included. Organisational factors were defined as non-medical factors. ED-LOS is defined as the time between ED arrival and ED discharge or admission. Prolonged ED-LOS is defined as >= 75th percentile of ED-LOS in the study population, which was 208 minutes. Results Data on 1782 emergency department visits by elderly patients and 597 emergency department visits by younger patients were analysed. Prolonged ED-LOS in elderly patients was associated with three organisational factors: >1 consultation during the emergency department visit (odds ratio (OR) 3.2, 95% confidence interval (CI) 2.3-4.3), a higher number of diagnostic tests (OR 1.2, 95% CI 1.16-1.33) and evaluation by a medical student or non-trainee resident compared with a medical specialist (OR 4.2, 95% CI 2.0-8.8 and OR 2.3, 95% CI 1.4-3.9). In younger patients, prolonged ED-LOS was associated with >1 consultation (OR 2.6, 95% CI 1.4-4.6). Factors associated with shorter ED-LOS were arrival during nights or weekends as well as a high urgency level in elderly patients and self-referral in younger patients. Conclusion Organisational factors, such as a higher number of consultations and tests in the emergency department and a lower seniority of the physician, were the main aspects associated with prolonged ED-LOS in elderly patients. Optimisation of the organisation and coordination of emergency care is important to accommodate the needs of the continuously growing number of elderly patients in a better way.	[Brouns, Steffie H. A.; Lambooij, Suze L. E.; Haak, Harm R.] Maxima Med Ctr, Dept Internal Med, Eindhoven, Netherlands; [Stassen, Patricia M.; Haak, Harm R.] Maastricht Univ Med Ctr, Div Gen Med, Sect Acute Med, Dept Internal Med, Maastricht, Netherlands; [Dieleman, Jeanne] Maxima Med Ctr Acad, Maxima Med Ctr, Eindhoven, Netherlands; [Vanderfeesten, Irene T. P.] Eindhoven Univ Technol, Sch Ind Engn, NL-5600 MB Eindhoven, Netherlands; [Haak, Harm R.] Maastricht Univ, Dept Hlth Serv Res, Maastricht, Netherlands; [Haak, Harm R.] CAPHRI Sch Publ Hlth & Primary Care, Maastricht, Netherlands	Maxima Medical Center; Maastricht University; Maastricht University Medical Centre (MUMC); Maxima Medical Center; Eindhoven University of Technology; Maastricht University; Maastricht University	Brouns, SHA (corresponding author), Maxima Med Ctr, Dept Internal Med, Eindhoven, Netherlands.	S.Brouns@mmc.nl	Vanderfeesten, Irene/B-6181-2019	Vanderfeesten, Irene/0000-0002-6670-5519				Aminzadeh F, 2002, ANN EMERG MED, V39, P238, DOI 10.1067/mem.2002.121523; Asplin BR, 2003, ANN EMERG MED, V42, P173, DOI 10.1067/mem.2003.302; Barba R, 2006, EUR J INTERN MED, V17, P322, DOI 10.1016/j.ejim.2006.01.003; Becker DJ, 2007, HEALTH SERV RES, V42, P1589, DOI 10.1111/j.1475-6773.2006.00663.x; Becker David J, 2008, Expert Rev Pharmacoecon Outcomes Res, V8, P23, DOI 10.1586/14737167.8.1.23; Bernstein SL, 2003, ACAD EMERG MED, V10, P938, DOI 10.1197/S1069-6563(03)00311-7; Bernstein SL, 2006, EMERG MED CLIN N AM, V24, P821, DOI 10.1016/j.emc.2006.06.013; Bernstein SL, 2009, ACAD EMERG MED, V16, P1, DOI 10.1111/j.1553-2712.2008.00295.x; Bucheli B, 2004, EUR J EMERG MED, V11, P29, DOI 10.1097/00063110-200402000-00006; Carr BG, 2011, ARCH SURG-CHICAGO, V146, P810, DOI 10.1001/archsurg.2011.60; Casalino E, 2014, EMERG MED J, V31, P361, DOI 10.1136/emermed-2012-202155; Chalfin DB, 2007, CRIT CARE MED, V35, P1477, DOI 10.1097/01.CCM.0000266585.74905.5A; Cram P, 2004, AM J MED, V117, P151, DOI 10.1016/j.amjmed.2004.02.035; Di Bari M, 2010, J GERONTOL A-BIOL, V65, P159, DOI 10.1093/gerona/glp043; Ding R, 2010, ACAD EMERG MED, V17, P813, DOI 10.1111/j.1553-2712.2010.00812.x; Elmer J, 2012, NEUROCRIT CARE, V17, P334, DOI 10.1007/s12028-011-9629-1; Gnjidic D, 2012, J CLIN EPIDEMIOL, V65, P989, DOI 10.1016/j.jclinepi.2012.02.018; Hastings SN, 2008, J AM GERIATR SOC, V56, P1651, DOI 10.1111/j.1532-5415.2008.01840.x; Herring A, 2009, ACAD EMERG MED, V16, P609, DOI 10.1111/j.1553-2712.2009.00428.x; Hollander JE, 2007, ANN EMERG MED, V50, P497, DOI 10.1016/j.annemergmed.2007.05.002; Holmes JL, 2010, EMERG MED AUSTRALAS, V22, P75, DOI 10.1111/j.1742-6723.2009.01259.x; Hwang U, 2006, J AM GERIATR SOC, V54, P270, DOI 10.1111/j.1532-5415.2005.00587.x; Hwang U, 2011, ACAD EMERG MED, V18, P526, DOI 10.1111/j.1553-2712.2011.01054.x; Jones P, 2010, EMERG MED AUSTRALAS, V22, P391, DOI 10.1111/j.1742-6723.2010.01330.x; Kocher KE, 2012, ACAD EMERG MED, V19, P525, DOI 10.1111/j.1553-2712.2012.01353.x; Kocher KE, 2010, ACAD EMERG MED, V17, P1306, DOI 10.1111/j.1553-2712.2010.00932.x; LaCalle E, 2010, ANN EMERG MED, V56, P42, DOI 10.1016/j.annemergmed.2010.01.032; Liew D, 2003, MED J AUSTRALIA, V179, P524, DOI 10.5694/j.1326-5377.2003.tb05676.x; Locker TE, 2005, BRIT MED J, V330, P1188, DOI 10.1136/bmj.38440.588449.AE; Mackway-Jones K, 2005, EMERGENCY TRIAGE; Mason S, 2012, ANN EMERG MED, V59, P341, DOI 10.1016/j.annemergmed.2011.08.017; McCarthy ML, 2011, ACAD EMERG MED, V18, P1269, DOI 10.1111/j.1553-2712.2011.01232.x; Needham DM, 2005, J CRIT CARE, V20, P12, DOI 10.1016/j.jcrc.2004.09.007; Rathlev NK, 2007, ANN EMERG MED, V49, P265, DOI 10.1016/j.annemergmed.2006.11.007; Retezar R, 2011, ANN EMERG MED, V57, P89, DOI 10.1016/j.annemergmed.2010.05.016; Richardson DB, 2006, MED J AUSTRALIA, V184, P213, DOI 10.5694/j.1326-5377.2006.tb00204.x; Roberts DC, 2008, ANN EMERG MED, V51, P769, DOI 10.1016/j.annemergmed.2007.09.011; Salvi F, 2007, INTERN EMERG MED, V2, P292, DOI 10.1007/s11739-007-0081-3; Salvi F, 2008, J AM GERIATR SOC, V56, P2131, DOI 10.1111/j.1532-5415.2008.01991.x; Samaras N, 2010, ANN EMERG MED, V56, P261, DOI 10.1016/j.annemergmed.2010.04.015; Schull MJ, 2004, ANN EMERG MED, V44, P577, DOI 10.1016/j.annemergmed.2004.05.004; Singer AJ, 2011, ACAD EMERG MED, V18, P1324, DOI 10.1111/j.1553-2712.2011.01236.x; Thijssen WAMH, 2012, EMERG MED J, V29, P6, DOI 10.1136/emermed-2011-200090; Vegting IL, 2011, NETH J MED, V69, P392; Weber EJ, 2012, ANN EMERG MED, V60, P699, DOI 10.1016/j.annemergmed.2012.08.009; Weber EJ, 2011, ANN EMERG MED, V57, P79, DOI 10.1016/j.annemergmed.2010.08.013; Wilber ST, 2006, ACAD EMERG MED, V13, P1345, DOI 10.1197/j.aem.2006.09.050; Wilber ST, 2003, ACAD EMERG MED, V10, P251, DOI 10.1111/j.1553-2712.2003.tb01999.x	48	26	26	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2015	10	8							e0135066	10.1371/journal.pone.0135066	http://dx.doi.org/10.1371/journal.pone.0135066			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CO9JT	26267794	gold, Green Published, Green Submitted			2023-01-03	WOS:000359492300074
J	Callaway, CW; Elmer, J; Guyette, FX; Molyneaux, BJ; Anderson, KB; Empey, PE; Gerstel, SJ; Holquist, K; Repine, MJ; Rittenberger, JC				Callaway, Clifton W.; Elmer, Jonathan; Guyette, Francis X.; Molyneaux, Bradley J.; Anderson, Kacey B.; Empey, Philip E.; Gerstel, Stacy J.; Holquist, Kate; Repine, Melissa J.; Rittenberger, Jon C.			Dexmedetomidine Reduces Shivering during Mild Hypothermia in Waking Subjects	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; PERCUTANEOUS CORONARY INTERVENTION; TARGETED TEMPERATURE MANAGEMENT; RANDOMIZED CLINICAL-TRIAL; 4-DEGREES-C NORMAL SALINE; AGITATION-SEDATION SCALE; HOSPITAL CARDIAC-ARREST; HEALTHY-VOLUNTEERS; INTENSIVE-CARE; ADDITIVELY REDUCE	Background and Purpose Reducing body temperature can prolong tolerance to ischemic injury such as stroke or myocardial infarction, but is difficult and uncomfortable in awake patients because of shivering. We tested the efficacy and safety of the alpha-2-adrenergic agonist dexmedetomidine for suppressing shivering induced by a rapid infusion of cold intravenous fluids. Methods Ten subjects received a rapid intravenous infusion of two liters of cold (4 degrees C) isotonic saline on two separate test days, and we measured their core body temperature, shivering, hemodynamics and sedation for two hours. On one test day, fluid infusion was preceded by placebo infusion. On the other test day, fluid infusion was preceded by 1.0 mu g/kg bolus of dexmedetomidine over 10 minutes. Results All ten subjects experienced shivering on placebo days, with shivering beginning at a mean (SD) temperature of 36.6 (0.3)degrees C. The mean lowest temperature after placebo was 36.0 (0.3)degrees C (range 35.7-36.5 degrees C). Only 3/10 subjects shivered on dexmedetomidine days, and the mean lowest temperature was 35.7 (0.4)degrees C (range 35.0-36.3 degrees C). Temperature remained below 36 degrees C for the full two hours in 6/10 subjects. After dexmedetomidine, subjects had moderate sedation and a mean 26 (13) mmHg reduction in blood pressure that resolved within 90 minutes. Heart rate declined a mean 23 (11) bpm after both placebo and dexmedetomidine. Dexmedetomidine produced no respiratory depression. Conclusion Dexmedetomidine decreases shivering in normal volunteers. This effect is associated with decreased systolic blood pressure and sedation, but no respiratory depression.	[Callaway, Clifton W.; Elmer, Jonathan; Guyette, Francis X.; Gerstel, Stacy J.; Holquist, Kate; Repine, Melissa J.; Rittenberger, Jon C.] Univ Pittsburgh, Appl Physiol Lab, Dept Emergency Med, Pittsburgh, PA 15260 USA; [Elmer, Jonathan; Molyneaux, Bradley J.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; [Anderson, Kacey B.; Empey, Philip E.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Rittenberger, JC (corresponding author), Univ Pittsburgh, Appl Physiol Lab, Dept Emergency Med, Pittsburgh, PA 15260 USA.	rittjc@upmc.edu	Empey, Philip/L-9604-2019; , Francis/AAE-1586-2022	Empey, Philip/0000-0001-7474-2339; 	Pittsburgh Emergency Medicine Foundation; National Heart, Lung and Blood Institute - NHLBI [5K12HL109068]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K12HL109068] Funding Source: NIH RePORTER	Pittsburgh Emergency Medicine Foundation; National Heart, Lung and Blood Institute - NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by Pittsburgh Emergency Medicine Foundation (www.pemf.net) (JCR), and National Heart, Lung and Blood Institute - NHLBI 5K12HL109068 (http://www.nhlbi.nih.gov/research/training/emergency-med-k12) (JE). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Badjatia N, 2008, STROKE, V39, P3242, DOI 10.1161/STROKEAHA.108.523654; Carollo DS, 2008, CURR OPIN ANESTHESIO, V21, P457, DOI 10.1097/ACO.0b013e328305e3ef; Choi HA, 2011, NEUROCRIT CARE, V14, P389, DOI 10.1007/s12028-010-9474-7; Clifton GL, 2012, J NEUROSURG, V117, P714, DOI 10.3171/2012.6.JNS111690; Dae MW, 2002, AM J PHYSIOL-HEART C, V282, pH1584, DOI 10.1152/ajpheart.00980.2001; De Georgia MA, 2004, NEUROLOGY, V63, P312, DOI 10.1212/01.WNL.0000129840.66938.75; De Wolf AM, 2001, ANESTH ANALG, V93, P1205, DOI 10.1097/00000539-200111000-00031; Dewhirst Elisabeth, 2011, J Pediatr Pharmacol Ther, V16, P113, DOI 10.5863/1551-6776-16.2.113; Dixon SR, 2002, J AM COLL CARDIOL, V40, P1928, DOI 10.1016/S0735-1097(02)02567-6; Doufas AG, 2003, STROKE, V34, P1218, DOI 10.1161/01.STR.0000068787.76670.A4; DYCK JB, 1993, ANESTHESIOLOGY, V78, P813, DOI 10.1097/00000542-199305000-00002; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Hemmen TM, 2010, STROKE, V41, P2265, DOI 10.1161/STROKEAHA.110.592295; Holliday SF, 2014, SCI WORLD J, DOI 10.1155/2014/805013; Hostler D, 2010, DRUG METAB DISPOS, V38, P781, DOI 10.1124/dmd.109.031377; Hostler D, 2009, APPL PHYSIOL NUTR ME, V34, P582, DOI 10.1139/H09-011; Iirola T, 2011, CRIT CARE, V15, DOI 10.1186/cc10518; Jakob SM, 2014, BRIT J ANAESTH, V112, P581, DOI 10.1093/bja/aeu032; Kandzari DE, 2004, AM J CARDIOL, V93, P636, DOI 10.1016/j.amjcard.2003.11.038; Kim F, 2005, CIRCULATION, V112, P715, DOI 10.1161/CIRCULATIONAHA.105.544528; Kim F, 2007, CIRCULATION, V115, P3064, DOI 10.1161/CIRCULATIONAHA.106.655480; Kimberger O, 2007, CRIT CARE, V11, DOI 10.1186/cc5709; Kollmar R, 2012, INT J STROKE, V7, P168, DOI 10.1111/j.1747-4949.2011.00707.x; Komatsu R, 2006, BRIT J ANAESTH, V96, P732, DOI 10.1093/bja/ael101; Kurz A, 1997, ANESTHESIOLOGY, V86, P1046, DOI 10.1097/00000542-199705000-00007; Lenhardt R, 2009, ANESTHESIOLOGY, V111, P110, DOI 10.1097/ALN.0b013e3181a979a3; Li WJ, 2009, J PHARMACEUT BIOMED, V50, P897, DOI 10.1016/j.jpba.2009.06.012; Liu Y, 2013, CASE REP MED, V2013, DOI 10.1155/2013/358182; Ly HQ, 2005, AM HEART J, V150, DOI 10.1016/j.ahj.200502.049; Lyden Patrick D, 2005, J Stroke Cerebrovasc Dis, V14, P107, DOI 10.1016/j.jstrokecerebrovasdis.2005.01.001; Lyden PD, 2014, INT J STROKE, V9, P117, DOI 10.1111/ijs.12151; Madden CJ, 2013, J NEUROSCI, V33, P2017, DOI 10.1523/JNEUROSCI.4701-12.2013; MCCLEARY P, 1982, NEUROPHARMACOLOGY, V21, P1337, DOI 10.1016/0028-3908(82)90143-5; Moore TM, 2008, ANN EMERG MED, V51, P153, DOI 10.1016/j.annemergmed.2007.07.012; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; O'Brien C, 1998, MED SCI SPORT EXER, V30, P468, DOI 10.1097/00005768-199803000-00020; Paris A, 2005, ANESTH ANALG, V100, P102, DOI 10.1213/01.ANE.0000139355.86522.D1; Richards JR, 2015, DRUG ALCOHOL DEPEN, V150, P1, DOI 10.1016/j.drugalcdep.2015.01.040; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Rincon F, 2014, INT J STROKE, V9, P646, DOI 10.1111/ijs.12220; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Takada K, 2002, ANESTHESIOLOGY, V96, P1420, DOI 10.1097/00000542-200206000-00022; Talke P, 1997, ANESTHESIOLOGY, V87, P835, DOI 10.1097/00000542-199710000-00017; Valitalo PA, 2013, CLIN DRUG INVEST, V33, P579, DOI 10.1007/s40261-013-0101-1; Venn RM, 2002, BRIT J ANAESTH, V88, P669, DOI 10.1093/bja/88.5.669	45	21	21	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2015	10	8							e0129709	10.1371/journal.pone.0129709	http://dx.doi.org/10.1371/journal.pone.0129709			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO1UY	26237219	Green Accepted, Green Submitted, Green Published, gold			2023-01-03	WOS:000358942400004
J	Unwin, D; Tobin, S				Unwin, David; Tobin, Simon			CASE REVIEW A patient request for some "deprescribing"	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							GAMMA-GLUTAMYL-TRANSFERASE; TREATMENT DECISION-MAKING; FATTY LIVER-DISEASE; METABOLIC SYNDROME; OUTCOMES; IMPACT		[Unwin, David; Tobin, Simon] Norwood Surg, Southport, Qld PR9 7EG, Australia		Unwin, D (corresponding author), Norwood Surg, Southport, Qld PR9 7EG, Australia.	unwin5@btinternet.com						Blonde L, 2004, CURR MED RES OPIN, V20, P565, DOI 10.1185/030079904125003278; Boussageon R, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001204; Chalasani N, 2012, AM J GASTROENTEROL, V107, P811, DOI 10.1038/ajg.2012.128; Deber RB, 2007, HEALTH EXPECT, V10, P248, DOI 10.1111/j.1369-7625.2007.00441.x; Dixon JB, 2006, OBES SURG, V16, P1278, DOI 10.1381/096089206778663805; Frank J.D., 1961, PERSUASION HEALING; Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6; Lee DS, 2007, ARTERIOSCL THROM VAS, V27, P127, DOI 10.1161/01.ATV.0000251993.20372.40; Mandelblatt J, 2006, J CLIN ONCOL, V24, P4908, DOI 10.1200/JCO.2006.07.1159; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Reeve E, 2014, BRIT J CLIN PHARMACO, V78, P738, DOI 10.1111/bcp.12386; Sattar N, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4596; Taylor R, 2013, DIABETIC MED, V30, P267, DOI 10.1111/dme.12039; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Volek Jeff S, 2005, Nutr Metab (Lond), V2, P31, DOI 10.1186/1743-7075-2-31; Volek JS, 2009, LIPIDS, V44, P297, DOI 10.1007/s11745-008-3274-2; Wilson SR, 2010, AM J RESP CRIT CARE, V181, P566, DOI 10.1164/rccm.200906-0907OC	17	5	5	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 3	2015	351								h4023	10.1136/bmj.h4023	http://dx.doi.org/10.1136/bmj.h4023			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CO8AO	26239952				2023-01-03	WOS:000359387100004
J	Wagner, K; Groger, M; McCook, O; Scheuerle, A; Asfar, P; Stahl, B; Huber-Lang, M; Ignatius, A; Jung, B; Duechs, M; Moller, P; Georgieff, M; Calzia, E; Radermacher, P; Wagner, F				Wagner, Katja; Groeger, Michael; McCook, Oscar; Scheuerle, Angelika; Asfar, Pierre; Stahl, Bettina; Huber-Lang, Markus; Ignatius, Anita; Jung, Birgit; Duechs, Matthias; Moeller, Peter; Georgieff, Michael; Calzia, Enrico; Radermacher, Peter; Wagner, Florian			Blunt Chest Trauma in Mice after Cigarette Smoke-Exposure: Effects of Mechanical Ventilation with 100% O-2	PLOS ONE			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; INDUCED LUNG INJURY; HEMORRHAGIC-SHOCK; SYSTEMIC INFLAMMATION; ALVEOLAR MACROPHAGES; MURINE MODEL; MOUSE MODEL; HYPEROXIA; OXYGEN; INHIBITION	Cigarette smoking (CS) aggravates post-traumatic acute lung injury and increases ventilator-induced lung injury due to more severe tissue inflammation and apoptosis. Hyper-inflammation after chest trauma is due to the physical damage, the drop in alveolar PO2, and the consecutive hypoxemia and tissue hypoxia. Therefore, we tested the hypotheses that 1) CS exposure prior to blunt chest trauma causes more severe post-traumatic inflammation and thereby aggravates lung injury, and that 2) hyperoxia may attenuate this effect. Immediately after blast wave-induced blunt chest trauma, mice (n=32) with or without 3-4 weeks of CS exposure underwent 4 hours of pressure-controlled, thoraco-pulmonary compliance-titrated, lung-protective mechanical ventilation with air or 100% O-2. Hemodynamics, lung mechanics, gas exchange, and acid-base status were measured together with blood and tissue cytokine and chemokine concentrations, heme oxygenase-1 (HO-1), activated caspase-3, and hypoxia-inducible factor 1-alpha (HIF-1 alpha) expression, nuclear factor-kappa B (NF-kappa B) activation, nitrotyrosine formation, purinergic receptor 2X(4) (P2XR(4)) and 2X(7) (P2XR(7)) expression, and histological scoring. CS exposure prior to chest trauma lead to higher pulmonary compliance and lower PaO2 and Horovitz-index, associated with increased tissue IL-18 and blood MCP-1 concentrations, a 2-4-fold higher inflammatory cell infiltration, and more pronounced alveolar membrane thickening. This effect coincided with increased activated caspase-3, nitrotyrosine, P2XR(4), and P2XR(7) expression, NF-kappa B activation, and reduced HIF-1 alpha expression. Hyperoxia did not further affect lung mechanics, gas exchange, pulmonary and systemic cytokine and chemokine concentrations, or histological scoring, except for some patchy alveolar edema in CS exposed mice. However, hyperoxia attenuated tissue HIF-1 alpha, nitrotyrosine, P2XR(7), and P2XR(4) expression, while it increased HO-1 formation in CS exposed mice. Overall, CS exposure aggravated post-traumatic inflammation, nitrosative stress and thereby organ dysfunction and injury; short-term, lung-protective, hyperoxic mechanical ventilation have no major beneficial effect despite attenuation of nitrosative stress, possibly due to compensation of by regional alveolar hypoxia and/or consecutive hypoxemia, resulting in down-regulation of HIF-1 alpha expression.	[Wagner, Katja; Groeger, Michael; McCook, Oscar; Stahl, Bettina; Calzia, Enrico; Radermacher, Peter; Wagner, Florian] Inst Anasthesiol Pathophysiol & Verfahrensentwick, Ulm, Germany; [Wagner, Katja; Georgieff, Michael; Wagner, Florian] Univ Ulm Klinikum, Anasthesiol Klin, Ulm, Germany; [Scheuerle, Angelika; Moeller, Peter] Univ Ulm Klinikum, Inst Pathol, Ulm, Germany; [Asfar, Pierre] Univ Angers, Dept Reanimat Med & Med Hyperbare, Ctr Hosp Univ,CNRS UMR 6214,INSERM U1083, Lab HIFIH,UPRES EA 3859,PRES UNAM,IFR 132, Angers, France; [Huber-Lang, Markus] Univ Ulm Klinikum, Klin Unfall Hand Plast & Wiederherstellungschirur, Ulm, Germany; [Ignatius, Anita] Univ Ulm Klinikum, Inst Unfallchirurg Forsch & Biomech, Ulm, Germany; [Jung, Birgit; Duechs, Matthias] Boehringer Ingelheim Pharma GmbH & Co KG, Abt Resp Dis Res, Biberach, Germany	Ulm University; Ulm University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Ulm University; Ulm University; Boehringer Ingelheim	Radermacher, P (corresponding author), Inst Anasthesiol Pathophysiol & Verfahrensentwick, Ulm, Germany.	peter.radermacher@uni-ulm.de	Ignatius, Anita/M-6012-2013; van Griensven, Martijn/F-5808-2012; McCook, Oscar/AAF-1647-2020; Huber-Lang, Markus/AAJ-2209-2020; Asfar, Pierre/K-1402-2015	Ignatius, Anita/0000-0002-4782-1979; van Griensven, Martijn/0000-0001-5104-9881; McCook, Oscar/0000-0001-7879-7695; 	Deutsche Forschungsgemeinschaft [Klinische Forschergruppe 200, DFG RA 396/9-2]; Ministry of Science, Research and the Arts of Baden-Wurttemberg [Az:32-729.55-0/239-5/32-7533.-6-10/15/1]; Boehringer Ingelheim Pharma GmbH Co. KG	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Ministry of Science, Research and the Arts of Baden-Wurttemberg; Boehringer Ingelheim Pharma GmbH Co. KG(Boehringer Ingelheim)	Supported by a grant of the Deutsche Forschungsgemeinschaft (Klinische Forschergruppe 200 "Die Entzundungsantwort nach muskuloskelettalem Trauma"; DFG RA 396/9-2) and a grant from the Ministry of Science, Research and the Arts of Baden-Wurttemberg (Az:32-729.55-0/239-5/32-7533.-6-10/15/1) to P.R. (Boehringer Ingelheim Ulm University BioCenter). The Deutsche Forschungsgemeinschaft had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Boehringer Ingelheim Pharma GmbH & Co. KG provided support in the form of salaries for authors B.J. and M.D., but did not have any additional role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of B.J. and M.D. are articulated in the "author contributions" section.	Albaiceta GM, 2008, J TRAUMA, V64, P470, DOI 10.1097/TA.0b013e31814931ac; Barth E, 2008, CRIT CARE MED, V36, P495, DOI 10.1097/01.CCM.0B013E318161FC45; Bitterman H, 1996, AM J PHYSIOL-HEART C, V271, pH203, DOI 10.1152/ajpheart.1996.271.1.H203; Blasiole B, 2013, ANESTHESIOLOGY, V118, P649, DOI 10.1097/ALN.0b013e318280a42d; Buras JA, 2006, CRIT CARE MED, V34, P2624, DOI 10.1097/01.CCM.0000239438.22758.E0; Calfee CS, 2011, AM J RESP CRIT CARE, V183, P1660, DOI 10.1164/rccm.201011-1802OC; Calvert JW, 2006, J APPL PHYSIOL, V101, P853, DOI 10.1152/japplphysiol.00268.2006; Cannizzaro V, 2009, RESP PHYSIOL NEUROBI, V165, P61, DOI 10.1016/j.resp.2008.10.006; Chao J, 2011, AM J RESP CELL MOL, V45, P53, DOI 10.1165/rcmb.2010-0264OC; Chao J, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-54; Chiao CW, 2008, J PHARMACOL EXP THER, V326, P864, DOI 10.1124/jpet.107.135350; Cicko S, 2010, J IMMUNOL, V185, P688, DOI 10.4049/jimmunol.0904042; DANTZKER DR, 1975, J APPL PHYSIOL, V38, P886, DOI 10.1152/jappl.1975.38.5.886; Dolinay T, 2012, AM J RESP CRIT CARE, V185, P1225, DOI 10.1164/rccm.201201-0003OC; Efrati S, 2008, NEPHROL DIAL TRANSPL, V23, P2213, DOI 10.1093/ndt/gfn093; Eltom S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024097; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Feinman R, 2010, AM J PHYSIOL-GASTR L, V299, pG833, DOI 10.1152/ajpgi.00065.2010; Fisarkova B, 2004, PHYSIOL RES, V53, P487; Frohlich S, 2013, AM J RESP CELL MOL, V48, P271, DOI 10.1165/rcmb.2012-0137TR; Geldmacher H, 2008, DEUT MED WOCHENSCHR, V133, P2609, DOI 10.1055/s-0028-1105858; Geraghty P, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00267; Gonzalez NC, 2010, ADV EXP MED BIOL, V662, P27, DOI 10.1007/978-1-4419-1241-1_3; Gould NS, 2010, AM J RESP CRIT CARE, V182, P1114, DOI 10.1164/rccm.201003-0442OC; Guan SP, 2013, BRIT J PHARMACOL, V168, P1707, DOI 10.1111/bph.12054; Hafner S, 2015, SHOCK, V43, P140, DOI 10.1097/SHK.0000000000000277; Hauser B, 2009, CRIT CARE MED, V37, P2465, DOI 10.1097/CCM.0b013e3181aee8ad; Hirsch J, 2014, CRIT CARE, V18, DOI 10.1186/cc13795; Hoth JJ, 2009, SHOCK, V31, P376, DOI 10.1097/SHK.0b013e3181862279; Hou LC, 2009, SHOCK, V32, P451, DOI 10.1097/SHK.0b013e31819c391a; Hsieh SJ, 2014, CRIT CARE MED, V42, P2058, DOI 10.1097/CCM.0000000000000418; Jiang H, 2012, ACTA PHARMACOL SIN, V33, P635, DOI 10.1038/aps.2012.5; Jiang H, 2010, ACTA BIOCH BIOPH SIN, V42, P483, DOI 10.1093/abbs/gmq041; Kallet RH, 2013, RESP CARE, V58, P123, DOI 10.4187/respcare.01963; Kawano A, 2012, BIOCHEM BIOPH RES CO, V420, P102, DOI 10.1016/j.bbrc.2012.02.122; Knoferl MW, 2003, SHOCK, V19, P519, DOI 10.1097/01.shk.0000070739.34700.f6; Kolliputi N, 2010, J IMMUNOL, V184, P5819, DOI 10.4049/jimmunol.0902766; Kotani N, 1999, ANESTHESIOLOGY, V91, P1823, DOI 10.1097/00000542-199912000-00037; Lee SH, 2014, CLIN BIOCHEM, V47, P552, DOI 10.1016/j.clinbiochem.2014.01.012; Lucattelli M, 2011, AM J RESP CELL MOL, V44, P423, DOI 10.1165/rcmb.2010-0038OC; Madjdpour C, 2003, AM J PHYSIOL-LUNG C, V284, pL360, DOI 10.1152/ajplung.00158.2002; Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST; McGrath-Morrow SA, 2011, AM J RESP CELL MOL, V45, P610, DOI 10.1165/rcmb.2010-0259OC; Meier J, 2004, SHOCK, V22, P240, DOI 10.1097/01.shk.0000131192.02909.4c; Metzen E, 2003, MOL BIOL CELL, V14, P3470, DOI 10.1091/mbc.e02-12-0791; Moncao-Ribeiro LC, 2011, RESP PHYSIOL NEUROBI, V179, P314, DOI 10.1016/j.resp.2011.09.015; Muller HC, 2010, THORAX, V65, P1077, DOI 10.1136/thx.2010.135996; Muller T, 2011, AM J RESP CELL MOL, V44, P456, DOI 10.1165/rcmb.2010-0129OC; Muller-Redetzky HC, 2014, CRIT CARE, V18, DOI 10.1186/cc13830; O'Donnell DE, 2006, EUR RESPIR REV, V15, P61, DOI 10.1183/09059180.00010002; Ohata Y, 2011, CIRC J, V75, P945, DOI 10.1253/circj.CJ-09-0575; Papandrinopoulou D, 2012, PULM MED, V2012, DOI 10.1155/2012/542769; Park JW, 2013, EUR J PHARMACOL, V706, P76, DOI 10.1016/j.ejphar.2013.02.049; Quinn DA, 2002, J APPL PHYSIOL, V93, P517, DOI 10.1152/japplphysiol.00570.2001; Reiss LK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024527; Rossi JL, 2007, AM J PHYSIOL-LUNG C, V292, pL1327, DOI 10.1152/ajplung.00380.2006; Schmidt E P, 2010, J Cell Death, V2010, P41; Seimetz M, 2011, CELL, V147, P293, DOI 10.1016/j.cell.2011.08.035; Shah CV, 2008, CRIT CARE MED, V36, P2309, DOI 10.1097/CCM.0b013e318180dc74; Sinclair SE, 2004, CRIT CARE MED, V32, P2496, DOI 10.1097/01.CCM.0000148231.04642.8D; Sukhotnik I, 2009, CRIT CARE MED, V37, P1054, DOI 10.1097/CCM.0b013e31819d0f5c; Suresh MV, 2014, CRIT CARE MED, V42, pE642, DOI 10.1097/CCM.0000000000000488; Thakur VS, 2014, TOXICOL LETT, V230, P322, DOI 10.1016/j.toxlet.2014.03.006; Tuder RM, 2012, J CLIN INVEST, V122, P2749, DOI 10.1172/JCI60324; Uematsu S, 2013, CRIT CARE MED, V41, P151, DOI 10.1097/CCM.0b013e318267606f; Vlaar APJ, 2010, INTENS CARE MED, V36, P879, DOI 10.1007/s00134-010-1802-z; Vlahos R, 2006, PULM PHARMACOL THER, V19, P12, DOI 10.1016/j.pupt.2005.02.006; Vuichard D, 2005, CLIN EXP IMMUNOL, V141, P248, DOI 10.1111/j.1365-2249.2005.02835.x; Wagner F, 2011, J TRAUMA, V71, P1659, DOI 10.1097/TA.0b013e318228842e; Wagner F, 2011, SHOCK, V35, P396, DOI 10.1097/SHK.0b013e3181ffff0e; Wagner K, 2013, INTENS CARE MED EXP, V1, DOI 10.1186/2197-425X-1-2; Waisman D, 2003, AM J PHYSIOL-HEART C, V285, pH643, DOI 10.1152/ajpheart.00900.2002; Waisman D, 2012, SHOCK, V37, P95, DOI 10.1097/SHK.0b013e3182356fc3; Weinhold K, 2010, CELL MOL LIFE SCI, V67, P2631, DOI 10.1007/s00018-010-0355-1; Wilson MR, 2012, CRIT CARE MED, V40, P2850, DOI 10.1097/CCM.0b013e31825b91ef; Wollin L, 2010, PULM PHARMACOL THER, V23, P345, DOI 10.1016/j.pupt.2010.03.008; Wolthuis EK, 2009, CRIT CARE, V13, DOI 10.1186/cc7688; Yasuo M, 2011, EUR RESPIR J, V37, P775, DOI 10.1183/09031936.00022910	79	22	24	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2015	10	7							e0132810	10.1371/journal.pone.0132810	http://dx.doi.org/10.1371/journal.pone.0132810			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO0JT	26225825	Green Submitted, gold, Green Published			2023-01-03	WOS:000358837700011
J	Lipchik, RJ				Lipchik, Randolph J.			In ICUs, 24-, 16-, and 12-hour overnight resident duty schedules did not differ for patient adverse events	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							INTERNAL-MEDICINE RESIDENCY; WORK HOURS; FAILURES; CARE		Med Coll Wisconsin, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Lipchik, RJ (corresponding author), Med Coll Wisconsin, Milwaukee, WI 53226 USA.							Arora V, 2005, QUAL SAF HEALTH CARE, V14, P401, DOI 10.1136/qshc.2005.015107; Goitein L, 2005, ARCH INTERN MED, V165, P2601, DOI 10.1001/archinte.165.22.2601; Landrigan CP, 2004, NEW ENGL J MED, V351, P1838, DOI 10.1056/NEJMoa041406; Lockley SW, 2007, JT COMM J QUAL PATIE, V33, P7, DOI 10.1016/S1553-7250(07)33109-7; Lockley SW, 2004, NEW ENGL J MED, V351, P1829, DOI 10.1056/NEJMoa041404; McMahon GT, 2010, NEW ENGL J MED, V362, P1304, DOI 10.1056/NEJMsa0908136	6	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 21	2015	163	2							JC12	10.7326/ACPJC-2015-163-2-012	http://dx.doi.org/10.7326/ACPJC-2015-163-2-012			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CN4NS	26192580				2023-01-03	WOS:000358407500012
J	Atif, F; Patel, NR; Yousuf, S; Stein, DG				Atif, Fahim; Patel, Neil R.; Yousuf, Seema; Stein, Donald G.			The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells	PLOS ONE			English	Article							GROWTH-FACTOR; UP-REGULATION; STEM-CELLS; APOPTOSIS; INVASION; MIGRATION; CANCER; EXPRESSION; PREGNANCY; RADIATION	Glioblastoma multiforme (GBM) is the most common and most aggressive malignant brain tumor. Despite optimal treatment and evolving standard of care, the median survival of patients diagnosed with GBM is only 12-15 months. In this study, we combined progesterone (PROG) and temozolomide (TMZ), a standard chemotherapeutic agent for human GBM, to test whether PROG enhances the antitumor effects of TMZ and reduces its side effects. Two WHO grade IV human GBM cells lines (U87MG and U118MG) and primary human dermal fibroblasts (HDFs) were repeatedly exposed to PROG and TMZ either alone or in combination for 3 and 6 days. Cell death was measured by MTT reduction assay. PROG and TMZ individually induced tumor cell death in a dose-dependent manner. PROG at high doses produced more cell death than TMZ alone. When combined, PROG enhanced the cell death-inducing effect of TMZ. In HDFs, PROG did not reduce viability even at the same high cytotoxic doses, but TMZ did so in a dose-dependent manner. In combination, PROG reduced TMZ toxicity in HDFs. PROG alone and in combination with TMZ suppressed the EGFR/PI3K/Akt/mTOR signaling pathway and MGMT expression in U87MG cells, thus suppressing cell proliferation. PROG and TMZ individually reduced cell migration in U87MG cells but did so more effectively in combination. PROG enhances the cytotoxic effects of TMZ in GBM cells and reduces its toxic side effects in healthy primary cells.	[Atif, Fahim; Patel, Neil R.; Yousuf, Seema; Stein, Donald G.] Emory Univ, Sch Med, Dept Emergency Med, Brain Res Lab, Atlanta, GA 30322 USA	Emory University	Atif, F (corresponding author), Emory Univ, Sch Med, Dept Emergency Med, Brain Res Lab, Atlanta, GA 30322 USA.	fatif@emory.edu	Stein, Donald/AAJ-5139-2020		Allen and Company; Marcus Foundation; Laney Graduate School of Emory University; Stein Family Research Fund	Allen and Company; Marcus Foundation; Laney Graduate School of Emory University; Stein Family Research Fund	This research was supported in part by gifts from Allen and Company, The Marcus Foundation, The Laney Graduate School of Emory University and the Stein Family Research Fund.	Anai S, 2014, CANCER SCI, V105, P583, DOI 10.1111/cas.12397; Arck P, 2007, AM J REPROD IMMUNOL, V58, P268, DOI 10.1111/j.1600-0897.2007.00512.x; Atif F, 2014, J STEROID BIOCH MOL; Atif F, 2011, MOL MED, V17, P1084, DOI 10.2119/molmed.2010.00255; Atif F, 2009, MOL MED, V15, P328, DOI 10.2119/molmed.2009.00016; Bolyard C, 2014, CLIN CANCER RES, V20, P6479, DOI 10.1158/1078-0432.CCR-14-0463; Bu SZ, 1997, CANCER, V79, P1944, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1944::AID-CNCR15>3.0.CO;2-V; Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659; Cattaneo M, 2014, J BIOL CHEM, V289, P2826, DOI 10.1074/jbc.M113.527754; Choi EJ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-17; Cong DM, 2014, CARCINOGENESIS, V35, P2014, DOI 10.1093/carcin/bgu089; Dressing GE, 2009, STEROIDS, V74, P573, DOI 10.1016/j.steroids.2008.12.001; Formby B, 1999, MOL CELL BIOCHEM, V202, P53, DOI 10.1023/A:1007081021483; Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573; Goffart N, 2015, NEURO-ONCOLOGY, V17, P81, DOI 10.1093/neuonc/nou144; Gratas C, 2014, ONCOTARGET; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hegi ME, 2008, J CLIN ONCOL, V26, P4189, DOI 10.1200/JCO.2007.11.5964; Horita K, 2001, ANTICANCER RES, V21, P3871; Huang L, 2014, J BIOL CHEM, V289, P2217, DOI 10.1074/jbc.M113.515932; Huang TT, 2013, CANCER GENE THER, V20, P544, DOI 10.1038/cgt.2013.51; Hurmath KF, 2014, CELL BIOL INT, V38, P1415, DOI 10.1002/cbin.10353; Kalyankrishna S, 2006, J CLIN ONCOL, V24, P2666, DOI 10.1200/JCO.2005.04.8306; Kim JK, 2014, CANCER LETT, V353, P194, DOI 10.1016/j.canlet.2014.07.034; Kita D, 2007, ACTA NEUROPATHOL, V113, P295, DOI 10.1007/s00401-006-0186-1; Li L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080363; Li RJ, 2014, J NEURO-ONCOL, V116, P25, DOI 10.1007/s11060-013-1255-7; Liccardi G, 2014, CLIN CANCER RES, V20, P3496, DOI 10.1158/1078-0432.CCR-13-2695; Lin F, 2014, CLIN CANCER RES, V20, P2703, DOI 10.1158/1078-0432.CCR-14-0084; Medina D, 2007, Ernst Schering Found Symp Proc, P109; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Ochs K, 2000, CANCER RES, V60, P5815; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Peck JD, 2002, CANCER EPIDEM BIOMAR, V11, P361; Rogers SJ, 2005, CANCER METAST REV, V24, P47, DOI 10.1007/s10555-005-5047-1; Shamji AF, 2003, MOL CELL, V12, P271, DOI 10.1016/j.molcel.2003.08.016; Stolimenov I, 2009, BIOCHEM SOC T, V37, P605, DOI 10.1042/BST0370605; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Uzzaman M, 2007, J NEUROSURG, V106, P646, DOI 10.3171/jns.2007.106.4.646; Valster A, 2005, METHODS, V37, P208, DOI 10.1016/j.ymeth.2005.08.001; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Zhang L, 2014, TUMOR BIOL, V35, P10707, DOI 10.1007/s13277-014-2386-y; Zou YH, 2014, MOL MED REP, V10, P411, DOI 10.3892/mmr.2014.2151	45	25	25	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2015	10	6							e0131441	10.1371/journal.pone.0131441	http://dx.doi.org/10.1371/journal.pone.0131441			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL4OY	26110872	gold, Green Published, Green Submitted			2023-01-03	WOS:000356933800149
J	Grapentin, C; Barnert, S; Schubert, R				Grapentin, Christoph; Barnert, Sabine; Schubert, Rolf			Monitoring the Stability of Perfluorocarbon Nanoemulsions by Cryo-TEM Image Analysis and Dynamic Light Scattering	PLOS ONE			English	Article							F-19 MRI; FLUOROCARBON EMULSIONS; MOLECULAR-DIFFUSION; OXYGEN; INFLAMMATION; CELLS; CHEMISTRY	Perfluorocarbon nanoemulsions (PFC-NE) are disperse systems consisting of nanoscale liquid perfluorocarbon droplets stabilized by an emulsifier, usually phospholipids. Perfluorocarbons are chemically inert and non-toxic substances that are exhaled after in vivo administration. The manufacture of PFC-NE can be done in large scales by means of high pressure homogenization or microfluidization. Originally investigated as oxygen carriers for cases of severe blood loss, their application nowadays is more focused on using them as marker agents in F-19 Magnetic Resonance Imaging (F-19 MRI). F-19 is scarce in organisms and thus PFC-NE are a promising tool for highly specific and non-invasive imaging of inflammation via F-19 MRI. Neutrophils, monocytes and macrophages phagocytize PFC-NE and subsequently migrate to inflamed tissues. This technique has proven feasibility in numerous disease models in mice, rabbits and mini pigs. The translation to clinical trials in human needs the development of a stable nanoemulsion whose droplet size is well characterized over a long storage time. Usually dynamic light scattering (DLS) is applied as the standard method for determining particle sizes in the nanometer range. Our study uses a second method, analysis of transmission electron microscopy images of cryo-fixed samples (Cryo-TEM), to evaluate stability of PFC-NE in comparison to DLS. Four nanoemulsions of different composition are observed for one year. The results indicate that DLS alone cannot reveal the changes in particle size, but can even mislead to a positive estimation of stability. The combination with Cryo-TEM images gives more insight in the particulate evolution, both techniques supporting one another. The study is one further step in the development of analytical tools for the evaluation of a clinically applicable perfluorooctylbromide nanoemulsion.	[Grapentin, Christoph; Barnert, Sabine; Schubert, Rolf] Univ Freiburg, Dept Pharmaceut Technol & Biopharm, Freiburg, Germany	University of Freiburg	Schubert, R (corresponding author), Univ Freiburg, Dept Pharmaceut Technol & Biopharm, Freiburg, Germany.	rolf.schubert@pharmazie.uni-freiburg.de			German Research Foundation (DFG) [SCHU800/8-1, SCHU800/8-2]	German Research Foundation (DFG)(German Research Foundation (DFG))	This work was supported by the German Research Foundation (DFG) by grants SCHU800/8-1 and SCHU800/8-2 (http://www.dfg.de/). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahrens ET, 2013, NAT REV IMMUNOL, V13, P755, DOI 10.1038/nri3531; Ahrens ET, 2013, NMR BIOMED, V26, P860, DOI 10.1002/nbm.2948; ARLAUSKAS RA, 1994, ARTIF CELL BLOOD SUB, V22, P1317, DOI 10.3109/10731199409138832; Bernsen MR, 2010, EUR RADIOL, V20, P255, DOI 10.1007/s00330-009-1540-1; Bonner F, 2015, EUR HEART J IN PRESS; Castro CI, 2010, ARTIF ORGANS, V34, P622, DOI 10.1111/j.1525-1594.2009.00944.x; CLARK LC, 1966, SCIENCE, V152, P1755, DOI 10.1126/science.152.3730.1755; Cohn SM, J TRAUMA, V54, P193; CORNELUS C, 1993, COLLOID SURFACE A, V70, P233, DOI 10.1016/0927-7757(93)80297-R; Diou O, 2012, BIOMATERIALS, V33, P5593, DOI 10.1016/j.biomaterials.2012.04.037; Ebner B, 2010, CIRC-CARDIOVASC IMAG, V3, P202, DOI 10.1161/CIRCIMAGING.109.902312; Flogel U, 2011, AM J TRANSPLANT, V11, P235, DOI 10.1111/j.1600-6143.2010.03372.x; Flogel U, 2008, CIRCULATION, V118, P140, DOI 10.1161/CIRCULATIONAHA.107.737890; GOLLAN F, 1968, EXP MED SURG, V26, P249; Grapentin C., 2014, NANOMED, P268, DOI DOI 10.1182/ASHEDUCATI0N-2014.1.268; Hertlein T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018246; HIGUCHI WI, 1962, J PHARM SCI, V51, P459, DOI 10.1002/jps.2600510514; Holzer M, 2009, J CHROMATOGR A, V1216, P5838, DOI 10.1016/j.chroma.2009.06.023; Jacoby C, 2014, NMR BIOMED, V27, P261, DOI 10.1002/nbm.3059; Janjic JM, 2009, WIRES NANOMED NANOBI, V1, P492, DOI 10.1002/wnan.35; KABALNOV AS, 1987, COLLOID SURFACE, V24, P19, DOI 10.1016/0166-6622(87)80258-5; Krafft MP, 2007, J POLYM SCI POL CHEM, V45, P1185, DOI 10.1002/pola.21937; KRAFFT MP, 1991, J PHYS CHEM-US, V95, P5673, DOI 10.1021/j100167a054; Mayenfels F, 2012, THESIS A LUDWIG U FR; O'Hagan D, 2008, CHEM SOC REV, V37, P308, DOI 10.1039/b711844a; Riess JG, 2005, ARTIF CELL BLOOD SUB, V33, P47, DOI 10.1081/BIO-200046659; Riess JG, 2001, CHEM REV, V101, P2797, DOI 10.1021/cr970143c; RIESS JG, 1992, BIOMAT ARTIF CELL IM, V20, P839, DOI 10.3109/10731199209119726; Ruiz-Cabello J, 2011, NMR BIOMED, V24, P114, DOI 10.1002/nbm.1570; Sandford G, 2003, TETRAHEDRON, V59, P437, DOI 10.1016/S0040-4020(02)01568-5; Soehnlein O, 2010, NAT REV IMMUNOL, V10, P427, DOI 10.1038/nri2779; Srinivas M, 2012, BIOMATERIALS, V33, P8830, DOI 10.1016/j.biomaterials.2012.08.048; Srinivas M, 2010, BIOMATERIALS, V31, P7070, DOI 10.1016/j.biomaterials.2010.05.069; Temme S, 2012, WIRES NANOMED NANOBI, V4, P329, DOI 10.1002/wnan.1163; Vasudeva K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090589; Vorob'ev SI, 2009, PHARM CHEM J, V43, P209, DOI 10.1007/s11094-009-0268-1; Waiczies H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021981; WEERS JG, 1994, COLLOID SURFACE A, V84, P81, DOI 10.1016/0927-7757(93)02662-X; Weibel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056317; Weise G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028143; WESTESEN K, 1993, COLLOID SURFACE A, V78, P125, DOI 10.1016/0927-7757(93)80318-9	41	43	43	1	56	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2015	10	6							e0130674	10.1371/journal.pone.0130674	http://dx.doi.org/10.1371/journal.pone.0130674			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL3FM	26098661	Green Published, gold, Green Submitted			2023-01-03	WOS:000356835800092
J	McLeod, M; Barber, N; Franklin, BD				McLeod, Monsey; Barber, Nicholas; Franklin, Bryony Dean			Facilitators and Barriers to Safe Medication Administration to Hospital Inpatients: A Mixed Methods Study of Nurses' Medication Administration Processes and Systems (the MAPS Study)	PLOS ONE			English	Article							HEALTH-CARE SETTINGS; ERRORS; INTERRUPTIONS; WORKAROUNDS; IMPACT	Context Research has documented the problem of medication administration errors and their causes. However, little is known about how nurses administer medications safely or how existing systems facilitate or hinder medication administration; this represents a missed opportunity for implementation of practical, effective, and low-cost strategies to increase safety. Aim To identify system factors that facilitate and/or hinder successful medication administration focused on three inter-related areas: nurse practices and workarounds, workflow, and interruptions and distractions. Methods We used a mixed-methods ethnographic approach involving observational fieldwork, field notes, participant narratives, photographs, and spaghetti diagrams to identify system factors that facilitate and/or hinder successful medication administration in three inpatient wards, each from a different English NHS trust. We supplemented this with quantitative data on interruptions and distractions among other established medication safety measures. Findings Overall, 43 nurses on 56 drug rounds were observed. We identified a median of 5.5 interruptions and 9.6 distractions per hour. We identified three interlinked themes that facilitated successful medication administration in some situations but which also acted as barriers in others: (1) system configurations and features, (2) behaviour types among nurses, and (3) patient interactions. Some system configurations and features acted as a physical constraint for parts of the drug round, however some system effects were partly dependent on nurses' inherent behaviour; we grouped these behaviours into 'task focused', and 'patient-interaction focused'. The former contributed to a more streamlined workflow with fewer interruptions while the latter seemed to empower patients to act as a defence barrier against medication errors by being: (1) an active resource of information, (2) a passive information resource, and/or (3) a 'double-checker'. Conclusions We have identified practical examples of system effects on work optimisation and nurse behaviours that potentially increase medication safety, and conceptualized ways in which patient involvement can increase medication safety in hospitals.	[McLeod, Monsey; Franklin, Bryony Dean] Imperial Coll Healthcare NHS Trust, Dept Pharm, Ctr Medicat Safety & Serv Qual, London, England; [McLeod, Monsey; Franklin, Bryony Dean] UCL Sch Pharm, Res Dept Practice & Policy, London, England; [Barber, Nicholas] Hlth Fdn, London, England	Imperial College London; University of London; University College London	Franklin, BD (corresponding author), Imperial Coll Healthcare NHS Trust, Dept Pharm, Ctr Medicat Safety & Serv Qual, London, England.	bryony.deanfranklin@imperial.nhs.uk	McLeod, Monsey/AAR-7989-2021	McLeod, Monsey/0000-0001-5571-2417	National Institute for Health Research (NIHR) Imperial Patient Safety Translational Research Centre	National Institute for Health Research (NIHR) Imperial Patient Safety Translational Research Centre	This paper represents independent research supported by the National Institute for Health Research (NIHR) Imperial Patient Safety Translational Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080378; ALLAN EL, 1990, AM J HOSP PHARM, V47, P555, DOI 10.1093/ajhp/47.3.555; [Anonymous], 2011, GOV ARR RES ETH COMM; Australian Council for Safety and Quality in Health Care, 2002, SAF QUAL COUNC 2 NAT; Barker KN, 1962, AM J HOSP PHARM, V19, P361; Berwick D, 2013, IMPROVING SAFETY PAT; Bevington J, 2004, HLTH SERV J, VII4, P28; Biron AD, 2009, WORLDV EVID-BASED NU, V6, P70, DOI 10.1111/j.1741-6787.2009.00151.x; Britten N, 2009, BRIT J CLIN PHARMACO, V67, P646, DOI 10.1111/j.1365-2125.2009.03421.x; Chaudhury H, 2009, ENVIRON BEHAV, V41, P755, DOI 10.1177/0013916508330392; Coiera E, 2012, BMJ QUAL SAF, V21, P357, DOI 10.1136/bmjqs-2012-000783; Dean B, 2001, AM J HEALTH-SYST PH, V58, P54, DOI 10.1093/ajhp/58.1.54; DEAN BS, 1995, AM J HEALTH-SYST PH, V52, P2543, DOI 10.1093/ajhp/52.22.2543; Debono DS, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-175; Department of Health, 2000, ORG MEM; Dixon-Woods M, 2014, BMJ QUAL SAF, V23, P106, DOI 10.1136/bmjqs-2013-001947; Donabedian A, 2003, INTRO QUALITY ASSURA; Flynn EA, 1999, AM J HEALTH-SYST PH, V56, P1319, DOI 10.1093/ajhp/56.13.1319; Francis R., 2013, REPORT MIDSTAFFORD 1, V1; Francis R, 2013, REPORT MID STAFFOR 1; Francis R, 2013, REPORT MIDSTAFFORDSH; Francis R., 2013, REPORT MIDSTAFFORDSH, V3; Franklin BD, 2007, QUAL SAF HEALTH CARE, V16, P279, DOI 10.1136/qshc.2006.019497; Goddard M, 1999, HEALTH POLICY, V48, P119, DOI 10.1016/S0168-8510(99)00035-4; Greenhalgh T, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-45; Halbesleben JRB, 2008, HEALTH CARE MANAGE R, V33, P2, DOI 10.1097/01.HMR.0000304495.95522.ca; Hundt A., 2007, J PATIENT SAF, V3, P34, DOI DOI 10.1097/PTS.0B013E3180319DE7; Keers RN, 2013, DRUG SAFETY, V36, P1045, DOI 10.1007/s40264-013-0090-2; Keers RN, 2013, ANN PHARMACOTHER, V47, P237, DOI 10.1345/aph.1R147; Kohn LT, 1999, ERR IS HUMAN BUILDIN; Koppel R, 2008, J AM MED INFORM ASSN, V15, P408, DOI 10.1197/jamia.M2616; Lofland J., 1995, ANAL SOCIAL SETTINGS; McLeod M, 2013, THESIS U COLL LONDON; McLeod M, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-93; McLeod MC, 2013, BMJ QUAL SAF, V22, P278, DOI 10.1136/bmjqs-2012-001330; Pape Theresa M, 2003, Medsurg Nurs, V12, P77; Pedersen CA, 2011, AM J HEALTH-SYST PH, V68, P669, DOI [10.2146/ajhp100711, 10.2146/ajhp090596]; Perrow C., 1984, NORMAL ACCIDENTS LIV; Popescu A, 2011, WORLDV EVID-BASED NU, V8, P15, DOI 10.1111/j.1741-6787.2010.00212.x; Reason J., 1990, HUMAN ERROR; Relihan E, 2010, QUAL SAF HEALTH CARE, V19, DOI 10.1136/qshc.2009.036871; Ritchie J., 2003, GUIDE SOCIAL SCI STU, V1, P77; Taxis K, 1999, PHARM WORLD SCI, V21, P25, DOI 10.1023/A:1008616622472; Westbrook JI, 2014, BMJ QUAL SAF, V23, P877, DOI 10.1136/bmjqs-2014-003372; Westbrook JI, 2010, ARCH INTERN MED, V170, P683, DOI 10.1001/archinternmed.2010.65; Young Judith, 2010, J Patient Saf, V6, P115, DOI 10.1097/PTS.0b013e3181de35f7	46	30	30	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2015	10	6							e0128958	10.1371/journal.pone.0128958	http://dx.doi.org/10.1371/journal.pone.0128958			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CL3FM	26098106	Green Submitted, Green Published, gold			2023-01-03	WOS:000356835800021
J	Sharfstein, JM; Charo, A				Sharfstein, Joshua M.; Charo, Alta			The Promotion of Medical Products in the 21st Century Off-label Marketing and First Amendment Concerns	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Sharfstein, Joshua M.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Charo, Alta] Univ Wisconsin, Sch Law, Madison, WI 53706 USA; [Charo, Alta] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Sharfstein, JM (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, 624 N Broadway St,Room 484, Baltimore, MD 21205 USA.	Joshua.Sharfstein@jhu.edu						[Anonymous], 1969, DRUG EFF STUD FIN RE; Food and Drug Administration, 2013, END MET DRUGS ADV CO; Kesselheim AS, 2015, FDA 21 CENTURY CHALL, P184; Sharfstein JM, 2015, MILBANK Q, V93, P459, DOI 10.1111/1468-0009.12130	4	11	12	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2015	314	17					1795	1796		10.1001/jama.2015.12045	http://dx.doi.org/10.1001/jama.2015.12045			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CV0RO	26367520	Bronze			2023-01-03	WOS:000363960200007
J	Wexner, SD				Wexner, Steven D.			Percutaneous tibial nerve stimulation in faecal incontinence	LANCET			English	Editorial Material							TRIAL		Ctr Digest Dis, Dept Colorectal Surg, Cleveland Clin, Weston, FL 33331 USA	Cleveland Clinic Foundation	Wexner, SD (corresponding author), Ctr Digest Dis, Dept Colorectal Surg, Cleveland Clin, Weston, FL 33331 USA.	wexners@ccf.org						Brown HW, 2012, INT J CLIN PRACT, V66, P1101, DOI 10.1111/ijcp.12018; Eleouet M, 2010, INT J COLORECTAL DIS, V25, P1127, DOI 10.1007/s00384-010-0960-3; George AT, 2013, BRIT J SURG, V100, P330, DOI 10.1002/bjs.9000; Horrocks EJ, 2014, BRIT J SURG, V101, P457, DOI 10.1002/bjs.9391; Hotouras A, 2012, COLORECTAL DIS, V14, P1101, DOI 10.1111/j.1463-1318.2011.02906.x; Kaiser AM, 2014, SURG ENDOSC, V28, P2277, DOI 10.1007/s00464-014-3464-3; Knowles CH, 2015, LANCET; Leroi AM, 2012, AM J GASTROENTEROL, V107, P1888, DOI 10.1038/ajg.2012.330; MARCIO J, 1993, DIS COLON RECTUM, V36, P77; Rothbarth J, 2001, DIS COLON RECTUM, V44, P67, DOI 10.1007/BF02234823; Thin NN, 2015, BRIT J SURG, V102, P349, DOI 10.1002/bjs.9695; Vaizey CJ, 1999, GUT, V44, P77, DOI 10.1136/gut.44.1.77; Wexner SD, 2010, ANN SURG, V251, P441, DOI 10.1097/SLA.0b013e3181cf8ed0	13	4	4	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 24	2015	386	10004					1605	1606		10.1016/S0140-6736(15)60508-6	http://dx.doi.org/10.1016/S0140-6736(15)60508-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CU0HS	26293316				2023-01-03	WOS:000363197500007
J	Robertson, CT				Robertson, Christopher T.			New DTCA Guidance - Enough to Empower Consumers?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Arizona, James E Rogers Coll Law, Tucson, AZ 85721 USA	University of Arizona	Robertson, CT (corresponding author), Univ Arizona, James E Rogers Coll Law, Tucson, AZ 85721 USA.			Robertson, Christopher/0000-0001-6188-8005				[Anonymous], 2015, GUID IND BRIEF SUMM; BEN-SHAHAR OMRI, 2014, MORE YOU WANTED KNOW; Biegler P, 2013, AM J BIOETHICS, V13, P3, DOI 10.1080/15265161.2013.776127; FUNG ARCHON, 2008, FULL DISCLOSURE PERI	4	6	6	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 17	2015	373	12					1085	1087		10.1056/NEJMp1508548	http://dx.doi.org/10.1056/NEJMp1508548			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CR7UG	26287748	Green Published			2023-01-03	WOS:000361556400001
J	Zoghi, M; Vaseghi, B; Bastani, A; Jaberzadeh, S; Galea, MP				Zoghi, Maryam; Vaseghi, Bita; Bastani, Andisheh; Jaberzadeh, Shapour; Galea, Mary P.			The Effects of Sex Hormonal Fluctuations during Menstrual Cycle on Cortical Excitability and Manual Dexterity (a Pilot Study)	PLOS ONE			English	Article							HUMAN MOTOR CORTEX; TRANSCRANIAL MAGNETIC STIMULATION; INTRACORTICAL INHIBITION; NEUROACTIVE STEROIDS; CORTICOCORTICAL INHIBITION; HIPPOCAMPAL-NEURONS; SALIVARY ESTRADIOL; OVARIAN HORMONES; PREMOTOR CORTEX; PRIMATE MOTOR	Aim To investigate whether hormonal fluctuations during the menstrual cycle affect corticospinal excitability, intracortical inhibition (ICI) or facilitation (ICF) in primary motor cortex, and also whether the hormonal fluctuations have any effect on manual dexterity in neurologically intact women. Materials and Methods Twenty volunteers (10 Female, 10 Male) were included in this study. The levels of progesterone and estradiol were measured from saliva during the women's menstrual follicular, ovulation and mid-luteal phases. Motor evoked potentials were recorded from the right first dorsal interosseous muscle. Single and paired-pulse Transcranial Magnetic Stimulation (TMS) were delivered in a block of 20 stimuli. With paired-pulse technique, 3ms and 10ms inter-stimulus intervals were used to assess ICI and ICF, respectively. The Grooved Pegboard Test (GPT) was completed in each session before the TMS assessments. Male participants were tested at similar time intervals as female participants. Results Mixed design ANOVA revealed that GPT score in female participants was significantly lower at the mid-luteal phase compared to the ovulation phase (p = 0.017). However, it was not correlated with progesterone or estrogen fluctuations during the menstrual cycle. The results also showed that the effect of phase, sex and the interaction of phase by sex for resting motor threshold, ICI or ICF were not significant (p > 0.05). Conclusion Manual dexterity performance fluctuates during the menstrual cycle in neurologically intact women, which might be due to the balance of the neuromodulatory effects of P4 and E2 in the motor cortex during different phases.	[Zoghi, Maryam; Bastani, Andisheh; Galea, Mary P.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic 3050, Australia; [Vaseghi, Bita; Jaberzadeh, Shapour] Monash Univ, Fac Med Nursing & Hlth Sci, Sch Primary Hlth Care, Melbourne, Vic 3004, Australia	Royal Melbourne Hospital; University of Melbourne; Monash University	Zoghi, M (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic 3050, Australia.	mzoghi@unimelb.edu.au	, Zoghi/AAF-9536-2019; Galea, Mary/F-4242-2010	, Zoghi/0000-0002-1819-6895; Galea, Mary/0000-0003-0045-7978; jaberzadeh, shapour/0000-0003-2957-4510				Aardal-Eriksson E, 1998, CLIN CHEM LAB MED, V36, P215, DOI 10.1515/CCLM.1998.037; Alexander GM, 2002, NEUROPSYCHOLOGIA, V40, P1293, DOI 10.1016/S0028-3932(01)00220-2; Andreescu CE, 2007, J NEUROSCI, V27, P10832, DOI 10.1523/JNEUROSCI.2588-07.2007; Backstrom T, 2014, PROG NEUROBIOL, V113, P88, DOI 10.1016/j.pneurobio.2013.07.005; Backstrom T, 2011, NEUROSCIENCE, V191, P46, DOI 10.1016/j.neuroscience.2011.03.061; BACKSTROM T, 1976, ACTA NEUROL SCAND, V54, P321; Bauer J, 2001, EPILEPSIA, V42, P20, DOI 10.1046/j.1528-1157.2001.042suppl.3020.x; BELKIEN LD, 1985, FERTIL STERIL, V44, P322; Beyenburg S, 2001, EPILEPSY RES, V44, P141, DOI 10.1016/S0920-1211(01)00194-2; Bolaji II, 1994, INT J GYNAECOL OBSTE, V45, P125; Butefisch C, 2000, TASK DEPENDENT IN S3, V15, P153; Comasco E, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00388; DEBOEVER J, 1986, CLIN CHEM, V32, P763; Deligiannidis KM, 2013, J PSYCHIATR RES, V47, P816, DOI 10.1016/j.jpsychires.2013.02.010; Devanne H, 2006, EUR J NEUROSCI, V23, P2467, DOI 10.1111/j.1460-9568.2006.04760.x; Di Lazzaro V, 2000, CLIN NEUROPHYSIOL, V111, P794, DOI 10.1016/S1388-2457(99)00314-4; Epting LK, 1998, BEHAV NEUROSCI, V112, P1304, DOI 10.1037/0735-7044.112.6.1304; Fernandez G, 2003, J NEUROSCI, V23, P3790; Finocchi C, 2011, NEUROL SCI, V32, pS31, DOI 10.1007/s10072-011-0532-5; HAMPSON E, 1990, PSYCHONEUROENDOCRINO, V15, P97, DOI 10.1016/0306-4530(90)90018-5; HAMPSON E, 1990, BRAIN COGNITION, V14, P26, DOI 10.1016/0278-2626(90)90058-V; Hanajima R, 1998, J PHYSIOL-LONDON, V509, P607, DOI 10.1111/j.1469-7793.1998.607bn.x; Hanajima R, 2003, EXP BRAIN RES, V151, P427, DOI 10.1007/s00221-003-1455-z; Hattemer K, 2007, CLIN ENDOCRINOL, V66, P387, DOI 10.1111/j.1365-2265.2007.02744.x; Hausmann M, 2002, NEUROPSYCHOLOGIA, V40, P808, DOI 10.1016/S0028-3932(01)00179-8; HENDRY SHC, 1987, J NEUROSCI, V7, P1503; Herzog AG, 2001, EPILEPSY BEHAV, V2, P367, DOI 10.1006/ebeh.2001.0232; Inghilleri M, 2004, CLIN NEUROPHYSIOL, V115, P1063, DOI 10.1016/j.clinph.2003.12.003; Joels M, 1997, FRONT NEUROENDOCRIN, V18, P2, DOI 10.1006/frne.1996.0144; JONES EG, 1993, CEREB CORTEX, V3, P361, DOI 10.1093/cercor/3.5.361-a; Jones EG, 1981, ANATOMY CEREBRAL COR; KEENAN PA, 1992, PSYCHONEUROENDOCRINO, V17, P179, DOI 10.1016/0306-4530(92)90056-D; KEENAN PA, 1995, BIOL PSYCHIAT, V38, P369, DOI 10.1016/0006-3223(94)00303-K; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Lang N, 2011, CEREB CORTEX, V21, P2299, DOI 10.1093/cercor/bhr003; Lemon R, 1995, ELECTROENCEPHALOGRAP, V97, pS6; Lemon RN, 1999, EXP BRAIN RES, V128, P6, DOI 10.1007/s002210050811; Liepert J, 1997, J NEURAL TRANSM, V104, P1207, DOI 10.1007/BF01294721; Lissek S, 2007, NEUROIMAGE, V37, P912, DOI 10.1016/j.neuroimage.2007.05.037; Lu YC, 1997, J IMMUNOASSAY, V18, P149, DOI 10.1080/01971529708005810; Lu YC, 1999, FERTIL STERIL, V71, P863, DOI 10.1016/S0015-0282(99)00093-X; Maki PM, 2002, NEUROPSYCHOLOGIA, V40, P518, DOI 10.1016/S0028-3932(01)00126-9; MATSUMURA M, 1991, J NEUROPHYSIOL, V65, P1542, DOI 10.1152/jn.1991.65.6.1542; MATSUMURA M, 1992, J NEUROPHYSIOL, V68, P692, DOI 10.1152/jn.1992.68.3.692; Morrell MJ, 1999, NEUROLOGY, V53, pS42; Murphy DD, 1998, J NEUROSCI, V18, P2550; Murphy DD, 2000, NEUROENDOCRINOLOGY, V72, P133, DOI 10.1159/000054580; Nakajima K, 2000, J NEUROPHYSIOL, V84, P698, DOI 10.1152/jn.2000.84.2.698; Nakamura H, 1997, J PHYSIOL-LONDON, V498, P817, DOI 10.1113/jphysiol.1997.sp021905; Oh SJ, 2003, CLIN ELECTROMYOGRAPH, V3rd, P231, DOI 10.1046/j.1468-1331.2003.00654.x; Perotto A.O., 2005, ANATOMICAL GUIDE ELE, V4th; Porter R, 1993, CORTICOSPINAL FUNCTI; Rupprecht R, 2001, BRAIN RES REV, V37, P59, DOI 10.1016/S0165-0173(01)00123-0; Schieber MH, 1998, J NEUROSCI, V18, P9038; Simic N, 2010, ARH HIG RADA TOKSIKO, V61, P407, DOI 10.2478/10004-1254-61-2010-2055; Smith MD, 2002, NEUROSCIENCE, V109, P517, DOI 10.1016/S0306-4522(01)00490-0; Smith MJ, 1999, NEUROLOGY, V53, P2069, DOI 10.1212/WNL.53.9.2069; Smith MJ, 2002, ANN NEUROL, V51, P599, DOI 10.1002/ana.10180; SMITH SS, 1987, BRAIN RES, V400, P353, DOI 10.1016/0006-8993(87)90634-2; Solis-Ortiz S, 2008, PSYCHONEUROENDOCRINO, V33, P989, DOI 10.1016/j.psyneuen.2008.04.003; Stahl S. M., 2008, DEPRESSION BIPOLAR D; Stinear CM, 2003, J NEUROPHYSIOL, V89, P2014, DOI 10.1152/jn.00925.2002; Toffoletto S, 2014, PSYCHONEUROENDOCRINO, V50, P28, DOI 10.1016/j.psyneuen.2014.07.025; van Broekhoven F, 2006, PSYCHONEUROENDOCRINO, V31, P1190, DOI 10.1016/j.psyneuen.2006.08.007; Van Wingen GA, 2008, MOL PSYCHIATR, V13, P325, DOI 10.1038/sj.mp.4002030; WANG DY, 1986, EUR J CANCER CLIN ON, V22, P487, DOI 10.1016/0277-5379(86)90116-1; Wang Mingde, 2011, Front Endocrinol (Lausanne), V2, P44, DOI 10.3389/fendo.2011.00044; Wang YC, 2011, J HAND THER, V24, P313, DOI 10.1016/j.jht.2011.05.001; Wood P, 2009, ANN CLIN BIOCHEM, V46, P183, DOI 10.1258/acb.2008.008208; WORTHMAN CM, 1990, CLIN CHEM, V36, P1769; Yancosek KE, 2009, J HAND THER, V22, P258, DOI 10.1016/j.jht.2008.11.004; Ziemann U, 1996, J PHYSIOL-LONDON, V496, P873, DOI 10.1113/jphysiol.1996.sp021734; Ziemann U, 1996, ANN NEUROL, V40, P367, DOI 10.1002/ana.410400306; Ziemann U, 1996, NEUROSCI LETT, V208, P187, DOI 10.1016/0304-3940(96)12575-1; Ziemann U, 1996, EXP BRAIN RES, V109, P127; Ziemann U, 1995, BRAIN, V118, P1437, DOI 10.1093/brain/118.6.1437; Ziemann U, 2015, CLIN NEUROPHYSIOL, V126, P1847, DOI 10.1016/j.clinph.2014.08.028; Zoghi M, 2003, J PHYSIOL-LONDON, V550, P933, DOI 10.1113/jphysiol.2003.042606	78	23	23	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2015	10	8							e0136081	10.1371/journal.pone.0136081	http://dx.doi.org/10.1371/journal.pone.0136081			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP7LO	26308341	gold, Green Published			2023-01-03	WOS:000360069400087
J	Klco, JM; Miller, CA; Griffith, M; Petti, A; Spencer, DH; Ketkar-Kulkarni, S; Wartman, LD; Christopher, M; Lamprecht, TL; Helton, NM; Duncavage, EJ; Payton, JE; Baty, J; Heath, SE; Griffith, OL; Shen, D; Hundal, J; Chang, GS; Fulton, R; O'Laughlin, M; Fronick, C; Magrini, V; Demeter, RT; Larson, DE; Kulkarni, S; Ozenberger, BA; Welch, JS; Walter, MJ; Graubert, TA; Westervelt, P; Radich, JP; Link, DC; Mardis, ER; DiPersio, JF; Wilson, RK; Ley, TJ				Klco, Jeffery M.; Miller, Christopher A.; Griffith, Malachi; Petti, Allegra; Spencer, David H.; Ketkar-Kulkarni, Shamika; Wartman, Lukas D.; Christopher, Matthew; Lamprecht, Tamara L.; Helton, Nicole M.; Duncavage, Eric J.; Payton, Jacqueline E.; Baty, Jack; Heath, Sharon E.; Griffith, Obi L.; Shen, Dong; Hundal, Jasreet; Chang, Gue Su; Fulton, Robert; O'Laughlin, Michelle; Fronick, Catrina; Magrini, Vincent; Demeter, Ryan T.; Larson, David E.; Kulkarni, Shashikant; Ozenberger, Bradley A.; Welch, John S.; Walter, Matthew J.; Graubert, Timothy A.; Westervelt, Peter; Radich, Jerald P.; Link, Daniel C.; Mardis, Elaine R.; DiPersio, John F.; Wilson, Richard K.; Ley, Timothy J.			Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINIMAL RESIDUAL DISEASE; COOPERATIVE-ONCOLOGY-GROUP; COMPLETE REMISSION; ADULT PATIENTS; CLONAL HEMATOPOIESIS; CYTOGENETIC ABNORMALITIES; PROGNOSTIC IMPACT; STEM-CELLS; RELAPSE; CANCER	IMPORTANCE Tests that predict outcomes for patients with acute myeloid leukemia (AML) are imprecise, especially for those with intermediate risk AML. OBJECTIVES To determine whether genomic approaches can provide novel prognostic information for adult patients with de novo AML. DESIGN, SETTING, AND PARTICIPANTS Whole-genome or exome sequencing was performed on samples obtained at disease presentation from 71 patients with AML (mean age, 50.8 years) treated with standard induction chemotherapy at a single site starting in March 2002, with follow-up through January 2015. In addition, deep digital sequencing was performed on paired diagnosis and remission samples from 50 patients (including 32 with intermediate-risk AML), approximately 30 days after successful induction therapy. Twenty-five of the 50 were from the cohort of 71 patients, and 25 were new, additional cases. EXPOSURES Whole-genome or exome sequencing and targeted deep sequencing. Risk of identification based on genetic data. MAIN OUTCOMES AND MEASURES Mutation patterns (including clearance of leukemia-associated variants after chemotherapy) and their association with event-free survival and overall survival. RESULTS Analysis of comprehensive genomic data from the 71 patients did not improve outcome assessment over current standard-of-care metrics. In an analysis of 50 patients with both presentation and documented remission samples, 24 (48%) had persistent leukemia-associated mutations in at least 5% of bone marrow cells at remission. The 24 with persistent mutations had significantly reduced event-free and overall survival vs the 26 who cleared all mutations. Patients with intermediate cytogenetic risk profiles had similar findings. [GRAPHICS] CONCLUSIONS AND RELEVANCE The detection of persistent leukemia-associated mutations in at least 5% of bone marrow cells in day 30 remission samples was associated with a significantly increased risk of relapse, and reduced overall survival. These data suggest that this genomic approach may improve risk stratification for patients with AML.	[Klco, Jeffery M.; Spencer, David H.; Duncavage, Eric J.; Payton, Jacqueline E.; Kulkarni, Shashikant] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA; [Klco, Jeffery M.; Lamprecht, Tamara L.] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; [Miller, Christopher A.; Griffith, Malachi; Petti, Allegra; Ketkar-Kulkarni, Shamika; Griffith, Obi L.; Shen, Dong; Hundal, Jasreet; Chang, Gue Su; Fulton, Robert; O'Laughlin, Michelle; Fronick, Catrina; Magrini, Vincent; Demeter, Ryan T.; Larson, David E.; Ozenberger, Bradley A.; Mardis, Elaine R.; Wilson, Richard K.; Ley, Timothy J.] Washington Univ, McDonnell Genome Inst, St Louis, MO USA; [Miller, Christopher A.; Petti, Allegra; Mardis, Elaine R.; Wilson, Richard K.] Washington Univ, Dept Med, Div Genom & Bioinformat, St Louis, MO USA; [Griffith, Malachi; Wartman, Lukas D.; Fulton, Robert; Magrini, Vincent; Larson, David E.; Kulkarni, Shashikant; Mardis, Elaine R.; Wilson, Richard K.; Ley, Timothy J.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; [Ketkar-Kulkarni, Shamika; Christopher, Matthew; Lamprecht, Tamara L.; Helton, Nicole M.; Heath, Sharon E.; Griffith, Obi L.; Ozenberger, Bradley A.; Welch, John S.; Walter, Matthew J.; Graubert, Timothy A.; Westervelt, Peter; Link, Daniel C.; DiPersio, John F.; Ley, Timothy J.] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA; [Baty, Jack] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA; [Shen, Dong] Medimmune AstraZeneca, Gaithersburg, MD USA; [Kulkarni, Shashikant] Washington Univ, Dept Pediat, Div Hematol Oncol, St Louis, MO 63130 USA; [Graubert, Timothy A.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Radich, Jerald P.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	Washington University (WUSTL); St Jude Children's Research Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); AstraZeneca; Medimmune; Washington University (WUSTL); Harvard University; Massachusetts General Hospital; Fred Hutchinson Cancer Center	Ley, TJ (corresponding author), Washington Univ, Sch Med, 660 South Euclid Ave,Campus Box 8007, St Louis, MO 63110 USA.	timley@wustl.edu	Griffith, Malachi/P-1285-2014; Miller, Christopher A./A-1060-2009; Walter, Matthew J/S-7758-2018; Wilson, Richard K./AAF-4139-2019; Klco, Jeffery/M-9717-2018; Mardis, Elaine/W-2202-2019; Magrini, Vincent/AAT-5830-2020; Griffith, Obi/P-1286-2014	Griffith, Malachi/0000-0002-6388-446X; Miller, Christopher A./0000-0003-4266-6700; Wilson, Richard K./0000-0002-1992-1358; Klco, Jeffery/0000-0003-2961-6960; Magrini, Vincent/0000-0002-2019-4872; Westover, Tamara/0000-0002-1000-6698; Larson, David/0000-0001-7934-5906; Griffith, Obi/0000-0002-0843-4271	National Institutes of Health [KO8 HL116605, PO1 CA101937, U54 HG003079]; Barnes-Jewish Hospital Foundation [00335-0505-02]; National Cancer Institute Cancer Center [P30CA91842]; Burroughs Wellcome Fund; NATIONAL CANCER INSTITUTE [K08CA166229, P30CA091842, P01CA101937, P01CA018029, P50CA171963] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL116605, K12HL087107] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG003079] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Barnes-Jewish Hospital Foundation; National Cancer Institute Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Burroughs Wellcome Fund(Burroughs Wellcome Fund); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This work was supported by grants KO8 HL116605 (Dr Klco), PO1 CA101937 (Dr Ley), and U54 HG003079 (Dr Wilson) from the National Institutes of Health and grant 00335-0505-02 (Dr Ley) from the Barnes-Jewish Hospital Foundation. Technical assistance was provided by the Alvin J. Siteman Cancer Center Tissue Procurement Core, the High Speed Cell Sorting Core, and the Molecular and Genomic Analysis Core at Washington University School of Medicine and Barnes-Jewish Hospital in St Louis, Missouri, which are all supported by grant P30CA91842 from the National Cancer Institute Cancer Center. Dr Klco reports holding a Career Award for Medical Scientists from the Burroughs Wellcome Fund.	Breems DA, 2005, J CLIN ONCOL, V23, P1969, DOI 10.1200/JCO.2005.06.027; Busque L, 2012, NAT GENET, V44, P1179, DOI 10.1038/ng.2413; Byrd JC, 2002, BLOOD, V100, P4325, DOI 10.1182/blood-2002-03-0772; Chen XY, 2015, J CLIN ONCOL, V33, P1258, DOI 10.1200/JCO.2014.58.3518; Chen YM, 2011, J CLIN ONCOL, V29, P2507, DOI 10.1200/JCO.2010.34.2873; Cheson BD, 2003, J CLIN ONCOL, V21, P4642, DOI 10.1200/JCO.2003.04.036; Cheson BD, 2004, J CLIN ONCOL, V22, P576; Corces-Zimmerman MR, 2014, P NATL ACAD SCI USA, V111, P2548, DOI 10.1073/pnas.1324297111; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; Genovese G, 2014, NEW ENGL J MED, V371, P2477, DOI 10.1056/NEJMoa1409405; Hourigan CS, 2013, NAT REV CLIN ONCOL, V10, P460, DOI 10.1038/nrclinonc.2013.100; Inaba H, 2012, J CLIN ONCOL, V30, P3625, DOI 10.1200/JCO.2011.41.5323; Jaiswal S, 2014, NEW ENGL J MED, V371, P2488, DOI 10.1056/NEJMoa1408617; Kihara R, 2014, LEUKEMIA, V28, P1586, DOI 10.1038/leu.2014.55; Klco JM, 2014, CANCER CELL, V25, P379, DOI 10.1016/j.ccr.2014.01.031; Kronke J, 2013, BLOOD, V122, P100, DOI 10.1182/blood-2013-01-479188; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Lindsley RC, 2015, BLOOD, V125, P1367, DOI 10.1182/blood-2014-11-610543; Loken MR, 2012, BLOOD, V120, P1581, DOI 10.1182/blood-2012-02-408336; Marcucci G, 2004, J CLIN ONCOL, V22, P2410, DOI 10.1200/JCO.2004.03.023; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; Paietta E, 2012, HEMATOL-AM SOC HEMAT, P35, DOI 10.1182/asheducation-2012.1.35; Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304; Ploen GG, 2014, BRIT J HAEMATOL, V167, P478, DOI 10.1111/bjh.13062; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Ravandi F, 2010, BLOOD, V116, P5818, DOI 10.1182/blood-2010-07-296392; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rowe JM, 2010, CANCER-AM CANCER SOC, V116, P5012, DOI 10.1002/cncr.25263; Schlenk RF, 2008, NEW ENGL J MED, V358, P1909, DOI 10.1056/NEJMoa074306; Shlush LI, 2014, NATURE, V506, P328, DOI 10.1038/nature13038; Terwijn M, 2013, J CLIN ONCOL, V31, P3889, DOI 10.1200/JCO.2012.45.9628; Walter RB, 2011, J CLIN ONCOL, V29, P4417, DOI 10.1200/JCO.2011.35.7525; Walter RB, 2010, J CLIN ONCOL, V28, P1766, DOI 10.1200/JCO.2009.25.1066; Xie MC, 2014, NAT MED, V20, P1472, DOI 10.1038/nm.3733	34	239	245	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2015	314	8					811	822		10.1001/jama.2015.9643	http://dx.doi.org/10.1001/jama.2015.9643			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CP6SA	26305651	Green Accepted, Bronze			2023-01-03	WOS:000360017200021
J	Shi, FM; Xiao, Y; Xiong, W; Zhou, Q; Yang, P; Huang, XQ				Shi, Fenmei; Xiao, Ying; Xiong, Wei; Zhou, Qin; Yang, Peng; Huang, Xiongqing			Effects of Fentanyl on Emergence Agitation in Children under Sevoflurane Anesthesia: Meta-Analysis of Randomized Controlled Trials	PLOS ONE			English	Article							INTRANASAL FENTANYL; PEDIATRIC-PATIENTS; DOSE FENTANYL; BILATERAL MYRINGOTOMY; DELIRIUM; DESFLURANE; PREVENTION; HALOTHANE; PROPOFOL; SURGERY	Background and Objectives The goal of this meta-analysis study was to assess the effects of fentanyl on emergence agitation (EA) under sevoflurane anesthesia in children. Subjects and Methods We searched electronic databases (PubMed, Embase, Web of Science and the Cochrane Central Register of Controlled Trials) for articles published until December 2014. Randomized controlled trials (RCTs) that assessed the effects of fentanyl and placebo on EA under sevoflurane anesthesia in children that the outcome were the incidence of EA, postoperative pain, emergence time or adverse effects were included in this meta-analysis. Results A total of 16 studies, including 1362 patients (737 patients for the fentanyl group and 625 for the placebo group), were evaluated in final analysis. We found that administration of fentanyl decreased the incidences of EA (RR = 0.37, 95% CI 0.27 similar to 0.49, P<0.00001) and postoperative pain (RR = 0.59, 95% CI 0.41 similar to 0.85, P = 0.004) but increased the incidence of postoperative nausea and vomiting (PONV) (RR = 2.23, 95% CI 1.33 similar to 3.77, P = 0.003). The extubation time (WMD = 0.71 min, 95% CI 0.12 similar to 1.3, P = 0.02), emergence time (WMD = 4.90 min, 95% CI 2.49 similar to 7.30, P<0.0001), and time in the postanesthesia care unit (PACU) (WMD = 2.65 min, 95% CI 0.76 similar to 4.53, P = 0.006) were slightly increased. There were no significant differences in the time to discharge of day patients (WMD = 3.72 min, 95% CI -2.80 similar to 10.24, P = 0.26). Conclusion Our meta-analysis suggests that fentanyl decreases the incidence of EA under sevoflurane anesthesia in children and postoperative pain, but has a higher incidence of PONV. Considering the inherent limitations of the included studies, more RCTs with extensive follow-up should be performed to validate our findings in the future.	[Shi, Fenmei] Sun Yat Sen Univ, Dept Anaesthesiol, Sun Yat Sen Mem Hosp, Guangzhou 510275, Guangdong, Peoples R China; [Xiao, Ying; Xiong, Wei; Zhou, Qin; Yang, Peng; Huang, Xiongqing] Sun Yat Sen Univ, Dept Anaesthesiol, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Huang, XQ (corresponding author), Sun Yat Sen Univ, Dept Anaesthesiol, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China.	hxiongqing@163.com						Abdelhalim Ashraf Arafat, 2013, Saudi J Anaesth, V7, P392, DOI 10.4103/1658-354X.121047; Aouad MT, 2007, ANESTHESIOLOGY, V107, P733, DOI 10.1097/01.anes.0000287009.46896.a7; Aouad MT, 2005, ACTA ANAESTH SCAND, V49, P300, DOI 10.1111/j.1399-6576.2005.00642.x; Bajwa SA, 2010, PEDIATR ANESTH, V20, P704, DOI 10.1111/j.1460-9592.2010.03328.x; Bakhamees HS, 2009, SAUDI MED J, V30, P500; Binstock W, 2004, PEDIATR ANESTH, V14, P759, DOI 10.1111/j.1460-9592.2004.01296.x; Bortone L, 2014, PEDIATR ANESTH, V24, P614, DOI 10.1111/pan.12388; Cohen IT, 2002, ANESTH ANALG, V94, P1178, DOI 10.1097/00000539-200205000-00023; Costi D, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007084.pub2; Cravero J, 2000, PAEDIATR ANAESTH, V10, P419, DOI 10.1046/j.1460-9592.2000.00560.x; Cravero JP, 2003, ANESTH ANALG, V97, P364, DOI 10.1213/01.ANE.0000070227.78670.43; Cravero JP, 2001, AN ABSTR SCI PAP ANN, P1222; Dahmani S, 2010, BRIT J ANAESTH, V104, P216, DOI 10.1093/bja/aep376; [DEM S MM R], 2014, EGYPTIAN J ANAESTHES, P2; Demirbilek S, 2004, EUR J ANAESTH, V21, P538, DOI 10.1017/S0265021504007069; [DY K CH K YJ K MJ I], 2004, KOREAN J ANESTHESIOL, P1; ECKENHOFF J, 1961, ANESTHESIOLOGY, V22, P667, DOI 10.1097/00000542-196109000-00002; Erdil F, 2009, ANAESTH INTENS CARE, V37, P571, DOI 10.1177/0310057X0903700405; Finkel J, 2000, AN ABSTR SCI PAP ANN, P1252; Finkel JC, 2001, ANESTH ANALG, V92, P1164; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Galinkin JL, 2000, AN ABSTR SCI PAP ANN, P1253; [关雷 GUAN Lei], 2011, [临床麻醉学杂志, The Journal of Clinical Anesthestology], V27, P644; Hedges LV, 2001, PSYCHOL METHODS, V6, P203, DOI 10.1037/1082-989X.6.3.203; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hippard HK, 2012, ANESTH ANALG, V115, P356, DOI 10.1213/ANE.0b013e31825afef3; Hozo S.P., 2005, BMC MED RES METHODOL, V5, P13, DOI [10.1186/1471-2288-5-13, DOI 10.1186/1471-2288-5-13]; Hung WT, 2005, J CLIN ANESTH, V17, P494, DOI 10.1016/j.jclinane.2004.09.014; Inomata S, 2010, BRIT J ANAESTH, V105, P361, DOI 10.1093/bja/aeq168; Ioannidis JP, 2009, PLOS MED, V6, pE; JIN HEE CHEOL, 2004, Korean Journal of Anesthesiology, V46, P524; Jung HJ, 2010, KOREAN J ANESTHESIOL, V58, P148, DOI 10.4097/kjae.2010.58.2.148; Juni P, 2002, INT J EPIDEMIOL, V31, P115, DOI 10.1093/ije/31.1.115; Kain ZN, 2004, ANESTH ANALG, V99, P1648, DOI 10.1213/01.ANE.0000136471.36680.97; 박성용, 2005, Korean Journal of Anesthesiology, V49, P502; Kim MS, 2013, BRIT J ANAESTH, V110, P274, DOI 10.1093/bja/aes382; Kuratani N, 2008, ANESTHESIOLOGY, V109, P225, DOI 10.1097/ALN.0b013e31817f5c18; Li J, 2011, CHINESE MED J-PEKING, V124, P3682, DOI 10.3760/cma.j.issn.0366-6999.2011.22.015; Li XZ, 2013, SAUDI MED J, V34, P40; Locatelli BG, 2013, PEDIATR ANESTH, V23, P301, DOI 10.1111/pan.12038; Lynch EP, 1998, ANESTH ANALG, V86, P781; [M A G E H E AA R BS E MY M], 2009, EGYPTIAN J ANAESTHES, P4; [M A AT D O K B I], 2005, TURK ANESTEZIYOLOJI, P5; [M H MY M SS E OM A], 2011, EGYPTIAN J ANAESTHES, P1; Moher D., 2009, BMJ-BRIT MED J, V6, DOI [DOI 10.1023/B:MEDI.0000005484.26741.79, 10.1371/journal.pmed1000097.]; Oh AY, 2005, ACTA ANAESTH SCAND, V49, P297, DOI 10.1111/j.1399-6576.2005.00687.x; Patel A, 2010, ANESTH ANALG, V111, P1004, DOI 10.1213/ANE.0b013e3181ee82fa; [裴春明 Pei Chunming], 2012, [临床麻醉学杂志, The Journal of Clinical Anesthestology], V28, P17; Pestieau SR, 2011, PEDIATR ANESTH, V21, P1128, DOI 10.1111/j.1460-9592.2011.03615.x; Rampersad S, 2010, PEDIATR ANESTH, V20, P1028, DOI 10.1111/j.1460-9592.2010.03427.x; [沈霞 Shen Xia], 2010, [中华麻醉学杂志, Chinese Journal of Anesthesiology], V30, P303; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; SM A, 2008, EGYPTIAN J ANAESTHES, P1; Somaini M, 2015, PEDIATR ANESTH, V25, P524, DOI 10.1111/pan.12580; Veyckemans F, 2001, Curr Opin Anaesthesiol, V14, P339, DOI 10.1097/00001503-200106000-00010; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8; Welborn LG, 1996, ANESTH ANALG, V83, P917, DOI 10.1097/00000539-199611000-00005; Zhang CL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099718; Zhang CM, 2013, CLIN THER, V35, P1622, DOI 10.1016/j.clinthera.2013.08.016; ZHANG YY, 2012, SHIP ELECT ENG, V32, P12; 김치효, 2007, Korean Journal of Anesthesiology, V53, P609; 김혜경, 2005, Korean Journal of Anesthesiology, V49, P370	63	11	13	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2015	10	8							e0135244	10.1371/journal.pone.0135244	http://dx.doi.org/10.1371/journal.pone.0135244			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO9KD	26275039	Green Published, gold, Green Submitted			2023-01-03	WOS:000359493600058
J	Gare, J; Kelly-Hanku, A; Ryan, CE; David, M; Kaima, P; Imara, U; Lote, N; Crowe, SM; Hearps, AC				Gare, Janet; Kelly-Hanku, Angela; Ryan, Claire E.; David, Matthew; Kaima, Petronia; Imara, Ulato; Lote, Namarola; Crowe, Suzanne M.; Hearps, Anna C.			Factors Influencing Antiretroviral Adherence and Virological Outcomes in People Living with HIV in the Highlands of Papua New Guinea	PLOS ONE			English	Article							SELF-REPORTED ADHERENCE; DRUG-RESISTANCE; THERAPY; PREDICTORS; BARRIERS	Adherence to antiretroviral therapy (ART) is paramount for virological suppression and positive treatment outcomes. ART has been rapidly scaled up in Papua New Guinea (PNG) in recent years, however clinical monitoring of HIV+ individuals on ART is limited. A cross-sectional study was conducted at two major sexual health clinics in high HIV prevalence provinces in the Highlands Region of PNG to assess ART adherence, factors affecting adherence and the relationship between ART adherence and virological outcomes. Ninety-five HIV+ individuals were recruited and administered a questionnaire to gather demographic and ART adherence information whilst clinical data and pill counts were extracted from patient charts and blood was collected for viral load testing. Bivariate analysis was performed to identify independent predictors of ART adherence. Fourteen percent (n = 12) of participants showed evidence of virological failure. Although the majority of participants self-reported excellent ART adherence in the last seven days (78.9%, 75/91), pill count measurements indicated only 40% (34/84) with >95% adherence in the last month. Taking other medications while on ART (p = 0.01) and taking ART for >= 1 year (p = 0.037) were positively associated with adherence by self-report and pill count, respectively. Participants who had never heard of drug resistance were more likely to show virological failure (p = 0.033). Misconception on routes of HIV transmission still persists in the studied population. These findings indicate that non-adherence to ART is high in this region of PNG and continued education and strategies to improve adherence are required to ensure the efficacy of ART and prevent HIV drug resistance.	[Gare, Janet; Kelly-Hanku, Angela; David, Matthew; Lote, Namarola] Papua New Guinea Inst Med Res, Sexual & Reprod Hlth Unit, Goroka, Eastern Highlan, Papua N Guinea; [Gare, Janet; Ryan, Claire E.; Crowe, Suzanne M.; Hearps, Anna C.] Burnet Inst, Ctr Biomed Res, Melbourne, Vic, Australia; [Gare, Janet; Crowe, Suzanne M.; Hearps, Anna C.] Monash Univ, Cent Clin Sch, Melbourne, Vic 3004, Australia; [Kelly-Hanku, Angela] Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW, Australia; [Kaima, Petronia] Natl Dept Hlth, HIV STI Highlands Reg, Mt Hagen, Western Highlan, Papua N Guinea; [Imara, Ulato] Goroka Gen Hosp, Michael Alpers Clin, Goroka, Eastern Highlan, Papua N Guinea	PNG Institute Of Medical Research; Burnet Institute; Monash University; University of New South Wales Sydney	Gare, J (corresponding author), Papua New Guinea Inst Med Res, Sexual & Reprod Hlth Unit, POB 60, Goroka, Eastern Highlan, Papua N Guinea.	jgare@burnet.edu.au	Nightingale, Claire Elizabeth/K-1667-2019	Nightingale, Claire Elizabeth/0000-0002-4103-6240	National AIDS Council Secretariat - Papua New Guinea [RES090012]	National AIDS Council Secretariat - Papua New Guinea	The National AIDS Council Secretariat - Papua New Guinea (Grant number: RES090012) funded this study. JG and CER received the funds. The funder has no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amberbir A, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-265; [Anonymous], 2010, STI HIV AIDS 2 Q SUR; [Anonymous], PAP NEW GUIN 2013 HI; [Anonymous], 2012, GLOB AIDS REP; Berg KM, 2006, JAIDS-J ACQ IMM DEF, V43, pS79, DOI 10.1097/01.qai.0000248337.97814.66; Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891; Daoni E, 2012, CLIN INFECT DIS, V54, pS303, DOI 10.1093/cid/cir994; Gare J, 2014, J ANTIMICROB CHEMOTH, V69, P2183, DOI 10.1093/jac/dku089; Gill CJ, 2010, AIDS BEHAV, V14, P785, DOI 10.1007/s10461-009-9555-9; Glass TR, 2006, JAIDS-J ACQ IMM DEF, V41, P385, DOI 10.1097/01.qai.0000186371.95301.52; Greengrass VL, 2009, J CLIN MICROBIOL, V47, P3011, DOI 10.1128/JCM.00805-09; HIV/AIDS Fact Sheets, 2014, PORT MOR; Kaldor J., 2006, IMPACTS HIVAIDS 2005; Kelly A, 2011, PAPUA NEW GUINEA MED, V54, P23; Kelly A, 2010, CURR HIV RES, V8, P630, DOI 10.2174/157016210794088191; Kelly A, 2011, AIDS CARE, V23, P734, DOI 10.1080/09540121.2010.532533; Kelly-Hanku A, 2014, SOC SCI MED, V119, P106, DOI 10.1016/j.socscimed.2014.08.020; Kelly-Hanku A, 2014, AIDS BEHAV, V18, P573, DOI 10.1007/s10461-013-0624-8; Kelly-Hanku A, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1108; Kisenyi RN, 2013, J RELIG HEALTH, V52, P307, DOI 10.1007/s10943-011-9473-9; Larson EC, 2014, J ETHNOPHARMACOL, V155, P1433, DOI 10.1016/j.jep.2014.07.023; Li JZ, 2014, AIDS, V28, P181, DOI 10.1097/QAD.0000000000000123; Liam C, 2014, FAITH HEALING REPLAC; Maibani G, 2011, PAPUA NEW GUINEA AUS, P1; Malagun M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112173; McBride William J, 2005, Emerg Med Australas, V17, P304, DOI 10.1111/j.1742-6723.2005.00751.x; Mills EJ, 2006, PLOS MED, V3, P2039, DOI 10.1371/journal.pmed.0030438; Mosha F, 2014, J INFECT DEV COUNTR, V8, P845, DOI 10.3855/jidc.3879; Obirikorang Christian, 2013, ISRN AIDS, V2013, P873939, DOI 10.1155/2013/873939; Portelli MS, 2012, ASIA PAC J PUBLIC HL; Rodrigues R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040723; Schonnesson LN, 2006, AIDS CARE, V18, P406, DOI 10.1080/09540120500456631a; Tadios Yonas, 2006, Ethiop Med J, V44, P237; Tiyou A, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-39; Tumwine C, 2012, RELIGIONS, V3, P817, DOI 10.3390/rel3030817; Wang HH, 2008, AIDS PATIENT CARE ST, V22, P71, DOI 10.1089/apc.2007.0047; Wanyama J, 2007, AIDS, V21, P1486, DOI 10.1097/QAD.0b013e32823ecf7f; Weiser S, 2003, JAIDS-J ACQ IMM DEF, V34, P281, DOI 10.1097/00126334-200311010-00004; Wouters E, 2009, SOC SCI MED, V69, P1177, DOI 10.1016/j.socscimed.2009.07.034	39	10	10	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2015	10	8							e0134918	10.1371/journal.pone.0134918	http://dx.doi.org/10.1371/journal.pone.0134918			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CO3MH	26244516	Green Published, gold			2023-01-03	WOS:000359061400130
J	Crins, MHP; Roorda, LD; Smits, N; de Vet, HCW; Westhovens, R; Cella, D; Cook, KF; Revicki, D; van Leeuwen, J; Boers, M; Dekker, J; Terwee, CB				Crins, Martine H. P.; Roorda, Leo D.; Smits, Niels; de Vet, Henrica C. W.; Westhovens, Rene; Cella, David; Cook, Karon F.; Revicki, Dennis; van Leeuwen, Jaap; Boers, Maarten; Dekker, Joost; Terwee, Caroline B.			Calibration and Validation of the Dutch-Flemish PROMIS Pain Interference Item Bank in Patients with Chronic Pain	PLOS ONE			English	Article							NECK DISABILITY INDEX; REPORTED OUTCOMES; R PACKAGE; PHYSICAL FUNCTION; BACK-PAIN; RESPONSIVENESS; RELIABILITY; QUESTIONNAIRE; TRANSLATION; SHOULDER	The Dutch-Flemish PROMIS Group translated the adult PROMIS Pain Interference item bank into Dutch-Flemish. The aims of the current study were to calibrate the parameters of these items using an item response theory (IRT) model, to evaluate the cross-cultural validity of the Dutch-Flemish translations compared to the original English items, and to evaluate their reliability and construct validity. The 40 items in the bank were completed by 1085 Dutch chronic pain patients. Before calibrating the items, IRT model assumptions were evaluated using confirmatory factor analysis (CFA). Items were calibrated using the graded response model (GRM), an IRT model appropriate for items with more than two response options. To evaluate cross-cultural validity, differential item functioning (DIF) for language (Dutch vs. English) was examined. Reliability was evaluated based on standard errors and Cronbach's alpha. To evaluate construct validity correlations with scores on legacy instruments (e.g., the Disabilities of the Arm, Shoulder and Hand Questionnaire) were calculated. Unidimensionality of the Dutch-Flemish PROMIS Pain Interference item bank was supported by CFA tests of model fit (CFI = 0.986, TLI = 0.986). Furthermore, the data fit the GRM and showed good coverage across the pain interference continuum (threshold-parameters range: -3.04 to 3.44). The Dutch-Flemish PROMIS Pain Interference item bank has good cross-cultural validity (only two out of 40 items showing DIF), good reliability (Cronbach's alpha = 0.98), and good construct validity (Pearson correlations between 0.62 and 0.75). A computer adaptive test ( CAT) and Dutch-Flemish PROMIS short forms of the Dutch-Flemish PROMIS Pain Interference item bank can now be developed.	[Crins, Martine H. P.; Roorda, Leo D.] Reade, Amsterdam Rehabil Res Ctr, Amsterdam, Netherlands; [Smits, Niels] Vrije Univ Amsterdam, Med Ctr, Dept Clin Psychol, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [Smits, Niels] Vrije Univ Amsterdam, Med Ctr, Dept Methodol, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [de Vet, Henrica C. W.; Boers, Maarten; Terwee, Caroline B.] Vrije Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [Westhovens, Rene] Katholieke Univ Leuven, Dept Dev & Regenerat, Skeletal Biol & Engn Res Ctr, Louvain, Belgium; [Westhovens, Rene] Katholieke Univ Leuven, Univ Hosp, Rheumatol, Louvain, Belgium; [Cella, David; Cook, Karon F.] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA; [Revicki, Dennis] Evidera, Outcomes Res, Bethesda, MD USA; [van Leeuwen, Jaap] Leones Grp BV, Amsterdam, Netherlands; [Boers, Maarten] Vrije Univ Amsterdam, Med Ctr, Dept Rheumatol, Amsterdam, Netherlands; [Dekker, Joost] Vrije Univ Amsterdam, Med Ctr, Dept Rehabil Med, Amsterdam, Netherlands; [Dekker, Joost] Vrije Univ Amsterdam, Med Ctr, Dept Psychiat, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; KU Leuven; KU Leuven; Northwestern University; Feinberg School of Medicine; Evidera; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Crins, MHP (corresponding author), Reade, Amsterdam Rehabil Res Ctr, Amsterdam, Netherlands.	m.crins@reade.nl		de Vet, Henrica/0000-0002-5454-2804; Terwee, Caroline/0000-0003-4570-2826; Dekker, Joost/0000-0003-2027-0027	Dutch Arthritis Association [BP 10-1-261]; Dutch Scientific College of Physical Therapy; Leones Group BV & Outcomes Research	Dutch Arthritis Association; Dutch Scientific College of Physical Therapy; Leones Group BV & Outcomes Research	The Dutch-Flemish translation of the PROMIS item banks was supported by a grant from the Dutch Arthritis Association (BP 10-1-261). Funding for the current calibration study was provided by a grant from the Dutch Scientific College of Physical Therapy. Leones Group BV & Outcomes Research provided support in the form of salaries for co-authors Jaap van Leeuwen & Dennis Revicki retrospectively, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the authors are articulated in the 'author contributions' section.	Ailliet L, 2015, EUR SPINE J, V24, P88, DOI 10.1007/s00586-014-3359-y; Amtmann D, 2010, PAIN, V150, P173, DOI 10.1016/j.pain.2010.04.025; Beurskens AJHM, 1996, PAIN, V65, P71, DOI 10.1016/0304-3959(95)00149-2; Bot SDM, 2004, ANN RHEUM DIS, V63, P335, DOI 10.1136/ard.2003.007724; Brouwer S, 2004, DISABIL REHABIL, V26, P162, DOI 10.1080/09638280310001639713; BURCKHARDT CS, 1991, J RHEUMATOL, V18, P728; Cella D, 2007, MED CARE, V45, pS3, DOI 10.1097/01.mlr.0000258615.42478.55; Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; Chang HH, 1996, APPL PSYCH MEAS, V20, P213, DOI 10.1177/014662169602000303; Choi SW, 2011, J STAT SOFTW, V39, P1; Cimmino MA, 2011, BEST PRACT RES CL RH, V25, P173, DOI 10.1016/j.berh.2010.01.012; Cohen J., 2013, STAT POWER ANAL BEHA; Cook KF, 2009, QUAL LIFE RES, V18, P447, DOI 10.1007/s11136-009-9464-4; Cook KF, 2014, QUAL LIFE RES; Crane PK, 2006, MED CARE, V44, pS115, DOI 10.1097/01.mlr.0000245183.28384.ed; Crins M, CALIBRATION DU UNPUB; Deyo RA, 2014, EUR SPINE J, V23, P2028, DOI 10.1007/s00586-014-3540-3; Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012; Edelen MO, 2015, QUAL LIFE RES, V24, P95, DOI 10.1007/s11136-013-0540-4; Embretson S. E., 2013, ITEM RESPONSE THEORY, DOI DOI 10.4324/9781410605269; Eremenco SL, 2005, EVAL HEALTH PROF, V28, P212, DOI 10.1177/0163278705275342; Fries J, 2011, J RHEUMATOL, V38, P1759, DOI 10.3899/jrheum.110402; Fries JF, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3461; Fries JF, 2009, J RHEUMATOL, V36, P2061, DOI 10.3899/jrheum.090358; GOMMANS IHB, 1997, NED TIJDSCHR FYSIOTH, V107, P28; Harstall C, 2003, PAIN CLIN UPDATES, V11, P1, DOI DOI 10.1016/S1070-7212(03)00004-6; Haverman L, 2015, QUAL LIFE RES; Hays RD, 2009, QUAL LIFE RES, V18, P873, DOI 10.1007/s11136-009-9496-9; Holland PW., 1993, DIFFERENTIAL ITEM FU; Hudak PL, 1996, AM J IND MED, V29, P602, DOI 10.1002/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L; Huisstede BMA, 2009, SPINE, V34, pE130, DOI 10.1097/BRS.0b013e318195a28b; Jorritsma W, 2012, EUR SPINE J, V21, P93, DOI 10.1007/s00586-011-1920-5; ke A, 1996, MEETINSTRUMENTEN CHR, P52; ke A, 1996, MEETINSTRUMENTEN CHR, P68; Khanna D, 2011, ARTHRIT CARE RES, V63, pS486, DOI 10.1002/acr.20581; Koke A, 1996, MEETINSTRUMENTEN CHR, P36; Lai JS, 2011, ARCH PHYS MED REHAB, V92, pS20, DOI 10.1016/j.apmr.2010.08.033; Magasi S, 2012, QUAL LIFE RES, V21, P739, DOI 10.1007/s11136-011-9990-8; Magis D, 2012, J STAT SOFTW, V48, P1; MCKINLEY RL, 1985, APPL PSYCH MEAS, V9, P49, DOI 10.1177/014662168500900105; Miles J, 2007, PERS INDIV DIFFER, V42, P869, DOI 10.1016/j.paid.2006.09.022; Mokken R. J., 1971, THEORY PROCEDURE SCA, DOI DOI 10.1515/9783110813203; Palmen C, 2004, NED TIJDSCHR FYSIOTH, V114, P30; Picavet HSJ, 2003, PAIN, V102, P167, DOI 10.1016/S0304-3959(02)00372-X; Reckase M.D., 1979, J ED BEHAV STAT J ED, V4, P207, DOI [10.3102/, DOI 10.3102/10769986004003207]; Reeve BB, 2007, MED CARE, V45, pS22, DOI 10.1097/01.mlr.0000250483.85507.04; Reid KJ, 2011, CURR MED RES OPIN, V27, P449, DOI 10.1185/03007995.2010.545813; Revicki DA, 2009, PAIN, V146, P158, DOI 10.1016/j.pain.2009.07.029; Rizopoulos D, 2007, J STAT SOFTW, V17, P1, DOI DOI 10.18637/jss.v017.i05; Rizopoulos D, 2007, LTM PACKAGE LATENT T; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Rosseel Y, 2012, J STAT SOFTW, V48, P1, DOI 10.18637/jss.v048.i02; Sijtsma K, 2008, QUAL LIFE RES, V17, P275, DOI 10.1007/s11136-007-9281-6; Terwee CB, 2014, QUAL LIFE RES, V23, P1733, DOI 10.1007/s11136-013-0611-6; van der Ark L. A., 2007, J STAT SOFTW, V20, P1, DOI DOI 10.18637/JSS.V020.I11; Veehof Martine M, 2002, J Hand Ther, V15, P347; VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409; Vos CJ, 2006, EUR SPINE J, V15, P1729, DOI 10.1007/s00586-006-0119-7; YEN WM, 1993, J EDUC MEAS, V30, P187, DOI 10.1111/j.1745-3984.1993.tb00423.x; Zijlstra TR, 2007, RHEUMATOLOGY, V46, P131, DOI 10.1093/rheumatology/kel171	60	27	27	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2015	10	7							e0134094	10.1371/journal.pone.0134094	http://dx.doi.org/10.1371/journal.pone.0134094			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CN7DN	26214178	Green Published, Green Submitted, gold			2023-01-03	WOS:000358594300049
J	James, L; Yan, K; Pence, L; Simpson, P; Bhattacharyya, S; Gill, P; Letzig, L; Kearns, G; Beger, R				James, Laura; Yan, Ke; Pence, Lisa; Simpson, Pippa; Bhattacharyya, Sudeepa; Gill, Pritmohinder; Letzig, Lynda; Kearns, Gregory; Beger, Richard			Comparison of Bile Acids and Acetaminophen Protein Adducts in Children and Adolescents with Acetaminophen Toxicity	PLOS ONE			English	Article							ACUTE LIVER-FAILURE; LIQUID-CHROMATOGRAPHY; HEPATIC-INJURY; NITRIC-OXIDE; OVERDOSE; SERUM; TAURINE; HEPATOTOXICITY; MULTICENTER; NECROSIS	Metabolomics approaches have enabled the study of new mechanisms of liver injury in experimental models of drug toxicity. Disruption of bile acid homeostasis is a known mechanism of drug induced liver injury. The relationship of individual bile acids to indicators of oxidative drug metabolism (acetaminophen protein adducts) and liver injury was examined in children with acetaminophen overdose, hospitalized children with low dose exposure to acetaminophen, and children with no recent exposure to acetaminophen. Nine bile acids were quantified through targeted metabolomic analysis in the serum samples of the three groups. Bile acids were compared to serum levels of acetaminophen protein adducts and alanine aminotransferase. Glycodeoxycholic acid, taurodeoxycholic acid, and glycochenodeoxycholic acid were significantly increased in children with acetaminophen overdose compared to healthy controls. Among patients with acetaminophen overdose, bile acids were higher in subjects with acetaminophen protein adduct values > 1.0 nmol/mL and modest correlations were noted for three bile acids and acetaminophen protein adducts as follows: taurodeoxycholic acid (R=0.604; p<0.001), glycodeoxycholic acid (R=0.581; p<0.001), and glycochenodeoxycholic acid (R=0.571; p<0.001). Variability in bile acids was greater among hospitalized children receiving low doses of acetaminophen than in healthy children with no recent acetaminophen exposure. Compared to bile acids, acetaminophen protein adducts more accurately discriminated among children with acetaminophen overdose, children with low dose exposure to acetaminophen, and healthy control subjects. In children with acetaminophen overdose, elevations of conjugated bile acids were associated with specific indicators of acetaminophen metabolism and non-specific indicators of liver injury.	[James, Laura; Bhattacharyya, Sudeepa; Gill, Pritmohinder; Letzig, Lynda] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72202 USA; [James, Laura; Bhattacharyya, Sudeepa; Gill, Pritmohinder; Letzig, Lynda] Arkansas Childrens Hosp, Res Inst, Little Rock, AR 72202 USA; [Yan, Ke; Simpson, Pippa] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Pence, Lisa; Beger, Richard] Natl Ctr Toxicol Res, Div Syst Biol, Jefferson, AR 72079 USA; [Kearns, Gregory] Childrens Mercy Hosp, Div Pediat Pharmacol Med Toxicol & Therapeut Inno, Kansas City, MO 64108 USA	University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; Medical College of Wisconsin; US Food & Drug Administration (FDA); Children's Mercy Hospital	James, L (corresponding author), Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72202 USA.	jameslaurap@uams.edu	simpson, pippa/AAI-8172-2020	simpson, pippa/0000-0003-1458-3748	National Institutes of Diabetes, Digestive and Kidney Diseases of the United States Department of Health and Human Services [DK75936]; Arkansas Biosciences Institute; Arkansas Tobacco Settlement Funds; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R41DK079387, R42DK079387] Funding Source: NIH RePORTER	National Institutes of Diabetes, Digestive and Kidney Diseases of the United States Department of Health and Human Services; Arkansas Biosciences Institute; Arkansas Tobacco Settlement Funds; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was funded in part by a grant (DK75936 to LJ) from the National Institutes of Diabetes, Digestive and Kidney Diseases of the United States Department of Health and Human Services and the Arkansas Biosciences Institute which is funded by Arkansas Tobacco Settlement Funds.	Alander SW, 2000, ARCH PEDIAT ADOL MED, V154, P346, DOI 10.1001/archpedi.154.4.346; Aleksunes LM, 2008, TOXICOL APPL PHARM, V226, P74, DOI 10.1016/j.taap.2007.08.022; Bhattacharyya S PL, 2013, METABOLITES, V3, P1, DOI [10.3390/metabo3010001, DOI 10.3390/METABO3010001]; Bhattacharyya S, 2014, BIOMARK MED, V8, P147, DOI 10.2217/bmm.13.150; Bhushan B, 2013, AM J PATHOL, V183, P1518, DOI 10.1016/j.ajpath.2013.07.012; Bi HC, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/985257; Chaudhuri S, 2011, TOXICOL APPL PHARM, V252, P211, DOI 10.1016/j.taap.2011.02.005; Chen C, 2009, CHEM RES TOXICOL, V22, P699, DOI 10.1021/tx800464q; Chiang JYL, 2013, COMPR PHYSIOL, V3, P1191, DOI 10.1002/cphy.c120023; Clayton TA, 2009, P NATL ACAD SCI USA, V106, P14728, DOI 10.1073/pnas.0904489106; Clayton TA, 2006, NATURE, V440, P1073, DOI 10.1038/nature04648; Das J, 2010, TOXICOLOGY, V269, P24, DOI 10.1016/j.tox.2010.01.003; Davern TJ, 2006, GASTROENTEROLOGY, V130, P687, DOI 10.1053/j.gastro.2006.01.033; Gardner CR, 1998, HEPATOLOGY, V27, P748, DOI 10.1002/hep.510270316; Hanawa N, 2008, J BIOL CHEM; James LP, 2008, CLIN PHARMACOL THER, V84, P684, DOI 10.1038/clpt.2008.190; James LP, 2009, DRUG METAB DISPOS, V37, P1779, DOI 10.1124/dmd.108.026195; James LP, 2003, DRUG METAB DISPOS, V31, P1499, DOI 10.1124/dmd.31.12.1499; James LP, 2012, EUR J CLIN PHARM; JAMES O, 1975, LANCET, V2, P579; Khandelwal N, 2011, HEPATOLOGY, V53, P567, DOI 10.1002/hep.24060; Kon K, 2004, HEPATOLOGY, V40, P1170, DOI 10.1002/hep.20437; Kostrubsky VE, 2003, TOXICOL SCI, V76, P220, DOI 10.1093/toxsci/kfg217; Lake AD, 2013, TOXICOL APPL PHARM, V268, P132, DOI 10.1016/j.taap.2013.01.022; Larson AM, 2005, HEPATOLOGY, V42, P1364, DOI 10.1002/hep.20948; Legido-Quigley C, 2011, ELECTROPHORESIS, V32, P2063, DOI 10.1002/elps.201000512; Luo LN, 2014, TOXICOL SCI, V137, P12, DOI 10.1093/toxsci/kft221; Milkiewicz P, 2002, GUT, V51, P113, DOI 10.1136/gut.51.1.113; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P185; Muldrew KL, 2002, DRUG METAB DISPOS, V30, P446, DOI 10.1124/dmd.30.4.446; PUMFORD NR, 1990, BIOCHEM PHARMACOL, V40, P573, DOI 10.1016/0006-2952(90)90558-3; Redmond HP, 1996, ARCH SURG-CHICAGO, V131, P1280; RUMACK BH, 1975, PEDIATRICS, V55, P871; RUMACK BH, 1986, PEDIATR CLIN N AM, V33, P691; Schnackenberg LK, 2006, PHARMACOGENOMICS, V7, P1077, DOI 10.2217/14622416.7.7.1077; Schwartz EA, 2009, ANN EMERG MED, V54, P421, DOI 10.1016/j.annemergmed.2008.10.001; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; Sullivan JE, 2011, PEDIATRICS, V127, P580, DOI 10.1542/peds.2010-3852; Sun J., 2013, J MOL BIOMARKERS DIA, pS1; Sun J, 2008, J CHROMATOGR B ANALY; Waters E, 2001, AM J PHYSIOL-GASTR L, V280, pG1274, DOI 10.1152/ajpgi.2001.280.6.G1274; Woolbright BL, 2014, TOXICOL SCI, V142, P436, DOI 10.1093/toxsci/kfu195; Yamazaki M, 2013, TOXICOL APPL PHARM, V268, P79, DOI 10.1016/j.taap.2013.01.018	43	17	17	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2015	10	7							e0131010	10.1371/journal.pone.0131010	http://dx.doi.org/10.1371/journal.pone.0131010			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN7NT	26208104	gold, Green Published, Green Submitted			2023-01-03	WOS:000358622000014
J	Sun, JJ; Liu, L; Shen, JY; Qi, TK; Wang, ZY; Song, W; Zhang, RF; Lu, HZ				Sun, Jianjun; Liu, Li; Shen, Jiayin; Qi, Tangkai; Wang, Zhenyan; Song, Wei; Zhang, Renfang; Lu, Hongzhou			Reasons and Risk Factors for the Initial Regimen Modification in Chinese Treatment-Naive Patients with HIV Infection: A Retrospective Cohort Analysis	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; INDIVIDUALS; DURABILITY; TENOFOVIR; HAART; DISCONTINUATION; ADOLESCENTS; RESISTANCE; EFFICACY; OUTCOMES	Background To investigate the reasons and risk factors for modification of the first combined antiretroviral therapy (cART) currently used for HIV infected patients who were treatment naive in Shanghai China. Methods Making a retrospective observational research on treatment naive patients with HIV infection who initiated cART during the period of September 1st 2005-December 1st 2013. The demographic and clinical data were collected from the first visit to the time of the first regimen modification or the last visit in December 1st, 2014. The reasons of treatment modification were recorded. Survival analysis of modification was made by Kaplan-Meier curves analysis and log rank test, and a Cox multiple regression model was constructed to identify related factors of modification. Results A total number of the eligible participants were 3372 and 871(25.8%) patients changed their first cART regimen. The median follow up was 22 months [interquartile range (IQR) 14-39]. Among patients who modified the original regimen, drug toxicity occurred in 805(92.4%) participants and 44(5.1%) experienced treatment failure. In multiple regression analysis regimen modification was associated with patients' age more than 40 years old (aHR 1.224, 95%CI 1.051-1.426, P = 0.010), CD4 less than 200(aHR 1.218, 95%CI 1.044-1.421, P = 0.012) and the initial regimen they received. Compared with the regimen of TDF+3TC+EFV, patients with regimen of d4T+3TC+NVP, d4T+3TC+EFV, AZT+3TC+NVP or AZT+3TC+EFV were 10.4, 8.2, 6.4, 2.5 times more likely to modify their initial regimen, respectively. Conclusions The main reason for the regimen switch was drug toxicity and main risk factors for regimen modification were age older than 40 years, CD4 cell counts less than 200 at baseline and regimen they received. Among the 2NRTI plus 1NNRTI regimens, the co-formulation of d4T+3TC+NVP had the highest risk for modification while the regimen of TDF+3TC+EFV was the most tolerable treatment regimen in first years' follow up.	[Sun, Jianjun; Liu, Li; Shen, Jiayin; Qi, Tangkai; Wang, Zhenyan; Song, Wei; Zhang, Renfang; Lu, Hongzhou] Fudan Univ, Dept Infect Dis, Shanghai Publ Hlth Clin Ctr, Key Lab Med Mol Virol MOE MOH, Shanghai 200433, Peoples R China; [Lu, Hongzhou] Fudan Univ, Dept Infect Dis, Huashan Hosp, Shanghai 200433, Peoples R China; [Lu, Hongzhou] Fudan Univ, Shanghai Med Coll, Dept Internal Med, Shanghai 200433, Peoples R China	Fudan University; Fudan University; Fudan University	Lu, HZ (corresponding author), Fudan Univ, Dept Infect Dis, Shanghai Publ Hlth Clin Ctr, Key Lab Med Mol Virol MOE MOH, Shanghai 200433, Peoples R China.	luhongzhou@fudan.edu.cn			grant of the 12th Five year Plan [2012ZX10001003]	grant of the 12th Five year Plan	HZL received the grant of the 12th Five year Plan (grant 2012ZX10001003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ait-Mohand H, 2008, HIV MED, V9, P738, DOI 10.1111/j.1468-1293.2008.00616.x; Anglemyer A, 2014, AIDS, V28, pS105, DOI 10.1097/QAD.0000000000000232; [Anonymous], 2013, LANCET, DOI DOI 10.1016/S0140-6736(12)61898-4; Brennan AT, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18794; Cao Y, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-301; Cicconi P, 2010, HIV MED, V11, P104, DOI 10.1111/j.1468-1293.2009.00750.x; De La Torre-Lima J, 2014, HIV CLIN TRIALS, V15, P27, DOI 10.1310/hct1501-27; Domingos H, 2009, BRAZ J INFECT DIS, V13, P130, DOI 10.1590/S1413-86702009000200012; Elzi L, 2010, ARCH INTERN MED, V170, P57, DOI 10.1001/archinternmed.2009.432; Ferradini L, 2007, AIDS, V21, P2293, DOI 10.1097/QAD.0b013e32828cc8b7; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; Huang HY, 2008, HIV MED, V9, P285, DOI 10.1111/j.1468-1293.2008.00561.x; Kumarasamy N, 2013, CURR OPIN HIV AIDS, V8, P586, DOI 10.1097/COH.0000000000000004; Ma Joseph D, 2010, PLoS Curr, V2, pRRN1203, DOI 10.1371/currents.RRN1203; Mihanovic MP, 2013, MED SCI MONITOR, V19, P483, DOI 10.12659/MSM.889283; Mocroft A, 2001, AIDS, V15, P185, DOI 10.1097/00002030-200101260-00007; Murphy RA, 2007, J INFECT DIS, V196, pS449, DOI 10.1086/521112; Njuguna C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063596; Palladino C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096307; Patel K, 2008, CLIN INFECT DIS, V46, P507, DOI 10.1086/526524; Robison LS, 2008, AIDS RES HUM RETROV, V24, P1347, DOI 10.1089/aid.2008.0083; Sarfo FS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094854; Sharma SK, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-52; Sun J, 2010, INT J STD AIDS, V21, P810, DOI 10.1258/ijsa.2010.010114; Sun Y, 2014, BIOSCI TRENDS, V8, P189, DOI 10.5582/bst.2014.01015; Thida A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108615; Vo TTN, 2008, J INFECT DIS, V197, P1685, DOI 10.1086/588141; WHO HIV Programme, 2013, CONSOLIDATED GUIDELI; Wu XH, 2015, APPL NURS RES, V28, P169, DOI 10.1016/j.apnr.2014.09.011; Xiao J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075915; Zhang FJ, 2011, LANCET INFECT DIS, V11, P516, DOI 10.1016/S1473-3099(11)70097-4; Zhang FJ, 2009, ANN INTERN MED, V151, P241, DOI 10.7326/0003-4819-151-4-200908180-00006; Zheng H, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-831	33	7	9	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2015	10	7							e0133242	10.1371/journal.pone.0133242	http://dx.doi.org/10.1371/journal.pone.0133242			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN7NT	26207639	gold, Green Published, Green Submitted			2023-01-03	WOS:000358622000069
J	Kim, M; Ku, JH; Kwak, C; Kim, HH; Lee, E; Keam, B; Kim, TM; Heo, DS; Lee, SH; Moon, KC				Kim, Miso; Ku, Ja Hyeon; Kwak, Cheol; Kim, Hyeon Hoe; Lee, Eunsik; Keam, Bhumsuk; Kim, Tae Min; Heo, Dae Seog; Lee, Se-Hoon; Moon, Kyung Chul			Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy	PLOS ONE			English	Article							TRANSITIONAL-CELL CARCINOMA; LONG-TERM-SURVIVAL; PHASE-III TRIAL; BLADDER-CANCER; ERCC1 EXPRESSION; LUNG-CANCER; DNA-REPAIR; CISPLATIN; METHOTREXATE; VINBLASTINE	Preclinical and clinical studies have suggested that expression of ribonucleotide reductase regulatory subunit M1 (RRM1) and excision repair cross-complementation group 1 (ERCC1) is associated with resistance to gemcitabine and cisplatin, respectively. We evaluated the significance of RRM1 and ERCC1 expression to predict tumor response to gemcitabine plus platinum chemotherapy (GP) and survival in advanced UC. We retrospectively collected tumor samples and reviewed clinical data of 53 patients with unresectable or metastatic UC, who were treated with first-line GP. RRM1 and ERCC1 expression were measured by immunohistochemistry. Among 53 patients, 12 (22.6%) and 26 (49.1%) patients had tumors that demonstrated a high expression for RRM1 and ERCC1, respectively. Twenty-nine (70.7%) of 41 patients with low RRM1 expression achieved a clinical response (complete + partial responses), but only 3 (25.0%) of 12 patients with high RRM1 expression achieved a clinical response after GP (P=0.007). Nineteen (70.4%) of 27 patients with low ERCC1 expression achieved a clinical response, while 13 (50.0%) of 26 patients with high ERCC1 expression achieved a clinical response (P=0.130). High RRM1 expression was associated with shorter progression free survival and overall survival (PFS P=0.006, OS P=0.006). Multivariate analysis confirmed that patients with high RRM1 expression had a significantly greater risk of progression and death than those with low RRM1 expression. ERCC1 status was not a significant predictor for PFS and OS. RRM1 expression was predictive and prognostic of clinical outcome in advanced UC treated with gemcitabine plus platinum combination chemotherapy.	[Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Heo, Dae Seog] Seoul Natl Univ Hosp, Dept Internal Med, Div Hematol Oncol, Seoul 110744, South Korea; [Ku, Ja Hyeon; Kwak, Cheol; Kim, Hyeon Hoe; Lee, Eunsik] Seoul Natl Univ Hosp, Dept Urol, Seoul 110744, South Korea; [Keam, Bhumsuk; Kim, Tae Min; Heo, Dae Seog] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea; [Lee, Se-Hoon] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea; [Moon, Kyung Chul] Seoul Natl Univ Hosp, Dept Pathol, Seoul 110744, South Korea	Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Sungkyunkwan University (SKKU); Samsung Medical Center; Seoul National University (SNU); Seoul National University Hospital	Moon, KC (corresponding author), Seoul Natl Univ Hosp, Dept Pathol, Seoul 110744, South Korea.	blue7270@snu.ac.kr	Ku, Ja Hyeon/E-6682-2016		Innovative Research Institute for Cell Therapy, Republic of Korea [A062260]	Innovative Research Institute for Cell Therapy, Republic of Korea	This work was supported by a grant from the Innovative Research Institute for Cell Therapy, Republic of Korea (A062260).	Bajorin DF, 1999, J CLIN ONCOL, V17, P3173, DOI 10.1200/JCO.1999.17.10.3173; Bellmunt J, 2007, ANN ONCOL, V18, P522, DOI 10.1093/annonc/mdl435; Bergman AM, 2005, CANCER RES, V65, P9510, DOI 10.1158/0008-5472.CAN-05-0989; Booton R, 2007, J THORAC ONCOL, V2, P902, DOI 10.1097/JTO.0b013e318155a637; Dreicer R, 2004, CANCER, V100, P1639, DOI 10.1002/cncr.20123; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Friboulet L, 2013, NEW ENGL J MED, V368, P1101, DOI 10.1056/NEJMoa1214271; Gong WY, 2012, LUNG CANCER, V75, P374, DOI 10.1016/j.lungcan.2011.08.003; Harshman LC, 2010, BJU INT, V106, P1805, DOI 10.1111/j.1464-410X.2010.09327.x; Hubner RA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025164; Jung KW, 2013, CANCER RES TREAT, V45, P1, DOI 10.4143/crt.2013.45.1.1; Kawashima A, 2011, CLIN CANCER RES, V17, P2561, DOI 10.1158/1078-0432.CCR-10-1963; Kim KH, 2010, APMIS, V118, P941, DOI 10.1111/j.1600-0463.2010.02648.x; Lapham RL, 1997, SEMIN SURG ONCOL, V13, P307, DOI 10.1002/(SICI)1098-2388(199709/10)13:5<307::AID-SSU4>3.0.CO;2-H; Lee KH, 2008, LUNG CANCER, V60, P401, DOI 10.1016/j.lungcan.2007.10.014; LOEHRER PJ, 1992, J CLIN ONCOL, V10, P1066, DOI 10.1200/JCO.1992.10.7.1066; MAZEMAN E, 1976, European Urology, V2, P120; Mini E, 2006, ANN ONCOL, V17, pV7, DOI 10.1093/annonc/mdj941; Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570; Reynolds C, 2009, J CLIN ONCOL, V27, P5808, DOI 10.1200/JCO.2009.21.9766; Shilkrut M, 2014, MOL CLIN ONCOL, V2, P479, DOI 10.3892/mco.2014.264; Sternberg CN, 2001, J CLIN ONCOL, V19, P2638, DOI 10.1200/JCO.2001.19.10.2638; von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068; von der Maase H, 2005, J CLIN ONCOL, V23, P4602, DOI 10.1200/JCO.2005.07.757; Yates DR, 2013, WORLD J UROL, V31, P21, DOI 10.1007/s00345-012-0946-6	26	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2015	10	7							e0133371	10.1371/journal.pone.0133371	http://dx.doi.org/10.1371/journal.pone.0133371			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN7EO	26200905	Green Published, Green Submitted, gold			2023-01-03	WOS:000358597100062
J	Lin, ZL; Green, RS; Chen, SQ; Wu, H; Liu, TT; Li, JY; Wei, J; Lin, J				Lin, Zhenlang; Green, Robert S.; Chen, Shangqin; Wu, Hui; Liu, Tiantian; Li, Jingyang; Wei, Jia; Lin, Jing			Quantification of EUGR as a Measure of the Quality of Nutritional Care of Premature Infants	PLOS ONE			English	Article							POSTNATAL-GROWTH FAILURE; BIRTH-WEIGHT INFANTS; HEALTH-CARE; RETARDATION; PERFORMANCE; PAY; OUTCOMES; UNIT	Objectives To develop an index of the quality of nutritional care of premature infants based on the change in weight Z score from birth to discharge and to illustrate the use of this index in comparing the performance of different NICUs. Methods Retrospective data analysis was performed to compare the growth of premature infants born in three perinatal centers. Infants with gestational age <= 32 weeks who survived to discharge from 2006 to 2010 were included. Weight Z scores at birth and discharge were calculated by the method of Fenton. Using data from one NICU as the reference, a multivariable linear regression model of change in weight Z score from birth to discharge was developed. Employing this model, a benchmark value of change in weight Z score was calculated for each baby. The difference between this calculated benchmark value and the baby's observed change in weight Z score was defined as the performance gap for that infant. The average value of the performance gaps in a NICU serves as its quality care index. Results 1,714 infants were included for analysis. Change in weight Z score is influenced by birth weight Z score and completed weeks of gestation; thus the model for calculating the benchmark change in weight Z score was adjusted for these two variables. We found statistically significant differences in the average performance gaps for the three units. Conclusions A quality care index was developed based on change in weight Z score from birth to discharge adjusted for two initial risk factors. This objective, easily calculated index may be used as a measurement of the quality of nutritional care to rank the performance of different NICUs.	[Lin, Zhenlang; Chen, Shangqin; Li, Jingyang; Wei, Jia; Lin, Jing] Wenzhou Med Univ, Affiliated Hosp 2, Dept Neonatol, Wenzhou 325027, Peoples R China; [Lin, Zhenlang; Chen, Shangqin; Li, Jingyang; Wei, Jia; Lin, Jing] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325027, Peoples R China; [Green, Robert S.; Lin, Jing] Icahn Sch Med Mt Sinai, Kravis Childrens Hosp, New York, NY 10029 USA; [Green, Robert S.; Lin, Jing] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA; [Wu, Hui; Liu, Tiantian] Jilin Univ, Hosp 1, Dept Neonatol, Changchun 130021, Peoples R China	Wenzhou Medical University; Wenzhou Medical University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Jilin University	Lin, J (corresponding author), Wenzhou Med Univ, Affiliated Hosp 2, Dept Neonatol, Wenzhou 325027, Peoples R China.	jing.lin@mssm.edu	Lin, Jing/I-5293-2019	Lin, Jing/0000-0002-4405-134X				Bloom BT, 2003, PEDIATRICS, V112, P8, DOI 10.1542/peds.112.1.8; Clark Reese H, 2003, J Perinatol, V23, P337, DOI 10.1038/sj.jp.7210937; Clark RH, 2003, PEDIATRICS, V111, P986, DOI 10.1542/peds.111.5.986; Cooke RJ, 2004, ARCH DIS CHILD-FETAL, V89, pF428, DOI 10.1136/adc.2001.004044; Ehrenkranz RA, 2006, PEDIATRICS, V117, P1253, DOI 10.1542/peds.2005-1368; Ehrenkranz RA, 1999, PEDIATRICS, V104, P280, DOI 10.1542/peds.104.2.280; Ehrenkranz RA, 2007, SEMIN PERINATOL, V31, P48, DOI 10.1053/j.semperi.2007.02.001; Eijkenaar F, 2012, MED CARE RES REV, V69, P251, DOI 10.1177/1077558711432891; Embleton NE, 2001, PEDIATRICS, V107, P270, DOI 10.1542/peds.107.2.270; Fanaroff Avroy A, 2007, Am J Obstet Gynecol, V196, DOI 10.1016/j.ajog.2006.09.014; Fenton TR, 2007, EUR J CLIN NUTR, V61, P1380, DOI 10.1038/sj.ejcn.1602667; Fenton Tanis R, 2003, BMC Pediatr, V3, P13; Lucas A, 1998, BRIT MED J, V317, P1481, DOI 10.1136/bmj.317.7171.1481; Maas C, 2015, ARCH DIS CHILD-FETAL, V100, pF76, DOI 10.1136/archdischild-2014-306195; Marks KA, 2006, ACTA PAEDIATR, V95, P236, DOI 10.1080/08035250500358315; Moltu SJ, 2014, J PEDIATR GASTR NUTR, V58, P344, DOI 10.1097/MPG.0000000000000220; Olsen IE, 2003, J CLIN EPIDEMIOL, V56, P998, DOI 10.1016/S0895-4356(03)00168-9; Olsen IE, 2002, PEDIATRICS, V110, P1125, DOI 10.1542/peds.110.6.1125; Profit J, 2007, PEDIATRICS, V119, P975, DOI 10.1542/peds.2006-1565; Profit J, 2014, PEDIATRICS, V134, P74, DOI 10.1542/peds.2013-3552; Radmacher Paula G, 2003, J Perinatol, V23, P392, DOI 10.1038/sj.jp.7210947; RICHARDSON DK, 1993, PEDIATRICS, V91, P617; Shan HM, 2009, EUR J PEDIATR, V168, P1055, DOI 10.1007/s00431-008-0885-9; Spitzer AR, 2010, CLIN PERINATOL, V37, P167, DOI 10.1016/j.clp.2010.01.010	24	16	16	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2015	10	7							e0132584	10.1371/journal.pone.0132584	http://dx.doi.org/10.1371/journal.pone.0132584			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN6LN	26193640	Green Published, gold, Green Submitted			2023-01-03	WOS:000358546400032
J	Qi, P; Chen, M; Zhang, LX; Song, RX; He, ZH; Wang, ZP				Qi, Ping; Chen, Ming; Zhang, Li-xiu; Song, Rui-xia; He, Zhen-hua; Wang, Zhi-ping			A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer	PLOS ONE			English	Article							ZIBOTENTAN ZD4054; CONTROLLED-TRIAL; PHASE-III; PLACEBO; DOCETAXEL; ATRASENTAN; COMBINATION; EFFICACY; SAFETY; MEN	Background Endothelin A (ET-A) receptor antagonists including zibotentan and atrasentan, have been suggested as a treatment for castration-resistant prostate cancer (CRPC). Our aim was to conduct a meta-analysis and indirect comparison to assess the efficacy and safety of ET-A receptor antagonists for treatment of CRPC. Methods We systematically searched PubMed, EMBASE, the Cochrane Library, and Web of Science from inception to November 2014 to identify randomized controlled trials (RCTs) which assessed ET-A receptor antagonists for treatment of CRPC. Meta-analysis was conducted by STATA version 12.0 software. Results Eight RCTs were identified, involving 6,065 patients. The results of direct comparison showed that compared with placebo, there was no statistically significant difference in the improvement of progression-free survival (PFS), overall survival (OS), time to disease progression (TTP), and total adverse events (AEs) with ET-A receptor antagonist treatment for CRPC. The results of ET-A receptor antagonists plus docetaxel versus docetaxel alone were similar. The indirect comparisons showed that there were no significant differences between zibotentan plus docetaxel versus atrasentan plus docetaxel when compared with docetaxel alone or zibotentan versus atrasenta compared with placebo in the improvement of PFS, OS, TTP, and total adverse events. Conclusions There were no significant benefits for ET-A receptor antagonists with or without docetaxel in the improvement of PFS, OS, TTP, and overall AEs. And there were no significant differences between zibotentan and atrasentan. Single-agent docetaxel should remain as one of the standard treatments.	[Qi, Ping; Zhang, Li-xiu; Song, Rui-xia; He, Zhen-hua; Wang, Zhi-ping] Lanzhou Univ, Hosp 2, Inst Urol, Lanzhou 730030, Peoples R China; [Song, Rui-xia; Wang, Zhi-ping] Key Lab Urol Dis Gansu Prov, Lanzhou 730030, Peoples R China; [Qi, Ping] Lanzhou Univ, Hosp 2, Dept Clin Lab, Lanzhou 730030, Peoples R China; [Chen, Ming] GanSu Prov Hosp Tradit Chinese Med, Dept Urol, Lanzhou 730050, Peoples R China; [He, Zhen-hua] Lanzhou Univ, Hosp 2, Dept Neurosurg, Lanzhou 730030, Peoples R China	Lanzhou University; Lanzhou University; Lanzhou University	Wang, ZP (corresponding author), Lanzhou Univ, Hosp 2, Inst Urol, Lanzhou 730030, Peoples R China.	erywzp@lzu.edu.cn						Carducci MA, 2007, CANCER-AM CANCER SOC, V110, P1959, DOI 10.1002/cncr.22996; Carter NJ, 2014, DRUGS, V74, P699, DOI 10.1007/s40265-014-0211-y; Fizazi KS, 2013, J CLIN ONCOL, V31, P1740, DOI 10.1200/JCO.2012.46.4149; Higgins JPT, 2013, COCHRANCE HDB SYSTEM; Il Kang D, 2013, ASIAN PAC J CANCER P, V14, P6913, DOI 10.7314/APJCP.2013.14.11.6913; James ND, 2010, BJU INT, V106, P966, DOI 10.1111/j.1464-410X.2010.09638.x; James ND, 2009, EUR UROL, V55, P1112, DOI 10.1016/j.eururo.2008.11.002; Kasper S, 2006, UROL CLIN N AM, V33, P201, DOI 10.1016/j.ucl.2005.12.010; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Miller K, 2013, PROSTATE CANCER P D, V16, P187, DOI 10.1038/pcan.2013.2; Moore MA, 2010, ASIAN PAC J CANCER P, V11, P67; Nelson JB, 2008, CANCER-AM CANCER SOC, V113, P2478, DOI 10.1002/cncr.23864; Nelson JB, 2012, CANCER-AM CANCER SOC, V118, P5709, DOI 10.1002/cncr.27674; Quinn DI, 2013, LANCET ONCOL, V14, P893, DOI 10.1016/S1470-2045(13)70294-8; Neto AS, 2011, CLIN GENITOURIN CANC, V9, P115, DOI 10.1016/j.clgc.2011.05.002; Shao N, 2013, INT J CANCER, V133, P1743, DOI 10.1002/ijc.28162; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Trump DL, 2011, PROSTATE, V71, P1264, DOI 10.1002/pros.21342; Zhou ZR, 2014, ASIAN PAC J CANCER P, V15, P1313, DOI 10.7314/APJCP.2014.15.3.1313	19	6	6	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2015	10	7							e0133803	10.1371/journal.pone.0133803	http://dx.doi.org/10.1371/journal.pone.0133803			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN6LN	26192308	Green Submitted, Green Published, gold			2023-01-03	WOS:000358546400120
J	Shafei, R; Goalby, R; Hutchinson, J				Shafei, Rachelle; Goalby, Rowena; Hutchinson, John			CASE REVIEW A case of breathlessness	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							INTERSTITIAL LUNG-DISEASE; RHEUMATOID-ARTHRITIS; METHOTREXATE; PNEUMONITIS; PROGNOSIS; SOCIETY		[Shafei, Rachelle] N Middlesex Hosp, Dept Med, London N18 1QX, England; [Hutchinson, John] Nottingham Univ Hosp Trust, Dept Resp Med, Nottingham, England	Nottingham University Hospital NHS Trust; University of Nottingham	Shafei, R (corresponding author), N Middlesex Hosp, Dept Med, London N18 1QX, England.	r.shafei@doctors.org.uk						BNF Online, METH; Bongartz T, 2010, ARTHRITIS RHEUM-US, V62, P1583, DOI 10.1002/art.27405; Cavagna L, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/759760; Chan E, 2013, INTERSTITITAL LUNG D; Collard HR, 2007, AM J RESP CRIT CARE, V176, P636, DOI 10.1164/rccm.200703-463PP; de Lauretis A, 2011, CHRON RESP DIS, V8, P53, DOI 10.1177/1479972310393758; du Bois R, 2007, THORAX, V62, P1008, DOI 10.1136/thx.2004.031039; Gaffo AL, 2008, ARCH INTERN MED, V168, P1927, DOI 10.1001/archinte.168.17.1927; Gochuico BR, 2008, ARCH INTERN MED, V168, P159, DOI 10.1001/archinternmed.2007.59; Hamblin MJ, 2011, PULM MED, V2011, DOI 10.1155/2011/872120; HARGREAVES MR, 1992, THORAX, V47, P628, DOI 10.1136/thx.47.8.628; Hozumi H, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003132; Imokawa S, 2000, EUR RESPIR J, V15, P373, DOI 10.1034/j.1399-3003.2000.15b25.x; Kim EJ, 2009, CHEST, V136, P1397, DOI 10.1378/chest.09-0444; Kinder AJ, 2005, RHEUMATOLOGY, V44, P61, DOI 10.1093/rheumatology/keh512; Koduri G, 2010, RHEUMATOLOGY, V49, P1483, DOI 10.1093/rheumatology/keq035; McLean-Tooke A, 2009, RHEUMATOLOGY, V48, P867, DOI 10.1093/rheumatology/kep101; O'Dwyer DN, 2013, EUR J INTERN MED, V24, P597, DOI 10.1016/j.ejim.2013.07.004; Saravanan V, 2006, RHEUMATOLOGY, V45, P787, DOI 10.1093/rheumatology/kel075; Sathi N, 2011, RHEUMATOLOGY, V50, P620, DOI 10.1093/rheumatology/keq426; Travis WD, 2013, AM J RESP CRIT CARE, V188, P733, DOI 10.1164/rccm.201308-1483ST; Wells AU, 2008, THORAX, V63, DOI 10.1136/thx.2008.101691	22	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 16	2015	351								h3515	10.1136/bmj.h3515	http://dx.doi.org/10.1136/bmj.h3515			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CN3CV	26185147				2023-01-03	WOS:000358302400002
J	Maurer, JM; Schellekens, RCA; van Rieke, HM; Wanke, C; Iordanov, V; Stellaard, F; Wutzke, KD; Dijkstra, G; van der Zee, M; Woerdenbag, HJ; Frijlink, HW; Kosterink, JGW				Maurer, Jacoba M.; Schellekens, Reinout C. A.; van Rieke, Helen M.; Wanke, Christoph; Iordanov, Ventzeslav; Stellaard, Frans; Wutzke, Klaus D.; Dijkstra, Gerard; van der Zee, Margot; Woerdenbag, Herman J.; Frijlink, Henderik W.; Kosterink, Jos G. W.			Gastrointestinal pH and Transit Time Profiling in Healthy Volunteers Using the IntelliCap System Confirms Ileo-Colonic Release of ColoPulse Tablets	PLOS ONE			English	Article							INTRALUMINAL PH; DOSAGE FORMS; LUMINAL PH; DELIVERY; BEHAVIOR	Introduction ColoPulse tablets are an innovative development in the field of oral dosage forms characterized by a distal ileum and colon-specific release. Previous studies in humans showed release in the ileo-colonic region, but the relationship between gastrointestinal pH and release was not experimentally proven in vivo. This information will complete the in vivo release-profile of ColoPulse tablets. Materials and Methods Release from ColoPulse tablets was studied in 16 healthy volunteers using the dual label isotope strategy. To determine gastrointestinal pH profiles and transit times the IntelliCap system was used. A ColoPulse tablet containing C-13-urea and an uncoated, immediate release tablet containing N-15(2)-urea were taken simultaneously followed by a standardized breakfast after three hours. Five minutes after intake of the tablets the IntelliCap capsule was swallowed and pH was measured until excretion in the feces. Breath and urine samples were collected for isotope analysis. Results Full analysis could be performed in 12 subjects. Median bioavailability of C-13-urea was 82% (95% CI 74-94%, range 61-114%). The median lag time (5% release of C-13) was 5: 42 h (95% CI 5: 18-6: 18 h, range 2: 36-6: 36 h,) There was no statistically significant difference between lag time based on isotope signal and colon arrival time (CAT) based on pH (median 5: 42 vs 5: 31 h p = 0.903). In all subjects an intestinal pH value of 7.0 was reached before release of C-13 from the ColoPulse tablet occurred. Discussion and Conclusions From the combined data from the IntelliCap system and the C-13-isotope signal it can be concluded that release from a ColoPulse tablet in vivo is not related to transit times but occurs in the ileo-colonic region after pH 7.0 is reached. This supports our earlier findings and confirms that the ColoPulse system is a promising delivery system for targeting the distal ileum and colon.	[Maurer, Jacoba M.; Schellekens, Reinout C. A.; van Rieke, Helen M.; Kosterink, Jos G. W.] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands; [Wanke, Christoph; Iordanov, Ventzeslav] Medimetr Personalized Drug Delivery BV, Eindhoven, Netherlands; [Stellaard, Frans] Univ Groningen, Univ Med Ctr Groningen, Dept Lab Med, Groningen, Netherlands; [Wutzke, Klaus D.] Univ Rostock, Childrens Hosp, Res Lab Gastroenterol & Nutr, D-18055 Rostock, Germany; [Dijkstra, Gerard] Univ Groningen, Univ Med Ctr Groningen, Dept Gastroenterol & Hepatol, Groningen, Netherlands; [van der Zee, Margot; Woerdenbag, Herman J.; Frijlink, Henderik W.] Univ Groningen, Dept Pharm, Sect Pharmaceut Technol & Biopharm, Groningen, Netherlands; [Kosterink, Jos G. W.] Univ Groningen, Sect Pharmacotherapy & Pharmaceut Care, Dept Pharm, Groningen, Netherlands	University of Groningen; University of Groningen; University of Rostock; University of Groningen; University of Groningen; University of Groningen	Maurer, JM (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands.	m.maurer@umcg.nl	Woerdenbag, Herman/HDM-2961-2022; Frijlink, Henderik Willem/AAD-7382-2020	Frijlink, Henderik Willem/0000-0001-7901-8198; /0000-0003-4563-7462; Kosterink, Jos/0000-0001-8358-765X; Woerdenbag, Herman/0000-0002-9450-5880	Medimetrics Personalized Drug Delivery, Eindhoven, The Netherlands; IntelliCap systems	Medimetrics Personalized Drug Delivery, Eindhoven, The Netherlands; IntelliCap systems	Medimetrics Personalized Drug Delivery, Eindhoven, The Netherlands, provided support in the form of salaries for authors CW and VI and IntelliCap systems, but did not have any role in study design and decision to publish. The specific roles of these authors are articulated in the author contributions section.	Becker D, 2014, AAPS PHARMSCITECH, V15, P1490, DOI 10.1208/s12249-014-0172-1; DAVIS SS, 1986, GUT, V27, P886, DOI 10.1136/gut.27.8.886; EVANS DF, 1988, GUT, V29, P1035, DOI 10.1136/gut.29.8.1035; Ewe K, 1999, DIGEST DIS SCI, V44, P1434, DOI 10.1023/A:1026664105112; FALLINGBORG J, 1993, DIGEST DIS SCI, V38, P1989, DOI 10.1007/BF01297074; Fallingborg J, 1998, DIGEST DIS SCI, V43, P702, DOI 10.1023/A:1018893409596; FALLINGBORG J, 1989, ALIMENT PHARM THERAP, V3, P605; Koziolek M, 2015, J PHARM SCI-US, V104, P2855, DOI 10.1002/jps.24274; Lalezari D, 2012, ANN GASTROENTEROL, V25, P333; Maqbool S, 2009, DIGEST DIS SCI, V54, P2167, DOI 10.1007/s10620-009-0899-9; Maurer JM, 2013, J CONTROL RELEASE, V172, P618, DOI 10.1016/j.jconrel.2013.09.021; Maurer MJM, 2013, ISOT ENVIRON HEALT S, V49, P473, DOI 10.1080/10256016.2013.803099; Maurer MJM, 2012, PHARM RES-DORDR, V29, P2070, DOI 10.1007/s11095-012-0735-3; McConnell EL, 2009, J DRUG TARGET, V17, P335, DOI 10.1080/10611860902839502; MELDRUM SJ, 1972, BRIT MED J, V2, P104; Nugent SG, 2001, GUT, V48, P571, DOI 10.1136/gut.48.4.571; Press AG, 1998, ALIMENT PHARM THER, V12, P673; RAIMUNDO A H, 1992, Gastroenterology, V102, pA681; Rubin DT, 2009, GASTROENTEROLOGY S1, V136, pM1097; Sasaki Y, 1997, AM J GASTROENTEROL, V92, P114; Schellekens RCA, 2007, EUR J PHARM SCI, V30, P15, DOI 10.1016/j.ejps.2006.09.004; Schellekens RCA, 2010, J CONTROL RELEASE, V146, P334, DOI 10.1016/j.jconrel.2010.05.028; Schellekens RCA, 2009, BRIT J PHARMACOL, V158, P532, DOI 10.1111/j.1476-5381.2009.00302.x; Schellekens RCA, 2012, PHARM DEV TECHNOL, V17, P40, DOI 10.3109/10837450.2010.513986; Schiller C, 2005, ALIMENT PHARM THER, V22, P971, DOI 10.1111/j.1365-2036.2005.02683.x; Singh Brahma N, 2007, Recent Pat Drug Deliv Formul, V1, P53, DOI 10.2174/187221107779814122; van der Schaar PJ, 2013, GASTROINTEST ENDOSC, V78, P520, DOI 10.1016/j.gie.2013.03.170	27	53	56	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2015	10	7							e0129076	10.1371/journal.pone.0129076	http://dx.doi.org/10.1371/journal.pone.0129076			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RL	26177019	gold, Green Published, Green Submitted			2023-01-03	WOS:000358197600012
J	Ladha, K; Melo, MFV; McLean, DJ; Wanderer, JP; Grabitz, SD; Kurth, T; Eikermann, M				Ladha, Karim; Melo, Marcos F. Vidal; McLean, Duncan J.; Wanderer, Jonathan P.; Grabitz, Stephanie D.; Kurth, Tobias; Eikermann, Matthias			Intraoperative protective mechanical ventilation and risk of postoperative respiratory complications: hospital based registry study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TIDAL-VOLUME VENTILATION; ACUTE LUNG INJURY; GENERAL-ANESTHESIA; FRACTIONAL POLYNOMIALS; ABDOMINAL-SURGERY; PATIENT SAFETY; FAILURE; PREDICTORS; REGRESSION; OUTCOMES	OBJECTIVE To evaluate the effects of intraoperative protective ventilation on major postoperative respiratory complications and to define safe intraoperative mechanical ventilator settings that do not translate into an increased risk of postoperative respiratory complications. DESIGN Hospital based registry study. SETTING Academic tertiary care hospital and two affiliated community hospitals in Massachusetts, United States. PARTICIPANTS 69 265 consecutively enrolled patients over the age of 18 who underwent a non-cardiac surgical procedure between January 2007 and August 2014 and required general anesthesia with endotracheal intubation. INTERVENTIONS Protective ventilation, defined as a median positive end expiratory pressure (PEEP) of 5 cmH(2)O or more, a median tidal volume of less than 10 mL/kg of predicted body weight, and a median plateau pressure of less than 30 cmH(2)O. MAIN OUTCOME MEASURE Composite outcome of major respiratory complications, including pulmonary edema, respiratory failure, pneumonia, and re-intubation. RESULTS Of the 69 265 enrolled patients 34 800 (50.2%) received protective ventilation and 34 465 (49.8%) received non-protective ventilation intraoperatively. Protective ventilation was associated with a decreased risk of postoperative respiratory complications in multivariable regression (adjusted odds ratio 0.90, 95% confidence interval 0.82 to 0.98, P = 0.013). The results were similar in the propensity score matched cohort (odds ratio 0.89, 95% confidence interval 0.83 to 0.97, P = 0.004). A PEEP of 5 cmH(2)O and median plateau pressures of 16 cmH(2)O or less were associated with the lowest risk of postoperative respiratory complications. CONCLUSIONS Intraoperative protective ventilation was associated with a decreased risk of postoperative respiratory complications. A PEEP of 5 cmH(2)O and a plateau pressure of 16 cmH(2)O or less were identified as protective mechanical ventilator settings. These findings suggest that protective thresholds differ for intraoperative ventilation in patients with normal lungs compared with those used for patients with acute lung injury.	[Ladha, Karim; Melo, Marcos F. Vidal; McLean, Duncan J.; Grabitz, Stephanie D.; Eikermann, Matthias] Massachusetts Gen Hosp, Dept Anesthesia Crit Care, Pain Med, Boston, MA 02114 USA; [Wanderer, Jonathan P.] Vanderbilt Univ, Dept Anesthesiol, Nashville, TN 37235 USA; [Kurth, Tobias] INSERM, Res Ctr Epidemiol & Biostat U897, Team Neuroepidemiol, Bordeaux, France; [Kurth, Tobias] Univ Bordeaux, Coll Hlth Sci, Bordeaux, France; [Kurth, Tobias] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA; [Eikermann, Matthias] Essen Duisburg Univ, Essen, Germany	Harvard University; Massachusetts General Hospital; Vanderbilt University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Harvard University; Brigham & Women's Hospital	Eikermann, M (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care, Pain Med, Boston, MA 02114 USA.	meikermann@partners.org	Melo, Marcos Vidal/AAN-7219-2020; Kurth, Tobias/A-9243-2012; Ladha, Karim/K-7170-2015	Kurth, Tobias/0000-0001-7169-2620; Ladha, Karim/0000-0001-7303-2458; Grabitz, Stephanie D./0000-0002-3071-873X; Wanderer, Jonathan/0000-0002-3119-6873	Buzen's Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL121228] Funding Source: NIH RePORTER	Buzen's Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was funded by a grant from the Buzen's Foundation.	Amato MBP, 2015, NEW ENGL J MED, V372, P747, DOI 10.1056/NEJMsa1410639; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; [Anonymous], P 26 ANN SAS USERSGR; Arozullah AM, 2000, ANN SURG, V232, P242, DOI 10.1097/00000658-200008000-00015; BENDIXEN HH, 1963, NEW ENGL J MED, V269, P991, DOI 10.1056/NEJM196311072691901; Bensley RP, 2013, J AM COLL SURGEONS, V216, P1159, DOI 10.1016/j.jamcollsurg.2013.01.060; Borzecki AM, 2011, J AM COLL SURGEONS, V212, P935, DOI 10.1016/j.jamcollsurg.2010.09.034; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Brueckmann B, 2013, ANESTHESIOLOGY, V118, P1276, DOI 10.1097/ALN.0b013e318293065c; Canver CC, 2003, ANN THORAC SURG, V75, P853, DOI 10.1016/S0003-4975(02)04493-4; Davenport DL, 2005, ANN SURG, V242, P463, DOI 10.1097/01.sla.0000183348.15117.ab; Dimick JB, 2004, J AM COLL SURGEONS, V199, P531, DOI 10.1016/j.jamcollsurg.2004.05.276; Eikermann M, 2015, ANESTHESIOLOGY; Fernandez-Perez ER, 2009, THORAX, V64, P121, DOI 10.1136/thx.2008.102228; Futier E, 2013, NEW ENGL J MED, V369, P428, DOI 10.1056/NEJMoa1301082; Glance LG, 2010, ANESTHESIOLOGY, V113, P859, DOI 10.1097/ALN.0b013e3181eff32e; Grosse-Sundrup M, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6329; Heisler CA, 2009, J AM COLL SURGEONS, V209, P119, DOI 10.1016/j.jamcollsurg.2009.03.017; Hemmes SNT, 2014, LANCET, V384, P495, DOI 10.1016/S0140-6736(14)60416-5; Hess DR, 2013, J CRIT CARE, V28, DOI 10.1016/j.jcrc.2012.11.014; Jaber S, 2012, ANAESTHESIA, V67, P999, DOI 10.1111/j.1365-2044.2012.07218.x; Johnson RG, 2007, J AM COLL SURGEONS, V204, P1188, DOI 10.1016/j.jamcollsurg.2007.02.070; Khuri SF, 2005, ANN SURG, V242, P326, DOI 10.1097/01.sla.0000179621.33268.83; Kurth T, 2006, AM J EPIDEMIOL, V163, P262, DOI 10.1093/aje/kwj047; Lawthers AG, 2000, MED CARE, V38, P785, DOI 10.1097/00005650-200008000-00003; Lellouche F, 2012, ANESTHESIOLOGY, V116, P1072, DOI 10.1097/ALN.0b013e3182522df5; Nafiu OO, 2011, EUR J ANAESTH, V28, P220, DOI 10.1097/EJA.0b013e328342659c; NUNN JF, 1962, LANCET, V2, P631, DOI 10.1016/S0140-6736(62)92541-2; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Ramachandran SK, 2011, ANESTHESIOLOGY, V115, P44, DOI 10.1097/ALN.0b013e31821cf6de; Royston P, 1999, INT J EPIDEMIOL, V28, P964, DOI 10.1093/ije/28.5.964; Sauerbrei W, 2006, COMPUT STAT DATA AN, V50, P3464, DOI 10.1016/j.csda.2005.07.015; Schultz MJ, 2007, ANESTHESIOLOGY, V106, P1226, DOI 10.1097/01.anes.0000267607.25011.e8; Serpa Neto A, 2015, ANESTHESIOLOGY; Severgnini P, 2013, ANESTHESIOLOGY, V118, P1307, DOI 10.1097/ALN.0b013e31829102de; Shah Bhumika, 2006, Nutr Clin Pract, V21, P312, DOI 10.1177/0115426506021003312; Smetana Gerald W, 2009, Cleve Clin J Med, V76 Suppl 4, pS60, DOI 10.3949/ccjm.76.s4.10; Treschan TA, 2012, BRIT J ANAESTH, V109, P263, DOI 10.1093/bja/aes140; Utter GH, 2010, J AM COLL SURGEONS, V211, P347, DOI 10.1016/j.jamcollsurg.2010.04.022; van Buuren S, 2007, STAT METHODS MED RES, V16, P219, DOI 10.1177/0962280206074463; Wellman TJ, 2014, CRIT CARE MED, V42, pE491, DOI 10.1097/CCM.0000000000000346; Yilmaz M, 2007, CRIT CARE MED, V35, P1660, DOI 10.1097/01.CCM.0000269037.66955.F0	42	170	182	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 14	2015	351								h3646	10.1136/bmj.h3646	http://dx.doi.org/10.1136/bmj.h3646			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CN3CO	26174419	Green Published, hybrid			2023-01-03	WOS:000358301600008
J	Dashti, SG; Chau, R; Ouakrim, DA; Buchanan, DD; Clendenning, M; Young, JP; Winship, IM; Arnold, J; Ahnen, DJ; Haile, RW; Casey, G; Gallinger, S; Thibodeau, SN; Lindor, NM; Le Marchand, L; Newcomb, PA; Potter, JD; Baron, JA; Hopper, JL; Jenkins, MA; Win, AK				Dashti, Seyedeh Ghazaleh; Chau, Rowena; Ouakrim, Driss Ait; Buchanan, Daniel D.; Clendenning, Mark; Young, Joanne P.; Winship, Ingrid M.; Arnold, Julie; Ahnen, Dennis J.; Haile, Robert W.; Casey, Graham; Gallinger, Steven; Thibodeau, Stephen N.; Lindor, Noralane M.; Le Marchand, Loic; Newcomb, Polly A.; Potter, John D.; Baron, John A.; Hopper, John L.; Jenkins, Mark A.; Win, Aung Ko			Female Hormonal Factors and the Risk of Endometrial Cancer in Lynch Syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; MUTATION CARRIERS; COLORECTAL-CANCER; REPRODUCTIVE FACTORS; BREAST-CANCER; WOMEN; AGE; EPIDEMIOLOGY; METAANALYSIS; CARCINOMAS	IMPORTANCE Apart from hysterectomy, there is no consensus recommendation for reducing endometrial cancer risk for women with a mismatch repair gene mutation ( Lynch syndrome). OBJECTIVE To investigate the association between hormonal factors and endometrial cancer risk in Lynch syndrome. DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort study included 1128 women with a mismatch repair gene mutation identified from the Colon Cancer Family Registry. Data were analyzed with a weighted cohort approach. Participants were recruited between 1997 and 2012 from centers across the United States, Australia, Canada, and New Zealand. EXPOSURES Age at menarche, first and last live birth, and menopause; number of live births; hormonal contraceptive use; and postmenopausal hormone use. MAIN OUTCOMES AND MEASURES Self-reported diagnosis of endometrial cancer. RESULTS Endometrial cancer was diagnosed in 133 women ( incidence rate per 100 person-years, 0.29; 95% CI, 0.24 to 0.34). Later age at menarche, parity (>= 1 live births), and hormonal contraceptive use (>= 1 year) were associated with a lower risk of endometrial cancer. [GRAPHICS] There was no statistically significant association between endometrial cancer and age at first and last live birth, age at menopause, and postmenopausal hormone use. CONCLUSIONS AND RELEVANCE For women with a mismatch repair gene mutation, some endogenous and exogenous hormonal factors were associated with a lower risk of endometrial cancer. These directions and strengths of associations were similar to those for the general population. If replicated, these findings suggest that women with a mismatch repair gene mutation may be counseled like the general population in regard to hormonal influences on endometrial cancer risk.	[Dashti, Seyedeh Ghazaleh; Chau, Rowena; Ouakrim, Driss Ait; Buchanan, Daniel D.; Hopper, John L.; Jenkins, Mark A.; Win, Aung Ko] Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne Sch Populat & Global Hlth, Parkville, Vic 3010, Australia; [Buchanan, Daniel D.; Clendenning, Mark] Univ Melbourne, Dept Pathol, Oncogenom Grp, Genet Epidemiol Lab, Parkville, Vic 3010, Australia; [Young, Joanne P.] Queen Elizabeth Hosp, Dept Haematol, Woodville, SA 5011, Australia; [Young, Joanne P.] Queen Elizabeth Hosp, Dept Oncol, Woodville, SA 5011, Australia; [Young, Joanne P.] Basil Hetzel Inst Translat Res, SAHMRI Colorectal Node, Woodville, SA, Australia; [Young, Joanne P.] Univ Adelaide, Sch Med, Adelaide, SA 5005, Australia; [Winship, Ingrid M.] Univ Melbourne, Dept Med, Parkville, Vic 3010, Australia; [Winship, Ingrid M.] Royal Melbourne Hosp, Genet Med, Parkville, Vic 3050, Australia; [Arnold, Julie] New Zealand Familial Gastrointestinal Canc Serv, Auckland, New Zealand; [Ahnen, Dennis J.] Univ Colorado, Sch Med, Dept Med, Denver, CO USA; [Haile, Robert W.] Stanford Univ, Dept Med, Inst Canc, Div Oncol, Stanford, CA 94305 USA; [Casey, Graham] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; [Casey, Graham] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; [Gallinger, Steven] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada; [Thibodeau, Stephen N.] Mayo Clin, Dept Lab Med & Pathol, Mol Genet Lab, Rochester, MN USA; [Lindor, Noralane M.] Mayo Clin Arizona, Dept Hlth Sci Res, Scottsdale, AZ USA; [Le Marchand, Loic] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA; [Newcomb, Polly A.; Potter, John D.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA; [Newcomb, Polly A.; Potter, John D.] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA; [Potter, John D.] Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand; [Baron, John A.] Univ N Carolina, Dept Med, Chapel Hill, NC USA; [Hopper, John L.] Seoul Natl Univ, Sch Publ Hlth, Dept Epidemiol, Seoul, South Korea; [Hopper, John L.] Seoul Natl Univ, Sch Publ Hlth, Inst Hlth & Environm, Seoul, South Korea	University of Melbourne; University of Melbourne; South Australian Health & Medical Research Institute (SAHMRI); University of Adelaide; University of Melbourne; Royal Melbourne Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Stanford University; University of Southern California; University of Southern California; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Mayo Clinic; Mayo Clinic; Mayo Clinic Phoenix; Cancer Research Center of Hawaii; University of Hawaii System; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Massey University; University of North Carolina; University of North Carolina Chapel Hill; Seoul National University (SNU); Seoul National University (SNU)	Win, AK (corresponding author), Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne Sch Populat & Global Hlth, Level 3,207 Bouverie St, Parkville, Vic 3010, Australia.	awin@unimelb.edu.au	Gallinger, Steven/E-4575-2013; Dashti, Seyedeh Ghazaleh/ABG-4363-2020; Win, Aung K./J-6204-2015; Winship, Ingrid M/D-7204-2016; Jenkins, Mark/P-7803-2015	Dashti, Seyedeh Ghazaleh/0000-0002-1399-7220; Win, Aung K./0000-0002-2794-5261; Jenkins, Mark/0000-0002-8964-6160; Young, Joanne/0000-0002-1514-1522; Buchanan, Daniel/0000-0003-2225-6675; Winship, Ingrid/0000-0001-8535-6003; Ait Ouakrim, Driss/0000-0001-7715-2561; Potter, John/0000-0001-5439-1500	National Cancer Institute, National Institutes of Health [UM1 CA167551]; National Health and Medical Research Council (NHMRC), Australia [APP1042021, APP1074383]; NATIONAL CANCER INSTITUTE [U24CA074806, U24CA074794, U01CA074800, P30CA015704, U01CA074806, U24CA097735, U24CA074800, U01CA097735, U01CA074794, U24CA074799, U01CA074783, U01CA074799, UM1CA167551, U24CA074783] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Health and Medical Research Council (NHMRC), Australia(National Health and Medical Research Council (NHMRC) of Australia); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grant UM1 CA167551 from the National Cancer Institute, National Institutes of Health, and through cooperative agreements with members of the Colon Cancer Family Registry and principal investigators. Collaborating centers include the Australasian Colorectal Cancer Family Registry (U01/U24 CA097735), Mayo Clinic Cooperative Family Registry for Colon Cancer Studies (U01/U24 CA074800), Ontario Familial Colorectal Cancer Registry (U01/U24 CA074783), Seattle Colorectal Cancer Family Registry (U01/U24 CA074794), Stanford Consortium Colorectal Cancer Family Registry (U01/U24 CA074799), and University of Hawaii Colorectal Cancer Family Registry (U01/U24 CA074806). This work was also supported by Centre for Research Excellence grant APP1042021 and program grant APP1074383 from the National Health and Medical Research Council (NHMRC), Australia. Dr Win is an NHMRC Early Career Fellow. Dr Jenkins is an NHMRC Senior Research Fellow. Dr Hopper is an NHMRC Senior Principal Research Fellow. Dr Buchanan is a University of Melbourne Research at Melbourne Accelerator Program Senior Research Fellow.	Ali AT, 2014, INT J GYNECOL CANCER, V24, P384, DOI 10.1097/IGC.0000000000000075; Amankwah EK, 2013, CANCER EPIDEM BIOMAR, V22, P1325, DOI 10.1158/1055-9965.EPI-13-0105; Amant F, 2005, LANCET, V366, P491, DOI 10.1016/S0140-6736(05)67063-8; Andrieu N, 2006, J CLIN ONCOL, V24, P3361, DOI 10.1200/JCO.2005.03.3126; Antoniou AC, 2005, GENET EPIDEMIOL, V29, P1, DOI 10.1002/gepi.20074; Antoniou AC, 2008, AM J HUM GENET, V82, P937, DOI 10.1016/j.ajhg.2008.02.008; Baglietto L, 2010, JNCI-J NATL CANCER I, V102, P193, DOI 10.1093/jnci/djp473; Blokhuis MM, 2010, FAM CANCER, V9, P357, DOI 10.1007/s10689-010-9334-9; Cleves M., 2008, INTRO SURVIVAL ANAL, V2; Crosbie EJ, 2010, CANCER EPIDEM BIOMAR, V19, P3119, DOI 10.1158/1055-9965.EPI-10-0832; Curado MP, 2007, IARC SCI PUBL, VIX; Dossus L, 2010, INT J CANCER, V127, P442, DOI 10.1002/ijc.25050; Dowty JG, 2013, HUM MUTAT, V34, P490, DOI 10.1002/humu.22262; Fujita M, 2008, TOHOKU J EXP MED, V216, P297, DOI 10.1620/tjem.216.297; Gierisch JM, 2013, CANCER EPIDEM BIOMAR, V22, P1931, DOI 10.1158/1055-9965.EPI-13-0298; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Grzankowski KS, 2012, GYNECOL ONCOL, V126, P408, DOI 10.1016/j.ygyno.2012.05.019; Haidopoulos D, 2010, ACTA OBSTET GYN SCAN, V89, P1326, DOI 10.3109/00016349.2010.515666; Hampel H, 2011, CANCER PREV RES, V4, P1, DOI 10.1158/1940-6207.CAPR-10-0345; Huang M, 2013, CANCER-AM CANCER SOC, V119, P3027, DOI 10.1002/cncr.28152; Joehlin-Price AS, 2014, GYNECOL ONCOL, V133, P43, DOI 10.1016/j.ygyno.2014.01.017; Lu KH, 2007, J CLIN ONCOL, V25, P5158, DOI 10.1200/JCO.2007.10.8597; Lu KH, 2013, CANCER PREV RES, V6, P774, DOI 10.1158/1940-6207.CAPR-13-0020; Lynch HT, 2014, CURR TREAT OPTION ON, V15, P429, DOI 10.1007/s11864-014-0293-5; MacDonald ND, 2000, CANCER RES, V60, P1750; Meyer LA, 2009, CANCER CONTROL, V16, P14, DOI 10.1177/107327480901600103; Newcomb PA, 2007, CANCER EPIDEM BIOMAR, V16, P2331, DOI 10.1158/1055-9965.EPI-07-0648; Pocobelli G, 2011, EPIDEMIOLOGY, V22, P638, DOI 10.1097/EDE.0b013e3182263018; Rogers William., 1993, STATA TECHNICAL B, V13, P19; Royston P, 2005, STATA J, V5, P188, DOI 10.1177/1536867X0500500204; Rumilla K, 2011, J MOL DIAGN, V13, P93, DOI 10.1016/j.jmoldx.2010.11.011; Sankaranarayanan R, 2006, BEST PRACT RES CL OB, V20, P207, DOI 10.1016/j.bpobgyn.2005.10.007; Schonfeld SJ, 2013, CANCER-AM CANCER SOC, V119, P1393, DOI 10.1002/cncr.27909; Senter L, 2008, GASTROENTEROLOGY, V135, P419, DOI 10.1053/j.gastro.2008.04.026; Setiawan VW, 2012, AM J EPIDEMIOL, V176, P269, DOI 10.1093/aje/kws129; Southey MC, 2005, J CLIN ONCOL, V23, P6524, DOI 10.1200/JCO.2005.04.671; StataCorp LP, 2013, LP GAS SAFETY REFERE; Uharcek P, 2008, INT J GYNECOL CANCER, V18, P324, DOI 10.1111/j.1525-1438.2007.00997.x; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; Williams RL, 2000, BIOMETRICS, V56, P645, DOI 10.1111/j.0006-341X.2000.00645.x; Win AK, 2013, J MED GENET, V50, P785, DOI 10.1136/jmedgenet-2013-101803; Win AK, 2012, JNCI-J NATL CANCER I, V104, P1363, DOI 10.1093/jnci/djs351; Win AK, 2011, OBSTET GYNECOL, V117, P899, DOI 10.1097/AOG.0b013e3182110ea3; Xu WH, 2004, INT J CANCER, V108, P613, DOI 10.1002/ijc.11598; Zhang YY, 2014, INT J BIOL MARKER, V29, pE21, DOI 10.5301/jbm.5000047; Zucchetto A, 2009, EUR J CANCER PREV, V18, P316, DOI 10.1097/CEJ.0b013e328329d830	46	44	50	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	2015	314	1					61	71		10.1001/jama.2015.6789	http://dx.doi.org/10.1001/jama.2015.6789			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CM1QR	26151267	Green Accepted, Green Submitted, Bronze			2023-01-03	WOS:000357455900015
J	Banik, S; Mansour, AA; Suresh, RV; Wykoff-Clary, S; Malik, M; McCormick, AA; Bakshi, CS				Banik, Sukalyani; Mansour, Ahd Ahmed; Suresh, Ragavan Varadharajan; Wykoff-Clary, Sherri; Malik, Meenakshi; McCormick, Alison A.; Bakshi, Chandra Shekhar			Development of a Multivalent Subunit Vaccine against Tularemia Using Tobacco Mosaic Virus (TMV) Based Delivery System	PLOS ONE			English	Article							OUTER-MEMBRANE PROTEIN; FRANCISELLA-TULARENSIS; IMMUNOREACTIVE ANTIGENS; PROTECTIVE IMMUNITY; STRAIN; LIPOPOLYSACCHARIDE; IDENTIFICATION; MUTANT; MICE; CHALLENGE	Francisella tularensis is a facultative intracellular pathogen, and is the causative agent of a fatal human disease known as tularemia. F. tularensis is classified as a Category A Biothreat agent by the CDC based on its use in bioweapon programs by several countries in the past and its potential to be used as an agent of bioterrorism. No licensed vaccine is currently available for prevention of tularemia. In this study, we used a novel approach for development of a multivalent subunit vaccine against tularemia by using an efficient tobacco mosaic virus (TMV) based delivery platform. The multivalent subunit vaccine was formulated to contain a combination of F. tularensis protective antigens: OmpA-like protein (OmpA), chaperone protein DnaK and lipoprotein Tul4 from the highly virulent F. tularensis SchuS4 strain. Two different vaccine formulations and immunization schedules were used. The immunized mice were challenged with lethal (10xLD(100)) doses of F. tularensis LVS on day 28 of the primary immunization and observed daily for morbidity and mortality. Results from this study demonstrate that TMV can be used as a carrier for effective delivery of multiple F. tularensis antigens. TMV-conjugate vaccine formulations are safe and multiple doses can be administered without causing any adverse reactions in immunized mice. Immunization with TMV-conjugated F. tularensis proteins induced a strong humoral immune response and protected mice against respiratory challenges with very high doses of F. tularensis LVS. This study provides a proof-of-concept that TMV can serve as a suitable platform for simultaneous delivery of multiple protective antigens of F. tularensis. Refinement of vaccine formulations coupled with TMV-targeting strategies developed in this study will provide a platform for development of an effective tularemia subunit vaccine as well as a vaccination approach that may broadly be applicable to many other bacterial pathogens.	[Banik, Sukalyani; Mansour, Ahd Ahmed; Suresh, Ragavan Varadharajan; Bakshi, Chandra Shekhar] New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA; [Wykoff-Clary, Sherri; McCormick, Alison A.] Touro Univ Calif, Coll Pharm, Vallejo, CA USA; [Malik, Meenakshi] Albany Coll Pharm & Hlth Sci, Albany, NY USA	New York Medical College; Touro University California; Albany College of Pharmacy & Health Sciences	Bakshi, CS (corresponding author), New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA.	Shekhar_Bakshi@nymc.edu	Malik, Meenakshi/F-1501-2015	Malik, Meenakshi/0000-0003-0051-4485	Touro University Seed Grant; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI107698] Funding Source: NIH RePORTER	Touro University Seed Grant; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by Touro University Seed Grant to AAM and CSB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altman Gaylene Bouska, 2002, AAOHN J, V50, P373; Apicella MA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011060; Ashtekar AR, 2008, J LEUKOCYTE BIOL, V84, P1434, DOI 10.1189/jlb.0308215; Ashtekar AR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050460; Atlas RM, 2002, ANNU REV MICROBIOL, V56, P167, DOI 10.1146/annurev.micro.56.012302.160616; Barker JH, 2006, INFECT IMMUN, V74, P3277, DOI 10.1128/IAI.02011-05; Baron SD, 2007, INFECT IMMUN, V75, P2152, DOI 10.1128/IAI.01606-06; Barry EM, 2009, HUM VACCINES, V5, P832, DOI 10.4161/hv.10297; Bossi P, 2003, PRESSE MED, V32, P1126; Cole LE, 2009, P NATL ACAD SCI USA, V106, P4343, DOI 10.1073/pnas.0813411106; Dennis DT, 2001, JAMA-J AM MED ASSOC, V285, P2763, DOI 10.1001/jama.285.21.2763; Dotson RJ, 2013, J BIOL CHEM, V288, P23844, DOI 10.1074/jbc.M113.490086; Eyles JE, 2008, MICROB PATHOGENESIS, V44, P164, DOI 10.1016/j.micpath.2007.08.009; Eyles JE, 2007, PROTEOMICS, V7, P2172, DOI 10.1002/pmic.200600985; FORSMAN M, 1994, INT J SYST BACTERIOL, V44, P38, DOI 10.1099/00207713-44-1-38; Foshay L, 1942, AM J PUBLIC HEALTH N, V32, P1131, DOI 10.2105/AJPH.32.10.1131; FULOP M, 1995, VACCINE, V13, P1220, DOI 10.1016/0264-410X(95)00062-6; Gregory SH, 2010, VACCINE, V28, P2908, DOI 10.1016/j.vaccine.2010.01.067; Griffin AJ, 2015, CLIN VACCINE IMMUNOL, V22, P119, DOI 10.1128/CVI.00648-14; Havlasova J, 2005, PROTEOMICS, V5, P2090, DOI 10.1002/pmic.200401123; Havlasova J, 2002, PROTEOMICS, V2, P857, DOI 10.1002/1615-9861(200207)2:7<857::AID-PROT857>3.0.CO;2-L; Hickey AJ, 2011, VACCINE, V29, P6941, DOI 10.1016/j.vaccine.2011.07.075; HOLLIS DG, 1989, J CLIN MICROBIOL, V27, P1601, DOI 10.1128/JCM.27.7.1601-1608.1989; HOLM SE, 1980, INT ARCH ALLER A IMM, V61, P136, DOI 10.1159/000232426; Huntley JF, 2008, INFECT IMMUN, V76, P3664, DOI 10.1128/IAI.00374-08; Huntley JF, 2007, J BACTERIOL, V189, P561, DOI 10.1128/JB.01505-06; Janovska S, 2007, IMMUNOL LETT, V108, P151, DOI 10.1016/j.imlet.2006.12.004; Jia QM, 2013, INFECT IMMUN, V81, P1550, DOI 10.1128/IAI.01013-12; Kaur R, 2012, CLIN VACCINE IMMUNOL, V19, P359, DOI 10.1128/CVI.05384-11; Khlebnikov VS, 1996, FEMS IMMUNOL MED MIC, V13, P227, DOI 10.1111/j.1574-695X.1996.tb00241.x; Lavine CL, 2007, EUR J IMMUNOL, V37, P3007, DOI 10.1002/eji.200737620; Liu RL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060621; Mahawar M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061539; Mahawar M, 2012, J BIOL CHEM, V287, P25216, DOI 10.1074/jbc.M112.367672; Mallajosyula JK, 2014, HUM VACC IMMUNOTHER, V10, P586, DOI 10.4161/hv.27567; Mara-Koosham G, 2011, INFECT IMMUN, V79, P1770, DOI 10.1128/IAI.00605-10; McCormick AA, 2006, VACCINE, V24, P6414, DOI 10.1016/j.vaccine.2006.06.003; McCormick AA, 2006, BIOCONJUGATE CHEM, V17, P1330, DOI 10.1021/bc060124m; Mohapatra SK, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-10; Noah CE, 2010, INFECT IMMUN, V78, P1797, DOI 10.1128/IAI.01135-09; Oyston PCF, 2008, J MED MICROBIOL, V57, P921, DOI 10.1099/jmm.0.2008/000653-0; Pechous R, 2006, INFECT IMMUN, V74, P4452, DOI 10.1128/IAI.00666-06; Rawool DB, 2008, J IMMUNOL, V180, P5548, DOI 10.4049/jimmunol.180.8.5548; Rockx-Brouwer D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037752; RUCHMAN I, 1949, J IMMUNOL, V61, P229; Sammons-Jackson WL, 2008, DNA CELL BIOL, V27, P387, DOI 10.1089/dna.2007.0687; Sebastian S, 2007, INFECT IMMUN, V75, P2591, DOI 10.1128/IAI.01789-06; Smith ML, 2007, VIROLOGY, V358, P321, DOI 10.1016/j.virol.2006.08.040; Smith ML, 2006, VIROLOGY, V348, P475, DOI 10.1016/j.virol.2005.12.039; Steiner DJ, 2014, INFECT DRUG RESIST, V7, P239, DOI 10.2147/IDR.S53700; Suresh RV, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124326; Svensson K, 2005, J BACTERIOL, V187, P3903, DOI 10.1128/JB.187.11.3903-3908.2005; Twine S, 2005, INFECT IMMUN, V73, P8345, DOI 10.1128/IAI.73.12.8345-8352.2005	53	38	39	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2015	10	6							e0130858	10.1371/journal.pone.0130858	http://dx.doi.org/10.1371/journal.pone.0130858			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL3FM	26098553	Green Published, Green Submitted, gold			2023-01-03	WOS:000356835800112
J	Ribas, A				Ribas, Antoni			Releasing the Brakes on Cancer Immunotherapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							T-CELLS		[Ribas, Antoni] Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90024 USA; [Ribas, Antoni] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Ribas, A (corresponding author), Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90024 USA.							HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; MCINTYRE BW, 1983, CELL, V34, P739, DOI 10.1016/0092-8674(83)90530-5; Ribas A, 2012, NEW ENGL J MED, V366, P2517, DOI 10.1056/NEJMe1205943; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]	5	169	181	0	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 15	2015	373	16					1490	1492		10.1056/NEJMp1510079	http://dx.doi.org/10.1056/NEJMp1510079			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT5VX	26348216				2023-01-03	WOS:000362880300004
J	Farokhzad, OC				Farokhzad, Omid C.			NANOTECHNOLOGY Platelet mimicry	NATURE			English	Editorial Material							NANOPARTICLES; VACCINATION; TOXINS		[Farokhzad, Omid C.] Brigham & Womens Hosp, Lab Nanomed & Biomat, Boston, MA 02115 USA; [Farokhzad, Omid C.] Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Farokhzad, OC (corresponding author), Brigham & Womens Hosp, Lab Nanomed & Biomat, Boston, MA 02115 USA.	ofarokhzad@bwh.harvard.edu		Farokhzad, Omid/0000-0003-2009-270X				Anselmo AC, 2014, ACS NANO, V8, P11243, DOI 10.1021/nn503732m; Cho WK, 2012, P NATL ACAD SCI USA, V109, P21289, DOI 10.1073/pnas.1216441109; Fang RH, 2014, NANO LETT, V14, P2181, DOI 10.1021/nl500618u; Fitzgerald JR, 2006, NAT REV MICROBIOL, V4, P445, DOI 10.1038/nrmicro1425; Hu CMJ, 2015, NATURE, V526, P118, DOI 10.1038/nature15373; Hu CMJ, 2013, NAT NANOTECHNOL, V8, P933, DOI [10.1038/NNANO.2013.254, 10.1038/nnano.2013.254]; Hu CMJ, 2013, NAT NANOTECHNOL, V8, P336, DOI [10.1038/NNANO.2013.54, 10.1038/nnano.2013.54]; Kamaly N, 2013, P NATL ACAD SCI USA, V110, P6506, DOI 10.1073/pnas.1303377110; Kamaly N, 2012, CHEM SOC REV, V41, P2971, DOI 10.1039/c2cs15344k; Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/NMAT2442, 10.1038/nmat2442]; Prendergast BD, 2010, CIRCULATION, V121, P1141, DOI 10.1161/CIRCULATIONAHA.108.773598; Pridgen EM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007049; Simberg D, 2007, P NATL ACAD SCI USA, V104, P932, DOI 10.1073/pnas.0610298104	13	30	32	2	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 1	2015	526	7571					47	48		10.1038/nature15218	http://dx.doi.org/10.1038/nature15218			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS5CY	26375011				2023-01-03	WOS:000362095100029
J	Fendler, TJ; Spertus, JA; Kennedy, KF; Chen, LM; Perman, SM; Chan, PS				Fendler, Timothy J.; Spertus, John A.; Kennedy, Kevin F.; Chen, Lena M.; Perman, Sarah M.; Chan, Paul S.		Amer Heart Assoc Get Guidelines	Alignment of Do-Not-Resuscitate Status With Patients' Likelihood of Favorable Neurological Survival After In-Hospital Cardiac Arrest	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMERICAN-HEART-ASSOCIATION; HEALTH-CARE-PROFESSIONALS; CARDIOPULMONARY-RESUSCITATION; STROKE-FOUNDATION; SOUTHERN-AFRICA; ORDERS; STATEMENT; COUNCILS; OUTCOMES; IMPACT	IMPORTANCE After patients survive an in-hospital cardiac arrest, discussions should occur about prognosis and preferences for future resuscitative efforts. OBJECTIVE To assess whether patients' decisions for do-not-resuscitate (DNR) orders after a successful resuscitation from in-hospital cardiac arrest are aligned with their expected prognosis. DESIGN, SETTING, AND PARTICIPANTS Within Get With The Guidelines-Resuscitation, we identified 26 327 patients with return of spontaneous circulation (ROSC) after in-hospital cardiac arrest between April 2006 and September 2012 at 406 US hospitals. Using a previously validated prognostic tool, each patient's likelihood of favorable neurological survival (ie, without severe neurological disability) was calculated. The proportion of patients with DNR orders within each prognosis score decile and the association between DNR status and actual favorable neurological survival were examined. EXPOSURES Do-not-resuscitate orders within 12 hours of ROSC. MAIN OUTCOMES AND MEASURES Likelihood of favorable neurological survival. RESULTS Overall, 5944 (22.6%[95% CI, 22.1%-23.1%]) patients had DNR orders within 12 hours of ROSC. This group was older and had higher rates of comorbidities (all P < .05) than patients without DNR orders. Among patients with the best prognosis (decile 1), 7.1% (95% CI, 6.1%-8.1%) had DNR orders even though their predicted rate of favorable neurological survival was 64.7%(95% CI, 62.8%-66.6%). Among patients with the worst expected prognosis (decile 10), 36.0%(95% CI, 34.2%-37.8%) had DNR orders even though their predicted rate for favorable neurological survival was 4.0%(95% CI, 3.3%-4.7%) (P for both trends <. 001). This pattern was similar when DNR orders were redefined as within 24 hours, 72 hours, and 5 days of ROSC. The actual rate of favorable neurological survival was higher for patients without DNR orders (30.5%[95% CI, 29.9%-31.1%]) than it was for those with DNR orders (1.8%[95% CI, 1.6%-2.0%]). This pattern of lower survival among patients with DNR orders was seen in every decile of expected prognosis. CONCLUSIONS AND RELEVANCE Although DNR orders after in-hospital cardiac arrest were generally aligned with patients' likelihood of favorable neurological survival, only one-third of patients with the worst prognosis had DNR orders. Patients with DNR orders had lower survival than those without DNR orders, including those with the best prognosis.	[Fendler, Timothy J.; Spertus, John A.; Kennedy, Kevin F.; Chan, Paul S.] St Lukes Mid Amer Heart Inst, Dept Cardiol, Kansas City, MO 64111 USA; [Chen, Lena M.] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA; [Perman, Sarah M.] Univ Colorado, Sch Med, Dept Emergency Med, Denver, CO USA	Saint Luke's Mid America Heart Institute; University of Michigan System; University of Michigan; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Fendler, TJ (corresponding author), St Lukes Mid Amer Heart Inst, Cardiovasc Outcomes Res, 4401 Wornall Rd,Fifth Floor,Ste 5603, Kansas City, MO 64111 USA.	fendlert@umkc.edu	Spertus, John/ABD-3075-2021		National Heart, Lung, and Blood Institute (NHLBI); NHLBI [1R01HL123980]; Agency for Healthcare Research and Quality [K08 HS020671]; American Heart Association; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS020671] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL123980, T32HL110837] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); American Heart Association(American Heart Association); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Dr Fendler is supported by grant T32HL110837 from the National Heart, Lung, and Blood Institute (NHLBI). Dr Chan is funded by grant 1R01HL123980 from the NHLBI. Dr Chen is supported by grant K08 HS020671 from Agency for Healthcare Research and Quality. Outcome, a Quintiles Company, is the data collection coordination center for the American Heart Association/American Stroke Association Get With the Guidelines programs.; The sponsors, including the American Heart Association, had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	Chan PS, 2008, NEW ENGL J MED, V358, P9, DOI 10.1056/NEJMoa0706467; Chan PS, 2014, CIRC-CARDIOVASC QUAL, V7, P889, DOI 10.1161/CIRCOUTCOMES.114.000925; Chan PS, 2013, NEW ENGL J MED, V368, P1019, DOI 10.1056/NEJMoa1200657; Chan PS, 2012, ARCH INTERN MED, V172, P947, DOI 10.1001/archinternmed.2012.2050; Chan PS, 2009, JAMA-J AM MED ASSOC, V302, P1195, DOI 10.1001/jama.2009.1340; Cummins RO, 1997, CIRCULATION, V95, P2213, DOI 10.1161/01.CIR.95.8.2213; Ebell MH, 2013, JAMA INTERN MED, V173, P1872, DOI 10.1001/jamainternmed.2013.10037; EBELL MH, 1992, J FAM PRACTICE, V34, P551; GEORGE AL, 1989, AM J MED, V87, P28; Girotra S, 2012, NEW ENGL J MED, V367, P1912, DOI 10.1056/NEJMoa1109148; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; Goldstein H, MULTILEVEL STAT MODE; Jackson EA, 2004, ARCH INTERN MED, V164, P776, DOI 10.1001/archinte.164.7.776; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Kelly AG, 2014, STROKE, V45, P822, DOI 10.1161/STROKEAHA.113.004573; KELSEY SF, 1986, AM J EMERG MED, V4, P72; Larkin GL, 2010, RESUSCITATION, V81, P302, DOI 10.1016/j.resuscitation.2009.11.021; Mamdani M, 2005, BMJ-BRIT MED J, V330, P960, DOI 10.1136/bmj.330.7497.960; Marrie TJ, 2002, J AM GERIATR SOC, V50, P290, DOI 10.1046/j.1532-5415.2002.50061.x; Merchant RM, 2011, CRIT CARE MED, V39, P2401, DOI 10.1097/CCM.0b013e3182257459; Niemann JT, 2001, RESUSCITATION, V51, P233, DOI 10.1016/S0300-9572(01)00425-7; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Peberdy MA, 2008, JAMA-J AM MED ASSOC, V299, P785, DOI 10.1001/jama.299.7.785; R Development Core Team, R LANG ENV STAT COMP; Richardson DK, 2013, RESUSCITATION, V84, P483, DOI 10.1016/j.resuscitation.2012.08.327; Shepardson LB, 1997, ARCH INTERN MED, V157, P1841, DOI 10.1001/archinte.157.16.1841; Topjian AA, 2010, CRIT CARE MED, V38, P1254, DOI 10.1097/CCM.0b013e3181d8ca43	27	20	21	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	2015	314	12					1264	1271		10.1001/jama.2015.11069	http://dx.doi.org/10.1001/jama.2015.11069			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CS5IE	26393849	Green Accepted, Green Published, Bronze			2023-01-03	WOS:000362110700015
J	Gebre, M; Gebremariam, A; Abebe, TA				Gebre, Merihun; Gebremariam, Abebe; Abebe, Tsedach Alemu			Birth Preparedness and Complication Readiness among Pregnant Women in Duguna Fango District, Wolayta Zone, Ethiopia	PLOS ONE			English	Article								Background Birth Preparedness and Complication Readiness is a strategy to promote the timely use of skilled maternal and neonatal care, especially during childbirth, based on the theory that preparing for childbirth and being ready for complications reduces delays in obtaining this care. Objective This study was conducted to assess birth preparedness and complication readiness and its associated factors among pregnant woman in Duguna Fango District in Wolayta Zone, South Ethiopia. Methods A community based cross-sectional study was conducted in 2013, on a sample of 578 pregnant women. Data were collected using pre-tested and structured questionnaire. The collected data were analyzed by SPSS for windows version 16.0. The women were asked whether they followed the desired five steps while pregnant: identified a trained birth attendant, identified a health facility, arranged for transport, identified blood donor and saved money for emergency. Taking at least three steps was considered being well-prepared. Results Among 578 pregnant women only one tenth (10.7%) of pregnant women identified skilled provider. Only 103 (18.1%) arranged transportation to health facility. Two hundred forty eight (43.6%) identified health facility for delivery and/or for obstetric emergencies. more than half (54.1%) of families saved money for incurred costs of delivery and emergency if needed. only few 17(3%) identified potential blood donor in case of emergency. Two hundred sixty four (46.4%) of the respondents reported that they intended to deliver at home, and more than half (53.6) planned to deliver at health facilities. Overall less than one fifth 18.3% of pregnant women were well prepared. The adjusted multivariate model showed that significant predictors for being well-prepared were maternal availing of antenatal services (AOR = 2.95, 95% Cl: 1.62-5.37), being pregnant for the first time (AOR = 3.37, 95% Cl: 1.45-7.82), having knowledge of at least two danger signs during pregnancy (AOR = 2.81, 95% Cl: 1.69-4.67) and history of past obstetric complication (AOR = 2.98, 95% Cl: 1.35-6.58). Conclusion Birth preparedness practice in the study area was found to be low. Information, Education and Communication (IEC) on birth preparedness and complication readiness for young people should start early adolescence. The government officials and partners that are working in areas of maternal health should come up with strategies to improve birth preparedness at individual and community level.	[Gebre, Merihun] Duguna Fango Dist Hlth Off, Wolayta, Ethiopia; [Gebremariam, Abebe; Abebe, Tsedach Alemu] Jimma Univ, Coll Publ Hlth & Med Sci, Jimma, Ethiopia	Jimma University	Abebe, TA (corresponding author), Jimma Univ, Coll Publ Hlth & Med Sci, Jimma, Ethiopia.	tsedachalemu@yahoo.com			Jimma University, College of Public Health and Medical Sciences	Jimma University, College of Public Health and Medical Sciences	The authors would like to thank Jimma University, College of Public Health and Medical Sciences, for financial support in undertaking this research.	Agarwal S, 2010, J HEALTH POPUL NUTR, V28, P383; [Anonymous], 2013, DUGUNA FANGO D UNPUB; [Anonymous], 2013, WOLAYTA ZONAL UNPUB; Anya Samuel E, 2008, BMC Pregnancy Childbirth, V8, P9, DOI 10.1186/1471-2393-8-9; Hailu M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021432; Hiluf M, 2007, ETHIOP J HEALTH DEV, V22, P14; Johns Hopkins Bloomberg School of Public Health Center for Communication Programs Family Care International Maternal and Neonatal Health, 2004, MON BIRTH PREP COMPL; Kabakyenga JK, 2011, REPROD HEALTH, V8, DOI 10.1186/1742-4755-8-33; McPherson RA, 2006, J HEALTH POPUL NUTR, V24, P479; Measure communication, 2000, MAK PREGN CHILDB SAF; Mutiso S M, 2008, East Afr Med J, V85, P275; THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7; The White Ribbon Alliance for Safe Motherhood/India, 2002, WHIT RIBB ALL SAF MO; USAID SCA MOH UKaid UNFPA UNICEF EHNRI CDC., 2012, 5TH DEM HLTH SURV 20; Wang W, 2011, LEVELS TRENDS USE MA; World Health Organization (WHO), 2012, TRENDS MAT MORT 1990	16	32	32	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2015	10	9							e0137570	10.1371/journal.pone.0137570	http://dx.doi.org/10.1371/journal.pone.0137570			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS0RH	26379231	Green Published, gold, Green Submitted			2023-01-03	WOS:000361769400018
J	Pless, M; Stupp, R; Ris, HB; Stahel, RA; Weder, W; Thierstein, S; Gerard, MA; Xyrafas, A; Fruh, M; Cathomas, R; Zippelius, A; Roth, A; Bijelovic, M; Ochsenbein, A; Meier, UR; Mamot, C; Rauch, D; Gautschi, O; Betticher, DC; Mirimanoff, RO; Peters, S				Pless, Miklos; Stupp, Roger; Ris, Hans-Beat; Stahel, Rolf A.; Weder, Walter; Thierstein, Sandra; Gerard, Marie-Aline; Xyrafas, Alexandros; Frueh, Martin; Cathomas, Richard; Zippelius, Alfred; Roth, Arnaud; Bijelovic, Milorad; Ochsenbein, Adrian; Meier, Urs R.; Mamot, Christoph; Rauch, Daniel; Gautschi, Oliver; Betticher, Daniel C.; Mirimanoff, Rene-Olivier; Peters, Solange		SAKK Lung Cancer Project Grp	Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial	LANCET			English	Article							NEOADJUVANT CHEMOTHERAPY; RADIOTHERAPY; SURGERY; CHEMORADIOTHERAPY; RESECTION; SURVIVAL	Background One of the standard options in the treatment of stage IIIA/N2 non-small-cell lung cancer is neoadjuvant chemotherapy and surgery. We did a randomised trial to investigate whether the addition of neoadjuvant radiotherapy improves outcomes. Methods We enrolled patients in 23 centres in Switzerland, Germany and Serbia. Eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer and were randomly assigned to treatment groups in a 1: 1 ratio. Those in the chemoradiotherapy group received three cycles of neoadjuvant chemotherapy (100 mg/m(2) cisplatin and 85 mg/m(2) docetaxel) followed by radiotherapy with 44 Gy in 22 fractions over 3 weeks, and those in the control group received neoadjuvant chemotherapy alone. All patients were scheduled to undergo surgery. Randomisation was stratified by centre, mediastinal bulk (less than 5 cm vs 5 cm or more), and weight loss (5% or more vs less than 5% in the previous 6 months). The primary endpoint was event-free survival. Analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov,number NCT00030771. Findings From 2001 to 2012, 232 patients were enrolled, of whom 117 were allocated to the chemoradiotherapy group and 115 to the chemotherapy group. Median event-free survival was similar in the two groups at 12.8 months (95% CI 9.7-22.9) in the chemoradiotherapy group and 11.6 months (8.4-15.2) in the chemotherapy group (p=0.67). Median overall survival was 37.1 months (95% CI 22.6-50.0) with radiotherapy, compared with 26.2 months (19.9-52.1) in the control group. Chemotherapy-related toxic effects were reported in most patients, but 91% of patients completed three cycles of chemotherapy. Radiotherapy-induced grade 3 dysphagia was seen in seven (7%) patients. Three patients died in the control group within 30 days after surgery. Interpretation Radiotherapy did not add any benefit to induction chemotherapy followed by surgery. We suggest that one definitive local treatment modality combined with neoadjuvant chemotherapy is adequate to treat resectable stage IIIA/N2 non-small-cell lung cancer.	[Pless, Miklos] Kantonsspital Winterthur, Dept Med Oncol, CH-8401 Winterthur, Switzerland; [Meier, Urs R.] Kantonsspital Winterthur, Dept Radiat Oncol, CH-8401 Winterthur, Switzerland; [Stupp, Roger] CHU Vaudois, Dept Med Oncol, Lausanne, Vaud, Switzerland; [Ris, Hans-Beat] CHU Vaudois, Dept Thorac Surg, Lausanne, Vaud, Switzerland; [Mirimanoff, Rene-Olivier] CHU Vaudois, Dept Radiat Oncol, Lausanne, Vaud, Switzerland; [Stupp, Roger] Univ Zurich Hosp, Dept Oncol, CH-8091 Zurich, Switzerland; [Stupp, Roger] Univ Zurich Hosp, Ctr Canc, CH-8091 Zurich, Switzerland; [Stahel, Rolf A.] Univ Zurich Hosp, Dept Med Oncol, CH-8091 Zurich, Switzerland; [Weder, Walter] Univ Zurich Hosp, Dept Thorac Surg, CH-8091 Zurich, Switzerland; [Thierstein, Sandra; Gerard, Marie-Aline] SAKK Coordinating Ctr, Bern, Switzerland; [Xyrafas, Alexandros] SAKK Dept Stat, Bern, Switzerland; [Frueh, Martin] Kantonsspital St Gallen, Dept Med Oncol, St Gallen, Switzerland; [Cathomas, Richard] Kantonsspital Graubunden, Dept Med Oncol, Chur, Switzerland; [Zippelius, Alfred] Univ Basel Hosp, Dept Med Oncol, CH-4031 Basel, Switzerland; [Roth, Arnaud] Hop Univ Geneve, Dept Med Oncol, Geneva, Switzerland; [Bijelovic, Milorad] Inst Pulm Dis Vojvodina, Dept Thorac Surg, Sremska Kamenica, Serbia; [Ochsenbein, Adrian] Univ Hosp Bern, Dept Med Oncol, CH-3010 Bern, Switzerland; [Mamot, Christoph] Kantonsspital Aarau, Dept Med Oncol, Aarau, Switzerland; [Rauch, Daniel] Reg Hosp, Dept Med Oncol, Thun, Switzerland; [Gautschi, Oliver] Kantonsspital Luzern, Dept Med Oncol, Luzern, Switzerland; [Betticher, Daniel C.] HFR Fribourg Hop cantonal, Dept Med Oncol, Fribourg, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; Kantonsspital St. Gallen; Kantonsspital Graubunden; University of Basel; University of Geneva; University of Bern; University Hospital of Bern; Kantonsspital Aarau AG (KSA); Lucerne Cantonal Hospital	Pless, M (corresponding author), Kantonsspital Winterthur, Dept Med Oncol, Brauerstr 15, CH-8401 Winterthur, Switzerland.	miklos.pless@ksw.ch; miklos.pless@ksw.ch	Stupp, Roger/L-3303-2019; peters, solange/ABF-2187-2020; Mamot, Christoph/GLU-1757-2022; Pless, Miklos/ABC-4054-2021	Ochsenbein, Adrian/0000-0003-1773-5436	Swiss State Secretariat for Education, Research and Innovation (SERI); Swiss Cancer League [KLS-02745-02-2011]; Sanofi	Swiss State Secretariat for Education, Research and Innovation (SERI); Swiss Cancer League; Sanofi(Sanofi-Aventis)	This study was supported by the Swiss State Secretariat for Education, Research and Innovation (SERI), the Swiss Cancer League (grant KLS-02745-02-2011 to MP), and Sanofi. We thank the patients and the investigators at all study sites for participation in the study.	Albain KS, 2009, LANCET, V374, P379, DOI 10.1016/S0140-6736(09)60737-6; ALBAIN KS, 1995, J CLIN ONCOL, V13, P1880, DOI 10.1200/JCO.1995.13.8.1880; Auperin A, 2010, LANCET, V375, P1267, DOI 10.1016/S0140-6736(10)60059-1; Auperin A, 2010, J CLIN ONCOL, V28, P2181, DOI 10.1200/JCO.2009.26.2543; Bentzen S, 2009, BASIC CLIN RADIOLOGY; Betticher DC, 2006, BRIT J CANCER, V94, P1099, DOI 10.1038/sj.bjc.6603075; Betticher DC, 2003, J CLIN ONCOL, V21, P1752, DOI 10.1200/JCO.2003.11.040; Burdett S, 2014, LANCET, V383, P1561, DOI 10.1016/S0140-6736(13)62159-5; Douillard JY, 2008, INT J RADIAT ONCOL, V72, P695, DOI 10.1016/j.ijrobp.2008.01.044; Eberhardt W, 2014, J CLIN ONCOL S, V32; Fleck J, 1993, P AN M AM SOC CLIN, V12, p1108a; Girard N, 2010, LUNG CANCER, V69, P86, DOI 10.1016/j.lungcan.2009.10.003; Goldstraw Peter, 2007, J Thorac Oncol, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Higgins K, 2009, INT J RADIAT ONCOL, V75, P1462, DOI 10.1016/j.ijrobp.2009.01.069; International Commission on Radiation Units and Measurement, 1993, 50 ICRU; Katakami N, 2012, CANCER-AM CANCER SOC, V118, P6126, DOI 10.1002/cncr.26689; Martini N, 1995, Chest Surg Clin N Am, V5, P189; O'Rourke N, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002140.pub3; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Stamatis G, 1999, ANN THORAC SURG, V68, P1144, DOI 10.1016/S0003-4975(99)00976-5; Stupp R, 2009, LANCET ONCOL, V10, P785, DOI 10.1016/S1470-2045(09)70172-X; Thomas M, 2008, LANCET ONCOL, V9, P636, DOI 10.1016/S1470-2045(08)70156-6; van Meerbeeck JP, 2007, JNCI-J NATL CANCER I, V99, P442, DOI 10.1093/jnci/djk093	23	202	215	1	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 12	2015	386	9998					1049	1056		10.1016/S0140-6736(15)60294-X	http://dx.doi.org/10.1016/S0140-6736(15)60294-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CR2VQ	26275735				2023-01-03	WOS:000361189200024
J	Geraedts, HAE; Zijlstra, W; Van Keeken, HG; Zhang, W; Stevens, M				Geraedts, Hilde A. E.; Zijlstra, Wiebren; Van Keeken, Helco G.; Zhang, Wei; Stevens, Martin			Validation and User Evaluation of a Sensor-Based Method for Detecting Mobility-Related Activities in Older Adults	PLOS ONE			English	Article							PHYSICAL-ACTIVITY QUESTIONNAIRE; AMBULATORY SYSTEM; GAIT; CLASSIFICATION; ACCELEROMETER; POSTURES; FRAIL; RELIABILITY; ACCURACY; BALANCE	Regular physical activity is essential for older adults to stay healthy and independent. However, daily physical activity is generally low among older adults and mainly consists of activities such as standing and shuffling around indoors. Accurate measurement of this low-energy expenditure daily physical activity is crucial for stimulation of activity. The objective of this study was to assess the validity of a necklace-worn sensor-based method for detecting time-on-legs and daily life mobility related postures in older adults. In addition user opinion about the practical use of the sensor was evaluated. Twenty frail and non-frail older adults performed a standardized and free movement protocol in their own home. Results of the sensor-based method were compared to video observation. Sensitivity, specificity and overall agreement of sensor outcomes compared to video observation were calculated. Mobility was assessed based on time-on-legs. Further assessment included the categories standing, sitting, walking and lying. Time-on-legs based sensitivity, specificity and percentage agreement were good to excellent and comparable to laboratory outcomes in other studies. Category-based sensitivity, specificity and overall agreement were moderate to excellent. The necklace-worn sensor is considered an acceptable valid instrument for assessing home-based physical activity based upon time-on-legs in frail and non-frail older adults, but category-based assessment of gait and postures could be further developed.	[Geraedts, Hilde A. E.; Zijlstra, Wiebren; Van Keeken, Helco G.] Univ Groningen, Univ Med Ctr Groningen, Ctr Human Movement Sci, Groningen, Netherlands; [Zijlstra, Wiebren] German Sport Univ Cologne, Inst Movement & Sport Gerontol, Cologne, Germany; [Zhang, Wei] Philips Res Europe, Eindhoven, Netherlands; [Stevens, Martin] Univ Groningen, Univ Med Ctr Groningen, Dept Orthopaed, Groningen, Netherlands	University of Groningen; German Sport University Cologne; Philips; Philips Research; University of Groningen	Geraedts, HAE (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Ctr Human Movement Sci, Groningen, Netherlands.	H.A.E.Geraedts@med.umcg.nl	Stevens, Martin/A-5196-2013	Stevens, Martin/0000-0001-8183-6894; Zhang, Wei/0000-0002-6022-6832	Netherlands Organisation for Health Research and Development (ZonMw) [40-00812-98-09014]; Philips Research Europe	Netherlands Organisation for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development); Philips Research Europe	This study is funded by The Netherlands Organisation for Health Research and Development (ZonMw; website URL http://www.zonmw.nl/en/), funder approval number 40-00812-98-09014. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The study was performed using technology and expertise provided by Philips Research Europe. Philips Research Europe provided support in the form of a salary for author W. Zhang, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the authors are articulated in the 'author contributions' section.	Adams SA, 2005, AM J EPIDEMIOL, V161, P389, DOI 10.1093/aje/kwi054; Aminian K, 2004, GAIT POSTURE, V20, P102, DOI 10.1016/S0966-6362(03)00093-6; Annegarn J, 2011, ARCH PHYS MED REHAB, V92, P1852, DOI 10.1016/j.apmr.2011.06.021; Bagala F, 2013, IEEE T NEUR SYS REH, V21, P624, DOI 10.1109/TNSRE.2012.2230189; Bergmann JHM, 2011, ANN BIOMED ENG, V39, P2299, DOI 10.1007/s10439-011-0339-9; Bergmann JHM, 2012, SENSORS-BASEL, V12, P16695, DOI 10.3390/s121216695; Blikman T, 2013, J ORTHOP SPORT PHYS, V43, P650, DOI 10.2519/jospt.2013.4422; Bussmann JBJ, 1998, PAIN, V74, P153, DOI 10.1016/S0304-3959(97)00161-9; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Dijkstra B, 2010, ARCH PHYS MED REHAB, V91, P1272, DOI 10.1016/j.apmr.2010.05.004; Dijkstra B, 2010, AGE AGEING, V39, P259, DOI 10.1093/ageing/afp249; Faber MJ, 2006, ARCH PHYS MED REHAB, V87, P885, DOI 10.1016/j.apmr.2006.04.005; Fleiss JL, 1981, STAT METHODS; Fried LP, 2004, J GERONTOL A-BIOL, V59, P255; Ganea R, 2012, IEEE T NEUR SYS REH, V20, P688, DOI 10.1109/TNSRE.2012.2202691; Godfrey A, 2011, MED ENG PHYS, V33, P1127, DOI 10.1016/j.medengphy.2011.05.002; Lally F, 2007, POSTGRAD MED J, V83, P16, DOI 10.1136/pgmj.2006.048587; Laufer Y, 2002, CLIN REHABIL, V16, P141, DOI 10.1191/0269215502cr481oa; Lindemann U, 2014, SENSORS-BASEL, V14, P1267, DOI 10.3390/s140101267; Mathie MJ, 2004, MED BIOL ENG COMPUT, V42, P679, DOI 10.1007/BF02347551; Murphy SL, 2009, PREV MED, V48, P108, DOI 10.1016/j.ypmed.2008.12.001; Paraschiv-Ionescu A, 2004, GAIT POSTURE, V20, P113, DOI 10.1016/j.gaitpost.2003.07.005; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Rydwik E, 2008, AGING CLIN EXP RES, V20, P159; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Shumway-Cook A, 2000, PHYS THER, V80, P896, DOI 10.1093/ptj/80.9.896; Steverink N, 2001, GERONTOLOGIST, V41, P236; Sun F, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-449; Taraldsen K, 2011, PHYS THER, V91, P277, DOI 10.2522/ptj.20100159; Taylor LM, 2014, ARCH PHYS MED REHAB, V95, P930, DOI 10.1016/j.apmr.2014.01.013; Tucker JM, 2011, AM J PREV MED, V40, P454, DOI 10.1016/j.amepre.2010.12.016; Tung JY, 2014, GAIT POSTURE, V39, P991, DOI 10.1016/j.gaitpost.2013.11.015; WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4; World Health Organization, PHYSICAL ACTIVITY AN; Zeng HS, 2011, SENSORS-BASEL, V11, P638, DOI 10.3390/s110100638; Zhang W, 2014, IEEE ENG MED BIO, P1830, DOI 10.1109/EMBC.2014.6943965	36	8	8	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2015	10	9							e0137668	10.1371/journal.pone.0137668	http://dx.doi.org/10.1371/journal.pone.0137668			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR0WB	26361009	Green Submitted, gold, Green Published			2023-01-03	WOS:000361043100071
J	Oliver, D				Oliver, David			ACUTE PERSPECTIVE David Oliver: What to do about end of life scare stories	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												davidoliver372@googlemail.com						Borland S, 2015, DAILY MAIL; Clark D, 2014, PALLIATIVE MED, V28, P474, DOI 10.1177/0269216314526443; Dreaper J., 2015, BBC HLTH NEWS   0904; Henry C, 2015, OBSERVER; National Institute for Health and Care Excellence, 2015, END LIF CAR DRAFT GU; Nuffield Trust, 2012, IMP M CUR NURS SERV; Office for National Statistics, 2015, NAT SURV BER PEOPL V; Parliamentary and Health Service Ombudsman, 2015, DYING DIGN INV COMPL; Pullicino P, 2015, DAILY TELEGRAPH; Regnard C, 2014, AGE AGEING, V43, P171, DOI 10.1093/ageing/aft195; The Gold Standards framework, 2013, ADV CAR PLANN	11	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 11	2015	351								h4846	10.1136/bmj.h4846	http://dx.doi.org/10.1136/bmj.h4846			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CR4EA	26362213	Bronze			2023-01-03	WOS:000361283400002
J	Perry, LK; Perlman, M; Lupyan, G				Perry, Lynn K.; Perlman, Marcus; Lupyan, Gary			Iconicity in English and Spanish and Its Relation to Lexical Category and Age of Acquisition	PLOS ONE			English	Article							SOUND-SYMBOLISM; SIGN-LANGUAGE; WINDOW	Signed languages exhibit iconicity (resemblance between form and meaning) across their vocabulary, and many non-Indo-European spoken languages feature sizable classes of iconic words known as ideophones. In comparison, Indo-European languages like English and Spanish are believed to be arbitrary outside of a small number of onomatopoeic words. In three experiments with English and two with Spanish, we asked native speakers to rate the iconicity of similar to 600 words from the English and Spanish MacArthur-Bates Communicative Developmental Inventories. We found that iconicity in the words of both languages varied in a theoretically meaningful way with lexical category. In both languages, adjectives were rated as more iconic than nouns and function words, and corresponding to typological differences between English and Spanish in verb semantics, English verbs were rated as relatively iconic compared to Spanish verbs. We also found that both languages exhibited a negative relationship between iconicity ratings and age of acquisition. Words learned earlier tended to be more iconic, suggesting that iconicity in early vocabulary may aid word learning. Altogether these findings show that iconicity is a graded quality that pervades vocabularies of even the most "arbitrary" spoken languages. The findings provide compelling evidence that iconicity is an important property of all languages, signed and spoken, including Indo-European languages.	[Perry, Lynn K.] Univ Miami, Coral Gables, FL 33124 USA; [Perlman, Marcus; Lupyan, Gary] Univ Wisconsin, Madison, WI USA	University of Miami; University of Wisconsin System; University of Wisconsin Madison	Perry, LK (corresponding author), Univ Miami, Coral Gables, FL 33124 USA.	lkp36@miami.edu	Perlman, Marcus/K-6972-2018	Perlman, Marcus/0000-0002-1269-3882; Lupyan, Gary/0000-0001-8441-7433; Perry, Lynn/0000-0001-6976-3741	National Science Foundation, Integrated NSF Support Promoting Interdisciplinary Research and Education (INSPIRE) [1344279]; Division Of Behavioral and Cognitive Sci [1344279] Funding Source: National Science Foundation	National Science Foundation, Integrated NSF Support Promoting Interdisciplinary Research and Education (INSPIRE); Division Of Behavioral and Cognitive Sci(National Science Foundation (NSF)NSF - Directorate for Social, Behavioral & Economic Sciences (SBE))	Funding was provided by the National Science Foundation, Integrated NSF Support Promoting Interdisciplinary Research and Education (INSPIRE) Award 1344279 awarded to GL.	Ahlner F., 2010, SIGN SYST STUD, V38, P298, DOI [10.12697/SSS.2010.38.1-4.11, DOI 10.12697/SSS.2010.38.1-4.11]; Armstrong D.F., 2007, GESTURAL ORIGIN LANG; Baayen RH, 2008, J MEM LANG, V59, P390, DOI 10.1016/j.jml.2007.12.005; Beavers J, 2010, J LINGUIST, V46, P331, DOI 10.1017/S0022226709990272; Bentley M, 1933, AM J PSYCHOL, V45, P76, DOI 10.2307/1414187; Bergen BK, 2004, LANGUAGE, V80, P290, DOI 10.1353/lan.2004.0056; Berlin B, 1994, EVIDENCE PERVASIVE S, P76, DOI DOI 10.1017/CBO9780511751806.006; BROWN R W, 1955, J Abnorm Psychol, V50, P388, DOI 10.1037/h0046820; Cuskley C, OXFORD HDB SYNAESTHE, P869; Cuskley C., 2013, PUBLIC J SEMIOTICS, V5, P39, DOI DOI 10.37693/pjos.2013.5.9651; Davies Mark, 2017, FREQUENCY DICT SPANI; De Saussure F., 1966, COURSE GEN LINGUISTI; Diffloth G., 1972, 8 REG M CHIC LING SO, P440; Dingemanse M, TRENDS COGN IN PRESS; Dingemanse M, 2014, PRAGMAT SOC, V5, P384, DOI 10.1075/ps.5.3.04din; Dingemanse M, 2012, LANG LINGUIST COMPAS, V6, P654, DOI 10.1002/lnc3.361; Farmer TA, 2006, P NATL ACAD SCI USA, V103, P12203, DOI 10.1073/pnas.0602173103; FENSON L, 1994, MONOGR SOC RES CHILD, V59, pR5; FRISHBERG N, 1975, LANGUAGE, V51, P696, DOI 10.2307/412894; GEBELS G, 1969, J VERB LEARN VERB BE, V8, P310, DOI 10.1016/S0022-5371(69)80083-6; HOCKETT CF, 1978, AM SPEECH, V53, P243, DOI 10.2307/455140; HOCKETT CF, 1960, SCI AM, V203, P88, DOI 10.1038/scientificamerican0960-88; Imai M, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0298; Imai M, 2008, COGNITION, V109, P54, DOI 10.1016/j.cognition.2008.07.015; Jackson-Maldonado D, 2003, USERS GUIDE TECHNICA; Jorgensen RN, 2010, J CHILD LANG, V37, P419, DOI 10.1017/S0305000909009544; Kantartzis K, 2011, COGNITIVE SCI, V35, P575, DOI 10.1111/j.1551-6709.2010.01169.x; La Polla R., 1994, SOUND SYMBOLISM; Lupyan G, 2015, LANG COGN, V7, P167, DOI 10.1017/langcog.2014.21; Masuda K., 2007, INSISTENT IMAGES, V5, P57; Monaghan P, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0299; Nielsen A, 2012, LANG COGN, V4, P115, DOI 10.1515/langcog-2012-0007; Nuckolls JanisB., 2003, P 11 ANN S LANG SOC; Nygaard LC, 2009, COGNITIVE SCI, V33, P127, DOI 10.1111/j.1551-6709.2008.01007.x; Padden C, 2013, GESTURE, V13, P287, DOI 10.1075/gest.13.3.03pad; Perlman M., 2014, COGN SCI; Perlman M, GESTURE IN PRESS; Perniss P, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0300; PINKER S, 1990, BEHAV BRAIN SCI, V13, P707, DOI 10.1017/S0140525X00081061; Plato, 1999, CRATYLUS; Ramachandran V, 2001, J CONSCIOUSNESS STUD, V8, P3; Reppen R., 2005, AM NATL CORPUS ANC 2; Shintel H, 2006, J MEM LANG, V55, P167, DOI 10.1016/j.jml.2006.03.002; Signs Morris C., 2011, LANGUAGE BEHAV; Strickland B, 2015, P NATL ACAD SCI USA, V112, P5968, DOI 10.1073/pnas.1423080112; TANZ C, 1971, LANG SPEECH, V14, P266, DOI 10.1177/002383097101400307; Taub S.F., 2001, LANGUAGE BODY ICONIC; Thompson RL, 2012, PSYCHOL SCI, V23, P1443, DOI 10.1177/0956797612459763; Tomasello M, 2008, JEAN NICOD LECT, P1; Ultan R., 1978, SIZE SOUND SYMBOLISM; Urban M, 2011, FOLIA LINGUIST, V45, P199, DOI 10.1515/FLIN.2011.007; Vigliocco G, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0292; Vinson DP, 2008, BEHAV RES METHODS, V40, P1079, DOI 10.3758/BRM.40.4.1079; Voeltz F.K. Erhard, 2001, IDEOPHONES; Wilcox S., 2009, ANN REV COGN LING, V7, P89, DOI [DOI 10.1075/ARCL.7.04WIL, 10.1075/arcl.7.04wil]; WILSON M, 1988, BEHAV RES METH INSTR, V20, P6, DOI 10.3758/BF03202594; Yoshida H, 2012, J COGN DEV, V13, P232, DOI 10.1080/15248372.2011.573515	57	95	95	2	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2015	10	9							e0137147	10.1371/journal.pone.0137147	http://dx.doi.org/10.1371/journal.pone.0137147			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	CQ6BA	26340349	Green Published, Green Submitted, gold			2023-01-03	WOS:000360688200026
J	Guo, SS; Tang, LQ; Chen, QY; Zhang, L; Liu, LT; Huang, PY; Cao, KJ; Guo, L; Mo, HY; Guo, X; Hong, MH; Zeng, MS; Qian, CN; Mai, HQ				Guo, Shan-Shan; Tang, Lin-Quan; Chen, Qiu-Yan; Zhang, Lu; Liu, Li-Ting; Huang, Pei-Yu; Cao, Ka-Jia; Guo, Ling; Mo, Hao-Yuan; Guo, Xiang; Hong, Ming-Huang; Zeng, Mu-Sheng; Qian, Chao-Nan; Mai, Hai-Qiang			Is Hemoglobin Level in Patients with Nasopharyngeal Carcinoma Still a Significant Prognostic Factor in the Era of Intensity-Modulated Radiotherapy Technology?	PLOS ONE			English	Article							EPSTEIN-BARR-VIRUS; SEQUENTIAL CHEMORADIOTHERAPY; TREATMENT RESISTANCE; ESOPHAGEAL CANCER; ANEMIA; HYPOXIA; SURVIVAL; IMPACT; TUMORS; DNA	Background Hemoglobin (Hb) levels are regarded as an important determinant of outcome in a number of cancers treated with radiotherapy. However, for patients treated with intensity modulated radiotherapy (IMRT), information regarding the prognostic value of hemoglobin level is scarce. Patients and Methods A total of 650 patients with nasopharyngeal carcinoma (NPC), enrolled between May, 2005, and November, 2012, were included in this study. The prognostic significance of hemoglobin level (anemia or no-anemia) at three different time points was investigated, including before treatment, during treatment and at the last week of treatment. Univariate and multivariate analyses were conducted using the log-rank test and the Cox proportional hazards model, respectively. Results The 5-year OS (overall survival) rate of patients who were anemia and no-anemia before treatment were 89.1%, and 80.7%(P = 0.01), respectively. The 5-year DMFS (distant metastasis-free survival) rate of patients who were anemia and no-anemia before treatment were 88.9%, and 78.2% (P = 0.01), respectively. The 5-year OS rate of patients who were anemia and no-anemia during treatment were 91.7% and 83.3% (P = 0.004). According to multivariate analysis, the pre-treatment Hb level predicted a decreased DMFS (P = 0.007, HR = 2.555, 95% CI1.294-5.046). Besides, the mid-treatment Hb level predicted a decreased OS (P = 0.013, HR = 2.333, 95% CI1.199-4.541). Conclusions Hemoglobin level is a useful prognostic factor in NPC patients receiving IMRT. It is important to control the level of hemoglobin both before and during chemoradiotherapy.	[Guo, Shan-Shan; Tang, Lin-Quan; Chen, Qiu-Yan; Zhang, Lu; Liu, Li-Ting; Huang, Pei-Yu; Cao, Ka-Jia; Guo, Ling; Mo, Hao-Yuan; Guo, Xiang; Hong, Ming-Huang; Zeng, Mu-Sheng; Qian, Chao-Nan; Mai, Hai-Qiang] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510275, Guangdong, Peoples R China; [Guo, Shan-Shan; Tang, Lin-Quan; Chen, Qiu-Yan; Zhang, Lu; Liu, Li-Ting; Huang, Pei-Yu; Cao, Ka-Jia; Guo, Ling; Mo, Hao-Yuan; Guo, Xiang; Qian, Chao-Nan; Mai, Hai-Qiang] Sun Yat Sen Univ, Dept Nasopharyngeal Carcinoma, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China; [Hong, Ming-Huang] Sun Yat Sen Univ, Canc Ctr, GCP Ctr, Guangzhou 510275, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Mai, HQ (corresponding author), Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510275, Guangdong, Peoples R China.	maihq@sysucc.org.cn			National Science Foundation for Distinguished Young Scholars of China [81425018]; National Natural Science Foundation of China [81072226]; 863 Project [2012AA02A501]; National Key Basic Research Program of China [2013CB910304]; Sci-Tech Project Foundation of Guangdong Province [2011B080701034, 2012B031800364]; Sci-Tech Project Foundation of Guangzhou City [2011J4300100]; Sun Yat-sen University Clinical Research 5010 Program; Fundamental Research Funds for the Central Universities	National Science Foundation for Distinguished Young Scholars of China(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 863 Project(National High Technology Research and Development Program of China); National Key Basic Research Program of China(National Basic Research Program of China); Sci-Tech Project Foundation of Guangdong Province; Sci-Tech Project Foundation of Guangzhou City; Sun Yat-sen University Clinical Research 5010 Program; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This research was supported by grants from the National Science Foundation for Distinguished Young Scholars of China (No. 81425018), the National Natural Science Foundation of China (No. 81072226), the 863 Project (No. 2012AA02A501), the National Key Basic Research Program of China (No. 2013CB910304), the Sci-Tech Project Foundation of Guangdong Province (No. 2011B080701034 and No. 2012B031800364), the Sci-Tech Project Foundation of Guangzhou City (No. 2011J4300100), the Sun Yat-sen University Clinical Research 5010 Program and the Fundamental Research Funds for the Central Universities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Becker A, 2000, INT J RADIAT ONCOL, V46, P459, DOI 10.1016/S0360-3016(99)00384-3; Chang ET, 2006, CANCER EPIDEM BIOMAR, V15, P1765, DOI 10.1158/1055-9965.EPI-06-0353; Chua DTT, 2004, CANCER, V101, P307, DOI 10.1002/cncr.20366; Cordella C, 2011, HEAD NECK ONCOL, V3, DOI 10.1186/1758-3284-3-35; Gao J, 2012, INT J RADIAT ONCOL, V82, P1471, DOI 10.1016/j.ijrobp.2011.05.009; Gao Jin, 2010, Chin J Cancer, V29, P561; Grogan M, 1999, CANCER, V86, P1528, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1528::AID-CNCR20>3.0.CO;2-E; Gu MF, 2013, INT J CANCER, V132, P215, DOI 10.1002/ijc.27638; Henke M, 2000, INT J RADIAT ONCOL, V48, P339, DOI 10.1016/S0360-3016(00)00595-2; Hong B, 2013, HEAD NECK-J SCI SPEC, V35, P133, DOI 10.1002/hed.21877; Kadokura Genmu, 2014, Gan To Kagaku Ryoho, V41, P416; Kong FF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091362; Kong FF, 2014, EUR ARCH OTO-RHINO-L, V271, P3283, DOI 10.1007/s00405-014-2900-2; Leung SF, 2014, ANN ONCOL, V25, P1204, DOI 10.1093/annonc/mdu117; Moretto F, 2014, RADIOL MED, V119, P634, DOI 10.1007/s11547-013-0359-7; Mujcic H, 2014, CURR MOL MED, V14, P565, DOI 10.2174/1566524014666140603115831; Munstedt K, 2004, ONCOL REP, V11, P711; Pattle SB, 2006, EXPERT OPIN BIOL TH, V6, P1193, DOI 10.1517/14712598.6.11.1193; Rades D, 2006, CLIN ONCOL-UK, V18, P139, DOI 10.1016/j.clon.2005.10.007; Vaupel P, 2001, MED ONCOL, V18, P243, DOI 10.1385/MO:18:4:243; Vaupel P, 2005, TRANSFUS CLIN BIOL, V12, P5, DOI 10.1016/j.tracli.2004.11.005; Walter CJ, 2013, COLORECTAL DIS, V15, P52, DOI 10.1111/j.1463-1318.2012.03112.x; Xu ZJ, 2013, CHIN J CANCER, V32, P453, DOI 10.5732/cjc.013.10118; Yoshino Ichiro, 2014, Gan To Kagaku Ryoho, V41, P426; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; Zenda S, 2008, DIS ESOPHAGUS, V21, P195, DOI 10.1111/j.1442-2050.2007.00750.x; Zhao Chong, 2004, Ai Zheng, V23, P1532; ZURHAUSE.H, 1970, NATURE, V228, P1056, DOI 10.1038/2281056a0	28	21	23	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2015	10	8							e0136033	10.1371/journal.pone.0136033	http://dx.doi.org/10.1371/journal.pone.0136033			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP8KZ	26313452	gold, Green Published, Green Submitted			2023-01-03	WOS:000360144000036
J	Meid, AD; Quinzler, R; Freigofas, J; Saum, KU; Schottker, B; Holleczek, B; Heider, D; Konig, HH; Brenner, H; Haefeli, WE				Meid, Andreas D.; Quinzler, Renate; Freigofas, Julia; Saum, Kai-Uwe; Schoettker, Ben; Holleczek, Bernd; Heider, Dirk; Koenig, Hans-Helmut; Brenner, Hermann; Haefeli, Walter E.			Medication Underuse in Aging Outpatients with Cardiovascular Disease: Prevalence, Determinants, and Outcomes in a Prospective Cohort Study	PLOS ONE			English	Article							OLDER-PEOPLE; ELDERLY-PATIENTS; SCREENING TOOL; ALERT DOCTORS; ALL-CAUSE; CRITERIA; POPULATION; POLYPHARMACY; PREVENTION; MORTALITY	Background Cardiovascular disease is a leading cause of death in older people, and the impact of being exposed or not exposed to preventive cardiovascular medicines is accordingly high. Underutilization of beneficial drugs is common, but prevalence estimates differ across settings, knowledge on predictors is limited, and clinical consequences are rarely investigated. Methods Using data from a prospective population-based cohort study, we assessed the prevalence, determinants, and outcomes of medication underuse based on cardiovascular criteria from Screening Tool To Alert to Right Treatment (START). Results Medication underuse was present in 69.1% of 1454 included participants (mean age 71.1 +/- 6.1 years) and was significantly associated with frailty (odds ratio: 2.11 [95% confidence interval: 1.24-3.63]), body mass index (1.03 [1.01-1.07] per kg/m(2)), and inversely with the number of prescribed drugs (0.84 [0.79-0.88] per drug). Using this information for adjustment in a follow-up evaluation (mean follow-up time 2.24 years) on cardiovascular and competing outcomes, we found no association of medication underuse with cardiovascular events (fatal and non-fatal) (hazard ratio: 1.00 [0.65-1.56]), but observed a significant association of medication underuse with competing deaths from non-cardiovascular causes (2.52 [1.01-6.30]). Conclusion Medication underuse was associated with frailty and adverse non-cardiovascular clinical outcomes. This may suggest that cardiovascular drugs were withheld because of serious co-morbidity or that concurrent illness can preclude benefit from cardiovascular prevention. In the latter case, adapted prescribing criteria should be developed and evaluated in those patients.	[Meid, Andreas D.; Quinzler, Renate; Freigofas, Julia; Haefeli, Walter E.] Heidelberg Univ, Dept Clin Pharmacol & Pharmacoepidemiol, Heidelberg, Germany; [Saum, Kai-Uwe; Schoettker, Ben; Brenner, Hermann] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany; [Holleczek, Bernd] Saarland Canc Registry, Saarbrucken, Germany; [Heider, Dirk; Koenig, Hans-Helmut] Univ Med Ctr Hamburg Eppendorf, Dept Hlth Econ & Hlth Serv Res, Hamburg Ctr Hlth Econ, Hamburg, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Hamburg; University Medical Center Hamburg-Eppendorf	Haefeli, WE (corresponding author), Heidelberg Univ, Dept Clin Pharmacol & Pharmacoepidemiol, Neuenheimer Feld 410, Heidelberg, Germany.	walter.emil.haefeli@med.uni-heidelberg.de	König, Hans-Helmut/P-1211-2018; Brenner, Hermann/B-4627-2017; Haefeli, Walter Emil/AAJ-3024-2020; Brenner, Hermann/ABE-6383-2020; Schöttker, Ben/F-8183-2014	König, Hans-Helmut/0000-0001-5711-6862; Brenner, Hermann/0000-0002-6129-1572; Haefeli, Walter Emil/0000-0003-0672-6876; Brenner, Hermann/0000-0002-6129-1572; Schöttker, Ben/0000-0002-1217-4521	German Federal Ministry of Education and Research (BMBF, Berlin, Germany) [01ET0717, 01ET1004B, 01GY1320B]	German Federal Ministry of Education and Research (BMBF, Berlin, Germany)(Federal Ministry of Education & Research (BMBF))	This work was supported in part by institutional funding and ADM, RQ, and JF received funding from the German Federal Ministry of Education and Research (BMBF, Berlin, Germany) under Grant Numbers 01ET0717, 01ET1004B, and 01GY1320B. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barry PJ, 2007, AGE AGEING, V36, P632, DOI 10.1093/ageing/afm118; Beer C, 2011, BRIT J CLIN PHARMACO, V71, P592, DOI 10.1111/j.1365-2125.2010.03875.x; Bohm M, 2013, AM HEART J, V166, P306, DOI 10.1016/j.ahj.2013.04.016; Byatt K, 2014, EVID BASED MED; Cherubini A, 2012, DRUG AGING, V29, P463, DOI 10.2165/11631750-000000000-00000; Cooper JA, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0484-6; Dalleur O, 2012, DRUG AGING, V29, P829, DOI 10.1007/s40266-012-0016-1; De Wilde S, 2003, LANCET, V362, P746, DOI 10.1016/S0140-6736(03)14216-X; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Gallagher P, 2008, INT J CLIN PHARM TH, V46, P72; Gallagher P, 2007, J CLIN PHARM THER, V32, P113, DOI 10.1111/j.1365-2710.2007.00793.x; Gallagher PF, 2011, CLIN PHARMACOL THER, V89, P845, DOI 10.1038/clpt.2011.44; Gallagher P, 2011, EUR J CLIN PHARMACOL, V67, P1175, DOI 10.1007/s00228-011-1061-0; Galvin R, 2014, EUR J CLIN PHARM; Gaw A, 2004, INT J CLIN PRACT, V58, P777, DOI 10.1111/j.1368-5031.2004.00300.x; Glynn RJ, 2006, J CLIN EPIDEMIOL, V59, P819, DOI 10.1016/j.jclinepi.2005.12.012; Hanlon JT, 2011, J AM GERIATR SOC, V59, P1412, DOI 10.1111/j.1532-5415.2011.03522.x; Hughes CM, 2004, DRUG AGING, V21, P793, DOI 10.2165/00002512-200421120-00004; Kuijpers MAJ, 2008, BRIT J CLIN PHARMACO, V65, P130, DOI 10.1111/j.1365-2125.2007.02961.x; Liu CL, 2012, ARCH GERONTOL GERIAT, V55, P148, DOI 10.1016/j.archger.2011.07.001; Neutel CI, 2007, CAN J PUBLIC HEALTH, V98, P412, DOI 10.1007/BF03405430; Ryan C, 2009, BRIT J CLIN PHARMACO, V68, P936, DOI 10.1111/j.1365-2125.2009.03531.x; Saum KU, 2012, J AM GERIATR SOC, V60, P2110, DOI 10.1111/j.1532-5415.2012.04192.x; Schottker B, 2013, AM J CLIN NUTR, V97, P782, DOI 10.3945/ajcn.112.047712; Steinman MA, 2006, J AM GERIATR SOC, V54, P1516, DOI 10.1111/j.1532-5415.2006.00889.x; Szadkowska I, 2010, ARCH GERONTOL GERIAT, V50, P114, DOI 10.1016/j.archger.2008.12.012; Ubeda Amalia, 2012, Pharmacy Pract (Granada), V10, P83, DOI 10.4321/s1886-36552012000200004; Weiss NS, 2014, EUR J EPIDEMIOL, V29, P147, DOI 10.1007/s10654-014-9899-y; Witticke D, 2013, DRUG SAFETY, V36, P31, DOI 10.1007/s40264-012-0007-5; Zint K, 2010, PHARMACOEPIDEM DR S, V19, P1248, DOI 10.1002/pds.2031	30	27	27	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 19	2015	10	8							e0136339	10.1371/journal.pone.0136339	http://dx.doi.org/10.1371/journal.pone.0136339			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CP6SN	26288222	Green Published, gold, Green Submitted			2023-01-03	WOS:000360018600132
J	Dold, L; Ahlenstiel, G; Althausen, E; Luda, C; Schwarze-Zander, C; Boesecke, C; Wasmuth, JC; Rockstroh, JK; Spengler, U				Dold, Leona; Ahlenstiel, Golo; Althausen, Eva; Luda, Carolin; Schwarze-Zander, Carolynne; Boesecke, Christoph; Wasmuth, Jan-Christian; Rockstroh, Juergen Kurt; Spengler, Ulrich			Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART)	PLOS ONE			English	Article							ANTIGEN CLASS-I; HEPATITIS-C; REPLICATION CAPACITY; DISEASE PROGRESSION; VIRAL REPLICATION; HIV-INFECTION; INITIATION; ALLELES; GENOTYPE; OUTCOMES	Background and aims HLA class I alleles, in particular HLA-B*57, constitute the most consistent host factor determining outcomes in untreated HCV- and HIV-infection. In this prospective cohort study, we analysed the impact of HLA class I alleles on all-cause mortality in patients with HIV-, HCV-and HIV/HCV-co-infection receiving HAART. Methods In 2003 HLA-A and B alleles were determined and patients were prospectively followed in 3-month intervals until 2013 or death. HLA-A and B alleles were determined by strand-specific oligonucleotide hybridisation and PCR in 468 Caucasian patients with HCV-(n=120), HIV- (n=186) and HIV/HCV-infection (n=162). All patients with HIV-infection were on HAART. In each patient group, HLA class I-associated survival was analysed by Kaplan-Meier method and Cox regression analysis. Results At recruitment the proportion of patients carrying a HLA-B*57 allele differed between HIV-(12.9%) and HCV-infection (4.2%). Kaplan Meier analysis revealed significantly increased mortality in HLA-B*57-positive patients with HIV-infection (p=0.032) and HIV/HCV-co-infection (p=0.004), which was apparently linked to non-viral infections. Cox logistic regression analysis confirmed HLA-B*57 (p=0.001), serum gamma-glutamyltranspeptidase (p=0.003), serum bilirubin (p=0.022) and CD4 counts (p=0.041) as independent predictors of death in HIV-infected patients. Conclusion Differences in the prevalence of HLA-B*57 at study entry between HIV- and HCV-infected patients may reflect immune selection in the absence of antiviral therapy. When patients were treated with HAART, however, HLA-B*57 was associated with increased mortality and risk to die from bacterial infections and sepsis, suggesting an ambiguous role of HLAB*57 for survival in HIV/HCV infection depending on the circumstances.	[Dold, Leona; Althausen, Eva; Luda, Carolin; Schwarze-Zander, Carolynne; Boesecke, Christoph; Wasmuth, Jan-Christian; Rockstroh, Juergen Kurt; Spengler, Ulrich] Univ Bonn, Dept Internal Med 1, Bonn, Germany; [Ahlenstiel, Golo] Univ Sydney, Westmead Clin Sch, Sydney, NSW 2006, Australia; [Dold, Leona; Althausen, Eva; Luda, Carolin; Schwarze-Zander, Carolynne; Boesecke, Christoph; Wasmuth, Jan-Christian; Rockstroh, Juergen Kurt; Spengler, Ulrich] German Ctr Infect Res DZIF, Cologne, Germany	University of Bonn; University of Sydney; German Center for Infection Research; University of Cologne	Dold, L (corresponding author), Univ Bonn, Dept Internal Med 1, Bonn, Germany.	Leona.Dold@ukb.uni-bonn.de	Ahlenstiel, Golo/U-1990-2017	Ahlenstiel, Golo/0000-0003-0026-1457	German Ministry for Research and Education (Bundesministerium fur Forschung und Bildung: Kompetenznetz HIV/AIDS); German center for infection research (DZIF)	German Ministry for Research and Education (Bundesministerium fur Forschung und Bildung: Kompetenznetz HIV/AIDS); German center for infection research (DZIF)	This work was supported by research grants to J.R. and U.S. from the German Ministry for Research and Education (Bundesministerium fur Forschung und Bildung: Kompetenznetz HIV/AIDS), and the German center for infection research (DZIF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahlenstiel G, 2007, CLIN VACCINE IMMUNOL, V14, P1266, DOI 10.1128/CVI.00169-07; Altfeld M, 2003, AIDS, V17, P2581, DOI 10.1097/00002030-200312050-00005; Bailey JR, 2009, J VIROL, V83, P88, DOI 10.1128/JVI.01958-08; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boesecke C, 2012, SEMIN LIVER DIS, V32, P130, DOI 10.1055/s-0032-1316468; Boutwell CL, 2009, J VIROL, V83, P2460, DOI 10.1128/JVI.01970-08; Brockman MA, 2010, J VIROL, V84, P11937, DOI 10.1128/JVI.01086-10; Brumme ZL, 2007, J INFECT DIS, V195, P1694, DOI 10.1086/516789; Carrington M, 2003, ANNU REV MED, V54, P535, DOI 10.1146/annurev.med.54.101601.152346; Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7; Fellay J, 2007, SCIENCE, V317, P944, DOI 10.1126/science.1143767; Feuth T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059302; Frater AJ, 2007, J VIROL, V81, P6742, DOI 10.1128/JVI.00022-07; French AL, 2013, J INFECT DIS, V208, P679, DOI 10.1093/infdis/jit225; French MA, 2009, J INFECT DIS, V200, P1212, DOI 10.1086/605890; Gonzalez VD, 2009, J VIROL, V83, P11407, DOI 10.1128/JVI.01211-09; Goulder PJR, 2012, IMMUNITY, V37, P426, DOI 10.1016/j.immuni.2012.09.005; Kim AY, 2011, GASTROENTEROLOGY, V140, P686, DOI 10.1053/j.gastro.2010.09.042; Kuniholm MH, 2011, J VIROL, V85, P10826, DOI 10.1128/JVI.00804-11; Kuniholm MH, 2010, HEPATOLOGY, V51, P1514, DOI 10.1002/hep.23515; Lederman MM, 2013, ADV IMMUNOL, V119, P51, DOI 10.1016/B978-0-12-407707-2.00002-3; Lo Re III V, 2014, ANN INTERN MED, V160, P369; Lopez-Larrea C, 2005, ARTHRITIS RHEUM-US, V52, P275, DOI 10.1002/art.20722; Lopez-Medrano F, 2011, TRANSPLANTATION, V92, P543, DOI 10.1097/TP.0b013e318225dbae; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; McKiernan SM, 2004, HEPATOLOGY, V40, P108, DOI 10.1002/hep.20261; Norris S, 2004, LIVER TRANSPLANT, V10, P1271, DOI 10.1002/lt.20233; Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271; Qurishi N, 2003, LANCET, V362, P1708, DOI 10.1016/S0140-6736(03)14844-1; Rauch A, 2008, CLIN INFECT DIS, V46, P1921, DOI 10.1086/588479; Shata Mohamed Tarek M, 2013, J Clin Pathol, V66, P967, DOI 10.1136/jclinpath-2013-201581	31	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2015	10	8							e0134158	10.1371/journal.pone.0134158	http://dx.doi.org/10.1371/journal.pone.0134158			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO1VB	26241854	Green Published, Green Submitted, gold			2023-01-03	WOS:000358942700035
J	Kayvanpour, E; Mansi, T; Sedaghat-Hamedani, F; Amr, A; Neumann, D; Georgescu, B; Seegerer, P; Kamen, A; Haas, J; Frese, KS; Irawati, M; Wirsz, E; King, V; Buss, S; Mereles, D; Zitron, E; Keller, A; Katus, HA; Comaniciu, D; Meder, B				Kayvanpour, Elham; Mansi, Tommaso; Sedaghat-Hamedani, Farbod; Amr, Ali; Neumann, Dominik; Georgescu, Bogdan; Seegerer, Philipp; Kamen, Ali; Haas, Jan; Frese, Karen S.; Irawati, Maria; Wirsz, Emil; King, Vanessa; Buss, Sebastian; Mereles, Derliz; Zitron, Edgar; Keller, Andreas; Katus, Hugo A.; Comaniciu, Dorin; Meder, Benjamin			Towards Personalized Cardiology: Multi-Scale Modeling of the Failing Heart	PLOS ONE			English	Article							CARDIAC RESYNCHRONIZATION THERAPY; ELECTROMECHANICAL MODEL; 12-LEAD ECG; PREDICTION; FRAMEWORK; ELECTROPHYSIOLOGY; UNCERTAINTY; MECHANICS; FAILURE; CRT	Background Despite modern pharmacotherapy and advanced implantable cardiac devices, overall prognosis and quality of life of HF patients remain poor. This is in part due to insufficient patient stratification and lack of individualized therapy planning, resulting in less effective treatments and a significant number of non-responders. Methods and Results State-of-the-art clinical phenotyping was acquired, including magnetic resonance imaging (MRI) and biomarker assessment. An individualized, multi-scale model of heart function covering cardiac anatomy, electrophysiology, biomechanics and hemodynamics was estimated using a robust framework. The model was computed on n=46 HF patients, showing for the first time that advanced multi-scale models can be fitted consistently on large cohorts. Novel multi-scale parameters derived from the model of all cases were analyzed and compared against clinical parameters, cardiac imaging, lab tests and survival scores to evaluate the explicative power of the model and its potential for better patient stratification. Model validation was pursued by comparing clinical parameters that were not used in the fitting process against model parameters. Conclusion This paper illustrates how advanced multi-scale models can complement cardiovascular imaging and how they could be applied in patient care. Based on obtained results, it becomes conceivable that, after thorough validation, such heart failure models could be applied for patient management and therapy planning in the future, as we illustrate in one patient of our cohort who received CRT-D implantation.	[Kayvanpour, Elham; Sedaghat-Hamedani, Farbod; Amr, Ali; Haas, Jan; Frese, Karen S.; Irawati, Maria; Buss, Sebastian; Mereles, Derliz; Zitron, Edgar; Katus, Hugo A.; Meder, Benjamin] Heidelberg Univ, Dept Med 3, Heidelberg, Germany; [Kayvanpour, Elham; Sedaghat-Hamedani, Farbod; Amr, Ali; Haas, Jan; Frese, Karen S.; Katus, Hugo A.; Meder, Benjamin] DZHK German Ctr Cardiovasc Res, Heidelberg, Germany; [Mansi, Tommaso; Neumann, Dominik; Georgescu, Bogdan; Seegerer, Philipp; Kamen, Ali; Comaniciu, Dorin] Siemens Corp, Corp Technol, Imaging & Comp Vis, Princeton, NJ USA; [Wirsz, Emil] Siemens AG, Corp Technol, Erlangen, Germany; [King, Vanessa] Siemens Corp, Corp Technol, Sensor Technol, Princeton, NJ USA; [Keller, Andreas] Biomarker Discovery Ctr Heidelberg, Heidelberg, Germany; [Keller, Andreas] Univ Saarland, Dept Human Genet, Homburg, Germany; [Katus, Hugo A.; Meder, Benjamin] Klaus Tschira Inst Computat Cardiol, Heidelberg, Germany	Ruprecht Karls University Heidelberg; German Centre for Cardiovascular Research; Siemens AG; Siemens AG; Siemens Germany; Siemens AG; Saarland University	Meder, B (corresponding author), Heidelberg Univ, Dept Med 3, Heidelberg, Germany.	Benjamin.Meder@med.uni-heidelberg.de	Seegerer, Philipp/AAE-3706-2020; Keller, Andreas/ABB-6412-2021	Seegerer, Philipp/0000-0002-4707-7991; Keller, Andreas/0000-0002-5361-0895; Comaniciu, Dorin/0000-0002-5238-8647; Mereles, Derliz/0000-0001-9601-7103	DZHK (German Centre for Cardiovascular Research); BMBF (German Ministry of Education and Research); European Union [GA 306031]	DZHK (German Centre for Cardiovascular Research); BMBF (German Ministry of Education and Research)(Federal Ministry of Education & Research (BMBF)); European Union(European Commission)	This work has been supported by the DZHK (German Centre for Cardiovascular Research), by the BMBF (German Ministry of Education and Research), and by the European Union FP7 (BestAgeing, GA 306031). This work was in part conducted within an industry supported project (Siemens AG, Siemens Research Project). Siemens provided support in the form of salaries for authors TM, DN, BG, PS, AK, EW, VK and DC, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Ackerman MJ, 2011, HEART RHYTHM, V8, P1308, DOI [10.1016/j.hrthm.2011.05.020, 10.1093/europace/eur245]; Allard J, 2007, STUD HEALTH TECHNOL, V125, P13; ARTS T, 1979, ANN BIOMED ENG, V7, P299, DOI 10.1007/BF02364118; Ashikaga H, 2013, HEART RHYTHM, V10, P1109, DOI 10.1016/j.hrthm.2013.04.015; Baillargeon B, 2014, EUR J MECH A-SOLID, V48, P38, DOI 10.1016/j.euromechsol.2014.04.001; Boulakia M, 2010, ANN BIOMED ENG, V38, P1071, DOI 10.1007/s10439-009-9873-0; Campbell SG, 2011, J R SOC INTERFACE, V8, P1550, DOI 10.1098/rsif.2011.0184; Comas O, 2008, LECT NOTES COMPUT SC, V5104, P28, DOI 10.1007/978-3-540-70521-5_4; Dye C., 2013, RESEARCH FOR UNIVERS; Georgescu B RS, 2013, MICCAI WORKSHOP2013; Guetter C, 2011, I S BIOMED IMAGING, P590, DOI 10.1109/ISBI.2011.5872476; Holzapfel GA, 2009, PHILOS T R SOC A, V367, P3445, DOI 10.1098/rsta.2009.0091; Hunter PJ, 2003, NAT REV MOL CELL BIO, V4, P237, DOI 10.1038/nrm1054; Huntjens PR, 2014, EUROPACE, V16, P62, DOI 10.1093/europace/euu231; Kerckhoffs RCP, 2008, PROG BIOPHYS MOL BIO, V97, P543, DOI 10.1016/j.pbiomolbio.2008.02.024; Kerckhoffs RCP, 2007, ANN BIOMED ENG, V35, P1, DOI 10.1007/s10439-006-9212-7; Konukoglu E, 2011, PROG BIOPHYS MOL BIO, V107, P134, DOI 10.1016/j.pbiomolbio.2011.07.002; Krishnamurthy A, 2013, J COMPUT PHYS, V244, P4, DOI 10.1016/j.jcp.2012.09.015; Kuijpers NHL, 2012, J CARDIOVASC TRANSL, V5, P159, DOI 10.1007/s12265-012-9346-y; Land S, 2013, INTERFACE FOCUS, V3, DOI 10.1098/rsfs.2012.0076; Lecoq G, 2005, EUR HEART J, V26, P1094, DOI 10.1093/eurheartj/ehi146; Levy WC, 2006, CIRCULATION, V113, P1424, DOI 10.1161/CIRCULATIONAHA.105.584102; Mansi T, 2010, APPLICATION TO TETRA; Marchesseau S, 2013, MED IMAGE ANAL, V17, P816, DOI 10.1016/j.media.2013.04.012; Marchesseau S, 2013, BIOMECH MODEL MECHAN, V12, P815, DOI 10.1007/s10237-012-0446-z; McMurray JJV, 2012, EUR HEART J, V33, P1787, DOI 10.1093/eurheartj/ehs104; Mitchell CC, 2003, B MATH BIOL, V65, P767, DOI 10.1016/S0092-8240(03)00041-7; Moat NE, 2011, J AM COLL CARDIOL, V58, P2130, DOI 10.1016/j.jacc.2011.08.050; Mollema SA, 2007, AM J CARDIOL, V100, P1665, DOI 10.1016/j.amjcard.2007.06.071; Neumann D, 2014, I S BIOMED IMAGING, P935, DOI 10.1109/ISBI.2014.6868025; Neumann D, 2014, LECT NOTES COMPUT SC, V8674, P9, DOI 10.1007/978-3-319-10470-6_2; Ng J, 2012, J AM COLL CARDIOL, V60, P423, DOI 10.1016/j.jacc.2012.03.029; Niederer SA, 2008, PROG BIOPHYS MOL BIO, V96, P90, DOI 10.1016/j.pbiomolbio.2007.08.001; Niederer SA, 2011, CARDIOVASC RES, V89, P336, DOI 10.1093/cvr/cvq318; NIELSEN PMF, 1991, AM J PHYSIOL, V260, pH1365, DOI 10.1152/ajpheart.1991.260.4.H1365; Nordsletten DA, 2011, PROG BIOPHYS MOL BIO, V104, P77, DOI 10.1016/j.pbiomolbio.2009.11.001; Potse M, 2014, EUROPACE EUROPEAN PA, V16, piv56, DOI [10.1093/europace/euu257, DOI 10.1093/EUR0PACE/EUU257]; Powell MJD, 2006, NONCON OPTIM ITS APP, V83, P255; Rapaka S, 2012, LECT NOTES COMPUT SC, V7511, P33, DOI 10.1007/978-3-642-33418-4_5; Relan J, 2011, INTERFACE FOCUS, V1, P396, DOI 10.1098/rsfs.2010.0041; Seegerer P, 2015, LECT NOTES COMPUT SC, V8896, P204, DOI 10.1007/978-3-319-14678-2_21; Segers P, 2008, JOURNAL OF ENGINEERI, V222, P417; Sermesant A, 2006, IEEE T MED IMAGING, V25, P612, DOI 10.1109/TMI.2006.872746; Sermesant M, 2012, MED IMAGE ANAL, V16, P201, DOI 10.1016/j.media.2011.07.003; Sermesant Maxime, 2008, Heart Fail Clin, V4, P289, DOI 10.1016/j.hfc.2008.02.014; ten Tusscher KHWJ, 2004, AM J PHYSIOL-HEART C, V286, pH1573, DOI 10.1152/ajpheart.00794.2003; Tobon-Gomez C, 2013, MED BIOL ENG COMPUT, V51, P1235, DOI 10.1007/s11517-013-1044-7; Trayanova NA, 2011, CIRC RES, V108, P113, DOI 10.1161/CIRCRESAHA.110.223610; Vogel B, 2013, EUR HEART J, V34, P2812, DOI 10.1093/eurheartj/eht256; Wallman M, 2014, MED IMAGE ANAL, V18, P228, DOI 10.1016/j.media.2013.10.006; Xi JH, 2013, MED IMAGE ANAL, V17, P133, DOI 10.1016/j.media.2012.08.001; Zettinig O, 2014, MED IMAGE ANAL, V18, P1361, DOI 10.1016/j.media.2014.04.011; Zettinig O, 2013, LECT NOTES COMPUT SC, V7945, P249, DOI 10.1007/978-3-642-38899-6_30; Zheng YF, 2008, IEEE T MED IMAGING, V27, P1668, DOI 10.1109/TMI.2008.2004421; Zhou LF, 2014, CIRC-ARRHYTHMIA ELEC, V7, P143, DOI 10.1161/CIRCEP.113.000600	56	51	52	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2015	10	7							e0134869	10.1371/journal.pone.0134869	http://dx.doi.org/10.1371/journal.pone.0134869			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO0JY	26230546	Green Submitted, Green Published, gold			2023-01-03	WOS:000358838400180
J	Clerencia-Sierra, M; Calderon-Larranaga, A; Martinez-Velilla, N; Vergara-Mitxeltorena, I; Aldaz-Herce, P; Poblador-Plou, B; Machon-Sobrado, M; Egues-Olazabal, N; Abellan-van Kan, G; Prados-Torres, A				Clerencia-Sierra, Mercedes; Calderon-Larranaga, Amaia; Martinez-Velilla, Nicolas; Vergara-Mitxeltorena, Itziar; Aldaz-Herce, Pablo; Poblador-Plou, Beatriz; Machon-Sobrado, Monica; Eguees-Olazabal, Nerea; Abellan-van Kan, Gabor; Prados-Torres, Alexandra			Multimorbidity Patterns in Hospitalized Older Patients: Associations among Chronic Diseases and Geriatric Syndromes	PLOS ONE			English	Article							HEALTH-SERVICES; RISK-FACTORS; FALLS; COMMUNITY; COMORBIDITY; DISABILITY; ADULTS; CARE; METAANALYSIS; POPULATION	Background/Objectives The clinical status of older individuals with multimorbidity can be further complicated by concomitant geriatric syndromes. This study explores multimorbidity patterns, encompassing both chronic diseases and geriatric syndromes, in geriatric patients attended in an acute hospital setting. Design Retrospective observational study. Setting Unit of Social and Clinical Assessment (UVSS), Miguel Servet University Hospital (HUMS), Zaragoza (Spain). Year, 2011. Participants A total of 924 hospitalized patients aged 65 years or older. Measurements Data on patients' clinical, functional, cognitive and social statuses were gathered through comprehensive geriatric assessments. To identify diseases and/or geriatric syndromes that cluster into patterns, an exploratory factor analysis was applied, stratifying by sex. The factors can be interpreted as multimorbidity patterns, i.e., diseases non-randomly associated with each other within the study population. The resulting patterns were clinically assessed by several physicians. Results The mean age of the study population was 82.1 years (SD 7.2). Multimorbidity burden was lower in men under 80 years, but increased in those over 80. Immobility, urinary incontinence, hypertension, falls, dementia, cognitive decline, diabetes and arrhythmia were among the 10 most frequent health problems in both sexes, with prevalence rates above 20%. Four multimorbidity patterns were identified that were present in both sexes: Cardiovascular, Induced Dependency, Falls and Osteoarticular. The number of conditions comprising these patterns was similar in men and women. Conclusion The existence of specific multimorbidity patterns in geriatric patients, such as the Induced Dependency and Falls patterns, may facilitate the early detection of vulnerability to stressors, thus helping to avoid negative health outcomes such as functional disability.	[Clerencia-Sierra, Mercedes] Miguel Servet Univ Hosp, Unit Social & Clin Assessment UVSS, Zaragoza, Spain; [Clerencia-Sierra, Mercedes; Calderon-Larranaga, Amaia; Poblador-Plou, Beatriz; Prados-Torres, Alexandra] Miguel Servet Univ Hosp, IIS Aragon, EpiChron Res Grp Chron Dis, Aragon Hlth Sci Inst IACS, Zaragoza, Spain; [Calderon-Larranaga, Amaia; Martinez-Velilla, Nicolas; Vergara-Mitxeltorena, Itziar; Poblador-Plou, Beatriz; Machon-Sobrado, Monica; Prados-Torres, Alexandra] Res Network Hlth Serv Chron Dis REDISSEC, Madrid, Spain; [Martinez-Velilla, Nicolas] Navarra Hlth Serv Osasunbidea, Geriatr Serv, Pamplona, Spain; [Vergara-Mitxeltorena, Itziar; Machon-Sobrado, Monica; Eguees-Olazabal, Nerea] IIS Biodonostia, Res Unit AP OSIS Gipuzkoa, San Sebastian, Spain; [Aldaz-Herce, Pablo] Navarra Hlth Serv Osasunbidea, San Juan Hlth Ctr, Pamplona, Spain; [Abellan-van Kan, Gabor] CHU Toulouse Purpan, Dept Geriatr Med, Gerontopole Toulouse, Frailty Day Hosp, Toulouse, France	Miguel Servet University Hospital; Miguel Servet University Hospital; Instituto de Investigacion Sanitaria Biodonostia; CHU de Toulouse	Calderon-Larranaga, A (corresponding author), Miguel Servet Univ Hosp, IIS Aragon, EpiChron Res Grp Chron Dis, Aragon Hlth Sci Inst IACS, Zaragoza, Spain.	acalderon.iacs@aragon.es	Poblador-Plou, Beatriz/ABC-7915-2020; Martinez-Velilla, Nicolas/A-6942-2017; Calderón-Larrañaga, Amaia/ABC-6828-2021; Prados-Torres, Alexandra/P-5818-2017	Poblador-Plou, Beatriz/0000-0002-5119-5093; Martinez-Velilla, Nicolas/0000-0001-9576-9960; Calderón-Larrañaga, Amaia/0000-0001-9064-9222; Prados-Torres, Alexandra/0000-0002-5704-6056	Trans-Pyrenean Biomedical Research Network (REFBIO) [REFBIO13/BIOD/002]	Trans-Pyrenean Biomedical Research Network (REFBIO)	This project has been funded by the Trans-Pyrenean Biomedical Research Network (REFBIO) for the establishment of a network of stable collaboration among biomedical research centers in the Pyrenees Area (European Program INTERREG IV POCTEFA-A; File: REFBIO13/BIOD/002). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albertsen PC, 2014, EUR UROL, V65, P565, DOI 10.1016/j.eururo.2013.10.032; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Bardales MY, 2012, REV ESP GERIATR GERO, V47, P220, DOI [10.1016/j.regg.2012.02.014, DOI 10.1016/J.REGG.2012.02.014]; Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Boyd CM, 2011, J AM GERIATR SOC, V59, P797, DOI 10.1111/j.1532-5415.2011.03391.x; CAMPBELL AJ, 1990, AGE AGEING, V19, P136, DOI 10.1093/ageing/19.2.136; Chen XJ, 2014, CLIN INTERV AGING, V9, P433, DOI 10.2147/CIA.S45300; Cigolle CT, 2007, ANN INTERN MED, V147, P156, DOI 10.7326/0003-4819-147-3-200708070-00004; Defloor T, 2005, J WOUND OSTOMY CONT, V32, P302, DOI 10.1097/00152192-200509000-00006; Dodge HH, 2005, GERONTOLOGIST, V45, P222, DOI 10.1093/geront/45.2.222; Donald RP, 1985, FACTOR ANAL RELATED; Dong HJ, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-120; Formiga F, 2013, EUR J INTERN MED, V24, P40, DOI 10.1016/j.ejim.2012.11.003; Gill TM, 2010, JAMA-J AM MED ASSOC, V304, P1919, DOI 10.1001/jama.2010.1568; Guillen Llera F, 1972, REV ESP GERIATR GERO, V7, P339; Harwood RH, 2001, AGE AGEING, V30, P13, DOI 10.1093/ageing/30.suppl_4.13; Inouye SK, 2007, J AM GERIATR SOC, V55, P780, DOI 10.1111/j.1532-5415.2007.01156.x; John R, 2003, GERONTOLOGIST, V43, P649, DOI 10.1093/geront/43.5.649; Jones DM, 2004, J AM GERIATR SOC, V52, P1929, DOI 10.1111/j.1532-5415.2004.52521.x; Kirchberger I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030556; Konecny T, 2014, AM J CARDIOL, V114, P272, DOI 10.1016/j.amjcard.2014.04.030; Kubinger K. D., 2003, PSYCHOL SCI, V45, P106, DOI DOI 10.1177/014662169101500105; Kvelde T, 2013, J AM GERIATR SOC, V61, P694, DOI 10.1111/jgs.12209; Lafont C, 2011, J NUTR HEALTH AGING, V15, P645, DOI 10.1007/s12603-011-0335-7; Lee PG, 2009, J AM GERIATR SOC, V57, P511, DOI 10.1111/j.1532-5415.2008.02150.x; Lyles KW, 2001, J AM GERIATR SOC, V49, P827; MAHONEY F I, 1965, Md State Med J, V14, P61; Marengoni A, 2011, AGEING RES REV, V10, P430, DOI 10.1016/j.arr.2011.03.003; Marengoni A, 2009, J AM GERIATR SOC, V57, P225, DOI 10.1111/j.1532-5415.2008.02109.x; Montalvo JIG., 2008, REV ESP GERIATR GERO, V43, P316, DOI 10.1016/S0211-139X(08)73574-1; Moyer VA, 2012, ANN INTERN MED, V157, P197, DOI 10.7326/0003-4819-157-3-201208070-00462; Multimorbidity. AGSEPotCoOAw, 2012, J AM GERIATR SOC, V60, P1957, DOI DOI 10.1111/J.1532-5415.2012.04187.X; Pagliarulo V, 2012, EUR UROL, V61, P11, DOI 10.1016/j.eururo.2011.08.026; Papaleontiou M, 2010, J AM GERIATR SOC, V58, P1353, DOI 10.1111/j.1532-5415.2010.02920.x; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; Prados-Torres A, 2014, J CLIN EPIDEMIOL, V67, P254, DOI 10.1016/j.jclinepi.2013.09.021; Prados-Torres A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032190; Rubenstein LZ, 2002, CLIN GERIATR MED, V18, P141, DOI 10.1016/S0749-0690(02)00002-2; Safford MM, 2007, J GEN INTERN MED, V22, P382, DOI 10.1007/s11606-007-0307-0; Salisbury C, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X548929; Schafer I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015941; Smith SM, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5205; Sociedad Espanola de Geriatria y Gerontologia SEdR, 2008, GUIA BUEN PRACT CLIN; Steinman MA, 2012, J AM GERIATR SOC, V60, P1872, DOI 10.1111/j.1532-5415.2012.04158.x; TINETTI ME, 1995, JAMA-J AM MED ASSOC, V273, P1348, DOI 10.1001/jama.273.17.1348; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; Valderas JM, 2009, ANN FAM MED, V7, P357, DOI 10.1370/afm.983; van den Akker M, 2001, J CLIN EPIDEMIOL, V54, P675, DOI 10.1016/S0895-4356(00)00358-9; World Health Organization, 2007, MAGN FALLS WORLDW OV	49	52	55	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2015	10	7							e0132909	10.1371/journal.pone.0132909	http://dx.doi.org/10.1371/journal.pone.0132909			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CN7NT	26208112	Green Published, Green Submitted, gold			2023-01-03	WOS:000358622000044
J	Ding, LL; Zhang, XY; Guo, HL; Yuan, JL; Li, SJ; Hu, WL; Golden, T; Wu, N				Ding, Lingling; Zhang, Xiaoyu; Guo, Hongliang; Yuan, Junliang; Li, Shujuan; Hu, Wenli; Golden, Teresa; Wu, Ning			The Functional Study of a Chinese Herbal Compounded Antidepressant Medicine - Jie Yu Chu Fan Capsule on Chronic Unpredictable Mild Stress Mouse Model	PLOS ONE			English	Article							BANXIA-HOUPU DECOCTION; MAJOR DEPRESSIVE DISORDER; EXTRACELLULAR SEROTONIN; GARDENIA-JASMINOIDES; SUCROSE PREFERENCE; OXIDATIVE STRESS; NEUROPEPTIDE-Y; RATS; FLUOXETINE; BRAIN	Jie Yu Chu Fan capsule (JYCF) is a new compounded Chinese herbal medicine for the treatment of depression. The present study was designed to explore the antidepressant effects and the possible mechanisms of JYCF by using chronic unpredictable mild stress (CUMS) mouse model and comparing results to that of fluoxetine. Behavioral tests including an open field test, sucrose preference test and forced swim test were performed to evaluate the antidepressant effects of JYCF. The concentrations of monoamine neurotransmitters and metabolic products including norepinephrine (NE), 5-hydroxytryptamine (5-HT), dopamine (DA), 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA) and 3,4dihydroxyphenylacetic acid (DOPAC) in the cerebral cortex and hippocampus of mice were determined by means of high performance liquid chromatography with electrochemical detection (HPLC-EC). The results show that a successful mouse CUMS model was established through 5 weeks of continuous unpredictable stimulation, as indicated by the significant decrease in sucrose preference and locomotor activity and increase in immobility time in the forced swim test. Chronic treatment of JYCF (1.25, 2.5 and 5 g/kg) and fluoxetine (20mg/kg) significantly reversed the CUMS-induced behavioral abnormalities. JYCF (1.25, 2.5 and 5 g/kg) significantly increased NE in CUMS mouse prefrontal cortex (P < 0.01, P < 0.01, P < 0.05 respectively) and 5-HT in hippocampus (P < 0.05). In summary, our findings suggest that JYCF exerts comparable antidepressant-like effects to that of fluoxetine in CUMS mice. Besides, the antidepressant-like effect of JYCF is mediated by the increase of monoaminergic transmitters including 5-HT and NE.	[Ding, Lingling; Zhang, Xiaoyu; Guo, Hongliang; Yuan, Junliang; Li, Shujuan; Hu, Wenli] Capital Med Univ, Beijing Chaoyang Hosp, Dept Neurol, Beijing, Peoples R China; [Golden, Teresa; Wu, Ning] Southeastern Oklahoma State Univ, Dept Biol Sci, Durant, OK USA	Capital Medical University	Hu, WL (corresponding author), Capital Med Univ, Beijing Chaoyang Hosp, Dept Neurol, Beijing, Peoples R China.	huwenli@sina.com	Zhang, xiaoyu/GXA-3206-2022					Becker AE, 2013, NEW ENGL J MED, V369, P66, DOI 10.1056/NEJMra1110827; Brunner E, 2014, NEUROPSYCHOPHARMACOL, V39, P2549, DOI 10.1038/npp.2014.101; Casarotto PC, 2007, EUR NEUROPSYCHOPHARM, V17, P735, DOI 10.1016/j.euroneuro.2007.03.001; D'Aquila PS, 2000, EUR J PHARMACOL, V399, P43, DOI 10.1016/S0014-2999(00)00332-0; Elhwuegi AS, 2004, PROG NEURO-PSYCHOPH, V28, P435, DOI 10.1016/j.pnpbp.2003.11.018; Gao S, 2013, BEHAV BRAIN RES, V238, P79, DOI 10.1016/j.bbr.2012.10.015; Guo YS, 2004, PHYTOTHER RES, V18, P204, DOI 10.1002/ptr.1394; Hou CL, 2006, BRAIN RES, V1095, P154, DOI 10.1016/j.brainres.2006.04.026; Huang CK, 2015, NEUROCHEM RES, V40, P27, DOI 10.1007/s11064-014-1461-5; Iguchi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114024; Invernizzi R, 1996, PHARMACOL BIOCHEM BE, V54, P143, DOI 10.1016/0091-3057(95)02159-0; Jindal A, 2013, PHARMACOL BIOCHEM BE, V105, P63, DOI 10.1016/j.pbb.2013.01.020; KATZ RJ, 1981, NEUROSCI BIOBEHAV R, V5, P247, DOI 10.1016/0149-7634(81)90005-1; Kim JH, 2012, BIOMOL THER, V20, P214, DOI 10.4062/biomolther.2012.20.2.214; Kupfer DJ, 2012, LANCET, V379, P1045, DOI 10.1016/S0140-6736(11)60602-8; Li JM, 2003, LIFE SCI, V74, P55, DOI 10.1016/j.lfs.2003.06.030; Liu DX, 2014, BEHAV BRAIN RES, V264, P9, DOI 10.1016/j.bbr.2014.01.039; Liu Y, 2013, PHARMACOL BIOCHEM BE, V104, P27, DOI 10.1016/j.pbb.2012.12.024; Lucca G, 2009, NEUROCHEM INT, V54, P358, DOI 10.1016/j.neuint.2009.01.001; Luo DD, 2008, BRAIN RES BULL, V77, P8, DOI 10.1016/j.brainresbull.2008.05.010; Ma XC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020955; Ma ZQ, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/213739; Mahar I, 2014, NEUROSCI BIOBEHAV R, V38, P173, DOI 10.1016/j.neubiorev.2013.11.009; Mao QQ, 2011, PROG NEURO-PSYCHOPH, V35, P1144, DOI 10.1016/j.pnpbp.2011.03.017; Ng F, 2008, INT J NEUROPSYCHOPH, V11, P851, DOI 10.1017/S1461145707008401; Perez-Caballero L, 2014, EXPERT OPIN DRUG DIS, V9, P567, DOI 10.1517/17460441.2014.907790; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Qiu J, 2014, J ETHNOPHARMACOL, V152, P320, DOI 10.1016/j.jep.2014.01.004; Russo E, 2013, NEUROPHARMACOLOGY, V64, P371, DOI 10.1016/j.neuropharm.2012.06.039; RUTTER JJ, 1994, NEUROSCI LETT, V171, P183, DOI 10.1016/0304-3940(94)90635-1; Saenz JCB, 2006, BEHAV BRAIN RES, V169, P57, DOI 10.1016/j.bbr.2005.12.001; Shaft S, 2014, PHARMACOL BIOCHEM BE, V122, P234, DOI 10.1016/j.pbb.2014.03.029; Sun YQ, 2012, PHYTOTHER RES, V26, P67, DOI 10.1002/ptr.3516; Tao WW, 2014, MOLECULES, V19, P19350, DOI 10.3390/molecules191219350; Tian JS, 2010, NEUROSCI LETT, V479, P236, DOI 10.1016/j.neulet.2010.05.069; Walker FR, 2013, NEUROPHARMACOLOGY, V67, P304, DOI 10.1016/j.neuropharm.2012.10.002; Wang YM, 2005, PHYTOTHER RES, V19, P526, DOI 10.1002/ptr.1697; Whiteford HA, 2013, LANCET, V382, P1575, DOI 10.1016/S0140-6736(13)61611-6; Williamson EM, 2001, PHYTOMEDICINE, V8, P401, DOI 10.1078/0944-7113-00060; Willner P, 2005, NEUROPSYCHOBIOLOGY, V52, P90, DOI 10.1159/000087097; WILLNER P, 1987, PSYCHOPHARMACOLOGY, V93, P358; Willner P, 1997, PSYCHOPHARMACOLOGY, V134, P319, DOI 10.1007/s002130050456; Yi LT, 2009, PROG NEURO-PSYCHOPH, V33, P616, DOI 10.1016/j.pnpbp.2009.03.001; Zhang WY, 2004, PHYTOTHER RES, V18, P200, DOI 10.1002/ptr.1391; Zhou XJ, 2012, J ETHNOPHARMACOL, V139, P422, DOI 10.1016/j.jep.2011.11.027	45	18	20	2	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2015	10	7							e0133405	10.1371/journal.pone.0133405	http://dx.doi.org/10.1371/journal.pone.0133405			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RV	26186537	Green Published, gold, Green Submitted			2023-01-03	WOS:000358198700133
J	Braun, DL; Rauch, A; Aouri, M; Durisch, N; Eberhard, N; Anagnostopoulos, A; Ledergerber, B; Mullhaupt, B; Metzner, KJ; Decosterd, L; Boni, J; Weber, R; Fehr, J				Braun, Dominique L.; Rauch, Andri; Aouri, Manel; Durisch, Nina; Eberhard, Nadia; Anagnostopoulos, Alexia; Ledergerber, Bruno; Muellhaupt, Beat; Metzner, Karin J.; Decosterd, Laurent; Boeni, Juerg; Weber, Rainer; Fehr, Jan		Swiss HIV Cohort Study	A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients	PLOS ONE			English	Article							GENOTYPE 1 INFECTION; HEPATITIS-C; TREATMENT FAILURE; OPEN-LABEL; TELAPREVIR; SOFOSBUVIR; PHARMACOKINETICS; RETREATMENT; RESISTANCE; LEDIPASVIR	Background The efficacy of first-generation protease inhibitor based triple-therapy against hepatitis C virus (HCV) infection is limited in HIV/HCV-coinfected patients with advanced liver fibrosis and non-response to previous peginterferon-ribavirin. These patients have a low chance of achieving a sustained virologic response (SVR) using first generation triple-therapy, with a success rate of only 20%. We investigated the efficacy and safety of lead-in therapy with intravenous silibinin followed by triple-therapy in this difficult-to-treat patient group. Methodology Inclusion criteria were HIV/HCV coinfection with advanced liver fibrosis and documented previous treatment failure on peginterferon-ribavirin. The intervention was a lead-in therapy with intravenous silibinin 20 mg/kg/day for 14 days, followed by triple-therapy (peginterferon- ribavirin and telaprevir) for 12 weeks, and peginterferon-ribavirin alone for 36 weeks. Outcome measurements were HCV-RNA after silibinin lead-in and during triple-therapy, SVR data at week 12, and safety and tolerability of silibinin. Results We examined sixteen HIV/HCV-coinfected patients with previous peginterferon-ribavirin failure, of whom 14 had a fibrosis grade METAVIR >= F3. All were on successful antiretroviral therapy. Median (IQR) HCV-RNA decline after silibinin therapy was 2.65 (2.1-2.8) log10 copies/mL. Fifteen of sixteen patients (94%) had undetectable HCV RNA at weeks 4 and 12, eleven patients (69%) showed end-of-treatment response (i.e., undetectable HCV-RNA at week 48), and ten patients (63%) reached SVR at week 12 (SVR 12). Six of the sixteen patients (37%) did not reach SVR 12: One patient had rapid virologic response (RVR) (i.e., undetectable HCV-RNA at week 4) but stopped treatment at week 8 due to major depression. Five patients had RVR, but experienced viral breakthroughs at week 21, 22, 25, or 32, or a relapse at week 52. The HIV RNA remained below the limit of detection in all patients during the complete treatment period. No serious adverse events and no significant drug-drug interactions were associated with silibinin. Conclusion A lead-in with silibinin before triple-therapy was safe and highly effective in difficult-to-treat HIV/HCV coinfected patients, with a pronounced HCV-RNA decline during the lead-in phase, which translates into 63% SVR. An add-on of intravenous silibinin to standard of care HCV treatment is worth further exploration in selected difficult-to-treat patients.	[Braun, Dominique L.; Durisch, Nina; Eberhard, Nadia; Anagnostopoulos, Alexia; Ledergerber, Bruno; Metzner, Karin J.; Weber, Rainer; Fehr, Jan] Univ Zurich, Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland; [Braun, Dominique L.; Metzner, Karin J.] Univ Zurich, Inst Med Virol, Zurich, Switzerland; [Rauch, Andri] Univ Hosp Bern, Dept Infect Dis, CH-3010 Bern, Switzerland; [Rauch, Andri] Univ Bern, Bern, Switzerland; [Aouri, Manel; Decosterd, Laurent] Univ Lausanne, Div Clin Pharmacol, Univ Hosp Ctr, Lausanne, Switzerland; [Muellhaupt, Beat] Univ Zurich, Univ Zurich Hosp, Clin Gastroenterol & Hepatol, Zurich, Switzerland; [Boeni, Juerg] Univ Zurich, Inst Med Virol, Swiss Natl Ctr Retroviruses, Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University of Bern; University Hospital of Bern; University of Bern; University of Lausanne; University of Zurich; University Zurich Hospital; University of Zurich	Braun, DL (corresponding author), Univ Zurich, Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland.	dominique.braun@usz.ch; jan.fehr@usz.ch	Ledergerber, Bruno/B-5656-2009; Weber, Rainer/D-5175-2012; Anagnostopoulos, Alexia/D-3687-2018; Decosterd, Laurent/E-8494-2019; Boeni, Juerg/B-8386-2015; Rauch, Andri/E-9948-2017; Fehr, Jan S/V-7499-2017; Metzner, Karin J/G-5319-2011; Mullhaupt, Beat/O-3744-2016; Kouyos, Roger/G-6226-2014	Ledergerber, Bruno/0000-0002-6881-4401; Anagnostopoulos, Alexia/0000-0001-6197-3023; Decosterd, Laurent/0000-0002-9840-1325; Rauch, Andri/0000-0001-5297-6062; Fehr, Jan S/0000-0003-1113-9895; Metzner, Karin J/0000-0003-4862-1503; Egger, Matthias/0000-0001-7462-5132; TARR, Philip/0000-0002-1488-5407; Mullhaupt, Beat/0000-0002-9020-8192; Kouyos, Roger/0000-0002-9220-8348; Braun, Dominique Laurent/0000-0003-4036-1030	Swiss National Science Foundation [33CS30_134277, 688]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	This study has been conducted within the framework of the Swiss HIV Cohort Study (SHCS), which is funded by the Swiss National Science Foundation (grant number 33CS30_134277, SHCS project 688). The investigational medicine product was provided by Rottapharm vertical bar Madaus. The members of the Swiss HIV Cohort Study are: Aubert V, Barth J, Battegay M, Bernasconi E, Boni J, Bucher HC, Burton-Jeangros C, Calmy A, Cavassini M, Egger M, Elzi L, Fehr J, Fellay J, Furrer H (Chairman of the Clinical and Laboratory Committee), Fux CA, Gorgievski M, Gunthard H (President of the SHCS), Haerry D (deputy of "Positive Council"), Hasse B, Hirsch HH, Hosli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Metzner K, Muller N, Nadal D, Pantaleo G, Rauch A (Chairman of the Scientific Board), Regenass S, Rickenbach M (Head of Data Center), Rudin C (Chairman of the Mother & Child Substudy), Schoni-Affolter F, Schmid P, Schultze D, Schupbach J, Speck R, Tarr P, Telenti A, Trkola A, Vernazza P, Weber R, Yerly S. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afdhal N, 2014, NEW ENGL J MED, V370, P1483, DOI 10.1056/NEJMoa1316366; Ahmed-Belcacem H, 2014, 2 SIL WORKSH MAY 23; [Anonymous], 2013, GUID US ANT AG HIV 1; Arab-Alameddine M, 2014, J ANTIMICROB CHEMOTH, V69, P2489, DOI 10.1093/jac/dku131; Berg T, 2011, 62 ANN M AASLD SAN F; Bichoupan K, 2014, CURR HIV AIDS REP; Blaising J, 2014, 2 SIL WORKSH MAY 23; Braun DL, 2014, HIV MED, V15, P625, DOI 10.1111/hiv.12166; Colombo S, 2006, ANTIMICROB AGENTS CH, V50, P3801, DOI 10.1128/AAC.00098-06; De Meyer S, 2012, HEPATOLOGY, V56, P2106, DOI 10.1002/hep.25962; Dienstag JL, 2011, HEPATOLOGY, V54, P396, DOI 10.1002/hep.24370; Fayet A, 2009, J CHROMATOGR B, V877, P1057, DOI 10.1016/j.jchromb.2009.02.057; Feeney ER, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g3308; Hezode C, 2014, GASTROENTEROLOGY, V147, P132, DOI 10.1053/j.gastro.2014.03.051; Karageorgopoulos DE, 2014, CURR OPIN INFECT DIS, V27, P36, DOI 10.1097/QCO.0000000000000034; Lawitz E, 2014, LANCET; Lawitz E, 2014, LANCET, V383, P515, DOI 10.1016/S0140-6736(13)62121-2; Lubomirov R, 2013, PHARMACOGENET GENOM, V23, P9, DOI 10.1097/FPC.0b013e32835ade82; Martinot-Peignoux M, 2010, HEPATOLOGY, V51, P1122, DOI 10.1002/hep.23444; Marzolini C, 2001, AIDS, V15, P71, DOI 10.1097/00002030-200101050-00011; Miailhes P, 2013, C EUR AIDS CLIN SOC; Molto J, 2012, ANTIMICROB AGENTS CH, V56, P2837, DOI 10.1128/AAC.00025-12; Osinusi A, 2014, ANN INTERN MED, V161, P634, DOI 10.7326/M14-1211; Polyak S, 2014, 2 SIL WORKSH MAY 23; Poordad F, 2014, NEW ENGL J MED, V370, P1973, DOI 10.1056/NEJMoa1402869; Poveda E, 2014, ANTIVIR RES, V108, P181, DOI 10.1016/j.antiviral.2014.05.015; Sala F, 2014, J CHROMATOGR B, V945, P1, DOI 10.1016/j.jchromb.2013.11.028; Solhi H, 2014, CASP J INTERN MED, V5, P9; Sulkowski MS, 2014, J HEPATOL, V61, pS108, DOI 10.1016/j.jhep.2014.08.006; Sulkowski MS, 2014, NEW ENGL J MED, V370, P211, DOI 10.1056/NEJMoa1306218; Vargas-Mendoza N, 2014, WORLD J HEPATOL, V6, P144, DOI 10.4254/wjh.v6.i3.144; Zeuzem S, 2011, NEW ENGL J MED, V364, P2417, DOI 10.1056/NEJMoa1013086	32	15	15	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2015	10	7							e0133028	10.1371/journal.pone.0133028	http://dx.doi.org/10.1371/journal.pone.0133028			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RL	26176696	Green Published, Green Accepted, gold			2023-01-03	WOS:000358197600203
J	Jatau, B; Avong, Y; Ogundahunsi, O; Shah, S; Smith, KT; van den Bergh, R; Zachariah, R; van Griensven, J; Ekong, E; Dakum, P				Jatau, Bolajoko; Avong, Yohanna; Ogundahunsi, Olumide; Shah, Safieh; Smith, Katherine Tayler; van den Bergh, Rafael; Zachariah, Rony; van Griensven, Johan; Ekong, Ernest; Dakum, Patrick			Procurement and Supply Management System for MDR-TB in Nigeria: Are the Early Warning Targets for Drug Stock Outs and Over Stock of Drugs Being Achieved?	PLOS ONE			English	Article								Background The World Health Organisation (WHO) introduced the twelve early warning indicators for monitoring and evaluating drug Procurement and Supply management (PSM) systems, intended to prevent drug stock-outs and overstocking. Nigeria- one of the high Multi Drug Resistant Tuberculosis (MDR-TB) burden countries, scaled-up treatment in 2012 with the concurrent implementation of a PSM system. Method We evaluated how well this system functioned using the WHO indicators, including all seven MDR-TB treatment centres in the country that were functional throughout 2013. Results The quantity of MDR-TB drugs ordered for 2013 matched the annual forecast and all central orders placed during the year were delivered in full and on time. Drug consumption was 81%-106% of the quantity allocated for routine consumption. Timely submission of complete inventory reports ranged from 86-100%, late submissions being 5-15 days late. Forty to 71% of treatment centres placed a drug order when stock was below the minimum level of three months. The proportion of drug orders received at the treatment centres in full and on time ranged from 29-80%, late orders being 1-19 days late. Conclusion The PSM was found to be performing well in terms of forecasting and procurement of MDR-TB drugs, but there were shortcomings in drug distribution, reporting at treatment centre level and in drug order placements. Despite these gaps, there were no stock outs. These findings indicate that where it matters most, namely ensuring that no drug stock outs affect patient management, the PSM system is effective. Addressing the observed shortcomings will help to strengthen the existing PSM system in anticipation of a growing MDR-TB case burden in the country.	[Jatau, Bolajoko; Avong, Yohanna; Ekong, Ernest; Dakum, Patrick] Inst Human Virol Nigeria, Abuja, Nigeria; [Ogundahunsi, Olumide] Special Program Res & Training Trop Dis, Geneva, Switzerland; [Shah, Safieh; Smith, Katherine Tayler; van den Bergh, Rafael; Zachariah, Rony] MSF Luxembourg, Operat Res Unit, Operat Ctr Brussels, Med Sans Frontieres, Luxembourg, Luxembourg; [van Griensven, Johan] Inst Trop Med, B-2000 Antwerp, Belgium	Doctors Without Borders; Institute of Tropical Medicine (ITM)	Jatau, B (corresponding author), Inst Human Virol Nigeria, Abuja, Nigeria.	bolajatau@gmail.com	Shah, Safieh/Z-2078-2018; Avong, Yohanna/AAS-4891-2020; Shah, Safieh/AAK-3257-2020	Shah, Safieh/0000-0001-5358-9240; Avong, Yohanna/0000-0001-6798-8576; Shah, Safieh/0000-0001-5358-9240; Van den Bergh, Rafael/0000-0001-6277-8713; zachariah, rony/0000-0002-2915-9328	WHO; MSF; The Union; Department for International Development (DFID)	WHO(World Health Organization); MSF; The Union; Department for International Development (DFID)	The programme was funded by MSF, The Union, the Department for International Development (DFID) and WHO. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2011, HARM MON EV IND PROC; [Anonymous], TUBERCULOSIS MULTIDR; Central Intelligence Agency, 2012, NIG PEOPL 2012; Geeta A., 2013, WALL STREET J, V6; Management Sciences for Health, 1997, MAN DRUG SUPPL; Nigeria Federal Ministry of Health, 2011, GUID CONTR CLIN MAN; Pasquet A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013414; Seaworth BJ, 2013, MMWR-MORBID MORTAL W, V62, P23; WHO, 2010, TREATMENT OF TUBERCULOSIS: GUIDELINES, FOURTH EDITION, P1; WHO, 2014, GLOB TUB REP 2014; Windisch R, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-25; World Health Organization, 2008, GUID PROGR MAN DRUG, DOI [10.1186/1471-2334-8-166, DOI 10.1186/1471-2334-8-166]	12	5	5	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2015	10	6							e0128500	10.1371/journal.pone.0128500	http://dx.doi.org/10.1371/journal.pone.0128500			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL3FM	26098673	gold, Green Published			2023-01-03	WOS:000356835800015
J	Rakotonjanahary, J; De Carli, E; Delion, M; Kalifa, C; Grill, J; Doz, F; Leblond, P; Bertozzi, AI; Rialland, X				Rakotonjanahary, Josue; De Carli, Emilie; Delion, Matthieu; Kalifa, Chantal; Grill, Jacques; Doz, Francois; Leblond, Pierre; Bertozzi, Anne-Isabelle; Rialland, Xavier		Brain Tumor Comm SFCE	Mortality in Children with Optic Pathway Glioma Treated with Up-Front BB-SFOP Chemotherapy	PLOS ONE			English	Article							LOW-GRADE GLIOMA; HIT-LGG 1996; PEDIATRIC-ONCOLOGY; PILOCYTIC ASTROCYTOMAS; TREATMENT STRATEGY; TUMORS; NEUROFIBROMATOSIS; SURVIVAL; NERVE; MULTICENTER	Background In terms of overall survival (OS), limited data are available for the very long-term outcomes of children treated for optic pathway glioma (OPG) with up-front chemotherapy. Therefore, we undertook this study with the aim of clarifying long-term OS and causes of death in these patients. Methods We initiated and analyzed a historical cohort study of 180 children with OPG treated in France with BB-SFOP chemotherapy between 1990 and 2004. The survival distributions were estimated using Kaplan-Meier method. The effect of potential risk factors on the risk of death was described using Cox regression analysis. Results The OS was 95% [95% CI: 90.6-97.3] 5 years after diagnosis and significantly decreased over time without ever stabilizing: 91.6% at 10 years [95% CI: 86.5-94.8], 80.7% at 15 years [95% CI: 72.7-86.8] and 75.5% [95% CI: 65.6-83] at 18 years. Tumor progression was the most common cause of death (65%). Age and intracranial hypertension at diagnosis were significantly associated with a worse prognosis. Risk of death was increased by 3.1[95% CI: 1.5-6.2] (p=0.002) for patients less than 1 year old at diagnosis and by 5.2[95% CI: 1.5-17.6] (p=0.007) for patients with initial intracranial hypertension. Boys without diencephalic syndrome had a better prognosis (HR: 0.3 [95% CI: 0.1-0.8], p=0.007). Conclusions This study shows that i) in children with OPG, OS is not as favorable as previously described and ii) patients can be classified into 2 groups depending on risk factors (age, intracranial hypertension, sex and diencephalic syndrome) with an OS rate of 50.4% at 18 years [95% CI: 31.4-66.6] in children with the worst prognosis. These findings could justify, depending on the initial risk, a different therapeutic approach to this tumor with more aggressive treatment (especially chemotherapy) in patients with high risk factors.	[Rakotonjanahary, Josue; De Carli, Emilie; Rialland, Xavier] Univ Hosp, Dept Pediat Oncol, Angers, France; [Rakotonjanahary, Josue] Univ Paris Diderot, Sorbonne Paris Cite, INSERM Robert Debre Hosp CIE5, AP HP, Paris, France; [Delion, Matthieu] Univ Hosp, Dept Neurosurg, Angers, France; [Kalifa, Chantal; Grill, Jacques] Inst Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France; [Doz, Francois] Inst Curie, Dept Pediat Oncol, Paris, France; [Doz, Francois] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Leblond, Pierre] Ctr Oscar Lambret, Dept Pediat Oncol, F-59020 Lille, France; [Bertozzi, Anne-Isabelle] Univ Hosp, Dept Pediat Oncol, Toulouse, France	Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; UNICANCER; Gustave Roussy; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Centre Oscar Lambret; CHU de Toulouse	Rakotonjanahary, J (corresponding author), Univ Hosp, Dept Pediat Oncol, Angers, France.	JoRakotonjanahary@chu-angers.fr	Grill, Jacques/R-8093-2019; Muracciole, Xavier/P-5640-2016; Carrie, Christian/K-5488-2014	LEBLOND, Pierre/0000-0002-7088-2614; Carrie, Christian/0000-0002-0766-2547; Doz, Francois/0000-0001-9286-4831; faure conter, cecile/0000-0002-4717-4943; ANDRE, Nicolas/0000-0002-6786-4968	Ligue Nationale Contre le Cancer; Pfizer Foundation, France	Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Pfizer Foundation, France	This work was supported by Ligue Nationale Contre le Cancer and by the Pfizer Foundation, France. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albers AC, 2009, EXPERT REV NEUROTHER, V9, P535, DOI [10.1586/ern.09.4, 10.1586/ERN.09.4]; Binning Mandy J, 2007, Neurosurg Focus, V23, pE2; BRAUNER R, 1990, EUR J PEDIATR, V149, P825, DOI 10.1007/BF02072067; Cappelli C, 1998, ARCH DIS CHILD, V79, P334, DOI 10.1136/adc.79.4.334; Chen YH, 2014, ONCOGENE, V33, P2019, DOI 10.1038/onc.2013.148; Colin C, 2013, NEUROPATH APPL NEURO, V39, P693, DOI 10.1111/nan.12013; DUTTON JJ, 1994, SURV OPHTHALMOL, V38, P427, DOI 10.1016/0039-6257(94)90173-2; Fisher MJ, 2014, ANN NEUROL, V75, P799, DOI 10.1002/ana.24157; Fouladi M, 2003, CANCER-AM CANCER SOC, V97, P1084, DOI 10.1002/cncr.11119; Gnekow AK, 2004, KLIN PADIATR, V216, P331, DOI 10.1055/s-2004-832355; Gnekow AK, 2012, NEURO-ONCOLOGY, V14, P1265, DOI 10.1093/neuonc/nos202; Grill J, 1999, ANN NEUROL, V45, P393, DOI 10.1002/1531-8249(199903)45:3<393::AID-ANA17>3.0.CO;2-B; Grill J, 2000, EUR J PEDIATR, V159, P692, DOI 10.1007/s004310000531; Hawkins C, 2011, CLIN CANCER RES, V17, P4790, DOI 10.1158/1078-0432.CCR-11-0034; Heideman RL., 1993, PRINCIPLES PRACTICE, P633; Henson JW, 2008, AM J NEURORADIOL, V29, P419, DOI 10.3174/ajnr.A0963; Jahraus CD, 2006, PEDIATR BLOOD CANCER, V46, P586, DOI 10.1002/pbc.20655; JENKIN D, 1993, INT J RADIAT ONCOL, V25, P215, DOI 10.1016/0360-3016(93)90342-S; Kaul A, 2012, GENE DEV, V26, P2561, DOI 10.1101/gad.200907.112; Kilday JP, 2014, J NEURO-ONCOL, V116, P195, DOI 10.1007/s11060-013-1284-2; Laithier V, 2003, J CLIN ONCOL, V21, P4572, DOI 10.1200/JCO.2003.03.043; Mahoney DH, 2000, NEURO-ONCOLOGY, V2, P213, DOI 10.1093/neuonc/2.4.213; Mirow C, 2014, PEDIATR BLOOD CANCER, V61, P457, DOI 10.1002/pbc.24729; Mishra MV, 2012, J NEURO-ONCOL, V107, P591, DOI 10.1007/s11060-011-0783-2; Nicolin G, 2009, PEDIATR BLOOD CANCER, V53, P1231, DOI 10.1002/pbc.22198; Opocher E, 2006, EUR J CANCER, V42, P1807, DOI 10.1016/j.ejca.2006.02.022; PACKER RJ, 1988, ANN NEUROL, V23, P79, DOI 10.1002/ana.410230113; Packer RJ, 1997, J NEUROSURG, V86, P747, DOI 10.3171/jns.1997.86.5.0747; Pfister S, 2008, J CLIN INVEST, V118, P1739, DOI 10.1172/JCI33656; PIERCE SM, 1990, CANCER, V65, P45, DOI 10.1002/1097-0142(19900101)65:1<45::AID-CNCR2820650111>3.0.CO;2-Z; Poussaint TY, 1997, AM J NEURORADIOL, V18, P1499; Prados MD, 1997, J NEURO-ONCOL, V32, P235, DOI 10.1023/A:1005736104205; Reis GF, 2013, MODERN PATHOL, V26, P1279, DOI 10.1038/modpathol.2013.79; Rodriguez FJ, 2012, J NEUROPATH EXP NEUR, V71, P789, DOI 10.1097/NEN.0b013e3182656ef8; Sadighi Z, 2013, J CHILD NEUROL, V28, P625, DOI 10.1177/0883073813476141; Sharif S, 2006, J CLIN ONCOL, V24, P2570, DOI 10.1200/JCO.2005.03.8349; Shuper A, 2000, PEDIATR HEMAT ONCOL, V17, P463, DOI 10.1080/08880010050120818; Stokland T, 2010, NEURO-ONCOLOGY, V12, P1257, DOI 10.1093/neuonc/noq092; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Vos MJ, 2003, NEUROLOGY, V60, P826, DOI 10.1212/01.WNL.0000049467.54667.92; WRIGHT JE, 1989, BRIT J OPHTHALMOL, V73, P967, DOI 10.1136/bjo.73.12.967	41	22	27	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2015	10	6							e0127676	10.1371/journal.pone.0127676	http://dx.doi.org/10.1371/journal.pone.0127676			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL3FM	26098902	Green Submitted, gold, Green Published			2023-01-03	WOS:000356835800008
J	Wang, HJ; Long, L; Cai, H; Wu, Y; Xu, J; Shu, C; Wang, P; Li, B; Wei, QY; Shang, XJ; Wang, XY; Zhang, MM; Xiong, CL; Yin, P				Wang, Hongjing; Long, Lu; Cai, Hui; Wu, Yue; Xu, Jing; Shu, Chang; Wang, Peng; Li, Bo; Wei, Qinyu; Shang, Xuejun; Wang, Xueyi; Zhang, Meimei; Xiong, Chengliang; Yin, Ping			Contraception and Unintended Pregnancy among Unmarried Female University Students: A Cross-sectional Study from China	PLOS ONE			English	Article							SEXUALLY-TRANSMITTED INFECTIONS; EMERGENCY CONTRACEPTION; COLLEGE-STUDENTS; WOMEN SEEKING; ABORTION; KNOWLEDGE; ATTITUDES; EXPERIENCE; BEHAVIORS; WUHAN	This study aims to understand the level of contraceptive knowledge and attitudes towards contraception, and then to explore the association between the contraceptive behavior and unintended pregnancy in unmarried female university students in China. A cross-sectional study was conducted of university students in 49 universities across 7 cities in China from September 2007 to January 2008. We distributed 74,800 questionnaires, of which 69,842 were returned. In this paper, the data from 35,383 unmarried female university students were analyzed. The prevalence of sexual intercourse in unmarried female university students was 10.2%. The prevalence of unintended pregnancy in those sexually active female university students, was 31.8%. Among students with pregnancy, 53.5% experienced two or more pregnancies. 28.3% of the students with sexual intercourse reported that they always adopted contraceptive methods, and of those 82.9% chose to use male condoms. The majority (83.9%) of students with unintended pregnancy chose to terminate the latest pregnancy by surgical abortion or medical abortion. The contraceptive knowledge level of students who experienced unintended pregnancy was lower than those who did not. In China, about one third of unmarried female students with sexual intercourse experience unintended pregnancy. A variety of contraceptive methods are adopted, but the frequency of contraceptive use is low. Most of unmarried female students who experienced unintended pregnancy would choose to terminate the pregnancy with surgical or medical abortion. University students, especially the ones who have experienced unintended pregnancy, lack contraceptive and reproductive health knowledge.	[Wang, Hongjing; Cai, Hui] Gansu Prov Hosp, Dept Med Affairs, Lanzhou, Gansu, Peoples R China; [Wang, Hongjing; Long, Lu; Shu, Chang; Wang, Peng; Li, Bo; Wei, Qinyu; Yin, Ping] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan 430074, Hubei, Peoples R China; [Wu, Yue] Gansu Prov Hosp, Lanzhou, Gansu, Peoples R China; [Xu, Jing] Henan Univ Tradit Chinese Med, Humanities Sch, Publ Management Teaching & Res Sect, Zhengzhou, Henan, Peoples R China; [Shang, Xuejun] Nanjing Univ, Sch Med, Jinling Hosp, Inst Lab Med, Nanjing 210008, Jiangsu, Peoples R China; [Wang, Xueyi] Sexual Hlth Educ Res Ctr, Inst Populat & Family Planning Chongqing City, Chongqing, Peoples R China; [Zhang, Meimei] Capital Normal Univ, Sexual Hlth Educ Res Ctr, Beijing, Peoples R China; [Xiong, Chengliang] Huazhong Univ Sci & Technol, Tongji Med Coll, Inst Family Planning, Wuhan 430074, Hubei, Peoples R China	Huazhong University of Science & Technology; Henan University of Traditional Chinese Medicine; Nanjing University; Capital Normal University; Huazhong University of Science & Technology	Yin, P (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan 430074, Hubei, Peoples R China.	pingyin2000@126.com		cai, hui/0000-0003-2440-4256	Chinese "11th Five-Year Plan" Supporting Science and Technology Project [2006BAI15B00]	Chinese "11th Five-Year Plan" Supporting Science and Technology Project(National Key Technology R&D Program)	This work was supported by The Chinese "11th Five-Year Plan" Supporting Science and Technology Project [No. 2006BAI15B00].	Agardh A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023670; Amin SF, 2009, EUR J SCI RES, V26, P108; BARRETT FM, 1980, ARCH SEX BEHAV, V9, P367, DOI 10.1007/BF02115939; Chen Bin, 2005, Zhonghua Nan Ke Xue, V11, P744; Cheng Y, 2004, INT J GYNECOL OBSTET, V87, P199, DOI 10.1016/j.ijgo.2004.06.010; Cheng YM, 1997, CONTRACEPTION, V55, P15; Cheng YM, 2002, J ADOLESCENT HEALTH, V31, P482, DOI 10.1016/S1054-139X(02)00449-4; China MOE, 2012, NUMB STUD SCH HIGH E, V12, P15; Huang J, 2005, AIDS PATIENT CARE ST, V19, P769, DOI 10.1089/apc.2005.19.769; Jones RK, 2002, PERSPECT SEX REPRO H, V34, P294, DOI 10.2307/3097748; Kelly J, 2001, SEX ROLES, V45, P785, DOI 10.1023/A:1015640419862; Kongnyuy EJ, 2007, BMC EMERG MED, V7, DOI 10.1186/1471-227X-7-7; Kuroki LM, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.03.049; Lakha F, 2006, LANCET, V368, P1782, DOI 10.1016/S0140-6736(06)69737-7; Ma QQ, 2008, CONTRACEPTION, V77, P108, DOI 10.1016/j.contraception.2007.10.008; Qian X, 2004, BMC HEALTH SERV RES, V4, DOI 10.1186/1472-6963-4-1; Ryan I J, 1988, Fam Pract Res J, V7, P153; Santelli JS, 1997, FAM PLANN PERSPECT, V29, P261, DOI 10.2307/2953414; Schwarz J, 2008, THESIS U WASHINGTON; Shah IH, 2004, REPROD CONTRACEPTION, V15, P1; Templeton A, 2011, NEW ENGL J MED, V365, P2198, DOI 10.1056/NEJMcp1103639; The Ministry of Health in P. R. China, 2010, ALM CHIN HLTH 2009; Turchik JA, 2009, ARCH SEX BEHAV, V38, P936, DOI 10.1007/s10508-008-9388-z; Yan H, 2010, WOMEN HEALTH, V50, P767, DOI 10.1080/03630242.2010.530926; Zhang DG, 2013, J INFECT DEV COUNTR, V7, P966, DOI 10.3855/jidc.3872; Zhang DX, 2010, ASIA-PAC J PUBLIC HE, V22, P118, DOI 10.1177/1010539509350614; Zhang K, 1999, AIDS CARE, V11, P581, DOI 10.1080/09540129947730; Zhang LY, 2002, SEX TRANSM DIS, V29, P212, DOI 10.1097/00007435-200204000-00005; Zhou M, 2005, REPROD CONTRACEPTION, V25; Zou YL, 2013, EUR J CONTRACEP REPR, V18, P127, DOI 10.3109/13625187.2013.772974	30	30	32	2	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2015	10	6							e0130212	10.1371/journal.pone.0130212	http://dx.doi.org/10.1371/journal.pone.0130212			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CL3FE	26091505	Green Submitted, Green Published, gold			2023-01-03	WOS:000356835000097
J	Zhou, XL; Wang, Y; Zhang, CJ; Wang, M; Zhang, M; Yu, LN; Yan, M				Zhou, Xuelong; Wang, Yin; Zhang, Chenjing; Wang, Min; Zhang, Mei; Yu, Lina; Yan, Min			The Role of Dopaminergic VTA Neurons in General Anesthesia	PLOS ONE			English	Article							ISOFLURANE ANESTHESIA; HISTAMINERGIC NEURONS; VOLATILE ANESTHETICS; PROPOFOL ANESTHESIA; SLEEP; INVOLVEMENT; MICE; DEXMEDETOMIDINE; MODULATION; ACTIVATION	Recent studies have demonstrated that the central dopaminergic system is implicated in the mechanism underlying general anesthesia. Here, we investigated whether dopaminergic ventral tegmental area (VTA) neurons participate in general anesthesia. Dopaminergic VTA neurons were selectively ablated from male Sprague Dawley rats via the bilateral infusion of 6-hydroxydopamine (6-OHDA) into the VTA. Two weeks after infusion, the number of dopaminergic neurons in the bilateral VTA was markedly reduced in the 6-OHDA-treated rats compared with the vehicle-treated rats. These bilateral VTA lesions significantly prolonged the recovery time for propofol but did not significantly alter its onset time or 50% effective dose (ED50) value. In addition, the anesthetic responses to isoflurane and ketamine were unaffected by the VTA lesions. Our findings suggested that dopaminergic VTA neurons might be involved in the emergence from propofol anesthesia.	[Zhou, Xuelong; Yu, Lina; Yan, Min] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Anesthesiol, Hangzhou 310000, Zhejiang, Peoples R China; [Wang, Yin] Tai Zhou Peoples Hosp, Dept Anesthesiol, Taizhou 225300, Peoples R China; [Zhang, Chenjing] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Gastroenterol, Hangzhou 310000, Zhejiang, Peoples R China; [Wang, Min; Zhang, Mei] Xuzhou Med Coll, Jiangsu Key Lab Anesthesiol, Xuzhou 221000, Peoples R China	Zhejiang University; Zhejiang University; Xuzhou Medical University	Yan, M (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Anesthesiol, Hangzhou 310000, Zhejiang, Peoples R China.	zryanmin@zju.edu.cn						Barrot M, 2012, J NEUROSCI, V32, P14094, DOI 10.1523/JNEUROSCI.3370-12.2012; Franks NP, 2006, BRIT J PHARMACOL, V147, pS72, DOI 10.1038/sj.bjp.0706441; Hosp JA, 2011, J NEUROSCI, V31, P2481, DOI 10.1523/JNEUROSCI.5411-10.2011; Hu FY, 2012, ANESTHESIOLOGY, V117, P1006, DOI 10.1097/ALN.0b013e3182700ab9; Irifune M, 1999, BRIT J ANAESTH, V83, P665, DOI 10.1093/bja/83.4.665; Kelz MB, 2008, P NATL ACAD SCI USA, V105, P1309, DOI 10.1073/pnas.0707146105; Kohrs R, 1998, ANESTH ANALG, V87, P1186, DOI 10.1097/00000539-199811000-00039; Laalou FZ, 2008, ANESTHESIOLOGY, V108, P888, DOI 10.1097/ALN.0b013e31816d919b; Leung LS, 2011, EXP NEUROL, V228, P259, DOI 10.1016/j.expneurol.2011.01.019; Luo T, 2011, ANESTHESIOLOGY, V115, P36, DOI 10.1097/ALN.0b013e3182207655; Mashour George A, 2012, Anesthesiol Clin, V30, P385, DOI 10.1016/j.anclin.2012.05.003; Monti JM, 2007, SLEEP MED REV, V11, P113, DOI 10.1016/j.smrv.2006.08.003; Moore JT, 2012, CURR BIOL, V22, P2008, DOI 10.1016/j.cub.2012.08.042; Nelson LE, 2003, ANESTHESIOLOGY, V98, P428, DOI 10.1097/00000542-200302000-00024; Nelson LE, 2002, NAT NEUROSCI, V5, P979, DOI 10.1038/nn913; Perogamvros L, 2012, NEUROSCI BIOBEHAV R, V36, P1934, DOI 10.1016/j.neubiorev.2012.05.010; Scharf M. T., 2013, CURR ANESTHESIOL REP, V3, P1; Solt K, 2014, ANESTHESIOLOGY, V121, P311, DOI 10.1097/ALN.0000000000000117; Tai SK, 2014, ANESTHESIOLOGY, V120, P392, DOI 10.1097/ALN.0b013e3182a7cab6; Taylor NE, 2013, ANESTHESIOLOGY, V118, P30, DOI 10.1097/ALN.0b013e318278c896; WAUD DR, 1972, J PHARMACOL EXP THER, V183, P577; Zecharia AY, 2012, J NEUROSCI, V32, P13062, DOI 10.1523/JNEUROSCI.2931-12.2012; Zecharia AY, 2009, J NEUROSCI, V29, P2177, DOI 10.1523/JNEUROSCI.4997-08.2009; Zhou XL, 2015, NEUROSCIENCE, V284, P546, DOI 10.1016/j.neuroscience.2014.10.025	24	28	29	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2015	10	9							e0138187	10.1371/journal.pone.0138187	http://dx.doi.org/10.1371/journal.pone.0138187			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS1BM	26398236	Green Submitted, gold, Green Published			2023-01-03	WOS:000361797500056
J	Kularatne, SAM				Kularatne, Senanayake A. M.			Dengue fever	BMJ-BRITISH MEDICAL JOURNAL			English	Review							HEMORRHAGIC-FEVER; CONTROLLED-TRIAL; PHASE-II; VACCINE; IMMUNOGENICITY; PATHOGENESIS; RECOMBINANT; CHILDREN; EFFICACY; SAFETY		[Kularatne, Senanayake A. M.] Univ Peradeniya, Dept Med, Fac Med, Peradeniya, Sri Lanka	University of Peradeniya	Kularatne, SAM (corresponding author), Univ Peradeniya, Dept Med, Fac Med, Peradeniya, Sri Lanka.	samkul@sltnet.lk						Ashley EA, 2011, TRENDS ANAESTH CRIT, V1, P39, DOI 10.1016/j.tacc.2010.10.002; Baldacchino F, 2015, PEST MANAG SCI; Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6; Centers for Disease Control and Prevention, 2014, CLIN GUID DENG VIR; Dung NM, 1999, CLIN INFECT DIS, V29, P787, DOI 10.1086/520435; Durbin AP, 2013, J INFECT DIS, V207, P957, DOI 10.1093/infdis/jis936; Gulati S, 2007, TROP MED INT HEALTH, V12, P1087, DOI 10.1111/j.1365-3156.2007.01891.x; Guzman MG, 2003, J CLIN VIROL, V27, P1, DOI 10.1016/S1386-6532(03)00010-6; GUZMAN MG, 1990, AM J TROP MED HYG, V42, P179, DOI 10.4269/ajtmh.1990.42.179; Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0; Kalayanarooj S., 1999, Dengue Bulletin, V23, P1; Kalayanarooj S, 1997, J INFECT DIS, V176, P313, DOI 10.1086/514047; Kularatne SAM, 2008, T ROY SOC TROP MED H, V102, P1053, DOI 10.1016/j.trstmh.2008.06.001; Kularatne SAM, 2007, T ROY SOC TROP MED H, V101, P804, DOI 10.1016/j.trstmh.2007.02.021; Kularatne SAM, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-141; Lanata CF, 2012, VACCINE, V30, P5935, DOI 10.1016/j.vaccine.2012.07.043; Leo YS, 2012, HUM VACC IMMUNOTHER, V8, P1259, DOI 10.4161/hv.21224; Libraty DH, 2002, J INFECT DIS, V186, P1165, DOI 10.1086/343813; Ministry of Health Sri Lanka, 2012, GUID MAN DENG FEV DE; Nguyen NM, 2013, J INFECT DIS, V207, P1442, DOI 10.1093/infdis/jis470; Nhan NT, 2001, CLIN INFECT DIS, V32, P204, DOI 10.1086/318479; Noble CG, 2010, ANTIVIR RES, V85, P450, DOI 10.1016/j.antiviral.2009.12.011; Pichainarong Natchaporn, 2006, Southeast Asian Journal of Tropical Medicine and Public Health, V37, P283; Pouliot SH, 2010, OBSTET GYNECOL SURV, V65, P107, DOI 10.1097/OGX.0b013e3181cb8fbc; Premaratna R, 2009, T ROY SOC TROP MED H, V103, P127, DOI 10.1016/j.trstmh.2008.07.024; Lima MDQ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000738; Rajapakse S, 2009, T ROY SOC TROP MED H, V103, P122, DOI 10.1016/j.trstmh.2008.07.022; Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7; Sawasdivorn Siraporn, 2001, Dengue Bulletin, V25, P56; Stephenson JR, 2005, B WORLD HEALTH ORGAN, V83, P308; Tam DTH, 2012, CLIN INFECT DIS, V55, P1216, DOI 10.1093/cid/cis655; Teixeira MG, 2009, BMJ-BRIT MED J, V339, P1189; Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037; Webster DP, 2009, LANCET INFECT DIS, V9, P678, DOI 10.1016/S1473-3099(09)70254-3; Whitehorn J, 2011, VACCINE, V29, P7221, DOI 10.1016/j.vaccine.2011.07.022; WHO, 2009, WHO TECH REP SER, V958, P1; Wilder-Smith A, 2008, MED CLIN N AM, V92, P1377, DOI 10.1016/j.mcna.2008.07.002; Wills BA, 2005, NEW ENGL J MED, V353, P877, DOI 10.1056/NEJMoa044057; World Health Organization, 2011, COMPR GUID PREV CONT; Zhang F, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003488.pub3	40	71	76	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 15	2015	351								h4661	10.1136/bmj.h4661	http://dx.doi.org/10.1136/bmj.h4661			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CR9LZ	26374064				2023-01-03	WOS:000361678600003
J	Nakagawa, H; Koizumi, N; Okumura, N; Suganami, H; Kinoshita, S				Nakagawa, Hiroko; Koizumi, Noriko; Okumura, Naoki; Suganami, Hideki; Kinoshita, Shigeru			Morphological Changes of Human Corneal Endothelial Cells after Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) Administration: A Prospective Open-Label Clinical Study	PLOS ONE			English	Article							ROCK INHIBITOR; Y-27632; ENHANCEMENT; DYSTROPHY	Purpose To investigate the effect and safety of a selective Rho kinase inhibitor, ripasudil 0.4% eye drops, on corneal endothelial cells of healthy subjects. Design Prospective, interventional case series. Methods In this study, 6 healthy subjects were administered ripasudil 0.4% in the right eye twice daily for 1 week. Morphological changes and corneal endothelial cell density were examined by noncontact and contact specular microscopy. Central corneal thickness and corneal volume of 5 mm-diameter area of center cornea were analyzed by Pentacam Scheimpflug topography. All the above measurements were conducted in both eyes before administration, 1.5 and 6 hours after the initial administration on day 0; and in the same manner after the final administration on day 7. Results By noncontact specular microscopy, indistinct cell borders with pseudo guttae were observed, but by contact specular microscopy, morphological changes of corneal endothelial cells were mild and pseudo guttae was not observed after single and repeated administration of ripasudil in all subjects. These changes resolved prior to the next administration, and corneal endothelial cell density, central corneal thickness and corneal volume were not changed throughout the study period. Conclusion Transient morphological changes of corneal endothelial cells such as indistinct cell borders with pseudo guttae were observed by noncontact specular microscopy in healthy subjects after ripasudil administration. Corneal edema was not observed and corneal endothelial cell density did not decrease after 1 week repetitive administration. These morphological changes were reversible and corneal endothelial cell morphology returned to normal prior to the next administration.	[Nakagawa, Hiroko; Koizumi, Noriko; Okumura, Naoki; Kinoshita, Shigeru] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto, Kyoto, Japan; [Koizumi, Noriko; Okumura, Naoki] Doshisha Univ, Fac Life & Med Sci, Dept Biomed Engn, Kyotanabe, Kyoto, Japan; [Suganami, Hideki] Kowa Co Ltd, Nagoya, Aichi, Japan	Kyoto Prefectural University of Medicine; Doshisha University; Kowa Company, Ltd.	Koizumi, N (corresponding author), Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto, Kyoto, Japan.	nkoizumi@mail.doshisha.ac.jp			Kowa Company, Ltd, Nagoya, Japan	Kowa Company, Ltd, Nagoya, Japan	This study was sponsored by Kowa Company, Ltd, Nagoya, Japan. The sponsor participated in design, study conduct, data collection, data management, data analysis, interpretation of the data of the study, and preparation, review, and approval of the manuscript.	Arita R, 2009, DIABETES, V58, P215, DOI 10.2337/db08-0762; Garnock-Jones K, 2014, DRUGS, V74, P2211, DOI 10.1007/s40265-014-0333-2; HOLDEN BA, 1985, INVEST OPHTH VIS SCI, V26, P1354; Honjo M, 2001, INVEST OPHTH VIS SCI, V42, P137; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Isobe T, 2014, CURR EYE RES, V39, P813, DOI 10.3109/02713683.2013.874444; Jhanji V, 2012, CURR OPIN OPHTHALMOL, V23, P324, DOI 10.1097/ICU.0b013e32835484a1; Jhanji V, 2010, CURR OPIN OPHTHALMOL, V21, P301, DOI 10.1097/ICU.0b013e32833a8dd3; Kameda T, 2012, INVEST OPHTH VIS SCI, V53, P3092, DOI 10.1167/iovs.11-8018; Koga T, 2006, EXP EYE RES, V82, P362, DOI 10.1016/j.exer.2005.07.006; Koizumi N, 2014, CORNEA, V33, pS25, DOI 10.1097/ICO.0000000000000240; Koizumi N, 2013, CORNEA, V32, P1167, DOI 10.1097/ICO.0b013e318285475d; Nagayama K, 2008, AM J PHYSIOL-CELL PH, V295, pC1569, DOI 10.1152/ajpcell.00098.2008; Okumura N, 2014, INVEST OPHTH VIS SCI, V55, P318, DOI 10.1167/iovs.13-12225; Okumura N, 2013, INVEST OPHTH VIS SCI, V54, P2493, DOI 10.1167/iovs.12-11320; Okumura N, 2011, BRIT J OPHTHALMOL, V95, P1006, DOI 10.1136/bjo.2010.194571; Okumura N, 2009, INVEST OPHTH VIS SCI, V50, P3680, DOI 10.1167/iovs.08-2634; SHIBUYA M, 1992, J NEUROSURG, V76, P571, DOI 10.3171/jns.1992.76.4.0571; Shimokawa H, 2005, ARTERIOSCL THROM VAS, V25, P1767, DOI 10.1161/01.ATV.0000176193.83629.c8; Tanihara H, 2015, ACTA OPHTHA IN PRESS; Tian B, 2001, CURR EYE RES, V22, P109, DOI 10.1076/ceyr.22.2.109.5529; Wato E, 2014, FUNDAM TOXICOL SCI, V1, P39, DOI DOI 10.2131/fts.1.39; ZANTOS SG, 1977, AM J OPTOM PHYS OPT, V54, P856	23	29	30	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2015	10	9							e0136802	10.1371/journal.pone.0136802	http://dx.doi.org/10.1371/journal.pone.0136802			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR8KS	26367375	Green Submitted, Green Published, gold			2023-01-03	WOS:000361601100026
J	Deshaies, RJ				Deshaies, Raymond J.			Prime time for PROTACs	NATURE CHEMICAL BIOLOGY			English	News Item							E3 UBIQUITIN LIGASE; DEGRADATION; COMPLEX; TARGET; LENALIDOMIDE; THALIDOMIDE; MODULATION; PROTEINS; CEREBLON; IKAROS		[Deshaies, Raymond J.] CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; [Deshaies, Raymond J.] CALTECH, Div Biol & Biol Engn, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Deshaies, RJ (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.	deshaies@its.caltech.edu	Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354	Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [R01 GM065997] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065997] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bondeson DP, 2015, NAT CHEM BIOL, V11, P611, DOI [10.1038/nchembio.1858, 10.1038/NCHEMBIO.1858]; Buckley DL, 2015, ACS CHEM BIOL, V10, P1831, DOI 10.1021/acschembio.5b00442; Buckley DL, 2014, ANGEW CHEM INT EDIT, V53, P2312, DOI 10.1002/anie.201307761; Chamberlain PP, 2014, NAT STRUCT MOL BIOL, V21, P803, DOI 10.1038/nsmb.2874; Fischer ES, 2014, NATURE, V512, P49, DOI 10.1038/nature13527; Gandhi AK, 2014, BRIT J HAEMATOL, V164, P811, DOI 10.1111/bjh.12708; Ito T, 2010, SCIENCE, V327, P1345, DOI 10.1126/science.1177319; Kronke J, 2014, SCIENCE, V343, P301, DOI 10.1126/science.1244851; Lu G, 2014, SCIENCE, V343, P305, DOI 10.1126/science.1244917; Lu J, 2015, CHEM BIOL, V22, P755, DOI 10.1016/j.chembiol.2015.05.009; Sakamoto KM, 2001, P NATL ACAD SCI USA, V98, P8554, DOI 10.1073/pnas.141230798; Winter GE, 2015, SCIENCE, V348, P1376, DOI 10.1126/science.aab1433; Zengerle M, 2015, ACS CHEM BIOL, V10, P1770, DOI 10.1021/acschembio.5b00216	13	94	101	2	57	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	SEP	2015	11	9					634	635		10.1038/nchembio.1887	http://dx.doi.org/10.1038/nchembio.1887			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CP5WC	26284668				2023-01-03	WOS:000359954700004
J	[Anonymous]				[Anonymous]			The House: Its Unique Problems in Hygiene (Reprinted from JAMA., vol 65, pg 802-803, 1915)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint																		[Anonymous], 1914, YB USDA, P339; Kinne Helen, 1914, SHELTER AND CLOTHING, P15; 1915, JAMA, V65, P802	3	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2015	314	8					839	839		10.1001/jama.2014.11944	http://dx.doi.org/10.1001/jama.2014.11944			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CP6SA	26305664				2023-01-03	WOS:000360017200031
J	Kahan, S; Theim, K				Kahan, Scott; Theim, Kelly			Review: Some commercial or proprietary weight-loss programs increase weight loss	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Kahan, Scott; Theim, Kelly] George Washington Univ, Natl Ctr Weight & Wellness, Washington, DC 20052 USA	George Washington University	Kahan, S (corresponding author), George Washington Univ, Natl Ctr Weight & Wellness, Washington, DC 20052 USA.			Kahan, Scott/0000-0002-3080-0661				Bray GA, 2009, LANCET, V374, P1677, DOI 10.1016/S0140-6736(09)61457-4; Foster GD, 1997, J CONSULT CLIN PSYCH, V65, P79, DOI 10.1037/0022-006X.65.1.79; Jensen MD, 2014, CIRCULATION, V129, pS102, DOI 10.1161/01.cir.0000437739.71477.ee; Kolasa KM, 2010, NUTR CLIN PRACT, V25, P502, DOI 10.1177/0884533610380057; Torgerson JS, 2004, DIABETES CARE, V27, P155, DOI 10.2337/diacare.27.1.155	5	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 18	2015	163	4					JC8	JC8		10.7326/ACPJC-2015-163-4-008	http://dx.doi.org/10.7326/ACPJC-2015-163-4-008			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CW0IT	26280443				2023-01-03	WOS:000364673500012
J	Konstantyner, T; Sesso, R; de Camargo, MF; Feltran, LD; Koch-Nogueira, PC				Konstantyner, Tulio; Sesso, Ricardo; de Camargo, Maria Fernanda; Feltran, Luciana de Santis; Koch-Nogueira, Paulo Cesar			Pediatric Chronic Dialysis in Brazil: Epidemiology and Regional Inequalities	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; RENAL REPLACEMENT THERAPY; CHILDREN; PREVALENCE	Introduction There are few reports in the literature estimating the epidemiologic characteristics of pediatric chronic dialysis. These patients have impaired physical growth, high number of comorbidities and great need for continuous attention of specialized services with high demand for complex and costly procedures. Objective The aim of this study was to estimate the incidence and prevalence rates and describe the characteristics of children and adolescents undergoing chronic dialysis treatment in a Brazilian demographic health survey. Materials and Methods A cross-sectional study was performed in a representative sample of dialysis centers (n(c) = 239) that was established from the 2011 Brazilian Nephrology Society Census (N-c = 708). We collected data encompassing the five Brazilian macro-regions. We analyzed the data from all patients under 19 years of age. The sample population consisted of 643 children and adolescents who were on chronic dialysis program anytime in 2012. Data collection was carried out in the dialysis services by means of patients' records reviews and personal interviews with the centers' leaders. Results We estimated that there were a total of 1,283 pediatric patients on chronic dialysis treatment in Brazil, resulting in a prevalence of 20.0 cases per million age-related population (pmarp) (95% CI: 14.8-25.3) and an incidence of 6.6 cases pmarp in 2012 (95% CI: 4.8-8.4). The South region had the highest prevalence and incidence rates of patients under dialysis therapy, 27.7 (95% CI: 7.3-48.1) and 11.0 (95% CI: 2.8-19.3) cases pmarp, respectively; the lowest prevalence and incidence rates were found in the North-Midwest region, 13.8 (95% CI: 6.2-21.4), and in the Northeast region, 3.8 (95% CI: 1.4-6.3) cases pmarp, respectively.	[Konstantyner, Tulio; Sesso, Ricardo; de Camargo, Maria Fernanda; Feltran, Luciana de Santis; Koch-Nogueira, Paulo Cesar] Soc Hosp Samaritano, Sao Paulo, Brazil; [Konstantyner, Tulio; Koch-Nogueira, Paulo Cesar] Univ Fed Sao Paulo, Div Pediat, Sao Paulo, Brazil; [Sesso, Ricardo] Univ Fed Sao Paulo, Div Nephrol, Sao Paulo, Brazil	Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP)	Konstantyner, T (corresponding author), Soc Hosp Samaritano, Sao Paulo, Brazil.	tkmed@uol.com.br	Nogueira, Paulo Cesar Koch/E-8376-2010; Feltran, Luciana S/F-2735-2013; Konstantyner, Tulio/N-1983-2013; Konstantyner, Tulio/H-3063-2019	Nogueira, Paulo Cesar Koch/0000-0002-9536-9665; Feltran, Luciana S/0000-0003-3339-0749; Konstantyner, Tulio/0000-0002-7931-9692; Konstantyner, Tulio/0000-0002-7931-9692; Sesso, Ricardo/0000-0002-1062-0073	Brazilian Ministry of Health by the 'Programa de Apoio ao Desenvolvimento Institucional do Sistema Unico de Saude - PROADI-SUS' [25000.180613/2011-11]	Brazilian Ministry of Health by the 'Programa de Apoio ao Desenvolvimento Institucional do Sistema Unico de Saude - PROADI-SUS'	'Sociedade Hospital Samaritano' received funding from the Brazilian Ministry of Health by the 'Programa de Apoio ao Desenvolvimento Institucional do Sistema Unico de Saude - PROADI-SUS', protocol number: 25000.180613/2011-11 (http://portalsaude.saude.gov.br/index.php?option=com_content&view=article&id=9538&Itemid=497). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ardissino G, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.4.e382; Chadha V, 2005, ADV CHRONIC KIDNEY D, V12, P343, DOI 10.1053/j.ackd.2005.07.013; Chesnaye N, 2014, PEDIAT NEPHROL; de Araujo EM, 2009, INTERFACE-BOTUCATU, V13, P383, DOI 10.1590/S1414-32832009000400012; Garcia-Garcia G, 2015, PEDIATR NEPHROL, V30, P183, DOI 10.1007/s00467-014-2996-z; Gregg M, 2008, FIELD EPIDEMIOLOGY, V3rd; Harambat J, 2012, PEDIATR NEPHROL, V27, P363, DOI 10.1007/s00467-011-1939-1; [Interagency Network of Health Information of the Ministry of Health of Brazil (RIPSA) Brazil Ministry of Health], 2012, INT NETW HLTH INF MI; Jager KJ, 2007, KIDNEY INT, V72, P412, DOI 10.1038/sj.ki.5002341; Kirkwood B.R., 2003, ESSENTIAL MED STAT, P165; Nogueira PCK, 2011, REV ASSOC MED BRAS, V57, P443, DOI 10.1590/S0104-42302011000400020; KORN EL, 1999, WILEY S PRO STAT SUR, P1; Lewis MA, 2010, NEPHRON CLIN PRACT, V115, pC279, DOI 10.1159/000301237; Liyanage T, 2015, LANCET, V385, P1975, DOI 10.1016/S0140-6736(14)61601-9; Matas AJ, 2015, AM J TRANSPLANT, V15, DOI 10.1111/ajt.13195; McDonald SP, 2004, NEW ENGL J MED, V350, P2654, DOI 10.1056/NEJMoa031643; McTaggart S, 2008, INCIDENCE PREVALENCE, P1; North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS), 2011, 2011 ANN DIAL REP; Paim J, 2011, LANCET; Prutsch U, 2014, HIST CIENC SAUDE-MAN, V21, P219, DOI 10.1590/S0104-59702014005000005; Registry ERA-EDTA, 2010, ERA EDTA REG ANN REP; Ribeiro Patricia Tavares, 2007, Cien Saude Colet, V12, P1525, DOI 10.1590/S1413-81232007000600014; Sesso Ricardo de Castro Cintra, 2012, J Bras Nefrol, V34, P272; StataCorp, 2013, STAT STAT SOFTW REL; Stengel B, 2006, J AM SOC NEPHROL, V17, P2094, DOI 10.1681/ASN.2006060636; The ESRD Incidence Study Group, 2006, NEPHROL DIAL TRANSPL; United Nations Development Programme, 2010, ATL HUM DEV BRAZ; United States Renal Data System, 2014, 2014 ANN DAT REP EP; van der Heijden BJ, 2004, PEDIATR NEPHROL, V19, P213, DOI 10.1007/s00467-003-1376-x; Warady BA, 2007, PEDIATR NEPHROL, V22, P1999, DOI 10.1007/s00467-006-0410-1	30	20	22	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 18	2015	10	8							e0135649	10.1371/journal.pone.0135649	http://dx.doi.org/10.1371/journal.pone.0135649			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP1VY	26285019	Green Published, Green Submitted, gold			2023-01-03	WOS:000359666100053
J	Kim, SH; Adhikari, BB; Cruz, S; Schramm, MP; Vinson, JA; Narayanaswami, V				Kim, Sea H.; Adhikari, Birendra Babu; Cruz, Siobanth; Schramm, Michael P.; Vinson, Joe A.; Narayanaswami, Vasanthy			Targeted Intracellular Delivery of Resveratrol to Glioblastoma Cells Using Apolipoprotein E-Containing Reconstituted HDL as a Nanovehicle	PLOS ONE			English	Article							LOW-DENSITY-LIPOPROTEIN; DRUG-DELIVERY; ALZHEIMERS-DISEASE; TRANS-RESVERATROL; E ISOFORMS; RECEPTOR; PROTEIN; BIOAVAILABILITY; FLUORESCENCE; BINDING	The objective of this study is to transport and deliver resveratrol to intracellular sites using apolipoprotein E3 (apoE3). Reconstituted high-density lipoprotein (rHDL) bearing resveratrol (rHDL/res) was prepared using phospholipids and the low-density lipoprotein receptor (LDLr)-binding domain of apoE3. Biophysical characterization revealed that resveratrol was partitioned into the phospholipid bilayer of discoidal rHDL/res particles (similar to 19 nm diameter). Co-immunoprecipitation studies indicated that the LDLr-binding ability of apoE3 was retained. Cellular uptake of resveratrol to intracellular sites was evaluated in glioblastoma A-172 cells by direct fluorescence using chemically synthesized NBD-labeled resveratrol (res/NBD) embedded in rHDL/res. Competition and inhibition studies indicate that the uptake is by receptor mediated endocytosis via the LDLr, with co-localization of apoE3 and res/NBD in late endosomes/lysosomes. We propose that rHDL provides an ideal hydrophobic milieu to sequester resveratrol and that rHDL containing apoE3 serves as an effective "nanovehicle" to transport and deliver resveratrol to targeted intracellular sites.	[Kim, Sea H.; Adhikari, Birendra Babu; Cruz, Siobanth; Schramm, Michael P.; Narayanaswami, Vasanthy] Calif State Univ Long Beach, Dept Chem & Biochem, Long Beach, CA 90840 USA; [Vinson, Joe A.] Univ Scranton, Loyola Sci Ctr, Dept Chem, Scranton, PA 18510 USA	California State University System; California State University Long Beach; University of Scranton	Narayanaswami, V (corresponding author), Calif State Univ Long Beach, Dept Chem & Biochem, Long Beach, CA 90840 USA.	vas.narayanaswami@csulb.edu		Narayanaswami, Vasanthy/0000-0001-7088-4057	National Institutes of Health/National Institute of General Medical Science [GM105561]; California State University Program to Enhance Research in Biotechnology Faculty Development Grant; National Institutes of Health/National Cancer Institute [SC2CA167636]; Maria Erlinda Co Sarno Scholarship; National Science Foundation [NSF-MRI CHE-1337559, MRI-DBI0722757]; NATIONAL CANCER INSTITUTE [SC2CA167636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [SC3GM105561] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of General Medical Science(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); California State University Program to Enhance Research in Biotechnology Faculty Development Grant; National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Maria Erlinda Co Sarno Scholarship; National Science Foundation(National Science Foundation (NSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by National Institutes of Health/National Institute of General Medical Science #GM105561 (to VN, www.nigms.nih.gov); California State University Program to Enhance Research in Biotechnology Faculty Development Grant (to VN, http://www.calstate.edu/csuperb), National Institutes of Health/National Cancer Institute #SC2CA167636 (to MPS, www.nih.gov) and the Maria Erlinda Co Sarno Scholarship (to SHK). The NMR spectrometer and the confocal microscope were obtained through grants from the National Science Foundation (NSF-MRI CHE-1337559 and MRI-DBI0722757, respectively). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5312, DOI 10.1021/bi00138a010; Adhikari BB, 2014, EUR J ORG CHEM, V2014, P2972, DOI 10.1002/ejoc.201400025; de la Lastral CA, 2007, BIOCHEM SOC T, V35, P1156, DOI 10.1042/BST0351156; Amri A, 2012, J CONTROL RELEASE, V158, P182, DOI 10.1016/j.jconrel.2011.09.083; Belguendouz L, 1998, BIOCHEM PHARMACOL, V55, P811, DOI 10.1016/S0006-2952(97)00544-3; Biasutto L, 2014, CURR DRUG METAB, V15, P77, DOI 10.2174/1389200214666131211160005; Brow KA, 2010, CANCER RES, V70, P4, DOI 10.1158/0008-5472.CAN-09-2257; Burkon A, 2008, MOL NUTR FOOD RES, V52, P549, DOI 10.1002/mnfr.200700290; Caddeo C, 2008, INT J PHARMACEUT, V363, P183, DOI 10.1016/j.ijpharm.2008.07.024; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Chung NS, 2004, ADV DRUG DELIVER REV, V56, P1315, DOI 10.1016/j.addr.2003.12.003; Delmas D, 2011, MOL NUTR FOOD RES, V55, P1142, DOI 10.1002/mnfr.201100065; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Feng XW, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0078846, 10.1371/journal.pone.0059888]; Figueiras TS, 2011, J FLUORESC, V21, P1897, DOI 10.1007/s10895-011-0886-3; Fisher C, 2004, BIOCHEMISTRY-US, V43, P1037, DOI 10.1021/bi035529y; FRANKEL EN, 1993, LANCET, V341, P1103, DOI 10.1016/0140-6736(93)92472-6; Frozza RL, 2013, MOL NEUROBIOL, V47, P1066, DOI 10.1007/s12035-013-8401-2; Gupta V, 2006, J BIOL CHEM, V281, P39294, DOI 10.1074/jbc.M608085200; Hatters DM, 2006, TRENDS BIOCHEM SCI, V31, P445, DOI 10.1016/j.tibs.2006.06.008; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Holtzman DM, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006312; Jain A, 2013, CRIT REV THER DRUG, V30, P293, DOI 10.1615/CritRevTherDrugCarrierSyst.2013006955; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Jannin B, 2004, BIOCHEM PHARMACOL, V68, P1113, DOI 10.1016/j.bcp.2004.04.028; Khadem-Ansari Mohammad H, 2010, Open Biochem J, V4, P96, DOI 10.2174/1874091X01004010096; Khumsupan P, 2011, BBA-BIOMEMBRANES, V1808, P352, DOI 10.1016/j.bbamem.2010.09.007; Kuhnle G, 2000, BIOCHEM BIOPH RES CO, V272, P212, DOI 10.1006/bbrc.2000.2750; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; Leonarduzzi G, 2010, CURR MED CHEM, V17, P74, DOI 10.2174/092986710789957760; Li J, 2012, J BIOL CHEM, V287, P44593, DOI 10.1074/jbc.M112.420224; Liang L, 2013, PHYTOMEDICINE, V20, P558, DOI 10.1016/j.phymed.2012.12.012; Maletinska L, 2000, CANCER RES, V60, P2300; Miksits M, 2005, XENOBIOTICA, V35, P1101, DOI 10.1080/00498250500354253; Narayanaswami V, 2004, J BIOL CHEM, V279, P14273, DOI 10.1074/jbc.M313318200; Nath A, 2007, BIOCHEMISTRY-US, V46, P2059, DOI 10.1021/bi602371n; Nikanjam M, 2007, INT J PHARMACEUT, V328, P86, DOI 10.1016/j.ijpharm.2006.07.046; Pal A, 2002, MOL BIOCHEM PARASIT, V122, P217, DOI 10.1016/S0166-6851(02)00096-8; Pal S, 2003, J NUTR, V133, P700, DOI 10.1093/jn/133.3.700; Pangeni R, 2014, EXPERT OPIN DRUG DEL, V11, P1285, DOI 10.1517/17425247.2014.919253; Park SJ, 2012, CELL, V148, P421, DOI 10.1016/j.cell.2012.01.017; Pervaiz S, 2003, FASEB J, V17, P1975, DOI 10.1096/fj.03-0168rev; Phillips MC, 2014, IUBMB LIFE, V66, P616, DOI 10.1002/iub.1314; Planas JM, 2012, ARCH BIOCHEM BIOPHYS, V527, P67, DOI 10.1016/j.abb.2012.06.004; Rajan SS, 2014, J CONTROL RELEASE, V194, P301, DOI 10.1016/j.jconrel.2014.08.031; Raussens V, 1998, J BIOL CHEM, V273, P25825, DOI 10.1074/jbc.273.40.25825; Salas M, 2013, AM J PHYSIOL-CELL PH, V305, pC90, DOI 10.1152/ajpcell.00387.2012; Seeman P, 2011, SYNAPSE, V65, P1289, DOI 10.1002/syn.20957; Tak JK, 2012, BMB REP, V45, P242, DOI 10.5483/BMBRep.2012.45.4.242; Teskac K, 2010, INT J PHARMACEUT, V390, P61, DOI 10.1016/j.ijpharm.2009.10.011; Torchilin VP, 2007, AAPS J, V9, pE128, DOI 10.1208/aapsj0902015; Vang O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019881; Walle T, 2004, DRUG METAB DISPOS, V32, P1377, DOI 10.1124/dmd.104.000885; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; Yamamoto M, 1997, CANCER RES, V57, P2799	57	20	20	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 10	2015	10	8							e0135130	10.1371/journal.pone.0135130	http://dx.doi.org/10.1371/journal.pone.0135130			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO7PJ	26258481	Green Published, gold, Green Submitted			2023-01-03	WOS:000359352600041
J	Simmons, KB; Rodriguez, MI				Simmons, Katharine B.; Rodriguez, Maria I.			Reducing unintended pregnancy through provider training	LANCET			English	Editorial Material							REVERSIBLE CONTRACEPTION; IMMEDIATE; INSERTION		[Simmons, Katharine B.; Rodriguez, Maria I.] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97239 USA	Oregon Health & Science University	Simmons, KB (corresponding author), Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97239 USA.	simmonka@ohsu.edu		Rodriguez, Maria Isabel/0000-0002-3127-2581				Bednarek PH, 2011, NEW ENGL J MED, V364, P2208, DOI 10.1056/NEJMoa1011600; Goodman S, 2008, CONTRACEPTION, V78, P143, DOI 10.1016/j.contraception.2008.03.003; Guttmacher Institute, 2013, UN PREGN US, P1; Guttmacher Institute, 2014, CONTR US US, P1; Harper CC, 2015, LANCET, V386, P562, DOI 10.1016/S0140-6736(14)62460-0; Kavanaugh ML, 2010, CONTRACEPTION, V82, P331, DOI 10.1016/j.contraception.2010.04.010; Langston AM, 2014, CONTRACEPTION, V89, P103, DOI 10.1016/j.contraception.2013.10.014; Peipert JF, 2011, OBSTET GYNECOL, V117, P1105, DOI 10.1097/AOG.0b013e31821188ad; Sedgh G, 2014, STUD FAMILY PLANN, V45, P301, DOI 10.1111/j.1728-4465.2014.00393.x; Thompson KMJ, 2011, CONTRACEPTION, V83, P41, DOI 10.1016/j.contraception.2010.06.008; Trussell J, 2011, CONTRACEPTION, V83, P397, DOI 10.1016/j.contraception.2011.01.021; U.S. Department of Health and Human Services. Centers for Disease Control and Prevention, EFF FAM PLANN METH; WHO, 2014, ENS HUM RIGHTS PROV, P34; Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855	14	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 8	2015	386	9993					514	516		10.1016/S0140-6736(14)62444-2	http://dx.doi.org/10.1016/S0140-6736(14)62444-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CO8PG	26091740				2023-01-03	WOS:000359431900009
J	Koehn, D; Meyer, KJ; Syed, NA; Anderson, MG				Koehn, Demelza; Meyer, Kacie J.; Syed, Nasreen A.; Anderson, Michael G.			Ketamine/Xylazine-Induced Corneal Damage in Mice	PLOS ONE			English	Article							BAND KERATOPATHY; MOUSE MODELS; KETAMINE; XYLAZINE; RATS; SUSCEPTIBILITY; ANESTHESIA; THICKNESS; CATARACT; GLAUCOMA	Purpose We have observed that the commonly used ketamine/xylazine anesthesia mix can induce a focally severe and permanent corneal opacity. The purpose of this study was to establish the clinical and histological features of this deleterious side effect, its sensitivity with respect to age and anesthesia protocol, and approaches for avoiding it. Methods Young C57BL/6J, C57BLKS/J, and SJL/J mice were treated with permutations of anesthesia protocols and compared using slit-lamp exams, optical coherence tomography, histologic analyses, and telemetric measurements of body temperature. Results Ketamine/xylazine induces corneal damage in mice with a variable frequency. Among 12 experimental cohorts, corneal damage associated with ketamine/xylazine was observed in 9 of them. Despite various treatments to avoid corneal dehydration during anesthesia, the frequency of corneas experiencing damage among responding cohorts was 42% (26% inclusive of all cohorts), which is significantly greater than the natural prevalence (5%). The damage was consistent with band keratopathy. It appeared as a white or gray horizontal band located proximal to the pupil and was positive for subepithelial calcium deposition with von Kossa stain. Conclusions The sum of our clinical and histological observations is consistent with ketamine/xylazine-induced band keratopathy in mice. This finding is relevant for mouse studies involving the eye and/or vision-dependent behavioral assays, which would both be prone to artifact without appreciation of the damage caused by ketamine/xylazine anesthesia. Use of yohimbine is suggested as a practical means of avoiding this complication.	[Koehn, Demelza; Meyer, Kacie J.; Anderson, Michael G.] Univ Iowa, Dept Mol Physiol & Biophys, Iowa City, IA 52242 USA; [Syed, Nasreen A.; Anderson, Michael G.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA; [Syed, Nasreen A.] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; [Anderson, Michael G.] Iowa City VA Hlth Care Syst, Ctr Prevent & Treatment Visual Loss, Iowa City, IA USA	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Anderson, MG (corresponding author), Univ Iowa, Dept Mol Physiol & Biophys, Iowa City, IA 52242 USA.	michael-g-anderson@uiowa.edu	Anderson, Michael/B-4580-2009	Anderson, Michael/0000-0001-5730-6105; Syed, Nasreen/0000-0002-7192-0774	National Institutes of Health [EY021436, EY017673, EY018825]; NATIONAL EYE INSTITUTE [R01EY017673, R01EY018825, F32EY021436] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was funded by the following: National Institutes of Health EY021436 (to DK) (http://www.nih.gov/) and National Institutes of Health EY017673 and EY018825 (to MGA) (http://www.nih.gov/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson MG, 2006, BMC BIOL, V4, DOI 10.1186/1741-7007-4-20; Bartsch U, 2013, INVEST OPHTH VIS SCI, V54, P6952, DOI 10.1167/iovs.13-12945; Bergman S A, 1999, Anesth Prog, V46, P10; Bhutta AT, 2007, SEMIN PERINATOL, V31, P303, DOI 10.1053/j.semperi.2007.07.005; CALDERONE L, 1986, EXP EYE RES, V42, P331, DOI 10.1016/0014-4835(86)90026-6; Ding C, 2011, EXP EYE RES, V92, P512, DOI 10.1016/j.exer.2011.03.016; Dolansky G, 2008, PAED CHILD HEALT-CAN, V13, P307, DOI 10.1093/pch/13.4.307; Dursun I, 2011, ALCOHOL CLIN EXP RES, V35, P2063, DOI 10.1111/j.1530-0277.2011.01557.x; Eagle RC., 2011, EYE PATHOLOGY ATLAS; Fario QA, 2004, OPHTHALMOLOGY; Gaertner DJ, 2008, AM COLL LAB, P239, DOI 10.1016/B978-012373898-1.50014-0; Graw J, 2009, J GENET, V88, P469, DOI 10.1007/s12041-009-0066-2; GREENE SA, 1988, J VET PHARMACOL THER, V11, P295, DOI 10.1111/j.1365-2885.1988.tb00189.x; GUILLET R, 1988, INVEST OPHTH VIS SCI, V29, P949; HOFFMAN RW, 1983, ARTHRITIS RHEUM, V26, P645, DOI 10.1002/art.1780260511; Islam MS, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/149452; Jhanji V, 2011, CURR OPIN OPHTHALMOL, V22, P283, DOI 10.1097/ICU.0b013e3283477d36; Jones NP, 2013, UVEITIS; Lively GD, 2010, PHYSIOL GENOMICS, V42, P281, DOI 10.1152/physiolgenomics.00140.2009; Lively GD, 2010, INVEST OPHTH VIS SCI, V51, P160, DOI 10.1167/iovs.09-3429; Mao M, 2011, INVEST OPHTH VIS SCI, V52, P2679, DOI 10.1167/iovs.10-5993; McKinnon SJ, 2009, EXP EYE RES, V88, P816, DOI 10.1016/j.exer.2008.12.002; O'Connor G R, 1972, Trans Am Ophthalmol Soc, V70, P58; Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003; Qiu YG, 2014, CURR EYE RES, V39, P365, DOI 10.3109/02713683.2013.845224; Seo S, 2013, INVEST OPHTH VIS SCI, V54, P6118, DOI 10.1167/iovs.13-11673; Sinner B., 2008, V182, P313, DOI 10.1007/978-3-540-74806-9_15; Skolnick P, 2009, TRENDS PHARMACOL SCI, V30, P563, DOI 10.1016/j.tips.2009.09.002; Son AI, 2013, MOL VIS, V19, P254; Song J, 2003, INVEST OPHTH VIS SCI, V44, P548, DOI 10.1167/iovs.02-0592; Starte JM, 2012, CORNEA, V31, P572, DOI 10.1097/ICO.0b013e31823f8af4; Stokes EL, 2009, LAB ANIM-UK, V43, P149, DOI 10.1258/la.2008.008020; Svenson KL, 2012, GENETICS, V190, P437, DOI 10.1534/genetics.111.132597; Tita B, 2001, OPHTHALMIC RES, V33, P345, DOI 10.1159/000055692; Turner PV, 2005, COMPARATIVE MED, V55, P175; Wood D, 2011, BJU INT, V107, P1881, DOI 10.1111/j.1464-410X.2010.10031.x; Zieske JD, 2004, INT J DEV BIOL, V48, P903, DOI 10.1387/ijdb.041860jz	37	26	26	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2015	10	7							e0132804	10.1371/journal.pone.0132804	http://dx.doi.org/10.1371/journal.pone.0132804			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO0JM	26222692	Green Submitted, gold, Green Published			2023-01-03	WOS:000358836800029
J	Hoffmann, K; Peersman, W; George, A; Dorner, TE				Hoffmann, Kathryn; Peersman, Wim; George, Aaron; Dorner, Thomas Ernst			Associations and Synergistic Effects for Psychological Distress and Chronic Back Pain on the Utilization of Different Levels of Ambulatory Health Care. A Cross-Sectional Study from Austria	PLOS ONE			English	Article							DISABILITY PENSION; SICK LEAVE; DEPRESSION; SERVICES; INTERVENTION; COMORBIDITY; EUROPE; ACCESS; ADULTS; TIME	The aim of this analysis was to assess the impact of chronic back pain and psychological distress on the utilization of primary and secondary levels of care in the ambulatory health care sector in Austria - a country without a gatekeeping system. Additionally, we aimed to determine if the joint effect of chronic back pain and psychological distress was higher than the impact of the sum of the two single conditions. The database used for this analysis was the Austrian Health Interview Survey, with data from 15,474 individuals. Statistical methods used were descriptive tests, regression models and the calculation of synergistic effects. Both chronic back pain and psychological distress had a positive association with the utilization of the primary (OR for chronic back pain 1.53 and psychological distress 1.33) and secondary (OR for chronic back pain 1.32 and psychological distress 1.24) levels of the health care sector. In the fully adjusted model, the synergistic effect of chronic back pain and psychological distress was significant for the secondary level of care (S 1.99, PAF 0.20), but not for the primary level of care (S 1.16, PAF 0.07). Synergistic effects and associations for chronic back pain and psychological distress on the utilization of both the primary and secondary levels of the ambulatory health care sector were observed, particularly for the secondary level of care. Our results demonstrate the utilization of health care services settings by individuals with these conditions, and offer opportunities to consider reorganization and structuring of the Austrian health care system.	[Hoffmann, Kathryn] Med Univ Vienna, Ctr Publ Hlth, Dept Gen Practice, Vienna, Austria; [Peersman, Wim] Univ Ghent, Dept Family Med & Primary Care, B-9000 Ghent, Belgium; [George, Aaron] Duke Med Ctr, Dept Community & Family Med, Durham, NC USA; [Dorner, Thomas Ernst] Med Univ Vienna, Ctr Publ Hlth, Inst Social Med, Vienna, Austria	Medical University of Vienna; Ghent University; Duke University; Medical University of Vienna	Hoffmann, K (corresponding author), Med Univ Vienna, Ctr Publ Hlth, Dept Gen Practice, Vienna, Austria.	kathryn.hoffmann@meduniwien.ac.at	Hoffmann, Kathryn/AAK-9099-2021; Peersman, Wim/K-3576-2019	Peersman, Wim/0000-0002-4276-7408; Hoffmann, Kathryn/0000-0001-8760-4250; Dorner, Thomas Ernst/0000-0002-5218-1160				Alexanderson K, 2012, J EPIDEMIOL COMMUN H, V66, P155, DOI 10.1136/jech.2010.126789; Anderson Daren, 2012, Qual Prim Care, V20, P421; Andersson T, 2005, EUR J EPIDEMIOL, V20, P575, DOI 10.1007/s10654-005-7835-x; [Anonymous], MED OUTC STUD 36 IT; [Anonymous], 2009, STROBE STAT CHECKL C; [Anonymous], 2012, PRIM CAR 21 CENT; Aromaa A, 2003, EUR J PUBLIC HEALTH, V13, P67, DOI 10.1093/eurpub/13.suppl_1.67; Bair MJ, 2003, ARCH INTERN MED, V163, P2433, DOI 10.1001/archinte.163.20.2433; Bakker Ingrid M, 2007, PLoS Clin Trials, V2, pe26, DOI 10.1371/journal.pctr.0020026; Bower P, 2006, BRIT J PSYCHIAT, V189, P484, DOI 10.1192/bjp.bp.106.023655; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Chouinard MC, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-49; De Maeseneer J, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X652553; Dorner TE, 2015, EUR J PAIN; Dorner TE, 2010, WIEN KLIN WOCHENSCHR, V122, P103, DOI 10.1007/s00508-010-1312-6; Eriksen J, 2004, EUR J PAIN, V8, P517, DOI 10.1016/j.ejpain.2003.12.001; Expert Panel on Effective Ways of Investing in Health, 2014, EXP PAN EFF WAYS INV; Fishbain DA, 1997, CLIN J PAIN, V13, P116, DOI 10.1097/00002508-199706000-00006; Gleicher Y, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-147; Hoffmann K, 2013, EUR J PUBLIC HEALTH, V23, P933, DOI 10.1093/eurpub/ckt008; Hofmarcher M, 2013, AUSTRIA HLTH SYSTEM; Klimont J, 2007, AUSTRIAN HLTH SURVEY; Kringos D, 2013, BRIT J GEN PRACT, V63, pE742, DOI 10.3399/bjgp13X674422; Lazarus R.S., 1984, STRESS APPRAISAL COP; Overland S, 2012, EUR J PAIN, V16, P611, DOI 10.1016/j.ejpain.2011.08.005; Pearson WS, 2009, INT J PUBLIC HEALTH, V54, P23, DOI 10.1007/s00038-009-0003-4; Peersman W, 2014, EUR J PUBLIC HEALTH, V24, P91, DOI 10.1093/eurpub/ckt079; Pichlhofer O, 2015, EUR J PUBLIC HEALTH, V25, P401, DOI 10.1093/eurpub/cku189; Pieber K, 2012, J REHABIL MED, V44, P658, DOI 10.2340/16501977-1010; Rumball-Smith J, 2014, BMC FAM PRACT, V15, DOI 10.1186/1471-2296-15-149; Saastamoinen P, 2012, PAIN, V153, P526, DOI 10.1016/j.pain.2011.11.005; Starfleld B, 2005, ANN FAM MED, V3, P215, DOI 10.1370/afm.307; Stein KV, 2010, SCHMERZ, V24, P468, DOI 10.1007/s00482-010-0962-7; Stewart WF, 2003, JAMA-J AM MED ASSOC, V290, P2443, DOI 10.1001/jama.290.18.2443; Stigler FL, 2013, FAM PRACT, V30, P185, DOI 10.1093/fampra/cms067; Stinson J, 2013, CLIN J PAIN, V29, P600, DOI 10.1097/AJP.0b013e31826dce65; Taloyan M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044721; Terluin B, 2009, BMC FAM PRACT, V10, DOI 10.1186/1471-2296-10-58; The European definition of General Practice / Family Medicine, 2011, EUR DEF GEN PRACT FA; Tripp D. A., 2006, PAIN RES MANAG, V11, P225, DOI DOI 10.1155/2006/720895; Ullrich PM, 2013, REHABIL PSYCHOL, V58, P158, DOI 10.1037/a0032047; Vandenbroucke JP, 2007, EPIDEMIOLOGY, V18, P805, DOI 10.1097/EDE.0b013e3181577511; Wagner EH, 2000, BMJ-BRIT MED J, V320, P569, DOI 10.1136/bmj.320.7234.569; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weimer MB, 2013, PAIN MED, V14, P1839, DOI 10.1111/pme.12177; WELLS JE, 1994, SOC PSYCH PSYCH EPID, V29, P155; WHO, 2008, WORLD HLTH REPORT 20	47	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2015	10	7							e0134136	10.1371/journal.pone.0134136	http://dx.doi.org/10.1371/journal.pone.0134136			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CN7ED	26218661	Green Published, Green Submitted, gold			2023-01-03	WOS:000358595900085
J	Liu, YN; Tan, DH; Shi, L; Liu, XW; Zhang, YB; Tong, CC; Song, DQ; Hou, MX				Liu, Yunen; Tan, Dehong; Shi, Lin; Liu, Xinwei; Zhang, Yubiao; Tong, Changci; Song, Dequn; Hou, Mingxiao			Blueberry Anthocyanins-Enriched Extracts Attenuate Cyclophosphamide-Induced Cardiac Injury	PLOS ONE			English	Article							OXIDATIVE STRESS; INDUCED CARDIOTOXICITY; MYOCARDIAL-INFARCTION; ANGIOTENSIN-II; INFLAMMATION; ACTIVATION; DAMAGE; MICE; RATS; APOPTOSIS	We sought to explore the effect of blueberry anthocyanins-enriched extracts (BAE) on cyclophosphamide (CTX)-induced cardiac injury. The rats were divided randomly into five groups including normal control, CTX 100 mg/kg, BAE 80mg/kg, CTX+BAE 20mg/kg and CTX+BAE 80mg/kg groups. The rats in the three BAE-treated groups were administered BAE for four weeks. Seven days after BAE administration, rats in CTX group and two BAE-treated groups were intraperitoneally injected with a single dose of 100 mg/kg CTX. Cardiac injury was assessed using physiological parameters, Echo, morphological staining, real-time PCR and western blot. In addition, cardiotoxicity indices, inflammatory cytokines expression and oxidative stress markers were also detected. Four weeks 20mg/kg and 80mg/kg dose of BAE treatment following CTX exposure attenuated mean arterial blood pressure, heart rate and activities of heart enzymes, improved cardiac dysfunction, left ventricular hypertrophy and fibrosis. Importantly, BAE also attenuated CTX-induced LV leukocyte infiltration and inflammatory cytokines expression, ameliorated oxidative stress as well as cardiomyocyte apoptosis. In conclusion, BAE attenuated the CTX-induced cardiac injury and the protective mechanisms were related closely to the anti-inflammatory, antioxidant and anti-inflammatory characteristics of BAE.	[Liu, Yunen; Shi, Lin; Liu, Xinwei; Zhang, Yubiao; Tong, Changci; Hou, Mingxiao] PLA, Lab Rescue Ctr Severe Wound & Trauma, Dept Emergency Med, Gen Hosp Shenyang Mil Command, Shenyang, Peoples R China; [Tan, Dehong; Song, Dequn] Shenyang Agr Univ, Coll Food, Shenyang 110161, Peoples R China	Shenyang Agricultural University	Hou, MX (corresponding author), PLA, Lab Rescue Ctr Severe Wound & Trauma, Dept Emergency Med, Gen Hosp Shenyang Mil Command, Shenyang, Peoples R China.	houmingxiao188@163.com	Yunen, Liu/X-4121-2019		Liaoning Province Key Scientific and Technological Project [2013225089]; PLA foundation of China during the Twelfth Five-year Plan Period [CSY12J002]	Liaoning Province Key Scientific and Technological Project; PLA foundation of China during the Twelfth Five-year Plan Period	This work was supported by the grants of Liaoning Province Key Scientific and Technological Project (No. 2013225089), and PLA foundation of China during the Twelfth Five-year Plan Period (CSY12J002).	Ahmet I, 2005, CIRCULATION, V112, P3115, DOI 10.1161/CIRCULATIONAHA.105.563817; Ahmet I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007975; Albini A, 2010, JNCI-J NATL CANCER I, V102, P14, DOI 10.1093/jnci/djp440; Asiri YA, 2010, OXID MED CELL LONGEV, V3, P308, DOI 10.4161/oxim.3.5.13107; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BUHL SN, 1978, CLIN CHEM, V24, P828; Chen SE, 2005, AM J PHYSIOL-CELL PH, V289, pC1179, DOI 10.1152/ajpcell.00062.2005; Dange RB, 2014, CARDIOVASC RES, V103, P17, DOI 10.1093/cvr/cvu067; DAVIES MH, 1984, J PHARMACOL METHOD, V12, P191, DOI 10.1016/0160-5402(84)90059-7; De Vito P, 2014, PEPTIDES, V58, P108, DOI 10.1016/j.peptides.2014.06.011; DeFuria J, 2009, J NUTR, V139, P1510, DOI 10.3945/jn.109.105155; El-Deeb WM, 2015, PARASITOLOGY, V142, P767, DOI 10.1017/S0031182014001899; El-Sheikh AAK, 2014, PPAR RES, V2014, DOI 10.1155/2014/626319; Elisia I, 2007, FOOD CHEM, V101, P1052, DOI 10.1016/j.foodchem.2006.02.060; Feng WG, 2000, BIOCHEM BIOPH RES CO, V269, P570, DOI 10.1006/bbrc.2000.2341; Gong G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089450; Gong P, 2014, ENVIRON TOXICOL PHAR, V37, P1015, DOI 10.1016/j.etap.2014.03.017; Hughes FM, 2014, AM J PHYSIOL-RENAL, V306, pF299, DOI 10.1152/ajprenal.00297.2013; Ismahil MA, 2011, AM J PHYSIOL-HEART C, V301, pH2050, DOI 10.1152/ajpheart.00120.2011; Joseph SV, 2014, J AGR FOOD CHEM, V62, P3886, DOI 10.1021/jf4044056; Kang PM, 2000, CIRC RES, V86, P1107; Karlsen A, 2007, J NUTR, V137, P1951; Li YW, 2014, GENE, V542, P46, DOI 10.1016/j.gene.2014.03.021; Li YC, 2007, FOOD SCI TECHNOL, V11, P029; Liang YT, 2013, EUR J NUTR, V52, P869, DOI 10.1007/s00394-012-0393-6; Lim S, 2000, AM J RESP CRIT CARE, V162, P1355, DOI 10.1164/ajrccm.162.4.9910097; Liu W, 2013, INT J MOL SCI, V14, P21447, DOI 10.3390/ijms141121447; Liu YX, 2012, BRIT J NUTR, V108, P16, DOI 10.1017/S000711451100523X; Ludeman SM, 1999, CURR PHARM DESIGN, V5, P627; McAnulty LS, 2011, APPL PHYSIOL NUTR ME, V36, P976, DOI [10.1139/h11-120, 10.1139/H11-120]; Milanski M, 2009, J NEUROSCI, V29, P359, DOI 10.1523/JNEUROSCI.2760-08.2009; MOORE VL, 1981, J IMMUNOL, V127, P339; Moze S, 2011, J AGR FOOD CHEM, V59, P6998, DOI 10.1021/jf200765n; Mythili Y, 2005, MOL CELL BIOCHEM, V276, P39, DOI 10.1007/s11010-005-2735-7; Nakahira K, 2006, J EXP MED, V203, P2377, DOI 10.1084/jem.20060845; Ni HB, 2015, J SPINAL CORD MED, V38, P199, DOI 10.1179/2045772313Y.0000000179; Ogawa K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069053; Patel BV, 2013, J IMMUNOL, V190, P4274, DOI 10.4049/jimmunol.1202437; Pingitore A, 2006, J CARD FAIL, V12, P520, DOI 10.1016/j.cardfail.2006.05.009; Preiser JC, 2012, JPEN-PARENTER ENTER, V36, P147, DOI 10.1177/0148607111434963; Routray W, 2011, COMPR REV FOOD SCI F, V10, P303, DOI 10.1111/j.1541-4337.2011.00164.x; Rudic M, 2012, AUDIOL NEURO-OTOL, V17, P169, DOI 10.1159/000335098; Saleem M, 2000, FOOD CHEM TOXICOL, V38, P939, DOI 10.1016/S0278-6915(00)00088-0; Sayed-Ahmed MM, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/452902; SEGGEV JS, 1991, CLIN IMMUNOL IMMUNOP, V60, P289, DOI 10.1016/0090-1229(91)90071-H; Serra AJ, 2010, J PHYSIOL-LONDON, V588, P2431, DOI 10.1113/jphysiol.2010.187310; Slatnar A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047880; Sui XZ, 2014, INT J MOL MED, V33, P227, DOI 10.3892/ijmm.2013.1546; Swamy AHMV, 2013, INDIAN J PHARMACOL, V45, P44, DOI 10.4103/0253-7613.106434; Taneja AK, 2014, INT J CARDIOL, V175, P253, DOI 10.1016/j.ijcard.2014.05.018; Todorova V, 2009, NUTRITION, V25, P812, DOI 10.1016/j.nut.2009.01.004; WU AHB, 1982, CLIN CHEM, V28, P2017; Wu LH, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq040; XUN CQ, 1994, BLOOD, V83, P2360; Zafra-Stone S, 2007, MOL NUTR FOOD RES, V51, P675, DOI 10.1002/mnfr.200700002; Zhang HJ, 2013, AQUAT TOXICOL, V140, P11, DOI 10.1016/j.aquatox.2013.05.009; Zuppinger C, 2007, CARDIOVASC TOXICOL, V7, P61, DOI 10.1007/s12012-007-0016-2	57	38	39	1	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2015	10	7							e0127813	10.1371/journal.pone.0127813	http://dx.doi.org/10.1371/journal.pone.0127813			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1CS	26133371	gold, Green Submitted, Green Published			2023-01-03	WOS:000358154400005
J	Luo, J; Kesselheim, AS				Luo, Jing; Kesselheim, Aaron S.			The Trans-Pacific Partnership Agreement and Implications for Access to Essential Medicines	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Luo, Jing; Kesselheim, Aaron S.] Harvard Univ, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law,Dept Med, Boston, MA 02115 USA; [Luo, Jing; Kesselheim, Aaron S.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Luo, J (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.	jluo1@partners.org	Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666				Gleeson DH, 2015, MED J AUSTRALIA, V202, P306, DOI 10.5694/mja14.01682; Kapczynski A, 2015, NEW ENGL J MED, V373, P201, DOI 10.1056/NEJMp1506158; Kapczynski A, 2013, NEW ENGL J MED, V369, P497, DOI 10.1056/NEJMp1304400; Knowledge Ecology International, 2015, CONS TEXT INT PROP C; Neuwelt PM, PATENTLY OBVIOUS PUB; Stastna K, ELI LILLY FILES 500M; Stiglitz JE, DONT TRADE AWAY OUR; Wang B, 2015, JAMA INTERN MED, V175, P635, DOI 10.1001/jamainternmed.2014.7968; Weisman J, PATENT PROTECTION DR	9	5	5	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	2015	314	15					1563	1564		10.1001/jama.2015.10872	http://dx.doi.org/10.1001/jama.2015.10872			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT7XK	26291894				2023-01-03	WOS:000363028500013
J	Gilbert, JL; Guthart, MJ; Gezan, SA; de Carvalho, MP; Schwieterman, ML; Colquhoun, TA; Bartoshuk, LM; Sims, CA; Clark, DG; Olmstead, JW				Gilbert, Jessica L.; Guthart, Matthew J.; Gezan, Salvador A.; de Carvalho, Melissa Pisaroglo; Schwieterman, Michael L.; Colquhoun, Thomas A.; Bartoshuk, Linda M.; Sims, Charles A.; Clark, David G.; Olmstead, James W.			Identifying Breeding Priorities for Blueberry Flavor Using Biochemical, Sensory, and Genotype by Environment Analyses	PLOS ONE			English	Article							VACCINIUM-CORYMBOSUM; VOLATILE COMPOSITION; INSTRUMENTAL MEASUREMENTS; AROMA; QUALITY; FRUIT; ODOR; TEXTURE; TASTE; IDENTIFICATION	Breeding for a subjective goal such as flavor is challenging, as many blueberry cultivars are grown worldwide, and identifying breeding targets relating to blueberry flavor biochemistry that have a high degree of genetic control and low environmental variability are priorities. A variety of biochemical compounds and physical characters induce the sensory responses of taste, olfaction, and somatosensation, all of which interact to create what is perceived flavor. The goal of this study was to identify the flavor compounds with a larger genetic versus environmental component regulating their expression over an array of cultivars, locations, and years. Over the course of three years, consumer panelists rated overall liking, texture, sweetness, sourness, and flavor intensity of 19 southern highbush blueberry (Vaccinium corymbosum hybrids) genotypes in 30 sensory panels. Significant positive correlations to overall liking of blueberry fruit (P<0.001) were found with sweetness (R-2 = 0.70), texture (R-2 = 0.68), and flavor (R-2 = 0.63). Sourness had a significantly negative relationship with overall liking (R-2 = 0.55). The relationship between flavor and texture liking was also linear (R-2 = 0.73, P<0.0001) demonstrating interaction between olfaction and somatosensation. Partial least squares analysis was used to identify sugars, acids, and volatile compounds contributing to liking and sensory intensities, and revealed strong effects of fructose, pH, and several volatile compounds upon all sensory parameters measured. To assess the feasibility of breeding for flavor components, a three year study was conducted to compare genetic and environmental influences on flavor biochemistry. Panelists could discern genotypic variation in blueberry sensory components, and many of the compounds affecting consumer favor of blueberries, such as fructose, pH, beta-caryophyllene oxide and 2-heptanone, were sufficiently genetically controlled that allocating resources for their breeding is worthwhile.	[Gilbert, Jessica L.; Schwieterman, Michael L.; Colquhoun, Thomas A.; Bartoshuk, Linda M.; Sims, Charles A.; Clark, David G.; Olmstead, James W.] Univ Florida, Inst Food & Agr Sci, Plant Innovat Ctr, Gainesville, FL 32611 USA; [Gilbert, Jessica L.; Guthart, Matthew J.; Olmstead, James W.] Univ Florida, Inst Food & Agr Sci, Dept Hort Sci, Gainesville, FL 32611 USA; [Gezan, Salvador A.; de Carvalho, Melissa Pisaroglo] Univ Florida, Inst Food & Agr Sci, Sch Forest Resources & Conservat, Gainesville, FL 32611 USA; [Schwieterman, Michael L.; Colquhoun, Thomas A.; Clark, David G.] Univ Florida, Inst Food & Agr Sci, Dept Environm Hort, Gainesville, FL 32611 USA; [Bartoshuk, Linda M.; Sims, Charles A.] Univ Florida, Inst Food & Agr Sci, Food Sci & Human Nutr, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Olmstead, JW (corresponding author), Univ Florida, Inst Food & Agr Sci, Plant Innovat Ctr, Gainesville, FL 32611 USA.	jwolmstead@ufl.edu			University of Florida Graduate Fellowship in Plant Molecular Breeding	University of Florida Graduate Fellowship in Plant Molecular Breeding	A University of Florida Graduate Fellowship in Plant Molecular Breeding was obtained by DGC and JWO in 2011 to fund this project. http://pmcb.ifas.ufl.edu/funding/index.shtml. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almenar E, 2010, J SCI FOOD AGR, V90, P1121, DOI 10.1002/jsfa.3922; Badoc A., 1991, Journal of Essential Oil Research, V3, P269; BALLINGTON JR, 1984, J AM SOC HORTIC SCI, V109, P684; BALOGA DW, 1995, ACS SYM SER, V596, P235; Barrett DM, 2010, CRIT REV FOOD SCI, V50, P369, DOI 10.1080/10408391003626322; Bartoshuk LM, 2005, CURR DIR PSYCHOL SCI, V14, P122, DOI 10.1111/j.0963-7214.2005.00346.x; Bartoshuk LM, 2004, PHYSIOL BEHAV, V82, P109, DOI 10.1016/j.physbeh.2004.02.033; Benn SM, 1996, J AGR FOOD CHEM, V44, P557, DOI 10.1021/jf9504172; Blaker KM, 2014, J SCI FOOD AGR, V94, P2785, DOI 10.1002/jsfa.6626; Bohlmann J, 1998, P NATL ACAD SCI USA, V95, P4126, DOI 10.1073/pnas.95.8.4126; Bojanowski V, 2012, PHYSIOL BEHAV, V107, P484, DOI 10.1016/j.physbeh.2012.03.001; Cebolla-Cornejo J, 2011, J AGR FOOD CHEM, V59, P2440, DOI 10.1021/jf1045427; Colquhoun TA, 2013, POSTHARVEST BIOL TEC, V86, P37, DOI 10.1016/j.postharvbio.2013.06.013; DARNELL RL, 1994, PHYSIOL PLANTARUM, V92, P336, DOI [10.1111/j.1399-3054.1994.tb05345.x, 10.1034/j.1399-3054.1994.920220.x]; de Kermadec F, 1997, FOOD QUAL PREFER, V8, P395, DOI 10.1016/S0950-3293(97)00026-8; DIMICK PS, 1983, CRC CR REV FOOD SCI, V18, P387, DOI 10.1080/10408398309527367; Du XF, 2011, J AGR FOOD CHEM, V59, P8347, DOI 10.1021/jf201184m; Eichholz I, 2011, FOOD CHEM, V126, P60, DOI 10.1016/j.foodchem.2010.10.071; Figueiredo AC, 2008, FLAVOUR FRAG J, V23, P213, DOI 10.1002/ffj.1875; Forney CF, 2001, HORTTECHNOLOGY, V11, P529, DOI 10.21273/HORTTECH.11.4.529; FRANK RA, 1993, PERCEPT PSYCHOPHYS, V54, P343, DOI 10.3758/BF03205269; FRANKE W, 1961, ARCH MIKROBIOL, V40, P73, DOI 10.1007/BF00408834; GALLETTA GJ, 1971, J AM SOC HORTIC SCI, V96, P758; Gilbert JL, 2014, HORTSCIENCE, V49, P864, DOI 10.21273/HORTSCI.49.7.864; Gilbert JL, 2013, HORTSCIENCE, V48, P835, DOI 10.21273/HORTSCI.48.7.835; Golebiowski M, 2008, CHEM NAT COMPD+, V44, P794, DOI 10.1007/s10600-009-9171-y; Gould W.A., 1983, TOMATO PRODUCTION PR; HIRVI T, 1983, J SCI FOOD AGR, V34, P992, DOI 10.1002/jsfa.2740340916; Hongsoongnern P, 2008, J SENS STUD, V23, P205, DOI 10.1111/j.1745-459X.2007.00150.x; HORVAT RJ, 1985, J FOOD SCI, V50, P429, DOI 10.1111/j.1365-2621.1985.tb13419.x; Hough G, 1996, FOOD QUAL PREFER, V7, P47, DOI 10.1016/0950-3293(94)00000-X; KADER F, 1993, FOOD SCI TECHNOL-LEB, V26, P593, DOI 10.1006/fstl.1993.1114; Kenward MG, 1997, BIOMETRICS, V53, P983, DOI 10.2307/2533558; Klesk K, 2004, J AGR FOOD CHEM, V52, P5155, DOI 10.1021/jf0498721; LARSEN M, 1992, Z LEBENSM UNTERS FOR, V195, P120, DOI 10.1007/BF01201770; Lawless H.T., 2010, SENSORY EVALUATION F, Vsecond; Mahawanich T, 2004, FOOD CHEM, V84, P169, DOI 10.1016/S0308-8146(03)00197-3; Mattheis JP, 1999, POSTHARVEST BIOL TEC, V15, P227, DOI 10.1016/S0925-5214(98)00087-8; Moore PP, 2002, ACTA HORTIC, P511, DOI 10.17660/ActaHortic.2002.585.82; MOSKOWIT.HR, 1970, PERCEPT PSYCHOPHYS, V7, P315, DOI 10.3758/BF03210175; MOSKOWITZ HR, 1971, AM J PSYCHOL, V84, P387, DOI 10.2307/1420470; Murthy CT, 2008, J FOOD ENG, V85, P18, DOI 10.1016/j.jfoodeng.2007.06.020; Niimura Y, 2012, CURR GENOMICS, V13, P103, DOI 10.2174/138920212799860706; Olender T, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-414; PANGBORN RM, 1960, FOOD TECHNOL-CHICAGO, V14, pB36; PARLIMENT TH, 1975, J FOOD SCI, V40, P762, DOI 10.1111/j.1365-2621.1975.tb00550.x; Paterson A, 2013, THEOR APPL GENET, V126, P33, DOI 10.1007/s00122-012-1957-9; Payne TJ, 2014, N AM HIGHBUSH BLUEBE; Pirbalouti AG, 2013, IND CROP PROD, V48, P43, DOI 10.1016/j.indcrop.2013.04.004; Qian MC, 2005, J FOOD SCI, V70, pC13, DOI 10.1111/j.1365-2621.2005.tb09013.x; Rohloff J, 2004, J FOOD AGRIC ENVIRON, V2, P74; Ryan D, 2008, TRENDS FOOD SCI TECH, V19, P383, DOI 10.1016/j.tifs.2008.01.007; Saftner R, 2008, POSTHARVEST BIOL TEC, V49, P19, DOI 10.1016/j.postharvbio.2008.01.008; Samykanno K, 2013, SCI HORTIC-AMSTERDAM, V164, P633, DOI 10.1016/j.scienta.2013.09.001; Sanchez G, 2014, BMC PLANT BIOL, V14, DOI 10.1186/1471-2229-14-137; SCHIEBERLE P, 1988, J AGR FOOD CHEM, V36, P797, DOI 10.1021/jf00082a031; Schwieterman ML, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088446; Styger G, 2011, J IND MICROBIOL BIOT, V38, P1145, DOI 10.1007/s10295-011-1018-4; SZCZESNIAK AS, 1988, J TEXTURE STUD, V19, P61, DOI 10.1111/j.1745-4603.1988.tb00925.x; Taylor AJ, 2004, FLAVOR PERCEPTION; Tenenhaus M, 2005, FOOD QUAL PREFER, V16, P315, DOI 10.1016/j.foodqual.2004.05.013; Tieman D, 2012, CURR BIOL, V22, P1035, DOI 10.1016/j.cub.2012.04.016; Togari N, 1995, FOOD RES INT, V28, P485, DOI 10.1016/0963-9969(95)00028-3; Toscas PJ, 1999, MEAT SCI, V52, P173, DOI 10.1016/S0309-1740(98)00165-X; Troje ZS, 1997, J CHROMATOGR A, V775, P101; Van Opstaele F, 2013, J AGR FOOD CHEM, V61, P10555, DOI 10.1021/jf402496t; Vigues S, 2009, RESULTS PROBL CELL D, V47, P187, DOI 10.1007/400_2008_2; Wang L, 2004, J I BREWING, V110, P57, DOI 10.1002/j.2050-0416.2004.tb00181.x; Weel KGC, 2002, J AGR FOOD CHEM, V50, P5149, DOI 10.1021/jf0202786; Werkhoff P, 1998, J AGR FOOD CHEM, V46, P1076, DOI 10.1021/jf970655s; Wolken WAM, 2001, APPL MICROBIOL BIOT, V57, P731, DOI 10.1007/s002530100821; Yarmolinsky DA, 2009, CELL, V139, P234, DOI 10.1016/j.cell.2009.10.001; YU TH, 1989, J AGR FOOD CHEM, V37, P730, DOI 10.1021/jf00087a033	73	54	56	8	68	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2015	10	9							e0138494	10.1371/journal.pone.0138494	http://dx.doi.org/10.1371/journal.pone.0138494			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS0RH	26378911	Green Published, gold, Green Submitted			2023-01-03	WOS:000361769400106
J	Allison, JP				Allison, James P.			Checkpoints	CELL			English	Editorial Material									[Allison, James P.] Circa, Berkeley, CA USA					Allison, James/0000-0001-8980-5697	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))			0	22	23	1	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 10	2015	162	6					1203	1205		10.1016/j.cell.2015.08.047	http://dx.doi.org/10.1016/j.cell.2015.08.047			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	CR3QL	26359978	Bronze			2023-01-03	WOS:000361247900007
J	Huston, RK; Christensen, JM; Alshahrani, SM; Mohamed, SM; Clark, SM; Nason, JA; Wu, YX				Huston, Robert K.; Christensen, J. Mark; Alshahrani, Sultan M.; Mohamed, Sumeia M.; Clark, Sara M.; Nason, Jeffrey A.; Wu, Ying Xing			Calcium Chloride in Neonatal Parenteral Nutrition Solutions with and without Added Cysteine: Compatibility Studies Using Laser and Micro-Flow Imaging Methodology	PLOS ONE			English	Article							INTRAVENOUS-FEEDING SOLUTIONS; INORGANIC-PHOSPHATE SALTS; ORGANIC CALCIUM; ALUMINUM CONTAMINATION; PHYSICAL COMPATIBILITY; SODIUM-PHOSPHATE; ADMIXTURES; INFANTS; PRECIPITATION; SOLUBILITY	Background Previous studies of compatibility of calcium chloride (CaCl2) and phosphates have not included particle counts in the range specified by the United States Pharmacopeia. Microflow imaging techniques have been shown to be comparable to light obscuration when determining particle count and size in pharmaceutical solutions. Objective The purpose of this study was to do compatibility testing for parenteral nutrition (PN) solutions containing CaCl2 using dynamic light scattering and micro-flow imaging techniques. Methods Solutions containing TrophAmine (Braun Medical Inc, Irvine, CA), CaCl2, and sodium phosphate (NaPhos) were compounded with and without cysteine. All solutions contained standard additives to neonatal PN solutions including dextrose, trace metals, and electrolytes. Control solutions contained no calcium or phosphate. Solutions were analyzed for particle size and particle count. Means of Z-average particle size and particle counts of controls were determined. Study solutions were compared to controls and United States Pharmacopeia (USP) Chapter 788 guidelines. The maximum amount of Phos that was compatible in solutions that contained at least 10 mmol/L of Ca in 2.5% amino acids (AA) was determined. Compatibility of these solutions was verified by performing analyses of 5 repeats of these solutions. Microscopic analyses of the repeats were also performed. Results Amounts of CaCl2 and NaPhos that were compatible in solutions containing 1.5%, 2%, 2.5%, and 3% AA were determined. The maximum amount of NaPhos that could be added to TrophAmine solutions of > = 2.5% AA containing at least 10 mmol/L of CaCl2 was 7.5 mmol/L. Adding 50 mg/dL of cysteine increased the amount of NaPhos that could be added to solutions containing 10 mmol/L of CaCl2 to 10 mmol/L. Conclusion Calcium chloride can be added to neonatal PN solutions containing NaPhos in concentrations that can potentially provide an intravenous intake of adequate amounts of calcium and phosphorus.	[Huston, Robert K.] Northwest Newborn Specialists PC, Portland, OR 97227 USA; [Huston, Robert K.] Pediatrix Med Grp, Portland, OR USA; [Christensen, J. Mark; Alshahrani, Sultan M.; Mohamed, Sumeia M.] Oregon State Univ, Coll Pharm, Dept Pharmaceut Sci, Corvallis, OR 97331 USA; [Clark, Sara M.] Providence St Vincent Med Ctr, Neonatal Pharm, Portland, OR USA; [Nason, Jeffrey A.] Oregon State Univ, Sch Chem Biol & Environm Engn, Corvallis, OR 97331 USA; [Wu, Ying Xing] Providence Hlth & Serv, Med Data Res Ctr, Portland, OR USA	Oregon State University; Oregon State University	Huston, RK (corresponding author), Northwest Newborn Specialists PC, Portland, OR 97227 USA.	Robert_Huston@pediatrix.com	Alshahrani, Sultan/CAF-7886-2022; Alshahrani, Sultan M./AAB-3081-2019	Alshahrani, Sultan/0000-0002-6194-7092; Alshahrani, Sultan M./0000-0002-6194-7092	Northwest Newborn Specialists, PC	Northwest Newborn Specialists, PC	The funder (Northwest Newborn Specialists, PC) provided support in the form of salary for RKH, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of RKH is articulated in the 'author contributions' section.	Bishop NJ, 1997, NEW ENGL J MED, V336, P1557, DOI 10.1056/NEJM199705293362203; Bohrer D, 2002, JPEN-PARENTER ENTER, V26, P382, DOI 10.1177/0148607102026006382; Bouchoud L, 2010, JPEN-PARENTER ENTER, V34, P542, DOI 10.1177/0148607110374615; BOULET M, 1962, ARCH BIOCHEM BIOPHYS, V96, P629, DOI 10.1016/0003-9861(62)90348-X; Braake FWJT, 2009, PEDIATRICS, V124, pE978, DOI 10.1542/peds.2008-2477; Driscoll DF, 2012, JPEN-PARENTER ENTER, V36, P497, DOI 10.1177/0148607112455064; Fewtrell MS, 2009, PEDIATRICS, V124, P1372, DOI 10.1542/peds.2009-0783; FITZGERALD KA, 1986, AM J HOSP PHARM, V43, P88, DOI 10.1093/ajhp/43.1.88; Food and Drug Administration, 2002, FED REGISTER, V67, P70691; Frey OR, 2000, ANN PHARMACOTHER, V34, P811, DOI 10.1345/aph.19306; Gonyon T, 2014, JPEN-PARENTER ENTER, V38, P717, DOI 10.1177/0148607113495415; HENRY RS, 1980, AM J HOSP PHARM, V37, P673, DOI 10.1093/ajhp/37.5.673; Huang CT, 2009, J PHARM SCI-US, V98, P3058, DOI 10.1002/jps.21575; Huston RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106825; Huston RK, 2012, JPEN-PARENTER ENTER, V36, P498, DOI 10.1177/0148607112456297; Kerner, 1983, MANUAL PEDIAT PARENT, P177; Kruger PC, 2014, JPEN-PARENTER ENTER, V38, P728, DOI 10.1177/0148607113491981; MacKay M, 2015, JPEN-PARENTER ENTER, V39, P725, DOI 10.1177/0148607114528982; MACMAHON P, 1990, ARCH DIS CHILD-FETAL, V65, P352, DOI 10.1136/adc.65.4_Spec_No.352; Mathaes R, 2013, INT J PHARMACEUT, V453, P620, DOI 10.1016/j.ijpharm.2013.05.046; Migaki EA, 2012, JPEN-PARENTER ENTER, V36, P470, DOI 10.1177/0148607111420154; Nehra D, 2013, JPEN-PARENTER ENTER, V37, P570, DOI 10.1177/0148607113487216; NICOLI DF, 1995, AM LAB, V27, P41; Oma P, 2010, PHARMACOPEIAL FORUM, V36, P311; Parikh MJ, 2005, AM J HEALTH-SYST PH, V62, P1177, DOI 10.1093/ajhp/62.11.1177; Poole RL, 2008, JPEN-PARENTER ENTER, V32, P242, DOI 10.1177/0148607108316187; RAUPP P, 1991, JPEN-PARENTER ENTER, V15, P469, DOI 10.1177/0148607191015004469; Singh H, 2009, PEDIATR CRIT CARE ME, V10, P213, DOI 10.1097/PCC.0b013e31819a3bf4; Soghier LM, 2009, COCHRANE DB SYST REV; United States Pharmacopeia, 2011, US PHARM, P326; Zolls S, 2013, AAPS J, V15, P1200, DOI 10.1208/s12248-013-9522-2	31	5	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2015	10	8							e0136894	10.1371/journal.pone.0136894	http://dx.doi.org/10.1371/journal.pone.0136894			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ0PO	26317344	Green Published, gold, Green Submitted			2023-01-03	WOS:000360299100163
J	Sanfelix-Gimeno, G; Hurtado, I; Sanfelix-Genoves, J; Baixauli-Perez, C; Rodriguez-Bernal, CL; Peiro, S				Sanfelix-Gimeno, Gabriel; Hurtado, Isabel; Sanfelix-Genoves, Jose; Baixauli-Perez, Cristobal; Rodriguez-Bernal, Clara L.; Peiro, Salvador			Overuse and Underuse of Antiosteoporotic Treatments According to Highly Influential Osteoporosis Guidelines: A Population-Based Cross-Sectional Study in Spain	PLOS ONE			English	Article							HEALTH-CARE SERVICES; FRACTURE RISK-FACTORS; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURE; ESOSVAL COHORT; UNITED-STATES; VALENCIA; QUALITY; PROBABILITY; PREVALENCE	Inappropriate prescribing of antiosteoporotic medications has been observed; however, the joint study of both overuse and underuse has barely been attempted. Spain, with its high utilization rates, constitutes a good example to assess differences in over and under use according to diverse highly-influential osteoporosis guidelines (HIOG) worldwide. We used data of a population-based cross-sectional study including 824 post-menopausal women >= 50 years old living in the city of Valencia, Spain and aimed to estimate the percentage of women eligible for treatment, and the proportion of overuse and underuse of antiosteoporotic treatment according to HIOG. The prevalence of antiosteoporotic treatment in postmenopausal women >= 50 in Valencia was 20.9% (95% CI: 17.6-24.4). The type of antiosteoporotic drugs prescribed varied greatly depending on the medical specialty responsible of the initial prescription. When applying the HIOG, the percentage of women 50 and over who should be treated varied from less than 9% to over 44%. In real terms, from the approximately eight million women of 50 years old and over in Spain, the number eligible for treatment would range from 0.7 to 3.8 million, depending on the guideline used. A huge proportion of inappropriate treatments was found when applying these guidelines to the Spanish population, combining a high overuse (42-78% depending on the guideline used) and underuse (7-41%). In conclusion, we found that the pharmacological management of osteoporosis in women of 50 and over in this population combines an important overuse and, to a lesser extent, underuse, although the level of inappropriateness varied strikingly depending on the CPG used. It seems urgent to reduce treatment overuse without neglecting underuse, as is urgent an attempt to reach wider agreement worldwide regarding osteoporosis management, in order to facilitate appropriate treatment and development of policies to reduce effectively treatment inappropriateness.	[Sanfelix-Gimeno, Gabriel; Hurtado, Isabel; Sanfelix-Genoves, Jose; Baixauli-Perez, Cristobal; Rodriguez-Bernal, Clara L.; Peiro, Salvador] Ctr Publ Hlth Res FISABIO, Hlth Serv Res Unit, Valencia, Spain; [Sanfelix-Gimeno, Gabriel; Hurtado, Isabel; Sanfelix-Genoves, Jose; Baixauli-Perez, Cristobal; Rodriguez-Bernal, Clara L.; Peiro, Salvador] Red Invest Serv Salud Enfermedades Cronicas REDIS, Valencia, Spain; [Sanfelix-Genoves, Jose] Fdn Invest Hosp Clin Univ, Inst Invest Sanitaria INCLIVA, Valencia, Spain		Sanfelix-Gimeno, G (corresponding author), Ctr Publ Hlth Res FISABIO, Hlth Serv Res Unit, Valencia, Spain.	sanfelix_gab@gva.es	Peiro, Salvador/H-5778-2017; Rodriguez-Bernal, Clara/ABF-9659-2021; Hurtado, Isabel/I-3395-2017; Sanfélix-Gimeno, Gabriel/E-9140-2012	Peiro, Salvador/0000-0002-3902-569X; Rodriguez-Bernal, Clara/0000-0003-2617-8635; Hurtado, Isabel/0000-0002-8475-8112; Sanfélix-Gimeno, Gabriel/0000-0001-7098-4576; Baixauli Perez, Cristobal/0000-0002-7567-0995	Ministry of Health of the Autonomous Government of Valencia [0018/2005]; Sanofi-Aventis	Ministry of Health of the Autonomous Government of Valencia; Sanofi-Aventis(Sanofi-Aventis)	The FRAVO study was funded by the Ministry of Health of the Autonomous Government of Valencia (Project 0018/2005) and a non-conditioned research grant from Sanofi-Aventis. None of the sponsors were involved in the design and conduct of the study; collection, management, analysis, or interpretation of the data; and preparation, review, or approval of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Center for Public Health Research (CSISP-FISABIO), Red de Investigacion en Servicios de Salud en Enfermedades Cronicas (REDISSEC), Valencia, Spain; or Fundacion de Investigacion del Hospital Clinico Universitario - Instituto de Investigacion Sanitaria INCLIVA. Valencia, Spain. No additional funding and support declared in our competing interest statement are specific to this study.	Andrade SE, 2003, ARCH INTERN MED, V163, P2052, DOI 10.1001/archinte.163.17.2052; [Anonymous], 2008, OST MAN AT PRIM; [Anonymous], 2010, GUIA PRACT CLIN OST; [Anonymous], 2006, DOC CLIN SEMERGEN OS; Bolland MJ, 2010, J CLIN ENDOCR METAB, V95, P1856, DOI 10.1210/jc.2009-2157; Chan KS, 2013, MED CARE RES REV, V70, P473, DOI 10.1177/1077558713492202; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; de Felipe R, 2010, ATEN PRIM, V42, P559, DOI 10.1016/j.aprim.2009.10.022; Diez-Perez A, 2011, BONE, V49, P493, DOI 10.1016/j.bone.2011.05.007; Eisenberg JM, 2002, MED CARE, V40, P1016, DOI 10.1097/00005650-200211000-00004; Emery DJ, 2013, JAMA INTERN MED, V173, P823, DOI 10.1001/jamainternmed.2013.3804; Salgueiro ME, 2013, MATURITAS, V74, P74, DOI 10.1016/j.maturitas.2012.10.002; GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915; Grupo de trabajo de la Guia de Practica Clinica sobre Osteoporosis y Prevencion de Fracturas por Fragilidad-Guia Salud. Guia de Practica Clinica sobre Osteoporosis yPrevencion de Fracturas por Fragilidad, 2010, GUIA PRACT CLIN OST; Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657-013-0136-1; Hurtado I, 2014, J CLIN ENDOCR METAB, V99, P142, DOI 10.1210/jc.2013-3448; Kale MS, 2013, JAMA INTERN MED, V173, P142, DOI 10.1001/2013.jamainternmed.1022; Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198-007-0543-5; Kanis JA, 2012, OSTEOPOROSIS INT, V23, P2239, DOI 10.1007/s00198-012-1964-3; Keyhani S, 2008, HEALTH SERV RES, V43, P1923, DOI 10.1111/j.1475-6773.2008.00920.x; Korenstein D, 2012, ARCH INTERN MED, V172, P171, DOI 10.1001/archinternmed.2011.772; Leslie WD, 2012, OSTEOPOROSIS INT, V23, P1623, DOI 10.1007/s00198-011-1630-1; Lipitz-Snyderman A, 2013, JAMA INTERN MED, V173, P1277, DOI 10.1001/jamainternmed.2013.6181; Liu SK, 2013, J AM GERIATR SOC, V61, P1855, DOI 10.1111/jgs.12507; Martinez JMO, 2008, REV CLIN ESP, V208, P247, DOI 10.1157/13119919; National Institute for Clinical Excellence (NICE), 2011, NICE TECHN APPR GUID, V217; National Osteoporosis Foundation (NOF), 2010, CLIN GUID PREV TREAT; National Osteoporosis Guideline Group (NOGG) on behalf of the Bone Research Society British Geriatrics Society British Orthopaedic Association British Society of Rheumatology National Osteoporosis Society Osteoporosis 2000 Osteoporosis Dorset Primary Care Rheumatology Society Royal College of Physicians and Society for Endocrinology, 2010, OST 2000 OST DORS PR; Naves M, 2003, OSTEOPOROSIS INT, V14, P520, DOI 10.1007/s00198-003-1405-4; Papaioannou A, 2010, CAN MED ASSOC J, V182, P1864, DOI 10.1503/cmaj.100771; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; Edo LP, 2011, REUMATOL CLIN, V7, P357, DOI 10.1016/j.reuma.2011.05.013; Richards M, 2010, EXTENT CAUSES INT VA; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sanfelix-Genoves J, 2013, OSTEOPOROSIS INT, V24, P1045, DOI 10.1007/s00198-012-2018-6; Sanfelix-Genoves J, 2012, OSTEOPOROSIS INT, V23, P2129, DOI 10.1007/s00198-011-1819-3; Sanfelix-Genoves J, 2014, MED CLIN-BARCELONA, V142, P15, DOI 10.1016/j.medcli.2012.10.025; Sanfelix-Genoves J, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-20; Sanfelix-Genoves J, 2010, BONE, V47, P610, DOI 10.1016/j.bone.2010.06.015; Sanfelix-Gimeno G, 2013, BONE, V52, P393, DOI 10.1016/j.bone.2012.10.022; Smetana GW, 2007, ARCH INTERN MED, V167, P10, DOI 10.1001/archinte.167.1.10; Wang L, 2013, PRIM HEALTH CARE RES, V14, P1, DOI 10.1017/S1463423612000114	42	7	7	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2015	10	8							e0135475	10.1371/journal.pone.0135475	http://dx.doi.org/10.1371/journal.pone.0135475			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CQ0PO	26317872	Green Submitted, Green Published, gold			2023-01-03	WOS:000360299100032
J	Teng, CLJ; Wang, CY; Chen, YH; Lin, CH; Hwang, WL				Teng, Chieh-Lin Jerry; Wang, Chen-Yu; Chen, Yi-Huei; Lin, Ching-Heng; Hwang, Wen-Li			Optimal Sequence of Irinotecan and Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer: A Population-Based Observational Study	PLOS ONE			English	Article							1ST-LINE TREATMENT; FLUOROURACIL; CHEMOTHERAPY; LEUCOVORIN; MULTICENTER; FOLFIRI; TRIALS	The optimal sequence of irinotecan and oxaliplatin-based regimens for metastatic colorectal cancer remains unclear. We conducted a population-based observational study by retrospectively reviewing records from Taiwan's National Health Insurance Research Database to explore this issue. Patients aged >= 20 years with metastatic colorectal cancer newly diagnosed between 2004 and 2008 (n = 9490) were enrolled in current study. Among these 9490 patients, 3895 patients (41.04%) did not receive any chemotherapy within the first three months after catastrophic illness registration. Patients who received best supportive care were older and had higher Charlson comorbidity indexes and incidences of comorbidities than those who received irinotecan-based regimens, oxaliplatin-based regimens, and 5-fluorouracil/capecitabine alone. Patients who received irinotecan followed by oxaliplatin-based regimens and those who received the reverse sequence were further stratified into arm A (n = 542) and arm B (n = 1156), respectively. The median first time to next treatment was not significantly different between arm A and arm B (210 days vs. 196 days; p = 0.17). However, the median second time to next treatment was longer in arm A than in arm B (155 days vs. 123 days; p = 0.006), which translated into a better overall survival (487 days vs. 454 days; p = 0.02). The crossover rate was higher in arm A than in arm B (47.84% vs. 41.61%; p<0.001). Multivariate Cox regression analyses showed that overall survival was comparable between the two chemotherapy sequences (p = 0.27). Our study suggested that irinotecan followed by oxaliplatin-based regimens might be a better chemotherapy treatment option for metastatic colorectal cancer than the reverse sequence given the higher crossover rate and potential overall survival benefit.	[Teng, Chieh-Lin Jerry; Hwang, Wen-Li] Taichung Vet Gen Hosp, Dept Med, Div Hematol Med Oncol, Taichung, Taiwan; [Teng, Chieh-Lin Jerry] Chung Shan Med Univ, Dept Med, Taichung, Taiwan; [Teng, Chieh-Lin Jerry] Tunghai Univ, Dept Life Sci, Taichung 40704, Taiwan; [Wang, Chen-Yu] Taichung Vet Gen Hosp, Dept Intens Care, Taichung, Taiwan; [Chen, Yi-Huei; Lin, Ching-Heng] Taichung Vet Gen Hosp, Dept Educ & Res, Taichung, Taiwan	Taichung Veterans General Hospital; Chung Shan Medical University; Tunghai University; Taichung Veterans General Hospital; Taichung Veterans General Hospital	Lin, CH (corresponding author), Taichung Vet Gen Hosp, Dept Educ & Res, Taichung, Taiwan.	epid@vghtc.gov.tw; kevinhwl@gmail.com			Taichung Veterans General Hospital [TCVGH-T1017802, TCVGH-1023703D, TCVGH-T1027802]	Taichung Veterans General Hospital	This work was supported in part by research grant TCVGH-T1017802, TCVGH-1023703D, TCVGH-1023703D, and TCVGH-T1027802 from Taichung Veterans General Hospital (Chieh-Lin Jerry Teng, MD, PhD) for laboratory maintenance. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ackland SP, 2005, BRIT J CANCER, V93, P1236, DOI 10.1038/sj.bjc.6602841; CALGB/ SWOG C80405, 2006, CLIN ADV HEMATOLOGY, P452; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Colucci G, 2005, J CLIN ONCOL, V23, P4866, DOI 10.1200/JCO.2005.07.113; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Goldberg RM, 2004, CANCER CHEMOTH PHARM, V54, pS57, DOI 10.1007/s00280-004-0888-9; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Lin CH, 2013, J INTERN MED, V273, P102, DOI 10.1111/joim.12000; Lin YL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086789; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Teng CLJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086714; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019	15	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2015	10	8							e0135673	10.1371/journal.pone.0135673	http://dx.doi.org/10.1371/journal.pone.0135673			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO9KD	26273837	gold, Green Published, Green Submitted			2023-01-03	WOS:000359493600092
J	Luangasanatip, N; Hongsuwan, M; Limmathurotsakul, D; Lubell, Y; Lee, AS; Harbarth, S; Day, NPJ; Graves, N; Cooper, BS				Luangasanatip, Nantasit; Hongsuwan, Maliwan; Limmathurotsakul, Direk; Lubell, Yoel; Lee, Andie S.; Harbarth, Stephan; Day, Nicholas P. J.; Graves, Nicholas; Cooper, Ben S.			Comparative efficacy of interventions to promote hand hygiene in hospital: systematic review and network meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							HEALTH-CARE WORKERS; INTERRUPTED TIME-SERIES; RESISTANT STAPHYLOCOCCUS-AUREUS; LEADERS-DIRECTED STRATEGY; IMPROVE NURSES ADHERENCE; SUSTAINED IMPROVEMENT; NOSOCOMIAL INFECTION; SEGMENTED REGRESSION; POSITIVE DEVIANCE; PROGRAM	OBJECTIVE To evaluate the relative efficacy of the World Health Organization 2005 campaign (WHO-5) and other interventions to promote hand hygiene among healthcare workers in hospital settings and to summarize associated information on use of resources. DESIGN Systematic review and network meta-analysis. DATA SOURCES Medline, Embase, CINAHL, NHS Economic Evaluation Database, NHS Centre for Reviews and Dissemination, Cochrane Library, and the EPOC register (December 2009 to February 2014); studies selected by the same search terms in previous systematic reviews (1980-2009). REVIEW METHODS Included studies were randomised controlled trials, non-randomised trials, controlled before-after trials, and interrupted time series studies implementing an intervention to improve compliance with hand hygiene among healthcare workers in hospital settings and measuring compliance or appropriate proxies that met predefined quality inclusion criteria. When studies had not used appropriate analytical methods, primary data were re-analysed. Random effects and network meta-analyses were performed on studies reporting directly observed compliance with hand hygiene when they were considered sufficiently homogeneous with regard to interventions and participants. Information on resources required for interventions was extracted and graded into three levels. RESULTS Of 3639 studies retrieved, 41 met the inclusion criteria (six randomised controlled trials, 32 interrupted time series, one non-randomised trial, and two controlled before-after studies). Meta-analysis of two randomised controlled trials showed the addition of goal setting to WHO-5 was associated with improved compliance (pooled odds ratio 1.35, 95% confidence interval 1.04 to 1.76; I-2= 81%). Of 22 pairwise comparisons from interrupted time series, 18 showed stepwise increases in compliance with hand hygiene, and all but four showed a trend for increasing compliance after the intervention. Network meta-analysis indicated considerable uncertainty in the relative effectiveness of interventions, but nonetheless provided evidence that WHO-5 is effective and that compliance can be further improved by adding interventions including goal setting, reward incentives, and accountability. Nineteen studies reported clinical outcomes; data from these were consistent with clinically important reductions in rates of infection resulting from improved hand hygiene for some but not all important hospital pathogens. Reported costs of interventions ranged from $225 to $4669 (146- pound 3035;(sic)204-(sic)4229) pound per 1000 bed days. CONCLUSION Promotion of hand hygiene with WHO-5 is effective at increasing compliance in healthcare workers. Addition of goal setting, reward incentives, and accountability strategies can lead to further improvements. Reporting of resources required for such interventions remains inadequate.	[Luangasanatip, Nantasit; Hongsuwan, Maliwan; Limmathurotsakul, Direk; Lubell, Yoel; Day, Nicholas P. J.; Cooper, Ben S.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand; [Luangasanatip, Nantasit; Graves, Nicholas] Queensland Univ Technol, Sch Publ Hlth, Brisbane, Qld 4001, Australia; [Limmathurotsakul, Direk] Mahidol Univ, Fac Trop Med, Dept Trop Hyg, Bangkok, Thailand; [Lubell, Yoel; Day, Nicholas P. J.; Cooper, Ben S.] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med & Global Hlth, Oxford, England; [Lee, Andie S.; Harbarth, Stephan] Univ Hosp Geneva, Infect Control Program, CH-1211 Geneva, Switzerland; [Lee, Andie S.; Harbarth, Stephan] Fac Med, CH-1211 Geneva, Switzerland; [Lee, Andie S.] Royal Prince Alfred Hosp, Dept Infect Dis, Sydney, NSW 2050, Australia; [Lee, Andie S.] Royal Prince Alfred Hosp, Dept Microbiol, Sydney, NSW 2050, Australia; [Graves, Nicholas] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia	Mahidol Oxford Tropical Medicine Research Unit (MORU); Mahidol University; Queensland University of Technology (QUT); Mahidol University; University of Oxford; University of Geneva; University of Geneva; University of Sydney; University of Sydney; Queensland University of Technology (QUT)	Luangasanatip, N (corresponding author), Mahidol Oxford Trop Med Res Unit, 420-6 60th Anniversary Chalermprakiat Bldg, Bangkok 10400, Thailand.	nantasit@tropmedres.ac	Cooper, Ben/HGC-7082-2022	Lubell, Yoel/0000-0002-0237-1070; Cooper, Ben/0000-0002-9445-7217; Graves, Nicholas/0000-0002-5559-3267	Wellcome Trust of Great Britain [089275/Z/09/Z]; Oak Foundation; Medical Research Council; Department for International Development [MR/K006924/1]; MRC [MR/K006924/1] Funding Source: UKRI; Medical Research Council [MR/K006924/1] Funding Source: researchfish	Wellcome Trust of Great Britain(Wellcome Trust); Oak Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department for International Development; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This research was part of the Wellcome Trust-Mahidol University-Oxford Tropical Medicine Research Programme supported by the Wellcome Trust of Great Britain (089275/Z/09/Z). BSC was supported by the Oak Foundation and the Medical Research Council and Department for International Development (grant No MR/K006924/1).	Aboelela SW, 2007, J HOSP INFECT, V66, P101, DOI 10.1016/j.jhin.2006.10.019; Al-Tawfiq JA, 2013, AM J INFECT CONTROL, V41, P482, DOI 10.1016/j.ajic.2012.08.009; Ansari F, 2003, J ANTIMICROB CHEMOTH, V52, P842, DOI 10.1093/jac/dkg459; Armellino D, 2013, AM J INFECT CONTROL, V41, P925, DOI 10.1016/j.ajic.2012.12.011; Armellino D, 2012, CLIN INFECT DIS, V54, P1, DOI 10.1093/cid/cir773; BAUER TM, 1990, J HOSP INFECT, V15, P301, DOI 10.1016/0195-6701(90)90087-5; Benning A, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d199; Bolker B.M., 2008, ECOLOGICAL MODELS DA; Borenstein M., 2009, INTRO META ANAL; Carroll C, 2007, IMPLEMENT SCI, V2, DOI 10.1186/1748-5908-2-40; Chan BP, 2013, INFECT CONT HOSP EP, V34, P987, DOI 10.1086/671729; Chou T, 2010, AM J INFECT CONTROL, V38, P575, DOI 10.1016/j.ajic.2010.01.016; Cochrane Effective Practice and Organisation of Care Review Group, 2013, DAT COLL CHECKL  POC; Crews JD, 2013, INFECT CONT HOSP EP, V34, P751, DOI 10.1086/671002; Dancer SJ, 1999, J HOSP INFECT, V43, P85, DOI 10.1053/jhin.1999.0616; Davey P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003543.pub3; Derde LPG, 2014, LANCET INFECT DIS, V14, P31, DOI 10.1016/S1473-3099(13)70295-0; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dias S, 2010, STAT MED, V29, P932, DOI 10.1002/sim.3767; Dijkstra R, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-53; Doron SI, 2011, JT COMM J QUAL PATIE, V37, P3, DOI 10.1016/S1553-7250(11)37001-8; Drummond MF, 2015, METHODS EC EVALUATIO; DUBBERT PM, 1990, INFECT CONT HOSP EP, V11, P191; Effective Practice and Organisation of Care (EPOC), 2013, WHAT STUD DES SHOULD; Eldridge NE, 2006, J GEN INTERN MED, V21, pS35, DOI 10.1111/j.1525-1497.2006.00361.x; Fisher DA, 2013, INFECT CONT HOSP EP, V34, P919, DOI 10.1086/671738; Fuller C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041617; Gould D, 1997, J CLIN NURS, V6, P55, DOI 10.1111/j.1365-2702.1997.tb00284.x; Gould DJ, 2011, COCHRANE DB SYST REV, V9; Graves N, 2007, INFECT CONT HOSP EP, V28, P178, DOI 10.1086/510787; Graves N, 2013, INFECT CONT HOSP EP, V34, P424, DOI 10.1086/669862; Grayson ML, 2008, MED J AUSTRALIA, V188, P633, DOI 10.5694/j.1326-5377.2008.tb01820.x; Hagel S, 2015, INFECT CONT HOSP EP, P1; Harbarth S, 2008, JAMA-J AM MED ASSOC, V299, P1149, DOI 10.1001/jama.299.10.1149; Helder OK, 2012, AM J INFECT CONTROL, V40, P951, DOI 10.1016/j.ajic.2011.12.003; Helms B, 2010, AM J INFECT CONTROL, V38, P572, DOI 10.1016/j.ajic.2009.08.020; Higgins A, 2013, J HOSP INFECT, V84, P32, DOI 10.1016/j.jhin.2013.02.004; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Huang Jin, 2002, J Contin Educ Nurs, V33, P217; Hugonnet S, 2000, CLIN MICROBIOL INFEC, V6, P350; Huis A, 2013, INT J NURS STUD, V50, P464, DOI 10.1016/j.ijnurstu.2012.08.004; Huis A, 2013, INT J NURS STUD, V50, P518, DOI 10.1016/j.ijnurstu.2012.11.016; Huis A, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-92; Jaggi N, 2012, J CLIN DIAGN RES, V6, P1372, DOI 10.7860/JCDR/2012/4229.2362; Jarvis WR, 1996, INFECT CONT HOSP EP, V17, P552; Johnson PDR, 2005, MED J AUSTRALIA, V183, P509, DOI 10.5694/j.1326-5377.2005.tb07151.x; Juni P, 2002, INT J EPIDEMIOL, V31, P115, DOI 10.1093/ije/31.1.115; Khatib M, 1999, CHEST, V116, P172, DOI 10.1378/chest.116.1.172; Kirkland KB, 2012, BMJ QUAL SAF, V21, P1019, DOI 10.1136/bmjqs-2012-000800; Koff MD, 2011, J CRIT CARE, V26, P489, DOI 10.1016/j.jcrc.2010.12.013; Lee AS, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003126; Lee YT, 2012, J ANTIBIOT, V65, P311, DOI 10.1038/ja.2012.20; Lipsitch M, 2000, P NATL ACAD SCI USA, V97, P1938, DOI 10.1073/pnas.97.4.1938; Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875; Marra AR, 2013, AM J INFECT CONTROL, V41, P984, DOI 10.1016/j.ajic.2013.05.013; Marra AR, 2011, AM J INFECT CONTROL, V39, P1, DOI 10.1016/j.ajic.2010.05.024; Marra AR, 2010, INFECT CONT HOSP EP, V31, P12, DOI 10.1086/649224; Marwick CA, 2014, BMJ QUAL SAF, V23, DOI 10.1136/bmjqs-2013-002176; Mayer J, 2011, INFECT CONT HOSP EP, V32, P59, DOI 10.1086/657666; Mertz D, 2010, INFECT CONT HOSP EP, V31, P1170, DOI 10.1086/656592; Mestre G, 2013, ANN MED, V96, P1; Mestre G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047200; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Morgan DJ, 2012, AM J INFECT CONTROL, V40, P955, DOI 10.1016/j.ajic.2012.01.026; Morrison A, 2012, INT J TECHNOL ASSESS, V28, P138, DOI 10.1017/S0266462312000086; Naikoba S, 2001, J HOSP INFECT, V47, P173, DOI 10.1053/jhin.2000.0882; NEWEY WK, 1987, ECONOMETRICA, V55, P703, DOI 10.2307/1913610; Page K, 2013, J HOSP INFECT, V84, P200, DOI 10.1016/j.jhin.2013.03.006; Peters JL, 2008, J CLIN EPIDEMIOL, V61, P991, DOI 10.1016/j.jclinepi.2007.11.010; R Core Team, 2021, R LANG ENV STAT COMP; Ramsay CR, 2003, INT J TECHNOL ASSESS, V19, P613, DOI 10.1017/S0266462303000576; Rosenthal VD, 2010, AM J INFECT CONTROL, V38, P95, DOI 10.1016/j.ajic.2009.12.004; Salamati P, 2013, INT J PREVENTIVE MED, V4, P441; Salmon S, 2013, ANTIMICROB RESIST IN, V2, DOI 10.1186/2047-2994-2-16; Schweizer ML, 2014, CLIN INFECT DIS, V58, P248, DOI 10.1093/cid/cit670; Spiegelhalter D., 2003, WINBUGS USER MANUAL; Srigley JA, 2014, BMJ QUAL SAF, V23, P974, DOI 10.1136/bmjqs-2014-003080; Stone Sheldon Paul, 2012, BMJ, V344, pe3005, DOI 10.1136/bmj.e3005; Sutton A, 2008, PHARMACOECONOMICS, V26, P753, DOI 10.2165/00019053-200826090-00006; Talbot TR, 2013, INFECT CONT HOSP EP, V34, P1129, DOI 10.1086/673445; Taljaard M, 2014, IMPLEMENT SCI, V9, DOI 10.1186/1748-5908-9-77; Tibballs J, 1996, MED J AUSTRALIA, V164, P395, DOI 10.5694/j.1326-5377.1996.tb122084.x; Turner RM, 2009, J R STAT SOC A STAT, V172, P21, DOI 10.1111/j.1467-985X.2008.00547.x; Vernaz N, 2008, J ANTIMICROB CHEMOTH, V62, P601, DOI 10.1093/jac/dkn199; Vidanapathirana J, 2005, COCHRANE DB SYST REV, V3; Weinstein RA, 1998, EMERG INFECT DIS, V4, P416, DOI 10.3201/eid0403.980320; Whitby M, 2008, AM J INFECT CONTROL, V36, P349, DOI 10.1016/j.ajic.2007.07.016; World Health Organization, 2009, WHO GUID HAND HYG HL; Yngstrom D, 2011, BMJ QUAL SAF, V20, P631, DOI 10.1136/bmjqs.2007.023846	89	182	191	8	61	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 28	2015	351								h3728	10.1136/bmj.h3728	http://dx.doi.org/10.1136/bmj.h3728			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CO2TX	26220070	Green Published, hybrid			2023-01-03	WOS:000359010600002
J	Camacho, M; Quintana, MD; Calabuig, P; Luzardo, OP; Boada, LD; Zumbado, M; Oros, J				Camacho, Maria; del Pino Quintana, Maria; Calabuig, Pascual; Luzardo, Octavio P.; Boada, Luis D.; Zumbado, Manuel; Oros, Jorge			Acid-Base and Plasma Biochemical Changes Using Crystalloid Fluids in Stranded Juvenile Loggerhead Sea Turtles (Caretta caretta)	PLOS ONE			English	Article							RESPIRATORY STATUS; TEMPERATURE; RESPONSES; BALANCE; STRESS; GAS	Aim The aim of this study was to compare the efficacy and effects on acid-base and electrolyte status of several crystalloid fluids in 57 stranded juvenile loggerhead turtles. Methods Within a rehabilitation program four different crystalloid fluids were administered (0.9% Na Cl solution; 5% dextrose + 0.9% Na Cl solutions 1:1; 0.9% Na Cl + lactated Ringer's solutions 1:1; lactated Ringer's solution). Crystalloid fluids were intracoelomically administered during three days (20 ml/kg/day). Animals were sampled at three different moments: Upon admission for evaluating the type of acid-base or biochemical disorder, post-fluid therapy treatment for controlling the evolution of the disorder, and post-recovery period for obtaining the baseline values for rehabilitated loggerhead turtles. Each sample was analyzed with a portable electronic blood analyzer for pH, pO(2), pCO(2), lactate, sodium, potassium, chloride, glucose, and BUN concentration. Admission and post-fluid therapy treatment values were compared with those obtained for each turtle immediately before release. Results The highest percentage of acid-base recovery and electrolyte balance was observed in turtles treated with mixed saline-lactated Ringer's solution (63.6%), followed by turtles treated with physiological saline solution (55%), lactated Ringer's solution (33.3%), and dextrose-saline solutions (10%). Most turtles treated with lactated Ringer's solution had lower lactate concentrations compared with their initial values; however, 66.6% of turtles treated with lactated Ringer's solution had metabolic alkalosis after therapy. Significant higher concentrations of glucose were detected after saline-dextrose administration compared with all the remaining fluids. Conclusions This is the first study evaluating the effects of several crystalloid fluids on the acid-base status and plasma biochemical values in stranded loggerhead sea turtles. Reference convalescent venous blood gas, acid-base, and plasma biochemical values, useful for veterinary surgeons involved in sea turtle conservation, are also provided.	[Camacho, Maria; Luzardo, Octavio P.; Boada, Luis D.; Zumbado, Manuel; Oros, Jorge] Univ Las Palmas Gran Canaria, Fac Vet, Arucas, Las Palmas, Spain; [del Pino Quintana, Maria] Univ Las Palmas Gran Canaria, Dept Math, Las Palmas Gran Canaria, Spain; [Calabuig, Pascual] Cabildo Gran Canaria, Tafira Wildlife Rehabil Ctr, Tafira Baja Las Palmas D, Spain	Universidad de Las Palmas de Gran Canaria; Universidad de Las Palmas de Gran Canaria	Oros, J (corresponding author), Univ Las Palmas Gran Canaria, Fac Vet, Arucas, Las Palmas, Spain.	jorge.oros@ulpgc.es	Luzardo, Octavio P./H-3045-2019; Calabuig, Pascual/AAB-1723-2019; Zumbado, Manuel/AAN-8373-2020; Zumbado, Manuel/B-4495-2010; Dominguez-Boada, Luis/L-5577-2015; Orós, Jorge/G-8824-2015; CAMACHO, MARIA/H-5085-2015; Staffieri, Francesco/K-4230-2016	Luzardo, Octavio P./0000-0002-4153-3028; Zumbado, Manuel/0000-0002-1534-7758; Dominguez-Boada, Luis/0000-0002-0195-4565; Orós, Jorge/0000-0002-8346-5393; CAMACHO, MARIA/0000-0003-2891-1474; Staffieri, Francesco/0000-0002-2085-376X; Quintana Montesdeoca, Maria del Pino/0000-0003-1276-7594				AGUIRRE AA, 1995, PHYSIOL ZOOL, V68, P831, DOI 10.1086/physzool.68.5.30163934; ASHWOOD ER, 1983, CLIN CHEM, V29, P1877; Bjorndal KA, 2001, FISH B-NOAA, V99, P240; Camacho M, 2013, JAVMA-J AM VET MED A, V242, P396, DOI 10.2460/javma.242.3.396; Casal AB, 2009, VET REC, V164, P663, DOI 10.1136/vr.164.21.663; Casal AB, 2009, VET CLIN PATH, V38, P213, DOI 10.1111/j.1939-165X.2008.00106.x; Chittick EJ, 2002, J AM VET MED ASSOC, V221, P1019, DOI 10.2460/javma.2002.221.1019; Chrisman CL, 1997, J AM VET MED ASSOC, V211, P1043; DiBartola SP, 2006, FLUID ELECTROLYTE, P325, DOI DOI 10.1016/B0-72-163949-6/50017-5; Flint M, 2010, J WILDLIFE DIS, V46, P731, DOI 10.7589/0090-3558-46.3.731; Gregory LF, 2001, GEN COMP ENDOCR, V124, P66, DOI 10.1006/gcen.2001.7683; Harms CA, 2003, J WILDLIFE DIS, V39, P366, DOI 10.7589/0090-3558-39.2.366; Innis CJ, 2007, J COMP PHYSIOL B, V177, P623, DOI 10.1007/s00360-007-0160-9; IUCN SSC, 2014, IUCN RED LIST THREAT; Jacobson ER, 2006, DIS AQUAT ORGAN, V70, P139, DOI 10.3354/dao070139; Kelly TR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115739; KRAUS DR, 1980, AM J PHYSIOL, V239, pR254, DOI 10.1152/ajpregu.1980.239.3.R254; LUTZ PL, 1989, J EXP BIOL, V144, P155; Mader D, 2006, REPTILE MED SURG 2 E, P533, DOI DOI 10.1016/B0-72-169327-X/50035-3; Martinez-Jimenez David, 2007, Veterinary Clinics of North America Exotic Animal Practice, V10, P557, DOI 10.1016/j.cvex.2007.02.003; Michell AR., 1989, VET FLUID THERAPY, P55; Mitchell M.A., 2006, REPTILE MED SURG, P631; Monzon-Arguello C, 2009, J EXP MAR BIOL ECOL, V373, P79, DOI 10.1016/j.jembe.2009.03.007; Norton Terry M., 2012, P239; Norton TM, 2005, SEMIN AVIAN EXOT PET, V14, P106, DOI 10.1053/j.saep.2005.04.005; Oros J, 2011, DIS AQUAT ORGAN, V95, P163, DOI 10.3354/dao02351; Prezant RM, 1997, PROCEEDINGS OF THE FOURTH ANNUAL CONFERENCE OF THE ASSOCIATION OF REPTILIAN AND AMPHIBIAN VETERINARIANS, P83; Seminoff Jeffrey A., 2004, Herpetological Review, V35, P24; STABENAU EK, 1991, COMP BIOCHEM PHYS A, V99, P107, DOI 10.1016/0300-9629(91)90243-6; Stabenau EK, 2003, FISH B-NOAA, V101, P889; STABENAU EK, 1993, J EXP BIOL, V180, P311; Stahl S., 2006, REPTILE MED SURG, V2e, P822; Wellman ML, 2006, FLUID ELECTROLYTE, P3, DOI DOI 10.1016/B0-72-163949-6/50004-7; Whitaker Brent R., 1999, P217; Wilkinson R, 2004, MED SURG TORTOISES T, P481; Wyneken J., 2006, REPTILE MED SURG, V2 nd ed, P972	36	14	15	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 13	2015	10	7							e0132217	10.1371/journal.pone.0132217	http://dx.doi.org/10.1371/journal.pone.0132217			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1PW	26167930	Green Published, gold			2023-01-03	WOS:000358193100029
J	Semigran, HL; Linder, JA; Gidengil, C; Mehrotra, A				Semigran, Hannah L.; Linder, Jeffrey A.; Gidengil, Courtney; Mehrotra, Ateev			Evaluation of symptom checkers for self diagnosis and triage: audit study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TELEPHONE TRIAGE; GENERAL-PRACTICE; UNITED-STATES; CARE; ACCURACY; INTERNET; CONSULTATION; INFORMATION; PHYSICIAN; RESOURCE	OBJECTIVE To determine the diagnostic and triage accuracy of online symptom checkers (tools that use computer algorithms to help patients with self diagnosis or self triage). DESIGN Audit study. SETTING Publicly available, free symptom checkers. PARTICIPANTS 23 symptom checkers that were in English and provided advice across a range of conditions. 45 standardized patient vignettes were compiled and equally divided into three categories of triage urgency: emergent care required (for example, pulmonary embolism), non-emergent care reasonable (for example, otitis media), and self care reasonable (for example, viral upper respiratory tract infection). MAIN OUTCOME MEASURES For symptom checkers that provided a diagnosis, our main outcomes were whether the symptom checker listed the correct diagnosis first or within the first 20 potential diagnoses (n= 770 standardized patient evaluations). For symptom checkers that provided a triage recommendation, our main outcomes were whether the symptom checker correctly recommended emergent care, non-emergent care, or self care (n= 532 standardized patient evaluations). RESULTS The 23 symptom checkers provided the correct diagnosis first in 34% (95% confidence interval 31% to 37%) of standardized patient evaluations, listed the correct diagnosis within the top 20 diagnoses given in 58% (55% to 62%) of standardized patient evaluations, and provided the appropriate triage advice in 57% (52% to 61%) of standardized patient evaluations. Triage performance varied by urgency of condition, with appropriate triage advice provided in 80% (95% confidence interval 75% to 86%) of emergent cases, 55% (47% to 63%) of non-emergent cases, and 33% (26% to 40%) of self care cases (P<0.001). Performance on appropriate triage advice across the 23 individual symptom checkers ranged from 33% (95% confidence interval 19% to 48%) to 78% (64% to 91%) of standardized patient evaluations. CONCLUSIONS Symptom checkers had deficits in both triage and diagnosis. Triage advice from symptom checkers is generally risk averse, encouraging users to seek care for conditions where self care is reasonable.	[Semigran, Hannah L.; Mehrotra, Ateev] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [Linder, Jeffrey A.] Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02115 USA; [Linder, Jeffrey A.] Harvard Univ, Sch Med, Boston, MA USA; [Gidengil, Courtney] Boston Childrens Hosp, Div Infect Dis, Boston, MA USA; [Gidengil, Courtney] RAND Corp, Boston, MA USA; [Mehrotra, Ateev] Beth Israel Deaconess Med Ctr, Div Gen Internal Med & Primary Care, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; RAND Corporation; Harvard University; Beth Israel Deaconess Medical Center	Mehrotra, A (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.	mehrotra@hcp.med.harvard.edu	Linder, Jeffrey/AAF-3424-2021; Mehrotra, Ateev/AAO-8454-2021	Linder, Jeffrey/0000-0003-2217-184X; Mehrotra, Ateev/0000-0003-2223-1582	US National Institute of Health (National Institute of Allergy and Infectious Disease) [R21 AI097759-01]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI097759] Funding Source: NIH RePORTER	US National Institute of Health (National Institute of Allergy and Infectious Disease); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was funded by the US National Institute of Health (National Institute of Allergy and Infectious Disease grant No R21 AI097759-01).	[Anonymous], 2014, ENG MED BIOL SOC EMB; Barnett ML, 2014, JAMA-J AM MED ASSOC, V311, P2020, DOI 10.1001/jama.2013.286141; Barnett ML, 2014, JAMA INTERN MED, V174, P138, DOI 10.1001/jamainternmed.2013.11673; Bierbrier R, 2014, J MED INTERNET RES, V16, DOI 10.2196/jmir.3062; Bisson LJ, 2014, AM J SPORT MED, V42, P2371, DOI 10.1177/0363546514541654; Black Peter, 2009, Br J Nurs, V18, P1157; Brigo F, 2014, EPILEPSY BEHAV, V31, P67, DOI 10.1016/j.yebeh.2013.11.020; Bunn F, 2005, BRIT J GEN PRACT, V55, P956; Campbell JL, 2014, LANCET, V384, P1859, DOI 10.1016/S0140-6736(14)61058-8; CDC NAMCS NHAMCS, 2010, ANN NUMB PERC DISTR; Cook DA, 2014, INTERACT J MED RES, V3, P15, DOI 10.2196/ijmr.2811; DeJong C, 2014, JAMA-J AM MED ASSOC, V311, P1287, DOI 10.1001/jama.2014.1026; Donnelly L., 2015, TELEGRAPH; Edney A, 2013, BUSINESSWEEK; Elliot AJ, 2015, EPIDEMIOL INFECT, P1, DOI DOI 10.1109/ECOC.2015.7341993; Eminovic N, 2004, J MED INTERNET RES, V6, DOI 10.2196/jmir.6.2.e17; Eysenbach G, 1999, ARCH DERMATOL, V135, P151, DOI 10.1001/archderm.135.2.151; Farmer SEJ, 2011, CLIN OTOLARYNGOL, V36, P517, DOI 10.1111/j.1749-4486.2011.02375.x; Fine AM, 2013, ANN INTERN MED, V159, P577, DOI 10.7326/0003-4819-159-9-201311050-00003; Fox S, 2013, HLTH ONLINE 2013 INT, P4; Gann B, 2012, Yearb Med Inform, V7, P70; Giesen P, 2007, QUAL SAF HEALTH CARE, V16, P181, DOI 10.1136/qshc.2006.018846; Gonzales R, 2001, CLIN INFECT DIS, V33, P757, DOI 10.1086/322627; Graber ML, 2013, BMJ QUAL SAF, V22, pii21, DOI 10.1136/bmjqs-2012-001615; Hartzband P, 2010, NEW ENGL J MED, V362, P1063, DOI 10.1056/NEJMp0911938; Husain I, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1887; Lattimer V, 1998, BMJ-BRIT MED J, V317, P1054; Lewis TL, 2014, J MED INTERNET RES, V16, DOI 10.2196/jmir.3133; Little P, 2005, JAMA-J AM MED ASSOC, V293, P3029, DOI 10.1001/jama.293.24.3029; Luger TM, 2014, J MED INTERNET RES, V16, DOI 10.2196/jmir.2924; Lupton D, 2015, SOC SCI MED, V133, P128, DOI 10.1016/j.socscimed.2015.04.004; Mehrotra A, 2013, JAMA INTERN MED, V173, P72, DOI 10.1001/2013.jamainternmed.305; Meyer AND, 2013, JAMA INTERN MED, V173, P1952, DOI 10.1001/jamainternmed.2013.10081; North F, 2012, TELEMED E-HEALTH, V18, P213, DOI 10.1089/tmj.2011.0127; North F, 2011, TELEMED E-HEALTH, V17, P19, DOI 10.1089/tmj.2010.0120; Orizio G, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1795; Poote AE, 2014, J TELEMED TELECARE, V20, P123, DOI 10.1177/1357633X14529246; Reuters, 2013, REUTERS; Richards DA, 2002, BRIT MED J, V325, P1214, DOI 10.1136/bmj.325.7374.1214; Saczynski JS, 2008, AM J CARDIOL, V102, P1589, DOI 10.1016/j.amjcard.2008.07.056; Sadeghi S, 2006, INT J MED INFORM, V75, P403, DOI 10.1016/j.ijmedinf.2005.07.028; Schmitt BD, 2012, PEDIAT TELEPHONE PRO; Stacey D, 2005, WORLDV EVID-BASED NU, V2, P184, DOI 10.1111/j.1741-6787.2005.00035.x; Staub GM, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-110; Thompson DA, 2013, ADULT TELEPHONE PROT; Usborne S, 2009, INDEPENDENT; White Ryen W, 2009, AMIA Annu Symp Proc, V2009, P696; Zhongbo C, 2010, AMYOTROPH LATERAL SC, V11, P566	48	202	206	1	25	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 8	2015	351								h3480	10.1136/bmj.h3480	http://dx.doi.org/10.1136/bmj.h3480			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CM8MP	26157077	Green Published, hybrid			2023-01-03	WOS:000357955800007
J	Yao, JJ; Zhou, GQ; Yu, XL; Tang, LL; Chen, L; Mao, YP; Lin, L; Zhang, LL; Shao, JY; Guo, Y; Ma, J; Sun, Y				Yao, Ji-Jin; Zhou, Guan-Qun; Yu, Xiao-Li; Tang, Ling-Long; Chen, Lei; Mao, Yan-Ping; Lin, Li; Zhang, Lu-Lu; Shao, Jian-Yong; Guo, Ying; Ma, Jun; Sun, Ying			Incidence of and Risk Factors for Mastoiditis after Intensity Modulated Radiotherapy in Nasopharyngeal Carcinoma	PLOS ONE			English	Article							SUPPURATIVE OTITIS-MEDIA; DISEASES; PLANS; MRI	Purpose To report the incidence of and risk factors for mastoiditis after intensity-modulated radiotherapy (IMRT) in nasopharyngeal carcinoma (NPC). Patients and Methods Retrospective analysis of pretreatment and follow-up magnetic resonance imaging (MRI) data for 451 patients with NPC treated with IMRT at a single institution. The diagnosis of mastoiditis was based on MRI; otomastoid opacification was rated as Grade 0 (none), 1 (mild), 2 (moderate) or 3 (severe) by radiologists blinded to clinical outcome. This study mainly focused on severe mastoiditis; patients were divided into three groups: the G0M (Grade 0 mastoiditis before treatment) group, G1-2M (Grade 1 to 2 mastoiditis before treatment) group and G3M (Grade 3 mastoiditis before treatment) group. The software SAS9.3 program was used to analyze the data. Results For the entire cohort, the incidence of Grade 3 mastoiditis was 20% before treatment and 31%, 19% and 17% at 3, 12 and 24 months after radiotherapy, respectively. In the G0M group, the incidence of severe mastoiditis was 0% before treatment and 23%, 15% and 13% at 3, 12 and 24 months after radiotherapy, respectively. Multivariate analysis revealed T category (OR=0.68, 95% CI = 0.469 to 0.984), time (OR=0.668, 95% CI = 0.59 to 0.757) and chemotherapy (OR= 0.598, 95% CI = 0.343 to 0.934) were independent factors associated with severe mastoiditis in the G0M group after treatment. Conclusions Mastoiditis, as diagnosed by MRI, occurs as a progressive process that regresses and resolves over time in patients with NPC treated using IMRT.	[Yao, Ji-Jin; Zhou, Guan-Qun; Tang, Ling-Long; Chen, Lei; Mao, Yan-Ping; Lin, Li; Zhang, Lu-Lu; Ma, Jun; Sun, Ying] Sun Yat Sen Univ, Dept Radiat Oncol, State Key Lab Oncol South China, Ctr Canc,Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China; [Yu, Xiao-Li] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Radiat Oncol, Guangzhou 510060, Guangdong, Peoples R China; [Shao, Jian-Yong] Sun Yat Sen Univ, Dept Pathol, State Key Lab Oncol South China, Ctr Canc,Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China; [Guo, Ying] Sun Yat Sen Univ, Ctr Canc, Dept Med Stat & Epidemiol, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University	Sun, Y (corresponding author), Sun Yat Sen Univ, Dept Radiat Oncol, State Key Lab Oncol South China, Ctr Canc,Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China.	sunying@sysucc.org.cn			National Natural Science Foundation of China [81372409]; Sun Yat-Sen University Clinical Research 5010 Program [2012011]; Natural Science Foundation of Guangdong Province [S2013010012220]; Science and Technology project of Guangzhou City, China [132000507]; Health & Medical Collaborative Innovation Project of Guangzhou City, China [201400000001]; National Science & Technology Pillar Program [2014BAI09B10]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sun Yat-Sen University Clinical Research 5010 Program; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Science and Technology project of Guangzhou City, China; Health & Medical Collaborative Innovation Project of Guangzhou City, China; National Science & Technology Pillar Program	This work was supported by grants from the National Natural Science Foundation of China (No. 81372409), the Sun Yat-Sen University Clinical Research 5010 Program (No. 2012011), the Natural Science Foundation of Guangdong Province (No. S2013010012220), the Science and Technology project of Guangzhou City, China (No. 132000507), the Health & Medical Collaborative Innovation Project of Guangzhou City, China (201400000001), and the National Science & Technology Pillar Program during the Twelfth Five-year Plan Period (2014BAI09B10). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BRILL AH, 1974, ARCH OTOLARYNGOL, V99, P406; Calabrese EJ, 2014, HUM EXP TOXICOL, V33, P542, DOI 10.1177/0960327113493303; Cooper J, 2002, AJCC CANC STAGING MA, P157; Edge SB, 2009, ARCH PATHOL LAB MED, V133, P1256, DOI [10.1043/1543-2165-133.8.1256, DOI 10.1043/1543-2165-133.8.1256]; HOLLIDAY RA, 1989, RADIOL CLIN N AM, V27, P283; Hsin CH, 2013, LARYNGOSCOPE, V123, P2148, DOI 10.1002/lary.23215; HSU MM, 1995, ANN OTO RHINOL LARYN, V104, P453, DOI 10.1177/000348949510400607; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kam MKM, 2003, INT J RADIAT ONCOL, V56, P145, DOI 10.1016/S0360-3016(03)00075-0; KANGSANARAK J, 1995, AM J OTOL, V16, P104; Lai PH, 2002, AM J NEURORADIOL, V23, P1369; Lai SZ, 2011, INT J RADIAT ONCOL, V80, P661, DOI 10.1016/j.ijrobp.2010.03.024; Lee N, 2009, J CLIN ONCOL, V27, P3684, DOI 10.1200/JCO.2008.19.9109; Lin SJ, 2009, INT J RADIAT ONCOL, V75, P1071, DOI 10.1016/j.ijrobp.2008.12.015; Low WK, 2006, J CLIN ONCOL, V24, P1904, DOI 10.1200/JCO.2005.05.0096; Melaku A, 1999, ETHIOPIAN MED J, V37, P237; Meredith JR, 2008, ENT-EAR NOSE THROAT, V87, P514, DOI 10.1177/014556130808700909; Nishimura R, 1997, INT J RADIAT ONCOL, V39, P155, DOI 10.1016/S0360-3016(97)00302-7; Pickles JO., 1999, INTRO PHYSL HEARING; Platzek I, 2014, ACTA RADIOL SHORT RE, V3; Polat S, 2011, EUR ARCH OTO-RHINO-L, V268, P1135, DOI 10.1007/s00405-011-1506-1; Rodel F, 2007, INT J RADIAT BIOL, V83, P357, DOI 10.1080/09553000701317358; Sanders CL, 2012, DOSE-RESPONSE, V10, P610, DOI 10.2203/dose-response.12-017.Sanders; Swart JD., 1996, HEAD NECK IMAGING, P1391; Tham IWK, 2009, INT J RADIAT ONCOL, V75, P1481, DOI 10.1016/j.ijrobp.2009.01.018; WALKER DA, 1989, MED PEDIATR ONCOL, V17, P48, DOI 10.1002/mpo.2950170110; Walker GV, 2011, INT J RADIAT ONCOL, V81, pE819, DOI 10.1016/j.ijrobp.2010.11.047; Xia P, 2000, INT J RADIAT ONCOL, V48, P329, DOI 10.1016/S0360-3016(00)00585-X	28	4	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 26	2015	10	6							e0131284	10.1371/journal.pone.0131284	http://dx.doi.org/10.1371/journal.pone.0131284			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1AM	26114761	Green Submitted, gold, Green Published			2023-01-03	WOS:000358147500139
J	Chang, CC; Pirozzi, G; Wen, SH; Chung, IH; Chiu, BL; Errico, S; Luongo, M; Lombardi, ML; Ferrone, S				Chang, Chien-Chung; Pirozzi, Giuseppe; Wen, Shao-Hsuan; Chung, I-Hsin; Chiu, Bau-Lin; Errico, Simona; Luongo, Monica; Lombardi, Maria Luisa; Ferrone, Soldano			Multiple Structural and Epigenetic Defects in the Human Leukocyte Antigen Class I Antigen Presentation Pathway in a Recurrent Metastatic Melanoma Following Immunotherapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; ANTIIDIOTYPIC MONOCLONAL-ANTIBODIES; HLA HAPLOTYPE LOSS; ENDOPLASMIC-RETICULUM; IMMUNE SELECTION; MALIGNANT-CELLS; DOWN-REGULATION; SOLID TUMORS; LUNG-CANCER; TAPASIN	Scant information is available about the molecular basis of multiple HLA class I antigen-processing machinery defects in malignant cells, although this information contributes to our understanding of the molecular immunoescape mechanisms utilized by tumor cells and may suggest strategies to counteract them. In the present study we reveal a combination of IFN-gamma-irreversible structural and epigenetic defects in HLA class I antigen-processing machinery in a recurrent melanoma metastasis after immunotherapy. These defects include loss of tapasin and one HLA haplotype as well as selective silencing of HLA-A3 gene responsiveness to IFN-gamma. Tapasin loss is caused by a germline frameshift mutation in exon 3 (TAPBP(684delA)) along with a somatic loss of the other gene copy. Selective silencing of HLA-A3 gene and its IFN-gamma responsiveness is associated with promoter CpG methylation nearby site-alpha and TATA box, reversible after DNA methyltransferase 1 depletion. This treatment combined with tapasin reconstitution and IFN-gamma stimulation restored the highest level of HLA class I expression and its ability to elicit cytotoxic T cell responses. These results represent a novel tumor immune evasion mechanism through impairing multiple components at various levels in the HLA class I antigen presentation pathway. These findings may suggest a rational design of combinatorial cancer immunotherapy harnessing DNA demethylation and IFN-gamma response.	[Chang, Chien-Chung; Wen, Shao-Hsuan; Chung, I-Hsin; Chiu, Bau-Lin] Natl Tsing Hua Univ, Inst Mol & Cellular Biol, Hsinchu 30013, Taiwan; [Pirozzi, Giuseppe; Errico, Simona; Luongo, Monica; Lombardi, Maria Luisa] Natl Canc Inst, Dept Expt Oncol, I-80131 Naples, Italy; [Ferrone, Soldano] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02114 USA; [Ferrone, Soldano] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthoped Surg, Boston, MA 02114 USA	National Tsing Hua University; IRCCS Fondazione Pascale; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Chang, CC (corresponding author), Natl Tsing Hua Univ, Inst Mol & Cellular Biol, 101 Sect 2,Kuang Fu Rd, Hsinchu 30013, Taiwan.	ccchang@life.nthu.edu.tw		Errico, Simona/0000-0002-2873-9339	Ministry of Science and Technology [NSC97-2320-B-007-001-MY3, NSC98-2320-B-007-004-MY3, MOST 103-2320-B-007-005]; Department of Health and Human Services, Public Health Service, National Institutes of Health [RO1 CA138188]; MURST, Cluster 03; NATIONAL CANCER INSTITUTE [R01CA138188] Funding Source: NIH RePORTER	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Department of Health and Human Services, Public Health Service, National Institutes of Health; MURST, Cluster 03(Ministry of Education, Universities and Research (MIUR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Ministry of Science and Technology Grants NSC97-2320-B-007-001-MY3, NSC98-2320-B-007-004-MY3, and MOST 103-2320-B-007-005 (to C.-C. C), Department of Health and Human Services, Public Health Service, National Institutes of Health Grant RO1 CA138188 (NCI; to S. F.), and MURST, Cluster 03 (to M. L. L). The authors declare that they have no conflicts of interest with the content of this article.	Bandoh N, 2005, TISSUE ANTIGENS, V66, P185, DOI 10.1111/j.1399-0039.2005.00462.x; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; Belicha-Villanueva A, 2008, IMMUNOLOGY, V124, P112, DOI 10.1111/j.1365-2567.2007.02746.x; Campoli M, 2008, ONCOGENE, V27, P5869, DOI 10.1038/onc.2008.273; Chang CC, 2005, ADV CANCER RES, V93, P189, DOI 10.1016/S0065-230X(05)93006-6; Chang CC, 2005, J IMMUNOL, V174, P1462, DOI 10.4049/jimmunol.174.3.1462; Chang CC, 2007, CANCER IMMUNOL IMMUN, V56, P227, DOI 10.1007/s00262-006-0183-1; Chang CC, 2006, J BIOL CHEM, V281, P18763, DOI 10.1074/jbc.M511525200; Chen HL, 1996, NAT GENET, V13, P210, DOI 10.1038/ng0696-210; Cresswell P, 2005, IMMUNOL REV, V207, P145, DOI 10.1111/j.0105-2896.2005.00316.x; Dai W, 2015, CANCER MED-US, V4, P1079, DOI 10.1002/cam4.451; Dissemond J, 2003, ARCH DERMATOL RES, V295, P43, DOI 10.1007/s00403-003-0393-8; Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005; Gollob JA, 2006, CLIN CANCER RES, V12, P4619, DOI 10.1158/1078-0432.CCR-06-0883; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hsueh EC, 2003, SEMIN CANCER BIOL, V13, P401, DOI 10.1016/j.semcancer.2003.09.003; Jimenez P, 1999, INT J CANCER, V83, P91, DOI 10.1002/(SICI)1097-0215(19990924)83:1<91::AID-IJC17>3.3.CO;2-W; Kloor M, 2005, CANCER RES, V65, P6418, DOI 10.1158/0008-5472.CAN-05-0044; KOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636; KUSAMA M, 1989, J IMMUNOL, V143, P3844; LAMPSON LA, 1983, J IMMUNOL, V130, P2471; Lee YG, 2013, BRIT J HAEMATOL, V161, P339, DOI 10.1111/bjh.12256; LEHMANN F, 1995, EUR J IMMUNOL, V25, P340, DOI 10.1002/eji.1830250206; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; Leone P, 2013, JNCI-J NATL CANCER I, V105, P1172, DOI 10.1093/jnci/djt184; Leonhardt RM, 2014, J IMMUNOL, V192, P2480, DOI 10.4049/jimmunol.1302637; Mani S, 2010, ADV GENET, V70, P327, DOI [10.1016/S0065-2660(10)70012-2, 10.1016/B978-0-12-380866-0.60012-5]; Momburg F, 2002, MOL IMMUNOL, V39, P217, DOI 10.1016/S0161-5890(02)00103-7; MoreauAubry A, 1997, INT J ONCOL, V10, P841; Nie Y, 2001, CARCINOGENESIS, V22, P1615, DOI 10.1093/carcin/22.10.1615; Ogino T, 2003, TISSUE ANTIGENS, V62, P385, DOI 10.1034/j.1399-0039.2003.00114.x; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; PEROSA F, 1988, HUM IMMUNOL, V23, P255, DOI 10.1016/0198-8859(88)90061-4; Perosa F, 2003, J IMMUNOL, V171, P1918, DOI 10.4049/jimmunol.171.4.1918; Ramal LM, 2000, TISSUE ANTIGENS, V55, P443, DOI 10.1034/j.1399-0039.2000.550507.x; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rodriguez T, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-34; Seliger B, 2001, CANCER RES, V61, P8647; Sernee MF, 1998, MOL IMMUNOL, V35, P177, DOI 10.1016/S0161-5890(98)00026-1; Serrano A, 2001, INT J CANCER, V94, P243, DOI 10.1002/ijc.1452; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Sheyhidin I, 2014, ASIAN PAC J CANCER P, V15, P10299, DOI 10.7314/APJCP.2014.15.23.10299; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; STAM NJ, 1986, J IMMUNOL, V137, P2299; Tan P, 2002, J IMMUNOL, V168, P1950, DOI 10.4049/jimmunol.168.4.1950; van den Elsen PJ, 1998, IMMUNOGENETICS, V48, P208, DOI 10.1007/s002510050425; Wang X, 2003, TISSUE ANTIGENS, V62, P139, DOI 10.1034/j.1399-0039.2003.00087.x; Wang XH, 2005, J IMMUNOL METHODS, V299, P139, DOI 10.1016/j.jim.2005.02.006; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; Yabe T, 2002, BLOOD, V100, P1496, DOI 10.1182/blood-2001-12-0252; Yamshchikov GV, 2005, J IMMUNOL, V174, P6863, DOI 10.4049/jimmunol.174.11.6863	53	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 30	2015	290	44					26562	26575		10.1074/jbc.M115.676130	http://dx.doi.org/10.1074/jbc.M115.676130			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CW2AO	26381407	Green Published, hybrid			2023-01-03	WOS:000364793600023
J	Klein, HG; Flegel, WA; Natanson, C				Klein, Harvey G.; Flegel, Willy A.; Natanson, Charles			Red Blood Cell Transfusion Precision vs Imprecision Medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SURGERY; TRIALS		[Klein, Harvey G.; Flegel, Willy A.] NIH, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA; [Natanson, Charles] NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Klein, HG (corresponding author), NIH, Dept Transfus Med, Bldg 10,Room 1C-711, Bethesda, MD 20892 USA.	hklein@dtm.cc.nih.gov	Flegel, Willy A/H-7404-2019	Flegel, Willy A/0000-0002-1631-7198	Intramural NIH HHS [Z99 CL999999] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Carson JL, 2012, ANN INTERN MED, V157, P49, DOI 10.7326/0003-4819-157-1-201206190-00429; Deans KJ, 2010, VOX SANG, V99, P16, DOI 10.1111/j.1423-0410.2010.01325.x; Flegel WA, 2015, LANCET HAEMATOL, V2, pE282, DOI 10.1016/S2352-3026(15)00090-3; FRIEDMAN BA, 1980, TRANSFUSION, V20, P179, DOI 10.1046/j.1537-2995.1980.20280169958.x; Holst LB, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1354; Murphy GJ, 2015, NEW ENGL J MED, V372, P997, DOI 10.1056/NEJMoa1403612; Ottenberg R, 1908, ANN SURG, V47, P486, DOI 10.1097/00000658-190804000-00002; Sim V, 2015, AM J SURG, V210, P45, DOI 10.1016/j.amjsurg.2014.08.024	8	28	29	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	2015	314	15					1557	1558		10.1001/jama.2015.10890	http://dx.doi.org/10.1001/jama.2015.10890			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT7XK	26355383	Green Accepted			2023-01-03	WOS:000363028500010
J	Johnston, SC; Lin, KL; Twenhafel, NA; Raymond, JLW; Shamblin, JD; Wollen, SE; Wlazlowski, CB; Wilkinson, ER; Botto, MA; Goff, AJ				Johnston, Sara C.; Lin, Kenny L.; Twenhafel, Nancy A.; Raymond, Jo Lynne W.; Shamblin, Joshua D.; Wollen, Suzanne E.; Wlazlowski, Carly B.; Wilkinson, Eric R.; Botto, Miriam A.; Goff, Arthur J.			Dose Response of MARV/Angola Infection in Cynomolgus Macaques following IM or Aerosol Exposure	PLOS ONE			English	Article							MARBURG-VIRUS-DISEASE; HEMORRHAGIC-FEVER; ANGOLA INFECTION; PATHOGENESIS; OUTBREAK	Marburg virus infection in humans causes a hemorrhagic disease with a high case fatality rate. Countermeasure development requires the use of well-characterized animal models that mimic human disease. To further characterize the cynomolgus macaque model of MARV/Angola, two independent dose response studies were performed using the intramuscular or aerosol routes of exposure. All animals succumbed at the lowest target dose; therefore, a dose effect could not be determined. For intramuscular-exposed animals, 100 PFU was the first target dose that was not significantly different than higher target doses in terms of time to disposition, clinical pathology, and histopathology. Although a significant difference was not observed between aerosol-exposed animals in the 10 PFU and 100 PFU target dose groups, 100 PFU was determined to be the lowest target dose that could be consistently obtained and accurately titrated in aerosol studies.	[Johnston, Sara C.; Shamblin, Joshua D.; Wollen, Suzanne E.; Wlazlowski, Carly B.; Wilkinson, Eric R.; Botto, Miriam A.; Goff, Arthur J.] US Army, Med Res Inst Infect Dis, Div Virol, Ft Detrick, MD 21702 USA; [Lin, Kenny L.] US Army, Med Res Inst Infect Dis, Nonclin Dev Div, Ft Detrick, MD 21702 USA; [Twenhafel, Nancy A.; Raymond, Jo Lynne W.] US Army, Med Res Inst Infect Dis, Div Pathol, Ft Detrick, MD 21702 USA		Johnston, SC (corresponding author), US Army, Med Res Inst Infect Dis, Div Virol, Ft Detrick, MD 21702 USA.	sara.c.johnston2.ctr@mail.mil	Twenhafel, Nancy/Z-1522-2019	Wollen-Roberts, Suzanne/0000-0002-9409-2756	Translational Medical Technologies; Joint Science and Technology Office for Chemical and Biological Defense	Translational Medical Technologies; Joint Science and Technology Office for Chemical and Biological Defense(United States Department of DefenseDefense Threat Reduction Agency)	This work was supported by Translational Medical Technologies and the Joint Science and Technology Office for Chemical and Biological Defense. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alves DA, 2010, VET PATHOL, V47, P831, DOI 10.1177/0300985810378597; Bausch DG, 2003, EMERG INFECT DIS, V9, P1531, DOI 10.3201/eid0912.030355; Beer B, 1999, NATURWISSENSCHAFTEN, V86, P8, DOI 10.1007/s001140050562; Borchert M, 2002, TROP MED INT HEALTH, V7, P902, DOI 10.1046/j.1365-3156.2002.00945.x; Bray M, 2002, ANTIVIR RES, V54, P1, DOI 10.1016/S0166-3542(02)00005-0; Colebunders R, 2007, J INFECT DIS, V196, pS148, DOI 10.1086/520543; Fauci AS, 2005, ACAD MED, V80, P1079, DOI 10.1097/00001888-200512000-00002; Feldmann H, 2011, LANCET, V377, P849, DOI 10.1016/S0140-6736(10)60667-8; GEAR JSS, 1975, BRIT MED J, V4, P489, DOI 10.1136/bmj.4.5995.489; Geisbert TW, 2007, J INFECT DIS, V196, pS372, DOI 10.1086/520608; KILEY MP, 1988, J GEN VIROL, V69, P1957, DOI 10.1099/0022-1317-69-8-1957; Ligon B Lee, 2005, Semin Pediatr Infect Dis, V16, P219, DOI 10.1053/j.spid.2005.05.001; Lin KL, 2015, J VIROL, V89, P9875, DOI 10.1128/JVI.01147-15; Mahanty S, 2004, LANCET INFECT DIS, V4, P487, DOI 10.1016/S1473-3099(04)01103-X; Martini G A, 1968, Ger Med Mon, V13, P457; Sanchez A, 2007, FIELDS VIROLOGY, V1, P1409; Slenczka WG, 1999, CURR TOP MICROBIOL, V235, P49; SMITH DH, 1982, LANCET, V1, P816	18	10	10	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2015	10	9							e0138843	10.1371/journal.pone.0138843	http://dx.doi.org/10.1371/journal.pone.0138843			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS6EO	26413900	Green Submitted, Green Published, gold			2023-01-03	WOS:000362170700024
J	Belkin, A				Belkin, Aaron			Caring for Our Transgender Troops - The Negligible Cost of Transition-Related Care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Calif San Francisco, Hastings Coll Law, San Francisco, CA 94102 USA	University of California System; University of California San Francisco	Belkin, A (corresponding author), Univ Calif San Francisco, Hastings Coll Law, San Francisco, CA 94102 USA.							BROWN GR, 1988, ARCH SEX BEHAV, V17, P527, DOI 10.1007/BF01542340; CAL. DEP'T OF INS, 2012, EC IMP ASS GEND NOND; Gates GJ., 2014, TRANSGENDER MILITARY; Herman J. L., 2013, COSTS BENEFITS PROVI	4	13	13	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 17	2015	373	12					1089	1092		10.1056/NEJMp1509230	http://dx.doi.org/10.1056/NEJMp1509230			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CR7UG	26267449				2023-01-03	WOS:000361556400003
J	Estrela, AB; Turck, P; Stutz, E; Abraham, WR				Estrela, Andreia Bergamo; Tuerck, Patrick; Stutz, Elaine; Abraham, Wolf-Rainer			Release of Periplasmic Nucleotidase Induced by Human Antimicrobial Peptide in E-coli Causes Accumulation of the Immunomodulator Adenosine	PLOS ONE			English	Article							INTRACELLULAR-LOCALIZATION; PSEUDOMONAS-AERUGINOSA; IMMUNE MODULATION; GUT MICROBIOTA; PANETH CELLS; DISEASE; 5-NUCLEOTIDASE; PURIFICATION; MECHANISMS; DEFENSINS	Previous work by our group described that human beta-defensin-2 induces accumulation of extracellular adenosine (Ado) in E. coli cultures through a non-lytic mechanism causing severe plasmolysis. Here, we investigate the presence of AMP as a direct precursor and the involvement of a bacterial enzyme in the generation of extracellular Ado by treated bacteria. Following hBD-2 treatment, metabolites were quantified in the supernatants using targeted HPLC-MS/MS analysis. Microbial growth was monitored by optical density and cell viability was determined by colony forming units counts. Phosphatase activity was measured using chromogenic substrate pNPP. The results demonstrate that defensin-treated E. coli strainWreleases AMP in the extracellular space, where it is converted to Ado by a bacterial soluble factor. An increase in phosphatase activity in the supernatant was observed after peptide treatment, similar to the effect of sucrose-induced osmotic stress, suggesting that the periplasmic 5'nucleotidase (5'-NT) is released following the plasmolysis event triggered by the peptide. Ado accumulation was enhanced in the presence of Co2+ ion and inhibited by EDTA, further supporting the involvement of a metallo-phosphatase such as 5'-NT in extracellular AMP conversion into Ado. The comparative analysis of hBD-induced Ado accumulation in different E. coli strains and in Pseudomonas aeruginosa revealed that the response is not correlated to the peptide's effect on cell viability, but indicates it might be dependent on the subcellular distribution of the nucleotidase. Taken together, these data shed light on a yet undescribed mechanism of host-microbial interaction: a human antimicrobial peptide inducing selective release of a bacterial enzyme (E. coli 5'-NT), leading to the formation of a potent immunomodulator metabolite (Ado).	[Estrela, Andreia Bergamo; Tuerck, Patrick; Stutz, Elaine; Abraham, Wolf-Rainer] Helmholtz Ctr Infect Res, Chem Microbiol, D-38124 Braunschweig, Germany	Helmholtz Association; Helmholtz-Center for Infection Research	Estrela, AB (corresponding author), Univ Fed Rio Grande do Norte, Lab Tecnol & Biotecnol Farmaceut, BR-59072970 Natal, RN, Brazil.	estrela.abe@gmail.com; Wolf-Rainer.Abraham@helmholtz-hzi.de	Turck, Patrick/ABE-3969-2021; Abraham, Wolf-Rainer/I-2179-2019; Estrela, Andreia/A-5162-2016	Abraham, Wolf-Rainer/0000-0002-2850-2649; Turck, Patrick/0000-0001-5994-5218	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	A.B.E. and P.T. acknowledge fellowships from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) and E.S. acknowledges a fellowship from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), all pertaining to the Brazilian program Science without Borders.	Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816; Bevins CL, 2011, NAT REV MICROBIOL, V9, P356, DOI 10.1038/nrmicro2546; BHATTI AR, 1976, CAN J MICROBIOL, V22, P1425, DOI 10.1139/m76-211; Boudeau J, 1999, INFECT IMMUN, V67, P4499, DOI 10.1128/IAI.67.9.4499-4509.1999; BROAD DF, 1981, J GEN MICROBIOL, V123, P241; Chan ESL, 2002, ARTHRITIS RES, V4, P266, DOI 10.1186/ar419; Crane JK, 2009, FEMS IMMUNOL MED MIC, V57, P214, DOI 10.1111/j.1574-695X.2009.00598.x; Drygiannakis I, 2011, IMMUNOL RES, V50, P69, DOI 10.1007/s12026-011-8207-0; Easton DM, 2009, TRENDS BIOTECHNOL, V27, P582, DOI 10.1016/j.tibtech.2009.07.004; Estrela AB, 2011, CURR MED CHEM, V18, P2791; Estrela AB, 2013, ANTIMICROB AGENTS CH, V57, P4387, DOI 10.1128/AAC.00820-13; Fjell CD, 2012, NAT REV DRUG DISCOV, V11, P37, DOI 10.1038/nrd3591; Fredholm BB, 2001, BIOCHEM PHARMACOL, V61, P443, DOI 10.1016/S0006-2952(00)00570-0; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; GLICK J, 1983, J GEN MICROBIOL, V129, P3085; Greenwell-Wild T, 2002, J IMMUNOL, V169, P6286, DOI 10.4049/jimmunol.169.11.6286; Hilchie AL, 2013, NAT CHEM BIOL, V9, P761, DOI [10.1038/NCHEMBIO.1393, 10.1038/nchembio.1393]; Huttenhower C, 2014, IMMUNITY, V40, P843, DOI 10.1016/j.immuni.2014.05.013; Kelly D, 2005, TRENDS IMMUNOL, V26, P326, DOI 10.1016/j.it.2005.04.008; Lee WJ, 2014, NAT CHEM BIOL, V10, P416, DOI 10.1038/nchembio.1535; Ley RE, 2008, NAT REV MICROBIOL, V6, P776, DOI 10.1038/nrmicro1978; NEU HC, 1967, J BIOL CHEM, V242, P3896; NEU HC, 1968, BIOCHEMISTRY-US, V7, P3766, DOI 10.1021/bi00850a059; Ochoa-Cortes F, 2014, INFLAMM BOWEL DIS, V20, P1259, DOI 10.1097/MIB.0000000000000047; Okamura S, J BIOCH, V73, P915; Powers JPS, 2003, PEPTIDES, V24, P1681, DOI 10.1016/j.peptides.2003.08.023; Qin N, 2014, NATURE, V513, P59, DOI 10.1038/nature13568; RINAS U, 1995, APPL ENVIRON MICROB, V61, P4147, DOI 10.1128/AEM.61.12.4147-4151.1995; STROHMEIER GR, 1995, J BIOL CHEM, V270, P2387, DOI 10.1074/jbc.270.5.2387; Thammavongsa V, 2009, J EXP MED, V206, P2417, DOI 10.1084/jem.20090097; WATANABE K, 1986, BIOCHEM BIOPH RES CO, V134, P527, DOI 10.1016/S0006-291X(86)80452-1; Watanabe K, 2011, BIOSCI BIOTECH BIOCH, V75, P7, DOI 10.1271/bbb.100063; Willyard C, 2011, NATURE, V479, pS5, DOI 10.1038/479S5a; Yeaman MR, 2003, PHARMACOL REV, V55, P27, DOI 10.1124/pr.55.1.2	35	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2015	10	9							e0138033	10.1371/journal.pone.0138033	http://dx.doi.org/10.1371/journal.pone.0138033			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR8LR	26371472	gold, Green Published, Green Submitted			2023-01-03	WOS:000361604400045
J	Zhao, JX; Wang, B; You, GX; Wang, Y; Chen, G; Wang, Q; Zhang, XG; Zhao, L; Zhou, H; He, YZ				Zhao, Jing-xiang; Wang, Bo; You, Guo-xing; Wang, Ying; Chen, Gan; Wang, Quan; Zhang, Xi-gang; Zhao, Lian; Zhou, Hong; He, Yue-zhong			Hypertonic Saline Dextran Ameliorates Organ Damage in Beagle Hemorrhagic Shock	PLOS ONE			English	Article							ADHESION MOLECULE-1 EXPRESSION; CARBON-DIOXIDE DIFFERENCE; FLUID RESUSCITATION; 6-PERCENT DEXTRAN-70; 7.5-PERCENT NACL; TRAUMA PATIENTS; EFFICACY; NEUTROPHIL; SALINE/DEXTRAN; HYPOTENSION	Objective The goal of this study was to investigate the effect of hypertonic saline with 6% Dextran-70 (HSD) resuscitation on organ damage and the resuscitation efficiency of the combination of HSD and lactated ringers (LR) in a model of hemorrhage shock in dogs. Methods Beagles were bled to hold their mean arterial pressure (MAP) at 50 +/- 5 mmHg for 1 h. After hemorrhage, beagles were divided into three groups (n = 7) to receive pre-hospital resuscitation for 1 h (R1): HSD (4 ml/kg), LR (40 ml/kg), and HSD+LR (a combination of 4 ml/kg HSD and 40 ml/kg LR). Next, LR was transfused into all groups as in-hospital resuscitation (R2). After two hours of observation (R3), autologous blood was transfused. Hemodynamic responses and systemic oxygenation were measured at predetermined phases. Three days after resuscitation, the animals were sacrificed and tissues including kidney, lung, liver and intestinal were obtained for pathological analysis. Results Although the initial resuscitation with HSD was shown to be faster than LR with regard to an ascending MAP, the HSD group showed a similar hemodynamic performance compared to the LR group throughout the experiment. Compared with the LR group, the systemic oxygenation performance in the HSD group was similar but showed a lower venous-to-arterial CO2 gradient (Pv-aCO(2)) at R3 (p < 0.05). Additionally, the histology score of the kidneys, lungs and liver were significantly lower in the HSD group than in the LR group (p < 0.05). The HSD+LR group showed a superior hemodynamic response but higher extravascular lung water (EVLW) and lower arterial oxygen tension (PaO2) than the other groups (p < 0.05). The HSD+LR group showed a marginally improved systemic oxygenation performance and lower histology score than other groups. Conclusions Resuscitation after hemorrhagic shock with a bolus of HSD showed a similar hemodynamic response compared with LR at ten times the volume of HSD, but HSD showed superior efficacy in organ protection. Our findings suggest that resuscitation with the combination of HSD and LR in the pre-hospital setting is an effective treatment.	[Zhao, Jing-xiang; Wang, Bo; You, Guo-xing; Wang, Ying; Chen, Gan; Wang, Quan; Zhao, Lian; Zhou, Hong] Acad Mil Med Sci, Inst Transfus Med, Beijing, Peoples R China; [Zhang, Xi-gang] Chinese Peoples Liberat Army 307 Hosp, Emergency Dept, Beijing, Peoples R China; [He, Yue-zhong] Acad Mil Med Sci, Sci & Technol Dept, Beijing, Peoples R China	Academy of Military Medical Sciences - China; Academy of Military Medical Sciences - China	Zhao, L (corresponding author), Acad Mil Med Sci, Inst Transfus Med, 27th Taiping Rd, Beijing, Peoples R China.	zhaolian@bmi.ac.cn; zhouhtt1966@163.com; yzhe751@163.com	Chen, Gan/O-8508-2019; zhao, jing/B-3868-2019	Chen, Gan/0000-0003-4586-4526; 	Capital Health Project of Beijing Science and Technology Commission [Z121100005312014]; National High Technology Research and Development Program of China [2012AA021902]	Capital Health Project of Beijing Science and Technology Commission; National High Technology Research and Development Program of China(National High Technology Research and Development Program of China)	This work was supported by grants from Capital Health Project of Beijing Science and Technology Commission (Z121100005312014) and the National High Technology Research and Development Program of China (No. 2012AA021902).	Alam HB, 2007, SURG CLIN N AM, V87, P55, DOI 10.1016/j.suc.2006.09.015; Alam HB, 2000, J SURG RES, V94, P145, DOI 10.1006/jsre.2000.6011; Alam HB, 2001, J AM COLL SURGEONS, V193, P255, DOI 10.1016/S1072-7515(01)01004-3; [Anonymous], 2013, UK AMB SERV CLIN PRA; Baker AJ, 2009, J NEUROTRAUM, V26, P1227, DOI 10.1089/neu.2008.0868; Banerjee A, 2013, SHOCK, V39, P366, DOI 10.1097/SHK.0b013e3182894016; BEHRMAN SW, 1991, J TRAUMA, V31, P589, DOI 10.1097/00005373-199105000-00001; BICKELL WH, 1992, ANN EMERG MED, V21, P1077, DOI 10.1016/S0196-0644(05)80648-1; Boldt J, 2006, SHOCK, V25, P103, DOI 10.1097/01.shk.0000189595.35661.40; Boldt J, 2010, INTENS CARE MED, V36, P1299, DOI 10.1007/s00134-010-1912-7; Bruscagin V, 2002, J TRAUMA, V52, P1147, DOI 10.1097/00005373-200206000-00021; Bulger EM, 2007, ANN SURG, V245, P635, DOI 10.1097/01.sla.0000251367.44890.ae; Bulger EM, 2011, ANN SURG, V253, P431, DOI 10.1097/SLA.0b013e3181fcdb22; Cabrales P, 2007, SHOCK, V27, P380, DOI 10.1097/01.shk.0000239782.71516.ba; Cuschieri J, 2005, INTENS CARE MED, V31, P818, DOI 10.1007/s00134-005-2602-8; De Backer D, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-27; Deitch EA, 2003, SHOCK, V19, P328, DOI 10.1097/00024382-200304000-00006; Delano MJ, 2015, SHOCK, V44, P25, DOI 10.1097/SHK.0000000000000368; Deree J, 2007, J TRAUMA, V62, P104, DOI 10.1097/TA.0b013e31802d96cb; Dubick MA, 2003, J TRAUMA, V54, pS43, DOI 10.1097/01.TA.0000064514.42470.3B; Dubick MA, 2006, SHOCK, V25, P321, DOI 10.1097/01.shk.0000209525.50990.28; DUBICK MA, 1994, J TRAUMA, V36, P323, DOI 10.1097/00005373-199403000-00007; Elgjo GI, 2000, CRIT CARE MED, V28, P163, DOI 10.1097/00003246-200001000-00027; HANNON JP, 1989, CIRC SHOCK, V29, P205; Junger WG, 2012, SHOCK, V38, P341, DOI 10.1097/SHK.0b013e3182635aca; Kerger H, 1999, AM J PHYSIOL-HEART C, V276, pH2035, DOI 10.1152/ajpheart.1999.276.6.H2035; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; MAZZONI MC, 1990, CIRC SHOCK, V31, P407; Monnet X, 2007, INTENS CARE MED, V33, P448, DOI 10.1007/s00134-006-0498-6; Monnet X, 2013, CRIT CARE MED, V41, P1412, DOI 10.1097/CCM.0b013e318275cece; Orso CO, 1999, J TRAUMA, V46, P417; Parlakpinar H, 2007, INT J UROL, V14, P743, DOI 10.1111/j.1442-2042.2007.01806.x; PRIST R, 1992, CIRC SHOCK, V36, P13; Rhee P, 2003, J TRAUMA, V54, pS52, DOI 10.1097/01.TA.0000064507.80390.10; Riddez L, 2001, MIL MED, V166, P695, DOI 10.1093/milmed/166.8.695; Rizoli SB, 2006, ANN SURG, V243, P47, DOI 10.1097/01.sla.0000193608.93127.b1; SAUAIA A, 1994, ARCH SURG-CHICAGO, V129, P39; SONDEEN JL, 1990, RESUSCITATION, V20, P231, DOI 10.1016/0300-9572(90)90006-Z; Stapley SA, 2002, SHOCK, V17, P146, DOI 10.1097/00024382-200202000-00011; Sun LL, 1999, SHOCK, V11, P416; Tollofsrud S, 1998, ACTA ANAESTH SCAND, V42, P145, DOI 10.1111/j.1399-6576.1998.tb05100.x; Vallee F, 2008, INTENS CARE MED, V34, P2218, DOI 10.1007/s00134-008-1199-0; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; Wade CE, 1997, SURGERY, V122, P609, DOI 10.1016/S0039-6060(97)90135-5; Wade CE, 1996, CLIN CHEM, V42, P779; Wade CE, 2003, J TRAUMA, V54, pS144, DOI 10.1097/01.TA.0000047223.62617.AB; Wade CE, 2003, J TRAUMA, V55, P413, DOI 10.1097/01.TA.0000057247.02378.5E; WADE CE, 1989, CIRC SHOCK, V29, P193; Wenzel V, 2004, NEW ENGL J MED, V350, P105, DOI 10.1056/NEJMoa025431; Yang DJ, 2014, EUR REV MED PHARMACO, V18, P3069; ZHANG HB, 1993, AM REV RESPIR DIS, V148, P867, DOI 10.1164/ajrccm/148.4_Pt_1.867; Zhang YD, 2013, SCI WORLD J, DOI 10.1155/2013/130134; Zhao L, 2009, RESUSCITATION, V80, P253, DOI 10.1016/j.resuscitation.2008.10.014	53	2	2	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2015	10	8							e0136012	10.1371/journal.pone.0136012	http://dx.doi.org/10.1371/journal.pone.0136012			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ0PO	26317867	Green Published, gold, Green Submitted			2023-01-03	WOS:000360299100056
J	De Sordi, L; Butt, MA; Pye, H; Kohoutova, D; Mosse, CA; Yahioglu, G; Stamati, I; Deonarain, M; Battah, S; Ready, D; Allan, E; Mullany, P; Lovat, LB				De Sordi, Luisa; Butt, M. Adil; Pye, Hayley; Kohoutova, Darina; Mosse, Charles A.; Yahioglu, Gokhan; Stamati, Ioanna; Deonarain, Mahendra; Battah, Sinan; Ready, Derren; Allan, Elaine; Mullany, Peter; Lovat, Laurence B.			Development of Photodynamic Antimicrobial Chemotherapy (PACT) for Clostridium difficile	PLOS ONE			English	Article							METHYLENE-BLUE; VISIBLE-LIGHT; BILE-ACIDS; INACTIVATION; THERAPY; RESISTANCE; INFECTION; BACTERIAL; OXYGEN; EPIDEMIOLOGY	Background Clostridium difficile is the leading cause of antibiotic-associated diarrhoea and pseudo membranous colitis in the developed world. The aim of this study was to explore whether Photodynamic Antimicrobial Chemotherapy (PACT) could be used as a novel approach to treating C. difficile infections. Methods PACT utilises the ability of light-activated photosensitisers (PS) to produce reactive oxygen species (ROS) such as free radical species and singlet oxygen, which are lethal to cells. We screened thirteen PS against C. difficile planktonic cells, biofilm and germinating spores in vitro, and cytotoxicity of effective compounds was tested on the colorectal adenocarcinoma cell-line HT-29. Results Three PS were able to kill 99.9% of bacteria in both aerobic and anaerobic conditions, both in the planktonic state and in a biofilm, after exposure to red laser light (0.2 J/cm(2)) without harming model colon cells. The applicability of PACT to eradicate C. difficile germinative spores indirectly was also shown, by first inducing germination with the bile salt taurocholate, followed by PACT. Conclusion This innovative and simple approach offers the prospect of a new antimicrobial therapy using light to treat C. difficile infection of the colon.	[De Sordi, Luisa; Butt, M. Adil; Pye, Hayley; Kohoutova, Darina; Mosse, Charles A.; Lovat, Laurence B.] UCL, Res Dept Tissue & Energy, London, England; [Butt, M. Adil; Kohoutova, Darina; Lovat, Laurence B.] Univ Coll London Hosp, Div Gastrointestinal Serv, London, England; [Yahioglu, Gokhan; Stamati, Ioanna] Univ London Imperial Coll Sci Technol & Med, Dept Chem, London SW7 2AY, England; [Yahioglu, Gokhan; Deonarain, Mahendra] PhotoBiotics Ltd, Imperial Coll London, London, England; [Deonarain, Mahendra] Univ London Imperial Coll Sci Technol & Med, Dept Life Sci, London, England; [Battah, Sinan] Organix Ltd, Colchester, Essex, England; [Battah, Sinan] Univ Essex, Sch Biol Sci, Colchester CO4 3SQ, Essex, England; [Ready, Derren] Publ Hlth Lab London, London, England	University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; Imperial College London; Imperial College London; Imperial College London; University of Essex; Public Health England	Butt, MA (corresponding author), UCL, Res Dept Tissue & Energy, London, England.	adil.butt@ucl.ac.uk	De Sordi, Luisa/ABC-2581-2021; Lovat, Laurence/C-1986-2009	Lovat, Laurence/0000-0003-4542-3915; De Sordi, Luisa/0000-0002-3785-550X; Ready, Derren/0000-0003-4894-3641	Charles Wolfson Charitable Trust [238043]; National Institute for Health Research Biomedical Research Centres; University College London Experimental Cancer Medicine Centre; PhotoBiotics Ltd.; Organix Ltd.	Charles Wolfson Charitable Trust; National Institute for Health Research Biomedical Research Centres; University College London Experimental Cancer Medicine Centre; PhotoBiotics Ltd.; Organix Ltd.	This work was primarily funded by the Charles Wolfson Charitable Trust (Charity number: 238043). This research was undertaken at University College London in laboratories part funded by the National Institute for Health Research Biomedical Research Centres funding scheme (https://www.uclh.nhs.uk/Research/BRC/Pages/Home.aspx) and the University College London Experimental Cancer Medicine Centre (http://www.ecmcnetwork.org.uk/network-centres/london-ucl/). PhotoBiotics Ltd., provided support in the form of salaries for authors GY & MD, and Organix Ltd., provided support in the form of salaries for author SB, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ananthakrishnan AN, 2011, NAT REV GASTRO HEPAT, V8, P17, DOI 10.1038/nrgastro.2010.190; Ashkenazi H, 2003, FEMS IMMUNOL MED MIC, V35, P17, DOI 10.1111/j.1574-695X.2003.tb00644.x; Bartlett JG, 2008, CLIN INFECT DIS, V46, pS12, DOI 10.1086/521863; Beirao S, 2014, PHOTOCHEM PHOTOBIOL, V90, P1387, DOI 10.1111/php.12331; Bush K, 2011, NAT REV MICROBIOL, V9, P894, DOI 10.1038/nrmicro2693; Calin MA, 2009, LASER MED SCI, V24, P453, DOI 10.1007/s10103-008-0588-5; Carter GP, 2012, TRENDS MICROBIOL, V20, P21, DOI 10.1016/j.tim.2011.11.003; Clifton Jack 2nd, 2003, Am J Ther, V10, P289; Cornaglia G., 2011, Lancet Infectious Diseases, V11, P381, DOI 10.1016/S1473-3099(11)70056-1; Costa L, 2011, ANTIVIR RES, V91, P278, DOI 10.1016/j.antiviral.2011.06.007; da Silva RN, 2012, MICROBIOL IMMUNOL, V56, P692, DOI 10.1111/j.1348-0421.2012.00493.x; Dai T, 2009, PHOTODIAGN PHOTODYN, V6, P170, DOI 10.1016/j.pdpdt.2009.10.008; Dapa T, 2013, J BACTERIOL, V195, P545, DOI 10.1128/JB.01980-12; Dawson LF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050527; Decraene V, 2006, APPL ENVIRON MICROB, V72, P4436, DOI 10.1128/AEM.02945-05; Demidova TN, 2005, APPL ENVIRON MICROB, V71, P6918, DOI 10.1128/AEM.71.11.6918-6925.2005; Demidova TN, 2005, ANTIMICROB AGENTS CH, V49, P2329, DOI 10.1128/AAC.49.6.2329-2335.2005; Denis TGS, 2011, VIRULENCE, V2, P509, DOI 10.4161/viru.2.6.17889; Donald RG, 2013, MICROBIOLOGY; Gad F, 2004, ANTIMICROB AGENTS CH, V48, P2173, DOI 10.1128/AAC.48.6.2173-2178.2004; Gao XW, 2010, AM J GASTROENTEROL, V105, P1636, DOI 10.1038/ajg.2010.11; Gardiner DF, 2009, VACCINE, V27, P3598, DOI 10.1016/j.vaccine.2009.03.058; Giuliani F, 2010, ANTIMICROB AGENTS CH, V54, P637, DOI 10.1128/AAC.00603-09; Hamblin MR, 2005, ANTIMICROB AGENTS CH, V49, P2822, DOI 10.1128/AAC.49.7.2822-2827.2005; Howerton A, 2011, J BACTERIOL, V193, P274, DOI 10.1128/JB.00980-10; Huang LY, 2012, FREE RADICAL BIO MED, V53, P2062, DOI 10.1016/j.freeradbiomed.2012.09.006; Khanna S, 2012, AM J GASTROENTEROL, V107, P89, DOI 10.1038/ajg.2011.398; KOOPMAN BJ, 1985, CLIN CHIM ACTA, V152, P115, DOI 10.1016/0009-8981(85)90182-2; Kraus CN, 2008, CURR OPIN MICROBIOL, V11, P434, DOI 10.1016/j.mib.2008.09.009; Leggett MJ, 2012, J APPL MICROBIOL, V113, P485, DOI 10.1111/j.1365-2672.2012.05336.x; Liu BC, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.8.088001; Lo Vecchio A, 2012, CURR OPIN GASTROEN, V28, P1, DOI 10.1097/MOG.0b013e32834bc9a9; Lowy I, 2010, NEW ENGL J MED, V362, P197, DOI 10.1056/NEJMoa0907635; Maclean M, 2008, J PHOTOCH PHOTOBIO B, V92, P180, DOI 10.1016/j.jphotobiol.2008.06.006; Maclean M, 2013, PHOTOCHEM PHOTOBIOL, V89, P120, DOI 10.1111/j.1751-1097.2012.01202.x; Maisch T, 2009, MINI-REV MED CHEM, V9, P974, DOI 10.2174/138955709788681582; Merrigan MM, 2009, INT J ANTIMICROB AG, V33, pS46, DOI 10.1016/S0924-8579(09)70017-2; Min D B, 2002, Compr Rev Food Sci Food Saf, V1, P58, DOI 10.1111/j.1541-4337.2002.tb00007.x; O'Donoghue C, 2011, CURR OPIN GASTROEN, V27, P38, DOI 10.1097/MOG.0b013e3283411634; OKUDA H, 1984, HEPATO-GASTROENTEROL, V31, P168; Oliveira A, 2009, J APPL MICROBIOL, V106, P1986, DOI 10.1111/j.1365-2672.2009.04168.x; OSEROFF AR, 1986, P NATL ACAD SCI USA, V83, P9729, DOI 10.1073/pnas.83.24.9729; PASS HI, 1993, JNCI-J NATL CANCER I, V85, P443, DOI 10.1093/jnci/85.6.443; Plusa S M, 1991, J R Coll Surg Edinb, V36, P303; Preuss A, 2013, J APPL MICROBIOL, V114, P36, DOI 10.1111/jam.12018; Sayedy L, 2010, WORLD J GASTRO ENDOS, V2, P293, DOI 10.4253/wjge.v2.i8.293; Soukos NS, 2005, ANTIMICROB AGENTS CH, V49, P1391, DOI 10.1128/AAC.49.4.1391-1396.2005; Stamati I, 2010, PHOTOCH PHOTOBIO SCI, V9, P1033, DOI 10.1039/c0pp00038h; Tardivo JP, 2006, PHOTOMED LASER SURG, V24, P528, DOI 10.1089/pho.2006.24.528; Tavares A, 2010, MAR DRUGS, V8, P91, DOI 10.3390/md8010091; Turner M, 2011, NATURE, V474, P137, DOI 10.1038/474137a; Usuda J, 2006, J THORAC ONCOL, V1, P489, DOI 10.1097/01243894-200606000-00018; VALDUGA G, 1993, J PHOTOCH PHOTOBIO B, V21, P81, DOI 10.1016/1011-1344(93)80168-9; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Via LD, 2001, CURR MED CHEM, V8, P1405, DOI 10.2174/0929867013372076; Vicente M, 2006, FEMS MICROBIOL REV, V30, P841, DOI 10.1111/j.1574-6976.2006.00038.x; Wainwright M, 2002, J CHEMOTHERAPY, V14, P431, DOI 10.1179/joc.2002.14.5.431; Wang S, 2010, EXPERT OPIN PHARMACO, V11, P133, DOI 10.1517/14656560903463893; WANG WY, 1991, JPEN-PARENTER ENTER, V15, P294, DOI 10.1177/0148607191015003294	59	16	16	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2015	10	8							e0135039	10.1371/journal.pone.0135039	http://dx.doi.org/10.1371/journal.pone.0135039			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP8KZ	26313448	Green Submitted, Green Published, gold			2023-01-03	WOS:000360144000012
J	Aloui, A; Briki, W; Baklouti, H; Chtourou, H; Driss, T; Chaouachi, A; Chamari, K; Souissi, N				Aloui, Asma; Briki, Walid; Baklouti, Hana; Chtourou, Hamdi; Driss, Tarak; Chaouachi, Anis; Chamari, Karim; Souissi, Nizar			Listening to Music during Warming-Up Counteracts the Negative Effects of Ramadan Observance on Short-Term Maximal Performance	PLOS ONE			English	Article							SPRINT PERFORMANCE; PERCEIVED EXERTION; ANAEROBIC PERFORMANCES; DIURNAL-VARIATIONS; POWER OUTPUT; EXERCISE; INTENSITY; STRENGTH; ANXIETY	Aim The aim of the present study was to examine whether listening to music during warming-up might influence short-term maximal performance (STMP), cognitive anxiety, self-confidence, and enjoyment during Ramadan, and whether these affects might predict STMP. Methods Nine male physical education students (age: 21 +/- 1.1 years; height: 1.8 +/- 0.04 m; body mass: 83 +/- 5 kg) volunteered to participate in the present study. A within-subjects design consisted of four experimental sessions: Two sessions occurred one week before Ramadan and two others took place during Ramadan. They were scheduled at 5 p.m. and were conducted as follows: After a 10-minute warm-up either with or without listening to music, each participant performed a 5-m multiple shuttle run test, after which he was asked to answer items intended to assess his affective state during the experimental task. Results Our findings revealed that STMP was lower during Ramadan than before Ramadan in the no-music condition. Additionally, it was found that STMP was higher in the music condition than in the no-music condition during Ramadan, and that STMP measured before Ramadan did not differ from that measured during Ramadan in the music condition. Regarding affects, the findings revealed that enjoyment was lower during Ramadan than before Ramadan in the music condition, and that cognitive anxiety was lower in the music condition than in the no-music condition before Ramadan. Self-confidence was not influenced by the experimental conditions. Conclusion This study showed that listening to music during warming-up not only would be beneficial for STMP in Ramadan fasters, but also would counteract the negative effects of Ramadan observance on STMP.	[Aloui, Asma; Baklouti, Hana; Chtourou, Hamdi; Chaouachi, Anis; Souissi, Nizar] Natl Ctr Med & Sci Sport, Res Lab Sport Performance Optimizat, Tunis, Tunisia; [Aloui, Asma] Univ Gafsa, High Inst Sport & Phys Educ Gafsa, Gafsa, Tunisia; [Briki, Walid] Qatar Univ, Coll Arts & Sci, Sport Sci Program, Doha, Qatar; [Chtourou, Hamdi] Univ Sfax, High Inst Sport & Phys Educ Sfax, Sfax, Tunisia; [Driss, Tarak] Univ Paris Ouest Nanterre La Def, UFR STAPS, Equipe Physiol Biomecan & Imagerie Mouvement, Lab CeRSM,EA 2931, Nanterre, France; [Chamari, Karim] Qatar Orthoped & Sports Med Hosp, Athlete Hlth & Performance Res Ctr, ASPETAR, Doha, Qatar	Centre National de la Medecine Sciences des Sports; Universite de Gafsa; Qatar University; Universite de Sfax; Universite Paris Nanterre; Aspetar Orthopaedic & Sports Medicine Hospital	Briki, W (corresponding author), Qatar Univ, Coll Arts & Sci, Sport Sci Program, Doha, Qatar.	briki.w@gmail.com	CHAMARI, Karim/AAJ-7938-2021; DRISS, Tarak/AAR-2823-2020; Nizar, Souissi/AAF-4490-2019; Chtourou, Hamdi/GVU-1967-2022; Aloui, Asma/J-1300-2019	CHAMARI, Karim/0000-0001-9178-7678; DRISS, Tarak/0000-0001-6109-7393; Nizar, Souissi/0000-0003-1227-8221; Chtourou, Hamdi/0000-0002-5482-9151; Aloui, Asma/0000-0001-5054-1540; Briki, Walid/0000-0002-6298-811X				Aloui A, 2013, INT J SPORT PHYSIOL, V8, P254, DOI 10.1123/ijspp.8.3.254; BECKER N, 1994, PERCEPT MOTOR SKILL, V79, P1043, DOI 10.2466/pms.1994.79.2.1043; BENWARE CA, 1984, AM EDUC RES J, V21, P755, DOI 10.3102/00028312021004755; Boddington MK, 2001, J SPORT SCI, V19, P223, DOI 10.1080/026404101750095394; BROWNLEY KA, 1995, INT J PSYCHOPHYSIOL, V19, P193, DOI 10.1016/0167-8760(95)00007-F; Chtourou H, 2012, INT J SPORTS MED, V33, P142, DOI 10.1055/s-0031-1286251; Chtourou H, 2012, INT J SPORTS MED, V33, P43, DOI 10.1055/s-0031-1284398; Chtourou Hamdi, 2011, Asian J Sports Med, V2, P177; Cooke A, 2013, J SPORT EXERCISE PSY, V35, P132, DOI 10.1123/jsep.35.2.132; Cooke A, 2011, BIOL PSYCHOL, V86, P370, DOI 10.1016/j.biopsycho.2011.01.009; Dyrlund AK, 2008, J MUSIC THER, V45, P114, DOI 10.1093/jmt/45.2.114; Elliott D., 2005, EUR J SPORT SCI, V5, P97, DOI [10.1080/17461390500171310, DOI 10.1080/17461390500171310]; Ghaderi M, 2009, S AFR J RES SPORT PH, V31, P29; Gillet N, 2010, PSYCHOL SPORT EXERC, V11, P155, DOI 10.1016/j.psychsport.2009.10.004; Girard O, 2012, SCI SPORT, V27, P237, DOI 10.1016/j.scispo.2011.09.006; GROLNICK WS, 1987, J PERS SOC PSYCHOL, V52, P890, DOI 10.1037/0022-3514.52.5.890; Hammoudi-Nassib S, 2014, J STRENGTH COND RES, V28, P3245, DOI 10.1519/JSC.0000000000000530; Hamouda O, 2012, BIOL RHYTHM RES, V43, P177, DOI 10.1080/09291016.2011.560050; Jarraya Mohamed, 2012, Asian J Sports Med, V3, P233; Judelson DA, 2007, SPORTS MED, V37, P907, DOI 10.2165/00007256-200737100-00006; Karageorghis C, 2008, INT J SPORTS MED, V29, P613, DOI 10.1055/s-2007-989266; Karageorghis C. I., 1997, Journal of Sport Behavior, V20, P54; Karageorghis C.I., 2009, SPORTING SOUNDS RELA, P13; Karageorghis CI, 1996, PERCEPT MOTOR SKILL, V83, P1347, DOI 10.2466/pms.1996.83.3f.1347; KRANE V, 1994, SPORT PSYCHOL, V8, P189, DOI 10.1123/tsp.8.2.189; Nakamura PM, 2010, PERCEPT MOTOR SKILL, V110, P257, DOI 10.2466/PMS.110.1.257-264; Potteiger JA, 2000, PERCEPT MOTOR SKILL, V91, P848, DOI 10.2466/PMS.91.7.848-854; RYAN RM, 1982, J PERS SOC PSYCHOL, V43, P450, DOI 10.1037/0022-3514.43.3.450; Simpson SD, 2006, J SPORT SCI, V24, P1095, DOI 10.1080/02640410500432789; Souissi N, 2007, CHRONOBIOL INT, V24, P991, DOI 10.1080/07420520701661914; Szmedra L, 1998, INT J SPORTS MED, V19, P32, DOI 10.1055/s-2007-971876; Woodman T, 2003, J SPORT SCI, V21, P443, DOI 10.1080/0264041031000101809; Yamashita S, 2006, J SPORT MED PHYS FIT, V46, P425	33	5	5	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2015	10	8							e0136400	10.1371/journal.pone.0136400	http://dx.doi.org/10.1371/journal.pone.0136400			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CP5VA	26301508	Green Published, gold, Green Submitted			2023-01-03	WOS:000359951900067
J	Herremans, SC; Van Schuerbeek, P; De Raedt, R; Matthys, F; Buyl, R; De Mey, J; Baeken, C				Herremans, Sarah C.; Van Schuerbeek, Peter; De Raedt, Rudi; Matthys, Frieda; Buyl, Ronald; De Mey, Johan; Baeken, Chris			The Impact of Accelerated Right Prefrontal High-Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) on Cue-Reactivity: An fMRI Study on Craving in Recently Detoxified Alcohol-Dependent Patients	PLOS ONE			English	Article							COMPULSIVE DRINKING SCALE; HF-RTMS; EMOTIONAL INFORMATION; ABSTINENT ALCOHOLICS; TALAIRACH ATLAS; CORTEX; ADDICTION; URGES; METAANALYSIS; VALIDATION	In alcohol-dependent patients craving is a difficult-to-treat phenomenon. It has been suggested that high-frequency (HF) repetitive transcranial magnetic stimulation (rTMS) may have beneficial effects. However, exactly how this application exerts its effect on the underlying craving neurocircuit is currently unclear. In an effort to induce alcohol craving and to maximize detection of HF-rTMS effects to cue-induced alcohol craving, patients were exposed to a block and event-related alcohol cue-reactivity paradigm while being scanned with fMRI. Hence, we assessed the effect of right dorsolateral prefrontal cortex (DLPFC) stimulation on cue-induced and general alcohol craving, and the related craving neurocircuit. Twenty-six recently detoxified alcohol-dependent patients were included. First, we evaluated the impact of one sham-controlled stimulation session. Second, we examined the effect of accelerated right DLPFC HF-rTMS treatment: here patients received 15 sessions in an open label accelerated design, spread over 4 consecutive days. General craving significantly decreased after 15 active HF-rTMS sessions. However, cue-induced alcohol craving was not altered. Our brain imaging results did not show that the cue-exposure affected the underlying craving neurocircuit after both one and fifteen active HF-rTMS sessions. Yet, brain activation changes after one and 15 HF-rTMS sessions, respectively, were observed in regions associated with the extended reward system and the default mode network, but only during the presentation of the event-related paradigm. Our findings indicate that accelerated HF-rTMS applied to the right DLPFC does not manifestly affect the craving neurocircuit during an alcohol-related cue-exposure, but instead it may influence the attentional network.	[Herremans, Sarah C.; Matthys, Frieda; Baeken, Chris] Vrije Univ Brussel, Dept Psychiat, Univ Ziekenhuis Brussel UZ Brussel, Brussels, Belgium; [Van Schuerbeek, Peter; De Mey, Johan] Vrije Univ Brussel, Dept Radiol, Univ Ziekenhuis Brussel UZ Brussel, Brussels, Belgium; [De Raedt, Rudi] Univ Ghent, Dept Expt Clin & Hlth Psychol, B-9000 Ghent, Belgium; [Buyl, Ronald] Vrije Univ Brussel, Dept Biostat & Med Informat, Brussels, Belgium; [Baeken, Chris] Univ Ghent, Dept Psychiat & Med Psychol, Univ Ziekenhuis Gent, B-9000 Ghent, Belgium	University Hospital Brussels; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University Hospital Brussels; Ghent University; Vrije Universiteit Brussel; Ghent University; Ghent University Hospital	Herremans, SC (corresponding author), Vrije Univ Brussel, Dept Psychiat, Univ Ziekenhuis Brussel UZ Brussel, Brussels, Belgium.	sarah.herremans@uzbrussel.be	De Raedt, Rudi/A-3269-2012; Buyl, Ronald/F-3862-2015; de Mey, Johan/AAL-9312-2021; matthys, frieda/AAW-2305-2021; Baeken, Chris/D-6790-2013; de Mey, Johan/F-3602-2011; De Raedt, Rudi/AAL-4093-2021	De Raedt, Rudi/0000-0001-6781-4808; Buyl, Ronald/0000-0002-6598-9505; matthys, frieda/0000-0002-0900-1478; De Raedt, Rudi/0000-0001-6781-4808; Van Schuerbeek, Peter/0000-0003-3647-4446; de Mey, Johan/0000-0002-3601-3212	Scientific Fund Willy Gepts [2012-03]	Scientific Fund Willy Gepts	This work was funded by Scientific Fund Willy Gepts 2012-03 (CB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amaro E, 2006, BRAIN COGNITION, V60, P220, DOI 10.1016/j.bandc.2005.11.009; Amiaz R, 2009, ADDICTION, V104, P653, DOI 10.1111/j.1360-0443.2008.02448.x; ANTON RF, 1995, ALCOHOL CLIN EXP RES, V19, P92, DOI 10.1111/j.1530-0277.1995.tb01475.x; Baeken C, 2013, J AFFECT DISORDERS, V151, P625, DOI 10.1016/j.jad.2013.07.008; Bauer J, 2013, NEUROPSYCHOPHARMACOL, V38, P1401, DOI 10.1038/npp.2013.45; Beck A, 2012, ARCH GEN PSYCHIAT, V69, P842, DOI 10.1001/archgenpsychiatry.2011.2026; Bellamoli E, 2014, BEHAV NEUROL, V2014, DOI 10.1155/2014/815215; Bennett CM, 2009, SOC COGN AFFECT NEUR, V4, P417, DOI 10.1093/scan/nsp053; Berlim MT, 2013, INT J NEUROPSYCHOPH, V16, P1173, DOI 10.1017/S1461145712001691; Berridge KC, 2013, CURR OPIN NEUROBIOL, V23, P294, DOI 10.1016/j.conb.2013.01.017; BOHN MJ, 1995, ALCOHOL CLIN EXP RES, V19, P600, DOI 10.1111/j.1530-0277.1995.tb01554.x; Camprodon JA, 2007, DRUG ALCOHOL DEPEN, V86, P91, DOI 10.1016/j.drugalcdep.2006.06.002; Craig AD, 2002, NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894; De Raedt R, 2010, BIOL PSYCHOL, V85, P487, DOI 10.1016/j.biopsycho.2010.09.015; de Wildt WAJM, 2005, ALCOHOL CLIN EXP RES, V29, P509, DOI 10.1097/01.ALC.0000158844.35608.48; Di X, 2014, NEUROIMAGE, V86, P53, DOI 10.1016/j.neuroimage.2013.07.071; Drummond DC, 2002, ADDICTION, V97, P1465, DOI 10.1046/j.1360-0443.2002.00252.x; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119; Grall-Bronnec M, 2014, NEUROSCI BIOBEHAV R, V47, P592, DOI 10.1016/j.neubiorev.2014.10.013; Grusser SM, 2004, PSYCHOPHARMACOLOGY, V175, P296, DOI 10.1007/s00213-004-1828-4; Hayashi T, 2013, P NATL ACAD SCI USA, V110, P4422, DOI 10.1073/pnas.1212185110; Heinz A, 2003, ALCOHOL ALCOHOLISM, V38, P35, DOI 10.1093/alcalc/agg005; Heinz A, 2009, ADDICT BIOL, V14, P108, DOI 10.1111/j.1369-1600.2008.00136.x; Herremans SC, 2012, DRUG ALCOHOL DEPEN, V120, P209, DOI 10.1016/j.drugalcdep.2011.07.021; Herremans SC, 2012, PSYCHIAT DANUB, V24, pS14; Hoppner J, 2011, WORLD J BIOL PSYCHIA, V12, P57, DOI 10.3109/15622975.2011.598383; Holtzheimer PE, 2010, DEPRESS ANXIETY, V27, P960, DOI 10.1002/da.20731; Jansen JM, 2013, NEUROSCI BIOBEHAV R, V37, P2472, DOI 10.1016/j.neubiorev.2013.07.009; Jasinska AJ, 2014, NEUROSCI BIOBEHAV R, V38, P1, DOI 10.1016/j.neubiorev.2013.10.013; Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110; Kuhn S, 2012, ADDICT BIOL, V18, P121, DOI [10.1111/j.1460-9568.2010.07590.x, DOI 10.1111/J.1460-9568.2010.07590.X]; Lancaster J.L., 1997, NEUROIMAGE, V5, pS633, DOI DOI 10.1002/(SICI)1097-0193(1997)5:4<238:AID-HBM6>3.0.C0;2-4; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Langosch JM, 2012, J CLIN PSYCHOPHARM, V32, P661, DOI 10.1097/JCP.0b013e318267b586; Leyman L, 2009, PSYCHOL MED, V39, P1019, DOI 10.1017/S0033291708004431; Liu X, 2011, NEUROSCI BIOBEHAV R, V35, P1219, DOI 10.1016/j.neubiorev.2010.12.012; Lukas SE, 2013, NEUROIMAGE, V78, P176, DOI 10.1016/j.neuroimage.2013.03.055; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Maldjian JA, 2004, NEUROIMAGE, V21, P450, DOI 10.1016/j.neuroimage.2003.09.032; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Mishra BR, 2010, ADDICTION, V105, P49, DOI 10.1111/j.1360-0443.2009.02777.x; Mishra BR, 2015, J NEUROPSYCH CLIN N, V27, pE54, DOI 10.1176/appi.neuropsych.13010013; Naqvi NH, 2010, BRAIN STRUCT FUNCT, V214, P435, DOI 10.1007/s00429-010-0268-7; Paret C, 2014, NEUROIMAGE, V103, P522, DOI 10.1016/j.neuroimage.2014.08.054; Paus T, 2004, J PSYCHIATR NEUROSCI, V29, P268; Peleman K, 2010, WORLD J BIOL PSYCHIA, V11, P425, DOI [10.1080/15622970802669564, 10.3109/15622970802669564]; Politi E, 2008, AM J ADDICTION, V17, P345, DOI 10.1080/10550490802139283; Ross S, 2009, CLIN NEUROPHARMACOL, V32, P277, DOI 10.1097/WNF.0b013e3181a91655; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rudebeck PH, 2013, NAT NEUROSCI, V16, P1140, DOI 10.1038/nn.3440; Schacht JP, 2013, ADDICT BIOL, V18, P121, DOI 10.1111/j.1369-1600.2012.00464.x; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Sheffer CE, 2013, J SUBST ABUSE TREAT, V45, P206, DOI 10.1016/j.jsat.2013.01.012; SULLIVAN JT, 1989, BRIT J ADDICT, V84, P1353; Sutherland MT, 2012, NEUROIMAGE, V62, P2281, DOI 10.1016/j.neuroimage.2012.01.117; TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147; Tiffany ST, 2012, ANN NY ACAD SCI, V1248, P1, DOI 10.1111/j.1749-6632.2011.06298.x; Vanderhasselt MA, 2007, BRAIN RES, V1137, P111, DOI 10.1016/j.brainres.2006.12.050; Wilson SJ, 2004, NAT NEUROSCI, V7, P211, DOI 10.1038/nn1200; Yalachkov Y, 2010, BEHAV BRAIN RES, V207, P215, DOI 10.1016/j.bbr.2009.09.015	62	42	42	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2015	10	8							e0136182	10.1371/journal.pone.0136182	http://dx.doi.org/10.1371/journal.pone.0136182			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP5MR	26295336	Green Published, Green Submitted, gold			2023-01-03	WOS:000359926900080
J	Htun, P; Nee, J; Ploeckinger, U; Eder, K; Geisler, T; Gawaz, M; Bocksch, W; Fateh-Moghadam, S				Htun, Patrik; Nee, Jens; Ploeckinger, Ursula; Eder, Klaus; Geisler, Tobias; Gawaz, Meinrad; Bocksch, Wolfgang; Fateh-Moghadam, Suzanne			Fish-Free Diet in Patients with Phenylketonuria Is Not Associated with Early Atherosclerotic Changes and Enhanced Platelet Activation	PLOS ONE			English	Article							CORONARY-HEART-DISEASE; POLYUNSATURATED FATTY-ACIDS; CARDIOVASCULAR RISK-FACTORS; MYOCARDIAL-INFARCTION; CONSUMPTION; MORTALITY; OMEGA-3-FATTY-ACIDS; SUPPLEMENTATION; PROGRESSION; OIL	Background and Purpose Since patients with phenylketonuria (PKU) have to follow a lifelong restriction of natural protein to lower phenylalanine-intake, they never eat fish. This diet may lead to a chronic deficit of omega-3 and omega-6 fatty acids with the risk of early atherosclerotic changes. The aim of the study was to analyse the fatty acid profile of PKU patients and to correlate the results with surrogate markers of early atherosclerotic changes [enhanced carotid intima media thickness (CIMT) and beta-stiffness index] and platelet activation. Methods In 43 PKU patients and in 58 healthy controls we prospectively examined the fatty acid profile, CIMT, beta-stiffness index and platelet activation (flow cytometric determination of markers of platelet activation). CIMT was measured bilaterally by ultrasound. CIMTmean was defined as the mean value of the sum of CIMTleft and CIMTright. Results Despite of lower HDL-cholesterol and higher triglyceride concentrations in the PKU group, there was no significant difference in the omega-6 or omega-3 fatty acid profile, CIMT, beta-stiffness index between both groups. Platelet activation was not enhanced in the PKU group. Conclusions Fish-free diet does not induce early atherosclerotic changes or enhanced platelet activation in PKU patients.	[Htun, Patrik] Zent Klinikum, Zent Notaufnahme & Med Klin 4, Augsburg, Germany; [Nee, Jens] Humboldt Univ, Charite Univ Med Campus Virchow Klinikum, Med Klin Schwerpunkt Nephrol & Intens Med, Tubingen, Germany; [Ploeckinger, Ursula] Humboldt Univ, Charite Univ Med Campus Virchow Klinikum, Interdisziplinaeres Stoffwechsel Ctr, Augsburg, Germany; [Eder, Klaus] Univ Giessen, Inst Tierernahrung & Ernahrungsphysiol, Giessen, Germany; [Geisler, Tobias; Gawaz, Meinrad; Bocksch, Wolfgang; Fateh-Moghadam, Suzanne] Univ Tubingen, Abt Kardiol & Kreislauferkrankungen, Med Klin 3, Tubingen, Germany	Humboldt University of Berlin; Humboldt University of Berlin; Justus Liebig University Giessen; Eberhard Karls University of Tubingen	Fateh-Moghadam, S (corresponding author), Univ Tubingen, Abt Kardiol & Kreislauferkrankungen, Med Klin 3, Tubingen, Germany.	suzanne.fateh-moghadam@med.uni-tuebingen.de	Geisler, Tobias/AAO-4472-2020		Charite Research Fund (Anschubfinanzierung); DFG - Klinische Forschergruppe Platelet-Basic Mechanisms and Translational Medicine [KFO274]; Deutsche Interessengemeinschaft Phenylketonurie und verwandte Stoffwechselstorungen e.V. (DIG-PKU)	Charite Research Fund (Anschubfinanzierung); DFG - Klinische Forschergruppe Platelet-Basic Mechanisms and Translational Medicine(German Research Foundation (DFG)); Deutsche Interessengemeinschaft Phenylketonurie und verwandte Stoffwechselstorungen e.V. (DIG-PKU)	This study was supported in part by grants from the Charite Research Fund (Anschubfinanzierung), by the DFG - Klinische Forschergruppe (KFO274) Platelet-Basic Mechanisms and Translational Medicine and "Deutsche Interessengemeinschaft Phenylketonurie und verwandte Stoffwechselstorungen e.V. (DIG-PKU)".	Angerer P, 2002, CARDIOVASC RES, V54, P183, DOI 10.1016/S0008-6363(02)00229-8; [Anonymous], 1985, N ENGL J MED, V313, P820; [Anonymous], 2001, METABOLIC MOL BASES, DOI DOI 10.1036/OMMBID.97; BANG HO, 1976, ACTA MED SCAND, V200, P69; Bosch J, 2012, NEW ENGL J MED, V367, P309, DOI 10.1056/NEJMoa1203859; Bowersox J, 2001, PEDIATRICS, V108, P972; BRADEN GA, 1990, CIRCULATION, V82, P178, DOI 10.1161/01.CIR.82.1.178; Bucher HC, 2002, AM J MED, V112, P298, DOI 10.1016/S0002-9343(01)01114-7; BURR ML, 1989, LANCET, V2, P757; CHETTY N, 1983, THROMB RES, V30, P619, DOI 10.1016/0049-3848(83)90270-0; Conquer JA, 1999, THROMB RES, V96, P239, DOI 10.1016/S0049-3848(99)00106-1; DOLECEK TA, 1991, WORLD REV NUTR DIET, V66, P205; EDER K, 1993, CLIN CHIM ACTA, V219, P93, DOI 10.1016/0009-8981(93)90200-N; Emoto M, 1998, DIABETES CARE, V21, P1178, DOI 10.2337/diacare.21.7.1178; Fateh-Moghadam S, 2005, ARTERIOSCL THROM VAS, V25, P1299, DOI 10.1161/01.ATV.0000165699.41301.c5; Fateh-Moghadam S, 2000, CIRCULATION, V102, P890; Fateh-Moghadam S, 2007, THROMB HAEMOSTASIS, V97, P974, DOI 10.1160/TH06-12-0725; Gawaz M, 1999, CIRCULATION, V99, P2; Hanley WB, 2004, AM J MED, V117, P590, DOI 10.1016/j.amjmed.2004.03.042; HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5; HIRAI T, 1989, CIRCULATION, V80, P78, DOI 10.1161/01.CIR.80.1.78; Hooper L, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003177.PUB2; Iannuzzi A, 2006, AM J CARDIOL, V97, P528, DOI 10.1016/j.amjcard.2005.08.072; KROMHOUT D, 1995, INT J EPIDEMIOL, V24, P340, DOI 10.1093/ije/24.2.340; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; LEAF A, 1994, CIRCULATION, V90, P2248, DOI 10.1161/01.CIR.90.5.2248; Li D, 1999, EUR J CLIN NUTR, V53, P612, DOI 10.1038/sj.ejcn.1600817; McCarty MF, 2004, MED HYPOTHESES, V63, P426, DOI 10.1016/j.mehy.2002.11.007; Mezzano D, 1999, THROMB HAEMOSTASIS, V81, P913; Mori TA, 1997, ARTERIOSCL THROM VAS, V17, P279, DOI 10.1161/01.ATV.17.2.279; MORRISON WR, 1964, J LIPID RES, V5, P600; Moseley K, 2002, J INHERIT METAB DIS, V25, P56, DOI 10.1023/A:1015142001578; Mozaffarian D, 2003, CIRCULATION, V107, P1372, DOI 10.1161/01.CIR.0000055315.79177.16; Myrup B, 2001, SCAND J CLIN LAB INV, V61, P349, DOI 10.1080/003655101316911387; Nelson GJ, 1997, LIPIDS, V32, P1129, DOI 10.1007/s11745-997-0145-6; Oomen CM, 2000, AM J EPIDEMIOL, V151, P999, DOI 10.1093/oxfordjournals.aje.a010144; PRISCO D, 1995, METABOLISM, V44, P562, DOI 10.1016/0026-0495(95)90111-6; Rodriguez BL, 1996, CIRCULATION, V94, P952, DOI 10.1161/01.CIR.94.5.952; Ruf A, 1997, BRIT J HAEMATOL, V98, P51, DOI 10.1046/j.1365-2141.1997.1502965.x; SACKS FM, 1995, J AM COLL CARDIOL, V25, P1492, DOI 10.1016/0735-1097(95)00095-L; Schoene NW, 2001, NUTRITION, V17, P793, DOI 10.1016/S0899-9007(01)00644-X; SISCOVICK DS, 1995, JAMA-J AM MED ASSOC, V274, P1363, DOI 10.1001/jama.274.17.1363; Yuan JM, 2001, AM J EPIDEMIOL, V154, P809, DOI 10.1093/aje/154.9.809	43	6	6	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2015	10	8							e0135930	10.1371/journal.pone.0135930	http://dx.doi.org/10.1371/journal.pone.0135930			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP5KH	26291823	gold, Green Published, Green Submitted			2023-01-03	WOS:000359919900042
J	McCay, L				McCay, Layla			Emotional motivators might improve hand hygiene among healthcare workers	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							BEHAVIOR		Global Publ Private Partnership Handwashing, Washington, DC 20008 USA		McCay, L (corresponding author), Global Publ Private Partnership Handwashing, 1825 Connecticut Ave NW, Washington, DC 20008 USA.	laylamccay@hotmail.com	McCay, Layla/H-4030-2017	McCay, Layla/0000-0003-1759-5218				Aiello AE, 2008, AM J PUBLIC HEALTH, V98, P1372, DOI 10.2105/AJPH.2007.124610; Allegranzi B, 2011, LANCET, V377, P228, DOI 10.1016/S0140-6736(10)61458-4; Bhalla A, 2004, INFECT CONT HOSP EP, V25, P164, DOI 10.1086/502369; Biran A, 2014, LANCET GLOB HEALTH, V2, pE145, DOI 10.1016/S2214-109X(13)70160-8; Carpenter CJ, 2010, HEALTH COMMUN, V25, P661, DOI 10.1080/10410236.2010.521906; CASEWELL M, 1977, BRIT MED J, V2, P1315, DOI 10.1136/bmj.2.6098.1315; Contzen N, 2015, SOC SCI MED, V124, P103, DOI 10.1016/j.socscimed.2014.11.006; Curtis VA, 2009, HEALTH EDUC RES, V24, P655, DOI 10.1093/her/cyp002; Erasmus V, 2010, INFECT CONT HOSP EP, V31, P283, DOI 10.1086/650451; Freeman MC, 2014, TROP MED INT HEALTH, V19, P906, DOI 10.1111/tmi.12339; Magill SS, 2014, NEW ENGL J MED, V370, P1198, DOI 10.1056/NEJMoa1306801; Pittet D, 1999, ARCH INTERN MED, V159, P821, DOI 10.1001/archinte.159.8.821	12	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 28	2015	351								h3968	10.1136/bmj.h3968	http://dx.doi.org/10.1136/bmj.h3968			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CO2TX	26220073				2023-01-03	WOS:000359010600005
J	Yan, LB; Kanada, M; Zhang, JY; Okazaki, S; Terakawa, S				Yan, Libo; Kanada, Masamitsu; Zhang, Jinyan; Okazaki, Shigetoshi; Terakawa, Susumu			Photodynamic Treatment of Tumor with Bacteria Expressing KillerRed	PLOS ONE			English	Article							CANCER GENE-THERAPY; DELIVERY; VECTORS; OXYGEN; CELLS	Photodynamic therapy (PDT) is a cancer treatment modality in which a photosensitizing dye is administered and exposed to light to kill tumor cells via the production of reactive oxygen species (ROS). A fundamental obstacle for PDT is the low specificity for staining solid tumors with dyes. Recently, a tumor targeting system guided by anaerobic bacteria was proposed for tumor imaging and treatment. Here, we explore the feasibility of the genetically encoded photosensitizer KillerRed, which is expressed in Escherichia coli, to treat tumors. Using nitroblue tetrazolium (NBT), we detected a lengthy ROS diffusion from the bodies of KillerRed-expressing bacteria in vitro, which demonstrated the feasibility of using bacteria to eradicate cells in their surroundings. In nude mice, Escherichia coli (E. coli) expressing KillerRed (KR-E. coli) were subcutaneously injected into xenografts comprising CNE2 cells, a human nasopharyngeal carcinoma cell line, and HeLa cells, a human cervical carcinoma cell line. KR-E. coli seemed to proliferate rapidly in the tumors as observed under an imaging system. When the intensity of fluorescence increased and the fluorescent area became as large as the tumor one day after KR-E. coli injection, the KR-E. coli-bearing tumor was irradiated with an orange light (lambda = 540 - 580 nm). In all cases, the tumors became necrotic the next day and were completely eliminated in a few days. No necrosis was observed after the irradiation of tumors injected with a vehicle solution or a vehicle carrying the E. coli without KillerRed. In successfully treated mice, no tumor recurrence was observed for more than two months. E. coli genetically engineered for KillerRed expression are highly promising for the diagnosis and treatment of tumors when the use of bacteria in patients is cleared for infection safety.	[Yan, Libo; Kanada, Masamitsu; Zhang, Jinyan; Okazaki, Shigetoshi; Terakawa, Susumu] Hamamatsu Univ Sch Med, Med Photon Res Ctr, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan	Hamamatsu University School of Medicine	Terakawa, S (corresponding author), Tokoha Univ, Dept Hlth Sci, Aoi Ku, Shizuoka, Japan.	terakawa@sz.tokoha-u.ac.jp	Kanada, Masamitsu/AAP-1664-2020	Zhang, Jinyan/0000-0002-9874-2744	Hamamatsu University School of Medicine	Hamamatsu University School of Medicine	This work was supported partly by an intramural grant for "Cancer Research by Photonics" from Hamamatsu University School of Medicine to S. T. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.	Baban Chwanrow K, 2010, Bioeng Bugs, V1, P385, DOI 10.4161/bbug.1.6.13146; Baumler W, 1999, BRIT J CANCER, V80, P360, DOI 10.1038/sj.bjc.6690363; Brown SB, 2004, LANCET ONCOL, V5, P497, DOI 10.1016/S1470-2045(04)01529-3; Bulina ME, 2006, NAT PROTOC, V1, P947, DOI 10.1038/nprot.2006.89; Bulina ME, 2006, NAT BIOTECHNOL, V24, P95, DOI 10.1038/nbt1175; Chen J, 2002, CANCER J, V8, P154, DOI 10.1097/00130404-200203000-00009; Cronin M, 2012, CANCER GENE THER, V19, P731, DOI 10.1038/cgt.2012.59; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Ell C, 1998, GUT, V43, P345, DOI 10.1136/gut.43.3.345; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; KHAN AU, 1979, P NATL ACAD SCI USA, V76, P6047, DOI 10.1073/pnas.76.12.6047; Lemmon MJ, 1997, GENE THER, V4, P791, DOI 10.1038/sj.gt.3300468; Liu SC, 2002, GENE THER, V9, P291, DOI 10.1038/sj.gt.3301659; [刘世东 Liu Shidong], 2011, [中国全科医学, Chinese General Practice], V14, P987; Min JJ, 2008, MOL IMAGING BIOL, V10, P54, DOI 10.1007/s11307-007-0120-5; Mose J R, 1967, Med Klin, V62, P189; Mueller G, 2010, J PHOTOCH PHOTOBIO B, V98, P95, DOI 10.1016/j.jphotobiol.2009.11.009; Nishiyama N, 2007, NEW J CHEM, V31, P1074, DOI 10.1039/b616050f; Nishiyama N, 2009, ADV DRUG DELIVER REV, V61, P327, DOI 10.1016/j.addr.2009.01.004; Odo J, 2010, CHEM PHARM BULL, V58, P1576, DOI 10.1248/cpb.58.1576; Okazaki S, 2010, CHEM PHYS LETT, V485, P202, DOI 10.1016/j.cplett.2009.12.055; ROSENTHAL I, 1995, INT J RADIAT BIOL, V67, P85, DOI 10.1080/09553009514550111; Ryan RM, 2009, GENE THER, V16, P329, DOI 10.1038/gt.2008.188; Serebrovskaya EO, 2011, BIOCHEM J, V435, P65, DOI 10.1042/BJ20101217; Serebrovskaya EO, 2009, P NATL ACAD SCI USA, V106, P9221, DOI 10.1073/pnas.0904140106; Shirmanova MV, 2012, J BIOPHOTONICS, V10, P1; Shu XK, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001041; Sternberg ED, 1998, TETRAHEDRON, V54, P4151, DOI 10.1016/S0040-4020(98)00015-5; Sznol M, 2000, J CLIN INVEST, V105, P1027, DOI 10.1172/JCI9818; Teh C, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-110; THIELE EH, 1964, CANCER RES, V24, P222; van Dongen GAMS, 2004, ADV DRUG DELIVER REV, V56, P31, DOI 10.1016/j.addr.2003.09.003; Vegh RB, 2011, CHEM COMMUN, V47, P4887, DOI 10.1039/c0cc05713d; Yazawa K, 2000, CANCER GENE THER, V7, P269, DOI 10.1038/sj.cgt.7700122; Yu YA, 2004, NAT BIOTECHNOL, V22, P313, DOI 10.1038/nbt937	37	17	18	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2015	10	7							e0131518	10.1371/journal.pone.0131518	http://dx.doi.org/10.1371/journal.pone.0131518			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN7DN	26213989	gold, Green Published, Green Submitted			2023-01-03	WOS:000358594300006
J	Knox, K				Knox, Kyle			PERSONAL VIEW Women should be able to get antibiotics for urinary tract infection without a prescription	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							EPIDEMIOLOGY; MANAGEMENT		Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford OX2 6NW, England	University of Oxford	Knox, K (corresponding author), Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford OX2 6NW, England.	kyle.knox@phc.ox.ac.uk						[Anonymous], 2013, RUSSIA TODAY    0124; Etienne M, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-137; Fenwick EAL, 2000, BRIT J GEN PRACT, V50, P635; Fleming DM, 2005, BRIT J GEN PRACT, V55, P589; Foxman B, 2000, ANN EPIDEMIOL, V10, P509, DOI 10.1016/S1047-2797(00)00072-7; Kassakian SZ, 2014, ANTIMICROB RESIST IN, V3, DOI 10.1186/2047-2994-3-9; Leydon GM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c279; Little P, 2010, BRIT J GEN PRACT, V60, P495, DOI 10.3399/bjgp10X514747; Milo G, 2005, COCHRANE DB SYST REV, V2; Public Health England, 2015, MAN INF GUID PRIM CA; Public Health England British Infection Association Health Protection Agency, 2014, DIAGN UTI QUICK REF; STAMM WE, 1982, NEW ENGL J MED, V307, P463, DOI 10.1056/NEJM198208193070802	12	6	6	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 15	2015	351								h3441	10.1136/bmj.h3441	http://dx.doi.org/10.1136/bmj.h3441			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CN3CU	26173946				2023-01-03	WOS:000358302300001
J	Rubin, GA				Rubin, Geoffrey A.			BECOMING A PHYSICIAN Breaking Up Is Hard to Do	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Columbia Univ, Med Ctr, New York, NY 10027 USA	Columbia University	Rubin, GA (corresponding author), Columbia Univ, Med Ctr, New York, NY 10027 USA.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 9	2015	373	2					107	109		10.1056/NEJMp1504477	http://dx.doi.org/10.1056/NEJMp1504477			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CM3QP	26154785				2023-01-03	WOS:000357598600003
J	Blyth, BJ; Kakinuma, S; Sunaoshi, M; Amasaki, Y; Hirano-Sakairi, S; Ogawa, K; Shirakami, A; Shang, Y; Tsuruoka, C; Nishimura, M; Shimada, Y				Blyth, Benjamin J.; Kakinuma, Shizuko; Sunaoshi, Masaaki; Amasaki, Yoshiko; Hirano-Sakairi, Shinobu; Ogawa, Kanae; Shirakami, Ayana; Shang, Yi; Tsuruoka, Chizuru; Nishimura, Mayumi; Shimada, Yoshiya			Genetic Analysis of T Cell Lymphomas in Carbon Ion-Irradiated Mice Reveals Frequent Interstitial Chromosome Deletions: Implications for Second Cancer Induction in Normal Tissues during Carbon Ion Radiotherapy	PLOS ONE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; COPY-NUMBER ALTERATIONS; ATOMIC-BOMB SURVIVORS; THYMIC LYMPHOMAS; HEAVY-ION; X-RAYS; RADIATION; NOTCH1; IKAROS; MUTATIONS	Monitoring mice exposed to carbon ion radiotherapy provides an indirect method to evaluate the potential for second cancer induction in normal tissues outside the radiotherapy target volume, since such estimates are not yet possible from historical patient data. Here, male and female B6C3F1 mice were given single or fractionated whole-body exposure(s) to a monoenergetic carbon ion radiotherapy beam at the Heavy Ion Medical Accelerator in Chiba, Japan, matching the radiation quality delivered to the normal tissue ahead of the tumour volume (average linear energy transfer = 13 keV. mu m(-1)) during patient radiotherapy protocols. The mice were monitored for the remainder of their lifespan, and a large number of T cell lymphomas that arose in these mice were analysed alongside those arising following an equivalent dose of Cs-137 gamma ray-irradiation. Using genome-wide DNA copy number analysis to identify genomic loci involved in radiation-induced lymphomagenesis and subsequent detailed analysis of Notch1, Ikzf1, Pten, Trp53 and Bcl11b genes, we compared the genetic profile of the carbon ion-and gamma ray-induced tumours. The canonical set of genes previously associated with radiation-induced T cell lymphoma was identified in both radiation groups. While the pattern of disruption of the various pathways was somewhat different between the radiation types, most notably Pten mutation frequency and loss of heterozygosity flanking Bcl11b, the most striking finding was the observation of large interstitial deletions at various sites across the genome in carbon ion-induced tumours, which were only seen infrequently in the gamma ray-induced tumours analysed. If such large interstitial chromosomal deletions are a characteristic lesion of carbon ion irradiation, even when using the low linear energy transfer radiation to which normal tissues are exposed in radiotherapy patients, understanding the dose-response and tissue specificity of such DNA damage could prove key to assessing second cancer risk in carbon ion radiotherapy patients.	[Blyth, Benjamin J.; Kakinuma, Shizuko; Sunaoshi, Masaaki; Amasaki, Yoshiko; Hirano-Sakairi, Shinobu; Ogawa, Kanae; Shirakami, Ayana; Shang, Yi; Tsuruoka, Chizuru; Nishimura, Mayumi; Shimada, Yoshiya] Natl Inst Radiol Sci, Res Ctr Radiat Protect, Radiobiol Childrens Hlth Program, Chiba 260, Japan	National Institutes for Quantum Science & Technology	Shimada, Y (corresponding author), Natl Inst Radiol Sci, Res Ctr Radiat Protect, Radiobiol Childrens Hlth Program, Chiba 260, Japan.	y_shimad@nirs.go.jp	Sunaoshi, Masaaki/ABF-3504-2021	SUNAOSHI, Masaaki/0000-0003-3970-0701; Blyth, Benjamin/0000-0003-4754-6249; Kakinuma, Shizuko/0000-0001-9635-8813	National Institute of Radiological Sciences, Japan; (Japan Society for the Promotion of Science) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan [21610029]; Radiation Effects Association, Japan [H26-06];  [17B241];  [22B269]	National Institute of Radiological Sciences, Japan; (Japan Society for the Promotion of Science) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Radiation Effects Association, Japan; ; 	This work was performed with funding from the National Institute of Radiological Sciences, Japan (http://www.nirs.go.jp) to SK and Y. Shimada and was partly conducted under the Heavy Ion Medical Accelerator in Chiba Projects #17B241 and #22B269. A Grant-In-Aid for Scientific Research (#21610029) (Japan Society for the Promotion of Science) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (https://www.jsps.go.jp) was received by Y. Shimada. BJB received funding from a research grant (H26-06) from the Radiation Effects Association, Japan (http://www.rea.or.jp/index.htm). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alkhatib A, 2012, J EXP MED, V209, P395, DOI 10.1084/jem.20110216; Ando K, 2009, INT J RADIAT BIOL, V85, P715, DOI 10.1080/09553000903072470; Ashworth TD, 2010, BLOOD, V116, P5455, DOI 10.1182/blood-2010-05-286328; Beverly LJ, 2003, CANCER CELL, V3, P551, DOI 10.1016/S1535-6108(03)00137-5; Boyden LM, 2008, NAT GENET, V40, P656, DOI 10.1038/ng.108; Champagne DP, 2014, MUTAT RES-FUND MOL M, V761, P34, DOI 10.1016/j.mrfmmm.2014.01.007; Demarest RM, 2008, ONCOGENE, V27, P5082, DOI 10.1038/onc.2008.222; Demarest RM, 2011, BLOOD, V117, P2901, DOI 10.1182/blood-2010-05-286351; Dudgeon C, 2014, GENE DEV, V28, P2613, DOI 10.1101/gad.252148.114; Eastmond D. A., 1997, CHEM RAD LEUKEMOGENE; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Friedrich T, 2015, RADIAT PROT DOSIM, V166, P61, DOI 10.1093/rpd/ncv147; Friedrich T, 2012, INT J RADIAT BIOL, V88, P103, DOI 10.3109/09553002.2011.611213; Genet SC, 2012, ONCOL REP, V28, P1591, DOI 10.3892/or.2012.1982; Go R, 2013, CANCER SCI, V104, P1009, DOI 10.1111/cas.12193; Gross A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038960; Gutierrez A, 2011, BLOOD, V118, P4169, DOI 10.1182/blood-2010-11-318873; Gutierrez A, 2009, BLOOD, V114, P647, DOI 10.1182/blood-2009-02-206722; Hamada N, 2010, J RADIAT RES, V51, P365, DOI 10.1269/jrr.09137; Haydu JE, 2012, BLOOD, V119, P5211, DOI 10.1182/blood-2011-10-388504; Imaoka T, 2007, INT J RADIAT ONCOL, V69, P194, DOI 10.1016/j.ijrobp.2007.05.026; Imaoka T, 2013, INT J RADIAT ONCOL, V85, P1134, DOI 10.1016/j.ijrobp.2012.08.035; Jeannet R, 2010, BLOOD, V116, P5443, DOI 10.1182/blood-2010-05-286658; Jen KY, 2012, BLOOD, V119, P805, DOI 10.1182/blood-2011-01-327619; Kang HM, 2006, CANCER GENET CYTOGEN, V166, P27, DOI 10.1016/j.cancergencyto.2005.08.002; Kastner Philippe, 2011, World J Biol Chem, V2, P108, DOI 10.4331/wjbc.v2.i6.108; Kaveh K, 2015, RADIAT ENVIRON BIOPH, V54, P25, DOI 10.1007/s00411-014-0576-z; Kawata T, 2001, ADV SPACE RES-SERIES, V27, P383, DOI 10.1016/S0273-1177(01)00006-0; Khong P-L., 2013, Annals of the ICRP, V42, P9, DOI 10.1016/j.icrp.2012.10.001; Kwon YW, 2012, MOL CANCER RES, V10, P834, DOI 10.1158/1541-7786.MCR-12-0025; Little MP, 2013, INT J RADIAT ONCOL, V85, P451, DOI 10.1016/j.ijrobp.2012.04.029; Little MP, 2009, RADIAT ENVIRON BIOPH, V48, P253, DOI 10.1007/s00411-009-0228-x; Llorente LG, 2014, PEDIATR BLOOD CANCER, V61, P788, DOI 10.1002/pbc.24852; Manem VSK, 2015, INT J RADIAT BIOL, V91, P209, DOI 10.3109/09553002.2014.980466; Marusyk A, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000324; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; Matsumoto K, 2009, MAGN RESON MED, V61, P1033, DOI 10.1002/mrm.21958; Mendes RD, 2014, BLOOD, V124, P567, DOI 10.1182/blood-2014-03-562751; Neumann M, 2015, ONCOTARGET, V6, P2754, DOI 10.18632/oncotarget.2218; Ofuchi T, 1999, J RADIAT RES, V40, P125, DOI 10.1269/jrr.40.125; Ohi H, 2007, ONCOGENE, V26, P5280, DOI 10.1038/sj.onc.1210325; Okada T, 2010, J RADIAT RES, V51, P355, DOI 10.1269/jrr.10016; Olsson L, 2015, BRIT J HAEMATOL, V169, P479, DOI 10.1111/bjh.13342; Onozawa M, 2012, GENE CHROMOSOME CANC, V51, P525, DOI 10.1002/gcc.21942; Paulsson K, 2008, P NATL ACAD SCI USA, V105, P6708, DOI 10.1073/pnas.0800408105; Pignalosa D, 2013, RADIOTHER ONCOL, V109, P256, DOI 10.1016/j.radonc.2013.09.021; Preston DL, 2007, RADIAT RES, V168, P1, DOI 10.1667/RR0763.1; Preston DL, 2008, JNCI-J NATL CANCER I, V100, P428, DOI 10.1093/jnci/djn045; Remke M, 2009, BLOOD, V114, P1053, DOI 10.1182/blood-2008-10-186536; Rivina L, 2013, INT J ENV RES PUB HE, V10, P107, DOI 10.3390/ijerph10010107; Schlaff CD, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-88; Sekine E, 2008, MUTAT RES-GEN TOX EN, V652, P95, DOI 10.1016/j.mrgentox.2008.01.003; Sontani Y, 2011, LEUKEMIA RES, V35, P1512, DOI 10.1016/j.leukres.2011.07.024; Takabatake T, 2008, RADIAT RES, V169, P426, DOI 10.1667/RR1180.1; Takabatake T, 2006, RADIAT RES, V166, P61, DOI 10.1667/RR3575.1; Tauchi H, 2009, J RADIAT RES, V50, P441, DOI 10.1269/jrr.09033; Tsuji H, 2003, CARCINOGENESIS, V24, P1257, DOI 10.1093/carcin/bgg071; Tsuji H, 2013, J RADIAT RES, V54, P453, DOI 10.1093/jrr/rrs128; Valentin J., 2005, Annals of the ICRP, V35, pIII, DOI 10.1016/j.icrp.2005.01.001; Wada M, 2013, J RADIAT RES, V54, P798, DOI 10.1093/jrr/rrt012; WARD JF, 1994, INT J RADIAT BIOL, V66, P427, DOI 10.1080/09553009414551401; Watanabe H, 1998, J RADIAT RES, V39, P93, DOI 10.1269/jrr.39.93; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Xu XG, 2008, PHYS MED BIOL, V53, pR193, DOI 10.1088/0031-9155/53/13/R01; Yamaguchi Y, 2010, MUTAT RES-FUND MOL M, V686, P30, DOI 10.1016/j.mrfmmm.2009.12.011; Yoshida MA, 2007, CANCER GENET CYTOGEN, V179, P1, DOI 10.1016/j.cancergencyto.2007.06.016; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725	67	13	14	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2015	10	6							e0130666	10.1371/journal.pone.0130666	http://dx.doi.org/10.1371/journal.pone.0130666			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1BR	26125582	Green Published, gold, Green Submitted			2023-01-03	WOS:000358151300021
J	Srinivasjois, R; Slimings, C; Einarsdottir, K; Burgner, D; Leonard, H				Srinivasjois, Ravisha; Slimings, Claudia; Einarsdottir, Kristjana; Burgner, David; Leonard, Helen			Association of Gestational Age at Birth with Reasons for Subsequent Hospitalisation: 18 Years of Follow-Up in a Western Australian Population Study	PLOS ONE			English	Article							PRETERM INFANTS; 1ST YEAR; MODERATE PRETERM; HEALTH-SERVICES; WEIGHT INFANTS; OTITIS-MEDIA; REHOSPITALIZATION; CHILDREN; MORBIDITY; LIFE	Background Preterm infants are at a higher risk of hospitalisation following discharge from the hospital after birth. The reasons for rehospitalisation and the association with gestational age are not well understood. Methods This was a retrospective birth cohort study of all live, singleton infants born in Western Australia between 1st January 1980 and 31st December 2010, followed to 18 years of age. Risks of rehospitalisation following birth discharge by principal diagnoses were compared for gestational age categories (< 32, 32-33, 34-36, 37-38 weeks) and term births (39-41weeks). Causes of hospitalisations at various gestational age categories were identified using ICD-based discharge diagnostic codes. Results Risk of rehospitalisation was inversely correlated with gestational age. Growth-related concerns were the main causes for rehospitalisation in the neonatal period (< 1 month of age) for all gestational ages. Infection was the most common reason for hospitalisation from 29 days to 1 year of age, and up to 5 years of age. Injury-related hospitalisations increased in prevalence from 5 years to 18 years of age. Risk of rehospitalisation was higher for all preterm infants for most causes. Conclusions The highest risks of rehospitalisation were for infection related causes for most GA categories. Compared with full term born infants, those born at shorter GA remain vulnerable to subsequent hospitalisation for a variety of causes up until 18 years of age.	[Srinivasjois, Ravisha] Univ Western Australia, Dept Paediat, Perth, WA 6027, Australia; [Slimings, Claudia; Einarsdottir, Kristjana] Univ Western Australia, Telethon Kids Inst, Perth, WA 6008, Australia; [Burgner, David] Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Burgner, David] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; [Burgner, David] Monash Univ, Dept Paediat, Clayton, Vic 3168, Australia	University of Western Australia; Telethon Kids Institute; University of Western Australia; Murdoch Children's Research Institute; University of Melbourne; Monash University	Leonard, H (corresponding author), Univ Western Australia, Telethon Kids Inst, Perth, WA 6008, Australia.	helen.leonard@telethonkids.org.au	Slimings, Claudia/AAE-6550-2019; Einarsdóttir, Kristjana/E-8337-2011; Leonard, Helen/A-1010-2013	Slimings, Claudia/0000-0001-7988-1186; Einarsdóttir, Kristjana/0000-0003-4931-7650; Leonard, Helen/0000-0001-6405-5834; Burgner, David/0000-0002-8304-4302	Australia's National Health and Medical Research Council (NHMRC) [572742]; NHMRC [634533, 572568]	Australia's National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	The study was funded by the Australia's National Health and Medical Research Council (NHMRC) Program Grant 572742. KE received funding from an NHMRC Postdoctoral Training Fellowship grant (634533), and HL received funding from an NHMRC Senior Research Fellowship grant (572568).	[Anonymous], 2013, Obstet Gynecol, V122, P1139, DOI 10.1097/01.AOG.0000437385.88715.4a; Australian Bureau of Statistics, 2007, HLTH CHILDR AUSTR SN; Australian Bureau of Statistics, 2013, REG POP GROWTH AUSTR; Bentdal YE, 2010, INT J PEDIATR OTORHI, V74, P168, DOI 10.1016/j.ijporl.2009.11.001; Berry JG, 2013, JAMA PEDIATR, V167, P170, DOI 10.1001/jamapediatrics.2013.432; Boyle EM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e896; Brissaud O, 2005, ARCH PEDIATRIE, V12, P1462, DOI 10.1016/j.arcped.2005.04.078; Calling S, 2013, ACTA PAEDIATR, V102, P287, DOI 10.1111/apa.12106; Carbonell-Estrany X, 2000, PEDIATR INFECT DIS J, V19, P592, DOI 10.1097/00006454-200007000-00002; Carville KS, 2007, PEDIATR INFECT DIS J, V26, P210, DOI 10.1097/01.inf.0000254148.09831.7f; Daly KA, 1999, PEDIATRICS, V103, P1158, DOI 10.1542/peds.103.6.1158; Doyle LW, 1999, MED J AUSTRALIA, V170, P528, DOI 10.5694/j.1326-5377.1999.tb127877.x; Elder DE, 1999, J PAEDIATR CHILD H, V35, P145, DOI 10.1046/j.1440-1754.1999.00308.x; Engel JAM, 2005, INT J PEDIATR OTORHI, V69, P533, DOI 10.1016/j.ijporl.2004.11.026; Engle WA, 2011, CLIN PERINATOL, V38, P493, DOI 10.1016/j.clp.2011.06.009; Escobar GJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.1.e2; Fanaroff AA, 2003, SEMIN PERINATOL, V27, P281, DOI 10.1016/S0146-0005(03)00055-7; Holman CDJ, 2008, AUST HEALTH REV, V32, P766, DOI 10.1071/AH080766; Holman CDJ, 1999, AUST NZ J PUBL HEAL, V23, P453, DOI 10.1111/j.1467-842X.1999.tb01297.x; Kramer MS, 2000, JAMA-J AM MED ASSOC, V284, P843, DOI 10.1001/jama.284.7.843; Kuzniewicz MW, 2013, CLIN PERINATOL, V40, P753, DOI [10.1016/j.c1p.2013.07.008, 10.1016/j.clp.2013.07.008]; Lamarche-Vadel A, 2004, ACTA PAEDIATR, V93, P1340, DOI 10.1080/08035250410032926; Luu TM, 2010, ARCH DIS CHILD-FETAL, V95, pF320, DOI 10.1136/adc.2009.173138; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; McLaurin KK, 2009, PEDIATRICS, V123, P653, DOI 10.1542/peds.2008-1439; Paranjothy S, 2013, PEDIATRICS, V132, pE1562, DOI 10.1542/peds.2013-1737; Pezzotti P, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-56; Qiu XM, 2012, AM J PERINAT, V29, P87, DOI 10.1055/s-0031-1295647; Ralser E, 2012, ACTA PAEDIATR, V101, pE1, DOI 10.1111/j.1651-2227.2011.02404.x; Ray Kristin N, 2013, Hosp Pediatr, V3, P194; ROBERTSON PA, 1992, AM J OBSTET GYNECOL, V166, P1629, DOI 10.1016/0002-9378(92)91551-K; Russell RB, 2007, PEDIATRICS, V120, pE1, DOI 10.1542/peds.2006-2386; Slattery MM, 2002, LANCET, V360, P1489, DOI 10.1016/S0140-6736(02)11476-0; Slimings C, 2014, PAEDIATR PERINAT EP, V28, P536, DOI 10.1111/ppe.12155; Szabo SM, 2014, J PEDIATR-US, V165, P123, DOI 10.1016/j.jpeds.2014.02.053; Underwood MA, 2007, J PERINATOL, V27, P614, DOI 10.1038/sj.jp.7211801; Vrijlandt EJLE, 2013, AM J RESP CRIT CARE, V187, P1234, DOI 10.1164/rccm.201211-2070OC; Wilson-Costello D, 2005, PEDIATRICS, V115, P997, DOI 10.1542/peds.2004-0221; Young PC, 2013, PEDIATRICS, V131, pE1538, DOI 10.1542/peds.2012-2634	39	31	31	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 26	2015	10	6							e0130535	10.1371/journal.pone.0130535	http://dx.doi.org/10.1371/journal.pone.0130535			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1AM	26114969	gold, Green Published			2023-01-03	WOS:000358147500077
J	Lamberti, LM; Walker, CLF; Taneja, S; Mazumder, S; Black, RE				Lamberti, Laura M.; Walker, Christa L. Fischer; Taneja, Sunita; Mazumder, Sarmila; Black, Robert E.			The Association between Provider Practice and Knowledge of ORS and Zinc Supplementation for the Treatment of Childhood Diarrhea in Bihar, Gujarat and Uttar Pradesh, India: A Multi-Site Cross-Sectional Study	PLOS ONE			English	Article								Introduction Programs aimed at reducing the burden of diarrhea among children under-five in low-resource settings typically allocate resources to training community-level health workers, but studies have suggested that provider knowledge does not necessarily translate into adequate practice. A diarrhea management program implemented in Bihar, Gujarat and Uttar Pradesh, India trained private sector rural medical practitioners (RMPs) and public sector Accredited Social Health Activists (ASHAs) and Anganwadi workers (AWWs) in adequate treatment of childhood diarrhea with oral rehydration salts (ORS) and zinc. We used cross-sectional program evaluation data to determine the association between observed diarrhea treatment practices and reported knowledge of ORS and zinc among each provider cadre. Methods We conducted principal components analysis on providers' responses to diarrhea treatment questions in order to generate a novel scale assessing ORS/zinc knowledge. We subsequently regressed a binary indicator of whether ORS/zinc was prescribed during direct observation onto the resulting knowledge scores, controlling for other relevant knowledge predictors. Results There was a positive association between ORS/zinc knowledge score and prescribing ORS and zinc to young children with diarrhea among private sector RMPs (aOR: 2.32; 95% CI: 1.29-4.17) and public sector ASHAs and AWWs (aOR 2.48; 95% CI: 1.90-3.24). Controlling for knowledge score, receipt of training in the preceding 6 months was a good predictor of adequate prescribing in the public but not the private sector. In the public sector, direct access to ORS and zinc supplies was also highly associated with prescribing. Conclusions To enhance the management of childhood diarrhea in India, programmatic activities should center on increasing knowledge of ORS and zinc among public and private sector providers through biannual trainings but should also focus on ensuring sustained access to an adequate supply chain.	[Lamberti, Laura M.; Walker, Christa L. Fischer; Black, Robert E.] Johns Hopkins Univ, Dept Int Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Taneja, Sunita; Mazumder, Sarmila] Soc Appl Studies, Ctr Hlth Res & Dev, New Delhi, India	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Lamberti, LM (corresponding author), Johns Hopkins Univ, Dept Int Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.	llamber3@jhu.edu	Mazumder, Sarmila/AAD-8952-2020	Mazumder, Sarmila/0000-0003-4200-6112	Bill and Melinda Gates Foundation; Children's Investment Fund Foundation	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Children's Investment Fund Foundation	Funding for data collection in Gujarat and Uttar Pradesh was provided by a grant from the Bill and Melinda Gates Foundation; Funding for Bihar was supported by a grant from the Children's Investment Fund Foundation. The funders had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2011, STAT STAT SOFTW REL; Bhatnagar S, 2007, INDIAN PEDIATR, V44, P380; Pham DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074882; George A, 2011, UNREGULATED UNFREE M; IAP, 2008, IAP GUID MAN DIARRH; International Institute for Population Sciences (IIPS) and Macro International, 2007, NAT FAM HLTH SURV NF; Kanjilal B., 2007, PARALLEL HLTH CARE M; Kolenikov K, 2005, USE DISCRETE DATA PC; Kumar R, 2007, HEALTH CARE ANAL, V15, P223, DOI 10.1007/s10728-007-0060-x; Liu L, 2014, LANCET; Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1; Mayo E., 1933, HUMAN PROBLEMS IND C; Nath I, 1998, LANCET, V351, P1265, DOI 10.1016/S0140-6736(98)03010-4; Sillah F, 2013, NUTRITION, V29, P1368, DOI 10.1016/j.nut.2013.05.014; Vyas S, 2006, HEALTH POLICY PLANN, V21, P459, DOI 10.1093/heapol/czl029; Williams RL, 2000, BIOMETRICS, V56, P645, DOI 10.1111/j.0006-341X.2000.00645.x	16	9	9	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2015	10	6							e0130845	10.1371/journal.pone.0130845	http://dx.doi.org/10.1371/journal.pone.0130845			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL3FM	26098305	Green Submitted, Green Published, gold			2023-01-03	WOS:000356835800110
J	Sanchez-Lopez, E; Flashner-Abramson, E; Shalapour, S; Zhong, Z; Taniguchi, K; Levitzki, A; Karin, M				Sanchez-Lopez, E.; Flashner-Abramson, E.; Shalapour, S.; Zhong, Z.; Taniguchi, K.; Levitzki, A.; Karin, M.			Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling	ONCOGENE			English	Article							FACTOR-I RECEPTOR; COLITIS-ASSOCIATED CANCER; ADENOMATOUS POLYPS; CIRCULATING LEVELS; MOUSE MODEL; GROWTH; TUMORIGENESIS; METASTASIS; ACTIVATION; CELLS	The tumor microenvironment (TME) exerts critical pro-tumorigenic effects through cytokines and growth factors that support cancer cell proliferation, survival, motility and invasion. Insulin-like growth factor-1 (IGF-1) and signal transducer and activator of transcription 3 (STAT3) stimulate colorectal cancer development and progression via cell autonomous and microenvironmental effects. Using a unique inhibitor, NT157, which targets both IGF-1 receptor (IGF-1R) and STAT3, we show that these pathways regulate many TME functions associated with sporadic colonic tumorigenesis in CPC-APC mice, in which cancer development is driven by loss of the Apc tumor suppressor gene. NT157 causes a substantial reduction in tumor burden by affecting cancer cells, cancer-associated fibroblasts (CAF) and myeloid cells. Decreased cancer cell proliferation and increased apoptosis were accompanied by inhibition of CAF activation and decreased inflammation. Furthermore, NT157 inhibited expression of protumorigenic cytokines, chemokines and growth factors, including IL-6, IL-11 and IL-23 as well as CCL2, CCL5, CXCL7, CXCL5, ICAM1 and TGF beta; decreased cancer cell migratory activity and reduced their proliferation in the liver. NT157 represents a new class of anticancer drugs that affect both the malignant cell and its supportive microenvironment.	[Sanchez-Lopez, E.; Shalapour, S.; Zhong, Z.; Taniguchi, K.; Karin, M.] Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA; [Sanchez-Lopez, E.; Shalapour, S.; Zhong, Z.; Taniguchi, K.; Karin, M.] Univ Calif San Diego, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA; [Flashner-Abramson, E.; Levitzki, A.] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel; [Taniguchi, K.] Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo, Japan	University of California System; University of California San Diego; University of California System; University of California San Diego; Hebrew University of Jerusalem; Keio University	Karin, M (corresponding author), Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.; Karin, M (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu	Sanchez-Lopez, Elsa/A-7131-2017	Sanchez-Lopez, Elsa/0000-0002-4236-1985; Zhong, Zhenyu/0000-0002-9441-7645	Sara Borrell fellowship ISCIII/MICINN program; ERC Advanced Grant [249898]; NIH grants [AI043477, CA118165]; NATIONAL CANCER INSTITUTE [R01CA118165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043477] Funding Source: NIH RePORTER	Sara Borrell fellowship ISCIII/MICINN program; ERC Advanced Grant(European Research Council (ERC)); NIH grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	ESL was supported by Sara Borrell fellowship ISCIII/MICINN program. SS and ZZ are CRI Irvington postdoctoral fellows. KT is Uehara Memorial Foundation Fellow. AL and EFA were supported by ERC Advanced Grant (249898) to AL. Research was supported by NIH grants (AI043477 and CA118165) to MK, who is an American Cancer Society Research Professor and holds the Ben and Wanda Hildyard Chair for Mitochondrial and Metabolic Diseases.	Albanell J, 2001, JNCI-J NATL CANCER I, V93, P1830, DOI 10.1093/jnci/93.24.1830; Arber N, 2006, NEW ENGL J MED, V355, P885, DOI 10.1056/NEJMoa061652; Bonapace L, 2014, NATURE, V515, DOI 10.1038/nature13862; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Chan B, 2008, J MAMMARY GLAND BIOL, V13, P415, DOI 10.1007/s10911-008-9101-9; Chang Q, 2002, CANCER RES, V62, P6035; Esposito DL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036190; Feng QY, 2014, WORLD J GASTROENTERO, V20, P4263, DOI 10.3748/wjg.v20.i15.4263; Giovannucci E, 2001, J NUTR, V131, p3109S, DOI 10.1093/jn/131.11.3109S; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; Grivennikov SI, 2011, ANN RHEUM DIS, V70, pI104, DOI 10.1136/ard.2010.140145; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Heron-Milhavet L, 2002, J BIOL CHEM, V277, P15600, DOI 10.1074/jbc.M111142200; Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735; Huang F, 2012, CLIN CANCER RES, V18, P1156, DOI 10.1158/1078-0432.CCR-11-1135; Jones HE, 2004, ENDOCR-RELAT CANCER, V11, P793, DOI 10.1677/erc.1.00799; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Lee J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103551; Lee KW, 2015, CANCER RES, V75, P73, DOI 10.1158/0008-5472.CAN-14-0350; Maeda S, 2009, HEPATOLOGY, V50, P1851, DOI 10.1002/hep.23199; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Ollberding NJ, 2012, CANCER EPIDEM BIOMAR, V21, P810, DOI 10.1158/1055-9965.EPI-11-1105; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; Prager GW, 2012, HAMOSTASEOLOGIE, V32, P105, DOI 10.5482/ha-1163; Putoczki TL, 2013, CANCER CELL, V24, P257, DOI 10.1016/j.ccr.2013.06.017; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Ramocki NM, 2008, ENDOCRINOLOGY, V149, P261, DOI 10.1210/en.2007-0869; Reuveni H, 2013, CANCER RES, V73, P4383, DOI 10.1158/0008-5472.CAN-12-3385; Rojas A, 2011, ONCOGENE, V30, P2345, DOI 10.1038/onc.2010.605; Ryan PD, 2008, ONCOLOGIST, V13, P16, DOI 10.1634/theoncologist.2007-0199; Schlussel AT, 2014, J GASTROINTEST ONCOL, V5, P326, DOI 10.3978/j.issn.2078-6891.2014.069; Shiratsuchi I, 2011, ANTICANCER RES, V31, P2541; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Soubry A, 2012, INT J CANCER, V131, P512, DOI 10.1002/ijc.26393; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Surmacz E, 2003, ONCOGENE, V22, P6589, DOI 10.1038/sj.onc.1206772; Tang Z, 2008, AM J SURG, V196, P690, DOI 10.1016/j.amjsurg.2008.08.001; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang KP, 2014, IMMUNITY, V41, P1052, DOI 10.1016/j.immuni.2014.11.009; Woodson K, 2004, JNCI-J NATL CANCER I, V96, P407, DOI 10.1093/jnci/djh042; Xiong H, 2014, INT J CANCER, V134, P2030, DOI 10.1002/ijc.28539; Zhang WZ, 2006, MOL CELL BIOL, V26, P413, DOI 10.1128/MCB.26.2.413-424.2006; Zhou SL, 2014, CARCINOGENESIS, V35, P597, DOI 10.1093/carcin/bgt397; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	50	95	104	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2634	2644		10.1038/onc.2015.326	http://dx.doi.org/10.1038/onc.2015.326			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26364612	Green Submitted, Green Accepted			2023-01-03	WOS:000376165700010
J	Lu, J; Yoshimura, K; Goto, K; Lee, C; Hamura, K; Kwon, O; Tamanoi, F				Lu, Jie; Yoshimura, Kohei; Goto, Koichi; Lee, Craig; Hamura, Ken; Kwon, Ohyun; Tamanoi, Fuyuhiko			Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells	PLOS ONE			English	Article							MESOPOROUS SILICA NANOPARTICLES; DRUG-DELIVERY; FARNESYLTRANSFERASE INHIBITORS; TRANSFERASE INHIBITORS; PROTEIN TRANSFERASE; POLYMERIC MICELLES; LUNG-CANCER; H-RAS; K-RAS; N-RAS	Small molecule inhibitors against protein geranylgeranyltransferase-I such as P61A6 have been shown to inhibit proliferation of a variety of human cancer cells and exhibit antitumor activity in mouse models. Development of these inhibitors could be dramatically accelerated by conferring tumor targeting and controlled release capability. As a first step towards this goal, we have encapsulated P61A6 into a new type of liposomes that open and release cargos only under low pH condition. These low pH-release type liposomes were prepared by adjusting the ratio of two types of phospholipid derivatives. Loading of geranylgeranyltransferase-I inhibitor (GGTI) generated liposomes with average diameter of 50-100 nm. GGTI release in solution was sharply dependent on pH values, only showing release at pH lower than 6. Release of cargos in a pH-dependent manner inside the cell was demonstrated by the use of a proton pump inhibitor Bafilomycin A1 that Increased lysosomal pH and inhibited the release of a dye carried in the pH-liposome. Delivery of GGTI to human pancreatic cancer cells was demonstrated by the inhibition of protein geranylgeranylation inside the cell and this effect was blocked by Bafilomycin A1. In addition, GGTI delivered by pH-liposomes induced proliferation inhibition, G1 cell cycle arrest that is associated with the expression of cell cycle regulator p21(CIP1/WAF1). Proliferation inhibition was also observed with various lung cancer cell lines. Availability of nanoformulated GGTI opens up the possibility to combine with other types of inhibitors. To demonstrate this point, we combined the liposomal-GGTI with farnesyltransferase inhibitor (FTI) to inhibit K-Ras signaling in pancreatic cancer cells. Our results show that the activated K-Ras signaling in these cells can be effectively inhibited and that synergistic effect of the two drugs is observed. Our results suggest a new direction in the use of GGTI for cancer therapy.	[Lu, Jie; Tamanoi, Fuyuhiko] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; [Yoshimura, Kohei; Hamura, Ken] NOF CORP, DDS Res Lab, Kawasaki, Kanagawa 2100865, Japan; [Goto, Koichi] Sojo Univ, Grad Sch Engn, Div Appl Life Sci, Kumamoto, Japan; [Lee, Craig; Kwon, Ohyun] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; Sojo University; University of California System; University of California Los Angeles	Tamanoi, F (corresponding author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.	fuyut@microbio.ucla.edu			NIH [CA41996, R01GM071779, P41GM081282]; NOF, Inc; NATIONAL CANCER INSTITUTE [R01CA041996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071779, P41GM081282] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NOF, Inc; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Funding: This work was supported by NIH grant CA41996 (to FT) and R01GM071779 and P41GM081282 (to OK), https://grants.nih.gov/grants/giwelcome.htm. A part of the work carried out in this paper was supported by a sponsored research agreement with NOF, Inc (to FT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ackerman D, 2014, TRENDS CELL BIOL, V24, P472, DOI 10.1016/j.tcb.2014.06.001; Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Barar J, 2013, BIOIMPACTS, V3, P149, DOI 10.5681/bi.2013.036; Basso AD, 2006, J LIPID RES, V47, P15, DOI 10.1194/jlr.R500012-JLR200; Berndt N, 2011, NAT REV CANCER, V11, P775, DOI 10.1038/nrc3151; BOS JL, 1989, CANCER RES, V49, P4682; Bozzuto G, 2015, INT J NANOMED, V10, P975, DOI 10.2147/IJN.S68861; Braude E. A., 1955, DETERMINATION ORGANI; Cabral H, 2014, J CONTROL RELEASE, V190, P465, DOI 10.1016/j.jconrel.2014.06.042; Castellano S, 2007, J AM CHEM SOC, V129, P5843, DOI 10.1021/ja070274n; Chan LN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026135; Chandrasekaran S, 2014, INT J MOL SCI, V15, P20209, DOI 10.3390/ijms151120209; Dai WM, 2005, CURR MED CHEM, V12, P1947, DOI 10.2174/0929867054546591; Dawidczyk CM, 2014, J CONTROL RELEASE, V187, P133, DOI 10.1016/j.jconrel.2014.05.036; DeSolms SJ, 2003, J MED CHEM, V46, P2973, DOI 10.1021/jm020587n; Doll RJ, 2004, CURR OPIN DRUG DISC, V7, P478; Douroumis D, 2013, CRIT REV BIOTECHNOL, V33, P229, DOI 10.3109/07388551.2012.685860; Eloy JO, 2014, COLLOID SURFACE B, V123, P345, DOI 10.1016/j.colsurfb.2014.09.029; Galdiero S, 2014, J PEPT SCI, V20, P468, DOI 10.1002/psc.2649; Gau CL, 2005, MOL CANCER THER, V4, P918, DOI 10.1158/1535-7163.MCT-04-0347; Gelb MH, 2006, NAT CHEM BIOL, V2, P518, DOI 10.1038/nchembio818; Gurudevan S, 2013, CURR GENE THER, V13, P322, DOI 10.2174/156652321305131212123558; Head Julia E, 2003, Expert Opin Emerg Drugs, V8, P163, DOI 10.1517/eoed.8.1.163.21041; Hwang AA, 2014, SMALL; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; Kohli AG, 2014, J CONTROL RELEASE, V190, P274, DOI 10.1016/j.jconrel.2014.04.047; Kraft JC, 2014, J PHARM SCI-US, V103, P29, DOI 10.1002/jps.23773; Kusama T, 2006, INT J ONCOL, V29, P217; Kuthati Y, 2013, J NANOSCI NANOTECHNO, V13, P2399, DOI 10.1166/jnn.2013.7363; Lee ES, 2003, J CONTROL RELEASE, V91, P103, DOI 10.1016/S0168-3659(03)00239-6; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Li ZX, 2012, CHEM SOC REV, V41, P2590, DOI 10.1039/c1cs15246g; Lobell RB, 2001, CANCER RES, V61, P8758; Lu J, 2009, MOL CANCER THER, V8, P1218, DOI 10.1158/1535-7163.MCT-08-1122; Maeda H., 2015, ADV DRUG DELIV REV; Matsumura Y, 2014, JPN J CLIN ONCOL, V44, P515, DOI 10.1093/jjco/hyu046; Mazet JL, 1999, FEBS LETT, V460, P235, DOI 10.1016/S0014-5793(99)01355-1; Ozpolat B, 2014, ADV DRUG DELIVER REV, V66, P110, DOI 10.1016/j.addr.2013.12.008; Perez-Herrero E, 2015, EUR J PHARM BIOPHARM; Prabhu RH, 2015, INT J NANOMED, V10, P1001, DOI 10.2147/IJN.S56932; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Sakaguchi N, 2008, BIOCONJUGATE CHEM, V19, P1040, DOI 10.1021/bc7004736; Sjogren AKM, 2007, J CLIN INVEST, V117, P1294, DOI 10.1172/JCI30868; Sun JZ, 2003, CANCER RES, V63, P8922; Tetlow AL, 2013, ENZYMES, V33, P1, DOI [10.1016/B978-0-12-416749-0.00001-4, 10.1016/B978-0-12-420146-0.00008-1]; Unzueta U, 2015, TRENDS BIOTECHNOL; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Watanabe M, 2008, J BIOL CHEM, V283, P9571, DOI 10.1074/jbc.M706229200; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Yachi K, 1996, BIOPHARM DRUG DISPOS, V17, P589, DOI 10.1002/(SICI)1099-081X(199610)17:7<589::AID-BDD976>3.3.CO;2-4; Yanes RE, 2012, THER DELIV, V3, P389, DOI [10.4155/tde.12.9, 10.4155/TDE.12.9]; Yokoyama M, 2014, J DRUG TARGET, V22, P576, DOI 10.3109/1061186X.2014.934688; Yuba E, 2014, BIOMATERIALS, V35, P3091, DOI 10.1016/j.biomaterials.2013.12.024; Yuba E, 2013, BIOMATERIALS, V34, P5711, DOI 10.1016/j.biomaterials.2013.04.007; Zimonjic DB, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-198	55	9	10	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2015	10	9							e0137595	10.1371/journal.pone.0137595	http://dx.doi.org/10.1371/journal.pone.0137595			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ9KG	26352258	gold, Green Submitted, Green Published			2023-01-03	WOS:000360932800100
J	Guo, W; Ren, J; Wang, BY; Zhu, Q				Guo, Wei; Ren, Jie; Wang, Biye; Zhu, Qin			Effects of Relaxing Music on Mental Fatigue Induced by a Continuous Performance Task: Behavioral and ERPs Evidence	PLOS ONE			English	Article							RESPONSE-INHIBITION; COGNITIVE PERFORMANCE; ATTENTION; TIME; N2; WAKEFULNESS; CHRONOMETRY; COMPONENTS; BENEFITS; LATENCY	The purpose of this study was to investigate whether listening to relaxing music would help reduce mental fatigue and to maintain performance after a continuous performance task. The experiment involved two fatigue evaluation phases carried out before and after a fatigue inducing phase. A 1-hour AX-continuous performance test was used to induce mental fatigue in the fatigue-inducing phase, and participants' subjective evaluation on the mental fatigue, as well as their neurobehavioral performance in a Go/NoGo task, were measured before and after the fatigue-inducing phase. A total of 36 undergraduate students (18-22 years) participated in the study and were randomly assigned to the music group and control group. The music group performed the fatigue-inducing task while listening to relaxing music, and the control group performed the same task without any music. Our results revealed that after the fatigue-inducing phase, (a) the music group demonstrated significantly less mental fatigue than control group, (b) reaction time significantly increased for the control group but not for the music group, (c) larger Go-P3 and NoGo-P3 amplitudes were observed in the music group, although larger NoGo-N2 amplitudes were detected for both groups. These results combined to suggest that listening to relaxing music alleviated the mental fatigue associated with performing an enduring cognitive-motor task.	[Guo, Wei; Wang, Biye] Shanghai Univ Sport, Sch Kinesiol, Shanghai, Peoples R China; [Ren, Jie] Shanghai Univ Sport, China Table Tennis Coll, Shanghai, Peoples R China; [Zhu, Qin] Univ Wyoming, Div Kinesiol & Hlth, Laramie, WY 82071 USA	Shanghai University of Sport; Shanghai University of Sport; University of Wyoming	Ren, J (corresponding author), Shanghai Univ Sport, China Table Tennis Coll, Shanghai, Peoples R China.	renjie@sus.edu.cn	zhu, qin/HIR-6291-2022	Guo, Wei/0000-0001-5487-0720	First-class Disciplines of Shanghai Colleges and Universities (Psychology)	First-class Disciplines of Shanghai Colleges and Universities (Psychology)	This study was supported by the First-class Disciplines of Shanghai Colleges and Universities (Psychology). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arikan MK, 1999, NEUROSCI LETT, V268, P21; AUZOU P, 1995, NEUROPSYCHOLOGIA, V33, P25, DOI 10.1016/0028-3932(94)00100-4; Baulk SD, 2007, SLEEP BIOL RHYTHMS, V5, P74, DOI 10.1111/j.1479-8425.2006.00249.x; Bekker EM, 2004, CLIN NEUROPHYSIOL, V115, P2001, DOI 10.1016/j.clinph.2004.04.008; Boksem MAS, 2006, BIOL PSYCHOL, V72, P123, DOI 10.1016/j.biopsycho.2005.08.007; Boksem MAS, 2005, COGNITIVE BRAIN RES, V25, P107, DOI 10.1016/j.cogbrainres.2005.04.011; Bruin KJ, 2001, CLIN NEUROPHYSIOL, V112, P1660, DOI 10.1016/S1388-2457(01)00601-0; Caldwell JA, 2004, MIL PSYCHOL, V16, P163, DOI 10.1207/s15327876mp1603_2; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Clayson PE, 2011, NEUROPSYCHOLOGIA, V49, P1953, DOI 10.1016/j.neuropsychologia.2011.03.023; DINGES DF, 1988, WORK STRESS, V2, P139, DOI 10.1080/02678378808259158; Donkers FCL, 2004, BRAIN COGNITION, V56, P165, DOI 10.1016/j.bandc.2004.04.005; DUNCANJOHNSON CC, 1981, PSYCHOPHYSIOLOGY, V18, P207; Faber LG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048073; Falkenstein M, 2002, J PSYCHOPHYSIOL, V16, P167, DOI 10.1027//0269-8803.16.3.167; Falkenstein M, 1999, ACTA PSYCHOL, V101, P267, DOI 10.1016/S0001-6918(99)00008-6; Gow RV, 2012, J CLIN NEUROPHYSIOL, V29, P181, DOI 10.1097/WNP.0b013e31824e1025; Jing L, 2008, J SPORT MED PHYS FIT, V48, P102; JODO E, 1992, ELECTROEN CLIN NEURO, V82, P477, DOI 10.1016/0013-4694(92)90054-L; KAPLAN S, 1995, J ENVIRON PSYCHOL, V15, P169, DOI 10.1016/0272-4944(95)90001-2; Kato Y, 2012, ERGONOMICS, V55, P1, DOI 10.1080/00140139.2011.633175; Kato Y, 2009, INT J PSYCHOPHYSIOL, V72, P204, DOI 10.1016/j.ijpsycho.2008.12.008; Kennedy DO, 2008, APPETITE, V50, P506, DOI 10.1016/j.appet.2007.10.007; Kennedy DO, 2010, PSYCHOPHARMACOLOGY, V211, P55, DOI 10.1007/s00213-010-1870-3; Kok A, 1997, BIOL PSYCHOL, V45, P19, DOI 10.1016/S0301-0511(96)05221-0; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; LEE KA, 1991, PSYCHIAT RES, V36, P291, DOI 10.1016/0165-1781(91)90027-M; Lorist MM, 2005, COGNITIVE BRAIN RES, V24, P199, DOI 10.1016/j.cogbrainres.2005.01.018; Matthews G, 2002, Q J EXP PSYCHOL-A, V55, P659, DOI 10.1080/02724980143000505; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; Sarnthein J, 1997, NEUROL RES, V19, P107; Savitha D, 2010, Indian J Physiol Pharmacol, V54, P32; Tanaka M, 2014, BRAIN RES, V1561, P60, DOI 10.1016/j.brainres.2014.03.009; van der Linden D, 2006, INT J PSYCHOPHYSIOL, V62, P168, DOI 10.1016/j.ijpsycho.2006.04.001; Verleger R, 1997, PSYCHOPHYSIOLOGY, V34, P131, DOI 10.1111/j.1469-8986.1997.tb02125.x; Yeung N, 2006, PSYCHOL SCI, V17, P164, DOI 10.1111/j.1467-9280.2006.01680.x	36	28	28	6	46	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 25	2015	10	8							e0136446	10.1371/journal.pone.0136446	http://dx.doi.org/10.1371/journal.pone.0136446			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CP6KK	26305353	Green Published, gold, Green Submitted			2023-01-03	WOS:000359995500076
J	Sink, KM; Espeland, MA; Castro, CM; Church, T; Cohen, R; Dodson, JA; Guralnik, J; Hendrie, HC; Jennings, J; Katula, J; Lopez, OL; McDermott, MM; Pahor, M; Reid, KF; Rushing, J; Verghese, J; Rapp, S; Williamson, JD				Sink, Kaycee M.; Espeland, Mark A.; Castro, Cynthia M.; Church, Timothy; Cohen, Ron; Dodson, John A.; Guralnik, Jack; Hendrie, Hugh C.; Jennings, Janine; Katula, Jeffery; Lopez, Oscar L.; McDermott, Mary M.; Pahor, Marco; Reid, Kieran F.; Rushing, Julia; Verghese, Joe; Rapp, Stephen; Williamson, Jeff D.		LIFE Study Investigators	Effect of a 24-Month Physical Activity Intervention vs Health Education on Cognitive Outcomes in Sedentary Older Adults The LIFE Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALZHEIMERS ASSOCIATION WORKGROUPS; STYLE INTERVENTIONS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; AEROBIC EXERCISE; DISEASE; RECOMMENDATIONS; INDEPENDENCE; PERFORMANCE; ELDERS	IMPORTANCE Epidemiological evidence suggests that physical activity benefits cognition, but results from randomized trials are limited and mixed. OBJECTIVE To determine whether a 24-month physical activity program results in better cognitive function, lower risk of mild cognitive impairment (MCI) or dementia, or both, compared with a health education program. DESIGN, SETTING, AND PARTICIPANTS A randomized clinical trial, the Lifestyle Interventions and Independence for Elders (LIFE) study, enrolled 1635 community-living participants at 8 US centers from February 2010 until December 2011. Participants were sedentary adults aged 70 to 89 years who were at risk for mobility disability but able to walk 400 m. INTERVENTIONS A structured, moderate-intensity physical activity program (n = 818) that included walking, resistance training, and flexibility exercises or a health education program (n = 817) of educational workshops and upper-extremity stretching. MAIN OUTCOMES AND MEASURES Prespecified secondary outcomes of the LIFE study included cognitive function measured by the Digit Symbol Coding (DSC) task subtest of the Wechsler Adult Intelligence Scale (score range: 0-133; higher scores indicate better function) and the revised Hopkins Verbal Learning Test (HVLT-R; 12-item word list recall task) assessed in 1476 participants (90.3%). Tertiary outcomes included global and executive cognitive function and incident MCI or dementia at 24 months. RESULTS At 24 months, DSC task and HVLT-R scores (adjusted for clinic site, sex, and baseline values) were not different between groups. The mean DSC task scores were 46.26 points for the physical activity group vs 46.28 for the health education group (mean difference, -0.01 points [95% CI, -0.80 to 0.77 points], P = .97). The mean HVLT-R delayed recall scores were 7.22 for the physical activity group vs 7.25 for the health education group (mean difference, -0.03 words [95% CI, -0.29 to 0.24 words], P = .84). No differences for any other cognitive or composite measures were observed. Participants in the physical activity group who were 80 years or older (n = 307) and those with poorer baseline physical performance (n = 328) had better changes in executive function composite scores compared with the health education group (P = .01 for interaction for both comparisons). Incident MCI or dementia occurred in 98 participants (13.2%) in the physical activity group and 91 participants (12.1%) in the health education group (odds ratio, 1.08 [95% CI, 0.80 to 1.46]). CONCLUSIONS AND RELEVANCE Among sedentary older adults, a 24-month moderate-intensity physical activity program compared with a health education program did not result in improvements in global or domain-specific cognitive function.	[Sink, Kaycee M.; Williamson, Jeff D.] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Sect Gerontol & Geriatr Med, Winston Salem, NC 27157 USA; [Espeland, Mark A.; Rushing, Julia] Wake Forest Univ, Bowman Gray Sch Med, Dept Biostat Sci, Winston Salem, NC 27157 USA; [Castro, Cynthia M.] Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Palo Alto, CA 94304 USA; [Church, Timothy] Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; [Cohen, Ron; Pahor, Marco] Univ Florida, Coll Med, Gainesville, FL USA; [Dodson, John A.] NYU, Dept Med, Sch Med, Leon H Charney Div Cardiol, New York, NY 10016 USA; [Guralnik, Jack] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Div Gerontol, Baltimore, MD 21201 USA; [Hendrie, Hugh C.] Indiana Univ, Dept Psychiat, Indianapolis, IN 46204 USA; [Hendrie, Hugh C.] Indiana Univ, Ctr Aging Res, Indianapolis, IN 46204 USA; [Jennings, Janine] Wake Forest Univ, Dept Psychol, Winston Salem, NC 27157 USA; [Katula, Jeffery] Wake Forest Univ, Dept Hlth & Exercise Sci, Winston Salem, NC 27157 USA; [Lopez, Oscar L.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; [Lopez, Oscar L.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA; [McDermott, Mary M.] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA; [Reid, Kieran F.] Tufts Univ, Nutr Exercise Physiol & Sarcopenia Lab, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA; [Verghese, Joe] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA; [Verghese, Joe] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA; [Rapp, Stephen] Wake Forest Univ, Bowman Gray Sch Med, Dept Psychiat, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Stanford University; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; State University System of Florida; University of Florida; New York University; University System of Maryland; University of Maryland Baltimore; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Wake Forest University; Wake Forest University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Northwestern University; Feinberg School of Medicine; Tufts University; United States Department of Agriculture (USDA); Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Wake Forest University; Wake Forest Baptist Medical Center	Sink, KM (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Sticht Ctr Aging, One Med Ctr Blvd, Winston Salem, NC 27157 USA.	kmsink@wakehealth.edu	Katula, Jeffrey Alan/K-5905-2013; Buford, Thomas W/B-1111-2011; Sink, Kaycee/AAY-5920-2020; Newman, Anne B./C-6408-2013; Stafford, Randall/F-3974-2017	Katula, Jeffrey Alan/0000-0003-2009-2443; Buford, Thomas W/0000-0002-9541-4358; Gill, Thomas/0000-0002-6450-0368; Spring, Bonnie/0000-0003-0692-9868; Glynn, Nancy/0000-0003-2265-0162; Handberg, Eileen/0000-0002-7805-9577; Newman, Anne B./0000-0002-0106-1150; Pepine, Carl/0000-0002-6011-681X; Leeuwenburgh, Christiaan/0000-0003-0826-4257; Kaplan, Robert/0000-0003-4837-5330; Stafford, Randall/0000-0003-1805-1271; Sink, Kaycee/0000-0001-9608-3856; Castro Sweet, Cynthia/0000-0001-6860-4095; King, Abby/0000-0002-7949-8811; Marsiske, Michael/0000-0001-5973-2116; Vaz Fragoso, Carlos/0000-0002-7045-3334	National Institutes of Health, National Institute on Aging [UO1 AG22376]; National Heart, Lung, and Blood Institute [3U01AG022376-05A2S]; National Institute on Aging, National Institutes of Health; Pepper Older Americans Independence Centers: Boston, Massachusetts [1P30AG031679]; Pepper Older Americans Independence Centers: Florida [1 P30 AG028740]; Pepper Older Americans Independence Centers: Pittsburgh, Pennsylvania [P30 AG024827]; Pepper Older Americans Independence Centers: Wake Forest University [1 P30 AG21332]; Pepper Older Americans Independence Centers: Yale University [P30AG021342]; US Department of Agriculture [58-1950-7-707]; NATIONAL INSTITUTE ON AGING [P30AG024827, P30AG028740, P30AG031679, P30AG021332, U01AG022376, P30AG021342] Funding Source: NIH RePORTER	National Institutes of Health, National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute on Aging, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Pepper Older Americans Independence Centers: Boston, Massachusetts; Pepper Older Americans Independence Centers: Florida; Pepper Older Americans Independence Centers: Pittsburgh, Pennsylvania; Pepper Older Americans Independence Centers: Wake Forest University; Pepper Older Americans Independence Centers: Yale University; US Department of Agriculture(United States Department of Agriculture (USDA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The Lifestyle Interventions and Independence for Elders (LIFE) study was funded by cooperative agreement UO1 AG22376 from the National Institutes of Health, National Institute on Aging and 3U01AG022376-05A2S from the National Heart, Lung, and Blood Institute; and sponsored in part by the Intramural Research Program, National Institute on Aging, National Institutes of Health. This research was also supported by the following grants awarded to Claude D. Pepper Older Americans Independence Centers: Boston, Massachusetts (1P30AG031679), Florida (1 P30 AG028740), Pittsburgh, Pennsylvania (P30 AG024827), Wake Forest University (1 P30 AG21332), and Yale University (P30AG021342). Dr Reid's contribution was partially supported by the US Department of Agriculture under agreement 58-1950-7-707.	Adlard PA, 2005, J NEUROSCI, V25, P4217, DOI 10.1523/JNEUROSCI.0496-05.2005; Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; Barnes DE, 2013, JAMA INTERN MED, V173, P797, DOI 10.1001/jamainternmed.2013.189; Brandt J, 2001, HOPKINS VERBAL LEARN; Burdette JH, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00023; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Colcombe SJ, 2006, J GERONTOL A-BIOL, V61, P1166, DOI 10.1093/gerona/61.11.1166; Coelho FGD, 2013, ARCH GERONTOL GERIAT, V56, P10, DOI 10.1016/j.archger.2012.06.003; Denkinger MD, 2012, Z GERONTOL GERIATR, V45, P11, DOI 10.1007/s00391-011-0262-6; Erickson KI, 2014, NEUROBIOL AGING, V35, pS20, DOI 10.1016/j.neurobiolaging.2014.03.034; Erickson Kirk I, 2013, Dialogues Clin Neurosci, V15, P99; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Espeland MA, 2014, J GERONTOL A-BIOL, V69, P1101, DOI 10.1093/gerona/glu031; Etnier JL, 2006, BRAIN RES REV, V52, P119, DOI 10.1016/j.brainresrev.2006.01.002; Fielding RA, 2011, J GERONTOL A-BIOL, V66, P1226, DOI 10.1093/gerona/glr123; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; Kaplan E., 1983, BOSTON NAMING TEST; KIRCHNER WK, 1958, J EXP PSYCHOL, V55, P352, DOI 10.1037/h0043688; Lautenschlager NT, 2008, JAMA-J AM MED ASSOC, V300, P1027, DOI 10.1001/jama.300.9.1027; Legault C, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-27; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Mielke MM, 2013, J GERONTOL A-BIOL, V68, P929, DOI 10.1093/gerona/gls256; Ngandu T, 2015, LANCET, V385, P2255, DOI 10.1016/S0140-6736(15)60461-5; Pahor M, 2014, JAMA-J AM MED ASSOC, V311, P2387, DOI 10.1001/jama.2014.5616; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; Reitan RM, 1986, TRAIL MAKING TEST MA; Rejeski WJ, 2005, CONTEMP CLIN TRIALS, V26, P141, DOI 10.1016/j.cct.2004.12.005; Robertson DA, 2014, J AM GERIATR SOC, V62, P2118, DOI 10.1111/jgs.13111; ROGERS RD, 1995, J EXP PSYCHOL GEN, V124, P207, DOI 10.1037/0096-3445.124.2.207; Sink KM, 2014, CLIN INTERV AGING, V9, P1425, DOI 10.2147/CIA.S65381; Smith PJ, 2010, PSYCHOSOM MED, V72, P239, DOI 10.1097/PSY.0b013e3181d14633; Snowden M, 2011, J AM GERIATR SOC, V59, P704, DOI 10.1111/j.1532-5415.2011.03323.x; Stern Y, 2012, LANCET NEUROL, V11, P1006, DOI 10.1016/S1474-4422(12)70191-6; Stewart AL, 2001, J GERONTOL A-BIOL, V56, pM465, DOI 10.1093/gerona/56.8.M465; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Verghese J, 2003, NEW ENGL J MED, V348, P2508, DOI 10.1056/NEJMoa022252; Wechsler D., 1997, WAIS 3 MANUAL; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; Williamson JD, 2009, J GERONTOL A-BIOL, V64, P688, DOI 10.1093/gerona/glp014; Yuan Y, 2011, J STAT SOFTW, V45, P1	40	227	240	17	179	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2015	314	8					781	790		10.1001/jama.2015.9617	http://dx.doi.org/10.1001/jama.2015.9617			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CP6SA	26305648	Bronze, Green Accepted			2023-01-03	WOS:000360017200018
J	Tranchida, F; Shintu, L; Rakotoniaina, Z; Tchiakpe, L; Deyris, V; Hiol, A; Caldarelli, S				Tranchida, Fabrice; Shintu, Laetitia; Rakotoniaina, Zo; Tchiakpe, Leopold; Deyris, Valerie; Hiol, Abel; Caldarelli, Stefano			Metabolomic and Lipidomic Analysis of Serum Samples following Curcuma longa Extract Supplementation in High-Fructose and Saturated Fat Fed Rats	PLOS ONE			English	Article							INDUCED INSULIN-RESISTANCE; SKELETAL-MUSCLE; ACID-CONCENTRATIONS; ETHANOL-METABOLISM; DIABETES-MELLITUS; MEMBRANE-FLUIDITY; PROTEIN-SYNTHESIS; LIVER; OBESE; GLUCOSE	We explored, using nuclear magnetic resonance (NMR) metabolomics and fatty acids profiling, the effects of a common nutritional complement, Curcuma longa, at a nutritionally relevant dose with human use, administered in conjunction with an unbalanced diet. Indeed, traditional food supplements have been long used to counter metabolic impairments induced by unbalanced diets. Here, rats were fed either a standard diet, a high level of fructose and saturated fatty acid (HFS) diet, a diet common to western countries and that certainly contributes to the epidemic of insulin resistance (IR) syndrome, or a HFS diet with a Curcuma longa extract (1% of curcuminoids in the extract) for ten weeks. Orthogonal projections to latent structures discriminant analysis (OPLS-DA) on the serum NMR profiles and fatty acid composition (determined by GC/MS) showed a clear discrimination between HFS groups and controls. This discrimination involved metabolites such as glucose, amino acids, pyruvate, creatine, phosphocholine/glycerophosphocholine, ketone bodies and glycoproteins as well as an increase of monounsaturated fatty acids (MUFAs) and a decrease of n-6 and n-3 polyunsaturated fatty acids (PUFAs). Although the administration of Curcuma longa did not prevent the observed increase of glucose, triglycerides, cholesterol and insulin levels, discriminating metabolites were observed between groups fed HFS alone or with addition of a Curcuma longa extract, namely some MUFA and n-3 PUFA, glycoproteins, glutamine, and methanol, suggesting that curcuminoids may act respectively on the fatty acid metabolism, the hexosamine biosynthesis pathway and alcohol oxidation. Curcuma longa extract supplementation appears to be beneficial in these metabolic pathways in rats. This metabolomic approach highlights important serum metabolites that could help in understanding further the metabolic mechanisms leading to IR.	[Tranchida, Fabrice; Shintu, Laetitia; Rakotoniaina, Zo; Deyris, Valerie; Caldarelli, Stefano] Aix Marseille Univ, CNRS, ISm2, Cent Marseille,UMR 7313, Marseille, France; [Tchiakpe, Leopold] Aix Marseille Univ, Lab Nutr Dietet, Fac Pharm, Marseille, France; [Hiol, Abel] Univ La Reunion, CIRAD, ESIROI, UMR QualiSud, St Denis, France; [Caldarelli, Stefano] CNRS, Inst Chim Subst Nat, UPR 2301, Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; CIRAD; University of La Reunion; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Saclay	Tranchida, F (corresponding author), Aix Marseille Univ, CNRS, ISm2, Cent Marseille,UMR 7313, Marseille, France.	fabrice.tranchida@univ-amu.fr; laetitia.shintu@univ-amu.fr	Stefano, Caldaralli/B-2750-2017; shintu, laetitia/B-6293-2009	Stefano, Caldaralli/0000-0001-9008-9392; shintu, laetitia/0000-0003-2730-121X				Araujo CAC, 2001, MEM I OSWALDO CRUZ, V96, P723, DOI 10.1590/S0074-02762001000500026; Astrup A, 2000, Obes Rev, V1, P57, DOI 10.1046/j.1467-789x.2000.00013.x; AXELROD J, 1965, SCIENCE, V150, P892, DOI 10.1126/science.150.3698.892; Balkau B, 2002, DIABETES METAB, V28, P364; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Binder E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074705; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRENNER RR, 1966, J BIOL CHEM, V241, P5213; Candiloros H, 1996, J CLIN ENDOCR METAB, V81, P2912, DOI 10.1210/jc.81.8.2912; CASTELLINO P, 1987, J CLIN INVEST, V80, P1784, DOI 10.1172/JCI113272; Cazzola R, 2004, J LIPID RES, V45, P1846, DOI 10.1194/jlr.M300509-JLR200; Clore JN, 2000, METABOLISM, V49, P232, DOI 10.1016/S0026-0495(00)91455-0; D'Angelo G, 2005, HYPERTENSION, V46, P806, DOI 10.1161/01.HYP.0000182697.39687.34; Dumas ME, 2006, P NATL ACAD SCI USA, V103, P12511, DOI 10.1073/pnas.0601056103; Evans JL, 2003, DIABETES, V52, P1, DOI 10.2337/diabetes.52.1.1; Faure P, 1997, J NUTR, V127, P103, DOI 10.1093/jn/127.1.103; FUKUDA N, 1982, J BIOL CHEM, V257, P4066; Ghafoorunissa, 2005, J NUTR, V135, P2634, DOI 10.1093/jn/135.11.2634; Girard A, 2005, NUTRITION, V21, P240, DOI 10.1016/j.nut.2004.04.022; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Gupta SC, 2013, AAPS J, V15, P195, DOI 10.1208/s12248-012-9432-8; Haffner HT, 1998, INT J LEGAL MED, V111, P27; HANDLER JA, 1988, FEBS LETT, V238, P139, DOI 10.1016/0014-5793(88)80243-6; Havel PJ, 2005, NUTR REV, V63, P133, DOI [10.1301/nr.2005.may.133-157, 10.1111/j.1753-4887.2005.tb00132.x]; He QH, 2012, J NUTR BIOCHEM, V23, P133, DOI 10.1016/j.jnutbio.2010.11.007; HIRANO T, 1989, AM J PHYSIOL, V256, pE559, DOI 10.1152/ajpendo.1989.256.4.E559; Huang DJ, 2002, J AGR FOOD CHEM, V50, P4437, DOI 10.1021/jf0201529; Joint Expert Committee on Food Additives, 2004, WHO TECHN REP SER, V922; JULIA P, 1987, EUR J BIOCHEM, V162, P179, DOI 10.1111/j.1432-1033.1987.tb10559.x; Katsanos CS, 2009, J CLIN ENDOCR METAB, V94, P2984, DOI 10.1210/jc.2008-2686; Kawashima H, 1996, BIOSCI BIOTECH BIOCH, V60, P108, DOI 10.1271/bbb.60.108; Kim HJ, 2011, J PROTEOME RES, V10, P722, DOI 10.1021/pr100892r; KORNFELD S, 1964, P NATL ACAD SCI USA, V52, P371, DOI 10.1073/pnas.52.2.371; Le KA, 2009, AM J CLIN NUTR, V89, P1760, DOI 10.3945/ajcn.2008.27336; Lin SH, 2011, MOL BIOSYST, V7, P1537, DOI 10.1039/c0mb00246a; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Lubas WA, 1997, J BIOL CHEM, V272, P9316; Mahendran Y, 2013, DIABETES, V62, P3618, DOI 10.2337/db12-1363; Malik VS, 2006, AM J CLIN NUTR, V84, P274; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Masood A, 2005, J LIPID RES, V46, P2299, DOI 10.1194/jlr.D500022-JLR200; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Na LX, 2011, NUTR METAB CARDIOVAS, V21, P526, DOI 10.1016/j.numecd.2009.11.009; Newgard CB, 2009, CELL METAB, V9, P311, DOI 10.1016/j.cmet.2009.02.002; Newman JC, 2014, TRENDS ENDOCRIN MET, V25, P42, DOI 10.1016/j.tem.2013.09.002; Neyrinck AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081252; Pari L, 2007, PLANT FOOD HUM NUTR, V62, P25, DOI 10.1007/s11130-006-0037-1; PATIL TN, 1971, INDIAN J EXP BIOL, V9, P167; Patti ME, 1999, DIABETES, V48, P1562, DOI 10.2337/diabetes.48.8.1562; Pongchaidecha A, 2009, NUTRITION, V25, P870, DOI 10.1016/j.nut.2009.02.001; Qin LQ, 2011, J NUTR, V141, P249, DOI 10.3945/jn.110.128520; Rippe JM, 2013, ADV NUTR, V4, P236, DOI 10.3945/an.112.002824; Sasaki H, 2011, BIOL PHARM BULL, V34, P660, DOI 10.1248/bpb.34.660; SCHNEIDER WJ, 1978, EUR J BIOCHEM, V85, P181, DOI 10.1111/j.1432-1033.1978.tb12226.x; SCHOLZ R, 1976, EUR J BIOCHEM, V63, P449, DOI 10.1111/j.1432-1033.1976.tb10247.x; SENSI M, 1993, DIABETOLOGIA, V36, P797, DOI 10.1007/BF00400352; Seo KI, 2008, MOL NUTR FOOD RES, V52, P995, DOI 10.1002/mnfr.200700184; Sestili P, 2011, AMINO ACIDS, V40, P1385, DOI 10.1007/s00726-011-0875-5; Shearer J, 2008, DIABETES OBES METAB, V10, P950, DOI 10.1111/j.1463-1326.2007.00837.x; Sreejayan N, 1997, INT J PHARM, V151, P127, DOI 10.1016/S0378-5173(97)04900-4; Stumvoll M, 1996, DIABETES, V45, P863, DOI 10.2337/diabetes.45.7.863; Taghibiglou C, 2002, J BIOL CHEM, V277, P793, DOI 10.1074/jbc.M106737200; TEPHLY TR, 1991, LIFE SCI, V48, P1031, DOI 10.1016/0024-3205(91)90504-5; Thresher JS, 2000, AM J PHYSIOL-REG I, V279, pR1334, DOI 10.1152/ajpregu.2000.279.4.R1334; TONG P, 1995, LANCET, V345, P357, DOI 10.1016/S0140-6736(95)90343-7; Tranchida F, 2012, J ZHEJIANG UNIV-SC B, V13, P307, DOI 10.1631/jzus.B1100090; Trygg J, 2002, J CHEMOMETR, V16, P119, DOI 10.1002/cem.695; Tsai J, 2009, AM J PHYSIOL-GASTR L, V296, pG1287, DOI 10.1152/ajpgi.90540.2008; TYGSTRUP N, 1965, J CLIN INVEST, V44, P817, DOI 10.1172/JCI105194; WOODS HG, 1970, BIOCHEM J, V119, P501, DOI 10.1042/bj1190501; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413; Zhang XY, 2009, J PROTEOME RES, V8, P5188, DOI 10.1021/pr900524z	72	17	18	0	46	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 19	2015	10	8							e0135948	10.1371/journal.pone.0135948	http://dx.doi.org/10.1371/journal.pone.0135948			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP6SN	26288372	Green Published, gold, Green Submitted			2023-01-03	WOS:000360018600089
J	Ye, JQ; Gaur, M; Zhang, Y; Sievers, RE; Woods, BJ; Aurigui, J; Bernstein, HS; Yeghiazarians, Y				Ye, Jianqin; Gaur, Meenakshi; Zhang, Yan; Sievers, Richard E.; Woods, Brandon J.; Aurigui, Julian; Bernstein, Harold S.; Yeghiazarians, Yerem			Treatment with hESC-Derived Myocardial Precursors Improves Cardiac Function after a Myocardial Infarction	PLOS ONE			English	Article							MESENCHYMAL STEM-CELLS; RAT HEARTS; TRANSPLANTATION; CARDIOMYOCYTES; THERAPY; PROTECTION; INJECTION; CYTOKINES; REPAIR	Background We previously reported the generation of a reporter line of human embryonic stem cells (hESCs) with enhanced green fluorescent protein (eGFP) expression driven by the alpha-myosin heavy chain (alpha MHC) promoter. The GFP(+)/alpha MHC+ cells derived from this cell line behave as multipotent, human myocardial precursors (hMPs) in vitro. In this study, we evaluated the therapeutic effects of GFP(+)/alpha MHC+ cells isolated from the reporter line in a mouse model of myocardial infarction (MI). Methods MI was generated in immunodeficient mice. hMPs were injected into murine infarcted hearts under ultrasound guidance at 3 days post-MI. Human fetal skin fibroblasts (hFFs) were injected as control. Cardiac function was evaluated by echocardiography. Infarct size, angiogenesis, apoptosis, cell fate, and teratoma formation were analyzed by immunohistochemical staining. Results Compared with control, hMPs resulted in improvement of cardiac function post-MI with smaller infarct size, induced endogenous angiogenesis, and reduced apoptosis of host cardiomyocytes at the peri-infarct zone at 28 days post-MI. Conclusion Intramyocardial injection of hMPs improved cardiac function post-MI. The engraftment rate of these cells in the myocardium post-MI was low, suggesting that the majority of effect occurs via paracrine mechanisms.	[Ye, Jianqin; Gaur, Meenakshi; Zhang, Yan; Sievers, Richard E.; Woods, Brandon J.; Yeghiazarians, Yerem] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Aurigui, Julian; Bernstein, Harold S.; Yeghiazarians, Yerem] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Bernstein, Harold S.; Yeghiazarians, Yerem] Univ Calif San Francisco, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Yeghiazarians, Y (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.	yeghiaza@medicine.ucsf.edu	ye, jian/GQH-3702-2022		California Institute of Regenerative Medicine [RC1-00104-1]	California Institute of Regenerative Medicine(California Institute for Regenerative Medicine)	This work was supported by a grant from the California Institute of Regenerative Medicine to HSB and YY (RC1-00104-1).	Bartunek J, 2013, J AM COLL CARDIOL, V61, P2329, DOI 10.1016/j.jacc.2013.02.071; Bernstein H. S., 2010, J VIS EXP; Bernstein HS, 2012, REGEN MED, V7, P697, DOI [10.2217/RME.12.46, 10.2217/rme.12.46]; Caspi O, 2007, J AM COLL CARDIOL, V50, P1884, DOI 10.1016/j.jacc.2007.07.054; Chimenti I, 2010, CIRC RES, V106, P971, DOI 10.1161/CIRCRESAHA.109.210682; Chong JJH, 2014, NATURE, V510, P273, DOI 10.1038/nature13233; Ebelt H, 2007, STEM CELLS, V25, P236, DOI 10.1634/stemcells.2006-0374; Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405-367; Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com; Hare JM, 2012, JAMA-J AM MED ASSOC, V308, P2369, DOI 10.1001/jama.2012.25321; Hatzistergos KE, 2010, CIRC RES, V107, P913, DOI 10.1161/CIRCRESAHA.110.222703; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Laflamme MA, 2007, NAT BIOTECHNOL, V25, P1015, DOI 10.1038/nbt1327; Loffredo FS, 2011, CELL STEM CELL, V8, P389, DOI 10.1016/j.stem.2011.02.002; Nussbaum J, 2007, FASEB J, V21, P1345, DOI 10.1096/fj.06-6769com; Ritner C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016004; Segers VFM, 2008, NATURE, V451, P937, DOI 10.1038/nature06800; Springer ML, 2005, AM J PHYSIOL-HEART C, V289, pH1307, DOI 10.1152/ajpheart.00164.2005; Stevens KR, 2009, P NATL ACAD SCI USA, V106, P16568, DOI 10.1073/pnas.0908381106; Sui RQ, 2011, STEM CELL REV REP, V7, P172, DOI 10.1007/s12015-010-9131-8; Takagawa J, 2007, J APPL PHYSIOL, V102, P2104, DOI 10.1152/japplphysiol.00033.2007; van Laake LW, 2010, CELL MOL LIFE SCI, V67, P277, DOI 10.1007/s00018-009-0179-z; van Laake LW, 2009, STEM CELL RES, V3, P106, DOI 10.1016/j.scr.2009.05.004; Venugopal JR, 2012, J R SOC INTERFACE, V9, P1, DOI 10.1098/rsif.2011.0301; Ye JQ, 2014, J CARDIOVASC PHARM, V63, P85, DOI 10.1097/FJC.0b013e318299ebc0; Ye JQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030329; Yeghiazarians Y, 2012, CYTOTHERAPY, V14, P223, DOI 10.3109/14653249.2011.623690; Yeghiazarians Y, 2009, MOL THER, V17, P1250, DOI 10.1038/mt.2009.85	28	8	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2015	10	7							e0131123	10.1371/journal.pone.0131123	http://dx.doi.org/10.1371/journal.pone.0131123			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO0JY	26230835	Green Submitted, Green Published, gold			2023-01-03	WOS:000358838400007
J	Zhang, GD; Wang, MQ; Duan, F; Yuan, K; Li, K; Yan, JY; Chang, ZF; Wang, Y				Zhang, Guodong; Wang, Maoqiang; Duan, Feng; Yuan, Kai; Li, Kai; Yan, Jieyu; Chang, Zhongfei; Wang, Yan			Radiological Findings of Prostatic Arterial Anatomy for Prostatic Arterial Embolization: Preliminary Study in 55 Chinese Patients with Benign Prostatic Hyperplasia	PLOS ONE			English	Article							CONE-BEAM CT	Objective To describe the prostatic arterial supply using Cone-beam computed tomography (CT) and digital subtraction angiography (DSA) before prostatic arterial embolization (PAE) for benign prostatic hyperplasia (BPH). Methods In a retrospective study from January 2012 to January 2014, 55 male patients (110 hemipelves) with BPH who underwent PAE were evaluated by Cone-beam CT in addition to pelvic DSA during embolization planning. Each hemipelvis was evaluated regarding the number of prostatic arteries (PA) and their origins, diameters, territorial perfusion, and anastomoses with adjacent arteries. Results A total of 114 PAs were identified in 110 hemipelves. There was one PA in 96.4% of the hemipelves (n=106), and two independent PAs in the other 3.6% (n=4). The PA was found to originate from the anterior trunk of the internal iliac artery in 39.5% of cases (n=45), from the superior vesical artery in 32.6%(n=37), and from the internal pudendal artery in 27.9% of cases (n=32). Extra-prostatic anastomoses between PA and adjacent arteries were found in 39.1% of hemipelves (n=43). Intra-prostatic anastomoses between PAs and contra- lateral prostatic branches were found in 61.8% of hemipelves (n=68). In 67.3% of our study population (n=37), the prostate was dominantly supplied via a unilateral PA. Conclusion The prostatic vascularization is complex with frequent anatomic variations. Knowledge of the vascular anatomy of the prostate may provide indications for planning PAE and avoiding nontarget embolization.	[Zhang, Guodong; Wang, Maoqiang; Duan, Feng; Yuan, Kai; Li, Kai; Yan, Jieyu; Chang, Zhongfei; Wang, Yan] Chinese Peoples Liberat Army Gen Hosp, Dept Intervent Radiol, Beijing, Peoples R China	Chinese People's Liberation Army General Hospital	Wang, MQ (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Intervent Radiol, Beijing, Peoples R China.	wangmq@vip.sina.com			fifth central health research projects in China	fifth central health research projects in China	This work was supported by the fifth central health research projects in China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antunes AA, 2013, CARDIOVASC INTER RAD, V36, P978, DOI 10.1007/s00270-013-0611-5; Bagla S, 2013, J VASC INTERV RADIOL, V24, P1603, DOI 10.1016/j.jvir.2013.06.024; Bilhim T, 2012, TECH VASC INTERV RAD, V15, P276, DOI 10.1053/j.tvir.2012.09.006; Bilhim T, 2012, J VASC INTERV RADIOL, V23, P1403, DOI 10.1016/j.jvir.2012.07.028; Bilhim T, 2011, EUR RADIOL, V21, P1119, DOI 10.1007/s00330-010-2015-0; BOUISSOU H, 1959, Ann Anat Pathol (Paris), V4, P63; CLEGG EJ, 1955, J ANAT, V89, P209; Ding HM, 2008, SURG RADIOL ANAT, V30, P437, DOI 10.1007/s00276-008-0348-z; Garcia-Monaco R, 2014, J VASC INTERV RADIOL, V25, P315, DOI 10.1016/j.jvir.2013.10.026; Kakeda S, 2007, J VASC INTERV RADIOL, V18, P1508, DOI 10.1016/j.jvir.2007.08.003; Louie JD, 2009, J VASC INTERV RADIOL, V20, P606, DOI 10.1016/j.jvir.2009.01.021; Moreira AM, 2013, CARDIOVASC INTER RAD, V36, P1690, DOI 10.1007/s00270-013-0739-3; Pisco J, 2013, RADIOLOGY, V266, P668, DOI 10.1148/radiol.12111601; Pisco JM, 2011, J VASC INTERV RADIOL, V22, P11, DOI 10.1016/j.jvir.2010.09.030; Venuti JM, 2004, CLIN ANAT, V17, P261, DOI 10.1002/ca.10233; Wallace MJ, 2007, J VASC INTERV RADIOL, V18, P1500, DOI 10.1016/j.jvir.2007.07.021; Wallace MJ, 2009, J VASC INTERV RADIOL, V20, pS523, DOI 10.1016/j.jvir.2009.04.059	17	18	20	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2015	10	7							e0132678	10.1371/journal.pone.0132678	http://dx.doi.org/10.1371/journal.pone.0132678			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN6LN	26191796	gold, Green Published, Green Submitted			2023-01-03	WOS:000358546400034
J	Nakajima, K; Fujita, J; Matsui, M; Tohyama, S; Tamura, N; Kanazawa, H; Seki, T; Kishino, Y; Hirano, A; Okada, M; Tabei, R; Sano, M; Goto, S; Tabata, Y; Fukuda, K				Nakajima, Kazuaki; Fujita, Jun; Matsui, Makoto; Tohyama, Shugo; Tamura, Noriko; Kanazawa, Hideaki; Seki, Tomohisa; Kishino, Yoshikazu; Hirano, Akinori; Okada, Marina; Tabei, Ryota; Sano, Motoaki; Goto, Shinya; Tabata, Yasuhiko; Fukuda, Keiichi			Gelatin Hydrogel Enhances the Engraftment of Transplanted Cardiomyocytes and Angiogenesis to Ameliorate Cardiac Function after Myocardial Infarction	PLOS ONE			English	Article							FIBROBLAST-GROWTH-FACTOR; STEM-CELLS; ISCHEMIC CARDIOMYOPATHY; HEART; THERAPY; INTRACORONARY; BIOMATERIALS; REGENERATION; MYOCYTES; TRIAL	Cell transplantation therapy will mean a breakthrough in resolving the donor shortage in cardiac transplantation. Cardiomyocyte (CM) transplantation, however, has been relatively inefficient in restoring cardiac function after myocardial infarction (MI) due to low engraftment of transplanted CM. In order to ameliorate engraftment of CM, the novel transplantation strategy must be invented. Gelatin hydrogel (GH) is a biodegradable water-soluble polymer gel. Gelatin is made of collagen. Although we observed that collagen strongly induced the aggregation of platelets to potentially cause coronary microembolization, GH did not enhance thrombogenicity. Therefore, GH is a suitable biomaterial in the cell therapy after heart failure. To assess the effect of GH on the improvement of cardiac function, fetal rat CM (5x10(6) or 1x10(6) cells) were transplanted with GH (10 mg/ml) to infarcted hearts. We compared this group with sham operated rats, CM in phosphate buffered saline (PBS), only PBS, and only GH-transplanted groups. Three weeks after transplantation, cardiac function was evaluated by echocardiography. The echocardiography confirmed that transplantation of 5x10(6) CM with GH significantly improved cardiac systolic function, compared with the CM+PBS group (fractional area change: 75.1 +/- 3.4% vs. 60.7 +/- 5.9%, p<0.05), only PBS, and only GH groups (60.1 +/- 6.5%, 65.0 +/- 2.8%, p<0.05). Pathological analyses demonstrated that in the CM+GH group, CM were efficiently engrafted in infarcted myocardium (p<0.01) and angiogenesis was significantly enhanced (p<0.05) in both central and peripheral areas of the scar. Moreover, quantitative RT-PCR revealed that angiogenic cytokines, such as basic fibroblast growth factor, vascular endothelial growth factor, and hepatocyte growth factor, were significantly enriched in the CM+GH group (p<0.05). Here, we report that GH confined the CM effectively in infarcted myocardium after transplantation, and that CM transplanted with GH improved cardiac function with a direct contraction effect and enhanced angiogenesis.	[Nakajima, Kazuaki; Fujita, Jun; Tohyama, Shugo; Kanazawa, Hideaki; Seki, Tomohisa; Kishino, Yoshikazu; Okada, Marina; Tabei, Ryota; Sano, Motoaki; Fukuda, Keiichi] Keio Univ, Sch Med, Dept Cardiol, Shinjuku Ku, Tokyo, Japan; [Hirano, Akinori] Keio Univ, Sch Med, Dept Cardiovasc Surg, Shinjuku Ku, Tokyo, Japan; [Matsui, Makoto; Tabata, Yasuhiko] Kyoto Univ, Dept Biomat, Inst Frontier Med Sci, Field Tissue Engn,Sakyo Ku, Kyoto, Japan; [Tamura, Noriko; Goto, Shinya] Tokai Univ, Sch Med, Dept Med Cardiol, Isehara, Kanagawa 25911, Japan; [Tohyama, Shugo] Japan Soc Promot Sci, Tokyo, Japan	Keio University; Keio University; Kyoto University; Tokai University; Japan Society for the Promotion of Science	Fujita, J (corresponding author), Keio Univ, Sch Med, Dept Cardiol, Shinjuku Ku, 35 Shinanomachi, Tokyo, Japan.	jfujita@a6.keio.jp	Goto, Shinya/AAU-6045-2020; Fukuda, Keiichi/L-3777-2013; Seki, Tomohisa/L-3524-2013; Sano, Motoaki/L-3405-2013	Goto, Shinya/0000-0002-6821-1504; Kishino, Yoshikazu/0000-0003-3291-2795; Seki, Tomohisa/0000-0002-4281-135X	Highway Program for Realization of Regenerative Medicine from Japan Science and Technology Agency	Highway Program for Realization of Regenerative Medicine from Japan Science and Technology Agency	The present work was supported by the Highway Program for Realization of Regenerative Medicine from Japan Science and Technology Agency (to KF, http://www.jst.go.jp/saisei-nw/highway/research/b.html).	Bui AL, 2011, NAT REV CARDIOL, V8, P30, DOI 10.1038/nrcardio.2010.165; Christman KL, 2006, J AM COLL CARDIOL, V48, P907, DOI 10.1016/j.jacc.2006.06.005; Fujita J, 2012, AM J PHYSIOL-HEART C, V303, pH1169, DOI 10.1152/ajpheart.00376.2012; Giordano FJ, 2001, P NATL ACAD SCI USA, V98, P5780, DOI 10.1073/pnas.091415198; Goto SY, 2002, CIRCULATION, V106, P266, DOI 10.1161/01.CIR.0000021427.87256.7E; Hato N, 2012, OTOLARYNG HEAD NECK, V146, P641, DOI 10.1177/0194599811431661; Hattan N, 2005, CARDIOVASC RES, V65, P334, DOI 10.1016/j.cardiores.2004.10.004; Hayashi K, 2011, ACTA BIOMATER, V7, P2797, DOI 10.1016/j.actbio.2011.04.013; Hemmi N, 2014, STEM CELL TRANSL MED, V3, P1473, DOI 10.5966/sctm.2014-0072; Kardami E, 2007, HEART FAIL REV, V12, P267, DOI 10.1007/s10741-007-9027-0; Kehat I, 2001, J CLIN INVEST, V108, P407, DOI 10.1172/JCI12131; Lund LH, 2013, J HEART LUNG TRANSPL, V32, P951, DOI 10.1016/j.healun.2013.08.006; Makkar RR, 2012, LANCET, V379, P895, DOI 10.1016/S0140-6736(12)60195-0; Marui A, 2007, CIRC J, V71, P1181, DOI 10.1253/circj.71.1181; Menasche P, 2008, CIRCULATION, V117, P1189, DOI 10.1161/CIRCULATIONAHA.107.734103; Olivetti G, 1996, J MOL CELL CARDIOL, V28, P1463, DOI 10.1006/jmcc.1996.0137; Ono K, 1997, CIRCULATION, V95, P2552, DOI 10.1161/01.CIR.95.11.2552; Ptaszek LM, 2012, LANCET, V379, P933, DOI 10.1016/S0140-6736(12)60075-0; Rane AA, 2011, J AM COLL CARDIOL, V58, P2615, DOI 10.1016/j.jacc.2011.11.001; Strauer BE, 2011, J AM COLL CARDIOL, V58, P1095, DOI 10.1016/j.jacc.2011.06.016; Tabata Y, 1998, BIOMATERIALS, V19, P807, DOI 10.1016/S0142-9612(98)00233-6; Tabata Y, 1999, BIOMATERIALS, V20, P2169, DOI 10.1016/S0142-9612(99)00121-0; Tabata Y, 2009, J R SOC INTERFACE, V6, pS311, DOI 10.1098/rsif.2008.0448.focus; Van Belle E, 1998, CIRCULATION, V97, P381; van Laake LW, 2007, STEM CELL RES, V1, P9, DOI 10.1016/j.scr.2007.06.001; YANAGISAWAMIWA A, 1992, SCIENCE, V257, P1401, DOI 10.1126/science.1382313; Zhang JH, 2009, CIRC RES, V104, pE30, DOI 10.1161/CIRCRESAHA.108.192237	27	32	33	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2015	10	7							e0133308	10.1371/journal.pone.0133308	http://dx.doi.org/10.1371/journal.pone.0133308			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RV	26186362	Green Published, Green Submitted, gold			2023-01-03	WOS:000358198700123
J	Dambacher, F; Schuhmann, T; Lobbestael, J; Arntz, A; Brugman, S; Sack, AT				Dambacher, Franziska; Schuhmann, Teresa; Lobbestael, Jill; Arntz, Arnoud; Brugman, Suzanne; Sack, Alexander T.			No Effects of Bilateral tDCS over Inferior Frontal Gyrus on Response Inhibition and Aggression	PLOS ONE			English	Article							DIRECT-CURRENT STIMULATION; BRAIN ACTIVITY; PROACTIVE AGGRESSION; ACTION CANCELLATION; PREFRONTAL CORTEX; AFFECTIVE VALENCE; ACTION RESTRAINT; SEX-DIFFERENCES; STOP-SIGNAL; ANGER	Response inhibition is defined as the capacity to adequately withdraw pre-planned responses. It has been shown that individuals with deficits in inhibiting pre-planned responses tend to display more aggressive behaviour. The prefrontal cortex is involved in both, response inhibition and aggression. While response inhibition is mostly associated with predominantly right prefrontal activity, the neural components underlying aggression seem to be left-lateralized. These differences in hemispheric dominance are conceptualized in cortical asymmetry theories on motivational direction, which assign avoidance motivation (relevant to inhibit responses) to the right and approach motivation (relevant for aggressive actions) to the left prefrontal cortex. The current study aimed to directly address the inverse relationship between response inhibition and aggression by assessing them within one experiment. Sixty-nine healthy participants underwent bilateral transcranial Direct Current Stimulation (tDCS) to the inferior frontal cortex. In one group we induced right-hemispheric fronto-cortical dominance by means of a combined right prefrontal anodal and left prefrontal cathodal tDCS montage. In a second group we induced left-hemispheric fronto-cortical dominance by means of a combined left prefrontal anodal and right prefrontal cathodal tDCS montage. A control group received sham stimulation. Response inhibition was assessed with a go/no-go task (GNGT) and aggression with the Taylor Aggression Paradigm (TAP). We revealed that participants with poorer performance in the GNGT displayed more aggression during the TAP. No effects of bilateral prefrontal tDCS on either response inhibition or aggression were observed. This is at odds with previous brain stimulation studies applying unilateral protocols. Our results failed to provide evidence in support of the prefrontal cortical asymmetry model in the domain of response inhibition and aggression. The absence of tDCS effects might also indicate that the methodological approach of shifting cortical asymmetry by means of bilateral tDCS protocols has failed.	[Dambacher, Franziska; Schuhmann, Teresa; Sack, Alexander T.] Maastricht Univ, Dept Cognit Neurosci, Maastricht, Netherlands; [Lobbestael, Jill; Arntz, Arnoud; Brugman, Suzanne] Maastricht Univ, Dept Clin Psychol Sci, Maastricht, Netherlands; [Dambacher, Franziska; Schuhmann, Teresa; Sack, Alexander T.] Maastricht Brain Imaging Ctr, Maastricht, Netherlands; [Arntz, Arnoud] Univ Amsterdam, Dept Clin Psychol, NL-1018 WB Amsterdam, Netherlands	Maastricht University; Maastricht University; Maastricht University; University of Amsterdam	Dambacher, F (corresponding author), Maastricht Univ, Dept Cognit Neurosci, Maastricht, Netherlands.	franziska.dambacher@maastrichtuniversity.nl	Arntz, Arnoud/M-3011-2013	Arntz, Arnoud/0000-0002-7992-2272; Sack, Alexander/0000-0002-1471-0885; Lobbestael, Jill/0000-0001-9205-3115	Netherlands Organization for Scientific Research (NWO) [HCMI 10-19]	Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO))	This work was supported by a grant from the Netherlands Organization for Scientific Research (NWO; HCMI 10-19).	Anderson CA, 2002, ANNU REV PSYCHOL, V53, P27, DOI 10.1146/annurev.psych.53.100901.135231; Anderson CA, 1999, CURR DIR PSYCHOL SCI, V8, P3, DOI 10.1111/1467-8721.00002; Archer J, 2004, REV GEN PSYCHOL, V8, P291, DOI 10.1037/1089-2680.8.4.291; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Asahi S, 2004, EUR ARCH PSY CLIN N, V254, P245, DOI 10.1007/s00406-004-0488-z; Beeli G, 2008, BEHAV BRAIN FUNCT, V4, DOI 10.1186/1744-9081-4-33; BERNSTEIN S, 1987, AGGRESSIVE BEHAV, V13, P15, DOI 10.1002/1098-2337(1987)13:1<15::AID-AB2480130104>3.0.CO;2-K; BJORKQVIST K, 1994, SEX ROLES, V30, P177, DOI 10.1007/BF01420988; Carver CS, 2009, PSYCHOL BULL, V135, P183, DOI 10.1037/a0013965; Chambers CD, 2006, J COGNITIVE NEUROSCI, V18, P444, DOI 10.1162/jocn.2006.18.3.444; Chambers CD, 2007, J NEUROPHYSIOL, V98, P3638, DOI 10.1152/jn.00685.2007; d'Alfonso AAL, 2000, NEUROSCI LETT, V280, P195, DOI 10.1016/S0304-3940(00)00781-3; Dambacher F, 2015, SOCIAL COGN IN PRESS; Dambacher F, 2015, SOC COGN AFFECT NEUR, V10, P508, DOI 10.1093/scan/nsu077; Dambacher F, 2014, J COGNITIVE NEUROSCI, V26, P1775, DOI 10.1162/jocn_a_00595; Dambacher F, 2014, EUR J NEUROSCI, V39, P821, DOI 10.1111/ejn.12425; de Graaf TA, 2011, NEUROSCI BIOBEHAV R, V35, P871, DOI 10.1016/j.neubiorev.2010.10.006; Eagle DM, 2008, PSYCHOPHARMACOLOGY, V199, P439, DOI 10.1007/s00213-008-1127-6; EAGLY AH, 1986, PSYCHOL BULL, V100, P309, DOI 10.1037/0033-2909.100.3.309; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Giancola PR, 2008, AGGRESSIVE BEHAV, V34, P214, DOI 10.1002/ab.20235; GIANCOLA PR, 1995, AGGRESSIVE BEHAV, V21, P199, DOI 10.1002/1098-2337(1995)21:3<199::AID-AB2480210303>3.0.CO;2-Q; Harmon-Jones E, 1998, J PERS SOC PSYCHOL, V74, P1310, DOI 10.1037/0022-3514.74.5.1310; Harmon-Jones E, 2004, BIOL PSYCHOL, V67, P51, DOI 10.1016/j.biopsycho.2004.03.003; Harmon-Jones E, 2001, J PERS SOC PSYCHOL, V80, P797, DOI 10.1037/0022-3514.80.5.797; Hoaken PNS, 2003, AGGRESSIVE BEHAV, V29, P15, DOI 10.1002/ab.10023; Horn NR, 2003, NEUROPSYCHOLOGIA, V41, P1959, DOI 10.1016/S0028-3932(03)00077-0; Hortensius R, 2012, SOC COGN AFFECT NEUR, V7, P342, DOI 10.1093/scan/nsr012; Horvath JC, 2015, BRAIN STIMUL, V8, P535, DOI 10.1016/j.brs.2015.01.400; Horvath JC, 2015, NEUROPSYCHOLOGIA, V66, P213, DOI 10.1016/j.neuropsychologia.2014.11.021; Jacobson L, 2011, J COGNITIVE NEUROSCI, V23, P3380, DOI 10.1162/jocn_a_00020; Karabanov A, 2015, BRAIN STIMUL, V8, P442, DOI 10.1016/j.brs.2015.01.404; LAGERSPETZ KMJ, 1988, AGGRESSIVE BEHAV, V14, P403, DOI 10.1002/1098-2337(1988)14:6<403::AID-AB2480140602>3.0.CO;2-D; Logan GD, 1997, PSYCHOL SCI, V8, P60, DOI 10.1111/j.1467-9280.1997.tb00545.x; Pawliczek CM, 2013, NEUROIMAGE, V79, P264, DOI 10.1016/j.neuroimage.2013.04.104; Poulin F, 2000, PSYCHOL ASSESSMENT, V12, P115, DOI 10.1037/1040-3590.12.2.115; Raine A, 2006, AGGRESSIVE BEHAV, V32, P159, DOI 10.1002/ab.20115; TAYLOR SP, 1967, J PERS, V35, P297, DOI 10.1111/j.1467-6494.1967.tb01430.x; van Honk J, 2006, PSYCHOL SCI, V17, P963, DOI 10.1111/j.1467-9280.2006.01813.x; Verbruggen F, 2010, P NATL ACAD SCI USA, V107, P13966, DOI 10.1073/pnas.1001957107; Ye H, 2015, BEHAV BRAIN RES, V286, P17, DOI 10.1016/j.bbr.2015.02.037; Ziemann U, 2008, BRAIN STIMUL, V1, P60, DOI 10.1016/j.brs.2007.08.003	42	45	48	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2015	10	7							e0132170	10.1371/journal.pone.0132170	http://dx.doi.org/10.1371/journal.pone.0132170			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CN1FD	26161664	Green Submitted, gold, Green Published			2023-01-03	WOS:000358162300101
J	Guo, HT; Callaway, JB; Ting, JPY				Guo, Haitao; Callaway, Justin B.; Ting, Jenny P-Y			Inflammasomes: mechanism of action, role in disease, and therapeutics	NATURE MEDICINE			English	Review							PATTERN-RECOGNITION RECEPTORS; GAMMA-INDUCING FACTOR; NLRP3 INFLAMMASOME; ADIPOSE-TISSUE; INSULIN-RESISTANCE; NALP3 INFLAMMASOME; BACTERIAL LIGANDS; AIM2 INFLAMMASOME; ADAPTER ASC; FATTY-ACIDS	The inflammasomes are innate immune system receptors and sensors that regulate the activation of caspase-1 and induce inflammation in response to infectious microbes and molecules derived from host proteins. They have been implicated in a host of inflammatory disorders. Recent developments have greatly enhanced our understanding of the molecular mechanisms by which different inflammasomes are activated. Additionally, increasing evidence in mouse models, supported by human data, strongly implicates an involvement of the inflammasome in the initiation or progression of diseases with a high impact on public health, such as metabolic disorders and neurodegenerative diseases. Finally, recent developments pointing toward promising therapeutics that target inflammasome activity in inflammatory diseases have been reported. This review will focus on these three areas of inflammasome research.	[Guo, Haitao; Callaway, Justin B.; Ting, Jenny P-Y] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Ting, Jenny P-Y] Univ N Carolina, Dept Genet, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ting, JPY (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	jenny_ting@med.unc.edu			US National Institutes of Health [R37-AI029564, CA156330]; National Multiple Sclerosis Society [1785G9/2]; NATIONAL CANCER INSTITUTE [R01CA156330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029564] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Multiple Sclerosis Society(National Multiple Sclerosis Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by US National Institutes of Health grants R37-AI029564 and CA156330 and National Multiple Sclerosis Society grant 1785G9/2 awarded to J.P.-Y.T.	Allam R, 2014, EMBO REP, V15, P982, DOI 10.15252/embr.201438463; Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363; Beraud Dawn, 2012, Parkinsonism Relat Disord, V18 Suppl 1, pS17, DOI 10.1016/S1353-8020(11)70008-6; Bhaskar V, 2011, ATHEROSCLEROSIS, V216, P313, DOI 10.1016/j.atherosclerosis.2011.02.026; Bryan NB, 2009, J IMMUNOL, V182, P3173, DOI 10.4049/jimmunol.0802367; Brydges SD, 2013, J CLIN INVEST, V123, P4695, DOI 10.1172/JCI71543; Cai X, 2014, CELL, V156, P1207, DOI 10.1016/j.cell.2014.01.063; Canna SW, 2014, NAT GENET, V46, P1140, DOI 10.1038/ng.3089; Cavelti-Weder Claudia, 2011, Diabetes Care, V34, pe158, DOI 10.2337/dc11-1196; Chalkiadaki A, 2012, CELL METAB, V16, P180, DOI 10.1016/j.cmet.2012.07.003; Chavarria-Smith J, 2015, IMMUNOL REV, V265, P22, DOI 10.1111/imr.12283; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Ferrari CC, 2006, NEUROBIOL DIS, V24, P183, DOI 10.1016/j.nbd.2006.06.013; Codolo G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055375; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Coll RC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029539; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; COOPER GJS, 1987, P NATL ACAD SCI USA, V84, P8628, DOI 10.1073/pnas.84.23.8628; de Nooijer R, 2004, ARTERIOSCL THROM VAS, V24, P2313, DOI 10.1161/01.ATV.0000147126.99529.0a; Dinarello CA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00289; Donath MY, 2011, NAT REV IMMUNOL, V11, P98, DOI 10.1038/nri2925; Dostert C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006510; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; Elhage R, 2003, CARDIOVASC RES, V59, P234, DOI 10.1016/S0008-6363(03)00343-2; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Finucane OM, 2015, DIABETES, V64, P2116, DOI 10.2337/db14-1098; Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754; Franklin BS, 2014, NAT IMMUNOL, V15, P727, DOI 10.1038/ni.2913; Freigang S, 2013, NAT IMMUNOL, V14, P1045, DOI 10.1038/ni.2704; Furlan R, 1999, J IMMUNOL, V163, P2403; Ganesan S, 2014, J IMMUNOL, V193, P2519, DOI 10.4049/jimmunol.1400276; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Goverman J, 2009, NAT REV IMMUNOL, V9, P393, DOI 10.1038/nri2550; Gringhuis SI, 2012, NAT IMMUNOL, V13, P246, DOI 10.1038/ni.2222; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Guarda G, 2011, IMMUNITY, V34, P213, DOI 10.1016/j.immuni.2011.02.006; Guilherme A, 2008, NAT REV MOL CELL BIO, V9, P367, DOI 10.1038/nrm2391; Gurung P, 2014, J IMMUNOL, V192, P1835, DOI 10.4049/jimmunol.1302839; Hagar JA, 2013, SCIENCE, V341, P1250, DOI 10.1126/science.1240988; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hara H, 2013, NAT IMMUNOL, V14, P1247, DOI 10.1038/ni.2749; He Y, 2014, J BIOL CHEM, V289, P1142, DOI 10.1074/jbc.M113.515080; Heneka MT, 2015, NAT IMMUNOL, V16, P229, DOI 10.1038/ni.3102; Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729; Honda H, 2014, J LEUKOCYTE BIOL, V96, P1087, DOI 10.1189/jlb.3A0114-005RR; Hook VYH, 2008, J BIOL CHEM, V283, P7745, DOI 10.1074/jbc.M708362200; Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOWARD AD, 1991, J IMMUNOL, V147, P2964; Huang MTH, 2009, J IMMUNOL, V182, P2395, DOI 10.4049/jimmunol.0800909; Inoue M, 2012, P NATL ACAD SCI USA, V109, P10480, DOI 10.1073/pnas.1201836109; Inoue M, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002767; Isakov E, 2014, BBA-GEN SUBJECTS, V1840, P3153, DOI 10.1016/j.bbagen.2014.07.012; Janson J, 1996, P NATL ACAD SCI USA, V93, P7283, DOI 10.1073/pnas.93.14.7283; Jesus AA, 2014, ANNU REV MED, V65, P223, DOI 10.1146/annurev-med-061512-150641; Jha S, 2010, J NEUROSCI, V30, P15811, DOI 10.1523/JNEUROSCI.4088-10.2010; Jin TC, 2013, J BIOL CHEM, V288, P13225, DOI 10.1074/jbc.M113.468033; Jin TC, 2012, IMMUNITY, V36, P561, DOI 10.1016/j.immuni.2012.02.014; Jourdan T, 2013, NAT MED, V19, P1132, DOI 10.1038/nm.3265; Juliana C, 2012, J BIOL CHEM, V287, P36617, DOI 10.1074/jbc.M112.407130; Juliana C, 2010, J BIOL CHEM, V285, P9792, DOI 10.1074/jbc.M109.082305; Kajiwara Y, 2014, J IMMUNOL, V193, P335, DOI 10.4049/jimmunol.1303424; Kang SJ, 2000, J CELL BIOL, V149, P613, DOI 10.1083/jcb.149.3.613; Katsnelson MA, 2015, J IMMUNOL, V194, P3937, DOI 10.4049/jimmunol.1402658; Kayagaki N, 2013, SCIENCE, V341, P1246, DOI 10.1126/science.1240248; Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558; Kirii H, 2003, ARTERIOSCL THROM VAS, V23, P656, DOI 10.1161/01.ATV.0000064374.15232.C3; Kofoed EM, 2011, NATURE, V477, P592, DOI 10.1038/nature10394; Kotas ME, 2013, P NATL ACAD SCI USA, V110, P4810, DOI 10.1073/pnas.1301996110; L'homme L, 2013, J LIPID RES, V54, P2998, DOI 10.1194/jlr.M037861; Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007; Lamkanfi M, 2012, ANNU REV CELL DEV BI, V28, P137, DOI 10.1146/annurev-cellbio-101011-155745; Lamkanfi M, 2009, J CELL BIOL, V187, P61, DOI 10.1083/jcb.200903124; Larsen CM, 2007, NEW ENGL J MED, V356, P1517, DOI 10.1056/NEJMoa065213; Lee GS, 2012, NATURE, V492, P123, DOI 10.1038/nature11588; Lee HM, 2013, DIABETES, V62, P194, DOI 10.2337/db12-0420; Lee SJ, 2008, J MOL NEUROSCI, V34, P17, DOI 10.1007/s12031-007-0012-9; Legrand-Poels S, 2014, BIOCHEM PHARMACOL, V92, P131, DOI 10.1016/j.bcp.2014.08.013; Lu A, 2014, CELL, V156, P1193, DOI 10.1016/j.cell.2014.02.008; Maedler K, 2002, J CLIN INVEST, V110, P851, DOI 10.1172/JCI200215318; Maier NK, 2015, J IMMUNOL, V194, P2776, DOI 10.4049/jimmunol.1401611; Mallat Z, 2001, CIRC RES, V89, pE41, DOI 10.1161/hh1901.098735; Man SM, 2015, NAT IMMUNOL, V16, P467, DOI 10.1038/ni.3118; Man SM, 2013, J IMMUNOL, V191, P5239, DOI 10.4049/jimmunol.1301581; Mandrup-Poulsen T, 2010, NAT REV ENDOCRINOL, V6, P158, DOI 10.1038/nrendo.2009.271; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Masters SL, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001902; Masters SL, 2010, NAT IMMUNOL, V11, P897, DOI 10.1038/ni.1935; Matsuki T, 2006, INT IMMUNOL, V18, P399, DOI 10.1093/intimm/dxh379; Matusiak M, 2015, P NATL ACAD SCI USA, V112, P1541, DOI 10.1073/pnas.1417945112; Menu P, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.18; Monie TP, 2015, IMMUNOL REV, V265, P181, DOI 10.1111/imr.12284; Murakami T, 2012, P NATL ACAD SCI USA, V109, P11282, DOI 10.1073/pnas.1117765109; Nagareddy PR, 2014, CELL METAB, V19, P821, DOI 10.1016/j.cmet.2014.03.029; Netea MG, 2006, NAT MED, V12, P650, DOI 10.1038/nm1415; Patel MN, 2015, P NATL ACAD SCI USA, V112, P506, DOI 10.1073/pnas.1414536112; Peelen E, 2015, MOL IMMUNOL, V63, P521, DOI 10.1016/j.molimm.2014.10.008; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Py BF, 2013, MOL CELL, V49, P331, DOI 10.1016/j.molcel.2012.11.009; Qu Y, 2012, NATURE, V490, P539, DOI 10.1038/nature11429; Rathinam VAK, 2012, NAT IMMUNOL, V13, P333, DOI 10.1038/ni.2237; Ratsimandresy RA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00440; Rayamajhi M, 2013, J IMMUNOL, V191, P3986, DOI 10.4049/jimmunol.1301549; Reboldi A, 2014, SCIENCE, V345, P679, DOI 10.1126/science.1254790; Robbins GR, 2014, MOL CELL, V54, P297, DOI 10.1016/j.molcel.2014.03.029; Rodgers MA, 2014, J EXP MED, V211, P1331, DOI 10.1084/jem.20132486; Romberg N, 2014, NAT GENET, V46, P1135, DOI 10.1038/ng.3066; Sagulenko V, 2013, CELL DEATH DIFFER, V20, P1149, DOI 10.1038/cdd.2013.37; Salvesen GS, 2014, SEMIN IMMUNOL, V26, P246, DOI 10.1016/j.smim.2014.03.005; Shaw PJ, 2010, J IMMUNOL, V184, P4610, DOI 10.4049/jimmunol.1000217; Sheedy FJ, 2013, NAT IMMUNOL, V14, P812, DOI 10.1038/ni.2639; Shi FD, 2000, J IMMUNOL, V165, P3099, DOI 10.4049/jimmunol.165.6.3099; Shi JJ, 2014, NATURE, V514, P187, DOI 10.1038/nature13683; Shulman JM, 2011, ANNU REV PATHOL-MECH, V6, P193, DOI 10.1146/annurev-pathol-011110-130242; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Stienstra R, 2012, CELL METAB, V15, P10, DOI 10.1016/j.cmet.2011.10.011; Stienstra R, 2011, P NATL ACAD SCI USA, V108, P15324, DOI 10.1073/pnas.1100255108; Stienstra R, 2010, CELL METAB, V12, P593, DOI 10.1016/j.cmet.2010.11.011; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; Sutterwala FS, 2014, ANN NY ACAD SCI, V1319, P82, DOI 10.1111/nyas.12458; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tan HW, 2010, ATHEROSCLEROSIS, V208, P350, DOI 10.1016/j.atherosclerosis.2009.07.053; Tenthorey JL, 2014, MOL CELL, V54, P17, DOI 10.1016/j.molcel.2014.02.018; Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552; Vanaja SK, 2015, TRENDS CELL BIOL, V25, P308, DOI 10.1016/j.tcb.2014.12.009; Vance RE, 2015, CURR OPIN IMMUNOL, V32, P84, DOI 10.1016/j.coi.2015.01.010; Vandanmagsar B, 2011, NAT MED, V17, P179, DOI 10.1038/nm.2279; Weber C, 2011, NAT MED, V17, P1410, DOI 10.1038/nm.2538; Wen HT, 2013, IMMUNITY, V39, P432, DOI 10.1016/j.immuni.2013.08.037; Wen HT, 2011, NAT IMMUNOL, V12, P408, DOI 10.1038/ni.2022; Yan YQ, 2015, CELL, V160, P62, DOI 10.1016/j.cell.2014.11.047; Yan YQ, 2013, IMMUNITY, V38, P1154, DOI 10.1016/j.immuni.2013.05.015; Yang JL, 2013, P NATL ACAD SCI USA, V110, P14408, DOI 10.1073/pnas.1306376110; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yin Z, 2014, MOL CELL ENDOCRINOL, V394, P80, DOI 10.1016/j.mce.2014.06.018; Youm YH, 2015, NAT MED, V21, P263, DOI 10.1038/nm.3804; Zhao Y, 2011, NATURE, V477, P596, DOI 10.1038/nature10510; Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831	139	1820	1889	26	583	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2015	21	7					677	687		10.1038/nm.3893	http://dx.doi.org/10.1038/nm.3893			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	CM3SO	26121197	Green Accepted, Green Submitted			2023-01-03	WOS:000357604600009
J	Almenning, I; Rieber-Mohn, A; Lundgren, KM; Lovvik, TS; Garnaes, KK; Moholdt, T				Almenning, Ida; Rieber-Mohn, Astrid; Lundgren, Kari Margrethe; Lovvik, Tone Shetelig; Garnaes, Kirsti Krohn; Moholdt, Trine			Effects of High Intensity Interval Training and Strength Training on Metabolic, Cardiovascular and Hormonal Outcomes in Women with Polycystic Ovary Syndrome: A Pilot Study	PLOS ONE			English	Article							AND/OR PHYSICAL-EXERCISE; ANTI-MULLERIAN HORMONE; FLOW-MEDIATED DILATION; INSULIN-RESISTANCE; OBESE WOMEN; BODY-COMPOSITION; FOLLOW-UP; ENDOTHELIAL FUNCTION; HYPOCALORIC DIET; OVERWEIGHT WOMEN	Background Polycystic ovary syndrome is a common endocrinopathy in reproductive-age women, and associates with insulin resistance. Exercise is advocated in this disorder, but little knowledge exists on the optimal exercise regimes. We assessed the effects of high intensity interval training and strength training on metabolic, cardiovascular, and hormonal outcomes in women with polycystic ovary syndrome. Materials and Methods Three-arm parallel randomized controlled trial. Thirty-one women with polycystic ovary syndrome (age 27.2 +/- 5.5 years; body mass index 26.7 +/- 6.0 kg/m(2)) were randomly assigned to high intensity interval training, strength training, or a control group. The exercise groups exercised three times weekly for 10 weeks. Results The main outcome measure was change in homeostatic assessment of insulin resistance (HOMA-IR). HOMA-IR improved significantly only after high intensity interval training, by -0.83 (95% confidence interval [CI], -1.45, -0.20), equal to 17%, with between-group difference (p = 0.014). After high intensity interval training, high-density lipoprotein cholesterol increased by 0.2 (95% CI, 0.02, 0.5) mmol/L, with between group difference (p = 0.04). Endothelial function, measured as flow-mediated dilatation of the brachial artery, increased significantly after high intensity interval training, by 2.0 (95% CI, 0.1, 4.0) %, between-group difference (p = 0.08). Fat percentage decreased significantly after both exercise regimes, without changes in body weight. After strength training, anti-Muallariahhormone was significantly reduc, by -14.8 (95% CI, -21.2, -8.4) pmol/L, between-group difference (p = 0.04). There were no significant changes in high-sensitivity C-reactive protein, adiponectin or leptin in any group. Conclusions High intensity interval training for ten weeks improved insulin resistance, without weight loss, in women with polycystic ovary syndrome. Body composition improved significantly after both strength training and high intensity interval training. This pilot study indicates that exercise training can improve the cardiometabolic profile in polycystic ovary syndrome in the absence of weight loss.	[Almenning, Ida; Rieber-Mohn, Astrid; Lundgren, Kari Margrethe; Garnaes, Kirsti Krohn; Moholdt, Trine] Norwegian Univ Sci & Technol, Fac Med, Dept Circulat & Med Imaging, N-7034 Trondheim, Norway; [Lovvik, Tone Shetelig; Moholdt, Trine] St Olavs Hosp, Dept Obstet & Gynecol, Trondheim, Norway; [Lovvik, Tone Shetelig] Norwegian Univ Sci & Technol, Dept Lab Med Childrens & Womens Hlth, N-7034 Trondheim, Norway	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU)	Moholdt, T (corresponding author), Norwegian Univ Sci & Technol, Fac Med, Dept Circulat & Med Imaging, N-7034 Trondheim, Norway.	trine.moholdt@ntnu.no	Lundgren, Kari Margrethe/HJA-2726-2022; Moholdt, Trine/J-5884-2014; Moholdt, Trine/ABC-8674-2021	Moholdt, Trine/0000-0003-1024-8088	Norwegian Fund for Research in Sports Medicine	Norwegian Fund for Research in Sports Medicine	Funding: The Norwegian Fund for Research in Sports Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al Kindi Manal K, 2012, Oman Med J, V27, P471, DOI 10.5001/omj.2012.112; Alvarez-Blasco F, 2006, ARCH INTERN MED, V166, P2081, DOI 10.1001/archinte.166.19.2081; Brown AJ, 2009, MED SCI SPORT EXER, V41, P497, DOI 10.1249/MSS.0b013e31818c6c0c; Costello MF, 2007, HUM REPROD, V22, P1200, DOI 10.1093/humrep/dem005; Croymans DM, 2013, J APPL PHYSIOL, V115, P1245, DOI 10.1152/japplphysiol.00485.2013; Diamanti-Kandarakis E, 2012, ENDOCR REV, V33, P981, DOI 10.1210/er.2011-1034; Dunaif A, 1999, ENDOCRIN METAB CLIN, V28, P341, DOI 10.1016/S0889-8529(05)70073-6; Earnest CP, 2013, INT J SPORTS MED, V34, P355, DOI 10.1055/s-0032-1311594; Fauser BCJM, 2004, HUM REPROD, V19, P41, DOI 10.1093/humrep/deh098; FERRIMAN D, 1961, J CLIN ENDOCR METAB, V21, P1440, DOI 10.1210/jcem-21-11-1440; Froelicher VF, 2006, EXERCISE HEART, VXI; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; Gibala M, 2009, APPL PHYSIOL NUTR ME, V34, P428, DOI 10.1139/H09-046; Harrison CL, 2012, CLIN ENDOCRINOL, V76, P351, DOI 10.1111/j.1365-2265.2011.04160.x; Harrison CL, 2011, HUM REPROD UPDATE, V17, P171, DOI 10.1093/humupd/dmq045; Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI [10.1249/mss.0b013e3180616b27, 10.1161/CIRCULATIONAHA.107.185649]; Hutchison SK, 2011, J CLIN ENDOCR METAB, V96, pE48, DOI 10.1210/jc.2010-0828; Kim Jin Ju, 2013, Obstet Gynecol Sci, V56, P137, DOI 10.5468/ogs.2013.56.3.137; Kirchengast S, 2001, HUM REPROD, V16, P1255, DOI 10.1093/humrep/16.6.1255; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Moran LJ, 2011, HORM METAB RES, V43, P977, DOI 10.1055/s-0031-1291208; Moran LJ, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007506.pub3; Moran LJ, 2009, FERTIL STERIL, V92, P1966, DOI 10.1016/j.fertnstert.2008.09.018; Nybacka A, 2013, FERTIL STERIL, V100, P1096, DOI 10.1016/j.fertnstert.2013.06.030; Nybacka A, 2011, FERTIL STERIL, V96, P1508, DOI 10.1016/j.fertnstert.2011.09.006; Palomba S, 2010, HUM REPROD, V25, P2783, DOI 10.1093/humrep/deq254; REAVEN GM, 1993, ANNU REV MED, V44, P121, DOI 10.1146/annurev.me.44.020193.001005; Repaci A, 2011, MOL CELL ENDOCRINOL, V335, P30, DOI 10.1016/j.mce.2010.08.002; Schmidt J, 2011, J CLIN ENDOCR METAB, V96, P3794, DOI 10.1210/jc.2011-1677; Skaug EA, 2013, EUR J PREV CARDIOL, V20, P531, DOI 10.1177/2047487312444234; Sprung VS, 2013, MED SCI SPORT EXER, V45, P2234, DOI 10.1249/MSS.0b013e31829ba9a1; Sprung VS, 2013, CLIN ENDOCRINOL, V78, P438, DOI 10.1111/j.1365-2265.2012.04490.x; Stener-Victorin E, 2009, AM J PHYSIOL-REG I, V297, pR387, DOI 10.1152/ajpregu.00197.2009; Stepto NK, 2013, HUM REPROD, V28, P777, DOI 10.1093/humrep/des463; Thomson RL, 2009, HUM REPROD, V24, P1976, DOI 10.1093/humrep/dep101; Thomson RL, 2008, J CLIN ENDOCR METAB, V93, P3373, DOI 10.1210/jc.2008-0751; Tjonna AE, 2008, CIRCULATION, V118, P346, DOI 10.1161/CIRCULATIONAHA.108.772822; Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123; Vigorito C, 2007, J CLIN ENDOCR METAB, V92, P1379, DOI 10.1210/jc.2006-2794; Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487; WILD RA, 1983, AM J OBSTET GYNECOL, V146, P602, DOI 10.1016/0002-9378(83)90998-5; Wild S, 2000, CLIN ENDOCRINOL, V52, P595, DOI 10.1046/j.1365-2265.2000.01000.x	42	66	66	0	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2015	10	9							e0138793	10.1371/journal.pone.0138793	http://dx.doi.org/10.1371/journal.pone.0138793			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS1CR	26406234	gold, Green Accepted, Green Published, Green Submitted			2023-01-03	WOS:000361800700098
J	Sjolund, BM; Wimo, A; Engstrom, M; von Strauss, E				Sjolund, Britt-Marie; Wimo, Anders; Engstrom, Maria; von Strauss, Eva			Incidence of ADL Disability in Older Persons, Physical Activities as a Protective Factor and the Need for Informal and Formal Care - Results from the SNAC-N Project	PLOS ONE			English	Article							QUALITY-OF-LIFE; DEMENTED ELDERLY PERSONS; RESOURCE UTILIZATION; FUNCTIONAL STATUS; RISK-FACTORS; POPULATION; ADULTS; HOME; EXERCISE; HEALTH	Background The aim of the study was to examine 1) the incidence of disability in Activities of Daily Living (ADL), in persons 78 years and older 2) explore whether being physical active earlier is a significant predictor of being disability free at follow-up and 3) describe the amount of informal and formal care in relation to ADL-disability. Methods Data were used from a longitudinal community-based study in Nordanstig (SNAC-N), a part of the Swedish National Study on Aging and Care (SNAC). To study objectives 1) and 2) all ADL-independent participants at baseline (N = 307) were included; for objective 3) all participants 78 years and older were included (N = 316). Data were collected at baseline and at 3- and 6-year follow-ups. ADL-disability was defined as a need for assistance in one or more activities. Informal and formal care were measured using the Resource utilization in Dementia (RUD)-instrument. Results The incidence rates for men were similar in the age groups 78-81and 84 years and older, 42.3 vs. 42.5/1000 person-years. For women the incidence rate for ADL-disability increased significantly from the age group 78-81 to the age group 84 years and older, 20.8 vs. 118.3/ 1000 person-years. In the age group 78-81 years, being physically active earlier (aOR 6.2) and during the past 12 month (aOR 2.9) were both significant preventive factors for ADLdisability. Both informal and formal care increased with ADL-disability and the amount of informal care was greater than formal care. The incidence rate for ADL-disability increases with age for women and being physically active is a protective factor for ADL-disability. Conclusion The incidence rate for ADL-disability increases with age for women, and being physical active is a protective factor for ADL-disability.	[Sjolund, Britt-Marie; Wimo, Anders; von Strauss, Eva] Karolinska Inst, Aging Res Ctr, Dept Neurobiol Care Sci & Soc NVS, Stockholm, Sweden; [Sjolund, Britt-Marie; Wimo, Anders; von Strauss, Eva] Stockholm Univ, S-10691 Stockholm, Sweden; [Sjolund, Britt-Marie; Engstrom, Maria] Univ Gavle, Dept Hlth & Caring Sci, Fac Hlth & Occupat Studies, Gavle, Sweden; [Wimo, Anders] Karolinska Inst, Div Neurogeriatr, Dept Neurobiol Care Sci & Soc NVS, Stockholm, Sweden; [Engstrom, Maria] Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden; [von Strauss, Eva] Swedish Red Cross Univ Coll, Stockholm, Sweden	Karolinska Institutet; Stockholm University; University of Gavle; Karolinska Institutet; Uppsala University	Sjolund, BM (corresponding author), Karolinska Inst, Aging Res Ctr, Dept Neurobiol Care Sci & Soc NVS, Stockholm, Sweden.	britt-marie.sjolund@hig.se	Engström, Maria/R-3969-2016; Wimo, Anders/ABA-2678-2021	Engström, Maria/0000-0002-9912-5350; von Strauss, Eva/0000-0001-5800-6454	Swedish Brain Power; Center for Gender Medicine at Karolinska Institutet; Alzheimer Foundation Sweden; Karolinska Institutet Foundations	Swedish Brain Power; Center for Gender Medicine at Karolinska Institutet(Karolinska Institutet); Alzheimer Foundation Sweden; Karolinska Institutet Foundations(Karolinska Institutet)	Funding: This study was supported by grants from the Swedish Brain Power, Center for Gender Medicine at Karolinska Institutet, the Alzheimer Foundation Sweden, and Karolinska Institutet Foundations. The sponsors had no role in the design, methods, participant recruitment, data collection, analysis, or preparation of the manuscript.	Alexandre TD, 2012, ARCH GERONTOL GERIAT, V55, P431, DOI 10.1016/j.archger.2012.04.001; Andel R, 2008, J GERONTOL A-BIOL, V63, P62, DOI 10.1093/gerona/63.1.62; Andren S, 2008, J CLIN NURS, V17, P790, DOI 10.1111/j.1365-2702.2007.02066.x; Balzi D, 2010, AGE AGEING, V39, P92, DOI 10.1093/ageing/afp209; Blankevoort CG, 2010, DEMENT GERIATR COGN, V30, P392, DOI 10.1159/000321357; Boyle PA, 2007, J AM GERIATR SOC, V55, P195, DOI 10.1111/j.1532-5415.2007.01038.x; Carpenter I, 2004, AGING CLIN EXP RES, V16, P259; Chou CH, 2012, ARCH PHYS MED REHAB, V93, P237, DOI 10.1016/j.apmr.2011.08.042; Christensen K, 2009, LANCET, V374, P1196, DOI 10.1016/S0140-6736(09)61460-4; Di Bari M, 2008, AGING CLIN EXP RES, V20, P31, DOI 10.1007/BF03324745; Feng QS, 2013, J GERONTOL B-PSYCHOL, V68, P476, DOI 10.1093/geronb/gbt012; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fries JF, 2002, B WORLD HEALTH ORGAN, V80, P245; Gill TM, 2013, AM J EPIDEMIOL, V178, P418, DOI 10.1093/aje/kws554; Gschwind YJ, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-105; Guralnik J M, 1997, J Am Med Womens Assoc (1972), V52, P113; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; Hardy SE, 2008, GERONTOLOGY, V54, P79, DOI 10.1159/000115004; Hellstrom Y, 2004, HEALTH SOC CARE COMM, V12, P504, DOI 10.1111/j.1365-2524.2004.00519.x; JOHANSSON L, 1991, HEALTH POLICY, V18, P231, DOI 10.1016/0168-8510(91)90024-R; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Keeler E, 2010, J GERONTOL A-BIOL, V65, P727, DOI 10.1093/gerona/glq029; King J, 2012, J AM GERIATR SOC, V60, P569, DOI 10.1111/j.1532-5415.2011.03844.x; Lagergren M, 2004, AGING CLIN EXP RES, V16, P158; Lin SF, 2012, AM J PUBLIC HEALTH, V102, P2157, DOI 10.2105/AJPH.2011.300602; Lindholm C, 2013, INT J GERIATR PSYCH, V28, P454, DOI 10.1002/gps.3844; Lutz W, 2008, NATURE, V451, P716, DOI 10.1038/nature06516; MANTON KG, 1995, J GERONTOL B-PSYCHOL, V50, pS194, DOI 10.1093/geronb/50B.4.S194; Nordberg G, 2005, INT J GERIATR PSYCH, V20, P862, DOI 10.1002/gps.1371; Olshansky S.J., 1991, J AGING HEALTH, V3, P194, DOI DOI 10.1177/089826439100300205; Pahor M, 2014, JAMA-J AM MED ASSOC, V311, P2387, DOI 10.1001/jama.2014.5616; Paillard-Borg S, 2012, J ALZHEIMERS DIS, V31, P835, DOI 10.3233/JAD-2012-120724; Palacios-Cena D, 2012, J AM MED DIR ASSOC, V13, P136, DOI 10.1016/j.jamda.2010.05.007; Perez LG, 2013, PREV CHRONIC DIS, V10, DOI 10.5888/pcd10.130032; Pinkhasov RM, 2010, INT J CLIN PRACT, V64, P465, DOI 10.1111/j.1742-1241.2009.02289.x; Rejeski WJ, 2008, J GERONTOL B-PSYCHOL, V63, pP19, DOI 10.1093/geronb/63.1.P19; Shah RC, 2012, BMC GERIATR, V12, DOI 10.1186/1471-2318-12-63; Tas U, 2007, PREV MED, V44, P272, DOI 10.1016/j.ypmed.2006.11.007; von Stauss E, 2000, J AM GERIATR SOC, V48, P1462, DOI 10.1111/j.1532-5415.2000.tb02638.x; Wimo A, 2011, INT J GERIATR PSYCH, V26, P56, DOI 10.1002/gps.2488; Wimo A, 2010, J NUTR HEALTH AGING, V14, P685, DOI 10.1007/s12603-010-0316-2; Wimo A, 2007, ARCH GERONTOL GERIAT, V44, P71, DOI 10.1016/j.archger.2006.03.001	42	24	26	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2015	10	9							e0138901	10.1371/journal.pone.0138901	http://dx.doi.org/10.1371/journal.pone.0138901			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CS1CR	26407207	gold, Green Published, Green Submitted			2023-01-03	WOS:000361800700115
J	Wang, Y; Dong, WZ; Mauk, K; Li, PY; Wan, J; Yang, G; Fang, LY; Huan, W; Chen, C; Hao, M				Wang, Ying; Dong, Weizhen; Mauk, Kristen; Li, Peiying; Wan, Jin; Yang, Guang; Fang, Lyuying; Huan, Wan; Chen, Chun; Hao, Mo			Nurses' Practice Environment and Their Job Satisfaction: A Study on Nurses Caring for Older Adults in Shanghai	PLOS ONE			English	Article							LONG-TERM-CARE; REGISTERED NURSES; HEALTH-SERVICE; WORK; LEAVE; INTENTIONS; PREDICTORS; CHINA; QUIT	Aim To examine the job satisfaction of nurses who are caring for older adults in healthcare settings in Shanghai, and to explore the underlying factors in order to explain and predict nurses' job satisfaction. Background China has the largest elderly population in the world, and its population is aging rapidly. Studies on job satisfaction of nurses providing care for the elderly in China can help to identify problem areas and develop strategies for the improvement of nurses' working conditions. However, to date, this subject matter has not been thoroughly studied in the Chinese context. Previous studies in other countries show that many factors impact nurses' job satisfaction, with the practice environment being a critical factor. There is a serious nursing shortage in China, especially in the big cities such as Shanghai. Given the increasing care demand of the aging population, learning about the job satisfaction level among nurses who are caring for older adults can provide essential information to help attract and retain nurses in this specialty area. Methods A cross-sectional survey was conducted among 444 nurses in 22 elderly care institutions in Shanghai. The Chinese version of the Index of Work Satisfaction (IWS) and the Nursing Practice Environment Scale were instruments used. Inferential statistical tests used to analyze the data included Spearman correlation analysis, one-way analysis of variance, and hierarchical regression tests. Results The average overall IWS (part B) score was 135.21 +/- 19.34. Personality, job and organizational characteristics were found to be the most influential factors, and the practice environment was identified as having the strongest impact on job satisfaction (Beta = 0.494). Conclusion Job satisfaction level among nurses who are caring for older adults in Shanghai is moderate, but the data suggest that this could be greatly increased if the nursing practice environment was improved.	[Wang, Ying; Wan, Jin; Yang, Guang; Fang, Lyuying; Huan, Wan; Hao, Mo] Fudan Univ, Res Inst Hlth Dev Strategies, Shanghai 200433, Peoples R China; [Dong, Weizhen] Univ Toronto, Munk Sch Global Affairs, Toronto, ON M5S 0A7, Canada; [Mauk, Kristen] Valparaiso Univ, Coll Nursing & Hlth Profess, Valparaiso, IN 46383 USA; [Li, Peiying] Hangzhou Vocat & Tech Coll, Sch Nursing, Hangzhou, Zhejiang, Peoples R China; [Chen, Chun] Wenzhou Med Coll, Coll Humanities & Management, Hangzhou, Zhejiang, Peoples R China	Fudan University; University of Toronto; Valparaiso University; Hangzhou Vocational & Technical College; Wenzhou Medical University	Chen, C (corresponding author), Wenzhou Med Coll, Coll Humanities & Management, Hangzhou, Zhejiang, Peoples R China.	chenchun408@126.com; haomo03@fudan.edu.cn	Chen, Chun/E-9759-2011; Hao, Mo/GRR-6669-2022		National Natural Science Foundation of China [70733002, 70703005]; Program for Changjiang Scholars, and Innovative Research Team in University (PCSIRT) [IRT_13R11]; Humanities and Social Sciences Research from the Ministry of Education of China [12YJCZH100]; National Social Science Fund of China [13AZD081]; Collaborative Innovation Center of Social Risks Governance in Health	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Changjiang Scholars, and Innovative Research Team in University (PCSIRT)(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); Humanities and Social Sciences Research from the Ministry of Education of China(Ministry of Education, China); National Social Science Fund of China; Collaborative Innovation Center of Social Risks Governance in Health	The project team is grateful to all of the participants in the study. This project was supported by the National Natural Science Foundation of China (grant number 70733002, 70703005), the Program for Changjiang Scholars, and Innovative Research Team in University (PCSIRT) (NO. IRT_13R11); the Humanities and Social Sciences Research (12YJCZH100) from the Ministry of Education of China; Program of National Social Science Fund of China [13AZD081]; and Collaborative Innovation Center of Social Risks Governance in Health also provided funding for the original research project. Mo Hao contributed in the study design, data collection.	Altier ME, 2006, J NURSES PROF DEV, V22, P70, DOI 10.1097/00124645-200603000-00006; Andrews Diane Randall, 2005, J Nurs Manag, V13, P286, DOI 10.1111/j.1365-2934.2005.00567.x; [Anonymous], 2011, CHINAS MAIN DEMOGRAP; Asadi A., 2008, J SOCIAL SCI, V4, P246; Burke Ronald J, 2003, Health Care Manag (Frederick), V22, P99; Caers R, 2008, J ADV NURS, V62, P521, DOI 10.1111/j.1365-2648.2008.04620.x; CARR KK, 1994, J ADV NURS, V19, P878, DOI 10.1111/j.1365-2648.1994.tb01164.x; Chan MF, 2009, J CLIN NURS, V18, P893, DOI 10.1111/j.1365-2702.2008.02463.x; China MoHo, 2013, CHIN HLTH STAT YB 20; Choi SPP, 2013, J NURS MANAGE, V21, P429, DOI 10.1111/j.1365-2834.2012.01415.x; Cimete G, 2003, J NURS CARE QUAL, V18, P151, DOI 10.1097/00001786-200304000-00009; Cohen JD, 2006, J HEALTHC MANAG, V51, P233, DOI 10.1097/00115514-200607000-00006; Curtis EA, 2007, INT NURS REV, V54, P92, DOI 10.1111/j.1466-7657.2007.00507.x; Evans MG, 1995, NURSING RES; Feng ZL, 2012, HEALTH AFFAIR, V31, P2764, DOI 10.1377/hlthaff.2012.0535; Fillion Lise, 2006, Palliat Support Care, V4, P333; Flanagan NA, 2002, RES NURS HEALTH, V25, P282, DOI 10.1002/nur.10042; Friese CR, 2005, ONCOLOGY NURSING FOR; Gardner Jane K, 2007, Nephrol Nurs J, V34, P271; Government SMPs, 2012, 5 YEAR PLAN 2011 201; Grant D, 2009, J HEALTH ECON, V28, P244, DOI 10.1016/j.jhealeco.2008.09.005; Hall Debra S, 2007, Nurs Adm Q, V31, P68; Happell B, 2003, INT J MENT HEALTH NU, V12, P39, DOI 10.1046/j.1440-0979.2003.00267.x; Hong T, 2010, CHINESE PRIMARY HLTH, V24, P17; IskraGolec I, 1996, WORK STRESS, V10, P251; Kacel Barbara, 2005, J Am Acad Nurse Pract, V17, P27, DOI 10.1111/j.1041-2972.2005.00007.x; Karanikola Maria N, 2007, J Nurs Manag, V15, P78, DOI 10.1111/j.1365-2934.2006.00673.x; Kash BA, 2010, HEALTH CARE MANAGE R, V35, P246, DOI 10.1097/HMR.0b013e3181dc826d; Lake ET, 2002, RES NURS HEALTH, V25, P176, DOI 10.1002/nur.10032; Larrabee JH, 2003, J NURS ADMIN, V33, P271, DOI 10.1097/00005110-200305000-00003; Ma CC, 2003, J NURS ADMIN, V33, P293, DOI 10.1097/00005110-200305000-00005; Manojlovich M, 2005, J NURS SCHOLARSHIP, V37, P367, DOI 10.1111/j.1547-5069.2005.00063.x; Manojlovich M, 2002, J NURS ADMIN, V32, P586, DOI 10.1097/00005110-200211000-00006; March J., 1958, ORGANIZATIONS; Microbell, 2012, SER POP AG CHIN INL; Ministry of Health of the Peoples Republic of China, 2006, NOT WEB CTR PEOPL GO; Mittra R, 2010, DIMENTION ED, P137; Patrician PA, 2010, RES NURS HEALTH, V33, P99, DOI 10.1002/nur.20370; PETTERSON IL, 1995, PSYCHOTHER PSYCHOSOM, V64, P9, DOI 10.1159/000288986; Ruggiero JS, 2005, J NURS ADMIN, V35, P254; Sheng z, 2012, CHINESE J NURSING ED, V9, P319; Shields MA, 2002, ECONOMICA, V69, P295, DOI 10.1111/1468-0335.00284; Shields MA, 2001, J HEALTH ECON, V20, P677, DOI 10.1016/S0167-6296(01)00092-3; Stamps P. L., 1997, NURSES WORK SATISFAC; Upenieks VV, 2002, J NURS ADMIN, V32, P564, DOI 10.1097/00005110-200211000-00004; Wu B, 2008, J AGING SOC POLICY, V20, P218, DOI 10.1080/08959420801977632; Wu L, 2007, STUDY WORK SATISFACT; Xinhua, CHIN POP AG HIGHL SH; Yang Y., 2011, RES STATUS POLICIES; Zangaro GA, 2005, J NURS MEAS, V13, P7, DOI 10.1891/jnum.2005.13.1.7; Zangaro GA, 2007, RES NURS HEALTH, V30, P445, DOI 10.1002/nur.20202; Zeng Q, 2008, STUDY WORK SATISFACT; Zheng X, 2009, NURSE JOB SATISFACTI	53	17	17	0	52	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2015	10	9							e0138035	10.1371/journal.pone.0138035	http://dx.doi.org/10.1371/journal.pone.0138035			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CS0ZE	26380980	Green Submitted, gold, Green Published			2023-01-03	WOS:000361790200050
J	Gebeyehu, E; Bantie, L; Azage, M				Gebeyehu, Endalew; Bantie, Laychiluh; Azage, Muluken			Inappropriate Use of Antibiotics and Its Associated Factors among Urban and Rural Communities of Bahir Dar City Administration, Northwest Ethiopia	PLOS ONE			English	Article							SELF-MEDICATION PRACTICES; KHARTOUM STATE; KNOWLEDGE; PRESCRIPTION; RESISTANCE; ATTITUDES; CHILDREN; MISUSE; NONADHERENCE; BEHAVIOR	Background Inappropriate use of antibiotics in the community plays a role in the emergence and spread of bacteria resistant to antibiotics which threatens human health significantly. The present study was designed to determine inappropriate use of antibiotics and its associated factors among urban and rural communities of Bahir Dar city administration. Methods A comparative cross sectional study design was conducted in urban and rural kebeles of Bahir Dar city administration from February 1 to March 28, 2014. A total of 1082 participants included in the study using a systematic random sampling technique. Data was collected using pre-tested and structured questionnaire. Data was coded and entered into SPSSS version 16 for statistical analysis. Bivariate and multivariate logistic regression model were used to identify factors associated with inappropriate use of antibiotics. Results Inappropriate use of antibiotics was 30.9% without significant difference between urban (33.1%) and rural (29.2%) communities. From the inappropriate antibiotic use practice, self-medication was 18.0% and the remaining (12.9%) was for family member medication. Respiratory tract symptoms (74.6%), diarrhea (74.4%), and physical injury/wound (64.3%) were the three main reasons that the communities had used antibiotics inappropriately. Factors associated with inappropriate use of antibiotics were low educational status, younger age, unsatisfaction with the health care services, engagement with a job, and low knowledge on the use of antibiotic preparations of human to animals. Conclusions Inappropriate use of antibiotic exists in the study area with no significant difference between urban and rural communities. The study indicated an insight on what factors that intervention should be made to reduce inappropriate use of antibiotics in the community. Interventions that consider age groups, educational status, common health problems and their jobs together with improvement of health care services should be areas of focus to reduce inappropriate use of antibiotics.	[Gebeyehu, Endalew; Bantie, Laychiluh] Bahir Dar Univ, Dept Pharmacol, Coll Med & Hlth Sci, Bahir Dar, Ethiopia; [Azage, Muluken] Bahir Dar Univ, Coll Med & Hlth Sci, Dept Publ Hlth, Bahir Dar, Ethiopia	Bahir Dar University; Bahir Dar University	Gebeyehu, E (corresponding author), Bahir Dar Univ, Dept Pharmacol, Coll Med & Hlth Sci, POB 79, Bahir Dar, Ethiopia.	endalew2008@gmail.com	Azage, Muluken/AAF-6515-2020; Mekonnen, Laychiluh/AGO-0752-2022	Azage, Muluken/0000-0003-3222-0158; 	Bahir Dar University	Bahir Dar University	Bahir Dar University paid perdium for data collectors during data collection. Thus, Bahir Dar University had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abula T., 2001, Ethiopian Journal of Health Development, V15, P25; Ahiabu MA, 2016, HEALTH POLICY PLANN, V31, P250, DOI 10.1093/heapol/czv048; Al-Tawfiq JA, 2010, EXPERT REV ANTI-INFE, V8, P765, DOI 10.1586/ERI.10.56; Awad A, 2005, J PHARM PHARM SCI, V8, P326; Awad AI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117910; Awad AI, 2006, EUR J CLIN PHARMACOL, V62, P317, DOI 10.1007/s00228-006-0107-1; Barah F., 2010, Eastern Mediterranean Health Journal, V16, P516; Berzanskyte Ausra, 2006, International Journal of Occupational Medicine and Environmental Health, V19, P246, DOI [10.2478/v10001-006-0030-9, 10.2478/v10001-006-0030.9]; Bi P, 2000, SOC SCI MED, V50, P1445, DOI 10.1016/S0277-9536(99)00304-4; Buke AC, 2003, INT J ANTIMICROB AG, V21, P63, DOI 10.1016/S0924-8579(02)00272-8; Cizman M, 2003, INT J ANTIMICROB AG, V21, P297, DOI 10.1016/S0924-8579(02)00394-1; Costelloe C, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2096; CSA, 2014, SUMM STAT REP 2007 P; DACA, 2009, ANT US RES CONT BAS; de Loyola AI, 2002, REV SAUDE PUBL, V36, P55, DOI 10.1590/S0034-89102002000100009; Desalegn AA, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-170; Endale Getachew, 2013, African Journal of Pharmacy and Pharmacology, V7, P2657; Fatokun O, 2014, INT J CLIN PHARM-NET, V36, P564, DOI 10.1007/s11096-014-9937-6; Fenta Ayaleneh, 2013, Ethiop Med J, V51, P33; Ferech M, 2006, J ANTIMICROB CHEMOTH, V58, P401, DOI 10.1093/jac/dkl188; Fernandes M, 2014, INT J CLIN PHARM-NET, V36, P86, DOI 10.1007/s11096-013-9850-4; Foroutan B, 2014, E MEDITERR HEALTH J, V20, P547, DOI 10.26719/2014.20.9.547; Grosso G, 2012, MOL MED REP, V5, P1305, DOI 10.3892/mmr.2012.818; Hennessy TW, 2002, CLIN INFECT DIS, V34, P1543, DOI 10.1086/340534; Jafari Faranak, 2015, Glob J Health Sci, V7, P360, DOI 10.5539/gjhs.v7n2p360; Jose Jimmy, 2013, Oman Med J, V28, P324, DOI 10.5001/omj.2013.95; Kardas P, 2005, INT J ANTIMICROB AG, V26, P106, DOI 10.1016/j.ijantimicag.2005.04.017; Liu YC, 1999, LANCET, V354, P1360, DOI 10.1016/S0140-6736(99)07446-2; Lyu H, 2013, JAMA SURG, V148, P362, DOI 10.1001/2013.jamasurg.270; Mistretta A, 2008, Ann Ig, V20, P287; Mitsi G, 2005, INT J ANTIMICROB AG, V25, P439, DOI 10.1016/j.ijantimicag.2005.02.009; Mossa D. A., 2012, Turk Silahli Kuvvetleri,  Koruyucu Hekimlik Bulteni, V11, P529; Napolitano F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084177; Nyazema N, 2007, J ANTIMICROB CHEMOTH, V59, P718, DOI 10.1093/jac/dkm013; Ocan M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092323; Okumura J, 2002, SOC SCI MED, V54, P1875, DOI 10.1016/S0277-9536(01)00155-1; Panagakou Sotiria G, 2012, ISRN Pediatr, V2012, P685302, DOI 10.5402/2012/685302; Pechere JC, 2001, CLIN INFECT DIS, V33, pS170, DOI 10.1086/321844; Pechere JC, 2007, INT J ANTIMICROB AG, V29, P245, DOI 10.1016/j.ijantimicag.2006.09.026; Radyowijati A, 2002, DETERMINANTS ANTIMIC; Ramalhinho I, 2014, INT J CLIN PHARM-NET, V36, P1039, DOI 10.1007/s11096-014-9992-z; Ramay BM, 2015, BMC PHARMACOL TOXICO, V16, DOI 10.1186/s40360-015-0011-3; Sabry NA, 2014, RES SOC ADMIN PHARM, V10, P168, DOI 10.1016/j.sapharm.2013.03.004; Saradamma RD, 2000, SOC SCI MED, V50, P891, DOI 10.1016/S0277-9536(99)00380-9; Scicluna Elizabeth Anne, 2009, J Infect Public Health, V2, P189, DOI 10.1016/j.jiph.2009.09.004; Shehadeh M, 2012, SAUDI PHARM J, V20, P125, DOI 10.1016/j.jsps.2011.11.005; Skliros E, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-58; Spellberg B, 2014, JAMA INTERN MED, V174, P432, DOI 10.1001/jamainternmed.2013.14019; Togoobaatar G, 2010, B WORLD HEALTH ORGAN, V88, P930, DOI 10.2471/BLT.10.079004; Vaandnen MH, 2006, HEALTH POLICY, V77, P166, DOI 10.1016/j.healthpol.2005.07.001; van Bijnen EME, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-293; Widayati Aris, 2011, BMC Res Notes, V4, P491, DOI 10.1186/1756-0500-4-491; World Health Organization, 2007, WORLD HLTH REP 2007; World Health Organization (WHO), 2000, OV ANT RES; Wun YT, 2013, PHARMACOEPIDEM DR S, V22, P241, DOI 10.1002/pds.3339; You JHS, 2008, INFECTION, V36, P153, DOI 10.1007/s15010-007-7214-5; Yu M, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-112	57	70	71	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2015	10	9							e0138179	10.1371/journal.pone.0138179	http://dx.doi.org/10.1371/journal.pone.0138179			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CS0RH	26379031	Green Published, Green Submitted, gold			2023-01-03	WOS:000361769400065
J	Shehata, N; Forster, AJ; Lawrence, N; Ducharme, R; Fergusson, DA; Chasse, M; Rothwell, DM; Hebert, PC; Tinmouth, AT; Wilson, K				Shehata, Nadine; Forster, Alan J.; Lawrence, Nadine; Ducharme, Robin; Fergusson, Dean A.; Chasse, Michael; Rothwell, Deanna M.; Hebert, Paul C.; Tinmouth, Alan T.; Wilson, Kumanan			Transfusion Patterns in All Patients Admitted to the Intensive Care Unit and in Those Who Die in Hospital: A Descriptive Analysis	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; BLOOD-TRANSFUSION; HEALTH-CARE; ANEMIA; MORTALITY; ICD-9-CM; SURGERY; LIFE	While it is known that the use of health care resources increases at the end of life in patients admitted to the Intensive Care Unit (ICU), the allocation of blood products at the end of life has not been described. The objective of this study was to describe overall transfusion patterns in the ICU, and specifically in patients who die in hospital. We conducted a retrospective cohort study of adult patients admitted to the ICU of a university-affiliated hospital, who were discharged or died between November 1, 2006 and June 30, 2012. During the study period, 10,642 patients were admitted at least once to the ICU. Of these patients, 4079 (38.3%) received red blood cells (RBCs), plasma or platelets in the ICU. The ICU mortality rate was 28.1% and in-hospital mortality rate was 32.3%. Among 39,591 blood product units transfused over the course of the study in the ICU (18,144 RBC units, 16,920 plasma units and 4527 platelet units), 46.2% were administered to patients who later died within the same hospitalization (41.2% of RBCs, 50.4% of plasma and 50.8% of platelets). Of all blood product units (RBCs, plasma and platelets) administered in the ICU over the study period, 11% were given within the last 24 hours before death. A large proportion of blood products used in the ICU are administered to patients who ultimately succumb to their illness in hospital, and many of these blood units are given in close proximity to death.	[Shehata, Nadine] Univ Toronto, Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; [Shehata, Nadine] Univ Toronto, Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada; [Shehata, Nadine] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Shehata, Nadine] Canadian Blood Serv, Toronto, ON, Canada; [Forster, Alan J.; Lawrence, Nadine; Ducharme, Robin; Fergusson, Dean A.; Chasse, Michael; Rothwell, Deanna M.; Tinmouth, Alan T.; Wilson, Kumanan] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; [Forster, Alan J.; Ducharme, Robin; Wilson, Kumanan] Inst Clin Evaluat Sci, Ottawa, ON, Canada; [Forster, Alan J.; Fergusson, Dean A.; Tinmouth, Alan T.; Wilson, Kumanan] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Fergusson, Dean A.; Chasse, Michael] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada; [Fergusson, Dean A.] Univ Ottawa, Dept Surg, Ottawa, ON, Canada; [Hebert, Paul C.] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; Canadian Blood Services; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa; Universite de Montreal	Wilson, K (corresponding author), Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.	kwilson@ohri.ca	Shehata, Nadine/AAG-1124-2019; Chassé, Michaël/L-7906-2017; Chassé, Michaël/Y-7820-2019	Chassé, Michaël/0000-0001-7075-1924; Shehata, Nadine/0000-0002-9267-6256; Fergusson, Dean/0000-0002-3389-2485; Ducharme, Robin/0000-0002-5665-7429	Canadian Institute of Health Research/Canadian Blood Services New Investigator Award; Canadian Blood Services' [XT0085]	Canadian Institute of Health Research/Canadian Blood Services New Investigator Award(Canadian Institutes of Health Research (CIHR)); Canadian Blood Services'	Nadine Shehata received support from the Canadian Institute of Health Research/Canadian Blood Services New Investigator Award. This study is funded by a Canadian Blood Services' (www.blood.ca.) intramural grant XT0085. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arnold DM, 2006, TRANSFUSION, V46, P1286, DOI 10.1111/j.1537-2995.2006.00892.x; Christensen Steffen, 2011, Clin Epidemiol, V3, P203, DOI 10.2147/CLEP.S20247; Como JJ, 2004, TRANSFUSION, V44, P809, DOI 10.1111/j.1537-2995.2004.03409.x; Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Fergusson DA, 2008, NEW ENGL J MED, V358, P2319, DOI 10.1056/NEJMoa0802395; Forster AJ, 2012, CAN MED ASSOC J, V184, P37, DOI 10.1503/cmaj.110543; Lauzier F, 2007, CRIT CARE MED, V35, P1655, DOI 10.1097/01.CCM.0000269370.59214.97; Middelburg RA, 2010, TRANSFUSION, V50, P1181, DOI 10.1111/j.1537-2995.2010.02675.x; Misset B, 2008, CRIT CARE, V12, DOI 10.1186/cc6969; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Reimche L, 2011, J CLIN PHARMACOL, V51, P1043, DOI 10.1177/0091270010378858; Reuben DB, 2011, JAMA-J AM MED ASSOC, V306, P430, DOI 10.1001/jama.2011.999; Schneeweiss S, 2003, HEALTH SERV RES, V38, P1103, DOI 10.1111/1475-6773.00165; Shehata N, 2013, TRANSFUSION, V53, P1688, DOI 10.1111/trf.12007; Stanworth SJ, 2013, TRANSFUSION, V53, P1050, DOI 10.1111/j.1537-2995.2012.03866.x; Stanworth SJ, 2011, CRIT CARE, V15, DOI 10.1186/cc10129; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; Unroe KT, 2011, ARCH INTERN MED, V171, P196, DOI 10.1001/archinternmed.2010.371; van Klei WA, 2009, ANESTHESIOLOGY, V111, P717, DOI 10.1097/ALN.0b013e3181b6a761; van Walraven C, 2011, J HOSP MED, V6, P389, DOI 10.1002/jhm.917; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Zhang BH, 2009, ARCH INTERN MED, V169, P480, DOI 10.1001/archinternmed.2008.587	23	7	7	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2015	10	9							e0138427	10.1371/journal.pone.0138427	http://dx.doi.org/10.1371/journal.pone.0138427			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS0RH	26378791	Green Submitted, Green Published, gold			2023-01-03	WOS:000361769400098
J	Gan, P; Xie, Y; Duan, WJ; Deng, Q; Yu, XL				Gan, Pei; Xie, Yan; Duan, Wenjie; Deng, Qing; Yu, Xiuli			Rumination and Loneliness Independently Predict Six-Month Later Depression Symptoms among Chinese Elderly in Nursing Homes	PLOS ONE			English	Article							PRIMARY-CARE; RISK-FACTORS; PREVALENCE; COMMUNITY; DISORDERS; RESIDENTS; QUALITY; ROLES; SCALE; MOOD	Background Previous studies conducted in Western countries independently demonstrated that loneliness and rumination are remarkable risk factors of depression among the elderly in both community and nursing homes. However, knowledge on the relationship between these three constructs among the elderly in Eastern countries is scarce. The current study aims to determine the relationship between loneliness, rumination, and depression among Chinese elderly in nursing homes. Methods A total of 71 elderly participants with an average age of 82.49 years completed this six-month longitudinal study. Physical reports indicated that none of the participants were clinically depressed before the study. At Time 1, their loneliness and rumination were measured using UCLA-8 Loneliness Scale and Ruminative Responses Scale. Six months later, the participants completed the Center for Epidemiologic Studies Depression Scale to assess depressive symptoms (Time 2). Results Multiple regression analysis revealed that both loneliness and rumination at Time 1 were the predictors of depression symptoms at Time 2 among the Chinese elderly in nursing homes. However, in the mediation analysis using PROCESS, the indirect effect between loneliness at Time 1 and depression symptoms at Time 2 was insignificant. Conclusions Results suggest that previous loneliness and rumination thinking are predictors of future depression symptoms among the Chinese elderly in nursing homes. However, the insignificant mediation further suggests that the differences between loneliness and rumination should be explored in future studies. Findings have important implications for mental health professionals in nursing homes in China.	[Gan, Pei; Xie, Yan; Deng, Qing; Yu, Xiuli] Chongqing Med Univ, Affiliated Hosp 1, Qinggang Senior Care Ctr, Chongqing, Peoples R China; [Duan, Wenjie] City Univ Hong Kong, Dept Appl Social Sci, Hong Kong, Hong Kong, Peoples R China	Chongqing Medical University; City University of Hong Kong	Xie, Y (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Qinggang Senior Care Ctr, Chongqing, Peoples R China.	zhourushui123@163.com; duan.w@outlook.com	Duan, Wenjie/C-8722-2016	Duan, Wenjie/0000-0002-1251-3685	National Key Clinical Specialties Construction Program of China (Nursing) [MOF-MOHRSS[2010]305]	National Key Clinical Specialties Construction Program of China (Nursing)	This study was supported by National Key Clinical Specialties Construction Program of China (Nursing, MOF-MOHRSS[2010]305).	Alexapoulos GS, 2005, LANCET, V365, P1961, DOI 10.1016/S0140-6736(05)66665-2; Asnani MR, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-40; Aylaz R, 2012, ARCH GERONTOL GERIAT, V55, P548, DOI 10.1016/j.archger.2012.03.006; Azam WMYWM, 2013, ASIA-PAC PSYCHIAT, V5, P134, DOI 10.1111/appy.12061; Barcelos-Ferreira R, 2013, J AFFECT DISORDERS, V150, P616, DOI 10.1016/j.jad.2013.02.024; Boorsma M, 2012, AM J GERIAT PSYCHIAT, V20, P932, DOI 10.1097/JGP.0b013e31825d08ac; Cacioppo JT, 2006, PSYCHOL AGING, V21, P140, DOI 10.1037/0882-7974.21.1.140; Casey DA, 2012, ASIA-PAC PSYCHIAT, V4, P160, DOI 10.1111/j.1758-5872.2012.00191.x; Cole MG, 1999, AM J PSYCHIAT, V156, P1182; Cole MG, 2003, AM J PSYCHIAT, V160, P1147, DOI 10.1176/appi.ajp.160.6.1147; DiTommaso E, 2004, EDUC PSYCHOL MEAS, V64, P99, DOI 10.1177/0013164403258450; Duan WJ, 2012, RES SOCIAL WORK PRAC, V22, P680, DOI 10.1177/1049731512450074; GUPTA R, 2001, J MENTAL HLTH AGING, V7, P257; Hansen NB, 2013, J HEALTH PSYCHOL, V18, P198, DOI 10.1177/1359105312440299; Hawkley LC, 2010, ANN BEHAV MED, V40, P218, DOI 10.1007/s12160-010-9210-8; Hayes A. F., 2013, MEDIATION MODERATION; HAYS RD, 1987, J PERS ASSESS, V51, P69, DOI 10.1207/s15327752jpa5101_6; Ingersoll-Dayton B, 2010, AGING MENT HEALTH, V14, P439, DOI 10.1080/13607860903483136; JONES WH, 1985, J PERS SOC PSYCHOL, V48, P1503, DOI 10.1037/0022-3514.48.6.1503; Jongenelis K, 2004, J AFFECT DISORDERS, V83, P135, DOI 10.1016/j.jad.2004.06.001; Liu LJ, 2016, J HEALTH PSYCHOL, V21, P750, DOI 10.1177/1359105314536941; McCusker J, 2005, J AM GERIATR SOC, V53, P1344, DOI 10.1111/j.1532-5415.2005.53404.x; Mechakra-Tahiri S, 2009, INT J GERIATR PSYCH, V24, P1226, DOI 10.1002/gps.2250; Mehta M, 2008, INT J GERIATR PSYCH, V23, P238, DOI 10.1002/gps.1868; NOLENHOEKSEMA S, 1991, J PERS SOC PSYCHOL, V61, P115, DOI 10.1037/0022-3514.61.1.115; Olivera J, 2008, INT J GERIATR PSYCH, V23, P915, DOI 10.1002/gps.2004; Ostbye T, 2004, CHRONIC DIS CANADA, V26, P93; Park J, 2013, J HEALTH PSYCHOL, V18, P226, DOI 10.1177/1359105312439731; Rabins PV, 1996, J GERONTOL A-BIOL, V51, pM319, DOI 10.1093/gerona/51A.6.M319; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RUSSELL D, 1978, J PERS ASSESS, V42, P290, DOI 10.1207/s15327752jpa4203_11; Smith JM, 2009, CLIN PSYCHOL REV, V29, P116, DOI 10.1016/j.cpr.2008.10.003; Sutcliffe C, 2007, AM J GERIAT PSYCHIAT, V15, P708, DOI 10.1097/JGP.0b013e3180381537; Treynor W, 2003, COGNITIVE THER RES, V27, P247, DOI 10.1023/A:1023910315561; Tsai FJ, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-567; Tucker RP, 2013, PERS INDIV DIFFER, V55, P606, DOI 10.1016/j.paid.2013.05.013; Underwood M, 2013, LANCET, V382, P41, DOI 10.1016/S0140-6736(13)60649-2; Vanhalst J, 2012, J PSYCHOL, V146, P259, DOI 10.1080/00223980.2011.555433; von Hippel W, 2008, COGNITIVE THER RES, V32, P474, DOI 10.1007/s10608-006-9034-9; Wang GY, 2011, INT J GERIATR PSYCH, V26, P1162, DOI 10.1002/gps.2656; WILSON D, 1992, J PERS ASSESS, V59, P72, DOI 10.1207/s15327752jpa5901_7; Yuen ANY, 2014, PSYCHO-ONCOLOGY, V23, P412, DOI 10.1002/pon.3433; YUM JO, 1988, COMMUN MONOGR, V55, P374, DOI 10.1080/03637758809376178; Zawadzki MJ, 2013, HEALTH PSYCHOL, V32, P212, DOI 10.1037/a0029007	44	33	35	4	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2015	10	9							e0137176	10.1371/journal.pone.0137176	http://dx.doi.org/10.1371/journal.pone.0137176			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CQ5AJ	26334298	gold, Green Published, Green Submitted			2023-01-03	WOS:000360615400042
J	Zaragoza, J; Babhadiashar, N; O'Brien, V; Chang, A; Blanco, M; Zabalegui, A; Lee, H; Asuri, P				Zaragoza, Josergio; Babhadiashar, Nasim; O'Brien, Victor; Chang, Andrew; Blanco, Matthew; Zabalegui, Aitor; Lee, Hohyun; Asuri, Prashanth			Experimental Investigation of Mechanical and Thermal Properties of Silica Nanoparticle-Reinforced Poly(acrylamide) Nanocomposite Hydrogels	PLOS ONE			English	Article							POLYMER NANOCOMPOSITES; POLY(ETHYLENE GLYCOL); CONDUCTIVITY; COMPOSITES; RESISTANCE; MELTS	Current studies investigating properties of nanoparticle-reinforced polymers have shown that nanocomposites often exhibit improved properties compared to neat polymers. However, over two decades of research, using both experimental studies and modeling analyses, has not fully elucidated the mechanistic underpinnings behind these enhancements. Moreover, few studies have focused on developing an understanding among two or more polymer properties affected by incorporation of nanomaterials. In our study, we investigated the elastic and thermal properties of poly(acrylamide) hydrogels containing silica nanoparticles. Both nanoparticle concentration and size affected hydrogel properties, with similar trends in enhancements observed for elastic modulus and thermal diffusivity. We also observed significantly lower swellability for hydrogel nanocomposites relative to neat hydrogels, consistent with previous work suggesting that nanoparticles can mediate pseudo crosslinking within polymer networks. Collectively, these results indicate the ability to develop next-generation composite materials with enhanced mechanical and thermal properties by increasing the average crosslinking density using nanoparticles.	[Zaragoza, Josergio; Babhadiashar, Nasim; O'Brien, Victor; Chang, Andrew; Blanco, Matthew; Asuri, Prashanth] Santa Clara Univ, Dept Bioengn, Santa Clara, CA 95053 USA; [Zabalegui, Aitor; Lee, Hohyun] Santa Clara Univ, Dept Mech Engn, Santa Clara, CA 95053 USA	Santa Clara University; Santa Clara University	Lee, H (corresponding author), Santa Clara Univ, Dept Mech Engn, Santa Clara, CA 95053 USA.	hlee@scu.edu; asurip@scu.edu			School of Engineering at Santa Clara University	School of Engineering at Santa Clara University	This project was funded by Sustainable Initiative Program and the School of Engineering at Santa Clara University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ashcroft N.W., 1976, SOLID STATE PHYS SAU; Blumm J, 2002, HIGH TEMP-HIGH PRESS, V34, P515, DOI 10.1068/htjr061; Carlsson L, 2010, SOFT MATTER, V6, P3619, DOI 10.1039/c0sm00009d; Deka BK, 2012, IND ENG CHEM RES, V51, P11881, DOI 10.1021/ie3003123; Fu SY, 2008, COMPOS PART B-ENG, V39, P933, DOI 10.1016/j.compositesb.2008.01.002; Gaharwar AK, 2011, BIOMACROMOLECULES, V12, P1641, DOI 10.1021/bm200027z; Goren K, 2010, J SUPERCRIT FLUID, V51, P420, DOI 10.1016/j.supflu.2009.09.007; Guo ZH, 2006, J MATER CHEM, V16, P2800, DOI 10.1039/b603020c; Huang JC, 2001, POLYMER, V42, P873, DOI 10.1016/S0032-3861(00)00411-0; Jancar J, 2010, POLYMER, V51, P3321, DOI 10.1016/j.polymer.2010.04.074; Jordan J, 2005, MAT SCI ENG A-STRUCT, V393, P1, DOI 10.1016/j.msea.2004.09.044; Ju S, 2014, EXPRESS POLYM LETT, V8, P682, DOI 10.3144/expresspolymlett.2014.71; Kutvonen A, 2012, J CHEM PHYS, V137, DOI 10.1063/1.4767517; Lee GW, 2006, COMPOS PART A-APPL S, V37, P727, DOI 10.1016/j.compositesa.2005.07.006; Lu XL, 2005, MACROMOLECULES, V38, P839, DOI 10.1021/ma0486896; Lundstrom M., 2009, FUNDAMENTALS CARRIER; Meera AP, 2012, J ELASTOM PLAST, V44, P369, DOI 10.1177/0095244311432611; Munstedt H, 2011, AIP CONF PROC, V1375, DOI 10.1063/1.3604479; Nan CW, 1997, J APPL PHYS, V81, P6692, DOI 10.1063/1.365209; NIELSEN LE, 1973, J APPL POLYM SCI, V17, P3819, DOI 10.1002/app.1973.070171224; Prado-Gotor R, 2014, J INORG BIOCHEM, V135, P77, DOI 10.1016/j.jinorgbio.2014.03.005; Rittigstein P, 2007, NAT MATER, V6, P278, DOI 10.1038/nmat1870; Rose S, 2014, NATURE, V505, P382, DOI 10.1038/nature12806; Schadler LS, 2007, MRS BULL, V32, P335, DOI 10.1557/mrs2007.232; Sen S, 2007, MACROMOLECULES, V40, P4059, DOI 10.1021/ma070512z; Senses E, 2014, SOFT MATTER, V10, P4464, DOI 10.1039/c4sm00460d; Senses E, 2013, MACROMOLECULES, V46, P1868, DOI 10.1021/ma302275f; Song WL, 2012, J MATER CHEM, V22, P17133, DOI 10.1039/c2jm32469e; Sternstein SS, 2002, MACROMOLECULES, V35, P7262, DOI 10.1021/ma020482u; Tanaka T, 2004, IEEE T DIELECT EL IN, V11, P763, DOI 10.1109/TDEI.2004.1349782; Tjong SC, 2006, MAT SCI ENG R, V53, P73, DOI 10.1016/j.mser.2006.06.001; Wang Q, 2011, J POLYM SCI POL PHYS, V49, P1421, DOI 10.1002/polb.22337; Weidenfeller B, 2004, COMPOS PART A-APPL S, V35, P423, DOI 10.1016/j.compositesa.2003.11.005; Wong CP, 1999, J APPL POLYM SCI, V74, P3396, DOI 10.1002/(SICI)1097-4628(19991227)74:14<3396::AID-APP13>3.0.CO;2-3; Wu CJ, 2013, MACROMOL BIOSCI, V13, P59, DOI 10.1002/mabi.201200362; Wu LL, 2012, POLYM BULL, V68, P309, DOI 10.1007/s00289-011-0536-6; Xia LW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3226; Yang J, 2013, ACS APPL MATER INTER, V5, P3199, DOI 10.1021/am4001997; Ye ZB, 2013, J CHEM NY; Zhang Q, 2002, LANGMUIR, V18, P10435, DOI 10.1021/la026338j; Zhang X, 2005, MACROMOL MATER ENG, V290, P573, DOI 10.1002/mame.200500075	41	24	24	1	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2015	10	8							e0136293	10.1371/journal.pone.0136293	http://dx.doi.org/10.1371/journal.pone.0136293			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP5VA	26301505	Green Submitted, gold, Green Published			2023-01-03	WOS:000359951900054
J	Rivera, LB; Bergers, G				Rivera, Lee B.; Bergers, Gabriele			Tumor angiogenesis, from foe to friend	SCIENCE			English	Editorial Material							COMBINATION THERAPY; ANGIOCRINE FACTORS; VASCULAR NICHE; GROWTH		[Rivera, Lee B.; Bergers, Gabriele] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Neurol Surg, Brain Tumor Res Ctr, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Rivera, LB (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Neurol Surg, Brain Tumor Res Ctr, San Francisco, CA 94158 USA.	lee.rivera@ucsf.edu; gabriele.bergers@ucsf.edu	Bergers, Gabriele/AAJ-5535-2020	Bergers, Gabriele/0000-0003-3545-5171				Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Butler JM, 2010, NAT REV CANCER, V10, P138, DOI 10.1038/nrc2791; Cao ZW, 2014, CANCER CELL, V25, P350, DOI 10.1016/j.ccr.2014.02.005; Hollebecque A, 2012, CURR OPIN ONCOL, V24, P305, DOI 10.1097/CCO.0b013e32835249de; Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025; Reynolds AR, 2009, NAT MED, V15, P392, DOI 10.1038/nm.1941; Tavora B, 2014, NATURE, V514, P112, DOI 10.1038/nature13541; Wong PP, 2015, CANCER CELL, V27, P123, DOI 10.1016/j.ccell.2014.10.015	10	78	82	1	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	2015	349	6249					694	695		10.1126/science.aad0862	http://dx.doi.org/10.1126/science.aad0862			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO8JO	26273044				2023-01-03	WOS:000359415100020
J	Karthikeyan, B; Kadhiravan, T; Deepanjali, S; Swaminathan, RP				Karthikeyan, Balasubramanian; Kadhiravan, Tamilarasu; Deepanjali, Surendran; Swaminathan, Rathinam Palamalai			Case-Mix, Care Processes, and Outcomes in Medically-Ill Patients Receiving Mechanical Ventilation in a Low-Resource Setting from Southern India: A Prospective Clinical Case Series	PLOS ONE			English	Article							VENOUS THROMBOEMBOLISM RISK; UNPLANNED EXTUBATION; CRITICALLY-ILL; MORTALITY; PROPHYLAXIS; PREDICTORS; PNEUMONIA; ENDORSE; SCORE; UNITS	Background Mechanical ventilation is a resource intensive organ support treatment, and historical studies from low-resource settings had reported a high mortality. We aimed to study the outcomes in patients receiving mechanical ventilation in a contemporary low-resource setting. Methods We prospectively studied the characteristics and outcomes (disease-related, mechanical ventilation-related, and process of care-related) in 237 adults mechanically ventilated for a medical illness at a teaching hospital in southern India during February 2011 to August 2012. Vital status of patients discharged from hospital was ascertained on Day 90 or later. Results Mean age of the patients was 40 +/- 17 years; 140 (51%) were men. Poisoning and envenomation accounted for 98 (41%) of 237 admissions. In total, 87 (37%) patients died in-hospital; 16 (7%) died after discharge; 115 (49%) were alive at 90-day assessment; and 19 (8%) were lost to follow-up. Weaning was attempted in 171 (72%) patients; most patients (78 of 99 [79%]) failing the first attempt could be weaned off. Prolonged mechanical ventilation was required in 20 (8%) patients. Adherence to head-end elevation and deep vein thrombosis prophylaxis were 164 (69%) and 147 (62%) respectively. Risk of nosocomial infections particularly ventilator-associated pneumonia was high (57.2 per 1,000 ventilator-days). Higher APACHE II score quartiles (adjusted HR [95% CI] quartile 2, 2.65 [1.19-5.89]; quartile 3, 2.98 [1.24-7.15]; quartile 4, 5.78 [2.45-13.60]), and new-onset organ failure (2.98 [1.94-4.56]) were independently associated with the risk of death. Patients with poisoning had higher risk of reintubation (43% vs. 20%; P = 0.001) and ventilator-associated pneumonia (75% vs. 53%; P = 0.001). But, their mortality was significantly lower compared to the rest (24% vs. 44%; P = 0.002). Conclusions The case-mix considerably differs from other settings. Mortality in this low-resource setting is similar to high-resource settings. But, further improvements in care processes and prevention of nosocomial infections are required.	[Karthikeyan, Balasubramanian; Kadhiravan, Tamilarasu; Deepanjali, Surendran; Swaminathan, Rathinam Palamalai] Jawaharlal Inst Postgrad Med Educ & Res, Dept Med, Dhanvantri Nagar, Puducherry, India	Jawaharlal Institute of Postgraduate Medical Education & Research	Kadhiravan, T (corresponding author), Jawaharlal Inst Postgrad Med Educ & Res, Dept Med, Dhanvantri Nagar, Puducherry, India.	kadhir@jipmer.edu.in	Kadhiravan, Tamilarasu/AAU-8104-2020; Deepanjali, Surendran/AAR-6341-2021; Deepanjali, Surendran/GQP-5858-2022	Deepanjali, Surendran/0000-0003-2151-4273; Kadhiravan, Tamilarasu/0000-0002-4676-743X				Adhikari NKJ, 2010, LANCET, V376, P1339, DOI 10.1016/S0140-6736(10)60446-1; Allegranzi B, 2011, LANCET, V377, P228, DOI 10.1016/S0140-6736(10)61458-4; Azevedo LCP, 2013, CRIT CARE, V17, DOI 10.1186/cc12594; Boles JM, 2007, EUR RESPIR J, V29, P1033, DOI 10.1183/09031936.00010206; Chevron V, 1998, CRIT CARE MED, V26, P1049, DOI 10.1097/00003246-199806000-00026; Cohen AT, 2008, LANCET, V371, P387, DOI 10.1016/S0140-6736(08)60202-0; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; Dudeck MA, 2013, AM J INFECT CONTROL, V41, P1148, DOI 10.1016/j.ajic.2013.09.002; Dunser MW, 2006, CRIT CARE MED, V34, P1234, DOI 10.1097/01.CCM.0000208360.70835.87; Eber MR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025298; Epstein SK, 2000, AM J RESP CRIT CARE, V161, P1912, DOI 10.1164/ajrccm.161.6.9908068; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Esteban A, 2013, AM J RESP CRIT CARE, V188, P220, DOI 10.1164/rccm.201212-2169OC; Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754; Gupta R, 2004, INDIAN J MED RES, V119, P273; Indira M, 2013, CLIN TOXICOL, V51, P838, DOI 10.3109/15563650.2013.837915; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; Luna CM, 2004, CRIT CARE, V8, P425, DOI 10.1186/cc2988; Lwanga S.K., 1991, SAMPLE SIZE DETERMIN; MacIntyre NR, 2005, CHEST, V128, P3937, DOI 10.1378/chest.128.6.3937; Melsen WG, 2013, LANCET INFECT DIS, V13, P665, DOI 10.1016/S1473-3099(13)70081-1; Murthy S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116949; Murthy Srinivas, 2013, Ann Am Thorac Soc, V10, P509, DOI 10.1513/AnnalsATS.201307-246OT; Pinjala R, 2012, INDIAN J MED RES, V136, P60; POTGIETER PD, 1985, CRIT CARE MED, V13, P798, DOI 10.1097/00003246-198510000-00005; RAJAPAKSE VPH, 1989, ANN ROY COLL SURG, V71, P344; Riviello ED, 2011, CRIT CARE MED, V39, P860, DOI 10.1097/CCM.0b013e318206d6d5; Rosenthal VD, 2006, ANN INTERN MED, V145, P582, DOI 10.7326/0003-4819-145-8-200610170-00007; Scotland Health Protection, 2011, INT CAR UN ASS INF N; SINCLAIR JR, 1988, ANN ROY COLL SURG, V70, P76; Sudarsanam TD, 2005, POSTGRAD MED J, V81, P780, DOI 10.1136/pgmj.2005.033076; Wunsch H, 2010, JAMA-J AM MED ASSOC, V303, P849, DOI 10.1001/jama.2010.216	32	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 11	2015	10	8							e0135336	10.1371/journal.pone.0135336	http://dx.doi.org/10.1371/journal.pone.0135336			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO7PP	26262995	Green Published, Green Submitted, gold			2023-01-03	WOS:000359353300074
J	Jeong, YJ; Kim, I; Cho, JH; Park, DW; Kwon, JE; Jung, MW; Meng, X; Jo, SM; Song, HS; Cho, YM; Song, SM; Ham, YM; Jung, YH; Kim, CS; Yoon, WJ; Kang, SC				Jeong, Yong Joon; Kim, Inhye; Cho, Joon Hyung; Park, Dae Won; Kwon, Jung Eun; Jung, Moon Won; Meng, Xue; Jo, Se Min; Song, Hae Seong; Cho, Young Mi; Song, Sang Mok; Ham, Young-Min; Jung, Yong-Hwan; Kim, Chang Sook; Yoon, Weon-Jong; Kang, Se Chan			Anti-Osteoarthritic Effects of the Litsea japonica Fruit in a Rat Model of Osteoarthritis Induced by Monosodium Iodoacetate	PLOS ONE			English	Article							MATRIX METALLOPROTEINASES; ARTICULAR-CARTILAGE; SUBCHONDRAL BONE; EXPRESSION; INHIBITORS; DISEASE; TIMP-1	Osteoarthritis (OA) is a degenerative chronic disease that affects various tissues surrounding the joints, such as the subchondral bone and articular cartilage. The onset of OA is associated with uncontrolled catabolic and anabolic remodeling processes of the joints, including the cartilage and subchondral bone, to adapt to local biological and biochemical signals. In this study, we determined whether 70% ethanolic (EtOH) extract of Litsea japonica fruit (LJFE) had beneficial effects on the articular cartilage, including structural changes in the tibial subchondral bone, matrix degradation, and inflammatory responses, in OA by using a rat model of monosodium iodoacetate-induced OA. Our results showed that administration of LJFE increased the bone volume and cross-section thickness, but the mean number of objects per slice in this group was lower than that in the OA control (OAC) group. In addition, the LJFE decreased the expression of inflammatory cytokines. Compared to the OAC group, the group treated with high doses of LJFE (100 and 200 mg/kg) showed a more than 80% inhibition of the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases. Our results suggest that LJFE can be used as a potential anti-osteoarthritic agent.	[Jeong, Yong Joon; Park, Dae Won; Kwon, Jung Eun; Jung, Moon Won; Meng, Xue; Jo, Se Min; Song, Hae Seong; Cho, Young Mi; Kang, Se Chan] Gachon Univ, Dept Life Sci, Songnam, South Korea; [Kim, Inhye] Hanyang Univ, Dept Food & Nutr, Seoul 133791, South Korea; [Cho, Joon Hyung] Dongguk Univ, Dept Biol & Environm Sci, Seoul, South Korea; [Song, Sang Mok; Ham, Young-Min; Jung, Yong-Hwan; Kim, Chang Sook; Yoon, Weon-Jong] Jeju Biodivers Res Inst, Jeju, South Korea	Gachon University; Hanyang University; Dongguk University	Yoon, WJ (corresponding author), Jeju Biodivers Res Inst, Jeju, South Korea.	yyjkl@jejutp.or.kr; sckang73@gachon.ac.kr	Ha, C/GZL-9046-2022; Kim, Il/L-6481-2019		High Value-added Food Technology Development Program, Ministry of Agriculture, Food and Rural Affairs (SRAA)	High Value-added Food Technology Development Program, Ministry of Agriculture, Food and Rural Affairs (SRAA)	This research was supported by High Value-added Food Technology Development Program, Ministry of Agriculture, Food and Rural Affairs (SRAA).	Ahmad R, 2009, OSTEOARTHR CARTILAGE, V17, P1049, DOI 10.1016/j.joca.2009.02.008; Ameye LG, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2016; Becher N, 2008, REPROD BIOL ENDOCRIN, V6, DOI 10.1186/1477-7827-6-45; Benedetti S, 2010, CLIN BIOCHEM, V43, P973, DOI 10.1016/j.clinbiochem.2010.05.004; Braza-Boils A, 2012, EXP GERONTOL, V47, P406, DOI 10.1016/j.exger.2012.03.005; Burrage PS, 2006, FRONT BIOSCI-LANDMRK, V11, P529, DOI 10.2741/1817; Cournil C, 2001, ARTHRITIS RES THER, V3; DUNHAM J, 1993, INT J EXP PATHOL, V74, P283; Ghosh P, 1999, SEMIN ARTHRITIS RHEU, V28, P211, DOI 10.1016/S0049-0172(99)80021-3; Guzman RE, 2003, TOXICOL PATHOL, V31, P619, DOI 10.1080/01926230390241800; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; Koo HJ, 2014, INT IMMUNOPHARMACOL, V22, P84, DOI 10.1016/j.intimp.2014.06.007; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lorenz H, 2006, PROG HISTOCHEM CYTO, V40, P135, DOI 10.1016/j.proghi.2006.02.003; Martel-Pelletier Johanne, 2004, Osteoarthritis Cartilage, V12 Suppl A, pS31; Martel-Pelletier Johanne, 1999, Frontiers in Bioscience, V4, pd694, DOI 10.2741/Martel; Min BS, 2003, J NAT PROD, V66, P1388, DOI 10.1021/np030227i; Mohan G, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3543; Naito K, 1999, RHEUMATOLOGY, V38, P510, DOI 10.1093/rheumatology/38.6.510; NII H, 1978, AGR BIOL CHEM TOKYO, V42, P1601; Pelletier JP, 2001, ARTHRITIS RHEUM-US, V44, P1237, DOI 10.1002/1529-0131(200106)44:6<1237::AID-ART214>3.0.CO;2-F; Sakata K, 2000, INT J ONCOL, V17, P673; Sarzi-Puttini P, 2005, SEMIN ARTHRITIS RHEU, V35, P1, DOI 10.1016/j.semarthrit.2005.01.013; Sharif M, 2000, ANN RHEUM DIS, V59, P71, DOI 10.1136/ard.59.1.71; Sohn E., 2013, EVID-BASED COMPL ALT, V2013; TAKEDA K, 1972, TETRAHEDRON, V28, P3757, DOI 10.1016/S0040-4020(01)93822-0; TANAKA H, 1990, PHYTOCHEMISTRY, V29, P857, DOI 10.1016/0031-9422(90)80033-D; Yang CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079662; Yoon WJ, 2010, J KOREAN SOC APPL BI, V53, P27, DOI 10.3839/jksabc.2010.005; Yoshihara Y, 2000, ANN RHEUM DIS, V59, P455, DOI 10.1136/ard.59.6.455	30	23	23	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2015	10	8							e0134856	10.1371/journal.pone.0134856	http://dx.doi.org/10.1371/journal.pone.0134856			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO3MH	26244981	gold, Green Submitted, Green Published			2023-01-03	WOS:000359061400114
J	Holm, LS; Thulstrup, PW; Kasimova, MR; van de Weert, M				Holm, Louise Stenstrup; Thulstrup, Peter W.; Kasimova, Marina R.; van de Weert, Marco			Preferential Interactions and the Effect of Protein PEGylation	PLOS ONE			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; ULTRAVIOLET CIRCULAR-DICHROISM; INCREASED THERMAL-STABILITY; GUANIDINE HYDROCHLORIDE; POLYETHYLENE-GLYCOL; THERAPEUTIC PROTEINS; SECONDARY-STRUCTURE; PHYSICAL STABILITY; NATIVE-STATE; HEN LYSOZYME	Background PEGylation is a strategy used by the pharmaceutical industry to prolong systemic circulation of protein drugs, whereas formulation excipients are used for stabilization of proteins during storage. Here we investigate the role of PEGylation in protein stabilization by formulation excipients that preferentially interact with the protein. Methodology/Principal Findings The model protein hen egg white lysozyme was doubly PEGylated on two lysines with 5 kDa linear PEGs (mPEG-succinimidyl valerate, MW 5000) and studied in the absence and presence of preferentially excluded sucrose and preferentially bound guanine hydrochloride. Structural characterization by far-and near-UV circular dichroism spectroscopy was supplemented by investigation of protein thermal stability with the use of differential scanning calorimetry, far and near-UV circular dichroism and fluorescence spectroscopy. It was found that PEGylated lysozyme was stabilized by the preferentially excluded excipient and destabilized by the preferentially bound excipient in a similar manner as lysozyme. However, compared to lysozyme in all cases the melting transition was lower by up to a few degrees and the calorimetric melting enthalpy was decreased to half the value for PEGylated lysozyme. The ratio between calorimetric and van't Hoff enthalpy suggests that our PEGylated lysozyme is a dimer. Conclusion/Significance The PEGylated model protein displayed similar stability responses to the addition of preferentially active excipients. This suggests that formulation principles using preferentially interacting excipients are similar for PEGylated and non-PEGylated proteins.	[Holm, Louise Stenstrup; Kasimova, Marina R.; van de Weert, Marco] Univ Copenhagen, Fac Hlth & Med Sci, Dept Pharm, Copenhagen, Denmark; [Thulstrup, Peter W.] Univ Copenhagen, Dept Chem, Dept Chem, DK-2100 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen	Holm, LS (corresponding author), Novo Nordisk AS, CMC Supply, Biopharm Formulat Dev, DK-2820 Gentofte, Denmark.	LouiseSHolm@gmail.com	Thulstrup, Peter Waaben/C-5598-2013; Thulstrup, Peter Waaben/V-6371-2019; van de Weert, Marco/AGR-7726-2022	Thulstrup, Peter Waaben/0000-0002-9241-4352; Thulstrup, Peter Waaben/0000-0002-9241-4352; van de Weert, Marco/0000-0002-8530-6441	Advanced Technology Foundation; Ministry of Science, Technology and Innovation; Apotekerfonden; Drug Research Academy; Danish Agency for Science, Technology and Innovation	Advanced Technology Foundation; Ministry of Science, Technology and Innovation(Ministry of Energy, Science, Technology, Environment and Climate Change (MESTECC), Malaysia); Apotekerfonden; Drug Research Academy; Danish Agency for Science, Technology and Innovation	Funding was kindly provided by the Advanced Technology Foundation and the Ministry of Science, Technology and Innovation for the NanoDSC instrument, by Apotekerfonden af 1991 for the Fluorolog, by the Drug Research Academy for the purchase of the NanoDrop 2000c and the Danish Agency for Science, Technology and Innovation for a PhD mobility stipend. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Co-author MRK is currently employed by Symphogen A/S, however, the work performed in connection with the article itself commenced prior to MRK's employment with Symphogen A/S and was then completed outside of her regular working hours at Symphogen A/S. MRK asked and received permission from Symphogen A/S to work on this paper. Symphogen A/S did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AHMAD F, 1982, J BIOL CHEM, V257, P2935; AHMAD F, 1992, BIOCHEM J, V287, P481, DOI 10.1042/bj2870481; Alconcel SNS, 2011, POLYM CHEM-UK, V2, P1442, DOI 10.1039/c1py00034a; Arakawa T, 2001, BIOSCI BIOTECH BIOCH, V65, P1321, DOI 10.1271/bbb.65.1321; ARAKAWA T, 1982, BIOCHEMISTRY-US, V21, P6536, DOI 10.1021/bi00268a033; ARAKAWA T, 1985, BIOCHEMISTRY-US, V24, P6756, DOI 10.1021/bi00345a005; AUNE KC, 1969, BIOCHEMISTRY-US, V8, P4579, DOI 10.1021/bi00839a052; BACK JF, 1979, BIOCHEMISTRY-US, V18, P5191, DOI 10.1021/bi00590a025; Bailon P, 2001, BIOCONJUGATE CHEM, V12, P195, DOI 10.1021/bc000082g; Blumlein A, 2013, BBA-PROTEINS PROTEOM, V1834, P2064, DOI 10.1016/j.bbapap.2013.06.001; Cueto M, 2003, INT J PHARM, V252, P159, DOI 10.1016/S0378-5173(02)00627-0; Dehouck Y, 2009, BIOINFORMATICS, V25, P2537, DOI 10.1093/bioinformatics/btp445; Ferreira M, 1997, J THERM ANAL, V48, P683, DOI 10.1007/bf01979514; Fishburn CS, 2008, J PHARM SCI-US, V97, P4167, DOI 10.1002/jps.21278; FORMOSO C, 1975, J BIOL CHEM, V250, P3738; Furness EL, 1998, BIOMATERIALS, V19, P1361, DOI 10.1016/S0142-9612(98)00007-6; GEKKO K, 1983, J BIOCHEM-TOKYO, V94, P199, DOI 10.1093/oxfordjournals.jbchem.a134330; GOUX WJ, 1980, BIOPOLYMERS, V19, P2191, DOI 10.1002/bip.1980.360191205; Greenfield NJ, 2006, NAT PROTOC, V1, P2876, DOI 10.1038/nprot.2006.202; GRIKO YV, 1995, J MOL BIOL, V252, P447, DOI 10.1006/jmbi.1995.0510; Harris JM, 2001, CLIN PHARMACOKINET, V40, P539, DOI 10.2165/00003088-200140070-00005; Hawe A, 2012, J PHARM SCI-US, V101, P895, DOI 10.1002/jps.22812; Heller MC, 1999, J PHARM SCI, V88, P58, DOI 10.1021/js980257j; Hinds K, 2000, BIOCONJUGATE CHEM, V11, P195, DOI 10.1021/bc9901189; Holm LS, 2014, J PHARM SCI-US, V103, P3043, DOI 10.1002/jps.24094; IMOTO T, 1972, P NATL ACAD SCI USA, V69, P1151, DOI 10.1073/pnas.69.5.1151; ITZHAKI LS, 1994, BIOCHEMISTRY-US, V33, P5212, DOI 10.1021/bi00183a026; Ivens IA, 2013, HAEMOPHILIA, V19, P11, DOI 10.1111/j.1365-2516.2012.02931.x; Jelesarov I, 1999, J MOL RECOGNIT, V12, P3, DOI 10.1002/(SICI)1099-1352(199901/02)12:1<3::AID-JMR441>3.0.CO;2-6; Kelly SM, 2005, BBA-PROTEINS PROTEOM, V1751, P119, DOI 10.1016/j.bbapap.2005.06.005; Kendrick BS, 1997, P NATL ACAD SCI USA, V94, P11917, DOI 10.1073/pnas.94.22.11917; Kim YS, 2003, PROTEIN SCI, V12, P1252, DOI 10.1110/ps.0242603; Kurtin WE, 2002, BIOCHEM MOL BIOL EDU, V30, P244, DOI 10.1002/bmb.2002.494030040083; Laurents DV, 1997, BIOCHEMISTRY-US, V36, P1496, DOI 10.1021/bi962198z; Lee H, 2003, J PHARM SCI-US, V92, P97, DOI 10.1002/jps.10270; LEE JC, 1981, J BIOL CHEM, V256, P7193; LEE JC, 1981, J BIOL CHEM, V256, P625; Liu W, 2005, BIOTECHNOL BIOENG, V90, P482, DOI 10.1002/bit.20442; Liu YF, 1996, BIOCHEMISTRY-US, V35, P3059, DOI 10.1021/bi952198j; MAKHATADZE GI, 1992, J MOL BIOL, V226, P491, DOI 10.1016/0022-2836(92)90963-K; Manning MC, 2010, PHARM RES-DORDR, V27, P544, DOI 10.1007/s11095-009-0045-6; Matsuo K, 2009, PROTEINS, V77, P191, DOI 10.1002/prot.22430; Mosharraf M, 2007, INT J PHARMACEUT, V336, P215, DOI 10.1016/j.ijpharm.2006.11.064; Nodake Y, 2000, BIOSCI BIOTECH BIOCH, V64, P767, DOI 10.1271/bbb.64.767; Nozaki Y, 1972, Methods Enzymol, V26, P43; Ohtake S, 2011, ADV DRUG DELIVER REV, V63, P1053, DOI 10.1016/j.addr.2011.06.011; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; Palm T, 2011, PHARM DEV TECHNOL, V16, P441, DOI 10.3109/10837450.2010.535830; Pantoliano MW, 2001, J BIOMOL SCREEN, V6, P429, DOI 10.1089/108705701753364922; Pasut G, 2007, PROG POLYM SCI, V32, P933, DOI 10.1016/j.progpolymsci.2007.05.008; Pasut G, 2006, ADV POLYM SCI, V192, P95, DOI 10.1007/12_022; Pedotti R, 2001, NAT IMMUNOL, V2, P216, DOI 10.1038/85266; Pfister D, 2014, J CONTROL RELEASE, V180, P134, DOI 10.1016/j.jconrel.2014.02.002; Pinholt C, 2011, EUR J PHARM BIOPHARM, V77, P139, DOI 10.1016/j.ejpb.2010.11.001; Plesner B, 2011, EUR J PHARM BIOPHARM, V79, P399, DOI 10.1016/j.ejpb.2011.05.003; PRIVALOV G, 1995, ANAL BIOCHEM, V232, P79, DOI 10.1006/abio.1995.9957; Rajan RS, 2006, PROTEIN SCI, V15, P1063, DOI 10.1110/ps.052004006; Roberts MJ, 2002, ADV DRUG DELIVER REV, V54, P459, DOI 10.1016/S0169-409X(02)00022-4; Schwalbe H, 2001, PROTEIN SCI, V10, P677, DOI 10.1110/ps.43301; Stigsnaes P, 2007, INT J PHARMACEUT, V330, P89, DOI 10.1016/j.ijpharm.2006.09.002; SUCKAU D, 1992, P NATL ACAD SCI USA, V89, P5630, DOI 10.1073/pnas.89.12.5630; TANFORD C, 1970, BIOCHEMISTRY-US, V9, P206, DOI 10.1021/bi00804a003; TANFORD C, 1973, J MOL BIOL, V73, P185, DOI 10.1016/0022-2836(73)90322-7; TANFORD C, 1966, J MOL BIOL, V15, P489, DOI 10.1016/S0022-2836(66)80123-7; Tattini V, 2005, INT J PHARMACEUT, V304, P124, DOI 10.1016/j.ijpharm.2005.08.006; Tuesca AD, 2009, PHARM RES-DORDR, V26, P727, DOI 10.1007/s11095-008-9816-8; van de Weert M, 2004, PHARM RES-DORDR, V21, P2354, DOI 10.1007/s11095-004-7689-z; Wei W, 1999, INT J PHARMACEUT, V185, P129, DOI 10.1016/S0378-5173(99)00152-0; Wu FG, 2011, PHYS CHEM CHEM PHYS, V13, P3429, DOI 10.1039/c0cp01184c; YUNUS WMB, 1988, APPL OPTICS, V27, P3341, DOI 10.1364/AO.27.003341; Zielenkiewicz W, 2006, J THERM ANAL CALORIM, V83, P587, DOI 10.1007/s10973-005-7417-x	71	11	11	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2015	10	7							e0133584	10.1371/journal.pone.0133584	http://dx.doi.org/10.1371/journal.pone.0133584			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO0JY	26230338	Green Published, gold, Green Submitted			2023-01-03	WOS:000358838400045
J	Schafer, MJ; Dolgalev, I; Alldred, MJ; Heguy, A; Ginsberg, SD				Schafer, Marissa J.; Dolgalev, Igor; Alldred, Melissa J.; Heguy, Adriana; Ginsberg, Stephen D.			Calorie Restriction Suppresses Age-Dependent Hippocampal Transcriptional Signatures	PLOS ONE			English	Article							AMYLOID PRECURSOR PROTEIN; GENE-EXPRESSION; NEUROTROPHIN EXPRESSION; MOUSE MODEL; MICE; PROFILE; MEMORY; LTP; NEURODEGENERATION; PLASTICITY	Calorie restriction (CR) enhances longevity and mitigates aging phenotypes in numerous species. Physiological responses to CR are cell-type specific and variable throughout the lifespan. However, the mosaic of molecular changes responsible for CR benefits remains unclear, particularly in brain regions susceptible to deterioration during aging. We examined the influence of long-term CR on the CA1 hippocampal region, a key learning and memory brain area that is vulnerable to age-related pathologies, such as Alzheimer's disease (AD). Through mRNA sequencing and NanoString nCounter analysis, we demonstrate that one year of CR feeding suppresses age-dependent signatures of 882 genes functionally associated with synaptic transmission-related pathways, including calcium signaling, long-term potentiation (LTP), and Creb signaling in wild-type mice. By comparing the influence of CR on hippocampal CA1 region transcriptional profiles at younger-adult (5 months, 2.5 months of feeding) and older-adult (15 months, 12.5 months of feeding) timepoints, we identify conserved upregulation of proteome quality control and calcium buffering genes, including heat shock 70 kDa protein 1b (Hspa1b) and heat shock 70 kDa protein 5 (Hspa5), protein disulfide isomerase family A member 4 (Pdia4) and protein disulfide isomerase family A member 6 (Pdia6), and calreticulin (Calr). Expression levels of putative neuroprotective factors, klotho (Kl) and transthyretin (Ttr), are also elevated by CR in adulthood, although the global CR-specific expression profiles at younger and older timepoints are highly divergent. At a previously unachieved resolution, our results demonstrate conserved activation of neuroprotective gene signatures and broad CR-suppression of age-dependent hippocampal CA1 region expression changes, indicating that CR functionally maintains a more youthful transcriptional state within the hippocampal CA1 sector.	[Schafer, Marissa J.; Ginsberg, Stephen D.] NYU, Cell & Mol Biol Program, Langone Med Ctr, New York, NY 11201 USA; [Schafer, Marissa J.; Alldred, Melissa J.; Ginsberg, Stephen D.] Nathan S Kline Inst Psychiat Res, Ctr Dementa Res, Orangeburg, NY USA; [Dolgalev, Igor; Heguy, Adriana] NYU, Genome Technol Ctr, Langone Med Ctr, New York, NY USA; [Alldred, Melissa J.; Ginsberg, Stephen D.] NYU, Dept Psychiat, Langone Med Ctr, New York, NY 10016 USA; [Heguy, Adriana] NYU, Dept Pathol, Langone Med Ctr, New York, NY 10016 USA; [Ginsberg, Stephen D.] NYU, Dept Neurosci & Physiol, Langone Med Ctr, New York, NY USA	New York University; NYU Langone Medical Center; Nathan Kline Institute for Psychiatric Research; New York University; NYU Langone Medical Center; New York University; NYU Langone Medical Center; New York University; NYU Langone Medical Center; New York University; NYU Langone Medical Center	Ginsberg, SD (corresponding author), NYU, Cell & Mol Biol Program, Langone Med Ctr, New York, NY 11201 USA.	ginsberg@nki.rfmh.org	Dolgalev, Igor/AAY-6406-2020; Heguy, Adriana/GPP-3907-2022; , SDG/AAB-3329-2022	Dolgalev, Igor/0000-0003-4451-126X; Ginsberg, Stephen/0000-0002-1797-4288	National Institutes of Health [AG043375, AG014449, AG017617, GM007238, RR029893, TR000038]; Alzheimer's Association [IIRG-12-237253]; NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001445] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR029893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG043375, P01AG014449, P01AG017617] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alzheimer's Association(Alzheimer's Association); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was supported by National Institutes of Health grants AG043375, AG014449, AG017617, GM007238, RR029893, TR000038, and the Alzheimer's Association (IIRG-12-237253).	Abraham CR, 2012, FUTURE MED CHEM, V4, P1671, DOI [10.4155/fmc.12.134, 10.4155/FMC.12.134]; Alldred MJ, 2015, BRAIN STRUC IN PRESS, DOI [10.1007/s00429-014-0839-0, DOI 10.1007/S00429-014-0839-C]; Bi H, 2002, J NEUROL SCI, V200, P11, DOI 10.1016/S0022-510X(02)00087-4; Blalock EM, 2003, J NEUROSCI, V23, P3807; Bough KJ, 2003, EPILEPSIA, V44, P752, DOI 10.1046/j.1528-1157.2003.55502.x; Burger C, 2007, NEUROBIOL LEARN MEM, V87, P21, DOI 10.1016/j.nlm.2006.05.003; Buxbaum JN, 2008, P NATL ACAD SCI USA, V105, P2681, DOI 10.1073/pnas.0712197105; Carroll JC, 2011, J NEUROSCI, V31, P14436, DOI 10.1523/JNEUROSCI.3836-11.2011; Choi SH, 2007, J NEUROSCI, V27, P7006, DOI 10.1523/JNEUROSCI.1919-07.2007; Dong HX, 2012, J ALZHEIMERS DIS, V28, P579, DOI 10.3233/JAD-2011-111328; Dubal DB, 2015, J NEUROSCI, V35, P2358, DOI 10.1523/JNEUROSCI.5791-12.2015; Eckles-Smith K, 2000, MOL BRAIN RES, V78, P154, DOI 10.1016/S0169-328X(00)00088-7; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; Ginsberg SD, 2000, ANN NEUROL, V48, P77, DOI 10.1002/1531-8249(200007)48:1<77::AID-ANA12>3.0.CO;2-A; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Hemond P, 2005, NEUROSCIENCE, V135, P413, DOI 10.1016/j.neuroscience.2005.05.044; HORI N, 1992, NEUROREPORT, V3, P1085, DOI 10.1097/00001756-199212000-00013; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Lee J, 2002, J NEUROCHEM, V80, P539, DOI 10.1046/j.0022-3042.2001.00747.x; Lu B, 2005, NAT REV NEUROSCI, V6, P603, DOI 10.1038/nrn1726; Magrane J, 2004, J NEUROSCI, V24, P1700, DOI 10.1523/JNEUROSCI.4330-03.2004; Mattson MP, 2006, NAT REV NEUROSCI, V7, P278, DOI 10.1038/nrn1886; MOROIFETTERS SE, 1989, NEUROBIOL AGING, V10, P317, DOI 10.1016/0197-4580(89)90042-0; Morrison JH, 2002, PROG BRAIN RES, V136, P467; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; Neves G, 2008, NAT REV NEUROSCI, V9, P65, DOI 10.1038/nrn2303; Oh MM, 2013, J NEUROSCI, V33, P7905, DOI 10.1523/JNEUROSCI.5457-12.2013; PATTERSON SL, 1992, NEURON, V9, P1081, DOI 10.1016/0896-6273(92)90067-N; Pawlowski TL, 2009, BRAIN RES, V1256, P101, DOI 10.1016/j.brainres.2008.12.039; PELLEGRINIGIAMPIETRO DE, 1994, NEUROSCIENCE, V61, P41, DOI 10.1016/0306-4522(94)90058-2; Prins D, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004069; Prolla TA, 2002, CHEM SENSES, V27, P299, DOI 10.1093/chemse/27.3.299; Rosenzweig ES, 2003, PROG NEUROBIOL, V69, P143, DOI 10.1016/S0301-0082(02)00126-0; Schafer MJ, 2015, NEUROBIOL AGING, V36, P1293, DOI 10.1016/j.neurobiolaging.2014.10.043; Schroeder JE, 2010, BBA-MOL BASIS DIS, V1802, P840, DOI 10.1016/j.bbadis.2010.04.007; Shiozaki M, 2008, NEUROSCIENCE, V152, P924, DOI 10.1016/j.neuroscience.2008.01.032; Stanika RI, 2010, NEUROBIOL DIS, V37, P403, DOI 10.1016/j.nbd.2009.10.020; Stein TD, 2004, J NEUROSCI, V24, P7707, DOI 10.1523/JNEUROSCI.2211-04.2004; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; Verbitsky M, 2004, LEARN MEMORY, V11, P253, DOI 10.1101/lm.68204; Wang J., 2005, FASEB J, V18, P1; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; WEST MJ, 1994, LANCET, V344, P769, DOI 10.1016/S0140-6736(94)92338-8; Yamamoto Y, 2009, PHYSIOL GENOMICS, V39, P227, DOI 10.1152/physiolgenomics.00082.2009; Yang YN, 1998, J BIOL CHEM, V273, P25552, DOI 10.1074/jbc.273.40.25552; Ye X, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.11.004; Zeier Z, 2011, MECH AGEING DEV, V132, P8, DOI 10.1016/j.mad.2010.10.006	50	43	43	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2015	10	7							e0133923	10.1371/journal.pone.0133923	http://dx.doi.org/10.1371/journal.pone.0133923			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO0JM	26221964	Green Published, gold, Green Submitted			2023-01-03	WOS:000358836800082
J	Kitagawa, H; Munekage, M; Matsumoto, T; Sadakane, C; Fukutake, M; Aoki, K; Watanabe, J; Maemura, K; Hattori, T; Kase, Y; Uezono, Y; Inui, A; Hanazaki, K				Kitagawa, Hiroyuki; Munekage, Masaya; Matsumoto, Takashi; Sadakane, Chiharu; Fukutake, Miwako; Aoki, Katsuyuki; Watanabe, Junko; Maemura, Kazuya; Hattori, Tomohisa; Kase, Yosio; Uezono, Yasuhito; Inui, Akio; Hanazaki, Kazuhiro			Pharmacokinetic Profiles of Active Ingredients and Its Metabolites Derived from Rikkunshito, a Ghrelin Enhancer, in Healthy Japanese Volunteers: A Cross-Over, Randomized Study	PLOS ONE			English	Article							CISPLATIN-INDUCED ANOREXIA; LICORICE-INDUCED PSEUDOALDOSTERONISM; 5-HT2C RECEPTOR; MEDICINE; DAIKENCHUTO; YOKUKANSAN; STOMACH; PEPTIDE; ACID; RATS	Background Rikkunshito, a traditional Japanese (Kampo) medicine, has been used to treat upper gastrointestinal disorders such as functional dyspepsia and gastroesophageal reflux. This study investigated the exposure and pharmacokinetics of the ingredients of rikkunshito in healthy volunteers. Methods and Results First, an exploratory nonrandomized, open-label, one-period, noncrossover study using four healthy Japanese volunteers to detect 32 typical ingredients of rikkunshito in plasma and urine. As a result, 18 or 21 of 32 ingredients was detected in plasma or urine samples after oral administration of rikkunshito (7.5 g/day). Furthermore, a randomized, open-label, three-arm, three-period, crossover study using 21 subjects was conducted to determine the amounts of exposure and pharmacokinetic parameters of nine ingredients derived from rikkunshito (atractylodin, atractylodin carboxylic acid, pachymic acid, 3,30,40,5,6,7,8-heptamethoxyflavone, naringenin, nobiletin, liquiritigenin, isoliquiritigenin, and 18 beta-glycyrrhetinic acid) after oral administration of rikkunshito at three different doses (2.5, 5.0, or 7.5 g/day) during each period. The pharmacokinetic profiles of the nine ingredients in plasma were characterized. The geometric means (95% confidence interval) for the Cmax of the ingredients at a dose of 7.5 g were 1570 (1210-2040), 14,300 (12,200-16,800), 91.0 (71.8-115), 105 (75.6-144), 1150 (802-1650), 35.9 (24.6-52.5), 800 (672-952), 42.8 (30.4-60.3), and 55,600 (39,600-78,100) pg/mL, respectively, and for the AUC(0-last) were 1760 (12902390), 12700 (11,100-14,600), 1210 (882-1650), 225 (157-322), 4630 (2930-7320), 35.7 (20.4-62.7), 4040 (3260-5010), 122 (88.2-168), and 832,000 (628,000-1,100,000) pg.h/mL respectively. Conclusions We identified the ingredients of rikkunshito that are absorbed in humans. Furthermore, we determined the pharmacokinetics of nine ingredients derived from rikkunshito. This information will be useful for elucidating the pharmacological effects of rikkunshito.	[Kitagawa, Hiroyuki; Munekage, Masaya; Hanazaki, Kazuhiro] Kochi Univ, Kochi Med Sch, Dept Surg, Kochi 780, Japan; [Matsumoto, Takashi; Sadakane, Chiharu; Fukutake, Miwako; Watanabe, Junko; Maemura, Kazuya; Hattori, Tomohisa; Kase, Yosio] Tsumura & Co, Kampo Sci Strategies Div, Tsumura Res Labs, Ibaraki, Japan; [Aoki, Katsuyuki] Tsumura & Co, Kampo Formulat Dev Ctr, Prod Div, Ibaraki, Japan; [Uezono, Yasuhito] Natl Canc Ctr, Res Inst, Div Canc Pathophysiol, Tokyo 104, Japan; [Inui, Akio] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Psychosomat Internal Med, Kagoshima 890, Japan	Kochi University; Tsumura & Company; Tsumura & Company; National Cancer Center - Japan; Kagoshima University	Matsumoto, T (corresponding author), Tsumura & Co, Kampo Sci Strategies Div, Tsumura Res Labs, Ibaraki, Japan.	matsumoto_takashi@mail.tsumura.co.jp			Tsumura Co.	Tsumura Co.(Tsumura & Company)	Tsumura & Co., provided support in the form of salaries for authors TM, CS, MF, KA, JW, KM, TH and YK. The specific roles of these authors are articulated in the 'author contributions' section. This study was funded by Tsumura & Co. Tsumura & Co. was responsible for the study design, and the collection, analysis and interpretation of data.	Asakawa A, 2001, GASTROENTEROLOGY, V120, P337, DOI 10.1053/gast.2001.22158; CONN JW, 1968, J AMER MED ASSOC, V205, P492, DOI 10.1001/jama.205.7.492; Fujitsuka N, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.25; Fujitsuka N, 2009, BIOL PSYCHIAT, V65, P748, DOI 10.1016/j.biopsych.2008.10.031; Gardana C, 2007, BRIT J NUTR, V98, P165, DOI 10.1017/S0007114507699358; Gough K., 1995, DRUG INF J, V29, P1039, DOI [10.1177/009286159502900324, DOI 10.1177/009286159502900324]; Hisada T., 2014, DIAGNOSIS TREATMENT, V102, P1577; Kanaze FI, 2007, EUR J CLIN NUTR, V61, P472, DOI 10.1038/sj.ejcn.1602543; Kanno H, 2015, J ETHNOPHARMACOL, V159, P122, DOI 10.1016/j.jep.2014.10.058; Kawakami Z, 2010, EUR J PHARMACOL, V626, P154, DOI 10.1016/j.ejphar.2009.09.046; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; KRAHENBUHL S, 1994, J CLIN ENDOCR METAB, V78, P581, DOI 10.1210/jc.78.3.581; Kushida H, 2013, BIOMED CHROMATOGR, V27, P1647, DOI 10.1002/bmc.2974; Lee KK, 2013, J ETHNOPHARMACOL, V145, P286, DOI 10.1016/j.jep.2012.11.005; Makino T, 2014, BIOL PHARM BULL, V37, P898, DOI 10.1248/bpb.b13-00997; Mondal MS, 2005, REGUL PEPTIDES, V126, P55, DOI 10.1016/j.regpep.2004.08.038; Munekage M, 2011, DRUG METAB DISPOS, V39, P1784, DOI 10.1124/dmd.111.040097; Nahata M, 2013, PSYCHONEUROENDOCRINO, DOI S0306-4530(13)00109-1 PMID: 23583320; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; Nishi A, 2012, NEUROSCIENCE, V207, P124, DOI 10.1016/j.neuroscience.2012.01.037; Sadakane C, 2011, BIOCHEM BIOPH RES CO, V412, P506, DOI 10.1016/j.bbrc.2011.08.002; Sakata Y, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-116; Smith BP, 2000, PHARMACEUT RES, V17, P1278, DOI 10.1023/A:1026451721686; Suzuki H, 2014, NEUROGASTROENT MOTIL, V26, P950, DOI 10.1111/nmo.12348; Takeda H, 2008, GASTROENTEROLOGY, V134, P2004, DOI 10.1053/j.gastro.2008.02.078; Tokita Y., 2007, Inflammopharmacology, V15, P65, DOI 10.1007/s10787-006-1552-2; Tominaga K, 2014, J GASTROENTEROL, V49, P1392, DOI 10.1007/s00535-013-0896-9; Wren AM, 2000, ENDOCRINOLOGY, V141, P4325, DOI 10.1210/en.141.11.4325; Yakabi K, 2010, REGUL PEPTIDES, V161, P97, DOI 10.1016/j.regpep.2010.02.003; Youdim KA, 2003, J NEUROCHEM, V85, P180, DOI 10.1046/j.1471-4159.2003.01652.x	30	31	32	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2015	10	7							e0133159	10.1371/journal.pone.0133159	http://dx.doi.org/10.1371/journal.pone.0133159			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RV	26186592	Green Submitted, gold, Green Published			2023-01-03	WOS:000358198700102
J	Kemmler, J; Bindl, R; McCook, O; Wagner, F; Groger, M; Wagner, K; Scheuerle, A; Radermacher, P; Ignatius, A				Kemmler, Julia; Bindl, Ronny; McCook, Oscar; Wagner, Florian; Groeger, Michael; Wagner, Katja; Scheuerle, Angelika; Radermacher, Peter; Ignatius, Anita			Exposure to 100% Oxygen Abolishes the Impairment of Fracture Healing after Thoracic Trauma	PLOS ONE			English	Article							BLUNT CHEST TRAUMA; MESENCHYMAL STEM-CELLS; INDUCED LUNG INJURY; HYPERBARIC-OXYGEN; SEPTIC SHOCK; OSTEOGENIC DIFFERENTIATION; SYSTEMIC INFLAMMATION; FECAL PERITONITIS; TIBIAL SHAFT; HYPEROXIA	In polytrauma patients a thoracic trauma is one of the most critical injuries and an important trigger of post-traumatic inflammation. About 50% of patients with thoracic trauma are additionally affected by bone fractures. The risk for fracture malunion is considerably increased in such patients, the pathomechanisms being poorly understood. Thoracic trauma causes regional alveolar hypoxia and, subsequently, hypoxemia, which in turn triggers local and systemic inflammation. Therefore, we aimed to unravel the role of oxygen in impaired bone regeneration after thoracic trauma. We hypothesized that short-term breathing of 100% oxygen in the early post-traumatic phase ameliorates inflammation and improves bone regeneration. Mice underwent a femur osteotomy alone or combined with blunt chest trauma 100% oxygen was administered immediately after trauma for two separate 3 hour intervals. Arterial blood gas tensions, microcirculatory perfusion and oxygenation were assessed at 3, 9 and 24 hours after injury. Inflammatory cytokines and markers of oxidative/nitrosative stress were measured in plasma, lung and fracture hematoma. Bone healing was assessed on day 7, 14 and 21. Thoracic trauma induced pulmonary and systemic inflammation and impaired bone healing. Short-term exposure to 100% oxygen in the acute post-traumatic phase significantly attenuated systemic and local inflammatory responses and improved fracture healing without provoking toxic side effects, suggesting that hyperoxia could induce anti-inflammatory and pro-regenerative effects after severe injury. These results suggest that breathing of 100% oxygen in the acute post-traumatic phase might reduce the risk of poorly healing fractures in severely injured patients.	[Kemmler, Julia; Bindl, Ronny; Ignatius, Anita] Univ Ulm, Inst Orthopaed Res & Biomech, Ctr Musculoskeletal Res, D-89069 Ulm, Germany; [McCook, Oscar; Wagner, Florian; Groeger, Michael; Wagner, Katja; Radermacher, Peter] Univ Ulm, Med Ctr, Inst Pathophysiol Anaesthesiol & Proc Engn, D-89069 Ulm, Germany; [Scheuerle, Angelika] Univ Ulm, Dept Pathol, Med Ctr, D-89069 Ulm, Germany	Ulm University; Ulm University; Ulm University	Ignatius, A (corresponding author), Univ Ulm, Inst Orthopaed Res & Biomech, Ctr Musculoskeletal Res, D-89069 Ulm, Germany.	anita.ignatius@uni-ulm.de	Ignatius, Anita/M-6012-2013; McCook, Oscar/AAF-1647-2020	Ignatius, Anita/0000-0002-4782-1979; McCook, Oscar/0000-0001-7879-7695	German Research Foundation (DFG) [KFO200, IG18/13-1, RA396/11-1]; Collaborative Research Center [CRC 1149]	German Research Foundation (DFG)(German Research Foundation (DFG)); Collaborative Research Center	This project was funded by the German Research Foundation (DFG), in the frameworks of the Clinical Research Unit KFO200 (IG18/13-1, RA396/11-1) and the Collaborative Research Center (CRC 1149).	Albuszies G, 2005, CRIT CARE MED, V33, P2332, DOI 10.1097/01.CCM.0000182817.20977.E9; Alcaraz MJ, 2003, CURR PHARM DESIGN, V9, P2541, DOI 10.2174/1381612033453749; Barth E, 2008, CRIT CARE MED, V36, P495, DOI 10.1097/01.CCM.0B013E318161FC45; Bastian O, 2011, J LEUKOCYTE BIOL, V89, P669, DOI 10.1189/jlb.0810446; Benjamin S, 2013, TISSUE ENG PT A, V19, P748, DOI [10.1089/ten.TEA.2012.0298, 10.1089/ten.tea.2012.0298]; Bennett MH, 2012, COCHRANE DB SYST REV, V12, P1; Bhandari M, 2003, J ORTHOP TRAUMA, V17, P353, DOI 10.1097/00005131-200305000-00006; Bitterman H, 2007, ISR MED ASSOC J, V9, P874; Bitterman H, 2009, CRIT CARE, V13, DOI 10.1186/cc7151; Bouachour G, 1996, J TRAUMA, V41, P333, DOI 10.1097/00005373-199608000-00023; Brahimi-Horn MC, 2007, FEBS LETT, V581, P3582, DOI 10.1016/j.febslet.2007.06.018; Butler J, 2006, EMERG MED J, V23, P571, DOI 10.1136/emj.2006.038539; Butterfield TA, 2006, J ATHL TRAINING, V41, P457; Cakir E, 2011, APMIS, V119, P574, DOI 10.1111/j.1600-0463.2011.02778.x; Calzia E, 2010, CRIT CARE MED, V38, pS559, DOI 10.1097/CCM.0b013e3181f1fe70; Chao J, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-54; Chen WJ, 2002, J TRAUMA, V52, P333, DOI 10.1097/00005373-200202000-00020; Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1; Cortes DO, 2015, MICROVASC RES, V98, P23, DOI 10.1016/j.mvr.2014.11.006; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Distler JHW, 2003, Q J NUCL MED, V47, P149; Dyson A, 2012, INTENS CARE MED, V38, P1868, DOI 10.1007/s00134-012-2712-z; Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Faller S, 2010, ANESTHESIOLOGY, V113, P104, DOI 10.1097/ALN.0b013e3181de7107; Flierl MA, 2008, SHOCK, V29, P25, DOI 10.1097/shk.0b013e3180556a0b; Fok TCO, 2008, ORAL SURG ORAL MED O, V105, P417, DOI 10.1016/j.tripleo.2007.07.015; Gebhard F, 2000, ARCH SURG-CHICAGO, V135, P291, DOI 10.1001/archsurg.135.3.291; GROGAARD B, 1990, ARCH ORTHOP TRAUM SU, V109, P268, DOI 10.1007/BF00419942; Groger M, 2005, MUTAT RES-FUND MOL M, V572, P167, DOI 10.1016/j.mrfmmm.2005.05.015; Hafner S, 2015, SHOCK, V43, P140, DOI 10.1097/SHK.0000000000000277; Hauser B, 2009, CRIT CARE MED, V37, P2465, DOI 10.1097/CCM.0b013e3181aee8ad; Hecke F, 1997, CRIT CARE MED, V25, P2015, DOI 10.1097/00003246-199712000-00019; Heilmann A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084232; Hensler T, 2002, J TRAUMA, V52, P962, DOI 10.1097/00005373-200205000-00023; Hou LC, 2009, SHOCK, V32, P451, DOI 10.1097/SHK.0b013e31819c391a; JAMIESON D, 1986, ANNU REV PHYSIOL, V48, P703, DOI 10.1146/annurev.ph.48.030186.003415; Karladani AH, 2001, ARCH ORTHOP TRAUM SU, V121, P325, DOI 10.1007/s004020000252; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; Knoferl MW, 2003, SHOCK, V19, P519, DOI 10.1097/01.shk.0000070739.34700.f6; Kolar P, 2010, TISSUE ENG PART B-RE, V16, P427, DOI [10.1089/ten.teb.2009.0687, 10.1089/ten.TEB.2009.0687]; Kolliputi N, 2010, J IMMUNOL, V184, P5819, DOI 10.4049/jimmunol.0902766; Lefering R, 2013, TRAUMAREGISTER ANN R, P29; Leijten J, 2014, P NATL ACAD SCI USA, V111, P13954, DOI 10.1073/pnas.1410977111; Lin SS, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-56; Lu CY, 2013, BONE, V52, P220, DOI 10.1016/j.bone.2012.09.037; Mak S, 2002, AM J PHYSIOL-HEART C, V282, pH2414, DOI 10.1152/ajpheart.00947.2001; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Pape HC, 2010, J ORTHOP TRAUMA, V24, P522, DOI 10.1097/BOT.0b013e3181ed1361; Quinn DA, 2002, J APPL PHYSIOL, V93, P517, DOI 10.1152/japplphysiol.00570.2001; Recknagel S, 2013, J TRAUMA ACUTE CARE, V74, P531, DOI 10.1097/TA.0b013e318278956d; Recknagel S, 2012, J ORTHOP RES, V30, P581, DOI 10.1002/jor.21561; Recknagel S, 2011, J ORTHOP RES, V29, P734, DOI 10.1002/jor.21299; Rontgen V, 2010, J ORTHOP RES, V28, P1456, DOI 10.1002/jor.21148; Seija M, 2012, SHOCK, V38, P403, DOI 10.1097/SHK.0b013e31826660f2; Seitz DH, 2011, J TRAUMA, V70, P189, DOI 10.1097/TA.0b013e3181d7693c; Shang J, 2014, CURR STEM CELL RES T, V9, P141, DOI 10.2174/1574888X09666131230142459; Simkova V, 2008, SHOCK, V30, P578, DOI 10.1097/SHK.0b013e31816a6e0f; Sinclair SE, 2004, CRIT CARE MED, V32, P2496, DOI 10.1097/01.CCM.0000148231.04642.8D; Stensballe J, 2009, ACTA ANAESTH SCAND, V53, P515, DOI 10.1111/j.1399-6576.2008.01801.x; Sugiura H, 2011, NITRIC OXIDE-BIOL CH, V25, P138, DOI 10.1016/j.niox.2011.03.079; Sukhotnik I, 2009, CRIT CARE MED, V37, P1054, DOI 10.1097/CCM.0b013e31819d0f5c; Tamura DY, 2002, SHOCK, V17, P269, DOI 10.1097/00024382-200204000-00005; Waisman D, 2003, AM J PHYSIOL-HEART C, V285, pH643, DOI 10.1152/ajpheart.00900.2002; Waisman D, 2012, SHOCK, V37, P95, DOI 10.1097/SHK.0b013e3182356fc3; Wang J, 2002, J Postgrad Med, V48, P226; Wehrle E, 2014, J ORTHOP RES, V32, P1006, DOI 10.1002/jor.22629; YABLON IG, 1968, J TRAUM, V8, P186, DOI 10.1097/00005373-196803000-00007	68	26	27	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2015	10	7							e0131194	10.1371/journal.pone.0131194	http://dx.doi.org/10.1371/journal.pone.0131194			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1DQ	26147725	gold, Green Published, Green Submitted			2023-01-03	WOS:000358157600068
J	Teng, MWL; Bowman, EP; McElwee, JJ; Smyth, MJ; Casanova, JL; Cooper, AM; Cua, DJ				Teng, Michele W. L.; Bowman, Edward P.; McElwee, Joshua J.; Smyth, Mark J.; Casanova, Jean-Laurent; Cooper, Andrea M.; Cua, Daniel J.			IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases	NATURE MEDICINE			English	Review							GENOME-WIDE ASSOCIATION; INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY; BACILLE CALMETTE-GUERIN; SEVERE PLAQUE PSORIASIS; TUMOR-NECROSIS-FACTOR; VERSUS-HOST-DISEASE; CONTROLLED PHASE-II; COLITIS-RISK LOCI; PROOF-OF-CONCEPT; DOUBLE-BLIND	The cytokine interleukin-12 (IL-12) was thought to have a central role in T cell-mediated responses in inflammation for more than a decade after it was first identified. Discovery of the cytokine IL-23, which shares a common p40 subunit with IL-12, prompted efforts to clarify the relative contribution of these two cytokines in immune regulation. Ustekinumab, a therapeutic agent targeting both cytokines, was recently approved to treat psoriasis and psoriatic arthritis, and related agents are in clinical testing for a variety of inflammatory disorders. Here we discuss the therapeutic rationale for targeting these cytokines, the unintended consequences for host defense and tumor surveillance and potential ways in which these therapies can be applied to treat additional immune disorders.	[Teng, Michele W. L.; Smyth, Mark J.] QIMR Berghofer Med Res Inst, Canc Immunoregulat & Immunotherapy & Immunol Canc, Herston, Qld, Australia; [Teng, Michele W. L.; Smyth, Mark J.] Univ Queensland, Sch Med, Herston, Qld, Australia; [Bowman, Edward P.; Cua, Daniel J.] Merck Res Labs, Palo Alto, CA 94304 USA; [McElwee, Joshua J.] Merck Res Labs, Boston, MA USA; [Casanova, Jean-Laurent] Rockefeller Univ, Rockefeller Branch, St Giles Lab Human Genet Infect Dis, New York, NY 10021 USA; [Casanova, Jean-Laurent] Howard Hughes Med Inst, New York, NY USA; [Casanova, Jean-Laurent] INSERM, Lab Human Genet Infect Dis, Necker Branch, Paris, France; [Casanova, Jean-Laurent] Necker Hosp Sick Children, Pediat Hematol & Immunol Unit, Paris, France; [Casanova, Jean-Laurent] Paris Descartes Univ, Imagine Inst, Paris, France; [Cooper, Andrea M.] Trudeau Inst Inc, Saranac Lake, NY USA	QIMR Berghofer Medical Research Institute; University of Queensland; Merck & Company; Merck & Company; Rockefeller University; Howard Hughes Medical Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Trudeau Institute	Cua, DJ (corresponding author), Merck Res Labs, Palo Alto, CA 94304 USA.	daniel.cua@merck.com	Smyth, Mark J/H-8709-2014; Casanova, Jean-Laurent/I-3418-2017; Teng, Michele WL/S-5055-2016	Smyth, Mark J/0000-0001-7098-7240; Teng, Michele WL/0000-0003-1886-9145; Casanova, Jean-Laurent/0000-0002-7782-4169; Cooper, Andrea/0000-0001-6050-3863	National Health and Medical Research Council of Australia (NH&MRC) CDF1 fellowship; NHMRC; Prostate Cancer Foundation of Australia and Cancer Council of Queensland (CCQ); NH&MRC Program Grant; NH&MRC Senior Principal Research Fellowship; Susan G. Komen; CCQ	National Health and Medical Research Council of Australia (NH&MRC) CDF1 fellowship(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Prostate Cancer Foundation of Australia and Cancer Council of Queensland (CCQ); NH&MRC Program Grant(National Health and Medical Research Council (NHMRC) of Australia); NH&MRC Senior Principal Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Susan G. Komen(Susan G. Komen Breast Cancer Foundation); CCQ(Cancer Council Queensland)	We thank J. Bustamante and S. Boisson-Dupuis for help in generating some of the figures. M.W.L.T. is supported by a National Health and Medical Research Council of Australia (NH&MRC) CDF1 fellowship and project grants from NH&MRC, and grants from the Prostate Cancer Foundation of Australia and Cancer Council of Queensland (CCQ). M.J.S. is supported by a NH&MRC Program Grant, NH&MRC Senior Principal Research Fellowship, Susan G. Komen and the CCQ.	Abel L, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0428; Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Airoldi I, 2005, BLOOD, V106, P3846, DOI 10.1182/blood-2005-05-2034; Al-Muhsen S, 2008, J ALLERGY CLIN IMMUN, V122, P1043, DOI 10.1016/j.jaci.2008.10.037; Alcais A, 2005, J EXP MED, V202, P1617, DOI 10.1084/jem.20052302; Alizadeh D, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/957878; Altare F, 1998, J CLIN INVEST, V102, P2035, DOI 10.1172/JCI4950; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; Altare F, 2001, J INFECT DIS, V184, P231, DOI 10.1086/321999; Anderson CA, 2011, NAT GENET, V43, P246, DOI 10.1038/ng.764; [Anonymous], 2004, FORM 10 K ANN REP; [Anonymous], 2011, PFIZER PIPELINE; Awasthi A, 2009, J IMMUNOL, V182, P5904, DOI 10.4049/jimmunol.0900732; Baeten D, 2013, LANCET, V382, P1705, DOI 10.1016/S0140-6736(13)61134-4; Baird AM, 2013, LUNG CANCER, V79, P83, DOI 10.1016/j.lungcan.2012.10.003; Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175; Barrett JC, 2009, NAT GENET, V41, P1330, DOI 10.1038/ng.483; Beecham AH, 2013, NAT GENET, V45, P1353, DOI 10.1038/ng.2770; Bending D, 2009, J CLIN INVEST, V119, P565, DOI 10.1172/JCI37865; Berg JV, 2013, J EXP MED, V210, P2803, DOI 10.1084/jem.20130678; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Blake SJ, 2014, ACTAS DERMO-SIFILOGR, V105, P41, DOI 10.1016/S0001-7310(14)70017-1; Blumberg H, 2010, J IMMUNOL, V185, P4354, DOI 10.4049/jimmunol.1000313; Bogunovic D, 2012, SCIENCE, V337, P1684, DOI 10.1126/science.1224026; Boisson B, 2013, IMMUNITY, V39, P676, DOI 10.1016/j.immuni.2013.09.002; Boisson-Dupuis S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018524; Bradfield JP, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002293; Bustamante J, 2014, SEMIN IMMUNOL, V26, P454, DOI 10.1016/j.smim.2014.09.008; Callis-Duffin K, 2014, J AM ACAD DERMATOL, V70, pAB162; Caragol I, 2003, CLIN INFECT DIS, V37, P302, DOI 10.1086/375587; Carvalho A, 2010, BONE MARROW TRANSPL, V45, P1645, DOI 10.1038/bmt.2010.28; Casanova JL, 2013, COLD SH Q B, V78, P157, DOI 10.1101/sqb.2013.78.019968; Casanova JL, 2002, ANNU REV IMMUNOL, V20, P581, DOI 10.1146/annurev.immunol.20.081501.125851; Cayatte C, 2012, CLIN TRANSL GASTROEN, V3, DOI 10.1038/ctg.2012.2; Chan IH, 2014, MUCOSAL IMMUNOL, V7, P842, DOI 10.1038/mi.2013.101; Chan JR, 2006, J EXP MED, V203, P2577, DOI 10.1084/jem.20060244; Chen DY, 2015, SCI REP-UK, V5, DOI 10.1038/srep08604; Chen Y, 2006, J CLIN INVEST, V116, P1317, DOI 10.1172/JCI25308; Chiricozzi A, 2014, EXPERT OPIN THER TAR, V18, P513, DOI 10.1517/14728222.2014.889686; Codarri L, 2011, NAT IMMUNOL, V12, P560, DOI 10.1038/ni.2027; Colombo MP, 2002, CYTOKINE GROWTH F R, V13, P155, DOI 10.1016/S1359-6101(01)00032-6; Conti HR, 2009, J EXP MED, V206, P299, DOI 10.1084/jem.20081463; Cooper AM, 2002, J IMMUNOL, V168, P1322, DOI 10.4049/jimmunol.168.3.1322; Cooper AM, 1997, J EXP MED, V186, P39, DOI 10.1084/jem.186.1.39; Cornelissen F, 2011, CURR OPIN IMMUNOL, V23, P361, DOI 10.1016/j.coi.2011.03.002; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Dauer DJ, 2005, ONCOGENE, V24, P3397, DOI 10.1038/sj.onc.1208469; de Beaucoudrey L, 2008, J EXP MED, V205, P1543, DOI 10.1084/jem.20080321; de Beaucoudrey L, 2010, MEDICINE, V89, P381, DOI 10.1097/MD.0b013e3181fdd832; de Jong R, 1998, SCIENCE, V280, P1435; Di Meglio P, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a015354; Di Meglio P, 2013, J INVEST DERMATOL, V133, P2381, DOI 10.1038/jid.2013.170; Di Meglio P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017160; Ding CG, 2008, CURR OPIN INVEST DR, V9, P515; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Eisenring M, 2010, NAT IMMUNOL, V11, P1030, DOI 10.1038/ni.1947; El-Behi M, 2011, NAT IMMUNOL, V12, P568, DOI 10.1038/ni.2031; Elmaagacli AH, 2008, BONE MARROW TRANSPL, V41, P821, DOI 10.1038/sj.bmt.1705980; Evans DM, 2011, NAT GENET, V43, P761, DOI 10.1038/ng.873; Eyerich S, 2010, TRENDS IMMUNOL, V31, P354, DOI 10.1016/j.it.2010.06.004; Farah CS, 2006, ORAL MICROBIOL IMMUN, V21, P252, DOI 10.1111/j.1399-302X.2006.00288.x; Fernandez O, 2013, REV NEUROLOGIA, V57, P317, DOI 10.33588/rn.5707.2013277; Filer C, 2008, ARTHRITIS RHEUM-US, V58, P3705, DOI 10.1002/art.24128; Filipe-Santos O, 2006, SEMIN IMMUNOL, V18, P347, DOI 10.1016/j.smim.2006.07.010; Filipe-Santos O, 2006, J EXP MED, V203, P1745, DOI 10.1084/jem.20060085; Franke A, 2010, NAT GENET, V42, P292, DOI 10.1038/ng.553; Fukuda M, 2010, MOL MED REP, V3, P89, DOI 10.3892/mmr_00000223; Gaffen SL, 2014, NAT REV IMMUNOL, V14, P585, DOI 10.1038/nri3707; Gangemi S, 2012, J CELL BIOCHEM, V113, P2122, DOI 10.1002/jcb.24083; Genovese MC, 2014, ARTHRITIS RHEUMATOL, V66, P1693, DOI 10.1002/art.38617; Ghoreschi K, 2010, NATURE, V467, P967, DOI 10.1038/nature09447; Godinez I, 2009, INFECT IMMUN, V77, P387, DOI 10.1128/IAI.00933-08; Gordon KB, 2012, J INVEST DERMATOL, V132, P304, DOI 10.1038/jid.2011.304; Gottlieb AB, 2011, BRIT J DERMATOL, V165, P652, DOI 10.1111/j.1365-2133.2011.10418.x; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; Grogan K., 2011, PHARMATIMES; Gruhn B, 2009, BIOL BLOOD MARROW TR, V15, P1571, DOI 10.1016/j.bbmt.2009.08.001; He SB, 2011, INT J MOL SCI, V12, P7424, DOI 10.3390/ijms12117424; Hirota K, 2011, NAT IMMUNOL, V12, P255, DOI 10.1038/ni.1993; Holscher C, 2001, J IMMUNOL, V167, P6957, DOI 10.4049/jimmunol.167.12.6957; Huang J, 2012, EUR J HUM GENET, V20, P801, DOI 10.1038/ejhg.2012.3; Hueber W, 2012, GUT, V61, P1693, DOI 10.1136/gutjnl-2011-301668; Huffmeier U, 2009, J INVEST DERMATOL, V129, P355, DOI 10.1038/jid.2008.233; Huppler AR, 2014, J IMMUNOL, V192, P1745, DOI 10.4049/jimmunol.1302265; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; Julia A, 2013, GUT, V62, P1440, DOI 10.1136/gutjnl-2012-302865; Kagami S, 2010, J IMMUNOL, V185, P5453, DOI 10.4049/jimmunol.1001153; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kenny EE, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002559; Khader SA, 2005, J IMMUNOL, V175, P788, DOI 10.4049/jimmunol.175.2.788; Khader SA, 2011, J IMMUNOL, V187, P5402, DOI 10.4049/jimmunol.1101377; Kimball AB, 2013, J EUR ACAD DERMATOL, V27, P1535, DOI 10.1111/jdv.12046; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Kopp T, 2003, J IMMUNOL, V170, P5438, DOI 10.4049/jimmunol.170.11.5438; Kortylewski M, 2009, CANCER CELL, V15, P114, DOI 10.1016/j.ccr.2008.12.018; Kryczek I, 2014, IMMUNITY, V40, P772, DOI 10.1016/j.immuni.2014.03.010; Kugathasan S, 2008, NAT GENET, V40, P1211, DOI 10.1038/ng.203; Langley RG, 2013, J EUR ACAD DERMATOL, V27, P1252, DOI 10.1111/j.1468-3083.2012.04705.x; Langley RG, 2014, NEW ENGL J MED, V371, P326, DOI 10.1056/NEJMoa1314258; Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Lee E, 2004, J EXP MED, V199, P125, DOI 10.1084/jem.20030451; Lee YK, 2009, IMMUNITY, V30, P92, DOI 10.1016/j.immuni.2008.11.005; Leonardi C, 2012, NEW ENGL J MED, V366, P1190, DOI 10.1056/NEJMoa1109997; Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4; Li J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046264; Li J, 2013, CARCINOGENESIS, V34, P658, DOI 10.1093/carcin/bgs384; Libioulle C, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030058; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Liu Y, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000041; Ljujic B, 2010, ARCH MED RES, V41, P182, DOI 10.1016/j.arcmed.2010.02.009; Luger D, 2008, J EXP MED, V205, P799, DOI 10.1084/jem.20071258; Lyakh L, 2008, IMMUNOL REV, V226, P112, DOI 10.1111/j.1600-065X.2008.00700.x; MacLennan C, 2004, J INFECT DIS, V190, P1755, DOI 10.1086/425021; Mannon PJ, 2004, NEW ENGL J MED, V351, P2069, DOI 10.1056/NEJMoa033402; Martin DA, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4347; McAllister F, 2014, CANCER CELL, V25, P621, DOI 10.1016/j.ccr.2014.03.014; McGovern DPB, 2010, NAT GENET, V42, P332, DOI 10.1038/ng.549; McInnes IB, 2014, ANN RHEUM DIS, V73, P349, DOI 10.1136/annrheumdis-2012-202646; McInnes IB, 2013, LANCET, V382, P780, DOI 10.1016/S0140-6736(13)60594-2; Mease PJ, 2014, NEW ENGL J MED, V370, P2295, DOI 10.1056/NEJMoa1315231; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Muranski P, 2013, BLOOD, V121, P2402, DOI 10.1182/blood-2012-09-378653; Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896; Nakajima K, 2011, J IMMUNOL, V186, P4481, DOI 10.4049/jimmunol.1000148; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; Ngiow SF, 2013, TRENDS IMMUNOL, V34, P548, DOI 10.1016/j.it.2013.07.004; Ngiow SF, 2010, BLOOD, V115, P2554, DOI 10.1182/blood-2009-11-254607; Okada Y, 2014, NATURE, V506, P376, DOI 10.1038/nature12873; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Ouederni M, 2014, CLIN INFECT DIS, V58, P204, DOI 10.1093/cid/cit722; Ozbek N, 2005, CLIN INFECT DIS, V40, pE55, DOI 10.1086/427879; Papp KA, 2013, BRIT J DERMATOL, V168, P844, DOI 10.1111/bjd.12214; Papp KA, 2013, BRIT J DERMATOL, V168, P412, DOI 10.1111/bjd.12110; Papp KA, 2008, LANCET, V371, P1675, DOI 10.1016/S0140-6736(08)60726-6; Papp KA, 2012, NEW ENGL J MED, V366, P1181, DOI 10.1056/NEJMoa1109017; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Parham C, 2002, J IMMUNOL, V168, P5699, DOI 10.4049/jimmunol.168.11.5699; Pedraza S, 2010, PEDIATRICS, V126, pE971, DOI 10.1542/peds.2009-2504; Pidasheva S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025038; Poddubnyy D, 2014, ANN RHEUM DIS, V73, P817, DOI 10.1136/annrheumdis-2013-204248; Prando C, 2013, MEDICINE, V92, P109, DOI 10.1097/MD.0b013e31828a01f9; Price JD, 2007, INFECT IMMUN, V75, P5753, DOI 10.1128/IAI.00971-07; Puel A, 2012, CURR OPIN ALLERGY CL, V12, P616, DOI 10.1097/ACI.0b013e328358cc0b; Raelson JV, 2007, P NATL ACAD SCI USA, V104, P14747, DOI 10.1073/pnas.0706645104; Reich K, 2011, NEW ENGL J MED, V365, P1586, DOI 10.1056/NEJMoa1010858; Reveille JD, 2010, NAT GENET, V42, P123, DOI 10.1038/ng.513; Rich P, 2013, BRIT J DERMATOL, V168, P402, DOI 10.1111/bjd.12112; Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032; Sabat R, 2014, NAT REV DRUG DISCOV, V13, P21, DOI 10.1038/nrd4176; Sandborn WJ, 2012, NEW ENGL J MED, V367, P1519, DOI 10.1056/NEJMoa1203572; Sands BE, 2015, J CROHNS COLITIS, V9, pS15; Sarin R, 2011, P NATL ACAD SCI USA, V108, P9560, DOI 10.1073/pnas.1017854108; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Schulz SM, 2008, J IMMUNOL, V181, P7891, DOI 10.4049/jimmunol.181.11.7891; Segal BM, 2008, LANCET NEUROL, V7, P796, DOI 10.1016/S1474-4422(08)70173-X; Sheibanie AF, 2004, FASEB J, V18, P1318, DOI 10.1096/fj.03-1367fje; Silverberg MS, 2009, NAT GENET, V41, P216, DOI 10.1038/ng.275; Smyth MJ, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28964; Smyth MJ, 2000, J EXP MED, V191, P661, DOI 10.1084/jem.191.4.661; Strange A, 2010, NAT GENET, V42, P985, DOI 10.1038/ng.694; Street SEA, 2002, J EXP MED, V196, P129, DOI 10.1084/jem.20020063; Strober BE, 2011, BRIT J DERMATOL, V165, P661, DOI 10.1111/j.1365-2133.2011.10419.x; Tabarsi P, 2011, J CLIN IMMUNOL, V31, P537, DOI 10.1007/s10875-011-9523-9; Targan SR, 2012, GASTROENTEROLOGY, V143, pE26, DOI 10.1053/j.gastro.2012.07.084; Teng MWL, 2012, CANCER RES, V72, P3987, DOI 10.1158/0008-5472.CAN-12-1337; Teng MWL, 2011, CANCER RES, V71, P2077, DOI 10.1158/0008-5472.CAN-10-3994; Teng MWL, 2010, P NATL ACAD SCI USA, V107, P8328, DOI 10.1073/pnas.1003251107; Tonel G, 2010, J IMMUNOL, V185, P5688, DOI 10.4049/jimmunol.1001538; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Uhlig HH, 2006, IMMUNITY, V25, P309, DOI 10.1016/j.immuni.2006.05.017; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; Vollmer TL, 2011, MULT SCLER J, V17, P181, DOI 10.1177/1352458510384496; von Scheidt B, 2014, CANCER RES, V74, P2412, DOI 10.1158/0008-5472.CAN-13-1646; Ward LD, 2012, NAT BIOTECHNOL, V30, P1095, DOI 10.1038/nbt.2422; Watford WT, 2004, IMMUNOL REV, V202, P139, DOI 10.1111/j.0105-2896.2004.00211.x; Wermke M, 2010, BIOL BLOOD MARROW TR, V16, P1718, DOI 10.1016/j.bbmt.2010.06.001; Wilke CM, 2011, TRENDS IMMUNOL, V32, P603, DOI 10.1016/j.it.2011.08.003; Wilke CM, 2011, CARCINOGENESIS, V32, P643, DOI 10.1093/carcin/bgr019; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Wu SG, 2009, NAT MED, V15, P1016, DOI 10.1038/nm.2015; Yang SK, 2014, GUT, V63, P80, DOI 10.1136/gutjnl-2013-305193; Yano J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046311; Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404; Yoshida YO, 2010, J IMMUNOL, V184, P4414, DOI 10.4049/jimmunol.0903332; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang L, 2014, CARCINOGENESIS, V35, P1330, DOI 10.1093/carcin/bgu017; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505; Zhu KJ, 2012, INFLAMM RES, V61, P1149, DOI 10.1007/s00011-012-0509-8; Zou WP, 2010, NAT REV IMMUNOL, V10, P248, DOI 10.1038/nri2742	195	492	529	12	121	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2015	21	7					719	729		10.1038/nm.3895	http://dx.doi.org/10.1038/nm.3895			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	CM3SO	26121196				2023-01-03	WOS:000357604600013
J	Kahn, JS				Kahn, James S.			I'm Sorry	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Kahn, James S.] VA Palo Alto Hlth Care Syst, Med Serv, Palo Alto, CA 94304 USA; [Kahn, James S.] Stanford Sch Med, Dept Med, Palo Alto, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Kahn, JS (corresponding author), VA Palo Alto Hlth Care Syst, Med Serv, Palo Alto, CA 94304 USA.	james.kahn@va.gov							0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	2015	313	24					2427	2428		10.1001/jama.2014.6507	http://dx.doi.org/10.1001/jama.2014.6507			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CL0WK	26103024				2023-01-03	WOS:000356663600009
J	Merino, D; Lok, SW; Visvader, JE; Lindeman, GJ				Merino, D.; Lok, S. W.; Visvader, J. E.; Lindeman, G. J.			Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer	ONCOGENE			English	Review							INDEPENDENT PROGNOSTIC MARKER; MAMMARY-TUMOR DEVELOPMENT; STRUCTURE-GUIDED DESIGN; BH3 MIMETIC ABT-737; RANDOMIZED PHASE-II; CELL LUNG-CANCER; X-L INHIBITOR; PROTEIN EXPRESSION; TRANSGENIC MICE; IN-VIVO	The last three decades have seen significant progress in our understanding of the role of the pro-survival protein BCL-2 and its family members in apoptosis and cancer. BCL-2 and other pro-survival family members including Mcl-1 and BCL-X-L have been shown to have a key role in keeping pro-apoptotic 'effector' proteins BAK and BAX in check. They also neutralize a group of 'sensor' proteins (such as BIM), which are triggered by cytotoxic stimuli such as chemotherapy. BCL-2 proteins therefore have a central role as guardians against apoptosis, helping cancer cells to evade cell death. More recently, an increasing number of BH3 mimetics, which bind and neutralize BCL-2 and/or its pro-survival relatives, have been developed. The utility of targeting BCL-2 in hematological malignancies has become evident in early-phase studies, with remarkable clinical responses seen in heavily pretreated patients. As BCL-2 is overexpressed in similar to 75% of breast cancer, there has been growing interest in determining whether this new class of drug could show similar promise in breast cancer. This review summarizes our current understanding of the role of BCL-2 and its family members in mammary gland development and breast cancer, recent progress in the development of new BH3 mimetics as well as their potential for targeting estrogen receptor-positive breast cancer.	[Merino, D.; Lok, S. W.; Visvader, J. E.; Lindeman, G. J.] Walter & Eliza Hall Inst Med Res, Stem Cells & Canc Div, 1G Royal Parade, Parkville, Vic 3052, Australia; [Merino, D.; Visvader, J. E.] Univ Melbourne, Dept Med Biol, Parkville, Vic 3052, Australia; [Lok, S. W.; Lindeman, G. J.] Royal Melbourne Hosp, Familial Canc Ctr, Parkville, Vic 3050, Australia; [Lok, S. W.; Lindeman, G. J.] Royal Melbourne Hosp, Dept Med Oncol, Parkville, Vic 3050, Australia; [Lindeman, G. J.] Univ Melbourne, Dept Med, Parkville, Vic 3052, Australia	Walter & Eliza Hall Institute; University of Melbourne; Royal Melbourne Hospital; Royal Melbourne Hospital; University of Melbourne	Lindeman, GJ (corresponding author), Walter & Eliza Hall Inst Med Res, Stem Cells & Canc Div, 1G Royal Parade, Parkville, Vic 3052, Australia.; Lindeman, GJ (corresponding author), Royal Melbourne Hosp, Familial Canc Ctr, Parkville, Vic 3050, Australia.; Lindeman, GJ (corresponding author), Royal Melbourne Hosp, Dept Med Oncol, Parkville, Vic 3050, Australia.; Lindeman, GJ (corresponding author), Univ Melbourne, Dept Med, Parkville, Vic 3052, Australia.	lindeman@wehi.edu.au	Merino, Delphine/L-9159-2017	Merino, Delphine/0000-0002-8075-6275; Lindeman, Geoffrey/0000-0001-9386-2416	NHMRC [1016701, 1040978, 1078730]; National Breast Cancer Foundation [NC-13-21, NT-13-06, ECF-13-06]; Victorian Cancer Agency [TRP13041]; Victorian Government; Australia Fellowship	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); National Breast Cancer Foundation; Victorian Cancer Agency; Victorian Government; Australia Fellowship	We thank P Maltezos for assistance with the figures, G Lessene for advice and F Vaillant for helpful comments on the manuscript. We apologize to authors whose contributions have not been cited due to space limitations. Our research in this area is supported by grants from the NHMRC (1016701, 1040978), National Breast Cancer Foundation (NC-13-21, NT-13-06), the Victorian Cancer Agency (TRP13041) and the Victorian Government. DM is supported by an Early Career Fellowship from the National Breast Cancer Foundation (ECF-13-06), JEV by an Australia Fellowship and GJL by a Research Fellowship from the NHMRC (1078730).	Abdel-Fatah TMA, 2013, ANN ONCOL, V24, P2801, DOI 10.1093/annonc/mdt277; Abdel-Fatah TMA, 2010, J PATHOL, V222, P388, DOI 10.1002/path.2775; Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Ali HR, 2012, J PATHOL, V226, P97, DOI 10.1002/path.2976; Anderson MA, 2014, SEMIN HEMATOL, V51, P219, DOI 10.1053/j.seminhematol.2014.05.008; Anderson MA, 2013, BLOOD, V122; Baggstrom MQ, 2011, J THORAC ONCOL, V6, P1757, DOI 10.1097/JTO.0b013e31822e2941; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Binder C, 1995, ANN ONCOL, V6, P1005, DOI 10.1093/oxfordjournals.annonc.a059064; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bozovic-Spasojevic I, 2014, BREAST, V23, P473, DOI 10.1016/j.breast.2014.03.012; Bruncko M, 2015, J MED CHEM, V58, P2180, DOI 10.1021/jm501258m; Callagy GM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-153; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chang J, 2003, CANCER-AM CANCER SOC, V97, P545, DOI 10.1002/cncr.11083; Chen J, 2011, MOL CANCER THER, V10, P2340, DOI 10.1158/1535-7163.MCT-11-0415; Choi JE, 2014, TUMOR BIOL, V35, P12255, DOI 10.1007/s13277-014-2534-4; Cory AH, 2003, ADV ENZYME REGUL, V43, P29, DOI 10.1016/S0065-2571(02)00026-2; Crawford Anatasha, 2011, Current Pharmacogenomics & Personalized Medicine, V9, P184; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722; Dawson SJ, 2010, BRIT J CANCER, V103, P668, DOI 10.1038/sj.bjc.6605736; DelBufalo D, 1997, FASEB J, V11, P947, DOI 10.1096/fasebj.11.12.9337147; Elledge RM, 1997, J CLIN ONCOL, V15, P1916, DOI 10.1200/JCO.1997.15.5.1916; Ellis MJ, 2013, CANCER DISCOV, V3, P27, DOI 10.1158/2159-8290.CD-12-0462; Ermiah E, 2013, TUMOR BIOL, V34, P1569, DOI 10.1007/s13277-013-0687-1; Fang C, 2014, ACS MED CHEM LETT, V5, P1308, DOI 10.1021/ml500388q; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Freneaux P, 2000, BRIT J CANCER, V83, P1318, DOI 10.1054/bjoc.2000.1438; Friberg A, 2013, J MED CHEM, V56, P15, DOI 10.1021/jm301448p; Fu NY, 2015, NAT CELL BIOL, V17, P365, DOI 10.1038/ncb3117; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; Hwang KT, 2012, INT J CANCER, V131, pE1109, DOI 10.1002/ijc.27539; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; Jamerson MH, 2004, BRIT J CANCER, V91, P1372, DOI 10.1038/sj.bjc.6602137; JOENSUU H, 1994, AM J PATHOL, V145, P1191; Juin P, 2013, NAT REV CANCER, V13, P455, DOI 10.1038/nrc3538; Kelly GL, 2014, GENE DEV, V28, P58, DOI 10.1101/gad.232009.113; Kerr Daniel Alan II, 2011, Hormones & Cancer, V2, P261, DOI 10.1007/s12672-011-0080-8; Kim HS, 2012, J BREAST CANCER, V15, P401, DOI 10.4048/jbc.2012.15.4.401; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Kutuk O, 2008, CANCER RES, V68, P7985, DOI 10.1158/0008-5472.CAN-08-1418; Langer CJ, 2014, LUNG CANCER, V85, P420, DOI 10.1016/j.lungcan.2014.05.003; Larsen MS, 2012, ACTA ONCOL, V51, P781, DOI 10.3109/0284186X.2011.653009; Lessene G, 2013, NAT CHEM BIOL, V9, P390, DOI [10.1038/nchembio.1246, 10.1038/NCHEMBIO.1246]; Leverson JD, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.561; Leverson JD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4642; Li JY, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-102; Lindeman GJ, 2013, BREAST CANCER MANAG, V2, P1; Lipponen P, 1999, ENDOCR-RELAT CANCER, V6, P13, DOI 10.1677/erc.0.0060013; Madjd Zahra, 2009, Cancer Immun, V9, P4; Mailleux AA, 2007, DEV CELL, V12, P221, DOI 10.1016/j.devcel.2006.12.003; Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037; Merino D, 2015, ONCOGENE, V34, P3926, DOI 10.1038/onc.2014.313; Merino D, 2012, BLOOD, V119, P5807, DOI 10.1182/blood-2011-12-400929; Moldoveanu T, 2014, TRENDS BIOCHEM SCI, V39, P101, DOI 10.1016/j.tibs.2013.12.006; Moore VD, 2008, BLOOD, V111, P2300, DOI 10.1182/blood-2007-06-098012; Moulder SL, 2008, CLIN CANCER RES, V14, P7909, DOI 10.1158/1078-0432.CCR-08-1104; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Nemati F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0080836; Nielsen TO, 2010, CLIN CANCER RES, V16, P5222, DOI 10.1158/1078-0432.CCR-10-1282; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; Oakes SR, 2012, P NATL ACAD SCI USA, V109, P2766, DOI 10.1073/pnas.1104778108; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Perez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj.bjc.6600126; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Perry AM, 2014, BRIT J HAEMATOL, V165, P382, DOI 10.1111/bjh.12763; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Print CG, 1998, P NATL ACAD SCI USA, V95, P12424, DOI 10.1073/pnas.95.21.12424; Ready N, 2011, J THORAC ONCOL, V6, P781, DOI 10.1097/JTO.0b013e31820a0ea6; Roberts AW, 2012, J CLIN ONCOL, V30, P488, DOI 10.1200/JCO.2011.34.7898; Rolland P, 2007, INT J CANCER, V120, P1311, DOI 10.1002/ijc.22430; Rom J, 2009, ANN ONCOL, V20, P1829, DOI 10.1093/annonc/mdp208; Rooswinkel RW, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.109; Roy S, 2000, J EXP MED, V192, pF21, DOI 10.1084/jem.192.8.F21; Rucker EB, 2011, GENESIS, V49, P24, DOI 10.1002/dvg.20691; Schorr K, 1999, CANCER RES, V59, P2541; Seveno C, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3214; Seymour JF, 2013, BLOOD, V122, p429s; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; Sleebs BE, 2013, J MED CHEM, V56, P5514, DOI 10.1021/jm400556w; Smerage JB, 2013, MOL ONCOL, V7, P680, DOI 10.1016/j.molonc.2013.02.013; Sonpavde G, 2012, ANN ONCOL, V23, P1803, DOI 10.1093/annonc/mdr555; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Tanaka Y, 2013, J MED CHEM, V56, P9635, DOI 10.1021/jm401170c; Tao ZF, 2014, ACS MED CHEM LETT, V5, P1088, DOI 10.1021/ml5001867; Tawfik K, 2012, HUM PATHOL, V43, P23, DOI 10.1016/j.humpath.2011.04.011; Trere D, 2007, ANN ONCOL, V18, P1004, DOI 10.1093/annonc/mdm074; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Vaillant F, 2013, CANCER CELL, V24, P120, DOI 10.1016/j.ccr.2013.06.002; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Visco C, 2013, HAEMATOLOGICA, V98, P255, DOI 10.3324/haematol.2012.066209; Wagner KU, 2000, DEVELOPMENT, V127, P4949; Walton KD, 2001, MECH DEVELOP, V109, P281, DOI 10.1016/S0925-4773(01)00549-4; Wang YC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3067; Whittle JR, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0523-1; Williams MM, 2015, ONCOTARGET, V6, P3519, DOI 10.18632/oncotarget.2792; Wong CW, 2001, CANCER RES, V61, P333; Yin ST, 2012, APOPTOSIS, V17, P388, DOI 10.1007/s10495-011-0687-9; Zheng L, 2011, CANCER LETT, V309, P27, DOI 10.1016/j.canlet.2011.05.011	114	93	95	3	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1877	1887		10.1038/onc.2015.287	http://dx.doi.org/10.1038/onc.2015.287			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26257067				2023-01-03	WOS:000374010300001
J	Kaplan, GS				Kaplan, Gary S.			Health Care Scheduling and Access A Report From the IOM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Virginia Mason Hlth Syst, Seattle, WA 98101 USA	Virginia Mason Medical Center	Kaplan, GS (corresponding author), Virginia Mason Hlth Syst, 1100 Ninth Ave, Seattle, WA 98101 USA.	gary.kaplan@vmmc.org						Affairs V, 2014, INT REP REV PAT WAIT; Cima RR, 2011, J AM COLL SURGEONS, V213, P83, DOI 10.1016/j.jamcollsurg.2011.02.009; Gallucci G, 2005, PSYCHIAT SERV, V56, P344, DOI 10.1176/appi.ps.56.3.344; Hoffman KA, 2011, HEALTH INFORM J, V17, P256, DOI 10.1177/1460458211420090; Institute of Medicine, 2015, TRANSF HLTH CAR SCHE; Jack BW, 2009, ANN INTERN MED, V150, P178, DOI 10.7326/0003-4819-150-3-200902030-00007; Smart NA, 2011, AM J MED, V124, P1073, DOI 10.1016/j.amjmed.2011.04.026	7	14	14	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	2015	314	14					1449	1450		10.1001/jama.2015.9431	http://dx.doi.org/10.1001/jama.2015.9431			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT2QI	26226620				2023-01-03	WOS:000362647800008
J	Liu, XJ; Pu, Y; Cron, K; Deng, LF; Kline, J; Frazier, WA; Xu, HR; Peng, H; Fu, YX; Xu, MM				Liu, Xiaojuan; Pu, Yang; Cron, Kyle; Deng, Liufu; Kline, Justin; Frazier, William A.; Xu, Hairong; Peng, Hua; Fu, Yang-Xin; Xu, Meng Michelle			CD47 blockade triggers T cell-mediated destruction of immunogenic tumors	NATURE MEDICINE			English	Article							ALPHA SIRP-ALPHA; CYCLIC GMP-AMP; I INTERFERON; STEM-CELLS; INNATE; ANTIBODY; CANCER; CALRETICULIN; CLEARANCE; IMMUNITY	Macrophage phagocytosis of tumor cells mediated by CD47-specific blocking antibodies has been proposed to be the major effector mechanism in xenograft models. Here, using syngeneic immunocompetent mouse tumor models, we reveal that the therapeutic effects of CD47 blockade depend on dendritic cell but not macrophage cross-priming of T cell responses. The therapeutic effects of anti-CD47 antibody therapy were abrogated in T cell-deficient mice. In addition, the antitumor effects of CD47 blockade required expression of the cytosolic DNA sensor STING, but neither MyD88 nor TRIF, in CD11c(+) cells, suggesting that cytosolic sensing of DNA from tumor cells is enhanced by anti-CD47 treatment, further bridging the innate and adaptive responses. Notably, the timing of administration of standard chemotherapy markedly impacted the induction of antitumor T cell responses by CD47 blockade. Together, our findings indicate that CD47 blockade drives T cell-mediated elimination of immunogenic tumors.	[Liu, Xiaojuan; Xu, Hairong; Peng, Hua; Fu, Yang-Xin] Chinese Acad Sci, Inst Biophys, Key Lab Infect & Immun, Inst Biophys & Univ Chicago Joint Grp Immunothera, Beijing 100080, Peoples R China; [Liu, Xiaojuan] Univ Chinese Acad Sci, Beijing, Peoples R China; [Pu, Yang; Cron, Kyle; Deng, Liufu; Fu, Yang-Xin; Xu, Meng Michelle] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; [Pu, Yang; Cron, Kyle; Deng, Liufu; Kline, Justin; Fu, Yang-Xin; Xu, Meng Michelle] Univ Chicago, Comm Immunol, Chicago, IL 60637 USA; [Kline, Justin] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Frazier, William A.] Washington Univ, Dept Biochem & Mol Biophys, St Louis, MO USA	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; University of Chicago; University of Chicago; University of Chicago; Washington University (WUSTL)	Fu, YX (corresponding author), Chinese Acad Sci, Inst Biophys, Key Lab Infect & Immun, Inst Biophys & Univ Chicago Joint Grp Immunothera, Beijing 100080, Peoples R China.	yfu@uchicago.edu	Deng, Liufu/AAG-7244-2021	Deng, Liufu/0000-0002-1164-6777	US National Institutes of Health [CA141975, C134563]; National 12.5 major project of China [2012ZX10001006002004]; Chinese Academy of Sciences [XDA09030303, 2012CB910203]; Washington University; NATIONAL CANCER INSTITUTE [R01CA166770, R01CA134563, R01CA141975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007090] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National 12.5 major project of China; Chinese Academy of Sciences(Chinese Academy of Sciences); Washington University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank R. Schreiber (Washington University, St. Louis) for providing us with anti-IFNAR antibody. Ifnar1<SUP>fl/fl</SUP> mice were kindly provided by U. Kalinke from the Institute for Experimental Infection Research. Anti-IFN-gamma neutralizing mAb (clone R46A2) was provided by Z. Qin (the Institute of Biophysics, CAS). Some anti-CD47 antibody (clone MIAP301) was provided by W. Frazier (Washington University, St. Louis). This research was in part supported by US National Institutes of Health grants CA141975 and C134563 to Y.-X.F., the National 12.5 major project of China (No. 2012ZX10001006002004) to Y.-X.F. and H.P., Chinese Academy of Sciences grant XDA09030303 and 2012CB910203 to Y.-X.F. and a Dean's Award from Washington University to W.A.F.	Barclay AN, 2014, ANNU REV IMMUNOL, V32, P25, DOI 10.1146/annurev-immunol-032713-120142; Blazar BR, 2001, J EXP MED, V194, P541, DOI 10.1084/jem.194.4.541; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Burnette BC, 2011, CANCER RES, V71, P2488, DOI 10.1158/0008-5472.CAN-10-2820; Chan KS, 2010, CURR OPIN UROL, V20, P393, DOI 10.1097/MOU.0b013e32833cc9df; Chan KS, 2009, P NATL ACAD SCI USA, V106, P14016, DOI 10.1073/pnas.0906549106; Chao MP, 2012, NAT REV CANCER, V12, P58, DOI 10.1038/nrc3171; Chao MP, 2011, BLOOD, V118, P4890, DOI 10.1182/blood-2011-02-338020; Chao MP, 2011, CANCER RES, V71, P1374, DOI 10.1158/0008-5472.CAN-10-2238; Chao MP, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001375; Chao MP, 2010, CELL, V142, P699, DOI 10.1016/j.cell.2010.07.044; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Danielsen JMR, 2007, BRIT J HAEMATOL, V138, P756, DOI 10.1111/j.1365-2141.2007.06729.x; Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019; Desmet CJ, 2012, NAT REV IMMUNOL, V12, P479, DOI 10.1038/nri3247; Diamond MS, 2011, J EXP MED, V208, P1989, DOI 10.1084/jem.20101158; Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; Jaiswal S, 2009, CELL, V138, P271, DOI 10.1016/j.cell.2009.05.046; Kono H, 2008, NAT REV IMMUNOL, V8, P279, DOI 10.1038/nri2215; Lee YJ, 2009, BLOOD, V114, P589, DOI 10.1182/blood-2009-02-206870; Li XD, 2013, SCIENCE, V341, P1390, DOI 10.1126/science.1244040; Ma YT, 2014, CANCER RES, V74, P436, DOI 10.1158/0008-5472.CAN-13-1265; Ma Y, 2013, IMMUNITY, V38, P729, DOI 10.1016/j.immuni.2013.03.003; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755; O'Neill LAJ, 2013, NAT REV IMMUNOL, V13, P453, DOI 10.1038/nri3446; Obeid M, 2007, IMMUNOL REV, V220, P22, DOI 10.1111/j.1600-065X.2007.00567.x; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Oldenborg PA, 2001, J EXP MED, V193, P855, DOI 10.1084/jem.193.7.855; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Olsson M, 2005, BLOOD, V105, P3577, DOI 10.1182/blood-2004-08-2980; POELS LG, 1986, JNCI-J NATL CANCER I, V76, P781; Rovero S, 2000, J IMMUNOL, V165, P5133, DOI 10.4049/jimmunol.165.9.5133; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Soto-Pantoja DR, 2014, CANCER RES, V74, P6771, DOI 10.1158/0008-5472.CAN-14-0037-T; Stagg J, 2011, P NATL ACAD SCI USA, V108, P7142, DOI 10.1073/pnas.1016569108; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Takenaka K, 2007, NAT IMMUNOL, V8, P1313, DOI 10.1038/ni1527; Tsai RK, 2008, J CELL BIOL, V180, P989, DOI 10.1083/jcb.200708043; Tseng D, 2013, P NATL ACAD SCI USA, V110, P11103, DOI 10.1073/pnas.1305569110; Weiskopf K, 2013, SCIENCE, V341, P88, DOI 10.1126/science.1238856; Willingham SB, 2012, P NATL ACAD SCI USA, V109, P6662, DOI 10.1073/pnas.1121623109; Woo SR, 2014, IMMUNITY, V41, P830, DOI 10.1016/j.immuni.2014.10.017; Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963; Yamao T, 2002, J BIOL CHEM, V277, P39833, DOI 10.1074/jbc.M203287200; Yamauchi T, 2013, BLOOD, V121, P1316, DOI 10.1182/blood-2012-06-440354; Yang XM, 2014, CANCER CELL, V25, P37, DOI 10.1016/j.ccr.2013.12.004	50	425	451	6	156	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2015	21	10					1209	+		10.1038/nm.3931	http://dx.doi.org/10.1038/nm.3931			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	CS8RG	26322579	Green Accepted			2023-01-03	WOS:000362355400023
J	Barron, EV; Roman-Bassaure, E; Sanchez-Sandoval, AL; Espinosa, AM; Guardado-Estrada, M; Medina, I; Juarez, E; Alfaro, A; Bermudez, M; Zamora, R; Garcia-Ruiz, C; Gomora, JC; Kofman, S; Perez-Armendariz, EM; Berumen, J				Valeria Barron, Eira; Roman-Bassaure, Edgar; Laura Sanchez-Sandoval, Ana; Maria Espinosa, Ana; Guardado-Estrada, Mariano; Medina, Ingrid; Juarez, Eligia; Alfaro, Ana; Bermudez, Miriam; Zamora, Ruben; Garcia-Ruiz, Carlos; Carlos Gomora, Juan; Kofman, Susana; Martha Perez-Armendariz, E.; Berumen, Jaime			CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer	PLOS ONE			English	Article							HUMAN-PAPILLOMAVIRUS; PROTEIN PHOSPHATASE; HEPATOCELLULAR-CARCINOMA; NEOADJUVANT CHEMOTHERAPY; CELL-PROLIFERATION; AMPLIFICATION; QUADRIVALENT; INHIBITION; VACCINE; GENE	The cyclin-dependent kinase inhibitor 3 (CDKN3) gene, involved in mitosis, is upregulated in cervical cancer (CC). We investigated CDKN3 mRNA as a survival biomarker and potential therapeutic target for CC. CDKN3 mRNA was measured in 134 CC and 25 controls by quantitative PCR. A 5-year survival study was conducted in 121 of these CC patients. Furthermore, CDKN3-specific siRNAs were used to investigate whether CDKN3 is involved in proliferation, migration, and invasion in CC-derived cell lines (SiHa, CaSki, HeLa). CDKN3 mRNA was on average 6.4-fold higher in tumors than in controls (p = 8 x 10(-6), Mann-Whitney). A total of 68.2% of CC patients over expressing CDKN3 gene (fold change >= 17) died within two years of diagnosis, independent of the clinical stage and HPV type (Hazard Ratio = 5.0, 95% CI: 2.5-10, p = 3.3 x 10(-6), Cox proportional-hazards regression). In contrast, only 19.2% of the patients with lower CDKN3 expression died in the same period. In vitro inactivation of CDKN3 decreased cell proliferation on average 67%, although it had no effect on cell migration and invasion. CDKN3 mRNA may be a good survival biomarker and potential therapeutic target in CC.	[Valeria Barron, Eira; Maria Espinosa, Ana; Guardado-Estrada, Mariano; Medina, Ingrid; Juarez, Eligia; Alfaro, Ana; Bermudez, Miriam; Garcia-Ruiz, Carlos; Berumen, Jaime] Univ Nacl Autonoma Mexico, Hosp Gen Mexico, Fac Med, Unidad Med Genom, Mexico City 04510, DF, Mexico; [Valeria Barron, Eira; Martha Perez-Armendariz, E.; Berumen, Jaime] Univ Nacl Autonoma Mexico, Dept Med Expt, Fac Med, Mexico City 04510, DF, Mexico; [Roman-Bassaure, Edgar] Hosp Gen Mexico City, Serv Oncol, Mexico City, DF, Mexico; [Laura Sanchez-Sandoval, Ana; Carlos Gomora, Juan] Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Div Neurociencias, Dept Neuropatol Mol, Mexico City 04510, DF, Mexico; [Zamora, Ruben] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Inmunol, Mexico City 04510, DF, Mexico; [Zamora, Ruben] Mexico Hosp Dr Luis Sanchez Bulnes, Asociac Evitar Ceguera, Lab Biol Mol, Mexico City, DF, Mexico; [Kofman, Susana] Univ Nacl Autonoma Mexico, Hosp Gen Mexico, Fac Med, Serv Genet, Mexico City 04510, DF, Mexico	Hospital General de Mexico; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; Hospital General de Mexico; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; Hospital General de Mexico; Universidad Nacional Autonoma de Mexico	Berumen, J (corresponding author), Univ Nacl Autonoma Mexico, Hosp Gen Mexico, Fac Med, Unidad Med Genom, Mexico City 04510, DF, Mexico.	jaimeberumen@hotmail.com	Sanchez-Sandoval, Ana Laura/GPK-6264-2022; Berumen, Jaime/AAL-5577-2020; Berumen, Jaime/F-7914-2018	Sanchez-Sandoval, Ana Laura/0000-0002-9478-4779; Berumen, Jaime/0000-0001-6707-3317; Berumen, Jaime/0000-0001-6707-3317; ESPINOSA GARCIA, ANA MARIA/0000-0003-3255-4051; Gomora, Juan Carlos/0000-0002-9871-1307; Barron, Eira Valeria/0000-0001-7901-4947	National Council of Science and Technology (CONACYT) [8135/A1, 24341]; National University of Mexico [SDI.PTID.05.2]; National Council of Science and Technology (CONACYT), scholarship	National Council of Science and Technology (CONACYT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); National University of Mexico; National Council of Science and Technology (CONACYT), scholarship	This work was supported by the National Council of Science and Technology (CONACYT, www.conacyt.mx), grant numbers 8135/A1, 24341 (to JB), National University of Mexico (www.unam.mx), grant number SDI.PTID.05.2 (to JB), and National Council of Science and Technology (CONACYT, www.conacyt.mx), scholarship (to EVB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrae B, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e900; Berumen J, 2014, EXPERT OPIN THER TAR, V18, P1149, DOI 10.1517/14728222.2014.941808; Bruni L, ICO INFORM CTR HPV C; Bryant C, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-147; Cao TW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103793; Chen QH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111611; Chhavi, 2010, J CANCER RES THER, V6, P167, DOI 10.4103/0973-1482.65242; Crosbie EJ, 2013, LANCET, V382, P889, DOI 10.1016/S0140-6736(13)60022-7; Cuzick J, 2010, GYNECOL ONCOL, V117, pS11, DOI 10.1016/j.ygyno.2010.01.025; Feng MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108502; Ferlay J., 2013, IARC CANCERBASE, V11; Gavrilov Kseniya, 2012, Yale Journal of Biology and Medicine, V85, P187; Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357; Guardado-Estrada M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109406; Guardado-Estrada M, 2012, J HUM GENET, V57, P269, DOI 10.1038/jhg.2012.17; Hu Q, 2014, INT J CLIN EXP PATHO, V7, P5057; Hunter KD, 2006, CANCER RES, V66, P7405, DOI 10.1158/0008-5472.CAN-06-0186; Hwang SJ, 2012, J ONCOL, V2012, DOI 10.1155/2012/507286; Jackson MW, 2014, ONCOTARGETS THER, V7, P751, DOI 10.2147/OTT.S49429; Kjaer SK, 2009, CANCER PREV RES, V2, P868, DOI 10.1158/1940-6207.CAPR-09-0031; Knight ZA, 2010, NAT REV CANCER, V10, P130, DOI 10.1038/nrc2787; Lai MW, 2012, UROL ONCOL-SEMIN ORI, V30, P871, DOI 10.1016/j.urolonc.2010.09.010; Lee JW, 2012, EURASIP J IMAGE VIDE, DOI 10.1186/1687-5281-2012-7; Lee SW, 2000, MOL CELL BIOL, V20, P1723, DOI 10.1128/MCB.20.5.1723-1732.2000; Lehtinen M, 2012, LANCET ONCOL, V13, P89, DOI 10.1016/S1470-2045(11)70286-8; Li TR, 2014, ONCOL REP, V31, P1825, DOI 10.3892/or.2014.3045; Lin WR, 2013, ONCOL REP, V29, P903, DOI 10.3892/or.2012.2208; Liu L, 2014, INT J NANOMED, V9, P3509, DOI 10.2147/IJN.S63717; MacDermed DM, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-16; Espinosa AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055975; Markowitz Lauri E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Mathew M, 2013, APOPTOSIS, V18, P882, DOI 10.1007/s10495-013-0840-8; McCormack M, 2013, BRIT J CANCER, V108, P2464, DOI 10.1038/bjc.2013.230; Medina-Martinez I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097842; Nalepa G, 2013, J CELL BIOL, V201, P997, DOI 10.1083/jcb.201205125; Natunen Kari, 2011, Infect Dis Obstet Gynecol, V2011, P675858, DOI 10.1155/2011/675858; Nogueira-Rodrigues A, 2014, CANCER-AM CANCER SOC, V120, P1187, DOI 10.1002/cncr.28471; Pappano WN, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-430; Pecorelli S, 2009, INT J GYNECOL OBSTET, V105, P103, DOI 10.1016/j.ijgo.2009.02.012; Phillips GDL, 2008, CANCER RES, V68, P9280, DOI 10.1158/0008-5472.CAN-08-1776; Romanowski B, 2011, HUM VACCINES, V7, P161, DOI 10.4161/hv.7.2.13690; Santin AD, 2005, VIROLOGY, V331, P269, DOI 10.1016/j.virol.2004.09.045; Saxena R, 2012, MED RES REV, V32, P166, DOI 10.1002/med.20209; Schiffman M, 2011, JNCI-J NATL CANCER I, V103, P368, DOI 10.1093/jnci/djq562; Schimmack S, 2014, EPIGENET CHROMATIN, V7, DOI 10.1186/1756-8935-7-15; Schmitt M, 2008, J CLIN MICROBIOL, V46, P1050, DOI 10.1128/JCM.02227-07; Shen SN, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-69; Singh RB, 2013, GYNECOL ONCOL, V129, P124, DOI 10.1016/j.ygyno.2013.01.011; Suh DH, 2014, J GYNECOL ONCOL, V25, P236, DOI 10.3802/jgo.2014.25.3.236; Thierry-Mieg D, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-s1-s12; Torti D, 2011, EMBO MOL MED, V3, P623, DOI 10.1002/emmm.201100176; Tsai CJ, 2013, GYNECOL ONCOL, V131, P645, DOI 10.1016/j.ygyno.2013.04.056; Van de Velde N, 2012, JNCI-J NATL CANCER I, V104, P1712, DOI 10.1093/jnci/djs395; Wan HY, 2014, CANCER LETT, V355, P148, DOI 10.1016/j.canlet.2014.09.005; Weaver BA, 2014, MOL BIOL CELL, V25, P2677, DOI 10.1091/mbc.E14-04-0916; Wen XX, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0092-7; Wu Z, 2013, INT J GYNECOL CANCER, V23, P906, DOI 10.1097/IGC.0b013e318292da82; Xing CY, 2012, BIOCHEM BIOPH RES CO, V420, P29, DOI 10.1016/j.bbrc.2012.02.107; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309; Yeh CT, 2000, CANCER RES, V60, P4697; Yeh CT, 2003, BIOCHEM BIOPH RES CO, V305, P311, DOI 10.1016/S0006-291X(03)00757-5; YOSHIKAWA H, 1991, JPN J CANCER RES, V82, P524, DOI 10.1111/j.1349-7006.1991.tb01882.x; Yu Y, 2007, CANCER RES, V67, P130, DOI 10.1158/0008-5472.CAN-06-2478; Yu Y, 2014, CARCINOGENESIS, V35, P1416, DOI 10.1093/carcin/bgu065	64	22	22	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2015	10	9							e0137397	10.1371/journal.pone.0137397	http://dx.doi.org/10.1371/journal.pone.0137397			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR8LR	26372210	Green Published, Green Submitted, gold			2023-01-03	WOS:000361604400020
J	Schick, MA; Baar, W; Bruno, RR; Wollborn, J; Held, C; Schneider, R; Flemming, S; Schlegel, N; Roewer, N; Neuhaus, W; Wunder, C				Schick, Martin Alexander; Baar, Wolfgang; Bruno, Raphael Romano; Wollborn, Jakob; Held, Christopher; Schneider, Reinhard; Flemming, Sven; Schlegel, Nicolas; Roewer, Norbert; Neuhaus, Winfried; Wunder, Christian			Balanced Hydroxyethylstarch (HES 130/0.4) Impairs Kidney Function In-Vivo without Inflammation	PLOS ONE			English	Article							ACUTE-RENAL-FAILURE; SEVERE SEPSIS; FLUID RESUSCITATION; INTENSIVE-CARE; STARCH; THERAPY; CRYSTALLOIDS; COLLOIDS; SAFETY; REPLACEMENT	Volume therapy is a standard procedure in daily perioperative care, and there is an ongoing discussion about the benefits of colloid resuscitation with hydroxyethylstarch (HES). In sepsis HES should be avoided due to a higher risk for acute kidney injury (AKI). Results of the usage of HES in patients without sepsis are controversial. Therefore we conducted an animal study to evaluate the impact of 6% HES 130/0.4 on kidney integrity with sepsis or under healthy conditions Sepsis was induced by standardized Colon Ascendens Stent Peritonitis (sCASP). sCASP-group as well as control group (C) remained untreated for 24 h. After 18 h sCASP+HES group (sCASP+VOL) and control+HES (C+VOL) received 50 ml/KG balanced 6% HES (VOL) 130/0.4 over 6h. After 24h kidney function was measured via Inulin- and PAH-Clearance in re-anesthetized rats, and serum urea, creatinine (crea), cystatin C and Neutrophil gelatinase-associated lipocalin (NGAL) as well as histopathology were analysed. In vitro human proximal tubule cells (PTC) were cultured +/- lipopolysaccharid (LPS) and with 0.1-4.0% VOL. Cell viability was measured with XTT-, cell toxicity with LDH-test. sCASP induced severe septic AKI demonstrated divergent results regarding renal function by clearance or creatinine measure focusing on VOL. Soleley HES (C+VOL) deteriorated renal function without sCASP. Histopathology revealed significantly derangements in all HES groups compared to control. In vitro LPS did not worsen the HES induced reduction of cell viability in PTC cells. For the first time, we demonstrated, that application of 50 ml/KG 6% HES 130/0.4 over 6 hours induced AKI without inflammation in vivo. Severity of sCASP induced septic AKI might be no longer susceptible to the way of volume expansion.	[Schick, Martin Alexander; Baar, Wolfgang; Bruno, Raphael Romano; Wollborn, Jakob; Roewer, Norbert; Neuhaus, Winfried; Wunder, Christian] Univ Hosp Wurzburg, Inst Anaesthesia & Crit Care, Wurzburg, Germany; [Baar, Wolfgang; Wollborn, Jakob] Univ Med Ctr Freiburg, Dept Anesthesiol & Intens Care Med, Freiburg, Germany; [Neuhaus, Winfried] Univ Vienna, Dept Med Chem, Vienna, Austria; [Held, Christopher; Schneider, Reinhard] Univ Hosp Wurzburg, Dept Internal Med 1, Wurzburg, Germany; [Flemming, Sven; Schlegel, Nicolas] Univ Wurzburg, Dept Gen Visceral Vasc & Paediat Surg, Dept Surg 1, D-97070 Wurzburg, Germany; [Neuhaus, Winfried] Med Univ Vienna, Inst Med Genet, Vienna, Austria	University of Wurzburg; University of Freiburg; University of Vienna; University of Wurzburg; University of Wurzburg; Medical University of Vienna	Schick, MA (corresponding author), Univ Hosp Wurzburg, Inst Anaesthesia & Crit Care, Wurzburg, Germany.	schick_m@ukw.de	Schick, Martin/ABH-6971-2020; Flemming, Sven/AAA-9950-2020	Flemming, Sven/0000-0002-6304-3169; Bruno, Raphael Romano/0000-0003-3776-3530; Neuhaus, Winfried/0000-0002-6552-7183	German Research Foundation (DFG); University of Wuerzburg	German Research Foundation (DFG)(German Research Foundation (DFG)); University of Wuerzburg	This publication was funded by the German Research Foundation (DFG) and the University of Wuerzburg in the funding programme Open Access Publishing.	Adamson RH, 2004, J PHYSIOL-LONDON, V557, P889, DOI 10.1113/jphysiol.2003.058255; Annane D, 2013, JAMA-J AM MED ASSOC, V310, P1809, DOI 10.1001/jama.2013.280502; Bayer O, 2012, CRIT CARE MED, V40, P2543, DOI 10.1097/CCM.0b013e318258fee7; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Bruno RR, 2014, ANESTH ANALG, V119, P570, DOI 10.1213/ANE.0000000000000325; Chen N, 2006, PEDIATR NEPHROL, V21, P160, DOI 10.1007/s00467-005-2105-4; Corrigan G, 1999, AM J PHYSIOL-RENAL, V277, pF312, DOI 10.1152/ajprenal.1999.277.2.F312; Flemming S, 2014, SHOCK, V41, P537, DOI 10.1097/SHK.0000000000000152; Guidet B, 2012, CRIT CARE, V16, DOI 10.1186/cc11358; Irwin MG, 2014, ANESTH ANALG, V119, P737, DOI 10.1213/ANE.0000000000000221; Li LX, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0815-y; Myburgh JA, 2012, NEW ENGL J MED, V367, P1901, DOI 10.1056/NEJMoa1209759; Neuhaus W, 2012, ANESTH ANALG, V114, P371, DOI 10.1213/ANE.0b013e3182367a54; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; Raghunathan K, 2014, ANESTH ANALG, V119, P731, DOI 10.1213/ANE.0000000000000186; Schick MA BW, 2014, INTENSIVE CARE MED E, V2; Schick MA, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-179; Schick MA, 2012, J PHYSIOL-LONDON, V590, P2693, DOI 10.1113/jphysiol.2012.232116; Schick MA, 2010, INTENS CARE MED, V36, P541, DOI 10.1007/s00134-009-1704-0; Schneider R, 2007, AM J PHYSIOL-RENAL, V292, pF1599, DOI 10.1152/ajprenal.00473.2006; Starling E H, 1896, J Physiol, V19, P312; Stumpner J, 2012, ACTA ANAESTH SCAND, V56, P904, DOI 10.1111/j.1399-6576.2012.02657.x; Van der Linden P, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0830-z; Weiskopf RB, 2014, ANESTH ANALG, V119, P509, DOI 10.1213/ANE.0000000000000323; Witt L, 2014, PEDIATR ANESTH, V24, P974, DOI 10.1111/pan.12445; Woodcock TE, 2012, BRIT J ANAESTH, V108, P384, DOI 10.1093/bja/aer515; Xu C, 2014, KIDNEY INT, V85, P72, DOI 10.1038/ki.2013.286	27	12	12	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2015	10	9							e0137247	10.1371/journal.pone.0137247	http://dx.doi.org/10.1371/journal.pone.0137247			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ6BA	26340751	Green Submitted, Green Published, gold			2023-01-03	WOS:000360688200040
J	McCartney, M				McCartney, Margaret			Margaret McCartney: Blaming doctors won't reduce antibiotic overuse	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Brookes-Howell L, 2014, FAM PRACT, V31, P102, DOI 10.1093/fampra/cmt052; Meikle J, 2015, GUARDIAN; National Institute for Health and Care Excellence, 2015, CALLS NHS CURB ANT P; NHS Choices, FEEL WEATH	4	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 1	2015	351								h4697	10.1136/bmj.h4697	http://dx.doi.org/10.1136/bmj.h4697			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CQ9JQ	26330400	Bronze			2023-01-03	WOS:000360931100012
J	Brooke, BS; Goodney, PP; Kraiss, LW; Gottlieb, DJ; Samore, MH; Finlayson, SRG				Brooke, Benjamin S.; Goodney, Philip P.; Kraiss, Larry W.; Gottlieb, Daniel J.; Samore, Matthew H.; Finlayson, Samuel R. G.			Readmission destination and risk of mortality after major surgery: an observational cohort study	LANCET			English	Article							AORTIC-ANEURYSM REPAIR; SURGICAL-PROCEDURES; INPATIENT SURGERY; PROPENSITY SCORE; CARE; VOLUME; CONTINUITY; QUALITY	Background Hospital readmissions are common after major surgery, although it is unknown whether patients achieve improved outcomes when they are readmitted to, and receive care at, the index hospital where their surgical procedure was done. We examined the association between readmission destination and mortality risk in the USA in Medicare beneficiaries after a range of common operations. Methods By use of claims data from Medicare beneficiaries in the USA between Jan 1, 2001, and Nov 15, 2011, we assessed patients who needed hospital readmission within 30 days after open abdominal aortic aneurysm repair, infrainguinal arterial bypass, aortobifemoral bypass, coronary artery bypass surgery, oesophagectomy, colectomy, pancreatectomy, cholecystectomy, ventral hernia repair, craniotomy, hip replacement, or knee replacement. We used logistic regression models incorporating inverse probability weighting and instrumental variable analysis to measure associations between readmission destination (index vs non-index hospital) and risk of 90 day mortality for patients who underwent surgery who needed hospital readmission. Findings 9 440 503 patients underwent one of 12 major operations, and the number of patients readmitted or transferred back to the index hospital where their operation was done varied from 186 336 (65.8%) of 283 131 patients who were readmitted after coronary artery bypass grafting, to 142 142 (83.2%) of 170 789 patients who were readmitted after colectomy. Readmission was more likely to be to the index hospital than to a non-index hospital if the readmission was for a surgical complication (189 384 [23%] of 834 070 patients readmitted to index hospital vs 36 792 [13%] of 276 976 patients readmitted non-index hospital, p<0.0001). Readmission to the index hospital was associated with a 26% lower risk of 90 day mortality than was readmission to a non-index hospital, with inverse probability weighting used to control for selection bias (odds ratio [OR] 0.74, 95% CI 0.66-0.83). This effect was significant (p<0.0001) for all procedures in inverse probability-weighted models, and was largest for patients who were readmitted after pancreatectomy (OR 0.56, 95% CI 0.45-0.69) and aortobifemoral bypass (OR 0.69, 95% CI 0.61-0.77). By use of hospital-level variation among regional index hospital readmission rates as an instrument, instrumental variable analysis showed that the patients with the highest probability of returning to the index hospital had 8% lower risk of mortality (OR 0.92 95% CI 0.91-0.94) than did patients who were less likely to be readmitted to the index hospital. Interpretation In the USA, patients who are readmitted to hospital after various major operations consistently achieve improved survival if they return to the hospital where their surgery took place. These findings might have important implications for cost-effectiveness-driven regional centralisation of surgical care.	[Brooke, Benjamin S.; Kraiss, Larry W.; Finlayson, Samuel R. G.] Univ Utah, Dept Surg, Sch Med, Salt Lake City, UT 84132 USA; [Samore, Matthew H.] Univ Utah, Div Epidemiol, Sch Med, Salt Lake City, UT 84132 USA; [Brooke, Benjamin S.; Samore, Matthew H.] VA Salt Lake City Hlth Care Syst, IDEAS Ctr, Salt Lake City, UT USA; [Goodney, Philip P.] Dartmouth Hitchcock Med Ctr, Vasc Surg Sect, Lebanon, NH 03766 USA; [Gottlieb, Daniel J.] Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Dartmouth College; Dartmouth College	Brooke, BS (corresponding author), Univ Utah, Dept Surg, Sch Med, Salt Lake City, UT 84132 USA.	benjamin.brooke@hsc.utah.edu			National Heart Lung and Blood Institute [K08 HL05676]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R21HS021581] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL105676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG046830] Funding Source: NIH RePORTER	National Heart Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was funded by BSB and SRGF. PPG was supported by a Career Development Award (K08 HL05676) from the National Heart Lung and Blood Institute.	Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786; Begg CB, 1998, JAMA-J AM MED ASSOC, V280, P1747, DOI 10.1001/jama.280.20.1747; Birkmeyer JD, 2004, J AM COLL SURGEONS, V198, P626, DOI 10.1016/j.jamcollsurg.2003.11.017; Brooke BS, 2014, JAMA SURG, V149, P821, DOI 10.1001/jamasurg.2014.157; Centers for Medicare and Medicaid Services, READM RED PROGR; Centers for Medicare and Medicaid Services, MED APPR FAC; Deloitte Center for Health Solutions, MED TOUR CONS SEARCH; Fontanarosa PB, 2013, JAMA-J AM MED ASSOC, V309, P398, DOI 10.1001/jama.2013.42; Fry DE, 2014, AM J SURG, V207, P326, DOI 10.1016/j.amjsurg.2013.09.007; Ghaferi AA, 2009, ANN SURG, V250, P1029, DOI 10.1097/SLA.0b013e3181bef697; Ghaferi AA, 2009, NEW ENGL J MED, V361, P1368, DOI 10.1056/NEJMsa0903048; Greenblatt DY, 2012, ANN SURG, V256, P595, DOI 10.1097/SLA.0b013e31826b4bfe; Greenblatt DY, 2010, ANN SURG, V251, P659, DOI 10.1097/SLA.0b013e3181d3d27c; Hall MH, 2014, ANN THORAC SURG, V97, P1488, DOI 10.1016/j.athoracsur.2013.12.049; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; Hollenbeck BK, 2005, NAT CLIN PRACT UROL, V2, P461, DOI 10.1038/ncpuro0322; Hussey PS, 2014, JAMA INTERN MED, V174, P742, DOI 10.1001/jamainternmed.2014.245; Ingraham Angela M, 2010, Adv Surg, V44, P251; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; Nyweide DJ, 2013, JAMA INTERN MED, V173, P1879, DOI 10.1001/jamainternmed.2013.10059; Radley DC, 2008, J CLIN EPIDEMIOL, V61, P580, DOI 10.1016/j.jclinepi.2007.08.001; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; Santry Charlotte, 2011, Health Serv J, V121, P13; Saultz John W, 2003, Ann Fam Med, V1, P134, DOI 10.1370/afm.23; Saunders RS, 2014, J VASC SURG, V59, P1502, DOI 10.1016/j.jvs.2013.12.015; Stukel TA, 2007, JAMA-J AM MED ASSOC, V297, P278, DOI 10.1001/jama.297.3.278; Tsai TC, 2015, JAMA SURG, V150, P59, DOI 10.1001/jamasurg.2014.2071; Tsai TC, 2013, NEW ENGL J MED, V369, P1134, DOI 10.1056/NEJMsa1303118; Wal-Mart McKenzie K., 2014, LOWES USE CORPORATE	30	118	118	0	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 29	2015	386	9996					884	895		10.1016/S0140-6736(15)60087-3	http://dx.doi.org/10.1016/S0140-6736(15)60087-3			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CQ0MJ	26093917	Green Accepted			2023-01-03	WOS:000360290000032
J	Lewis, M; Chesterton, LS; Sim, J; Mallen, CD; Hay, EM; van der Windt, DA				Lewis, Martyn; Chesterton, Linda S.; Sim, Julius; Mallen, Christian D.; Hay, Elaine M.; van der Windt, Danielle A.			An Economic Evaluation of TENS in Addition to Usual Primary Care Management for the Treatment of Tennis Elbow: Results from the TATE Randomized Controlled Trial	PLOS ONE			English	Article							ELECTRICAL NERVE-STIMULATION; PREFERENCE-BASED MEASURE; COST-EFFECTIVENESS; CORTICOSTEROID INJECTIONS; LATERAL EPICONDYLITIS; PHYSIOTHERAPY; HEALTH; PREVALENCE; PAIN	Background The TATE trial was a multicentre pragmatic randomized controlled trial of supplementing primary care management (PCM)-consisting of a GP consultation followed by information and advice on exercises-with transcutaneous electrical nerve stimulation (TENS), to reduce pain intensity in patients with tennis elbow. This paper reports the health economic evaluation. Methods and Findings Adults with new diagnosis of tennis elbow were recruited from 38 general practices in the UK, and randomly allocated to PCM (n = 120) or PCM plus TENS (n = 121). Outcomes included reduction in pain intensity and quality-adjusted-life-years (QALYs) based on the EQ5D and SF6D. Two economic perspectives were evaluated: (i) healthcare-inclusive of NHS and private health costs for the tennis elbow; (ii) societal-healthcare costs plus productivity losses through work absenteeism. Mean outcome and cost differences between the groups were evaluated using a multiple imputed dataset as the base case evaluation, with uncertainty represented in cost-effectiveness planes and through probabilistic cost-effectiveness acceptability curves). Incremental healthcare cost was 33 pound (95% CI -40, 106) and societal cost 65 pound (95% CI -307, 176) for PCM plus TENS. Mean differences in outcome were: 0.11 (95% CI -0.13, 0.35) for change in pain (0-10 pain scale); -0.015 (95% CI -0.058, 0.029) for QALY(EQ5D); 0.007 (95% CI -0.022, 0.035) for QALY(SF6D) (higher score differences denote greater benefit for PCM plus TENS). The ICER (incremental cost effectiveness ratio) for the main evaluation of mean difference in societal cost () pound relative to mean difference in pain outcome was -582 (95% CI -8666, 8113). However, incremental ICERs show differences in cost-effectiveness of additional TENS, according to the outcome being evaluated. Conclusion Our findings do not provide evidence for or against the cost-effectiveness of TENS as an adjunct to primary care management of tennis elbow.	[Lewis, Martyn; Chesterton, Linda S.; Sim, Julius; Mallen, Christian D.; Hay, Elaine M.; van der Windt, Danielle A.] Keele Univ, Arthrit Res UK Primary Care Ctr, Inst Primary Care & Hlth Sci, Keele ST5 5BG, Staffs, England	Keele University	Lewis, M (corresponding author), Keele Univ, Arthrit Res UK Primary Care Ctr, Inst Primary Care & Hlth Sci, Keele ST5 5BG, Staffs, England.	a.m.lewis@keele.ac.uk			National Institute for Health Research (NIHR) under the Research for Patient Benefit Programme [PB-PG-0407-13189]; Arthritis Research UK clinician scientist award; Arthritis Research UK Primary Care Centre of Excellence [20202]; National Institute for Health Research [NF-SI-0611-10078, PB-PG-0407-13189] Funding Source: researchfish; Versus Arthritis [19634] Funding Source: researchfish	National Institute for Health Research (NIHR) under the Research for Patient Benefit Programme(National Institute for Health Research (NIHR)); Arthritis Research UK clinician scientist award(Versus Arthritis); Arthritis Research UK Primary Care Centre of Excellence(Versus Arthritis); National Institute for Health Research(National Institute for Health Research (NIHR)); Versus Arthritis(Versus Arthritis)	This paper presents independent research funded by the National Institute for Health Research (NIHR) under the Research for Patient Benefit Programme (grant reference No PB-PG-0407-13189). CDM is supported by an Arthritis Research UK clinician scientist award. EMH is an NIHR senior investigator. The Institute for Primary Care and Health Sciences at Keele has been awarded the Arthritis Research UK Primary Care Centre of Excellence (grant No 20202). The NIHR had no role in the conduct of the study, collection, management, analysis, and interpretation of the data, or preparation and review of the manuscript. The conclusions and views expressed in this article are those of the authors and not necessarily those of the NHS, NIHR, or Department of Health.	ALLANDER E, 1974, SCAND J RHEUMATOL, V3, P145, DOI 10.3109/03009747409097141; Bisset L, 2006, BMJ-BRIT MED J, V333, P939, DOI 10.1136/bmj.38961.584653.AE; Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8; Brazier JE, 2004, MED CARE, V42, P851, DOI 10.1097/01.mlr.0000135827.18610.0d; Chesterton LS, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5160; Chesterton LS, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-156; Coombes BK, 2010, LANCET, V376, P1751, DOI 10.1016/S0140-6736(10)61160-9; Curtis L, 2015, UNIT COSTS HLTH SOCI; Dolan P, 1996, HEALTH ECON, V5, P141, DOI 10.1002/(SICI)1099-1050(199603)5:2<141::AID-HEC189>3.0.CO;2-N; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; Fenwick E, 2004, HEALTH ECON, V13, P405, DOI 10.1002/hec.903; Fenwick E, 2001, HEALTH ECON, V10, P779, DOI 10.1002/hec.635; Gabel Gerard T., 1999, Current Opinion in Rheumatology, V11, P138, DOI 10.1097/00002281-199903000-00010; HAMILTON PG, 1986, J ROY COLL GEN PRACT, V36, P464; Hay EM, 1999, BRIT MED J, V319, P964, DOI 10.1136/bmj.319.7215.964; Jack K, 2010, MANUAL THER, V15, P220, DOI 10.1016/j.math.2009.12.004; Johnson MI, 2011, EXPERT REV NEUROTHER, V11, P735, DOI [10.1586/ern.11.48, 10.1586/ERN.11.48]; Joint Formulary Committee, 2011, 61 BNF BRIT MED ASS; Korthals-de Bos IBC, 2004, PHARMACOECONOMICS, V22, P185, DOI 10.2165/00019053-200422030-00004; Korthals-de Bos IBC, 2003, BRIT MED J, V326, P911; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; Moher D, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c869; National Institute for Health and Clinical Excellence (NICE), 2008, GUID METH TECHN APPR; Obradovic M, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-110; Office for National Statistics, 2011, ANN SURV HOURS EARN; Office of National Statistics, 2000, STAND OCC CLASS 2000, V2; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Smidt N, 2002, LANCET, V359, P657, DOI 10.1016/S0140-6736(02)07811-X; Smidt N, 2006, BMJ-BRIT MED J, V333, P927, DOI 10.1136/bmj.39017.396389.BE; Struijs PAA, 2006, BRIT J SPORT MED, V40, P637, DOI 10.1136/bjsm.2006.026187; Thompson SG, 2000, BRIT MED J, V320, P1197, DOI 10.1136/bmj.320.7243.1197; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Watson T, 2000, MANUAL THER, V5, P132, DOI 10.1054/math.2000.0363; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Whitehurst DGT, 2011, MED DECIS MAKING, V31, pE34, DOI 10.1177/0272989X11421529; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	36	9	9	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2015	10	8							e0135460	10.1371/journal.pone.0135460	http://dx.doi.org/10.1371/journal.pone.0135460			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CQ0PO	26317528	Green Submitted, Green Published, gold, Green Accepted			2023-01-03	WOS:000360299100029
J	Cook, D; Swinton, M; Toledo, F; Clarke, F; Rose, T; Hand-Breckenridge, T; Boyle, A; Woods, A; Zytaruk, N; Heels-Ansdell, D; Sheppard, R				Cook, Deborah; Swinton, Marilyn; Toledo, Feli; Clarke, France; Rose, Trudy; Hand-Breckenridge, Tracey; Boyle, Anne; Woods, Anne; Zytaruk, Nicole; Heels-Ansdell, Diane; Sheppard, Robert			Personalizing Death in the Intensive Care Unit: The 3 Wishes Project A Mixed-Methods Study	ANNALS OF INTERNAL MEDICINE			English	Article							OF-LIFE CARE; PALLIATIVE CARE; HEALTH-CARE; QUALITATIVE RESEARCH; COMMUNICATION; MEDICINE; DIGNITY	Background: Dying in the complex, efficiency-driven environment of the intensive care unit can be dehumanizing for the patient and have profound, long-lasting consequences for all persons attendant to that death. Objective: To bring peace to the final days of a patient's life and to ease the grieving process. Design: Mixed-methods study. Setting: 21-bed medical-surgical intensive care unit. Participants: Dying patients and their families and clinicians. Intervention: To honor each patient, a set of wishes was generated by patients, family members, or clinicians. The wishes were implemented before or after death by patients, families, clinicians (6 of whom were project team members), or the project team. Measurements: Quantitative data included demographic characteristics, processes of care, and scores on the Quality of End-of-Life Care-10 instrument. Semistructured interviews of family members and clinicians were transcribed verbatim, and qualitative description was used to analyze them. Results: Participants included 40 decedents, at least 1 family member per patient, and 3 clinicians per patient. The 159 wishes were implemented and classified into 5 categories: humanizing the environment, tributes, family reconnections, observances, and "paying it forward."Scores on the Quality of End-of-Life Care-10 instrument were high. The central theme from 160 interviews of 170 persons was how the 3 Wishes Project personalized the dying process. For patients, eliciting and customizing the wishes honored them by celebrating their lives and dignifying their deaths. For families, it created positive memories and individualized end-of-life care for their loved ones. For clinicians, it promoted interprofessional care and humanism in practice. Limitation: Impaired consciousness limited understanding of patients' viewpoints. Conclusion: The 3 Wishes Project facilitated personalization of the dying process through explicit integration of palliative and spiritual care into critical care practice. Primary Funding Source: Hamilton Academy of Health Science Research Organization, Canadian Intensive Care Foundation.	[Cook, Deborah] McMaster Univ, Hlth Sci Ctr, Dept Med, Hamilton, ON L8N 3Z5, Canada; [Cook, Deborah] McMaster Univ, Hlth Sci Ctr, Dept Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; [Swinton, Marilyn] McMaster Univ, Hamilton, ON L8N 3Z5, Canada; [Toledo, Feli; Rose, Trudy; Hand-Breckenridge, Tracey] St Josephs Healthcare, Spiritual Care Dept, Hamilton, ON L8N 4A6, Canada; [Clarke, France] St Josephs Healthcare, Hamilton, ON L8N 4A6, Canada; [Boyle, Anne; Woods, Anne] St Josephs Healthcare Hamilton, Palliat Care Serv, Hamilton, ON L8N 4A6, Canada; [Zytaruk, Nicole] St Josephs Healthcare Hamilton, Hamilton, ON L8N 4A6, Canada; [Heels-Ansdell, Diane] McMaster Univ, Dept Clin Epidemiol, Hamilton, ON L8S 4K1, Canada; [Sheppard, Robert] North Cypress Med Ctr, Cypress, TX 77429 USA	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; McMaster University; McMaster University; McMaster University	Cook, D (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Med, Room 2C11,1200 Main St West, Hamilton, ON L8N 3Z5, Canada.	debcook@mcmaster.ca			Hamilton Academy of Health Science Research Organization; Canadian Intensive Care Foundation	Hamilton Academy of Health Science Research Organization; Canadian Intensive Care Foundation	Hamilton Academy of Health Science Research Organization, Canadian Intensive Care Foundation.	Adamson Keith, 2012, Healthc Q, V15, P63; Aslakson RA, 2014, CRIT CARE MED, V42, P2418, DOI 10.1097/CCM.0000000000000573; Azoulay E, 2005, AM J RESP CRIT CARE, V171, P987, DOI 10.1164/rccm.200409-1295OC; Back AL, 2014, J PALLIAT MED, V17, P1019, DOI 10.1089/jpm.2013.0651; Chochinov H, 2007, BRIT MED J, V335, P184, DOI 10.1136/bmj.39244.650926.47; Chochinov HM, 2013, CANCER-AM CANCER SOC, V119, P1706, DOI 10.1002/cncr.27949; Clarke EB, 2003, CRIT CARE MED, V31, P2255, DOI 10.1097/01.CCM.0000084849.96385.85; Cook D, 2014, NEW ENGL J MED, V370, P2506, DOI 10.1056/NEJMra1208795; Cook DJ, 1999, CAN MED ASSOC J, V161, P1109; Curtis JR, 2001, J GEN INTERN MED, V16, P41; End-of-Life Care Research Program University of Washington School of Medicine, INSTR; Ho LA, 2011, CRIT CARE MED, V39, P975, DOI 10.1097/CCM.0b013e31820a91db; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Johnson N, 2000, CULT MED PSYCHIAT, V24, P275, DOI 10.1023/A:1005690501494; Mays N, 2000, BMJ-BRIT MED J, V320, P50, DOI 10.1136/bmj.320.7226.50; Patton M. Q, 2015, QUALITATIVE RES EVAL, V4th; Puchalski C, 2009, J PALLIAT MED, V12, P885, DOI 10.1089/jpm.2009.0142; RODGERS BL, 1993, RES NURS HEALTH, V16, P219, DOI 10.1002/nur.4770160309; Sabo Brenda, 2011, Online J Issues Nurs, V16, P1, DOI 10.3912/OJIN.Vol16No01Man01; Sandelowski M, 2000, RES NURS HEALTH, V23, P334, DOI 10.1002/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G; Scheunemann LP, 2011, CHEST, V139, P543, DOI 10.1378/chest.10-0595; Stajduhar KI, 2008, SOC SCI MED, V67, P1789, DOI 10.1016/j.socscimed.2008.09.012; Strauss Anslem, 1990, BASICS QUALITATIVE R, P23; Sulmasy DP, 2009, CHEST, V135, P1634, DOI 10.1378/chest.08-2241; Thurmond VA, 2001, J NURS SCHOLARSHIP, V33, P253, DOI 10.1111/j.1547-5069.2001.00253.x; Truog RD, 2008, CRIT CARE MED, V36, P953, DOI 10.1097/CCM.0B013E3181659096; Verghese A, 2008, NEW ENGL J MED, V359, P2748, DOI 10.1056/NEJMp0807461; who, WHO DEF PALL CAR; Wolpaw DR, 2014, NEW ENGL J MED, V370, P1283, DOI 10.1056/NEJMp1315661; [No title captured]	30	55	57	2	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 18	2015	163	4					271	+		10.7326/M15-0502	http://dx.doi.org/10.7326/M15-0502			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CQ0LC	26167721				2023-01-03	WOS:000360286400005
J	Kempf, H; Bleicher, M; Meyer-Hermann, M				Kempf, Harald; Bleicher, Marcus; Meyer-Hermann, Michael			Spatio-Temporal Dynamics of Hypoxia during Radiotherapy	PLOS ONE			English	Article							MULTICELLULAR TUMOR SPHEROIDS; OXYGEN ENHANCEMENT RATIO; SOLID TUMORS; IN-VIVO; RADIATION-THERAPY; CYCLING HYPOXIA; 3 DIMENSIONS; CELLS; MODEL; GROWTH	Tumour hypoxia plays a pivotal role in cancer therapy for most therapeutic approaches from radiotherapy to immunotherapy. The detailed and accurate knowledge of the oxygen distribution in a tumour is necessary in order to determine the right treatment strategy. Still, due to the limited spatial and temporal resolution of imaging methods as well as lacking fundamental understanding of internal oxygenation dynamics in tumours, the precise oxygen distribution map is rarely available for treatment planing. We employ an agent-based in silico tumour spheroid model in order to study the complex, localized and fast oxygen dynamics in tumour micro-regions which are induced by radiotherapy. A lattice-free, 3D, agent-based approach for cell representation is coupled with a high-resolution diffusion solver that includes a tissue density-dependent diffusion coefficient. This allows us to assess the space-and time-resolved reoxygenation response of a small subvolume of tumour tissue in response to radiotherapy. In response to irradiation the tumour nodule exhibits characteristic reoxygenation and re-depletion dynamics which we resolve with high spatio-temporal resolution. The reoxygenation follows specific timings, which should be respected in treatment in order to maximise the use of the oxygen enhancement effects. Oxygen dynamics within the tumour create windows of opportunity for the use of adjuvant chemotherapeutica and hypoxia-activated drugs. Overall, we show that by using modelling it is possible to follow the oxygenation dynamics beyond common resolution limits and predict beneficial strategies for therapy and in vitro verification. Models of cell cycle and oxygen dynamics in tumours should in the future be combined with imaging techniques, to allow for a systematic experimental study of possible improved schedules and to ultimately extend the reach of oxygenation monitoring available in clinical treatment.	[Kempf, Harald; Meyer-Hermann, Michael] Helmholtz Ctr Infect Res, Dept Syst Immunol, Braunschweig, Germany; [Kempf, Harald; Meyer-Hermann, Michael] Helmholtz Ctr Infect Res, Braunschweig Integrated Ctr Syst Biol, Braunschweig, Germany; [Kempf, Harald; Bleicher, Marcus] Frankfurt Inst Adv Studies, Frankfurt, Germany; [Meyer-Hermann, Michael] Tech Univ Carolo Wilhelmina Braunschweig, Inst Biochem Biotechnol & Bioinformat, D-38106 Braunschweig, Germany	Helmholtz Association; Helmholtz-Center for Infection Research; Helmholtz Association; Helmholtz-Center for Infection Research; Braunschweig University of Technology	Meyer-Hermann, M (corresponding author), Helmholtz Ctr Infect Res, Dept Syst Immunol, Braunschweig, Germany.	michael.meyer-hermann@theoretical-biology.de	Bleicher, Marcus J./A-2758-2010		Human Frontier Science Program [RGP0017/2011]; German Federal Ministry of Education and Research within the GerontoSys initiative (BMBF GerontoSys project GerontoShield) [FKZ 0315890A]; German Federal Ministry of Education and Research within the Measures for the Establishment of Systems Medicine, project SYSIMIT (BMBF eMed project SYSIMIT) [FKZ: 01ZX1308B]; German Federal Ministry of Education and Research within the Measures for the Establishment of Systems Medicine, project SysStomach (BMBF eMed project SysStomach) [FKZ: 01ZX1310C]; Helmholtz Association cross-program activity Metabolic Dysfunction and Human Disease; Helmholtz Initiative on Personalized Medicine (iMed)	Human Frontier Science Program(Human Frontier Science Program); German Federal Ministry of Education and Research within the GerontoSys initiative (BMBF GerontoSys project GerontoShield); German Federal Ministry of Education and Research within the Measures for the Establishment of Systems Medicine, project SYSIMIT (BMBF eMed project SYSIMIT); German Federal Ministry of Education and Research within the Measures for the Establishment of Systems Medicine, project SysStomach (BMBF eMed project SysStomach); Helmholtz Association cross-program activity Metabolic Dysfunction and Human Disease; Helmholtz Initiative on Personalized Medicine (iMed)	This work was supported by the Human Frontier Science Program (RGP0017/2011), by the German Federal Ministry of Education and Research within the GerontoSys initiative (BMBF GerontoSys project GerontoShield, FKZ 0315890A), within the Measures for the Establishment of Systems Medicine, projects SYSIMIT (BMBF eMed project SYSIMIT, FKZ: 01ZX1308B) and SysStomach (BMBF eMed project SysStomach, FKZ: 01ZX1310C), the Helmholtz Association cross-program activity Metabolic Dysfunction and Human Disease, and the Helmholtz Initiative on Personalized Medicine (iMed). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alarcon T, 2004, PROG BIOPHYS MOL BIO, V85, P451, DOI 10.1016/j.pbiomolbio.2004.02.004; ALPER T, 1956, NATURE, V178, P978, DOI 10.1038/178978a0; Angus SD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114098; Ansari N, 2012, METHOD CELL BIOL, V113, P295, DOI 10.1016/B978-0-12-407239-8.00013-6; AWWAD HK, 1986, INT J RADIAT ONCOL, V12, P1329, DOI 10.1016/0360-3016(86)90165-3; Bache M, 2008, CURR MED CHEM, V15, P322, DOI 10.2174/092986708783497391; Badeer HS, 2001, ADV PHYSIOL EDUC, V25, P44, DOI 10.1152/advances.2001.25.1.44; Bayer C, 2011, INT J RADIAT ONCOL, V80, P965, DOI 10.1016/j.ijrobp.2011.02.049; Bennewith KL, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-504; Bentzen SM, 2005, LANCET ONCOL, V6, P112, DOI 10.1016/S1470-2045(05)01737-7; Beyer T, 2005, COMPUT PHYS COMMUN, V172, P86, DOI 10.1016/j.cpc.2005.06.009; Beyer T, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.021929; Brown JM, 2002, CANCER BIOL THER, V1, P453, DOI 10.4161/cbt.1.5.157; Brown JM, 1998, CANCER RES, V58, P1408; Buffa FM, 2001, INT J RADIAT ONCOL, V49, P1109, DOI 10.1016/S0360-3016(00)01533-9; Busk M, 2008, ACTA ONCOL, V47, P1201, DOI 10.1080/02841860802307716; Cardenas-Navia LI, 2008, CANCER RES, V68, P5812, DOI 10.1158/0008-5472.CAN-07-6387; Carlin S, 2012, J NUCL MED, V53, P1171, DOI 10.2967/jnumed.111.099770; Carlson DJ, 2011, INT J RADIAT ONCOL, V79, P1188, DOI 10.1016/j.ijrobp.2010.10.007; CASCIARI JJ, 1988, CANCER RES, V48, P3905; Chu YS, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.028102; Cotran RS, 1999, ROBBINS PATHOLOGY SE; Dasu A, 2003, PHYS MED BIOL, V48, P2829, DOI 10.1088/0031-9155/48/17/307; Dewhirst MW, 2008, NAT REV CANCER, V8, P425, DOI 10.1038/nrc2397; Dionysiou DD, 2004, J THEOR BIOL, V230, P1, DOI 10.1016/j.jtbi.2004.03.024; Fenton BM, 2001, RADIAT RES, V155, P360, DOI 10.1667/0033-7587(2001)155[0360:EOROTI]2.0.CO;2; Festjens N, 2006, BBA-BIOENERGETICS, V1757, P1371, DOI 10.1016/j.bbabio.2006.06.014; FREYER JP, 1985, J CELL PHYSIOL, V124, P516, DOI 10.1002/jcp.1041240323; Gregoire V, 2007, J NUCL MED, V48, p68S; GROTE J, 1977, PFLUG ARCH EUR J PHY, V372, P37, DOI 10.1007/BF00582204; Hall E.J, 2006, RADIOBIOLOGY RADIOLO, V6, P576; Harada H, 2011, J RADIAT RES, V52, P545, DOI 10.1269/jrr.11056; Harriss W, 2010, AUSTRALAS PHYS ENG S, V33, P251, DOI 10.1007/s13246-010-0032-6; Hatzikirou H, 2015, CANCER THERAPEUTIC P, P1; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Helmlinger G, 1997, NAT BIOTECHNOL, V15, P778, DOI 10.1038/nbt0897-778; Hill AV, 1928, P R SOC LOND B-CONTA, V109, P39; Horing E, 2012, ACTA NEUROPATHOL, V124, P83, DOI 10.1007/s00401-011-0940-x; Horsman MR, 2012, NAT REV CLIN ONCOL, V9, P674, DOI 10.1038/nrclinonc.2012.171; Jain RK, 2010, NAT REV CLIN ONCOL, V7, P653, DOI 10.1038/nrclinonc.2010.139; Kallinowski F, 1989, J CELL PHYSL, V191, P138, DOI DOI 10.1002/JCP.1041380124; Kaur B, 2004, J NEURO-ONCOL, V70, P229, DOI 10.1007/s11060-004-2752-5; Kelada OJ, 2014, RADIAT RES, V181, P335, DOI 10.1667/RR13590.1; Kempf H, 2010, EUR PHYS J D, V60, P177, DOI 10.1140/epjd/e2010-00178-4; Kempf H, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003295; KIM IH, 1994, INT J RADIAT ONCOL, V29, P493, DOI 10.1016/0360-3016(94)90444-8; Krause BJ, 2006, Q J NUCL MED MOL IM, V50, P28; Leschner S, 2010, J MOL MED, V88, P763, DOI 10.1007/s00109-010-0636-z; Lin A, 2012, SEMIN NUCL MED, V42, P343, DOI 10.1053/j.semnuclmed.2012.04.002; Alfonso JCL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089380; Lyng H, 1997, RADIOTHER ONCOL, V44, P163, DOI 10.1016/S0167-8140(97)01920-8; Masunaga SI, 2008, RADIAT MED, V26, P270, DOI 10.1007/s11604-008-0227-x; MASUNAGA SI, 1991, RADIAT RES, V125, P243, DOI 10.2307/3578105; Matsumoto S, 2010, CANCER RES, V70, P10019, DOI 10.1158/0008-5472.CAN-10-2821; Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893; Pampaloni F, 2013, CELL TISSUE RES, V352, P161, DOI 10.1007/s00441-013-1589-7; Powathil G, 2012, COMPUT MATH METHOD M, V2012, DOI 10.1155/2012/410602; Powathil GG, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003120; Powathil GG, 2012, J THEOR BIOL, V308, P1, DOI 10.1016/j.jtbi.2012.05.015; Primeau AJ, 2005, CLIN CANCER RES, V11, P8782, DOI 10.1158/1078-0432.CCR-05-1664; Ryan RM, 2009, GENE THER, V16, P329, DOI 10.1038/gt.2008.188; Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3; Schaller G, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.051910; Schaller G, 2004, COMPUT PHYS COMMUN, V162, P9, DOI 10.1016/j.cpc.2004.06.066; Scifoni E, 2013, PHYS MED BIOL, V58, P3871, DOI 10.1088/0031-9155/58/11/3871; SINCLAIR WK, 1968, RADIAT RES, V33, P620, DOI 10.2307/3572419; Staab A, 2004, RADIAT RES, V161, P219, DOI 10.1667/RR3113; Stein W., 1990, CHANNELS CARRIERS PU; Thorwarth D, 2010, RADIOTHER ONCOL, V97, P172, DOI 10.1016/j.radonc.2010.05.012; Titz B, 2008, PHYS MED BIOL, V53, P4471, DOI 10.1088/0031-9155/53/17/001; Toma-Dasu I, 2004, PHYS MED BIOL, V49, P4463, DOI 10.1088/0031-9155/49/19/002; Toma-Dasu I, 2013, COMPUT MATH METHOD M, V2013, DOI 10.1155/2013/141087; Tung YC, 2011, ANALYST, V136, P473, DOI 10.1039/c0an00609b; Vaupel P, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-90005-10; Vaupel P, 2004, SEMIN RADIAT ONCOL, V14, P198, DOI 10.1016/j.semradonc.2004.04.008; VAUPEL P, 1989, CANCER RES, V49, P6449; Verwer EE, 2014, WORLD J CLIN ONCOL, V5, P824, DOI 10.5306/wjco.v5.i5.824; Wehrle JP, 2000, NMR BIOMED, V13, P349, DOI 10.1002/1099-1492(200010)13:6<349::AID-NBM652>3.0.CO;2-X; Wenzl T, 2011, PHYS MED BIOL, V56, P3251, DOI 10.1088/0031-9155/56/11/006; YAES RJ, 1991, INT J RADIAT ONCOL, V20, P1353, DOI 10.1016/0360-3016(91)90249-4; Yahiro T, 2005, J RADIAT RES, V46, P363, DOI 10.1269/jrr.46.363; Yasui H, 2010, CANCER RES, V70, P6427, DOI 10.1158/0008-5472.CAN-10-1350; Zacharaki EI, 2004, COMPUT METH PROG BIO, V76, P193, DOI 10.1016/j.cmpb.2004.07.003; Zheng XC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6834	84	15	15	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2015	10	8							e0133357	10.1371/journal.pone.0133357	http://dx.doi.org/10.1371/journal.pone.0133357			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO9KD	26273841	Green Published, gold, Green Submitted			2023-01-03	WOS:000359493600012
J	Roth, BL; Kroeze, WK				Roth, Bryan L.; Kroeze, Wesley K.			Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PHARMACOLOGICAL CHARACTERIZATION; STRUCTURAL BASIS; OPIOID RECEPTOR; DRUG; DISCOVERY; AGONIST; SAFETY; FENFLURAMINE; TOLERABILITY; ANTAGONIST	G-protein-coupled receptors (GPCRs) are frequent and fruitful targets for drug discovery and development, as well as being off-targets for the side effects of a variety of medications. Much of the druggable non-olfactory human GPCR-ome remains under-interrogated, and we present here various approaches that we and others have used to shine light into these previously dark corners of the human genome.	[Roth, Bryan L.; Kroeze, Wesley K.] Univ N Carolina, Chapel Hill Sch Med, Dept Pharmacol, Chapel Hill, NC 27514 USA	University of North Carolina; University of North Carolina Chapel Hill	Roth, BL (corresponding author), Univ N Carolina, Chapel Hill Sch Med, Dept Pharmacol, 4072 Genet Med Bldg,120 Mason Farms Rd, Chapel Hill, NC 27599 USA.	bryan_roth@med.unc.edu	Roth, Bryan/ABE-7032-2020; Roth, Bryan L/F-3928-2010	Roth, Bryan/0000-0002-0561-6520; 	National Institutes of Health [U01MH104974, U19MH82441, RO1MH61887]; NIMH Psychoactive Drug Screening Program Contract; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061887, U19MH082441, U01MH104974] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIMH Psychoactive Drug Screening Program Contract; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported by National Institutes of Health Grants U01MH104974, U19MH82441, and RO1MH61887 and the NIMH Psychoactive Drug Screening Program Contract (to B. L. R.). This is the first article in the Thematic Minireview series "New Directions in G Protein-coupled Receptor Pharmacology." The authors declare that they have no conflicts of interest with the contents of this article.	Allen JA, 2011, ANNU REV PHARMACOL, V51, P117, DOI 10.1146/annurev-pharmtox-010510-100553; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.97.7.3684; Armbruster BN, 2005, J BIOL CHEM, V280, P5129, DOI 10.1074/jbc.R400030200; Barak LS, 1999, J BIOL CHEM, V274, P7565, DOI 10.1074/jbc.274.11.7565; Barnea G, 2008, P NATL ACAD SCI USA, V105, P64, DOI 10.1073/pnas.0710487105; BARTHOLINI G, 1975, J PHARMACOL EXP THER, V193, P523; Becker RC, 2009, LANCET, V373, P919, DOI 10.1016/S0140-6736(09)60230-0; Beets I, 2011, METHODS MOL BIOL, V789, P377, DOI 10.1007/978-1-61779-310-3_25; Besnard J, 2012, NATURE, V492, P215, DOI 10.1038/nature11691; Bouyssou T, 2010, J PHARMACOL EXP THER, V334, P53, DOI 10.1124/jpet.110.167007; Bush MA, 2009, DIABETES OBES METAB, V11, P498, DOI 10.1111/j.1463-1326.2008.00992.x; Carlsson J, 2011, NAT CHEM BIOL, V7, P769, DOI 10.1038/nchembio.662; Chey WD, 2014, NEW ENGL J MED, V370, P2387, DOI 10.1056/NEJMoa1310246; Coward P, 1999, ANAL BIOCHEM, V270, P242, DOI 10.1006/abio.1999.4061; Coward P, 1998, P NATL ACAD SCI USA, V95, P352, DOI 10.1073/pnas.95.1.352; Cox CD, 2010, J MED CHEM, V53, P5320, DOI 10.1021/jm100541c; Edwards AM, 2011, NATURE, V470, P163, DOI 10.1038/470163a; Fenalti G, 2014, NATURE, V506, P191, DOI 10.1038/nature12944; Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777; Glaesner W, 2010, DIABETES-METAB RES, V26, P287, DOI 10.1002/dmrr.1080; Gralla RJ, 2014, ANN ONCOL, V25, P1333, DOI 10.1093/annonc/mdu096; Gregori-Puigjane E, 2012, P NATL ACAD SCI USA, V109, P11178, DOI 10.1073/pnas.1204524109; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Huang XP, 2009, MOL PHARMACOL, V76, P710, DOI 10.1124/mol.109.058057; Inoue A, 2012, NAT METHODS, V9, P1021, DOI [10.1038/NMETH.2172, 10.1038/nmeth.2172]; Isserlin R, 2011, ARXIV11020448; Jenkins L, 2011, BRIT J PHARMACOL, V162, P733, DOI 10.1111/j.1476-5381.2010.01082.x; Jensen NH, 2008, COMB CHEM HIGH T SCR, V11, P420, DOI 10.2174/138620708784911483; Jin CY, 2014, ACS CHEM NEUROSCI, V5, P576, DOI 10.1021/cn500082p; Kaufmann H, 2014, NEUROLOGY, V83, P328, DOI 10.1212/WNL.0000000000000615; Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284; Keiser MJ, 2009, NATURE, V462, P175, DOI 10.1038/nature08506; Kotsikorou E, 2013, BIOCHEMISTRY-US, V52, P9456, DOI 10.1021/bi4008885; Kotsikorou E, 2011, BIOCHEMISTRY-US, V50, P5633, DOI 10.1021/bi200010k; Kroeze WK, 2015, NAT STRUCT MOL BIOL, V22, P362, DOI 10.1038/nsmb.3014; Laggner C, 2012, NAT CHEM BIOL, V8, P144, DOI 10.1038/nchembio.732; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Lemieux GA, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001712; Lin H, 2013, NAT METHODS, V10, P140, DOI [10.1038/NMETH.2324, 10.1038/nmeth.2324]; Lin XY, 2012, J MED CHEM, V55, P5749, DOI 10.1021/jm300338m; Lounkine E, 2012, NATURE, V486, P361, DOI 10.1038/nature11159; Matthews JE, 2008, J CLIN ENDOCR METAB, V93, P4810, DOI 10.1210/jc.2008-1518; Meltzer HY, 2013, J CLIN INVEST, V123, P4986, DOI 10.1172/JCI70678; O'Connor KA, 2005, NAT REV DRUG DISCOV, V4, P1005, DOI 10.1038/nrd1900; Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199; Rajaratnam SMW, 2009, LANCET, V373, P482, DOI 10.1016/S0140-6736(08)61812-7; Rask-Andersen M, 2011, NAT REV DRUG DISCOV, V10, P579, DOI 10.1038/nrd3478; Roth BL, 2000, NEUROSCIENTIST, V6, P252, DOI 10.1177/107385840000600408; Roth BL, 2004, NAT REV DRUG DISCOV, V3, P353, DOI 10.1038/nrd1346; Roth BL, 2002, P NATL ACAD SCI USA, V99, P11934, DOI 10.1073/pnas.182234399; Roth BL, 2007, NEW ENGL J MED, V356, P6, DOI 10.1056/NEJMp068265; Rothman RB, 2000, CIRCULATION, V102, P2836; Seiler KP, 2008, NUCLEIC ACIDS RES, V36, pD351, DOI 10.1093/nar/gkm843; Setola V, 2003, MOL PHARMACOL, V63, P1223, DOI 10.1124/mol.63.6.1223; Shapiro DA, 2003, NEUROPSYCHOPHARMACOL, V28, P1400, DOI 10.1038/sj.npp.1300203; Strachan RT, 2006, DRUG DISCOV TODAY, V11, P708, DOI 10.1016/j.drudis.2006.06.012; Thompson AA, 2012, NATURE, V485, P395, DOI 10.1038/nature11085; Thomsen WJ, 2008, J PHARMACOL EXP THER, V325, P577, DOI 10.1124/jpet.107.133348; Vickers SP, 1999, PSYCHOPHARMACOLOGY, V143, P309, DOI 10.1007/s002130050952; Violin JD, 2014, TRENDS PHARMACOL SCI, V35, P308, DOI 10.1016/j.tips.2014.04.007; Wacker D, 2013, SCIENCE, V340, P615, DOI 10.1126/science.1232808; Wang C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5355; Wang C, 2013, NATURE, V497, P338, DOI 10.1038/nature12167; Wang C, 2013, SCIENCE, V340, P610, DOI 10.1126/science.1232807; Wang JH, 2006, J BIOL CHEM, V281, P22021, DOI 10.1074/jbc.M603503200; Wang YL, 2009, NUCLEIC ACIDS RES, V37, pW623, DOI 10.1093/nar/gkp456; Weiss DR, 2013, ACS CHEM BIOL, V8, P1018, DOI 10.1021/cb400103f; White KL, 2014, MOL PHARMACOL, V85, P83, DOI 10.1124/mol.113.089649; Wootten D, 2013, NAT REV DRUG DISCOV, V12, P630, DOI 10.1038/nrd4052; Wu HX, 2012, NATURE, V485, P327, DOI 10.1038/nature10939; Zanettini R, 2007, NEW ENGL J MED, V356, P39, DOI 10.1056/NEJMoa054830; Zhao PW, 2010, MOL PHARMACOL, V78, P560, DOI 10.1124/mol.110.066746	72	56	56	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	2015	290	32					19471	19477		10.1074/jbc.R115.654764	http://dx.doi.org/10.1074/jbc.R115.654764			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CO7TL	26100629	Green Published, hybrid			2023-01-03	WOS:000359364600008
J	Parke, HL; Epiphaniou, E; Pearce, G; Taylor, SJC; Sheikh, A; Griffiths, CJ; Greenhalgh, T; Pinnock, H				Parke, Hannah L.; Epiphaniou, Eleni; Pearce, Gemma; Taylor, Stephanie J. C.; Sheikh, Aziz; Griffiths, Chris J.; Greenhalgh, Trish; Pinnock, Hilary			Self-Management Support Interventions for Stroke Survivors: A Systematic Meta-Review	PLOS ONE			English	Review							CHRONIC DISEASE; OCCUPATIONAL-THERAPY; CASE-FATALITY; CARE; POPULATION; EFFICACY	Background There is considerable policy interest in promoting self-management in patients with long-term conditions, but it remains uncertain whether these interventions are effective in stroke patients. Design Systematic meta-review of the evidence for self-management support interventions with stroke survivors to inform provision of healthcare services. Methods We searched MEDLINE, EMBASE, CINAHL, PsychINFO, AMED, BNI, Database of Abstracts of Reviews for Effectiveness, and Cochrane Database of Systematic Reviews for systematic reviews of self-management support interventions for stroke survivors. Quality was assessed using the R-AMSTAR tool, and data extracted using a customised data extraction form. We undertook a narrative synthesis of the reviews' findings. Results From 12,400 titles we selected 13 systematic reviews (published 2003-2012) representing 101 individual trials. Although the term 'self-management' was rarely used, key elements of self-management support such as goal setting, action planning, and problem solving were core components of therapy rehabilitation interventions. We found high quality evidence that supported self-management in the context of therapy rehabilitation delivered soon after the stroke event resulted in short-term (<1 year) improvements in basic and extended activities of daily living, and a reduction in poor outcomes (dependence/death). There is some evidence that rehabilitation and problem solving interventions facilitated reintegration into the community. Conclusions Self-management terminology is rarely used in the context of stroke. However, therapy rehabilitation currently successfully delivers elements of self-management support to stroke survivors and their caregivers with improved outcomes. Future research should focus on managing the emotional, medical and social tasks of long-term survivorship.	[Parke, Hannah L.; Epiphaniou, Eleni; Taylor, Stephanie J. C.; Griffiths, Chris J.] Barts & London Queen Marys Sch Med & Dent, Blizard Inst, Ctr Primary Care & Publ Hlth, mEsh, London, England; [Pearce, Gemma] Coventry Univ, CTEHR, Coventry, W Midlands, England; [Sheikh, Aziz; Pinnock, Hilary] Univ Edinburgh, Usher Inst Med Informat & Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Greenhalgh, Trish] Univ Oxford, Div Med Sci, Nuffield Dept Primary Care Hlth Sci, Oxford, England	University of London; Queen Mary University London; Coventry University; University of Edinburgh; University of Oxford	Pinnock, H (corresponding author), Univ Edinburgh, Usher Inst Med Informat & Populat Hlth Sci, Edinburgh, Midlothian, Scotland.	hilary.pinnock@ed.ac.uk	TAYLOR, STEPHANIE/GYV-4768-2022; Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088; Taylor, Stephanie/0000-0001-7454-6354; Pearce, Gemma/0000-0002-2928-0048; Sheikh, Aziz/0000-0001-7022-3056	National Institute for Health Research Health Services and Delivery Research Programme [11/1014/04]; Chief Scientist's Office of the Scottish Government; National Institute for Health Research [NF-SI-0512-10031, 11/1014/04] Funding Source: researchfish	National Institute for Health Research Health Services and Delivery Research Programme; Chief Scientist's Office of the Scottish Government; National Institute for Health Research(National Institute for Health Research (NIHR))	This project was funded by the National Institute for Health Research Health Services and Delivery Research Programme (project number 11/1014/04. http://www.nets.nihr.ac.uk/projects/hsdr/11101404). The funders wrote the brief, called for applications, arranged peer review, and approved the study design, but had no role in data collection and analysis, decision to publish, or preparation of the manuscript. HP was supported at the time of the study by a Primary Care Research Career Award from the Chief Scientist's Office of the Scottish Government.	Adams K., 2004, I MED US COMMITTEE C; [Anonymous], 2010, MULT CHRON COND STRA; Aziz NA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005952.pub2; Bandura A., 1978, ADV BEHAV RES THER, V1, P139, DOI [10.1016/0146-6402(78)90002-4, DOI 10.1016/0146-6402(78)90002-4]; Becker L. A., 2011, COCHRANE HDB SYSTEMA; Black AD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000387; Corbin J.M., 1988, UNENDING WORK CARE M; Ellis G, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005066.pub2; Expert Patients Programme, CONTR YOUR COND DONT; Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0; Greveson G, 1991, Health Trends, V23, P161; Hoffmann T, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006430.pub2; Hollander M, 2003, J NEUROL NEUROSUR PS, V74, P317, DOI 10.1136/jnnp.74.3.317; Jones F, 2006, DISABIL REHABIL, V28, P841, DOI 10.1080/09638280500534952; Kennedy A, 2007, BMJ-BRIT MED J, V335, P968, DOI 10.1136/bmj.39372.540903.94; Ko H, 2010, QUAL SAF HEALTH CARE, V19, DOI 10.1136/qshc.2009.037531; Korpershoek C, 2011, J ADV NURS, V67, P1876, DOI 10.1111/j.1365-2648.2011.05659.x; Kung Jason, 2010, Open Dent J, V4, P84, DOI 10.2174/1874210601004020084; Latham CAT., 2014, OCCUPATIONAL THERAPY; Lawrence Maggie, 2011, JBI Libr Syst Rev, V9, P1782; Legg LA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003585.pub2; Lorig KR, 2003, ANN BEHAV MED, V26, P1, DOI 10.1207/S15324796ABM2601_01; Lui MHL, 2005, STROKE, V36, P2514, DOI 10.1161/01.STR.0000185743.41231.85; National Health Service, YOUR HLTH YOUR WAY Y; National Institute for Health and Clinical Excellence, 2008, MAN TYP 2 DIAB NICE; Outpatient Service Trialists, 2003, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD002925; Poulin V, 2012, TOP STROKE REHABIL, V19, P158, DOI 10.1310/tsr1902-158; Rae-Grant AD, 2011, J REHABIL RES DEV, V48, P1087, DOI 10.1682/JRRD.2010.08.0159; Rosamond W, 2007, CIRCULATION, V115, pE69, DOI 10.1161/CIRCULATIONAHA.106.179918; Royal College of Physicians Intercollegiate Stroke Working Party, 2012, NAT CLIN GUID STROK; Scottish Intercollegiate Guideline Network British Thoracic Society, 2008, THORAX S4, V63, pS1; Secretary of State for Health, 2006, OUR HLTH OUR CAR OUR; Smith J, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001919.pub2; Steultjens EMJ, 2003, STROKE, V34, P676, DOI 10.1161/01.STR.0000057576.77308.30; Taylor SJC, 2014, HLTH SERV DELIV RES, V2, P54, DOI DOI 10.3310/HSDR02530; Walker MF, 2004, STROKE, V35, P2226, DOI 10.1161/01.STR.0000137766.17092.fb; World Health Organization, 2003, WORLD HLTH REP 2003; World Health Organization, 2002, INNOVATIVE CARE CHRO	38	73	74	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2015	10	7							e0131448	10.1371/journal.pone.0131448	http://dx.doi.org/10.1371/journal.pone.0131448			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CN7NJ	26204266	Green Published, gold			2023-01-03	WOS:000358621000003
J	Craddock, TJA; Del Rosario, RR; Rice, M; Zysman, JP; Fletcher, MA; Klimas, NG; Broderick, G				Craddock, Travis J. A.; Del Rosario, Ryan R.; Rice, Mark; Zysman, Joel P.; Fletcher, Mary Ann; Klimas, Nancy G.; Broderick, Gordon			Achieving Remission in Gulf War Illness: A Simulation-Based Approach to Treatment Design	PLOS ONE			English	Article							PITUITARY-ADRENAL AXIS; GLUCOCORTICOID-RECEPTOR ANTAGONISTS; POSTTRAUMATIC-STRESS-DISORDER; IFN-GAMMA; MULTIPLE-SCLEROSIS; MUSCULOSKELETAL MANIFESTATIONS; ENDOCRINE DISORDERS; REGULATORY NETWORKS; ALZHEIMERS-DISEASE; ANTIBODIES	Gulf War Illness (GWI) is a chronic multi-symptom disorder affecting up to one-third of the 700,000 returning veterans of the 1991 Persian Gulf War and for which there is no known cure. GWI symptoms span several of the body's principal regulatory systems and include debilitating fatigue, severe musculoskeletal pain, cognitive and neurological problems. Using computational models, our group reported previously that GWI might be perpetuated at least in part by natural homeostatic regulation of the neuroendocrine-immune network. In this work, we attempt to harness these regulatory dynamics to identify treatment courses that might produce lasting remission. Towards this we apply a combinatorial optimization scheme to the Monte Carlo simulation of a discrete ternary logic model that represents combined hypothalamic-pituitary-adrenal (HPA), gonadal (HPG), and immune system regulation in males. In this work we found that no single intervention target allowed a robust return to normal homeostatic control. All combined interventions leading to a predicted remission involved an initial inhibition of Th1 inflammatory cytokines (Th1Cyt) followed by a subsequent inhibition of glucocorticoid receptor function (GR). These first two intervention events alone ended in stable and lasting return to the normal regulatory control in 40% of the simulated cases. Applying a second cycle of this combined treatment improved this predicted remission rate to 2 out of 3 simulated subjects (63%). These results suggest that in a complex illness such as GWI, a multi-tiered intervention strategy that formally accounts for regulatory dynamics may be required to reset neuroendocrine-immune homeostasis and support extended remission.	[Craddock, Travis J. A.; Del Rosario, Ryan R.; Rice, Mark; Fletcher, Mary Ann; Klimas, Nancy G.; Broderick, Gordon] Nova SE Univ, Inst Neuro Immune Med, Ft Lauderdale, FL 33314 USA; [Craddock, Travis J. A.; Broderick, Gordon] Nova SE Univ, Ctr Psychol Studies, Ft Lauderdale, FL 33314 USA; [Craddock, Travis J. A.] Nova SE Univ, Grad Sch Comp & Informat Sci, Ft Lauderdale, FL 33314 USA; [Craddock, Travis J. A.; Fletcher, Mary Ann; Klimas, Nancy G.; Broderick, Gordon] Nova SE Univ, Coll Osteopath Med, Ft Lauderdale, FL 33314 USA; [Zysman, Joel P.] Univ Miami, Ctr Computat Sci, Miami, FL USA; [Klimas, Nancy G.] Vet Affairs Med Ctr, Miami, FL 33125 USA; [Broderick, Gordon] Nova SE Univ, Coll Pharm, Ft Lauderdale, FL 33314 USA	Nova Southeastern University; Nova Southeastern University; Nova Southeastern University; Nova Southeastern University; University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA); Nova Southeastern University	Craddock, TJA (corresponding author), Nova SE Univ, Inst Neuro Immune Med, Ft Lauderdale, FL 33314 USA.	tcraddock@nova.edu		Craddock, Travis/0000-0001-7244-6317	U.S. Department of Defense [W81XWH-10-1-0774, W81XWH-09-2-0071]; U.S. Department of Veterans Affairs	U.S. Department of Defense(United States Department of Defense); U.S. Department of Veterans Affairs(US Department of Veterans Affairs)	This work was funded under U.S. Department of Defense (CDMRP program cdmrp.army.mil) grant W81XWH-10-1-0774 (G. Broderick, PI) and grant W81XWH-09-2-0071 (N. Klimas, PI). Additional funding was received from the U.S. Department of Veterans Affairs (va.gov) (Merit Award, N. Klimas, PI). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen JS, 2006, CLIN INFECT DIS, V43, P1, DOI 10.1086/504806; Amourette C, 2009, BEHAV BRAIN RES, V203, P207, DOI 10.1016/j.bbr.2009.05.002; Barbier L, 2009, BEHAV BRAIN RES, V197, P292, DOI 10.1016/j.bbr.2008.08.032; Ben-Zvi A, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000273; Bielekova B, 2010, NEUROLOGY, V74, pS31, DOI 10.1212/WNL.0b013e3181c97ed3; Boswell SB, 2014, CLIN IMAG, V38, P384, DOI 10.1016/j.clinimag.2014.02.014; Broderick G, 2013, BRAIN BEHAV IMMUN, V28, P159, DOI 10.1016/j.bbi.2012.11.007; Broderick G, 2011, BRAIN BEHAV IMMUN, V25, P302, DOI 10.1016/j.bbi.2010.10.011; Clark RD, 2008, CURR TOP MED CHEM, V8, P813, DOI 10.2174/156802608784535011; Craddock TJA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084839; Day J, 2006, J THEOR BIOL, V242, P237, DOI 10.1016/j.jtbi.2006.02.015; Dunn James P, 2004, Curr Opin Ophthalmol, V15, P293, DOI 10.1097/00055735-200408000-00003; Fritsch P, 2014, SYSTEMS BIOMED, V1, P0; Gaffen SL, 2004, CYTOKINE, V28, P109, DOI 10.1016/j.cyto.2004.06.010; Golier J, 2008, CONTROLLED TRIAL MIF; Golier J. A., 2012, DEPRESS RES TREAT, V2012, DOI DOI 10.1155/2012/393251; Golier JA, 2007, BIOL PSYCHIAT, V62, P1175, DOI 10.1016/j.biopsych.2007.04.027; Groeneweg FL, 2011, J ENDOCRINOL, V209, P153, DOI 10.1530/JOE-10-0472; Gupta S, 2007, THEOR BIOL MED MODEL, V4, DOI 10.1186/1742-4682-4-8; Harigai M, 2008, J IMMUNOL, V181, P2211, DOI 10.4049/jimmunol.181.3.2211; Healy DL, 2009, AUST PRESCR, V32, P152; Jacobs-Kosmin D, 2005, CURR OPIN RHEUMATOL, V17, P64, DOI 10.1097/01.bor.0000150950.43282.df; Kim SE, 2009, PHARMACOTHERAPY, V29, P227, DOI 10.1592/phco.29.2.227; Lamproglou I, 2009, BEHAV BRAIN RES, V197, P301, DOI 10.1016/j.bbr.2008.08.031; Lees JR, 2007, J CLIN INVEST, V117, P297, DOI 10.1172/JCI31254; Liscinsky M, 2012, FDA APPROVES KORLYM; Lupien SJ, 2009, NAT REV NEUROSCI, V10, P434, DOI 10.1038/nrn2639; Mendoza L, 2006, THEOR BIOL MED MODEL, V3, DOI 10.1186/1742-4682-3-13; Mikics E, 2004, PSYCHONEUROENDOCRINO, V29, P618, DOI 10.1016/S0306-4530(03)00090-8; Nicolson GL, 2000, CLIN PRACT ALTERN ME, V1, P92; Peeters BWMM, 2004, STRESS, V7, P233, DOI 10.1080/10253890400019672; Rankin J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030978; Rasmuson S, 2011, INT PSYCHOGERIATR, V23, P1386, DOI 10.1017/S1041610211000810; Research Advisory Committee on Gulf War Veterans' Illness (RAC-GWVI), 2008, GULF WAR ILLN HLTH G; Sigidin YA, 2001, SCAND J RHEUMATOL, V30, P203; Skowera A, 2004, J CLIN IMMUNOL, V24, P66, DOI 10.1023/B:JOCI.0000018065.64685.82; Skurkovich B, 2006, E SCHERING RES FDN W, V56, P1; Skurkovich S, 2001, MULT SCLER, V7, P277, DOI 10.1177/135245850100700502; Strittmatter M, 2005, SCHMERZ, V19, P109, DOI 10.1007/s00482-004-0330-6; Swanwick GRJ, 1998, AM J PSYCHIAT, V155, P286; Takemura S, 2001, J IMMUNOL, V167, P1072, DOI 10.4049/jimmunol.167.2.1072; Tennant F, 2013, PAIN THER, V2, P75, DOI 10.1007/s40122-013-0015-x; THOMAS R, 1991, J THEOR BIOL, V153, P1, DOI 10.1016/S0022-5193(05)80350-9; Vinther F, 2011, J MATH BIOL, V63, P663, DOI 10.1007/s00285-010-0384-2; Walker JJ, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001341; Walker JJ, 2010, P ROY SOC B-BIOL SCI, V277, P1627, DOI 10.1098/rspb.2009.2148; Weiner MW, 2011, MIL MED, V176, P896, DOI 10.7205/MILMED-D-10-00332; Whitley D, 2003, LECT NOTES COMPUT SC, V2724, P1469; Wilson CGM, 2011, CURR TOP MICROBIOL, V348, P25, DOI 10.1007/82_2010_93; Yeh S, 2008, J AUTOIMMUN, V31, P91, DOI 10.1016/j.jaut.2008.05.001; Zhang QW, 1999, CLIN DIAGN LAB IMMUN, V6, P6, DOI 10.1128/CDLI.6.1.6-13.1999	51	20	21	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2015	10	7							e0132774	10.1371/journal.pone.0132774	http://dx.doi.org/10.1371/journal.pone.0132774			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN6LN	26192591	Green Published, Green Submitted, gold			2023-01-03	WOS:000358546400038
J	Li, QW; Li, W; Wang, L; Wang, WD; Niu, SQ; Bi, XW; Wang, HY; Zhang, YJ				Li, Qiwen; Li, Wei; Wang, Liang; Wang, Weida; Niu, Shaoqing; Bi, Xiwen; Wang, Hanyu; Zhang, Yujing			Consolidation Radiotherapy in Stage IE- IIE, Non-Bulky Primary Gastric Diffuse Large B-Cell Lymphoma with Post-Chemotherapy Complete Remission	PLOS ONE			English	Article							NON-HODGKINS-LYMPHOMA; LOCALIZED AGGRESSIVE LYMPHOMA; INVOLVED-FIELD RADIOTHERAPY; CHOP PLUS RADIOTHERAPY; CLINICAL-FEATURES; ONCOLOGY-GROUP; CHEMOTHERAPY; SURGERY; TRIAL; EXPERIENCE	Background To investigate the effects of consolidation radiation in patients with stage IE-IIE, non-bulky primary gastric diffuse large B-cell lymphoma (DLBCL). Methods A cohort consisted of 71 consecutive patients with stage IE-IIE, non-bulky primary gastric DLBCL was retrospectively analyzed. All of them had been in complete remission after receiving at least four cycles of chemotherapy, containing rituximab or not. Consolidation radiation was delivered thereafter in 28 patients while other 43 received clinical observation only. Locoregional relapse-free survival (LRFS), disease-free survival (DFS), overall survival (OS) and distant metastasis-free survival (DMFS) were compared between patients with or without radiotherapy. Results The 10-year LRFS, DFS, OS and DMFS were 100% and 81.4%(p = 0.028), 91.7% and 77.1% (p = 0.14), 91.7% and 77.8% (p = 0.67), 91.7% and 78.0%(p = 0.42) for patients with or without radiotherapy. Conclusions Radiotherapy is associated with improved locoregional control of patients with early stage primary gastric DLBCL, who have achieved complete remission following at least four cycles of chemotherapy.	[Li, Qiwen; Wang, Hanyu; Zhang, Yujing] Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China; [Li, Wei] Sun Yat Sen Univ, Ctr Canc, Dept Anesthesiol, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China; [Wang, Liang; Wang, Weida] Sun Yat Sen Univ, Ctr Canc, Dept Hematol Oncol, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China; [Niu, Shaoqing] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Radiat Oncol, Guangzhou 510275, Guangdong, Peoples R China; [Bi, Xiwen] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University	Zhang, YJ (corresponding author), Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China.	zhangyj@sysucc.org.cn	Wang, Weida/HGV-1933-2022					AMER MH, 1994, GASTROENTEROLOGY, V106, P846, DOI 10.1016/0016-5085(94)90742-0; Aviles A, 2004, ANN SURG, V240, P44, DOI 10.1097/01.sla.0000129354.31318.f1; Bonnet C, 2007, J CLIN ONCOL, V25, P787, DOI 10.1200/JCO.2006.07.0722; BROOKS JJ, 1983, CANCER, V51, P701, DOI 10.1002/1097-0142(19830215)51:4<701::AID-CNCR2820510425>3.0.CO;2-D; DAMORE F, 1994, J CLIN ONCOL, V12, P1673, DOI 10.1200/JCO.1994.12.8.1673; Ferreri AJM, 1999, LEUKEMIA LYMPHOMA, V33, P531, DOI 10.3109/10428199909058457; Fischbach W, 2011, Z GASTROENTEROL, V49, P430, DOI 10.1055/s-0029-1246012; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; HERRMANN R, 1980, CANCER, V46, P215, DOI 10.1002/1097-0142(19800701)46:1<215::AID-CNCR2820460136>3.0.CO;2-6; Horning SJ, 2004, J CLIN ONCOL, V22, P3032, DOI 10.1200/JCO.2004.06.088; Koch P, 2001, J CLIN ONCOL, V19, P3861, DOI 10.1200/JCO.2001.19.18.3861; Liu HT, 2000, AM J HEMATOL, V64, P175, DOI 10.1002/1096-8652(200007)64:3<175::AID-AJH6>3.3.CO;2-Z; Liu Hui, 2013, Zhonghua Wei Chang Wai Ke Za Zhi, V16, P36; Mafune K I, 2001, Gastric Cancer, V4, P137, DOI 10.1007/PL00011736; Martinelli G, 2009, LEUKEMIA LYMPHOMA, V50, P925, DOI 10.1080/10428190902912478; Mihaljevic B, 2006, MED ONCOL, V23, P225, DOI 10.1385/MO:23:2:225; Miller TP, 1998, NEW ENGL J MED, V339, P21, DOI 10.1056/NEJM199807023390104; Narita M, 1996, PATHOL INT, V46, P623, DOI 10.1111/j.1440-1827.1996.tb03664.x; Persky DO, 2008, J CLIN ONCOL, V26, P2258, DOI 10.1200/JCO.2007.13.6929; Pfreundschuh M, 2011, LANCET ONCOL, V12, P1013, DOI 10.1016/S1470-2045(11)70235-2; Phan Jack, 2010, J Clin Oncol, V28, P4170, DOI 10.1200/JCO.2009.27.3441; Reyes F, 2005, NEW ENGL J MED, V352, P1197, DOI 10.1056/NEJMoa042040; Sbitti Y, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-23; Shenkier TN, 2002, J CLIN ONCOL, V20, P197, DOI 10.1200/JCO.20.1.197	24	4	5	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2015	10	7							e0133469	10.1371/journal.pone.0133469	http://dx.doi.org/10.1371/journal.pone.0133469			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN6LN	26193661	gold, Green Published, Green Submitted			2023-01-03	WOS:000358546400092
J	Renault, KM; Carlsen, EM; Norgaard, K; Nilas, L; Pryds, O; Secher, NJ; Olsen, SF; Halldorsson, TI				Renault, Kristina M.; Carlsen, Emma M.; Norgaard, Kirsten; Nilas, Lisbeth; Pryds, Ole; Secher, Niels J.; Olsen, Sjurdur F.; Halldorsson, Thorhallur I.			Intake of Sweets, Snacks and Soft Drinks Predicts Weight Gain in Obese Pregnant Women: Detailed Analysis of the Results of a Randomised Controlled Trial	PLOS ONE			English	Article							NATIONAL-BIRTH-COHORT; GLYCEMIC-INDEX DIET; OBSTETRIC OUTCOMES; PHYSICAL-ACTIVITY; MATERNAL WEIGHT; LIFE-STYLE; INTERVENTION; SUGAR; LOAD; MEN	Background Lifestyle interventions targeting obese pregnant women often result in modest reduction in gestational weight gain, pregnancy complications and related risk factors. Examining adherence to the intervention can, however, provide valuable information on the importance of the different factors targeted. Objective To evaluate improvements and relevance of different dietary factors targeted with respect to gestational weight gain in a 3-arm Randomised Controlled Trial (n=342) among obese pregnant women with BMI >= 30 kg/m(2). Methods Randomisation 1:1:1 to either hypocaloric Mediterranean type of diet and physical activity intervention (D+PA); physical activity intervention alone (PA); or control (C). Diet was assessed at baseline (weeks 11-14) and endpoint (weeks 36-37) using a validated food frequency questionnaire. Results During the intervention women in the D+PA group significantly lowered their intakes of added sugars and saturated fat and increased their protein intake by similar to 1% of total energy compared to controls. Of these dietary variables only intakes of added sugar appeared to be related to GWG, while no association was observed for saturated fat or protein. Further analyses revealed that foods that contributed to intake of added sugars, including sweets, snacks, cakes, and soft drinks were strongly associated with weight gain, with women consuming sweets >= 2/day having 5.4 kg (95% CI 2.1-8.7) greater weight gain than those with a low (<1wk) intake. The results for soft drinks were more conflicting, as women with high weight gain tended to favour artificially sweetened soft drinks. Conclusion In our sample of obese pregnant women, craving for sweets, snacks, and soft drinks strongly predicts GWG. Emphasis on reducing intakes of these foods may be more relevant for limiting gestational weight gain than encouraging strict compliance to more specific diets.	[Renault, Kristina M.; Nilas, Lisbeth] Univ Copenhagen, Hvidovre Hosp, Dept Obstet & Gynaecol, Copenhagen, Denmark; [Renault, Kristina M.] Univ Southern Denmark, Odense Univ Hosp, Dept Obstet & Gynaecol, Odense, Denmark; [Carlsen, Emma M.; Pryds, Ole] Univ Copenhagen, Hvidovre Hosp, Dept Paediat, Copenhagen, Denmark; [Norgaard, Kirsten] Univ Copenhagen, Hvidovre Hosp, Dept Endocrinol, Copenhagen, Denmark; [Secher, Niels J.] Univ Copenhagen, Rigshosp, Juliane Marie Ctr, Res Unit Womens & Childrens Hlth, DK-2100 Copenhagen, Denmark; [Olsen, Sjurdur F.; Halldorsson, Thorhallur I.] Statens Serum Inst, Ctr Foetal Programming, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark; [Olsen, Sjurdur F.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Halldorsson, Thorhallur I.] Univ Iceland, Fac Food Sci & Nutr, Reykjavik, Iceland	University of Copenhagen; University of Southern Denmark; Odense University Hospital; University of Copenhagen; University of Copenhagen; Rigshospitalet; University of Copenhagen; Statens Serum Institut; Harvard University; Harvard T.H. Chan School of Public Health; University of Iceland	Renault, KM (corresponding author), Univ Copenhagen, Hvidovre Hosp, Dept Obstet & Gynaecol, Copenhagen, Denmark.	krta@dadlnet.dk	Halldorsson, Tohrhallur/M-1823-2015; Nørgaard, Kirsten/AAC-9803-2020; Renault, Kristina Martha/H-7265-2019	Halldorsson, Tohrhallur/0000-0001-5115-0162; Nørgaard, Kirsten/0000-0003-1620-8271; Carlsen, Emma Malchau/0000-0002-5563-1964; Olsen, Sjurdur/0000-0003-3017-7096; Halldorsson, Thorhallur/0000-0002-3488-0777; Renault, Kristina Martha/0000-0002-6387-9652	Danish Council for Strategic Research (Centre for Fetal Programming) [09067124]	Danish Council for Strategic Research (Centre for Fetal Programming)	"Sygekassernes Helsefond" and "Brodrene Hartmann Fonden" were not involved in data collection, management or analysis of the data, nor the decision to submit the manuscript for publication. The Danish Council for Strategic Research (09067124, Centre for Fetal Programming): to finance processing and development of questionnaire data regarding dietary intake and physical activity in pregnancy.	Clapp JF, 2002, P NUTR SOC, V61, P45, DOI 10.1079/PNS2001129; de Koning L, 2011, AM J CLIN NUTR, V93, P1321, DOI 10.3945/ajcn.110.007922; Deierlein AL, 2008, AM J CLIN NUTR, V88, P693, DOI 10.1093/ajcn/88.3.693; Guelinckx I, 2008, OBES REV, V9, P140, DOI 10.1111/j.1467-789X.2007.00464.x; Guelinckx I, 2010, AM J CLIN NUTR, V91, P373, DOI 10.3945/ajcn.2009.28166; HEITMANN BL, 1995, BRIT MED J, V311, P986; Hinkle SN, 2010, AM J CLIN NUTR, V92, P644, DOI 10.3945/ajcn.2010.29726; Jensen DM, 2005, DIABETES CARE, V28, P2118, DOI 10.2337/diacare.28.9.2118; Kahn R, 2014, DIABETES CARE, V37, P957, DOI 10.2337/dc13-2506; Khoury J, 2005, AM J OBSTET GYNECOL, V193, P1292, DOI 10.1016/j.ajog.2005.05.016; Knudsen VK, 2013, BRIT J NUTR, V109, P1471, DOI 10.1017/S0007114512003443; Kral JG, 2006, PEDIATRICS, V118, pE1644, DOI 10.1542/peds.2006-1379; Mikkelsen TB, 2006, PUBLIC HEALTH NUTR, V9, P771, DOI 10.1079/PHN2005883; Moses RG, 2006, AM J CLIN NUTR, V84, P807, DOI 10.1093/ajcn/84.4.807; Mozaffarian D, 2011, NEW ENGL J MED, V364, P2392, DOI 10.1056/NEJMoa1014296; Olsen S, 2005, REPORT NO 38, P1; Olsen SF, 2007, PAEDIATR PERINAT EP, V21, P76, DOI 10.1111/j.1365-3016.2007.00777.x; Ovesen P, 2011, OBSTET GYNECOL, V118, P305, DOI 10.1097/AOG.0b013e3182245d49; Pedersen AN, 2010, DIETARY HABITS IN DE; Poston L, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-148; Rasmussen KM, 2009, WEIGHT GAIN DURING PREGNANCY: REEXAMINING THE GUIDELINES, P1; Renault K, 2010, ACTA OBSTET GYN SCAN, V89, P956, DOI 10.3109/00016341003792459; Renault KM, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2013.09.029; Schack-Nielsen L, 2010, INT J OBESITY, V34, P67, DOI 10.1038/ijo.2009.206; Thangaratinam S, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2088; Walsh JM, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5605; Willett WC, 2013, NUTRITIONAL EPIDEMIO; Wolff S, 2008, INT J OBESITY, V32, P495, DOI 10.1038/sj.ijo.0803710; Zilko CEM, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.12.007	29	36	37	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2015	10	7							e0133041	10.1371/journal.pone.0133041	http://dx.doi.org/10.1371/journal.pone.0133041			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN6LN	26192183	Green Published, gold, Green Submitted			2023-01-03	WOS:000358546400047
J	Vassbakk-Brovold, K; Berntsen, S; Fegran, L; Lian, H; Mjaland, O; Mjaland, S; Seiler, S; Kersten, C				Vassbakk-Brovold, Karianne; Berntsen, Sveinung; Fegran, Liv; Lian, Henrik; Mjaland, Odd; Mjaland, Svein; Seiler, Stephen; Kersten, Christian			Individualized Comprehensive Lifestyle Intervention in Patients Undergoing Chemotherapy with Curative or Palliative Intent: Who Participates?	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; CANCER-PATIENTS; BREAST; CARE	Objective Knowledge about determinants of participation in lifestyle interventions in cancer patients undergoing chemotherapy, particularly with palliative intent, remains poor. The objective of the present study was to identify determinants of participating in a 12 month individualized, comprehensive lifestyle intervention, focusing on diet, physical activity, mental stress and smoking cessation, in cancer patients receiving chemotherapy with curative or palliative intent. The secondary objective was to identify participation determinants 4 months into the study. Methods Newly diagnosed cancer patients starting chemotherapy at the cancer center in Kristiansand/Norway (during a 16 month inclusion period) were screened. Demographic and medical data (age, sex, body mass index, education level, marital status, smoking status, Eastern Cooperative Oncology Group performance status (ECOG), diagnosis, tumor stage and treatment intention) was analyzed for screened patients. Results 100 of 161 invited patients participated. There were more females (69 vs. 48%; P = 0.004), breast cancer patients (46 vs. 25%; P = 0.007), non-smokers (87 vs. 74%; P = 0.041), younger (mean age 60 vs. 67 yrs; P < 0.001) and fitter (82 vs. 64% with EGOC 0; P = 0.036) participants vs. non-participants included. In multivariate logistic regression analyses, age (Odds Ratio 0.94, 95% Confidence Interval 0.91, 0.97) and smoking (0.42, 0.18, 0.99) were negatively associated with participation. After 4 months, 63 participants were still participating. Cancer type, smoking and age increased the probability of dropping out. Multivariate logistic regression revealed that age was the only significant determinant of 4 month participation (0.95, 0.91, 0.99). Patients aged > 70 years were less likely to participate at baseline and 4 months. Conclusion Individualized lifestyle interventions in cancer patients undergoing chemotherapy appear to facilitate a high participation rate that declines with increasing age; both during the enrollment process and completing the intervention. Neither oncologic nor socioeconomic variables deterred participation.	[Vassbakk-Brovold, Karianne; Mjaland, Svein; Kersten, Christian] Southern Hosp Trust, Dept Oncol, Kristiansand, Norway; [Vassbakk-Brovold, Karianne; Berntsen, Sveinung; Seiler, Stephen] Univ Agder, Fac Hlth Sport Sci, Dept Publ Hlth Sport & Nutr, Kristiansand, Norway; [Fegran, Liv] Univ Agder, Fac Hlth & Sport Sci, Dept Hlth & Nursing Sci, Kristiansand, Norway; [Lian, Henrik] Southern Hosp Trust, Dept Phys Med & Prevent, Kristiansand, Norway; [Mjaland, Odd] Southern Hosp Trust, Dept Surg, Kristiansand, Norway	University of Agder; University of Agder	Vassbakk-Brovold, K (corresponding author), Southern Hosp Trust, Dept Oncol, Kristiansand, Norway.	karianne.vassbakk.brovold@sshf.no	fegran, liv/AAW-2160-2020	Fegran, Liv/0000-0001-5470-8686	Oddrun Mjaland Foundation for Cancer Research	Oddrun Mjaland Foundation for Cancer Research	The salary of the PhD-student was funded by the Oddrun Mjaland Foundation for Cancer Research (KVB). Grant number or URL to funders website is NA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamsen L, 2006, SUPPORT CARE CANCER, V14, P116, DOI 10.1007/s00520-005-0864-x; Adamsen L, 2009, BMJ, V339; Brubaker PH, 2014, CURR GERIATR REP, V3, P291, DOI 10.1007/s13670-014-0104-7; Buffart LM, 2014, CANCER TREAT REV, V40, P327, DOI 10.1016/j.ctrv.2013.06.007; Cancer Registry of Norway, 2013, CANC NORW 2011 CANC; Courneya K, 2008, INT J BEHAV NUTR PHY, V5; Courneya KS, 2008, MED SCI SPORT EXER, V40, P1180, DOI 10.1249/MSS.0b013e318168da45; Courneya KS, 2008, ANN BEHAV MED, V35, P116, DOI 10.1007/s12160-007-9009-4; Courneya KS, 2014, INT J BEHAV NUTR PHY, V11, DOI 10.1186/s12966-014-0085-0; Courneya KS, 2015, RES Q EXERC SPORTS, P1; DiaGraphIT AS-Clinical monitoring software, 2012, DIAGRAPHIT AS CLIN M; George SM, 2011, CANCER CAUSE CONTROL, V22, P589, DOI 10.1007/s10552-011-9732-9; Gibson TM, 2010, SEMIN ONCOL, V37, P282, DOI 10.1053/j.seminoncol.2010.05.011; Helsedirektoratet (The Norwegian Directorate of Health), 2011, KOSTR FREMM FOLK FOR; Helsedirektoratet (The Norwegian Directorate of Health), 2012, HELS PLAN SYST KUNNS; Hosmer D.W., 2000, APPL LOGISTIC REGRES, V2nd; Husebo AML, 2013, J CLIN NURS, V22, P4, DOI 10.1111/j.1365-2702.2012.04322.x; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kim HS, 2002, CANCER NURS, V25, P425, DOI 10.1097/00002820-200212000-00004; Kreftregisteret (Cancer Registry of Norway), 2014, FAKT OM KREFT; Lutgendorf SK, 2010, J CLIN ONCOL, V28, P4094, DOI 10.1200/JCO.2009.26.9357; Meyerhardt JA, 2006, J CLIN ONCOL, V24, P3535, DOI 10.1200/JCO.2006.06.0863; Midtgaard M, 2009, EUR J ONCOL NURS, V13, P116, DOI 10.1016/j.ejon.2009.01.006; Moller T, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003556; NIoP Health, 2010, SMOK SMOK TOB NORW F; Nordin K, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-167; Oldervoll Line M, 2005, Palliat Support Care, V3, P281; Oldervoll LM, 2006, J PAIN SYMPTOM MANAG, V31, P421, DOI 10.1016/j.jpainsymman.2005.10.004; Ornish D, 2008, LANCET ONCOL, V9, P1048, DOI 10.1016/S1470-2045(08)70234-1; Pekmezi DW, 2011, ACTA ONCOL, V50, P167, DOI 10.3109/0284186X.2010.529822; Rock Cheryl L, 2012, CA Cancer J Clin, V62, P243, DOI 10.3322/caac.21142; Rubin H, 2013, P NATL ACAD SCI USA, V110, P13927, DOI 10.1073/pnas.1312831110; Sallis J F, 1990, Exerc Sport Sci Rev, V18, P307; Schulz MD, 2014, NATURE, V514, P508, DOI 10.1038/nature13398; Shiels MS, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju294; Thomsen TG, 2010, J CLIN NURS, V19, P3410, DOI 10.1111/j.1365-2702.2009.03154.x; Tsianakas V, 2012, SUPPORT CARE CANCER, V20, P2639, DOI 10.1007/s00520-012-1470-3; Voerman B, 2007, PSYCHO-ONCOL, V16, P1092, DOI 10.1002/pon.1160; WHO, 2014, OB OV	39	12	12	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2015	10	7							e0131355	10.1371/journal.pone.0131355	http://dx.doi.org/10.1371/journal.pone.0131355			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CN1RL	26176950	Green Submitted, Green Published, gold			2023-01-03	WOS:000358197600041
J	Li, YN; Zhou, Q; Hu, Z; Yang, B; Li, QS; Wang, JH; Zheng, JH; Cao, WW				Li, Yongning; Zhou, Qi; Hu, Zheng; Yang, Bin; Li, Qingsong; Wang, Jianhua; Zheng, Jinhua; Cao, Wenwu			5-Aminolevulinic Acid-Based Sonodynamic Therapy Induces the Apoptosis of Osteosarcoma in Mice	PLOS ONE			English	Article							LOW-INTENSITY ULTRASOUND; CELLS IN-VITRO; PROTOPORPHYRIN IX; TUMOR-GROWTH; K562 CELLS; HEMATOPORPHYRIN; SONOSENSITIZER; CANCER	Objective Sonodynamic therapy (SDT) is promising for treatment of cancer, but its effect on osteosarcoma is unclear. This study examined the effect of 5-Aminolevulinic Acid (5-ALA)-based SDT on the growth of implanted osteosarcoma and their potential mechanisms in vivo and in vitro. Methods The dose and metabolism of 5-ALA and ultrasound periods were optimized in a mouse model of induced osteosarcoma and in UMR-106 cells. The effects of ALA-SDT on the proliferation and apoptosis of UMR-106 cells and the growth of implanted osteosarcoma were examined. The levels of mitochondrial membrane potential (Delta psi M), ROS production, BcL-2, Bax, p53 and caspase 3 expression in UMR-106 cells were determined. Results Treatment with 5-ALA for eight hours was optimal for ALA-SDT in the mouse tumor model and treatment with 2 mM 5-ALA for 6 hours and ultrasound (1.0 MHz 2.0 W/cm(2)) for 7 min were optimal for UMR-106 cells. SDT, but not 5-ALA, alone inhibited the growth of implanted osteosarcoma in mice (P<0.01) and reduced the viability of UMR-106 cells (p<0.05). ALA-SDT further reduced the tumor volumes and viability of UMR-106 cells (p<0.01 for both). Pre-treatment with 5-ALA significantly enhanced the SDT-mediated apoptosis (p<0.01) and morphological changes. Furthermore, ALA-SDT significantly reduced the levels of Delta psi M, but increased levels of ROS in UMR-106 cells (p<0.05 or p<0.01 vs. the Control or the Ultrasound). Moreover, ALA-SDT inhibited the proliferation of osteosarcoma cells and BcL-2 expression, but increased levels of Bax, p53 and caspase 3 expression in the implanted osteosarcoma tissues (p<0.05 or p<0.01 vs. the Control or the Ultrasound). Conclusions The ALA-SDT significantly inhibited osteosarcoma growth in vivo and reduced UMR-106 cell survival by inducing osteosarcoma cell apoptosis through the ROS-related mitochondrial pathway.	[Li, Yongning; Cao, Wenwu] Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150080, Peoples R China; [Zhou, Qi; Hu, Zheng; Yang, Bin] Harbin Inst Technol, Lab Photo & Sonotheranost Technol, Harbin 150080, Peoples R China; [Zhou, Qi; Hu, Zheng; Yang, Bin] Harbin Inst Technol, Condensed Matter Sci & Technol Inst, Harbin 150080, Peoples R China; [Li, Qingsong] Dalian Med Univ, Affiliated Hosp 1, Cardiovasc Inst, Dalian 116011, Peoples R China; [Wang, Jianhua; Zheng, Jinhua] Harbin Med Univ, Coll Basic Med Sci, Dept Anat, Harbin 150080, Peoples R China; [Cao, Wenwu] Penn State Univ, Mat Res Inst, University Pk, PA 16802 USA	Harbin Institute of Technology; Harbin Institute of Technology; Harbin Institute of Technology; Dalian Medical University; Harbin Medical University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Cao, WW (corresponding author), Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150080, Peoples R China.	dzk@psu.edu	Cao, Wenwu/F-6091-2012; 金华, 郑/GWM-7529-2022; Hu, Zheng/AAI-3025-2020	Cao, Wenwu/0000-0002-2447-1486; Hu, Zheng/0000-0002-3323-0369	National Key Technology R&D Program of China [2013BAI03B06]	National Key Technology R&D Program of China(National Key Technology R&D Program)	This work was supported by the National Key Technology R&D Program of China (Grant No. 2013BAI03B06).	Ahmadi F, 2012, PROG BIOPHYS MOL BIO, V108, P119, DOI 10.1016/j.pbiomolbio.2012.01.004; Cheng JL, 2013, INT J NANOMED, V8, P669, DOI 10.2147/IJN.S39844; Chou Alexander J, 2008, Paediatr Drugs, V10, P315, DOI 10.2165/00148581-200810050-00005; Gao ZXZ, 2013, CANCER LETT, V335, P93, DOI 10.1016/j.canlet.2013.02.006; Hagiya Y, 2013, PHOTODIAGN PHOTODYN, V10, P288, DOI 10.1016/j.pdpdt.2013.02.001; Hasanzadeh H, 2011, ULTRASON SONOCHEM, V18, P394, DOI 10.1016/j.ultsonch.2010.07.005; He Y, 2010, ULTRASONICS, V50, P777, DOI 10.1016/j.ultras.2010.03.004; Ketola A, 2008, CANCER RES, V68, P8342, DOI 10.1158/0008-5472.CAN-08-0251; Kinoshita M, 2006, RADIAT RES, V165, P299, DOI 10.1667/RR3510.1; Komori C, 2009, ANTICANCER RES, V29, P2411; Li HX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059473; Li YS, 2008, CANCER LETT, V266, P156, DOI 10.1016/j.canlet.2008.02.041; Lv YH, 2012, CELL PHYSIOL BIOCHEM, V30, P321, DOI 10.1159/000339067; Rosenthal I, 2004, ULTRASON SONOCHEM, V11, P349, DOI 10.1016/j.ultsonch.2004.03.004; Sakamoto A, 2008, REV RECENT CLIN TRIA, V3, P228, DOI 10.2174/157488708785700267; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Shibaguchi H, 2011, ANTICANCER RES, V31, P2425; Song W, 2011, ANTICANCER RES, V31, P39; Spierings D, 2005, SCIENCE, V310, P66, DOI 10.1126/science.1117105; Su XM, 2014, ULTRASONICS, V54, P275, DOI 10.1016/j.ultras.2013.07.015; Tang W, 2010, ULTRASONICS, V50, P567, DOI 10.1016/j.ultras.2009.12.001; Tang W, 2009, ULTRASONICS, V49, P786, DOI 10.1016/j.ultras.2009.06.002; Tian ZD, 2010, INTEGR CANCER THER, V9, P365, DOI 10.1177/1534735410379013; Tian ZD, 2009, J ULTRAS MED, V28, P1695, DOI 10.7863/jum.2009.28.12.1695; Tsuang YH, 2011, ARTIF ORGANS, V35, P373, DOI 10.1111/j.1525-1594.2010.01086.x; Tsuru H, 2012, FREE RADICAL BIO MED, V53, P464, DOI 10.1016/j.freeradbiomed.2012.04.025; Uto Y, 2014, ANTICANCER RES, V34, P4583; Wang S, 2014, ULTRASOUND MED BIOL, V40, P2125, DOI 10.1016/j.ultrasmedbio.2014.05.007; Wang XB, 2010, ULTRASOUND MED BIOL, V36, P667, DOI 10.1016/j.ultrasmedbio.2009.09.006; Wang XB, 2010, ULTRASONICS, V50, P803, DOI 10.1016/j.ultras.2010.04.004; Xiang JY, 2011, ULTRASONICS, V51, P390, DOI 10.1016/j.ultras.2010.11.005; YUMITA N, 1989, JPN J CANCER RES, V80, P219, DOI 10.1111/j.1349-7006.1989.tb02295.x	32	27	28	3	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2015	10	7							e0132074	10.1371/journal.pone.0132074	http://dx.doi.org/10.1371/journal.pone.0132074			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1FD	26161801	gold, Green Submitted, Green Published			2023-01-03	WOS:000358162300090
J	Chiu, EC; Lee, Y; Lai, KY; Kuo, CJ; Lee, SC; Hsieh, CL				Chiu, En-Chi; Lee, Yen; Lai, Kuan-Yu; Kuo, Chian-Jue; Lee, Shu-Chun; Hsieh, Ching-Lin			Construct Validity of the Chinese Version of the Activities of Daily Living Rating Scale III in Patients with Schizophrenia	PLOS ONE			English	Article							FUNCTIONAL REMISSION; PERFORMANCE; SKILLS	Background The Chinese version of the Activities of Daily Living Rating Scale III (ADLRS-III), which has 10 domains, is commonly used for assessing activities of daily living (ADL) in patients with schizophrenia. However, construct validity (i.e., unidimensionality) for each domain of the ADLRS-III is unknown, limiting the explanations of the test results. Purpose This main purpose of this study was to examine unidimensionality of each domain in the ADLRS-III. We also examined internal consistency and ceiling/floor effects in patients with schizophrenia. Methods From occupational therapy records, we obtained 304 self-report data of the ADLRS-III. Confirmatory factor analysis (CFA) was conducted to examine the 10 one-factor structures. If a domain showed an insufficient model fit, exploratory factor analysis (EFA) was performed to investigate the factor structure and choose one factor representing the original construct. Internal consistency was examined using Cronbach's alpha (alpha). Ceiling and floor effects were determined by the percentage of patients with the maximum and minimum scores in each domain, respectively. Results CFA analyses showed that 4 domains (i.e., leisure, picture recognition, literacy ability, communication tools use) had sufficient model fits. These 4 domains had acceptable internal consistency (alpha = 0.79-0.87) and no ceiling/floor effects, except the leisure domain which had a ceiling effect. The other 6 domains showed insufficient model fits. The EFA results showed that these 6 domains were two-factor structures. Conclusion The results supported unidimensional constructs of the leisure, picture recognition, literacy ability, and communication tool uses domains. The sum scores of these 4 domains can be used to represent their respective domain-specific functions. Regarding the 6 domains with insufficient model fits, we have explained the two factors of each domain and chosen one factor to represent its original construct. Future users may use the items from the chosen factors to assess domain-specific functions in patients with schizophrenia.	[Chiu, En-Chi; Lee, Shu-Chun; Hsieh, Ching-Lin] Natl Taiwan Univ, Coll Med, Sch Occupat Therapy, Taipei 10764, Taiwan; [Lee, Yen] Univ Wisconsin, Dept Educ Psychol, Madison, WI 53706 USA; [Lai, Kuan-Yu; Kuo, Chian-Jue; Lee, Shu-Chun] Taipei City Hosp, Taipei City Psychiat Ctr, Taipei, Taiwan; [Kuo, Chian-Jue] Taipei Med Univ, Sch Med, Dept Psychiat, Taipei, Taiwan; [Kuo, Chian-Jue] Taipei Med Univ Hosp, Psychiat Res Ctr, Taipei, Taiwan; [Hsieh, Ching-Lin] Natl Taiwan Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan	National Taiwan University; University of Wisconsin System; University of Wisconsin Madison; Taipei City Hospital; Taipei Medical University; Taipei Medical University; Taipei Medical University Hospital; National Taiwan University; National Taiwan University Hospital	Lee, SC (corresponding author), Natl Taiwan Univ, Coll Med, Sch Occupat Therapy, Taipei 10764, Taiwan.	A1057@tpech.gov.tw	Hsieh, Ching-Lin/G-6057-2011; Lee, Yen/HHN-1719-2022	Hsieh, Ching-Lin/0000-0001-9468-9969; Lee, Shu-Chun/0000-0002-8007-0409	Taipei City Government [63]	Taipei City Government	This study was supported by a research grant from the Taipei City Government (No. 63).	Bellack AS, 2007, SCHIZOPHRENIA BULL, V33, P805, DOI 10.1093/schbul/sbl035; Bond TG, 2007, APPL RASCH MODEL FDN; Bowie CR, 2006, AM J PSYCHIAT, V163, P418, DOI 10.1176/appi.ajp.163.3.418; Campo JA, 2004, ACTA NEUROPSYCHIATR, V16, P138, DOI 10.1111/j.0924-2708.2004.00065.x; CASANOVA JS, 1976, AM J OCCUP THER, V30, P101; Chou SC, 2002, INT J QUAL HEALTH C, V14, P49, DOI 10.1093/intqhc/14.1.49; CHU TF, 2004, J TAIWAN OCCUP THER, V22, P1; Chu TF., 1997, ACTIVITIES DAILY LIV; Cintron JA, 2005, J ANXIETY DISORD, V19, P51, DOI 10.1016/j.janxdis.2003.10.007; Culler KH., 1993, WILLARD SPACKMANS OC, P206; Cureton E.E., 1983, FACTOR ANAL APPL APP; Fischer EP, 2002, PSYCHIAT SERV, V53, P724, DOI 10.1176/appi.ps.53.6.724; Forero CG, 2009, STRUCT EQU MODELING, V16, P625, DOI 10.1080/10705510903203573; Haigh EAP, 2011, ASSESSMENT, V18, P11, DOI 10.1177/1073191110386342; Hair J.F., 2010, MULTIVARIATE DATA AN, DOI 10.1016/j.ijpharm.2011.02.019; Harvey PD, 2014, J CLIN PSYCHIAT, V75, P15, DOI 10.4088/JCP.13049su1c.03; Harvey PD, 2013, SCHIZOPHR RES, V147, P86, DOI 10.1016/j.schres.2013.02.018; Holmes WC, 1997, QUAL LIFE RES, V6, P561, DOI 10.1023/A:1018464200708; Hooper D., 2008, ELECT J BUSINESS RES, V6, P53, DOI 10.21427/D7CF7R; Huang C, 2009, INT J GERIATR PSYCH, V24, P1166, DOI 10.1002/gps.2241; Karow A, 2012, EUR PSYCHIAT, V27, P401, DOI 10.1016/j.eurpsy.2011.01.012; Lam WW, 2012, HLTH EXPECT; Liu YC, 2011, PERCEPT MOTOR SKILL, V112, P703, DOI 10.2466/02.09.13.PMS.112.3.703-710; Llorca PM, 2009, SCHIZOPHR RES, V113, P218, DOI 10.1016/j.schres.2009.04.029; MacCallum RC, 1996, PSYCHOL METHODS, V1, P130, DOI 10.1037/1082-989X.1.2.130; Minrdila D., 2010, INT J DIGIT SOC, V1, P60; Mosey AC, 1976, ACTIVITIES THERAPY; Nunnally J. C., 1978, PSYCHOMETRIC THEORY; Patterson TL, 2001, SCHIZOPHRENIA BULL, V27, P235, DOI 10.1093/oxfordjournals.schbul.a006870; Riazi A, 2002, J NEUROL NEUROSUR PS, V73, P701, DOI 10.1136/jnnp.73.6.701; Rogers JC, 1998, WILLARD SPACKMANS OC, P185; Semkovska M, 2004, SCHIZOPHR RES, V69, P289, DOI 10.1016/j.schres.2003.07.005; Siegert RJ, 2010, J REHABIL MED, V42, P302, DOI 10.2340/16501977-0511; Stuart GW, 1987, REHABIL PSYCHIAT NUR, V23, P320; Su CY, 2007, AM J OCCUP THER, V61, P108, DOI 10.5014/ajot.61.1.108; Wang RH, 2012, J NURS RES, V20, P122, DOI 10.1097/jnr.0b013e318254eb47; Wu HW, 2010, J TAIWAN OCCUP THER, V6, P25; ZWICK WR, 1986, PSYCHOL BULL, V99, P432, DOI 10.1037/0033-2909.99.3.432	38	3	3	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2015	10	6							e0130702	10.1371/journal.pone.0130702	http://dx.doi.org/10.1371/journal.pone.0130702			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CN1BL	26121246	Green Submitted, Green Published, gold			2023-01-03	WOS:000358150400056
J	Nasef, NA; Mehta, S; Powell, P; Marlow, G; Wileman, T; Ferguson, LR				Nasef, Noha Ahmed; Mehta, Sunali; Powell, Penny; Marlow, Gareth; Wileman, Tom; Ferguson, Lynnette R.			Extracts of Feijoa Inhibit Toll-Like Receptor 2 Signaling and Activate Autophagy Implicating a Role in Dietary Control of IBD	PLOS ONE			English	Article							INFLAMMATORY-BOWEL-DISEASE; IN-VITRO; POLYPHENOLS; TLR4; CD14	Background Inflammatory bowel disease (IBD) is a heterogeneous chronic inflammatory disease affecting the gut with limited treatment success for its sufferers. This suggests the need for better understanding of the different subtypes of the disease as well as nutritional interventions to compliment current treatments. In this study we assess the ability of a hydrophilic feijoa fraction (F3) to modulate autophagy a process known to regulate inflammation, via TLR2 using IBD cell lines. Method Mouse embryonic fibroblasts (MEF) deleted for ATG5, and two intestinal epithelial cells HCT15 and HCT116, were used to test the anti-inflammatory effect of F3 after stimulating the cells with a TLR2 specific ligand PAM3CSK4. Results F3 was able to reduce TLR2 specific inflammation and stimulate autophagy in MEFs and HCT15 cells but not in HCT116 cells. The anti-inflammatory effect was reduced in the MEF cells deleted for ATG5. In addition, the activation of autophagy by F3 was enhanced by PAM3CSK4. Conclusion F3 of feijoa can interact with cells via a TLR2 specific mechanism and reduce Nuclear factor kappa B (NF-kappa B) activation in part due to stimulation of autophagy. These results suggest that there is potential benefit in using feijoa extracts as part of dietary interventions to manage IBD in patients.	[Nasef, Noha Ahmed; Mehta, Sunali; Marlow, Gareth; Ferguson, Lynnette R.] Univ Auckland, Fac Med & Hlth Sci, Auckland 1, New Zealand; [Powell, Penny; Wileman, Tom] UEA, Norwich Med Sch, Biomed Res Ctr, Norwich, Norfolk, England	University of Auckland; University of East Anglia	Ferguson, LR (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Auckland 1, New Zealand.	l.ferguson@auckland.ac.nz	Mehta, Sunali/O-8459-2019	Mehta, Sunali/0000-0002-1777-1245; Marlow, Gareth/0000-0002-7608-9086; Powell, Penny/0000-0002-5347-0490	Nutrigenomics New Zealand; Ministry of Business, Innovation and Employment (MBIE); Kate Edger Educational Charitable Trust	Nutrigenomics New Zealand; Ministry of Business, Innovation and Employment (MBIE)(New Zealand Ministry of Business, Innovation and Employment (MBIE)); Kate Edger Educational Charitable Trust	LF and NAN were supported by Nutrigenomics New Zealand and the Ministry of Business, Innovation and Employment (MBIE) to perform the studies in this Manuscript. NAN was also funded by the Kate Edger Educational Charitable Trust for this study and manuscript preparation. The funders had no role in study design, data collection and analysis. Nutrigenomics New Zealand had a role in the decision to publish of this material but had no role in the preparation of the manuscript.	Abbas AK., 2012, CELL MOL IMMUNOL; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Bravo L, 1998, NUTR REV, V56, P317, DOI 10.1111/j.1753-4887.1998.tb01670.x; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; De Cruz P, 2012, INFLAMM BOWEL DIS, DOI [10.1002/ibd.21751, DOI 10.1002/IBD.21751]; Del Rio D, 2010, NUTR METAB CARDIOVAS, V20, P1, DOI 10.1016/j.numecd.2009.05.015; Fiocchi C., 2013, DIG DIS, V30, P2; Frolova L, 2008, J HISTOCHEM CYTOCHEM, V56, P267, DOI 10.1369/jhc.7A7303.2007; Fukata M, 2009, INFLAMM BOWEL DIS, V15, P997, DOI 10.1002/ibd.20880; Gonzalez R, 2011, CRIT REV FOOD SCI, V51, P331, DOI 10.1080/10408390903584094; Hommes DW, 2009, J PEDIATR GASTR NUTR, V48, pS52, DOI 10.1097/MPG.0b013e3181a11785; Hou JK, 2011, AM J GASTROENTEROL, V106, P563, DOI 10.1038/ajg.2011.44; Huebner C, 2010, INFLAMM BOWEL DIS, V16, P282, DOI 10.1002/ibd.21043; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Li DS, 2006, CELL RES, V16, P855, DOI 10.1038/sj.cr.7310110; Li FX, 2005, CAN J GASTROENTEROL, V19, P567, DOI 10.1155/2005/943547; Li YY, 2011, INT J MOL MED, V27, P337, DOI 10.3892/ijmm.2011.596; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006; Nasef NA, 2014, NUTRIENTS, V6, P5265, DOI 10.3390/nu6115265; Priego S, 2008, MOL CANCER THER, V7, P3330, DOI 10.1158/1535-7163.MCT-08-0363; Ranoa DRE, 2013, J BIOL CHEM, V288, P9729, DOI 10.1074/jbc.M113.453266; Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Scalbert A, 2002, BIOMED PHARMACOTHER, V56, P276, DOI 10.1016/S0753-3322(02)00205-6; Scalbert A, 2005, CRIT REV FOOD SCI, V45, P287, DOI 10.1080/1040869059096; Seow Cynthia H, 2009, Curr Gastroenterol Rep, V11, P509; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Shapiro H, 2007, GUT, V56, P426, DOI 10.1136/gut.2006.094599; Shin DM, 2010, CELL MICROBIOL, V12, P1648, DOI 10.1111/j.1462-5822.2010.01497.x; Sies H, 2010, ARCH BIOCHEM BIOPHYS, V501, P2, DOI 10.1016/j.abb.2010.04.006; Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780; Zhao L, 2007, J BIOL CHEM, V282, P11618, DOI 10.1074/jbc.M608644200	34	10	10	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2015	10	6							e0130910	10.1371/journal.pone.0130910	http://dx.doi.org/10.1371/journal.pone.0130910			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL4OY	26110654	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000356933800097
J	Siu, AL				Siu, Albert L.		US Preventive Services Task Force	Behavioral and Pharmacotherapy Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Women: US Preventive Services Task Force Recommendation Statement	ANNALS OF INTERNAL MEDICINE			English	Article							ELECTRONIC CIGARETTES; UNITED-STATES; NICOTINE PATCHES; SMOKERS; TRENDS; POLICY; TRIAL	Description: Update of the 2009 U.S. Preventive Services Task Force (USPSTF) recommendation on counseling and interventions to prevent tobacco use and tobacco-related disease in adults, including pregnant women. Methods: The USPSTF reviewed the evidence on interventions for tobacco smoking cessation that are relevant to primary care (behavioral interventions, pharmacotherapy, and complementary or alternative therapy) in adults, including pregnant women. Population: This recommendation applies to adults aged 18 years or older, including pregnant women. Recommendations: The USPSTF recommends that clinicians ask all adults about tobacco use, advise them to stop using tobacco, and provide behavioral interventions and U.S. Food and Drug Administration-approved pharmacotherapy for cessation to adults who use tobacco. (A recommendation) The USPSTF recommends that clinicians ask all pregnant women about tobacco use, advise them to stop using tobacco, and provide behavioral interventions for cessation to pregnant women who use tobacco. (A recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of pharmacotherapy interventions for tobacco cessation in pregnant women. (I statement) The USPSTF concludes that the current evidence is insufficient to recommend electronic nicotine delivery systems for tobacco cessation in adults, including pregnant women. The USPSTF recommends that clinicians direct patients who smoke tobacco to other cessation interventions with established effectiveness and safety (previously stated). (I statement)	[Siu, Albert L.; US Preventive Services Task Force] US Prevent Serv Task Force, Rockville, MD 20850 USA		Siu, AL (corresponding author), US Prevent Serv Task Force, Rockville, MD 20850 USA.							Agaku IT, 2014, MMWR-MORBID MORTAL W, V63, P542; American Academy of Family Physicians, 2008, CLIN PRACT GUID TOB; American College of Physicians, 2010, TOB CONT PREV; [Anonymous], 2011, Obstet Gynecol, V118, P746, DOI 10.1097/AOG.0b013e3182310ca9; Berlin I, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1622; Bhatnagar A, 2014, CIRCULATION, V130, P1418, DOI 10.1161/CIR.0000000000000107; Bullen C, 2013, LANCET, V382, P1629, DOI 10.1016/S0140-6736(13)61842-5; Cahill K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009329.pub2, 10.1002/14651858.CD006103.pub6]; Callahan-Lyon P, 2014, TOB CONTROL, V23, P36, DOI 10.1136/tobaccocontrol-2013-051470; Caponnetto P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066317; Centers for Disease Control and Prevention, TOB US PREGN; Centers for Disease Control and Prevention, 2014, SMOK CESS REP SURG G; Chamberlain Catherine, 2013, Cochrane Database Syst Rev, pCD001055, DOI 10.1002/14651858.CD001055.pub4; Chatham-Stephens K, 2014, MMWR-MORBID MORTAL W, V63, P292; Cooper S, 2014, LANCET RESP MED, V2, P728, DOI 10.1016/S2213-2600(14)70157-2; Dempsey DA, 2001, DRUG SAFETY, V24, P277, DOI 10.2165/00002018-200124040-00005; Fiore MC, 2008, CLIN PRACTICE GUIDEL; Goniewicz ML, 2014, TOB CONTROL, V23, P133, DOI 10.1136/tobaccocontrol-2012-050859; Hartmann-Boyce J, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001118.pub3; Hughes JR, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000031.pub3, 10.1002/14651858.CD000031.pub4]; Jamal A, 2014, MMWR-MORBID MORTAL W, V63, P1108; Kandra KL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103462; Kattapong VJ, 1998, AM J PREV MED, V15, P160, DOI 10.1016/S0749-3797(98)00036-1; King BA, 2015, NICOTINE TOB RES, V17, P219, DOI 10.1093/ntr/ntu191; Le Cook B, 2014, JAMA-J AM MED ASSOC, V311, P172, DOI 10.1001/jama.2013.284985; Mills EJ, 2014, CIRCULATION, V129, P28, DOI 10.1161/CIRCULATIONAHA.113.003961; Mills Edward J, 2010, Tob Induc Dis, V8, P8, DOI 10.1186/1617-9625-8-8; Office on Smoking and Health (US), 2010, TOB SMOK CAUS DIS BI; Oncken C, 2008, OBSTET GYNECOL, V112, P859, DOI 10.1097/AOG.0b013e318187e1ec; Patnode CD, 2015, ANN INTERN MED, V163, P608, DOI 10.7326/M15-0171; Rice VH, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001188.pub4; ROSE G, 1992, J EPIDEMIOL COMMUN H, V46, P75, DOI 10.1136/jech.46.1.75; Schmidt L, 2014, PREV CHRONIC DIS, V11, DOI 10.5888/pcd11.140283; Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub3; Stead LF, 2012, COCHRANE DB SYST REV, V12, DOI DOI 10.1002/14651858; Stead LF, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008286.pub2; Stead LF, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000165.pub4; Substance Abuse and Mental Health Services Administration, 2013, RES 2012 NAT SURV DR; Tong VT, 2013, MMWR SURVEILL SUMM, V62, P1; U.S. Department of Health and Human Services, 2001, 2001 SURG GEN REP WO; U.S. Food and Drug Administration, 2012, CHANT VAR SAF COMM U; U.S. Food and Drug Administration, 2015, CHANT VAR DRUG SAF C; US Preventive Serv Task Force, 2009, ANN INTERN MED, V150, P551, DOI 10.7326/0003-4819-150-8-200904210-00009; White AR, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000009.pub4; World Health Organization, 2013, WHO REC PREV MAN TOB	45	308	309	1	37	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 20	2015	163	8					622	+		10.7326/M15-2023	http://dx.doi.org/10.7326/M15-2023			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CU7QV	26389730				2023-01-03	WOS:000363737400020
J	Wunderlich, R; Lau, P; Stein, A; Engell, A; Wollbrink, A; Rudack, C; Pantev, C				Wunderlich, Robert; Lau, Pia; Stein, Alwina; Engell, Alva; Wollbrink, Andreas; Rudack, Claudia; Pantev, Christo			Impact of Spectral Notch Width on Neurophysiological Plasticity and Clinical Effectiveness of the Tailor-Made Notched Music Training	PLOS ONE			English	Article							TINNITUS HANDICAP QUESTIONNAIRE; AUDITORY-CORTEX ACTIVITY; LATERAL INHIBITION; ENHANCEMENT; TRIALS	Tinnitus, the ringing in the ears that is unrelated to any external source, causes a significant loss in quality of life, involving sleep disturbance and depression for 1 to 3% of the general population. While in the first place tinnitus may be triggered by damage to the inner ear cells, the neural generators of subjective tinnitus are located in central regions of the nervous system. A loss of lateral inhibition, tonotopical reorganization and a gain-increase in response to the sensory deprivation result in hypersensitivity and hyperactivity in certain regions of the auditory cortex. In the tailor-made notched music training (TMNMT) patients listen to music from which the frequency spectrum of the tinnitus has been removed. This evokes strong lateral inhibition from neurons tuned to adjacent frequencies onto the neurons involved in the tinnitus percept. A reduction of tinnitus loudness and tinnitus-related neural activity was achieved with TMNMT in previous studies. As the effect of lateral inhibition depends on the bandwidth of the notch, in the current study we altered the notch width to find the most effective notch width for TMNMT. We compared 1-octave notch width with 1/2-octave and 1/4-octave. Participants chose their favorite music for the training that included three month of two hours daily listening. The outcome was measured by means of standardized questionnaires and magnetoencephalography. We found a general reduction of tinnitus distress in all administered tinnitus questionnaires after the training. Additionally, tinnitus-related neural activity was reduced after the training. Nevertheless, notch width did not have an influence on the behavioral or neural effects of TMNMT. This could be due to a non-linear resolution of lateral inhibition in high frequencies.	[Wunderlich, Robert; Lau, Pia; Stein, Alwina; Engell, Alva; Wollbrink, Andreas; Pantev, Christo] Univ Hosp Munster, Inst Biomagnetism & Biosignalanal, Munster, Germany; [Wunderlich, Robert] Univ Bielefeld, Inst Physiol Psychol, D-33615 Bielefeld, Germany; [Rudack, Claudia] Univ Hosp Munster, Dept Otolaryngol, Munster, Germany	University of Munster; University of Bielefeld; University of Munster	Pantev, C (corresponding author), Univ Hosp Munster, Inst Biomagnetism & Biosignalanal, Munster, Germany.	pantev@uni-muenster.de			"Interdisziplinares Zentrum fur klinische Forschung" IZKF [CRA05]	"Interdisziplinares Zentrum fur klinische Forschung" IZKF	This research was funded by "Interdisziplinares Zentrum fur klinische Forschung" IZKF (CRA05). Website: http://campus.uni-muenster.de/izkf.html. The funding was recieved by CR and CP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AXELSSON A, 1989, British Journal of Audiology, V23, P53, DOI 10.3109/03005368909077819; De Ridder D, 2011, P NATL ACAD SCI USA, V108, P8075, DOI 10.1073/pnas.1018466108; Diesch E, 2004, EUR J NEUROSCI, V19, P1093, DOI 10.1111/j.0953-816X.2004.03191.x; Diesch E, 2010, NEUROSCIENCE, V167, P540, DOI 10.1016/j.neuroscience.2010.02.003; Diesch E, 2010, NEUROIMAGE, V50, P1545, DOI 10.1016/j.neuroimage.2010.01.067; Dobie RA, 2003, OTOLARYNG CLIN N AM, V36, P383, DOI 10.1016/S0030-6665(02)00168-8; Dobie RA, 1999, LARYNGOSCOPE, V109, P1202, DOI 10.1097/00005537-199908000-00004; Eggermont JJ, 2004, TRENDS NEUROSCI, V27, P676, DOI 10.1016/j.tins.2004.08.010; Engelien A, 2000, HEARING RES, V148, P153, DOI 10.1016/S0378-5955(00)00148-9; Figueiredo RR, 2011, BRAZ J OTORHINOLAR, V77, P293, DOI 10.1590/S1808-86942011000300004; GOEBEL G, 1994, HNO, V42, P166; Heller AJ, 2003, OTOLARYNG CLIN N AM, V36, P239, DOI 10.1016/S0030-6665(02)00160-3; Henry JA, 2001, J REHABIL RES DEV, V38, P557; HOUTGAST T, 1972, J ACOUST SOC AM, V51, P1885, DOI 10.1121/1.1913048; KUK FK, 1990, EAR HEARING, V11, P434, DOI 10.1097/00003446-199012000-00005; Landgrebe M, 2012, J PSYCHOSOM RES, V73, P112, DOI 10.1016/j.jpsychores.2012.05.002; Maes IHL, 2013, EAR HEARING, V34, P508, DOI 10.1097/AUD.0b013e31827d113a; Muhlnickel W, 1998, P NATL ACAD SCI USA, V95, P10340, DOI 10.1073/pnas.95.17.10340; NEWMAN CW, 1995, ANN OTO RHINOL LARYN, V104, P718, DOI 10.1177/000348949510400910; Newman CW, 1996, ARCH OTOLARYNGOL, V122, P143; Norena A, 2002, AUDIOL NEURO-OTOL, V7, P358, DOI 10.1159/000066156; Norena AJ, 2011, NEUROSCI BIOBEHAV R, V35, P1089, DOI 10.1016/j.neubiorev.2010.11.003; Okamoto H, 2005, EUR J NEUROSCI, V21, P1957, DOI 10.1111/j.1460-9568.2005.04022.x; Okamoto H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017022; Okamoto H, 2010, P NATL ACAD SCI USA, V107, P1207, DOI 10.1073/pnas.0911268107; Pantev C, 2004, EUR J NEUROSCI, V19, P2337, DOI 10.1111/j.0953-816X.2004.03296.x; Pantev C, 2014, BMC NEUROL, V14, DOI 10.1186/1471-2377-14-40; Rajan R, 1998, NAT NEUROSCI, V1, P138, DOI 10.1038/388; Ross B, 2002, HEARING RES, V165, P68, DOI 10.1016/S0378-5955(02)00285-X; Stein A, 2015, CLIN NEUROPHYSIOL, V126, P1007, DOI 10.1016/j.clinph.2014.08.017; Stein A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080899; Teismann H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089904; Teismann H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024685; TESCHE CD, 1995, ELECTROEN CLIN NEURO, V95, P189, DOI 10.1016/0013-4694(95)00064-6; Wunderlich R, 2015, J AM ACAD AUDIOL, V26, P205, DOI 10.3766/jaaa.26.2.9; Zirke N, 2010, HNO, V58, P726, DOI 10.1007/s00106-009-2050-9	36	19	20	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2015	10	9							e0138595	10.1371/journal.pone.0138595	http://dx.doi.org/10.1371/journal.pone.0138595			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS1CR	26406446	Green Published, Green Submitted, gold			2023-01-03	WOS:000361800700060
J	von Kanel, R; Fardad, N; Steurer, N; Horak, N; Hindermann, E; Fischer, F; Gessler, K				von Kaenel, Roland; Fardad, Nasser; Steurer, Nadine; Horak, Nicole; Hindermann, Esther; Fischer, Franz; Gessler, Katharina			Vitamin D Deficiency and Depressive Symptomatology in Psychiatric Patients Hospitalized with a Current Depressive Episode: A Factor Analytic Study	PLOS ONE			English	Article							D-RECEPTOR; D SUPPLEMENTATION; HEART-DISEASE; METAANALYSIS; SYMPTOMS; ASSOCIATION; EXPRESSION; DISORDER; KETAMINE; NEURONS	Background Low vitamin D levels have been associated with depressive symptoms in population-based studies and non-clinical samples as well as with clinical depression. This study aimed to examine the association of vitamin D levels with the severity and dimensions of depressive symptoms in hospitalized patients with a current episode of depression taking into account confounding variables. Methods We investigated 380 patients (mean age 47 +/- 12 years, 70% women) who were consecutively hospitalized with a main diagnosis of an ICD-10 depressive episode. All patients self-rated depressive symptom severity with the Hospital Anxiety and Depression Scale (HADS-D), the Beck Depression Inventory-II (BDI-II), and the Brief Symptom Inventory. A principal component analysis was performed with all 34 items of these questionnaires and serum levels of 25-hydroxyvitamin D3 (25-OH D) were measured. Results Vitamin D deficiency (<50 nmol/l), insufficiency (50-75 nmol/l), and sufficiency (>75 nmol/l) were present in 55.5%, 31.8% and 12.6%, respectively, of patients. Patients with vitamin D deficiency scored higher on the HADS-D scale and on an anhedonia symptom factor than those with insufficient (p-values <= 0.023) or sufficient (p-values <= 0.008) vitamin D. Vitamin D deficient patients also scored higher on the BDI-II scale than those with sufficient vitamin D (p = 0.007); BDI-II cognitive/affective symptoms, but not somatic/affective symptoms, were higher in patients with vitamin D deficiency (p = 0.005) and insufficiency (p = 0.041) relative to those with sufficient vitamin D. Effect sizes suggested clinically relevant findings. Conclusions Low vitamin D levels are frequent in hospitalized patients with a current episode of depression. Especially 25-OH D levels <50 nmol/l were associated with cognitive/affective depressive symptoms, and anhedonia symptoms in particular.	[von Kaenel, Roland; Fardad, Nasser; Steurer, Nadine; Horak, Nicole; Hindermann, Esther; Gessler, Katharina] Clin Barmelweid, Dept Psychosomat Med, Barmelweid, Switzerland; [von Kaenel, Roland] Univ Hosp Bern, Inselspital, Dept Neurol, CH-3010 Bern, Switzerland; [von Kaenel, Roland] Univ Bern, Bern, Switzerland; [von Kaenel, Roland] Univ Bern, Dept Clin Res, Bern, Switzerland; [Fischer, Franz] Psymeta GmbH, Schafisheim, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University of Bern	von Kanel, R (corresponding author), Clin Barmelweid, Dept Psychosomat Med, Barmelweid, Switzerland.	roland.vonkaenel@insel.ch	von Känel, Roland/B-1811-2019	von Känel, Roland/0000-0002-8929-5129	Psymeta GmbH	Psymeta GmbH	The authors received no specific funding for this work. Psymeta GmbH provided support in the form of salaries for author F.F., but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of this author is articulated in the "author contributions" section.	Anglin RES, 2013, BRIT J PSYCHIAT, V202, P100, DOI 10.1192/bjp.bp.111.106666; Annweiler C, 2013, J CLIN PSYCHIAT, V74, P1121, DOI 10.4088/JCP.13ac08783; Azevedo RD, 2014, PSYCHOL MED, V44, P2689, DOI 10.1017/S0033291714000063; Beck A., 1996, PSYCHOL ASSESS, V2; Begre S, 2010, SOC PSYCH PSYCH EPID, V45, P17, DOI 10.1007/s00127-009-0036-2; Berk M, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-200; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Brennan C, 2010, J PSYCHOSOM RES, V69, P371, DOI 10.1016/j.jpsychores.2010.04.006; Cieslak K, 2014, SCHIZOPHR RES, V159, P543, DOI 10.1016/j.schres.2014.08.031; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cui X, 2013, NEUROSCIENCE, V236, P77, DOI 10.1016/j.neuroscience.2013.01.035; De Jonge P, 2007, PSYCHOSOM MED, V69, P735, DOI 10.1097/PSY.0b013e31815743ca; Derogatis L, 1983, BRIEF SYMPTOM INVENT, V13, P595, DOI DOI 10.1017/S0033291700048017; Di Stefano C., 2009, PRACT ASSESS RES EVA, V14, P11; Eyles DW, 2005, J CHEM NEUROANAT, V29, P21, DOI 10.1016/j.jchemneu.2004.08.006; Franke GH., 2000, BRIEF SYMPTOM INVENT; Ganji Vijay, 2010, Int Arch Med, V3, P29, DOI 10.1186/1755-7682-3-29; Gezen-Ak D, 2013, NEUROL SCI, V34, P1453, DOI 10.1007/s10072-012-1268-6; Harms LR, 2011, BEST PRACT RES CL EN, V25, P657, DOI 10.1016/j.beem.2011.05.009; Hautzinger M., 2006, DTSCH BEARBEITUNG HD; Herrmann C., 1995, HADS D HOSP ANXIETY; Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385; Hossein-nezhad A, 2013, MAYO CLIN PROC, V88, P720, DOI 10.1016/j.mayocp.2013.05.011; Jiang P, 2013, PSYCHONEUROENDOCRINO, V38, P2091, DOI 10.1016/j.psyneuen.2013.03.017; Ju SY, 2013, J NUTR HEALTH AGING, V17, P447, DOI 10.1007/s12603-012-0418-0; KEDDIE KMG, 1987, BRIT J PSYCHIAT, V150, P394, DOI 10.1192/bjp.150.3.394; Khoraminya N, 2013, AUST NZ J PSYCHIAT, V47, P271, DOI 10.1177/0004867412465022; Lally N, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.105; Lally N, 2015, J PSYCHOPHARMACOL, V29, P596, DOI 10.1177/0269881114568041; Lux V, 2010, PSYCHOL MED, V40, P1679, DOI 10.1017/S0033291709992157; Maddock J, 2013, CLIN NUTR, V32, P758, DOI 10.1016/j.clnu.2013.01.006; Modan-Moses D, 2015, INT J EAT DISORDER, V48, P607, DOI 10.1002/eat.22347; Patrick RP, 2014, FASEB J, V28, P2398, DOI 10.1096/fj.13-246546; Pramyothin P, 2012, CURR OPIN GASTROEN, V28, P139, DOI 10.1097/MOG.0b013e32835004dc; Shaffer JA, 2014, PSYCHOSOM MED, V76, P190, DOI 10.1097/PSY.0000000000000044; Snellman G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011555; Spedding S, 2014, NUTRIENTS, V6, P1501, DOI 10.3390/nu6041501; Tang M, 2013, BRAIN RES, V1513, P127, DOI 10.1016/j.brainres.2013.03.042; Vanheule S, 2008, ASSESSMENT, V15, P177, DOI 10.1177/1073191107311261; von Kanel R, 2014, PAIN MED, V15, P1609, DOI 10.1111/pme.12454; Zhou CC, 2006, J CLIN INVEST, V116, P1703, DOI 10.1172/JCI27793; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	42	23	23	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2015	10	9							e0138550	10.1371/journal.pone.0138550	http://dx.doi.org/10.1371/journal.pone.0138550			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS1BM	26397113	Green Published, Green Submitted, gold			2023-01-03	WOS:000361797500076
J	Lu, CS; Chang, PY; Chen, YG; Chen, JH; Wu, YY; Ho, CL				Lu, Chieh-Sheng; Chang, Ping-Ying; Chen, Yu-Guang; Chen, Jia-Hong; Wu, Yi-Ying; Ho, Ching-Liang			Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70	PLOS ONE			English	Article							METASTATIC COLORECTAL-CANCER; TEGAFUR PLUS LEUCOVORIN; PHASE-III; INTRAVENOUS FLUOROURACIL; POSTMENOPAUSAL WOMEN; FINAL REPORT; ORAL URACIL; OXALIPLATIN; SURVIVAL; TRIAL	Background The aim of this study was to examine the specific chemoregimens selected for adjuvant therapy in the patients with stage III colon cancer. We investigated the trends in chemotherapeutic prescribing patterns and looked for adequate therapeutic setting for these patients. Methods 288 patients presenting with stage III colon cancer and undergoing adjuvant therapies after curative surgery for more than 3-month were enrolled between January 2006 and December 2011. Demographic characteristics and therapeutic factors were analyzed, including age, gender, histological grade, tumor sizes, tumor location, pathologic stage, performance status, serum carcinoembryonic antigen, regimens selection, interval from the operation to the start of adjuvant therapy and prolonged adjuvant therapy. Kaplan-Meier methods were utilized for drawing survival curves and Cox model was used to analyze survival, prognostic factors. Results The analysis showed that the patients aged under 70 received more intensive therapies than those aged over 70 (P<0.001). Later, advanced analysis in therapeutic factors was conducted between the patients aged under 70 and those over 70. In the patients aged under 70, significant differences in 4-year overall survival (OS) were noted between UFUR (oral tegafur-uracil plus leucovorin) groups and FOLFOX (5-FU plus oxaliplatin) [65.6% versus (vs) 89.8%, relative risk (RR) 3.780, 95% confidence interval (CI) 1.263-11.315, P = 0.017]. There were also differences in 4-year OS between these patients with and without oxaliplatin-contained regimens (92.1% vs 83.4%, respectively, RR 0.385, 95% CI 0.157-0.946, P = 0.037). In addition, the patients who received intravenous or combined therapy also had higher 4-year OS than those only received oral regimens (92.1% vs 76.6%, P = 0.077), though the finding did not reach statistical significance. In contrast to the survival benefits of above therapeutic settings for the patients aged under 70, there was less advantage in the old patients when they received intensive therapies or even oxaliplatin-contained regimens. Prolonged cycles of adjuvant therapy resulted in no significant benefit to survival rates regardless of ages. Conclusions The adequate individualized therapeutic strategy plays an important role for stage III colon cancer. Our findings suggested that benefit of oxaliplatin-contained therapy is limited to patients aged under 70 and oral fluoropyrimidines may be an effective option for old patients. In addition, prolonged adjuvant setting is suggested to be unbeneficial for managing stage III colon cancer.	[Lu, Chieh-Sheng] Kaohsiung Armed Forces Gen Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Lu, Chieh-Sheng; Chang, Ping-Ying; Chen, Yu-Guang; Chen, Jia-Hong; Wu, Yi-Ying; Ho, Ching-Liang] Natl Def Med Ctr, Triserv Gen Hosp, Dept Internal Med, Div Hematol & Oncol, Taipei, Taiwan	National Defense Medical Center; Tri-Service General Hospital	Lu, CS (corresponding author), Kaohsiung Armed Forces Gen Hosp, Dept Internal Med, Kaohsiung, Taiwan.	chengsem@gmail.com; hochingliang@yahoo.com.tw		Lu, Chieh-Sheng/0000-0002-9056-3135; Wu, Yi-Ying/0000-0003-0411-6265				Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Andre T, 1999, EUR J CANCER, V35, P1343, DOI 10.1016/S0959-8049(99)00150-1; Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Andre T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771; Benson AB, 2000, J CLIN ONCOL, V18, P3586, DOI 10.1200/JCO.2000.18.20.3586; Biagi JJ, 2011, JAMA-J AM MED ASSOC, V305, P2335, DOI 10.1001/jama.2011.749; Booth CM, 2012, J CLIN ONCOL, V30, P1030, DOI 10.1200/JCO.2011.38.7571; Chan A, 2014, CURR ONCOL, V21, P181, DOI 10.3747/co.21.1963; Cheeseman SL, 2002, BRIT J CANCER, V87, P393, DOI 10.1038/sj.bjc.6600467; Chlebowski RT, 2004, NEW ENGL J MED, V350, P991, DOI 10.1056/NEJMoa032071; Des Guetz G, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007046.pub2; Des Guetz G, 2010, EUR J CANCER, V46, P1049, DOI 10.1016/j.ejca.2010.01.020; Edge S.B., 2010, AJCC CANC STAGING MA, V649; Ferlitsch M, 2011, JAMA-J AM MED ASSOC, V306, P1352, DOI 10.1001/jama.2011.1362; Haller DG, 2011, J CLIN ONCOL, V29, P1465, DOI 10.1200/JCO.2010.33.6297; Haller DG, 2005, J CLIN ONCOL, V23, P8671, DOI 10.1200/JCO.2004.00.5686; Health Promotion Administration Ministry of Health and Welfare Taiwan, TAIW CANC REG ANN RE; Hershman D, 2006, CANCER-AM CANCER SOC, V107, P2581, DOI 10.1002/cncr.22316; Ishihara S, 2014, INT J SURG, V12, P925, DOI 10.1016/j.ijsu.2014.07.270; Kim DJ, 2003, YONSEI MED J, V44, P665, DOI 10.3349/ymj.2003.44.4.665; Kuebler JP, 2007, J CLIN ONCOL, V25, P2198, DOI 10.1200/JCO.2006.08.2974; Lembersky BC, 2006, J CLIN ONCOL, V24, P2059, DOI 10.1200/JCO.2005.04.7498; Maindrault-Goebel F, 2000, ANN ONCOL, V11, P1477, DOI 10.1023/A:1026520812351; McCleary NAJ, 2009, J CLIN ONCOL, V27; McCleary NJ, 2013, J CLIN ONCOL, V31, P2600, DOI 10.1200/JCO.2013.49.6638; McCleary NJ, 2013, CLIN COLORECTAL CANC, V12, P62, DOI 10.1016/j.clcc.2012.09.001; MOERTEL CG, 1995, ANN INTERN MED, V122, P321, DOI 10.7326/0003-4819-122-5-199503010-00001; Qin Qiong, 2013, Zhonghua Zhong Liu Za Zhi, V35, P212, DOI 10.3760/cma.j.issn.0253-3766.2013.03.011; Regula J, 2006, NEW ENGL J MED, V355, P1863, DOI 10.1056/NEJMoa054967; Resch A, 2013, WORLD J GASTROENTERO, V19, P8515, DOI 10.3748/wjg.v19.i46.8515; Saha S, 2013, J CLIN ONCOL, V31; Scheer Adena, 2009, Clin Colon Rectal Surg, V22, P242, DOI 10.1055/s-0029-1242464; Schmoll HJ, 2007, J CLIN ONCOL, V25, P102, DOI 10.1200/JCO.2006.08.1075; Shimada Y, 2014, EUR J CANCER, V50, P2231, DOI 10.1016/j.ejca.2014.05.025; Sugimoto K, 2015, ANN SURG ONCOL, V22, P528, DOI 10.1245/s10434-014-4015-9; Taiwan Cancer Registry, AG STAND INC LONG TE; Twelves C, 2005, NEW ENGL J MED, V352, P2696, DOI 10.1056/NEJMoa043116; Wu Xiaocheng, 2004, J La State Med Soc, V156, P255	38	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2015	10	9							e0138632	10.1371/journal.pone.0138632	http://dx.doi.org/10.1371/journal.pone.0138632			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS0ZE	26382962	Green Submitted, gold, Green Published			2023-01-03	WOS:000361790200142
J	Onodera, K; Arimura, Y; Isshiki, H; Kawakami, K; Nagaishi, K; Yamashita, K; Yamamoto, E; Niinuma, T; Naishiro, Y; Suzuki, H; Imai, K; Shinomura, Y				Onodera, Kei; Arimura, Yoshiaki; Isshiki, Hiroyuki; Kawakami, Kentaro; Nagaishi, Kanna; Yamashita, Kentaro; Yamamoto, Eiichiro; Niinuma, Takeshi; Naishiro, Yasuyoshi; Suzuki, Hiromu; Imai, Kohzoh; Shinomura, Yasuhisa			Low-Frequency IL23R Coding Variant Associated with Crohn's Disease Susceptibility in Japanese Subjects Identified by Personal Genomics Analysis	PLOS ONE			English	Article							INFLAMMATORY-BOWEL-DISEASE; WIDE ASSOCIATION; LOCI; POLYMORPHISMS; IL-23R; GENE; PRIORITIZATION; STRATEGIES; DISORDERS; ATG16L1	Background The common disease-common variant hypothesis is insufficient to explain the complexities of Crohn's disease (CD) genetics; therefore, rare variants are expected to be important in the disease. We explored rare variants associated with susceptibility to CD in Japanese individuals by personal genomic analysis. Methods Two-step analyses were performed. The first step was a trio analysis with whole-exome sequence (WES) analysis and the second was a follow-up case-control association study. The WES analysis pipeline comprised Burrows-Wheeler Aligner, Picard, Genome Analysis Toolkit, and SAMTOOLS. Single nucleotide variants (SNVs)/indels were annotated and filtered by using programs implemented in ANNOVAR in combination with identity-by-descent (IBD), subsequently were subjected to the linkage based, and de novo based strategies. Finally, we conducted an association study that included 176 unrelated subjects with CD and 358 healthy control subjects. Results In family members, 234,067-297,523 SNVs/indels were detected and they were educed to 106-146 by annotation based filtering. Fifty-four CD variants common to both individuals of the affected sib pair were identified. The linkage based strategy detected five candidate variants whereas the de novo based strategy identified no variants. Consequently, five candidates were analyzed in the case-control association study. CD showed a significant association with one variant in exon 4 of IL23R, G149R [rs76418789, P = 3.9E-5, odds ratio (OR) 0.21, 95% confidence interval (CI) 0.09-0.47 for the dominant model (AA + AG versus GG), and P = 7.3E-5, OR 0.21, 95% CI 0.10-0.48 for AG versus GG, and P = 7.2E-5, OR 0.23, 95% CI 0.10-0.50 for the allele model]. Conclusions The present study, using personal genomics analysis of a small CD pedigree, is the first to show that the low-frequency non-synonymous variant of IL23R, rs76418789, protects against CD development in Japanese subjects.	[Onodera, Kei; Arimura, Yoshiaki; Isshiki, Hiroyuki; Kawakami, Kentaro; Yamashita, Kentaro; Yamamoto, Eiichiro; Shinomura, Yasuhisa] Sapporo Med Univ, Dept Gastroenterol Rheumatol & Clin Immunol, Sapporo, Hokkaido, Japan; [Nagaishi, Kanna] Sapporo Med Univ, Dept Anat, Sapporo, Hokkaido, Japan; [Niinuma, Takeshi; Suzuki, Hiromu] Sapporo Med Univ, Dept Mol Biol, Sapporo, Hokkaido, Japan; [Naishiro, Yasuyoshi] Sapporo Med Univ, Dept Educ Dev, Sapporo, Hokkaido, Japan; [Imai, Kohzoh] Univ Tokyo, Inst Med Sci, Ctr Antibody & Vaccine Therapy, Tokyo, Japan	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University; Sapporo Medical University; University of Tokyo	Arimura, Y (corresponding author), Sapporo Med Univ, Dept Gastroenterol Rheumatol & Clin Immunol, Sapporo, Hokkaido, Japan.	arimura@sapmed.ac.jp			Grants-in-Aid for Scientific Research [25460954, 221S0001] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Adzhubei Ivan A., 1994, NAT MED, V7, P248, DOI [10.1038/nmeth0410-248.A, DOI 10.1038/NMETH0410-248.A]; Arimura Y, 2014, J GASTROENTEROL, V49, P1217, DOI 10.1007/s00535-013-0866-2; Bailey SL, 2007, NAT IMMUNOL, V8, P172, DOI 10.1038/ni1430; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Chen B, 2009, J GENET, V88, P191, DOI 10.1007/s12041-009-0027-9; Cheng R, 2005, FINE MAPPING FUNCTIO, P102; Clark MJ, 2011, NAT BIOTECHNOL, V29, P908, DOI 10.1038/nbt.1975; Cortes A, 2013, NAT GENET, V45, P730, DOI 10.1038/ng.2667; Dainel Podolsky, 2007, NEW ENGL J MED, V347, P1; Do R, 2012, HUM MOL GENET, V21, pR1, DOI 10.1093/hmg/dds387; Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245; Gasche C, 2000, INFLAMM BOWEL DIS, V6, P8, DOI 10.1097/00054725-200002000-00002; Gilissen C, 2012, EUR J HUM GENET, V20, P490, DOI 10.1038/ejhg.2011.258; Group NW, 2007, REPLICATING GENOTYPE, V447, P655; Ju YS, 2011, NAT GENET, V43, P745, DOI 10.1038/ng.872; Kim SW, 2011, GUT, V60, P1527, DOI 10.1136/gut.2011.238477; Koboldt DC, 2014, AM J HUM GENET, V94, P373, DOI 10.1016/j.ajhg.2014.01.016; Krawitz PM, 2010, NAT GENET, V42, P827, DOI 10.1038/ng.653; Little J, 2006, ANN INTERN MED, V2006, P50; Martin M., 2011, EMBNET J, V17, P10, DOI 10.14806/ej.17.1.200; Momozawa Y, 2011, NAT GENET, V43, P43, DOI 10.1038/ng.733; Nakahara S, 2008, DIS COLON RECTUM, V51, P598, DOI 10.1007/s10350-008-9208-5; Newport M, 2007, NAT GENET, V39, P1329, DOI 10.1038/ng.2007.17; Okazaki T, 2008, INFLAMM BOWEL DIS, V14, P1528, DOI 10.1002/ibd.20512; Ott J, 2011, NAT REV GENET, V12, P465, DOI 10.1038/nrg2989; Parham C, 2002, J IMMUNOL, V168, P5699, DOI 10.4049/jimmunol.168.11.5699; Pidasheva S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025038; Roedelsperger C, 2011, BIOINFORMATICS, V27, P829, DOI 10.1093/bioinformatics/btr022; Santoni FA, 2014, GENOME RES, V24, P349, DOI 10.1101/gr.163832.113; Skol AD, 2006, NAT GENET, V38, P209, DOI 10.1038/ng1706; Smith RL, 2008, J INVEST DERMATOL, V128, P1325, DOI 10.1038/sj.jid.5701140; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Yamazaki K, 2007, J HUM GENET, V52, P575, DOI 10.1007/s10038-007-0156-z; Yang SK, 2014, GUT, V63, P80, DOI 10.1136/gutjnl-2013-305193; Zollner S, 2012, EUR J HUM GENET, V20, P1085, DOI 10.1038/ejhg.2012.58	35	6	6	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2015	10	9							e0137801	10.1371/journal.pone.0137801	http://dx.doi.org/10.1371/journal.pone.0137801			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR8NH	26375822	Green Published, Green Submitted, gold			2023-01-03	WOS:000361610200053
J	Ackermann, RT				Ackermann, Ronald T.			Diabetes Prevention at the Tipping Point: Aligning Clinical and Public Health Recommendations	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							RISK-FACTORS; ADULTS		[Ackermann, Ronald T.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Ackermann, RT (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, 750 North Lake Shore Dr,10th Floor, Chicago, IL 60611 USA.	r.ackermann@northwestern.edu						Balk EM, 2015, ANN INTERN MED, V163, P437, DOI 10.7326/M15-0452; Centers for Disease Control and Prevention, 2012, NAT DIAB PREV PROGR; Gakhar M., 2015, MEASURABLE PROGR UNL; Geiss LS, 2010, AM J PREV MED, V38, P403, DOI 10.1016/j.amepre.2009.12.029; LeFevre ML, 2014, ANN INTERN MED, V161, P587, DOI 10.7326/M14-1796; Li R, 2015, ANN INTERN MED, V163, P452, DOI 10.7326/M15-0469; Pronk NP, 2015, ANN INTERN MED, V163, P465, DOI 10.7326/M15-1029; Ratner R, 2005, DIABETES CARE, V28, P888, DOI 10.2337/diacare.28.4.888; Selvin E, 2011, DIABETES CARE, V34, P84, DOI 10.2337/dc10-1235; U.S. Preventive Services Task Force, 2014, DRAFT REC STAT ABN G	10	9	9	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	2015	163	6					475	476		10.7326/M15-1563	http://dx.doi.org/10.7326/M15-1563			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CR5FL	26168323				2023-01-03	WOS:000361365900025
J	Hoek, P; Grandjean, I; Verhagen, CAHHVM; Jansen-Landheer, MLEA; Schers, HJ; Galesloot, C; Vissers, KCP; Engels, Y; Hasselaar, JGJ				Hoek, Patrick; Grandjean, Ilse; Verhagen, Constans A. H. H. V. M.; Jansen-Landheer, Marlies L. E. A.; Schers, Henk J.; Galesloot, Cilia; Vissers, Kris C. P.; Engels, Yvonne; Hasselaar, Jeroen G. J.			Addressing Palliative Sedation during Expert Consultation: A Descriptive Analysis of the Practice of Dutch Palliative Care Consultation Teams	PLOS ONE			English	Article							CONTINUOUS DEEP SEDATION; TERMINALLY-ILL PATIENTS; PATIENTS NEARING DEATH; OF-LIFE PRACTICES; REFRACTORY SYMPTOMS; CANCER-PATIENTS; EUTHANASIA LAW; END; NETHERLANDS; PATTERNS	Main Objective Since palliative sedation is considered a complex intervention, consultation teams are increasingly established to support general practice. This study aims to offer insight into the frequency and characteristics of expert consultations regarding palliative sedation. Methods We performed a retrospective analysis of a longitudinal database. This database contained all patient-related consultations by Dutch Palliative Care Consultation teams, that were requested between 2004 and 2011. We described the frequency and characteristics of these consultations, in particular of the subgroup of consultations in which palliative sedation was addressed (i.e. PSa consultations). We used multivariate regression analysis to explore consultation characteristics associated with a higher likelihood of PSa consultations. Main Results and Their Significance Of the 44,443 initial consultations, most were requested by general practitioners (73%) and most concerned patients with cancer (86%). Palliative sedation was addressed in 18.1% of all consultations. Palliative sedation was relatively more often discussed during consultations for patients with a neurologic disease (OR 1.79; 95% CI: 1.51-2.12) or COPD (OR 1.39; 95% CI: 1.15-1.69) than for patients with cancer. We observed a higher likelihood of PSa consultations if the following topics were also addressed during consultation: dyspnoea (OR 1.30; 95% CI: 1.22-1.40), agitation/delirium (OR 1.57; 95% CI: 1.47-1.68), exhaustion (OR 2.89; 95% CI: 2.61-3.20), euthanasia-related questions (OR 2.65; 95% CI: 2.37-2.96) or existential issues (OR 1.55; 95% CI: 1.31-1.83). Conclusion In conclusion, PSa consultations accounted for almost one-fifth of all expert consultations and were associated with several case-related characteristics. These characteristics may help clinicians in identifying patients at risk for a more complex disease trajectory at the end of life.	[Hoek, Patrick; Verhagen, Constans A. H. H. V. M.; Vissers, Kris C. P.; Engels, Yvonne; Hasselaar, Jeroen G. J.] Radboud Univ Nijmegen, Med Ctr, Dept Anesthesiol Pain & Palliat Med, Nijmegen, Netherlands; [Grandjean, Ilse; Jansen-Landheer, Marlies L. E. A.; Galesloot, Cilia] Comprehens Canc Ctr Netherlands, Utrecht, Netherlands; [Schers, Henk J.] Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Hoek, P (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Anesthesiol Pain & Palliat Med, Nijmegen, Netherlands.	Patrick.Hoek@Radboudumc.nl	Vissers, Kris/H-8110-2014; Verhagen, C.A.H.H.V.M./L-4710-2015; Hoek, Patrick D/P-6160-2015; Hasselaar, Jeroen/C-9446-2011; Schers, H.J./L-4631-2015; Vissers, Kris C.P./D-3569-2009; Engels, Yvonne/I-1814-2015	Vissers, Kris/0000-0002-2919-6356; Hoek, Patrick D/0000-0001-8905-3472; Schers, H.J./0000-0002-9362-9451; Vissers, Kris C.P./0000-0002-2919-6356; Engels, Yvonne/0000-0002-7669-1018				Anquinet L, 2011, EUR J GEN PRACT, V17, P5, DOI 10.3109/13814788.2010.536529; Beernaert K, 2013, RESP MED, V107, P1731, DOI 10.1016/j.rmed.2013.06.003; Bilsen J, 2009, NEW ENGL J MED, V361, P1119, DOI 10.1056/NEJMc0904292; Brinkkemper T, 2011, J ADV NURS, V67, P1719, DOI 10.1111/j.1365-2648.2011.05614.x; Broeckaert, 2012, RICHTLIJN PALLIATIEV; Bush SH, 2014, J PAIN SYMPTOM MANAG, V48, P215, DOI 10.1016/j.jpainsymman.2014.05.009; Chambaere K, 2010, ARCH INTERN MED, V170, P490, DOI 10.1001/archinternmed.2009.542; Cherny NI, 2014, ANN ONCOL, V25, P143, DOI 10.1093/annonc/mdu238; Cherny NI, 2009, PALLIATIVE MED, V23, P581, DOI 10.1177/0269216309107024; Chiu TY, 2001, J PAIN SYMPTOM MANAG, V21, P467, DOI 10.1016/S0885-3924(01)00286-X; De Graeff A, 2007, J PALLIAT MED, V10, P67, DOI 10.1089/jpm.2006.0139; Dean MM, 2012, J PALLIAT MED, V15, P870, DOI 10.1089/jpm.2011.0498; Donker GA, 2013, BRIT J GEN PRACT, V63, pE669, DOI 10.3399/bjgp13X673676; Fainsinger RL, 2000, PALLIATIVE MED, V14, P257, DOI 10.1191/026921600666097479; Grandjean I, 2013, CONSULTATIE PALLIATI; Hasselaar JGJ, 2007, ARCH INTERN MED, V167, P1166, DOI 10.1001/archinte.167.11.1166; Hasselaar JGJ, 2009, ARCH INTERN MED, V169, P430, DOI 10.1001/archinternmed.2008.613; Kirk TW, 2010, J PAIN SYMPTOM MANAG, V39, P914, DOI 10.1016/j.jpainsymman.2010.01.009; Kohara Hiroyuki, 2005, J Palliat Med, V8, P20, DOI 10.1089/jpm.2005.8.20; Koper I, 2014, SUPPORT CARE CANCER, V22, P225, DOI 10.1007/s00520-013-1972-7; Lo B, 2005, JAMA-J AM MED ASSOC, V294, P1810, DOI 10.1001/jama.294.14.1810; Maltoni M, 2012, J CLIN ONCOL, V30, P1378, DOI 10.1200/JCO.2011.37.3795; Miccinesi G, 2006, J PAIN SYMPTOM MANAG, V31, P122, DOI 10.1016/j.jpainsymman.2005.07.004; Morita T, 2004, SUPPORT CARE CANCER, V12, P584, DOI 10.1007/s00520-004-0603-8; Morita T, 2002, J PAIN SYMPTOM MANAG, V24, P447, DOI 10.1016/S0885-3924(02)00499-2; Morita Tatsuya, 2005, J Palliat Med, V8, P716, DOI 10.1089/jpm.2005.8.716; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Onwuteaka-Philipsen BD, 2012, LANCET, V380, P908, DOI 10.1016/S0140-6736(12)61034-4; Papavasiliou EE, 2014, SUPPORT CARE CANC; Potter J, 2003, PALLIATIVE MED, V17, P310, DOI 10.1191/0269216303pm760oa; Report of the Council on Ethical and Judicial Affairs, 2008, 5A08 CEJA; Rietjens JAC, 2006, ARCH INTERN MED, V166, P749, DOI 10.1001/archinte.166.7.749; Rietjens JAC, 2004, ANN INTERN MED, V141, P178, DOI 10.7326/0003-4819-141-3-200408030-00006; Rietjens J, 2008, BRIT MED J, V336, P810, DOI 10.1136/bmj.39504.531505.25; Robijn L, 2014, SUPPORT CARE CANC; Royal Dutch Medical Association (KNMG), 2009, GUID PALL SED; Schrijnemaekers V, 2005, J PAIN SYMPTOM MANAG, V29, P552, DOI 10.1016/j.jpainsymman.2004.09.002; Seale C, 2010, J PAIN SYMPTOM MANAG, V39, P44, DOI 10.1016/j.jpainsymman.2009.06.007; Seymour J, 2014, PALLIAT MED; Swart S, 2012, BMJ SUPPORTIVE PALLI; Swart SJ, 2012, J PAIN SYMPTOM MANAG, V43, P172, DOI 10.1016/j.jpainsymman.2011.04.004; Tsai JS, 2006, PALLIATIVE MED, V20, P617, DOI 10.1177/0269216306071065; van der Heide A., 2010, HAAG ZONMW, V2012, P70	43	4	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2015	10	8							e0136309	10.1371/journal.pone.0136309	http://dx.doi.org/10.1371/journal.pone.0136309			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP5VA	26301746	Green Submitted, Green Published, gold			2023-01-03	WOS:000359951900057
J	Kelley, AS; Morrison, RS				Kelley, Amy S.; Morrison, R. Sean			Palliative Care for the Seriously Ill	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIAL; ADVANCED CANCER-PATIENTS; QUALITY-OF-LIFE; SPIRITUAL CARE; NEAR-DEATH; ADVANCED ILLNESS; MEDICAL-CARE; LAST WEEK; END; COMMUNICATION		[Kelley, Amy S.; Morrison, R. Sean] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY 10029 USA; [Kelley, Amy S.; Morrison, R. Sean] James J Peters Vet Affairs Med Ctr, Bronx, NY USA	Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center	Kelley, AS (corresponding author), Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA.	amy.kelley@mssm.edu			NATIONAL INSTITUTE ON AGING [P30AG028741, K24AG022345, R24AG044300, K23AG040774] Funding Source: NIH RePORTER; NIA NIH HHS [K23 AG040774, K24 AG022345, R24 AG044300, P30 AG028741] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson H, 2001, PALLIATIVE MED, V15, P279, DOI 10.1191/026921601678320269; Au DH, 2012, CHEST, V141, P726, DOI 10.1378/chest.11-0362; Back AL, 2003, J CLIN ONCOL, V21, P2433, DOI 10.1200/JCO.2003.09.073; Back AL, 2009, MASTERING COMMUNICAT; Bakitas M, 2009, JAMA-J AM MED ASSOC, V302, P741, DOI 10.1001/jama.2009.1198; Balboni TA, 2007, J CLIN ONCOL, V25, P555, DOI 10.1200/JCO.2006.07.9046; Balboni TA, 2010, J CLIN ONCOL, V28, P445, DOI 10.1200/JCO.2009.24.8005; Bausewein C., 2011, OUTCOME MEASUREMENT; Bausewein C, 2010, J PALLIAT MED, V13, P1109, DOI 10.1089/jpm.2010.0068; Block Susan D, 2002, J Palliat Med, V5, P243, DOI 10.1089/109662102753641214; Butler M, 2014, ANN INTERN MED, V161, P408, DOI 10.7326/M14-0644; Center to Advance Palliative Care, 2008, STAT STAT CARD ACC P; Ciemins EL, 2006, J PALLIAT MED, V9, P1401, DOI 10.1089/jpm.2006.9.1401; Eagar K, 2010, AUST HEALTH REV, V34, P186, DOI 10.1071/AH08718; Edmonds P, 2010, MULT SCLER J, V16, P627, DOI 10.1177/1352458510364632; El Nawawi NM, 2012, CURR OPIN SUPPORT PA, V6, P269, DOI 10.1097/SPC.0b013e3283530d13; Fainsinger RL, 2007, J PAIN SYMPTOM MANAG, V33, P634, DOI 10.1016/j.jpainsymman.2007.02.012; Gelfman LP, 2013, J PALLIAT MED, V16, P125, DOI 10.1089/jpm.2012.0427; GOMES B, 2013, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD007760.PUB2; Gomez-Batiste X, 2012, J PAIN SYMPTOM MANAG, V43, P783, DOI 10.1016/j.jpainsymman.2011.05.006; Hanratty B, 2006, PALLIATIVE MED, V20, P493, DOI 10.1191/0269216306pm1162oa; Higginson IJ, 2002, J PAIN SYMPTOM MANAG, V23, P96, DOI 10.1016/S0885-3924(01)00406-7; Higginson IJ, 2014, LANCET RESP MED, V2, P979, DOI 10.1016/S2213-2600(14)70226-7; Hoyert Donna L, 2012, Natl Vital Stat Rep, V61, P1; Johnson JR, 2014, CRIT CARE MED, V42, P1991, DOI 10.1097/CCM.0000000000000412; Johnson KS, 2013, J PALLIAT MED, V16, P1329, DOI 10.1089/jpm.2013.9468; Karus D, 2005, J PAIN SYMPTOM MANAG, V30, P408, DOI 10.1016/j.jpainsymman.2005.04.011; Kelley AS, 2013, J PALLIAT MED, V16, P730, DOI 10.1089/jpm.2013.9498; Lupu D, 2010, J PAIN SYMPTOM MANAG, V40, P899, DOI 10.1016/j.jpainsymman.2010.07.004; May P, 2014, J PALLIAT MED, V17, P1054, DOI 10.1089/jpm.2013.0594; Miller SC, 2010, J AM GERIATR SOC, V58, P1481, DOI 10.1111/j.1532-5415.2010.02968.x; Mitchell SL, 2009, NEW ENGL J MED, V361, P1529, DOI 10.1056/NEJMoa0902234; Modonesi C, 2005, J PAIN SYMPTOM MANAG, V30, P367, DOI 10.1016/j.jpainsymman.2005.04.007; Moens K, 2014, J PAIN SYMPTOM MANAG, V48, P660, DOI 10.1016/j.jpainsymman.2013.11.009; Morrison RS, 2004, NEW ENGL J MED, V350, P2582, DOI 10.1056/NEJMcp035232; [National Center for Health Statistics Centers for Disease Control and Prevention], 2012, NAT NURS HOM SURV 20; National Consensus Project for Quality Palliative Care, 2013, CLIN PRACTICE GUIDEL; National Palliative Care Registry, 2014, ANN SURV SUMM RES 20; Nordgren Lena, 2003, Eur J Cardiovasc Nurs, V2, P213; Oi-Ling K, 2005, PALLIATIVE MED, V19, P228, DOI 10.1191/0269216305pm1001oa; Pautex S, 2007, J AM GERIATR SOC, V55, P1316, DOI 10.1111/j.1532-5415.2007.01267.x; Phelps AC, 2009, JAMA-J AM MED ASSOC, V301, P1140, DOI 10.1001/jama.2009.341; Potter J, 2003, PALLIATIVE MED, V17, P310, DOI 10.1191/0269216303pm760oa; Rabow M, 2013, J PALLIAT MED, V16, P1540, DOI 10.1089/jpm.2013.0153; Rodin D, 2015, SUPPORT CARE CANC; Schenker Y, 2014, J ONCOL PRACT, V10, pE37, DOI 10.1200/JOP.2013.001130; Smith S, 2014, PALLIATIVE MED, V28, P130, DOI 10.1177/0269216313493466; Spettell CM, 2009, J PALLIAT MED, V12, P827, DOI 10.1089/jpm.2009.0089; Sudore RL, 2010, ANN INTERN MED, V153, P256, DOI 10.7326/0003-4819-153-4-201008170-00008; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; The Joint Commission, 2011, ADV CERT PALL CAR PR; Tulsky JA, 2011, ANN INTERN MED, V155, P593, DOI 10.7326/0003-4819-155-9-201111010-00007; Walsh D, 2000, SUPPORT CARE CANCER, V8, P175, DOI 10.1007/s005200050281; Winkelman WD, 2011, J PALLIAT MED, V14, P1022, DOI 10.1089/jpm.2010.0536; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665	56	399	413	6	67	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 20	2015	373	8					747	755		10.1056/NEJMra1404684	http://dx.doi.org/10.1056/NEJMra1404684			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CP2LU	26287850	Green Accepted			2023-01-03	WOS:000359709400011
J	Zhu, WJ; Xu, BH				Zhu, Wenjie; Xu, Binghe			Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study	PLOS ONE			English	Article							HEMOGLOBIN LEVELS; TREATMENT RESISTANCE; RADIATION-THERAPY; PROGNOSTIC-FACTOR; TUMOR HYPOXIA; CELLS; IMPACT; ERYTHROPOIETIN; CARCINOMA; OUTCOMES	Background Anemia related to adjuvant chemotherapy might predict compromised survival in patients with breast cancer. The present population-based study was to investigate the correlation of pretreatment anemia with pathological response and long-term prognosis of breast cancer patients receiving neoadjuvant chemotherapy (NCT). Methods From 1999 to 2011, a total of 655 patients with operable or locally advanced breast cancer who underwent NCT before definitive surgery were reviewed. The patients were subdivided into anemic (baseline hemoglobin (Hb)<12.0g/dL) and non-anemic (Hb >= 12.0g/dL) groups. Comparison was made between anemic and non-anemic groups concerning the rate of pathological complete response (pCR), relapse-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS). Logistic and Cox regression models were utilized to determine the predictive value of pretreatment anemia in outcomes of patients undergoing NCT. Results 166 women (25.3%) were anemic before treatment. Patients in the anemic group were less likely to achieve pCR in NCT than their non-anemic counterparts (odds ratio (OR) 0.428, 95% confidence interval (CI) 0.198-0.927, p = 0.031). Patients with baseline anemia displayed inferior 10-year RFS (59.1% vs 66.0%, p = 0.022 by log-rank), OS (75.3% vs 90.9%, p <0.001) and CSS (82.4% vs 94.4%, p<0.001) compared with those without. After adjustment for confounders, pretreatment anemia was demonstrated to correlate with elevated risk of relapse (hazard ratio (HR) 1.453, 95% CI 1.077-1.962, p = 0.015), cancer-specific mortality (HR 2.961, 95% CI 1.679-5.222, p<0.001) and all-cause mortality (HR 2.873, 95% CI 1.757-4.699, p<0.001). Conclusions Pretreatment anemia was associated with worse pathological response to NCT as well as survival status in breast cancer. Further studies are warranted to identify optimal interventions and improve the prognosis of this subgroup.	[Xu, Binghe] Chinese Acad Med Sci, Dept Med Oncol, Canc Hosp, Beijing 100730, Peoples R China; Peking Union Med Coll, Beijing 100021, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Xu, BH (corresponding author), Chinese Acad Med Sci, Dept Med Oncol, Canc Hosp, Beijing 100730, Peoples R China.	bhxu@hotmail.com						Aapro M, 2015, ANN ONCOL, V26, P688, DOI 10.1093/annonc/mdu579; Beresford MJ, 2006, CLIN ONCOL-UK, V18, P453, DOI 10.1016/j.clon.2006.04.006; Boehm DU, 2007, ANTICANCER RES, V27, P1223; Bottini A, 2003, BRIT J CANCER, V89, P977, DOI 10.1038/sj.bjc.6601216; Caro JJ, 2001, CANCER-AM CANCER SOC, V91, P2214, DOI 10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P; Dubsky P, 2008, CLIN CANCER RES, V14, P2082, DOI 10.1158/1078-0432.CCR-07-2068; DUNPHY EP, 1989, INT J RADIAT ONCOL, V16, P1173, DOI 10.1016/0360-3016(89)90277-0; Feldmann HJ, 2001, LUNG CANCER S1, V33, P77; Flamant L, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-391; Flamant L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-191; Gilreath JA, 2014, AM J HEMATOL, V89, P203, DOI 10.1002/ajh.23628; Green SL, 1998, CANCER J SCI AM, V4, P218; Grogan M, 1999, CANCER, V86, P1528, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1528::AID-CNCR20>3.0.CO;2-E; Harrison LB, 2002, ONCOLOGIST, V7, P492, DOI 10.1634/theoncologist.7-6-492; Hedley BD, 2011, CLIN CANCER RES, V17, P6151, DOI 10.1158/1078-0432.CCR-10-3298; Henke M, 2004, STRAHLENTHER ONKOL, V180, P45, DOI 10.1007/s00066-004-1123-7; Hu Kenneth, 2005, Curr Treat Options Oncol, V6, P31, DOI 10.1007/s11864-005-0011-4; Kamby C, 1999, CLIN ONCOL-UK, V11, P156, DOI 10.1053/clon.1999.9033; Khorana AA, 2008, ARCH INTERN MED, V168, P2377, DOI 10.1001/archinte.168.21.2377; Knight K, 2004, AM J MED, V116, P11, DOI 10.1016/j.amjmed.2003.12.008; Matthews NE, 2001, J NATL CANCER I, V93, P1879, DOI 10.1093/jnci/93.24.1879; PAN SS, 1981, MOL PHARMACOL, V19, P184; Rodgers GM, 2012, J NATL COMPR CANC NE, V10, P628, DOI 10.6004/jnccn.2012.0064; Sullivan R, 2008, MOL CANCER THER, V7, P1961, DOI 10.1158/1535-7163.MCT-08-0198; Thompson CA, 2006, BRIT J HAEMATOL, V135, P405, DOI 10.1111/j.1365-2141.2006.06295.x; Todaro M, 2013, CANCER RES, V73, P6393, DOI 10.1158/0008-5472.CAN-13-0248; Vaupel P, 2001, MED ONCOL, V18, P243, DOI 10.1385/MO:18:4:243; Vaupel P, 2005, TRANSFUS CLIN BIOL, V12, P5, DOI 10.1016/j.tracli.2004.11.005; Wilson J, 2007, HEALTH TECHNOL ASSES, V11, P1; Zhang YJ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-844	30	10	13	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2015	10	8							e0136268	10.1371/journal.pone.0136268	http://dx.doi.org/10.1371/journal.pone.0136268			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP5KH	26291454	gold, Green Published, Green Submitted			2023-01-03	WOS:000359919900071
J	Sun, JH; Nie, CH; Zhang, YL; Zhou, GH; Ai, J; Zhou, TY; Zhu, TY; Zhang, AB; Wang, WL; Zheng, SS				Sun, Jun-Hui; Nie, Chun-Hui; Zhang, Yue-Lin; Zhou, Guan-Hui; Ai, Jing; Zhou, Tan-Yang; Zhu, Tong-Yin; Zhang, Ai-Bin; Wang, Wei-Lin; Zheng, Shu-Sen			Transcatheter Arterial Embolization Alone for Giant Hepatic Hemangioma	PLOS ONE			English	Article							CAVERNOUS HEMANGIOMA; LIVER HEMANGIOMAS; HEPATOCELLULAR-CARCINOMA; CT FINDINGS; RESECTION; PINGYANGMYCIN; TUMORS; CHEMOEMBOLIZATION; ASSOCIATION; ULTRASOUND	Giant hepatic hemangioma is a benign liver condition that may be treated using surgery. We studied the digital subtraction angiographic (DSA) characteristics of giant hepatic hemangioma, and the effectiveness of transcatheter arterial embolization (TAE) alone for its treatment. This was a retrospective study of 27 patients diagnosed with giant hepatic hemangioma and treated with TAE alone (using lipiodol mixed with pingyangmycin) at the Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University, between January 2010 and March 2013. The feeding arteries were identified using DSA. All patients were followed up for between three weeks and 12 months. Changes in tumor diameter and symptoms were observed. The 27 patients included had giant hepatic hemangiomas ranging from 5.3 to 24.5 cm (mean, 11.24 +/- 5.08 cm) in the right (n = 13), left (n = 1) or both (n = 13) lobes. Preoperative hepatic angiography showed multiple abnormal vascular lakes in the early phase, known as the " early leaving but late returning, hanging nut on a twig" sign. On the day after TAE, hepatic transaminase levels were increased (ALT: 22.69 +/- 17.95 to 94.88 +/- 210.32 U/L; ALT: 24.00 +/- 12.37 to 99.70 +/- 211.54 U/L; both P<0.05), but not total bilirubin. Six patients complained of abdominal pain, and 12 experienced transient fever. In the months after TAE, tumor size decreased (baseline: 11.24 +/- 5.08; 3 months: 8.95 +/- 4.33; 6 months: 7.60 +/- 3.90 cm; P<0.05), and the patients' condition improved. These results indicated that TAE was effective and safe for treating giant hepatic hemangioma. TAE may be a useful alternative to surgery for the treatment of hepatic hemangioma.	[Sun, Jun-Hui; Nie, Chun-Hui; Zhang, Yue-Lin; Zhou, Guan-Hui; Zhou, Tan-Yang; Zhu, Tong-Yin; Zhang, Ai-Bin; Wang, Wei-Lin; Zheng, Shu-Sen] Zhejiang Univ, Sch Med, Hepatobiliary & Pancreat Intervent Treatment Ctr, Div Hepatobiliary & Pancreat Surg,Affiliated Hosp, Hangzhou 310003, Zhejiang, Peoples R China; [Ai, Jing] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Ophthalmol,Binjiang Branch, Hangzhou 310003, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University	Zheng, SS (corresponding author), Zhejiang Univ, Sch Med, Hepatobiliary & Pancreat Intervent Treatment Ctr, Div Hepatobiliary & Pancreat Surg,Affiliated Hosp, Hangzhou 310003, Zhejiang, Peoples R China.	medscisjh@126.com			National Clinical Key Subject Construction Project; National Natural Science Foundation of China [81371658]; Zhejiang Provincial Natural Science Foundation of China [LQ14H120001, Y2110183]; Medical Health Fund of Zhejiang Province [2013KYB097]	National Clinical Key Subject Construction Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Natural Science Foundation of China(Natural Science Foundation of Zhejiang Province); Medical Health Fund of Zhejiang Province	This study was supported by the National Clinical Key Subject Construction Project (General Surgery), the National Natural Science Foundation of China (No. 81371658), Zhejiang Provincial Natural Science Foundation of China (No. LQ14H120001 and NO.Y2110183), and Medical Health Fund of Zhejiang Province (No. 2013KYB097).	Akamatsu Nobuhisa, 2010, J Med Case Rep, V4, P283, DOI 10.1186/1752-1947-4-283; Anderson SW, 2009, RADIOGRAPHICS, V29, P211, DOI 10.1148/rg.291085099; BELLI L, 1992, SURG GYNECOL OBSTET, V174, P474; Duxbury MS, 2010, DIGEST SURG, V27, P7, DOI 10.1159/000268108; FARGES O, 1995, WORLD J SURG, V19, P19, DOI 10.1007/BF00316974; GANDOLFI L, 1991, GUT, V32, P677, DOI 10.1136/gut.32.6.677; Gedaly R, 1999, ARCH SURG-CHICAGO, V134, P407, DOI 10.1001/archsurg.134.4.407; GRAHAM E, 1993, OBSTET GYNECOL, V81, P813; Ho Hui-Yu, 2012, Chang Gung Med J, V35, P70; Hochwald S N, 2000, HPB Surg, V11, P413, DOI 10.1155/2000/25954; Hoekstra LT, 2013, EXPERT REV GASTROENT, V7, P263, DOI [10.1586/EGH.13.10, 10.1586/egh.13.10]; Hou J, 2011, INT J ORAL MAX SURG, V40, P1246, DOI 10.1016/j.ijom.2011.07.906; Huang YD, 2014, EXP THER MED, V7, P473, DOI 10.3892/etm.2013.1428; Jain Vaibhav, 2010, Saudi J Gastroenterol, V16, P116, DOI 10.4103/1319-3767.61240; Jang HJ, 2003, AM J ROENTGENOL, V180, P135, DOI 10.2214/ajr.180.1.1800135; Jangjoo Ali, 2010, Acta Med Iran, V48, P419; JOHN TG, 1994, ANN SURG, V220, P711, DOI 10.1097/00000658-199412000-00002; Kaido T, 2003, NEW ENGL J MED, V349, pE19, DOI 10.1056/ENEJMicm010097; Kim GE, 2006, LIVER INT, V26, P334, DOI 10.1111/j.1478-3231.2005.01226.x; Kim JT, 2009, J NEUROIMAGING, V19, P394, DOI 10.1111/j.1552-6569.2009.00380.x; KRISTIDIS P, 1991, J PAEDIATR CHILD H, V27, P57, DOI 10.1111/j.1440-1754.1991.tb00348.x; Lee MG, 1996, J COMPUT ASSIST TOMO, V20, P905, DOI 10.1097/00004728-199611000-00007; Lehmann FS, 1999, J HEPATOL, V30, P951, DOI 10.1016/S0168-8278(99)80152-4; Lerner SM, 2004, ARCH SURG-CHICAGO, V139, P818, DOI 10.1001/archsurg.139.8.818; Lupinacci RM, 2011, G CHIR, V32, P469; Mahajan D, 2008, J HEPATOL, V49, P867, DOI 10.1016/j.jhep.2008.06.028; MCFARLAND EG, 1994, RADIOLOGY, V193, P43, DOI 10.1148/radiology.193.1.8090920; Ozden I, 2000, ARCH SURG-CHICAGO, V135, P978, DOI 10.1001/archsurg.135.8.978; Perkins AB, 2000, J CLIN ULTRASOUND, V28, P159, DOI 10.1002/(SICI)1097-0096(200005)28:4<159::AID-JCU1>3.0.CO;2-B; SAEGUSA T, 1995, INTERNAL MED, V34, P207, DOI 10.2169/internalmedicine.34.207; Seo HI, 2009, WORLD J GASTROENTERO, V15, P3437, DOI 10.3748/wjg.15.3437; TRASTEK VF, 1983, AM J SURG, V145, P49, DOI 10.1016/0002-9610(83)90165-4; Unal E, 2011, EXP CLIN TRANSPLANT, V9, P344; Wang ZJ, 2012, J CLIN PATHOL, V65, P146, DOI 10.1136/jclinpath-2011-200365; Yamashita Y, 1997, RADIOLOGY, V203, P121, DOI 10.1148/radiology.203.1.9122378; Yu JS, 2001, RADIOLOGY, V221, P429, DOI 10.1148/radiol.2212010339; Yue H, 2013, BRIT J OPHTHALMOL, V97, P739, DOI 10.1136/bjophthalmol-2012-302900; Zeng QG, 2004, CARDIOVASC INTER RAD, V27, P481; Zhou JX, 2013, WORLD J GASTROENTERO, V19, P2974, DOI 10.3748/wjg.v19.i19.2974	39	30	38	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 19	2015	10	8							e0135158	10.1371/journal.pone.0135158	http://dx.doi.org/10.1371/journal.pone.0135158			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP6SN	26287964	Green Submitted, gold, Green Published			2023-01-03	WOS:000360018600037
J	Fusco, F; D'Anzeo, G; Henneges, C; Rossi, A; Buttner, H; Nickel, JC				Fusco, Ferdinando; D'Anzeo, Gianluca; Henneges, Carsten; Rossi, Andrea; Buettner, Hartwig; Nickel, J. Curtis			Predictors of Individual Response to Placebo or Tadalafil 5mg among Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: An Integrated Clinical Data Mining Analysis	PLOS ONE			English	Article							ERECTILE DYSFUNCTION; HEALTH-STATUS; IMPACT INDEX; POOLED DATA; QUESTIONNAIRES; MANAGEMENT	Background A significant percentage of patients with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) achieve clinically meaningful improvement when receiving placebo or tadalafil 5mg once daily. However, individual patient characteristics associated with treatment response are unknown. Methods This integrated clinical data mining analysis was designed to identify factors associated with a clinically meaningful response to placebo or tadalafil 5mg once daily in an individual patient with LUTS-BPH. Analyses were performed on pooled data from four randomized, placebo-controlled, double-blind, clinical studies, including about 1,500 patients, from which 107 baseline characteristics were selected and 8 response criteria. The split set evaluation method (1,000 repeats) was used to estimate prediction accuracy, with the database randomly split into training and test subsets. Logistic Regression (LR), Decision Tree (DT), Support Vector Machine (SVM) and Random Forest (RF) models were then generated on the training subset and used to predict response in the test subset. Prediction models were generated for placebo and tadalafil 5mg once daily Receiver Operating Curve (ROC) analysis was used to select optimal prediction models lying on the ROC surface. Findings International Prostate Symptom Score (IPSS) baseline group (mild/moderate vs. severe) for active treatment and placebo achieved the highest combined sensitivity and specificity of 70% and similar to 50% for all analyses, respectively. This was below the sensitivity and specificity threshold of 80% that would enable reliable allocation of an individual patient to either the responder or non-responder group Conclusions This extensive clinical data mining study in LUTS-BPH did not identify baseline clinical or demographic characteristics that were sufficiently predictive of an individual patient response to placebo or once daily tadalafil 5mg. However, the study reaffirms the efficacy of tadalalfil 5mg once daily in the treatment of LUTS-BPH in the majority of patients and the importance of evaluating individual patient need in selecting the most appropriate treatment.	[Fusco, Ferdinando] Univ Naples Federico II, Urol Clin, Naples, Italy; [D'Anzeo, Gianluca; Rossi, Andrea] Eli Lilly Italy SpA, Sesto Fiorentino, FI, Italy; [Henneges, Carsten; Buettner, Hartwig] Lilly Deutschland GmbH, Bad Homburg, Germany; [Nickel, J. Curtis] Queens Univ, Dept Urol, Kingston, ON, Canada	University of Naples Federico II; Eli Lilly; Eli Lilly; Lilly Deutschland GmbH; Queens University - Canada	Henneges, C (corresponding author), Lilly Deutschland GmbH, Bad Homburg, Germany.	henneges_carsten@lilly.com	Rossi, Andrea/AAT-1759-2021	Rossi, Andrea/0000-0003-4019-4412; Fusco, Ferdinando/0000-0002-5158-5526	Eli Lilly and Company	Eli Lilly and Company(Eli Lilly)	This work was funded by Eli Lilly and Company. The funders were involved in the study design, data collection and analysis, decision to publish and preparation of the manuscript.	AUA Practice Guidelines Committee, 2010, AUA GUID MAN BEN PRO; Barry MJ, 2013, J UROLOGY, V189, P987, DOI 10.1016/j.juro.2012.08.257; BARRY MJ, 1995, MED CARE, V33, pAS145; BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; BARRY MJ, 1995, J UROLOGY, V154, P1770, DOI 10.1016/S0022-5347(01)66780-6; Bechara A, 2014, J SEX MED, V11, P498, DOI 10.1111/jsm.12386; Bender R, 1997, J ROY COLL PHYS LOND, V31, P546; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Breiman L., 1993, CLASSIFICATION REGRE; Brock G, 2013, BJU INT, V112, P990, DOI 10.1111/bju.12251; Brock GB, 2014, J UROLOGY, V191, P405, DOI 10.1016/j.juro.2013.09.057; Chapple CR, 2015, EUR UROL, V67, P114, DOI 10.1016/j.eururo.2014.08.072; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018; de Vet HC, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-54; Egerdie RB, 2012, J SEX MED, V9, P271, DOI 10.1111/j.1743-6109.2011.02504.x; Fawcett T, 2006, PATTERN RECOGN LETT, V27, P861, DOI 10.1016/j.patrec.2005.10.010; Gacci M, 2012, EUR UROL, V61, P994, DOI 10.1016/j.eururo.2012.02.033; Godman B, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-179; Govorov A, 2014, CENT EUR J UROL, V67, P167, DOI 10.5173/ceju.2014.02.art10; Gravas S, 2014, GUIDELINES MANAGEMEN; Hoffmann TC, 2014, JAMA-J AM MED ASSOC, V312, P1295, DOI 10.1001/jama.2014.10186; Homma Y, 1996, Int J Urol, V3, P267, DOI 10.1111/j.1442-2042.1996.tb00532.x; Iavindrasana J, 2009, Yearb Med Inform, P121; Kaplan Steven A, 2005, Rev Urol, V7 Suppl 7, pS34; Lepor Herbert, 2004, Rev Urol, V6 Suppl 1, pS8; McVary KT, 2011, J UROLOGY, V185, P1793, DOI 10.1016/j.juro.2011.01.074; Meyer D, PACKAGE E1071 MISC F; Nickel JC, 2015, BJU INT, V115, P815, DOI 10.1111/bju.12926; Oelke M, 2014, J UROLOGY, DOI [10.1016/j.juro.2014.11.094, DOI 10.1016/J.JUR0.2014.11.094]; Oelke M, 2012, EUR UROL, V61, P917, DOI 10.1016/j.eururo.2012.01.013; Park NC, 2014, SIGNIFICANCE TESTOST; Podgorelec Vili, 2002, J Med Syst, V26, P445, DOI 10.1023/A:1016409317640; Porst H, 2013, UROLOGY, V82, P667, DOI 10.1016/j.urology.2013.05.005; Porst H, 2013, J SEX MED, V10, P2044, DOI 10.1111/jsm.12212; Porst H, 2011, EUR UROL, V60, P1105, DOI 10.1016/j.eururo.2011.08.005; Roehrborn CG, 2008, J UROLOGY, V180, P1228, DOI 10.1016/j.juro.2008.06.079; Roehrborn CG, 2014, J UROLOGY, V191, P1045, DOI 10.1016/j.juro.2013.10.074; Roehrborn Claus G, 2008, Rev Urol, V10, P14; Rosen R, 2003, EUR UROL, V44, P637, DOI 10.1016/j.eururo.2003.08.015; Therneau TM, 2012, RPART RECURSIVE PART; Um YH, 2014, NEUROENDOCRINOL LETT, V35, P116; Vermeulen A, 1999, J CLIN ENDOCR METAB, V84, P3666, DOI 10.1210/jc.84.10.3666; Viktrup L, 2012, BMC UROL, V12, DOI 10.1186/1471-2490-12-30; Yang YJ, 2014, J KOREAN MED SCI, V29, P1145, DOI 10.3346/jkms.2014.29.8.1145	44	3	4	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 18	2015	10	8							e0135484	10.1371/journal.pone.0135484	http://dx.doi.org/10.1371/journal.pone.0135484			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP1VY	26284523	Green Published, gold, Green Submitted			2023-01-03	WOS:000359666100041
J	Prochaska, JJ				Prochaska, Judith J.			Nicotine Replacement Therapy as a Maintenance Treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SMOKING-CESSATION; VARENICLINE	IMPORTANCE The US Food and Drug Administration adopted labeling for nicotine patches to allow use beyond the standard 8 weeks. This decision was based in part on data showing increased efficacy for 24 weeks of treatment. Few studies have examined whether the use of nicotine patches beyond 24 weeks provides additional therapeutic benefit. OBJECTIVE To compare 8 (standard), 24 (extended), and 52 (maintenance) weeks of nicotine patch treatment for promoting tobacco abstinence. DESIGN, SETTING, AND PARTICIPANTS We recruited 525 treatment-seeking smokers for a randomized clinical trial conducted from June 22, 2009, through April 15, 2014, through 2 universities. INTERVENTIONS Smokers received 12 smoking cessation behavioral counseling sessions and were randomized to 8, 24, or 52 weeks of nicotine patch treatment. MAIN OUTCOMES AND MEASURES The primary outcome was 7-day point prevalence abstinence, confirmed with breath levels of carbonmonoxide at 6 and 12 months (intention to treat). RESULTS At 24 weeks, 21.7% of participants in the standard treatment arm were abstinent, compared with 27.2% of participants in the extended and maintenance treatment arms (chi(2)(1) = 1.98; P = .17). In a multivariate model controlled for covariates, participants in the extended and maintenance treatment arms reported significantly greater abstinence rates at 24 weeks compared with participants in the standard treatment arm (odds ratio [OR], 1.70 [95% CI, 1.03-2.81]; P = .04), had a longer duration of abstinence until relapse (beta = 21.30 [95% CI, 10.30-32.25]; P < .001), reported smoking fewer cigarettes per day if not abstinent (mean [SD], 5.8 [5.3] vs 6.4 [5.1] cigarettes per day; beta = 0.43 [95% CI, 0.06-0.82]; P = .02), and reported more abstinent days (mean [SD], 80.5 [38.1] vs 68.2 [43.7] days; OR, 1.55 [95% CI, 1.06-2.26]; P = .02). At 52 weeks, participants in the maintenance treatment arm did not report significantly greater abstinence rates compared with participants in the standard and extended treatment arms (20.3% vs 23.8%; OR, 1.17 [95% CI, 0.69-1.98]; P = .57). Similarly, we found no difference in week 52 abstinence rates between participants in the extended and standard treatment arms (26.0% vs 21.7%; OR, 1.33 [95% CI, 0.72-2.45]; P = .36). Treatment duration was not associated with any adverse effects or adherence to the counseling regimen, but participants in the maintenance treatment arm reported lower adherence to the nicotine patch regimen compared with those in the standard and extended treatment arms (mean [SD], 3.94 [2.5], 4.61 [2.0], and 4.7 [2.4] patches/wk, respectively; F-2,F-522 = 6.03; P = .003). CONCLUSIONS AND RELEVANCE The findings support the safety of long-term use of nicotine patch treatment, although they do not support efficacy beyond 24 weeks of treatment in a broad group of smokers.	[Prochaska, Judith J.] Stanford Univ, Stanford Prevent Res Ctr, Dept Med, Stanford, CA 94305 USA	Stanford University	Prochaska, JJ (corresponding author), Stanford Univ, MSOB X316,1265 Welch Rd, Stanford, CA 94305 USA.	jpro@stanford.edu	Prochaska, Judith J/I-4510-2013	Prochaska, Judith J/0000-0001-7925-326X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL117736] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA009253] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL117736, R01 HL117736] Funding Source: Medline; NIDA NIH HHS [P50 DA009253] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		[Anonymous], 2015, TOBACCO ATLAS; Cahill K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009329.pub2, 10.1002/14651858.CD006103.pub6]; Evins AE, 2014, JAMA-J AM MED ASSOC, V311, P145, DOI 10.1001/jama.2013.285113; Hall SM, 2011, AM J PUBLIC HEALTH, V101, P2349, DOI 10.2105/AJPH.2010.300084; Hall SM, 2009, ADDICTION, V104, P1043, DOI 10.1111/j.1360-0443.2009.02548.x; Hays JT, 2001, ANN INTERN MED, V135, P423, DOI 10.7326/0003-4819-135-6-200109180-00011; Lerman C, 2015, LANCET RESP MED, V3, P131, DOI 10.1016/S2213-2600(14)70294-2; Schnoll RA, 2015, JAMA INTERN MED, V175, P504, DOI 10.1001/jamainternmed.2014.8313; Tonstad S, 2006, JAMA-J AM MED ASSOC, V296, P64, DOI 10.1001/jama.296.1.64	9	8	8	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2015	314	7					718	719		10.1001/jama.2015.7460	http://dx.doi.org/10.1001/jama.2015.7460			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CP6SS	26284723	Green Accepted			2023-01-03	WOS:000360019100020
J	Zhang, LL; Si, T; Fischer, AJ; Letson, A; Yuan, S; Roberts, CJ; Xu, RX				Zhang, Leilei; Si, Ting; Fischer, Andrew J.; Letson, Alan; Yuan, Shuai; Roberts, Cynthia J.; Xu, Ronald X.			Coaxial Electrospray of Ranibizumab-Loaded Microparticles for Sustained Release of Anti-VEGF Therapies	PLOS ONE			English	Article							AGE-RELATED MACULOPATHY; PHOTORECEPTOR CELL-DEATH; MACULAR DEGENERATION; MULLER GLIA; PIGMENTED EPITHELIUM; RETINITIS-PIGMENTOSA; CHICKEN RETINA; NANOPARTICLES; DELIVERY; DAMAGE	Age-related macular degeneration (AMD) is the leading cause of vision loss and blindness in people over age 65 in industrialized nations. Intravitreous injection of anti-VEGF (vascular endothelial growth factor) therapies, such as ranibizumab (trade name: Lucentis), provides an effective treatment option for neovascular AMD. We have developed an improved coaxial electrospray (CES) process to encapsulate ranibizumab in poly(lactic-co-glycolic) acid (PLGA) microparticles (MPs) for intravitreous injection and sustained drug release. This microencapsulation process is advantageous for maintaining the stability of the coaxial cone-jet configurations and producing drug-loaded MPs with as high as 70% encapsulation rate and minimal loss of bioactivitiy. The utility of this emerging process in intravitreous drug delivery has been demonstrated in both benchtop and in vivo experiments. The benchtop test simulates ocular drug release using PLGA MPs encapsulating a model drug. The in vivo experiment evaluates the inflammation and retinal cell death after intravitreal injection of the MPs in a chick model. The experimental results show that the drug-load MPs are able to facilitate sustained drug release for longer than one month. No significant long term microglia reaction or cell death is observed after intravitreal injection of 200 mu g MPs. The present study demonstrates the technical feasibility of using the improved CES process to encapsulate water-soluble drugs at a high concentration for sustained release of anti-VEGF therapy.	[Zhang, Leilei; Si, Ting; Roberts, Cynthia J.; Xu, Ronald X.] Ohio State Univ, Dept Biomed Engn, Columbus, OH 43210 USA; [Si, Ting; Yuan, Shuai; Xu, Ronald X.] Univ Sci & Technol China, Sch Engn Sci, Hefei 230027, Anhui, Peoples R China; [Fischer, Andrew J.] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; [Letson, Alan; Roberts, Cynthia J.] Ohio State Univ, Dept Ophthalmol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Xu, RX (corresponding author), Ohio State Univ, Dept Biomed Engn, Columbus, OH 43210 USA.	xu.ronald@hotmail.com	Si, Ting/D-9203-2018	Si, Ting/0000-0001-9071-8646	Ohio Lion's Eye Research Foundation; National Natural Science Foundation of China [11472270, 81327803]; Fundamental Research Funds for the Central Universities	Ohio Lion's Eye Research Foundation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	Leilei Zhang is supported by a research fellowship provided by Ohio Lion's Eye Research Foundation. This work is partially supported by the National Natural Science Foundation of China (11472270, 81327803) and the Fundamental Research Funds for the Central Universities.	Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002; Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4; Arroba AI, 2011, INVEST OPHTH VIS SCI, V52, P9124, DOI 10.1167/iovs.11-7736; Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529; Bejjani R, 2005, MOL VIS, V11, P124; Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068; Cebulla CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044257; Cruysberg LPJ, 2002, J OCUL PHARMACOL TH, V18, P559, DOI 10.1089/108076802321021108; D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027; Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108; Fischer AJ, 1999, J COMP NEUROL, V405, P1, DOI 10.1002/(SICI)1096-9861(19990301)405:1<1::AID-CNE1>3.0.CO;2-U; Fischer AJ, 2004, MOL VIS, V10, P973; Fischer AJ, 2004, MOL CELL NEUROSCI, V27, P531, DOI 10.1016/j.mcn.2004.08.007; Fischer AJ, 1999, VISION RES, V39, P685, DOI 10.1016/S0042-6989(98)00178-3; Fischer AJ, 1998, J COMP NEUROL, V393, P1; Fischer AJ, 2002, J NEUROSCI, V22, P9387; Fischer AJ, 2010, GLIA, V58, P633, DOI 10.1002/glia.20950; Fischer AJ, 2009, GLIA, V57, P166, DOI 10.1002/glia.20743; Ghai K, 2010, J NEUROSCI, V30, P3101, DOI 10.1523/JNEUROSCI.4919-09.2010; Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P155; Kaur C, 2008, CLIN OPHTHALMOL, V2, P879, DOI 10.2147/opth.s3361; KLEIN R, 1992, OPHTHALMOLOGY, V99, P933; MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450; Muller RH, 2004, J BIOTECHNOL, V113, P151, DOI 10.1016/j.jbiotec.2004.06.007; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; Putney SD, 1998, NAT BIOTECHNOL, V16, P153, DOI 10.1038/nbt0298-153; QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774; Ritchey ER, 2012, EXP EYE RES, V99, P1, DOI 10.1016/j.exer.2012.03.019; Ritchey ER, 2011, MOL VIS, V17, P2440; Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027; Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119; SHAHINFAR S, 1991, CURR EYE RES, V10, P47, DOI 10.3109/02713689109007610; Si T, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.7.075003; Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051; Tomlinson IM, 2004, NAT BIOTECHNOL, V22, P521, DOI 10.1038/nbt0504-521; Votruba M, 2001, EYE, V15, P424, DOI 10.1038/eye.2001.147; Zhang LL, 2012, EXPERT REV MED DEVIC, V9, P595, DOI [10.1586/ERD.12.58, 10.1586/erd.12.58]; Zulliger R, 2011, GRAEF ARCH CLIN EXP, V249, P859, DOI 10.1007/s00417-010-1584-6	38	22	26	0	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2015	10	8							e0135608	10.1371/journal.pone.0135608	http://dx.doi.org/10.1371/journal.pone.0135608			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO9KD	26273831	Green Published, Green Submitted, gold			2023-01-03	WOS:000359493600082
J	Chung, SC; Sundstrom, J; Gale, CP; James, S; Deanfield, J; Wallentin, L; Timmis, A; Jernberg, T; Hemingway, H				Chung, Sheng-Chia; Sundstrom, Johan; Gale, Chris P.; James, Stefan; Deanfield, John; Wallentin, Lars; Timmis, Adam; Jernberg, Tomas; Hemingway, Harry			Comparison of hospital variation in acute myocardial infarction care and outcome between Sweden and United Kingdom: population based cohort study using nationwide clinical registries	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PERCUTANEOUS CORONARY INTERVENTION; STANDARDIZED MORTALITY-RATES; SHORT-TERM SURVIVAL; PERFORMING HOSPITALS; FOCUSED UPDATE; ASSOCIATION; MANAGEMENT; QUALITY; GUIDELINES; STATES	OBJECTIVE To assess the between hospital variation in use of guideline recommended treatments and clinical outcomes for acute myocardial infarction in Sweden and the United Kingdom. DESIGN Population based longitudinal cohort study using nationwide clinical registries. SETTING AND PARTICIPANTS Nationwide registry data comprising all hospitals providing acute myocardial infarction care in Sweden (SWEDEHEART/RIKS-HIA, n=87; 119 786 patients) and the UK (NICOR/MINAP, n=242; 391 077 patients), 2004-10. MAIN OUTCOME MEASURES Between hospital variation in 30 day mortality of patients admitted with acute myocardial infarction. RESULTS Case mix standardised 30 day mortality from acute myocardial infarction was lower in Swedish hospitals (8.4%) than in UK hospitals (9.7%), with less variation between hospitals (interquartile range 2.6% v 3.5%). In both countries, hospital level variation and 30 day mortality were inversely associated with provision of guideline recommended care. Compared with the highest quarter, hospitals in the lowest quarter for use of primary percutaneous coronary intervention had higher volume weighted 30 day mortality for ST elevation myocardial infarction (10.7% v 6.6% in Sweden; 12.7% v 5.8% in the UK). The adjusted odds ratio comparing the highest with the lowest quarters for hospitals' use of primary percutaneous coronary intervention was 0.70 (95% confidence interval 0.62 to 0.79) in Sweden and 0.68 (0.60 to 0.76) in the UK. Differences in risk between hospital quarters of treatment for non-ST elevation myocardial infarction and secondary prevention drugs for all discharged acute myocardial infarction patients were smaller than for reperfusion treatment in both countries. CONCLUSION Between hospital variation in 30 day mortality for acute myocardial infarction was greater in the UK than in Sweden. This was associated with, and may be partly accounted for by, the higher practice variation in acute myocardial infarction guideline recommended treatment in the UK hospitals. High quality healthcare across all hospitals, especially in the UK, with better use of guideline recommended treatment, may not only reduce unacceptable practice variation but also deliver improved clinical outcomes for patients with acute myocardial infarction.	[Chung, Sheng-Chia; Hemingway, Harry] UCL, Farr Inst Hlth Informat Res, London NW1 2DA, England; [Chung, Sheng-Chia; Hemingway, Harry] UCL, Inst Hlth Informat, London NW1 2DA, England; [Sundstrom, Johan; James, Stefan; Wallentin, Lars] Uppsala Univ, Dept Med Sci, Cardiol, Uppsala, Sweden; [Gale, Chris P.] Uppsala Clin Res Ctr, Uppsala, Sweden; [Deanfield, John] Univ Leeds, Cardiovasc Hlth Sci, Leeds, W Yorkshire, England; [Timmis, Adam] Natl Ctr Cardiovasc Prevent & Outcomes, London, England; [Jernberg, Tomas] Barts Hlth London, Natl Inst Hlth Res, Cardiovasc Biomed Res Unit, London, England; Karolinska Inst, Cardiol Sect, Huddinge, Dept Med, Stockholm, Sweden	University of London; University College London; University of London; University College London; Uppsala University; Uppsala University; University of Leeds; Barts Health NHS Trust; Karolinska Institutet	Chung, SC (corresponding author), UCL, Farr Inst Hlth Informat Res, London NW1 2DA, England.	s.chung@ucl.ac.uk	James, Stefan K/J-4554-2014; Sundström, Johan/A-6286-2009; Sundstrom, Johan/R-2139-2019; Demchuk, Andrew M/E-1103-2012; Hemingway, Harry/C-1219-2009	Sundström, Johan/0000-0003-2247-8454; Sundstrom, Johan/0000-0003-2247-8454; Demchuk, Andrew M/0000-0002-4930-7789; Deanfield, John/0000-0001-8806-6052; Gale, Chris/0000-0003-4732-382X; Chung, Sheng-Chia/0000-0001-6025-9207; Hemingway, Harry/0000-0003-2279-0624	European Implementation Score project - EU [223153]; National Institute for Health Research [RP-PG-0407-10314]; Wellcome Trust [086091/Z/08/Z]; Medical Research Council Population Health Scientist Fellowship [MR/M015084/1]; Medical Research Council Prognosis Research Strategy (PROGRESS) Partnership [G0902393/99558]; Medical Research Council; Arthritis Research UK; British Heart Foundation; Cancer Research UK; Chief Scientist Office; Economic and Social Research Council; Engineering and Physical Sciences Research Council; National Institute for Health Research; National Institute for Social Care and Health Research; Wellcome Trust; Barts and the London Cardiovascular Biomedical Research Unit - National Institute for Health Research; Swedish Heart Lung Foundation; Swedish Research Council [2007-5942, 2010-1078]; Medical Research Council [MR/M015084/1, MR/K006584/1, MR/L01629X/1] Funding Source: researchfish; MRC [MR/L01629X/1, MR/M015084/1] Funding Source: UKRI	European Implementation Score project - EU; National Institute for Health Research(National Institute for Health Research (NIHR)); Wellcome Trust(Wellcome Trust); Medical Research Council Population Health Scientist Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council Prognosis Research Strategy (PROGRESS) Partnership(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Arthritis Research UK(Versus Arthritis); British Heart Foundation(British Heart Foundation); Cancer Research UK(Cancer Research UK); Chief Scientist Office; Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); National Institute for Health Research(National Institute for Health Research (NIHR)); National Institute for Social Care and Health Research; Wellcome Trust(Wellcome Trust); Barts and the London Cardiovascular Biomedical Research Unit - National Institute for Health Research; Swedish Heart Lung Foundation(Swedish Heart-Lung Foundation); Swedish Research Council(Swedish Research CouncilEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study has been supported by the European Implementation Score project, funded by the EU 7th Framework Programme (grant agreement 223153), National Institute for Health Research (programme grant RP-PG-0407-10314), Wellcome Trust (086091/Z/08/Z), Medical Research Council Population Health Scientist Fellowship (S-CC: grant MR/M015084/1), and Medical Research Council Prognosis Research Strategy (PROGRESS) Partnership (G0902393/99558) (HH, AT) and by awards to establish the Farr Institute of Health Informatics Research, London, from the Medical Research Council, Arthritis Research UK, British Heart Foundation, Cancer Research UK, Chief Scientist Office, Economic and Social Research Council, Engineering and Physical Sciences Research Council, National Institute for Health Research, National Institute for Social Care and Health Research, and Wellcome Trust (S-CC). AT acknowledges the support of Barts and the London Cardiovascular Biomedical Research Unit, funded by the National Institute for Health Research. The Swedish Heart Lung Foundation (JS, TJ, and SJ) and the Swedish Research Council (JS: grants 2007-5942 and 2010-1078) supported the study. The sponsors had no role in the study design, the data collection, analysis, and interpretation, or the writing of the report.	Anderson JL, 2013, J AM COLL CARDIOL, V61, pE179, DOI 10.1016/j.jacc.2013.01.014; [Anonymous], SWEDEHEART 2011 ANN; Appleby J., 2011, VARIATIONS HLTH CARE; Bannink Lot, 2006, N Z Med J, V119, pU2313; Birkmeyer JD, 2009, ANNU REV MED, V60, P405, DOI 10.1146/annurev.med.60.062107.101214; Boggon R, 2011, EUR HEART J, V32, P2376, DOI 10.1093/eurheartj/ehr340; Boyle R., 2007, CORONARY HEART DIS 1; Bradley EH, 2006, JAMA-J AM MED ASSOC, V296, P72, DOI 10.1001/jama.296.1.72; Bradley EH, 2012, ANN INTERN MED, V156, P618, DOI 10.7326/0003-4819-156-9-201205010-00003; Bradley EH, 2010, AM J CARDIOL, V106, P1108, DOI 10.1016/j.amjcard.2010.06.014; Brown, 2006, APPL MIXED MODELS ME; Carlsson P, 2004, INT J TECHNOL ASSESS, V20, P44, DOI 10.1017/S0266462304000777; Chung SC, 2014, LANCET, V383, P1305, DOI 10.1016/S0140-6736(13)62070-X; Curry LA, 2011, ANN INTERN MED, V154, P384, DOI 10.7326/0003-4819-154-6-201103150-00003; Denaxas Spiros C, 2012, Int J Epidemiol, V41, P1625, DOI 10.1093/ije/dys188; Gale CP, 2012, EUR HEART J, V33, P630, DOI 10.1093/eurheartj/ehr381; Gale Christopher P, 2006, BMC Cardiovasc Disord, V6, P34, DOI 10.1186/1471-2261-6-34; Ghaferi AA, 2009, NEW ENGL J MED, V361, P1368, DOI 10.1056/NEJMsa0903048; Hamm CW, 2011, EUR HEART J, V32, P2999, DOI 10.1093/eurheartj/ehr236; Hemingway H, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e5595; Herrett E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2350; Herrett E, 2014, EUR HEART J, V35, P2363, DOI 10.1093/eurheartj/ehu286; Herrett E, 2010, HEART, V96, P1264, DOI 10.1136/hrt.2009.192328; Jernberg T, 2011, JAMA-J AM MED ASSOC, V305, P1677, DOI 10.1001/jama.2011.522; Jernberg T, 2010, HEART, V96, P1617, DOI 10.1136/hrt.2010.198804; Krumholz HM, 2009, JAMA-J AM MED ASSOC, V302, P767, DOI 10.1001/jama.2009.1178; Kushner FG, 2009, J AM COLL CARDIOL, V54, P2205, DOI [10.1016/j.jacc.2009.10.015, 10.1002/ccd.22351]; Laut KG, 2013, EUROINTERVENTION, V9, P469, DOI 10.4244/EIJV9I4A76; Li J, 2015, LANCET, V385, P441, DOI 10.1016/S0140-6736(14)60921-1; Limb M, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2380; McLenachan JM, 2010, NATL ROLL OUT PRIMAR; McNamara RL, 2014, INT J CARDIOL, V175, P240, DOI 10.1016/j.ijcard.2014.04.270; Murphy NF, 2005, HEART, V91, P726, DOI 10.1136/hrt.2004.042929; Myocardial Ischaemia National Audit Project (MINAP), 2011, 10 MINAP; Organisation for Economic Co-operation and Development, OECD STATEXTRACTS; Packer C, 2006, INT J TECHNOL ASSESS, V22, P419, DOI 10.1017/S0266462306051336; Peterson ED, 2006, JAMA-J AM MED ASSOC, V295, P1912, DOI 10.1001/jama.295.16.1912; Peterson ED, 2009, CIRC-CARDIOVASC QUAL, V2, P491, DOI 10.1161/CIRCOUTCOMES.108.847145; Popescu I, 2009, CIRC-CARDIOVASC QUAL, V2, P221, DOI 10.1161/CIRCOUTCOMES.108.813790; Rapsomaniki E, 2014, INT COMP OUTCOMES 14; Ross JS, 2010, NEW ENGL J MED, V362, P1110, DOI 10.1056/NEJMsa0907130; Thygesen K, 2007, CIRCULATION, V116, P2634, DOI 10.1161/CIRCULATIONAHA.107.187397; Tsai TC, 2013, NEW ENGL J MED, V369, P1134, DOI 10.1056/NEJMsa1303118; Van de Werf F, 2009, REV ESP CARDIOL, V62, P293, DOI 10.1016/S1885-5857(09)71559-2; West RM, 2011, EUR HEART J, V32, P706, DOI 10.1093/eurheartj/ehq476; Widimsky P, 2010, EUR HEART J, V31, P943, DOI 10.1093/eurheartj/ehp492; World Health Organization Regional Office for Europe, HLTH ALL DAT HFA DB	47	80	81	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 7	2015	351								h3913	10.1136/bmj.h3913	http://dx.doi.org/10.1136/bmj.h3913			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CO8AV	26254445	hybrid, Green Published			2023-01-03	WOS:000359387800001
J	Chen, KC; Hsieh, YS; Tseng, YF; Shieh, MJ; Chen, JS; Lai, HS; Lee, JM				Chen, Ke-Cheng; Hsieh, Yi-Shan; Tseng, Ying-Fan; Shieh, Ming-Jium; Chen, Jin-Shing; Lai, Hong-Shiee; Lee, Jang-Ming			Pleural Photodynamic Therapy and Surgery in Lung Cancer and Thymoma Patients with Pleural Spread	PLOS ONE			English	Article							FORTHCOMING 7TH EDITION; TNM CLASSIFICATION; INVASIVE THYMOMA; STAGING PROJECT; REVISION; PROPOSALS; EFFUSION; DISSEMINATION; CHEMOTHERAPY; DESCRIPTORS	Pleural spread is difficult to treat in malignancies, especially in lung cancer and thymoma. Monotherapy with surgery fails to have a better survival benefit than palliative chemotherapy, the currently accepted treatment. Photodynamic therapy utilizes a photosensitizer to target the tumor site, and the tumor is exposed to light after performing a pleurectomy and tumor resection. However, the benefits of this procedure to lung cancer or thymoma patients are unknown. We retrospectively reviewed the clinical characteristics and treatment outcomes of patients with lung cancer or thymoma with pleural seeding who underwent pleural photodynamic therapy and surgery between 2005 and 2013. Eighteen patients enrolled in this study. The mean patient age was 52.9 +/- 12.2 years. Lung cancer was the inciting cancer of pleural dissemination in 10 patients (55.6%), and thymoma in 8 (44.4%). There was no procedure-related mortality. Using Kaplan-Meier survival analysis, the 3-year survival rate and the 5-year survival rate were 68.9% and 57.4%, respectively. We compared the PDT lung cancer patients with those receiving chemotherapy or target therapy (n = 51) and found that the PDT group had better survival than non-PDT patients (mean survival time: 39.0 versus 17.6 months; P = .047). With proper patient selection, radical surgical resection combined with intrapleural photodynamic therapy for pleural spread in patients with non-small cell lung cancer or thymoma is feasible and may provide a survival benefit.	[Chen, Ke-Cheng; Shieh, Ming-Jium] Natl Taiwan Univ, Inst Biomed Engn, Coll Med, Taipei 10764, Taiwan; [Chen, Ke-Cheng; Shieh, Ming-Jium] Natl Taiwan Univ, Coll Engn, Taipei, Taiwan; [Chen, Ke-Cheng; Tseng, Ying-Fan; Chen, Jin-Shing; Lai, Hong-Shiee; Lee, Jang-Ming] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; [Hsieh, Yi-Shan] Tao Yuan Gen Hosp, Minist Hlth & Welf, Dept Surg, Taoyuan, Taiwan; [Shieh, Ming-Jium] Natl Taiwan Univ Hosp, Dept Oncol, Taipei 100, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Lee, JM (corresponding author), Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan.	jangminglee@gmail.com		Lai, Hong-Shiee/0000-0002-7958-2183; LEE, JANG-MING/0000-0001-9727-227X; CHEN, JIN-SHING/0000-0001-5077-4483	National Science Council (NSC) [101-2314-B002-020-MY3]; National Health Research Institute [NHRI-EX102-10032BI]; Ministry of Health and Welfare [DOH101-TD-I-111-NSC003]; Excellent Translational Medicine Research Projects of National Taiwan University [102C101-51]; National Taiwan University Hospital of Republic of China [NTUH.102-S2140, NTUH 102-N2253, NTUH 104-M2914]	National Science Council (NSC)(Ministry of Science and Technology, Taiwan); National Health Research Institute(National Health Research Institutes - Taiwan); Ministry of Health and Welfare(Ministry of Health, Labour and Welfare, Japan); Excellent Translational Medicine Research Projects of National Taiwan University; National Taiwan University Hospital of Republic of China(National Taiwan University)	This study was supported by the National Science Council (NSC 101-2314-B002-020-MY3), National Health Research Institute (NHRI-EX102-10032BI), Ministry of Health and Welfare (DOH101-TD-I-111-NSC003), Excellent Translational Medicine Research Projects of National Taiwan University (102C101-51), and National Taiwan University Hospital (NTUH.102-S2140, NTUH 102-N2253, NTUH 104-M2914) of the Republic of China.	Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Friedberg JS, 2012, ANN THORAC SURG, V93, P1658, DOI 10.1016/j.athoracsur.2012.02.009; Friedberg JS, 2004, J CLIN ONCOL, V22, P2192, DOI 10.1200/JCO.2004.07.097; Goldstraw Peter, 2007, J Thorac Oncol, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; GOMER CJ, 1979, CANCER RES, V39, P146; Hahn SM, 1999, REV CONTEMP PHARMACO, V10, P69; ICHINOSE Y, 1993, J SURG ONCOL, V54, P180, DOI 10.1002/jso.2930540311; Ishikawa Y, 2009, ANN THORAC SURG, V88, P952, DOI 10.1016/j.athoracsur.2009.05.019; Liu TJ, 2014, ANN SURG ONCOL, V21, P322, DOI 10.1245/s10434-013-3228-7; Lucchi M, 2009, J THORAC CARDIOV SUR, V137, P1185, DOI 10.1016/j.jtcvs.2008.09.033; MARTINI N, 1975, CANCER, V35, P734, DOI 10.1002/1097-0142(197503)35:3<734::AID-CNCR2820350328>3.0.CO;2-N; Mordant P, 2011, EUR J CARDIO-THORAC, V40, P1444, DOI 10.1016/j.ejcts.2011.02.076; Mott FE, 2001, CHEST, V119, P317, DOI 10.1378/chest.119.1.317; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; Murakawa T, 2015, EUR J CARDIO-THORAC, V47, P567, DOI 10.1093/ejcts/ezu210; Postmus PE, 2007, J THORAC ONCOL, V2, P686, DOI 10.1097/JTO.0b013e31811f4703; Rami-Porta R, 2007, J THORAC ONCOL, V2, P593, DOI 10.1097/JTO.0b013e31807a2f81; REYES L, 1991, J THORAC CARDIOV SUR, V101, P946; Wang BY, 2011, J SURG RES, V169, pE1, DOI 10.1016/j.jss.2011.02.028; Werner-Wasik M, 2000, INT J RADIAT ONCOL, V48, P1475, DOI 10.1016/S0360-3016(00)00801-4; Yu L, 2013, ONCOTARGETS THER, V6, P517, DOI 10.2147/OTT.S41347	21	23	23	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2015	10	7							e0133230	10.1371/journal.pone.0133230	http://dx.doi.org/10.1371/journal.pone.0133230			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN6LN	26193470	Green Published, Green Submitted, gold			2023-01-03	WOS:000358546400067
J	Tan, JY; Suen, LKP; Wang, T; Molassiotis, A				Tan, Jing-Yu; Suen, Lorna K. P.; Wang, Tao; Molassiotis, Alexander			Sham Acupressure Controls Used in Randomized Controlled Trials: A Systematic Review and Critique	PLOS ONE			English	Article							REDUCING POSTOPERATIVE NAUSEA; P6 ACUPRESSURE; DOUBLE-BLIND; PREHOSPITAL ANALGESIA; SPINAL-ANESTHESIA; SANYINJIAO POINT; ACUPUNCTURE; EFFICACY; PAIN; PREVENTION	Objectives To explore the commonly utilized sham acupressure procedures in existing acupressure trials, and to assess whether different types of sham interventions yield different therapeutic outcomes, and, as far as possible, to identify directions for the future development of an adequate sham acupressure method. Methods Randomized controlled trials comparing true acupressure with sham interventions were included. Thirteen electronic databases were adopted to locate relevant studies from inception to July 3, 2014. Meanwhile, eight Chinese journals on complementary and alternative medicine were manually searched to locate eligible articles. In addition, eligible studies listed in the reference lists of the included papers and other related systematic reviews on acupressure were also screened to further search any potentially eligible trials. Methodological quality of the included studies was evaluated using the risk of bias assessment tool developed by the Cochrane Back Review Group. Descriptive analysis was adopted to summarize the therapeutic outcomes. Results Sixty-six studies with 7265 participants were included. Methodological quality of the included trials was generally satisfactory. Six types of sham acupressure approaches were identified and "non-acupoint" stimulation was the most frequently utilized sham point while an acupressure device was the most commonly used approach for administering sham treatments. Acupressure therapy was a beneficial approach in managing a variety of health problems and the therapeutic effect was found to be more effective in the true acupressure groups than that in the sham comparative groups. No clear association could be identified between different sham acupressure modalities and the reported treatment outcomes. Conclusions A great diversity of sham acupressure controls have been used in clinical practice and research. A solid conclusion whether different sham alternatives are related to different treatment outcomes cannot be derived because of significant clinical heterogeneity among the analyzed trials. Non-acupoints are generally recommended but the definite locations should be identified with caution. For studies using single sham acupoints on hands or legs, it is suggested to apply identical acupressure devices on the same acupoint as in the active intervention without any stimulation. While for studies on pain, stimulation of sham acupoints should be avoided.	[Tan, Jing-Yu; Suen, Lorna K. P.; Molassiotis, Alexander] Hong Kong Polytech Univ, Sch Nursing, Kowloon, Hong Kong, Peoples R China; [Tan, Jing-Yu] Fujian Univ Tradit Chinese Med, Sch Nursing, Fuzhou, Fujian, Peoples R China; [Wang, Tao] Fujian Univ Tradit Chinese Med, Affiliated Peoples Hosp 2, Fuzhou, Fujian, Peoples R China	Hong Kong Polytechnic University; Fujian University of Traditional Chinese Medicine; Fujian University of Traditional Chinese Medicine	Molassiotis, A (corresponding author), Hong Kong Polytech Univ, Sch Nursing, Kowloon, Hong Kong, Peoples R China.	alex.molasiotis@polyu.edu.hk	Tan, Jing-Yu/AAE-5262-2022; Suen, Lorna KP/F-5077-2014	Tan, Jing-Yu/0000-0002-1609-6890; Suen, Lorna KP/0000-0002-0126-6674; MOLASIOTIS, Alex/0000-0002-5225-1739; WANG, Tao/0000-0001-9845-3988; Molassiotis, Alex/0000-0001-6351-9991				Adib-Hajbaghery M, 2013, J RES MED SCI, V18, P482; Agarwal A, 2000, CAN J ANAESTH, V47, P319, DOI 10.1007/BF03020945; Alessandrini M, 2012, J ALTERN COMPLEM MED, V18, P1121, DOI 10.1089/acm.2011.0384; Alkaissi A, 1999, ACTA ANAESTH SCAND, V43, P270, DOI 10.1034/j.1399-6576.1999.430306.x; Alkaissi A, 2005, CAN J ANAESTH, V52, P703, DOI 10.1007/BF03016557; Alkaissi A, 2002, CAN J ANAESTH, V49, P1034, DOI 10.1007/BF03017897; Atrian MK, 2013, IRAN RED CRESCENT ME, V15, P848, DOI 10.5812/ircmj.12719; Azad A, 2013, J CLIN ONCOL, V31, P2057, DOI 10.1200/JCO.2012.47.8750; Bao T, 2011, J PAIN SYMPTOM MANAG, V41, P995, DOI 10.1016/j.jpainsymman.2010.08.012; BAYREUTHER J, 1994, COMPLEMENT THER MED, V2, P70, DOI DOI 10.1016/0965-2299(94)90002-7; BELLUOMINI J, 1994, OBSTET GYNECOL, V84, P245; Bertalanffy P, 2004, ANESTH ANALG, V98, P220, DOI 10.1213/01.ANE.0000093252.56986.29; Chang KKP, 2011, AM J CHINESE MED, V39, P1139, DOI 10.1142/S0192415X11009469; Chao Hui-Lin, 2013, Oncol Nurs Forum, V40, pE61, DOI 10.1188/13.ONF.E61-E68; Chen LL, 2003, AM J CHINESE MED, V31, P781, DOI 10.1142/S0192415X03001466; Dent HE, 2003, COMPLEMENT THER MED, V11, P72, DOI 10.1016/S0965-2299(03)00058-X; Dincer F, 2003, COMPLEMENT THER MED, V11, P235, DOI 10.1016/S0965-2299(03)00124-9; Duggal KN, 1998, INT J OBSTET ANESTH, V7, P231, DOI 10.1016/S0959-289X(98)80044-7; Ebrahim Soltani Ali Reza, 2011, Acta Med Iran, V49, P208; Ernst E, 1997, SCAND J RHEUMATOL, V26, P444, DOI 10.3109/03009749709065717; Fan CF, 1997, ANESTH ANALG, V84, P821, DOI 10.1097/00000539-199704000-00023; Felhendler D, 1996, CLIN J PAIN, V12, P326, DOI 10.1097/00002508-199612000-00012; Furlan AD, 2009, SPINE, V34, P1929, DOI 10.1097/BRS.0b013e3181b1c99f; Hamidzadeh A, 2012, J MIDWIFERY WOM HEAL, V57, P133, DOI 10.1111/j.1542-2011.2011.00138.x; Harmon D, 2000, BRIT J ANAESTH, V84, P463; Harmon D, 1999, BRIT J ANAESTH, V82, P387, DOI 10.1093/bja/82.3.387; Heazell A, 2006, AM J OBSTET GYNECOL, V194, P815, DOI 10.1016/j.ajog.2005.08.042; Hjelmstedt A, 2010, ACTA OBSTET GYN SCAN, V89, P1453, DOI 10.3109/00016349.2010.514323; Ho CM, 2006, ANESTH ANALG, V102, P900, DOI 10.1213/01.ane.0000195553.82409.00; Hrobjartsson A, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003974.pub3; Hsu W., 2006, J EVID BASED NURS, V2, P331; Hughes JG, 2013, BMC COMPLEM ALTERN M, V13, P1; Hughes JG, 2014, COMPLEMENT THER MED, V22, P903, DOI 10.1016/j.ctim.2014.07.005; Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F; Itoh Kazunori, 2006, Acupunct Med, V24, P5; Kashanian M, 2010, J MATERN-FETAL NEO M, V23, P638, DOI 10.3109/14767050903277662; Kashefi F, 2011, J ALTERN COMPLEM MED, V17, P1141, DOI 10.1089/acm.2010.0589; Kelley JM, 2009, PSYCHOSOM MED, V71, P789, DOI 10.1097/PSY.0b013e3181acee12; Klein AA, 2004, J CARDIOTHOR VASC AN, V18, P68, DOI 10.1053/j.jvca.2003.10.014; Kober A, 2002, ANESTH ANALG, V95, P723, DOI 10.1097/00000539-200209000-00035; KONDZIOLKA D, 1994, J NEUROSURG, V80, P993, DOI 10.3171/jns.1994.80.6.0993; Lang T, 2007, AM J EMERG MED, V25, P887, DOI 10.1016/j.ajem.2007.01.016; Lee MK, 2004, J ALTERN COMPLEM MED, V10, P959; LEWIS IH, 1991, BRIT J ANAESTH, V67, P73, DOI 10.1093/bja/67.1.73; Linde K, 2005, JAMA-J AM MED ASSOC, V293, P2118, DOI 10.1001/jama.293.17.2118; Linde K, 2010, FORSCH KOMPLEMENTMED, V17, P259, DOI 10.1159/000320374; Lund Irene, 2009, Chin Med, V4, P1, DOI 10.1186/1749-8546-4-1; Lundeberg Thomas, 2007, Acupunct Med, V25, P100; Lundeberg T, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep049; Lundeberg T, 2008, ACUPUNCT MED, V26, P239, DOI 10.1136/aim.26.4.239; Maa SH, 2007, J CLIN NURS, V16, P794, DOI 10.1111/j.1365-2702.2005.01515.x; MacPherson H, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000261; Majholm B, 2011, EUR J ANAESTH, V28, P412, DOI 10.1097/EJA.0b013e32833f6f42; McFadden KL, 2012, COMPLEMENT THER MED, V20, P175, DOI 10.1016/j.ctim.2011.12.003; McFadden KL, 2011, J NEUROTRAUM, V28, P21, DOI 10.1089/neu.2010.1515; McFadden KL, 2010, COMPLEMENT THER MED, V18, P42, DOI 10.1016/j.ctim.2010.01.001; McGovern DPB., 2001, KEY TOPICS EVIDENCE, P26; Mirbagher-Ajorpaz Neda, 2011, Complement Ther Clin Pract, V17, P33, DOI 10.1016/j.ctcp.2010.06.005; Moher D, 2001, BMC Med Res Methodol, V1, P2, DOI 10.1186/1471-2288-1-2; Molassiotis A, 2013, HEALTH TECHNOL ASSES, V17, DOI 10.3310/hta17260; Molsberger AF, 2010, PAIN, V151, P146, DOI 10.1016/j.pain.2010.06.036; Nilsson I, 2015, J NEUROSURG ANESTH, V27, P42, DOI 10.1097/ANA.0000000000000089; Nordio M, 2008, Minerva Med, V99, P539; Norheim AJ, 2001, SCAND J PRIM HEALTH, V19, P43, DOI 10.1080/028134301300034666; Noroozinia Heydar, 2013, Acta Med Iran, V51, P163; OBrien B, 1996, AM J OBSTET GYNECOL, V174, P708, DOI 10.1016/S0002-9378(96)70454-4; Olausson H, 2002, NAT NEUROSCI, V5, P900, DOI 10.1038/nn896; Pan Li-Jia, 2014, Zhongguo Zhen Jiu, V34, P83; Rad MN, 2012, IRAN RED CRESCENT ME, V14, P697, DOI 10.5812/ircmj.2153; Reza Hoseinabadi, 2010, Complement Ther Clin Pract, V16, P81, DOI 10.1016/j.ctcp.2009.07.003; Samad K, 2003, J Pak Med Assoc, V53, P68; Scharf HP, 2006, ANN INTERN MED, V145, P12, DOI 10.7326/0003-4819-145-1-200607040-00005; Schultz AA, 2003, APPL NURS RES, V16, P256, DOI 10.1016/S0897-1897(03)00057-0; Sehhatie-Shafaie Fahimeh, 2013, J Caring Sci, V2, P123, DOI 10.5681/jcs.2013.015; Shapiro AK, 1978, HDB PSYCHOTHERAPY BE, P371; Shin HS, 2007, J ADV NURS, V59, P510, DOI 10.1111/j.1365-2648.2007.04342.x; Sinha A, 2011, INT J OBSTET ANESTH, V20, P110, DOI 10.1016/j.ijoa.2010.10.005; Soltanzadeh M, 2012, LIFE SCI J, V9, P871; Steele N M, 2001, J Obstet Gynecol Neonatal Nurs, V30, P61; Suh Eunyoung Eunice, 2012, Oncol Nurs Forum, V39, pE1, DOI 10.1188/12.ONF.E1-E9; Sun JL, 2010, INT J NURS STUD, V47, P798, DOI 10.1016/j.ijnurstu.2009.12.003; Sun Y, 2008, ANESTH ANALG, V107, P2038, DOI 10.1213/ane.0b013e318187c76a; Tang WR, 2014, COMPLEMENT THER MED, V22, P581, DOI 10.1016/j.ctim.2014.05.006; Tsay SL, 2003, INT J NURS STUD, V40, P1, DOI 10.1016/S0020-7489(02)00019-6; Turgut S, 2007, EUR J ANAESTH, V24, P87, DOI 10.1017/S0265021506001190; Valiee S, 2012, J PERIANESTH NURS, V27, P259, DOI 10.1016/j.jopan.2012.05.003; Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654; Wang SM, 2008, ANESTH ANALG, V107, P811, DOI 10.1213/ane.0b013e3181804441; Wang SM, 2005, ANESTH ANALG, V101, P666, DOI 10.1213/01.ANE.0000175212.17642.45; White PF, 2012, ANESTH ANALG, V115, P31, DOI 10.1213/ANE.0b013e3182536f27; Wood L, 2008, BMJ-BRIT MED J, V336, P601, DOI 10.1136/bmj.39465.451748.AD; Woods RM, 1999, PERICARDIUM 6 ACUPRE; Wu HS, 2004, J ADV NURS, V45, P252, DOI 10.1046/j.1365-2648.2003.02886.x; Wu HS, 2007, J ALTERN COMPLEM MED, V13, P253, DOI 10.1089/acm.2006.5342; Zhang CS, 2014, J ALTERN COMPLEM MED, V20, P147, DOI 10.1089/acm.2013.0238; Zhang Hong-wei, 2003, Zhongguo Zhong Xi Yi Jie He Za Zhi, V23, P247; Zhang Hongwei, 2010, Chin Med, V5, P1, DOI 10.1186/1749-8546-5-1	97	45	48	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2015	10	7							e0132989	10.1371/journal.pone.0132989	http://dx.doi.org/10.1371/journal.pone.0132989			40	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RL	26177378	Green Published, Green Submitted, gold			2023-01-03	WOS:000358197600196
J	Lee, MTG; Wang, HM; Ho, JAA; Fan, NC; Yang, YL; Lee, CC; Chen, SC				Lee, Meng-Tse Gabriel; Wang, Hsuan-Mao; Ho, Ja-An Annie; Fan, Nien-Chu; Yang, Ya-Lin; Lee, Chien-Chang; Chen, Shyr-Chyr			Resuscitation Using Liposomal Vasopressin in an Animal Model of Uncontrolled Hemorrhagic Shock	PLOS ONE			English	Article							INJECTION IMMUNOANALYTICAL SYSTEM; MASSIVE SPLENIC INJURY; FLUID RESUSCITATION; RAT; AORTOTOMY; SURVIVAL; DELIVERY; CARRIERS; SWINE	Background Current research suggests that administration of vasopressin to patients with uncontrolled hemorrhagic shock (UHS) can avoid the detrimental effects associated with aggressive fluid resuscitation. However, vasopressin has a short half-life of 10 similar to 35 minutes in in vivo use and precludes its use in the pre-hospital setting. To increase the half-life of vasopressin, we proposed to synthesize liposome-encapsulated vasopressin and test it in a rat model of UHS. Methods The film hydration method was used to prepare liposomal vasopressin consisting of: Dipalmitoylphosphatidylcholine, cholesterol, and dipalmitoyl phosphatidylethanolamine (20: 20: 1 mole ratio). 42 rats were subjected to UHS and randomly received 5 different treatments (vasopressin, liposomal vasopressin, lactate ringer (LR), liposome only and sham). Outcome of UHS were measured using 4 common prognostic tests: mean arterial pressure (MAP), serum lactate level, inflammatory profile and pulmonary edema. Results The dynamic light scattering results confirmed that we had prepared a successful liposomal vasopressin complex. Comparing the serum vasopressin concentration of liposomal vasopressin and vasopressin treated animals by ELISA, we found that the concentration of vasopressin for the liposomal vasopressin treated group is higher at 60 minutes. However, there was no significant difference between the MAP profile of rats treated with vasopressin and liposomal vasopressin in UHS. We also observed that animals treated with liposomal vasopressin performed indifferently to vasopressin treated rats in serum lactate level, inflammatory profile and edema profile. For most of our assays, the liposome only control behaves similarly to LR resuscitation in UHS rats. Conclusion We have synthesized a liposomal vasopressin complex that can prolong the serum concentration of vasopressin in a rat model of UHS. Although UHS rats treated with either liposomal vasopressin or vasopressin showed no statistical differences, it would be worthwhile to repeat the experiments with different liposomal compositions.	[Lee, Meng-Tse Gabriel; Wang, Hsuan-Mao; Yang, Ya-Lin; Lee, Chien-Chang; Chen, Shyr-Chyr] Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei, Taiwan; [Ho, Ja-An Annie; Fan, Nien-Chu] Natl Taiwan Univ, Dept Biochem Sci & Technol, Taipei 10764, Taiwan; [Lee, Chien-Chang] Natl Taiwan Univ Hosp, Yunlin Branch, Dept Emergency Med, Touliu, Taiwan; [Lee, Chien-Chang] Natl Taiwan Univ Hosp, Yunlin Branch, Dept Gen Med, Touliu, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Lee, CC (corresponding author), Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei, Taiwan.	cclee100@gmail.com; scchen@ntu.edu.tw	Wang, Hsuan Mao/AAG-3017-2021; Hsiao, Wei-Hung/B-9931-2013; Lee, Chien-Chang/HHM-5986-2022	LEE, CHIEN-CHANG/0000-0002-1243-2463; Ho, Annie/0000-0001-6684-1118; CHEN, SHYR-CHYR/0000-0002-5858-3013	Taiwan National Science Foundation [NSC101-2314-B-002 -055-MY3]; National Taiwan University [UN102-024]; National Taiwan University Hospital Yunlin Branch Research Grant [NTUHYL104.S008]	Taiwan National Science Foundation; National Taiwan University(National Taiwan University); National Taiwan University Hospital Yunlin Branch Research Grant	This study is supported by Taiwan National Science Foundation Grant NSC101-2314-B-002 -055-MY3; National Taiwan University Grant UN102-024; and National Taiwan University Hospital Yunlin Branch Research Grant, NTUHYL104.S008. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BADIN J, 2011, CRIT CARE, V15, P45384, DOI DOI 10.1186/cc10253; BICKELL WH, 1991, SURGERY, V110, P529; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BICKELL WH, 1989, CIRC SHOCK, V28, P321; Burris D, 1999, J TRAUMA, V46, P216, DOI 10.1097/00005373-199902000-00003; CAPONE A, 1995, RESUSCITATION, V29, P143, DOI 10.1016/0300-9572(95)00829-I; COUVREUR P, 1991, PHARMACEUT RES, V8, P1079, DOI 10.1023/A:1015885814417; DEAKIN CD, 1994, J ACCID EMERG MED, V11, P154; Delmas A, 2005, CRIT CARE, V9, P212, DOI 10.1188/cc2945; Haas T, 2004, J TRAUMA, V57, P177, DOI 10.1097/01.TA.0000044357.25191.1B; Ho JA, 2005, ANAL CHEM, V77, P3431, DOI 10.1021/ac0484474; Ho JAA, 2007, ANAL CHEM, V79, P246, DOI 10.1021/ac060889n; Ho JAA, 2012, TALANTA, V99, P683, DOI 10.1016/j.talanta.2012.06.077; Holmes JF, 2002, ACAD EMERG MED, V9, P267, DOI 10.1111/j.1553-2712.2002.tb01317.x; HSU MJ, 1982, BIOCHIM BIOPHYS ACTA, V720, P411, DOI 10.1016/0167-4889(82)90120-3; JANAKY T, 1982, J ENDOCRINOL, V93, P295, DOI 10.1677/joe.0.0930295; Jesorka A, 2008, ANNU REV ANAL CHEM, V1, P801, DOI 10.1146/annurev.anchem.1.031207.112747; Kim A, 1999, INT J PHARM, V180, P75, DOI 10.1016/S0378-5173(98)00408-6; Krausz MM, 2001, SHOCK, V16, P383, DOI 10.1097/00024382-200116050-00011; Krismer AC, 2005, ANAESTHESIST, V54, P220, DOI 10.1007/s00101-004-0793-y; Lee CC, 2005, SHOCK, V24, P177, DOI 10.1097/01.shk.0000171870.42900.15; Lee CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095821; Leppaniemi A, 1996, J SURG RES, V63, P413, DOI 10.1006/jsre.1996.0285; Mock C, 2004, LANCET, V363, P2172, DOI 10.1016/S0140-6736(04)16510-0; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; PANICO AM, 1992, INT J PHARM, V80, P93, DOI 10.1016/0378-5173(92)90266-5; Poloujadoff MP, 2007, ANESTHESIOLOGY, V107, P591, DOI 10.1097/01.anes.0000281926.54940.6a; Scarpati G, 2013, TRANSL MED UNISA, V5, P32; Silva-Barcellos NM, 2001, HYPERTENSION, V38, P1266, DOI 10.1161/hy1201.096056; Solomonov E, 2000, CRIT CARE MED, V28, P749, DOI 10.1097/00003246-200003000-00024; STERN SA, 1993, ANN EMERG MED, V22, P155, DOI 10.1016/S0196-0644(05)80195-7; Tamion F, 1997, AM J PHYSIOL-GASTR L, V273, pG314, DOI 10.1152/ajpgi.1997.273.2.G314; Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632; WEINER A L, 1989, Advanced Drug Delivery Reviews, V3, P307, DOI 10.1016/0169-409X(89)90026-4; Were LM, 2003, J AGR FOOD CHEM, V51, P8073, DOI 10.1021/jf0348368; WOODLE MC, 1992, PHARMACEUT RES, V9, P260, DOI 10.1023/A:1018953810705; Zingarelli B, 2010, AM J PHYSIOL-GASTR L, V298, pG133, DOI 10.1152/ajpgi.00262.2009	37	1	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2015	10	7							e0130655	10.1371/journal.pone.0130655	http://dx.doi.org/10.1371/journal.pone.0130655			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1EJ	26154286	Green Submitted, Green Published, gold			2023-01-03	WOS:000358159700034
J	Woldesenbet, S; Jackson, D; Lombard, C; Dinh, TH; Puren, A; Sherman, G; Ramokolo, V; Doherty, T; Mogashoa, M; Bhardwaj, S; Chopra, M; Shaffer, N; Pillay, Y; Goga, A				Woldesenbet, Selamawit; Jackson, Debra; Lombard, Carl; Dinh, Thu-Ha; Puren, Adrian; Sherman, Gayle; Ramokolo, Vundli; Doherty, Tanya; Mogashoa, Mary; Bhardwaj, Sanjana; Chopra, Mickey; Shaffer, Nathan; Pillay, Yogan; Goga, Ameena		South African PMTCT Evaluation SAP	Missed Opportunities along the Prevention of Mother-to-Child Transmission Services Cascade in South Africa: Uptake, Determinants, and Attributable Risk (the SAPMTCTE)	PLOS ONE			English	Article							IMMUNIZATION CLINICS; HIV; PREGNANCY; WOMEN; CAPE	Objectives We examined uptake of prevention of mother-to-child HIV transmission (PMTCT) services, predictors of missed opportunities, and infant HIV transmission attributable to missed opportunities along the PMTCT cascade across South Africa. Methods A cross-sectional survey was conducted among 4-8 week old infants receiving first immunisations in 580 nationally representative public health facilities in 2010. This included maternal interviews and testing infants' dried blood spots for HIV. A weighted analysis was performed to assess uptake of antenatal and perinatal PMTCT services along the PMTCT cascade (namely: maternal HIV testing, CD4 count test/result, and receiving maternal and infant antiretroviral treatment) and predictors of dropout. The population attributable fraction associated with dropouts at each service point are estimated. Results Of 9,803 mothers included, 31.7% were HIV-positive as identified by reactive infant antibody tests. Of these 80.4% received some form of maternal and infant antiretroviral treatment. More than a third (34.9%) of mothers dropped out from one or more steps in the PMTCT service cascade. In a multivariable analysis, the following characteristics were associated with increased dropout from the PMTCT cascade: adolescent (<20 years) mothers, low socioeconomic score, low education level, primiparous mothers, delayed first antenatal visit, homebirth, and non-disclosure of HIV status. Adolescent mothers were twice (adjusted odds ratio: 2.2, 95% confidence interval: 1.5-3.3) as likely to be unaware of their HIV-positive status and had a significantly higher rate (85.2%) of unplanned pregnancies compared to adults aged >= 20 years (55.5%, p = 0.0001). A third (33.8%) of infant HIV infections were attributable to dropout in one or more steps in the cascade. Conclusion A third of transmissions attributable to missed opportunities of PMTCT services can be prevented by optimizing the uptake of PMTCT services. Identified risk factors for low PMTCT service uptake should be addressed through health facility and community-level interventions, including raising awareness, promoting women education, adolescent focused interventions, and strengthening linkages/referral-system between communities and health facilities.	[Woldesenbet, Selamawit; Lombard, Carl; Ramokolo, Vundli; Doherty, Tanya] MRC, Hlth Syst Res Unit, Cape Town, South Africa; [Jackson, Debra; Doherty, Tanya; Chopra, Mickey] Univ Western Cape, Sch Publ Hlth, Cape Town, South Africa; [Jackson, Debra; Chopra, Mickey] United Nations Childrens Fund, New York, NY USA; [Dinh, Thu-Ha] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA USA; [Puren, Adrian; Sherman, Gayle] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Johannesburg, South Africa; [Puren, Adrian] Univ Witwatersrand, Fac Hlth Sci, Div Virol & Communicable Dis, Johannesburg, South Africa; [Sherman, Gayle] Univ Witwatersrand, Fac Hlth Sci, Dept Paediat & Child Hlth, Johannesburg, South Africa; [Doherty, Tanya] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa; [Mogashoa, Mary] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Pretoria, South Africa; [Bhardwaj, Sanjana] United Nations Childrens Fund, Pretoria, South Africa; [Shaffer, Nathan] World Hlth Org, Geneva, Switzerland; [Pillay, Yogan] Natl Dept Hlth, Pretoria, South Africa; [Goga, Ameena] Univ Pretoria, Dept Paediat & Child Hlth, ZA-0002 Pretoria, South Africa; [Goga, Ameena] MRC, Hlth Syst Res Unit, Pretoria, South Africa	University of the Western Cape; UNICEF; Centers for Disease Control & Prevention - USA; National Health Laboratory Service; National Institute for Communicable Diseases (NICD); National Institute for Communicable Diseases (NICD); University of Witwatersrand; University of Witwatersrand; University of Witwatersrand; World Health Organization; University of Pretoria	Woldesenbet, S (corresponding author), MRC, Hlth Syst Res Unit, Cape Town, South Africa.	woldeselam@gmail.com	Puren, Adrian/AAC-2065-2020; Puren, Adrian/W-1679-2018	Puren, Adrian/0000-0001-7531-4010; Puren, Adrian/0000-0001-7531-4010; Jackson, Debra/0000-0003-3307-632X; ramokolo, vundli/0000-0002-9596-1909; Lombard, Carl/0000-0002-2136-6533	CDC [1U2GPS001137-02, 1U2GPS001137-03]; United Nations Children's Fund (UNICEF); National Department of Health, South Africa; South Africa National Research Foundation; South African Centre for Epidemiological Modelling and Analysis (SACEMA); African Doctoral Dissertation Research Fellowship; MRC [1U2GPS001137-02, 1U2GPS001137-03]	CDC(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); United Nations Children's Fund (UNICEF); National Department of Health, South Africa; South Africa National Research Foundation(National Research Foundation - South Africa); South African Centre for Epidemiological Modelling and Analysis (SACEMA); African Doctoral Dissertation Research Fellowship; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the President's Emergency Plan for AIDS Relief under the Cooperative Agreement between CDC and MRC (1U2GPS001137-02 and 1U2GPS001137-03)- A, The United Nations Children's Fund (UNICEF) - A, National Department of Health, South Africa-A, South Africa National Research Foundation-D, South African Centre for Epidemiological Modelling and Analysis (SACEMA) - S, African Doctoral Dissertation Research Fellowship-S. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2014, S AFRICAS NEW HIGHLY; [Anonymous], 2013, GLOBAL REPORT UNAIDS; [Anonymous], 2009, NATL ANTENATL SENTIN; Basu S, 1995, AM J EPIDEMIOL, V142, P1338, DOI 10.1093/oxfordjournals.aje.a117602; Chasela CS, 2010, NEW ENGL J MED, V362, P2271, DOI 10.1056/NEJMoa0911486; Drake AL, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001608; Fatti G., 2014, 4 INT WORKSH HIV WOM; Goga A., 2011, SAPMTCTE REPORT EARL; Goga A., 2014, J EPIDEMIOL COMMUNIT; Goga A, 2010, EVALUATION EFFECTIVE; Horwood C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074568; Horwood C, 2012, B WORLD HEALTH ORGAN, V90, P168, DOI 10.2471/BLT.11.092056; Hussain A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027907; Jones DL, 2013, AIDS CARE, V25, P702, DOI 10.1080/09540121.2013.772280; Kim HY, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-138; Marazzi M., 2009, 5 INT AIDS SOC C HIV; Meda N, 2011, LANCET INFECT DIS, V11, P171, DOI 10.1016/S1473-3099(10)70288-7; NDOH, POLICY GUIDELINES IM; Reagon G., 2003, NATL PRIMARY HLTH CA; Rollins N, 2007, AIDS, V21, P1341, DOI 10.1097/QAD.0b013e32814db7d4; Rollins N, 2009, AIDS, V23, P1851, DOI 10.1097/QAD.0b013e32832d84fd; Stinson K., 2014, LAY HLTH WORKER SUPP; Stinson K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063328; Stinson K, 2012, JAIDS-J ACQ IMM DEF, V60, P199, DOI 10.1097/QAI.0b013e31824d985e; Stinson K, 2010, TROP MED INT HEALTH, V15, P825, DOI 10.1111/j.1365-3156.2010.02538.x; Thomas TK, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001015; Villar-Loubet OM, 2013, CULT HEALTH SEX, V15, P253, DOI 10.1080/13691058.2012.716166; World Health Organization, 2012, GUIDANCE COUPLES HIV	28	56	58	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2015	10	7							e0132425	10.1371/journal.pone.0132425	http://dx.doi.org/10.1371/journal.pone.0132425			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1DQ	26147598	Green Published, Green Submitted, gold			2023-01-03	WOS:000358157600265
J	Cho, JH; Feldman, M				Cho, Judy H.; Feldman, Marc			Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies	NATURE MEDICINE			English	Review							NECROSIS-FACTOR-ALPHA; ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY; ACTIVE ANKYLOSING-SPONDYLITIS; INFLAMMATORY-BOWEL-DISEASE; PLACEBO-CONTROLLED TRIAL; GENOME-WIDE ASSOCIATION; PROOF-OF-CONCEPT; RHEUMATOID-ARTHRITIS; PSORIATIC-ARTHRITIS; SUSCEPTIBILITY LOCI	Recent advances in genome-wide association studies (GWAS) across autoimmune and immune-mediated diseases have augmented our understanding of pathogenic mechanisms underlying these diseases. This has further highlighted their heterogeneous nature, both within and between diseases. Furthermore, varying responses to therapy have also served to underline the importance of this heterogeneity in the manner in which these diseases are diagnosed and treated. Here we discuss our current understanding of the shared pathways of autoimmunity, including the tumor necrosis factor (TNF), major histocompatibility complex (MHC), interleukin 23 receptor (IL23R) and protein tyrosine phosphatase non-receptor type 22 (PTPN22) pathways. In addition, we summarize effective specific therapies tested across major autoimmune diseases, highlighting the insight they have provided into disease mechanisms and their implications for potential future improvements.	[Cho, Judy H.] Icahn Sch Med Mt Sinai, Dept Genet, Div Gastroenterol, New York, NY 10029 USA; [Cho, Judy H.] Icahn Sch Med Mt Sinai, Dept Med, Div Gastroenterol, New York, NY 10029 USA; [Feldman, Marc] Univ Oxford, Kennedy Inst Rheumatol, Oxford, England	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Oxford	Cho, JH (corresponding author), Icahn Sch Med Mt Sinai, Dept Genet, Div Gastroenterol, New York, NY 10029 USA.	judy.cho@mssm.edu			US National Institutes of Health [U01 DK62429, U01 DK062422, R01 DK092235]; SUCCESS; Helmsley Charitable Trust; Sanford J. Grossman Charitable Trust; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK092235, U01DK062422, U01DK062429] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); SUCCESS; Helmsley Charitable Trust; Sanford J. Grossman Charitable Trust; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	J.H.C. is supported by US National Institutes of Health grants U01 DK62429, U01 DK062422, R01 DK092235, SUCCESS, by he Helmsley Charitable Trust and by the Sanford J. Grossman Charitable Trust.	Aaltonen KJ, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0043508, 10.1371/journal.pone.0030275]; Ahern PP, 2010, IMMUNITY, V33, P279, DOI 10.1016/j.immuni.2010.08.010; [Anonymous], 2015, J CRONHS COLITIS S1, V9, pS15; Arechiga AF, 2009, J IMMUNOL, V182, P3343, DOI 10.4049/jimmunol.0713370; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Baert F, 2003, NEW ENGL J MED, V348, P601, DOI 10.1056/NEJMoa020888; Baeten D, 2013, LANCET, V382, P1705, DOI 10.1016/S0140-6736(13)61134-4; Belasco J, 2015, ARTHRITIS RHEUMATOL, V67, P934, DOI 10.1002/art.38995; Blom DJ, 2014, NEW ENGL J MED, V370, P1809, DOI 10.1056/NEJMoa1316222; Bogdanos DP, 2012, J AUTOIMMUN, V38, pJ156, DOI 10.1016/j.jaut.2011.11.003; Bowes J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7046; Breedveld F, 2011, CLIN RHEUMATOL, V30, pS33, DOI 10.1007/s10067-010-1638-5; BRENNAN FM, 1989, LANCET, V2, P244; Cargill M, 2007, AM J HUM GENET, V80, P273, DOI 10.1086/511051; Chaudhari U, 2001, LANCET, V357, P1842, DOI 10.1016/S0140-6736(00)04954-0; Cho JH, 2008, NAT REV IMMUNOL, V8, P458, DOI 10.1038/nri2340; Cho JH, 2011, NEW ENGL J MED, V365, P1612, DOI 10.1056/NEJMra1100030; Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Collins FS, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002747; Cooper JD, 2012, HUM MOL GENET, V21, P5202, DOI 10.1093/hmg/dds357; Criswell LA, 2005, AM J HUM GENET, V76, P561, DOI 10.1086/429096; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Cui J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003394; Di Meglio P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017160; DICK HM, 1978, BRIT MED BULL, V34, P271, DOI 10.1093/oxfordjournals.bmb.a071510; Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245; Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534; Eyre S, 2012, NAT GENET, V44, P1336, DOI 10.1038/ng.2462; Fairfax BP, 2014, SCIENCE, V343, P1118, DOI 10.1126/science.1246949; Fattah Z, 2014, EXPERT OPIN BIOL TH, V14, P311, DOI 10.1517/14712598.2014.871256; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Ferber IA, 1996, J IMMUNOL, V156, P5; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Fung TC, 2014, IMMUNOL REV, V260, P35, DOI 10.1111/imr.12186; Genovese MC, 2005, NEW ENGL J MED, V353, P1114, DOI 10.1056/NEJMoa050524; Genovese MC, 2004, ARTHRITIS RHEUM-US, V50, P1412, DOI 10.1002/art.20221; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Goekoop-Ruiterman YPM, 2005, ARTHRITIS RHEUM-US, V52, P3381, DOI [10.1002/art.21405, 10.1002/art.23364]; Gorman JD, 2002, NEW ENGL J MED, V346, P1349, DOI 10.1056/NEJMoa012664; Gottlieb AB, 2005, J IMMUNOL, V175, P2721, DOI 10.4049/jimmunol.175.4.2721; Gottlieb A, 2013, THER ADV MUSCULOSKEL, V5, P277, DOI 10.1177/1759720X13501021; Gregory AP, 2012, NATURE, V488, P508, DOI 10.1038/nature11307; Griffiths CEM, 2010, NEW ENGL J MED, V362, P118, DOI 10.1056/NEJMoa0810652; Harlow L, 2012, INNATE IMMUN-LONDON, V18, P876, DOI 10.1177/1753425912446714; Hasegawa K, 2004, SCIENCE, V303, P685, DOI 10.1126/science.1092138; Hauser SL, 2008, NEW ENGL J MED, V358, P676, DOI 10.1056/NEJMoa0706383; Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490; Hradetzky S, 2013, J INVEST DERMATOL, V133, P2289, DOI 10.1038/jid.2013.161; Hu XL, 2011, AM J HUM GENET, V89, P496, DOI 10.1016/j.ajhg.2011.09.002; Hueber W, 2012, GUT, V61, P1693, DOI 10.1136/gutjnl-2011-301668; Jacobs J., 1906, JEWISH ENCY; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Kandala N. B., 2013, BMJ OPEN; Kaser A, 2014, BEST PRACT RES CL GA, V28, P437, DOI 10.1016/j.bpg.2014.04.005; Kau AL, 2011, NATURE, V474, P327, DOI 10.1038/nature10213; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Klareskog L, 2009, LANCET, V373, P659, DOI 10.1016/S0140-6736(09)60008-8; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Krueger GG, 2007, NEW ENGL J MED, V356, P580, DOI 10.1056/NEJMoa062382; Krueger J. G., 2015, J ALLERGY CLIN IMMUN; Krueger JG, 2012, NAT MED, V18, P1750, DOI 10.1038/nm.3025; Kuchroo VK, 2002, ANNU REV IMMUNOL, V20, P101, DOI 10.1146/annurev.immunol.20.081701.141316; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248; Langley RG, 2014, NEW ENGL J MED, V371, P326, DOI 10.1056/NEJMoa1314258; Lavin Y, 2014, CELL, V159, P1312, DOI 10.1016/j.cell.2014.11.018; Leiper K, 2011, GUT, V60, P1520, DOI 10.1136/gut.2010.225482; Leonardi CL, 2003, NEW ENGL J MED, V349, P2014, DOI 10.1056/NEJMoa030409; Li MO, 2008, CELL, V134, P392, DOI 10.1016/j.cell.2008.07.025; Li MO, 2007, IMMUNITY, V26, P579, DOI 10.1016/j.immuni.2007.03.014; Lichtenstein GR, 2012, AM J GASTROENTEROL, V107, P1409, DOI 10.1038/ajg.2012.218; Littman DR, 2010, CELL, V140, P845, DOI 10.1016/j.cell.2010.02.021; MacArthur DG, 2014, NATURE, V508, P469, DOI 10.1038/nature13127; Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0; McDonagh J, 2014, JAMA INTERN MED, V174, P1889, DOI 10.1001/jamainternmed.2014.5376; McInnes IB, 2014, ANN RHEUM DIS, V73, P349, DOI 10.1136/annrheumdis-2012-202646; McInnes IB, 2013, LANCET, V382, P780, DOI 10.1016/S0140-6736(13)60594-2; Mease PJ, 2014, NEW ENGL J MED, V370, P2295, DOI 10.1056/NEJMoa1315231; Mease PJ, 2002, ANN RHEUM DIS, V61, P298, DOI 10.1136/ard.61.4.298; Nair RP, 2009, NAT GENET, V41, P199, DOI 10.1038/ng.311; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; Nicolae DL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000888; O'Connor W, 2009, NAT IMMUNOL, V10, P603, DOI 10.1038/ni.1736; Okada Y, 2014, NATURE, V506, P376, DOI 10.1038/nature12873; Onengut-Gumuscu S, 2015, NAT GENET, V47, P381, DOI 10.1038/ng.3245; Parkes M, 2013, NAT REV GENET, V14, P661, DOI 10.1038/nrg3502; Pidasheva S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025038; Poddubnyy D, 2014, ANN RHEUM DIS, V73, P817, DOI 10.1136/annrheumdis-2013-204248; Present DH, 1999, NEW ENGL J MED, V340, P1398, DOI 10.1056/NEJM199905063401804; Pritchard JK, 2010, NAT REV GENET, V11, P665, DOI 10.1038/nrg2880; Quintana-Murci L, 2013, NAT REV IMMUNOL, V13, P280, DOI 10.1038/nri3421; Reveille JD, 2010, NAT GENET, V42, P123, DOI 10.1038/ng.513; Robinson JG, 2015, NEW ENGL J MED, V372, P1489, DOI 10.1056/NEJMoa1501031; ROSS GL, 1978, J RHEUMATOL, V5, P373; Rutgeerts P, 2005, NEW ENGL J MED, V353, P2462, DOI 10.1056/NEJMoa050516; Sabatine MS, 2015, NEW ENGL J MED, V372, P1500, DOI 10.1056/NEJMoa1500858; Salvetti M, 2000, IMMUNOL TODAY, V21, P342, DOI 10.1016/S0167-5699(00)01658-3; Sandborn WJ, 2012, NEW ENGL J MED, V367, P1519, DOI 10.1056/NEJMoa1203572; Sandborn WJ, 2012, GASTROENTEROLOGY, V143, P62, DOI 10.1053/j.gastro.2012.04.010; Sarin R, 2011, P NATL ACAD SCI USA, V108, P9560, DOI 10.1073/pnas.1017854108; Scher JU, 2013, ELIFE, V2, DOI 10.7554/eLife.01202; Schett G, 2013, NAT MED, V19, P822, DOI 10.1038/nm.3260; Sfikakis PP, 2002, ANN RHEUM DIS, V61, P51, DOI 10.1136/ard.61.suppl_2.ii51; Shankar G, 2006, TRENDS BIOTECHNOL, V24, P274, DOI 10.1016/j.tibtech.2006.04.001; Song IH, 2010, ARTHRITIS RHEUM-US, V62, P1290, DOI 10.1002/art.27383; Stanford SM, 2014, NAT REV RHEUMATOL, V10, P602, DOI 10.1038/nrrheum.2014.109; Stein EA, 2012, NEW ENGL J MED, V366, P1108, DOI 10.1056/NEJMoa1105803; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Trynka G, 2011, NAT GENET, V43, P1193, DOI 10.1038/ng.998; Vang T, 2005, NAT GENET, V37, P1317, DOI 10.1038/ng1673; Weinblatt M, 2007, ANN RHEUM DIS, V66, P228, DOI 10.1136/ard.2006.055111; Wen L, 2008, NATURE, V455, P1109, DOI 10.1038/nature07336; Wendling D, 2012, J RHEUMATOL, V39, P2327, DOI 10.3899/jrheum.120201; WILLIAMS RO, 1993, CLIN EXP IMMUNOL, V92, P323, DOI 10.1111/j.1365-2249.1993.tb03399.x; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Zeissig S., 2014, GUT; Zhang JY, 2011, NAT GENET, V43, P902, DOI 10.1038/ng.904; Zhou L, 2009, IMMUNITY, V30, P646, DOI 10.1016/j.immuni.2009.05.001; Zielinski CE, 2012, NATURE, V484, P514, DOI 10.1038/nature10957; Zikherman J, 2009, J IMMUNOL, V182, P4093, DOI 10.4049/jimmunol.0803317	120	144	161	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2015	21	7					730	738		10.1038/nm.3897	http://dx.doi.org/10.1038/nm.3897			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	CM3SO	26121193	Green Accepted			2023-01-03	WOS:000357604600014
J	Lu, JY; Cheung, MLM; Li, M; Huang, BT; Xie, WJ; Xie, LX				Lu, Jia-Yang; Cheung, Michael Lok-Man; Li, Mei; Huang, Bao-Tian; Xie, Wen-Jia; Xie, Liang-Xi			Dosimetric Evaluation of a Simple Planning Technique for Improving Intensity-Modulated Radiotherapy for Nasopharyngeal Cancer	PLOS ONE			English	Article							DIRECT APERTURE OPTIMIZATION; QUALITY-OF-LIFE; RADIATION-THERAPY; ORAL MUCOSITIS; NECK-CANCER; CARCINOMA; IMRT; HEAD; PLANS; TOMOTHERAPY	Purpose To evaluate the dosimetric outcomes of a simple planning technique for improving intensit-ymodulated radiotherapy (IMRT) for nasopharyngeal cancer (NPC). Methods For 39 NPC cases, generally acceptable original plans were generated and were improved by the two planning techniques, respectively: (1) a basal-dose-compensation (BDC) technique, in which the treatment plans were re-optimized based on the original plans; (2) a local-dose-control (LDC) technique, in which the original plans were re-optimized with constraints for hot and cold spots. The BDC, original, and LDC plans were then compared regarding homogeneity index (HI) and conformity index (CI) of planning target volumes (PTVs), organ-at-risk (OAR) sparing and monitor units (MUs) per fraction. The whole planning times were also compared between the BDC and LDC plans. Results The BDC plans had superior HIs / CIs, by 13-24% / 3-243%, respectively, over the original plans. Compared to the LDC plans, the BDC plans provided better HIs only for PTVnx (the PTV of nasopharyngeal primary tumor) by 11% and better CIs for all PTVs by 2-134%. The BDC technique spared most OARs, by 1-9%. The average MUs of the BDC, original, and LDC plans were 2149, 2068 and 2179, respectively. The average whole planning times were 48 and 69 minutes for the BDC and LDC plans, respectively. Conclusions For the IMRT of nasopharyngeal cancer, the BDC planning technique can improve target dose homogeneity, conformity and OAR sparing, with better planning efficiency.	[Lu, Jia-Yang; Li, Mei; Huang, Bao-Tian; Xie, Wen-Jia; Xie, Liang-Xi] Shantou Univ, Canc Hosp, Coll Med, Dept Radiat Oncol, Shantou, Guangdong, Peoples R China; [Cheung, Michael Lok-Man] Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China	Shantou University; Chinese University of Hong Kong; Prince of Wales Hospital	Xie, LX (corresponding author), Shantou Univ, Canc Hosp, Coll Med, Dept Radiat Oncol, Shantou, Guangdong, Peoples R China.	xieliangxi1@qq.com			National Natural Science Foundation of China [81171994]; Shantou University Medical College Clinical Research Enhancement Initiative [201425]; German Research Foundation; Open Access Publication Funds of the TU Dresden	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shantou University Medical College Clinical Research Enhancement Initiative; German Research Foundation(German Research Foundation (DFG)); Open Access Publication Funds of the TU Dresden	This work was sponsored in part by both National Natural Science Foundation of China (Grant No. 81171994) and Shantou University Medical College Clinical Research Enhancement Initiative (Grant No. 201425). The authors' also acknowledge support from the German Research Foundation and the Open Access Publication Funds of the TU Dresden. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDERSON NJ, 2014, ACTA ONCOL, P1, DOI DOI 10.3109/0284186X.2014.958533; Broderick M, 2009, RADIAT ONCOL, V4, DOI 10.1186/1748-717X-4-8; Budrukkar Ashwini N, 2004, Australas Radiol, V48, P45, DOI 10.1111/j.1440-1673.2004.01241.x; Chau RMC, 2008, CLIN ONCOL-UK, V20, P134, DOI 10.1016/j.clon.2007.10.006; Chen AM, 2012, BRIT J RADIOL, V85, pE537, DOI 10.1259/bjr/23807619; Cheng MC, 2014, MED DOSIM, V39, P246, DOI 10.1016/j.meddos.2014.03.003; Dobler B, 2007, RADIAT ONCOL, V2, DOI 10.1186/1748-717X-2-33; Dogan N, 2006, MED PHYS, V33, P4033, DOI 10.1118/1.2357835; Ee VPC, 2013, ASIAN PAC J CANCER P, V14, P2243, DOI 10.7314/APJCP.2013.14.4.2243; Hodapp N, 2012, STRAHLENTHER ONKOL, V188, P97, DOI 10.1007/s00066-011-0015-x; Hsiung CY, 2006, INT J RADIAT ONCOL, V66, P454, DOI 10.1016/j.ijrobp.2006.04.033; Jabbari S, 2005, INT J RADIAT ONCOL, V63, P725, DOI 10.1016/j.ijrobp.2005.02.045; Jang-Chun L, 2014, ACTA OTORHINOLARYNGO, V34, P241; Jeraj R, 2002, PHYS MED BIOL, V47, P391, DOI 10.1088/0031-9155/47/3/303; Jones S, 2008, MED DOSIM, V33, P86, DOI 10.1016/j.meddos.2007.04.002; Kan Monica W K, 2012, J Appl Clin Med Phys, V13, P3887, DOI 10.1120/jacmp.v13i6.3887; Kwong DLW, 2004, CANCER, V101, P1584, DOI 10.1002/cncr.20552; Lee FKH, 2014, MED DOSIM, V39, P44, DOI 10.1016/j.meddos.2013.09.004; Li QL, 2013, TECHNOL CANCER RES T, V12, P403, DOI 10.7785/tcrt.2012.500340; Paddick I, 2000, J NEUROSURG, V93, P219, DOI 10.3171/jns.2000.93.supplement_3.0219; Rodriguez-Caballero A, 2012, INT J ORAL MAX SURG, V41, P225, DOI 10.1016/j.ijom.2011.10.011; Siala W, 2009, CANCER RADIOTHER, V13, P709, DOI 10.1016/j.canrad.2009.05.006; Suss P, 2013, PHYS MED BIOL, V58, P1855, DOI 10.1088/0031-9155/58/6/1855; Verbakel WFAR, 2012, INT J RADIAT ONCOL, V83, pE297, DOI 10.1016/j.ijrobp.2011.12.059; Vineberg KA, 2002, INT J RADIAT ONCOL, V52, P1159, DOI 10.1016/S0360-3016(01)02800-0; White P, 2013, J RADIAT RES, V54, P532, DOI 10.1093/jrr/rrs111; Wu SX, 2010, RADIOTHER ONCOL, V97, P113, DOI 10.1016/j.radonc.2010.08.003; Xhaferllari I, 2013, J APPL CLIN MED PHYS, V14, P176, DOI 10.1120/jacmp.v14i1.4052; Xue WQ, 2013, AM J EPIDEMIOL, V178, P325, DOI 10.1093/aje/kws479; Zacarias AS, 2009, J APPL CLIN MED PHYS, V10, P281, DOI 10.1120/jacmp.v10i4.3061; Zhang HB, 2013, CURR ONCOL, V20, pE577, DOI 10.3747/co.20.1485	31	1	1	2	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2015	10	7							e0129461	10.1371/journal.pone.0129461	http://dx.doi.org/10.1371/journal.pone.0129461			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1CG	26132167	Green Submitted, gold, Green Published			2023-01-03	WOS:000358153000029
J	Muller-Dahlhaus, F; Lucke, C; Lu, MK; Arai, N; Herrmann, AFE; Ziemann, U				Mueller-Dahlhaus, Florian; Luecke, Caroline; Lu, Ming-Kuei; Arai, Noritoshi; Herrmann, Anna Fuhl Eva; Ziemann, Ulf			Augmenting LTP-Like Plasticity in Human Motor Cortex by Spaced Paired Associative Stimulation	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; HOMEOSTATIC-LIKE PLASTICITY; DEPRESSION-LIKE PLASTICITY; CORTICAL PLASTICITY; SYNAPTIC PLASTICITY; VISUAL-CORTEX; DEPENDENT CHANGES; IN-VIVO; METAPLASTICITY; MODULATION	Paired associative stimulation (PAS(LTP)) of the human primary motor cortex (M1) can induce LTP-like plasticity by increasing corticospinal excitability beyond the stimulation period. Previous studies showed that two consecutive PAS(LTP) protocols interact by homeostatic metaplasticity, but animal experiments provided evidence that LTP can be augmented by repeated stimulation protocols spaced by similar to 30min. Here we tested in twelve healthy selected PAS(LTP) responders the possibility that LTP-like plasticity can be augmented in the human M1 by systematically varying the interval between two consecutive PAS(LTP) protocols. The first PAS(LTP) protocol (PAS1) induced strong LTP-like plasticity lasting for 30-60min. The effect of a second identical PAS(LTP) protocol (PAS(2)) critically depended on the time between PAS(1) and PAS(2). At 10min, PAS(2) prolonged the PAS(1)-induced LTP-like plasticity. At 30min, PAS(2) augmented the LTP-like plasticity induced by PAS(1), by increasing both magnitude and duration. At 60min and 180min, PAS(2) had no effect on corticospinal excitability. The cumulative LTP-like plasticity after PAS(1) and PAS(2) at 30min exceeded significantly the effect of PAS(1) alone, and the cumulative PAS(1) and PAS(2) effects at 60min and 180min. In summary, consecutive PAS(LTP) protocols interact in human M1 in a time-dependent manner. If spaced by 30min, two consecutive PAS(LTP) sessions can augment LTP-like plasticity in human M1. Findings may inspire further research on optimized therapeutic applications of non-invasive brain stimulation in neurological and psychiatric diseases.	[Mueller-Dahlhaus, Florian; Luecke, Caroline; Lu, Ming-Kuei; Arai, Noritoshi; Ziemann, Ulf] Goethe Univ Frankfurt, Dept Neurol, D-60054 Frankfurt, Germany; [Mueller-Dahlhaus, Florian; Ziemann, Ulf] Univ Tubingen, Dept Neurol & Stroke, Tubingen, Germany; [Mueller-Dahlhaus, Florian; Ziemann, Ulf] Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany; [Lu, Ming-Kuei] China Med Univ Hosp, Dept Neurol, Taichung, Taiwan; [Herrmann, Anna Fuhl Eva] Goethe Univ Frankfurt, Inst Biostat & Math Modelling, D-60054 Frankfurt, Germany	Goethe University Frankfurt; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan; Goethe University Frankfurt	Ziemann, U (corresponding author), Goethe Univ Frankfurt, Dept Neurol, D-60054 Frankfurt, Germany.	ulf.ziemann@uni-tuebingen.de	Lu, Ming-Kuei/AAF-3338-2020; Lu, Ming-Kuei/M-2435-2013; Ziemann, Ulf/AAY-9125-2020	Lu, Ming-Kuei/0000-0002-2768-4399; Lu, Ming-Kuei/0000-0002-2768-4399; 				Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; Abraham WC, 2008, NAT REV NEUROSCI, V9, P387, DOI 10.1038/nrn2356; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; Cheyne JE, 2008, MOL CELL NEUROSCI, V37, P432, DOI 10.1016/j.mcn.2007.10.015; Clem RL, 2008, SCIENCE, V319, P101, DOI 10.1126/science.1143808; Cooke SF, 2006, BRAIN, V129, P1659, DOI 10.1093/brain/awl082; Emond MR, 2010, J PHYSIOL-LONDON, V588, P1929, DOI 10.1113/jphysiol.2010.187229; Florian J, 2007, EUR J NEUROSCI, V25, P3461, DOI 10.1111/j.1460-9568.2007.05603.x; Fratello F, 2006, CLIN NEUROPHYSIOL, V117, P2667, DOI 10.1016/j.clinph.2006.07.315; Fricke K, 2011, J NEUROPHYSIOL, V105, P1141, DOI 10.1152/jn.00608.2009; Fusi S, 2005, NEURON, V45, P599, DOI 10.1016/j.neuron.2005.02.001; Gamboa OL, 2011, BRAIN STIMU IN PRESS; Goldsworthy MR, 2012, EUR J NEUROSCI, V35, P125, DOI 10.1111/j.1460-9568.2011.07924.x; Goldsworthy MR, 2014, CEREB CORTEX, DOI [10.1093/cercor/bht353, DOI 10.1093/CERC0R/BHT353]; Hamada M, 2008, J PHYSIOL-LONDON, V586, P3927, DOI 10.1113/jphysiol.2008.152793; Hamada M, 2014, J NEUROSCI, V34, P12837, DOI 10.1523/JNEUROSCI.1960-14.2014; Hamada M, 2012, J PHYSIOL-LONDON, V590, P2365, DOI 10.1113/jphysiol.2012.230540; Heidegger T, 2010, EUR J NEUROSCI, V32, P1215, DOI 10.1111/j.1460-9568.2010.07375.x; Hulme SR, 2013, TRENDS NEUROSCI, V36, P353, DOI 10.1016/j.tins.2013.03.007; Jung P, 2009, J NEUROSCI, V29, P5597, DOI 10.1523/JNEUROSCI.0222-09.2009; Kang JS, 2011, CEREB CORTEX, V21, P1203, DOI 10.1093/cercor/bhq204; Keel JC, 2001, CLIN NEUROPHYSIOL, V112, P720, DOI 10.1016/S1388-2457(00)00518-6; Lee MC, 2010, NEURON, V66, P859, DOI 10.1016/j.neuron.2010.05.015; Maggio N, 2014, NEUROSCIENCE, V281, P135, DOI 10.1016/j.neuroscience.2014.09.041; Mastroeni C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057957; Mockett Bruce G., 2008, Journal of Integrative Neuroscience, V7, P315, DOI 10.1142/S0219635208001782; Monte-Silva K, 2013, BRAIN STIMUL, V6, P424, DOI 10.1016/j.brs.2012.04.011; Monte-Silva K, 2010, J NEUROPHYSIOL, V103, P1735, DOI 10.1152/jn.00924.2009; Montgomery JM, 2004, TRENDS NEUROSCI, V27, P744, DOI 10.1016/j.tins.2004.10.006; Montgomery JM, 2002, NEURON, V33, P765, DOI 10.1016/S0896-6273(02)00606-2; Muller-Dahlhaus F, 2015, NEUROSCIENTIST, V21, P185, DOI 10.1177/1073858414526645; Muller-Dahlhaus JFM, 2008, EXP BRAIN RES, V187, P467, DOI 10.1007/s00221-008-1319-7; Muller-Dahlhaus Florian, 2010, Front Synaptic Neurosci, V2, P34, DOI 10.3389/fnsyn.2010.00034; Murakami T, 2012, J PHYSIOL-LONDON, V590, P5765, DOI 10.1113/jphysiol.2012.238519; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Nitsche MA, 2007, J NEUROSCI, V27, P3807, DOI 10.1523/JNEUROSCI.5348-06.2007; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Peineau S, 2007, NEURON, V53, P703, DOI 10.1016/j.neuron.2007.01.029; Philpot BD, 2007, NEURON, V53, P495, DOI 10.1016/j.neuron.2007.01.027; Potter-Nerger M, 2009, J NEUROPHYSIOL, V102, P3180, DOI 10.1152/jn.91046.2008; Quartarone A, 2005, BRAIN, V128, P1943, DOI 10.1093/brain/awh527; Quinlan EM, 1999, NAT NEUROSCI, V2, P352, DOI 10.1038/7263; Rioult-Pedotti MS, 2000, SCIENCE, V290, P533, DOI 10.1126/science.290.5491.533; Rosenkranz K, 2007, J NEUROSCI, V27, P12058, DOI 10.1523/JNEUROSCI.2663-07.2007; Stefan K, 2004, J NEUROPHYSIOL, V92, P66, DOI 10.1152/jn.00383.2003; Stefan K, 2002, J PHYSIOL-LONDON, V543, P699, DOI 10.1113/jphysiol.2002.023317; Stefan K, 2006, CEREB CORTEX, V16, P376, DOI 10.1093/cercorbhi116; Stefan K, 2000, BRAIN, V123, P572, DOI 10.1093/brain/123.3.572; Teo JTH, 2011, CEREB CORTEX, V21, P1627, DOI 10.1093/cercor/bhq231; Vlachos A, 2012, J NEUROSCI, V32, P17514, DOI 10.1523/JNEUROSCI.0409-12.2012; Wankerl K, 2010, J NEUROSCI, V30, P6197, DOI 10.1523/JNEUROSCI.4673-09.2010; Wolters A, 2003, J NEUROPHYSIOL, V89, P2339, DOI 10.1152/jn.00900.2002; Xu Z, 2009, J NEUROSCI, V29, P8764, DOI 10.1523/JNEUROSCI.1014-09.2009; Ziemann U, 2004, J NEUROSCI, V24, P1666, DOI 10.1523/JNEUROSCI.5016-03.2004; Ziemann U, 2008, BRAIN STIMUL, V1, P60, DOI 10.1016/j.brs.2007.08.003; Ziemann U, 2008, BRAIN STIMUL, V1, P164, DOI 10.1016/j.brs.2008.06.006	56	22	22	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2015	10	6							e0131020	10.1371/journal.pone.0131020	http://dx.doi.org/10.1371/journal.pone.0131020			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL4OY	26110758	Green Published, gold, Green Submitted			2023-01-03	WOS:000356933800110
J	Hohenauer, E; Taeymans, J; Baeyens, JP; Clarys, P; Clijsen, R				Hohenauer, Erich; Taeymans, Jan; Baeyens, Jean-Pierre; Clarys, Peter; Clijsen, Ron			The Effect of Post-Exercise Cryotherapy on Recovery Characteristics: A Systematic Review and Meta-Analysis	PLOS ONE			English	Article							COLD-WATER IMMERSION; WHOLE-BODY CRYOTHERAPY; PHYSICAL PERFORMANCE; MUSCLE SORENESS; EXERCISE; SYMPTOMS; INJURY; INDEXES; BOUT; INTERVENTIONS	The aim of this review and meta-analysis was to critically determine the possible effects of different cooling applications, compared to non-cooling, passive post-exercise strategies, on recovery characteristics after various, exhaustive exercise protocols up to 96 hours (hrs). A total of n = 36 articles were processed in this study. To establish the research question, the PICO-model, according to the PRISMA guidelines was used. The Cochrane's risk of bias tool, which was used for the quality assessment, demonstrated a high risk of performance bias and detection bias. Meta-analyses of subjective characteristics, such as delayed-onset muscle soreness (DOMS) and ratings of perceived exertion (RPE) and objective characteristics like blood plasma markers and blood plasma cytokines, were performed. Pooled data from 27 articles revealed, that cooling and especially cold water immersions affected the symptoms of DOMS significantly, compared to the control conditions after 24 hrs recovery, with a standardized mean difference (Hedges' g) of -0.75 with a 95% confidence interval (CI) of -1.20 to -0.30. This effect remained significant after 48 hrs (Hedges' g: -0.73, 95% CI: -1.20 to -0.26) and 96 hrs (Hedges' g: -0.71, 95% CI: -1.10 to -0.33). A significant difference in lowering the symptoms of RPE could only be observed after 24 hrs of recovery, favouring cooling compared to the control conditions (Hedges' g: -0.95, 95% CI: -1.89 to -0.00). There was no evidence, that cooling affects any objective recovery variable in a significant way during a 96 hrs recovery period.	[Hohenauer, Erich; Clijsen, Ron] Univ Appl Sci & Arts Southern Switzerland, Dept Business Econ Hlth & Social Care, Landquart Manno, Switzerland; [Taeymans, Jan] Bern Univ Appl Sci, Dept Hlth, Bern, Switzerland; [Taeymans, Jan; Baeyens, Jean-Pierre; Clarys, Peter; Clijsen, Ron] Vrije Univ Brussel, Fac Phys Educ & Physiotherapy, Brussels, Belgium; [Hohenauer, Erich; Baeyens, Jean-Pierre; Clijsen, Ron] Univ Coll Physiotherapy Thim van der Laan, Landquart, GR, Switzerland; [Taeymans, Jan] Univ Antwerp, Fac Med & Hlth Sci, B-2020 Antwerp, Belgium; [Baeyens, Jean-Pierre] Univ Antwerp, Fac Appl Engn, B-2020 Antwerp, Belgium	Vrije Universiteit Brussel; University of Antwerp; University of Antwerp	Hohenauer, E (corresponding author), Univ Appl Sci & Arts Southern Switzerland, Dept Business Econ Hlth & Social Care, Landquart Manno, Switzerland.	erich.hohenauer@supsi.ch		Baeyens, Jean-Pierre/0000-0003-2630-1912; Taeymans, Jan/0000-0003-1583-4043				Ascensao A, 2011, J SPORT SCI, V29, P217, DOI 10.1080/02640414.2010.526132; Bacon NT, 2012, J STRENGTH COND RES, V26, P1348, DOI 10.1519/JSC.0b013e318231a610; Bailey DM, 2007, J SPORT SCI, V25, P1163, DOI 10.1080/02640410600982659; Banfi G, 2010, SPORTS MED, V40, P509, DOI 10.2165/11531940-000000000-00000; Barnett A, 2006, SPORTS MED, V36, P781, DOI 10.2165/00007256-200636090-00005; Bastos FN, 2012, INT J SPORTS MED, V33, P873, DOI 10.1055/s-0032-1301905; Bleakley CM, 2012, BRIT J SPORT MED, V46, P296, DOI 10.1136/bjsm.2011.086116; Bleakley C, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008262.pub2; Borenstein M., 2009, INTRO META ANAL; Broatch JR, 2014, MED SCI SPORT EXER, V46, P2139, DOI 10.1249/MSS.0000000000000348; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Costello JT, 2012, SCAND J MED SCI SPOR, V22, P190, DOI 10.1111/j.1600-0838.2011.01292.x; Crowe MJ, 2007, INT J SPORTS MED, V28, P994, DOI 10.1055/s-2007-965118; Crystal NJ, 2013, EUR J APPL PHYSIOL, V113, P2577, DOI 10.1007/s00421-013-2693-9; De Pauw K, 2014, INT J SPORT PHYSIOL, V9, P240, DOI [10.1123/IJSPP.2012-0366, 10.1123/ijspp.2012-0366]; Delextrat A, 2013, J SPORT SCI, V31, P11, DOI 10.1080/02640414.2012.719241; Elias GP, 2012, INT J SPORT PHYSIOL, V7, P357, DOI 10.1123/ijspp.7.4.357; Eston R, 1999, J SPORT SCI, V17, P231, DOI 10.1080/026404199366136; Goodall S, 2008, J SPORT SCI MED, V7, P235; Grahn DA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3156812; Gregson W, 2011, AM J SPORT MED, V39, P1316, DOI 10.1177/0363546510395497; Guilhem G, 2013, AM J SPORT MED, V41, P1942, DOI 10.1177/0363546513490648; Hausswirth C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027749; Herrera E, 2010, PHYS THER, V90, P581, DOI 10.2522/ptj.20090131; Heyman E, 2009, MED SCI SPORT EXER, V41, P1303, DOI 10.1249/MSS.0b013e318195107d; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Howatson G, 2009, EUR J APPL PHYSIOL, V105, P615, DOI 10.1007/s00421-008-0941-1; Ingram J, 2009, J SCI MED SPORT, V12, P417, DOI 10.1016/j.jsams.2007.12.011; Jakeman JR, 2009, ERGONOMICS, V52, P456, DOI 10.1080/00140130802707733; King M, 2009, J STRENGTH COND RES, V23, P1795, DOI 10.1519/JSC.0b013e3181b3f81f; Koch AJ, 2014, J MUSCULOSKEL NEURON, V14, P68; Kuligowski LA, 1998, J ATHL TRAINING, V33, P222; Leal EC, 2011, LASER MED SCI, V26, P493, DOI 10.1007/s10103-010-0866-x; Leeder J, 2012, BRIT J SPORT MED, V46, P233, DOI 10.1136/bjsports-2011-090061; Marin DP, 2011, OXID MED CELL LONGEV, V2011, DOI 10.1155/2011/804873; MEEUSEN R, 1986, SPORTS MED, V3, P398, DOI 10.2165/00007256-198603060-00002; Minett GM, 2012, J SPORT SCI, V30, P907, DOI 10.1080/02640414.2012.679677; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Montgomery PG, 2008, J SPORT SCI, V26, P1135, DOI 10.1080/02640410802104912; Myrer JW, 2001, J ATHL TRAINING, V36, P32; Paddon-Jones DJ, 1997, INT J SPORTS MED, V18, P588, DOI 10.1055/s-2007-972686; Pointon M, 2012, EUR J APPL PHYSIOL, V112, P2483, DOI 10.1007/s00421-011-2218-3; Pointon M, 2012, MED SCI SPORT EXER, V44, P206, DOI 10.1249/MSS.0b013e31822b0977; Pointon M, 2011, EUR J APPL PHYSIOL, V111, P2977, DOI 10.1007/s00421-011-1924-1; Pournot H, 2011, EUR J APPL PHYSIOL, V111, P1287, DOI 10.1007/s00421-010-1754-6; Rowsell GJ, 2009, J SPORT SCI, V27, P565, DOI 10.1080/02640410802603855; Rupp KA, 2012, J STRENGTH COND RES, V26, P2043, DOI 10.1519/JSC.0b013e318239c3a1; Schaser KD, 2007, AM J SPORT MED, V35, P93, DOI 10.1177/0363546506294569; Sellwood KL, 2007, BRIT J SPORT MED, V41, P392, DOI 10.1136/bjsm.2006.033985; Stanley J, 2013, EUR J APPL PHYSIOL, V113, P371, DOI 10.1007/s00421-012-2445-2; Takagi R, 2011, J APPL PHYSIOL, V110, P382, DOI 10.1152/japplphysiol.01187.2010; Tiidus PM, 2015, CURR REV MUSCULOSKE, V8, P162, DOI 10.1007/s12178-015-9261-3; Tseng CY, 2013, J STRENGTH COND RES, V27, P1354, DOI 10.1519/JSC.0b013e318267a22c; Tucker TJ, 2012, J SPORT MED PHYS FIT, V52, P158; Vaile J, 2008, EUR J APPL PHYSIOL, V102, P447, DOI 10.1007/s00421-007-0605-6; White GE, 2013, EXTREME PHYSIOL MED, V2, DOI 10.1186/2046-7648-2-26; Yanagisawa O, 2003, MED SCI SPORT EXER, V35, P1517, DOI 10.1249/01.MSS.0000084418.96898.2E; Yanagisawa O, 2003, EUR J APPL PHYSIOL, V89, P53, DOI 10.1007/s00421-002-0749-3	59	96	97	0	60	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2015	10	9							e0139028	10.1371/journal.pone.0139028	http://dx.doi.org/10.1371/journal.pone.0139028			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS6EO	26413718	Green Published, gold, Green Submitted			2023-01-03	WOS:000362170700033
J	Chiang, JK; Kao, YH; Lai, NS				Chiang, Jui-Kun; Kao, Yee-Hsin; Lai, Ning-Sheng			The Impact of Hospice Care on Survival and Healthcare Costs for Patients with Lung Cancer: A National Longitudinal Population-Based Study in Taiwan	PLOS ONE			English	Article							OF-LIFE CARE; PALLIATIVE-CARE; CARDIOPULMONARY-RESUSCITATION; COMORBIDITY INDEX; CONTROLLED-TRIAL; END; QUALITY; HOME; INDICATORS; AGGRESSIVENESS	Background The healthcare costs of cancer care are highest in the last month of life. The effect of hospice care on end-of-life (EOL) healthcare costs is not clearly understood. Purpose The purpose of this study was to evaluate the effect of hospice care on survival and healthcare costs for lung cancer patients in their final month of life. Methods We adopted Taiwan's National Health Insurance Research Claims Database to analyze data for 3399 adult lung cancer patients who died in 1997-2011. A logistic regression analysis was performed to determine the predictors of high healthcare cost, defined as costs falling above the 90th percentile. Patients who received hospice cares were assigned to a hospice (H) group and those who did not were assigned to a non-hospice (non-H) group. Results The patients in the H group had a longer mean (median) survival time than those in the non-H group did (1.40 +/- 1.61 y (0.86) vs. 1.10 +/- 1.47 (0.61), p<0.001). The non-H group had a lower mean healthcare cost than the H group (US $1,821 +/- 2,441 vs. US $1,839 +/- 1,638, p<0.001). And, there were a total of 340 patients (10%) with the healthcare costs exceeding the 90th percentile (US $4,721) as the cutoff value of high cost. The non-H group had a higher risk of high cost than the H group because many more cases in the non-H group had lower costs. Moreover, the risk of high health care costs were predicted for patients who did not receive hospice care (odds ratio [OR]: 3.68, 95% confidence interval [CI]: 2.44-5.79), received chemotherapy (OR: 1.51, 95% CI: 1.18-1.96) and intubation (OR: 2.63, 95% CI: 1.64-4.16), and those who had more emergency department visits (OR: 1.78, 95% CI: 1.24-2.52), longer hospital admission in days (OR: 1.08, 95% CI: 1.07-1.09), and received radiotherapy (OR: 1.33, 95% CI: 1.00-1.78). Lower risks of high health care costs were observed in patients with low socioeconomic status (OR: 0.58, 95% CI: 0.40-0.83), or previous employment (OR: 0.66, 95% CI: 0.47-0.92). After propensity-score matching, the patients of the non-H group had a higher mean cost and a higher risk of high cost. Similar results were obtained from logistic regression analysis in propensity score-matched patients. Conclusions The survival of the hospice group was longer than non-H group, and patients in the non-H group were 3.74 times more likely to have high healthcare costs at EOL. The positive predictors for high health care costs were patients who did not receive hospice care, who received chemotherapy and intubation, who had more emergency department visits and longer hospital admission, and who received radiotherapy. Negative predictors were patients who had a low socioeconomic status or previous employment. The issue of how to reduce the high health care costs for patients with lung cancer in the last month of life is a challenge for policy makers and health care providers.	[Chiang, Jui-Kun] Buddhist Dalin Tzu Chi Hosp, Dept Family Med, Chiayi, Taiwan; [Kao, Yee-Hsin] Tainan Municipal Hosp, Dept Family Med, Tainan, Taiwan; [Lai, Ning-Sheng] Buddhist Dalin Tzu Chi Hosp, Dept Allergy Immunol & Rheumatol, Chiayi, Taiwan; [Lai, Ning-Sheng] Tzu Chi Univ, Sch Med, Hualien, Taiwan	Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Buddhist Tzu Chi General Hospital; Dalin Tzu Chi Hospital; Tzu Chi University	Chiang, JK (corresponding author), Tainan Municipal Hosp, Dept Family Med, Tainan, Taiwan.	m2200767@gmail.com; tzuchilai@gmail.com			Buddhist Dalin Tzu Chi Hospital [DTCRD 102(2)-E-01, DTCRD 103(2)-E-03]	Buddhist Dalin Tzu Chi Hospital	JK Chiang received research grants from Buddhist Dalin Tzu Chi Hospital (DTCRD 102(2)-E-01, DTCRD 103(2)-E-03).	Brumley R, 2007, J AM GERIATR SOC, V55, P993, DOI 10.1111/j.1532-5415.2007.01234.x; Campbell DE, 2004, ANN INTERN MED, V140, P269, DOI 10.7326/0003-4819-140-4-200402170-00009; Carlson MDA, 2010, J CLIN ONCOL, V28, P4371, DOI 10.1200/JCO.2009.26.1818; Chang CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040590; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chastek B, 2012, J ONCOL PRACT, V8, p75S, DOI 10.1200/JOP.2011.000469; Chen YS, 2008, LANCET, V372, P554, DOI 10.1016/S0140-6736(08)60958-7; Connor SR, 2007, J PAIN SYMPTOM MANAG, V33, P238, DOI 10.1016/j.jpainsymman.2006.10.010; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; DiMartino LD, 2014, J PALLIAT MED, V17, P1384, DOI 10.1089/jpm.2014.0092; Dudgeon DJ, 2008, J PAIN SYMPTOM MANAG, V35, P573, DOI 10.1016/j.jpainsymman.2007.07.013; Dy SM, 2010, CANCER-AM CANCER SOC, V116, P3267, DOI 10.1002/cncr.25109; Earle CC, 2005, INT J QUAL HEALTH C, V17, P505, DOI 10.1093/intqhc/mzi061; Earle CC, 2003, J CLIN ONCOL, V21, P1133, DOI 10.1200/JCO.2003.03.059; Earle CC, 2008, J CLIN ONCOL, V26, P3860, DOI 10.1200/JCO.2007.15.8253; Fassbender K, 2005, PALLIATIVE MED, V19, P513, DOI 10.1191/0269216305pm1071oa; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Finlay IG, 2002, ANN ONCOL, V13, P257, DOI 10.1093/annonc/mdf668; Forrest LF, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001376; Gomes B, 2013, PROG PALLIAT CARE, V21, P204, DOI 10.1179/1743291X13Y.0000000065; Gomes B, 2014, JAMA-J AM MED ASSOC, V311, P1060, DOI 10.1001/jama.2014.553; Gomes B, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007760.pub2, 10.1590/1516-3180.20161341T2]; Gomez-Batiste X, 2012, J PAIN SYMPTOM MANAG, V43, P783, DOI 10.1016/j.jpainsymman.2011.05.006; Gonsalves WI, 2011, J PALLIAT MED, V14, P1231, DOI 10.1089/jpm.2011.0131; Grande GE, 2000, PALLIATIVE MED, V14, P375, DOI 10.1191/026921600701536200; Grunfeld E, 2008, CANCER, V112, P2301, DOI 10.1002/cncr.23428; Grunfeld E, 2006, PALLIATIVE MED, V20, P769, DOI 10.1177/0269216306072553; Hatziandreu E, 2008, THE POTENTIAL COST S; Higginson IJ, 2003, J PAIN SYMPTOM MANAG, V25, P150, DOI 10.1016/S0885-3924(02)00599-7; Ho TH, 2011, J CLIN ONCOL, V29, P1587, DOI 10.1200/JCO.2010.31.9897; Hughes SL, 2000, JAMA-J AM MED ASSOC, V284, P2877, DOI 10.1001/jama.284.22.2877; Hurria A, 2008, J CLIN ONCOL, V26, P5386, DOI 10.1200/JCO.2008.17.6891; Jordhoy MS, 2000, LANCET, V356, P888, DOI 10.1016/S0140-6736(00)02678-7; KANE RL, 1984, LANCET, V1, P890; Kim YA, 2014, ANN SURG, V259, P569, DOI 10.1097/SLA.0b013e318291db9d; Klabunde CN, 2000, J CLIN EPIDEMIOL, V53, P1258, DOI 10.1016/S0895-4356(00)00256-0; Klinger CA, 2014, PALLIATIVE MED, V28, P111, DOI 10.1177/0269216313493342; Kreng VB, 2011, HEALTH POLICY, V100, P203, DOI 10.1016/j.healthpol.2010.08.003; Langton JM, 2014, PALLIATIVE MED, V28, P1167, DOI 10.1177/0269216314533813; Lee CC, 2011, STROKE, V42, P48, DOI 10.1161/STROKEAHA.110.597070; Lin CC, 2005, J FORMOS MED ASSOC, V104, P157; Lo JC, 2002, SOC SCI MED, V54, P981, DOI 10.1016/S0277-9536(01)00071-5; Lorenz KA, 2006, J CLIN ONCOL, V24, P4933, DOI 10.1200/JCO.2006.06.8650; Marcus MW, 2015, ONCOL LETT, V9, P1902, DOI 10.3892/ol.2015.2916; Morrison RS, 2008, ARCH INTERN MED, V168, P1783, DOI 10.1001/archinte.168.16.1783; Morss S, 2011, J PALLIAT MED, V14, P451, DOI 10.1089/jpm.2010.0434; Obermeyer Z, 2014, JAMA-J AM MED ASSOC, V312, P1888, DOI 10.1001/jama.2014.14950; Rabow MW, 2004, ARCH INTERN MED, V164, P83, DOI 10.1001/archinte.164.1.83; Riley GF, 2010, HEALTH SERV RES, V45, P565, DOI 10.1111/j.1475-6773.2010.01082.x; Rodrigues G, 2011, PRACT RADIAT ONCOL, V1, P60, DOI 10.1016/j.prro.2011.01.005; Saito AM, 2011, J PALLIAT MED, V14, P929, DOI 10.1089/jpm.2010.0522; Seeger JD, 2005, PHARMACOEPIDEM DR S, V14, P465, DOI 10.1002/pds.1062; Seow H, 2009, CANCER-AM CANCER SOC, V115, P3820, DOI 10.1002/cncr.24439; Smith S, 2014, PALLIATIVE MED, V28, P130, DOI 10.1177/0269216313493466; Smith Thomas J, 2003, J Palliat Med, V6, P699, DOI 10.1089/109662103322515202; Tang ST, 2009, ANN ONCOL, V20, P343, DOI 10.1093/annonc/mdn602; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Teno JM, 2014, JAMA-J AM MED ASSOC, V312, P1868, DOI 10.1001/jama.2014.14949; Wang HM, 2011, J PAIN SYMPTOM MANAG, V42, P400, DOI 10.1016/j.jpainsymman.2010.12.011; Yabroff KR, 2008, JNCI-J NATL CANCER I, V100, P630, DOI 10.1093/jnci/djn103; Yu KH, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3806; Zhang Z, 2015, AM J HOSP PALLIAT ME, V32, P210, DOI 10.1177/1049909113520215	63	13	13	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2015	10	9							e0138773	10.1371/journal.pone.0138773	http://dx.doi.org/10.1371/journal.pone.0138773			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CS1CR	26406871	Green Submitted, Green Published, gold			2023-01-03	WOS:000361800700092
J	Cunningham, S; Rodriguez, A; Adams, T; Boyd, KA; Butcher, I; Enderby, B; MacLean, M; McCormick, J; Paton, JY; Wee, F; Thomas, H; Riding, K; Turner, SW; Williams, C; McIntosh, E; Lewis, SC				Cunningham, Steve; Rodriguez, Aryelly; Adams, Tim; Boyd, Kathleen A.; Butcher, Isabella; Enderby, Beth; MacLean, Morag; McCormick, Jonathan; Paton, James Y.; Wee, Fiona; Thomas, Huw; Riding, Kay; Turner, Steve W.; Williams, Chris; McIntosh, Emma; Lewis, Steff C.		Bronchiolitis Infancy Discharge	Oxygen saturation targets in infants with bronchiolitis (BIDS): a double-blind, randomised, equivalence trial	LANCET			English	Article							CHILDREN; SUPPORT	Background The American Academy of Pediatrics recommends a permissive hypoxaemic target for an oxygen saturation of 90% for children with bronchiolitis, which is consistent with the WHO recommendations for targets in children with lower respiratory tract infections. No evidence exists to support this threshold. We aimed to assess whether the 90% or higher target for management of oxygen supplementation was equivalent to a normoxic 94% or higher target for infants admitted to hospital with viral bronchiolitis. Methods We did a parallel-group, randomised, controlled, equivalence trial of infants aged 6 weeks to 12 months of age with physician-diagnosed bronchiolitis newly admitted into eight paediatric hospital units in the UK (the Bronchiolitis of Infancy Discharge Study [BIDS]). A central computer randomly allocated (1: 1) infants, in varying length blocks of four and six and without stratifi cation, to be clipped to standard oximeters (patients treated with oxygen if pulse oxygen saturation [SpO(2)] < 94%) or modified oximeters (displayed a measured value of 90% as 94%, therefore oxygen not given until SpO2 < 90%). All parents, clinical staff, and outcome assessors were masked to allocation. The primary outcome was time to resolution of cough (prespecified equivalence limits of plus or minus 2 days) in the intention-to-treat population. This trial is registered with ISRCTN, number ISRCTN28405428. Findings Between Oct 3, and March 30, 2012, and Oct 1, and March 29, 2013, we randomly assigned 308 infants to standard oximeters and 307 infants to modifi ed oximeters. Cough resolved by 15.0 days (median) in both groups (95% CI for difference -1 to 2) and so oxygen thresholds were equivalent. We recorded 35 serious adverse events in 32 infants in the standard care group and 25 serious adverse events in 24 infants in the modifi ed care group. In the standard care group, eight infants transferred to a high-dependency unit, 23 were readmitted, and one had a prolonged hospital stay. In the modifi ed care group, 12 infants were transferred to a high-dependency unit and 12 were readmitted to hospital. Recorded adverse events did not diff er significantly. Interpretation Management of infants with bronchiolitis to an oxygen saturation target of 90% or higher is as safe and clinically effective as one of 94% or higher. Future research should assess the benefits and risks of different oxygen saturation targets in acute respiratory infection in older children, particularly in developing nations where resources are scarce. Copyright (C) Cunningham et al. Open Access article distributed under the terms of CC BY-NC-ND.	[Cunningham, Steve; Riding, Kay] Univ Edinburgh, Dept Child Life & Hlth, Edinburgh EH9 1LF, Midlothian, Scotland; [Rodriguez, Aryelly; Butcher, Isabella; Lewis, Steff C.] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh EH9 1LF, Midlothian, Scotland; [MacLean, Morag] Univ Edinburgh, Edinburgh Clin Trials Unit, Edinburgh EH9 1LF, Midlothian, Scotland; [Adams, Tim] Crosshouse Hosp, Dept Paediat, Kilmarnock, Scotland; [Boyd, Kathleen A.; McIntosh, Emma] Univ Glasgow, Hlth Econ & Hlth Technol Assessment, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland; [Paton, James Y.] Univ Glasgow, Sch Med, Glasgow, Lanark, Scotland; [Enderby, Beth] Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England; [McCormick, Jonathan] Univ Dundee, Ninewells Hosp & Med Sch, Dept Paediat, Dundee DD1 9SY, Scotland; [Thomas, Huw] Bristol Childrens Hosp, Dept Resp Med, Bristol, Avon, England; [Turner, Steve W.] Royal Aberdeen Childrens Hosp, Aberdeen, Scotland; [Williams, Chris] Royal Cornwall Hosp, Truro, England	University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Glasgow; University of Glasgow; University of Exeter; University of Dundee; Bristol Royal Hospital For Children; University of Aberdeen; Royal Cornwall Hospital	Cunningham, S (corresponding author), Univ Edinburgh, Dept Child Life & Hlth, Edinburgh EH9 1LF, Midlothian, Scotland.	steve.cunningham@nhs.net		Lewis, Steff/0000-0003-1210-2314; Boyd, Kathleen/0000-0002-9764-0113; McIntosh, Emma/0000-0001-6340-3083; MacLean, Morag/0000-0002-4037-0247; Gamble, Carrol/0000-0002-3021-1955; Lyttle, Mark/0000-0002-8634-7210; Tonner, Sharon/0000-0002-7775-9926; Cunningham, Steve/0000-0001-7342-251X	National Institute for Health Research, Health Technology Assessment programme; UK National Institute for Health Research (NIHR), Health Technology Assessment (HTA) programme [09/91/16]; NHS Research Scotland (NRS), through the Edinburgh Clinical Research Facility; National Institute for Health Research [09/91/16] Funding Source: researchfish	National Institute for Health Research, Health Technology Assessment programme(National Institute for Health Research (NIHR)); UK National Institute for Health Research (NIHR), Health Technology Assessment (HTA) programme; NHS Research Scotland (NRS), through the Edinburgh Clinical Research Facility; National Institute for Health Research(National Institute for Health Research (NIHR))	National Institute for Health Research, Health Technology Assessment programme.; We were funded by the UK National Institute for Health Research (NIHR), Health Technology Assessment (HTA) programme (project number 09/91/16) and will be published in full in Health Technology Assessment. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the HTA programme, NIHR, NHS, or the UK Department of Health. The BIDS study team acknowledges the financial support of NHS Research Scotland (NRS), through the Edinburgh Clinical Research Facility. We also received non-financial support from the Scottish Children's Research Network (ScotCRN) and the NIHR Clinical Research Network. Masimo, CA, USA, produced oxygen saturation monitors with standard and altered algorithm to the specification required for the study, which we then bought from Masimo. We thank Michael Shields (Queen's University Belfast), Colin Powell (University of Cardiff), and Clare Murray (University of Manchester) for serving as the trial steering committee, and to Sheila McKenzie (NHS Highland), Mike McKean (Newcastle University), and Carrol Gamble (University of Liverpool) for serving as the data monitoring committee.	Ali S, 2013, J IMMUNOL, V190, P3949, DOI 10.4049/jimmunol.1201015; Altman DG, 1989, STAT CONFIDENCE, P19; [Anonymous], 2014, THORAX, V69, P1; Bass JL, 2007, PEDIATRICS, V119, P611, DOI 10.1542/peds.2006-3002; Carlo WA, 2010, NEW ENGL J MED, V362, P1959, DOI 10.1056/NEJMoa0911781; Cunningham S, 2012, ARCH DIS CHILD, V97, P361, DOI 10.1136/adc.2010.205211; Drazen JM, 2013, NEW ENGL J MED, V368, P1929, DOI 10.1056/NEJMe1304996; Duke T, 2008, LANCET, V372, P1328, DOI 10.1016/S0140-6736(08)61164-2; Harris M, 2011, THORAX, V66, pII1, DOI 10.1136/thoraxjnl-2011-200598; Hasegawa K, 2013, PEDIATRICS, V132, P28, DOI 10.1542/peds.2012-3877; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Hudson KL, 2013, NEW ENGL J MED, V368, P2349, DOI 10.1056/NEJMp1306986; Lieberthal AS, 2006, PEDIATRICS, V118, P1774, DOI 10.1542/peds.2006-2223; Macklin R, 2013, NEW ENGL J MED, V369, pE3, DOI 10.1056/NEJMc1308015; Marcus CL, 2013, NEW ENGL J MED, V368, P2366, DOI 10.1056/NEJMoa1215881; National Guideline Clearinghouse (NGC), GUID SYNTH PREV DIAG; Network SIG, 2006, BRONCH CHILDR SIGN 9; Plint AC, 2009, NEW ENGL J MED, V360, P2079, DOI 10.1056/NEJMoa0900544; Ralston SL, 2014, PEDIATRICS, V134, pE1474, DOI 10.1542/peds.2014-2742; ROJAS MX, 2009, COCHRANE DB SYST REV, V1; Schuh S, 2014, JAMA-J AM MED ASSOC, V312, P712, DOI 10.1001/jama.2014.8637; Schwarze J, 2013, THORAX, V68, P108, DOI 10.1136/thoraxjnl-2012-202291; Shields Michael D, 2013, Cough, V9, P11, DOI 10.1186/1745-9974-9-11; Skjerven HO, 2013, NEW ENGL J MED, V368, P2286, DOI 10.1056/NEJMoa1301839; Stenson BJ, 2013, NEW ENGL J MED, V368, P2094, DOI 10.1056/NEJMoa1302298; Thompson M, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7027; UK Department of Health, NAT SCHED REF COSTS; Unger S, 2008, PEDIATRICS, V121, P470, DOI 10.1542/peds.2007-1135; World Health Organization, 2013, POCK BOOK HOSP CAR C; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	30	85	87	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 12	2015	386	9998					1041	1048		10.1016/S0140-6736(15)00163-4	http://dx.doi.org/10.1016/S0140-6736(15)00163-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CR2VQ	26382998	Green Published, hybrid, Green Accepted			2023-01-03	WOS:000361189200023
J	Shann, F; Lange, T				Shann, Frank; Lange, Theis			Bubble CPAP for pneumonia: perils of stopping trials early	LANCET			English	Editorial Material							RANDOMIZED CLINICAL-TRIALS; BENEFIT; EFFICACY		[Shann, Frank] Royal Childrens Hosp, Intens Care Unit, Parkville, Vic 3052, Australia; [Shann, Frank] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; [Lange, Theis] Univ Copenhagen, Fac Hlth & Med Sci, Sect Biostat, Copenhagen, Denmark	Royal Children's Hospital Melbourne; University of Melbourne; University of Copenhagen	Shann, F (corresponding author), Royal Childrens Hosp, Intens Care Unit, Flemington Rd, Parkville, Vic 3052, Australia.	frank.shann@rch.org.au	Shann, Frank/C-9510-2011	Lange, Theis/0000-0001-6807-8347				Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; Abraham E, 2003, JAMA-J AM MED ASSOC, V290, P238, DOI 10.1001/jama.290.2.238; Andres AM, 1997, BIOMETRICAL J, V39, P935; Bassler D, 2008, J CLIN EPIDEMIOL, V61, P241, DOI 10.1016/j.jclinepi.2007.07.016; Bassler D, 2010, JAMA-J AM MED ASSOC, V303, P1180, DOI 10.1001/jama.2010.310; Chisti MJ, 2015, LANCET; Duke T, 2014, PAEDIATR INT CHILD H, V34, P3, DOI 10.1179/2046905513Y.0000000102; Lechat P, 1999, LANCET, V353, P9; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Pocock S, 2005, AM HEART J, V149, P939, DOI 10.1016/j.ahj.2004.10.038; Pocock SJ, 2005, JAMA-J AM MED ASSOC, V294, P2228, DOI 10.1001/jama.294.17.2228; Wheatley K, 2003, CONTROL CLIN TRIALS, V24, P66, DOI 10.1016/S0197-2456(02)00273-8; Zannad F, 2012, CIRC-HEART FAIL, V5, P294, DOI 10.1161/CIRCHEARTFAILURE.111.965707	13	8	8	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 12	2015	386	9998					1020	1022		10.1016/S0140-6736(15)60691-2	http://dx.doi.org/10.1016/S0140-6736(15)60691-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CR2VQ	26311458				2023-01-03	WOS:000361189200007
J	Grams, ST; Kimoto, KYM; Azevedo, EMD; Lanca, M; de Albuquerque, ALP; de Brito, CMM; Yamaguti, WP				Grams, Samantha Torres; Mota Kimoto, Karen Yumi; de Oliveira Azevedo, Elen Moda; Lanca, Marina; Pereira de Albuquerque, Andre Luis; Moran de Brito, Christina May; Yamaguti, Wellington Pereira			Unidirectional Expiratory Valve Method to Assess Maximal Inspiratory Pressure in Individuals without Artificial Airway	PLOS ONE			English	Article							RESPIRATORY PRESSURES; REFERENCE VALUES; MANEUVERS; TESTS; AGE	Introduction Maximal Inspiratory Pressure (MIP) is considered an effective method to estimate strength of inspiratory muscles, but still leads to false positive diagnosis. Although MIP assessment with unidirectional expiratory valve method has been used in patients undergoing mechanical ventilation, no previous studies investigated the application of this method in subjects without artificial airway. Objectives This study aimed to compare the MIP values assessed by standard method (MIPsta) and by unidirectional expiratory valve method (MIPuni) in subjects with spontaneous breathing without artificial airway. MIPuni reproducibility was also evaluated. Methods This was a crossover design study, and 31 subjects performed MIPsta and MIPuni in a random order. MIPsta measured MIP maintaining negative pressure for at least one second after forceful expiration. MIPuni evaluated MIP using a unidirectional expiratory valve attached to a face mask and was conducted by two evaluators (A and B) at two moments (Tests 1 and 2) to determine interobserver and intraobserver reproducibility of MIP values. Intraclass correlation coefficient (ICC[2,1]) was used to determine intraobserver and interobserver reproducibility. Results The mean values for MIPuni were 14.3% higher (-117.3 +/- 24.8 cmH(2)O) than the mean values for MIPsta (-102.5 +/- 23.9 cmH(2)O) (p<0.001). Interobserver reproducibility assessment showed very high correlation for Test 1 (ICC[2,1] = 0.91), and high correlation for Test 2 (ICC[2,1] = 0.88). The assessment of the intraobserver reproducibility showed high correlation for evaluator A (ICC[2,1] = 0.86) and evaluator B (ICC[2,1] = 0.77). Conclusions MIPuni presented higher values when compared with MIPsta and proved to be reproducible in subjects with spontaneous breathing without artificial airway.	[Grams, Samantha Torres; Mota Kimoto, Karen Yumi; de Oliveira Azevedo, Elen Moda; Lanca, Marina; Pereira de Albuquerque, Andre Luis; Moran de Brito, Christina May; Yamaguti, Wellington Pereira] HSL, Dept Rehabil, Sao Paulo, SP, Brazil; [Pereira de Albuquerque, Andre Luis] HSL, NAT, Dept Pulm Funct, Sao Paulo, SP, Brazil		Yamaguti, WP (corresponding author), HSL, Dept Rehabil, Sao Paulo, SP, Brazil.	wellington.psyamaguti@hsl.org.br	de Brito, Christina May Moran/I-7269-2012; Albuquerque, Andre L P/C-8835-2012	de Brito, Christina May Moran/0000-0003-3775-6533; Albuquerque, Andre L P/0000-0003-3486-5240				Aldrich TK, 2002, AM J RESP CRIT CARE, V166, P548, DOI 10.1164/rccm.166.4.518; BLACK LF, 1969, AM REV RESPIR DIS, V99, P696; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Caruso P, 1999, CHEST, V115, P1096, DOI 10.1378/chest.115.4.1096; Costa D, 2010, J BRAS PNEUMOL, V36, P306, DOI 10.1590/S1806-37132010000300007; FEELEY TW, 1975, NEW ENGL J MED, V292, P903, DOI 10.1056/NEJM197504242921707; Fiore Junior Julio Flavio, 2004, J. bras. pneumol., V30, P515, DOI 10.1590/S1806-37132004000600005; FIZ JA, 1989, THORAX, V44, P419, DOI 10.1136/thx.44.5.419; Fregonezi GAD, 2005, CHEST, V128, P1524, DOI 10.1378/chest.128.3.1524; Gayraud J, 2010, PEDIATR PULM, V45, P552, DOI 10.1002/ppul.21204; Gosselink R, 2011, EUR RESPIR J, V37, P416, DOI 10.1183/09031936.00031810; Grant S, 1999, CHEST, V116, P1208, DOI 10.1378/chest.116.5.1208; Lin Suh-Jen, 2012, Cardiopulm Phys Ther J, V23, P29; MARINI J J, 1986, Journal of Critical Care, V1, P32, DOI 10.1016/S0883-9441(86)80114-9; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Munro B., 1997, STAT METHODS HLTH CA; Neder JA, 1999, BRAZ J MED BIOL RES, V32, P719, DOI 10.1590/S0100-879X1999000600007; Parreira VF, 2007, BRAZ J PHYS THER, V11, P361, DOI 10.1590/S1413-35552007000500006; Parreira VF, 2012, BRAZ J PHYS THER, V16, P225, DOI 10.1590/S1413-35552012000300008; Pereira Carlos Alberto de Castro, 2007, J. bras. pneumol., V33, P397, DOI 10.1590/S1806-37132007000400008; SAHN SA, 1973, CHEST, V63, P1002, DOI 10.1378/chest.63.6.1002; SMYTH RJ, 1984, CHEST, V86, P568, DOI 10.1378/chest.86.4.568; Souza RB, 2002, J PNEUMOL S3, V28, P155; Steier J, 2007, THORAX, V62, P975, DOI 10.1136/thx.2006.072884; Terzano C, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-8; TRUWIT JD, 1992, CHEST, V102, P1216, DOI 10.1378/chest.102.4.1216; Tzanis G, 2011, BMC ANESTHESIOL, V11, DOI 10.1186/1471-2253-11-14; Wen AS, 1997, CHEST, V111, P802, DOI 10.1378/chest.111.3.802; Wohlgemuth M, 2003, EUR RESPIR J, V22, P1001, DOI 10.1183/09031936.03.00028103; Yamaguti WPS, 2004, REV BRAS TER INTENSI, V16, P142	30	2	2	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2015	10	9							e0137825	10.1371/journal.pone.0137825	http://dx.doi.org/10.1371/journal.pone.0137825			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR0WB	26360255	Green Published, Green Submitted, gold			2023-01-03	WOS:000361043100090
J	Salmasi, S; Khan, TM; Hong, YH; Ming, LC; Wong, TW				Salmasi, Shahrzad; Khan, Tahir Mehmood; Hong, Yet Hoi; Ming, Long Chiau; Wong, Tin Wui			Medication Errors in the Southeast Asian Countries: A Systematic Review	PLOS ONE			English	Review							ADMINISTRATION ERRORS; CARE; HOSPITALS; SINGAPORE; HEALTH	Background Medication error (ME) is a worldwide issue, but most studies on ME have been undertaken in developed countries and very little is known about ME in Southeast Asian countries. This study aimed systematically to identify and review research done on ME in Southeast Asian countries in order to identify common types of ME and estimate its prevalence in this region. Methods The literature relating to MEs in Southeast Asian countries was systematically reviewed in December 2014 by using; Embase, Medline, Pubmed, ProQuest Central and the CINAHL. Inclusion criteria were studies (in any languages) that investigated the incidence and the contributing factors of ME in patients of all ages. Results The 17 included studies reported data from six of the eleven Southeast Asian countries: five studies in Singapore, four in Malaysia, three in Thailand, three in Vietnam, one in the Philippines and one in Indonesia. There was no data on MEs in Brunei, Laos, Cambodia, Myanmar and Timor. Of the seventeen included studies, eleven measured administration errors, four focused on prescribing errors, three were done on preparation errors, three on dispensing errors and two on transcribing errors. There was only one study of reconciliation error. Three studies were interventional. Discussion The most frequently reported types of administration error were incorrect time, omission error and incorrect dose. Staff shortages, and hence heavy workload for nurses, doctor/nurse distraction, and misinterpretation of the prescription/medication chart, were identified as contributing factors of ME. There is a serious lack of studies on this topic in this region which needs to be addressed if the issue of ME is to be fully understood and addressed.	[Salmasi, Shahrzad; Khan, Tahir Mehmood] Monash Univ Malaysia, Sch Pharm, Sunway City, Selangor, Malaysia; [Hong, Yet Hoi] Univ Malaya, Fac Med, Dept Physiol, Kuala Lumpur, Malaysia; [Ming, Long Chiau] Univ Teknol MARA, Fac Pharm, Brain Degenerat & Therapeut Grp, Pharmaceut & Life Sci CoRe, Puncak Alam, Selangor, Malaysia; [Wong, Tin Wui] Univ Teknol MARA, Nondestruct Biomed & Pharmaceut Res Ctr, iPROMISE, Puncak Alam, Selangor, Malaysia	Universiti Malaya; Universiti Teknologi MARA; Universiti Teknologi MARA	Khan, TM (corresponding author), Monash Univ Malaysia, Sch Pharm, Sunway City, Selangor, Malaysia.	tahir.mehmood@monash.edu; ming.long@bath.edu	Khan, Yusra Habib/AFK-9024-2022; Khan, Tahir/ABA-6714-2021; Ming, Long Chiau/J-5210-2015; HONG, YET HOI/B-5229-2010; Wong, Tin Wui/B-8668-2012	Khan, Yusra Habib/0000-0002-9479-6147; Ming, Long Chiau/0000-0002-6971-1383; HONG, YET HOI/0000-0003-2739-580X; Wong, Tin Wui/0000-0002-9131-6937; Khan, Tahir/0000-0003-0081-1957; Salmasi, Shahrzad/0000-0003-1330-3388	Research Acculturation Grant Scheme (RAGS), Malaysia [RAGS/2013/UITM/SKK02/5, SKK02/3]; Monash University Malaysia, Universiti Teknologi MARA, Ministry of Education, Malaysia	Research Acculturation Grant Scheme (RAGS), Malaysia; Monash University Malaysia, Universiti Teknologi MARA, Ministry of Education, Malaysia	This work was supported by Research Acculturation Grant Scheme (RAGS), Malaysia (RAGS/2013/UITM/SKK02/5, SKK02/3). The authors would like to express their gratitude to Monash University Malaysia, Universiti Teknologi MARA, Ministry of Education, Malaysia for financial support for this research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdullah Dellemin Che, 2004, Malays J Med Sci, V11, P52; Alsulami Z, 2013, EUR J CLIN PHARMACOL, V69, P995, DOI 10.1007/s00228-012-1435-y; Anderson Stuart, 2002, J Interprof Care, V16, P391, DOI 10.1080/1356182021000008337; Aronson JK, 2009, BRIT J CLIN PHARMACO, V67, P599, DOI 10.1111/j.1365-2125.2009.03415.x; Biswas P, 2013, J PHARMACOL PHARMACO, V4, pS7, DOI 10.4103/0976-500X.120941; Cheung KC, 2009, BRIT J CLIN PHARMACO, V67, P676, DOI 10.1111/j.1365-2125.2009.03428.x; Chongsuvivatwong V, 2011, LANCET, V377, P429, DOI 10.1016/S0140-6736(10)61507-3; Choo J, 2014, NURS HEALTH SCI, V16, P245, DOI 10.1111/nhs.12078; Choo J, 2013, NURS HEALTH SCI, V15, P101, DOI 10.1111/j.1442-2018.2012.00706.x; Chua SS, 2009, J CLIN PHARM THER, V34, P215, DOI 10.1111/j.1365-2710.2008.00997.x; Chua SS, 2010, EUR J PEDIATR, V169, P603, DOI 10.1007/s00431-009-1084-z; Ernawati DK, 2014, THER CLIN RISK MANAG, V10, P413, DOI 10.2147/TCRM.S61687; Fahimi F, 2009, ARCH IRAN MED, V12, P173; Gautam Parshotam Lal, 2013, J Anaesthesiol Clin Pharmacol, V29, P293, DOI 10.4103/0970-9185.117037; Hashim J., 2012, HLTH HEALTHCARE SYST; Nguyen HT, 2014, BMJ QUAL SAF, V23, P319, DOI 10.1136/bmjqs-2013-002357; Nguyen HT, 2014, NURS RES, V63, P68, DOI 10.1097/NNR.0000000000000010; Institute of Medicine, 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Iyer US, 2011, ANAESTH INTENS CARE, V39, P1151; Kaboli PJ, 2006, ARCH INTERN MED, V166, P955, DOI 10.1001/archinte.166.9.955; Keers RN, 2013, ANN PHARMACOTHER, V47, P237, DOI 10.1345/aph.1R147; Kirk RC, 2005, DRUG SAFETY, V28, P817, DOI 10.2165/00002018-200528090-00006; Kohn L. T., 2000, ERR IS HUMAN BUILDIN, V6; Nguyen HT, ERRORS MED IN PRESS; Nosek RA, 2005, ADV PATIENT SAFETY R, V4, P361; Nwokike J, 2013, COMP ANAL PHARMACOVI; Ong W M, 2013, Med J Malaysia, V68, P52; Patel I, 2010, INDIAN J PHARM SCI, V72, P539, DOI 10.4103/0250-474X.78518; Valdez LP, 2013, NURS EDUC TODAY, V33, P222, DOI 10.1016/j.nedt.2012.01.001; Rothschild JM, 2010, ANN EMERG MED, V55, P513, DOI 10.1016/j.annemergmed.2009.10.012; Sangtawesin Varaporn, 2003, J Med Assoc Thai, V86 Suppl 3, pS570; Sanguansak T, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000539; Smetzer JL, 2007, MED ERRORS; Thanoo Hintong MD, 2005, J MED ASS THAI, V88, P118; U.S. Food and Drug Administration, 2015, MED ERR; United Nations Statistic Division, COMP MAC CONT REG GE; United Nations' Department of Economic and Social Affairs, WORLD POP PROSP 2012; World Health Organization (WHO), 2014, REP LEARN SYST MED E; World Health Organization (WHO), 2006, WORLD HLTH REP 2006; Yi SB, 2013, INT J HEALTH CARE Q, V26, P31, DOI 10.1108/09526861311288622; Yoelao D, 2014, INT J BEHAV SCI, V9, P53, DOI 10.14456/ijbs.2014.5	41	60	64	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2015	10	9							e0136545	10.1371/journal.pone.0136545	http://dx.doi.org/10.1371/journal.pone.0136545			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CQ6BA	26340679	Green Submitted, Green Published, gold			2023-01-03	WOS:000360688200009
J	Xing, JJ; Liu, XF; Xiong, XM; Huang, L; Lao, CY; Yang, M; Gao, S; Huang, QY; Yang, W; Zhu, YF; Zhang, DH				Xing, Ji-Juan; Liu, Xiu-Fen; Xiong, Xiao-Ming; Huang, Li; Lao, Cheng-Yi; Yang, Mei; Gao, Shan; Huang, Qiong-Yan; Yang, Wei; Zhu, Yun-Feng; Zhang, Di-Hua			Effects of Combined Spinal-Epidural Analgesia during Labor on Postpartum Electrophysiological Function of Maternal Pelvic Floor Muscle: A Randomized Controlled Trial	PLOS ONE			English	Article							PRESSURE MEASUREMENTS; VAGINAL DELIVERY; REDUCE; RISK; PAIN	Objective Combined spinal-epidural analgesia (CSEA) is sometimes used for difficult births, but whether it contributes to postpartum pelvic muscle disorder is unclear. This randomized controlled trial examined whether CSEA given during labor affects the electrophysiological index of postpartum pelvic floor muscle function. Methods A consecutive sample of primiparous women who delivered vaginally at term were randomly assigned to a CSEA group (n = 143) and control group (n = 142) between June 2013 and June 2014. All were assessed 6-8 weeks later for electrophysiological function of pelvic floor muscle. Results The two groups were similar in the degree of muscle strength, muscle fatigue, and pelvic dynamic pressure of pelvic floor muscle. The CSEA and control groups showed similar proportions of women with normal muscle strength (score >= 4) in type I pelvic fibers (23.1% vs. 14.1%, P = 0.051) and type II pelvic fibers (28.0% vs. 24.6%, P = 0.524). The groups also contained similar proportions of women who showed no fatigue in type I fibers (54.5% vs. 48.6%, P = 0.315) or type II fibers (88.8% vs. 87.3%, P = 0.699). Similarly low proportions of women in the CSEA group and control group showed normal pelvic dynamic pressure 11.2% vs. 7.7%, P = 0.321). However, women in the CSEA group spent significantly less time in labor than those in the control group (7.25 vs. 9.52 h, P <0.001). Conclusions CSEA did not affect the risk of postpartum pelvic muscle disorder in this cohort of primiparous women who gave birth vaginally. A significant shorter duration of labour was observed in the CSEA-group.	[Xing, Ji-Juan; Lao, Cheng-Yi; Huang, Qiong-Yan; Yang, Wei; Zhu, Yun-Feng] Maternal & Child Hlth Hosp Nanning City, Dept Anesthesia, Nanning 530011, Peoples R China; [Liu, Xiu-Fen; Huang, Li] Peking Univ, Affiliated Hosp 1, Pain Management Dept, Beijing 100034, Peoples R China; [Xiong, Xiao-Ming] Maternal & Child Hlth Hosp Nandan Cty, Dept Obstet & Gynecol, Hechi 547200, Peoples R China; [Yang, Mei; Gao, Shan] Maternal & Child Hlth Hosp Nanning City, Matern Care Dept, Nanning 530011, Peoples R China; [Zhang, Di-Hua] Maternal & Child Hlth Hosp Nanning City, Child Care Dept, Nanning 530011, Peoples R China	Peking University	Zhu, YF (corresponding author), Maternal & Child Hlth Hosp Nanning City, Dept Anesthesia, Nanning 530011, Peoples R China.	xingjijuan123@163.com; 1069052046@qq.com			Scientific and Technological Key Project of Nanning City [20133189]	Scientific and Technological Key Project of Nanning City	This work was supported by the Scientific and Technological Key Project of Nanning City (no. 20133189).	Ashton-Miller JA, 2009, ANNU REV BIOMED ENG, V11, P163, DOI 10.1146/annurev-bioeng-061008-124823; BO K, 1990, NEUROUROL URODYNAM, V9, P479, DOI 10.1002/nau.1930090504; BO K, 1992, NEUROUROL URODYNAM, V11, P107, DOI 10.1002/nau.1930110205; Bo K, 1990, NEUROUROL URODYNAM, V9, P395; Caroci AD, 2010, J CLIN NURS, V19, P2424, DOI 10.1111/j.1365-2702.2010.03289.x; Costantini S, 2006, ULTRASOUND OBST GYN, V27, P183, DOI 10.1002/uog.2663; Ding T, 2014, ANESTH ANALG, V119, P383, DOI 10.1213/ANE.0000000000000107; Feng BB, 2013, CLIN EXP OBSTET GYN, V40, P574; Frawley HC, 2006, INT UROGYNECOL J, V17, P365, DOI 10.1007/s00192-005-0016-3; Gambling D, 2013, ANESTH ANALG, V116, P636, DOI 10.1213/ANE.0b013e31827e4e29; Gou WL, 2003, DELIVERY; Handa VL, 2011, OBSTET GYNECOL, V118, P777, DOI 10.1097/AOG.0b013e3182267f2f; Long Yan, 2007, Zhonghua Fu Chan Ke Za Zhi, V42, P808; Lovett RW, 1916, J AMER MED ASSOC, V66, P729; Memon H, 2012, CURR OPIN OBSTET GYN, V24, P349, DOI 10.1097/GCO.0b013e328357628b; Oliveira LS, 2014, SAO PAULO MED J, V132, P231, DOI 10.1590/1516-3180.2014.1324710; Panayi DC, 2009, CURR OPIN OBSTET GYN, V21, P97, DOI 10.1097/GCO.0b013e328321e44b; Qaseem A, 2006, ANN INTERN MED, V144, P575, DOI 10.7326/0003-4819-144-8-200604180-00008; Rofaeel A, 2007, CAN J ANAESTH, V54, P15, DOI 10.1007/BF03021894; Salvesen KA, 2004, BMJ-BRIT MED J, V329, P378, DOI 10.1136/bmj.38163.724306.3A; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI [10.1136/bmj.c332, 10.1186/1741-7015-8-18]; Shan XM, 2012, CHIN J CLIN OBSTET G, V13, P92; Simmons SW, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003401.pub2; Simmons Scott W, 2012, Cochrane Database Syst Rev, V10, pCD003401, DOI 10.1002/14651858.CD003401.pub3; Singh N, 2014, ANN CARD ANAESTH, V17, P177, DOI 10.4103/0971-9784.129892; Torrisi G, 2012, EUR J OBSTET GYN R B, V160, P110, DOI 10.1016/j.ejogrb.2011.10.010; Tsen LC, 1999, ANESTHESIOLOGY, V91, P920, DOI 10.1097/00000542-199910000-00010; Van de Velde M, 2004, ANESTH ANALG, V98, P1153, DOI 10.1213/01.ANE.0000101980.34587.66; Wang SS, 2014, CONT MED, V20, P97; Wisner KL, 2014, ANESTH ANALG, V119, P219, DOI 10.1213/ANE.0000000000000322; Yao ZC, 2014, NURS PRAC RES, V11, P6	31	8	10	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2015	10	9							e0137267	10.1371/journal.pone.0137267	http://dx.doi.org/10.1371/journal.pone.0137267			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ6BA	26340002	Green Published, Green Submitted, gold			2023-01-03	WOS:000360688200043
J	Dyer, O; White, C; Rada, AG				Dyer, Owen; White, Caroline; Garcia Rada, Aser			BRIEFING Assisted dying: law and practice around the world	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material														Garcia Rada, Aser/0000-0003-1026-2453				[Anonymous], 2014, CBC NEWS; Commission Nationale de Controle et d'Evaluation de la loi du, 2015, LOI 16 MARS 2009 EUT; Dierickx S, 2015, JAMA INTERN MED, V175, P1703, DOI 10.1001/jamainternmed.2015.3982; Dugan A., 2015, US SUPPORT DOCTOR AS; El Pais, 2014, PAIS; Gauthier S, 2015, J MED ETHICS, V41, P611, DOI 10.1136/medethics-2014-102091; Government of Quebec, 2015, PROV QUEB LAW END LI; Guzman D., 2012, MEDICO QUE HA PRACTI; Institut Europeen de Bioethique, 2014, RAPP COMM EV EUTH 20; Ipsos, 2015, EC ASS DYING RES 201; Kane L., 2014, MEDSCAPE ETHICS RE 1; La eutanasia de su padre bajo el trazo de, EL TIEMPO; Matador, 2015, EL TIEMPO       0705; Ministry of Health, 2010, EUTH ASS SUIC 25 QUE; Ogilvie AD, 1997, BRIT MED J, V314, P1849; Regional Euthanasia Review Committees, 2013, REG EUTH REV COMM AN; Thienpont L, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007454; Vincent D., 2015, TORONTO STAR; Washington State Department of Health, 2014, 2014 DEATH DIGN ACT	19	27	28	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 19	2015	351								h4481	10.1136/bmj.h4481	http://dx.doi.org/10.1136/bmj.h4481			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CP7PU	26290517				2023-01-03	WOS:000360081100011
J	Price, A				Price, Annabel			PERSONAL VIEW Mental capacity as a safeguard in assisted dying: clarity is needed	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SUICIDE		Univ Cambridge, Dept Psychiat, Cambridge CB2 0SP, England	University of Cambridge	Price, A (corresponding author), Univ Cambridge, Dept Psychiat, Cambridge CB2 0SP, England.							Ganzini L, 2000, AM J PSYCHIAT, V157, P595, DOI 10.1176/appi.ajp.157.4.595; Hotopf M, 2011, BRIT J PSYCHIAT, V198, P83, DOI 10.1192/bjp.bp.110.083634; Price A, 2014, BMC MED ETHICS, V15, DOI 10.1186/1472-6939-15-32; Price Annabel, 2011, BMJ Support Palliat Care, V1, P140, DOI 10.1136/bmjspcare-2011-000011; Wessely S, 2014, PRESIDENTS BLOG ASSI	5	6	6	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 19	2015	351								h4461	10.1136/bmj.h4461	http://dx.doi.org/10.1136/bmj.h4461			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CP7PU	26294758				2023-01-03	WOS:000360081100008
J	Chan, DL; Pavlakis, N; Shapiro, J; Price, TJ; Karapetis, CS; Tebbutt, NC; Segelov, E				Chan, David L.; Pavlakis, Nick; Shapiro, Jeremy; Price, Timothy J.; Karapetis, Christos S.; Tebbutt, Niall C.; Segelov, Eva			Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature	PLOS ONE			English	Article							PHASE-III TRIAL; RANDOMIZED CONTROLLED-TRIAL; PLUS CETUXIMAB TREATMENT; KRAS WILD-TYPE; 1ST-LINE TREATMENT; RAS MUTATIONS; OPEN-LABEL; FLUOROURACIL; BEVACIZUMAB; LEUCOVORIN	Importance The EGFR inhibitors (EGFR-I) cetuximab and panitumumab and the angiogenesis inhibitors (AIs) bevacizumab and aflibercept have demonstrated varying efficacy in mCRC. Objective To document the overall impact of specific chemotherapy regimens on the efficacy of targeted agents in treating patients with mCRC. Data sources: MEDLINE, EMBASE and Cochrane databases were searched to 2014, supplemented by hand-searching ASCO/ESMO conference abstracts. Study Selection Published RCTs of patients with histologically confirmed mCRC were included if they investigated either 1) chemotherapy with or without a biological agent or 2) different chemotherapy regimens with the same biological agent. EGFR-I trials were restricted to KRAS exon 2 wild-type (WT) populations. Data Extraction and Synthesis Data were independently abstracted by two authors and trial quality assessed according to Cochrane criteria. The primary outcome was overall survival with secondary endpoints progression free survival (PFS), overall response rate (ORR) and toxicity. Results EGFR-I added to irinotecan-based chemotherapy modestly improved OS with HR 0.90 (95% CI 0.81-1.00, p = 0.04), but more so PFS with HR 0.77 (95% CI 0.69-0.86, p< 0.00001). No benefit was evident for EGFR-I added to oxaliplatin-based chemotherapy (OS HR 0.97 (95% CI 0.87-1.09) and PFS HR 0.92 (95% CI 0.83-1.02)). Significant oxaliplatin-irinotecan subgroup interactions were present for PFS with I-2 = 82%, p = 0.02. Further analyses of oxaliplatin+EGFR-I trials showed greater efficacy with infusional 5FU regimens (PFS HR 0.82, 95% CI 0.72-0.94) compared to capecitabine (HR 1.09; 95% CI 0.91-1.30) and bolus 5FU (HR 1.07; 95% CI 0.79-1.45); subgroup interaction was present with I-2 = 72%, p = 0.03. The oxaliplatin-irinotecan interaction was not evident for infusional 5FU regimens. For AIs, OS benefit was observed with both oxaliplatin-based (HR 0.83) and irinotecan- based (HR 0.77) regimens without significant subgroup interactions. Oxaliplatin+AI trials showed no subgroup interactions by type of FP, whilst an interaction was present for irinotecan+AI trials although aflibercept was only used with infusional FP (I-2 = 89.7%, p = 0.002). Conclusion and Relevance The addition of EGFR-I to irinotecan-based chemotherapy has consistent efficacy, regardless of FP regimen, whereas EGFR-I and oxaliplatin-based regimens were most active with infusional 5FU. No such differential activity was observed with the varying chemotherapy schedules when combined with AIs.	[Chan, David L.; Pavlakis, Nick] Univ Sydney, Royal N Shore Hosp, Northern Clin Sch, St Leonards, NSW 2065, Australia; [Shapiro, Jeremy] Monash Univ, Dept Med Oncol, Clayton, Vic 3800, Australia; [Price, Timothy J.] Queen Elizabeth Hosp, Woodville South, SA, Australia; [Price, Timothy J.] Univ Adelaide, Adelaide, SA 5005, Australia; [Karapetis, Christos S.] Flinders Univ S Australia, Bedford Pk, SA 5042, Australia; [Karapetis, Christos S.] Flinders Ctr Innovat Canc, Flinders Med Ctr, Bedford Pk, SA, Australia; [Tebbutt, Niall C.] Austin Hlth, Heidelberg, Vic, Australia; [Segelov, Eva] Univ New S Wales, St Vincents Clin Sch, Sydney, NSW 2052, Australia	Royal North Shore Hospital; University of Sydney; Monash University; University of Adelaide; Flinders University South Australia; Flinders Medical Centre; Flinders University South Australia; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of New South Wales Sydney	Chan, DL (corresponding author), Univ Sydney, Royal N Shore Hosp, Northern Clin Sch, St Leonards, NSW 2065, Australia.	dlhchan1@gmail.com	Segelov, Eva/Q-7611-2019; Chan, David L/E-7149-2017	Segelov, Eva/0000-0002-4410-6144; Karapetis, Christos/0000-0003-1741-996X	Sanofi; Roche	Sanofi(Sanofi-Aventis); Roche(Roche Holding)	DC has received honoraria from Roche and a travel grant from Sanofi. NP has received honoraria from Bayer, Roche and Sanofi, provided advice to Roche, Merck, Bayer, Sanofi and Amgen, and received a travel grant from Roche. JS has provided advice to Merck, Sanofi and Roche. TP has provided advice to Merck, Amgen, Sanofi and Roche. CK has provided advice to Merck, Amgen and Roche. ES has provided advice to Merck, Amgen, Sanofi and Roche. This does not alter the authors' adherence to all PLOS ONE policies on sharing data and materials.	Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1; Bokemeyer C, 2015, EUR J CANCER, V51, P1243, DOI 10.1016/j.ejca.2015.04.007; Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397; Borner M, 2008, ANN ONCOL, V19, P1288, DOI 10.1093/annonc/mdn058; Cassidy J, 2011, BRIT J CANCER, V105, P58, DOI 10.1038/bjc.2011.201; Cunningham D, 2013, LANCET ONCOL, V14, P1077, DOI 10.1016/S1470-2045(13)70154-2; Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275; Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860; Folprecht G, 2010, LANCET ONCOL, V11, P38, DOI 10.1016/S1470-2045(09)70330-4; Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305; Guan Zhong-Zhen, 2011, Chin J Cancer, V30, P682, DOI 10.5732/cjc.011.10188; Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Hurwitz HI, 2013, ONCOLOGIST, V18, P1004, DOI 10.1634/theoncologist.2013-0107; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; Kabbinavar FF, 2008, ONCOLOGIST, V13, P1021, DOI 10.1634/theoncologist.2008-0003; Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3697, DOI 10.1200/JCO.2005.05.112; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Khattak MA, 2015, CLIN COLORECTAL CANC, V14, P81, DOI 10.1016/j.clcc.2014.12.011; Loupakis F, 2012, CANCER-AM CANCER SOC, V118, P1523, DOI 10.1002/cncr.26460; Masi G, 2013, ASCO M, V31, P3615; Maughan TS, 2011, LANCET, V377, P2103, DOI 10.1016/S0140-6736(11)60613-2; Moosmann N, 2011, J CLIN ONCOL, V29, P1050, DOI 10.1200/JCO.2010.31.1936; Ocvirk J, 2010, WORLD J GASTROENTERO, V16, P3133, DOI 10.3748/wjg.v16.i25.3133; Passardi A, 2015, ANNALS OF ONCOLOGY O; Pericay C, 2012, ANN ONCOL, V23, P16, DOI 10.1016/S0923-7534(19)66488-4; Primrose J, 2014, LANCET ONCOL, V15, P601, DOI 10.1016/S1470-2045(14)70105-6; Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930; Seymour MT, 2013, LANCET ONCOL, V14, P749, DOI 10.1016/S1470-2045(13)70163-3; Sobrero AF, 2008, J CLIN ONCOL, V26, P2311, DOI 10.1200/JCO.2007.13.1193; Tebbutt NC, 2010, J CLIN ONCOL, V28, P3191, DOI 10.1200/JCO.2009.27.7723; Tveit KM, 2012, J CLIN ONCOL, V30, P1755, DOI 10.1200/JCO.2011.38.0915; Vale CL, 2012, CANCER TREAT REV, V38, P618, DOI 10.1016/j.ctrv.2011.11.002; Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812; Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Venook AP, 2014, J CLIN ONCOLOGY OFFI, V32; Ye LC, 2013, J CLIN ONCOL, V31, P1931, DOI 10.1200/JCO.2012.44.8308; Zhou SW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050925	40	21	23	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2015	10	8							e0135599	10.1371/journal.pone.0135599	http://dx.doi.org/10.1371/journal.pone.0135599			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO9KD	26275292	Green Published, gold			2023-01-03	WOS:000359493600081
J	Onofriescu, M; Siriopol, D; Voroneanu, L; Hogas, S; Nistor, I; Apetrii, M; Florea, L; Veisa, G; Mititiuc, I; Kanbay, M; Sascau, R; Covic, A				Onofriescu, Mihai; Siriopol, Dimitrie; Voroneanu, Luminita; Hogas, Simona; Nistor, Ionut; Apetrii, Mugurel; Florea, Laura; Veisa, Gabriel; Mititiuc, Irina; Kanbay, Mehmet; Sascau, Radu; Covic, Adrian			Overhydration, Cardiac Function and Survival in Hemodialysis Patients	PLOS ONE			English	Article							LEFT-VENTRICULAR HYPERTROPHY; RANDOMIZED CONTROLLED-TRIAL; GUIDED FLUID MANAGEMENT; CHRONIC KIDNEY-DISEASE; MAINTENANCE HEMODIALYSIS; DIALYSIS PATIENTS; MORTALITY RISK; DRY-WEIGHT; BIOIMPEDANCE; ASSOCIATION	Background and objectives Chronic subclinical volume overload occurs very frequently and may be ubiquitous in hemodialysis (HD) patients receiving the standard thrice-weekly treatment. It is directly associated with hypertension, increased arterial stiffness, left ventricular hipertrophy, heart failure, and eventually, higher mortality and morbidity. We aimed to assess for the first time if the relationship between bioimpedance assessed overhydration and survival is maintained when adjustments for echocardiographic parameters are considered. Design, setting, participants and measurements A prospective cohort trial was conducted to investigate the impact of overhydration on all cause mortality and cardiovascular events (CVE), by using a previously reported cut-off value for overhydration and also investigating a new cut-off value derived from our analysis of this specific cohort. The body composition of 221 HD patients from a single center was assessed at baseline using bioimpedance. In 157 patients supplemental echocardiography was performed (echocardiography subgroup). Comparative survival analysis was performed using two cut-off points for relative fluid overload (RFO): 15% and 17.4%(a value determined by statistical analysis to have the best predictive value for mortality in our cohort). Results In the entire study population, patients considered overhydrated (using both cut-offs) had a significant increased risk for all-cause mortality in both univariate (HR = 2.12, 95% CI = 1.30-3.47 for RFO> 15% and HR = 2.86, 95% CI = 1.72-4.78 for RFO> 17.4%, respectively) and multivariate (HR = 1.87, 95% CI = 1.12-3.13 for RFO> 15% and HR = 2.72, 95% CI = 1.60-4.63 for RFO> 17.4%, respectively) Cox survival analysis. In the echocardiography subgroup, only the 17.4% cut-off remained associated with the outcome after adjustment for different echocardiographic parameters in the multivariate survival analysis. The number of CVE was significantly higher in overhydrated patients in both univariate (HR = 2.46, 95% CI = 1.56-3.87 for RFO > 15% and HR = 3.67, 95% CI = 2.29-5.89 for RFO > 17.4%) and multivariate (HR = 2.31, 95% CI = 1.42-3.77 for RFO > 15% and HR = 4.17, 95% CI = 2.48-7.02 for RFO > 17.4%) Cox regression analysis. Conclusions The study shows that the hydration status is associated with the mortality risk in a HD population, independently of cardiac morphology and function. We also describe and propose a new cut-off for RFO, in order to better define the relationship between overhydration and mortality risk. Further studies are needed to properly validate this new cut-off in other HD populations.	[Onofriescu, Mihai; Siriopol, Dimitrie; Voroneanu, Luminita; Hogas, Simona; Nistor, Ionut; Apetrii, Mugurel; Florea, Laura; Veisa, Gabriel; Mititiuc, Irina; Covic, Adrian] Univ Med & Pharm Gr T Popa, Dept Nephrol, Iasi, Romania; [Sascau, Radu] Univ Med & Pharm Gr T Popa, Dept Cardiol, Iasi, Romania; [Kanbay, Mehmet] Koc Univ, Sch Med, Div Nephrol, Dept Med, Istanbul, Turkey	Grigore T Popa University of Medicine & Pharmacy; Grigore T Popa University of Medicine & Pharmacy; Koc University	Covic, A (corresponding author), Univ Med & Pharm Gr T Popa, Dept Nephrol, Iasi, Romania.	accovic@gmail.com	Siriopol, Dimitrie/AAA-4704-2020; Onofriescu, Mihai/HGE-3410-2022; Onofriescu, Mihai/GWQ-4875-2022; Covic, Adrian/G-5017-2016; Apetrii, Mugurel/AAQ-6163-2020; 1, 1/L-6277-2019	Siriopol, Dimitrie/0000-0003-1297-0648; Covic, Adrian/0000-0002-9985-2486; 	University of Medicine and Pharmacy [1643/01.02.2013]; UEFISCDI IDEI PCE [PN-II-ID-PCE-2011-3-0637]	University of Medicine and Pharmacy; UEFISCDI IDEI PCE(Consiliul National al Cercetarii Stiintifice (CNCS)Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii (UEFISCDI))	This research was partially funded by University of Medicine and Pharmacy "Gr. T. Popa" Iasi, Grant no. 1643/01.02.2013 and UEFISCDI IDEI PCE, Grant nr. PN-II-ID-PCE-2011-3-0637. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Charra B, 1996, NEPHROL DIAL TRANSPL, V11, P16; CHARRA B, 1992, KIDNEY INT, V41, P1286, DOI 10.1038/ki.1992.191; Chazot C, 1999, NEPHROL DIAL TRANSPL, V14, P121, DOI 10.1093/ndt/14.1.121; Chazot C, 2012, NEPHROL DIAL TRANSPL, V27, P2404, DOI 10.1093/ndt/gfr678; Covic AC, 2013, ANN NONINVAS ELECTRO, V18, P188, DOI 10.1111/anec.12007; Davies SJ, 2014, KIDNEY INT, V86, P489, DOI 10.1038/ki.2014.207; Ferrario M, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-26; FOLEY RN, 1995, J AM SOC NEPHROL, V5, P2024; Grambsch PM, 1995, BIOMETRICS, V51, P1469, DOI 10.2307/2533277; Hur E, 2013, AM J KIDNEY DIS, V61, P957, DOI 10.1053/j.ajkd.2012.12.017; Innes A, 1999, NEPHROL DIAL TRANSPL, V14, P919, DOI 10.1093/ndt/14.4.919; Kramer A, 2012, CLIN J AM SOC NEPHRO, V7, P1655, DOI 10.2215/CJN.10461011; Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005; Liu S, 2012, HEMODIAL INT, V16, P504, DOI 10.1111/j.1542-4758.2012.00700.x; London GM, 2001, J AM SOC NEPHROL, V12, P2759, DOI 10.1681/ASN.V12122759; Machek P, 2010, NEPHROL DIAL TRANSPL, V25, P538, DOI 10.1093/ndt/gfp487; Moissl U, 2013, CLIN J AM SOC NEPHRO, V8, P1575, DOI 10.2215/CJN.12411212; Onofriescu M, 2014, AM J KIDNEY DIS, V64, P111, DOI 10.1053/j.ajkd.2014.01.420; SILBERBERG JS, 1989, KIDNEY INT, V36, P286, DOI 10.1038/ki.1989.192; Tonelli M, 2006, J AM SOC NEPHROL, V17, P2034, DOI 10.1681/ASN.2005101085; Wabel P, 2008, NEPHROL DIAL TRANSPL, V23, P2965, DOI 10.1093/ndt/gfn228; Wizemann V, 2009, NEPHROL DIAL TRANSPL, V24, P1574, DOI 10.1093/ndt/gfn707; Yu WC, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-115; Zoccali C, 2001, J AM SOC NEPHROL, V12, P2768, DOI 10.1681/ASN.V12122768	24	64	69	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2015	10	8							e0135691	10.1371/journal.pone.0135691	http://dx.doi.org/10.1371/journal.pone.0135691			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO9KD	26274811	Green Published, Green Submitted, gold			2023-01-03	WOS:000359493600096
J	Wang, L; Haberland, C; Thurm, C; Bhattacharya, J; Park, KT				Wang, Louise; Haberland, Corinna; Thurm, Cary; Bhattacharya, Jay; Park, K. T.			Health Outcomes in US Children with Abdominal Pain at Major Emergency Departments Associated with Race and Socioeconomic Status	PLOS ONE			English	Article							RACIAL DISPARITIES; CARE; MANAGEMENT; VISITS; ETHNICITY; BURDEN; BIAS	Objective Over 9.6 million ED visits occur annually for abdominal pain in the US, but little is known about the medical outcomes of these patients based on demographics. We aimed to identify disparities in outcomes among children presenting to the ED with abdominal pain linked to race and SES. Methods Data from 4.2 million pediatric encounters of abdominal pain were analyzed from 43 tertiary US children's hospitals, including 2.0 million encounters in the emergency department during 2004-2011. Abdominal pain was categorized as functional or organic abdominal pain. Appendicitis (with and without perforation) was used as a surrogate for abdominal pain requiring emergent care. Multivariate analysis estimated likelihood of hospitalizations, radiologic imaging, ICU admissions, appendicitis, appendicitis with perforation, and time to surgery and hospital discharge. Results Black and low income children had increased odds of perforated appendicitis (aOR, 1.42, 95% CI, 1.32-1.53; aOR, 1.20, 95% CI 1.14 - 1.25). Blacks had increased odds of an ICU admission (aOR, 1.92, 95% CI 1.53 - 2.42) and longer lengths of stay (aHR, 0.91, 95% CI 0.86 - 0.96) than Whites. Minorities and low income also had lower rates of imaging for their appendicitis, including CT scans. The combined effect of race and income on perforated appendicitis, hospitalization, and time to surgery was greater than either separately. Conclusions Based on race and SES, disparity of health outcomes exists in the acute ED setting among children presenting with abdominal pain, with differences in appendicitis with perforation, length of stay, and time until surgery.	[Wang, Louise] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Haberland, Corinna] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA; [Thurm, Cary] Childrens Hosp Assoc, Overland Pk, KS USA; [Bhattacharya, Jay; Park, K. T.] Stanford Univ, Ctr Hlth Policy Primary Care Outcomes Res, Stanford, CA 94305 USA; [Bhattacharya, Jay] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; [Bhattacharya, Jay] Stanford Univ, Dept Econ, Stanford, CA 94305 USA; [Park, K. T.] Stanford Univ, Sch Med, Dept Pediat, Div Gastroenterol Hepatol & Nutr, Stanford, CA 94305 USA	Stanford University; Stanford University; Children's Mercy Hospital; Stanford University; Stanford University; Stanford University; Stanford University	Park, KT (corresponding author), Stanford Univ, Ctr Hlth Policy Primary Care Outcomes Res, Stanford, CA 94305 USA.	ktpark@stanford.edu			Medical Scholars Program at Stanford University School of Medicine; NASPGHAN Foundation; CDEHA [P30 AG17253]; NIH [R21 AG041112, DK094868]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK094868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG041112] Funding Source: NIH RePORTER	Medical Scholars Program at Stanford University School of Medicine; NASPGHAN Foundation; CDEHA; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	LW received research support from the Medical Scholars Program at Stanford University School of Medicine and the NASPGHAN Foundation for this study. JB is supported by CDEHA P30 AG17253 and NIH R21 AG041112. KP is supported by NIH DK094868. The manuscript contents are solely the responsibility of the authors, performed independent of all funding sources, and do not necessarily represent the official views of the NIH, NASPGHAN, or Stanford University.	Ben-Isaac E, 2010, PEDIATRICS, V125, P454, DOI 10.1542/peds.2009-0544; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Byrne A, 2015, ADV HEALTH SCI EDUC, V20, P1255, DOI 10.1007/s10459-015-9600-6; Cone DC, 2003, ACAD EMERG MED, V10, P1176, DOI 10.1197/S1069-6563(03)00486-X; Dhroove G, 2010, J PEDIATR GASTR NUTR, V51, P579, DOI 10.1097/MPG.0b013e3181de0639; Doobinin KA, 2003, PEDIATR EMERG CARE, V19, P10, DOI 10.1097/00006565-200302000-00003; Groholt EK, 2003, EUR J EPIDEMIOL, V18, P965, DOI 10.1023/A:1025889912964; Haltiwanger Katherine A, 2006, Cal J Emerg Med, V7, P26; Hambrook JT, 2010, CONGENIT HEART DIS, V5, P285, DOI 10.1111/j.1747-0803.2010.00414.x; Henneman PL, 2009, ANN EMERG MED, V53, P249, DOI 10.1016/j.annemergmed.2008.07.016; Hofer TP, 1998, HEALTH SERV RES, V33, P243; Horwitz L., 2009, ARCH INTERN MED, V169, P1857, DOI DOI 10.1001/ARCHINTERNMED.2009.336; Hyams JS, 1998, J PEDIATR-US, V133, P473, DOI 10.1016/S0022-3476(98)70053-8; Inst Med, 2006, ACAD EMERG MED, V13, P1081, DOI 10.1197/j.aem.2006.07.011; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; Johnson TJ, 2013, PEDIATRICS, V132, pE851, DOI 10.1542/peds.2012-3127; Kokoska ER, 2007, J SURG RES, V137, P83, DOI 10.1016/j.jss.2006.06.020; Lester C W, 1941, Bull N Y Acad Med, V17, P844; Leung AKC, 2003, AM FAM PHYSICIAN, V67, P2321; Lowe RA, 2001, ACAD EMERG MED, V8, P259, DOI 10.1111/j.1553-2712.2001.tb01302.x; Luo X, 2011, AM ACAD PEDIAT, V112, P314, DOI [10.1542/peds.112.2.314, DOI 10.1542/PEDS.112.2.314]; Macy ML, 2012, J HOSP MED, V7, P530, DOI 10.1002/jhm.1923; Mendoza Fernando S, 2009, Pediatrics, V124 Suppl 3, pS187, DOI 10.1542/peds.2009-1100F; Mills AM, 2011, AM J EMERG MED, V29, P752, DOI 10.1016/j.ajem.2010.02.023; Myer PA, 2013, AM J GASTROENTEROL, V108, P1496, DOI 10.1038/ajg.2013.199; National Health Insurance Service and Health Insurance Review and Assessment Service, 2012, NAT SAMPL CENS AGR 2, P1; Park CY, 2009, HEALTH SERV RES, V44, P2022, DOI 10.1111/j.1475-6773.2009.01020.x; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Peery AF, 2012, GASTROENTEROLOGY, V143, P1179, DOI 10.1053/j.gastro.2012.08.002; Petersen LA, 1998, MED CARE, V36, P1249, DOI 10.1097/00005650-199808000-00012; Pines JM, 2008, ANN EMERG MED, V51, P1, DOI 10.1016/j.annemergmed.2007.07.008; Pines JM, 2009, ACAD EMERG MED, V16, P403, DOI 10.1111/j.1553-2712.2009.00381.x; Ponsky TA, 2004, JAMA-J AM MED ASSOC, V292, P1977, DOI 10.1001/jama.292.16.1977; Rinderknecht AS, 2010, PEDIATRICS, V126, P917, DOI 10.1542/peds.2010-0364; Rust G, 2008, ARCH INTERN MED, V168, P1705, DOI 10.1001/archinte.168.15.1705; Schrader CD, 2013, J EMERG MED, V44, P511, DOI 10.1016/j.jemermed.2012.05.010; Schwille IJD, 2009, CLIN GASTROENTEROL H, V7, P1062, DOI 10.1016/j.cgh.2009.07.002; Smink DS, 2005, PEDIATRICS, V115, P920, DOI 10.1542/peds.2004-1363; Sonnenfeld N, 2012, MED CARE, V50, P335, DOI 10.1097/MLR.0b013e318245a53c; Stone J, 2011, MED EDUC, V45, P768, DOI 10.1111/j.1365-2923.2011.04026.x; Tang N, 2010, JAMA-J AM MED ASSOC, V304, P664, DOI 10.1001/jama.2010.1112; Teal CR, 2010, J GEN INTERN MED, V25, pS115, DOI 10.1007/s11606-009-1243-y; Torpy Janet M, 2007, JAMA, V297, P2836, DOI 10.1001/jama.297.24.2836; van Ryn M, 2000, SOC SCI MED, V50, P813, DOI 10.1016/S0277-9536(99)00338-X; Yu Stella M, 2009, Pediatrics, V124 Suppl 4, pS414, DOI 10.1542/peds.2009-1255M; Ziv A, 1998, PEDIATRICS, V101, P987, DOI 10.1542/peds.101.6.987	46	23	23	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2015	10	8							e0132758	10.1371/journal.pone.0132758	http://dx.doi.org/10.1371/journal.pone.0132758			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CO9JT	26267816	Green Submitted, Green Published, gold			2023-01-03	WOS:000359492300008
J	Dong, Y; Cao, WJ; Ren, JM; Nair, DS; Parker, S; Jahnel, JL; Swanson-Devlin, TG; Beck, JM; Mathews, M; McNeil, CJ; Upadhyaya, M; Gao, Y; Dong, Q; Wang, DZ				Dong, Yi; Cao, Wenjie; Ren, Jinma; Nair, Deepak S.; Parker, Sarah; Jahnel, Jan L.; Swanson-Devlin, Teresa G.; Beck, Judith M.; Mathews, Maureen; McNeil, Clayton J.; Upadhyaya, Manas; Gao, Yuan; Dong, Qiang; Wang, David Z.			Vascular Risk Factors in Patients with Different Subtypes of Ischemic Stroke May Affect Their Outcome after Intravenous tPA	PLOS ONE			English	Article							THROMBOLYSIS; RECANALIZATION; HYPERGLYCEMIA; RECURRENCE; ALTEPLASE; CRITERIA; LACUNAR	Intravenous (IV) tissue-type plasminogen activator (tPA) is the only approved noninvasive therapy for acute ischemic stroke (AIS). However, after tPA treatment, the outcome of patients with different subtypes of stroke according to their vascular risk factors remains to be elucidated. We aim to explore the relationship between the outcome and different risk factors in patients with different subtype of acute strokes treated with IV tPA. Records of patients in this cohort were reviewed. Data collected and analysed included the demographics, vascular risk factors, baseline National Institutes of Health Stroke Scale (NIHSS) scores, 90-day modified Rankin Scores (mRS), and subtypes of stroke. By using the 90-day mRS, patients were dichotomized into favorable versus unfavorable outcome in each subtype of stroke. We identified the vascular risk factors that are likely associated with the poor outcome in each subtype. Among 570 AIS patients received IV tPA, 217 were in the large artery atherosclerosis (LAA) group, 146 in the small vessel occlusion(SVO) group, and 140 in the cardioaortic embolism(CE) group. Lower NIHSS score on admission was related to favorable outcome in patients in all subtypes. Patients with history of dyslipidemia were likely on statin treatment before their admission and hence less likely to have elevated cholesterol level on admission. Therefore, there was a possible paradoxical effect on the outcome in patients with LAA and SVO subtypes of strokes. SVO patients with history of diabetes had higher risk of unfavorable outcome. SVO patients had favorable outcome if their time from onset to treatment was short. In conclusion, the outcome of patients treated with IV tPA may be related to different vascular risk factors associated with different subtypes of stroke.	[Dong, Yi; Cao, Wenjie; Dong, Qiang] Fudan Univ, Huashan Hosp, Dept Neurol, State Key Lab Neurobiol, Shanghai 200433, Peoples R China; [Ren, Jinma] Univ Illinois, Coll Med, Ctr Outcomes Res, Peoria, IL 61656 USA; [Dong, Yi; Nair, Deepak S.; Parker, Sarah; Jahnel, Jan L.; Swanson-Devlin, Teresa G.; Beck, Judith M.; Mathews, Maureen; McNeil, Clayton J.; Upadhyaya, Manas; Wang, David Z.] Univ Illinois, Coll Med, Dept Neurol, INI Stroke Network,OSF Healthcare Syst, Peoria, IL 61656 USA; [Gao, Yuan] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou 450052, Henan, Peoples R China	Fudan University; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; Zhengzhou University	Wang, DZ (corresponding author), Univ Illinois, Coll Med, Dept Neurol, INI Stroke Network,OSF Healthcare Syst, Peoria, IL 61656 USA.	dwang@uic.edu	Dong, YI/B-9314-2019; Dong, Yi/AAF-6154-2019	Dong, YI/0000-0001-6630-112X; Dong, Yi/0000-0001-6630-112X	Institute for US-CHINA Neuroscience and Stroke Initiative	Institute for US-CHINA Neuroscience and Stroke Initiative	Y.D. received funding from Institute for US-CHINA Neuroscience and Stroke Initiative and was under training at Illinois Neurological Institute. Other authors had no funding sources. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ay H, 2005, ANN NEUROL, V58, P688, DOI 10.1002/ana.20617; Blinzler C, 2011, CEREBROVASC DIS, V31, P185, DOI 10.1159/000321869; Caso V, 2007, VASC HEALTH RISK MAN, V3, P749; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Jackson C, 2005, BRAIN, V128, P2507, DOI 10.1093/brain/awh636; Kolominsky-Rabas PL, 2001, STROKE, V32, P2735, DOI 10.1161/hs1201.100209; Kwiatkowski Thomas G., 1999, New England Journal of Medicine, V340, P1781, DOI 10.1056/NEJM199906103402302; Li J, 2015, NEUROLOGY, V84, P1, DOI DOI 10.1016/j.actamat.2014.10.032; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marler JR, 2000, NEUROLOGY, V55, P1649, DOI 10.1212/WNL.55.11.1649; Mohan KM, 2009, J NEUROL NEUROSUR PS, V80, P1012, DOI 10.1136/jnnp.2008.170456; Molina CA, 2004, STROKE, V35, P486, DOI 10.1161/01.STR.0000110219.67054.BF; Mustanoja S, 2011, STROKE, V42, P102, DOI 10.1161/STROKEAHA.110.597534; Prefasi D, 2013, J THROMB THROMBOLYSI; Ribo M, 2007, J CEREBR BLOOD F MET, V27, P1616, DOI 10.1038/sj.jcbfm.9600460; Rubiera M, 2009, STROKE, V40, P2568, DOI 10.1161/STROKEAHA.108.538587; Shobha N, 2011, CEREBROVASC DIS, V31, P223, DOI 10.1159/000321893; Trost Susanne, 2006, Curr Diab Rep, V6, P47, DOI 10.1007/s11892-006-0052-5; Tziomalos K, 2014, WORLD J DIABETES, V5, P939, DOI 10.4239/wjd.v5.i6.939; Urbach H, 2002, NEURORADIOLOGY, V44, P695, DOI 10.1007/s00234-002-0762-6; Uyttenboogaart M, 2007, BRAIN, V130, P1626, DOI 10.1093/brain/awm087; Wang YJ, 2013, NEW ENGL J MED, V369, P11, DOI 10.1056/NEJMoa1215340	22	11	11	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2015	10	8							e0131487	10.1371/journal.pone.0131487	http://dx.doi.org/10.1371/journal.pone.0131487			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO3MQ	26247772	gold, Green Published, Green Submitted			2023-01-03	WOS:000359062300006
J	van der Plas, AGM; Vissers, KC; Francke, AL; Donker, GA; Jansen, WJJ; Deliens, L; Onwuteaka-Philipsen, BD				van der Plas, Annicka G. M.; Vissers, Kris C.; Francke, Anneke L.; Donker, Ge A.; Jansen, Wim J. J.; Deliens, Luc; Onwuteaka-Philipsen, Bregje D.			Involvement of a Case Manager in Palliative Care Reduces Hospitalisations at the End of Life in Cancer Patients; A Mortality Follow-Back Study in Primary Care	PLOS ONE			English	Article							GENERAL-PRACTITIONERS; PREFERENCES	Background Case managers have been introduced in primary palliative care in the Netherlands; these are nurses with expertise in palliative care who offer support to patients and informal carers in addition to the care provided by the general practitioner (GP) and home-care nurse. Objectives To compare cancer patients with and without additional support from a case manager on: 1) the patients' general characteristics, 2) characteristics of care and support given by the GP, 3) palliative care outcomes. Methods This article is based on questionnaire data provided by GPs participating in two different studies: the Sentimelc study (280 cancer patients) and the Capalca study (167 cancer patients). The Sentimelc study is a mortality follow-back study amongst a representative sample of GPs that monitors the care provided via GPs to a general population of end-of-life patients. Data from 2011 and 2012 were analysed. The Capalca study is a prospective study investigating the implementation and outcome of the support provided by case managers in primary palliative care. Data were gathered between March 2011 and December 2013. Results The GP is more likely to know the preferred place of death (OR 7.06; CI 3.47-14.36), the place of death is more likely to be at the home (OR 2.16; CI 1.33-3.51) and less likely to be the hospital (OR 0.26; CI 0.13-0.52), and there are fewer hospitalisations in the last 30 days of life (none: OR 1.99; CI 1.12-3.56 and one: OR 0.54; CI 0.30-0.96), when cancer patients receive additional support from a case manager compared with patients receiving the standard GP care. Conclusions Involvement of a case manager has added value in addition to palliative care provided by the GP, even though the role of the case manager is 'only' advisory and he or she does not provide hands-on care or prescribe medication.	[van der Plas, Annicka G. M.; Francke, Anneke L.; Onwuteaka-Philipsen, Bregje D.] Vrije Univ Amsterdam, Med Ctr, Dept Publ & Occupat Hlth, Amsterdam, Netherlands; [van der Plas, Annicka G. M.; Francke, Anneke L.; Jansen, Wim J. J.; Onwuteaka-Philipsen, Bregje D.] Vrije Univ Amsterdam, Med Ctr, Ctr Expertise Palliat Care, Amsterdam, Netherlands; [van der Plas, Annicka G. M.; Francke, Anneke L.; Onwuteaka-Philipsen, Bregje D.] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands; [Vissers, Kris C.] Radboud Univ Nijmegen, Dept Anaesthesiol Pain & Palliat Med, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Francke, Anneke L.] NIVEL Netherlands Inst Hlth Serv Res, Nursing Care, Utrecht, Netherlands; [Donker, Ge A.] NIVEL Primary Care Database, Sentinel Practices, Utrecht, Netherlands; [Jansen, Wim J. J.] Vrije Univ Amsterdam, Med Ctr, Dept Anaesthesiol, Amsterdam, Netherlands; [Deliens, Luc] Vrije Univ Brussel, End Of Life Care Res Grp, Brussels, Belgium; [Deliens, Luc] Univ Ghent, Brussels, Belgium; [Deliens, Luc] Vrije Univ Brussel, End Of Life Care Res Grp, Ghent, Belgium; [Deliens, Luc] Univ Ghent, B-9000 Ghent, Belgium	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Radboud University Nijmegen; Netherlands Institute for Health Services Research; Netherlands Institute for Health Services Research; Vrije Universiteit Amsterdam; Vrije Universiteit Brussel; Ghent University; Vrije Universiteit Brussel; Ghent University	van der Plas, AGM (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Publ & Occupat Hlth, Amsterdam, Netherlands.	eol@vumc.nl	Vissers, Kris C.P./D-3569-2009; Vissers, Kris/H-8110-2014; Donker, Gé/AAX-8564-2021	Vissers, Kris C.P./0000-0002-2919-6356; Vissers, Kris/0000-0002-2919-6356; Deliens, Luc/0000-0002-8158-2422; van der Plas, Annicka/0000-0003-4599-1795; Onwuteaka-Philipsen, Bregje/0000-0002-9440-1248	Netherlands Organisation for Health Research and Development (ZonMw) [80-82100-98-066]	Netherlands Organisation for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development)	The authors wish to thank the Netherlands Organisation for Health Research and Development (ZonMw) [grant number 80-82100-98-066] for their financial support. The funders had no role in study design, data collection and analysis, selection of respondents, decision to publish, or preparation of the manuscript.	Abarshi E, 2011, J PALLIAT MED, V14, P323, DOI 10.1089/jpm.2010.0312; Abarshi E, 2009, J PAIN SYMPTOM MANAG, V38, P568, DOI 10.1016/j.jpainsymman.2008.12.007; Becker G, 2010, BMC MED EDUC, V10, DOI 10.1186/1472-6920-10-43; Central Bureau for Statistics, POP COUNT; College Bescherming Persoonsgegevens [Dutch Data Protection Authority], INF DUTCH DAT PROT A; de Korte-Verhoef MC, 2014, THESIS VU U; De Roo ML, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093762; Dutch Government, WET BESCH PERS; Earle CC, 2003, J CLIN ONCOL, V21, P1133, DOI 10.1200/JCO.2003.03.059; Gomes B, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-7; Gomes B, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007760.pub2, 10.1590/1516-3180.20161341T2]; Groot MM, 2005, PALLIATIVE MED, V19, P111, DOI 10.1191/0269216305pm937oa; Ko W, 2013, EUR J CANCER, V49, P1967, DOI 10.1016/j.ejca.2013.01.006; Middelburg-Hebly M, 2014, PALLIATIEVE ZORG BEE; Minkman MMN, 2009, HEALTH SOC CARE COMM, V17, P485, DOI 10.1111/j.1365-2524.2009.00850.x; Nursing Staff Panel, 2012, SURV END LIF CAR; Quill TE, 2013, NEW ENGL J MED, V368, P1173, DOI 10.1056/NEJMp1215620; Rolden HJA, 2014, SOC SCI MED, V120, P110, DOI 10.1016/j.socscimed.2014.09.020; Sepulveda C, 2002, J PAIN SYMPTOM MANAG, V24, P91, DOI 10.1016/S0885-3924(02)00440-2; Shipman C, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1720; Van den Block L, 2013, BMC FAM PRACT, V14, DOI 10.1186/1471-2296-14-73; van der Plas AGM, BMC PALLIAT IN PRESS; van der Plas AGM, 2014, J PALLIATIV IN PRESS; van der Plas AGM, 2013, INT J NURS STUD, V50, P1504, DOI 10.1016/j.ijnurstu.2013.03.002; van der Velden Lud F J, 2009, BMC Palliat Care, V8, P4, DOI 10.1186/1472-684X-8-4; Vroomen JM, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-132	26	12	12	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2015	10	7							e0133197	10.1371/journal.pone.0133197	http://dx.doi.org/10.1371/journal.pone.0133197			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CN7NT	26208099	Green Published, Green Submitted, gold			2023-01-03	WOS:000358622000064
J	Arshad, A; Yang, B; Bienemann, AS; Barua, NU; Wyatt, MJ; Woolley, M; Johnson, DE; Edler, KJ; Gill, SS				Arshad, Azeem; Yang, Bin; Bienemann, Alison S.; Barua, Neil U.; Wyatt, Marcella J.; Woolley, Max; Johnson, Dave E.; Edler, Karen J.; Gill, Steven S.			Convection-Enhanced Delivery of Carboplatin PLGA Nanoparticles for the Treatment of Glioblastoma	PLOS ONE			English	Article							MALIGNANT GLIOMA; GLIADEL WAFERS; BRAIN; DRUG; RELEASE; TRIAL; FLOW	We currently use Convection-Enhanced Delivery (CED) of the platinum-based drug, carboplatin as a novel treatment strategy for high grade glioblastoma in adults and children. Although initial results show promise, carboplatin is not specifically toxic to tumour cells and has been associated with neurotoxicity at high infused concentrations in pre-clinical studies. Our treatment strategy requires intermittent infusions due to rapid clearance of carboplatin from the brain. In this study, carboplatin was encapsulated in lactic acid-glycolic acid copolymer (PLGA) to develop a novel drug delivery system. Neuronal and tumour cytotoxicity were assessed in primary neuronal and glioblastoma cell cultures. Distribution, tissue clearance and toxicity of carboplatin nanoparticles following CED was assessed in rat and porcine models. Carboplatin nanoparticles conferred greater tumour cytotoxicity, reduced neuronal toxicity and prolonged tissue half-life. In conclusion, this drug delivery system has the potential to improve the prognosis for patients with glioblastomas.	[Arshad, Azeem; Bienemann, Alison S.; Barua, Neil U.; Wyatt, Marcella J.; Gill, Steven S.] Univ Bristol, Sch Clin Sci, Funct Neurosurg Res Grp, Bristol, Avon, England; [Woolley, Max; Johnson, Dave E.] Renishaw Plc, Neurol Applicat Div, London, Glos, England; [Yang, Bin; Edler, Karen J.] Univ Bath, Dept Chem, Bath BA2 7AY, Avon, England	University of Bristol; Renishaw plc; University of Bath	Gill, SS (corresponding author), Univ Bristol, Sch Clin Sci, Funct Neurosurg Res Grp, Bristol, Avon, England.	steven.gill@nbt.nhs.uk	Edler, Karen/A-7324-2011	Edler, Karen/0000-0001-5822-0127; Yang, Bin/0000-0002-6810-9585	Medical Research Council [MR/J005134/1]; MRC [MR/J005134/1] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The study was funded by the Medical Research Council (http://www.mrc.ac.uk) Ref number: MR/J005134/1. Co-authors M. Woolley and D.E. Johnson are employed by Renishaw Plc. Renishaw Plc., were involved in the Medical Research Council grant application where they provided 'in kind contribution' support for the grant application MR/J005134/1 and provided support in the form of salaries for authors M. Woolley and D.E. Johnson, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Barua NU, 2013, ACTA NEUROCHIR, V155, P1459, DOI 10.1007/s00701-013-1700-6; Barua NU, 2013, J NEUROSCI METH, V214, P223, DOI 10.1016/j.jneumeth.2013.02.007; Barua NU, 2012, FLUIDS BARRIERS CNS, V9, DOI 10.1186/2045-8118-9-2; Barua NU, 2014, DRUG DELIVERY; Barua NU, 2013, ACTA NEUROCHIR WIEN; Bienemann A, 2012, J NEUROSCI METH, V203, P284, DOI 10.1016/j.jneumeth.2011.10.002; Birks SM, 2011, NEURO-ONCOLOGY, V13, P950, DOI 10.1093/neuonc/nor108; BOBO RH, 1994, P NATL ACAD SCI USA, V91, P2076, DOI 10.1073/pnas.91.6.2076; Bogdahn U, 2011, NEURO-ONCOLOGY, V13, P132, DOI 10.1093/neuonc/noq142; Bregy A, 2013, EXPERT REV ANTICANC, V13, P1453, DOI 10.1586/14737140.2013.840090; Bruce JN, 2011, NEUROSURGERY; Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043; Fleming AB, 2002, CLIN PHARMACOKINET, V41, P403, DOI 10.2165/00003088-200241060-00002; Govender T, 1999, J CONTROL RELEASE, V57, P171, DOI 10.1016/S0168-3659(98)00116-3; Groothuis DR, 2007, J CEREBR BLOOD F MET, V27, P43, DOI 10.1038/sj.jcbfm.9600315; MacKay JA, 2005, BRAIN RES, V1035, P139, DOI 10.1016/j.brainres.2004.12.007; Mehta Ankit I, 2012, Curr Drug Discov Technol, V9, P305; Nance EA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003594; PARDRIDGE WM, 1989, NEUROBIOL AGING, V10, P636, DOI 10.1016/0197-4580(89)90160-7; Parker KA, 2006, APOPTOSIS OF HUMAN M; PAXINOS G, 1985, J NEUROSCI METH, V13, P139, DOI 10.1016/0165-0270(85)90026-3; Saito R, 2006, J NEUROSCI METH, V154, P225, DOI 10.1016/j.jneumeth.2005.12.027; Sawyer AJ, 2011, DRUG DELIV TRANSL RE, V1, P34, DOI 10.1007/s13346-010-0001-3; Skinner EK, 2012, CHEM COMMUN, V48, P9260, DOI 10.1039/c2cc34926d; Song XR, 2010, J PHARM SCI-US, V99, P4874, DOI 10.1002/jps.22200; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2007, J CLIN ONCOL, V25, P4127, DOI 10.1200/JCO.2007.11.8554; WALLNER KE, 1989, INT J RADIAT ONCOL, V16, P1405, DOI 10.1016/0360-3016(89)90941-3; Westphal M, 2003, NEURO-ONCOLOGY, V5, P79, DOI 10.1215/15228517-5-2-79; White E, 2012, J NEURO-ONCOL, V108, P77, DOI 10.1007/s11060-012-0833-4; White E, 2012, CONTEMP CLIN TRIALS, V33, P320, DOI 10.1016/j.cct.2011.10.010; White E, 2011, J NEUROSCI METH, V199, P87, DOI 10.1016/j.jneumeth.2011.04.027; Whittle IR, 1999, BRIT J NEUROSURG, V13, P132, DOI 10.1080/02688699943871; Yanamandra N, 2004, ONCOGENE, V23, P2339, DOI 10.1038/sj.onc.1207406; Zhang ZP, 2008, PHARM RES-DORDR, V25, P1925, DOI 10.1007/s11095-008-9611-6; Zhou JB, 2013, P NATL ACAD SCI USA, V110, P11751, DOI 10.1073/pnas.1304504110	36	54	54	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2015	10	7							e0132266	10.1371/journal.pone.0132266	http://dx.doi.org/10.1371/journal.pone.0132266			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RV	26186224	Green Published, Green Submitted, gold			2023-01-03	WOS:000358198700034
J	Ozaki, T; Nakazawa, M; Yamashita, T; Ishiguro, SI				Ozaki, Taku; Nakazawa, Mitsuru; Yamashita, Tetsuro; Ishiguro, Sei-Ichi			Delivery of Topically Applied Calpain Inhibitory Peptide to the Posterior Segment of the Rat Eye	PLOS ONE			English	Article							OPTIC-NERVE; RABBIT EYE; PHARMACOKINETICS; MITOCHONDRIA; ACTIVATION; ANTIBODY; RETINA	We developed an inhibitory peptide that specifically acts against mitochondrial mu-calpain (Tat-mu CL, 23 amino acid, 2857.37 Da) and protects photoreceptors in retinal dystrophic rats. In the present study, we topically administered Tat-mu CL to the eyes of Sprague-Dawley rats for 7 days to determine both the delivery route of the peptide to the posterior segment of the eye and the kinetics after topical application in adult rats. Distribution of the peptide was determined by immunohistochemical analysis, and enzyme-linked immune-absorbent assay was used to quantify the accumulation in the retina. Peptides were prominently detected in both the anterior and posterior segments of the eye at 1 h after the final eye drop application. Immunohistochemically positive reactions were observed in the retina, optic nerve, choroid, sclera and the retrobulbar tissues, even in the posterior portion of the eye. Immunoactivities gradually diminished at 3 and 6 h after the final eye drop. Quantitative estimations of the amount of peptide in the retina were 15.3, 5.8 and 1.0 pg/mu g protein at 1, 3 and 6 h after the final instillation, respectively. Current results suggest that while the topically applied Tat-mu CL peptide reaches the posterior segment of the retina and the optic nerve, the sufficient concentration (>IC50) is maintained for at least 6 h in the rat retina. Our findings suggest that delivery of topically applied peptide to the posterior segment and optic nerve occurs through the conjunctiva, periocular connective tissue, sclera and optic nerve sheath.	[Ozaki, Taku; Nakazawa, Mitsuru] Hirosaki Univ, Grad Sch Med, Dept Ophthalmol, Hirosaki, Aomori, Japan; [Yamashita, Tetsuro] Iwate Univ, Fac Agr, Dept Biol Chem, Morioka, Iwate 020, Japan; [Ishiguro, Sei-Ichi] Hirosaki Univ, Fac Agr & Life Sci, Dept Biochem & Mol Biol, Hirosaki, Aomori, Japan	Hirosaki University; Iwate University; Hirosaki University	Nakazawa, M (corresponding author), Hirosaki Univ, Grad Sch Med, Dept Ophthalmol, Hirosaki, Aomori, Japan.	mitsuru@hirosaki-u.ac.jp	Nakazawa, Mitsuru/ABI-7897-2020	Nakazawa, Mitsuru/0000-0001-6095-5712; Ozaki, Taku/0000-0001-8183-5453	Japan Society for the Promotion of Science (Tokyo, Japan) [24592616, 25861611]	Japan Society for the Promotion of Science (Tokyo, Japan)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This study was supported in part by a Grant-in-Aid for Scientific Research C-24592616 (M. N.) and a Grant-in-Aid for Young Investigators B-25861611 (T.O.) from the Japan Society for the Promotion of Science (Tokyo, Japan).	El Sanharawi M, 2010, PROG RETIN EYE RES, V29, P443, DOI 10.1016/j.preteyeres.2010.04.001; Endo S, 1999, BBA-MOL CELL RES, V1450, P385, DOI 10.1016/S0167-4889(99)00062-2; Furrer E, 2009, INVEST OPHTH VIS SCI, V50, P771, DOI 10.1167/iovs.08-2370; Inserte J, 2012, CARDIOVASC RES, V96, P23, DOI 10.1093/cvr/cvs232; Koevary SB, 2001, INVEST OPHTH VIS SCI, V43, P797; Lambiase A, 2005, INVEST OPHTH VIS SCI, V46, P3800, DOI 10.1167/iovs.05-0301; Mizukoshi S, 2010, EXP EYE RES, V91, P353, DOI 10.1016/j.exer.2010.06.004; Ozaki T, 2009, BIOCHIM BIOPHYS ACTA, V1783, P1955; Ozaki T, 2013, PLOS ONE, V2013, P1; Ozaki T, 2007, J BIOCHEM, V142, P365, DOI 10.1093/jb/mvm143; Ozaki T, 2013, CELL STRUCT FUNCT, V38, P205, DOI 10.1247/csf.13008; Ozaki T, 2012, BBA-MOL BASIS DIS, V1822, P1783, DOI 10.1016/j.bbadis.2012.07.018; Ozaki T, 2011, ARCH BIOCHEM BIOPHYS, V507, P254, DOI 10.1016/j.abb.2010.12.003; Suzuki K, 2004, DIABETES, V53, pS12, DOI 10.2337/diabetes.53.2007.S12; TAVARES A, 1991, BIOMED BIOCHIM ACTA, V50, P523; Williams KA, 2005, EYE, V19, P910, DOI 10.1038/sj.eye.6701669; YOSHIDA A, 1993, INVEST OPHTH VIS SCI, V34, P3154	17	8	8	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2015	10	6							e0130986	10.1371/journal.pone.0130986	http://dx.doi.org/10.1371/journal.pone.0130986			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL4OM	26107400	Green Published, gold, Green Submitted			2023-01-03	WOS:000356932500135
J	Di Staso, M; Gravina, GL; Zugaro, L; Bonfili, P; Gregori, L; Franzese, P; Marampon, F; Vittorini, F; Moro, R; Tombolini, V; Di Cesare, E; Masciocchi, C				Di Staso, Mario; Gravina, Giovanni Luca; Zugaro, Luigi; Bonfili, Pierluigi; Gregori, Lorenzo; Franzese, Pietro; Marampon, Francesco; Vittorini, Francesca; Moro, Roberto; Tombolini, Vincenzo; Di Cesare, Ernesto; Masciocchi, Carlo			Treatment of Solitary Painful Osseous Metastases with Radiotherapy, Cryoablation or Combined Therapy: Propensity Matching Analysis in 175 Patients	PLOS ONE			English	Article							CELL LUNG-CANCER; PERCUTANEOUS RADIOFREQUENCY ABLATION; IMAGE-GUIDED CRYOABLATION; FUTURE CLINICAL-TRIALS; BONE METASTASES; RADIATION-THERAPY; INTERNATIONAL CONSENSUS; THERMAL ABLATION; END-POINTS; DISEASE	Purpose aim of this study was to identify outcomes in pain relief and quality of life in patients with a solitary painful osseous metastasis treated by radiotherapy, cryoablation or the combination using a propensity score matching study design. Materials and Methods 175 patients with painful bone metastases were included in the study. Twenty-five of them underwent a radiation course (20 Gy in five daily fractions) 15 days after the cryoablation. These subjects were retrospectively matched by propensity analysis with a group of subjects treated by radiotherapy (125 subjects) and with a group treated by Cryoablation (25 subjects). The pain relief in terms of complete response, rate of subjects requiring analgesics after treatments and the changes in self-rated quality of life were measured. Informed consent was obtained from the subject and the study was approved by the local Ethical Committee. Results An higher proportion of subjects treated by cryoablation (32%) or cryoablation followed by RT (72%;) experienced a complete response compared with patients treated by radiotherapy alone (11.2%). After Bonferroni correction strategy, the addition of radiotherapy to cryoablation significantly improved the rate of complete response compared with cryoablation alone (p = 0.011) and this paralleled with an improved self-rated quality of life. Seventeen subjects (13.6%) of patients in the radiotherapy group, 9 (36%) in the cryoablation group, and 19 (76)% in the cryoablation-radiotherapy group did not require narcotic medications. Conclusions The addition of radiotherapy to cryoablation favorably impacts on perceived pain, with a favorable toxicity profile. However, our data should be interpreted with caution and could serve as a framework around which to design future trials.	[Di Staso, Mario; Gravina, Giovanni Luca; Bonfili, Pierluigi; Franzese, Pietro; Marampon, Francesco; Di Cesare, Ernesto] Univ Aquila, Sch Med, S Salvatore Hosp, Dept Biotechnol & Appl Clin Sci,Div Radiat Oncol, I-67100 Laquila, Italy; [Zugaro, Luigi; Gregori, Lorenzo; Masciocchi, Carlo] Univ Aquila, Sch Med, S Salvatore Hosp, Dept Biotechnol & Appl Clin Sci,Div Radiol, I-67100 Laquila, Italy; [Tombolini, Vincenzo] Univ Roma La Sapienza, Dept Radiol Oncol & Anatomopathol Sci, I-00185 Rome, Italy; [Vittorini, Francesca; Moro, Roberto] San Salvatore Hosp, Serv Med Phys, Laquila, Italy	University of L'Aquila; University of L'Aquila; Sapienza University Rome	Gravina, GL (corresponding author), Univ Aquila, Sch Med, S Salvatore Hosp, Dept Biotechnol & Appl Clin Sci,Div Radiat Oncol, I-67100 Laquila, Italy.	giovanniluca.gravina@libero.it	Di Staso, Mario/AAD-9008-2019; di Cesare, Ernesto/AAC-7428-2022; di cesare, ernesto/D-8381-2016	Marampon, Francesco/0000-0002-0588-3039; Gravina, Giovanni Luca/0000-0002-6797-8324; di cesare, ernesto/0000-0002-0995-3081; Tombolini, Vincenzo/0000-0001-5359-9991				Andrade RS, 2010, INT J RADIAT ONCOL, V78, P855, DOI 10.1016/j.ijrobp.2009.09.002; Callstrom MR, 2006, RADIOLOGY, V241, P572, DOI 10.1148/radiol.2412051247; Callstrom MR, 2013, CANCER-AM CANCER SOC, V119, P1033, DOI 10.1002/cncr.27793; Callstrom MR, 2002, RADIOLOGY, V224, P87, DOI 10.1148/radiol.2241011613; Chan MD, 2011, BRACHYTHERAPY, V10, P253, DOI 10.1016/j.brachy.2010.07.002; Chow E, 2002, RADIOTHER ONCOL, V64, P275, DOI 10.1016/S0167-8140(02)00170-6; Chow E, 2012, INT J RADIAT ONCOL, V82, P1730, DOI 10.1016/j.ijrobp.2011.02.008; COHEN SR, 1995, PALLIATIVE MED, V9, P207, DOI 10.1177/026921639500900306; Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210; Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931; Di Staso M, 2011, EUR RADIOL, V21, P2004, DOI 10.1007/s00330-011-2133-3; Di Staso M, 2011, CLIN ONCOL-UK, V23, P65, DOI 10.1016/j.clon.2010.11.002; DIPETRILLO TA, 2003, SEMIN INTERVENT RAD, V20, P341; Dupuy DE, 2013, J VASC INTERV RADIOL, V24, P1139, DOI 10.1016/j.jvir.2013.04.021; Dupuy DE, 2010, CANCER-AM CANCER SOC, V116, P989, DOI 10.1002/cncr.24837; Dupuy DE, 2006, CHEST, V129, P738, DOI 10.1378/chest.129.3.738; Goetz MP, 2004, J CLIN ONCOL, V22, P300, DOI 10.1200/JCO.2004.03.097; Grieco CA, 2007, AM J CLIN ONCOL-CANC, V30, P361, DOI 10.1097/COC.0b013e318033e76a; Grieco CA, 2006, J VASC INTERV RADIOL, V17, P1117, DOI 10.1097/01.RVI.0000228373.58498.6E; Harvey HA, 2007, CLIN BREAST CANCER, V7, pS7, DOI 10.3816/CBC.2007.s.001; Horkan C, 2005, RADIOLOGY, V235, P81, DOI 10.1148/radiol.2351040269; Howell DD, 2013, CANCER-AM CANCER SOC, V119, P888, DOI 10.1002/cncr.27616; Lutz S, 2009, CLIN ONCOL-UK, V21, P659, DOI 10.1016/j.clon.2009.07.013; Lutz S, 2011, INT J RADIAT ONCOL, V79, P965, DOI 10.1016/j.ijrobp.2010.11.026; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Rosenthal D, 2012, RADIOLOGY, V262, P765, DOI 10.1148/radiol.11101384; Silverman SG, 2000, RADIOLOGY, V217, P657, DOI 10.1148/radiology.217.3.r00dc40657; Smith HS, 2011, PAIN PHYSICIAN, V14, pE373; Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227; Suva LJ, 2009, ENDOCR-RELAT CANCER, V16, P703, DOI 10.1677/ERC-09-0012; Tharmalingam Sukirtha, 2008, J Pain Res, V1, P49; Timmerman RD, 2009, CA-CANCER J CLIN, V59, P145, DOI 10.3322/caac.20013; WIDMANN G, 2009, CANC IMAGING, V9, P63, DOI DOI 10.1102/1470-7330.2009.0011; Yu HHM, 2012, CANCER CONTROL, V19, P84	34	33	33	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2015	10	6							e0129021	10.1371/journal.pone.0129021	http://dx.doi.org/10.1371/journal.pone.0129021			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL4DD	26103516	Green Submitted, Green Published, gold			2023-01-03	WOS:000356901900011
J	Hong, EH; Song, JH; Shim, A; Lee, BR; Kwon, BE; Song, HH; Kim, YJ; Chang, SY; Jeong, HG; Kim, JG; Seo, SU; Kim, H; Kwon, Y; Ko, HJ				Hong, Eun-Hye; Song, Jae-Hyoung; Shim, Aeri; Lee, Bo-Ra; Kwon, Bo-Eun; Song, Hyuk-Hwan; Kim, Yeon-Jeong; Chang, Sun-Young; Jeong, Hyeon Gun; Kim, Jong Geal; Seo, Sang-Uk; Kim, HyunPyo; Kwon, YongSoo; Ko, Hyun-Jeong			Coadministration of Hedera helix L. Extract Enabled Mice to Overcome Insufficient Protection against Influenza A/PR/8 Virus Infection under Suboptimal Treatment with Oseltamivir	PLOS ONE			English	Article							NEURAMINIDASE INHIBITORS; GENE-EXPRESSION; IVY PLANT; TNF-ALPHA; TRITERPENOID SAPONINS; ANTIVIRAL ACTIVITY; RESISTANT; RESPONSES; IMMUNOPATHOLOGY; CYTOKINE	Several anti-influenza drugs that reduce disease manifestation exist, and although these drugs provide clinical benefits in infected patients, their efficacy is limited by the emergence of drug-resistant influenza viruses. In the current study, we assessed the therapeutic strategy of enhancing the antiviral efficacy of an existing neuraminidase inhibitor, oseltamivir, by coadministering with the leaf extract from Hedera helix L, commonly known as ivy. Ivy extract has anti-inflammatory, antibacterial, antifungal, and antihelminthic properties. In the present study, we investigated its potential antiviral properties against influenza A/PR/8 (PR8) virus in a mouse model with suboptimal oseltamivir that mimics a poor clinical response to antiviral drug treatment. Suboptimal oseltamivir resulted in insufficient protection against PR8 infection. Oral administration of ivy extract with suboptimal oseltamivir increased the antiviral activity of oseltamivir. Ivy extract and its compounds, particularly hedrasaponin F, significantly reduced the cytopathic effect in PR8-infected A549 cells in the presence of oseltamivir. Compared with oseltamivir treatment alone, coadministration of the fraction of ivy extract that contained the highest proportion of hedrasaponin F with oseltamivir decreased pulmonary inflammation in PR8-infected mice. Inflammatory cytokines and chemokines, including tumor necrosis factor-alpha and chemokine (C-C motif) ligand 2, were reduced by treatment with oseltamivir and the fraction of ivy extract. Analysis of inflammatory cell infiltration in the bronchial alveolar of PR8-infected mice revealed that CD11b(+-)Ly6G(+) and CD11b(+)Ly6C(int) cells were recruited after virus infection; coadministration of the ivy extract fraction with oseltamivir reduced infiltration of these inflammatory cells. In a model of suboptimal oseltamivir treatment, coadministration of ivy extract fraction that includes hedrasaponin F increased protection against PR8 infection that could be explained by its antiviral and anti-inflammatory activities.	[Hong, Eun-Hye; Song, Jae-Hyoung; Shim, Aeri; Lee, Bo-Ra; Kwon, Bo-Eun; Kim, HyunPyo; Kwon, YongSoo; Ko, Hyun-Jeong] Kangwon Natl Univ, Coll Pharm, Lab Microbiol & Immunol, Chunchon, South Korea; [Song, Hyuk-Hwan] Korea Res Inst Biosci & Biotechnol, Nat Med Res Ctr, Chungcheongbuk Do, South Korea; [Kim, Yeon-Jeong] Inje Univ, Coll Pharm, Gimhae, South Korea; [Chang, Sun-Young] Ajou Univ, Coll Pharm, Suwon 441749, South Korea; [Jeong, Hyeon Gun; Kim, Jong Geal] Ahngook Pharm, R&D Ctr, Seoul, South Korea; [Seo, Sang-Uk] Int Vaccine Inst, Mucosal Immunol Sect, Seoul, South Korea	Kangwon National University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Inje University; Ajou University; International Vaccine Institute	Kwon, Y (corresponding author), Kangwon Natl Univ, Coll Pharm, Lab Microbiol & Immunol, Chunchon, South Korea.	yskwon@kangwon.ac.kr; hjko@kangwon.ac.kr		Ko, Hyun-Jeong/0000-0002-3844-928X	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and future Planning [NRF-428 2014R1A2A2A01002576]; Ahngook pharm.	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and future Planning; Ahngook pharm.	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and future Planning (NRF-428 2014R1A2A2A01002576). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. HGJ and JGK are employed by Ahngook pharm. Ahngook pharm. provided support in the form of salaries for authors HGJ and JGK and provided hederasaponin F, after isolating and identifying the structure of hederasaponin F, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Abdel-Ghafar AN, 2008, NEW ENGL J MED, V358, P261, DOI 10.1056/NEJMra0707279; An SC, 2011, MED HYPOTHESES, V77, P1054, DOI 10.1016/j.mehy.2011.09.001; Burch J, 2009, LANCET INFECT DIS, V9, P537, DOI 10.1016/S1473-3099(09)70199-9; Cady SD, 2010, NATURE, V463, P689, DOI 10.1038/nature08722; Canini L, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003568; CIOACA C, 1978, PHARMAZIE, V33, P609; Damjanovic D, 2011, AM J PATHOL, V179, P2963, DOI 10.1016/j.ajpath.2011.09.003; De Clercq E, 2006, NAT REV DRUG DISCOV, V5, P1015, DOI 10.1038/nrd2175; de Jong MD, 2005, NEW ENGL J MED, V353, P2667, DOI 10.1056/NEJMoa054512; DeBerge MP, 2014, J IMMUNOL, V192, P5839, DOI 10.4049/jimmunol.1302729; Fazio S, 2009, PHYTOMEDICINE, V16, P17, DOI 10.1016/j.phymed.2006.05.003; Fischer MA, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002374; Fritz RS, 1999, J INFECT DIS, V180, P586, DOI 10.1086/314938; Gepdiremen A, 2005, PHYTOMEDICINE, V12, P440, DOI 10.1016/j.phymed.2004.04.005; GRISHKOVETS VI, 1995, BIOORG KHIM+, V21, P468; Han LT, 2013, EVID-BASED COMPL ALT, V517931, P2013, DOI DOI 10.1155/2013/517931; Hehlgans T, 2005, IMMUNOLOGY, V115, P1, DOI 10.1111/j.1365-2567.2005.02143.x; Hocaoglu AB, 2012, IRAN J ALLERGY ASTHM, V11, P316, DOI 011.04/ijaai.316323; Hufford MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046581; Hurt AC, 2014, CURR OPIN VIROL, V8, P22, DOI 10.1016/j.coviro.2014.04.009; Hurt AC, 2009, J VIROL, V83, P10366, DOI 10.1128/JVI.01200-09; Jeisy-Scott V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025242; JULIEN J, 1985, PLANTA MED, V51, P205, DOI 10.1055/s-2007-969457; Julkunen I, 2000, VACCINE, V19, pS32, DOI 10.1016/S0264-410X(00)00275-9; Julkunen I, 2001, CYTOKINE GROWTH F R, V12, P171, DOI 10.1016/S1359-6101(00)00026-5; Kok WL, 2012, J LEUKOCYTE BIOL, V91, P357, DOI 10.1189/jlb.0411184; MAJESTERSAVORNIN B, 1991, PLANTA MED, V57, P260, DOI 10.1055/s-2006-960086; Matikainen S, 2006, J VIROL, V80, P3515, DOI 10.1128/JVI.80.7.3515-3522.2006; Monto AS, 2006, ANTIMICROB AGENTS CH, V50, P2395, DOI 10.1128/AAC.01339-05; Moulin-Traffort J, 1998, MYCOSES, V41, P411, DOI 10.1111/j.1439-0507.1998.tb00362.x; Mshvildadze V, 2004, CHEM PHARM BULL, V52, P1411, DOI 10.1248/cpb.52.1411; Ozdemir C, 2003, HAUTARZT, V54, P966, DOI 10.1007/s00105-003-0584-4; Pizzorno A, 2011, J INFECT DIS, V203, P25, DOI 10.1093/infdis/jiq010; Samson M, 2013, ANTIVIR RES, V98, P174, DOI 10.1016/j.antiviral.2013.03.014; Seo SU, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001304; Shale Matt, 2010, Therap Adv Gastroenterol, V3, P173, DOI 10.1177/1756283X10366368; Shim DH, 2007, VACCINE, V25, P4828, DOI 10.1016/j.vaccine.2007.03.050; Simoes CMO, 1999, PHYTOTHER RES, V13, P323, DOI 10.1002/(SICI)1099-1573(199906)13:4&lt;323::AID-PTR448&gt;3.0.CO;2-C; Song J, 2014, BIOMOL THER, V22, P41, DOI 10.4062/biomolther.2013.108; Suleyman H, 2003, PHYTOMEDICINE, V10, P370, DOI 10.1078/0944-7113-00260; Trute A, 1997, PLANTA MED, V63, P125, DOI 10.1055/s-2006-957627; Veckman V, 2006, VIROLOGY, V345, P96, DOI 10.1016/j.virol.2005.09.043; Youn HJ, 2007, VACCINE, V25, P5189, DOI 10.1016/j.vaccine.2007.04.081; Yu XL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028680	44	9	10	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2015	10	6							e0131089	10.1371/journal.pone.0131089	http://dx.doi.org/10.1371/journal.pone.0131089			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL3FM	26098681	Green Published, gold, Green Submitted			2023-01-03	WOS:000356835800147
J	Noyan, H; El-Mounayri, O; Isserlin, R; Arab, S; Momen, A; Cheng, HS; Wu, J; Afroze, T; Li, RK; Fish, JE; Bader, GD; Husain, M				Noyan, Hossein; El-Mounayri, Omar; Isserlin, Ruth; Arab, Sara; Momen, Abdul; Cheng, Henry S.; Wu, Jun; Afroze, Talat; Li, Ren-Ke; Fish, Jason E.; Bader, Gary D.; Husain, Mansoor			Cardioprotective Signature of Short-Term Caloric Restriction	PLOS ONE			English	Article							CARDIOMYOCYTE CIRCADIAN CLOCK; ACTIVATED PROTEIN-KINASE; DIETARY RESTRICTION; LIFE-SPAN; MEDIATES CARDIOPROTECTION; MITOCHONDRIAL BIOGENESIS; MYOCARDIAL-ISCHEMIA; OXIDATIVE STRESS; RHESUS-MONKEYS; DISEASE	Objective To understand the molecular pathways underlying the cardiac preconditioning effect of short-term caloric restriction (CR). Background Lifelong CR has been suggested to reduce the incidence of cardiovascular disease through a variety of mechanisms. However, prolonged adherence to a CR life-style is difficult. Here we reveal the pathways that are modulated by short-term CR, which are associated with protection of the mouse heart from ischemia. Methods Male 10-12 wk old C57bl/6 mice were randomly assigned to an ad libitum(AL) diet with free access to regular chow, or CR, receiving 30% less food for 7 days (d), prior to myocardial infarction (MI) via permanent coronary ligation. At d8, the left ventricles (LV) of AL and CR mice were collected for Western blot, mRNA and microRNA (miR) analyses to identify cardio-protective gene expression signatures. In separate groups, infarct size, cardiac hemodynamics and protein abundance of caspase 3 was measured at d2 post-MI. Results This short-term model of CR was associated with cardio-protection, as evidenced by decreased infarct size (18.5 +/- 2.4% vs. 26.6 +/- 1.7%, N=10/group; P=0.01). mRNA and miR profiles pre-MI (N=5/group) identified genes modulated by short-term CR to be associated with circadian clock, oxidative stress, immune function, apoptosis, metabolism, angiogenesis, cytoskeleton and extracellular matrix (ECM). Western blots pre-MI revealed CR-associated increases in phosphorylated Akt and GSK3 beta, reduced levels of phosphorylated AMPK and mitochondrial related proteins PGC-1 alpha, cytochrome C and cyclooxygenase (COX) IV, with no differences in the levels of phosphorylated eNOS or MAPK (ERK1/2; p38). CR regimen was also associated with reduced protein abundance of cleaved caspase 3 in the infarcted heart and improved cardiac function.	[Noyan, Hossein; El-Mounayri, Omar; Arab, Sara; Momen, Abdul; Afroze, Talat; Husain, Mansoor] Toronto Gen Res Inst, Div Expt Therapeut, Toronto, ON, Canada; [Isserlin, Ruth; Bader, Gary D.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada; [Cheng, Henry S.; Wu, Jun; Li, Ren-Ke; Fish, Jason E.] Toronto Gen Res Inst, Div Adv Diagnost, Toronto, ON, Canada; [Fish, Jason E.; Husain, Mansoor] Univ Toronto, Dept Lab Med Pathobiol, Toronto, ON, Canada; [Li, Ren-Ke; Fish, Jason E.; Husain, Mansoor] Univ Toronto, Heart & Stroke Richard Lewar Ctr Excellence Cardi, Toronto, ON, Canada; [Bader, Gary D.] Univ Toronto, Donnelly Ctr, Toronto, ON, Canada; [Li, Ren-Ke; Fish, Jason E.; Husain, Mansoor] Univ Hlth Network, Peter Munk Cardiac Ctr, Toronto, ON, Canada; [Husain, Mansoor] Univ Toronto, Dept Med, Toronto, ON, Canada; [Husain, Mansoor] Univ Hlth Network, Ted Rogers Ctr Heart Res, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Toronto; University of Toronto; University of Toronto; Peter Munk Cardiac Centre; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Husain, M (corresponding author), Toronto Gen Res Inst, Div Expt Therapeut, Toronto, ON, Canada.	mansoor.husain@uhn.ca	Bader, Gary/C-1176-2009	Bader, Gary/0000-0003-0185-8861; Cheng, Henry/0000-0002-4254-962X; Fish, Jason/0000-0003-0640-7277; Husain, Mansoor/0000-0002-3740-6739; Li, Ren-Ke/0000-0002-2584-060X	Heart and Stroke Foundation of Ontario (HSFO) [T6757]; Career Investigator Award of the HSFO [CI6824]; NATIONAL CANCER INSTITUTE [R01CA121941] Funding Source: NIH RePORTER	Heart and Stroke Foundation of Ontario (HSFO)(Heart & Stroke Foundation of Ontario); Career Investigator Award of the HSFO; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was funded by an operating grant to MH from the Heart and Stroke Foundation of Ontario (HSFO; T6757). MH is recipient of a Career Investigator Award of the HSFO (CI6824).	Arad M, 2007, CIRC RES, V100, P474, DOI 10.1161/01.RES.0000258446.23525.37; Aurora AB, 2012, J CLIN INVEST, V122, P1222, DOI 10.1172/JCI59327; Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694; Bishop NA, 2007, NAT REV GENET, V8, P835, DOI 10.1038/nrg2188; Bonney S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071493; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; Bornfeldt KE, 2011, CELL METAB, V14, P575, DOI 10.1016/j.cmet.2011.07.015; Broderick TL, 2002, MOL CELL BIOCHEM, V233, P119, DOI 10.1023/A:1015506327849; Calvillo L, 2011, J CARDIOVASC PHARM, V58, P500, DOI 10.1097/FJC.0b013e31822b7204; Cao SX, 2001, P NATL ACAD SCI USA, V98, P10630, DOI 10.1073/pnas.191313598; Cava E, 2013, AGING-US, V5, P507, DOI 10.18632/aging.100581; Chandrasekar B, 2001, AM J PHYSIOL-HEART C, V280, pH2094, DOI 10.1152/ajpheart.2001.280.5.H2094; Chung KW, 2013, EXP GERONTOL, V48, P1049, DOI 10.1016/j.exger.2012.11.007; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Cushing L, 2011, AM J RESP CELL MOL, V45, P287, DOI 10.1165/rcmb.2010-0323OC; Dhahbi JM, 2004, P NATL ACAD SCI USA, V101, P5524, DOI 10.1073/pnas.0305300101; Dolinsky VW, 2011, BBA-MOL BASIS DIS, V1812, P1477, DOI 10.1016/j.bbadis.2011.06.010; Durgan DJ, 2010, CIRC RES, V106, P647, DOI 10.1161/CIRCRESAHA.109.209957; Durgan DJ, 2010, CIRC RES, V106, P546, DOI 10.1161/CIRCRESAHA.109.209346; Eckle T, 2012, NAT MED, V18, P774, DOI 10.1038/nm.2728; Edwards AG, 2010, MECH AGEING DEV, V131, P739, DOI 10.1016/j.mad.2010.09.007; Fan D, 2014, CIRC RES, V114, P889, DOI 10.1161/CIRCRESAHA.114.302335; Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Han XF, 2012, J NUTR BIOCHEM, V23, P1592, DOI 10.1016/j.jnutbio.2011.11.002; Ji F, 2013, BONE, V56, P220, DOI 10.1016/j.bone.2013.05.020; Juhaszova M, 2009, CIRC RES, V104, P1240, DOI 10.1161/CIRCRESAHA.109.197996; Kennedy BK, 2007, CELL MOL LIFE SCI, V64, P1323, DOI 10.1007/s00018-007-6470-y; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kunuthur SP, 2012, J CELL MOL MED, V16, P1739, DOI 10.1111/j.1582-4934.2011.01491.x; Lamia KA, 2008, P NATL ACAD SCI USA, V105, P15172, DOI 10.1073/pnas.0806717105; Lee J, 2010, AGING-US, V2, P527, DOI 10.18632/aging.100184; Lemmer B, 2006, PHARMACOL THERAPEUT, V111, P629, DOI 10.1016/j.pharmthera.2005.11.008; Libby P, 2000, CIRCULATION, V102, P1874, DOI 10.1161/01.CIR.102.16.1874; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Liu N, 2010, DEV CELL, V18, P510, DOI 10.1016/j.devcel.2010.03.010; Longo VD, 2014, CELL METAB, V19, P181, DOI 10.1016/j.cmet.2013.12.008; Lopez-Lluch G, 2006, P NATL ACAD SCI USA, V103, P1768, DOI 10.1073/pnas.0510452103; Maillet M, 2013, NAT REV MOL CELL BIO, V14, P38, DOI 10.1038/nrm3495; Mair W, 2003, SCIENCE, V301, P1731, DOI 10.1126/science.1086016; Mair W, 2008, ANNU REV BIOCHEM, V77, P727, DOI 10.1146/annurev.biochem.77.061206.171059; Marzetti E, 2009, CLIN GERIATR MED, V25, P715, DOI 10.1016/j.cger.2009.07.002; Mattison JA, 2012, NATURE, V489, P318, DOI 10.1038/nature11432; MCCAY CM, 1989, NUTRITION, V5, P155; Mercken EM, 2013, AGING CELL, V12, P645, DOI 10.1111/acel.12088; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Mishra PK, 2013, BBA-MOL BASIS DIS, V1832, P2271, DOI 10.1016/j.bbadis.2013.09.004; Noyan-Ashraf MH, 2005, NUTR NEUROSCI, V8, P101, DOI 10.1080/10284150500069470; Noyan-Ashraf MH, 2006, FASEB J, V20, P371, DOI 10.1096/fj.05-4889fje; Noyan-Ashraf MH, 2013, CIRCULATION, V127, P74, DOI 10.1161/CIRCULATIONAHA.112.091215; Noyan-Ashraf MH, 2009, DIABETES, V58, P975, DOI 10.2337/db08-1193; Oshima Y, 2005, CARDIOVASC RES, V65, P428, DOI 10.1016/j.cardiores.2004.10.021; Ouyang YB, 2012, MITOCHONDRION, V12, P213, DOI 10.1016/j.mito.2011.09.001; Paschos GK, 2010, CIRC RES, V106, P833, DOI 10.1161/CIRCRESAHA.109.211706; Pearson KJ, 2008, P NATL ACAD SCI USA, V105, P2325, DOI 10.1073/pnas.0712162105; Piper MDW, 2008, CELL METAB, V8, P99, DOI 10.1016/j.cmet.2008.06.012; Pospisilik JA, 2007, CELL, V131, P476, DOI 10.1016/j.cell.2007.08.047; Robertson LT, 2013, EXP GERONTOL, V48, P1043, DOI 10.1016/j.exger.2013.01.009; Rose BA, 2010, PHYSIOL REV, V90, P1507, DOI 10.1152/physrev.00054.2009; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shinmura K, 2005, J MOL CELL CARDIOL, V39, P285, DOI 10.1016/j.yjmcc.2005.03.010; Shinmura K, 2011, CIRC RES, V109, P396, DOI 10.1161/CIRCRESAHA.111.243097; Shinmura K, 2008, AM J PHYSIOL-HEART C, V295, pH2348, DOI 10.1152/ajpheart.00602.2008; Silver AC, 2012, IMMUNITY, V36, P251, DOI 10.1016/j.immuni.2011.12.017; Small EM, 2011, NATURE, V469, P336, DOI 10.1038/nature09783; Small EM, 2010, CIRCULATION, V121, P1022, DOI 10.1161/CIRCULATIONAHA.109.889048; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sussman MA, 2011, PHYSIOL REV, V91, P1023, DOI 10.1152/physrev.00024.2010; Swindell WR, 2008, MECH AGEING DEV, V129, P138, DOI 10.1016/j.mad.2007.11.003; Swindell WR, 2011, AGEING RES REV, V10, P132, DOI 10.1016/j.arr.2010.09.007; Swindell WR, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-585; Swindell WR, 2008, MECH AGEING DEV, V129, P580, DOI 10.1016/j.mad.2008.06.001; Trepanowski JF, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-107; Ungvari Z, 2008, CIRC RES, V102, P519, DOI 10.1161/CIRCRESAHA.107.168369; van Heemst D, 2005, AGING CELL, V4, P79, DOI 10.1111/j.1474-9728.2005.00148.x; Varady KA, 2007, AM J CLIN NUTR, V86, P7, DOI 10.1093/ajcn/86.1.7; Vigneron F, 2011, CARDIOVASC RES, V90, P49, DOI 10.1093/cvr/cvr002; Vora M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003737; Wang Q, 2011, ONCOGENE, V30, P3875, DOI 10.1038/onc.2011.103; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; Wu LY, 2004, P NATL ACAD SCI USA, V101, P7094, DOI 10.1073/pnas.0402004101; Wu QL, 2012, SHOCK, V38, P165, DOI 10.1097/SHK.0b013e31825b5633; Zhang LH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-290; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	87	43	43	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2015	10	6							e0130658	10.1371/journal.pone.0130658	http://dx.doi.org/10.1371/journal.pone.0130658			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL3FM	26098549	Green Published, gold, Green Submitted			2023-01-03	WOS:000356835800090
J	Rea, T; Eisenberg, M				Rea, Thomas; Eisenberg, Mickey			Sudden Cardiac Arrest: A Call to Action From the Institute of Medicine	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							RESUSCITATION; SURVIVAL				Rea, T (corresponding author), 401 5th Ave,Suite 1200, Seattle, WA 98104 USA.	rea123@u.washington.edu						[Anonymous], 2015, CIRCULATION, DOI DOI 10.1161/CIR.0000000000000152; [Anonymous], ABCS OF MEASURING; Chan PS, 2014, CIRCULATION, V130, P1876, DOI 10.1161/CIRCULATIONAHA.114.009711; Kragholm K, 2015, CIRCULATION, V131, P1682, DOI 10.1161/CIRCULATIONAHA.114.011366; McNally Bryan, 2011, Morbidity and Mortality Weekly Report, V60, P1; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Nolan JP, 2010, RESUSCITATION, V81, pE1, DOI 10.1016/j.resuscitation.2010.08.002; Rea TD, 2010, CIRCULATION, V121, P1134, DOI 10.1161/CIRCULATIONAHA.109.899799; Theophanous Christos, 2015, Ann Intern Med, V163, P238, DOI 10.7326/M15-0195	9	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 17	2015	163	10					794	U304		10.7326/M15-1926	http://dx.doi.org/10.7326/M15-1926			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CX5MQ	26343457				2023-01-03	WOS:000365746400024
J	Aiga, H				Aiga, Hirotsugu			PERSONAL VIEW Hidden out-of-pocket payments can burden patients' families but are under-recognised	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Aiga, Hirotsugu] Japan Int Cooperat Agcy, Dept Human Dev, Hlth & Nutr, Chiyoda Ku, Tokyo 1028012, Japan; [Aiga, Hirotsugu] George Washington Univ, Sch Publ Hlth, Milken Inst, Dept Global Hlth, Washington, DC 20052 USA	George Washington University	Aiga, H (corresponding author), Japan Int Cooperat Agcy, Dept Human Dev, Hlth & Nutr, Chiyoda Ku, 3rd Floor,Nibancho Ctr Bldg 5-25,Niban Cho, Tokyo 1028012, Japan.	aiga.hirotsugu@jica.go.jp						DiFazio R, 2011, J PEDIATR NURS, V26, P78, DOI 10.1016/j.pedn.2010.01.010; EPI Join Stock Company Baomoi, 2013, GREET NEW YEAR SUN S; Gandon Julien, 2013, Rev Infirm, P38; Johnson A, 2012, SOC SCI MED, V75, P1786, DOI 10.1016/j.socscimed.2012.07.015; O'Donnell O., 2008, Analyzing health equity using household survey data: a guide to techniques and their implementation; Tien N, 2012, SOHA NEWS       1212; World Bank, 2014, MOV UN COV SOC HLTH; World Health Organization, 2014, MON PROGR UN HLTH CO; Xu K, 2003, LANCET, V362, P111, DOI 10.1016/S0140-6736(03)13861-5; Xu K, 2007, HEALTH AFFAIR, V26, P972, DOI 10.1377/hlthaff.26.4.972; Zing.vn, 2014, ZING            0630	11	4	4	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 23	2015	351								h4990	10.1136/bmj.h4990	http://dx.doi.org/10.1136/bmj.h4990			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CS3FL	26400068				2023-01-03	WOS:000361957200011
J	Cortes-Castell, E; Sanchez-Gonzalez, P; Palazon-Bru, A; Bosch-Gimenez, V; Manero-Soler, H; Juste-Ruiz, M; Rizo-Baeza, MM; Gil-Guillen, VF				Cortes-Castell, Ernesto; Sanchez-Gonzalez, Pablo; Palazon-Bru, Antonio; Bosch-Gimenez, Vicente; Manero-Soler, Herminia; Juste-Ruiz, Mercedes; Mercedes Rizo-Baeza, Maria; Francisco Gil-Guillen, Vicente			Highest Plasma Phenylalanine Levels in (Very) Premature Infants on Intravenous Feeding; A Need for Concern	PLOS ONE			English	Article							AMINO-ACIDS; PRETERM INFANTS; PARENTERAL-NUTRITION; PROTEIN; VALUES	Objective To analyse the association in newborns between blood levels of phenylalanine and feeding method and gestational age. Study Design This observational, cross-sectional study included a sample of 11,829 infants between 2008 and 2013 in a Spanish region. Data were recorded on phenylalanine values, feeding method [breast, formula, mixed (breast plus formula), or partial or fully intravenous feeding], gestational age in weeks (<32, 32-37, >= 37), gender and days since birth at the moment of blood collection. Outcomes were [phenylalanine] and [phenylalanine] >= 95th percentile. Associations were analysed using multivariate models [linear (means difference) and logistic regression (adjusted odds ratios)]. Results Higher phenylalanine values were associated with lower gestational age (p<0.001) and with intravenous feeding (p<0.001). Conclusion The degree of prematurity and intravenous feeding influenced the plasma concentration of phenylalanine in the newborn. Caution should be taken in [phenylalanine] for newborns with intravenous feeding, monitoring them carefully. Very preterm infants given the recommended amount of amino acids should also be strictly monitored. These findings should be taken into consideration and call for adapting the amounts to the needs of the infant.	[Cortes-Castell, Ernesto; Juste-Ruiz, Mercedes] Miguel Hernandez Univ, Dept Pharmacol Paediat & Organ Chem, Alacant, Spain; [Sanchez-Gonzalez, Pablo; Manero-Soler, Herminia] Alicante Gen Univ Hosp, Clin Anal Dept, Alicante, Spain; [Palazon-Bru, Antonio; Francisco Gil-Guillen, Vicente] Miguel Hernandez Univ, Dept Clin Med, Alacant, Spain; [Bosch-Gimenez, Vicente] Univ Murcia, Dept Surg Paediat Obstet & Gynaecol, Murcia, Spain; [Mercedes Rizo-Baeza, Maria] Univ Alicante, Dept Nursing, San Vicente Del Raspeig, Spain	Universidad Miguel Hernandez de Elche; General University Hospital of Alicante; Universidad Miguel Hernandez de Elche; University of Murcia; Universitat d'Alacant	Palazon-Bru, A (corresponding author), Miguel Hernandez Univ, Dept Pharmacol Paediat & Organ Chem, Alacant, Spain.	antonio.pb23@gmail.com	Guillén, Vicente Francisco Gil/AAE-8201-2019; Rizo-Baeza, Mercedes/J-3974-2017; Cortés-Castell, Ernesto/H-8528-2019	Rizo-Baeza, Mercedes/0000-0002-6754-6505; Sanhez, Pablo/0000-0002-2844-6843; Gil-Guillen, Vicente F/0000-0003-3793-9786; CORTES CASTELL, ERNESTO/0000-0002-8079-1695				Agostoni C, 2010, J PEDIATR GASTR NUTR, V50, P85, DOI 10.1097/MPG.0b013e3181adaee0; Beath S V, 2003, Semin Neonatol, V8, P337; Blau N, 2010, LANCET, V376, P1417, DOI 10.1016/S0140-6736(10)60961-0; Chow S., 2007, CHAPMAN HALL CRC BIO; Conselleria de Sanitat Universal i Salut Publica, 2021, CONS SAN UN SAL PUBL; Corte Z, 2010, CLIN CHEM LAB MED, V48, P99, DOI 10.1515/CCLM.2010.008; Castell EC, 2013, NUTR HOSP, V28, P1536, DOI 10.3305/nh.2013.28.5.6500; Cortes E, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0166-9; Darling PB, 2004, J NUTR, V134, P2540, DOI 10.1093/jn/134.10.2540; Embleton ND, 2014, WORLD REV NUTR DIET, V110, P177, DOI 10.1159/000358466; Espada M, 2001, QUIMICA CLIN, V20, P81; Fingerhut R, 2010, J INHERIT METAB DIS, V33, pS235, DOI 10.1007/s10545-010-9167-6; Hay WW, 2010, PEDIATR NEONATOL, V51, P198, DOI 10.1016/S1875-9572(10)60039-3; Heine WE, 1994, PROTEIN METABOLISM I, P121; Kalhan SC, 2008, ANNU REV NUTR, V28, P389, DOI 10.1146/annurev.nutr.28.061807.155333; Klein CJ, 2002, J NUTR, V132, p1395S, DOI 10.1093/jn/132.6.1395S; Lin HJ, 2011, J PERINATOL, V31, P507, DOI 10.1038/jp.2010.207; Llanos M Adolfo, 2004, Rev. chil. pediatr., V75, P107; Marin Soria JL, 2009, PROGRAMAS DE CRIBADO; Medina JM, 1992, PERINATAL BIOCH, P234; Morisaki N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088392; Moro G, 1999, ACTA PAEDIATR, V88, P885, DOI 10.1080/08035259950168838; Ploder M, 2008, AMINO ACIDS, V35, P303, DOI 10.1007/s00726-007-0625-x; Quigley MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002971.pub2; RASSIN DK, 1994, NESTLE NUTR WORKS SE, V33, P183; Rellan S, 2008, PROTOCOLOS DIAGNOSTI; SCOTT PH, 1990, CLIN CHEM, V36, P1922; Zaffanello M, 2005, J PERINAT MED, V33, P246, DOI 10.1515/JPM.2005.045; Ziegler EE, 2011, ANN NUTR METAB, V58, P8, DOI 10.1159/000323381	29	1	1	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2015	10	9							e0138532	10.1371/journal.pone.0138532	http://dx.doi.org/10.1371/journal.pone.0138532			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS0ZM	26389596	Green Published, Green Submitted, gold			2023-01-03	WOS:000361791000037
J	Chen, LD; Liu, JN; Lin, L; Wu, Z; Li, H; Ye, YM; Xu, QZ; Lin, QC				Chen, Li-Da; Liu, Jian-Nan; Lin, Li; Wu, Zhi; Li, Hao; Ye, Yu-Ming; Xu, Qiao-Zhen; Lin, Qi-Chang			Effect of Continuous Positive Airway Pressure on Adiponectin in Patients with Obstructive Sleep Apnea: A Meta-Analysis	PLOS ONE			English	Article							INSULIN-RESISTANCE; HYPOPNEA SYNDROME; OXIDATIVE STRESS; PLASMA-LEVELS; CPAP; OBESITY; DISEASE; MEN	Objective Obstructive sleep apnea (OSA) has been suggested to be associated with low levels of adiponectin. Continuous positive airway pressure (CPAP) is the gold standard treatment for OSA; however, previous studies assessing the effect of CPAP on adiponectin in patients with OSA yielded conflicting results. The present meta-analysis was performed to determine whether CPAP therapy could increase adiponectin levels. Methods Two reviewers independently searched PubMed, Cochrane library, Embase and Web of Science before February 2015. Information on characteristics of subjects, study design and pre-and post-CPAP treatment of serum adiponectin was extracted for analysis. Standardized mean difference (SMD) was used to analyze the summary estimates for CPAP therapy. Results Eleven studies involving 240 patients were included in this meta-analysis, including ten observational studies and one randomized controlled study. The meta-analysis showed that there was no change of adiponectin levels before and after CPAP treatment in OSA patients (SMD = 0.059, 95% confidence interval (CI) = -0.250 to 0.368, z = 0.37, p = 0.710). Subgroup analyses indicated that the results were not affected by age, baseline body mass index, severity of OSA, CPAP therapy duration, sample size and racial differences. Conclusions This meta-analysis suggested that CPAP therapy has no impact on adiponectin in OSA patients, without significant changes in body weight. Further large-scale, well-designed long-term interventional investigations are needed to clarify this issue.	[Chen, Li-Da; Liu, Jian-Nan; Lin, Li; Wu, Zhi; Li, Hao; Ye, Yu-Ming; Xu, Qiao-Zhen] Fujian Med Univ, Zhangzhou Affiliated Hosp, Dept Resp Med, Zhangzhou 363000, Fujian Province, Peoples R China; [Lin, Qi-Chang] Fujian Med Univ, Affiliated Hosp 1, Fujian Prov Sleep Disordered Breathing Clin Ctr, Lab Resp Dis,Dept Resp Med, Fuzhou 350005, Fujian Province, Peoples R China	Fujian Medical University; Fujian Medical University	Lin, QC (corresponding author), Fujian Med Univ, Affiliated Hosp 1, Fujian Prov Sleep Disordered Breathing Clin Ctr, Lab Resp Dis,Dept Resp Med, 20 Chazhong Rd, Fuzhou 350005, Fujian Province, Peoples R China.	chang4e@126.com	LIN, QI/HDO-8145-2022	Li, Hao/0000-0003-0868-9925				Carneiro G, 2009, METAB SYNDR RELAT D, V7, P537, DOI 10.1089/met.2009.0019; Chami HA, 2011, CIRCULATION, V123, P1280, DOI 10.1161/CIRCULATIONAHA.110.974022; Delporte ML, 2002, BIOCHEM J, V367, P677, DOI 10.1042/BJ20020610; Fasshauer M, 2001, FEBS LETT, V507, P142, DOI 10.1016/S0014-5793(01)02960-X; Garcia JM, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-80; Harsch IA, 2004, RESPIRATION, V71, P580, DOI 10.1159/000081758; Higgins JP, 2005, COCHRANE HANDBOOK FO; Hoyos CM, 2012, THORAX, V67, P1081, DOI 10.1136/thoraxjnl-2011-201420; de Lima AMJ, 2010, RESPIRATION, V79, P370, DOI 10.1159/000227800; Kim J, 2010, ARCH OTOLARYNGOL, V136, P896, DOI 10.1001/archoto.2010.142; Kohler M, 2009, THORAX, V64, P67, DOI 10.1136/thx.2008.097931; Kritikou I, 2014, EUR RESPIR J, V43, P145, DOI 10.1183/09031936.00126712; Li AM, 2010, CHEST, V137, P529, DOI 10.1378/chest.09-2153; Lindberg E, 2000, SLEEP MED REV, V4, P411, DOI 10.1053/smrv.2000.0118; Malhotra A, 2000, Curr Opin Pulm Med, V6, P490, DOI 10.1097/00063198-200011000-00005; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; Martinez D, 2012, SLEEP BREATH, V16, P695, DOI 10.1007/s11325-011-0559-0; Masserini B, 2006, J ENDOCRINOL INVEST, V29, P700, DOI 10.1007/BF03344179; Nakagawa Y, 2008, AM J PHYSIOL-ENDOC M, V294, pE778, DOI 10.1152/ajpendo.00709.2007; Ohashi K, 2012, BIOCHIMIE, V94, P2137, DOI 10.1016/j.biochi.2012.06.008; Ouchi N, 2003, CURR OPIN LIPIDOL, V14, P561, DOI 10.1097/00041433-200312000-00003; Patsopoulos NA, 2008, INT J EPIDEMIOL, V37, P1148, DOI 10.1093/ije/dyn065; Salord N, 2013, RESPIROLOGY, V18, P1135, DOI 10.1111/resp.12131; Sanchez-de-la-Torre M, 2012, SLEEP BREATH, V16, P649, DOI 10.1007/s11325-011-0552-7; Simon S, 2012, CHEST, V142, P1645, DOI 10.1378/chest.12-2391; Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0; Sumi K, 2006, QJM-INT J MED, V99, P545, DOI 10.1093/qjmed/hcl074; Takahashi KI, 2008, ANTIOXID REDOX SIGN, V10, P715, DOI 10.1089/ars.2007.1949; Vgontzas AN, 2008, EUR J CLIN INVEST, V38, P585, DOI 10.1111/j.1365-2362.2008.01984.x; West SD, 2007, THORAX, V62, P969, DOI 10.1136/thx.2006.074351; Wolk R, 2005, OBES RES, V13, P186, DOI 10.1038/oby.2005.24; Yoshikawa M, 2014, LUNG, V192, P289, DOI 10.1007/s00408-013-9550-9; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Zhang XL, 2007, CHINESE MED J-PEKING, V120, P1477, DOI 10.1097/00029330-200709010-00002; Zhang XL, 2006, RESPIRATION, V73, P73, DOI 10.1159/000088690	35	8	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2015	10	9							e0136837	10.1371/journal.pone.0136837	http://dx.doi.org/10.1371/journal.pone.0136837			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR8KS	26367527	gold, Green Published, Green Submitted			2023-01-03	WOS:000361601100027
J	Relja, B; Weber, R; Maraslioglu, M; Wagner, N; Borsello, T; Jobin, C; Marzi, I; Lehnert, M				Relja, Borna; Weber, Roxane; Maraslioglu, Miriam; Wagner, Nils; Borsello, Tiziana; Jobin, Christian; Marzi, Ingo; Lehnert, Mark			Differential Relevance of NF-kappa B and JNK in the Pathophysiology of Hemorrhage/Resususcitation-Induced Liver Injury after Chronic Ethanol Feeding	PLOS ONE			English	Article							TERMINAL KINASE PROTECTS; C-JUN; PEPTIDE INHIBITOR; HEMORRHAGIC-SHOCK; INFLAMMATORY RESPONSE; HEPATIC-INJURY; CASPASE-3 ACTIVATION; SIGNAL-TRANSDUCTION; REPERFUSION INJURY; CEREBRAL-ISCHEMIA	Background Chronic ethanol (EtOH) abuse worsens pathophysiological derangements after hemorrhagic shock and resuscitation (H/R) that induce hepatic injury and strong inflammatory changes via JNK and NF-kappa B activation. Inhibiting JNK with a cell-penetrating, proteaseresistant peptide D-JNKI-1 after H/R in mice with healthy livers ameliorated these effects. Here, we studied if JNK inhibition by D-JNKI-1 in chronically EtOH-fed mice after hemorrhagic shock prior to the onset of resuscitation also confers protection. Methods Male mice were fed a Lieber-DeCarli diet containing EtOH or an isocaloric control (ctrl) diet for 4 weeks. Animals were hemorrhaged for 90 min (32 +/- 2 mm Hg) and randomly received either D-JNKI-1 (11 mg/kg, intraperitoneally, i.p.) or sterile saline as vehicle (veh) immediately before the onset of resuscitation. Sham animals underwent surgical procedures without H/R and were either D-JNKI-1 or veh treated. Two hours after resuscitation, blood samples and liver tissue were harvested. Results H/R induced hepatic injury with increased systemic interleukin (IL)-6 levels, and enhanced local gene expression of NF-kappa B-controlled genes such as intercellular adhesion molecule (ICAM)-1 and matrix metallopeptidase (MMP) 9. c-Jun and NF-kappa B phosphorylation were increased after H/R. These effects were further increased in EtOH-fed mice after H/R. D-JNKI-1 application inhibited the proinflammatory changes and reduced significantly hepatic injury after H/R in ctrl-fed mice. Moreover, D-JNKI-1 reduces in ctrl-fed mice the H/R-induced c-Jun and NF-kappa B phosphorylation. However, in chronically EtOH-fed mice, JNK inhibition did not prevent the H/R-induced hepatic damage and proinflammatory changes nor c-Jun and NF-kappa B phosphorylation after H/R. Conclusions These results indicate, that JNK inhibition is protective only in not pre-harmed liver after H/R. In contrast, the pronounced H/R-induced liver damage in mice being chronically fed with ethanol cannot be prevented by JNK inhibition after H/R and seems to be under the control of NF-kappa B.	[Relja, Borna; Weber, Roxane; Maraslioglu, Miriam; Wagner, Nils; Marzi, Ingo; Lehnert, Mark] Goethe Univ Frankfurt, Univ Hosp Frankfurt, Dept Trauma Hand & Reconstruct Surg, D-60054 Frankfurt, Germany; [Borsello, Tiziana] Ist Ric Farmacol Mario Negri, Neuronal Death & Neuroprotect Unit, Milan, Italy; [Jobin, Christian] Univ Florida, Dept Med, Div Gastroenterol Hepatol & Nutr, Gainesville, FL USA	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; State University System of Florida; University of Florida	Relja, B (corresponding author), Goethe Univ Frankfurt, Univ Hosp Frankfurt, Dept Trauma Hand & Reconstruct Surg, D-60054 Frankfurt, Germany.	info@bornarelja.com	Borsello, Tiziana/ABG-7759-2020; Maraslioglu, M./I-8306-2019; Relja, Borna/B-6642-2016; Borsello, Tiziana/J-8232-2016	Maraslioglu, M./0000-0002-2071-2801; Relja, Borna/0000-0002-5625-8823; Borsello, Tiziana/0000-0002-9729-7642	Deutsche Forschungsgemeinschaft (DE) [LE 1346/2-1]	Deutsche Forschungsgemeinschaft (DE)(German Research Foundation (DFG))	This work was supported by the Deutsche Forschungsgemeinschaft (DE) grant nr. LE 1346/2-1.	Aroor AR, 2011, ALCOHOL CLIN EXP RES, V35, P2128, DOI 10.1111/j.1530-0277.2011.01577.x; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Benakis C, 2010, BRAIN BEHAV IMMUN, V24, P800, DOI 10.1016/j.bbi.2009.11.001; Bertelsen M, 2005, ASSAY DRUG DEV TECHN, V3, P261, DOI 10.1089/adt.2005.3.261; Bogner V, 2009, EUR J MED RES, V14, P284, DOI 10.1186/2047-783X-14-7-284; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Bradford BU, 2008, TOXICOL APPL PHARM, V232, P236, DOI 10.1016/j.taap.2008.06.022; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Davoli E, 2014, J PHARMACOL TOX MET, V70, P55, DOI 10.1016/j.vascn.2014.04.001; DECARLI LM, 1967, J NUTR, V91, P331, DOI 10.1093/jn/91.3_Suppl.331; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dietz GPH, 2005, BRAIN RES BULL, V68, P103, DOI 10.1016/j.brainresbull.2005.08.015; Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005; Eshraghi AA, 2007, HEARING RES, V226, P168, DOI 10.1016/j.heares.2006.09.008; Fan CG, 2004, J CLIN INVEST, V113, P746, DOI 10.1172/JCI17337; Greiffenstein P, 2007, ALCOHOL CLIN EXP RES, V31, P704, DOI 10.1111/j.1530-0277.2007.00355.x; Koteish A, 2002, J BIOL CHEM, V277, P13037, DOI 10.1074/jbc.M101632200; Lehnert M, 2008, SHOCK, V30, P159, DOI 10.1097/SHK.0b013e31815dd623; LIEBER CS, 1982, ALCOHOL CLIN EXP RES, V6, P523, DOI 10.1111/j.1530-0277.1982.tb05017.x; Maraslioglu M, 2013, BRIT J PHARMACOL, V170, P506, DOI 10.1111/bph.12224; Maraslioglu M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/808695; Meng ZH, 2001, AM J PHYSIOL-CELL PH, V280, pC343, DOI 10.1152/ajpcell.2001.280.2.C343; Milano G, 2007, AM J PHYSIOL-HEART C, V292, pH1828, DOI 10.1152/ajpheart.01117.2006; Nau C, 2012, INJURY; Ono M, 2004, SHOCK, V21, P519, DOI 10.1097/01.shk.0000126905.75237.07; Pandit V, 2014, J SURG RES, V190, P634, DOI 10.1016/j.jss.2014.04.039; Peden M, 2002, BRIT MED J, V324, P1153, DOI 10.1136/bmj.324.7346.1153; Reinecke K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030985; Relja B, 2012, BRIT J PHARMACOL, V165, P1188, DOI 10.1111/j.1476-5381.2011.01595.x; Relja B, 2014, MEDIAT INFLAMM, V2014, DOI DOI 10.1155/2014/781519; Relja B, 2010, PLANT POLYPHENOLS AT; Relja B, 2013, SCAND J GASTROENTERO, V48, P448, DOI 10.3109/00365521.2013.772228; Relja B, 2011, BRIT J NUTR, V105, P1791, DOI 10.1017/S000711451000560X; Relja B, 2010, SHOCK, V34, P46, DOI 10.1097/SHK.0b013e3181cd8d05; Relja B, 2009, SHOCK, V32, P509, DOI 10.1097/SHK.0b013e3181a2530d; Rensing H, 2001, CRIT CARE MED, V29, P1962, DOI 10.1097/00003246-200110000-00019; Repici M, 2007, NEUROSCIENCE, V150, P40, DOI 10.1016/j.neuroscience.2007.08.021; Rushing GD, 2008, ANN SURG, V247, P929, DOI 10.1097/SLA.0b013e31816757f7; Sabio G, 2014, SEMIN IMMUNOL, V26, P237, DOI 10.1016/j.smim.2014.02.009; Sakran JV, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-64; Shimizu T, 2007, J HEPATOL, V46, P1047, DOI 10.1016/j.jhep.2007.01.019; Szabo G, 2009, ALCOHOL CLIN EXP RES, V33, P220, DOI 10.1111/j.1530-0277.2008.00842.x; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Touchard E, 2010, INVEST OPHTH VIS SCI, V51, P4683, DOI 10.1167/iovs.09-4733; van Meurs M, 2008, SHOCK, V29, P291, DOI 10.1097/shk.0b013e318145a7c1; Wang J, 2003, J NEUROSCI, V23, P8596; Wang XD, 2009, FREE RADICAL BIO MED, V47, P518, DOI 10.1016/j.freeradbiomed.2009.05.021; Wetzel G, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930419	50	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2015	10	9							e0137875	10.1371/journal.pone.0137875	http://dx.doi.org/10.1371/journal.pone.0137875			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR8KS	26367181	Green Published, Green Submitted, gold			2023-01-03	WOS:000361601100164
J	Yin, L; Bian, XH; Wang, X; Chen, M; Wu, J; Xu, JH; Qian, PD; Guo, WJ; Jiang, XS; Zhu, HF; Gu, JJ; Wu, JF; Zhang, YW; He, X				Yin, Li; Bian, Xiu-Hua; Wang, Xue; Chen, Meng; Wu, Jing; Xu, Jian-Hua; Qian, Pu-Dong; Guo, Wen-Jie; Jiang, Xue-Song; Zhu, Huan-Feng; Gu, Jia-Jia; Wu, Jian-Feng; Zhang, Ye-wei; He, Xia			Long-Term Results of Concurrent Chemoradiotherapy for Advanced N2-3 Stage Nasopharyngeal Carcinoma	PLOS ONE			English	Article							INTENSITY-MODULATED RADIOTHERAPY; PHASE-II TRIAL; NECK-CANCER; TREATMENT OUTCOMES; RANDOMIZED-TRIALS; RADIATION-THERAPY; CHEMOTHERAPY; NEDAPLATIN; HEAD; METAANALYSIS	Background N-stage is related to distant metastasis in nasopharyngeal carcinoma (NPC) patients. The purpose of this study was to evaluate the efficacy and toxicity of different nedaplatin-based chemotherapy regimens in advanced N2-3 stage NPC patients treated with intensity modulated radiation therapy (IMRT). Patients and Methods Between April 2005 and December 2009, a total of 128 patients with N2-3 advanced NPC were retrospectively analyzed. Patients were treated with IMRT concurrent with 2 cycles of chemotherapy consisting of either nedaplatin plus paclitaxel (NP group, n = 67) or nedaplatin plus fluorouracil and paclitaxel (NFP group, n = 61). Two to four cycles of adjuvant chemotherapy were then administered every 21 days following concurrent chemoradiotherapy. Results With a median follow-up of 60 months, the 5-year overall survival (OS), progression-free survival (PFS), local-regional recurrence-free survival (LRRFS), and distant metastasis-free survival (DMFS) for all patients were 81.4%, 71.5%, 87.8% and 82.0%, respectively. No significant difference in PFS (66.6% vs. 76.7%, P = 0.212) and LRRFS rates (89.0% vs. 86.3%, P = 0.664) was observed between the NP and NFP groups. The 5-year OS (75.4% vs. 88.5%, P = 0.046) and DMFS (75.1% vs. 89.0%, P = 0.042) rate were superior in the NFP group compared with the NP group. The NFP group had a higher incidence of grade 3-4 acute toxicities including bone marrow suppression (leukopenia: chi(2) = 3.935, P = 0.047; anemia: chi(2) = 9.760, P = 0.002; thrombocytopenia: chi(2) = 8.821, P = 0.003), and both liver and renal dysfunction (chi(2) = 5.206, P = 0.023) compared with the NP group. Late toxicities were moderate and no difference was observed between the two groups. Conclusion IMRT concurrent with nedaplatin-based chemotherapy is an advocated regimen for patients with advanced N2-3 stage NPC. Patients with advanced N2-3 stage may be better candidates for the NFP regimen although this regimen was associated with a high acute toxicity rate.	[Yin, Li; Bian, Xiu-Hua; Chen, Meng; Wu, Jing; Xu, Jian-Hua; Qian, Pu-Dong; Guo, Wen-Jie; Jiang, Xue-Song; Zhu, Huan-Feng; Gu, Jia-Jia; Wu, Jian-Feng; He, Xia] Nanjing Med Univ, Affiliated Jiangsu Canc Hosp, Dept Radiat Oncol, Nanjing, Jiangsu, Peoples R China; [Yin, Li; Bian, Xiu-Hua; Chen, Meng; Wu, Jing; Xu, Jian-Hua; Qian, Pu-Dong; Guo, Wen-Jie; Jiang, Xue-Song; Zhu, Huan-Feng; Gu, Jia-Jia; Wu, Jian-Feng; Zhang, Ye-wei; He, Xia] Nanjing Med Univ, Jiangsu Inst Canc Res, Nanjing, Jiangsu, Peoples R China; [Wang, Xue] Jilin Canc Hosp, Dept Radiat Oncol, Changchun, Peoples R China; [Zhang, Ye-wei] Nanjing Med Univ, Affiliated Jiangsu Canc Hosp, Dept Hepatobiliary & Pancreat Surg, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University	He, X (corresponding author), Nanjing Med Univ, Affiliated Jiangsu Canc Hosp, Dept Radiat Oncol, Nanjing, Jiangsu, Peoples R China.	hexia200302@tom.com	Qian, Pu/GZM-2400-2022		JiangSu Clinical medicine Science and Technology Special Fund [BL2014091]; JiangSu Provincial Commission of Health and Family Planning Young Scholars Award [Q201501]	JiangSu Clinical medicine Science and Technology Special Fund; JiangSu Provincial Commission of Health and Family Planning Young Scholars Award	This research was supported by grants from the JiangSu Clinical medicine Science and Technology Special Fund (No:BL2014091, http://www.jstd.gov.cn/), the JiangSu Provincial Commission of Health and Family Planning Young Scholars Award (Q201501, http://www.jswst.gov.cn/jsswshjhsywyh/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Sarraf M, 1998, J CLIN ONCOL, V16, P1310, DOI 10.1200/JCO.1998.16.4.1310; Argiris A, 2011, ANN ONCOL, V22, P773, DOI 10.1093/annonc/mdq426; Bae WK, 2010, CANCER CHEMOTH PHARM, V65, P589, DOI 10.1007/s00280-009-1152-0; Baujat B, 2006, INT J RADIAT ONCOL, V64, P47, DOI 10.1016/j.ijrobp.2005.06.037; Hui EP, 2009, J CLIN ONCOL, V27, P242, DOI 10.1200/JCO.2008.18.1545; Ji XM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056208; Kalogera-Fountzila A, 2006, STRAHLENTHER ONKOL, V182, P458, DOI 10.1007/s00066-006-1538-4; Kodaira T, 2006, ANTICANCER RES, V26, P2265; Kong Lin, 2010, Chin J Cancer, V29, P551; Lai SZ, 2011, INT J RADIAT ONCOL, V80, P661, DOI 10.1016/j.ijrobp.2010.03.024; Langendijk JA, 2004, J CLIN ONCOL, V22, P4604, DOI 10.1200/JCO.2004.10.074; Lee AWM, 2012, SEMIN RADIAT ONCOL, V22, P233, DOI 10.1016/j.semradonc.2012.03.008; Lee AWM, 2010, JNCI-J NATL CANCER I, V102, P1188, DOI 10.1093/jnci/djq258; Lee N, 2009, J CLIN ONCOL, V27, P3684, DOI 10.1200/JCO.2008.19.9109; Leung TW, 2005, HEAD NECK-J SCI SPEC, V27, P555, DOI 10.1002/hed.20189; Li XX, 2013, 2013 SEVENTH INTERNATIONAL CONFERENCE ON INTERNET COMPUTING FOR ENGINEERING AND SCIENCE (ICICSE 2013), P48, DOI 10.1109/ICICSE.2013.17; Lo KW, 2012, SEMIN CANCER BIOL, V22, P79, DOI 10.1016/j.semcancer.2011.12.011; Lorch JH, 2011, LANCET ONCOL, V12, P153, DOI 10.1016/S1470-2045(10)70279-5; Ma J, 2001, INT J RADIAT ONCOL, V50, P1181, DOI 10.1016/S0360-3016(01)01537-1; Ohashi T, 2011, JPN J CLIN ONCOL, V41, P348, DOI 10.1093/jjco/hyq196; Shen ZT, 2013, WORLD J GASTROENTERO, V19, P9447, DOI 10.3748/wjg.v19.i48.9447; Shenouda G, 2015, INT J RADIAT ONCOL, V91, P907, DOI 10.1016/j.ijrobp.2014.12.018; Sun XM, 2014, RADIOTHER ONCOL, V110, P398, DOI 10.1016/j.radonc.2013.10.020; Sun XM, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-265; Wong FCS, 2010, INT J RADIAT ONCOL, V76, P138, DOI 10.1016/j.ijrobp.2009.01.084; Wu F, 2014, RADIOTHER ONCOL, V112, P106, DOI 10.1016/j.radonc.2014.05.005; Xu JH, 2013, CANCER RADIOTHER, V17, P297, DOI 10.1016/j.canrad.2013.03.006; Xu JH, 2014, HEAD NECK-J SCI SPEC, V36, P1474, DOI 10.1002/hed.23487; Zhang L, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-558	29	4	5	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2015	10	9							e0137383	10.1371/journal.pone.0137383	http://dx.doi.org/10.1371/journal.pone.0137383			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR8KS	26367317	Green Submitted, Green Published, gold			2023-01-03	WOS:000361601100067
J	Qi, Y; Dai, XF; Zhang, H; He, Y; Zhang, YY; Han, JJ; Zhu, P; Zhang, YX; Zheng, QX; Li, X; Zhao, C; Pang, JJ				Qi, Yan; Dai, Xufeng; Zhang, Hua; He, Ying; Zhang, Yangyang; Han, Juanjuan; Zhu, Ping; Zhang, Yuxin; Zheng, Qinxiang; Li, Xia; Zhao, Chen; Pang, Jijing			Trans-Corneal Subretinal Injection in Mice and Its Effect on the Function and Morphology of the Retina	PLOS ONE			English	Article							MEDIATED GENE-THERAPY; MOUSE MODEL; RD10 MOUSE; IN-VIVO; DEGENERATION; VECTOR; PHOTORECEPTOR; VISION; RESCUE; TRANSDUCTION	Purpose To introduce a practical method of subretinal injection in mice and evaluate injection-induced retinal detachment (RD) and damage using a dynamic imaging system, electrophysiology, and histology. Methods After full dilation of a 2-month-old C57BL/6J mouse pupil, the cornea near the limbus was punctured with a 30 1/2-gague disposable beveled needle. A 33 1/2-gauge blunt needle was inserted through the corneal perforation into the anterior chamber, avoiding the lens before going deeper into the vitreous cavity, and penetrating the inner retina to reach the subretinal space. The mice were divided into four groups: in group 1, about 80-100% of the retina was filled with subretinally injected solution; in group 2, approximately 50-70% of the retina was filled with injected solution; in group 3, the procedures were stopped before solution injection; and non-injected eyes were used as the negative control in group 4. An optical coherence tomography (OCT) imaging system was used to monitor retinal reattachment during the first three days following the injections. Histological and functional changes were examined by light microscopy and electroretinography (ERG) at five weeks post-injection. Results After a short-term training, a 70% success rate with 50% or more coverage (i.e., retinal blebs occupied 50% or more retinal area and filled with the injected solution) with minimal injection-related damages can be achieved. Bleb formation was associated with retinal detachment (RD) between the neuroretina and the retinal pigment epithelium (RPE) layer. Partial RD could be observed at post-injection day 1, and by day 2 most of the retina had reattached. At 5 weeks post-injection, compared to uninjected control group 4, the b-wave amplitudes of ERG decreased 22% in group 1, 16% in group 2, and 7% in group 3; the b-wave amplitudes were statistically different between the uninjected group and the groups with either 50-70% or 80-100% coverage. The subretinal injection-induced RD reattached and became stable at five weeks post-injection, although some photoreceptor damage could still be observed in and around the injection sites, especially in 80-100% coverage group. Conclusions Trans-corneal subretinal injection is effective and practical, although subretinal injection-related damages can cause some morphological and functional loss.	[Qi, Yan; Dai, Xufeng; Zhang, Hua; He, Ying; Zhang, Yangyang; Han, Juanjuan; Zheng, Qinxiang; Pang, Jijing] Wenzhou Med Univ, Hosp Eye, Sch Ophthalmol & Optometry, Wenzhou, Zhejiang, Peoples R China; [Han, Juanjuan] Shanxi Med Univ, Fenyang Coll, Fenyang, Shanxi, Peoples R China; [Zhu, Ping; Zhang, Yuxin; Pang, Jijing] Univ Florida, Coll Med, Dept Ophthalmol, Gainesville, FL 32610 USA; [Zhang, Yuxin; Zhao, Chen; Pang, Jijing] Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanjing, Jiangsu, Peoples R China; [Li, Xia] Guangxi Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanning, Guangxi, Peoples R China	Wenzhou Medical University; Shanxi Medical University; State University System of Florida; University of Florida; Nanjing Medical University; Guangxi Medical University	Pang, JJ (corresponding author), Wenzhou Med Univ, Hosp Eye, Sch Ophthalmol & Optometry, Wenzhou, Zhejiang, Peoples R China.	jpangoph@hotmail.com	zhang, yangyang/GZG-7467-2022		National Natural Science Foundation of China [81371060, 81260155]; Wenzhou Medical University, Wenzhou, China [QTJ11018]; Wenzhou Science and Technology Bureau, China [Y20140352, Y20140355]; NIH [EY023543, EY021721]; UF FEO award; FFB; MVRF; RPB Inc.; Jiangsu Province Foundation for Research Innovative Team; NATIONAL EYE INSTITUTE [R21EY023543, R21EY018331, P30EY021721] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Wenzhou Medical University, Wenzhou, China; Wenzhou Science and Technology Bureau, China; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UF FEO award; FFB; MVRF; RPB Inc.; Jiangsu Province Foundation for Research Innovative Team; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	Supported by grants from the National Natural Science Foundation of China (81371060 and 81260155), a retinal gene therapy study grant from Wenzhou Medical University, Wenzhou, China (QTJ11018), scientific research funds from Wenzhou Science and Technology Bureau, China (Y20140352 and Y20140355), the Jiangsu Province Foundation for Research Innovative Team, NIH grants EY023543, EY021721, UF FEO award, FFB, MVRF, and RPB Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baker SA, 2013, CURR TOP MEMBR, V72, P231, DOI 10.1016/B978-0-12-417027-8.00007-6; Bennett J, 1996, NAT MED, V2, P649, DOI 10.1038/nm0696-649; Cideciyan AV, 2009, NEW ENGL J MED, V361, P725, DOI 10.1056/NEJMc0903652; Cideciyan AV, 2008, P NATL ACAD SCI USA, V105, P15112, DOI 10.1073/pnas.0807027105; Dai XF, 2014, INVEST OPHTH VIS SCI, V55, P1724, DOI 10.1167/iovs.13-13654; Gouras P, 2002, INVEST OPHTH VIS SCI, V43, P3307; Jacobson SG, 2012, ARCH OPHTHALMOL-CHIC, V130, P9, DOI 10.1001/archophthalmol.2011.298; Kong FS, 2010, EXP EYE RES, V90, P546, DOI 10.1016/j.exer.2010.01.011; Lai Chooi-May, 2004, Genet Vaccines Ther, V2, P3, DOI 10.1186/1479-0556-2-3; Li WS, 2009, MOL VIS, V15, P267; Li X, 2011, INVEST OPHTH VIS SCI, V52, P7, DOI 10.1167/iovs.10-6138; Mao HY, 2012, HUM GENE THER, V23, P356, DOI 10.1089/hum.2011.213; Nour M, 2003, INVEST OPHTH VIS SCI, V44, P4505, DOI 10.1167/iovs.03-0453; Pang J, 2010, GENE THER, V17, P815, DOI 10.1038/gt.2010.29; Pang JJ, 2008, INVEST OPHTH VIS SCI, V49, P4278, DOI 10.1167/iovs.07-1622; Pang JJ, 2008, VISION RES, V48, P377, DOI 10.1016/j.visres.2007.08.009; Pang JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035250; Pang JJ, 2011, MOL THER, V19, P234, DOI 10.1038/mt.2010.273; Pang JJ, 2006, MOL VIS, V12, P756; Pang JJ, 2006, MOL THER, V13, P565, DOI 10.1016/j.ymthe.2005.09.001; Stieger K, 2010, CURR OPIN MOL THER, V12, P471; Takahashi M, 1999, J VIROL, V73, P7812, DOI 10.1128/JVI.73.9.7812-7816.1999; Timmers A, 2001, MOL VIS, V7, P131; Wert KJ, 2012, JOVE-J VIS EXP, DOI 10.3791/4286; Yao HL, 2014, NEURAL REGEN RES, V9, P1047, DOI 10.4103/1673-5374.133169; Zeng R, 2012, INVEST OPHTH VIS SCI, V53, P1685, DOI 10.1167/iovs.11-8241; Zheng QX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044855	27	27	29	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2015	10	8							e0136523	10.1371/journal.pone.0136523	http://dx.doi.org/10.1371/journal.pone.0136523			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ0PO	26317758	Green Published, Green Submitted, gold			2023-01-03	WOS:000360299100095
J	Raiten, JM				Raiten, Jesse M.			Lessons of the Gacaca	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA	University of Pennsylvania	Raiten, JM (corresponding author), Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA.	j.raiten@gmail.com						[Anonymous], UNDP IN RWAND; Clover J, IMPROVING ACCESS ED; Gundersen I, UMUGANDA TOOL RECONC; Ingelaere B, GACACA COURTS RWANDA; Umuganda, UM	5	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	2015	314	5					451	452		10.1001/jama.2015.6829	http://dx.doi.org/10.1001/jama.2015.6829			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CO1OI	26241595				2023-01-03	WOS:000358924500008
J	Su, Z; Robinson, A; Hu, L; Klein, JD; Hassounah, F; Li, M; Wang, HD; Cai, H; Wang, XNH				Su, Zhen; Robinson, Alayna; Hu, Li; Klein, Janet D.; Hassounah, Faten; Li, Min; Wang, Haidong; Cai, Hui; Wang, Xiaonan H.			Acupuncture plus Low-Frequency Electrical Stimulation (Acu-LFES) Attenuates Diabetic Myopathy by Enhancing Muscle Regeneration	PLOS ONE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; PROTEIN-DEGRADATION; PROTEOLYSIS; ACTIVATION; EXERCISE; PATHWAY; ATROPHY; DYSFUNCTION; EXPRESSION; INHIBITOR	Mortality and morbidity are increased in patients with muscle atrophy resulting from catabolic diseases such as diabetes. At present there is no pharmacological treatment that successfully reverses muscle wasting from catabolic conditions. We hypothesized that acupuncture plus low frequency electric stimulation (Acu-LFES) would mimic the impact of exercise and prevent diabetes-induced muscle loss. Streptozotocin (STZ) was used to induce diabetes in mice. The mice were then treated with Acu-LFES for 15 minutes daily for 14 days. Acupuncture points were selected according to the WHO Standard Acupuncture Nomenclature guide. The needles were connected to an SDZ-II electronic acupuncture device delivering pulses at 20Hz and 1mA. Acu-LFES prevented soleus and EDL muscle weight loss and increased hind-limb muscle grip function in diabetic mice. Muscle regeneration capacity was significantly increased by Acu-LFES. The expression of Pax7, MyoD, myogenin and embryo myosin heavy chain (eMyHC) was significantly decreased in diabetic muscle vs. control muscle. The suppressed levels in diabetic muscle were reversed by Acu-LFES. The IGF-1 signaling pathway was also upregulated by Acu-LFES. Phosphorylation of Akt, mTOR and p70S6K were downregulated by diabetes leading to a decline in muscle mass, however, Acu-LFES countered the diabetes-induced decline. In addition, microRNA-1 and -206 were increased by Acu-LFES after 24 days of treatment. We conclude that Acu-LFES is effective in counteracting diabetes-induced skeletal muscle atrophy by increasing IGF-1 and its stimulation of muscle regeneration.	[Su, Zhen] Wenzhou Med Univ, Affiliated Hosp 1, Dept Nephrol, Wenzhou, Zhejiang, Peoples R China; [Hu, Li] Shanghai Univ Tradit Chinese Med, Coll Acumox & Tuina, Acumox & Tuina Res Sect, Shanghai, Peoples R China; [Su, Zhen; Robinson, Alayna; Hu, Li; Klein, Janet D.; Hassounah, Faten; Li, Min; Wang, Haidong; Cai, Hui; Wang, Xiaonan H.] Emory Univ, Dept Med, Div Renal, Atlanta, GA 30322 USA	Wenzhou Medical University; Shanghai University of Traditional Chinese Medicine; Emory University	Wang, XNH (corresponding author), Emory Univ, Dept Med, Div Renal, Atlanta, GA 30322 USA.	xwang03@emory.edu			NIAMS [R01 AR060268]; National Natural Science Foundation of China [30871179]; Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR060268] Funding Source: NIH RePORTER	NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	NIAMS R01 AR060268 to XW (PI), National Natural Science Foundation of China (30871179) to ZS (PI), and Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents to ZS (PI).	Brack AS, 2012, CELL STEM CELL, V10, P504, DOI 10.1016/j.stem.2012.04.001; Butterfield GE, 1997, AM J PHYSIOL-ENDOC M, V272, pE94, DOI 10.1152/ajpendo.1997.272.1.E94; Caron AZ, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-185; Chen Y, 2008, KIDNEY INT, V73, P848, DOI 10.1038/sj.ki.5002801; Cirak S, 2011, LANCET, V378, P595, DOI 10.1016/S0140-6736(11)60756-3; Cohn RD, 2007, NAT MED, V13, P204, DOI 10.1038/nm1536; D'Souza DM, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00379; Eddins MJ, 2011, CELL BIOCHEM BIOPHYS, V60, P113, DOI 10.1007/s12013-011-9175-7; Ernst G, 2003, COMPLEMENT THER MED, V11, P93, DOI 10.1016/S0965-2299(03)00004-9; Gagan J, 2012, J BIOL CHEM, V287, P40360, DOI 10.1074/jbc.M112.378414; Goljanek-Whysall K, 2012, J CELL SCI, V125, P3590, DOI 10.1242/jcs.101758; Grefte S, 2007, STEM CELLS DEV, V16, P857, DOI 10.1089/scd.2007.0058; Griffiths RD, 1996, NUTRITION, V12, P456, DOI 10.1016/S0899-9007(96)00141-4; Hu JP, 2008, ENDOCRINOLOGY, V149, P5384, DOI 10.1210/en.2008-0132; Hu JP, 2010, J AM SOC NEPHROL, V21, P1174, DOI 10.1681/ASN.2009101011; Hu L, 2015, J AM SOC NEPHROL, V26, P626, DOI 10.1681/ASN.2014020144; Hu ZY, 2014, AGING-US, V6, P160, DOI 10.18632/aging.100643; Hua YN, 2012, J CELL MOL MED, V16, P83, DOI 10.1111/j.1582-4934.2011.01307.x; Jamart C, 2011, MUSCLE NERVE, V43, P708, DOI 10.1002/mus.21949; Kopple JD, 2007, J AM SOC NEPHROL, V18, P2975, DOI 10.1681/ASN.2006070794; Lam DW, 2012, CURR OPIN ENDOCRINOL, V19, P93, DOI 10.1097/MED.0b013e328350583a; Lee SW, 2004, J AM SOC NEPHROL, V15, P1537, DOI 10.1097/01.ASN.0000127211.86206.E1; Lim S, 2010, EVID-BASED COMPL ALT, V7, P167, DOI 10.1093/ecam/nep006; Lin RT, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/371475; Liu N, 2012, J CLIN INVEST, V122, P2054, DOI 10.1172/JCI62656; Macdonald JH, 2007, NEPHRON CLIN PRACT, V106, P125, DOI 10.1159/000103000; MacPherson H, 2001, BMJ-BRIT MED J, V323, P486, DOI 10.1136/bmj.323.7311.486; Majchrzak KM, 2008, NEPHROL DIAL TRANSPL, V23, P1362, DOI 10.1093/ndt/gfm773; Man KM, 2011, EUR J ANAESTH, V28, P420, DOI 10.1097/EJA.0b013e32833fad52; Nakasa T, 2010, J CELL MOL MED, V14, P2495, DOI 10.1111/j.1582-4934.2009.00898.x; Onda A, 2011, BIOCHEM BIOPH RES CO, V410, P434, DOI 10.1016/j.bbrc.2011.05.152; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Song YH, 2005, J CLIN INVEST, V115, P451, DOI 10.1172/JCI200522324; Takaoka Y, 2007, PHYSIOL GENOMICS, V30, P102, DOI 10.1152/physiolgenomics.00057.2006; Ten Broek RW, 2010, J CELL PHYSIOL, V224, P7, DOI 10.1002/jcp.22127; Wang XH, 2007, GENE THER, V14, P711, DOI 10.1038/sj.gt.3302927; Wang XN, 2006, ENDOCRINOLOGY, V147, P4160, DOI 10.1210/en.2006-0251; Wang XNH, 2014, NAT REV NEPHROL, V10, P504, DOI 10.1038/nrneph.2014.112; Wang XNH, 2013, INT J BIOCHEM CELL B, V45, P2230, DOI 10.1016/j.biocel.2013.06.027; Wang XNH, 2013, CURR OPIN CLIN NUTR, V16, P258, DOI 10.1097/MCO.0b013e32835f81b9; Wang XNH, 2009, KIDNEY INT, V76, P751, DOI 10.1038/ki.2009.260; WINDSOR JA, 1988, ANN SURG, V208, P209, DOI 10.1097/00000658-198808000-00013; Zhang LP, 2013, CELL METAB, V18, P368, DOI 10.1016/j.cmet.2013.07.012; Zhang LP, 2011, FASEB J, V25, P1653, DOI 10.1096/fj.10-176917; Zhang LP, 2010, J AM SOC NEPHROL, V21, P419, DOI 10.1681/ASN.2009060571; Zhou Q, 2007, ENDOCRINOLOGY, V148, P5696, DOI 10.1210/en.2007-0183	46	31	35	2	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2015	10	7							e0134511	10.1371/journal.pone.0134511	http://dx.doi.org/10.1371/journal.pone.0134511			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO0JY	26230945	Green Published, gold			2023-01-03	WOS:000358838400129
J	Hirsch, C				Hirsch, Calvin			Review: Multicomponent nonpharmacologic interventions reduce incident delirium in inpatients	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Calif Davis, Sacramento, CA 95817 USA	University of California System; University of California Davis	Hirsch, C (corresponding author), Univ Calif Davis, Sacramento, CA 95817 USA.							Rothberg MB, 2013, J AM GERIATR SOC, V61, P923, DOI 10.1111/jgs.12253; Yue JR, 2014, J AM GERIATR SOC, V62, P754, DOI 10.1111/jgs.12768; Zhang H, 2013, CRIT CARE, V17, DOI 10.1186/cc12566	3	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 21	2015	163	2							JC4	10.7326/ACPJC-2015-163-2-004	http://dx.doi.org/10.7326/ACPJC-2015-163-2-004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CN4NS	26192584				2023-01-03	WOS:000358407500004
J	Lancaster, T; Cahill, K				Lancaster, Tim; Cahill, Kate			Review: Varenicline does not differ from placebo for adverse neuropsychiatric events	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Lancaster, Tim; Cahill, Kate] Univ Oxford, Oxford, England	University of Oxford	Lancaster, T (corresponding author), Univ Oxford, Oxford, England.			Lancaster, Timothy Ross/0000-0002-0580-1099				Cahill K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009329.pub2, 10.1002/14651858.CD006103.pub6]; Pfizer, STUD EV SAF EFF VAR	2	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 21	2015	163	2							JC6	10.7326/ACPJC-2015-163-2-006	http://dx.doi.org/10.7326/ACPJC-2015-163-2-006			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CN4NS	26192586				2023-01-03	WOS:000358407500006
J	Kitagawa, H; Munekage, M; Ichikawa, K; Fukudome, I; Munekage, E; Takezaki, Y; Matsumoto, T; Igarashi, Y; Hanyu, H; Hanazaki, K				Kitagawa, Hiroyuki; Munekage, Masaya; Ichikawa, Kengo; Fukudome, Ian; Munekage, Eri; Takezaki, Yuka; Matsumoto, Takashi; Igarashi, Yasushi; Hanyu, Haruo; Hanazaki, Kazuhiro			Pharmacokinetics of Active Components of Yokukansan, a Traditional Japanese Herbal Medicine after a Single Oral Administration to Healthy Japanese Volunteers: A Cross-Over, Randomized Study	PLOS ONE			English	Article							GLYCYRRHETIC ACID; PSYCHOLOGICAL SYMPTOMS; RATS; DEMENTIA; LICORICE; DECOCTION; KAMPO; ROOT	Context Yokukansan (YKS) is a traditional Japanese herbal medicine called kampo medicine in Japan. Its extract comprises seven crude drugs: Atractylodis lanceae rhizoma, Poria, Cnidii rhizoma, Uncariae uncis cum ramulus, Angelicae radix, Bupleuri radix, and Glycyrrhizae radix. YKS is used to treat neurosis, insomnia, as well as behavioral and psychological symptoms of dementia. Objective To confirm the exposure and pharmacokinetics of the active components of YKS in healthy volunteers. Design, Setting, and Participants A randomized, open-label, 3-arm, 3-period, crossover trial was conducted on 21 healthy Japanese volunteers at the Kochi Medical University between May 2012 and November 2012. Interventions Single oral administration of YKS (2.5 g, 5.0 g, or 7.5 g/day) during each period. Main Outcome Measure Plasma concentrations of three active compounds in YKS, namely 18 beta-glycyrrhetinic acid (GA), geissoschizine methyl ether (GM), and hirsuteine (HTE). Results The mean maximum plasma concentrations (C-max) of GM and HTE increased dose-dependently (ranges: 0.650-1.98 ng/mL and 0.138-0.450 ng/mL, respectively). The times to maximum plasma concentration after drug administration (t(max)) were 0.500 h for GM and 0.975-1.00 h for HTE. The apparent elimination half-lives (t(1/2)) were 1.72-1.95 h for GM and 2.47-3.03 h for HTE. These data indicate the rapid absorption and elimination of GM and HTE. On the other hand, the C-max, t(max), and t(1/2) of GA were 57.7-108 ng/mL, 8.00-8.01 h, and 9.39-12.3 h, respectively. Conclusion We demonstrated that pharmacologically active components of YKS are detected in humans. Further, we determined the pharmacokinetics of GM, HTE, and GA. This information will be useful to elucidate the pharmacological effects of YKS.	[Kitagawa, Hiroyuki; Munekage, Masaya; Fukudome, Ian; Munekage, Eri; Takezaki, Yuka; Hanazaki, Kazuhiro] Kochi Univ, Kochi Med Sch, Dept Surg, Kochi 780, Japan; [Ichikawa, Kengo] Gifu Univ, Sch Med, Dept Surg Oncol, Gifu 500, Japan; [Matsumoto, Takashi] Tsumura & Co, Kampo Sci Strategies Div, Tsumura Res Labs, Ibaraki, Japan; [Igarashi, Yasushi] Tsumura & Co, Kampo Sci Strategies Div, Kampo Formulat Dev Ctr, Ibaraki, Japan; [Hanyu, Haruo] Tokyo Med Univ, Dept Elderly Gen Med, Tokyo 1608402, Japan	Kochi University; Gifu University; Tsumura & Company; Tsumura & Company; Tokyo Medical University	Matsumoto, T (corresponding author), Tsumura & Co, Kampo Sci Strategies Div, Tsumura Res Labs, Ibaraki, Japan.	matsumoto_takashi@mail.tsumura.co.jp			Tsumura Co.	Tsumura Co.(Tsumura & Company)	Tsumura & Co. provided support in the form of salaries for authors TM and YI. This study was funded by Tsumura & Co., which was responsible for the study design, and the collection, analysis and interpretation of data.	CANTELLIFORTI G, 1994, ENVIRON HEALTH PERSP, V102, P65, DOI 10.1289/ehp.94102s965; Egashira N, 2008, PROG NEURO-PSYCHOPH, V32, P1516, DOI 10.1016/j.pnpbp.2008.05.010; GOLDSTEIN JA, 1994, PHARMACOGENETICS, V4, P285, DOI 10.1097/00008571-199412000-00001; Gough K., 1995, DRUG INF J, V29, P1039, DOI [10.1177/009286159502900324, DOI 10.1177/009286159502900324]; HATTORI M, 1983, PLANTA MED, V48, P38, DOI 10.1055/s-2007-969875; Hou YC, 2005, LIFE SCI, V76, P1167, DOI 10.1016/j.lfs.2004.10.020; Imamura S, 2011, CELL MOL NEUROBIOL, V31, P787, DOI 10.1007/s10571-011-9676-3; Iwasaki K, 2012, PSYCHOGERIATRICS, V12, P235, DOI 10.1111/j.1479-8301.2012.00413.x; Kawakami Z, 2009, NEUROSCIENCE, V159, P1397, DOI 10.1016/j.neuroscience.2009.02.004; Kawakami Z, 2010, EUR J PHARMACOL, V626, P154, DOI 10.1016/j.ejphar.2009.09.046; KRAHENBUHL S, 1994, STEROIDS, V59, P121, DOI 10.1016/0039-128X(94)90088-4; Kushida H, 2013, BIOMED CHROMATOGR, V27, P1647, DOI 10.1002/bmc.2974; Matsuda Y, 2013, HUM PSYCHOPHARM CLIN, V28, P80, DOI 10.1002/hup.2286; Miyamura M, 1996, YAKUGAKU ZASSHI, V116, P209, DOI 10.1248/yakushi1947.116.3_209; Mizuhara Y, 2005, BIOL PHARM BULL, V28, P1897, DOI 10.1248/bpb.28.1897; Mizukami K, 2009, INT J NEUROPSYCHOPH, V12, P191, DOI 10.1017/S146114570800970X; Nakazawa T, 2006, BIOL PHARM BULL, V29, P1671, DOI 10.1248/bpb.29.1671; Nishi A, 2012, NEUROSCIENCE, V207, P124, DOI 10.1016/j.neuroscience.2012.01.037; Raggi M A, 1994, Boll Chim Farm, V133, P704; Smith BP, 2000, PHARMACEUT RES, V17, P1278, DOI 10.1023/A:1026451721686; Tabuchi M, 2012, CELL MOL NEUROBIOL, V32, P1139, DOI 10.1007/s10571-012-9839-x; Takeda A, 2008, NEUROCHEM INT, V53, P230, DOI 10.1016/j.neuint.2008.07.009; Takeda S, 1996, J PHARM PHARMACOL, V48, P902, DOI 10.1111/j.2042-7158.1996.tb05998.x; TERASAWA K, 1986, J PHARMACOBIO-DYNAM, V9, P95; Terawaki K, 2010, J ETHNOPHARMACOL, V127, P306, DOI 10.1016/j.jep.2009.11.003; Xu CH, 2013, J ETHNOPHARMACOL, V149, P443, DOI 10.1016/j.jep.2013.06.049	26	23	23	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2015	10	7							e0131165	10.1371/journal.pone.0131165	http://dx.doi.org/10.1371/journal.pone.0131165			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1EC	26151135	gold, Green Published, Green Submitted			2023-01-03	WOS:000358158900018
J	Kaptchuk, TJ; Miller, FG				Kaptchuk, Ted J.; Miller, Franklin G.			Placebo Effects in Medicine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Kaptchuk, Ted J.] Beth Israel Deaconess Med Ctr, Program Placebo Studies, Boston, MA 02215 USA; [Kaptchuk, Ted J.] Harvard Univ, Sch Med, Boston, MA USA; [Miller, Franklin G.] NIH, Ctr Clin, Dept Bioeth, Bethesda, MD 20892 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Kaptchuk, TJ (corresponding author), Beth Israel Deaconess Med Ctr, Program Placebo Studies, Boston, MA 02215 USA.							Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2; Hall KT, 2015, TRENDS MOL MED, V21, P285, DOI 10.1016/j.molmed.2015.02.009; Kam-Hansen S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3006175; Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25; Wechsler ME, 2011, NEW ENGL J MED, V365, P119, DOI 10.1056/NEJMoa1103319	5	255	259	0	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	2015	373	1					8	9		10.1056/NEJMp1504023	http://dx.doi.org/10.1056/NEJMp1504023			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CL8IS	26132938				2023-01-03	WOS:000357218700003
J	Hu, CMJ; Fang, RH; Wang, KC; Luk, BT; Thamphiwatana, S; Dehaini, D; Nguyen, P; Angsantikul, P; Wen, CH; Kroll, AV; Carpenter, C; Ramesh, M; Qu, V; Patel, SH; Zhu, J; Shi, W; Hofman, FM; Chen, TC; Gao, WW; Zhang, K; Chien, S; Zhang, LF				Hu, Che-Ming J.; Fang, Ronnie H.; Wang, Kuei-Chun; Luk, Brian T.; Thamphiwatana, Soracha; Dehaini, Diana; Phu Nguyen; Angsantikul, Pavimol; Wen, Cindy H.; Kroll, Ashley V.; Carpenter, Cody; Ramesh, Manikantan; Qu, Vivian; Patel, Sherrina H.; Zhu, Jie; Shi, William; Hofman, Florence M.; Chen, Thomas C.; Gao, Weiwei; Zhang, Kang; Chien, Shu; Zhang, Liangfang			Nanoparticle biointerfacing by platelet membrane cloaking	NATURE			English	Article							POLYMERIC NANOPARTICLES; BACTERIAL PATHOGENS; BLOOD-PLATELETS; SURFACE; COMPLEMENT; DELIVERY; EXPRESSION; BINDING; PROTEIN; TOXINS	Development of functional nanoparticles can be encumbered by unanticipated material properties and biological events, which can affect nanoparticle effectiveness in complex, physiologically relevant systems(1-3). Despite the advances in bottom-up nanoengineering and surface chemistry, reductionist functionalization approaches remain inadequate in replicating the complex interfaces present in nature and cannot avoid exposure of foreign materials. Here we report on the preparation of polymeric nanoparticles enclosed in the plasma membrane of human platelets, which are a unique population of cellular fragments that adhere to a variety of disease-relevant substrates(4-7). The resulting nanoparticles possess a right-side-out unilamellar membrane coating functionalized with immunomodulatory and adhesion antigens associated with platelets. Compared to uncoated particles, the platelet membrane-cloaked nanoparticles have reduced cellular uptake by macrophage-like cells and lack particle-induced complement activation in autologous human plasma. The cloaked nanoparticles also display platelet-mimicking properties such as selective adhesion to damaged human and rodent vasculatures as well as enhanced binding to platelet-adhering pathogens. In an experimental rat model of coronary restenosis and a mouse model of systemic bacterial infection, docetaxel and vancomycin, respectively, show enhanced therapeutic efficacy when delivered by the platelet-mimetic nanoparticles. The multifaceted biointerfacing enabled by the platelet membrane cloaking method provides a new approach in developing functional nanoparticles for disease-targeted delivery.	[Hu, Che-Ming J.; Fang, Ronnie H.; Thamphiwatana, Soracha; Dehaini, Diana; Angsantikul, Pavimol; Kroll, Ashley V.; Carpenter, Cody; Ramesh, Manikantan; Qu, Vivian; Gao, Weiwei; Zhang, Kang; Zhang, Liangfang] Univ Calif San Diego, Dept NanoEngn, La Jolla, CA 92093 USA; [Hu, Che-Ming J.; Fang, Ronnie H.; Luk, Brian T.; Thamphiwatana, Soracha; Dehaini, Diana; Angsantikul, Pavimol; Kroll, Ashley V.; Gao, Weiwei; Zhang, Liangfang] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Wang, Kuei-Chun; Luk, Brian T.; Phu Nguyen; Chien, Shu] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; [Wang, Kuei-Chun; Phu Nguyen; Zhang, Kang; Chien, Shu; Zhang, Liangfang] Univ Calif San Diego, Inst Engn Med, La Jolla, CA 92093 USA; [Wen, Cindy H.; Patel, Sherrina H.; Zhu, Jie; Zhang, Kang] Univ Calif San Diego, Shiley Eye Inst, La Jolla, CA 92093 USA; [Hofman, Florence M.; Chen, Thomas C.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; [Zhang, Kang] Vet Adm Healthcare Syst, San Diego, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Southern California	Zhang, LF (corresponding author), Univ Calif San Diego, Dept NanoEngn, La Jolla, CA 92093 USA.	kang.zhang@gmail.com; shuchien@ucsd.edu; zhang@ucsd.edu	Hu, Che-Ming/N-7674-2018; Thamphiwatana, Soracha D./B-5338-2017; Wang, Kuei-Chun (Mark)/N-3419-2017; Wang, Kuei-Chun/N-3089-2017; Zhu, Jie/AAD-1330-2022; Angsantikul, Pavimol/AAS-7240-2020; Zhang, Kang/Y-2740-2019	Hu, Che-Ming/0000-0002-0988-7029; Thamphiwatana, Soracha D./0000-0003-3664-9488; Zhu, Jie/0000-0001-6862-9022; Angsantikul, Pavimol/0000-0002-1671-9373; Zhang, Kang/0000-0002-4549-1697; Shi, William/0000-0001-5452-2902	National Institutes of Health [R01DK095168, R01HL108735, R01EY25090]; Defense Threat Reduction Agency Joint Science and Technology Office for Chemical and Biological Defense [HDTRA1-14-1-0064]; National Institutes of Health from the National Cancer Institute [R25CA153915]; NATIONAL CANCER INSTITUTE [R25CA153915] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY025090] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL108735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK095168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM112584] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Defense Threat Reduction Agency Joint Science and Technology Office for Chemical and Biological Defense(United States Department of DefenseDefense Threat Reduction Agency); National Institutes of Health from the National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work is supported by the National Institutes of Health under Award Numbers R01DK095168 (L.Z.), R01HL108735 (S.C.) and R01EY25090 (K.Z.), and partially by the Defense Threat Reduction Agency Joint Science and Technology Office for Chemical and Biological Defense under Grant Number HDTRA1-14-1-0064 (L.Z.). R.H.F. is supported by a National Institutes of Health R25CA153915 training grant from the National Cancer Institute.	Andersen AJ, 2009, J BIOMED NANOTECHNOL, V5, P364, DOI 10.1166/jbn.2009.1045; Anselmo AC, 2014, ACS NANO, V8, P11243, DOI 10.1021/nn503732m; Bertram JP, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000397; BORN GVR, 1963, J PHYSIOL-LONDON, V168, P178, DOI 10.1113/jphysiol.1963.sp007185; Chan JM, 2010, P NATL ACAD SCI USA, V107, P2213, DOI 10.1073/pnas.0914585107; Fitzgerald JR, 2006, NAT REV MICROBIOL, V4, P445, DOI 10.1038/nrmicro1425; GACHET C, 1993, J CELL BIOL, V120, P1021, DOI 10.1083/jcb.120.4.1021; Hu CMJ, 2013, NAT NANOTECHNOL, V8, P933, DOI [10.1038/NNANO.2013.254, 10.1038/nnano.2013.254]; Hu CMJ, 2013, NAT NANOTECHNOL, V8, P336, DOI [10.1038/NNANO.2013.54, 10.1038/nnano.2013.54]; Hu CMJ, 2013, NANOSCALE, V5, P2664, DOI 10.1039/c3nr00015j; Hu CMJ, 2011, P NATL ACAD SCI USA, V108, P10980, DOI 10.1073/pnas.1106634108; Hughes CE, 2010, BLOOD, V115, P2947, DOI 10.1182/blood-2009-08-237834; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kamaly N, 2013, P NATL ACAD SCI USA, V110, P6506, DOI 10.1073/pnas.1303377110; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; Law SKA, 1997, PROTEIN SCI, V6, P263; Luk BT, 2014, NANOSCALE, V6, P2730, DOI 10.1039/c3nr06371b; Modery-Pawlowski CL, 2013, BIOMATERIALS, V34, P526, DOI 10.1016/j.biomaterials.2012.09.074; Nieswandt B, 2003, BLOOD, V102, P449, DOI 10.1182/blood-2002-12-3882; Olsson M, 2005, BLOOD, V105, P3577, DOI 10.1182/blood-2004-08-2980; Pelaz B, 2013, SMALL, V9, P1573, DOI 10.1002/smll.201201229; Peters D, 2009, P NATL ACAD SCI USA, V106, P9815, DOI 10.1073/pnas.0903369106; Rodriguez PL, 2013, SCIENCE, V339, P971, DOI 10.1126/science.1229568; Salvati A, 2013, NAT NANOTECHNOL, V8, P137, DOI [10.1038/nnano.2012.237, 10.1038/NNANO.2012.237]; Siboo IR, 2005, INFECT IMMUN, V73, P2273, DOI 10.1128/IAI.73.4.2273-2280.2005; Simberg D, 2007, P NATL ACAD SCI USA, V104, P932, DOI 10.1073/pnas.0610298104; SIMS PJ, 1989, J BIOL CHEM, V264, P19228; Tenzer S, 2013, NAT NANOTECHNOL, V8, P772, DOI 10.1038/nnano.2013.181; TERSTAPPEN LWMM, 1992, J LEUKOCYTE BIOL, V52, P652, DOI 10.1002/jlb.52.6.652; Yeaman MR, 2010, CELL MOL LIFE SCI, V67, P525, DOI 10.1007/s00018-009-0210-4	30	920	947	61	1125	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 1	2015	526	7571					118	+		10.1038/nature15373	http://dx.doi.org/10.1038/nature15373			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS5CY	26374997	Green Accepted			2023-01-03	WOS:000362095100045
J	Lei, J; Osen, W; Gardyan, A; Hotz-Wagenblatt, A; Wei, GC; Gissmann, L; Eichmuller, S; Lochelt, M				Lei, Janet; Osen, Wolfram; Gardyan, Adriane; Hotz-Wagenblatt, Agnes; Wei, Guochao; Gissmann, Lutz; Eichmueller, Stefan; Loechelt, Martin			Replication-Competent Foamy Virus Vaccine Vectors as Novel Epitope Scaffolds for Immunotherapy	PLOS ONE			English	Article							LEUKOCYTE ADHESION DEFICIENCY; BROADLY NEUTRALIZING ANTIBODIES; CROSS-SPECIES TRANSMISSION; T-LYMPHOCYTE EPITOPE; FELINE FOAMY; ANTIGEN PRESENTATION; RETROVIRAL VECTORS; GENE-THERAPY; INNATE IMMUNITY; MHC MOLECULES	The use of whole viruses as antigen scaffolds is a recent development in vaccination that improves immunogenicity without the need for additional adjuvants. Previous studies highlighted the potential of foamy viruses (FVs) in prophylactic vaccination and gene therapy. Replication-competent FVs can trigger immune signaling and integrate into the host genome, resulting in persistent antigen expression and a robust immune response. Here, we explored feline foamy virus (FFV) proteins as scaffolds for therapeutic B and T cell epitope delivery in vitro. Infection-and cancer-related B and T cell epitopes were grafted into FFV Gag, Env, or Bet by residue replacement, either at sites of high local sequence homology between the epitope and the host protein or in regions known to tolerate sequence alterations. Modified proviruses were evaluated in vitro for protein steady state levels, particle release, and virus titer in permissive cells. Modification of Gag and Env was mostly detrimental to their function. As anticipated, modification of Bet had no impact on virion release and affected virus titers of only some recombinants. Further evaluation of Bet as an epitope carrier was performed using T cell epitopes from the model antigen chicken ovalbumin (OVA), human tyrosinase-related protein 2 (TRP-2), and oncoprotein E7 of human papillomavirus type 16 (HPV16E7). Transfection of murine cells with constructs encoding Bet-epitope chimeric proteins led to efficient MHC-I-restricted epitope presentation as confirmed by interferon-gamma enzyme-linked immunospot assays using epitope-specific cytotoxic T lymphocyte (CTL) lines. FFV infection-mediated transduction of cells with epitope-carrying Bet also induced T-cell responses, albeit with reduced efficacy, in a process independent from the presence of free peptides. We show that primate FV Bet is also a promising T cell epitope carrier for clinical translation. The data demonstrate the utility of replication-competent and -attenuated FVs as antigen carriers in immunotherapy.	[Lei, Janet; Wei, Guochao; Gissmann, Lutz; Loechelt, Martin] German Canc Res Ctr, Res Program Infect & Canc, Div Mol Diagnost Oncogen Infect, Heidelberg, Germany; [Osen, Wolfram; Gardyan, Adriane; Eichmueller, Stefan] German Canc Res Ctr, Res Program Tumor Immunol, Div Translat Immunol, Heidelberg, Germany; [Hotz-Wagenblatt, Agnes] German Canc Res Ctr, Bioinformat Core Facil, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Lochelt, M (corresponding author), German Canc Res Ctr, Res Program Infect & Canc, Div Mol Diagnost Oncogen Infect, Heidelberg, Germany.	m.loechelt@dkfz.de	Eichmüller, Stefan B/A-5053-2008	Eichmüller, Stefan B/0000-0002-3497-6904; Wei, Guochao/0000-0002-7768-2404; Lei, Janet/0000-0001-6486-9651	DKFZ Graduate School; Helmholtz Graduate School for Cancer Research	DKFZ Graduate School; Helmholtz Graduate School for Cancer Research	Support was provided by DKFZ Graduate School; JL is supported by a PhD stipend from the Helmholtz Graduate School for Cancer Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alke A, 2000, VIROLOGY, V275, P170, DOI 10.1006/viro.2000.0537; Alke A, 2001, VIROLOGY, V287, P310, DOI 10.1006/viro.2001.1065; Amanna IJ, 2009, ANTIVIR RES, V84, P119, DOI 10.1016/j.antiviral.2009.08.008; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; Barker PA, 2002, J NEUROSCI RES, V67, P705, DOI 10.1002/jnr.10160; Bastone P, 2007, GENE THER, V14, P613, DOI 10.1038/sj.gt.3302890; Bauer TR, 2011, GENE THER, V18, P553, DOI 10.1038/gt.2010.169; Bauer TR, 2008, NAT MED, V14, P93, DOI 10.1038/nm1695; Bauer TR, 2013, MOL THER, V21, P964, DOI 10.1038/mt.2013.34; Betsem E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002306; Bleiholder A, 2012, EVALUATION FELINE FO; Boyer SN, 1996, CANCER RES, V56, P4620; Chareza S, 2012, VIROLOGY, V424, P138, DOI 10.1016/j.virol.2011.12.017; Cohen WM, 2006, J IMMUNOL, V176, P5401, DOI 10.4049/jimmunol.176.9.5401; COLAS S, 1995, J GEN VIROL, V76, P661, DOI 10.1099/0022-1317-76-3-661; Comber JD, 2014, HEPAT RES TREAT, V2014, DOI [DOI 10.1155/2014/860562, 10.1155/2014/860562]; Dalba C, 2007, MOL THER, V15, P457, DOI 10.1038/sj.mt.6300054; Dell K, 2006, INT J CANCER, V118, P364, DOI 10.1002/ijc.21360; Deyle DR, 2013, GENE THER, V20, P868, DOI 10.1038/gt.2013.6; Engel G, 2006, AM J PRIMATOL, V68, P934, DOI 10.1002/ajp.20299; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FELTKAMP MCW, 1993, EUR J IMMUNOL, V23, P2242, DOI 10.1002/eji.1830230929; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Holmgren J, 2012, CURR OPIN IMMUNOL, V24, P343, DOI 10.1016/j.coi.2012.03.014; Hsu Jennifer L, 2013, S D Med, VSpec no, P33; Huang F, 2012, AIDS RES HUM RETROV, V28, P591, DOI [10.1089/AID.2011.0305, 10.1089/aid.2011.0305]; Katzourakis A, 2009, SCIENCE, V325, P1512, DOI 10.1126/science.1174149; Kehl T, 2013, VIRUSES-BASEL, V5, P2169, DOI 10.3390/v5092169; Khan AS, 2009, EXPERT REV ANTI-INFE, V7, P569, DOI [10.1586/eri.09.39, 10.1586/ERI.09.39]; Kloetzel PM, 2004, BBA-MOL CELL RES, V1695, P225, DOI 10.1016/j.bbamcr.2004.10.004; Lindemann D, 2011, VIRUSES-BASEL, V3, P561, DOI 10.3390/v3050561; Liu WB, 2013, VIRUSES-BASEL, V5, P1702, DOI 10.3390/v5071702; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; Lochelt M, 2005, P NATL ACAD SCI USA, V102, P7982, DOI 10.1073/pnas.0501445102; Lukic DS, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-76; Maier P, 2010, FUTURE MICROBIOL, V5, P1507, DOI 10.2217/FMB.10.100; Materniak M, 2013, J VIROL, V87, P3516, DOI 10.1128/JVI.02447-12; Maul RW, 2010, ADV IMMUNOL, V105, P159, DOI 10.1016/S0065-2776(10)05006-6; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Mergia A, 1996, J MED PRIMATOL, V25, P2, DOI 10.1111/j.1600-0684.1996.tb00185.x; Monath TP, 2011, BIRKHAUSER ADV INFEC, P47, DOI 10.1007/978-3-0346-0277-8_3; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; Mouinga-Ondeme A, 2013, VIRUSES-BASEL, V5, P1536, DOI 10.3390/v5061536; Muhle M, 2013, ANTIVIR RES, V100, P314, DOI 10.1016/j.antiviral.2013.09.009; Muhle M, 2013, IMMUNOL RES, V56, P61, DOI 10.1007/s12026-013-8387-x; MUNGER K, 1993, BIOCHIM BIOPHYS ACTA, V1155, P111, DOI 10.1016/0304-419X(93)90025-8; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; Neefjes J, 2013, NAT CHEM BIOL, V9, P769, DOI [10.1038/NCHEMBIO.1391, 10.1038/nchembio.1391]; Niedermann G, 1999, IMMUNOL REV, V172, P29, DOI 10.1111/j.1600-065X.1999.tb01354.x; Nowrouzi A, 2006, J GEN VIROL, V87, P1339, DOI 10.1099/vir.0.81554-0; OLD LJ, 1965, CANCER RES, V25, P813; Parham P, 1996, SCIENCE, V272, P67, DOI 10.1126/science.272.5258.67; Parkhurst MR, 1998, CANCER RES, V58, P4895; Pascolo S, 2001, CANCER RES, V61, P4072; Perkovic M, 2009, J BIOL CHEM, V284, P5819, DOI 10.1074/jbc.M808853200; Petrovsky N, 2004, IMMUNOL CELL BIOL, V82, P488, DOI 10.1111/j.0818-9641.2004.01272.x; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; Rappuoli R, 2011, NAT REV IMMUNOL, V11, P865, DOI 10.1038/nri3085; Rethwilm A, 2007, CURR GENE THER, V7, P261; Rua R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077072; Rua R, 2012, J VIROL, V86, P909, DOI 10.1128/JVI.06235-11; Russell RA, 2005, J VIROL, V79, P8724, DOI 10.1128/JVI.79.14.8724-8731.2005; Samorski R, 2006, IMMUNOL LETT, V107, P41, DOI 10.1016/j.imlet.2006.07.003; Sang MX, 2011, VACCINE, V29, P8496, DOI 10.1016/j.vaccine.2011.09.014; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schwantes A, 2003, J VIROL, V77, P7830, DOI 10.1128/JVI.77.14.7830-7842.2003; Schwantes A, 2002, VIROLOGY, V301, P53, DOI 10.1006/viro.2002.1543; Smith KM, 2012, PLOS ONE, V7, P71, DOI 10.1371/journal.pone.0029505; Speidel K, 1997, EUR J IMMUNOL, V27, P2391, DOI 10.1002/eji.1830270938; Stanford MM, 2008, CURR OPIN MOL THER, V10, P32; Switzer WM, 2005, NATURE, V434, P376, DOI 10.1038/nature03341; Tang DL, 2012, IMMUNOL REV, V249, P158, DOI 10.1111/j.1600-065X.2012.01146.x; Tang Y, 2007, CANCER IMMUNOL IMMUN, V56, P319, DOI 10.1007/s00262-006-0195-x; Tatsumi T, 2003, CLIN CANCER RES, V9, P947; Toes REM, 2001, J EXP MED, V194, P1, DOI 10.1084/jem.194.1.1; Trobridge GD, 2009, EXPERT OPIN BIOL TH, V9, P1427, DOI 10.1517/14712590903246388; van Kasteren SI, 2014, CURR OPIN IMMUNOL, V26, P21, DOI 10.1016/j.coi.2013.10.005; Vita R, 2009, NUCL ACIDS RES, P38; Weikel J, 2003, J VET MED A, V50, P415, DOI 10.1046/j.0931-184X.2003.00565.x; Whisnant AW, 2014, J VIROL, V88, P4679, DOI 10.1128/JVI.03587-13; Wuhle M, 2011, VIROLOGY, V412, P333, DOI 10.1016/j.virol.2011.01.023; Zemba M, 2000, VIROLOGY, V266, P150, DOI 10.1006/viro.1999.0037; Zhao F, 2009, CLIN CANCER RES, V15, P4382, DOI 10.1158/1078-0432.CCR-09-0399; zur Hausen H, 2009, VIROLOGY, V384, P260, DOI 10.1016/j.virol.2008.11.046; Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001	85	15	16	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2015	10	9							e0138458	10.1371/journal.pone.0138458	http://dx.doi.org/10.1371/journal.pone.0138458			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS1BM	26397953	Green Published, Green Submitted, gold			2023-01-03	WOS:000361797500066
J	Cowie, MR; Woehrle, H; Wegscheider, K; Angermann, C; d'Ortho, MP; Erdmann, E; Levy, P; Simonds, AK; Somers, VK; Zannad, F; Teschler, H				Cowie, Martin R.; Woehrle, Holger; Wegscheider, Karl; Angermann, Christiane; d'Ortho, Marie-Pia; Erdmann, Erland; Levy, Patrick; Simonds, Anita K.; Somers, Virend K.; Zannad, Faiez; Teschler, Helmut			Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITIVE AIRWAY PRESSURE; CHEYNE-STOKES RESPIRATION; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; DYSFUNCTION; MORTALITY; MULTICENTER; TRIAL	BACKGROUND Central sleep apnea is associated with poor prognosis and death in patients with heart failure. Adaptive servo-ventilation is a therapy that uses a noninvasive ventilator to treat central sleep apnea by delivering servo-controlled inspiratory pressure support on top of expiratory positive airway pressure. We investigated the effects of adaptive servo-ventilation in patients who had heart failure with reduced ejection fraction and predominantly central sleep apnea. METHODS We randomly assigned 1325 patients with a left ventricular ejection fraction of 45% or less, an apnea-hypopnea index (AHI) of 15 or more events (occurrences of apnea or hypopnea) per hour, and a predominance of central events to receive guideline-based medical treatment with adaptive servo-ventilation or guideline-based medical treatment alone (control). The primary end point in the time-to-event analysis was the first event of death from any cause, lifesaving cardiovascular intervention (cardiac transplantation, implantation of a ventricular assist device, resuscitation after sudden cardiac arrest, or appropriate lifesaving shock), or unplanned hospitalization for worsening heart failure. RESULTS In the adaptive servo-ventilation group, the mean AHI at 12 months was 6.6 events per hour. The incidence of the primary end point did not differ significantly between the adaptive servo-ventilation group and the control group (54.1% and 50.8%, respectively; hazard ratio, 1.13; 95% confidence interval [CI], 0.97 to 1.31; P = 0.10). All-cause mortality and cardiovascular mortality were significantly higher in the adaptive servo-ventilation group than in the control group (hazard ratio for death from any cause, 1.28; 95% CI, 1.06 to 1.55; P = 0.01; and hazard ratio for cardiovascular death, 1.34; 95% CI, 1.09 to 1.65; P = 0.006). CONCLUSIONS Adaptive servo-ventilation had no significant effect on the primary end point in patients who had heart failure with reduced ejection fraction and predominantly central sleep apnea, but all-cause and cardiovascular mortality were both increased with this therapy.	[Cowie, Martin R.] Univ London Imperial Coll Sci Technol & Med, London SW3 6LY, England; [Simonds, Anita K.] Royal Brompton Hosp, London, England; [Woehrle, Holger] ResMed Germany, ResMed Sci Ctr, Martinsried, Germany; [Woehrle, Holger] Resp Ctr Ulm, Sleep & Ventilat Ctr Blaubeuren, Ulm, Germany; [Wegscheider, Karl] Univ Med Ctr Eppendorf, Dept Med Biometry & Epidemiol, Hamburg, Germany; [Angermann, Christiane] Univ Hosp, Dept Med 1, Wurzburg, Germany; [Angermann, Christiane] Univ Hosp, Comprehens Heart Failure Ctr, Wurzburg, Germany; [Angermann, Christiane] Univ Wurzburg, D-97070 Wurzburg, Germany; [Erdmann, Erland] Univ Cologne, Ctr Heart, D-50931 Cologne, Germany; [Teschler, Helmut] Univ Duisburg Essen, Univ Hosp Essen, West German Lung Ctr, Ruhrlandklin,Dept Pneumol, Essen, Germany; [d'Ortho, Marie-Pia] Univ Paris Diderot, Sorbonne Paris Cite, Hop Bichat,Explorat Fonct, AP HP,Dept Hosp Univ Fight Inflammat & Remodeling, Paris, France; [Levy, Patrick] CHU Grenoble, F-38043 Grenoble, France; [Zannad, Faiez] Univ Lorraine, CHU Nancy, INSERM, Nancy, France; [Somers, Virend K.] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	Imperial College London; Royal Brompton Hospital; ResMed; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Cologne; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Duisburg Essen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU de Nancy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; Mayo Clinic	Cowie, MR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Cardiol, Dovehouse St, London SW3 6LY, England.	m.cowie@imperial.ac.uk	Zannad, Faiez/K-4649-2019; Cowie, Martin R/AAQ-2818-2020; LEVY, Patrick/AAX-2802-2020	Cowie, Martin R/0000-0001-7457-2552; LEVY, Patrick/0000-0003-3174-7935	ResMed; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065176] Funding Source: NIH RePORTER	ResMed; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Funded by ResMed and others; SERVE-HF ClinicalTrials.gov number, NCT00733343.	Acosta B, 2000, CHEST, V118, P1004, DOI 10.1378/chest.118.4.1004; Arzt M, 2007, CIRCULATION, V115, P3173, DOI 10.1161/CIRCULATIONAHA.106.683482; Bitter T, 2011, EUR HEART J, V32, P61, DOI 10.1093/eurheartj/ehq327; Bradley TD, 2005, NEW ENGL J MED, V353, P2025, DOI 10.1056/NEJMoa051001; BRADLEY TD, 1992, AM REV RESPIR DIS, V145, P377, DOI 10.1164/ajrccm/145.2_Pt_1.377; Cowie MR, 2013, EUR J HEART FAIL, V15, P937, DOI 10.1093/eurjhf/hft051; DEHOYOS A, 1995, CLIN SCI, V88, P173, DOI 10.1042/cs0880173; GRACE MP, 1982, CRIT CARE MED, V10, P358, DOI 10.1097/00003246-198206000-00002; Gray AJ, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/hta13330; Hastings PC, 2010, INT J CARDIOL, V139, P17, DOI 10.1016/j.ijcard.2008.08.022; Javaheri S, 2007, J AM COLL CARDIOL, V49, P2028, DOI 10.1016/j.jacc.2007.01.084; Kasai T, 2012, CIRCULATION, V126, P1495, DOI 10.1161/CIRCULATIONAHA.111.070813; Lenique F, 1997, AM J RESP CRIT CARE, V155, P500, DOI 10.1164/ajrccm.155.2.9032185; Levy P, 2007, SLEEP MED CLIN, V2, P615, DOI 10.1016/j.jsmc.2007.08.001; Momomura S, 2015, CIRC J, V79, P981, DOI 10.1253/circj.CJ-15-0221; Nakamura S, 2015, CLIN RES CARDIOL, V104, P208, DOI 10.1007/s00392-014-0774-3; Naughton MT, 2012, THORAX, V67, P357, DOI 10.1136/thoraxjnl-2011-200927; Oldenburg O, 2008, EUR J HEART FAIL, V10, P581, DOI 10.1016/j.ejheart.2008.04.007; Oldenburg O, 2007, EUR J HEART FAIL, V9, P251, DOI 10.1016/j.ejheart.2006.08.003; Oldenburg O, 2009, SLEEP MED, V10, P726, DOI 10.1016/j.sleep.2008.08.004; Philip-Joet F, 1999, RESPIRATION, V66, P136, DOI 10.1159/000029355; Sharma BK, 2012, CHEST, V142, P1211, DOI 10.1378/chest.12-0815; Somers VK, 2008, J AM COLL CARDIOL, V52, P686, DOI 10.1016/j.jacc.2008.05.002; Takama N, 2012, CIRC J, V76, P661, DOI 10.1253/circj.CJ-11-0299; Teschler H, 2001, AM J RESP CRIT CARE, V164, P614, DOI 10.1164/ajrccm.164.4.9908114; Yumino D, 2009, HEART, V95, P819, DOI 10.1136/hrt.2008.160952	26	601	627	1	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 17	2015	373	12					1095	1105		10.1056/NEJMoa1506459	http://dx.doi.org/10.1056/NEJMoa1506459			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CR7UG	26323938	Green Accepted, Bronze, Green Published			2023-01-03	WOS:000361556400005
J	Hursel, R; Martens, EAP; Gonnissen, HKJ; Hamer, HM; Senden, JMG; van Loon, LJC; Westerterp-Plantenga, MS				Hursel, Rick; Martens, Eveline A. P.; Gonnissen, Hanne K. J.; Hamer, Henrike M.; Senden, Joan M. G.; van Loon, Luc J. C.; Westerterp-Plantenga, Margriet S.			Prolonged Adaptation to a Low or High Protein Diet Does Not Modulate Basal Muscle Protein Synthesis Rates - A Substudy	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; SKELETAL-MUSCLE; AMINO-ACIDS; BODY-WEIGHT; ENERGY-EXPENDITURE; MEN; MAINTENANCE; METABOLISM; KINETICS; LEUCINE	Background Based on controlled 36 h experiments a higher dietary protein intake causes a positive protein balance and a negative fat balance. A positive net protein balance may support fat free mass accrual. However, few data are available on the impact of more prolonged changes in habitual protein intake on whole-body protein metabolism and basal muscle protein synthesis rates. Objective To assess changes in whole-body protein turnover and basal muscle protein synthesis rates following 12 weeks of adaptation to a low versus high dietary protein intake. Methods A randomized parallel study was performed in 40 subjects who followed either a high protein (2.4 g protein/kg/d) or low protein (0.4 g protein/kg/d) energy-balanced diet (30/35/35% or 5/60/35% energy from protein/carbohydrate/fat) for a period of 12 weeks. A subgroup of 7 men and 8 women (body mass index: 22.8 +/- 2.3 kg/m(2), age: 24.3 +/- 4.9 y) were selected to evaluate the impact of prolonged adaptation to either a high or low protein intake on whole body protein metabolism and basal muscle protein synthesis rates. After the diet, subjects received continuous infusions with L-[ring-H-2(5)]phenylalanine and L-[ring-H-2(2)]tyrosine in an overnight fasted state, with blood samples and muscle biopsies being collected to assess post-absorptive whole-body protein turnover and muscle protein synthesis rates in vivo in humans. Results After 12 weeks of intervention, whole-body protein balance in the fasted state was more negative in the high protein treatment when compared with the low protein treatment (-4.1 +/- 0.5 vs -2.7 +/- 0.6 mu mol phenylalanine/kg/h; P<0.001). Whole-body protein breakdown (43.0 +/- 4.4 vs 37.8 +/- 3.8 mu mol phenylalanine/kg/h; P<0.03), synthesis (38.9 +/- 4.2 vs 35.1 +/- 3.6 mu mol phenylalanine/kg/h; P<0.01) and phenylalanine hydroxylation rates (4.1 +/- 0.6 vs 2.7 +/- 0.6 mu mol phenylalanine/kg/h; P<0.001) were significantly higher in the high vs low protein group. Basal muscle protein synthesis rates were maintained on a low vs high protein diet (0.042 +/- 0.01 vs 0.045 +/- 0.01%/h; P = 0.620). Conclusions In the overnight fasted state, adaptation to a low-protein intake (0.4 g/kg/d) does not result in a more negative whole-body protein balance and does not lower basal muscle protein synthesis rates when compared to a high-protein intake.	[Hursel, Rick; Martens, Eveline A. P.; Gonnissen, Hanne K. J.; Westerterp-Plantenga, Margriet S.] Maastricht Univ, Sch Nutr & Translat Res Metab, Dept Human Biol, Maastricht, Netherlands; [Hamer, Henrike M.; Senden, Joan M. G.; van Loon, Luc J. C.] Maastricht Univ, Sch Nutr & Translat Res Metab, Dept Human Movement Sci, Maastricht, Netherlands	Maastricht University; Maastricht University	Hursel, R (corresponding author), Maastricht Univ, Sch Nutr & Translat Res Metab, Dept Human Biol, Maastricht, Netherlands.	rick.hursel@maastrichtuniversity.nl	van Loon, Luc J.C./ABG-9158-2020; van Loon, Luc J C/G-5920-2010	van Loon, Luc J.C./0000-0002-6768-9231; van Loon, Luc J C/0000-0002-6768-9231	European Union Seventh Framework Programme (FP7) [266408]	European Union Seventh Framework Programme (FP7)	This work was supported by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 266408. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABUMRAD NN, 1981, METABOLISM, V30, P936, DOI 10.1016/0026-0495(81)90074-3; BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; BERGSTROM J, 1975, SCAND J CLIN LAB INV, V35, P606, DOI 10.3109/00365517509095787; Boirie Y, 1996, AM J PHYSIOL-ENDOC M, V271, pE1083, DOI 10.1152/ajpendo.1996.271.6.E1083; Bray GA, 2012, JAMA-J AM MED ASSOC, V307, P47, DOI 10.1001/jama.2011.1918; Burd NA, 2013, EXERC SPORT SCI REV, V41, P169, DOI 10.1097/JES.0b013e318292f3d5; Cermak NM, 2012, AM J CLIN NUTR, V96, P1454, DOI 10.3945/ajcn.112.037556; Dangin M, 2003, J PHYSIOL-LONDON, V549, P635, DOI 10.1113/jphysiol.2002.036897; Dideriksen K, 2013, NUTRIENTS, V5, P852, DOI 10.3390/nu5030852; Fujita S, 2007, AM J PHYSIOL-ENDOC M, V292, pE77, DOI 10.1152/ajpendo.00173.2006; Harris JA, 1918, P NATL ACAD SCI USA, V4, P370, DOI 10.1073/pnas.4.12.370; HEGSTED DM, 1976, J NUTR, V106, P307; Henderson GC, 2009, FASEB J, V23, P631, DOI 10.1096/fj.08-117200; HUSEK P, 1991, FEBS LETT, V280, P354, DOI 10.1016/0014-5793(91)80330-6; Jahn LA, 1999, J CLIN ENDOCR METAB, V84, P1007, DOI 10.1210/jc.84.3.1007; Koopman R, 2006, AM J CLIN NUTR, V84, P623, DOI 10.1093/ajcn/84.3.623; Koopman R, 2009, AM J CLIN NUTR, V90, P106, DOI 10.3945/ajcn.2009.27474; Martens EA, 2015, CLIN NUTR, V34, P968, DOI 10.1016/j.clnu.2014.10.007; Matthews DE, 2007, J NUTR, V137, p1549S, DOI 10.1093/jn/137.6.1549S; MILLWARD DJ, 1991, P NUTR SOC, V50, P197, DOI 10.1079/PNS19910030; Pennings B, 2011, AM J CLIN NUTR, V93, P997, DOI 10.3945/ajcn.110.008102; Smith GI, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-11; Smith GI, 2009, J APPL PHYSIOL, V107, P1308, DOI 10.1152/japplphysiol.00348.2009; Soenen S, 2013, J NUTR, V143, P591, DOI 10.3945/jn.112.167593; Soenen S, 2010, PHYSIOL BEHAV, V101, P635, DOI 10.1016/j.physbeh.2010.09.014; STUNKARD AJ, 1985, J PSYCHOSOM RES, V29, P71, DOI 10.1016/0022-3999(85)90010-8; Summerbell CD, 2009, INT J OBESITY, V33, pS1, DOI 10.1038/ijo.2009.80; Symons TB, 2009, J AM DIET ASSOC, V109, P1582, DOI 10.1016/j.jada.2009.06.369; van Loon LJC, 2011, NESTLE NUTR WORKS SE, V69, P79, DOI 10.1159/000329287; VANEIJK HMH, 1993, J CHROMATOGR-BIOMED, V620, P143, DOI 10.1016/0378-4347(93)80062-9; WESTERTERP KR, 1995, BRIT J NUTR, V73, P337, DOI 10.1079/BJN19950037; Westerterp-Plantenga MS, 2009, ANNU REV NUTR, V29, P21, DOI 10.1146/annurev-nutr-080508-141056; Westerterp-Plantenga MS, 2012, BRIT J NUTR, V108, pS105, DOI 10.1017/S0007114512002589; Wolfe R.R., 2005, ISOTOPE TRACERMETA, Vsecond; Wolfe RR, 2002, J NUTR, V132, p3219S, DOI 10.1093/jn/131.10.3219S; YOUNG V R, 1986, Journal of Nutrition, V116, P700; YOUNG VR, 1987, HUM NUTR-CLIN NUTR, V41C, P1	37	18	18	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2015	10	9							e0137183	10.1371/journal.pone.0137183	http://dx.doi.org/10.1371/journal.pone.0137183			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR8KS	26367529	Green Published, Green Submitted, gold			2023-01-03	WOS:000361601100055
J	McNab, S				McNab, Sarah			Isotonic vs Hypotonic Intravenous Fluids for Hospitalized Children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MAINTENANCE FLUIDS; HYPONATREMIA	CLINICAL QUESTION Is isotonic fluid associated with a lower incidence of hyponatremia when compared with hypotonic fluid for maintenance intravenous fluid therapy in children? BOTTOM LINE Compared with hypotonic fluid, isotonic fluid is associated with a lower incidence of hyponatremia, without evidence of an increase in adverse outcomes.	[McNab, Sarah] Royal Childrens Hosp, Dept Gen Med, Melbourne, Vic, Australia; [McNab, Sarah] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [McNab, Sarah] Univ Melbourne, Dept Pediat, Melbourne, Vic, Australia	Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; University of Melbourne	McNab, S (corresponding author), Royal Childrens Hosp Melbourne, Dept Gen Med, 52 Flemington Rd, Parkville, Vic 3052, Australia.	sarah.mcnab@rch.org.au						Friedman JN, 2015, JAMA PEDIATR, V169, P445, DOI 10.1001/jamapediatrics.2014.3809; Hoorn EJ, 2004, PEDIATRICS, V113, P1279, DOI 10.1542/peds.113.5.1279; Baron FAJ, 2013, ARCH ARGENT PEDIATR, V111, P281, DOI 10.5546/aap.2013.281; McNab S, 2014, COCHRANE DB SYST REV, V12, P1; Mcnab S, 2015, LANCET, V385, P1190, DOI 10.1016/S0140-6736(14)61459-8; National Patient Safety Agency, RED RISK HYP ADM INT; Pemde HK, 2015, INDIAN J PEDIATR, V82, P13, DOI 10.1007/s12098-014-1436-1; Shamim A, 2014, INDIAN PEDIATR, V51, P969, DOI 10.1007/s13312-014-0542-5	8	11	11	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2015	314	7					720	721		10.1001/jama.2015.7918	http://dx.doi.org/10.1001/jama.2015.7918			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CP6SS	26284724				2023-01-03	WOS:000360019100021
J	Seymour, CW; Rosengart, MR				Seymour, Christopher W.; Rosengart, Matthew R.			Septic Shock Advances in Diagnosis and Treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							GOAL-DIRECTED THERAPY; CRITICALLY-ILL PATIENTS; SEVERE SEPSIS; HYDROXYETHYL STARCH; FLUID RESUSCITATION; HYDROCORTISONE THERAPY; ADULTS; METAANALYSIS; MORTALITY; OUTCOMES	IMPORTANCE Septic shock is a clinical emergency that occurs in more than 230 000 US patients each year. OBSERVATIONS AND ADVANCES In the setting of suspected or documented infection, septic shock is typically defined in a clinical setting by low systolic (<= 90 mm Hg) or mean arterial blood pressure (<= 65 mm Hg) accompanied by signs of hypoperfusion (eg, oliguria, hyperlactemia, poor peripheral perfusion, or altered mental status). Focused ultrasonography is recommended for the prompt recognition of complicating physiology (eg, hypovolemia or cardiogenic shock), while invasive hemodynamic monitoring is recommended only for select patients. In septic shock, 3 randomized clinical trials demonstrate that protocolized care offers little advantage compared with management without a protocol. Hydroxyethyl starch is no longer recommended, and debate continues about the role of various crystalloid solutions and albumin. CONCLUSIONS AND RELEVANCE The prompt diagnosis of septic shock begins with obtainment of medical history and performance of a physical examination for signs and symptoms of infection and may require focused ultrasonography to recognize more complex physiologic manifestations of shock. Clinicians should understand the importance of prompt administration of intravenous fluids and vasoactive medications aimed at restoring adequate circulation, and the limitations of protocol-based therapy, as guided by recent evidence.	[Seymour, Christopher W.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, 3550 Terrace St,Scaife Hall,Off 639, Pittsburgh, PA 15261 USA; [Seymour, Christopher W.] Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA 15261 USA; [Seymour, Christopher W.; Rosengart, Matthew R.] Clin Res Invest & Syst Modeling Acute Illness CRI, Pittsburgh, PA USA; [Rosengart, Matthew R.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Seymour, CW (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, 3550 Terrace St,Scaife Hall,Off 639, Pittsburgh, PA 15261 USA.	seymourcw@upmc.edu			National Institutes of Health (NIH) [K23GM104022]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K23GM104022] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by a grant from the National Institutes of Health (NIH) (K23GM104022).	Andrews B, 2014, CRIT CARE MED, V42, P2315, DOI 10.1097/CCM.0000000000000541; Angus DC, 2015, INTENS CARE MED, V41, P1549, DOI 10.1007/s00134-015-3822-1; Angus DC, 2013, NEW ENGL J MED, V369, P2063, DOI 10.1056/NEJMc1312359; Annane D, 2013, JAMA-J AM MED ASSOC, V310, P1809, DOI 10.1001/jama.2013.280502; Annane D, 2009, JAMA-J AM MED ASSOC, V301, P2362, DOI 10.1001/jama.2009.815; [Anonymous], 2014, NEW ENGL J MED, DOI DOI 10.1056/NEJMoa1401602; Asfar P, 2014, NEW ENGL J MED, V370, P1583, DOI 10.1056/NEJMoa1312173; Boomer JS, 2011, JAMA-J AM MED ASSOC, V306, P2594, DOI 10.1001/jama.2011.1829; Boyd JH, 2011, CRIT CARE MED, V39, P259, DOI 10.1097/CCM.0b013e3181feeb15; Bulger EM, 2011, ANN SURG, V253, P431, DOI 10.1097/SLA.0b013e3181fcdb22; Caironi P, 2014, NEW ENGL J MED, V370, P1412, DOI 10.1056/NEJMoa1305727; Cecconi M, 2014, INTENS CARE MED, V40, P1795, DOI 10.1007/s00134-014-3525-z; Clermont G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022512; D'Aragon F, 2015, SHOCK, V43, P530, DOI 10.1097/SHK.0000000000000348; De Backer D, 2012, CRIT CARE MED, V40, P725, DOI 10.1097/CCM.0b013e31823778ee; De Backer D, 2010, NEW ENGL J MED, V362, P779, DOI 10.1056/NEJMoa0907118; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Finfer S, 2010, CRIT CARE, V14, DOI 10.1186/cc9293; Goldenberg NM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002011; Gomez H, 2015, JAMA-J AM MED ASSOC, V313, P194, DOI 10.1001/jama.2014.13811; Hernandez G, 2013, INTENS CARE MED, V39, P1435, DOI 10.1007/s00134-013-2982-0; Holst LB, 2014, NEW ENGL J MED, V371, P1381, DOI 10.1056/NEJMoa1406617; Hoste EA, 2014, BRIT J ANAESTH, V113, P740, DOI 10.1093/bja/aeu300; Huang DT, 2013, INTENS CARE MED, V39, P1760, DOI 10.1007/s00134-013-3024-7; Jansen TC, 2010, AM J RESP CRIT CARE, V182, P752, DOI 10.1164/rccm.200912-1918OC; Jones AE, 2010, JAMA-J AM MED ASSOC, V303, P739, DOI 10.1001/jama.2010.158; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Labovitz AJ, 2010, J AM SOC ECHOCARDIOG, V23, P1225, DOI 10.1016/j.echo.2010.10.005; Langley RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005893; Levy MM, 2010, INTENS CARE MED, V36, P222, DOI 10.1007/s00134-009-1738-3; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Lewis RJ, 2010, JAMA-J AM MED ASSOC, V303, P777, DOI 10.1001/jama.2010.203; Lipcsey M, 2015, CRIT CARE RESUSC, V17, P6; LIU V, 2013, ANN AM THORAC SOC, V10, P466, DOI DOI 10.1513/AnnalsATS.201304-099OC; Manji RA, 2009, CRIT CARE CLIN, V25, P1, DOI 10.1016/j.ccc.2008.12.013; Millham FH, 2010, SURGERY, V148, P1026, DOI 10.1016/j.surg.2010.02.014; Morgan TJ, 2013, CURR OPIN CRIT CARE, V19, P299, DOI 10.1097/MCC.0b013e3283632d46; Mouncey PR, 2015, NEW ENGL J MED, V372, P1301, DOI 10.1056/NEJMoa1500896; Murray CJL, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI 10.1001/jama.2013.13805; Myburgh JA, 2013, NEW ENGL J MED, V369, P2462, DOI 10.1056/NEJMc1313345; Myburgh JA, 2012, NEW ENGL J MED, V367, P1901, DOI 10.1056/NEJMoa1209759; Opal SM, 2013, JAMA-J AM MED ASSOC, V309, P1154, DOI 10.1001/jama.2013.2194; PARKER MM, 1984, ANN INTERN MED, V100, P483, DOI 10.7326/0003-4819-100-4-483; Patel GP, 2012, AM J RESP CRIT CARE, V185, P133, DOI 10.1164/rccm.201011-1897CI; Peake SL, 2014, NEW ENGL J MED, V371, P1496, DOI 10.1056/NEJMoa1404380; Pearse RM, 2014, JAMA-J AM MED ASSOC, V311, P2181, DOI 10.1001/jama.2014.5305; Perner A, 2014, INTENS CARE MED, V40, P927, DOI 10.1007/s00134-014-3311-y; Perner A, 2012, NEW ENGL J MED, V367, P124, DOI 10.1056/NEJMoa1204242; Polito A, 2012, INTENS CARE MED, V38, P9, DOI 10.1007/s00134-011-2407-x; Puskarich MA, 2011, RESUSCITATION, V82, P1289, DOI 10.1016/j.resuscitation.2011.06.015; Rajaram SS, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003408.pub3; Ranieri VM, 2012, NEW ENGL J MED, V366, P2055, DOI 10.1056/NEJMoa1202290; Reddy SK, 2014, CRIT CARE RESUSC, V16, P274; Reinhart K, 2012, CLIN MICROBIOL REV, V25, P609, DOI 10.1128/CMR.00016-12; Richard JC, 2015, CRIT CARE, V19, DOI 10.1186/s13054-014-0734-3; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Rochwerg B, 2015, INTENS CARE MED, V41, P1561, DOI 10.1007/s00134-015-3794-1; Rochwerg B, 2014, ANN INTERN MED, V161, P347, DOI 10.7326/M14-0178; Rusconi AM, 2015, INTERN EMERG MED, V10, P731, DOI 10.1007/s11739-015-1248-y; Neto AS, 2012, CRIT CARE, V16, DOI 10.1186/cc11469; Shankar-Hari M, 2015, INTENS CARE MED, V41, P909, DOI 10.1007/s00134-015-3680-x; Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366; Takala J, 2011, CRIT CARE, V15, DOI 10.1186/cc10273; Tisherman SA, 2004, J TRAUMA, V57, P898, DOI 10.1097/01.TA.0000133577.25793.E5; Vincent JL, 2013, NEW ENGL J MED, V369, P1726, DOI 10.1056/NEJMra1208943; Wang CS, 2014, ANESTH ANALG, V118, P346, DOI 10.1213/ANE.0000000000000050; Weil M H, 1971, Adv Exp Med Biol, V23, P13; Wiener RS, 2007, JAMA-J AM MED ASSOC, V298, P423, DOI 10.1001/jama.298.4.423; Wong HR, 2011, CRIT CARE MED, V39, P2511, DOI 10.1097/CCM.0b013e3182257675; Yunos NM, 2012, JAMA-J AM MED ASSOC, V308, P1566, DOI 10.1001/jama.2012.13356; Zhang L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0312-9; Zhang ZH, 2015, INTENS CARE MED, V41, P444, DOI 10.1007/s00134-014-3638-4; [No title captured]; [No title captured]; [No title captured]; [No title captured]	76	99	109	0	41	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2015	314	7					708	717		10.1001/jama.2015.7885	http://dx.doi.org/10.1001/jama.2015.7885			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CP6SS	26284722	Green Accepted			2023-01-03	WOS:000360019100019
J	Shang, N; Saleem, A; Musallam, L; Walshe-Roussel, B; Badawi, A; Cuerrier, A; Arnason, JT; Haddad, PS				Shang, Nan; Saleem, Ammar; Musallam, Lina; Walshe-Roussel, Brendan; Badawi, Alaa; Cuerrier, Alain; Arnason, John T.; Haddad, Pierre S.			Novel Approach to Identify Potential Bioactive Plant Metabolites: Pharmacological and Metabolomics Analyses of Ethanol and Hot Water Extracts of Several Canadian Medicinal Plants of the Cree of Eeyou Istchee	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; NUCLEAR RECEPTOR SHP; HEPATIC GLUCONEOGENESIS; SKELETAL-MUSCLE; METFORMIN; CELLS; ADIPOCYTES; NATION; QUEBEC	We evaluated and compared the antidiabetic potential and molecular mechanisms of 17 Cree plants' ethanol extracts (EE) and hot water extracts (HWE) on glucose homeostasis in vitro and used metabolomics to seek links with the content of specific phytochemicals. Several EE of medical plants stimulated muscle glucose uptake and inhibited hepatic G6Pase activity. Some HWE partially or completely lost these antidiabetic activities in comparison to EE. Only R. groenlandicum retained similar potential between EE and HWE in both assays. In C2C12 muscle cells, EE of R. groenlandicum, A. incana and S. purpurea stimulated glucose uptake by activating AMP-activated protein kinase (AMPK) pathway and increasing glucose transporter type 4 (GLUT4) expression. In comparison to EE, HWE of R. groenlandicum exhibited similar activities; HWE of A. incana completely lost its effect on all parameters; interestingly, HWE of S. purpurea activated insulin pathway instead of AMPK pathway to increase glucose uptake. In the liver, for a subset of 5 plants, HWE and EE activated AMPK pathway whereas the EE and HWE of S. purpurea and K. angustifolia also activated insulin pathways. Quercetin-3-O-galactoside and quercetin 3-O-alpha-L-arabinopyranoside, were successfully identified by discriminant analysis as biomarkers of HWE plant extracts that stimulate glucose uptake in vitro. More importantly, the latter compound was not identified by previous bioassay-guided fractionation.	[Shang, Nan; Musallam, Lina; Haddad, Pierre S.] Univ Montreal, Dept Pharmacol, Nat Hlth Prod & Metab Dis Lab, Montreal, PQ H3C 3J7, Canada; [Shang, Nan; Musallam, Lina; Haddad, Pierre S.] Univ Montreal, Montreal Diabet Res Ctr, Montreal, PQ H3C 3J7, Canada; [Shang, Nan; Saleem, Ammar; Musallam, Lina; Walshe-Roussel, Brendan; Cuerrier, Alain; Arnason, John T.; Haddad, Pierre S.] Canadian Inst Hlth Res, Team Aboriginal Antidiabet Med, Montreal, PQ, Canada; [Shang, Nan; Haddad, Pierre S.] Univ Laval, Inst Nutraceut & Funct Foods, Quebec City, PQ, Canada; [Saleem, Ammar; Walshe-Roussel, Brendan; Arnason, John T.] Univ Ottawa, Ctr Adv Res Environm Genom, Ottawa, ON, Canada; [Badawi, Alaa] Publ Hlth Agcy Canada, Off Biotechnol Genom & Populat Hlth, Toronto, ON, Canada; [Cuerrier, Alain] Univ Montreal, Jardin Bot Montreal, Inst Rech Biol Vegetale, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal; Institute for Work & Health; Laval University; University of Ottawa; Public Health Agency of Canada; Universite de Montreal	Haddad, PS (corresponding author), Univ Montreal, Dept Pharmacol, Nat Hlth Prod & Metab Dis Lab, Montreal, PQ H3C 3J7, Canada.	pierre.haddad@umontreal.ca	Arnason, John Thor/GXM-3860-2022; Badawi, Alaa/ABC-1300-2021		Canadian Institutes of Health Research (CIHR Team in Aboriginal Antidiabetic Medicines) [CTP-79855]; Office of Biotechnology; Genomics and Population Health of Health Canada [4500252806]	Canadian Institutes of Health Research (CIHR Team in Aboriginal Antidiabetic Medicines)(Canadian Institutes of Health Research (CIHR)); Office of Biotechnology; Genomics and Population Health of Health Canada	This work was supported by a Team Grant from the Canadian Institutes of Health Research (CTP-79855) (CIHR Team in Aboriginal Antidiabetic Medicines) to PSH, JTA and AC, and by funding from the Office of Biotechnology, Genomics and Population Health of Health Canada (4500252806), http://www.cihr-irsc.gc.ca/e/193.html.	Boustead JN, 2004, J MOL ENDOCRINOL, V32, P33, DOI 10.1677/jme.0.0320033; CHANDLER RF, 1979, J ETHNOPHARMACOL, V1, P49, DOI 10.1016/0378-8741(79)90016-3; CONSOLI A, 1992, DIABETES CARE, V15, P430, DOI 10.2337/diacare.15.3.430; Dufour D, 2007, J ETHNOPHARMACOL, V111, P22, DOI 10.1016/j.jep.2006.10.021; Eid HM, 2010, MOL NUTR FOOD RES, V54, P991, DOI 10.1002/mnfr.200900218; FERRANNINI E, 1988, METABOLISM, V37, P79, DOI 10.1016/0026-0495(88)90033-9; GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068; Gunther E., 1973, ETHNOBOTANY W WASHIN; Haddad PS, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/893426; Harbilas D, 2009, CAN J PHYSIOL PHARM, V87, P479, DOI [10.1139/Y09-029, 10.1139/y09-029]; Kim YD, 2008, DIABETES, V57, P306, DOI 10.2337/db07-0381; KLIP A, 1990, DIABETES CARE, V13, P696, DOI 10.2337/diacare.13.6.696; Leduc C, 2006, J ETHNOPHARMACOL, V105, P55, DOI 10.1016/j.jep.2005.09.038; Moerman DE, 2000, NATIVE AM ETHNOBOTAN; Muhammad A, 2012, J NAT PROD, V75, P1284, DOI 10.1021/np3001317; Musi N, 2002, DIABETES, V51, P2074, DOI 10.2337/diabetes.51.7.2074; Nachar A, 2013, EVID-BASED COMPL ALT, V2013, DOI [10.1155/2013/189819, DOI 10.1155/2013/189819]; Niu WY, 2010, AM J PHYSIOL-ENDOC M, V298, pE1058, DOI 10.1152/ajpendo.00773.2009; Peyron-Caso E, 2002, HORM METAB RES, V34, P360, DOI 10.1055/s-2002-33467; Spoor DCA, 2006, CAN J PHYSIOL PHARM, V84, P847, DOI 10.1139/Y06-018; Takazawa Kazuo, 2008, Kobe J Med Sci, V54, pE14; Yuan HD, 2012, CHEM-BIOL INTERACT, V195, P35, DOI 10.1016/j.cbi.2011.10.006; Zhang M, 2012, MOL CELL ENDOCRINOL, V363, P122, DOI 10.1016/j.mce.2012.08.006	23	28	28	0	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 11	2015	10	8							e0135721	10.1371/journal.pone.0135721	http://dx.doi.org/10.1371/journal.pone.0135721			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO7PP	26263160	gold, Green Published, Green Submitted			2023-01-03	WOS:000359353300099
J	Markham, BE; Kernodle, S; Nemzek, J; Wilkinson, JE; Sigler, R				Markham, Bruce E.; Kernodle, Stace; Nemzek, Jean; Wilkinson, John E.; Sigler, Robert			Chronic Dosing with Membrane Sealant Poloxamer 188 NF Improves Respiratory Dysfunction in Dystrophic Mdx and Mdx/Utrophin(-/-) Mice	PLOS ONE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; HEART-FAILURE; UTROPHIN; SKELETAL; MODEL; MOUSE; CARDIOMYOPATHY; MECHANISMS; FIBROSIS; FENTANYL	Poloxamer 188 NF (national formulary (NF) grade of P-188) improves cardiac muscle function in the mdx mouse and golden retriever muscular dystrophy models. However in vivo effects on skeletal muscle have not been reported. We postulated that P-188 NF might protect diaphragm muscle membranes from contraction-induced injury in mdx and mdx/utrophin(-/-) (dko) muscular dystrophy models. In the first study 7-month old mdx mice were treated for 22 weeks with subcutaneous (s.c.) injections of saline or P-188 NF at 3 mg/Kg. In the second, dkos were treated with saline or P-188 NF (1 mg/Kg) for 8 weeks beginning at age 3 weeks. Prednisone was the positive control in both studies. Respiratory function was monitored using unrestrained whole body plethysmography. P-188 NF treatment affected several respiratory parameters including tidal volume/BW and minute volume/BW in mdx mice. In the more severe dko model, P-188 NF (1 mg/Kg) significantly slowed the decline in multiple respiratory parameters compared with saline-treated dko mice. Prednisone's effects were similar to those seen with P-188 NF. Diaphragms from P-188 NF or prednisone treated mdx and dko mice showed signs of muscle fiber protection including less centralized nuclei, less variation in fiber size, greater fiber density, and exhibited a decreased amount of collagen deposition. P-188 NF at 3 mg/Kg s.c. also improved parameters of systolic and diastolic function in mdx mouse hearts. These results suggest that P-188 NF may be useful in treating respiratory and cardiac dysfunction, the leading causes of death in Duchenne muscular dystrophy patients.	[Markham, Bruce E.; Kernodle, Stace] Phrixus Pharmaceut Inc, Ann Arbor, MI 48104 USA; [Nemzek, Jean; Wilkinson, John E.; Sigler, Robert] Univ Michigan, Sch Med, Unit Lab Anim Med, Ann Arbor, MI USA; [Wilkinson, John E.] Univ Michigan, Sch Med, Dept Pathol & Comparat Med, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Markham, BE (corresponding author), Phrixus Pharmaceut Inc, Ann Arbor, MI 48104 USA.	bruce.markham@phrixuspharmaceuticals.com			Small Business Innovative Research Grants from the NINDS [R43 NS070327]; NHLBI [R43 HL110464]; Duchenne Alliance; Phrixus Pharmaceuticals; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R43HL110464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R43NS070327] Funding Source: NIH RePORTER	Small Business Innovative Research Grants from the NINDS; NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Duchenne Alliance; Phrixus Pharmaceuticals; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by Small Business Innovative Research Grants R43 NS070327 from the NINDS, and R43 HL110464 from the NHLBI and a grant from the Duchenne Alliance to BEM. Phrixus Pharmaceuticals provided support in the form of salaries for authors [BEM, SK]. The funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Agarwal J, 2005, ANN NY ACAD SCI, V1066, P295, DOI 10.1196/annals.1363.027; Allen DG, 2011, INT J BIOCHEM CELL B, V43, P290, DOI 10.1016/j.biocel.2010.11.005; Bach JR, 2010, AM J PHYS MED REHAB, V89, P620, DOI 10.1097/PHM.0b013e3181e72207; BLAIR JR, 1989, ANESTHESIOLOGY, V71, P565, DOI 10.1097/00000542-198910000-00015; BOYD Y, 1986, J MED GENET, V23, P484, DOI 10.1136/jmg.23.6.484; Briguet A, 2004, NEUROMUSCULAR DISORD, V14, P675, DOI 10.1016/j.nmd.2004.06.008; Brookes ZLS, 2003, ANESTH ANALG, V96, P456, DOI 10.1097/00000539-200302000-00030; Call JA, 2011, J APPL PHYSIOL, V111, P200, DOI 10.1152/japplphysiol.00248.2011; Cheng XP, 2014, NAT MED, V20, P1187, DOI 10.1038/nm.3611; Chetboul V, 2004, EUR HEART J, V25, P1934, DOI 10.1016/j.ehj.2004.09.007; Cui GL, 2002, SCAND J GASTROENTERO, V37, P750, DOI 10.1080/00365520213249; DAVIES KE, 1983, NUCLEIC ACIDS RES, V11, P2303, DOI 10.1093/nar/11.8.2303; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Dubach-Powell J, 2008, QUANTITATIVE DETERMI; Duncan DJ, 2007, BRIT J PHARMACOL, V150, P720, DOI 10.1038/sj.bjp.0707147; EDMONDSSEAL J, 1970, BRIT J ANAESTH, V42, P207, DOI 10.1093/bja/42.3.207; Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U; Emery AEH, 2002, LANCET, V359, P687, DOI 10.1016/S0140-6736(02)07815-7; Finsterer J, 2013, CARDIOVASC PATHOL, V22, P389, DOI 10.1016/j.carpath.2012.12.008; Fisher A, 2010, INT J CLIN PHARM TH, V48, P138; Gayraud J, 2007, J MUSCLE RES CELL M, V28, P29, DOI 10.1007/s10974-007-9101-1; Goonasekera SA, 2014, HUM MOL GENET, V23, P3706, DOI 10.1093/hmg/ddu079; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Guerron AD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011220; Harisseh R, 2013, AM J PHYSIOL-CELL PH, V304, pC881, DOI 10.1152/ajpcell.00182.2012; HERTSENS R, 1984, BIOCHIM BIOPHYS ACTA, V769, P411, DOI 10.1016/0005-2736(84)90325-0; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Houang EM, 2015, MDA SCI SESS MARCH 2; Huang P, 2011, MUSCLE NERVE, V43, P263, DOI 10.1002/mus.21848; Ilsar I, 2010, J AM COL CARDIOL, V55; Ishizaki M, 2008, NEUROMUSCULAR DISORD, V18, P342, DOI 10.1016/j.nmd.2008.02.002; Juneman EB, 2012, J CARDIOVASC PHARM, V60, P293, DOI 10.1097/FJC.0b013e31825f6f88; Kamogawa Y, 2001, CARDIOVASC RES, V50, P509, DOI 10.1016/S0008-6363(01)00205-X; Khurana TS, 2008, RESP SYSTEM EVALUATI; Lee B, 2008, BIOMACROMOLECULES, V9, P1541, DOI 10.1021/bm701348r; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Liu F, 2001, Mol Interv, V1, P168; Lorin C, 2015, CARDIOVASC RES, V106, P153, DOI 10.1093/cvr/cvv021; Lynch GS, 2004, CLIN EXP PHARMACOL P, V31, P557, DOI 10.1111/j.1440-1681.2004.04026.x; Manzur AY, 2008, ARCH DIS CHILD, V93, P986, DOI 10.1136/adc.2007.118141; Maskarinec SA, 2005, ANN NY ACAD SCI, V1066, P310, DOI 10.1196/annals.1363.018; Melacini P, 1998, NEUROMUSCULAR DISORD, V8, P585, DOI 10.1016/S0960-8966(98)00071-6; MENKE A, 1995, J CELL SCI, V108, P727; Nelson CA, 2011, AM J PATHOL, V178, P2611, DOI 10.1016/j.ajpath.2011.02.024; Ng R, 2008, AM J PHYSIOL-CELL PH, V295, pC146, DOI 10.1152/ajpcell.00017.2008; NIGRO G, 1990, INT J CARDIOL, V26, P271, DOI 10.1016/0167-5273(90)90082-G; PADANILAM JT, 1994, ANN NY ACAD SCI, V720, P111, DOI 10.1111/j.1749-6632.1994.tb30439.x; Quinlan JG, 2006, NEUROMUSCULAR DISORD, V16, P855, DOI 10.1016/j.nmd.2006.09.016; Ryall JG, 2007, FASEB J, V21, pA945; Schaer GL, 1996, CIRCULATION, V94, P298, DOI 10.1161/01.CIR.94.3.298; Serbest G, 2005, J NEUROTRAUM, V22, P119, DOI 10.1089/neu.2005.22.119; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Steinhardt RA, 2005, ANN NY ACAD SCI, V1066, P152, DOI 10.1196/annals.1363.017; Suzuki N, 2012, NEUROSCI RES, V72, P181, DOI 10.1016/j.neures.2011.10.005; Terry RL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091221; Townsend D, 2010, J CLIN INVEST, V120, P1140, DOI 10.1172/JCI41329; Turgeman T, 2008, NEUROMUSCULAR DISORD, V18, P857, DOI 10.1016/j.nmd.2008.06.386; Wallace GQ, 2009, ANNU REV PHYSIOL, V71, P37, DOI 10.1146/annurev.physiol.010908.163216; Weir AP, 2002, J BIOL CHEM, V277, P45285, DOI 10.1074/jbc.M205177200; Willmann R, 2009, NEUROMUSCULAR DISORD, V19, P241, DOI 10.1016/j.nmd.2008.11.015; Yasuda S, 2005, NATURE, V436, P1025, DOI 10.1038/nature03844; Zhou L, 2008, J NEUROL SCI, V264, P106, DOI 10.1016/j.jns.2007.08.029	62	21	21	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2015	10	8							e0134832	10.1371/journal.pone.0134832	http://dx.doi.org/10.1371/journal.pone.0134832			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO3MQ	26248188	Green Published, Green Submitted, gold			2023-01-03	WOS:000359062300069
J	Rejc, E; Angeli, C; Harkema, S				Rejc, Enrico; Angeli, Claudia; Harkema, Susan			Effects of Lumbosacral Spinal Cord Epidural Stimulation for Standing after Chronic Complete Paralysis in Humans	PLOS ONE			English	Article							LUMBAR CORD; NEUROPHYSIOLOGICAL ASSESSMENT; INTRASPINAL MICROSTIMULATION; SENSORIMOTOR INTERACTIONS; ELECTRICAL-STIMULATION; POSTERIOR STRUCTURES; EVOKED-POTENTIALS; INJURY; LOCOMOTION; REFLEXES	Sensory and motor complete spinal cord injury (SCI) has been considered functionally complete resulting in permanent paralysis with no recovery of voluntary movement, standing or walking. Previous findings demonstrated that lumbosacral spinal cord epidural stimulation can activate the spinal neural networks in one individual with motor complete, but sensory incomplete SCI, who achieved full body weight-bearing standing with independent knee extension, minimal self-assistance for balance and minimal external assistance for facilitating hip extension. In this study, we showed that two clinically sensory and motor complete participants were able to stand over-ground bearing full body-weight without any external assistance, using their hands to assist balance. The two clinically motor complete, but sensory incomplete participants also used minimal external assistance for hip extension. Standing with the least amount of assistance was achieved with individual-specific stimulation parameters, which promoted overall continuous EMG patterns in the lower limbs' muscles. Stimulation parameters optimized for one individual resulted in poor standing and additional need of external assistance for hip and knee extension in the other participants. During sitting, little or negligible EMG activity of lower limb muscles was induced by epidural stimulation, showing that the weight-bearing related sensory information was needed to generate sufficient EMG patterns to effectively support full weight-bearing standing. In general, electrode configurations with cathodes selected in the caudal region of the array at relatively higher frequencies (25-60 Hz) resulted in the more effective EMG patterns for standing. These results show that human spinal circuitry can generate motor patterns effective for standing in the absence of functional supraspinal connections; however the appropriate selection of stimulation parameters is critical.	[Rejc, Enrico; Angeli, Claudia; Harkema, Susan] Univ Louisville, Kentucky Spinal Cord Injury Res Ctr, Louisville, KY 40292 USA; [Angeli, Claudia; Harkema, Susan] Kentucky One Hlth, Frazier Rehab Inst, Louisville, KY USA	University of Louisville	Harkema, S (corresponding author), Univ Louisville, Kentucky Spinal Cord Injury Res Ctr, Louisville, KY 40292 USA.	SusanHarkema@KentuckyOneHealth.org		Angeli, Claudia/0000-0003-4127-7121	US National Institutes of Health, NIBIB [R01EB007615]; NIGMS [P30 GM103507]; Christopher and Dana Reeve Foundation; Kessler Foundation; Leona M. and Harry B. Helmsley Charitable Trust; Kentucky Spinal Cord Injury Research Center; Jewish Hospital; St. Mary's Foundation; University of Louisville Foundation; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB007615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103507] Funding Source: NIH RePORTER	US National Institutes of Health, NIBIB(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Christopher and Dana Reeve Foundation; Kessler Foundation; Leona M. and Harry B. Helmsley Charitable Trust; Kentucky Spinal Cord Injury Research Center; Jewish Hospital; St. Mary's Foundation; University of Louisville Foundation; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by: US National Institutes of Health, NIBIB, under the award number R01EB007615 and NIGMS P30 GM103507, Christopher and Dana Reeve Foundation, Kessler Foundation, the Leona M. and Harry B. Helmsley Charitable Trust, Kentucky Spinal Cord Injury Research Center, University of Louisville Foundation, Jewish Hospital and St. Mary's Foundation.	Angeli CA, 2014, BRAIN; Arber S, 2012, NEURON, V74, P975, DOI 10.1016/j.neuron.2012.05.011; Barthelemy D, 2007, J NEUROPHYSIOL, V97, P1986, DOI 10.1152/jn.00818.2006; Beauparlant J, 2013, BRAIN, V136, P3347, DOI 10.1093/brain/awt204; Biering-Sorensen F, 2003, J SPINAL CORD MED S1, V26, pS50, DOI [DOI 10.1080/10790268.2003.11754575, 10.1080/10790268.2003.11754575]; Budh CN, 2007, CLIN REHABIL, V21, P89, DOI 10.1177/0269215506070313; BURNS S, 2012, TOP SPINAL CORD INJ, V18, P85, DOI DOI 10.1310/SCI1801-85; Capogrosso M, 2013, J NEUROSCI, V33, P19326, DOI 10.1523/JNEUROSCI.1688-13.2013; Courtine G, 2009, NAT NEUROSCI, V12, P1333, DOI 10.1038/nn.2401; de Leon RD, 1999, J NEUROPHYSIOL, V81, P85, DOI 10.1152/jn.1999.81.1.85; Dimitrijevic M R, 1988, Adv Neurol, V47, P138; DIMITRIJEVIC MR, 1992, ELECTROEN CLIN NEURO, V85, P365, DOI 10.1016/0168-5597(92)90049-H; DIMITRIJEVIC MR, 1983, J NEUROL SCI, V60, P253, DOI 10.1016/0022-510X(83)90067-9; Dimitrijevic MR, 1998, ANN NY ACAD SCI, V860, P360, DOI 10.1111/j.1749-6632.1998.tb09062.x; DIMITRIJEVIC MR, 1992, J NEUROTRAUM, V9, pS293; Etlin A, 2010, J NEUROSCI, V30, P10324, DOI 10.1523/JNEUROSCI.1208-10.2010; Gad P, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-2; Gaunt RA, 2006, J NEUROPHYSIOL, V96, P2995, DOI 10.1152/jn.00061.2006; Gerasimenko Yu P, 2002, Neurosci Behav Physiol, V32, P417, DOI 10.1023/A:1015836428932; Gerasimenko Y, 2008, EXP NEUROL, V209, P417, DOI 10.1016/j.expneurol.2007.07.015; Gerasimenko YP, 2007, J NEUROPHYSIOL, V98, P2525, DOI 10.1152/jn.00836.2007; Gerasimenko YP, 2006, J NEUROSCI METH, V157, P253, DOI 10.1016/j.jneumeth.2006.05.004; GRILLNER S, 1985, SCIENCE, V228, P143, DOI 10.1126/science.3975635; Harkema SJ, 1997, J NEUROPHYSIOL, V77, P797, DOI 10.1152/jn.1997.77.2.797; Harkema S, 2011, LANCET, V377, P1938, DOI 10.1016/S0140-6736(11)60547-3; Harkema SJ, 2012, ARCH PHYS MED REHAB, V93, P1588, DOI 10.1016/j.apmr.2012.04.032; Hiersemenzel LP, 2000, NEUROLOGY, V54, P1574, DOI 10.1212/WNL.54.8.1574; Ivanenko YP, 2006, J NEUROPHYSIOL, V95, P602, DOI 10.1152/jn.00767.2005; IWAHARA T, 1992, BRAIN RES BULL, V28, P99, DOI 10.1016/0361-9230(92)90235-P; Jilge B, 2004, BIOL CYBERN, V91, P359, DOI 10.1007/s00422-004-0511-5; Jilge B, 2004, EXP BRAIN RES, V154, P308, DOI 10.1007/s00221-003-1666-3; Lavrov I, 2006, J NEUROPHYSIOL, V96, P1699, DOI 10.1152/jn.00325.2006; Li K, 2012, J NEUROSURG-SPINE, V17, P77, DOI 10.3171/2012.6.AOSPINE12117; Mckay WB, 2011, SPINAL CORD, V49, P421, DOI 10.1038/sc.2010.145; McKay WB, 1997, J NEUROTRAUM, V14, P539, DOI 10.1089/neu.1997.14.539; McKay WB, 2004, NEUROREHAB NEURAL RE, V18, P144, DOI 10.1177/0888439004267674; Minassian K, 2007, HUM MOVEMENT SCI, V26, P275, DOI 10.1016/j.humov.2007.01.005; Minassian K, 2004, SPINAL CORD, V42, P401, DOI 10.1038/sj.sc.3101615; Murg M, 2000, SPINAL CORD, V38, P394, DOI 10.1038/sj.sc.3101038; Musienko P E, 2013, Ross Fiziol Zh Im I M Sechenova, V99, P392; Musienko PE, 2010, J NEUROPHYSIOL, V103, P1080, DOI 10.1152/jn.00575.2009; Musienko P, 2012, EXP NEUROL, V235, P100, DOI 10.1016/j.expneurol.2011.08.025; Musienko P, 2012, J NEUROPHYSIOL, V107, P2072, DOI 10.1152/jn.00730.2011; NELSON SG, 1978, J NEUROPHYSIOL, V41, P778, DOI 10.1152/jn.1978.41.3.778; Rattay F, 2000, SPINAL CORD, V38, P473, DOI 10.1038/sj.sc.3101039; Rossignol S, 2006, PHYSIOL REV, V86, P89, DOI 10.1152/physrev.00028.2005; Rossignol S, 2008, BRAIN RES REV, V57, P228, DOI 10.1016/j.brainresrev.2007.06.019; Sayenko DG, 2014, J NEUROPHYSIOL, V111, P1088, DOI 10.1152/jn.00489.2013; Schindler-Ivens S, 2000, EXP BRAIN RES, V133, P233, DOI 10.1007/s002210000377; Tseng SC, 2013, CLIN NEUROPHYSIOL, V124, P982, DOI 10.1016/j.clinph.2012.10.020; van den Brand R, 2012, SCIENCE, V336, P1182, DOI 10.1126/science.1217416; Varma AK, 2013, NEUROCHEM RES, V38, P895, DOI 10.1007/s11064-013-0991-6; Waring WP, 2010, J SPINAL CORD MED, V33, P346, DOI 10.1080/10790268.2010.11689712; WATERS RL, 1992, ARCH PHYS MED REHAB, V73, P784	54	92	97	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2015	10	7							e0133998	10.1371/journal.pone.0133998	http://dx.doi.org/10.1371/journal.pone.0133998			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN7NT	26207623	Green Published, gold, Green Submitted			2023-01-03	WOS:000358622000189
J	Nakahara, S; Tomio, J; Ichikawa, M; Nakamura, F; Nishida, M; Takahashi, H; Morimura, N; Sakamoto, T				Nakahara, Shinji; Tomio, Jun; Ichikawa, Masao; Nakamura, Fumiaki; Nishida, Masamichi; Takahashi, Hideto; Morimura, Naoto; Sakamoto, Tetsuya			Association of Bystander Interventions With Neurologically Intact Survival Among Patients With Bystander-Witnessed Out-of-Hospital Cardiac Arrest in Japan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AUTOMATED EXTERNAL DEFIBRILLATORS; PUBLIC-ACCESS DEFIBRILLATION; AMERICAN-HEART-ASSOCIATION; EMERGENCY CARDIOVASCULAR CARE; CARDIOPULMONARY-RESUSCITATION; COST-EFFECTIVENESS; LIFE-SUPPORT; GUIDELINES; LOCATION; PROFESSIONALS	IMPORTANCE Neurologically intact survival after out-of-hospital cardiac arrest (OHCA) has been increasing in Japan. However, associations between increased prehospital care, including bystander interventions and increases in survival, have not been well estimated. OBJECTIVE To estimate the associations between bystander interventions and changes in neurologically intact survival among patients with OHCA in Japan. DESIGN, SETTING, AND PARTICIPANTS Retrospective descriptive study using data from Japan's nationwide OHCA registry, which started in January 2005. The registry includes all patients with OHCA transported to the hospital by emergency medical services (EMS) and recorded patients' characteristics, prehospital interventions, and outcomes. Participants were 167 912 patients with bystander-witnessed OHCA of presumed cardiac origin in the registry between January 2005 and December 2012. EXPOSURES Prehospital interventions by bystander, including defibrillation using public-access automated external defibrillators and chest compression. MAIN OUTCOMES AND MEASURES Neurologically intact survival was defined as Glasgow-Pittsburgh cerebral performance category score 1 or 2 and overall performance category scores 1 or 2 at 1 month or at discharge. The association between the interventions and neurologically intact survival was evaluated. RESULTS From 2005 to 2012, the number of bystander-witnessed OHCAs of presumed cardiac origin increased from 17 882 (14.0 per 100 000 persons [95% CI, 13.8-14.2]) to 23 797 (18.7 per 100 000 persons [95% CI, 18.4-18.9]), and neurologically intact survival increased from 587 cases (age-adjusted proportion, 3.3%[95% CI, 3.0%-3.5%]) to 1710 cases (8.2%[95% CI, 7.8%-8.6%]). The rates of bystander chest compression increased from 38.6% to 50.9%, bystander-only defibrillation increased from 0.1% to 2.3%, bystander defibrillation combined with EMS defibrillation increased from 0.1% to 1.4%, and EMS-only defibrillation decreased from 26.6% to 23.5%. Performance of bystander chest compression, compared with no bystander chest compression, was associated with increased neurologically intact survival (8.4%[6594 survivors/78 592 cases] vs 4.1% [3595 survivors/88 720 cases]; odds ratio [OR], 1.52 [95% CI, 1.45-1.60]). Compared with EMS-only defibrillation (15.0%[6445 survivors/42 916 cases]), bystander-only defibrillation (40.7% [931 survivors/2287 cases]) was associated with increased neurologically intact survival (OR, 2.24 [95% CI, 1.93-2.61]), as was combined bystander and EMS defibrillation (30.5%[444 survivors/1456 cases]; OR, 1.50 [95% CI, 1.31-1.71]), whereas no defibrillation (2.0% [2369 survivors/120 653 cases]) was associated with reduced survival (OR, 0.43 [95% CI, 0.39-0.48]). CONCLUSIONS AND RELEVANCE In Japan, between 2005 and 2012, the rates of bystander chest compression and bystander defibrillation increased and were associated with increased odds of neurologically intact survival.	[Nakahara, Shinji] Kanagawa Univ Human Serv, Dept Liberal Arts & Human Dev, Yokosuka, Kanagawa, Japan; [Tomio, Jun; Nakamura, Fumiaki] Univ Tokyo, Grad Sch Med, Dept Publ Hlth, Tokyo, Japan; [Ichikawa, Masao] Univ Tsukuba, Fac Med, Tsukuba, Ibaraki, Japan; [Nishida, Masamichi] Toranomon Gen Hosp, Dept Emergency Med, Tokyo, Japan; [Takahashi, Hideto] Fukushima Med Univ, Sch Med, Fukushima, Japan; [Morimura, Naoto] Yokohama City Univ, Sch Med, Dept Emergency Med, Yokohama, Kanagawa 232, Japan; [Sakamoto, Tetsuya] Teikyo Univ, Sch Med, Dept Emergency Med, Tokyo 173, Japan	University of Tokyo; University of Tsukuba; Toranomon Hospital; Fukushima Medical University; Yokohama City University; Teikyo University	Nakahara, S (corresponding author), Teikyo Univ, Sch Med, Dept Emergency Med, Itabashi Ku, 2-11-1 Kaga, Tokyo 1738606, Japan.	snakahara-tky@umin.net		Nakahara, Shinji/0000-0001-7243-4797				Bardy GH, 2008, NEW ENGL J MED, V358, P1793, DOI 10.1056/NEJMoa0801651; Berdowski J, 2010, RESUSCITATION, V81, P1479, DOI 10.1016/j.resuscitation.2010.08.006; Brooks SC, 2013, ANN EMERG MED, V61, P530, DOI 10.1016/j.annemergmed.2012.10.037; Culley LL, 2004, CIRCULATION, V109, P1859, DOI 10.1161/01.CIR.0000124721.83385.B2; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; Davies CS, 2005, HEART, V91, P1299, DOI 10.1136/hrt.2003.032631; Fire and Disaster Management Agency, 2014, KYUK NO GENK 2013; Folke F, 2009, CIRCULATION, V120, P510, DOI 10.1161/CIRCULATIONAHA.108.843755; Gold LS, 2007, CURR OPIN CARDIOL, V22, P1, DOI 10.1097/HCO.0b013e32801173c1; Greenland S., 2008, MODERN EPIDEMIOLOGY, P283; Hallstrom AP, 2004, NEW ENGL J MED, V351, P637; Hansen CM, 2014, CIRCULATION, V130, P1859, DOI 10.1161/CIRCULATIONAHA.114.008850; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Kitamura T, 2012, CIRCULATION, V126, P2834, DOI 10.1161/CIRCULATIONAHA.112.109496; Kitamura T, 2010, NEW ENGL J MED, V362, P994, DOI 10.1056/NEJMoa0906644; Kramer AA, 2007, CRIT CARE MED, V35, P2052, DOI 10.1097/01.CCM.0000275267.64078.B0; Link MS, 2010, CIRCULATION, V122, pS706, DOI 10.1161/CIRCULATIONAHA.110.970954; Marukawa S, 2014, JUNKANKISIKKANTOUNO, P146; Murakami Y, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000533; Muraoka H, 2006, CIRC J, V70, P827, DOI 10.1253/circj.70.827; Nakahara S, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6829; Nakamura F, 2013, RESUSCITATION, V84, P747, DOI 10.1016/j.resuscitation.2012.11.012; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Pell JP, 2007, CURR OPIN CARDIOL, V22, P5, DOI 10.1097/HCO.0b013e3280118fec; Pell JP, 2002, BMJ-BRIT MED J, V325, P515; Rothman K., 2008, MEASURES EFFECT MEAS, P51; Sasaki M, 2011, CIRC J, V75, P2821, DOI 10.1253/circj.CJ-11-0316; Stiell IG, 2004, NEW ENGL J MED, V351, P647, DOI 10.1056/NEJMoa040325; Travers AH, 2010, CIRCULATION, V122, pS676, DOI 10.1161/CIRCULATIONAHA.110.970913; Weisfeldt ML, 2010, J AM COLL CARDIOL, V55, P1712, DOI 10.1016/j.jacc.2009.11.077; Winkle RA, 2010, CLIN CARDIOL, V33, P396, DOI 10.1002/clc.20790; Wissenberg M, 2013, JAMA-J AM MED ASSOC, V310, P1377, DOI 10.1001/jama.2013.278483	33	113	115	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	2015	314	3					247	254		10.1001/jama.2015.8068	http://dx.doi.org/10.1001/jama.2015.8068			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CN2CM	26197185	Bronze			2023-01-03	WOS:000358228000019
J	Lin, CH; Chou, LW; Luo, HJ; Tsai, PY; Lieu, FK; Chiang, SL; Chiang, L; Sung, WH				Lin, Chueh-Ho; Chou, Li-Wei; Luo, Hong-Ji; Tsai, Po-Yi; Lieu, Fu-Kong; Chiang, Shang-Lin; Chiang, Lin; Sung, Wen-Hsu			Effects of Computer-Aided Interlimb Force Coupling Training on Paretic Hand and Arm Motor Control following Chronic Stroke: A Randomized Controlled Trial	PLOS ONE			English	Article							STATIC BIMANUAL MANIPULATION; UPPER-EXTREMITY FUNCTION; ADULT SQUIRREL-MONKEYS; UPPER-LIMB; HEMIPARETIC STROKE; ASSESSMENT SCALE; POST-STROKE; CORTEX; COORDINATION; GRIP	Objective We investigated the training effects of interlimb force coupling training on paretic upper extremity outcomes in patients with chronic stroke and analyzed the relationship between motor recovery of the paretic hand, arm and functional performances on paretic upper limb. Design A randomized controlled trial with outcome assessment at baseline and after 4 weeks of intervention. Setting Taipei Veterans General Hospital, National Yang-Ming University. Participants Thirty-three subjects with chronic stroke were recruited and randomly assigned to training (n = 16) and control groups (n = 17). Interventions The computer-aided interlimb force coupling training task with visual feedback included different grip force generation methods on both hands. Main Outcome Measures The Barthel Index (BI), the upper extremity motor control Fugl-Meyer Assessment (FMA-UE), the Motor Assessment Score (MAS), and the Wolf Motor Function Test (WMFT). All assessments were executed by a blinded evaluator, and data management and statistical analysis were also conducted by a blinded researcher. Results The training group demonstrated greater improvement on the FMA-UE (p<.001), WMFT (p<.001), MAS (p = .004) and BI (p = .037) than the control group after 4 weeks of intervention. In addition, a moderate correlation was found between the improvement of scores for hand scales of the FMA and other portions of the FMA UE (r = .528, p = .018) or MAS (r = .596, p = .015) in the training group. Conclusion Computer-aided interlimb force coupling training improves the motor recovery of a paretic hand, and facilitates motor control and enhances functional performance in the paretic upper extremity of people with chronic stroke.	[Lin, Chueh-Ho] Taipei Med Univ, Sch Gerontol Hlth Management, Taipei, Taiwan; [Lin, Chueh-Ho] Taipei Med Univ, Master Program Long Term Care, Taipei, Taiwan; [Chou, Li-Wei; Luo, Hong-Ji; Chiang, Shang-Lin; Chiang, Lin; Sung, Wen-Hsu] Natl Yang Ming Univ, Dept Phys Therapy & Assist Technol, Taipei 112, Taiwan; [Tsai, Po-Yi] Taipei Vet Gen Hosp, Phys Med & Rehabil Dept, Taipei, Taiwan; [Lieu, Fu-Kong] Cheng Hsin Hosp, Taipei, Taiwan; [Chiang, Lin] Tri Serv Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Chiang, Lin] Natl Def Med Ctr, Sch Med, Dept Phys Med & Rehabil, Taipei, Taiwan	Taipei Medical University; Taipei Medical University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; Cheng Hsin General Hospital; Tri-Service General Hospital; National Defense Medical Center	Sung, WH (corresponding author), Natl Yang Ming Univ, Dept Phys Therapy & Assist Technol, 155 Sec 2,Linong St, Taipei 112, Taiwan.	whsung@ym.edu.tw			Ministry of Science and Technology of Taiwan [MOST 103-2221-E-010-008-MY2]; Taipei Medical University [TMU103-AE1-B24]	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); Taipei Medical University	This study was supported by the Ministry of Science and Technology of Taiwan (MOST 103-2221-E-010-008-MY2) and Taipei Medical University (TMU103-AE1-B24). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Blennerhassett JM, 2008, J HAND THER, V21, P245, DOI 10.1197/j.jht.2007.10.021; Bohannon R. W., 1987, PHYS THER, V67, P206; Calautti C, 2003, STROKE, V34, P1553, DOI 10.1161/01.STR.0000071761.36075.A6; Carey JR, 2002, BRAIN, V125, P773, DOI 10.1093/brain/awf091; CARR JH, 1985, PHYS THER, V65, P175, DOI 10.1093/ptj/65.2.175; Carson RG, 2005, BRAIN RES REV, V49, P641, DOI 10.1016/j.brainresrev.2005.03.005; Cauraugh JH, 2010, HUM MOVEMENT SCI, V29, P853, DOI 10.1016/j.humov.2009.09.004; Cauraugh JH, 2005, PROG NEUROBIOL, V75, P309, DOI 10.1016/j.pneurobio.2005.04.001; Colle F., 2006, Annales de Readaptation et de Medecine Physique, V49, P361, DOI 10.1016/j.annrmp.2006.04.010; Cramer SC, 1997, STROKE, V28, P2518, DOI 10.1161/01.STR.28.12.2518; DUNCAN PW, 1994, PHYS THER, V74, P399, DOI 10.1093/ptj/74.5.399; FLANAGAN JR, 1995, EXP BRAIN RES, V105, P455; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FUGLMEYER AR, 1980, SCAND J REHABIL MED, P85; GOWLAND C, 1992, PHYS THER, V72, P624, DOI 10.1093/ptj/72.9.624; Hendricks HT, 2002, ARCH PHYS MED REHAB, V83, P1629, DOI 10.1053/apmr.2002.35473; Hu XG, 2011, EXP BRAIN RES, V208, P533, DOI 10.1007/s00221-010-2502-1; Jaric S, 2006, EXP BRAIN RES, V168, P88, DOI 10.1007/s00221-005-0070-6; Jaric S, 2005, J ELECTROMYOGR KINES, V15, P556, DOI 10.1016/j.jelekin.2005.03.003; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; Kang N, 2015, NEUROSCI RES, V94, P79, DOI 10.1016/j.neures.2014.12.005; Kang N, 2015, NEUROSCI LETT, V587, P41, DOI 10.1016/j.neulet.2014.12.028; Kazennikov O, 1999, NEUROSCIENCE, V89, P661, DOI 10.1016/S0306-4522(98)00348-0; Kilbreath SL, 2005, AUST J PHYSIOTHER, V51, P119, DOI 10.1016/S0004-9514(05)70040-4; Krishnan V, 2010, MOTOR CONTROL, V14, P528, DOI 10.1123/mcj.14.4.528; Kwakkel G, 2003, STROKE, V34, P2181, DOI 10.1161/01.STR.0000087172.16305.CD; Liepert J, 2000, MUSCLE NERVE, V23, P1761, DOI 10.1002/1097-4598(200011)23:11<1761::AID-MUS14>3.0.CO;2-M; Lin JH, 2009, PHYS THER, V89, P840, DOI 10.2522/ptj.20080285; Lodha N, 2012, CLIN NEUROPHYSIOL, V123, P787, DOI 10.1016/j.clinph.2011.08.014; Mayo NE, 1999, DISABIL REHABIL, V21, P258; Morris DM, 2001, ARCH PHYS MED REHAB, V82, P750, DOI 10.1053/apmr.2001.23183; Naik SK, 2011, EXP BRAIN RES, V211, P1, DOI 10.1007/s00221-011-2637-8; NUDO RJ, 1992, J NEUROSCI, V12, P2918, DOI 10.1523/JNEUROSCI.12-08-02918.1992; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Plautz EJ, 2000, NEUROBIOL LEARN MEM, V74, P27, DOI 10.1006/nlme.1999.3934; Reistetter T, 2009, OCCUP THER INT, V16, P218, DOI 10.1002/oti.278; Rose Dorian K, 2004, Top Stroke Rehabil, V11, P20, DOI 10.1310/XAUM-LPBM-0RXD-RLDK; Rosenstein L, 2008, AM J OCCUP THER, V62, P28, DOI 10.5014/ajot.62.1.28; Rouiller EM, 1998, EUR J NEUROSCI, V10, P729, DOI 10.1046/j.1460-9568.1998.00075.x; Sabari JS, 2005, ARCH PHYS MED REHAB, V86, P1609, DOI 10.1016/j.apmr.2004.12.028; Stinear JW, 2002, J PHYSIOL-LONDON, V543, P307, DOI 10.1113/jphysiol.2002.023986; Sveen U, 1999, DISABIL REHABIL, V21, P372, DOI 10.1080/096382899297477; Swinnen SP, 2004, TRENDS COGN SCI, V8, P18, DOI 10.1016/j.tics.2003.10.017; van Delden AEQ, 2012, STROKE RES TREAT, V2012, DOI 10.1155/2012/972069; van Delden AEQ, 2013, STROKE, V44, P2613, DOI 10.1161/STROKEAHA.113.001969; van Delden AEQ, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-57; Whitall J, 2000, STROKE, V31, P2390, DOI 10.1161/01.STR.31.10.2390; WOLF SL, 1989, EXP NEUROL, V104, P125, DOI 10.1016/S0014-4886(89)80005-6; Wolf SL, 2001, STROKE, V32, P1635, DOI 10.1161/01.STR.32.7.1635; Wu CY, 2011, NEUROREHAB NEURAL RE, V25, P130, DOI 10.1177/1545968310380686	51	8	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2015	10	7							e0131048	10.1371/journal.pone.0131048	http://dx.doi.org/10.1371/journal.pone.0131048			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN6LN	26193492	Green Published, Green Submitted, gold			2023-01-03	WOS:000358546400009
J	Li, T; Wang, BY; Wang, ZH; Ragaz, J; Zhang, J; Sun, S; Cao, J; Lv, FF; Wang, LP; Zhang, S; Ni, C; Wu, ZH; Xie, J; Hu, XC				Li, Ting; Wang, Biyun; Wang, Zhonghua; Ragaz, Joseph; Zhang, Jian; Sun, Si; Cao, Jun; Lv, Fangfang; Wang, Leiping; Zhang, Sheng; Ni, Chen; Wu, Zhenhua; Xie, Jie; Hu, Xichun			Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial	PLOS ONE			English	Article							1ST-LINE TREATMENT; COLORECTAL-CANCER; OPEN-LABEL; NEOADJUVANT CHEMOTHERAPY; 2ND-LINE TREATMENT; PLUS CAPECITABINE; NON-INFERIORITY; DOUBLE-BLIND; OXALIPLATIN; PACLITAXEL	Background Bevacizumab combined with modified FOLFOX6 is a standard regimen for colorectal cancer. The present study was to determine the efficacy and safety of bevacizumab-modified FOLFOX6 regimen in heavily pretreated patients with human epidermal growth factor receptor 2 (HER2/neu)-negative MBC. Methods Bevacizumab, 5 mg/kg every two weeks or 7.5 mg/kg every three weeks, was administered with modified FOLFOX6 (oxaliplatin 85 mg/m(2), leucovorin 400 mg/m(2), 5-FU 400 mg/m(2) on day 1, followed by 5-FU 2400 mg/m(2) intravenous infusion over 46 hours every 2 weeks) to patients who failed at least 1 chemotherapy regimen in the metastatic setting. The primary objective was progression free survival (PFS). Secondary objectives included objective response rate (ORR), clinical benefit rate (CBR), overall survival (OS), safety, and the change of tumor size and Eastern Cooperative Oncology Group (ECOG) performance status. Results 69 patients were enrolled. The median PFS was 6.8 months (95% CI, 5.0 to 8.5 months), ORR was 50.0% and median OS was 10.5 months (95% CI, 7.9 to 13.1 months). Patients showing objective responses had a 4.2-month median PFS gain and 5.7-month median OS gain compared with those who did not (P < 0.05). Grade 3 or 4 adverse events occurring in more than one patient were neutropenia (53/69, 76.8%), leukopenia (36/69, 52.2%), thrombocytopenia (13/69, 18.8%), anemia (3/69, 4.3%) and hypertension (3/69, 4.3%). Conclusions Adding bevacizumab to modified FOLFOX6 does have significant anti-tumor activity and good safety profile in heavily pretreated HER2/neu-negative MBC patients. Further trials are required to confirm whether the high ORR can translate into a long-term PFS and even OS benefit.	[Li, Ting; Wang, Biyun; Wang, Zhonghua; Zhang, Jian; Sun, Si; Cao, Jun; Lv, Fangfang; Zhang, Sheng; Ni, Chen; Wu, Zhenhua; Xie, Jie; Hu, Xichun] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai 200032, Peoples R China; [Li, Ting; Wang, Biyun; Wang, Zhonghua; Zhang, Jian; Sun, Si; Cao, Jun; Lv, Fangfang; Wang, Leiping; Zhang, Sheng; Ni, Chen; Wu, Zhenhua; Xie, Jie; Hu, Xichun] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Ragaz, Joseph] Univ British Columbia, Fac Med, Sch Populat & Publ Hlth, Vancouver, BC V6T 1Z4, Canada	Fudan University; Fudan University; University of British Columbia	Hu, XC (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai 200032, Peoples R China.	huxicun@gmail.com			Natural Science Foundation of China [81372846]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This is an investigator-initiated clinical trial (IIT). All of the work including study design, running of the trial and data collection was done by the investigators. The cost for protocol review and revision as well as statistics came from the grant of Natural Science Foundation of China (grant number: 81372846; the URL: http://www.nsfc.gov.cn/). The medical insurance for recruited patients in the trial was provided by the Fudan University Shanghai Cancer Center, the authors' institution. No financial support was from pharmaceuticals. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABRAMS JS, 1995, J CLIN ONCOL, V13, P2056, DOI 10.1200/JCO.1995.13.8.2056; Allegra CJ, 2009, J CLIN ONCOL, V27, P3385, DOI 10.1200/JCO.2009.21.9220; Aogi K, 2012, ANN ONCOL, V23, P1441, DOI 10.1093/annonc/mdr444; Bagri A, 2010, CLIN CANCER RES, V16, P3887, DOI 10.1158/1078-0432.CCR-09-3100; Bear HD, 2012, NEW ENGL J MED, V366, P310, DOI 10.1056/NEJMoa1111097; Brufsky AM, 2011, J CLIN ONCOL, V29, P4286, DOI 10.1200/JCO.2010.34.1255; Chia SK, 2007, CANCER, V110, P973, DOI 10.1002/cncr.22867; Choueiri TK, 2011, J CLIN ONCOL, V29, P632, DOI 10.1200/JCO.2010.31.9129; Cortes J, 2012, EUR J CANCER, V48, P475, DOI 10.1016/j.ejca.2011.11.021; Cortes J, 2010, J CLIN ONCOL, V28, P3922, DOI 10.1200/JCO.2009.25.8467; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Fan MH, 2014, BREAST CANCER RES TR, V143, P141, DOI 10.1007/s10549-013-2793-6; Fumoleau P, 2009, AM J CLIN ONCOL-CANC, V32, P375, DOI 10.1097/COC.0b013e31818f2d2f; Garufi C, 2001, ANN ONCOL, V12, P179, DOI 10.1023/A:1008386419047; Geiger-Gritsch S, 2010, ONCOLOGIST, V15, P1179, DOI 10.1634/theoncologist.2009-0155; Gligorov J, 2014, LANCET ONCOL, V15, P1351, DOI 10.1016/S1470-2045(14)70444-9; Hochster HS, 2008, J CLIN ONCOL, V26, P3523, DOI 10.1200/JCO.2007.15.4138; Hu XC, 2014, INT J CANCER, V135, P1961, DOI 10.1002/ijc.28829; Huang HX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089960; Izzedine H, 2010, EUR J CANCER, V46, P439, DOI 10.1016/j.ejca.2009.11.001; Khoja L, 2014, J CLIN GASTROENTEROL, V48, P430, DOI 10.1097/MCG.0b013e3182a8804c; Lang I, 2013, LANCET ONCOL, V14, P125, DOI 10.1016/S1470-2045(12)70566-1; Miles DW, 2010, J CLIN ONCOL, V28, P3239, DOI 10.1200/JCO.2008.21.6457; Miller K, 2014, J CLIN ONCOL S, V32, p5s; Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113; Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098; Mir O, 2011, ONCOLOGIST, V16, P1325, DOI 10.1634/theoncologist.2010-0002; Modi Shanu, 2005, Clin Breast Cancer, V6, P55, DOI 10.3816/CBC.2005.n.009; National Comprehensive Cancer Network (NCCN), 2015, NCCN CLIN PRACT GUID; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Pectasides D, 2003, ANN ONCOL, V14, P537, DOI 10.1093/annonc/mdg172; Polyzos A, 2011, CANCER CHEMOTH PHARM, V68, P217, DOI 10.1007/s00280-010-1475-x; Rha SU, 2005, BREAST CANCER RES TR, V90, P215, DOI 10.1007/s10549-004-2468-4; Rivera E, 2000, CANCER, V89, P2195, DOI 10.1002/1097-0142(20001201)89:11<2195::AID-CNCR7>3.0.CO;2-W; Robert NJ, 2011, J CLIN ONCOL, V29, P1252, DOI 10.1200/JCO.2010.28.0982; Rugo HS, 2012, J CLIN ONCOL, V30, DOI 10.1200/jco.2012.30.27_suppl.75; Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930; Scartozzi M, 2009, ANN ONCOL, V20, P227, DOI 10.1093/annonc/mdn637; Schmoll HJ, 2012, J CLIN ONCOL, V30, P3588, DOI 10.1200/JCO.2012.42.5355; Schneider BP, 2013, CLIN CANCER RES, V19, P1281, DOI 10.1158/1078-0432.CCR-12-3029; Seo HY, 2011, INVEST NEW DRUG, V29, P360, DOI 10.1007/s10637-009-9357-y; Sikov WM, 2015, J CLIN ONCOL, V33, P13, DOI 10.1200/JCO.2014.57.0572; Smorenburg CH, 2001, BREAST CANCER RES TR, V66, P83, DOI 10.1023/A:1010679127390; SPSS Inc, 2010, IBM SPSS ADVANCED ST; Sun S, 2012, MED ONCOL, V29, P418, DOI 10.1007/s12032-011-9839-6; US Department of Health and Human Services, 2010, COMM TERM CRIT ADV E; Vaziri SAJ, 2010, CURR ONCOL REP, V12, P102, DOI 10.1007/s11912-010-0085-4; von Minckwitz G, 2014, LANCET ONCOL, V15, P1269, DOI 10.1016/S1470-2045(14)70439-5; von Minckwitz G, 2012, NEW ENGL J MED, V366, P299, DOI 10.1056/NEJMoa1111065; Yamada Y, 2013, LANCET ONCOL, V14, P1278, DOI 10.1016/S1470-2045(13)70490-X; Zelek L, 2002, J CLIN ONCOL, V20, P2551, DOI 10.1200/JCO.2002.06.164	51	7	7	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2015	10	7							e0133133	10.1371/journal.pone.0133133	http://dx.doi.org/10.1371/journal.pone.0133133			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RV	26186012	gold, Green Published, Green Submitted			2023-01-03	WOS:000358198700097
J	Oliveira, HC; Stolf-Moreira, R; Martinez, CBR; Grillo, R; de Jesus, MB; Fraceto, LF				Oliveira, Halley Caixeta; Stolf-Moreira, Renata; Reis Martinez, Claudia Bueno; Grillo, Renato; de Jesus, Marcelo Bispo; Fraceto, Leonardo Fernandes			Nanoencapsulation Enhances the Post-Emergence Herbicidal Activity of Atrazine against Mustard Plants	PLOS ONE			English	Article							NANOPARTICLES; PROTECTION; RELEASE; DAMAGE	Poly(epsilon-caprolactone) (PCL) nanocapsules have been recently developed as a modified release system for atrazine, an herbicide that can have harmful effects in the environment. Here, the post-emergence herbicidal activity of PCL nanocapsules containing atrazine was evaluated using mustard (Brassica juncea) as target plant species model. Characterization of atrazine-loaded PCL nanocapsules by nanoparticle tracking analysis indicated a concentration of 7.5 x 10(12) particles mL(-1) and an average size distribution of 240.7 nm. The treatment of mustard plants with nanocapsules carrying atrazine at 1 mg mL(-1) resulted in a decrease of net photosynthesis and PSII maximum quantum yield, and an increase of leaf lipid peroxidation, leading to shoot growth inhibition and the development of severe symptoms. Time course analysis until 72 h after treatments showed that nanoencapsulation of atrazine enhanced the herbicidal activity in comparison with a commercial atrazine formulation. In contrast to the commercial formulation, ten-fold dilution of the atrazine-containing nanocapsules did not compromise the herbicidal activity. No effects were observed when plants were treated with nanocapsules without herbicide compared to control leaves sprayed with water. Overall, these results demonstrated that atrazine-containing PCL nanocapsules provide very effective post-emergence herbicidal activity. More importantly, the use of nanoencapsulated atrazine enables the application of lower dosages of the herbicide, without any loss of efficiency, which could provide environmental benefits.	[Oliveira, Halley Caixeta; Stolf-Moreira, Renata] UEL Univ Londrina, Dept Anim & Plant Biol, Londrina, Parana, Brazil; [Reis Martinez, Claudia Bueno] UEL Univ Londrina, Dept Physiol Sci, Londrina, Parana, Brazil; [Grillo, Renato; Fraceto, Leonardo Fernandes] Univ Estadual Campinas, UNICAMP, Inst Biol, Dept Biochem, Campinas, SP, Brazil; [Grillo, Renato; Fraceto, Leonardo Fernandes] Univ Estadual Paulista, UNESP, Dept Environm Engn, Sorocaba, SP, Brazil; [de Jesus, Marcelo Bispo] Univ Estadual Campinas, UNICAMP, Inst Biol, Nanocell Interact Lab, Campinas, SP, Brazil	Universidade de Sao Paulo; Universidade Estadual de Campinas; Universidade Estadual Paulista; Universidade de Sao Paulo; Universidade Estadual de Campinas	Oliveira, HC (corresponding author), UEL Univ Londrina, Dept Anim & Plant Biol, Londrina, Parana, Brazil.	halley@uel.br; leonardo@sorocaba.unesp.br	Grillo, Renato/H-6532-2013; Oliveira, Halley C/I-8539-2012; de Jesus, Marcelo Bispo/C-6736-2013; Fraceto, Leonardo Fernandes/ABF-2797-2021; Moreira, Renata Stolf/Q-4776-2019; Fraceto, Leonardo/C-4468-2012	Grillo, Renato/0000-0002-0284-5782; Oliveira, Halley C/0000-0002-5487-4964; de Jesus, Marcelo Bispo/0000-0003-0812-1491; Fraceto, Leonardo Fernandes/0000-0002-2827-2038; Moreira, Renata Stolf/0000-0002-3146-7848; 	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [2013/12322-2, 2011/01872-6]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico; Fundunesp; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior; CBRM: INCT-TA/CNPq [573949/2008-5]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundunesp; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CBRM: INCT-TA/CNPq	This work was supported by the following sources of funding. LFF: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (2013/12322-2), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Fundunesp and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior. RG: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (2011/01872-6), CBRM: INCT-TA/CNPq (573949/2008-5). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bortoluzzi Edson C., 2006, Rev. bras. eng. agríc. ambient., V10, P881, DOI 10.1590/S1415-43662006000400015; Brain RA, 2012, ECOTOX ENVIRON SAFE, V79, P55, DOI 10.1016/j.ecoenv.2011.12.001; Camejo G, 1998, Methods Mol Biol, V108, P377; CAMPOS EVR, 2014, ADV SCI ENG MED, V6, P1, DOI DOI 10.1166/ASEM.2014.1538; Chen HD, 2011, TRENDS FOOD SCI TECH, V22, P585, DOI 10.1016/j.tifs.2011.09.004; Clemente Z, 2014, J NANOSCI NANOTECHNO, V14, P4911, DOI 10.1166/jnn.2014.8681; Dalton RL, 2010, ENVIRON TOXICOL CHEM, V29, P2304, DOI 10.1002/etc.277; de Oliveira JL, 2015, J AGR FOOD CHEM, V63, P422, DOI 10.1021/jf5059045; Gammon DW, 2005, PEST MANAG SCI, V61, P331, DOI 10.1002/ps.1000; Ghormade V, 2011, BIOTECHNOL ADV, V29, P792, DOI 10.1016/j.biotechadv.2011.06.007; Graymore M, 2001, ENVIRON INT, V26, P483, DOI 10.1016/S0160-4120(01)00031-9; Grillo R, 2014, J HAZARD MATER, V278, P163, DOI 10.1016/j.jhazmat.2014.05.079; Grillo R, 2012, J HAZARD MATER, V231, P1, DOI 10.1016/j.jhazmat.2012.06.019; Grillo R, 2010, J POLYM ENVIRON, V18, P26, DOI 10.1007/s10924-009-0153-8; Guillette LJ, 2012, SCIENCE, V337, P1614, DOI 10.1126/science.1226985; Hess FD, 2000, WEED SCI, V48, P160, DOI 10.1614/0043-1745(2000)048[0160:LDHAO]2.0.CO;2; Hoagland D. R., 1950, CALIFORNIA AGR EXPT, P347; Kah M, 2013, CRIT REV ENV SCI TEC, V43, P1823, DOI 10.1080/10643389.2012.671750; Kah M, 2014, ENVIRON INT, V63, P224, DOI 10.1016/j.envint.2013.11.015; Khot LR, 2012, CROP PROT, V35, P64, DOI 10.1016/j.cropro.2012.01.007; Kumar S, 2014, CARBOHYD POLYM, V101, P1061, DOI 10.1016/j.carbpol.2013.10.025; Rondina ABL, 2014, J TROP ECOL, V30, P599, DOI 10.1017/S0266467414000509; Murchie EH, 2013, J EXP BOT, V64, P3983, DOI 10.1093/jxb/ert208; Namasivayam SKR, 2014, RES J BIOTECHNOL, V9, P19; Pereira AES, 2014, J HAZARD MATER, V268, P207, DOI 10.1016/j.jhazmat.2014.01.025; Quina FH, 2004, QUIM NOVA, V27, P1028, DOI 10.1590/S0100-40422004000600031; RODRIGUES B. N., 2011, GUIA HERBICIDAS; Roy A, 2014, CENT EUR J CHEM, V12, P453, DOI 10.2478/s11532-013-0405-2; Santos TG, 2012, CHEMOSPHERE, V89, P1118, DOI 10.1016/j.chemosphere.2012.05.096; Vitor SC, 2013, PLANTA, V238, P475, DOI 10.1007/s00425-013-1906-0; Woodruff MA, 2010, PROG POLYM SCI, V35, P1217, DOI 10.1016/j.progpolymsci.2010.04.002	31	41	41	3	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2015	10	7							e0132971	10.1371/journal.pone.0132971	http://dx.doi.org/10.1371/journal.pone.0132971			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RV	26186597	Green Published, gold, Green Submitted			2023-01-03	WOS:000358198700078
J	Jung, PS; Kim, DY; Lee, SW; Park, JY; Suh, DS; Kim, JH; Kim, YM; Kim, YT; Nam, JH				Jung, Phill-Seung; Kim, Dae-Yeon; Lee, Shin-Wha; Park, Jeong-Yeol; Suh, Dae-Shik; Kim, Jong-Hyeok; Kim, Yong-Man; Kim, Young-Tak; Nam, Joo-Hyun			Clinical Role of Adjuvant Chemotherapy after Radical Hysterectomy for FIGO Stage IB-IIA Cervical Cancer: Comparison with Adjuvant RT/CCRT Using Inverse-Probability-of-Treatment Weighting	PLOS ONE			English	Article							PELVIC RADIATION-THERAPY; NEOADJUVANT CHEMOTHERAPY; INTERMEDIATE-RISK; RANDOMIZED-TRIAL; UTERINE CERVIX; CARCINOMA; TRACHELECTOMY; COMPLICATIONS; RADIOTHERAPY; SURGERY	Objective To evaluate the clinical role of adjuvant chemotherapy (AC) in FIGO stage IB-IIA cervical cancer patients. Study Design A cohort of 262 patients with cervical cancer who received radical hysterectomy (RH) and adjuvant therapy at Asan Medical Center between 1992 and 2012 was enrolled. In this cohort, 85 patients received adjuvant chemotherapy (AC), and 177 received adjuvant radiotherapy or concurrent chemoradiation therapy (AR). Oncologic outcomes and adverse events in both treatment arms were compared using weighted Cox proportional hazards regression models with inverse-probability-of-treatment weighting (IPTW) to reduce the impact of treatment selection bias and potential confounding factors. Results During a 46.8-month median follow-up duration, 39 patients (14.9%) had recurrences, and 18 patients (6.9%) died of disease. In multivariate analysis, the hazard ratio (HR) for recurrence and death was not significantly different in patients in either treatment arm (p=0.62 and 0.12, respectively). Also, after IPTW matching, the HR for recurrence did not significantly differ between the arms (HR 1.57, 95% CI 0.68-3.62, p=0.29). Similarly, disease-free survival and overall survival were not significantly different between the arms (p=0.47 and 0.13, respectively). In addition, patients with AC had a much lower prevalence of long-term complications (lymphedema: n=8 (9.4%) vs. 46 (26.0%), p=0.03; ureteral stricture: n=0 vs. 9 (6.2%), p=0.05). Conclusion Patients with FIGO stage IB-IIA cervical cancer can benefit from AC after RH with fewer long-term complications and non-inferior therapeutic effect to AR. Chemotherapy may therefore be an alternative adjuvant treatment option for cervical cancer, particularly in younger patients.	[Jung, Phill-Seung; Kim, Dae-Yeon; Lee, Shin-Wha; Park, Jeong-Yeol; Suh, Dae-Shik; Kim, Jong-Hyeok; Kim, Yong-Man; Kim, Young-Tak; Nam, Joo-Hyun] Univ Ulsan, Div Gynecol Oncol, Dept Obstet & Gynecol, Coll Med,Asan Med Ctr, Seoul, South Korea	University of Ulsan	Nam, JH (corresponding author), Univ Ulsan, Div Gynecol Oncol, Dept Obstet & Gynecol, Coll Med,Asan Med Ctr, Seoul, South Korea.	jhnam@amc.seoul.kr						Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3; EIFEL PJ, 1995, INT J RADIAT ONCOL, V32, P1289, DOI 10.1016/0360-3016(95)00118-I; Hosaka M, 2008, J OBSTET GYNAECOL RE, V34, P552, DOI 10.1111/j.1447-0756.2008.00739.x; Hosaka M, 2012, J SURG ONCOL, V105, P612, DOI 10.1002/jso.22136; Huguet F, 2008, INT J RADIAT ONCOL, V72, P1508, DOI 10.1016/j.ijrobp.2008.03.054; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Lahousen M, 1999, GYNECOL ONCOL, V73, P196, DOI 10.1006/gyno.1999.5343; Lanowska M, 2014, INT J GYNECOL CANCER, V24, P586, DOI 10.1097/IGC.0000000000000080; Lee KB, 2008, INT J GYNECOL CANCER, V18, P1027, DOI 10.1111/j.1525-1438.2007.01136.x; Lee MY, 2007, GYNECOL ONCOL, V104, P95, DOI 10.1016/j.ygyno.2006.07.021; Lee YH, 2012, J GYNECOL ONCOL, V23, P16, DOI 10.3802/jgo.2012.23.1.16; Marchiole P, 2011, GYNECOL ONCOL, V122, P484, DOI 10.1016/j.ygyno.2011.05.010; Matsuura Y, 2006, INT J GYNECOL CANCER, V16, P294, DOI 10.1111/j.1525-1438.2006.00354.x; Monk BJ, 2005, GYNECOL ONCOL, V96, P721, DOI 10.1016/j.ygyno.2004.11.007; Mossa B, 2010, EUR J GYNAECOL ONCOL, V31, P545; Peters WA, 2000, J CLIN ONCOL, V18, P1606, DOI 10.1200/JCO.2000.18.8.1606; Plante M, 2013, INT J GYNECOL CANCER, V23, P982, DOI 10.1097/IGC.0b013e318295906b; Rotman M, 2006, INT J RADIAT ONCOL, V65, P169, DOI 10.1016/j.ijrobp.2005.10.019; Sedlis A, 1999, GYNECOL ONCOL, V73, P177, DOI 10.1006/gyno.1999.5387; Sugihara M, 2010, PHARM STAT, V9, P21, DOI 10.1002/pst.365; Takeshima N, 2006, GYNECOL ONCOL, V103, P618, DOI 10.1016/j.ygyno.2006.04.019; Viswanathan AN, 2014, CANCER-AM CANCER SOC, V120, P3870, DOI 10.1002/cncr.28849	23	8	9	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2015	10	7							e0132298	10.1371/journal.pone.0132298	http://dx.doi.org/10.1371/journal.pone.0132298			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RL	26176626	Green Published, Green Submitted, gold			2023-01-03	WOS:000358197600097
J	Akhtar, S; Al-Zaid, B; El-Hashim, AZ; Chandrasekhar, B; Attur, S; Yousif, MHM; Benter, IF				Akhtar, Saghir; Al-Zaid, Bashayer; El-Hashim, Ahmed Z.; Chandrasekhar, Bindu; Attur, Sreeja; Yousif, Mariam H. M.; Benter, Ibrahim F.			Cationic Polyamidoamine Dendrimers as Modulators of EGFR Signaling In Vitro and In Vivo	PLOS ONE			English	Article							GROWTH-FACTOR RECEPTOR; DRUG-DELIVERY SYSTEMS; PAMAM DENDRIMERS; GENE-EXPRESSION; POLY(AMIDOAMINE) DENDRIMERS; DIABETIC-NEPHROPATHY; TOXICOGENOMICS; MECHANISMS; POLYMERS; TRANSACTIVATION	Cationic polyamidoamine (PAMAM) dendrimers are branch-like spherical polymers being investigated for a variety of applications in nanomedicine including nucleic acid drug delivery. Emerging evidence suggests they exhibit intrinsic biological and toxicological effects but little is known of their interactions with signal transduction pathways. We previously showed that the activated (fragmented) generation (G) 6 PAMAM dendrimer, Superfect (SF), stimulated epidermal growth factor receptor (EGFR) tyrosine kinase signaling-an important signaling cascade that regulates cell growth, survival and apoptosis-in cultured human embryonic kidney (HEK 293) cells. Here, we firstly studied the in vitro effects of Polyfect (PF), a non-activated (intact) G6 PAMAM dendrimer, on EGFR tyrosine kinase signaling via extracellular-regulated kinase 1/2 (ERK1/2) and p38 mitogen-activated protein kinase (MAPK) in cultured HEK 293 cells and then compared the in vivo effects of a single administration (10mg/kg i.p) of PF or SF on EGFR signaling in the kidneys of normal and diabetic male Wistar rats. Polyfect exhibited a dose- and time-dependent inhibition of EGFR, ERK1/2 and p38 MAPK phosphorylation in HEK-293 cells similar to AG1478, a selective EGFR inhibitor. Administration of dendrimers to non-diabetic or diabetic animals for 24h showed that PF inhibited whereas SF stimulated EGFR phosphorylation in the kidneys of both sets of animals. PF-mediated inhibition of EGFR phosphorylation as well as SF or PF-mediated apoptosis in HEK 293 cells could be significantly reversed by co-treatment with antioxidants such as tempol implying that both these effects involved an oxidative stress-dependent mechanism. These results show for the first time that SF and PF PAMAM dendrimers can differentially modulate the important EGFR signal transduction pathway in vivo and may represent a novel class of EGFR modulators. These findings could have important clinical implications for the use of PAMAM dendrimers in nanomedicine.	[Akhtar, Saghir; Al-Zaid, Bashayer; Chandrasekhar, Bindu; Attur, Sreeja; Yousif, Mariam H. M.; Benter, Ibrahim F.] Kuwait Univ, Fac Med, Dept Pharmacol & Toxicol, Safat 13110, Jabriya, Kuwait; [El-Hashim, Ahmed Z.] Kuwait Univ, Fac Pharm, Dept Pharmacol & Therapeut, Safat 13110, Jabriya, Kuwait; [Benter, Ibrahim F.] Eastern Mediterranean Univ, Fac Med, Gazimagusa, North Cyprus, Cyprus	Kuwait University; Kuwait University; Eastern Mediterranean University	Akhtar, S (corresponding author), Kuwait Univ, Fac Med, Dept Pharmacol & Toxicol, Safat 13110, Jabriya, Kuwait.	Saghir@hsc.edu.kw	Benter, Ibrahim Fadil/AAY-2527-2020	Akhtar, Saghir/0000-0003-3177-946X; Yousif, Mariam/0000-0002-6464-031X	Research Administration/Sector at Kuwait University [MR01/13]; OMICS Research Unit/RCF; General Facility Grant [SRUL02/13]	Research Administration/Sector at Kuwait University; OMICS Research Unit/RCF; General Facility Grant	This research is funded by a grant from the Research Administration/Sector at Kuwait University (MR01/13). The authors also acknowledge support from the OMICS Research Unit/RCF and the General Facility Grant (SRUL02/13).	Advani A, 2011, NEPHROLOGY, V16, P573, DOI 10.1111/j.1440-1797.2011.01451.x; Akhtar S, 2006, GENE THER, V13, P739, DOI 10.1038/sj.gt.3302692; Akhtar S, 2007, J CLIN INVEST, V117, P3623, DOI 10.1172/JCI33494; Akhtar S, 2007, ADV DRUG DELIVER REV, V59, P164, DOI 10.1016/j.addr.2007.03.010; Akhtar S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067813; Akhtar S, 2013, INT J PHARMACEUT, V448, P239, DOI 10.1016/j.ijpharm.2013.03.039; Akhtar S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039066; Akhtar S, 2012, BRIT J PHARMACOL, V165, P1390, DOI 10.1111/j.1476-5381.2011.01613.x; Akhtar S, 2010, EXPERT OPIN DRUG MET, V6, P1347, DOI 10.1517/17425255.2010.518611; Alaoui-Jamali M, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00017; Albertazzi L, 2010, MOL PHARMACEUT, V7, P680, DOI 10.1021/mp9002464; Arkhipov A, 2013, CELL, V152, P557, DOI 10.1016/j.cell.2012.12.030; Avaritt BR, 2014, PHARM RES-DORDR, V31, P2429, DOI 10.1007/s11095-014-1338-y; Benter IF, 2009, VASC PHARMACOL, V51, P101, DOI 10.1016/j.vph.2009.04.004; Benter IF, 2005, BRIT J PHARMACOL, V145, P829, DOI 10.1038/sj.bjp.0706238; Chauhan AS, 2009, BIOMACROMOLECULES, V10, P1195, DOI 10.1021/bm9000298; Conti DS, 2014, MOL PHARMACEUT, V11, P1808, DOI 10.1021/mp4006358; Cui J, 2014, TUMOR BIOL, V35, P11701, DOI 10.1007/s13277-014-2660-z; Dhomen Nathalie S., 2012, Critical Reviews in Oncogenesis, V17, P31; Duncan R, 2005, ADV DRUG DELIVER REV, V57, P2215, DOI 10.1016/j.addr.2005.09.019; Duran-Lara E, 2013, EUR J MED CHEM, V69, P601, DOI 10.1016/j.ejmech.2013.08.047; Endres NF, 2014, TRENDS BIOCHEM SCI, V39, P437, DOI 10.1016/j.tibs.2014.08.001; Forstner P, 2014, BIOMACROMOLECULES, V15, P2461, DOI 10.1021/bm500328v; Francois H, 2004, FASEB J, V18, P926, DOI 10.1096/fj.03-0702fje; Han JY, 2012, THER DELIV, V3, P263, DOI 10.4155/TDE.11.151; Hollins AJ, 2007, J DRUG TARGET, V15, P83, DOI 10.1080/10611860601151860; Hong SP, 2006, BIOCONJUGATE CHEM, V17, P728, DOI 10.1021/bc060077y; Jain S, 2012, P NATL ACAD SCI USA, V109, P12938, DOI 10.1073/pnas.1204928109; Jones CF, 2012, MOL PHARMACEUT, V9, P1599, DOI 10.1021/mp2006054; Juliano RL, 2013, J DRUG TARGET, V21, P27, DOI 10.3109/1061186X.2012.740674; Kabanov AV, 2006, ADV DRUG DELIVER REV, V58, P1597, DOI 10.1016/j.addr.2006.09.019; Kanwar YS, 2008, EXP BIOL MED, V233, P4, DOI 10.3181/0705-MR-134; Kovacs E, 2015, ANNU REV BIOCHEM, V84, P739, DOI 10.1146/annurev-biochem-060614-034402; Kuo JHS, 2010, MOL PHARMACEUT, V7, P805, DOI 10.1021/mp900303s; Labieniec M, 2010, BIOCHIMIE, V92, P1296, DOI 10.1016/j.biochi.2010.06.002; Labieniec Magdalena, 2008, Int J Pharm, V364, P142, DOI 10.1016/j.ijpharm.2008.08.001; Labieniec-Watala M, 2015, J PHARM SCI-US, V104, P2, DOI 10.1002/jps.24222; Labieniec-Watala M, 2014, INT J PHARMACEUT, V464, P152, DOI 10.1016/j.ijpharm.2014.01.011; Lee JH, 2009, TOXICOL LETT, V190, P202, DOI 10.1016/j.toxlet.2009.07.018; Lemmon MA, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a020768; Li Y, 2014, NANOTOXICOLOGY, V8, P36, DOI 10.3109/17435390.2013.855827; Lill NL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003341; Luo K, 2014, BIOTECHNOL ADV, V32, P818, DOI 10.1016/j.biotechadv.2013.12.008; Movassaghian S, 2011, J DRUG TARGET, V19, P925, DOI 10.3109/1061186X.2011.628396; Mukherjee SP, 2010, TOXICOL APPL PHARM, V248, P259, DOI 10.1016/j.taap.2010.08.016; Mukherjee SP, 2010, TOXICOL IN VITRO, V24, P169, DOI 10.1016/j.tiv.2009.09.014; Naha PC, 2010, TOXICOL APPL PHARM, V246, P91, DOI 10.1016/j.taap.2010.04.014; Nyitrai G, 2013, BBA-BIOMEMBRANES, V1828, P1873, DOI 10.1016/j.bbamem.2013.04.004; Omerovic J, 2012, J PROTEOME RES, V11, P5157, DOI 10.1021/pr3007304; Omidi Y, 2003, J DRUG TARGET, V11, P311, DOI 10.1080/10611860310001636908; Pettit MW, 2011, THER DELIV, V2, P907, DOI 10.4155/TDE.11.55; Price KAR, 2015, ORAL ONCOL, V51, P399, DOI 10.1016/j.oraloncology.2015.01.018; Roskoski R, 2014, PHARMACOL RES, V79, P34, DOI 10.1016/j.phrs.2013.11.002; Sadekar S, 2012, ADV DRUG DELIVER REV, V64, P571, DOI 10.1016/j.addr.2011.09.010; Sadekar S, 2011, BIOMACROMOLECULES, V12, P88, DOI 10.1021/bm101046d; Seib FP, 2007, J CONTROL RELEASE, V117, P291, DOI 10.1016/j.jconrel.2006.10.020; Shakhbazau A, 2010, INT J PHARMACEUT, V383, P228, DOI 10.1016/j.ijpharm.2009.09.020; Shcharbin D, 2014, J CONTROL RELEASE, V181, P40, DOI 10.1016/j.jconrel.2014.02.021; Shcharbin D, 2013, EXPERT OPIN DRUG DEL, V10, P1687, DOI 10.1517/17425247.2013.853661; Siddiqui S, 2012, INT J ENDOCRINOL, V2012, DOI 10.1155/2012/739428; Sun Y, 2015, PART FIBRE TOXICOL, V12, DOI 10.1186/s12989-015-0080-x; Sur S, 2014, CURR VASC PHARMACOL, V12, P190, DOI 10.2174/1570161112666140226123745; Tang MX, 1997, GENE THER, V4, P823, DOI 10.1038/sj.gt.3300454; Tang MX, 1996, BIOCONJUGATE CHEM, V7, P703, DOI 10.1021/bc9600630; Tang Y, 2015, BIOMACROMOLECULES, V16, P174, DOI 10.1021/bm501390d; Tomalia DA, 2007, BIOCHEM SOC T, V35, P61, DOI 10.1042/BST0350061; Wilcox CS, 2010, PHARMACOL THERAPEUT, V126, P119, DOI 10.1016/j.pharmthera.2010.01.003; Zhang MZ, 2014, DIABETES, V63, P2063, DOI 10.2337/db13-1279; Zhang Y, 2012, PHARM RES-DORDR, V29, P1627, DOI 10.1007/s11095-012-0676-x	69	18	18	2	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 13	2015	10	7							e0132215	10.1371/journal.pone.0132215	http://dx.doi.org/10.1371/journal.pone.0132215			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1PW	26167903	gold, Green Published, Green Submitted			2023-01-03	WOS:000358193100028
J	Dorywalska, M; Strop, P; Melton-Witt, JA; Hasa-Moreno, A; Farias, SE; Casas, MG; Delaria, K; Lui, V; Poulsen, K; Sutton, J; Bolton, G; Zhou, DH; Moine, L; Dushin, R; Tran, TT; Liu, SH; Rickert, M; Foletti, D; Shelton, DL; Pons, J; Rajpal, A				Dorywalska, Magdalena; Strop, Pavel; Melton-Witt, Jody A.; Hasa-Moreno, Adela; Farias, Santiago E.; Casas, Meritxell Galindo; Delaria, Kathy; Lui, Victor; Poulsen, Kris; Sutton, Janette; Bolton, Gary; Zhou, Dahui; Moine, Ludivine; Dushin, Russell; Thomas-Toan Tran; Liu, Shu-Hui; Rickert, Mathias; Foletti, Davide; Shelton, David L.; Pons, Jaume; Rajpal, Arvind			Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy	PLOS ONE			English	Article							THERAPEUTIC ACTIVITY; STABILITY; ANTIBODIES; CONJUGATE	The efficacy of an antibody-drug conjugate (ADC) is dependent on the properties of its linker-payload which must remain stable while in systemic circulation but undergo efficient processing upon internalization into target cells. Here, we examine the stability of a non-cleavable Amino-PEG6-based linker bearing the monomethyl auristatin D (MMAD) payload site-specifically conjugated at multiple positions on an antibody. Enzymatic conjugation with transglutaminase allows us to create a stable amide linkage that remains intact across all tested conjugation sites on the antibody, and provides us with an opportunity to examine the stability of the auristatin payload itself. We report a position-dependent degradation of the C terminus of MMAD in rodent plasma that has a detrimental effect on its potency. The MMAD cleavage can be eliminated by either modifying the C terminus of the toxin, or by selection of conjugation site. Both approaches result in improved stability and potency in vitro and in vivo. Furthermore, we show that the MMAD metabolism in mouse plasma is likely mediated by a serine-based hydrolase, appears much less pronounced in rat, and was not detected in cynomolgus monkey or human plasma. Clarifying these species differences and controlling toxin degradation to optimize ADC stability in rodents is essential to make the best ADC selection from preclinical models. The data presented here demonstrate that site selection and toxin susceptibility to mouse plasma degradation are important considerations in the design of non-cleavable ADCs, and further highlight the benefits of site-specific conjugation methods.	[Dorywalska, Magdalena; Strop, Pavel; Melton-Witt, Jody A.; Hasa-Moreno, Adela; Farias, Santiago E.; Casas, Meritxell Galindo; Delaria, Kathy; Lui, Victor; Poulsen, Kris; Sutton, Janette; Bolton, Gary; Thomas-Toan Tran; Liu, Shu-Hui; Rickert, Mathias; Foletti, Davide; Shelton, David L.; Pons, Jaume; Rajpal, Arvind] Pfizer Inc, Rinat Labs, San Francisco, CA 94080 USA; [Zhou, Dahui; Moine, Ludivine; Dushin, Russell] Pfizer Inc, Worldwide Med Chem, Groton, CT 06340 USA	Pfizer; Pfizer	Strop, P (corresponding author), Pfizer Inc, Rinat Labs, 230 East Grand Ave, San Francisco, CA 94080 USA.	pavel.strop@pfizer.com		Galindo Casas, Meritxell/0000-0002-5034-1722	Pfizer Inc.	Pfizer Inc.(Pfizer)	Pfizer Inc. provided support in the form of salaries for authors M.D., P.S., J.A.M.-W., A. H.-M., S. E.F., M.G.C., K.D., V.L., K.P., J.S., G.B., D.Z., L.M., R. D., T.-T.T., S.-H.L M.R., D.F., D.L.S., J.P., and A.R., but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Alley SC, 2008, BIOCONJUGATE CHEM, V19, P759, DOI 10.1021/bc7004329; Bender B, 2014, AAPS J, V16, P994, DOI 10.1208/s12248-014-9618-3; Dennler P, 2014, BIOCONJUGATE CHEM, V25, P569, DOI 10.1021/bc400574z; Doronina SO, 2006, BIOCONJUGATE CHEM, V17, P114, DOI 10.1021/bc0502917; Doronina SO, 2003, NAT BIOTECHNOL, V21, P778, DOI 10.1038/nbt832; Dorywalska M, 2015, BIOCONJUGATE CHEM, V26, P650, DOI 10.1021/bc5005747; Ducry L, 2010, BIOCONJUGATE CHEM, V21, P5, DOI 10.1021/bc9002019; Farias SE, 2014, BIOCONJUGATE CHEM, V25, P240, DOI 10.1021/bc4003794; Girish S, 2012, CANCER CHEMOTH PHARM, V69, P1229, DOI 10.1007/s00280-011-1817-3; Jackson D, 2015, PHARM RES-DORDR, V32, P3458, DOI 10.1007/s11095-014-1536-7; Jeger S, 2010, ANGEW CHEM INT EDIT, V49, P9995, DOI 10.1002/anie.201004243; Junutula JR, 2010, CLIN CANCER RES, V16, P4769, DOI 10.1158/1078-0432.CCR-10-0987; Lambert JM, 2013, BRIT J CLIN PHARMACO, V76, P248, DOI 10.1111/bcp.12044; Lyon RP, 2014, NAT BIOTECHNOL, V32, P1059, DOI 10.1038/nbt.2968; Maderna A, 2014, J MED CHEM, V57, P10527, DOI 10.1021/jm501649k; McCombs JR, 2015, AAPS J, V17, P339, DOI 10.1208/s12248-014-9710-8; Panowski S, 2014, MABS-AUSTIN, V6, P34, DOI 10.4161/mabs.27022; PETTIT GR, 1987, J AM CHEM SOC, V109, P6883, DOI 10.1021/ja00256a070; Pillow TH, 2014, J MED CHEM, V57, P7890, DOI 10.1021/jm500552c; Rostami S, 2014, J ANTIBODY DRUG CONJ; Sanderson RJ, 2005, CLIN CANCER RES, V11, P843; Shen BQ, 2012, NAT BIOTECHNOL, V30, P184, DOI 10.1038/nbt.2108; Sievers EL, 2013, ANNU REV MED, V64, P15, DOI 10.1146/annurev-med-050311-201823; Sigma-Aldrich, 2009, LIFE SCI BIOFILES, V4; SMYTH DG, 1964, BIOCHEM J, V91, P589, DOI 10.1042/bj0910589; Strop P., 2012, Patent No. [WO 2012059882A2, 2012059882]; Strop P, 2013, CHEM BIOL, V20, P161, DOI 10.1016/j.chembiol.2013.01.010; Tannir NM, 2014, INVEST NEW DRUG, V32, P1246, DOI 10.1007/s10637-014-0151-0; Tumey LN, 2014, BIOCONJUGATE CHEM, V25, P1871, DOI 10.1021/bc500357n	29	39	41	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2015	10	7							e0132282	10.1371/journal.pone.0132282	http://dx.doi.org/10.1371/journal.pone.0132282			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1FD	26161543	Green Submitted, gold, Green Published			2023-01-03	WOS:000358162300112
J	Turjeman, K; Bavli, Y; Kizelsztein, P; Schilt, Y; Allon, N; Katzir, TB; Sasson, E; Raviv, U; Ovadia, H; Barenholz, Y				Turjeman, Keren; Bavli, Yaelle; Kizelsztein, Pablo; Schilt, Yaelle; Allon, Nahum; Katzir, Tamar Blumenfeld; Sasson, Efrat; Raviv, Uri; Ovadia, Haim; Barenholz, Yechezkel			Nano-Drugs Based on Nano Sterically Stabilized Liposomes for the Treatment of Inflammatory Neurodegenerative Diseases	PLOS ONE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; DOSE INTRAVENOUS METHYLPREDNISOLONE; MYELIN BASIC-PROTEIN; MULTIPLE-SCLEROSIS; BLOOD-BRAIN; SPINAL-CORD; VASCULAR-PERMEABILITY; BARRIER PERMEABILITY; ALZHEIMERS-DISEASE	The present study shows the advantages of liposome-based nano-drugs as a novel strategy of delivering active pharmaceutical ingredients for treatment of neurodegenerative diseases that involve neuroinflammation. We used the most common animal model for multiple sclerosis (MS), mice experimental autoimmune encephalomyelitis (EAE). The main challenges to overcome are the drugs' unfavorable pharmacokinetics and biodistribution, which result in inadequate therapeutic efficacy and in drug toxicity (due to high and repeated dosage). We designed two different liposomal nano-drugs, i.e., nano sterically stabilized liposomes (NSSL), remote loaded with: (a) a "water-soluble" amphipathic weak acid glucocorticosteroid prodrug, methylprednisolone hemisuccinate (MPS) or (b) the amphipathic weak base nitroxide, Tempamine (TMN). For the NSSL-MPS we also compared the effect of passive targeting alone and of active targeting based on short peptide fragments of ApoE or of beta-amyloid. Our results clearly show that for NSSL-MPS, active targeting is not superior to passive targeting. For the NSSL-MPS and the NSSL-TMN it was demonstrated that these nano-drugs ameliorate the clinical signs and the pathology of EAE. We have further investigated the MPS nano-drug's therapeutic efficacy and its mechanism of action in both the acute and the adoptive transfer EAE models, as well as optimizing the perfomance of the TMN nano-drug. The highly efficacious anti-inflammatory therapeutic feature of these two nano-drugs meets the criteria of disease-modifying drugs and supports further development and evaluation of these nano-drugs as potential therapeutic agents for diseases with an inflammatory component.	[Turjeman, Keren; Bavli, Yaelle; Kizelsztein, Pablo; Allon, Nahum; Barenholz, Yechezkel] Hebrew Univ Jerusalem, Hadassah Med Sch, Inst Med Res Israel Canada, Lab Membrane & Liposome Res,Dept Biochem & Mol Bi, IL-91010 Jerusalem, Israel; [Schilt, Yaelle; Raviv, Uri] Hebrew Univ Jerusalem, Inst Chem, IL-91904 Jerusalem, Israel; [Katzir, Tamar Blumenfeld; Sasson, Efrat] BioImage MRI Res & Consulting, Tel Aviv, Israel; [Ovadia, Haim] Hadassah Univ Hosp, Dept Neurol, Agnes Ginges Ctr Human Neurogenet, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Turjeman, K (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Inst Med Res Israel Canada, Lab Membrane & Liposome Res,Dept Biochem & Mol Bi, IL-91010 Jerusalem, Israel.	kerenbarhum@gmail.com	Raviv, Uri/C-3600-2019	Bavli, Yaelle/0000-0002-2408-542X	Barenholz Fund; Hebrew University regular support system	Barenholz Fund; Hebrew University regular support system	This study was supported in part by the Barenholz Fund. The Barenholz Fund is a fund established by Professor Barenholz from royalties that the Hebrew University and Professor Barenholz get from various patents which are dedicated to support research in his lab. There are no connections between the patents for which he gets the royalties and this research, so it is basically a research fund. The other support was the Hebrew University regular support system. No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors TBK and ES are employed by BioImage MRI Research & Consulting. The company was hired to perform the MRI and to process the data obtained but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	AFZAL V, 1984, INVEST RADIOL, V19, P549, DOI 10.1097/00004424-198411000-00014; Allon N, 2012, J CONTROL RELEASE, V160, P217, DOI 10.1016/j.jconrel.2011.10.033; ANDERSON BD, 1981, J PHARM SCI, V70, P181, DOI 10.1002/jps.2600700217; Avnir Y, 2008, ARTHRITIS RHEUM-US, V58, P119, DOI 10.1002/art.23230; Avnir Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025721; Barenholz Y, 2000, PHYSICAL CHEMISTRY OF BIOLOGICAL INTERFACES, P171; Barenholz Y, 2001, CURR OPIN COLLOID IN, V6, P66, DOI 10.1016/S1359-0294(00)00090-X; Barenholz Y, 2002, TEMPAMINE COMPOSITIO; Barenholz Y, 2000, PHYS CHEM BIOL INTER; Barenholz Y, 2011, J COLLOID INTERF SCI, V356, P46, DOI 10.1016/j.jcis.2010.11.062; BARLOW CF, 1956, J NEUROPATH EXP NEUR, V15, P196, DOI 10.1097/00005072-195604000-00005; BARNES MP, 1985, J NEUROL NEUROSUR PS, V48, P157, DOI 10.1136/jnnp.48.2.157; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Ben-Nun T, 2010, J APPL CRYSTALLOGR, V43, P1522, DOI 10.1107/S0021889810032772; Borlongan C V, 1996, J Fla Med Assoc, V83, P335; BRANN DW, 1995, J STEROID BIOCHEM, V52, P113, DOI 10.1016/0960-0760(94)00160-N; Brusaferri F, 2000, J NEUROL, V247, P435, DOI 10.1007/s004150070172; Buttgereit F, 1998, ARTHRITIS RHEUM, V41, P761, DOI 10.1002/1529-0131(199805)41:5<761::AID-ART2>3.0.CO;2-M; Cern A, 2011, J CONTROLLED RELEASE; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; CUTLER RWP, 1967, J NEUROPATH EXP NEUR, V26, P558, DOI 10.1097/00005072-196710000-00004; DEGRAFF WG, 1992, FREE RADICAL BIO MED, V13, P479, DOI 10.1016/0891-5849(92)90142-4; DURELLI L, 1986, NEUROLOGY, V36, P238, DOI 10.1212/WNL.36.2.238; Ebadi M, 1996, PROG NEUROBIOL, V48, P1, DOI 10.1016/0301-0082(95)00029-1; Emanuel N, 1996, PHARMACEUT RES, V13, P861, DOI 10.1023/A:1016096910822; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; Floris S, 2004, BRAIN, V127, P616, DOI 10.1093/brain/awh068; Gaillard PJ, 2012, J CONTROLLED RELEASE; Garbuzenko O, 2005, CHEM PHYS LIPIDS, V135, P117, DOI 10.1016/j.chemphyslip.2005.02.003; GASS A, 1994, ANN NEUROL, V36, P62, DOI 10.1002/ana.410360113; Gold R, 2001, J NEUROIMMUNOL, V117, P1, DOI 10.1016/S0165-5728(01)00330-7; Gold R, 2006, BRAIN, V129, P1953, DOI 10.1093/brain/awl075; Hahn SM, 1997, FREE RADICAL BIO MED, V23, P879, DOI 10.1016/S0891-5849(97)00079-8; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; Hammersley AP, 1996, HIGH PRESSURE RES, V14, P235, DOI 10.1080/08957959608201408; HAWKINS CP, 1991, BRAIN, V114, P801, DOI 10.1093/brain/114.2.801; Hoven J.M., 2011, INT J PHARMACEUT, V416, P471, DOI DOI 10.1016/J.IJPHARM.2011.03.025; JUHLER M, 1984, BRAIN RES, V302, P347, DOI 10.1016/0006-8993(84)90249-X; Kappos L, 1990, MULTIPLE SCLEROSIS D, P127; Karlik SJ, 1999, MAGN RESON IMAGING, V17, P731, DOI 10.1016/S0730-725X(98)00216-1; KERMODE AG, 1990, BRAIN, V113, P1477, DOI 10.1093/brain/113.5.1477; KESSELRING J, 1989, J NEUROL NEUROSUR PS, V52, P14, DOI 10.1136/jnnp.52.1.14; Kizelsztein P, 2009, J NEUROIMMUNOL, V213, P20, DOI 10.1016/j.jneuroim.2009.05.019; Kornek B, 2000, AM J PATHOL, V157, P267, DOI 10.1016/S0002-9440(10)64537-3; KRISHNA MC, 1992, P NATL ACAD SCI USA, V89, P5537, DOI 10.1073/pnas.89.12.5537; LEIBOWITZ S, 1972, IMMUNOLOGY, V22, P859; Linker RA, 2008, EXP NEUROL, V211, P397, DOI 10.1016/j.expneurol.2008.02.005; Lu FM, 2000, J NEUROL SCI, V177, P95, DOI 10.1016/S0022-510X(00)00343-9; Mabrey S, 1978, METHODS MEMBR BIOL, P237, DOI [10.1007/978-1-4613-4036-2_3, DOI 10.1007/978-1-4613-4036-2_3]; Maier C, 2005, J CELL SCI, V118, P3353, DOI 10.1242/jcs.02462; Markesbery WR, 1999, BRAIN PATHOL, V9, P133; McCombe PA, 1996, J NEUROIMMUNOL, V70, P93, DOI 10.1016/S0165-5728(96)00043-4; MILLER DH, 1992, J NEUROL NEUROSUR PS, V55, P450, DOI 10.1136/jnnp.55.6.450; MILLER H, 1961, LANCET, V2, P1120; MILLIGAN NM, 1987, J NEUROL NEUROSUR PS, V50, P511, DOI 10.1136/jnnp.50.5.511; MITCHELL JB, 1991, ARCH BIOCHEM BIOPHYS, V289, P62, DOI 10.1016/0003-9861(91)90442-L; Morrissey SP, 1996, BRAIN, V119, P239, DOI 10.1093/brain/119.1.239; Nessler S, 2007, BRAIN, V130, P2186, DOI 10.1093/brain/awm105; NINOMIYA H, 1993, J CELL BIOL, V121, P879, DOI 10.1083/jcb.121.4.879; Pozzilli C, 2004, J NEUROL SCI, V223, P47, DOI 10.1016/j.jns.2004.04.019; Re F, 2011, J BIOTECHNOL, V156, P341, DOI 10.1016/j.jbiotec.2011.06.037; Reichardt Holger M, 2006, Expert Rev Neurother, V6, P1657, DOI 10.1586/14737175.6.11.1657; Saper G, 2013, NUCLEIC ACIDS RES, V41, P1569, DOI 10.1093/nar/gks1270; Sarsero JP, 2003, J GENE MED, V5, P72, DOI 10.1002/jgm.320; Schellenberg AE, 2007, MAGN RESON MED, V58, P298, DOI 10.1002/mrm.21289; Schmidt J, 2003, BRAIN, V126, P1895, DOI 10.1093/brain/awg176; Stein W., 2012, TRANSPORT DIFFUSION; Szekely P, 2010, LANGMUIR, V26, P13110, DOI 10.1021/la101433t; THOMPSON AJ, 1989, NEUROLOGY, V39, P969, DOI 10.1212/WNL.39.7.969; Tischner D, 2007, MOL CELL ENDOCRINOL, V275, P62, DOI 10.1016/j.mce.2007.03.007; TRIARHOU LC, 1986, ARCH NEUROL-CHICAGO, V43, P121, DOI 10.1001/archneur.1986.00520020015008; TROIANO R, 1984, ANN NEUROL, V15, P257, DOI 10.1002/ana.410150309; Ulmansky R, 2011, J CONTROLLED RELEASE; Vosoughi R, 2010, CLIN NEUROL NEUROSUR, V112, P365, DOI 10.1016/j.clineuro.2010.03.010; Wasserman V, 2007, LANGMUIR, V23, P1937, DOI 10.1021/la060218k; Yong VW, 2010, NEUROSCIENTIST, V16, P408, DOI 10.1177/1073858410371379; YOUL BD, 1991, BRAIN, V114, P2437, DOI 10.1093/brain/114.6.2437; Zamir E, 1999, FREE RADICAL BIO MED, V27, P7, DOI 10.1016/S0891-5849(99)00026-X; Zlokovic BV, 2008, NEUROTHERAPEUTICS, V5, P409, DOI 10.1016/j.nurt.2008.05.011; Zucker D, 2009, J CONTROL RELEASE, V139, P73, DOI 10.1016/j.jconrel.2009.05.036	80	49	49	1	45	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2015	10	7							e0130442	10.1371/journal.pone.0130442	http://dx.doi.org/10.1371/journal.pone.0130442			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1DQ	26147975	gold, Green Submitted, Green Published			2023-01-03	WOS:000358157600036
J	Momplaisir, FM; Brady, KA; Fekete, T; Thompson, DR; Roux, AD; Yehia, BR				Momplaisir, Florence M.; Brady, Kathleen A.; Fekete, Thomas; Thompson, Dana R.; Roux, Ana Diez; Yehia, Baligh R.			Time of HIV Diagnosis and Engagement in Prenatal Care Impact Virologic Outcomes of Pregnant Women with HIV	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS TYPE-1; TO-CHILD TRANSMISSION; FINANCIAL INCENTIVES; CONTROLLED-TRIAL; PERINATAL TRANSMISSION; HIV-1-INFECTED WOMEN; ZIDOVUDINE TREATMENT; UNINFECTED INFANTS; HEALTH-CARE	Background HIV suppression at parturition is beneficial for maternal, fetal and public health. To eliminate mother-to-child transmission of HIV, an understanding of missed opportunities for antiretroviral therapy (ART) use during pregnancy and HIV suppression at delivery is required. Methodology We performed a retrospective analysis of 836 mother-to-child pairs involving 656 HIV-infected women in Philadelphia, 2005-2013. Multivariable regression examined associations between patient (age, race/ethnicity, insurance status, drug use) and clinical factors such as adequacy of prenatal care measured by the Kessner index which classifies prenatal care as inadequate, intermediate, or adequate prenatal care; timing of HIV diagnosis; and the outcomes: receipt of ART during pregnancy and viral suppression at delivery. Results Overall, 25% of the sample was diagnosed with HIV during pregnancy; 39%, 38%, and 23% were adequately, intermediately, and inadequately engaged in prenatal care. Eight-five percent of mother-to-child pairs received ART during pregnancy but only 52% achieved suppression at delivery. Adjusting for patient factors, pairs diagnosed with HIV during pregnancy were less likely to receive ART (AOR 0.39, 95% CI 0.25-0.61) and achieve viral suppression (AOR 0.70, 95% CI 0.49-1.00) than those diagnosed before pregnancy. Similarly, women with inadequate prenatal care were less likely to receive ART (AOR 0.06, 95% CI 0.03-0.11) and achieve viral suppression (AOR 0.31, 95% CI 0.20-0.47) than those with adequate prenatal care. Conclusions Targeted interventions to diagnose HIV prior to pregnancy and engage HIV-infected women in prenatal care have the potential to improve HIV related outcomes in the perinatal period.	[Momplaisir, Florence M.] Drexel Univ, Sch Med, Div Infect Dis & HIV Med, Philadelphia, PA 19104 USA; [Brady, Kathleen A.] Philadelphia Dept Publ Hlth, AIDS Act & Coordinating Off, Philadelphia, PA USA; [Brady, Kathleen A.; Yehia, Baligh R.] Univ Penn, Div Infect Dis, Philadelphia, PA 19104 USA; [Fekete, Thomas] Temple Univ Hosp & Med Sch, Div Infect Dis, Philadelphia, PA 19140 USA; [Thompson, Dana R.] Christiana Care Hlth Syst, Ctr Womens & Childrens Hlth Res, Greenville, DC USA; [Roux, Ana Diez] Drexel Univ, Sch Publ Hlth, Philadelphia, PA 19104 USA; [Yehia, Baligh R.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA	Drexel University; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Christiana Care Health System; Drexel University; University of Pennsylvania	Momplaisir, FM (corresponding author), Drexel Univ, Sch Med, Div Infect Dis & HIV Med, Philadelphia, PA 19104 USA.	Florence.Momplaisir@drexelmed.edu	Fekete, Thomas/AFI-5367-2022					Binford MC, 2012, CURR HIV-AIDS REP, V9, P287, DOI 10.1007/s11904-012-0134-8; Branson B., 2006, REVISED RECOMMENDATI; Centers_for_Disease_Control_and_Prevention, 2005, HIV SURV SUPPL REP 2; Chasela CS, 2010, NEW ENGL J MED, V362, P2271, DOI 10.1056/NEJMoa0911486; Chilongozi D, 2008, PEDIATR INFECT DIS J, V27, P808, DOI 10.1097/INF.0b013e31817109a4; Clerici M, 2000, BLOOD, V96, P3866, DOI 10.1182/blood.V96.12.3866.h8003866_3866_3871; Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009; De Cock KM, 2000, JAMA-J AM MED ASSOC, V283, P1175, DOI 10.1001/jama.283.9.1175; Dickover RE, 1996, JAMA-J AM MED ASSOC, V275, P599, DOI 10.1001/jama.275.8.599; Duff P, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-37; Economides A, 1998, CLIN DIAGN LAB IMMUN, V5, P230, DOI 10.1128/CDLI.5.2.230-234.1998; Gardner LI, 2005, AIDS, V19, P423, DOI 10.1097/01.aids.0000161772.51900.eb; Hatano H, 2011, J INFECT DIS, V203, P960, DOI 10.1093/infdis/jiq138; Haukoos JS, 2005, ACAD EMERG MED, V12, P617, DOI 10.1197/j.aem.2005.02.016; Katz IT, 2015, ANN INTERN MED, V162, P90, DOI 10.7326/M13-2005; Katz IT, 2010, JAIDS-J ACQ IMM DEF, V54, P27, DOI 10.1097/QAI.0b013e3181caea89; Keller SC, 2014, AIDS PATIENT CARE ST, V28, P198, DOI 10.1089/apc.2014.0001; Kessner DM, 1973, INFANT DEATH ANAL MA, VI; Kirsten I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021020; Kuhn L, 2005, CLIN INFECT DIS, V41, P1654, DOI 10.1086/498029; Long JA, 2012, ANN INTERN MED, V156, P416, DOI 10.7326/0003-4819-156-6-201203200-00004; Mepham S, 2011, AIDS CARE, V23, P741, DOI 10.1080/09540121.2010.516341; Merenstein D, 2009, AIDS PATIENT CARE ST, V23, P289, DOI 10.1089/apc.2008.0161; Naar-King S, 2009, AIDS CARE, V21, P868, DOI 10.1080/09540120802612824; Nachega JB, 2012, AIDS, V26, P2039, DOI 10.1097/QAD.0b013e328359590f; Nassali M, 2009, AIDS CARE, V21, P1124, DOI 10.1080/09540120802707467; Nesheim S, 2012, PEDIATRICS, V130, P738, DOI 10.1542/peds.2012-0194; Ngarina M, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-450; Panel on Antiretroviral Guidelines for Adults and Adolescents, 2009, GUIDELINES USE ANTIR; Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, REC US ANT DRUGS PRE; Purcell DW, 2007, JAIDS-J ACQ IMM DEF, V46, pS35, DOI 10.1097/QAI.0b013e31815767c4; Romano MF, 2006, VIRAL IMMUNOL, V19, P363, DOI 10.1089/vim.2006.19.363; Siddiqui R, 2014, AIDS PATIENT CARE ST, V28, P248, DOI 10.1089/apc.2013.0321; SIMONON A, 1994, J ACQ IMMUN DEF SYND, V7, P952; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; Taron-Brocard C, 2014, CLIN INFECT DIS, V59, P1332, DOI 10.1093/cid/ciu586; Townsend CL, 2014, AIDS, V28, P1049, DOI 10.1097/QAD.0000000000000212; Turner BJ, 2003, J GEN INTERN MED, V18, P248, DOI 10.1046/j.1525-1497.2003.20122.x; Volpp KG, 2009, NEW ENGL J MED, V360, P699, DOI 10.1056/NEJMsa0806819; Warszawski J, 2008, AIDS, V22, P289, DOI 10.1097/QAD.0b013e3282f3d63c; Whitmore SK, 2012, PEDIATRICS, V129, pE74, DOI 10.1542/peds.2010-3691; Yehia BR, 2013, AIDS BEHAV, P1, DOI [10.1007/s10461-012-0321-z, DOI 10.1007/S10461-012-0321-Z]; Zaba B, 2005, EPIDEMIOLOGY, V16, P275, DOI 10.1097/01.ede.0000155507.47884.43	43	36	37	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2015	10	7							e0132262	10.1371/journal.pone.0132262	http://dx.doi.org/10.1371/journal.pone.0132262			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1CG	26132142	Green Submitted, gold, Green Published			2023-01-03	WOS:000358153000167
J	Kalra, L; Irshad, S; Hodsoll, J; Simpson, M; Gulliford, M; Smithard, D; Patel, A; Rebollo-Mesa, I				Kalra, Lalit; Irshad, Saddif; Hodsoll, John; Simpson, Matthew; Gulliford, Martin; Smithard, David; Patel, Anita; Rebollo-Mesa, Irene		STROKE-INF Investigators	Prophylactic antibiotics after acute stroke for reducing pneumonia in patients with dysphagia (STROKE-INF): a prospective, cluster-randomised, open-label, masked endpoint, controlled clinical trial	LANCET			English	Article							CLOSTRIDIUM-DIFFICILE; INFECTION; RISK; METAANALYSIS; DIAGNOSIS; OUTCOMES; CARE	Background Post-stroke pneumonia is associated with increased mortality and poor functional outcomes. This study assessed the effectiveness of antibiotic prophylaxis for reducing pneumonia in patients with dysphagia after acute stroke. Methods We did a prospective, multicentre, cluster-randomised, open-label controlled trial with masked endpoint assessment of patients older than 18 years with dysphagia after new stroke recruited from 48 stroke units in the UK, accredited and included in the UK National Stroke Audit. We excluded patients with contraindications to antibiotics, pre-existing dysphagia, or known infections, or who were not expected to survive beyond 14 days. We randomly assigned the units (1: 1) by computer to give either prophylactic antibiotics for 7 days plus standard stroke unit care or standard stroke unit care only to patients clustered in the units within 48 h of stroke onset. We did the randomisation with minimisation to stratify for number of admissions and access to specialist care. Patient and staff who did the assessments and analyses were masked to stroke unit allocation. The primary outcome was post-stroke pneumonia in the first 14 days, assessed with both a criteria-based, hierarchical algorithm and by physician diagnosis in the intention-to-treat population. Safety was also analysed by intention to treat. This trial is closed to new participants and is registered with isrctn.com, number ISRCTN37118456. Findings Between April 21, 2008, and May 17, 2014, we randomly assigned 48 stroke units (and 1224 patients clustered within the units) to the two treatment groups: 24 to antibiotics and 24 to standard care alone (control). 11 units and seven patients withdrew after randomisation before 14 days, leaving 1217 patients in 37 units for the intention-to-treat analysis (615 patients in the antibiotics group, 602 in control). Prophylactic antibiotics did not affect the incidence of algorithm-defined post-stroke pneumonia (71 [13%] of 564 patients in antibiotics group vs 52 [10%] of 524 in control group; marginal adjusted odds ratio [OR] 1.21 [95% CI 0.71-2.08], p=0.489, intraclass correlation coefficient [ICC] 0.06 [95% CI 0.02-0.17]. Algorithm-defined post-stroke pneumonia could not be established in 129 (10%) patients because of missing data. Additionally, we noted no differences in physician-diagnosed post-stroke pneumonia between groups (101 [16%] of 615 patients vs 91 [15%] of 602, adjusted OR 1.01 [95% CI 0.61-1.68], p=0.957, ICC 0.08 [95% CI 0.03-0.21]). The most common adverse events were infections unrelated to post-stroke pneumonia (mainly urinary tract infections), which were less frequent in the antibiotics group (22 [4%] of 615 vs 45 [7%] of 602; OR 0.55 [0.32-0.92], p=0.02). Diarrhoea positive for Clostridium difficile occurred in two patients (<1%) in the antibiotics group and four (<1%) in the control group, and meticillin-resistant Staphylococcus aureus colonisation occurred in 11 patients (2%) in the antibiotics group and 14 (2%) in the control group. Interpretation Antibiotic prophylaxis cannot be recommended for prevention of post-stroke pneumonia in patients with dysphagia after stroke managed in stroke units.	[Kalra, Lalit; Irshad, Saddif] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Basic & Clin Neurosci, London SE5 8AF, England; [Hodsoll, John; Rebollo-Mesa, Irene] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Biostat, Kings Clin Trials Unit, London SE5 8AF, England; [Patel, Anita] Kings Coll London, Inst Psychiat Psychol & Neurosci, Ctr Econ Mental & Phys Hlth, London SE5 8AF, England; [Simpson, Matthew] Guys & St Thomas Hosp, Kings Hlth Partners, UK Joint Clin Trials Off, London SE1 9RT, England; [Gulliford, Martin] Kings Coll London, Div Hlth & Social Care Res, Fac Life Sci & Med, London SE5 8AF, England; [Smithard, David] Univ Kent, Canterbury, Kent, England; [Hodsoll, John] South London & Maudsley NHS Fdn Trust, UK & NIHR Biomed Res Ctr Mental Hlth, London, England; [Hodsoll, John] Kings Coll London, Inst Psychiat Psychol & Neurosci, London SE5 8AF, England	University of London; King's College London; University of London; King's College London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London; University of Kent; South London & Maudsley NHS Trust; University of London; King's College London	Kalra, L (corresponding author), Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Basic & Clin Neurosci, London SE5 8AF, England.	lalit.kalra@kcl.ac.uk	Patel, Anita/F-9832-2010; Gulliford, Martin C/I-8606-2018	Gulliford, Martin C/0000-0003-1898-9075; Patel, Anita/0000-0003-0769-1732	UK National Institute for Health Research; National Institute for Health Research (NIHR) [PB-PG-0906-11103]; UK Stroke Research Network; NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London; NIHR Maudsley Biomedical Research Centre; National Institute for Health Research [PB-PG-0906-11103] Funding Source: researchfish	UK National Institute for Health Research(National Institute for Health Research (NIHR)); National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); UK Stroke Research Network; NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London; NIHR Maudsley Biomedical Research Centre; National Institute for Health Research(National Institute for Health Research (NIHR))	UK National Institute for Health Research.; The views expressed in this publication are those of the authors, and not necessarily those of the NHS, NIHR, or the UK Department of Health. This report is independent research funded by the National Institute for Health Research (NIHR; project number PB-PG-0906-11103) and supported by the UK Stroke Research Network. MG was supported by the NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London. JH was supported by the NIHR Maudsley Biomedical Research Centre. The trial protocol, statistical analysis plan, and detailed governance arrangements have been submitted as online supplementary material. The study was approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA; EudraCT number 2007-004298-24), the West London National Research Ethics Committee (08/H0803/1), and the local Ethics Committee at each participating site. Oversight was provided by a trials steering committee and a data monitoring and ethics committee conforming to NIHR guidelines. The trial was done in accordance with Good Clinical Practice GCP standards. Data were monitored for quality and integrity by the King's Healthcare Partners Clinical Trials Office with established verification and validation processes. We did the statistical analyses in accordance with GCP and MHRA guidelines by the King's Clinical Trials Unit, Institute of Psychiatry, Psychology and Neurosciences, King's College London. The trial management group are Lalit Kalra, Saddif Irshad, Martin Gulliford, Matthew Simpson, Salma Ayis, Anita Patel, John Hodsoll, and Irene Rebello-Mesa. We thank the trial steering committee (Hugh Markus, Patrick Pullicino, David Smithard, Vivien Kearney, Ann Marie Murtagh, and Gaye Hadfield [Stroke Research Network representatives]), the data monitoring and ethics committee (Helen Rodgers, Thomas Chadwick, Sheila McCulloch, Jonathan Edgeworth, and Paul Holmes), all the patients who participated in this study, the clinical and pharmacy staff in all participating centres, and the NIHR Stroke Research Network staff involved; and the following people for their contributions: application for funding Charles Wolfe, Anthony Rudd, and Robin Cant; statistical advice Andrew Grieve and Salma Ayis; sponsor duties or study monitoring Jackie Pullen, Helen Critchley, Michelle Giles, and Jane Good; data management Michael Hong, Ramya Dhonti, and Jaya Buchupalli; and administration: Amanda Davies, Iram Ahmed, Claire Potter, and Isabelle Leung.	[Anonymous], 2014, PNEUM DIAGN MAN COMM; Brown K, 2015, JAMA INTERN MED, V175, P626, DOI 10.1001/jamainternmed.2014.8273; Campbell MK, 2001, STAT MED, V20, P391, DOI 10.1002/1097-0258(20010215)20:3<391::AID-SIM800>3.0.CO;2-Z; Eldridge S, 2012, PRACTICAL GUIDE CLUS, P150; Evans S, MINIM ALLOCATION MIN; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Finlayson O, 2011, NEUROLOGY, V77, P1338, DOI 10.1212/WNL.0b013e31823152b1; Forster AJ, 2012, CAN MED ASSOC J, V184, P37, DOI 10.1503/cmaj.110543; Harms H, 2012, J NEUROL NEUROSUR PS, V83, P1225, DOI 10.1136/jnnp-2012-302194; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; Hu FB, 1998, AM J EPIDEMIOL, V147, P694; Intercollegiate Stroke Working Party, 2008, NAT CLIN GUID STROK; Kishore AK, 2015, STROKE, V46, P1202, DOI 10.1161/STROKEAHA.114.007843; Koennecke HC, 2011, NEUROLOGY, V77, P965, DOI 10.1212/WNL.0b013e31822dc795; Long J. S., 2014, REVIEW; Martino R, 2005, STROKE, V36, P2756, DOI 10.1161/01.STR.0000190056.76543.eb; Naidech AM, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.11.009; Ramsey DJC, 2003, STROKE, V34, P1252, DOI 10.1161/01.STR.0000066309.06490.B8; Royal College of Physicians, 2008, NAT SENT AUD STROK; Sentinel Stroke National Audit Programme, 2019, MOV DIAL STROK CAR 6; Team R.C., 2021, R FOUN DATION STAT C; Titsworth WL, 2013, STROKE, V44, P3154, DOI 10.1161/STROKEAHA.111.000204; Vargas M, 2006, STROKE, V37, P461, DOI 10.1161/01.STR.0000199138.73365.b3; Westendorp WF, 2015, LANCET, V385, P1519, DOI 10.1016/S0140-6736(14)62456-9; Westendorp WF, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008530.pub2; Westendorp WF, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-110	26	158	168	4	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 7	2015	386	10006					1835	1844		10.1016/S0140-6736(15)00126-9	http://dx.doi.org/10.1016/S0140-6736(15)00126-9			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CV3VO	26343840	Bronze			2023-01-03	WOS:000364194700034
J	Shushimita, S; van der Pol, P; de Bruin, RWF; Ijzermans, JNM; van Kooten, C; Dor, FJMF				Shushimita, Shushimita; van der Pol, Pieter; de Bruin, Ron W. F.; Ijzermans, Jan N. M.; van Kooten, Cees; Dor, Frank J. M. F.			Mannan-Binding Lectin Is Involved in the Protection against Renal Ischemia/Reperfusion Injury by Dietary Restriction	PLOS ONE			English	Article							ISCHEMIA-REPERFUSION INJURY; CALORIE RESTRICTION; COMPLEMENT-SYSTEM; LIFE-SPAN; MECHANISMS; PATHWAYS; ACTIVATION; RAPAMYCIN; STRESS	Preoperative fasting and dietary restriction offer robust protection against renal ischemia/reperfusion injury (I/RI) in mice. We recently showed that Mannan-binding lectin (MBL), the initiator of the lectin pathway of complement activation, plays a pivotal role in renal I/RI. Based on these findings, we investigated the effect of short-term DR (30% reduction of total food intake) or three days of water only fasting on MBL in 10-12 weeks old male C57/Bl6 mice. Both dietary regimens significantly reduce the circulating levels of MBL as well as its mRNA expression in liver, the sole production site of MBL. Reconstitution of MBL abolished the protection afforded by dietary restriction, whereas in the fasting group the protection persisted. These data show that modulation of MBL is involved in the protection against renal I/RI induced by dietary restriction, and suggest that the mechanisms of protection induced by dietary restriction and fasting may be different.	[Shushimita, Shushimita; de Bruin, Ron W. F.; Ijzermans, Jan N. M.; Dor, Frank J. M. F.] Univ Med Ctr, Div Transplant Surg, Dept Surg, Erasmus MC, Rotterdam, Netherlands; [van der Pol, Pieter; van Kooten, Cees] Leiden Univ, Med Ctr, Dept Nephrol, Leiden, Netherlands	Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Dor, FJMF (corresponding author), Univ Med Ctr, Div Transplant Surg, Dept Surg, Erasmus MC, Rotterdam, Netherlands.	f.dor@erasmusmc.nl	van Kooten, Cees/E-5694-2018	van Kooten, Cees/0000-0002-6257-0899	Erasmus MC Fellowship	Erasmus MC Fellowship	This work was funded by an Erasmus MC Fellowship.	Alic N, 2011, CURR OPIN CELL BIOL, V23, P738, DOI 10.1016/j.ceb.2011.07.006; Arumugam TV, 2004, SHOCK, V21, P401, DOI 10.1097/00024382-200405000-00002; Bjedov I, 2010, CELL METAB, V11, P35, DOI 10.1016/j.cmet.2009.11.010; Boros P, 2006, AM J TRANSPLANT, V6, P652, DOI 10.1111/j.1600-6143.2005.01228.x; Cefalu WT, 1997, J GERONTOL A-BIOL, V52, pB10, DOI 10.1093/gerona/52A.1.B10; Chan RK, 2006, J IMMUNOL, V177, P8080, DOI 10.4049/jimmunol.177.11.8080; Collard CD, 2000, AM J PATHOL, V156, P1549, DOI 10.1016/S0002-9440(10)65026-2; de Vries B, 2004, AM J PATHOL, V165, P1677, DOI 10.1016/S0002-9440(10)63424-4; Diepenhorst GMP, 2009, ANN SURG, V249, P889, DOI 10.1097/SLA.0b013e3181a38f45; Dilova I, 2007, CELL MOL LIFE SCI, V64, P752, DOI 10.1007/s00018-007-6381-y; Fok WC, 2013, J GERONTOL A-BIOL, V68, P108, DOI 10.1093/gerona/gls127; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Gorsuch WB, 2012, IMMUNOBIOLOGY, V217, P1026, DOI 10.1016/j.imbio.2012.07.024; Hansen S, 2000, J IMMUNOL, V164, P2610, DOI 10.4049/jimmunol.164.5.2610; Harper JM, 2006, MECH AGEING DEV, V127, P687, DOI 10.1016/j.mad.2006.04.002; Hart ML, 2005, J IMMUNOL, V174, P6373, DOI 10.4049/jimmunol.174.10.6373; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Jordan JE, 2001, CIRCULATION, V104, P1413, DOI 10.1161/hc3601.095578; Ko GJ, 2010, IMMUNOL RES, V47, P78, DOI 10.1007/s12026-009-8140-7; Lameire N, 2005, LANCET, V365, P417; Lee C, 2011, ONCOGENE, V30, P3305, DOI 10.1038/onc.2011.91; Libert S, 2013, ANNU REV PHYSIOL, V75, P669, DOI 10.1146/annurev-physiol-030212-183800; Lutz J, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-27; Mair W, 2008, ANNU REV BIOCHEM, V77, P727, DOI 10.1146/annurev.biochem.77.061206.171059; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; McCullough JW, 2013, SEMIN NEPHROL, V33, P543, DOI 10.1016/j.semnephrol.2013.08.005; Mitchell JR, 2010, AGING CELL, V9, P40, DOI 10.1111/j.1474-9726.2009.00532.x; Moller-Kristensen M, 2005, SCAND J IMMUNOL, V61, P426, DOI 10.1111/j.1365-3083.2005.01591.x; Morgan T. E., 2007, V35, P83; Morrison H, 2011, CURR NEUROVASC RES, V8, P52, DOI 10.2174/156720211794520260; Oroszlan M, 2007, MOL IMMUNOL, V44, P1150, DOI 10.1016/j.molimm.2006.06.015; Orsini F, 2012, CIRCULATION, V126, P1484, DOI 10.1161/CIRCULATIONAHA.112.103051; Owens W, 2003, ENVIRON HEALTH PERSP, V111, P1527, DOI 10.1289/ehp.6413; Palevsky PM, 2008, NEW ENGL J MED, V359, P7, DOI 10.1056/NEJMoa0802639; Roth GS, 1999, J AM GERIATR SOC, V47, P896, DOI 10.1111/j.1532-5415.1999.tb03851.x; Sacks SH, 2012, NAT REV IMMUNOL, V12, P431, DOI 10.1038/nri3225; Shushimita S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087772; Star RA, 1998, KIDNEY INT, V54, P1817, DOI 10.1046/j.1523-1755.1998.00210.x; Thurman JM, 2003, J IMMUNOL, V170, P1517, DOI 10.4049/jimmunol.170.3.1517; van der Pol P, 2012, AM J TRANSPLANT, V12, P877, DOI 10.1111/j.1600-6143.2011.03887.x; van Ginhoven TM, 2011, CLIN TRANSPLANT, V25, P486, DOI 10.1111/j.1399-0012.2010.01313.x; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Walsh MC, 2005, J IMMUNOL, V175, P541, DOI 10.4049/jimmunol.175.1.541	43	12	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2015	10	9							e0137795	10.1371/journal.pone.0137795	http://dx.doi.org/10.1371/journal.pone.0137795			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR8KS	26367533	Green Published, Green Submitted, gold			2023-01-03	WOS:000361601100139
J	Friedman, D; Devinsky, O				Friedman, Daniel; Devinsky, Orrin			Cannabinoids in the Treatment of Epilepsy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MEDICAL MARIJUANA; ENDOCANNABINOID SYSTEM; PLANT CANNABINOIDS; STATUS EPILEPTICUS; OROMUCOSAL SPRAY; DOUBLE-BLIND; CANNABIDIOL; RECEPTOR; CB1; ANTICONVULSANT		[Friedman, Daniel; Devinsky, Orrin] NYU, Langone Sch Med, Dept Neurol, New York, NY 10016 USA	New York University; NYU Langone Medical Center	Friedman, D (corresponding author), NYU, Langone Sch Med, Dept Neurol, 223 E 34th St, New York, NY 10016 USA.	daniel.friedman@nyumc.org		Devinsky, Orrin/0000-0003-0044-4632	GW Pharmaceuticals; Novartis; Marinus Pharmaceuticals; Eisai; SK Biopharmaceuticals; Upsher-Smith Laboratories; Pfizer	GW Pharmaceuticals; Novartis(Novartis); Marinus Pharmaceuticals; Eisai(Eisai Co Ltd); SK Biopharmaceuticals; Upsher-Smith Laboratories; Pfizer(Pfizer)	Dr. Devinsky reports receiving grant support from GW Pharmaceuticals and Novartis and serving on the scientific advisory board of MiaMed; and Dr. Friedman, receiving fees for serving on an advisory board for Marinus Pharmaceuticals and consulting fees from Eisai, Marinus Pharmaceuticals, SK Biopharmaceuticals, Upsher-Smith Laboratories, and Pfizer, all of which were paid to the Epilepsy Study Consortium. No other potential conflict of interest relevant to this article was reported.	AMES FR, 1986, S AFR MED J, V69, P14; [Anonymous], 2014, HDB OF CANNABIS, DOI DOI 10.1093/ACPROF:OSO/9780199662685.003.0007; Behnke M, 2013, PEDIATRICS, V131, pE1009, DOI 10.1542/peds.2012-3931; Bergamaschi MM, 2011, CURR DRUG SAF, V6, P237, DOI 10.2174/157488611798280924; Brodie MJ, 2012, NEUROLOGY, V78, P1548, DOI 10.1212/WNL.0b013e3182563b19; Brust J C, 1992, Trans Am Clin Climatol Assoc, V103, P176; Campos AC, 2012, J PSYCHIATR RES, V46, P1501, DOI 10.1016/j.jpsychires.2012.08.012; Carrier EJ, 2006, P NATL ACAD SCI USA, V103, P7895, DOI 10.1073/pnas.0511232103; Castillo PE, 2012, NEURON, V76, P70, DOI 10.1016/j.neuron.2012.09.020; CHAN HSL, 1987, PEDIATRICS, V79, P946; Collin C, 2007, EUR J NEUROL, V14, P290, DOI 10.1111/j.1468-1331.2006.01639.x; CONSROE PF, 1975, JAMA-J AM MED ASSOC, V234, P306, DOI 10.1001/jama.234.3.306; CUNHA JM, 1980, PHARMACOLOGY, V21, P175, DOI 10.1159/000137430; DAVIS JP, 1949, FED PROC, V8, P284; De Petrocellis L, 2011, BRIT J PHARMACOL, V163, P1479, DOI 10.1111/j.1476-5381.2010.01166.x; Deshpande LS, 2007, EUR J PHARMACOL, V558, P52, DOI 10.1016/j.ejphar.2006.11.030; Deshpande LS, 2007, NEUROSCI LETT, V411, P11, DOI 10.1016/j.neulet.2006.09.046; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Devinsky O, 2015, ANN M AM AC NEUR WAS; Devinsky O, 2015, EPILEPSIA, V56, P7, DOI 10.1111/epi.12853; Devinsky O, 2014, EPILEPSIA, V55, P791, DOI 10.1111/epi.12631; Drug Enforcement Agency, DRUG SCHED DRUG SCHE; ELLISON JM, 1990, J CLIN PSYCHIAT, V51, P439; ElSohly M., 2014, HDB CANNABIS, P3; FEENEY DM, 1976, JAMA-J AM MED ASSOC, V235, P1105, DOI 10.1001/jama.1976.03260370015003; Friedman D., 2014, AES M SEATTL WA AES; Gloss D, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009270.pub3; Gordon E, 2001, EPILEPSIA, V42, P1266, DOI 10.1046/j.1528-1157.2001.19301.x; Gowers WR, 1881, EPILEPSY OTHER CHRON; Gross DW, 2004, NEUROLOGY, V62, P2095, DOI 10.1212/01.WNL.0000127623.03766.75; Guggenhuber S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015707; Hall W, 1998, LANCET, V352, P1611, DOI 10.1016/S0140-6736(98)05021-1; Hamerle M, 2014, EUR J NEUROL, V21, P167, DOI 10.1111/ene.12081; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; Healy J, 2015, NY TIMES, pA1; Hegde M, 2012, EPILEPSY BEHAV, V25, P563, DOI 10.1016/j.yebeh.2012.09.024; Henderson GE, 2007, PLOS MED, V4, P1735, DOI 10.1371/journal.pmed.0040324; Hill TDM, 2013, BRIT J PHARMACOL, V170, P679, DOI 10.1111/bph.12321; Iannotti FA, 2014, ACS CHEM NEUROSCI, V5, P1131, DOI 10.1021/cn5000524; Jatoi A, 2002, J CLIN ONCOL, V20, P567, DOI 10.1200/JCO.20.2.567; Karanian DA, 2007, J PHARMACOL EXP THER, V322, P1059, DOI 10.1124/jpet.107.120147; KEELER MH, 1967, DIS NERV SYST, V28, P474; Koppel BS, 2014, NEUROLOGY, V82, P1556, DOI 10.1212/WNL.0000000000000363; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Lorenzetti V, 2015, BRIT J PSYCHIAT, V206, P77, DOI 10.1192/bjp.bp.114.151407; Ludanyi A, 2008, J NEUROSCI, V28, P2976, DOI 10.1523/JNEUROSCI.4465-07.2008; Maa E, 2014, EPILEPSIA, V55, P783, DOI 10.1111/epi.12610; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; Mathern GW, 2015, EPILEPSIA, V56, P1, DOI 10.1111/epi.12843; MECHOULAM R, 1978, NATURWISSENSCHAFTEN, V65, P174, DOI 10.1007/BF00450585; Meier MH, 2012, P NATL ACAD SCI USA, V109, pE2657, DOI 10.1073/pnas.1206820109; Monory K, 2006, NEURON, V51, P455, DOI 10.1016/j.neuron.2006.07.006; Mortati Katherine, 2007, Rev Neurol Dis, V4, P103; Ng YT, 2011, NEUROLOGY, V77, P1473, DOI 10.1212/WNL.0b013e318232de76; Patsalos PN, 2003, LANCET NEUROL, V2, P347, DOI 10.1016/S1474-4422(03)00409-5; Pertwee RG, 2008, BRIT J PHARMACOL, V153, P199, DOI 10.1038/sj.bjp.0707442; Pertwee R. G., 2014, HDB CANNABIS; Perucca P, 2012, LANCET NEUROL, V11, P792, DOI 10.1016/S1474-4422(12)70153-9; Porter BE, 2013, EPILEPSY BEHAV, V29, P574, DOI 10.1016/j.yebeh.2013.08.037; Press CA, 2015, EPILEPSY BEHAV, V45, P49, DOI 10.1016/j.yebeh.2015.02.043; Rheims S, 2008, PLOS MED, V5, P1223, DOI 10.1371/journal.pmed.0050166; Robson P, 2011, EXPERT OPIN DRUG SAF, V10, P675, DOI 10.1517/14740338.2011.575778; Rogeberg O, 2013, P NATL ACAD SCI USA, V110, P4251, DOI 10.1073/pnas.1215678110; Romigi A, 2010, EPILEPSIA, V51, P768, DOI 10.1111/j.1528-1167.2009.02334.x; Schoedel KA, 2011, HUM PSYCHOPHARM CLIN, V26, P224, DOI 10.1002/hup.1196; SCHULTES RE, 1973, NAT HIST, V82, P59; Stout SM, 2014, DRUG METAB REV, V46, P86, DOI 10.3109/03602532.2013.849268; Sylantyev S, 2013, P NATL ACAD SCI USA, V110, P5193, DOI 10.1073/pnas.1211204110; Tofighi B, 2012, J ADDICT MED, V6, P240, DOI 10.1097/ADM.0b013e3182619004; Trembly B, 1990, MAR 90 INT C CANN C; Volkow ND, 2014, NEW ENGL J MED, V370, P2219, DOI 10.1056/NEJMra1402309; Wallace MJ, 2003, J PHARMACOL EXP THER, V307, P129, DOI 10.1124/jpet.103.051920; Wang GS, 2013, JAMA PEDIATR, V167, P630, DOI 10.1001/jamapediatrics.2013.140; Weimer K, 2013, PEDIATR RES, V74, P96, DOI 10.1038/pr.2013.66; Whalley BJ., 2013, ENDOCANNABINOIDS MOL, P164; Zajicek JP, 2005, J NEUROL NEUROSUR PS, V76, P1664, DOI 10.1136/jnnp.2005.070136	76	172	180	1	126	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 10	2015	373	11					1048	1058		10.1056/NEJMra1407304	http://dx.doi.org/10.1056/NEJMra1407304			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CQ9TV	26352816				2023-01-03	WOS:000360959000010
J	Halder, B; Singh, S; Thakur, SS				Halder, Babli; Singh, Shruti; Thakur, Suman S.			Withania somnifera Root Extract Has Potent Cytotoxic Effect against Human Malignant Melanoma Cells	PLOS ONE			English	Article							CANCER; MICE; SKIN; CARCINOMA; LEAVES; LINES	In Ayurveda, Withania somnifera is commonly known as Ashwagandha, its roots are specifically used in medicinal and clinical applications. It possesses numerous therapeutic actions which include anti-inflammatory, sedative, hypnotic and narcotic. Extracts from this plant have been reported for its anticancer properties. In this study we evaluated for the first time, the cytotoxic effect of Withania root extract on human malignant melanoma A375 cells. The crude extract of Withania was tested for cytotoxicity against A375 cells by MTT assay. Cell morphology of treated A375 cells was visualized through phase contrast as well as fluorescence microscopy. Agarose gel electrophoresis was used to check DNA fragmentation of the crude extract treated cells. Crude extract of Withania root has the potency to reduce viable cell count in dose as well as time dependent manner. Morphological change of the A375 cells was also observed in treated groups in comparison to untreated or vehicle treated control. Apoptotic body and nuclear blebbing were observed in DAPI stained treated cells under fluorescence microscope. A ladder of fragmented DNA was noticed in treated cells. Thus it might be said that the crude water extract of Withania somnifera has potent cytotoxic effect on human malignant melanoma A375 cells.	[Halder, Babli; Singh, Shruti; Thakur, Suman S.] CCMB, CSIR, Telengana 500007, India	Council of Scientific & Industrial Research (CSIR) - India	Thakur, SS (corresponding author), CCMB, CSIR, Uppal Rd, Telengana 500007, India.	sst@ccmb.res.in		Thakur, Suman/0000-0001-5928-8836	Department of Biotechnology, India; Council of Scientific and Industrial Research, India	Department of Biotechnology, India(Department of Biotechnology (DBT) India); Council of Scientific and Industrial Research, India(Council of Scientific & Industrial Research (CSIR) - India)	The authors are thankful to the Department of Biotechnology, India and Council of Scientific and Industrial Research, India for funding.	Aggarwal BB, 2006, EXPERT OPIN THER TAR, V10, P87, DOI 10.1517/14728222.10.1.87; Ahmad M, 2005, HUM EXP TOXICOL, V24, P137, DOI 10.1191/0906327105ht209oa; Bhattacharya A, 2001, J ETHNOPHARMACOL, V74, P1, DOI 10.1016/S0378-8741(00)00309-3; Bhattacharya S K, 1997, Indian J Exp Biol, V35, P236; Bone K, 1996, MONOGRAPHS W HERBAL; BREKHMAN II, 1969, ANNU REV PHARMACOLOG, V9, P419, DOI 10.1146/annurev.pa.09.040169.002223; Chatterjee A, 1995, NEW DELHI PUBLICATIO, V4, P208; Chatterjee A., 1995, TREATISE INDIAN MED, V4, P208; Davis L, 2002, J EXP CLIN CANC RES, V21, P585; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; Jayaprakasam B, 2003, LIFE SCI, V74, P125, DOI 10.1016/j.lfs.2003.07.007; Jerant AF, 2000, AM FAM PHYSICIAN, V62, P357; Kaur K, 2004, FOOD CHEM TOXICOL, V42, P2015, DOI 10.1016/j.fct.2004.07.015; Malik F, 2007, APOPTOSIS, V12, P2115, DOI 10.1007/s10495-007-0129-x; Mathur S, 2004, PHYTOMEDICINE, V11, P452, DOI 10.1016/j.phymed.2003.05.004; Muralikrishnan G, 2010, IMMUNOL INVEST, V39, P688, DOI 10.3109/08820139.2010.487083; Nagashayana N, 2000, J NEUROL SCI, V176, P124, DOI 10.1016/S0022-510X(00)00329-4; Prakash J, 2002, NUTR CANCER, V42, P91, DOI 10.1207/S15327914NC421_12; Singh B, 2001, PHYTOTHER RES, V15, P311, DOI 10.1002/ptr.858; SINGH N, 1982, International Journal of Crude Drug Research, V20, P29; SINGH N, 1986, International Journal of Crude Drug Research, V24, P90; Singh N, 1986, ANN NAT ACAD IND MED, V2, P14; Singh N, 1976, P IND PHARM SOC, V17; Singh SP, 1979, P 11 ANN C IND PHARM, V11, P65; Yadav B, 2010, INDIAN J PHARM SCI, V72, P659, DOI 10.4103/0250-474X.78543; Yang ES, 2011, CHEM-BIOL INTERACT, V190, P9, DOI 10.1016/j.cbi.2011.01.015; Yu YK, 2010, BIOCHEM PHARMACOL, V79, P542, DOI 10.1016/j.bcp.2009.09.017	27	22	22	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2015	10	9							e0137498	10.1371/journal.pone.0137498	http://dx.doi.org/10.1371/journal.pone.0137498			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ5AJ	26334881	gold, Green Published, Green Submitted			2023-01-03	WOS:000360615400062
J	Nable, JV; Tupe, CL; Gehle, BD; Brady, WJ				Nable, Jose V.; Tupe, Christina L.; Gehle, Bruce D.; Brady, William J.			In-Flight Medical Emergencies during Commercial Travel	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PUBLIC-ACCESS DEFIBRILLATION; HEART-ASSOCIATION GUIDELINES; AIR-TRAVEL; CARDIOPULMONARY-RESUSCITATION; ISSUES; COMPRESSION; MANAGEMENT; MORTALITY; SURVIVAL; CPR		[Nable, Jose V.] Georgetown Univ, Sch Med, MedStar Georgetown Univ Hosp, Dept Emergency Med, Washington, DC USA; [Tupe, Christina L.] Univ Maryland, Sch Med, Dept Emergency Med, Baltimore, MD 21201 USA; [Gehle, Bruce D.] Piedmont Liabil Trust, Charlottesville, VA USA; [Brady, William J.] Univ Virginia, Sch Med, Dept Emergency Med, Charlottesville, VA 22908 USA	Georgetown University; University System of Maryland; University of Maryland Baltimore; University of Virginia	Brady, WJ (corresponding author), POB 800699, Charlottesville, VA 22908 USA.	wb4z@virginia.edu		Nable, Jose/0000-0002-8727-2740	Allianz Global Assistance	Allianz Global Assistance	Dr. Brady reports receiving salary support for serving as medical director for Allianz Global Assistance. No other potential conflict of interest relevant to this article was reported.	Aerosp Med Assoc, 2008, AVIAT SPACE ENVIR MD, V79, P433, DOI 10.3357/ASEM.2272.2008; Aerospace Med Assoc, 2003, AVIAT SPACE ENVIR MD, V74, pA1; Aerospace Medical Association Air Transport Medicine Committee, 2013, MED EM MAN IN FLIGHT; [Anonymous], 2006, 1234B AC FED AV ADM; Baio Jon, 2012, Morbidity and Mortality Weekly Report, V61, P1; Baker SP, 2009, AVIAT SPACE ENVIR MD, V80, P1001, DOI 10.3357/ASEM.2575.2009; Baltsezak S, 2008, J TRAVEL MED, V15, P391, DOI 10.1111/j.1708-8305.2008.00233.x; Bunch Andy, 2013, Air Med J, V32, P268, DOI 10.1016/j.amj.2013.01.003; Caffrey SL, 2002, NEW ENGL J MED, V347, P1242, DOI 10.1056/NEJMoa020932; Coker RK, 2007, EUR RESPIR J, V30, P1057, DOI 10.1183/09031936.00024707; Coker RK, 2002, THORAX, V57, P289; COTTRELL JJ, 1988, CHEST, V93, P81, DOI 10.1378/chest.93.1.81; CUMMINS RO, 1989, JAMA-J AM MED ASSOC, V261, P1295, DOI 10.1001/jama.261.9.1295; DeHart RL, 2003, ANNU REV PUBL HEALTH, V24, P133, DOI 10.1146/annurev.publhealth.24.100901.140853; Federal Aviation Administration (FAA) DOT, 2001, Fed Regist, V66, P19028; Gendreau MA, 2002, NEW ENGL J MED, V346, P1067, DOI 10.1056/NEJMra012774; Goodwin T, 2000, BRIT MED J, V321, P1338, DOI 10.1136/bmj.321.7272.1338; Gupta JK, 2012, INDOOR AIR, V22, P388, DOI 10.1111/j.1600-0668.2012.00773.x; Hallstrom AP, 2004, NEW ENGL J MED, V351, P637; Han ZY, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-434; Hu XW, 2014, CHEST, V145, P688, DOI 10.1378/chest.13-2363; Huff JS, 2007, ANN EMERG MED, V49, P431, DOI 10.1016/j.annemergmed.2007.02.001; Humphreys S, 2005, ANAESTHESIA, V60, P458, DOI 10.1111/j.1365-2044.2005.04124.x; International Air Transport Association, 2006, MED MAN; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Kitamura T, 2010, NEW ENGL J MED, V362, P994, DOI 10.1056/NEJMoa0906644; Kurz MC, 2013, ROSENS EMERGENCY MED; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; Madan K, 2012, RESPIRATION, V83, P554, DOI 10.1159/000334698; Matsumoto K, 2001, AVIAT SPACE ENVIR MD, V72, P919; Morrison LJ, 2010, CIRCULATION, V122, pS665, DOI 10.1161/CIRCULATIONAHA.110.970905; Mosesso VN, 1998, ANN EMERG MED, V32, P200, DOI 10.1016/S0196-0644(98)70137-4; Newman DG, 2006, B20060171 AUSTR TRAN; O'Connor RE, 2010, CIRCULATION, V122, pS787, DOI 10.1161/CIRCULATIONAHA.110.971028; Oh JH, 1999, ARCH INTERN MED, V159, P375, DOI 10.1001/archinte.159.4.375; Peterson DC, 2013, NEW ENGL J MED, V368, P2075, DOI 10.1056/NEJMoa1212052; Rea TD, 2010, NEW ENGL J MED, V363, P423, DOI 10.1056/NEJMoa0908993; Roubinian N, 2012, CHEST, V142, P885, DOI 10.1378/chest.11-2016; Silverman D, 2009, LANCET, V373, P2067, DOI 10.1016/S0140-6736(09)60209-9; Svensson L, 2010, NEW ENGL J MED, V363, P434, DOI 10.1056/NEJMoa0908991	40	54	55	1	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 3	2015	373	10					939	945		10.1056/NEJMra1409213	http://dx.doi.org/10.1056/NEJMra1409213			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CQ2OB	26332548				2023-01-03	WOS:000360439500009
J	Park, JI; Bae, E; Kim, YL; Kang, SW; Yang, CW; Kim, NH; Lee, JP; Kim, DK; Joo, KW; Kim, YS; Lee, H				Park, Ji In; Bae, Eunjin; Kim, Yong-Lim; Kang, Shin-Wook; Yang, Chul Woo; Kim, Nam-Ho; Lee, Jung Pyo; Kim, Dong Ki; Joo, Kwon Wook; Kim, Yon Su; Lee, Hajeong			Glycemic Control and Mortality in Diabetic Patients Undergoing Dialysis Focusing on the Effects of Age and Dialysis Type: A Prospective Cohort Study in Korea	PLOS ONE			English	Article							INTENSIVE GLUCOSE CONTROL; FOLLOW-UP; HEMODIALYSIS; SURVIVAL; HEMOGLOBIN; OUTCOMES; THERAPY; DEATH	Background Active glycemic control has been proven to delay the onset and slow the progression of diabetic retinopathy, nephropathy, and neuropathy in diabetic patients, but the optimal level is obscure in end-stage renal disease. In this study, we evaluated the effect of hemoglobin A1c (HbA1c) on mortality of diabetic patients on dialysis, focusing on age and dialysis type. Methods Of 3,302 patients enrolled in the prospective cohort for end-stage renal disease in Korea between August 2008 and October 2013, 1,239 diabetic patients who had been diagnosed with diabetes or having HbA1c >= 6.5% at the time of enrollment were analyzed. Age was categorized as <55, 55-64 and >= 65 years old. Age, sex, modified Charlson comorbidity index, hemoglobin, primary renal disease, body mass index, and dialysis duration were adjusted. Results A total of 873 patients received hemodialysis (HD) and 366 underwent peritoneal dialysis (PD). During the mean follow-up of 19.1 months, 141 patients died. Patients with poor glucose control (HbA1c >= 8%) showed worse survival than patients with HbA1c<8% (hazard ratio [HR], 2.2; 95% confidence interval [CI], 1.48-3.29; P<0.001). Subgroup analysis divided by age revealed that HbA1c >= 8% was a predictor of mortality in age <55 (HR, 4.3; 95% CI, 1.78-10.41; P = 0.001) and age 55-64 groups (HR, 3.3; 95% CI, 1.56-7.05; P = 0.002), but not in age >= 65 group. Combining dialysis type and age, poor glucose control negatively affected survival only in age < 55 group among HD patients, but it was significant in age < 55 and age 55-64 groups in PD patients. Deaths from infection were more prevalent in the PD group, and poor glucose control tended to correlate with more deaths from infection in PD patients (P = 0.050). Conclusions In this study, the effect of glycemic control differed according to age and dialysis type in diabetic patients. Thus, the target of glycemic control should be customized; further observational studies may strengthen the clinical relevance.	[Park, Ji In] Kangwon Natl Univ, Dept Internal Med, Coll Med, Chunchon, South Korea; [Park, Ji In; Bae, Eunjin; Kim, Yong-Lim; Kang, Shin-Wook; Yang, Chul Woo; Kim, Nam-Ho; Lee, Jung Pyo; Kim, Dong Ki; Joo, Kwon Wook; Kim, Yon Su; Lee, Hajeong] Clin Res Ctr End Stage Renal Dis Korea, Daegu, South Korea; [Bae, Eunjin; Kim, Dong Ki; Joo, Kwon Wook; Kim, Yon Su; Lee, Hajeong] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea; [Kim, Yong-Lim] Kyungpook Natl Univ, Dept Internal Med, Sch Med, Daegu, South Korea; [Kang, Shin-Wook] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Yang, Chul Woo] Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul, South Korea; [Kim, Nam-Ho] Chonnam Natl Univ, Dept Internal Med, Sch Med, Gwangju, South Korea; [Lee, Jung Pyo] Seoul Natl Univ, Dept Internal Med, Boramae Med Ctr, Seoul, South Korea	Kangwon National University; Seoul National University (SNU); Kyungpook National University; Yonsei University; Yonsei University Health System; Catholic University of Korea; Chonnam National University; Seoul National University (SNU); Seoul National University Hospital	Lee, H (corresponding author), Clin Res Ctr End Stage Renal Dis Korea, Daegu, South Korea.	mdhjlee@gmail.com	Kim, Dong Ki/J-5389-2012	Kim, Dong Ki/0000-0002-5195-7852; Park, Ji In/0000-0003-4662-3759	Korea Healthcare Technology RD Project; Ministry of Health and Welfare, Republic of Korea [HI10C2020]	Korea Healthcare Technology RD Project; Ministry of Health and Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	This study was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI10C2020). Clinical research center for end-stage renal disease received the funding, and the leader of the center is YLK. The "Ministry of Health and Welfare" URL is: http://www.mw.go.kr/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adler A, 2014, DIABETES CARE, V37, P1304, DOI 10.2337/dc13-0553; American Diabetes Association, 2015, Diabetes Care, V38 Suppl, pS67, DOI 10.2337/dc15-S013; [Anonymous], 2015, DIABETES CARE, V38, pS33, DOI 10.2337/dc15-S009; Bolton K, 2005, AM J KIDNEY DIS, V45, pS7, DOI 10.1053/j.ajkd.2005.01.016; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Collins Allan J, 2014, Am J Kidney Dis, V63, pA7, DOI 10.1053/j.ajkd.2013.11.001; Currie CJ, 2010, LANCET, V375, P481, DOI 10.1016/S0140-6736(09)61969-3; Duong U, 2011, CLIN J AM SOC NEPHRO, V6, P1041, DOI 10.2215/CJN.08921010; Hemmelgarn BR, 2003, AM J KIDNEY DIS, V42, P125, DOI 10.1016/S0272-6386(03)00415-3; Hill CJ, 2014, AM J KIDNEY DIS, V63, P84, DOI 10.1053/j.ajkd.2013.06.020; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; Huang ES, 2011, DIABETES CARE, V34, P1329, DOI 10.2337/dc10-2377; Jin Dong Chan, 2011, Korean Journal of Internal Medicine, V26, P123, DOI 10.3904/kjim.2011.26.2.123; Kim TN, 2010, DIABETES CARE, V33, P1497, DOI 10.2337/dc09-2310; Kirkman MS, 2012, J AM GERIATR SOC, V60, P2342, DOI 10.1111/jgs.12035; Levin A, 2013, KIDNEY INT SUPPL, V3, P5, DOI 10.1038/kisup.2012.77; Marron B, 2008, KIDNEY INT, V73, pS42, DOI 10.1038/sj.ki.5002600; Nathan DM, 2005, NEW ENGL J MED, V353, P2643, DOI 10.1056/nejmoa052187; Oomichi T, 2006, DIABETES CARE, V29, P1496, DOI 10.2337/dc05-1887; Patel A, 2008, NEW ENGL J MED, V358, P2560, DOI 10.1056/NEJMoa0802987; Perkovic V, 2013, KIDNEY INT, V83, P517, DOI 10.1038/ki.2012.401; Ramirez SPB, 2012, DIABETES CARE, V35, P2527, DOI 10.2337/dc12-0573; Ricks J, 2012, DIABETES, V61, P708, DOI 10.2337/db11-1015; Sekercioglu N, 2012, INT UROL NEPHROL, V44, P1861, DOI 10.1007/s11255-012-0180-6; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Wu MS, 1999, PERITONEAL DIALYSIS; Yoo DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030072; Yu CC, 1997, PERITON DIALYSIS INT, V17, P262; Zoungas S, 2014, NEW ENGL J MED, V371, P1392, DOI 10.1056/NEJMoa1407963	30	13	13	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 18	2015	10	8							e0136085	10.1371/journal.pone.0136085	http://dx.doi.org/10.1371/journal.pone.0136085			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP1VY	26285034	Green Published, Green Submitted, gold			2023-01-03	WOS:000359666100101
J	Taylor, DL; Kahawita, TM; Cairncross, S; Ensink, JHJ				Taylor, Dawn L.; Kahawita, Tanya M.; Cairncross, Sandy; Ensink, Jeroen H. J.			The Impact of Water, Sanitation and Hygiene Interventions to Control Cholera: A Systematic Review	PLOS ONE			English	Review							DRINKING-WATER; SOLAR DISINFECTION; RISK-FACTORS; TRANSMISSION; OUTBREAK; DIARRHEA; STORAGE; O1; CHLORINATION; CHILDREN	Background and Methods Cholera remains a significant threat to global public health with an estimated 100,000 deaths per year. Water, sanitation and hygiene (WASH) interventions are frequently employed to control outbreaks though evidence regarding their effectiveness is often missing. This paper presents a systematic literature review investigating the function, use and impact of WASH interventions implemented to control cholera. Results The review yielded eighteen studies and of the five studies reporting on health impact, four reported outcomes associated with water treatment at the point of use, and one with the provision of improved water and sanitation infrastructure. Furthermore, whilst the reporting of function and use of interventions has become more common in recent publications, the quality of studies remains low. The majority of papers (>60%) described water quality interventions, with those at the water source focussing on ineffective chlorination of wells, and the remaining being applied at the point of use. Interventions such as filtration, solar disinfection and distribution of chlorine products were implemented but their limitations regarding the need for adherence and correct use were not fully considered. Hand washing and hygiene interventions address several transmission routes but only 22% of the studies attempted to evaluate them and mainly focussed on improving knowledge and uptake of messages but not necessarily translating this into safer practices. The use and maintenance of safe water storage containers was only evaluated once, under-estimating the considerable potential for contamination between collection and use. This problem was confirmed in another study evaluating methods of container disinfection. One study investigated uptake of household disinfection kits which were accepted by the target population. A single study in an endemic setting compared a combination of interventions to improve water and sanitation infrastructure, and the resulting reductions in cholera incidence. Discussion and Recommendations This review highlights a focus on particular routes of transmission, and the limited number of interventions tested during outbreaks. There is a distinct gap in knowledge of which interventions are most appropriate for a given context and as such a clear need for more robust impact studies evaluating a wider array of WASH interventions, in order to ensure effective cholera control and the best use of limited resources.	[Taylor, Dawn L.; Kahawita, Tanya M.; Cairncross, Sandy; Ensink, Jeroen H. J.] Univ London London Sch Hyg & Trop Med, Environm Hlth Grp, London WC1E 7HT, England; [Taylor, Dawn L.] Med Sans Frontieres Artsen Zonder Grenzen, NL-1001 EA Amsterdam, Netherlands	University of London; London School of Hygiene & Tropical Medicine	Ensink, JHJ (corresponding author), Univ London London Sch Hyg & Trop Med, Environm Hlth Grp, Keppel St, London WC1E 7HT, England.	jeroen.ensink@lshtm.ac.uk			Department for International Development (DFID) as part of the SHARE Research Programme [P04990]	Department for International Development (DFID) as part of the SHARE Research Programme	The research was funded by UK aid from the Department for International Development (DFID) as part of the SHARE Research Programme (grant nr P04990). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acosta CJ, 2001, EMERG INFECT DIS, V7, P583; AZURIN JC, 1974, B WORLD HEALTH ORGAN, V51, P19; Blanchet K., 2013, EVIDENCE REV RES HLT; BLUM D, 1983, INT J EPIDEMIOL, V12, P357, DOI 10.1093/ije/12.3.357; Bompangue D, 2008, EMERG INFECT DIS, V14, P798, DOI 10.3201/eid1405.071260; Brown J., 2012, Waterlines, V31, P11, DOI 10.3362/1756-3488.2012.004; Cairncross S., 2004, Waterlines, V22, P4, DOI 10.3362/0262-8104.2004.003; Cairncross S, 2010, INT J EPIDEMIOL, V39, P193, DOI 10.1093/ije/dyq035; Cavallaro EC, 2011, J WATER HEALTH, V9, P394, DOI 10.2166/wh.2011.122; Clasen TF, 2004, TROP MED INT HEALTH, V9, P187, DOI 10.1046/j.1365-3156.2003.01191.x; Clasen T, 2007, BMJ-BRIT MED J, V334, P782, DOI 10.1136/bmj.39118.489931.BE; Clasen T, 2009, ENVIRON SCI TECHNOL, V43, P5542, DOI 10.1021/es9008147; Colwell RR, 2003, P NATL ACAD SCI USA, V100, P1051, DOI 10.1073/pnas.0237386100; Conroy RM, 1996, LANCET, V348, P1695, DOI 10.1016/S0140-6736(96)02309-4; Conroy RM, 2001, ARCH DIS CHILD, V85, P293, DOI 10.1136/adc.85.4.293; De Rochars VEMB, 2011, EMERG INFECT DIS, V17, P2158, DOI 10.3201/eid1711.110818; DEB BC, 1986, B WORLD HEALTH ORGAN, V64, P127; DEB BC, 1982, INDIAN J MED RES, V76, P814; Department for International Development (DfID), 2013, WAT SAN HYG; DuBois AE, 2006, EPIDEMIOL INFECT, V134, P1226, DOI 10.1017/S0950268806006273; Dunston C, 2001, AM J PUBLIC HEALTH, V91, P1574, DOI 10.2105/AJPH.91.10.1574; Einarsdottir J, 2001, Int J Infect Dis, V5, P133, DOI 10.1016/S1201-9712(01)90087-6; ESREY SA, 1991, B WORLD HEALTH ORGAN, V69, P609; Feachem R G, 1982, Trop Dis Bull, V79, P1; Fewtrell L, 2005, LANCET INFECT DIS, V5, P42, DOI 10.1016/S1473-3099(04)01253-8; Garandeau R., 2006, Waterlines, V24, P19, DOI 10.3362/0262-8104.2006.008; Gartley M, 2013, J WATER HEALTH, V11, P623, DOI 10.2166/wh.2013.050; Guevart E, 2008, Med Trop (Mars), V68, P507; Hunter PR, 2009, ENVIRON SCI TECHNOL, V43, P8991, DOI 10.1021/es9028217; HUQ A, 1984, APPL ENVIRON MICROB, V48, P420, DOI 10.1128/AEM.48.2.420-424.1984; Huq A, 2010, MBIO, V1, DOI 10.1128/mBio.00034-10; Hutin Yvan, 2003, Journal of Water and Health, V1, P45; Jensen PK, 2002, TROP MED INT HEALTH, V7, P604, DOI 10.1046/j.1365-3156.2002.00901.x; Kone-Coulibaly A, 2010, East Afr J Public Health, V7, P311; Lantagne DS, 2012, ENVIRON SCI TECHNOL, V46, P11352, DOI 10.1021/es301842u; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Mahadik V J, 1983, Med J Zambia, V17, P32; Patrick M, 2013, AM J TROP MED HYG, V89, P647, DOI 10.4269/ajtmh.13-0308; [Private Partnership for Handwashing Initiative Global Public], 2008, HANDW HDB GUID DEV H; Quick RE, 1996, AM J TROP MED HYG, V54, P511, DOI 10.4269/ajtmh.1996.54.511; Quick RE, 1996, INT J EPIDEMIOLOGY, V25; Rowe Alexander K., 1998, International Journal of Environmental Health Research, V8, P339, DOI 10.1080/09603129873444; Schmidt WP, 2009, ENVIRON SCI TECHNOL, V43, P986, DOI 10.1021/es802232w; Schulz KF, 2010, J PHARMACOL PHARMACO, V1, P100, DOI [10.1016/j.jclinepi.2010.02.005, 10.4103/0976-500X.72352, 10.1016/j.ijsu.2011.09.004, 10.1186/1741-7015-8-18]; Shapiro RL, 1999, AM J TROP MED HYG, V60, P271, DOI 10.4269/ajtmh.1999.60.271; Share Consortium, 2012, EV REV RES PRIOR WAT; Shultz A, 2009, AM J TROP MED HYG, V80, P640, DOI 10.4269/ajtmh.2009.80.640; Siddiqui FJ, 2006, T ROY SOC TROP MED H, V100, P476, DOI 10.1016/j.trstmh.2005.07.019; Sobsey MD, 2008, ENVIRON SCI TECHNOL, V42, P4261, DOI 10.1021/es702746n; Steele A, 2008, J WATER HEALTH, V6, P559, DOI 10.2166/wh.2008.072; UNICEF, 2013, CHOL TOOLK; von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]; Waddington H., 2009, WATER SANITATION HYG; WHO, 2012, FACT SHEET NO 107; WHO, 1983, INT DRINK WAT SUPPL; WHO, 2014, 31 WHO	56	105	106	1	75	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 18	2015	10	8							e0135676	10.1371/journal.pone.0135676	http://dx.doi.org/10.1371/journal.pone.0135676			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP1VY	26284367	Green Accepted, Green Published, gold, Green Submitted			2023-01-03	WOS:000359666100056
J	Tripathy, D; Choudhary, A; Banerjee, UC; Singh, IP; Chatterjee, A				Tripathy, Debabrata; Choudhary, Alka; Banerjee, Uttam Chand; Singh, Inder Pal; Chatterjee, Anupam			Induction of Apoptosis and Reduction of Endogenous Glutathione Level by the Ethyl-Acetate Soluble Fraction of the Methanol Extract of the Roots of Potentilla fulgens in Cancer Cells	PLOS ONE			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; NATURAL-PRODUCTS; URSOLIC ACID; ANTIOXIDANT; MODULATION; PREVENTION; TUMORS; DRUGS; MICE	Potentilla fulgens root traditionally used as a folk remedy in Meghalaya, India. However, systematic evaluation of its anticancer efficacy was limited. We investigated the anticancer potentials of the various extracts prepared by partitioning of the methanol extract of the root with the aim to discover major contributing factors from the most effective fractions. Methanol extract of P. fulgens roots (PRE) was prepared by maceration which was subsequently fractionated into hexane, ethyl-acetate (EA) and n-butanol soluble fractions. Various assays (clonogenic assay, Flow cytometry analysis, western blot, semiquantitative RT-PCR and the level of endogenous glutathione) were used to evaluate different parameters, such as Cell survivability, PARP-1 proteolysis, expression pattern of anti-apoptotic and.-glutamylcysteine synthetase heavy subunit (GCSC) genes in both MCF-7 and U87 cancer cell lines. Since the EA-fraction showed most efficient growth inhibitory effect, it was further purified and a total of nine compounds and some monomeric and dimeric flavan-3-ols were identified and characterized. Three compounds viz., epicatechin (EC), gallic acid (GA) and ursolic acid (UA) were taken on the basis of their higher yield and 10 mu g/ml of each was mixed together. The concentration used in this study for PRE, EA-and Hex-fraction was 100 mu g/ml, which was higher than the IC50 value. Apoptotic cell death in the PRE, EA-fraction and EC+GA+UA treated cancer cell cultures was significantly greater than in normal cells due to suppression of anti-apoptotic protein Bcl2 following treatment. Depletion of glutathione by downregulating GCSC was also observed. Induction of apoptosis and lowering the level of glutathione are considered to be positive activity for an anticancer agent. Therefore, modulation of GSH concentration in tumor cells by PRE and its EA-fraction opened up the possibility of a new therapeutic approach because these plant products are not harmful to normal cells and may regulate the tumor cellular response to different anticancer treatments. Thus, it would be interesting to examine efficacy of these plant products or EA-fraction in human cancer treatment.	[Tripathy, Debabrata; Chatterjee, Anupam] North Eastern Hill Univ, Dept Biotechnol & Bioinformat, Mol Genet Lab, Shillong 793022, Meghalaya, India; [Choudhary, Alka; Banerjee, Uttam Chand] Natl Inst Pharmaceut Educ & Res, Dept Pharmaceut Technol Biotechnol, Sect 67, Sas Nagar 160062, Punjab, India; [Singh, Inder Pal] Natl Inst Pharmaceut Educ & Res, Dept Nat Prod, Sect 67, Sas Nagar 160062, Punjab, India	North Eastern Hill University; National Institute of Pharmaceutical Education & Research (NIPER); National Institute of Pharmaceutical Education & Research, S.A.S. Nagar (Mohali); National Institute of Pharmaceutical Education & Research (NIPER); National Institute of Pharmaceutical Education & Research, S.A.S. Nagar (Mohali)	Chatterjee, A (corresponding author), North Eastern Hill Univ, Dept Biotechnol & Bioinformat, Mol Genet Lab, Shillong 793022, Meghalaya, India.	chatterjeeanupam@hotmail.com		Tripathy, Debabrata/0000-0003-1081-2232; Banerjee, uttam Chand/0000-0002-7363-4042	DBT, Govt. of India [BT/59/NE/TBP/2010]; DBT fellowship; DST-Inspire fellowship [IF 120044]	DBT, Govt. of India(Department of Biotechnology (DBT) India); DBT fellowship; DST-Inspire fellowship	This work was supported by DBT, Govt. of India (BT/59/NE/TBP/2010) to AC, UCB, and IPS; DBT fellowship and DST-Inspire fellowship (IF 120044) to Alka Choudhary; DBT-fellowship to DT.	Akerboom T P, 1981, Methods Enzymol, V77, P373; Amin ARMR, 2009, J CLIN ONCOL, V27, P2712, DOI 10.1200/JCO.2008.20.6235; Chattopadhyay A, 1999, INT J RADIAT BIOL, V75, P1283, DOI 10.1080/095530099139449; Choudhary A, 2015, PHYTOCHEM ANALYSIS, V26, P161, DOI 10.1002/pca.2547; Choudhary A, 2013, FITOTERAPIA, V91, P290, DOI 10.1016/j.fitote.2013.09.008; Circu ML, 2012, BBA-MOL CELL RES, V1823, P1767, DOI 10.1016/j.bbamcr.2012.06.019; Coseri S, 2009, MINI-REV MED CHEM, V9, P560, DOI 10.2174/138955709788167592; De Angel RE, 2010, NUTR CANCER, V62, P1074, DOI 10.1080/01635581.2010.492092; Elbaz HA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088322; ESTRELA JM, 1995, NAT MED, V1, P84, DOI 10.1038/nm0195-84; Estrela JM, 2006, CRIT REV CL LAB SCI, V43, P143, DOI 10.1080/10408360500523878; Fang Y, 2012, J BIOL CHEM, V287, P35234, DOI 10.1074/jbc.M112.389494; Franco R, 2009, CELL DEATH DIFFER, V16, P1303, DOI 10.1038/cdd.2009.107; Franklin CC, 2009, MOL ASPECTS MED, V30, P86, DOI 10.1016/j.mam.2008.08.009; Gamcsik MP, 2012, BIOMARKERS, V17, P671, DOI 10.3109/1354750X.2012.715672; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Ishige K, 2001, FREE RADICAL BIO MED, V30, P433, DOI 10.1016/S0891-5849(00)00498-6; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jenny Marcel, 2005, J Carcinog, V4, P15, DOI 10.1186/1477-3163-4-15; Jew S, 2009, J MED FOOD, V12, P925, DOI 10.1089/jmf.2008.0268; Lauterburg Bernhard H, 2002, Am J Ther, V9, P225, DOI 10.1097/00045391-200205000-00008; Lauthier F, 2000, ANTI-CANCER DRUG, V11, P737; Lu Y, 2010, EUR J PHARMACOL, V641, P102, DOI 10.1016/j.ejphar.2010.05.043; Myhrstad MCW, 2002, FREE RADICAL BIO MED, V32, P386, DOI 10.1016/S0891-5849(01)00812-7; Newman DJ, 2008, J MED CHEM, V51, P2589, DOI 10.1021/jm0704090; Ortega Angel L, 2011, Cancers (Basel), V3, P1285, DOI 10.3390/cancers3011285; POOT M, 1995, J CELL PHYSIOL, V163, P555, DOI 10.1002/jcp.1041630316; Prasad S, 2011, J BIOL CHEM, V286, P5546, DOI 10.1074/jbc.M110.183699; Radhika M, 2012, J COMPLEMENTARY INTE, V9, P1; Ramos AA, 2010, MUTAT RES-FUND MOL M, V692, P6, DOI 10.1016/j.mrfmmm.2010.07.004; Rosangkima G., 2004, Indian Journal of Experimental Biology, V42, P981; Safarzadeh E, 2014, ADV PHARM BULL, V4, P421, DOI 10.5681/apb.2014.062; Shushunov S, 2009, J MED FOOD, V12, P1173, DOI 10.1089/jmf.2008.0281; Siegelin MD, 2008, MOL CANCER THER, V7, P3566, DOI 10.1158/1535-7163.MCT-08-0236; Soldani C, 2001, EXP CELL RES, V269, P193, DOI 10.1006/excr.2001.5293; Syiem D, 2002, J ETHNOPHARMACOL, V83, P55, DOI 10.1016/S0378-8741(02)00190-3; Thayyullathil F, 2011, BIOCHEM BIOPH RES CO, V411, P1, DOI 10.1016/j.bbrc.2011.05.156; Tomczyk M, 2010, MOLECULES, V15, P4639, DOI 10.3390/molecules15074639; Tomczyk M, 2009, J ETHNOPHARMACOL, V122, P184, DOI 10.1016/j.jep.2008.12.022; Verma S, 2013, ENVIRON TOXICOL PHAR, V35, P473, DOI 10.1016/j.etap.2013.02.011; Wang SS, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-321; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zamzami N, 2005, CELL DEATH DIFFER, V12, P1478, DOI 10.1038/sj.cdd.4401682; Zhao YL, 2008, PHYTOMEDICINE, V15, P253, DOI 10.1016/j.phymed.2008.01.005	45	9	10	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 18	2015	10	8							e0135890	10.1371/journal.pone.0135890	http://dx.doi.org/10.1371/journal.pone.0135890			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP1VY	26284809	Green Published, Green Submitted, gold			2023-01-03	WOS:000359666100083
J	Park, DR; Shawl, AI; Ha, TG; Park, KH; Kim, SY; Kim, UH				Park, Dae-Ryoung; Shawl, Asif Iqbal; Ha, Tae-Geun; Park, Kwang-Hyun; Kim, Seon-Young; Kim, Uh-Hyun			Arginine Thiazolidine Carboxylate Stimulates Insulin Secretion through Production of Ca2+-Mobilizing Second Messengers NAADP and cADPR in Pancreatic Islets	PLOS ONE			English	Article							CYCLIC ADP-RIBOSE; ADENINE-DINUCLEOTIDE PHOSPHATE; CALCIUM-MOBILIZING METABOLITE; NITRIC-OXIDE; BETA-CELLS; L-2-OXOTHIAZOLIDINE-4-CARBOXYLIC ACID; NAD GLYCOHYDROLASE; HYDROGEN-SULFIDE; CYCLASE ACTIVITY; L-CYSTEINE	Oxothiazolidine carboxylic acid is a prodrug of cysteine that acts as an anti-diabetic agent via insulin secretion and the formation of the Ca2+-mobilizing second messenger, cyclic ADP-ribose (cADPR). Here we show that a hybrid compound, arginine thiazolidine carboxylate (ATC), increases cytoplasmic Ca2+ in pancreatic beta-cells, and that the ATC-induced Ca2+ signals result from the sequential formation of two Ca2+-mobilizing second messengers: nicotinic acid adenine dinucleotide phosphate (NAADP) and cADPR. Our data demonstrate that ATC has potent insulin-releasing properties, due to the additive action of its two components; thiazolidine carboxylate (TC) and L-arginine. TC increases glutathione (GSH) levels, resulting in cAMP production, followed by a cascade pathway of NAADP/nitric oxide (NO)/cGMP/cADPR synthesis. L-arginine serves as the substrate for NO synthase (NOS), which results in cADPR synthesis via cGMP formation. Neuronal NOS is specifically activated in pancreatic beta-cells upon ATC treatment. These results suggest that ATC is an ideal candidate as an anti-diabetic, capable of modulating the physiological Ca2+ signalling pathway to stimulate insulin secretion.	[Park, Dae-Ryoung; Shawl, Asif Iqbal; Ha, Tae-Geun; Park, Kwang-Hyun; Kim, Seon-Young; Kim, Uh-Hyun] Chonbuk Natl Univ, Sch Med, Dept Biochem, Jeonju, South Korea; [Park, Dae-Ryoung; Shawl, Asif Iqbal; Ha, Tae-Geun; Park, Kwang-Hyun; Kim, Seon-Young; Kim, Uh-Hyun] Chonbuk Natl Univ, Natl Creat Res Lab Signaling Network Ca2, Jeonju, South Korea; [Kim, Uh-Hyun] Chonbuk Natl Univ, Inst Cardiovasc Res, Jeonju, South Korea	Jeonbuk National University; Jeonbuk National University; Jeonbuk National University	Kim, UH (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Biochem, Jeonju, South Korea.	uhkim@chonbuk.ac.kr		Kim, Uh-Hyun/0000-0003-3304-7190	National Research Foundation Grant - Korean government [2012R1A3A2026453]	National Research Foundation Grant - Korean government(National Research Foundation of Korea)	This work was supported by the National Research Foundation Grant 2012R1A3A2026453 funded by the Korean government (to U.-H.K.).	Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; AMMON HPT, 1982, N-S ARCH PHARMACOL, V319, P243, DOI 10.1007/BF00495873; An NH, 2001, BIOCHEM BIOPH RES CO, V282, P781, DOI 10.1006/bbrc.2001.4654; Billington RA, 2006, FASEB J, V20, P521, DOI 10.1096/fj.05-5058fje; Bramato C, 1982, Minerva Dietol Gastroenterol, V28, P65; Cho YS, 1998, COMP BIOCHEM PHYS B, V120, P175, DOI 10.1016/S0305-0491(98)10006-8; FITZPATRICK PF, 1982, J BIOL CHEM, V257, P1166; Friebe A, 2003, CIRC RES, V93, P96, DOI 10.1161/01.RES.0000082524.34487.31; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GLICK DL, 1991, CELL REGUL, V2, P211, DOI 10.1091/mbc.2.3.211; Graeff RM, 2003, COMB CHEM HIGH T SCR, V6, P367; Han MK, 2002, J BIOL CHEM, V277, P5315, DOI 10.1074/jbc.M106439200; HAN MK, 1994, J LEUKOCYTE BIOL, V56, P792, DOI 10.1002/jlb.56.6.792; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; Institute of Laboratory Animal Research Commision of Life Sciences National Research Council, 1996, GUIDE OF THE CARE AN; Johnson JD, 2002, P NATL ACAD SCI USA, V99, P14566, DOI 10.1073/pnas.222099799; Kaneko Y, 2006, DIABETES, V55, P1391, DOI 10.2337/db05-1082; Kaneko Y, 2009, FEBS LETT, V583, P377, DOI 10.1016/j.febslet.2008.12.026; Kim BJ, 2008, DIABETES, V57, P868, DOI 10.2337/db07-0443; Kim HL, 2004, ACTA CRYSTALLOGR D, V60, P948, DOI 10.1107/S0907444904005591; Kim YM, 2011, ANTIOXID REDOX SIGN, V14, P137, DOI 10.1089/ars.2010.3153; KONG SK, 1994, BIOCHEM BIOPH RES CO, V199, P234, DOI 10.1006/bbrc.1994.1219; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; Lee HC, 2006, MOL MED, V12, P317, DOI 10.2119/2006-00086.Lee; Lee HC, 2011, SCI CHINA LIFE SCI, V54, P699, DOI 10.1007/s11427-011-4197-3; Lee YC, 2004, FASEB J, V18, P1917, DOI 10.1096/fj.04-2212fje; Looms DK, 2001, BIOCHEM J, V355, P87, DOI 10.1042/bj3550087; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Lundquist I, 2003, AM J PHYSIOL-ENDOC M, V285, pE1055, DOI 10.1152/ajpendo.00498.2002; Malavasi F, 2008, PHYSIOL REV, V88, P841, DOI 10.1152/physrev.00035.2007; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; Masgrau R, 2003, CURR BIOL, V13, P247, DOI 10.1016/S0960-9822(03)00041-1; MESINA JE, 1989, BRAIN RES, V478, P181, DOI 10.1016/0006-8993(89)91494-7; Mitchell KJ, 2003, J BIOL CHEM, V278, P11057, DOI 10.1074/jbc.M210257200; MUKHERJEE SP, 1979, BIOCHIM BIOPHYS ACTA, V568, P224, DOI 10.1016/0005-2744(79)90289-4; Oiry J, 1999, J MED CHEM, V42, P4733, DOI 10.1021/jm980289j; Park KH, 2013, J BIOL CHEM, V288, P35548, DOI 10.1074/jbc.M113.489278; PORTA P, 1991, J PHARMACOL EXP THER, V257, P331; Rah SY, 2007, J BIOL CHEM, V282, P5653, DOI 10.1074/jbc.M609478200; Rah SY, 2005, J BIOL CHEM, V280, P2888, DOI 10.1074/jbc.M409592200; SCHMIDT HHHW, 1992, SCIENCE, V255, P721, DOI 10.1126/science.1371193; SCHUIT FC, 1985, ENDOCRINOLOGY, V117, P834, DOI 10.1210/endo-117-3-834; Song EK, 2012, CELL REP, V2, P1607, DOI 10.1016/j.celrep.2012.10.018; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; Tang G, 2013, DIABETOLOGIA, V56, P533, DOI 10.1007/s00125-012-2806-8; Thams P, 1999, EUR J ENDOCRINOL, V140, P87, DOI 10.1530/eje.0.1400087; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; Vita JA, 1998, J CLIN INVEST, V101, P1408, DOI 10.1172/JCI1155; WARD WK, 1984, J CLIN INVEST, V74, P1318, DOI 10.1172/JCI111542; WILLIAMSON JM, 1981, P NATL ACAD SCI-BIOL, V78, P936, DOI 10.1073/pnas.78.2.936; Willmott N, 1996, J BIOL CHEM, V271, P3699; WILLMOTT NJ, 1995, FEBS LETT, V371, P99, DOI 10.1016/0014-5793(95)00848-4; WLODEK L, 1993, BIOCHEM PHARMACOL, V46, P1917, DOI 10.1016/0006-2952(93)90632-7; You H, 2011, AM J PHYSIOL-ENDOC M, V300, pE435, DOI 10.1152/ajpendo.00398.2010	55	2	2	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2015	10	8							e0134962	10.1371/journal.pone.0134962	http://dx.doi.org/10.1371/journal.pone.0134962			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO3MQ	26247205	Green Submitted, gold, Green Published			2023-01-03	WOS:000359062300082
J	Iwase, S; Kawaguchi, T; Tokoro, A; Yamada, K; Kanai, Y; Matsuda, Y; Kashiwaya, Y; Okuma, K; Inada, S; Ariyoshi, K; Miyaji, T; Azuma, K; Ishiki, H; Unezaki, S; Yamaguchi, T				Iwase, Satoru; Kawaguchi, Takashi; Tokoro, Akihiro; Yamada, Kimito; Kanai, Yoshiaki; Matsuda, Yoshinobu; Kashiwaya, Yuko; Okuma, Kae; Inada, Shuji; Ariyoshi, Keisuke; Miyaji, Tempei; Azuma, Kanako; Ishiki, Hiroto; Unezaki, Sakae; Yamaguchi, Takuhiro			Assessment of Cancer-Related Fatigue, Pain, and Quality of Life in Cancer Patients at Palliative Care Team Referral: A Multicenter Observational Study (JORTC PAL-09)	PLOS ONE			English	Article							EUROPEAN-ORGANIZATION; CONSULTATION TEAM; JAPANESE VERSION; QUESTIONNAIRE; VALIDATION; OUTCOMES	Introduction Cancer-related fatigue greatly influences quality of life in cancer patients; however, no specific treatments have been established for cancer-related fatigue, and at present, no medication has been approved in Japan. Systematic research using patient-reported outcome to examine symptoms, particularly fatigue, has not been conducted in palliative care settings in Japan. The objective was to evaluate fatigue, pain, and quality of life in cancer patients at the point of intervention by palliative care teams. Materials and Methods Patients who were referred to palliative care teams at three institutions and met the inclusion criteria were invited to complete the Brief Fatigue Inventory, Brief Pain Inventory, and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 15-Palliative. Results Of 183 patients recruited, the majority (85.8%) were diagnosed with recurrence or metastasis. The largest group (42.6%) comprised lung cancer patients, of whom 67.2% had an Eastern Cooperative Oncology Group Performance Status of 0-1. The mean value for global health status/quality of life was 41.4, and the highest mean European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 15-Palliative symptom item score was for pain (51.0). The mean global fatigue score was 4.1, and 9.8%, 30.6%, 38.7%, and 20.8% of patients' fatigue severity was classified as none (score 0), mild (1-3), moderate (4-6), and severe (7-10), respectively. Discussion Cancer-related fatigue, considered to occur more frequently in cancer patients, was successfully assessed using patient-reported outcomes with the Brief Fatigue Inventory for the first time in Japan. Results suggested that fatigue is potentially as problematic as pain, which is the main reason for palliative care.	[Iwase, Satoru; Ariyoshi, Keisuke; Ishiki, Hiroto] Univ Tokyo, Inst Med Sci, Dept Palliat Med, Tokyo, Japan; [Kawaguchi, Takashi; Unezaki, Sakae] Tokyo Univ Pharm & Life Sci, Dept Pract Pharm, Tokyo, Japan; [Tokoro, Akihiro; Matsuda, Yoshinobu] Natl Hosp Org, Kinki Chuo Chest Med Ctr, Dept Psychosomat Internal Med, Sakai, Osaka, Japan; [Yamada, Kimito] Tokyo Med Univ Hosp, Dept Breast Surg, Tokyo, Japan; [Kanai, Yoshiaki; Okuma, Kae; Inada, Shuji] Tokyo Univ Hosp, Dept Palliat Med, Tokyo 113, Japan; [Kashiwaya, Yuko] Tokyo Med Univ Hosp, Dept Palliat Med, Tokyo, Japan; [Okuma, Kae] Tokyo Univ Hosp, Dept Radiol, Tokyo 113, Japan; [Inada, Shuji] Tokyo Univ Hosp, Dept Psychosomat Med, Tokyo 113, Japan; [Ariyoshi, Keisuke; Miyaji, Tempei; Ishiki, Hiroto; Yamaguchi, Takuhiro] NPO, JORTC, Tokyo, Japan; [Miyaji, Tempei; Yamaguchi, Takuhiro] Univ Tokyo, Grad Sch Med, Dept Clin Trial Data Management, Tokyo, Japan; [Azuma, Kanako] Tokyo Med Univ Hosp, Dept Pharm, Tokyo, Japan; [Yamaguchi, Takuhiro] Tohoku Univ, Div Biostat, Grad Sch Med, Sendai, Miyagi 980, Japan	University of Tokyo; Tokyo University of Pharmacy & Life Sciences; Tokyo Medical University; University of Tokyo; Tokyo Medical University; University of Tokyo; University of Tokyo; University of Tokyo; Tokyo Medical University; Tohoku University	Miyaji, T (corresponding author), NPO, JORTC, Tokyo, Japan.	tmiyaji@m.u-tokyo.ac.jp	Hiroto, Ishiki/AHC-0321-2022					AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Ahlberg K, 2003, LANCET, V362, P640, DOI 10.1016/S0140-6736(03)14186-4; Basch E, 2009, JNCI-J NATL CANCER I, V101, P1624, DOI 10.1093/jnci/djp386; Carson MG, 2000, PALLIATIVE MED, V14, P25, DOI 10.1191/026921600677786382; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; de Santiago A, 2012, SUPPORT CARE CANCER, V20, P2199, DOI 10.1007/s00520-012-1476-x; Delgado-Guay MO, 2009, CANCER-AM CANCER SOC, V115, P437, DOI 10.1002/cncr.24017; Dhillon N, 2008, J PALLIAT MED, V11, P191, DOI 10.1089/jpm.2007.0094; Groenvold M, 2006, EUR J CANCER, V42, P55, DOI 10.1016/j.ejca.2005.06.022; Horneber M, 2012, DTSCH ARZTEBL INT, V109, P161, DOI 10.3238/arztebl.2012.0161; Iwase Satoru, 2007, Am J Hosp Palliat Care, V24, P29, DOI 10.1177/1049909106295302; Koizumi M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-423; Laird BJA, 2011, J PAIN SYMPTOM MANAG, V42, P1, DOI 10.1016/j.jpainsymman.2010.10.261; Lee YJ, SUPPOR IN PRESS 0301; Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N; Minton O, 2009, ANN ONCOL, V20, P17, DOI 10.1093/annonc/mdn537; Miyazaki K, 2012, QUAL LIFE RES, V21, P335, DOI 10.1007/s11136-011-9939-y; Morita T, 2005, J PAIN SYMPTOM MANAG, V29, P458, DOI 10.1016/j.jpainsymman.2004.08.013; Mortimer JE, 2010, J NATL COMPR CANC NE, V8, P1331, DOI 10.6004/jnccn.2010.0101; Okuyama T, 2003, J PAIN SYMPTOM MANAG, V25, P106, DOI 10.1016/S0885-3924(02)00596-1; Okuyama T, 2000, J PAIN SYMPTOM MANAG, V19, P5, DOI 10.1016/S0885-3924(99)00138-4; Peuckmann V, 2010, COCHRANE DB SYST REV, V10, P11; Stone P, 1999, BRIT J CANCER, V79, P1479, DOI 10.1038/sj.bjc.6690236; Uki J, 1998, J PAIN SYMPTOM MANAG, V16, P364, DOI 10.1016/S0885-3924(98)00098-0; Walsh D, 2006, SUPPORT CARE CANCER, V14, P831, DOI 10.1007/s00520-005-0899-z; Yennurajalingam S, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.20564; Yennurajalingam S, 2008, SUPPORT CARE CANCER, V16, P1125, DOI 10.1007/s00520-008-0466-5; Yennurajalingam S, 2007, SUPPORT CARE CANCER, V15, P471, DOI 10.1007/s00520-006-0172-0; Yennurajalingam S, 2013, J CLIN ONCOL, V31, P3076, DOI 10.1200/JCO.2012.44.4661	30	22	24	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2015	10	8							e0134022	10.1371/journal.pone.0134022	http://dx.doi.org/10.1371/journal.pone.0134022			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO3MH	26244975	Green Published, gold, Green Submitted			2023-01-03	WOS:000359061400065
J	Lin, ZJ; Zhao, ZH; Xu, HH; Zhang, X; Wang, TT; Kan, HD; Norback, D				Lin, Zhijing; Zhao, Zhuohui; Xu, Huihui; Zhang, Xin; Wang, Tingting; Kan, Haidong; Norback, Dan			Home Dampness Signs in Association with Asthma and Allergic Diseases in 4618 Preschool Children in Urumqi, China-The Influence of Ventilation/Cleaning Habits	PLOS ONE			English	Article							RESPIRATORY SYMPTOMS; HOUSING CHARACTERISTICS; ENVIRONMENTAL-FACTORS; CHILDHOOD ASTHMA; EARLY-LIFE; HEALTH; PREVALENCE; BUILDINGS; MOLDS; SCHOOLCHILDREN	There is an increasing prevalence of childhood asthma and allergic diseases in mainland of China. Few studies investigated the indoor dampness, ventilation and cleaning habits and their interrelationship with childhood asthma and allergic diseases. A large-scale cross-sectional study was performed in preschool children in Urumqi, China. Questionnaire was used to collect information on children's health, home dampness and ventilation/cleaning (V/C) habits. Multiple logistic regressions were applied to analyze the associations between childhood asthma/allergic diseases and each sign of home dampness, dampness levels, each V/C habit and total V/C scores. The associations between dampness and health were further performed by strata analyses in two groups with low and high V/C scores. Totally 4618 (81.7%) of 5650 children returned the questionnaire. Reports on home dampness were most common for water condensation on windows (20.8%) followed by damp beddings (18.0%). The most common ventilation measure was the use of exhaust fan in bathroom (59.3%), followed by daily home cleaning (48.3%), frequently putting beddings to sunshine (29.9%) and frequently opening windows in winter (8.4%). There were positive associations between the 6 signs of home dampness and children's health particularly the symptoms last 12 months. By comparing with the reference dampness level (dampness scored 0), both the low dampness (scored 1 similar to 2) level and the high dampness level (scored 3 similar to 6) showed significantly increasing associations with childhood symptoms. There were crude negative associations between V/C habits and childhood health but not significant adjusting for home dampness levels. The risks of home dampness on children's health were lower in the group with higher V/C score but the differences were not statistically significant. Home dampness is a potential risk factor for childhood asthma and allergic symptoms in preschool children in Urumqi, China. No significant effects were observed for ordinary home ventilation and cleaning habits in reducing the risks of home dampness on childhood asthma and allergic diseases in Urumqi, China.	[Lin, Zhijing; Zhao, Zhuohui; Kan, Haidong] Fudan Univ, Dept Environm Hlth, Sch Publ Hlth, Key Lab Publ Hlth Safety,Minist Educ, Shanghai 200032, Peoples R China; [Xu, Huihui] Shanghai Municipal Ctr Dis Control & Prevent, Dept Environm Hlth, Shanghai 200032, Peoples R China; [Zhang, Xin] Shanxi Univ, Inst Environm Sci, Taiyuan 030006, Peoples R China; [Wang, Tingting] Xinjiang Med Univ, Sch Publ Hlth, Dept Maternal Child & Adolescent Hlth, Urumqi, Peoples R China; [Norback, Dan] Uppsala Univ, Dept Med Sci Occupat & Environm Med, SE-751 Uppsala, Sweden	Fudan University; Shanghai Center for Disease Control & Prevention; Shanxi University; Xinjiang Medical University; Uppsala University	Zhao, ZH (corresponding author), Fudan Univ, Dept Environm Hlth, Sch Publ Hlth, Key Lab Publ Hlth Safety,Minist Educ, Shanghai 200032, Peoples R China.	zhzhao@fudan.edu.cn	Kan, Haidong/AGU-0328-2022; wang, tingting/AAK-2640-2020	Norback, Dan/0000-0002-5174-6668				Aberg N, 1996, ALLERGY, V51, P232, DOI 10.1111/j.1398-9995.1996.tb04598.x; Akinbami LJ, 2009, PEDIATRICS, V123, pS131, DOI 10.1542/peds.2008-2233C; [Anonymous], 2009, WHO GUID IND AIR QUA; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Asher MI, 1998, EUR RESPIR J, V12, P315; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bornehag CG, 2005, INDOOR AIR, V15, P48, DOI 10.1111/j.1600-0668.2005.00306.x; Bornehag CG, 2001, INDOOR AIR, V11, P72; Bornehag CG, 2004, INDOOR AIR, V14, P59, DOI 10.1111/j.1600-0668.2004.00274.x; Braun FC, 2004, EUR J RESP, V23, P407; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363, DOI 10.1164/ajrccm/140.5.1363; Butler Sarnia, 2003, N Z Med J, V116, pU494; Chang P, 1954, COLLECTED SCI PAPERS, P273; Chen Yu-zhi, 2004, Zhonghua Jiehe He Huxi Zazhi, V27, P112; Claeson AS, 2007, J ENVIRON MONITOR, V9, P240, DOI 10.1039/b614766f; DALES RE, 1991, AM J EPIDEMIOL, V134, P196, DOI 10.1093/oxfordjournals.aje.a116072; Dong GH, 2008, RESPIRATION, V76, P82, DOI 10.1159/000121370; Dong GH, 2008, INT J ENVIRON HEAL R, V18, P267, DOI 10.1080/09603120701842864; Dong GH, 2008, REV EPIDEMIOL SANTE, V56, P97, DOI 10.1016/j.respe.2007.12.002; Engvall K, 2001, INT J TUBERC LUNG D, V5, P468; Gunnbjornsdottir MI, 2006, THORAX, V61, P221, DOI 10.1136/thx.2005.057430; Hsu NY, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/158248; Hu Y, 2014, INDOOR AIR, V24, P450, DOI 10.1111/ina.12104; Karvonen AM, 2009, PEDIATRICS, V124, pE329, DOI 10.1542/peds.2008-1590; Lee IS, 2003, YONSEI MED J, V44, P313, DOI 10.3349/ymj.2003.44.2.313; Leech JA, 2002, J EXPO ANAL ENV EPID, V12, P427, DOI 10.1038/sj.jea.7500244; Leung R, 1997, EUR RESPIR J, V10, P354, DOI 10.1183/09031936.97.10020354; Li XF, 2013, HV AC, V43, P46; Mudarri D, 2007, INDOOR AIR, V17, P226, DOI 10.1111/j.1600-0668.2007.00474.x; National Bureau of Statistics-People's Republic of China, 2011, CHIN STAT YB 2010 20; National Cooperative Group on Childhood Asthma, 2013, Zhonghua Er Ke Za Zhi, V51, P729; Naydenov K, 2008, PEDIAT ALLERG IMM-UK, V19, P702, DOI 10.1111/j.1399-3038.2008.00721.x; Pirhonen I, 1996, EUR RESPIR J, V9, P2618, DOI 10.1183/09031936.96.09122618; PLATT SD, 1989, BRIT MED J, V298, P1673, DOI 10.1136/bmj.298.6689.1673; Sauni R, 2013, EVID BASED CHILD HLT, V8, P994; Sun Y, 2011, INDOOR AIR, V21, P277, DOI 10.1111/j.1600-0668.2010.00699.x; Sun YX, 2011, SCI TOTAL ENVIRON, V409, P4229, DOI 10.1016/j.scitotenv.2011.07.011; Tham KW, 2007, PEDIAT ALLERG IMM-UK, V18, P418, DOI 10.1111/j.1399-3038.2007.00544.x; VERHOEFF AP, 1995, AM J EPIDEMIOL, V141, P103, DOI 10.1093/oxfordjournals.aje.a117398; Wang H, 2013, CHINESE SCI BULL, V58, P4259, DOI 10.1007/s11434-013-5774-6; Wang Hong-yu, 2006, Zhonghua Er Ke Za Zhi, V44, P41; Wang TT, 2013, CHINESE SCI BULL, V58, P4237, DOI 10.1007/s11434-013-5727-0; Yang CY, 1997, PEDIATR PULM, V24, P73, DOI 10.1002/(SICI)1099-0496(199708)24:2<73::AID-PPUL1>3.0.CO;2-J; Zhang M, 2013, CHINESE SCI BULL, V58, P4223, DOI 10.1007/s11434-013-5687-4; Zhang YP, 2013, CHINESE SCI BULL, V58, P4182, DOI 10.1007/s11434-013-5914-z; Zhang YP, 2013, ENVIRON HEALTH PERSP, V121, P751, DOI 10.1289/ehp.1205983; Zhao ZH, 2013, CHINESE SCI BULL, V58, P4245, DOI 10.1007/s11434-013-5705-6	47	14	14	2	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2015	10	7							e0134359	10.1371/journal.pone.0134359	http://dx.doi.org/10.1371/journal.pone.0134359			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO0JY	26230849	gold, Green Submitted, Green Published			2023-01-03	WOS:000358838400106
J	Liu, YQ; Wang, ZY; Su, JP; Liu, WW; Dhiloo, KH; Guo, YY				Liu, Yongqiang; Wang, Zhongyue; Su, Junping; Liu, Weiwei; Dhiloo, Khalid Hussain; Guo, Yuyuan			The Efficacy of Chinese Medicinal Herbs towards Grape Phylloxera (Daktulosphaira vitifoliae Fitch) (Hemiptera, Phylloxeridae)	PLOS ONE			English	Article							INSECT GROWTH-REGULATOR; HOMOPTERA; PESTICIDES; MANAGEMENT; MORTALITY; EXTRACTS; BIOTYPES; BIOLOGY; OIL	Bio-insecticidal effects of seven Chinese medicinal herbs on mortality, fecundity, developmental periods and life table parameters of the grape phylloxera were investigated. In an excised root bioassay experiment aqueous extracts from seven Chinese medicinal herbs increased grape phylloxera first instar mortality (26.00-38.50%) compared to other instars. The intrinsic rate of increase (r(m)), finite rate of increase (lambda), fecundity rate and net reproductive rate (R-0) were significantly reduced by A. bidentata, A. tataricus, O. basilicum, P. frutescensand N. cataria. In a glasshouse pot trial, eggs, nymphs, adults and total population were significantly reduced before population establishment compared to those after its population established, by A. bidentata, A. tataricus and O. basilicum. Overall, A. bidentata, A. tataricus and O. basilicum can be used to suppress all life-stages of grape phylloxera.	[Liu, Yongqiang; Wang, Zhongyue; Su, Junping; Liu, Weiwei; Dhiloo, Khalid Hussain; Guo, Yuyuan] Chinese Acad Agr Sci, Inst Plant Protect, State Key Lab Biol Plant Dis & Insect Pests, Beijing 100193, Peoples R China	Chinese Academy of Agricultural Sciences; Institute of Plant Protection, CAAS	Guo, YY (corresponding author), Chinese Acad Agr Sci, Inst Plant Protect, State Key Lab Biol Plant Dis & Insect Pests, Beijing 100193, Peoples R China.	yyguo@ippcaas.cn			National Technology System project for Grape Industry [nycytx-30]	National Technology System project for Grape Industry	The work was supported by the National Technology System project for Grape Industry (nycytx-30). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad N, 2012, CROP PROT, V38, P7, DOI 10.1016/j.cropro.2012.03.006; Athanassiou CG, 2005, J ECON ENTOMOL, V98, P1733, DOI 10.1603/0022-0493-98.5.1733; Benheim D, 2012, ANN APPL BIOL, V161, P91, DOI 10.1111/j.1744-7348.2012.00561.x; Bickerton MW, 2011, THESIS STATE U NEW J; BIRCH LC, 1948, J ANIM ECOL, V17, P15, DOI 10.2307/1605; CAHILL M, 1995, B ENTOMOL RES, V85, P181, DOI 10.1017/S0007485300034258; Charleston DS, 2004, THESIS, P1; Che PiLian, 2007, Journal of Shanghai Jiaotong University - Agricultural Science, V25, P587; Chokechaijaroenporn O, 1994, Phytomedicine, V1, P135, DOI 10.1016/S0944-7113(11)80031-0; DEBENEDICTIS JA, 1992, J ECON ENTOMOL, V85, P1527, DOI 10.1093/jee/85.4.1527; Dixon A.F.G., 1987, World Crop Pests, V2A, P269; Donald WL, 2000, THESIS; Dunstone RJ, 2003, AUST J GRAPE WINE R, V9, P107, DOI 10.1111/j.1755-0238.2003.tb00260.x; Forbes VE, 1999, ENVIRON TOXICOL CHEM, V18, P1544, DOI 10.1002/etc.5620180729; FUKAI S, 1993, FIELD CROP RES, V34, P247, DOI 10.1016/0378-4290(93)90117-6; GALET P, 1982, MALADIES PARASITES V, V2, P1059; GRANETT J, 1985, J ECON ENTOMOL, V78, P1463, DOI 10.1093/jee/78.6.1463; Granett J, 2001, ANNU REV ENTOMOL, V46, P387, DOI 10.1146/annurev.ento.46.1.387; Hao Hui-Ling, 2006, Acta Entomologica Sinica, V49, P533; Herbert KS, 2010, B ENTOMOL RES, V100, P671, DOI 10.1017/S0007485310000027; Herbert K, 2008, J ECON ENTOMOL, V101, P1934, DOI 10.1603/0022-0493-101.6.1934; Hummel JD, 2009, THESIS U ALBERTA CAN; Jeyabalan D, 2003, BIORESOURCE TECHNOL, V89, P185, DOI 10.1016/S0960-8524(03)00036-1; Kraiss H, 2008, PEST MANAG SCI, V64, P660, DOI 10.1002/ps.1541; Kumar P, 2011, IND CROP PROD, V34, P802, DOI 10.1016/j.indcrop.2011.02.019; Powell KS, 2013, ADV INSECT PHYSIOL, V45, P159, DOI 10.1016/B978-0-12-417165-7.00004-0; RANI PU, 1989, INSECT SCI APPL, V10, P327, DOI 10.1017/S1742758400003568; Ren Wei, 2007, Sichuan Journal of Zoology, V26, P635; Sisodia S., 2010, J AGR EXTENSION RURA, V2, P22, DOI DOI 10.5897/JAERD.9000005; Stark JD, 1997, ECOTOX ENVIRON SAFE, V37, P273, DOI 10.1006/eesa.1997.1552; STARK JD, 1995, J ECON ENTOMOL, V88, P1089, DOI 10.1093/jee/88.5.1089; Stark JD, 2007, J ECON ENTOMOL, V100, P1027, DOI 10.1603/0022-0493(2007)100[1027:IERMOP]2.0.CO;2; Tapondjou LA, 2002, J STORED PROD RES, V38, P395, DOI 10.1016/S0022-474X(01)00044-3; Walthall WK, 1997, ECOTOX ENVIRON SAFE, V37, P45, DOI 10.1006/eesa.1997.1521; Wang YX, 2009, THESIS NE NORMAL U J; WILLIAMS RN, 1988, ANN ENTOMOL SOC AM, V81, P1, DOI 10.1093/aesa/81.1.1; Worwood V. A., 1993, COMPLETE BOOK ESSENT; YANG RZ, 1988, ECON BOT, V42, P376, DOI 10.1007/BF02860162; ZHANG GZ, 2000, J QINGHAI U, V18, P3; Zhang HuaGe, 2009, Journal of Fruit Science, V26, P306; Zhong GH, 2001, J APPL ENTOMOL, V125, P563, DOI 10.1046/j.1439-0418.2001.00590.x; [No title captured]	42	1	1	0	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2015	10	7							e0128038	10.1371/journal.pone.0128038	http://dx.doi.org/10.1371/journal.pone.0128038			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RV	26186216	Green Published, Green Submitted, gold			2023-01-03	WOS:000358198700002
J	Nagaoka, K; Matoba, T; Mao, YJ; Nakano, Y; Ikeda, G; Egusa, S; Tokutome, M; Nagahama, R; Nakano, K; Sunagawa, K; Egashira, K				Nagaoka, Kazuhiro; Matoba, Tetsuya; Mao, Yajing; Nakano, Yasuhiro; Ikeda, Gentaro; Egusa, Shizuka; Tokutome, Masaki; Nagahama, Ryoji; Nakano, Kaku; Sunagawa, Kenji; Egashira, Kensuke			A New Therapeutic Modality for Acute Myocardial Infarction: Nanoparticle-Mediated Delivery of Pitavastatin Induces Cardioprotection from Ischemia-Reperfusion Injury via Activation of PI3K/Akt Pathway and Anti-Inflammation in a Rat Model	PLOS ONE			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; GLYCOGEN-SYNTHASE KINASE-3-BETA; INDUCED CARDIOMYOCYTE APOPTOSIS; CELLULAR BIOLOGY; OXIDATIVE STRESS; EUROPEAN-SOCIETY; WORKING GROUP; MICE; ISCHEMIA/REPERFUSION; MONOCYTES	Aim There is an unmet need to develop an innovative cardioprotective modality for acute myocardial infarction (AMI), for which the effectiveness of interventional reperfusion therapy is hampered by myocardial ischemia-reperfusion (IR) injury. Pretreatment with statins before ischemia is shown to reduce MI size in animals. However, no benefit was found in animals and patients with AMI when administered at the time of reperfusion, suggesting insufficient drug targeting into the IR myocardium. Here we tested the hypothesis that nanoparticle-mediated targeting of pitavastatin protects the heart from IR injury. Methods and Results In a rat IR model, poly(lactic acid/glycolic acid) (PLGA) nanoparticle incorporating FITC accumulated in the IR myocardium through enhanced vascular permeability, and in CD11b-positive leukocytes in the IR myocardium and peripheral blood after intravenous treatment. Intravenous treatment with PLGA nanoparticle containing pitavastatin (Pitavastatin-NP, 1 mg/kg) at reperfusion reduced MI size after 24 hours and ameliorated left ventricular dysfunction 4-week after reperfusion; by contrast, pitavastatin alone (as high as 10 mg/kg) showed no therapeutic effects. The therapeutic effects of Pitavastatin-NP were blunted by a PI3K inhibitor wortmannin, but not by a mitochondrial permeability transition pore inhibitor cyclosporine A. Pitavastatin-NP induced phosphorylation of Akt and GSK3 beta, and inhibited inflammation and cardiomyocyte apoptosis in the IR myocardium. Conclusions Nanoparticle-mediated targeting of pitavastatin induced cardioprotection from IR injury by activation of PI3K/Akt pathway and inhibition of inflammation and cardiomyocyte death in this model. This strategy can be developed as an innovative cardioprotective modality that may advance currently unsatisfactory reperfusion therapy for AMI.	[Nagaoka, Kazuhiro; Matoba, Tetsuya; Mao, Yajing; Nakano, Yasuhiro; Ikeda, Gentaro; Tokutome, Masaki; Sunagawa, Kenji; Egashira, Kensuke] Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Fukuoka 812, Japan; [Egusa, Shizuka; Nagahama, Ryoji; Nakano, Kaku; Egashira, Kensuke] Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Res Dev & Translat Med, Fukuoka 812, Japan	Kyushu University; Kyushu University	Egashira, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Fukuoka 812, Japan.	egashira@cardiol.med.kyushu-u.ac.jp	Ikeda, Gentaro/AAC-4164-2022	Ikeda, Gentaro/0000-0003-4019-8990; Matoba, Tetsuya/0000-0003-4563-304X	Ministry of Education, Science, and Culture, Tokyo, Japan; Health Science Research Grants (Research on Translational Research, Intractable Diseases, and Nanomedicine) from the Ministry of Health Labor and Welfare, Tokyo, Japan; Japanese Government; Sentan Medical Inc	Ministry of Education, Science, and Culture, Tokyo, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Health Science Research Grants (Research on Translational Research, Intractable Diseases, and Nanomedicine) from the Ministry of Health Labor and Welfare, Tokyo, Japan; Japanese Government; Sentan Medical Inc	This study was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, and Culture, Tokyo, Japan and by Health Science Research Grants (Research on Translational Research, Intractable Diseases, and Nanomedicine) from the Ministry of Health Labor and Welfare, Tokyo, Japan. Dr. Egashira reports grant support from the Japanese Government as mentioned above to conduct this study, and personal fees from Sentan Medical Inc outside the submitted work. The specific roles of these authors are articulated in the 'author contributions' section.	Acharya S, 2011, ADV DRUG DELIVER REV, V63, P170, DOI 10.1016/j.addr.2010.10.008; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Becatti M, 2012, CELL MOL LIFE SCI, V69, P2245, DOI 10.1007/s00018-012-0925-5; Bergmann MW, 2004, J MOL CELL CARDIOL, V37, P681, DOI 10.1016/j.yjmcc.2004.05.025; Chen L, 2011, HYPERTENSION, V57, P343, DOI 10.1161/HYPERTENSIONAHA.110.157032; DAUBER IM, 1990, CIRC RES, V66, P986, DOI 10.1161/01.RES.66.4.986; Downey JM, 2009, CIRC J, V73, P1171, DOI 10.1253/circj.CJ-09-0338; Egashira K, 2003, HYPERTENSION, V41, P834, DOI 10.1161/01.HYP.0000051642.65283.36; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Gomez L, 2008, CIRCULATION, V117, P2761, DOI 10.1161/CIRCULATIONAHA.107.755066; Gong R, 2008, AM J TRANSPLANT, V8, P1852, DOI 10.1111/j.1600-6143.2008.02319.x; Hausenloy DJ, 2013, CARDIOVASC RES, V98, P7, DOI 10.1093/cvr/cvt004; Hayasaki T, 2006, CIRC J, V70, P342, DOI 10.1253/circj.70.342; Jones SP, 2002, J AM COLL CARDIOL, V40, P1172, DOI 10.1016/S0735-1097(02)02115-0; Jones SP, 2001, ARTERIOSCL THROM VAS, V21, P2059, DOI 10.1161/hq1201.099509; Juhaszova M, 2004, J CLIN INVEST, V113, P1535, DOI 10.1172/JCI200419906; Katsuki S, 2014, CIRCULATION, V129, P896, DOI 10.1161/CIRCULATIONAHA.113.002870; Kawaguchi M, 2011, CIRCULATION, V123, P594, DOI 10.1161/CIRCULATIONAHA.110.982777; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kimura S, 2008, CIRCULATION, V118, pS65, DOI 10.1161/CIRCULATIONAHA.107.740613; Kimura S, 2009, HYPERTENSION, V53, P877, DOI 10.1161/HYPERTENSIONAHA.108.121418; Kinugawa S, 2000, CIRC RES, V87, P392; Kocsis GF, 2008, AM J PHYSIOL-HEART C, V294, pH2406, DOI 10.1152/ajpheart.00862.2007; Kubo M, 2009, ARTERIOSCL THROM VAS, V29, P796, DOI 10.1161/ATVBAHA.108.182584; Lal H, 2012, CIRCULATION, V125, P65, DOI 10.1161/CIRCULATIONAHA.111.050666; Lefer AM, 1999, CIRCULATION, V100, P178, DOI 10.1161/01.CIR.100.2.178; Leuschner F, 2011, NAT BIOTECHNOL, V29, P1005, DOI 10.1038/nbt.1989; Lewis EF, 2003, J AM COLL CARDIOL, V42, P1446, DOI 10.1016/S0735-1097(03)01057-X; Lin MJ, 2013, ELIFE, V2, DOI 10.7554/eLife.01295; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; Matsuki A, 2006, CIRC J, V70, P1643, DOI 10.1253/circj.70.1643; Monceau V, 2006, AM J PHYSIOL-HEART C, V291, pH965, DOI 10.1152/ajpheart.01053.2005; Nagahama R, 2012, ARTERIOSCLER THROMB; Nahrendorf M, 2010, CIRCULATION, V121, P2437, DOI 10.1161/CIRCULATIONAHA.109.916346; Nakano K, 2009, JACC-CARDIOVASC INTE, V2, P277, DOI 10.1016/j.jcin.2008.08.023; Oda S, 2010, J VASC SURG, V52, P412, DOI 10.1016/j.jvs.2010.03.020; Okumura H, 2004, CIRCULATION, V109, P242, DOI 10.1161/01.CIR.0000109214.30211.7C; Ovize M, 2010, CARDIOVASC RES, V87, P406, DOI 10.1093/cvr/cvq129; Patti G, 2007, J AM COLL CARDIOL, V49, P1272, DOI 10.1016/j.jacc.2007.02.025; Post S, 2012, CATHETER CARDIOVASC; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Sanada S, 2004, CIRCULATION, V110, P2143, DOI 10.1161/01.CIR.0000143830.59419.73; Sitniewska EM, 2001, REGUL PEPTIDES, V96, P105, DOI 10.1016/S0167-0115(00)00131-2; Steffens S, 2009, THROMB HAEMOSTASIS, V102, P240, DOI 10.1160/TH08-12-0837; Takahama H, 2009, J AM COLL CARDIOL, V53, P709, DOI 10.1016/j.jacc.2008.11.014; Tsukie N, 2013, J ATHEROSCLER THROMB, V20, P32, DOI 10.5551/jat.13862; Tuuminen R, 2011, CIRCULATION, V124, P1138, DOI 10.1161/CIRCULATIONAHA.110.005249; Wang XL, 2007, APOPTOSIS, V12, P1209, DOI 10.1007/s10495-007-0055-y; Xi JK, 2009, EUR J PHARMACOL, V604, P111, DOI 10.1016/j.ejphar.2008.12.024; Yellon DM, 2007, NEW ENGL J MED, V357, P1121, DOI 10.1056/NEJMra071667; Zhai PY, 2011, CIRC RES, V109, P502, DOI 10.1161/CIRCRESAHA.111.249532; Zhao ZQ, 2001, APOPTOSIS, V6, P279, DOI 10.1023/A:1011335525219	52	67	70	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 13	2015	10	7							e0132451	10.1371/journal.pone.0132451	http://dx.doi.org/10.1371/journal.pone.0132451			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1PW	26167913	gold, Green Submitted, Green Published, Green Accepted			2023-01-03	WOS:000358193100044
J	Yan, S; Tian, SX; Kang, QW; Xia, YF; Li, CX; Chen, Q; Zhang, SK; Li, ZG				Yan, Shu; Tian, Shuxia; Kang, Qingwei; Xia, Yafei; Li, Caixia; Chen, Qing; Zhang, Shukun; Li, Zhigang			Rhizoma Paridis Saponins Suppresses Tumor Growth in a Rat Model of N-Nitrosomethylbenzylamine-Induced Esophageal Cancer by Inhibiting Cyclooxygenases-2 Pathway	PLOS ONE			English	Article							IN-VITRO; HEPATOCARCINOMA MICE; PENNOGENYL SAPONINS; EXPRESSION; APOPTOSIS; XENOGRAFTS; CHINA; CELLS; COX-2; VIVO	Rhizoma Paridis Saponins (RPS), a natural compound purified from Rhizoma Paridis, has been found to inhibit cancer growth in vitro and in animal models of cancer. However, its effects on esophageal cancer remain unexplored. The purpose of this study was to investigate the effects of RPS on tumor growth in a rat model of esophageal cancer and the molecular mechanism underlying the effects. A rat model of esophageal cancer was established by subcutaneous injection of N-nitrosomethylbenzylamine (NMBA, 1mg/kg) for 10 weeks. RPS (350 mg/kg or 100mg/kg) was administered by oral gavage once daily for 24 weeks starting at the first NMBA injection. RPS significantly reduced the size and number of tumors in the esophagus of rats exposed to NMBA and inhibited the viability, migration, and invasion of esophageal cancer cells EC9706 and KYSE150 in a dose dependent manner (all P < 0.01). Flow cytometry revealed that RPS induced apoptosis and cell cycle G2/M arrest in the esophageal cancer cells. The expression of cyclooxygenases-2 (COX-2) and Cyclin D1 in rat esophageal tissues and the esophageal cancer cells were also significantly reduced by RPS (all P < 0.01). Consistently, RPS also significantly decreased the release of prostaglandin E2, a downstream molecule of COX-2, in a dose-dependent manner (P < 0.01). Our study suggests that RPS inhibit esophageal cancer development by promoting apoptosis and cell cycle arrest and inhibiting the COX-2 pathway. RPS might be a promising therapeutic agent for esophageal cancer.	[Yan, Shu; Tian, Shuxia; Kang, Qingwei; Xia, Yafei] Nankai Hosp, Dept Pharmacol, Tianjin, Peoples R China; [Li, Caixia; Zhang, Shukun] Nankai Hosp, Inst Integrat Med Therapy Acute Abdominal Dis Tia, Tianjin, Peoples R China; [Li, Zhigang] Nankai Hosp, Dept Thorac Surg, Tianjin, Peoples R China; [Chen, Qing] Taizhou Hosp, Dept Pharmacol, Taizhou City, Zhejiang, Peoples R China		Li, ZG (corresponding author), Nankai Hosp, Dept Thorac Surg, Tianjin, Peoples R China.	zhigli38@hotmail.com		Li, Zhigang/0000-0001-7164-1049	Tianjin Science and Technology Plan Project of China [10JCYBJC15100]; National Natural Science Foundation of China [30973383]	Tianjin Science and Technology Plan Project of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	SY was supported by 2010 Tianjin Science and Technology Plan Project of China (10JCYBJC15100) ZL was supported by and the National Natural Science Foundation of China (No. 30973383 http://www.nsfc.gov.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chen WQ, 2013, J THORAC DIS, V5, P19, DOI 10.3978/j.issn.2072-1439.2013.01.04; Chen YS, 2014, STEROIDS, V83, P39, DOI 10.1016/j.steroids.2014.01.014; D'Journo XB, 2014, J THORAC DIS, V6, pS253, DOI 10.3978/j.issn.2072-1439.2014.04.16; Jiang H, 2014, MOL MED REP, V9, P2265, DOI 10.3892/mmr.2014.2108; Li P, 2008, WORLD J INTEGRATED T, V3, P297; Lin YS, 2013, J EPIDEMIOL, V23, P233, DOI 10.2188/jea.JE20120162; Liu Z, 2014, ENVIRON TOXICOL PHAR, V38, P31, DOI 10.1016/j.etap.2014.04.026; Liu Z, 2012, J ETHNOPHARMACOL, V144, P67, DOI 10.1016/j.jep.2012.08.027; Man SL, 2014, STEROIDS, V84, P17, DOI 10.1016/j.steroids.2014.03.005; Man SL, 2014, STEROIDS, V80, P1, DOI 10.1016/j.steroids.2013.11.015; Man SL, 2014, J ETHNOPHARMACOL, V151, P407, DOI 10.1016/j.jep.2013.10.051; Man SL, 2011, J ETHNOPHARMACOL, V137, P1221, DOI 10.1016/j.jep.2011.07.045; Man SL, 2011, ARCH PHARM RES, V34, P43, DOI 10.1007/s12272-011-0105-4; Man SL, 2009, STEROIDS, V74, P1051, DOI 10.1016/j.steroids.2009.08.004; Misra S, 2014, CURR DRUG TARGETS, V15, P347, DOI 10.2174/1389450115666140127102915; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Sahin IH, 2014, CANCER LETT, V345, P249, DOI 10.1016/j.canlet.2013.09.001; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Xiao X, 2014, CANCER CHEMOTH PHARM, V73, P807, DOI 10.1007/s00280-014-2408-x; Xiao X, 2012, BIOSCI TRENDS, V6, P201, DOI 10.5582/bst.2012.v6.4.201; Xiao X, 2009, MOL CANCER THER, V8, P1179, DOI 10.1158/1535-7163.MCT-08-0939; Yan L. L., 2009, Experimental Oncology, V31, P27; Yu HP, 2004, J GASTROEN HEPATOL, V19, P638, DOI 10.1111/j.1440-1746.2004.03345.x; Zhang WJ, 2014, EUR J MED RES, V19, DOI 10.1186/2047-783X-19-41	24	14	15	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2015	10	7							e0131560	10.1371/journal.pone.0131560	http://dx.doi.org/10.1371/journal.pone.0131560			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1DQ	26147856	Green Published, Green Submitted, gold			2023-01-03	WOS:000358157600106
J	Stern, RJ; Murphy, EJ				Stern, Rachel J.; Murphy, Elizabeth J.			Metformin as Initial Oral Therapy in Type 2 Diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ALGORITHM; ASSOCIATION; MANAGEMENT; STATEMENT; MELLITUS; DRUGS		[Stern, Rachel J.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Internal Med, Primary Care Residency, San Francisco, CA USA; [Murphy, Elizabeth J.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Murphy, Elizabeth J.] San Francisco Gen Hosp, Div Endocrinol, San Francisco, CA 94110 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center	Stern, RJ (corresponding author), San Francisco Gen Hosp, 1001 Potrero Ave,Ward 13,Bldg 10,Third Floor, San Francisco, CA 94110 USA.	rachel.stern@ucsf.edu						Bennett WL, 2011, ANN INTERN MED, V154, P602, DOI 10.7326/0003-4819-154-9-201105030-00336; Berkowitz SA, 2014, JAMA INTERN MED, V174, P1955, DOI 10.1001/jamainternmed.2014.5294; Eurich DT, 2007, BMJ-BRIT MED J, V335, P497, DOI 10.1136/bmj.39314.620174.80; Garber AJ, 2013, ENDOCR PRACT, V19, P100, DOI 10.4158/EP12325.OR; Hampp C, 2014, DIABETES CARE, V37, P1367, DOI 10.2337/dc13-2289; Inzucchi SE, 2014, JAMA-J AM MED ASSOC, V312, P2668, DOI 10.1001/jama.2014.15298; Nathan DM, 2006, DIABETES CARE, V29, P1963, DOI 10.2337/dc06-9912; Rodbard HW, 2009, ENDOCR PRACT, V15, P540, DOI 10.4158/EP.15.6.540	8	6	6	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 23	2015	313	24					2484	2485		10.1001/jama.2015.2765	http://dx.doi.org/10.1001/jama.2015.2765			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CL0WK	26103032				2023-01-03	WOS:000356663600017
J	Flashner-Abramson, E; Klein, S; Mullin, G; Shoshan, E; Song, R; Shir, A; Langut, Y; Bar-Eli, M; Reuveni, H; Levitzki, A				Flashner-Abramson, E.; Klein, S.; Mullin, G.; Shoshan, E.; Song, R.; Shir, A.; Langut, Y.; Bar-Eli, M.; Reuveni, H.; Levitzki, A.			Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling	ONCOGENE			English	Article							MONOCLONAL-ANTIBODIES; OVERCOME RESISTANCE; TUMOR PROGRESSION; CANCER; INHIBITOR; ACTIVATION; THERAPIES	It is well known that specific signal transduction inhibitors rarely suffice as anti-cancer agents. In most cases, tumors possess primary drug resistance due to their inherent heterogeneity, or acquire drug resistance due to genomic instability and acquisition of mutations. Here we expand our previous study of the novel compound, NT157, and show that it acts as a dual-targeting agent that invokes the blockage of two signal transduction pathways that are central to the development and maintenance of multiple human cancers. We show that NT157 targets not only IGF1R-IRS1/2, as previously reported, but also the Stat3 signaling pathway and demonstrates remarkable anti-cancer characteristics in A375 human melanoma cells and in a metastatic melanoma model in mice.	[Flashner-Abramson, E.; Klein, S.; Mullin, G.; Shir, A.; Langut, Y.; Reuveni, H.; Levitzki, A.] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel; [Shoshan, E.; Song, R.; Bar-Eli, M.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Unit 173, Houston, TX 77030 USA; [Reuveni, H.] NovoTyr Ltd, Tel Hai, Israel	Hebrew University of Jerusalem; University of Texas System; UTMD Anderson Cancer Center	Levitzki, A (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel.; Reuveni, H (corresponding author), TyrNovo Ltd, 8 Abba Eban Ave, IL-4672526 Herzliyya, Israel.	hadas.reuveni@gmail.com; alex.levitzki@mail.huji.ac.il	Mullin, Gerry/H-5294-2019	Mullin, Gerry/0000-0001-5317-6788	ERC Advanced Grant [249898]; NIH Skin Cancer SPORE p50 [CA093459]; Office of the Chief Scientist in the Ministry of Industry, Trade and Labor of Israel; Algen Biopharmaceuticals Ltd; NATIONAL CANCER INSTITUTE [P50CA093459] Funding Source: NIH RePORTER	ERC Advanced Grant; NIH Skin Cancer SPORE p50; Office of the Chief Scientist in the Ministry of Industry, Trade and Labor of Israel; Algen Biopharmaceuticals Ltd; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Professor Martin Myers (UMMS) for the Jak2 expression plasmids and Professor Scott Weed (WVU) for the GFP-Src expression plasmids. We thank Professor Ruth Halaban (Yale University) and Yale SPORE in Skin Cancer for providing us with the patient-derived melanoma cells (YUMAC and YUSIK), and Dr Michal Lotem (Hadassah Hospital) for providing us the patient-derived melanoma cells (M571 and M2068). We acknowledge Dr Salim Joubran from our laboratory who was instrumental in the chemistry of NT157. This study was supported by an ERC Advanced Grant (No. 249898) to AL by the NIH Skin Cancer SPORE p50 (No. CA093459), by four grants from the Office of the Chief Scientist in the Ministry of Industry, Trade and Labor of Israel to NovoTyr (HR, 2005-2012) and by Algen Biopharmaceuticals Ltd.	Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Daub H, 2004, NAT REV DRUG DISCOV, V3, P1001, DOI 10.1038/nrd1579; DILLMAN RO, 1984, CRC CR REV ONCOL-HEM, V1, P357, DOI 10.1016/S1040-8428(84)80008-6; Druker BJ, 2008, BLOOD, V112, P4808, DOI 10.1182/blood-2008-07-077958; Ibuki N, 2014, MOL CANCER THER, V13, P2827, DOI 10.1158/1535-7163.MCT-13-0842; Kortylewski M, 2005, CANCER METAST REV, V24, P315, DOI 10.1007/s10555-005-1580-1; Levitzki A, 2006, ANNU REV BIOCHEM, V75, P93, DOI 10.1146/annurev.biochem.75.103004.142657; Levitzki A, 2013, ANNU REV PHARMACOL, V53, P161, DOI 10.1146/annurev-pharmtox-011112-140341; Levitzki A, 2010, MOL ASPECTS MED, V31, P287, DOI 10.1016/j.mam.2010.04.001; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; Liu F, 2013, J INVEST DERMATOL, V133, P2041, DOI 10.1038/jid.2013.32; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; Mano Y, 2013, PATHOBIOLOGY, V80, P146, DOI 10.1159/000346196; OLDHAM RK, 1983, J CLIN ONCOL, V1, P582, DOI 10.1200/JCO.1983.1.9.582; Page BDG, 2011, EXPERT OPIN THER PAT, V21, P65, DOI 10.1517/13543776.2011.539205; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Qualls J, 2012, J IMMUNOL, V188, P34; Reuveni H, 2013, CANCER RES, V73, P4383, DOI 10.1158/0008-5472.CAN-12-3385; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Stivarou T, 2015, CANCERS, V7, P238, DOI 10.3390/cancers7010238; WARD HWC, 1973, BMJ-BRIT MED J, V1, P13, DOI 10.1136/bmj.1.5844.13; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818	25	27	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2675	2680		10.1038/onc.2015.229	http://dx.doi.org/10.1038/onc.2015.229			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26119932				2023-01-03	WOS:000376165700014
J	Krauss, BS; Calligaris, L; Green, SM; Barbi, E				Krauss, Baruch S.; Calligaris, Lorenzo; Green, Steven M.; Barbi, Egidio			Current concepts in management of pain in children in the emergency department	LANCET			English	Review							RANDOMIZED CONTROLLED-TRIAL; PEDIATRIC PAIN; INTRANASAL FENTANYL; INTRAVENOUS CANNULATION; PROCEDURAL SEDATION; VAPOCOOLANT SPRAY; ABDOMINAL-PAIN; CEREBRAL-PALSY; ANALGESIA; ACETAMINOPHEN	Pain is common in children presenting to emergency departments with episodic illnesses, acute injuries, and exacerbation of chronic disorders. We review recognition and assessment of pain in infants and children and discuss the manifestations of pain in children with chronic illness, recurrent pain syndromes, and cognitive impairment, including the difficulties of pain management in these patients. Non-pharmacological interventions, as adjuncts to pharmacological management for acute anxiety and pain, are described by age and development. We discuss the pharmacological management of acute pain and anxiety, reviewing invasive and non-invasive routes of administration, pharmacology, and adverse effects.	[Krauss, Baruch S.] Boston Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; [Krauss, Baruch S.] Harvard Univ, Sch Med, Boston, MA USA; [Calligaris, Lorenzo; Barbi, Egidio] IRCCS Burlo Garofolo, Inst Maternal & Child Hlth, Trieste, Italy; [Green, Steven M.] Loma Linda Univ, Med Ctr, Dept Emergency Med, Loma Linda, CA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; IRCCS Burlo Garofolo; Loma Linda University	Krauss, BS (corresponding author), Boston Childrens Hosp, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	baruch.krauss@childrens.harvard.edu	Barbi, Egidio/K-4016-2018; Krauss, Baruch/U-6182-2019	Barbi, Egidio/0000-0002-6343-846X; 				Akorn, EMLA CREAM US PACK I; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; [Anonymous], LEX DRUGS DRUG DAT; Association of Paediatric Anaesthetists of Great Britain and Ireland, 2012, PAEDIATR ANAESTH, V22, P11; Balottin U, 2013, CEPHALALGIA, V33, P112, DOI 10.1177/0333102412468386; Barbi E, 2003, BRIT MED J, V327, P681, DOI 10.1136/bmj.327.7416.681; Bauman BH, 2005, EMERG MED CLIN N AM, V23, P393, DOI 10.1016/j.emc.2004.12.008; Bendall JC, 2011, PREHOSP EMERG CARE, V15, P158, DOI 10.3109/10903127.2010.541980; Berde CB, 2002, NEW ENGL J MED, V347, P1094, DOI 10.1056/NEJMra012626; Bianciotto M, 2013, ARCH DIS CHILD, V98, P218, DOI 10.1136/archdischild-2012-302100; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland M, 2011, EMERG MED AUSTRALAS, V23, P202, DOI 10.1111/j.1742-6723.2011.01391.x; Boyd RJ, 2005, EMERG MED J, V22, P30, DOI 10.1136/emj.2002.003574; Breau LM, 2003, ARCH PEDIAT ADOL MED, V157, P1219, DOI 10.1001/archpedi.157.12.1219; Breau LM, 2009, PAIN RES MANAG, V14, P116, DOI 10.1155/2009/642352; Chiaretti A, 2013, EUR REV MED PHARMACO, V17, P112; Ciszkowski C, 2009, NEW ENGL J MED, V361, P827, DOI 10.1056/NEJMc0904266; Cohen Lindsey L, 2008, Pediatrics, V122 Suppl 3, pS134, DOI 10.1542/peds.2008-1055f; Cohen LL, 2001, J PEDIATR PSYCHOL, V26, P367, DOI 10.1093/jpepsy/26.6.367; Cole J, 2009, EMERG MED AUSTRALAS, V21, P395, DOI 10.1111/j.1742-6723.2009.01216.x; Cooper C, 2004, J BONE MINER RES, V19, P1976, DOI 10.1359/JBMR.040902; Corwin DJ, 2012, PEDIATR EMERG CARE, V28, P524, DOI 10.1097/PEC.0b013e3182587d27; Costello M, 2006, CLIN PEDIATR, V45, P628, DOI 10.1177/0009922806291013; Di Lorenzo C, 2005, J PEDIATR GASTR NUTR, V40, P245, DOI 10.1097/01.MPG.0000155367.44628.21; Diamanti A, 2010, AM J EMERG MED, V28, P189, DOI 10.1016/j.ajem.2008.11.016; Downing A, 2006, EMERG MED J, V23, P391, DOI 10.1136/emj.2005.025411; Drendel AL, 2011, PEDIATR EMERG CARE, V27, P773, DOI 10.1097/PEC.0b013e31822877f7; Duff AJA, 2003, ARCH DIS CHILD, V88, P931, DOI 10.1136/adc.88.10.931; Eidelman A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005364.pub2; Eisen S, 2007, ARCH DIS CHILD, V92, P828, DOI 10.1136/adc.2007.123372; Eslick GD, 2010, PEDIATR CLIN N AM, V57, P1211, DOI 10.1016/j.pcl.2010.09.013; Farion KJ, 2008, CAN MED ASSOC J, V179, P31, DOI 10.1503/cmaj.070874; Finley GA, 2014, CAN J ANESTH, V61, P180, DOI 10.1007/s12630-013-0076-7; Fitzgerald M, 2003, PAIN INFANTS CHILDRE, V2nd, P19; Flavell JH, 1997, CHILD DEV, V68, P39, DOI 10.1111/j.1467-8624.1997.tb01923.x; Flavell JH, 2001, PSYCHOL SCI, V12, P430, DOI 10.1111/1467-9280.00379; FRANK NC, 1995, J PEDIATR PSYCHOL, V20, P277, DOI 10.1093/jpepsy/20.3.277; Gaffney A, 2003, PAIN INFANTS CHILDRE; Galinski M, 2011, AM J EMERG MED, V29, P1062, DOI 10.1016/j.ajem.2010.06.031; Gibb IA, 2008, ARCH DIS CHILD, V93, P241, DOI 10.1136/adc.2007.126896; GOLDMAN A, 2003, PAIN INFANTS CHILDRE, P539; Goldschneider KR, 2012, PAIN RES MANAG, V17, P386, DOI 10.1155/2012/854159; Grant PS, 2006, AM J EMERG MED, V24, P806, DOI 10.1016/j.ajem.2006.05.004; Green SM, 2011, ANN EMERG MED, V57, P449, DOI 10.1016/j.annemergmed.2010.11.030; Grindlay J, 2009, EMERG MED AUSTRALAS, V21, P4, DOI 10.1111/j.1742-6723.2009.01153.x; Harrison D, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008408.pub2; Hearst D, 2009, PEDIATR ANESTH, V19, P1014, DOI 10.1111/j.1460-9592.2009.03146.x; Heimer L, 2006, NEUROSCI BIOBEHAV R, V30, P126, DOI 10.1016/j.neubiorev.2005.06.006; Hennequin H, 2000, LANCET, V356, P1882, DOI 10.1016/S0140-6736(00)03259-1; Hoving MA, 2009, EUR J PAEDIATR NEURO, V13, P240, DOI 10.1016/j.ejpn.2008.04.013; Hryhorczuk AL, 2012, RADIOLOGY, V263, P778, DOI 10.1148/radiol.12111726; Johnston CC, 2003, PAIN INFANTS CHILDRE, P105; Kagan J., 2005, YOUNG MIND GROWING B; Kassab M, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008411.pub2; Kendall JM, 2001, BMJ-BRIT MED J, V322, P261, DOI 10.1136/bmj.322.7281.261; Kennedy Robert M, 2004, Paediatr Drugs, V6, P11; Konner M., 2010, EVOLUTION CHILDHOOD; Krauss B, 2006, LANCET, V367, P766, DOI 10.1016/S0140-6736(06)68230-5; Kuttner L, 2010, A CHILD IN PAIN; Lander JA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004236.pub2; Lavonas EJ, 2010, PEDIATRICS, V126, pE1430, DOI 10.1542/peds.2009-3352; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Liebelt E.L., 2000, CLIN PEDIATR EMERG M, V1, P260, DOI [10.1016/S1522-8401(00)90038-7, DOI 10.1016/S1522-8401(00)90038-7]; Mafrica F, 2006, THESCIENTIFICWORLDJO, V6, P140, DOI 10.1100/tsw2006.27; Mak WY, 2011, EXPERT OPIN PHARMACO, V12, P865, DOI 10.1517/14656566.2011.542751; Manworren Renee C B, 2003, Pediatr Nurs, V29, P140; Marzuillo P, 2014, ACTA PAEDIATR, V103, P1110, DOI 10.1111/apa.12738; Marzuillo P, 2014, EUR J PEDIATR, V173, P415, DOI 10.1007/s00431-013-2239-5; Massaro M, 2013, EUR J PEDIATR, V172, P9, DOI 10.1007/s00431-012-1720-x; Massaro M, 2014, ACTA PAEDIATR, V103, pE495, DOI 10.1111/apa.12748; Mednick L, 2010, TXB PEDIAT PSYCHOSOM; Merry AF, 2010, BRIT J ANAESTH, V104, P80, DOI 10.1093/bja/aep338; Michiels EA, ANN EMERG M IN PRESS; Migita RT, 2006, ARCH PEDIAT ADOL MED, V160, P46, DOI 10.1001/archpedi.160.1.46; Misurac JM, 2013, J PEDIATR-US, V162, P1153, DOI 10.1016/j.jpeds.2012.11.069; Morgane PJ, 2006, NEUROSCI BIOBEHAV R, V30, P119, DOI 10.1016/j.neubiorev.2005.04.020; Murthy BVS, 2000, BRIT J ANAESTH, V84, P346, DOI 10.1093/oxfordjournals.bja.a013437; Nader R, 2004, CLIN J PAIN, V20, P88, DOI 10.1097/00002508-200403000-00005; Nelson K, 1996, 5 7 YEAR SHIFT AGE R; Neri E, 2013, ARCH DIS CHILD, V98, P721, DOI 10.1136/archdischild-2012-303527; O'Connor RE, 2011, ANN EMERG MED, V58, P365, DOI 10.1016/j.annemergmed.2011.06.020; Parkinson KN, 2013, ARCH DIS CHILD, V98, P434, DOI 10.1136/archdischild-2012-303482; Perez RS, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-20; Perquin CW, 2000, PAIN, V87, P51, DOI 10.1016/S0304-3959(00)00269-4; Piaget J, 2003, PSYCHOL INTELLIGENCE; Pillow BH, 2008, J GENET PSYCHOL, V169, P297, DOI 10.3200/GNTP.169.4.297-321; Pitts Stephen R, 2008, Natl Health Stat Report, P1; Porter FL, 1999, J DEV BEHAV PEDIATR, V20, P253, DOI 10.1097/00004703-199908000-00008; Priestley S, 2003, ANN EMERG MED, V42, P34, DOI 10.1067/mem.2003.207; Primavera G, 2010, PEDIATRICS, V125, pE155, DOI 10.1542/peds.2009-0295; Racoosin JA, 2013, NEW ENGL J MED, V368, P2155, DOI 10.1056/NEJMp1302454; Ramelet Anne-Sylvie, 2004, Aust Crit Care, V17, P33, DOI 10.1016/S1036-7314(05)80048-7; Rask CU, 2012, DAN MED J, V59; Rasquin A, 2006, GASTROENTEROLOGY, V130, P1527, DOI 10.1053/j.gastro.2005.08.063; Rattaz C, 2013, PAIN, V154, P2007, DOI 10.1016/j.pain.2013.06.011; Resch K, 1998, ANN EMERG MED, V32, P693, DOI 10.1016/S0196-0644(98)70069-1; Saunders M, 2010, ACAD EMERG MED, V17, P1155, DOI 10.1111/j.1553-2712.2010.00905.x; Schechter NL, 1999, J DEV BEHAV PEDIATR, V20, P209, DOI 10.1097/00004703-199908000-00001; Smith C, 2012, CAN FAM PHYSICIAN, V58, P645; Smith & Nephew, AM 40MG G GEL UK PRO; Somers LJ, 2001, EMERG MED J, V18, P159, DOI 10.1136/emj.18.3.159; Sonneveld LP, 2013, J PEDIATR GASTR NUTR, V56, P475, DOI 10.1097/MPG.0b013e31828b5145; Synera, SYN PATCH US PACK IN; Taylor SE, 2013, EMERG MED AUSTRALAS, V25, P316, DOI 10.1111/1742-6723.12103; The Joint Commission, 2022, E DIT HOSP ACCR REQ; Todd KH, 2007, J PAIN, V8, P460, DOI 10.1016/j.jpain.2006.12.005; TOMASELLO M, 1993, BEHAV BRAIN SCI, V16, P495, DOI 10.1017/S0140525X0003123X; Tsao JC, 2012, PAIN RES MANAG, V17, P103, DOI 10.1155/2012/592108; van Staa A, 2011, PATIENT PREFER ADHER, V5, DOI 10.2147/PPA.S17184; Voepel-Lewis T, 2011, ANESTH ANALG, V112, P415, DOI 10.1213/ANE.0b013e318203f495; Walker DM, 2008, CURR OPIN PEDIATR, V20, P248, DOI 10.1097/MOP.0b013e3282ff6308; Ward RM, 2001, PEDIATRICS, V108, P1020; Weisner TS, 1996, 5 7 YEAR SHIFT AGE R; White SH, 1996, 5 7 YEAR SHIFT AGE R; Wilson JA, 1997, J ACCID EMERG MED, V14, P70; Young KD, 2005, ANN EMERG MED, V45, P160, DOI 10.1016/j.annemergmed.2004.09.019; Zelter LK, 2011, NELSON TXB PEDIAT	117	96	98	1	39	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 2	2016	387	10013					83	92		10.1016/S0140-6736(14)61686-X	http://dx.doi.org/10.1016/S0140-6736(14)61686-X			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CZ9ZU	26095580	Green Submitted			2023-01-03	WOS:000367457300030
J	Schenker, Y; Arnold, R				Schenker, Yael; Arnold, Robert			The Next Era of Palliative Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Schenker, Yael; Arnold, Robert] Univ Pittsburgh, Sect Palliat Care & Med Eth, Div Gen Internal Med, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Schenker, Y (corresponding author), Univ Pittsburgh, Sect Palliat Care & Med Eth, Div Gen Internal Med, 230 McKee Pl,Ste 600, Pittsburgh, PA 15213 USA.	schenkery@upmc.edu			NCATS NIH HHS [KL2 TR000146, KL2TR000146] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000146] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))		Gelfman LP, 2013, J PALLIAT MED, V16, P125, DOI 10.1089/jpm.2012.0427; Kellehear, 2014, INNER LIFE DYING PER; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Krumholz HM, 2015, JAMA-J AM MED ASSOC, V314, P355, DOI 10.1001/jama.2015.8035; Morrison R, 2011, STATE BY STATE REPOR; Murtagh FEM, 2014, PALLIATIVE MED, V28, P49, DOI 10.1177/0269216313489367; Quill TE, 2013, NEW ENGL J MED, V368, P1173, DOI 10.1056/NEJMp1215620; Schenker Y, 2014, J ONCOL PRACT, V10, pE37, DOI 10.1200/JOP.2013.001130	8	59	60	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	2015	314	15					1565	1566		10.1001/jama.2015.11217	http://dx.doi.org/10.1001/jama.2015.11217			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT7XK	26334719	Green Accepted			2023-01-03	WOS:000363028500014
J	Schwaberger, B; Pichler, G; Avian, A; Binder-Heschl, C; Baik, N; Urlesberger, B				Schwaberger, Bernhard; Pichler, Gerhard; Avian, Alexander; Binder-Heschl, Corinna; Baik, Nariae; Urlesberger, Berndt			Do Sustained Lung Inflations during Neonatal Resuscitation Affect Cerebral Blood Volume in Preterm Infants? A Randomized Controlled Pilot Study	PLOS ONE			English	Article							END-EXPIRATORY PRESSURE; FUNCTIONAL RESIDUAL CAPACITY; REGIONAL OXYGEN-SATURATION; BIRTH-WEIGHT INFANTS; CARDIOPULMONARY-RESUSCITATION; PREMATURE-INFANTS; DELIVERY ROOM; TRANSITION; VENTILATION; HEMORRHAGE	Background Sustained lung inflations (SLI) during neonatal resuscitation may promote alveolar recruitment in preterm infants. While most of the studies focus on respiratory outcome, the impact of SLI on the brain hasn't been investigated yet. Objective Do SLI affect cerebral blood volume (CBV) in preterm infants? Methods Preterm infants of gestation 28 weeks 0 days to 33 weeks 6 days with requirement for respiratory support (RS) were included in this randomized controlled pilot trial. Within the first 15 minutes after birth near-infrared spectroscopy (NIRS) measurements using 'NIRO-200-NX' (Hamamatsu, Japan) were performed to evaluate changes in CBV and cerebral tissue oxygenation. Two groups were compared based on RS: In SLI group RS was given by applying 1-3 SLI (30 cmH(2)O for 15 s) continued by respiratory standard care. Control group received respiratory standard care only. Results 40 infants (20 in each group) with mean gestational age of 32 weeks one day (+/- 2 days) and birth weight of 1707 (+/- 470) g were included. In the control group Delta CBV was significantly decreasing, whereas in SLI group Delta CBV showed similar values during the whole period of 15 minutes. Comparing both groups within the first 15 minutes Delta CBV showed a tendency toward different overall courses (p = 0.051). Conclusion This is the first study demonstrating an impact of SLI on CBV. Further studies are warranted including reconfirmation of the present findings in infants with lower gestational age. Future investigations on SLI should not only focus on respiratory outcome but also on the consequences on the developing brain.	[Schwaberger, Bernhard; Pichler, Gerhard; Binder-Heschl, Corinna; Baik, Nariae; Urlesberger, Berndt] Med Univ Graz, Res Unit Cerebral Dev & Oximetry, Graz, Austria; [Schwaberger, Bernhard; Pichler, Gerhard; Binder-Heschl, Corinna; Baik, Nariae; Urlesberger, Berndt] Med Univ Graz, Res Unit Neonatal Micro & Macrocirculat, Graz, Austria; [Schwaberger, Bernhard; Pichler, Gerhard; Binder-Heschl, Corinna; Baik, Nariae; Urlesberger, Berndt] Med Univ Graz, Dept Pediat, Div Neonatol, Graz, Austria; [Avian, Alexander] Med Univ Graz, Inst Med Informat Stat & Documentat, Graz, Austria	Medical University of Graz; Medical University of Graz; Medical University of Graz; Medical University of Graz	Urlesberger, B (corresponding author), Med Univ Graz, Res Unit Cerebral Dev & Oximetry, Graz, Austria.	berndt.urlesberger@medunigraz.at	Schwaberger, Bernhard/M-7929-2019	Schwaberger, Bernhard/0000-0001-5499-3712; Urlesberger, Berndt/0000-0003-0648-5785; Avian, Alexander/0000-0003-1084-5763; Pichler, Gerhard/0000-0003-2405-7143	Jubilaeumsfond, Oesterreichische Nationalbank [14312]	Jubilaeumsfond, Oesterreichische Nationalbank	Funding: Funding provided by Jubilaeumsfond, Oesterreichische Nationalbank (Grant No. 14312), BU received the funding. http://www.oenb.at/en/About-Us/Research-Promotion/The-OeNB-Anniversary-Fund.html. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Binder C, 2013, J PEDIATR-US, V163, P394, DOI 10.1016/j.jpeds.2013.01.026; BIONDI JW, 1988, ANESTH ANALG, V67, P144; Bjorklund LJ, 1997, PEDIATR RES, V42, P348; Dawson JA, 2010, PEDIATRICS, V125, pE1340, DOI 10.1542/peds.2009-1510; du Plessis AJ, 2008, CLIN PERINATOL, V35, P609, DOI 10.1016/j.clp.2008.07.010; Duldink J, 2008, ARCH DIS CHILD-FETAL, V93, pF201, DOI 10.1136/adc.2007.118067; Fuchs H, 2012, J PERINATOL, V32, P356, DOI 10.1038/jp.2011.110; Fuchs H, 2011, PEDIATR RES, V70, P176, DOI 10.1203/PDR.0b013e318220c1e0; GhaziBirry HS, 1997, AM J NEURORADIOL, V18, P219; HAUSDORF G, 1987, CRIT CARE MED, V15, P661, DOI 10.1097/00003246-198707000-00007; Hillman NH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113473; Jobe AH, 2008, NEONATOLOGY, V94, P190, DOI 10.1159/000143721; Kattwinkel J, 2010, CIRCULATION, V122, pS909, DOI 10.1161/CIRCULATIONAHA.110.971119; Kluckow M, 2000, ARCH DIS CHILD-FETAL, V82, pF188, DOI 10.1136/fn.82.3.F188; Lindner W, 2005, ACTA PAEDIATR, V94, P303, DOI 10.1080/08035250410023647; Lindner W, 1999, PEDIATRICS, V103, P961, DOI 10.1542/peds.103.5.961; Lista G, 2015, PEDIATRICS, V135, pE457, DOI 10.1542/peds.2014-1692; MIRRO R, 1987, J PEDIATR-US, V111, P101, DOI 10.1016/S0022-3476(87)80354-2; Patterson SW, 1914, J PHYSIOL-LONDON, V48, P357; Perlman JM, 2010, CIRCULATION, V122, P8516, DOI 10.1161/CIRCULATIONAHA.110.971127; Pichler G, 2013, J PEDIATR-US, V163, P1558, DOI 10.1016/j.jpeds.2013.07.007; Pocivalnik M, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3575647; Polglase GR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039535; Schmolzer GM, 2015, ARCH DIS CHILD-FETAL, V100, pF361, DOI 10.1136/archdischild-2014-306836; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI [10.1136/bmj.c332, 10.1186/1741-7015-8-18]; Schwaberger B, 2015, NEONATOLOGY, V108, P253, DOI 10.1159/000437347; Schwaberger B, 2014, PHYSIOL MEAS, V35, P2085, DOI 10.1088/0967-3334/35/10/2085; Skiold B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095804; Sweet DG, 2010, NEONATOLOGY, V97, P402, DOI 10.1159/000297773; Pas ABT, 2007, PEDIATRICS, V120, P322, DOI 10.1542/peds.2007-0114; te Pas AB, 2009, PEDIATR RES, V66, P295, DOI 10.1203/PDR.0b013e3181b1bca4; te Pas AB, 2009, PEDIATR RES, V65, P537, DOI 10.1203/PDR.0b013e31819da21b; Thabane L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-1; Urlesberger B, 2011, J PEDIATR-US, V159, P404, DOI 10.1016/j.jpeds.2011.02.030; van Vonderen JJ, 2014, J PEDIATR-US, V165, P903, DOI 10.1016/j.jpeds.2014.06.007; VANDERZEE P, 1992, ADV EXP MED BIOL, V316, P143; WYATT JS, 1991, PEDIATR RES, V29, P553, DOI 10.1203/00006450-199106010-00007	37	32	38	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2015	10	9							e0138964	10.1371/journal.pone.0138964	http://dx.doi.org/10.1371/journal.pone.0138964			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS1CR	26406467	Green Published, Green Submitted, gold			2023-01-03	WOS:000361800700130
J	Witte, K; Koch, E; Volk, HD; Wolk, K; Sabat, R				Witte, Katrin; Koch, Egon; Volk, Hans-Dieter; Wolk, Kerstin; Sabat, Robert			The Pelargonium sidoides Extract EPs 7630 Drives the Innate Immune Defense by Activating Selected MAP Kinase Pathways in Human Monocytes	PLOS ONE			English	Article							NITRIC-OXIDE SYNTHASE; GROUP A-STREPTOCOCCI; DOUBLE-BLIND; IN-VITRO; IL-22; CELLS; KERATINOCYTES; EFFICACY; DIFFERENTIATION; EXPRESSION	Pelargonium sidoides is a medical herb and respective extracts are used very frequently for the treatment of respiratory tract infections. However, the effects of Pelargonium sidoides and a special extract prepared from its roots (EPs 7630) on human immune cells are not fully understood. Here we demonstrate that EPs 7630 induced a rapid and dose-dependent production of TNF-alpha, IL-6, and IL-10 by human blood immune cells. This EPs 7630-induced cytokine profile was more pro-inflammatory in comparison with the profile induced by viral or bacterial infection-mimicking agents. The search for EPs 7630 target cells revealed that T-cells did not respond to EPs 7630 stimulation by production of TNF-alpha, IL-6, or IL-10. Furthermore, pretreatment of T-cells with EPs 7630 did not modulate their TNF-alpha, IL-6, and IL-10 secretion during subsequent activation. In contrast to lymphocytes, monocytes showed clear intracellular TNF-alpha staining after EPs 7630 treatment. Accordingly, EPs 7630 predominantly provoked activation of MAP kinases and inhibition of p38 strongly reduced the monocyte TNF-alpha production. The pretreatment of blood immune cells with EPs 7630 lowered their secretion of TNF-alpha and IL-10 and caused an IL-6 dominant response during second stimulation with viral or bacterial infection-mimicking agents. In summary, we demonstrate that EPs 7630 activates human monocytes, induces MAP kinase-dependent pro-inflammatory cytokines in these cells, and specifically modulates their production capacity of mediators known to lead to an increase of acute phase protein production in the liver, neutrophil generation in the bone marrow, and the generation of adaptive Th17 and Th22 cells.	[Witte, Katrin; Wolk, Kerstin; Sabat, Robert] Univ Hosp Charite, Interdisciplinary Grp Mol Immunopathol Dermatol M, Berlin, Germany; [Witte, Katrin; Volk, Hans-Dieter; Wolk, Kerstin] Univ Hosp Charite, Berlin Brandenburg Ctr Regenerat Therapies, Berlin, Germany; [Koch, Egon] Dr Willmar Schwabe GmbH & Co KG, Preclin Res, Karlsruhe, Germany; [Volk, Hans-Dieter] Univ Hosp Charite, Inst Med Immunol, Berlin, Germany; [Wolk, Kerstin; Sabat, Robert] Univ Hosp Charite, Psoriasis Res & Treatment Ctr, Berlin, Germany; [Sabat, Robert] Univ Hosp Charite, Res Ctr Immunosci, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Dr. Willmar Schwabe GmbH & Co. KG; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Sabat, R (corresponding author), Univ Hosp Charite, Interdisciplinary Grp Mol Immunopathol Dermatol M, Berlin, Germany.	robert.sabat@charite.de	volk, hans-dieter/AAV-8053-2021	volk, hans-dieter/0000-0002-7743-6668; Wolk, Kerstin/0000-0002-7689-4130	Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany	Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany	RS received a research grant from Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany. Additionally, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany provided support in the form of research material (EPs 7630) and salaries for author EK. The funder did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Agbabiaka TB, 2008, PHYTOMEDICINE, V15, P378, DOI 10.1016/j.phymed.2007.11.023; Bachert C, 2009, RHINOLOGY, V47, P51; BEIL W, 2007, PHYTOMEDICINE S1, V14, P5, DOI DOI 10.1016/J.PHYMED.2006.11.024]; Bereznoy VV, 2003, ALTERN THER HEALTH M, V9, P68; Brendler T, 2008, J ETHNOPHARMACOL, V119, P420, DOI 10.1016/j.jep.2008.07.037; Conrad A, 2007, PHYTOMEDICINE, V14, P46, DOI 10.1016/j.phymed.2006.11.016; Duhen T, 2009, NAT IMMUNOL, V10, P857, DOI 10.1038/ni.1767; Helfer M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087487; Janecki A, 2011, J ETHNOPHARMACOL, V133, P147, DOI 10.1016/j.jep.2010.09.018; Janecki A, 2010, MOLECULES, V15, P7139, DOI 10.3390/molecules15107139; Kolls JK, 2010, CYTOKINE GROWTH F R, V21, P443, DOI 10.1016/j.cytogfr.2010.11.002; Kolodziej H, 2005, BIOORGAN MED CHEM, V13, P6470, DOI 10.1016/j.bmc.2005.07.012; Kolodziej H, 2003, PHYTOMEDICINE, V10, P18, DOI 10.1078/1433-187X-00307; Kolodziej H, 2007, PHYTOMEDICINE, V14, P9, DOI 10.1016/j.phymed.2006.11.021; Kumari S, 2013, IMMUNITY, V39, P899, DOI 10.1016/j.immuni.2013.10.009; Lizogub VG, 2007, EXPLORE-NY, V3, P573, DOI 10.1016/j.explore.2007.09.004; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; Matthys H, 2013, RESP MED, V107, P691, DOI 10.1016/j.rmed.2013.02.011; Michaelis M, 2011, PHYTOMEDICINE, V18, P384, DOI 10.1016/j.phymed.2010.09.008; Neugebauer P, 2005, PHYTOMEDICINE, V12, P46, DOI 10.1016/j.phymed.2003.11.005; Pugh ND, 2008, INT IMMUNOPHARMACOL, V8, P1023, DOI 10.1016/j.intimp.2008.03.007; Sabat R, 2014, NAT REV DRUG DISCOV, V13, P21, DOI 10.1038/nrd4176; Schnitzler P, 2008, PHYTOMEDICINE, V15, P1108, DOI 10.1016/j.phymed.2008.06.009; Schoetz K, 2008, PLANTA MED, V74, P667, DOI 10.1055/s-2008-1074515; Thale C, 2011, PLANTA MED, V77, P718, DOI 10.1055/s-0030-1250567; Theisen LL, 2012, ANTIVIR RES, V94, P147, DOI 10.1016/j.antiviral.2012.03.006; Trun W, 2006, PHYTOMEDICINE, V13, P570, DOI 10.1016/j.phymed.2005.07.004; Witte E, 2014, J INVEST DERMATOL, V134, P2757, DOI 10.1038/jid.2014.308; Wittschier N, 2007, PHYTOMEDICINE, V14, P285, DOI 10.1016/j.phymed.2006.12.008; Wolk K, 2002, J IMMUNOL, V168, P5397, DOI 10.4049/jimmunol.168.11.5397; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Wolk K, 2008, J LEUKOCYTE BIOL, V83, P1181, DOI 10.1189/jlb.0807525; Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503; Wolk K, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006245; Wolk K, 2011, J IMMUNOL, V186, P1228, DOI 10.4049/jimmunol.0903907; Wolk K, 2009, EUR J IMMUNOL, V39, P3570, DOI 10.1002/eji.200939687; Wolk K, 2009, J MOL MED, V87, P523, DOI 10.1007/s00109-009-0457-0	37	17	18	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2015	10	9							e0138075	10.1371/journal.pone.0138075	http://dx.doi.org/10.1371/journal.pone.0138075			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS1CR	26406906	gold, Green Published, Green Submitted			2023-01-03	WOS:000361800700032
J	Holyoake, T; Vetrie, D				Holyoake, Tessa; Vetrie, David			CANCER Repositioned to kill stem cells	NATURE			English	Editorial Material							PHILADELPHIA-CHROMOSOME; LEUKEMIA		[Holyoake, Tessa; Vetrie, David] Univ Glasgow, Inst Canc Sci, Glasgow G12 0ZD, Lanark, Scotland	University of Glasgow	Holyoake, T (corresponding author), Univ Glasgow, Inst Canc Sci, Glasgow G12 0ZD, Lanark, Scotland.	tessa.holyoake@glasgow.ac.uk; david.vetrie@glasgow.ac.uk		Vetrie, David/0000-0003-2075-4662				Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Kranc KR, 2009, CELL STEM CELL, V5, P659, DOI 10.1016/j.stem.2009.11.001; Pemovska T, 2015, NATURE, V519, P102, DOI 10.1038/nature14119; Prost S, 2008, J CLIN INVEST, V118, P1765, DOI 10.1172/JCI33037; Prost S, 2015, NATURE, V525, P380, DOI 10.1038/nature15248	7	4	4	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 17	2015	525	7569					328	329		10.1038/nature15213	http://dx.doi.org/10.1038/nature15213			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR4JL	26331538	Green Accepted			2023-01-03	WOS:000361297900031
J	Prost, S; Relouzat, F; Spentchian, M; Ouzegdouh, Y; Saliba, J; Massonnet, G; Beressi, JP; Verhoeyen, E; Raggueneau, V; Maneglier, B; Castaigne, S; Chomienne, C; Chretien, S; Rousselot, P; Leboulch, P				Prost, Stephane; Relouzat, Francis; Spentchian, Marc; Ouzegdouh, Yasmine; Saliba, Joseph; Massonnet, Gerald; Beressi, Jean-Paul; Verhoeyen, Els; Raggueneau, Victoria; Maneglier, Benjamin; Castaigne, Sylvie; Chomienne, Christine; Chretien, Stany; Rousselot, Philippe; Leboulch, Philippe			Erosion of the chronic myeloid leukaemia stem cell pool by PPAR gamma agonists	NATURE			English	Article							IMATINIB; STAT5; PATHWAY; CITED2; HEMATOPOIESIS; HIF-1-ALPHA; INHIBITION; QUIESCENCE; ACTIVATION; RESISTANCE	Whether cancer is maintained by a small number of stem cells or is composed of proliferating cells with approximate phenotypic equivalency is a central question in cancer biology(1). In the stem cell hypothesis, relapse after treatment may occur by failure to eradicate cancer stem cells. Chronic myeloid leukaemia (CML) is quintessential to this hypothesis. CML is a myeloproliferative disorder that results from dysregulated tyrosine kinase activity of the fusion oncoprotein BCR-ABL(2). During the chronic phase, this sole genetic abnormality (chromosomal translocation Ph+: t(9;22)(q34;q11)) at the stem cell level causes increased proliferation of myeloid cells without loss of their capacity to differentiate. Without treatment, most patients progress to the blast phase when additional oncogenic mutations result in a fatal acute leukaemia made of proliferating immature cells. Imatinib mesylate and other tyrosine kinase inhibitors (TKIs) that target the kinase activity of BCR-ABL have improved patient survival markedly. However, fewer than 10% of patients reach the stage of complete molecular response (CMR), defined as the point when BCR-ABL transcripts become undetectable in blood cells(3). Failure to reach CMR results from the inability of TKIs to eradicate quiescent CML leukaemia stem cells (LSCs)(2-4). Here we show that the residual CML LSC pool can be gradually purged by the glitazones, antidiabetic drugs that are agonists of peroxisome proliferator-activated receptor-gamma (PPAR gamma). We found that activation of PPAR gamma by the glitazones decreases expression of STAT5 and its downstreamtargets HIF2 alpha(5) and CITED2(6), which are key guardians of the quiescence and stemness of CML LSCs. When pioglitazone was given temporarily to three CML patients in chronic residual disease in spite of continuous treatment with imatinib, all of them achieved sustained CMR, up to 4.7 years after withdrawal of pioglitazone. This suggests that clinically relevant cancer eradication may become a generally attainable goal by combination therapy that erodes the cancer stem cell pool.	[Prost, Stephane; Relouzat, Francis; Ouzegdouh, Yasmine; Saliba, Joseph; Chretien, Stany; Leboulch, Philippe] Inst Emerging Dis & Innovat Therapies iMETI, CEA, F-92265 Fontenay Aux Roses, France; [Spentchian, Marc] Hop Mignot, Dept Biol Med, F-78150 Le Chesnay, France; [Massonnet, Gerald; Chomienne, Christine; Rousselot, Philippe] Univ Paris Diderot, Hop St Louis,Inst Univ Hematol, UMR S 940, Unite Biol Cellulaire, F-75010 Paris, France; [Beressi, Jean-Paul] Hop Mignot, Serv Endocrinol & Diabetol, F-78150 Le Chesnay, France; [Verhoeyen, Els] Univ Lyon 1, CNRS, Int Ctr Infectiol Res,ENS Lyon, CIRI,EVIR Team,Inserm,U1111,UMR5308, F-69007 Lyon, France; [Verhoeyen, Els] INSERM, U895, Ctr Med Mol C3M, Equipe 3, F-06204 Nice, France; [Raggueneau, Victoria] Ctr Hosp Versailles, Lab Hematol, F-78150 Le Chesnay, France; [Maneglier, Benjamin] Ctr Hosp Versailles, Serv Biol Med, Unite Pharmacol, F-78150 Le Chesnay, France; [Castaigne, Sylvie; Chomienne, Christine; Rousselot, Philippe] Univ Versailles St Quentin En Yvelines, Serv Hematol & Oncol, Hop Mignot, F-78150 Le Chesnay, France; [Chretien, Stany] Inst Emerging Dis & Innovat Therapies iMETI, INSERM, F-92265 Fontenay Aux Roses, France; [Leboulch, Philippe] Brigham & Womens Hosp, Genet Div, Boston, MA 02115 USA; [Leboulch, Philippe] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Leboulch, Philippe] Ramathibodi Hosp, Hematol Div, Bangkok 10400, Thailand; [Leboulch, Philippe] Mahidol Univ, Bangkok 10400, Thailand	CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre Hospitalier de Versailles; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre Hospitalier de Versailles; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre Hospitalier de Versailles; UDICE-French Research Universities; Universite Paris Saclay; Centre Hospitalier de Versailles; UDICE-French Research Universities; Universite Paris Saclay; Centre Hospitalier de Versailles; UDICE-French Research Universities; Universite Paris Saclay; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Mahidol University; Mahidol University	Prost, S (corresponding author), Inst Emerging Dis & Innovat Therapies iMETI, CEA, F-92265 Fontenay Aux Roses, France.	stephane.prost@cea.fr; pleboulch@rics.bwh.harvard.edu	PROST, Stephane/I-8362-2015; Verhoeyen, Els/H-6360-2016; Chretien, Stany/M-5166-2018; Verhoeyen, Els/AAW-4853-2021	PROST, Stephane/0000-0002-8567-8253; Verhoeyen, Els/0000-0001-9224-5491; OUZEGDOUH MAMMASSE, Yasmine/0000-0001-6361-8885; CHOMIENNE, Christine/0000-0001-5513-5752	Association Laurette Fugain, Paris, France; Association pour la Recherche sur le Cancer, Villejuif, France; Chaire industrielle de l'Agence Nationale pour la Recherche (ANR)	Association Laurette Fugain, Paris, France; Association pour la Recherche sur le Cancer, Villejuif, France(Fondation ARC pour la Recherche sur le Cancer); Chaire industrielle de l'Agence Nationale pour la Recherche (ANR)(French National Research Agency (ANR))	We thank C. Costa, V. Tran Chau, F. Goullieux, A. Krief, P. Raynal, C. Terre, S. Tabore and T. Andrieu for their experimental contributions. This work was supported by the Association Laurette Fugain, Paris, France, by the Association pour la Recherche sur le Cancer, Villejuif, France to S. P., P.R. and P.L. and by the Chaire industrielle de l'Agence Nationale pour la Recherche (ANR) to P.L.	Avagyan S, 2011, BLOOD, V118, P6078, DOI 10.1182/blood-2011-07-365080; Berria R, 2007, CLIN PHARMACOL THER, V82, P275, DOI 10.1038/sj.clpt.6100146; Chen YY, 2009, NAT GENET, V41, P783, DOI 10.1038/ng.389; Chen Y, 2007, BLOOD, V110, P2889, DOI 10.1182/blood-2007-01-066316; Chomel JC, 2011, ONCOTARGET, V2, P713; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Copland M, 2006, BLOOD, V107, P4532, DOI 10.1182/blood-2005-07-2947; Corbin AS, 2011, J CLIN INVEST, V121, P396, DOI 10.1172/JCI35721; Davies GF, 2009, DRUG DES DEV THER, V3, P79; de Lavallade H, 2008, J CLIN ONCOL, V26, P3358, DOI 10.1200/JCO.2007.15.8154; Du JW, 2013, CURR OPIN HEMATOL, V20, P301, DOI 10.1097/MOH.0b013e3283606022; Du JW, 2012, BLOOD, V119, P2789, DOI 10.1182/blood-2011-10-387902; Fatrai S, 2011, BLOOD, V117, P3320, DOI 10.1182/blood-2010-08-303669; Gabert J, 2003, LEUKEMIA, V17, P2318, DOI 10.1038/sj.leu.2403135; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Hoelbl A, 2010, EMBO MOL MED, V2, P98, DOI 10.1002/emmm.201000062; Hu CJ, 2007, MOL BIOL CELL, V18, P4528, DOI 10.1091/mbc.E06-05-0419; Ito K, 2012, NAT MED, V18, P1350, DOI 10.1038/nm.2882; Jorgensen HG, 2007, BLOOD, V109, P4016, DOI 10.1182/blood-2006-11-057521; Kieslinger M, 2000, GENE DEV, V14, P232; Kominsky DJ, 2009, CLIN CANCER RES, V15, P3442, DOI 10.1158/1078-0432.CCR-08-3291; Koschmieder S, 2011, AM J BLOOD RES, V1, P65; Liu SH, 2014, MOL CANCER THER, V13, P1194, DOI 10.1158/1535-7163.MCT-13-0341; Lu DS, 2010, EUR J PHARMACOL, V636, P198, DOI 10.1016/j.ejphar.2010.03.010; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Negre D, 2000, GENE THER, V7, P1613, DOI 10.1038/sj.gt.3301292; Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184; Pitulis N, 2009, ANTICANCER RES, V29, P2331; Prost S, 2008, J CLIN INVEST, V118, P1765, DOI 10.1172/JCI33037; Roth O, 2010, CLIN CHIM ACTA, V411, P140, DOI 10.1016/j.cca.2009.10.007; Rousselot P, 2012, ASH ANN M; Szanto A, 2005, MOL PHARMACOL, V67, P1935, DOI 10.1124/mol.104.006445; Wang LH, 2012, EXP HEMATOL, V40, P811, DOI 10.1016/j.exphem.2012.05.013; Wang ZQ, 2009, BLOOD, V113, P4856, DOI 10.1182/blood-2008-09-181107; Yuan HF, 2012, BLOOD, V119, P1904, DOI 10.1182/blood-2011-06-361691	36	201	206	0	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 17	2015	525	7569					380	+		10.1038/nature15248	http://dx.doi.org/10.1038/nature15248			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR4JL	26331539	Green Submitted			2023-01-03	WOS:000361297900044
J	Park, WY; Koh, ES; Kim, SH; Kim, YO; Jin, DC; Song, HC; Choi, EJ; Kim, YL; Kim, YS; Kang, SW; Kim, NH; Yang, CW; Kim, YK				Park, Woo Yeong; Koh, Eun Sil; Kim, Su-Hyun; Kim, Young Ok; Jin, Dong Chan; Song, Ho Chul; Choi, Euy Jin; Kim, Yong-Lim; Kim, Yon-Su; Kang, Shin-Wook; Kim, Nam-Ho; Yang, Chul Woo; Kim, Yong Kyun			Serum Gamma-Glutamyltransferase Levels Predict Clinical Outcomes in Hemodialysis Patients	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; OXIDATIVE STRESS; CARDIOVASCULAR-DISEASE; ALANINE AMINOTRANSFERASE; OXIDANT STRESS; MORTALITY; CANCER; RISK; ABSTAINERS; COHORT	Background Gamma-glutamyltransferase (GGT) is a biomarker of liver injury. GGT has also been reported to be a marker of oxidative stress and a predictor of mortality in the general population. Hemodialysis (HD) patients suffer from oxidative stress. The aim of our study was to investigate the relationship between serum GGT levels and clinical outcomes in HD patients. Methods A total of 1,634 HD patients were enrolled from the Clinical Research Center registry for end-stage renal disease, a prospective cohort in Korea. Patients were categorized into three groups by tertiles of serum GGT levels. The primary outcome was all-cause, cardiovascular, or infection-related mortality and hospitalization. Results During the median follow-up period of 30 months, the highest tertile of serum GGT levels had a significantly higher risk for all-cause mortality (hazard ratio (HR) 2.39, 95% confidence interval (CI), 1.55-3.69, P<0.001), cardiovascular mortality (HR 2.14, 95% CI, 1.07-4.26, P = 0.031) and infection-related mortality (HR 3.07, 95% CI, 1.30-7.25, P = 0.011) using tertile 1 as the reference group after adjusting for clinical variables including liver diseases. The highest tertile also had a significantly higher risk for first hospitalization (HR 1.22, 95% CI, 1.00-1.48, P = 0.048) and cardiovascular hospitalization (HR 1.42, 95% CI, 1.06-1.92, P = 0.028). Conclusions Our data demonstrate that high serum GGT levels were an independent risk factor for all-cause, cardiovascular, and infection-related mortality, as well as cardiovascular hospitalization in HD patients. These findings suggest that serum GGT levels might be a useful biomarker to predict clinical outcomes in HD patients.	[Park, Woo Yeong; Koh, Eun Sil; Kim, Young Ok; Jin, Dong Chan; Song, Ho Chul; Choi, Euy Jin; Yang, Chul Woo; Kim, Yong Kyun] Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul, South Korea; [Kim, Su-Hyun] Chung Ang Univ, Coll Med, Dept Internal Med, Seoul 156756, South Korea; [Kim, Yong-Lim] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; [Kim, Yon-Su; Kang, Shin-Wook] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea; [Kang, Shin-Wook] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Kim, Nam-Ho] Chonnam Natl Univ, Sch Med, Dept Internal Med, Gwangju, South Korea; [Kim, Yong Kyun] Catholic Univ Korea, Cell Death Dis Res Ctr, Seoul, South Korea	Catholic University of Korea; Chung Ang University; Chung Ang University Hospital; Kyungpook National University; Seoul National University (SNU); Yonsei University; Yonsei University Health System; Chonnam National University; Catholic University of Korea	Kim, YK (corresponding author), Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul, South Korea.	drkimyk@catholic.ac.kr			Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [HI10C2020]	Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea	This work was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI10C2020).	Alatalo P, 2009, ALCOHOL ALCOHOLISM, V44, P199, DOI 10.1093/alcalc/agn099; Sette LHBC, 2014, CLINICS, V69, P271, DOI 10.6061/clinics/2014(04)09; Breitling LP, 2011, J HEPATOL, V55, P594, DOI 10.1016/j.jhep.2010.12.029; Canaud B, 1999, BLOOD PURIFICAT, V17, P99, DOI 10.1159/000014381; Dalrymple LS, 2015, AM J KIDNEY DIS, V65, P754, DOI 10.1053/j.ajkd.2014.11.030; Del Vecchio L, 2011, SEMIN DIALYSIS, V24, P56, DOI 10.1111/j.1525-139X.2010.00819.x; Dominici S, 2005, METHOD ENZYMOL, V401, P484, DOI 10.1016/S0076-6879(05)01029-3; Emdin M, 2005, CIRCULATION, V112, P2078, DOI 10.1161/CIRCULATIONAHA.105.571919; Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039; Franzini M, 2013, DRUG ALCOHOL DEPEN, V127, P239, DOI 10.1016/j.drugalcdep.2012.06.004; Handelman GJ, 2000, BLOOD PURIFICAT, V18, P343, DOI 10.1159/000014460; Hann HW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047687; Harel Z, 2015, J AM SOC NEPHROL, V26, P3141, DOI 10.1681/ASN.2014060614; Huang CF, 2014, J HEPATOL, V61, P67, DOI 10.1016/j.jhep.2014.02.022; Jiang SY, 2013, EXP CLIN CARDIOL, V18, P53; Lee DH, 2004, FREE RADICAL RES, V38, P535, DOI 10.1080/10715760410001694026; Locatelli F, 2000, NEPHROL DIAL TRANSPL, V15, P69, DOI 10.1093/ndt/15.suppl_5.69; Locatelli F, 2003, NEPHROL DIAL TRANSPL, V18, P1272, DOI 10.1093/ndt/gfg074; Long Y, 2014, FREE RADICAL RES, V48, P716, DOI 10.3109/10715762.2014.902055; Nakayama E, 2000, J AM SOC NEPHROL, V11, P1896, DOI 10.1681/ASN.V11101896; Petta S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051165; Pohanka M, 2013, FOLIA MICROBIOL, V58, P503, DOI 10.1007/s12223-013-0239-5; Postorino M, 2008, KIDNEY INT, V74, pS64, DOI 10.1038/ki.2008.515; Ruhl CE, 2009, GASTROENTEROLOGY, V136, P477, DOI 10.1053/j.gastro.2008.10.052; Ruttmann E, 2005, CIRCULATION, V112, P2130, DOI 10.1161/CIRCULATIONAHA.105.552547; Sluik D, 2012, DIABETES-METAB RES, V28, P284, DOI 10.1002/dmrr.2261; Strasak AM, 2008, INT J CANCER, V123, P1902, DOI 10.1002/ijc.23714; Tetta C, 1999, BLOOD PURIFICAT, V17, P118, DOI 10.1159/000014383; Van Hemelrijck M, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-895; Van Hemelrijck M, 2011, EUR J CANCER, V47, P2033, DOI 10.1016/j.ejca.2011.03.010; YOUDEN W. J., 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; Yun KE, 2009, ATHEROSCLEROSIS, V205, P533, DOI 10.1016/j.atherosclerosis.2008.12.012	32	5	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2015	10	9							e0138159	10.1371/journal.pone.0138159	http://dx.doi.org/10.1371/journal.pone.0138159			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR8NH	26376075	gold, Green Submitted, Green Published			2023-01-03	WOS:000361610200081
J	Balk, EM; Earley, A; Raman, G; Avendano, EA; Pittas, AG; Remington, PL				Balk, Ethan M.; Earley, Amy; Raman, Gowri; Avendano, Esther A.; Pittas, Anastassios G.; Remington, Patrick L.			Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Review							LIFE-STYLE INTERVENTION; IMPAIRED GLUCOSE-TOLERANCE; HEALTHY-LIVING PARTNERSHIPS; FOLLOW-UP; WEIGHT-LOSS; METABOLIC SYNDROME; PRIMARY-CARE; REAL-WORLD; CARDIOVASCULAR-DISEASE; SOCIOECONOMIC-STATUS	Background: Trials have shown efficacy of rigorous diet and physical activity promotion programs to reduce diabetes incidence and improve glycemic measures in adults at increased risk for type 2 diabetes. Purpose: To evaluate diet and physical activity promotion programs for persons at increased risk for type 2 diabetes, primarily to reduce diabetes risk and decrease body weight and glycemia. Data Sources: MEDLINE, the Cochrane Central Register of Controlled Trials, CAB Abstracts, Global Health, and Ovid HealthSTAR from 1991 through 27 February 2015, with no language restriction. Study Selection: 8 researchers screened articles for singlegroup or comparative studies of combined diet and physical activity promotion programs with at least 2 sessions over at least 3 months in participants at increased risk for type 2 diabetes. Data Extraction: 7 researchers extracted data on study design; participant, intervention, and outcome descriptions; and results and assessed study quality. Data Synthesis: 53 studies (30 of diet and physical activity promotion programs vs. usual care, 13 of more intensive vs. less intensive programs, and 13 of single programs) evaluated 66 programs. Compared with usual care, diet and physical activity promotion programs reduced type 2 diabetes incidence (risk ratio [RR], 0.59 [95% CI, 0.52 to 0.66]) (16 studies), decreased body weight (net change, -2.2% [CI, -2.9% to -1.4%]) (24 studies) and fasting blood glucose level (net change, -0.12 mmol/L [-2.2 mg/dL] [CI, -0.20 to -0.05 mmol/L {-3.6 to -0.9 mg/dL}]) (17 studies), and improved other cardiometabolic risk factors. Evidence for clinical events was limited. More intensive programs were more effective. Limitations: Wide variation in diet and physical activity promotion programs limited identification of features most relevant to effectiveness. Evidence on clinical outcomes and in children was sparse. Conclusion: Combined diet and physical activity promotion programs are effective at decreasing diabetes incidence and improving cardiometabolic risk factors in persons at increased risk. More intensive programs are more effective.	[Balk, Ethan M.] Brown Univ, Sch Publ Hlth, Providence, RI 02912 USA; [Raman, Gowri; Avendano, Esther A.] Tufts Med Ctr, Ctr Clin Evidence Synth, Boston, MA 02111 USA; [Pittas, Anastassios G.] Tufts Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02111 USA; Mapi Grp, Boston, MA USA; Univ Wisconsin, Madison, WI USA	Brown University; Tufts Medical Center; Tufts Medical Center; University of Wisconsin System; University of Wisconsin Madison	Balk, EM (corresponding author), Brown Univ, Sch Publ Hlth, Box G-S121-8, Providence, RI 02912 USA.	ethan_balk@brown.edu	Balk, Ethan/AAJ-2547-2020		Centers for Disease Control and Prevention Community Preventive Services Task Force; CDC [200-2012-53787]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK098245] Funding Source: NIH RePORTER	Centers for Disease Control and Prevention Community Preventive Services Task Force; CDC(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Centers for Disease Control and Prevention Community Preventive Services Task Force.; By contract 200-2012-53787 from the CDC.	Absetz P, 2007, DIABETES CARE, V30, P2465, DOI 10.2337/dc07-0171; Absetz P, 2009, DIABETES CARE, V32, P1418, DOI 10.2337/dc09-0039; Ackermann RT, 2014, OBESITY, V22, P1601, DOI 10.1002/oby.20762; Ackermann RT, 2008, AM J PREV MED, V35, P357, DOI 10.1016/j.amepre.2008.06.035; Admiraal WM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068605; Agency for Healthcare Research and Quality, 2012, AHRQ PUBLICATION; Aguiar EJ, 2014, INT J BEHAV NUTR PHY, V11, DOI 10.1186/1479-5868-11-2; Albright AL, 2013, AM J PREV MED, V44, pS346, DOI 10.1016/j.amepre.2012.12.009; Alibasic Esad, 2013, Mater Sociomed, V25, P80, DOI 10.5455/msm.2013.25.80-82; Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI 10.2337/dc10-s062; Azar KMJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/191209; Bhopal RS, 2014, LANCET DIABETES ENDO, V2, P218, DOI 10.1016/S2213-8587(13)70204-3; Bouchard DR, 2012, DIABETES RES CLIN PR, V96, P129, DOI 10.1016/j.diabres.2011.12.019; Bray GA, 2009, LANCET, V374, P1677, DOI 10.1016/S0140-6736(09)61457-4; Bray GA, 1999, DIABETES CARE, V22, P623; Briss PA, 2000, AM J PREV MED, V18, P35, DOI 10.1016/S0749-3797(99)00119-1; Carr DB, 2005, DIABETES, V54, P340, DOI 10.2337/diabetes.54.2.340; Cezaretto A, 2012, QUAL LIFE RES, V21, P105, DOI 10.1007/s11136-011-9919-2; Cole RE, 2013, DIABETES EDUCATOR, V39, P344, DOI 10.1177/0145721713484812; Costa B, 2012, DIABETOLOGIA, V55, P1319, DOI 10.1007/s00125-012-2492-6; Crandall J, 2006, J GERONTOL A-BIOL, V61, P1075; Critchley CR, 2012, DIABETES CARE, V35, P699, DOI 10.2337/dc11-1183; De la Rosa A, 2008, ETHNIC DIS, V18, pS16; Delahanty LM, 2013, DIABETES CARE, V36, P34, DOI 10.2337/dc12-0733; den Boer AT, 2013, NUTR METAB CARDIOVAS, V23, P1147, DOI 10.1016/j.numecd.2012.12.005; Diabet Prevention Program Res Grp, 2005, DIABETES, V54, P1566; Dunbar JA, 2010, INT J DIABETES MELLI, V2, P95, DOI DOI 10.1016/j.ijdm.2010.05.002; Dunkley AJ, 2014, DIABETES CARE, V37, P922, DOI 10.2337/dc13-2195; Eriksson J, 1999, DIABETOLOGIA, V42, P793, DOI 10.1007/s001250051229; Eriksson KF, 1998, DIABETOLOGIA, V41, P1010, DOI 10.1007/s001250051024; ERIKSSON KF, 1991, DIABETOLOGIA, V34, P891, DOI 10.1007/BF00400196; Gagnon C, 2011, DIABETES METAB, V37, P410, DOI 10.1016/j.diabet.2011.01.003; Gerstein HC, 2007, DIABETES RES CLIN PR, V78, P305, DOI 10.1016/j.diabres.2007.05.004; Gilis-Januszewska A., 2011, BR J DIABETES VASC D, V11, P198, DOI DOI 10.1177/1474651411412429; GILLETT M, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI DOI 10.3310/hta16330; Gillison F, 2015, INT J BEHAV NUTR PHY, V12, DOI 10.1186/s12966-014-0160-6; Gong Q, 2011, DIABETOLOGIA, V54, P300, DOI 10.1007/s00125-010-1948-9; Harbord RM, 2009, STATA J, V9, P197, DOI 10.1177/1536867X0900900202; Hardy RJ, 1996, STAT MED, V15, P619, DOI 10.1002/(SICI)1097-0258(19960330)15:6<619::AID-SIM188>3.0.CO;2-A; Hosper K, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-406; Huang ES, 2009, DIABETES CARE, V32, P2225, DOI 10.2337/dc09-0459; Hydrie MZI, 2012, J NUTR METAB, V2012, DOI 10.1155/2012/867604; Ilanne-Parikka P, 2008, DIABETES CARE, V31, P805, DOI 10.2337/dc07-1117; Institute of Medicine, 2011, FIND WHAT WORKS HLTH; International Diabetes Federation, 2014, IDF DIABETES ATLAS, V6th; Islam NS, 2014, INT J ENV RES PUB HE, V11, P5462, DOI 10.3390/ijerph110505462; JANUS ED, 2012, TRIALS, V13, pNIL_0001, DOI DOI 10.1186/1745-6215-13-152; Jiang LH, 2013, DIABETES CARE, V36, P2027, DOI 10.2337/dc12-1250; Kanaya AM, 2012, AM J PUBLIC HEALTH, V102, P1551, DOI 10.2105/AJPH.2011.300456; Katula JA, 2013, AM J PREV MED, V44, pS324, DOI 10.1016/j.amepre.2012.12.015; Katula JA, 2011, DIABETES CARE, V34, P1451, DOI 10.2337/dc10-2115; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Knowler WC, 2015, DIABETES CARE, V38, P51, DOI 10.2337/dc14-0886; Kosaka K, 2005, DIABETES RES CLIN PR, V67, P152, DOI 10.1016/j.diabres.2004.06.010; Kulzer B, 2009, DIABETES CARE, V32, P1143, DOI 10.2337/dc08-2141; Kyrios M, 2009, MED J AUSTRALIA, V190, pS81; Laatikainen T, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-249; Li GW, 2008, LANCET, V371, P1783, DOI 10.1016/S0140-6736(08)60766-7; Li GW, 2014, LANCET DIABETES ENDO, V2, P474, DOI 10.1016/S2213-8587(14)70057-9; Liao D, 2002, DIABETES CARE, V25, P1504, DOI 10.2337/diacare.25.9.1504; Lindstrom J, 2013, DIABETOLOGIA, V56, P284, DOI 10.1007/s00125-012-2752-5; Lindstrom J, 2003, J AM SOC NEPHROL, V14, pS108, DOI 10.1097/01.ASN.0000070157.96264.13; Lindstrom J, 2003, DIABETES CARE, V26, P3230, DOI 10.2337/diacare.26.12.3230; Lindstrom J, 2008, DIABETES CARE, V31, P857, DOI 10.2337/dc07-2162; Lindstrom J, 2006, LANCET, V368, P1673, DOI 10.1016/S0140-6736(06)69701-8; Ma J, 2013, JAMA INTERN MED, V173, P113, DOI 10.1001/2013.jamainternmed.987; Makrilakis K, 2010, DIABETIC MED, V27, P459, DOI 10.1111/j.1464-5491.2010.02918.x; Makrilakis K, 2012, HORM-INT J ENDOCRINO, V11, P316, DOI 10.14310/horm.2002.1360; Merriam PA, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-20; Moore SM, 2011, PSYCHOL HEALTH, V26, P485, DOI 10.1080/08870440903548749; Nilsen V, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-893; Ockene IS, 2012, AM J PUBLIC HEALTH, V102, P336, DOI 10.2105/AJPH.2011.300357; Oldroyd JC, 2006, DIABETES RES CLIN PR, V72, P117, DOI 10.1016/j.diabres.2005.09.018; Oldroyd JC, 2001, DIABETES RES CLIN PR, V52, P29, DOI 10.1016/S0168-8227(00)00244-8; Orchard TJ, 2013, DIABETIC MED, V30, P46, DOI 10.1111/j.1464-5491.2012.03750.x; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; Patrick Kevin, 2013, J Diabetes Sci Technol, V7, P759; Penn L, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003585; Penn L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057143; Penn L, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-342; Perreault L, 2008, DIABETES CARE, V31, P1416, DOI 10.2337/dc07-2390; Perreault L, 2012, LANCET, V379, P2243, DOI 10.1016/S0140-6736(12)60525-X; Perreault L, 2009, DIABETES CARE, V32, P1583, DOI 10.2337/dc09-0523; Ramachandran A, 2006, DIABETOLOGIA, V49, P289, DOI 10.1007/s00125-005-0097-z; Ramachandran A, 2009, DIABETOLOGIA, V52, P1019, DOI 10.1007/s00125-009-1315-x; Ramachandran A, 2013, LANCET DIABETES ENDO, V1, P191, DOI 10.1016/S2213-8587(13)70067-6; Ramachandran A, 2010, DIABETES CARE, V33, P2164, DOI 10.2337/dc09-1150; Ratner R, 2005, DIABETES CARE, V28, P888, DOI 10.2337/diacare.28.4.888; Rautio N, 2012, DIABETIC MED, V29, P207, DOI 10.1111/j.1464-5491.2011.03388.x; Rautio N, 2014, PRIM CARE DIABETES, V8, P43, DOI 10.1016/j.pcd.2013.10.005; Rautio N, 2013, J PRIM CARE COMMUNIT, V4, P59, DOI 10.1177/2150131912444130; Rautio N, 2012, PRIM CARE DIABETES, V6, P277, DOI 10.1016/j.pcd.2012.07.002; Rautio N, 2011, SCAND J PUBLIC HEALT, V39, P561, DOI 10.1177/1403494811408482; Roumen C, 2008, DIABETIC MED, V25, P597, DOI 10.1111/j.1464-5491.2008.02417.x; Roumen C, 2011, EUR J CLIN NUTR, V65, P1141, DOI 10.1038/ejcn.2011.74; Saaristo T, 2010, DIABETES CARE, V33, P2146, DOI 10.2337/dc10-0410; Saito T, 2011, ARCH INTERN MED, V171, P1352, DOI 10.1001/archinternmed.2011.275; Sakane N, 2014, BMJ OPEN DIAB RES CA, V2, DOI 10.1136/bmjdrc-2013-000003; Sakane N, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-40; Savoye M, 2014, DIABETES CARE, V37, P317, DOI 10.2337/dc13-1571; Schellenberg ES, 2013, ANN INTERN MED, V159, P543, DOI 10.7326/0003-4819-159-8-201310150-00007; Sepah SC, 2014, DIABETES EDUCATOR, V40, P435, DOI 10.1177/0145721714531339; Snehalatha C, 2009, DIABETES CARE, V32, P1796, DOI 10.2337/dc09-0676; Swanson CM, 2012, ENDOCR PRACT, V18, P200, DOI 10.4158/EP11226.OR; Tate DF, 2003, JAMA-J AM MED ASSOC, V289, P1833, DOI 10.1001/jama.289.14.1833; The Community Guide, DAT ABSTR FORM; Trief PM, 2014, OBESITY, V22, P2532, DOI 10.1002/oby.20916; Tuomilehto Jaakko, 2001, New England Journal of Medicine, V344, P1343, DOI 10.1056/NEJM200105033441801; US Department of Health and Human Services, 2020, NATL VITAL STAT REP; Uusitupa M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005656; Uusitupa MI, 2011, DIABETES CARE, V34, P418, DOI 10.2337/dc10-1013; Vanderwood KK, 2010, DIABETES CARE, V33, P2543, DOI 10.2337/dc10-0862; Vermunt PWA, 2012, DIABETIC MED, V29, pE223, DOI 10.1111/j.1464-5491.2012.03648.x; Vermunt PWA, 2011, DIABETES CARE, V34, P1919, DOI 10.2337/dc10-2293; Vlaar EMA, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-371; Vojta D, 2013, AM J PREV MED, V44, pS301, DOI 10.1016/j.amepre.2012.12.018; Wallace B.C., 2012, P ACM INT HLTH INF S, DOI DOI 10.1145/2110363.2110464; Weinstock RS, 2013, J GEN INTERN MED, V28, P1620, DOI 10.1007/s11606-013-2529-7; West DS, 2008, OBESITY, V16, P1413, DOI 10.1038/oby.2008.224; Wikstrom Katja, 2009, Diabetes Res Clin Pract, V86, pe1, DOI 10.1016/j.diabres.2009.06.014; Wing RR, 2004, OBES RES, V12, P1426; Xiao L, 2013, NUTR DIABETES, V3, DOI 10.1038/nutd.2013.17; Zaza S, 2000, AM J PREV MED, V18, P44, DOI 10.1016/S0749-3797(99)00122-1	123	206	208	3	66	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	2015	163	6					437	+		10.7326/M15-0452	http://dx.doi.org/10.7326/M15-0452			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CR5FL	26167912	Green Accepted			2023-01-03	WOS:000361365900018
J	Gilman, M; Hockenberry, JM; Adams, EK; Milstein, AS; Wilson, IB; Becker, ER				Gilman, Matlin; Hockenberry, Jason M.; Adams, E. Kathleen; Milstein, Arnold S.; Wilson, Ira B.; Becker, Edmund R.			The Financial Effect of Value-Based Purchasing and the Hospital Readmissions Reduction Program on Safety-Net Hospitals in 2014 A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; QUALITY-OF-CARE; PERFORMANCE-MEASURES; HEART-FAILURE; MORTALITY-RATES; HEALTH-CARE; OUTCOMES; EXPERIENCE; CALIFORNIA; POLICY	Background: Medicare's value-based purchasing (VBP) and the Hospital Readmissions Reduction Program (HRRP) could disproportionately affect safety-net hospitals. Objective: To determine whether safety-net hospitals incur larger financial penalties than other hospitals under VBP and HRRP. Design: Cross-sectional analysis. Setting: United States in 2014. Participants: 3022 acute care hospitals participating in VBP and the HRRP. Measurements: Safety-net hospitals were defined as being in the top quartile of the Medicare disproportionate share hospital (DSH) patient percentage and Medicare uncompensated care (UCC) payments per bed. The differences in penalties in both total dollars and dollars per bed between safety-net hospitals and other hospitals were estimated with the use of bivariate and graphical regression methods. Results: Safety-net hospitals in the top quartile of each measure were more likely to be penalized under VBP than other hospitals (62.9% vs. 51.0% under the DSH definition and 60.3% vs. 51.5% under the UCC per-bed definition). This was also the case under the HRRP (80.8% vs. 69.0% and 81.9% vs. 68.7%, respectively). Safety-net hospitals also had larger payment penalties ($115 900 vs. $66 600 and $150 100 vs. $54 900, respectively). On a perbed basis, this translated to $436 versus $332 and $491 versus $314, respectively. Sensitivity analysis setting the cutoff at the top decile rather than the top quartile decile led to similar conclusions with somewhat larger differences between safety-net and other hospitals. The quadratic fit of the data indicated that the larger effect of these penalties is in the middle of the distribution of the DSH and UCC measures. Limitation: Only 2 measures of safety-net status were included in the analyses. Conclusion: Safety-net hospitals were disproportionately likely to be affected under VBP and the HRRP, but most incurred relatively small payment penalties in 2014.	[Gilman, Matlin; Hockenberry, Jason M.; Adams, E. Kathleen; Becker, Edmund R.] Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, 1518 Clifton Rd, Atlanta, GA 30322 USA; [Milstein, Arnold S.] Stanford Sch Med, Clin Excellence Res Ctr, Palo Alto, CA USA; [Wilson, Ira B.] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, Providence, RI 02912 USA	Emory University; Rollins School Public Health; Stanford University; Brown University	Hockenberry, JM (corresponding author), Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, 1518 Clifton Rd, Atlanta, GA 30322 USA.	jason.hockenberry@emory.edu	Wilson, Ira/F-9190-2016	Wilson, Ira/0000-0002-0246-738X; Gilman, Matlin/0000-0001-7432-4823	Patient-Centered Outcomes Research Institute	Patient-Centered Outcomes Research Institute(Patient-Centered Outcomes Research Institute - PCORI)	Patient-Centered Outcomes Research Institute.	Aaronson DS, 2013, J HEALTHC QUAL, V35, P15, DOI 10.1111/j.1945-1474.2011.00173.x; [Anonymous], 2013, FED REG, V78, P78; Berenson Robert A, 2013, TIMELY ANAL IMMED HL; Bernheim SM, 2012, 2012 MEASURES MAINTE; Bradley EH, 2006, JAMA-J AM MED ASSOC, V296, P72, DOI 10.1001/jama.296.1.72; Burgess JF, 2014, HEALTH ECON POLICY L, V9, P193, DOI 10.1017/S1744133113000340; Chatterjee P, 2012, ARCH INTERN MED, V172, P1204, DOI 10.1001/archinternmed.2012.3158; Conover M., 2012, HOSP WIDE ALL CAUSE; Fonarow GC, 2007, JAMA-J AM MED ASSOC, V297, P61, DOI 10.1001/jama.297.1.61; Fonarow GC, 2009, JAMA-J AM MED ASSOC, V302, P792, DOI 10.1001/jama.2009.1180; Gilman M, 2014, HEALTH AFFAIR, V33, P1314, DOI 10.1377/hlthaff.2014.0138; Goldman LE, 2007, MED CARE, V45, P579, DOI 10.1097/MLR.0b013e318041f723; Gu Q, 2014, HEALTH SERV RES, V49, P818, DOI 10.1111/1475-6773.12150; Hasnain-Wynia R, 2007, ARCH INTERN MED, V167, P1233, DOI 10.1001/archinte.167.12.1233; Hockenberry JM, 2013, MED CARE, V51, P13, DOI 10.1097/MLR.0b013e31825c2fec; Hockenberry JM, 2013, MED CARE, V51, P23, DOI 10.1097/MLR.0b013e3182785a5d; James J, 2013, HLTH AFF MILLWO 1112; Jha AK, 2007, ARCH INTERN MED, V167, P1177, DOI 10.1001/archinte.167.11.1177; Jha AK, 2013, JAMA-J AM MED ASSOC, V309, P347, DOI 10.1001/jama.2012.196646; Jha AK, 2009, NEW ENGL J MED, V361, P2637, DOI 10.1056/NEJMsa0904859; Keyhani S, 2014, ANN INTERN MED, V161, P775, DOI 10.7326/M14-0361; Kind AJH, 2014, ANN INTERN MED, V161, P765, DOI 10.7326/M13-2946; Krumholz HM, 2014, ANN INTERN MED, V161, P833, DOI 10.7326/M14-2308; Lipstein SH, 2014, ANN INTERN MED, V161, P594, DOI 10.7326/M14-1601; McHugh M, 2009, MED CARE RES REV, V66, P590, DOI 10.1177/1077558709334895; Mohan A, 2013, INT J HEALTH SERV, V43, P321, DOI 10.2190/HS.43.2.h; Nardin R., 2013, UNINSURED IMPLEMENTA; Neuhausen K, 2012, ARCH INTERN MED, V172, P1202, DOI 10.1001/archinternmed.2012.3175; Nicholas LH, 2010, ARCH SURG-CHICAGO, V145, P999, DOI 10.1001/archsurg.2010.191; Rau J, 2012, KAISER HLTH NEWS; Romley JA, 2011, ANN INTERN MED, V154, P160, DOI 10.7326/0003-4819-154-3-201102010-00005; Ross JS, 2007, HEALTH AFFAIR, V26, P238, DOI 10.1377/hlthaff.26.1.238; Ross JS, 2012, HEALTH AFFAIR, V31, P1739, DOI 10.1377/hlthaff.2011.1028; Ryan AM, 2015, HEALTH SERV RES, V50, P81, DOI 10.1111/1475-6773.12206; Ryan AM, 2009, INQUIRY-J HEALTH CAR, V46, P274, DOI 10.5034/inquiryjrnl_46.03.274; Suter LG, 2012, MEDICARE HOSP QUALIT; The Henry J, 2014, FACTS MED SPEND FIN; Werner RM, 2006, JAMA-J AM MED ASSOC, V296, P2694, DOI 10.1001/jama.296.22.2694	38	96	96	0	19	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	2015	163	6					427	+		10.7326/M14-2813	http://dx.doi.org/10.7326/M14-2813			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CR5FL	26343790				2023-01-03	WOS:000361365900017
J	Pronk, NP; Remington, PL				Pronk, Nicolaas P.; Remington, Patrick L.		Community Preventive Serv	Combined Diet and Physical Activity Promotion Programs for Prevention of Diabetes: Community Preventive Services Task Force Recommendation Statement	ANNALS OF INTERNAL MEDICINE			English	Article							LIFE-STYLE INTERVENTION; INCREASED RISK; TYPE-2	Description: Community Preventive Services Task Force recommendation on the use of combined diet and physical activity promotion programs to reduce progression to type 2 diabetes in persons at increased risk. Methods: The Task Force commissioned an evidence review that assessed the benefits and harms of programs to promote and support individual improvements in diet, exercise, and weight and supervised a review on the economic efficiency of these programs in clinical trial, primary care, and primary care-referable settings. Population: Adolescents and adults at increased risk for progression to type 2 diabetes. Recommendation: The Task Force recommends the use of combined diet and physical activity promotion programs by health care systems, communities, and other implementers to provide counseling and support to clients identified as being at increased risk for type 2 diabetes. Economic evidence indicates that these programs are cost-effective.	[Pronk, Nicolaas P.; Remington, Patrick L.; Community Preventive Serv] Community Prevent Serv Task Force, Atlanta, GA 30329 USA		Pronk, NP (corresponding author), Community Prevent Serv Task Force, Atlanta, GA 30329 USA.			, Ron/0000-0003-4989-4108; Omenn, Gilbert S./0000-0002-8976-6074	Merck Foundation	Merck Foundation(Merck & Company)	Dr. Chin reports a grant from the Merck Foundation outside the submitted work. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOf InterestForms.do?msNum=M15-1029.	Ackermann RT, 2007, DIABETES EDUCATOR, V33, P69, DOI 10.1177/0145721706297743; Albright AL, 2013, AM J PREV MED, V44, pS346, DOI 10.1016/j.amepre.2012.12.009; Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI 10.2337/dc10-s062; Balk EM, 2015, ANN INTERN MED, V163, P437, DOI 10.7326/M15-0452; Barber SR, 2014, DIABETES RES CLIN PR, V105, P1, DOI 10.1016/j.diabres.2014.03.007; Jiang LH, 2013, DIABETES CARE, V36, P2027, DOI 10.2337/dc12-1250; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Li R, 2015, ANN INTERN MED, V163, P452, DOI 10.7326/M15-0469; Lindstrom J, 2003, DIABETES CARE, V26, P725, DOI 10.2337/diacare.26.3.725; Tuomilehto Jaakko, 2001, New England Journal of Medicine, V344, P1343, DOI 10.1056/NEJM200105033441801; Vanderwood KK, 2010, DIABETES CARE, V33, P2543, DOI 10.2337/dc10-0862; Vojta D, 2013, AM J PREV MED, V44, pS301, DOI 10.1016/j.amepre.2012.12.018	12	45	45	0	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	2015	163	6					465	+		10.7326/M15-1029	http://dx.doi.org/10.7326/M15-1029			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CR5FL	26168073				2023-01-03	WOS:000361365900021
J	Yi, J; Xiang, ZY; Deng, XM; Fan, T; Fu, RQ; Geng, WM; Guo, RH; He, N; Li, CH; Li, L; Li, M; Li, TZ; Tian, M; Wang, G; Wang, L; Wang, TL; Wu, AS; Wu, D; Xue, XD; Xu, MJ; Yang, XM; Yang, ZM; Yuan, JH; Zhao, QH; Zhou, GQ; Zuo, MZ; Pan, S; Zhan, LJ; Yao, M; Huang, YG				Yi, Jie; Xiang, Ziyong; Deng, Xiaoming; Fan, Ting; Fu, Runqiao; Geng, Wanming; Guo, Ruihong; He, Nong; Li, Chenghui; Li, Lei; Li, Min; Li, Tianzuo; Tian, Ming; Wang, Geng; Wang, Lei; Wang, Tianlong; Wu, Anshi; Wu, Di; Xue, Xiaodong; Xu, Mingjun; Yang, Xiaoming; Yang, Zhanmin; Yuan, Jianhu; Zhao, Qiuhua; Zhou, Guoqing; Zuo, Mingzhang; Pan, Shuang; Zhan, Lujing; Yao, Min; Huang, Yuguang			Incidence of Inadvertent Intraoperative Hypothermia and Its Risk Factors in Patients Undergoing General Anesthesia in Beijing: A Prospective Regional Survey	PLOS ONE			English	Article							POSTOPERATIVE HYPOTHERMIA; WOUND-INFECTION; BLOOD-LOSS; FLUID; IMPLEMENTATION; NORMOTHERMIA	Background/Objective Inadvertent intraoperative hypothermia (core temperature <36 degrees C) is a recognized risk in surgery and has adverse consequences. However, no data about this complication in China are available. Our study aimed to determine the incidence of inadvertent intraoperative hypothermia and its associated risk factors in a sample of Chinese patients. Methods We conducted a regional cross-sectional survey in Beijing from August through December, 2013. Eight hundred thirty patients who underwent various operations under general anesthesia were randomly selected from 24 hospitals through a multistage probability sampling. Multivariate logistic regression analyses were applied to explore the risk factors of developing hypothermia. Results The overall incidence of intraoperative hypothermia was high, 39.9%. All patients were warmed passively with surgical sheets or cotton blankets, whereas only 10.7% of patients received active warming with space heaters or electric blankets. Pre-warmed intravenous fluid were administered to 16.9% of patients, and 34.6% of patients had irrigation of wounds with pre-warmed fluid. Active warming (OR = 0.46, 95% CI 0.26-0.81), overweight or obesity (OR = 0.39, 95% CI 0.28-0.56), high baseline core temperature before anesthesia (OR = 0.08, 95% CI 0.04-0.13), and high ambient temperature (OR = 0.89, 95% CI 0.79-0.98) were significant protective factors for hypothermia. In contrast, major-plus operations (OR = 2.00, 95% CI 1.32-3.04), duration of anesthesia (1-2 h) (OR = 3.23, 95% CI 2.19-4.78) and >2 h (OR = 3.44, 95% CI 1.90-6.22,), and intravenous un-warmed fluid (OR = 2.45, 95% CI 1.45-4.12) significantly increased the risk of hypothermia. Conclusions The incidence of inadvertent intraoperative hypothermia in Beijing is high, and the rate of active warming of patients during operation is low. Concern for the development of intraoperative hypothermia should be especially high in patients undergoing major operations, requiring long periods of anesthesia, and receiving un-warmed intravenous fluids.	[Yi, Jie; Huang, Yuguang] Peking Union Med Coll Hosp, Beijing, Peoples R China; [Xiang, Ziyong; Pan, Shuang; Zhan, Lujing; Yao, Min] 3M China R&D Ctr, Shanghai, Peoples R China; [Deng, Xiaoming] PUMC, CAMS, Plast Surg Hosp & Inst, Beijing, Peoples R China; [Fan, Ting] Tsinghua Univ, Yuquan Hosp, Beijing 100084, Peoples R China; [Fu, Runqiao] Beijing Chuiyangliu Hosp, Beijing, Peoples R China; [Geng, Wanming] Capital Med Univ, Beijing Chest Hosp, Beijing, Peoples R China; [Guo, Ruihong] Miyunxian Hosp, Beijing, Peoples R China; [He, Nong] Peking Univ, Shougang Hosp, Beijing 100871, Peoples R China; [Li, Chenghui] China Japan Friendship Hosp, Beijing, Peoples R China; [Li, Lei] China Meitan Gen Hosp, Beijing, Peoples R China; [Li, Min] Peking Univ, Hosp 3, Beijing 100871, Peoples R China; [Li, Tianzuo] Capital Med Univ, Beijing Tongren Hosp, Beijing, Peoples R China; [Tian, Ming] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China; [Wang, Geng] Beijing Jishuitan Hosp, Beijing, Peoples R China; [Wang, Lei] Haidian Maternal & Child Hlth Hosp, Beijing, Peoples R China; [Wang, Tianlong] Capital Med Univ, Xuanwu Hosp, Beijing, Peoples R China; [Wu, Anshi] Beijing Chao Yang Hosp, Beijing, Peoples R China; [Wu, Di] Capital Med Univ, Luhe Teaching Hosp, Beijing, Peoples R China; [Xue, Xiaodong; Yang, Xiaoming] PLA, Air Force Gen Hosp, Beijing, Peoples R China; [Xu, Mingjun] Capital Med Univ, Beijing Obstet & Gynecol Hosp, Beijing, Peoples R China; [Yang, Zhanmin] China Aerosp Corp, Cent Hosp, Beijing, Peoples R China; [Yuan, Jianhu] Beijing Rectum Hosp, Beijing, Peoples R China; [Zhao, Qiuhua] Beijing Shi Jing Shan Hosp, Beijing, Peoples R China; [Zhou, Guoqing] Beijing Pinggu Hosp, Beijing, Peoples R China; [Zuo, Mingzhang] Minist Hlth, Beijing Hosp, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; 3M; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Plastic Surgery Hospital - CAMS; Tsinghua University; Capital Medical University; Peking University; China-Japan Friendship Hospital; Peking University; Capital Medical University; Capital Medical University; Capital Medical University; Capital Medical University; Capital Medical University; Air Force General Hospital PLA; Capital Medical University; Beijing Hospital	Huang, YG (corresponding author), Peking Union Med Coll Hosp, Beijing, Peoples R China.	huangyg@pumch.cn			China National Health and Planned Parenthood Committee Health Quality Improvement Award [201402017]; China National Nature Science Foundation [31070930]; unrestricted research grant from 3M China [MDI0077]	China National Health and Planned Parenthood Committee Health Quality Improvement Award; China National Nature Science Foundation(National Natural Science Foundation of China (NSFC)); unrestricted research grant from 3M China	This study was funded by the China National Health and Planned Parenthood Committee Health Quality Improvement Award (ID# 201402017, principle investigator Yuguang Huang, MD), China National Nature Science Foundation (Grant# 31070930, principle investigator Yuguang Huang, MD), and an unrestricted research grant (MDI0077, principle investigator Yuguang Huang, MD) from 3M China.	Andrzejowski JC, 2010, ANAESTHESIA, V65, P942, DOI 10.1111/j.1365-2044.2010.06473.x; Barclay KL, 2013, ANZ J SURG; Barthel ER, 2012, J TRAUMA ACUTE CARE, V72, P1588, DOI 10.1097/TA.0b013e31824a7943; Burger Leona, 2009, Br J Nurs, V18, P1116; Burns SM, 2010, J PERIANESTH NURS, V25, P286, DOI 10.1016/j.jopan.2010.07.001; BUSH HL, 1995, J VASC SURG, V21, P392, DOI 10.1016/S0741-5214(95)70281-4; Forbes SS, 2008, J AM COLL SURGEONS, V207, P336, DOI 10.1016/j.jamcollsurg.2008.03.014; Forbes SS, 2009, J AM COLL SURGEONS, V209, P492, DOI 10.1016/j.jamcollsurg.2009.07.002; Frank SM, 1997, JAMA-J AM MED ASSOC, V277, P1127, DOI 10.1001/jama.277.14.1127; FRANK SM, 1993, ANESTHESIOLOGY, V78, P468, DOI 10.1097/00000542-199303000-00010; Guest James D, 2004, Spine J, V4, P130, DOI 10.1016/j.spinee.2003.08.027; Han SB, 2014, TRANSPL P, V46, P705, DOI 10.1016/j.transproceed.2013.11.091; Hedrick TL, 2007, J AM COLL SURGEONS, V205, P432, DOI 10.1016/j.jamcollsurg.2007.04.042; HEIER T, 1991, ANESTHESIOLOGY, V74, P815, DOI 10.1097/00000542-199105000-00003; Jeyadoss J, 2013, ANAESTH INTENS CARE, V41, P759, DOI 10.1177/0310057X1304100611; JORIS J, 1994, ANESTHESIOLOGY, V80, P268, DOI 10.1097/00000542-199402000-00006; Karalapillai D, 2009, ANAESTHESIA, V64, P968, DOI 10.1111/j.1365-2044.2009.05989.x; Kongsayreepong S, 2003, ANESTH ANALG, V96, P826, DOI 10.1213/01.ANE.0000048822.27698.28; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Leijtens B, 2013, J ARTHROPLASTY, V28, P895, DOI 10.1016/j.arth.2012.10.006; Leslie Kate, 2003, Best Pract Res Clin Anaesthesiol, V17, P485, DOI 10.1016/S1521-6896(03)00049-1; Long KC, 2013, GYNECOL ONCOL, V131, P525, DOI 10.1016/j.ygyno.2013.08.034; Moola S, 2011, INT J EVID-BASED HEA, V9, P337, DOI 10.1111/j.1744-1609.2011.00227.x; Ng SF, 2003, ANESTH ANALG, V96, P171, DOI 10.1097/00000539-200301000-00036; NICE, 2003, PREOP TESTS US PREOP; Oshvandi Khodayar, 2014, Iran J Nurs Midwifery Res, V19, P64; Raymond CJ, 2006, ANESTH ANALG, V103, P1605, DOI 10.1213/01.ane.0000246442.83235.dc; Schmied H, 1996, LANCET, V347, P289, DOI 10.1016/S0140-6736(96)90466-3; Sessler DI, 2000, ANESTHESIOLOGY, V92, P578, DOI 10.1097/00000542-200002000-00042; SLOTMAN GJ, 1985, AM J SURG, V149, P495, DOI 10.1016/S0002-9610(85)80046-5; Smith CE, 1998, J CLIN ANESTH, V10, P380, DOI 10.1016/S0952-8180(98)00049-X; Tander B, 2005, PEDIATR ANESTH, V15, P574, DOI 10.1111/j.1460-9592.2005.01504.x; Tappen R M, 1996, AORN J, V63, P639, DOI 10.1016/S0001-2092(06)63411-X; VAUGHAN MS, 1981, ANESTH ANALG, V60, P746; Weaver MD, 2014, PREHOSP EMERG CARE, V18, P335, DOI 10.3109/10903127.2013.864354; Winkler M, 2000, ANESTH ANALG, V91, P978, DOI 10.1097/00000539-200010000-00039	36	46	56	3	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2015	10	9							e0136136	10.1371/journal.pone.0136136	http://dx.doi.org/10.1371/journal.pone.0136136			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR0WB	26360773	gold, Green Published, Green Submitted			2023-01-03	WOS:000361043100009
J	Kim, ED; Han, SJ; Byun, YH; Yoon, SC; Choi, KS; Seong, BL; Seo, KY				Kim, Eun-Do; Han, Soo Jung; Byun, Young-Ho; Yoon, Sang Chul; Choi, Kyoung Sub; Seong, Baik Lin; Seo, Kyoung Yul			Inactivated Eyedrop Influenza Vaccine Adjuvanted with Poly( I:C) Is Safe and Effective for Inducing Protective Systemic and Mucosal Immunity	PLOS ONE			English	Article							DOUBLE-STRANDED-RNA; CROSS-PROTECTION; VIRUS INFECTION; MICE; RESPONSES; NANOPARTICLES; PROTEINS; ANTIBODY; HUMANS; ROUTE	The eye route has been evaluated as an efficient vaccine delivery routes. However, in order to induce sufficient antibody production with inactivated vaccine, testing of the safety and efficacy of the use of inactivated antigen plus adjuvant is needed. Here, we assessed various types of adjuvants in eyedrop as an anti-influenza serum and mucosal Ab production-enhancer in BALB/c mice. Among the adjuvants, poly (I:C) showed as much enhancement in antigen-specific serum IgG and mucosal IgA antibody production as cholera toxin (CT) after vaccinations with trivalent hemagglutinin-subunits or split H1N1 vaccine antigen in mice. Vaccination with split H1N1 eyedrop vaccine antigen plus poly(I:C) showed a similar or slightly lower efficacy in inducing antibody production than intranasal vaccination; the eyedrop vaccine-induced immunity was enough to protect mice from lethal homologous influenza A/California/04/09 (H1N1) virus challenge. Additionally, ocular inoculation with poly(I:C) plus vaccine antigen generated no signs of inflammation within 24 hours:no increases in the mRNA expression levels of inflammatory cytokines nor in the infiltration of mononuclear cells to administration sites. In contrast, CT administration induced increased expression of IL-6 cytokine mRNA and mononuclear cell infiltration in the conjunctiva within 24 hours of vaccination. Moreover, inoculated visualizing materials by eyedrop did not contaminate the surface of the olfactory bulb in mice; meanwhile, intranasally administered materials defiled the surface of the brain. On the basis of these findings, we propose that the use of eyedrop inactivated influenza vaccine plus poly(I:C) is a safe and effective mucosal vaccine strategy for inducing protective anti-influenza immunity.	[Kim, Eun-Do; Han, Soo Jung; Yoon, Sang Chul; Seo, Kyoung Yul] Yonsei Univ, Coll Med, Dept Ophthalmol, Eye & Ear Hosp,Severance Hosp,Inst Vis Res, Seoul, South Korea; [Kim, Eun-Do] Yonsei Univ, Brain Korea Project Med Sci 21, Seoul 120749, South Korea; [Byun, Young-Ho; Seong, Baik Lin] Yonsei Univ, Coll Med, Dept Biotechnol, Seoul, South Korea; [Choi, Kyoung Sub] Yonsei Univ, Grad Sch, Seoul 120749, South Korea; [Byun, Young-Ho; Seong, Baik Lin] Yonsei Univ, Vaccine Translat Res Ctr, Seoul 120749, South Korea; [Choi, Kyoung Sub] Ilsan Hosp, Natl Hlth Insurance Corp, Dept Ophthalmol, Gyounggi Do, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University; NHIS Ilsan Hospital	Seo, KY (corresponding author), Yonsei Univ, Coll Med, Dept Ophthalmol, Eye & Ear Hosp,Severance Hosp,Inst Vis Res, Seoul, South Korea.	seoky@yuhs.ac	Seo, Kyoung Yul/I-5484-2019	Yoon, Sangchul/0000-0003-0454-9597; Seo, Kyoung Yul/0000-0002-9855-1980	TEPIK (Transgovernmental Enterprise for Pandemic Influenza in Korea) [A103001]; Vaccine Translational Research Center by Ministry of Health & Welfare, Republic of Korea [HI13Co826]	TEPIK (Transgovernmental Enterprise for Pandemic Influenza in Korea); Vaccine Translational Research Center by Ministry of Health & Welfare, Republic of Korea	This study was supported by a grant of the TEPIK (Transgovernmental Enterprise for Pandemic Influenza in Korea) (Grant No.: A103001) and Vaccine Translational Research Center (Grant No: HI13Co826), in part of Korea Healthcare technology R&D Project by Ministry of Health & Welfare, Republic of Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Baz M, 2012, CLIN VACCINE IMMUNOL, V19, P209, DOI 10.1128/CVI.05441-11; Belshe RB, 2007, NEW ENGL J MED, V356, P685, DOI 10.1056/NEJMoa065368; Brandtzaeg P, 2004, TRENDS IMMUNOL, V25, P570, DOI 10.1016/j.it.2004.09.005; Cai QY, 2007, INVEST RADIOL, V42, P797, DOI 10.1097/RLI.0b013e31811ecdcd; Caskey M, 2011, J EXP MED, V208, P2357, DOI 10.1084/jem.20111171; CDC, INVL VACC LIV ATT VA; Centers for Disease Control and Prevention (CDC), 2012, INFL VACC LIV INTR 2; Cho HJ, 2010, VACCINE, V28, P2598, DOI 10.1016/j.vaccine.2010.01.013; Choi KS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100229; Martins RD, 2012, J CONTROL RELEASE, V162, P553, DOI 10.1016/j.jconrel.2012.07.030; Hafner AM, 2013, ADV DRUG DELIVER REV, V65, P1386, DOI 10.1016/j.addr.2013.05.013; Hikono H, 2013, VET IMMUNOL IMMUNOP, V151, P83, DOI 10.1016/j.vetimm.2012.10.005; Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213; Ichinohe T, 2005, J VIROL, V79, P2910, DOI 10.1128/JVI.79.5.2910-2919.2005; Ichinohe T, 2007, J INFECT DIS, V196, P1313, DOI 10.1086/521304; Jang YH, 2014, VACCINE, V32, P535, DOI 10.1016/j.vaccine.2013.12.002; Jansson B, 2004, THESIS FACULTY PHARM, P305; Kaufman DR, 2008, J IMMUNOL, V181, P4188, DOI 10.4049/jimmunol.181.6.4188; KRISTENSSON K, 1971, ACTA NEUROPATHOL, V19, P145, DOI 10.1007/BF00688493; LIEW FY, 1984, EUR J IMMUNOL, V14, P350, DOI 10.1002/eji.1830140414; Malik B, 2014, INT IMMUNOPHARMACOL, V19, P17, DOI 10.1016/j.intimp.2013.12.023; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; Miyaki C, 2010, VACCINE, V28, P2505, DOI 10.1016/j.vaccine.2010.01.044; Mo JS, 2001, EUR J IMMUNOL, V31, P3806, DOI 10.1002/1521-4141(200112)31:12<3806::AID-IMMU3806>3.0.CO;2-M; Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595; Nagatake T, 2009, J EXP MED, V206, P2351, DOI 10.1084/jem.20091436; NISBET AD, 1981, EUR J BIOCHEM, V115, P335, DOI 10.1111/j.1432-1033.1981.tb05243.x; Okada H, 2011, J CLIN ONCOL, V29, P330, DOI 10.1200/JCO.2010.30.7744; Okada K, 2011, ADV OTO-RHINO-LARYNG, V72, P31, DOI 10.1159/000324591; Pedersen GK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026973; Quintilio W, 2009, VACCINE, V27, P4219, DOI 10.1016/j.vaccine.2009.04.047; Rosenfeld MR, 2010, NEURO-ONCOLOGY, V12, P1071, DOI 10.1093/neuonc/noq071; Seo KY, 2010, J IMMUNOL, V185, P3610, DOI 10.4049/jimmunol.1000680; Sircar P, 2013, MUCOSAL IMMUNOL, V6, P93, DOI 10.1038/mi.2012.52; Song JH, 2008, P NATL ACAD SCI USA, V105, P1644, DOI 10.1073/pnas.0708684105; Stahl-Hennig C, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000373; Steven P, 2008, INVEST OPHTH VIS SCI, V49, P1512, DOI 10.1167/iovs.07-0809; Tamura S, 2010, JPN J INFECT DIS, V63, P8; UNDERDOWN BJ, 1986, ANNU REV IMMUNOL, V4, P389, DOI 10.1146/annurev.iy.04.040186.002133; van Ginkel FW, 2000, J IMMUNOL, V165, P4778, DOI 10.4049/jimmunol.165.9.4778; Veglia F, 2011, INFECT IMMUN, V79, P1300, DOI 10.1128/IAI.01181-10	42	18	20	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2015	10	9							e0137608	10.1371/journal.pone.0137608	http://dx.doi.org/10.1371/journal.pone.0137608			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ9WL	26355295	gold, Green Published, Green Submitted			2023-01-03	WOS:000360965800070
J	Kong, LN; Guo, Y; Qin, B; Peng, X; Zhu, WF				Kong, Ling-Na; Guo, Ying; Qin, Bo; Peng, Xin; Zhu, Wen-Fen			Development of Self-Management Indicators for Chronic Hepatitis B Patients on Antiviral Therapy: Results of a Chinese Delphi Panel Survey	PLOS ONE			English	Article							VIRUS INFECTION; DISEASE; INSTRUMENT; ADHERENCE; HISTORY; PEOPLE	Objective This study aimed to develop a set of indicators that could be used to measure and monitor the self-management performance for chronic hepatitis B (CHB) patients on antiviral therapy in China. Methods A two-round Delphi study via e-mail correspondence was conducted, with a group of 30 Chinese experts. The Delphi questionnaire consisted of 53 indicators identified from a literature review. Experts rated and scored the importance of indicators on a five-point Likert scale. Consensus was considered to be reached if a median score in the top tertile (4-5) and >= 80% of panel ratings in the top tertile (4-5) after Round 2. The included indicators were validated with a group of 106 CHB patients. Results The response rates for the first and second rounds were 90.9% (n=30) and 86.7% (n=26), respectively. Three new indicators were suggested in the first round. 55 indicators were included in the second round after modified. 45 (81.8%) indicators achieved on the level of consensus, all of which had an inter-quartile range of 1 or below. The final set included 4 domains and 45 indicators which were well accepted and understandable by CHB patients. Conclusion This Delphi study produced a set of 45 self-management indicators for CHB patients on antiviral therapy in China. These indicators could be used to measure and monitor the patients' self-management performance, with the goal of improving the quality of life in this population.	[Kong, Ling-Na; Qin, Bo] Chongqing Univ, Dept Infect Dis, Affiliated Hosp Chongqing Med 1, Chongqing 630044, Peoples R China; [Kong, Ling-Na; Zhu, Wen-Fen] Chongqing Med Univ, Coll Nursing, Chongqing, Peoples R China; [Guo, Ying] Harbin Med Univ, Dept Internal Med, Outpatient Dept, Affiliated Hosp 2, Harbin, Peoples R China; [Peng, Xin] Jilin Univ, Sch Nursing, Changchun 130023, Peoples R China	Chongqing University; Chongqing Medical University; Harbin Medical University; Jilin University	Qin, B (corresponding author), Chongqing Univ, Dept Infect Dis, Affiliated Hosp Chongqing Med 1, Chongqing 630044, Peoples R China.	cqqinbo@126.com						Aronson BD, 2012, AM J PHARM EDUC, V76, DOI 10.5688/ajpe767125; Barlow J, 2002, PATIENT EDUC COUNS, V48, P177, DOI 10.1016/S0738-3991(02)00032-0; Bonner JE, 2012, J VIRAL HEPATITIS, V19, P316, DOI 10.1111/j.1365-2893.2011.01550.x; Cai SF, 2012, CHI MOD MED, V19, P144; Chen KH, 2008, J ADV NURS, V64, P595, DOI 10.1111/j.1365-2648.2008.04821.x; Cooke GS, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b5429; Corbin J. S A, 1988, UNENDING WORK AND CA; Dalkey NC, 1969, THE DELPHI METHOD AN; Deane KHO, 2003, BRIT J OCCUPATIONAL, V66, P247, DOI DOI 10.1177/030802260306600603; Foundation DH, 2009, CHRONIC HEPATITIS B; Fry M, 2012, PSYCHOL HEALTH, V27, P460, DOI 10.1080/08870446.2011.592982; Fung J, 2011, J ANTIMICROB CHEMOTH, V66, P2715, DOI 10.1093/jac/dkr388; Ganem D, 2004, NEW ENGL J MED, V350, P1118, DOI 10.1056/NEJMra031087; Giang L, 2012, WORLD J HEPATOL, V4, P43, DOI 10.4254/wjh.v4.i2.43; Groessl EJ, 2011, J VIRAL HEPATITIS, V18, P358, DOI 10.1111/j.1365-2893.2010.01328.x; Groessl EJ, 2008, J GEN INTERN MED, V23, P1959, DOI 10.1007/s11606-008-0790-y; Kamezaki H, 2013, INT J MED SCI, V10, P567, DOI 10.7150/ijms.5795; Kleynen M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100227; Li H, 2014, INT J NURS STUD, V51, P208, DOI 10.1016/j.ijnurstu.2013.05.012; Li HX, 2008, CHIN J PRACL NURS, V24, P43; Liaw YF, 2012, HEPATOL INT, V6, P531, DOI 10.1007/s12072-012-9365-4; Lin CW, 2013, J HEPATOL, V58, P730, DOI 10.1016/j.jhep.2012.11.045; Lin CC, 2008, RES NURS HEALTH, V31, P370, DOI 10.1002/nur.20258; Lorig KR, 2003, ANN BEHAV MED, V26, P1, DOI 10.1207/S15324796ABM2601_01; Lu FM, 2009, CHINESE MED J-PEKING, V122, P3, DOI 10.3760/cma.j.issn.0366-6999.2009.01.001; Maarsingh OR, 2009, BMC FAM PRACT, V10, DOI 10.1186/1471-2296-10-12; McGinn CA, 2012, BMC MED INFORM DECIS, V12, DOI 10.1186/1472-6947-12-105; Palter VN, 2011, AM J SURG, V201, P251, DOI 10.1016/j.amjsurg.2010.01.031; Petersen J, 2012, EXPERT REV GASTROENT, V6, P683, DOI [10.1586/egh.12.52, 10.1586/EGH.12.52]; Powell C, 2003, J ADV NURS, V41, P376, DOI 10.1046/j.1365-2648.2003.02537.x; Shen J, 2012, CHIN NURS SCI, V26, P1963; Shepard CW, 2006, EPIDEMIOL REV, V28, P112, DOI 10.1093/epirev/mxj009; Stevens Bonnie, 2006, BMC Pediatr, V6, P1, DOI 10.1186/1471-2431-6-1; Stoller EP, 2009, AM J HEALTH BEHAV, V33, P376, DOI 10.5993/AJHB.33.4.4; Tolsgaard MG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057687; Xu W., 2011, J NURS SCI, V26, P38; YANG J, 2013, J APPL MATH, DOI DOI 10.1155/2013/; Yang YF, 2009, NURS J CHIN PLA, V26, P27; Zhang CH, 2013, RESP CARE, V58, P1931, DOI 10.4187/respcare.02269; Zhao X, 2013, PHYSIOLOGICAL AND SU	40	13	13	2	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2015	10	9							e0134125	10.1371/journal.pone.0134125	http://dx.doi.org/10.1371/journal.pone.0134125			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CQ2NK	26327606	Green Submitted, Green Published, gold			2023-01-03	WOS:000360437700010
J	Rousseau, E; Joubert, M; Trzepla, G; Parienti, JJ; Freret, T; Vanthygem, MC; Desailloud, R; Lefebvre, H; Coquerel, A; Reznik, Y				Rousseau, Elise; Joubert, Michael; Trzepla, Geraldine; Parienti, Jean Jacques; Freret, Thomas; Vanthygem, Marie Christine; Desailloud, Rachel; Lefebvre, Herve; Coquerel, Antoine; Reznik, Yves		PHAD Study Grp	Usefulness of Time-Point Serum Cortisol and ACTH Measurements for the Adjustment of Glucocorticoid Replacement in Adrenal Insufficiency	PLOS ONE			English	Article							MODIFIED-RELEASE HYDROCORTISONE; SUBJECTIVE HEALTH-STATUS; BONE-MINERAL DENSITY; QUALITY-OF-LIFE; ADDISONS-DISEASE; PRODUCTION-RATES; PLASMA ACTH; THERAPY; SUBSTITUTION; MEN	Background Adjustment of daily hydrocortisone dose on clinical criteria lacks sensitivity for fine tuning. Long term hydrocortisone (HC) over-replacement may lead to increased morbidity and mortality in patients with adrenal insufficiency (AI). Biochemical criteria may help detecting over-or under-replacement but have been poorly evaluated. Methods Multicenter, institutional, pharmacokinetic study on ACTH and cortisol plasma profiles during HC replacement in 27 AI patients compared to 29 matched controls. All AI patients were administered HC thrice daily at doses of 6, 10 and 14 mg/m(2)/d. Blood samples were drawn hourly from 0800h to 1900h. The main outcome measures were: i) plasma peak cortisol and cortisol area under the curve (AUC) in AI patients compared to controls, ii) correlations between cortisol AUC vs single-point cortisol or ACTH decrease from baseline (Delta ACTH) and iii) the predictive value of the two latters for obtaining AI patients' cortisol AUC in the control range. Results Cortisol peaks were observed 1h after each HC intake and a dose response was demonstrated for cortisol peak and cortisol AUC. The comparison of AI patients' cortisol AUC to controls showed that 81.5% AI patients receiving 6mg/m(2)/d were adequately replaced, whereas most patients receiving higher doses were over-replaced. The correlation coefficient between 1000h/1400h cortisol concentrations and 0800-1900h cortisol AUC were 0.93/0.88 respectively, whereas the 0800-1200h Delta ACTH fairly correlated with 0800-1900h cortisol AUC (R = 0.57). ROC curve analysis indicated that the 1000h and 1400h cortisol concentrations best predicted over-replacement. Conclusions Patients receiving a 6mg/m(2) hydrocortisone daily dose exhibited the most physiological daytime cortisol profile. Single point plasma cortisol correlated with daytime cortisol AUC in AI patients. Although hydrocortisone dose should be currently determined on clinical grounds, our data suggest that single point plasma cortisol may be an adjunct for further hydrocortisone dose adjustment in AI patients.	[Rousseau, Elise; Joubert, Michael; Trzepla, Geraldine; Reznik, Yves] Caen Univ Hosp, Dept Endocrinol, F-14033 Caen, France; [Parienti, Jean Jacques] Caen Univ Hosp, Dept Clin Res, F-14033 Caen, France; [Freret, Thomas] Univ Caen Basse Normandie, UFR Sci Pharmaceut, EA4259, F-14032 Caen, France; [Vanthygem, Marie Christine] Lille Univ Hosp, Dept Endocrinol, F-59037 Lille, France; [Desailloud, Rachel] Hop SUD, Amiens Univ Hosp, Dept Endocrinol, F-80054 Amiens, France; [Lefebvre, Herve] Rouen Univ Hosp, Dept Endocrinol, F-76031 Rouen, France; [Lefebvre, Herve] Rouen Univ Hosp, INSERM, U413, IFRMP23, F-76031 Rouen, France; [Coquerel, Antoine] Caen Univ Hosp, Dept Pharmacol, F-14033 Caen, France; [Parienti, Jean Jacques; Freret, Thomas; Coquerel, Antoine; Reznik, Yves] Univ Caen Basse Normandie, Sch Med, F-14032 Caen, France	CHU de Caen NORMANDIE; Universite de Caen Normandie; CHU de Caen NORMANDIE; Universite de Caen Normandie; Universite de Caen Normandie; Universite de Lille - ISITE; CHU Lille; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; CHU de Rouen; CHU de Rouen; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Caen NORMANDIE; Universite de Caen Normandie; Universite de Caen Normandie; Universite de Franche-Comte	Reznik, Y (corresponding author), Caen Univ Hosp, Dept Endocrinol, F-14033 Caen, France.	reznik-y@chu-caen.fr	freret, thomas/AAA-2491-2019; Parienti, Jean-Jacques/AAD-1701-2021; Vantyghem, Marie-Christine/P-2939-2017; freret, thomas/B-2068-2012	freret, thomas/0000-0002-4446-4451; Parienti, Jean-Jacques/0000-0002-4774-5590; Vantyghem, Marie-Christine/0000-0002-9369-0463; freret, thomas/0000-0002-4446-4451; Lefebvre, Herve/0000-0002-6181-9648	Programme Hospitalier de Recherche Clinique, EudraCT [2007-005170-30]	Programme Hospitalier de Recherche Clinique, EudraCT	This study was supported by a grant from the Programme Hospitalier de Recherche Clinique 2007, EudraCT number 2007-005170-30.	AANDERUD S, 1982, ACTA ENDOCRINOL-COP, V100, P588, DOI 10.1530/acta.0.1000588; Arlt W, 2006, CLIN ENDOCRINOL, V64, P384, DOI 10.1111/j.1365-2265.2006.02473.x; Arlt W, 2003, LANCET, V361, P1881, DOI 10.1016/S0140-6736(03)13492-7; Behan LA, 2014, EUR J ENDOCRINOL, V170, P141, DOI 10.1530/EJE-13-0596; Bergthorsdottir R, 2006, J CLIN ENDOCR METAB, V91, P4849, DOI 10.1210/jc.2006-0076; Bliesener N, 2003, EXP CLIN ENDOCR DIAB, V111, P443, DOI 10.1055/s-2003-44292; Crown A, 2005, CLIN ENDOCRINOL, V63, P483, DOI 10.1111/j.1365-2265.2005.02320.x; Debono M, 2009, J CLIN ENDOCR METAB, V94, P1548, DOI 10.1210/jc.2008-2380; DERENDORF H, 1991, J CLIN PHARMACOL, V31, P473, DOI 10.1002/j.1552-4604.1991.tb01906.x; ESTEBAN NV, 1990, STEROIDS, V55, P152, DOI 10.1016/0039-128X(90)90103-I; FEEK CM, 1981, CLIN ENDOCRINOL, V14, P451, DOI 10.1111/j.1365-2265.1981.tb00634.x; GROVES RW, 1988, J ROY SOC MED, V81, P514, DOI 10.1177/014107688808100906; Hahner S, 2007, J CLIN ENDOCR METAB, V92, P3912, DOI 10.1210/jc.2007-0685; Howlett TA, 1997, CLIN ENDOCRINOL, V46, P263, DOI 10.1046/j.1365-2265.1997.1340955.x; Husebye ES, 2014, J INTERN MED, V275, P104, DOI 10.1111/joim.12162; Jodar E, 2003, CLIN ENDOCRINOL, V58, P617, DOI 10.1046/j.1365-2265.2003.01761.x; Johannsson G, 2007, HORM RES, V68, P182, DOI 10.1159/000110621; Kraan GPB, 1998, J CLIN ENDOCR METAB, V83, P1247, DOI 10.1210/jc.83.4.1247; Lovas K, 2006, J ENDOCRINOL INVEST, V29, P727, DOI 10.1007/BF03344183; Lovas K, 2002, CLIN ENDOCRINOL, V56, P581, DOI 10.1046/j.1365-2265.2002.01466.x; Mah PM, 2004, CLIN ENDOCRINOL, V61, P367, DOI 10.1111/j.1365-2265.2004.02106.x; Newell-Price J, 2008, CLIN ENDOCRINOL, V68, P130, DOI 10.1111/j.1365-2265.2007.03011.x; Peacey SR, 1997, CLIN ENDOCRINOL, V46, P255, DOI 10.1046/j.1365-2265.1997.780907.x; PEHUETFIGONI M, 1989, ANN ENDOCRINOL-PARIS, V50, P54; Purnell JQ, 2004, J CLIN ENDOCR METAB, V89, P281, DOI 10.1210/jc.2003-030440; Ragnarsson O, 2014, EUR J ENDOCRINOL, V171, P571, DOI 10.1530/EJE-14-0397; SCOTT RS, 1978, CLIN ENDOCRINOL, V9, P571, DOI 10.1111/j.1365-2265.1978.tb01516.x; Simon N, 2010, CLIN PHARMACOKINET, V49, P455, DOI 10.2165/11531290-000000000-00000; VALERO MA, 1994, BONE MINER, V26, P9, DOI 10.1016/S0169-6009(08)80158-4; Wichers M, 1999, CLIN ENDOCRINOL, V50, P759, DOI 10.1046/j.1365-2265.1999.00723.x; ZELISSEN PMJ, 1994, ANN INTERN MED, V120, P207, DOI 10.7326/0003-4819-120-3-199402010-00005; Zueger T, 2012, J CLIN ENDOCR METAB, V97, pE1938, DOI 10.1210/jc.2012-2432	32	15	15	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2015	10	8							e0135975	10.1371/journal.pone.0135975	http://dx.doi.org/10.1371/journal.pone.0135975			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ0PO	26317782	gold, Green Published, Green Submitted			2023-01-03	WOS:000360299100055
J	Moore, SE; Decker, A; Hubbard, A; Callcut, RA; Fox, EE; del Junco, DJ; Holcomb, JB; Rahbar, MH; Wade, CE; Schreiber, MA; Alarcon, LH; Brasel, KJ; Bulger, EM; Cotton, BA; Muskat, P; Myers, JG; Phelan, HA; Cohen, MJ				Moore, Sara E.; Decker, Anna; Hubbard, Alan; Callcut, Rachael A.; Fox, Erin E.; del Junco, Deborah J.; Holcomb, John B.; Rahbar, Mohammad H.; Wade, Charles E.; Schreiber, Martin A.; Alarcon, Louis H.; Brasel, Karen J.; Bulger, Eileen M.; Cotton, Bryan A.; Muskat, Peter; Myers, John G.; Phelan, Herb A.; Cohen, Mitchell J.		PROMMTT Study Grp	Statistical Machines for Trauma Hospital Outcomes Research: Application to the PRospective, Observational, Multi-Center Major Trauma Transfusion (PROMMTT) Study	PLOS ONE			English	Article							MASSIVE TRANSFUSION; PROPENSITY SCORE; MORTALITY; BENEFITS; TRIGGERS	Improving the treatment of trauma, a leading cause of death worldwide, is of great clinical and public health interest. This analysis introduces flexible statistical methods for estimating center-level effects on individual outcomes in the context of highly variable patient populations, such as those of the PRospective, Observational, Multi-center Major Trauma Transfusion study. Ten US level I trauma centers enrolled a total of 1,245 trauma patients who survived at least 30 minutes after admission and received at least one unit of red blood cells. Outcomes included death, multiple organ failure, substantial bleeding, and transfusion of blood products. The centers involved were classified as either large or small-volume based on the number of massive transfusion patients enrolled during the study period. We focused on estimation of parameters inspired by causal inference, specifically estimated impacts on patient outcomes related to the volume of the trauma hospital that treated them. We defined this association as the change in mean outcomes of interest that would be observed if, contrary to fact, subjects from large-volume sites were treated at small-volume sites (the effect of treatment among the treated). We estimated this parameter using three different methods, some of which use data-adaptive machine learning tools to derive the outcome models, minimizing residual confounding by reducing model misspecification. Differences between unadjusted and adjusted estimators sometimes differed dramatically, demonstrating the need to account for differences in patient characteristics in clinic comparisons. In addition, the estimators based on robust adjustment methods showed potential impacts of hospital volume. For instance, we estimated a survival benefit for patients who were treated at large-volume sites, which was not apparent in simpler, unadjusted comparisons. By removing arbitrary modeling decisions from the estimation process and concentrating on parameters that have more direct policy implications, these potentially automated approaches allow methodological standardization across similar comparativeness effectiveness studies.	[Moore, Sara E.; Decker, Anna; Hubbard, Alan] Univ Calif Berkeley, Div Biostat, Berkeley, CA 94720 USA; [Callcut, Rachael A.; Cohen, Mitchell J.] Univ Calif San Francisco, Sch Med, Dept Surg, Div Gen Surg, San Francisco, CA 94143 USA; [Fox, Erin E.; del Junco, Deborah J.; Holcomb, John B.; Wade, Charles E.; Cotton, Bryan A.] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res, Div Acute Care Surg, Dept Surg,Med Sch, Houston, TX 77030 USA; [Rahbar, Mohammad H.] Univ Texas Hlth Sci Ctr Houston, Div Clin & Translat Sci, Dept Internal Med, Sch Med, Houston, TX 77030 USA; [Schreiber, Martin A.] Oregon Hlth & Sci Univ, Sch Med, Div Trauma Crit Care & Acute Care Surg, Portland, OR 97201 USA; [Alarcon, Louis H.] Univ Pittsburgh, Sch Med, Dept Surg, Div Trauma & Gen Surg, Pittsburgh, PA USA; [Brasel, Karen J.] Med Coll Wisconsin, Dept Surg, Div Trauma & Crit Care, Milwaukee, WI 53226 USA; [Bulger, Eileen M.] Univ Washington, Sch Med, Dept Surg, Div Trauma & Crit Care, Seattle, WA 98195 USA; [Muskat, Peter] Univ Cincinnati, Coll Med, Dept Surg, Div Trauma Crit Care, Cincinnati, OH USA; [Myers, John G.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, Dept Surg, Div Trauma, San Antonio, TX 78229 USA; [Phelan, Herb A.] Univ Texas SW Med Ctr Dallas, Div Burn Trauma Crit Care, Dept Surg, Sch Med, Dallas, TX 75390 USA	University of California System; University of California Berkeley; University of California System; University of California San Francisco; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; Oregon Health & Science University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Medical College of Wisconsin; University of Washington; University of Washington Seattle; University System of Ohio; University of Cincinnati; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Southwestern Medical Center Dallas	Hubbard, A (corresponding author), Univ Calif Berkeley, Div Biostat, Berkeley, CA 94720 USA.	hubbard@berkeley.edu; Mohammad.H.Rahbar@uth.tmc.edu	Callcut, Rachael/ABE-1484-2021	holcomb, john/0000-0001-8312-9157	United States Army Medical Research and Materiel Command [W81XWH-08-C-0712]; National Institutes of Health [UL1 RR024148]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024148] Funding Source: NIH RePORTER	United States Army Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	MHR obtained an United States Army Medical Research and Materiel Command (http://mrmc.amedd.army.mil/) subcontract W81XWH-08-C-0712. Infrastructure for the Data Coordinating Center was supported by Clinical and Translational Science Award (https://www.ctsacentral.org/) funds from National Institutes of Health (http://www.nih.gov/) grant UL1 RR024148. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Callcut RA, 2013, J TRAUMA ACUTE CARE, V74, P59, DOI 10.1097/TA.0b013e3182788b34; Callcut RA, 2011, J TRAUMA, V70, P794, DOI 10.1097/TA.0b013e3182127e40; Centers for Disease Control and Prevention, 2010, LEAD CAUS DEATH; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Efron B., 1993, INTRO BOOTSTRAP, DOI [10.1007/978-1-4899-4541-9, DOI 10.1111/1467-9639.00050]; Freedman DA, 2006, AM STAT, V60, P299, DOI 10.1198/000313006X152207; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; Hurtuk M, 2006, J TRAUMA, V61, P243, DOI 10.1097/01.ta.0000231353.06095.8d; Ihaka R., 1996, J COMPUT GRAPH STAT, V5, P299, DOI [DOI 10.1080/10618600.1996.10474713, 10.2307/1390807]; Malone DL, 2006, J TRAUMA, V60, pS91, DOI 10.1097/01.ta.0000199549.80731.e6; Norton R, 2013, NEW ENGL J MED, V368, P1723, DOI 10.1056/NEJMra1109343; Nunez TC, 2009, J TRAUMA, V66, P346, DOI 10.1097/TA.0b013e3181961c35; PHILLIPS GR, 1994, POSTGRAD MED, V95, P61; Polley E, 2012, SUPERLEARNER SUPER L; ROBINS J, 1986, MATH MODELLING, V7, P1393, DOI 10.1016/0270-0255(86)90088-6; Rogers FB, 1997, ARCH SURG-CHICAGO, V132, P376; Rose S, 2011, SPRINGER SER STAT, P3, DOI 10.1007/978-1-4419-9782-1; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; RUBIN DB, 1974, J EDUC PSYCHOL, V66, P688, DOI 10.1037/h0037350; Sekhon JS, 2011, J STAT SOFTW, V42, P1; van der Laan MJ, 2007, STAT APPL GENET MOL, V6, DOI 10.2202/1544-6115.1309; van der Laan MJ, 2010, INT J BIOSTAT, V6, DOI [10.2202/1557-4679.1181, 10.2202/1557-4679.1260]	22	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2015	10	8							e0136438	10.1371/journal.pone.0136438	http://dx.doi.org/10.1371/journal.pone.0136438			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP5MR	26296088	Green Accepted, Green Published, Green Submitted, gold			2023-01-03	WOS:000359926900113
J	Huang, G; Mouraux, A				Huang, Gan; Mouraux, Andre			MEP Latencies Predict the Neuromodulatory Effect of cTBS Delivered to the Ipsilateral and Contralateral Sensorimotor Cortex	PLOS ONE			English	Article							THETA-BURST-STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; PRIMARY MOTOR CORTEX; CORTICAL EXCITABILITY; EVOKED-POTENTIALS; TMS; RTMS; PLASTICITY; EEG; REPRODUCIBILITY	Background Recently, it was shown that the highly variable after-effect of continuous theta-burst stimulation (cTBS) of the primary motor cortex (M1) can be predicted by the latency of motorevoked potentials (MEPs) recorded before cTBS. This suggests that at least part of this inter-individual variability is driven by differences in the neuronal populations preferentially activated by transcranial magnetic stimulation (TMS). Methods Here, we recorded MEPs, TMS-evoked brain potentials (TEPs) and somatosensory-evoked potentials (SEPs) to investigate the effects of cTBS delivered over the primary sensorimotor cortex on both the ipsilateral and contralateral M1, and the ipsilateral and contralateral primary somatosensory cortex (S1). Results We confirm that the after-effects of cTBS can be predicted by the latency of MEPs recorded before cTBS. Over the hemisphere onto which cTBS was delivered, short-latency MEPs at baseline were associated with an increase of MEP magnitude (i.e. an excitatory effect of cTBS) whereas late-latency MEPs were associated with reduced MEPs (i.e. an inhibitory effect of cTBS). This relationship was reversed over the contralateral hemisphere, indicating opposite effects of cTBS on the responsiveness of the ipsilateral and contralateral M1. Baseline MEP latencies also predicted changes in the magnitude of the N100 wave of TEPs elicited by stimulation of the ipsilateral and contralateral hemisphere, indicating that this TEP component is specifically dependent on the state of M1. Finally, there was a reverse relationship between MEP latency and the effects of cTBS on the SEP waveforms (50-130 ms), indicating that after-effects of cTBS on S1 are opposite to those on M1. Conclusion Taken together, our results confirm that the variable after-effects of cTBS can be explained by differences in the neuronal populations activated by TMS. Furthermore, our results show that this variability also determines remote effects of cTBS in S1 and the contralateral hemisphere, compatible with inter-hemispheric and sensorimotor interactions.	[Huang, Gan; Mouraux, Andre] Catholic Univ Louvain, Inst Neurosci IoNS, B-1200 Brussels, Belgium	Universite Catholique Louvain	Huang, G (corresponding author), Catholic Univ Louvain, Inst Neurosci IoNS, B-1200 Brussels, Belgium.	gan.huang@uclouvain.be	Mouraux, Andre/F-3724-2012	Mouraux, Andre/0000-0003-1056-5980	Belgian National Foundation for Scientific Research (Mandat d'impulsion scientifique FNRS) [14613969]; ERC Starting Grant [PROBING-PAIN 336130]	Belgian National Foundation for Scientific Research (Mandat d'impulsion scientifique FNRS)(Fonds de la Recherche Scientifique - FNRS); ERC Starting Grant(European Research Council (ERC))	GH and AM received support from the Belgian National Foundation for Scientific Research (Mandat d'impulsion scientifique FNRS 14613969). AM received support from an ERC Starting Grant (PROBING-PAIN 336130).	Blankenburg F, 2008, J NEUROSCI, V28, P13202, DOI 10.1523/JNEUROSCI.3043-08.2008; Bonato C, 2006, CLIN NEUROPHYSIOL, V117, P1699, DOI 10.1016/j.clinph.2006.05.006; BUCHNER H, 1995, EXP BRAIN RES, V104, P511; Di Lazzaro V, 2008, J PHYSIOL-LONDON, V586, P3871, DOI 10.1113/jphysiol.2008.152736; Di Lazzaro V, 2008, CLIN NEUROPHYSIOL, V119, P715, DOI 10.1016/j.clinph.2007.11.049; Di Lazzaro V, 2005, J PHYSIOL-LONDON, V565, P945, DOI 10.1113/jphysiol.2005.087288; Di Lazzaro V, 2011, J NEUROPHYSIOL, V105, P2150, DOI 10.1152/jn.00781.2010; Di Lazzaro V, 2008, BRAIN STIMUL, V1, P345, DOI 10.1016/j.brs.2008.07.004; Duque J, 2012, J NEUROSCI, V32, P806, DOI 10.1523/JNEUROSCI.4299-12.2012; Fitzgerald PB, 2006, CLIN NEUROPHYSIOL, V117, P2584, DOI 10.1016/j.clinph.2006.06.712; Fox P, 1997, NEUROREPORT, V8, P2787, DOI 10.1097/00001756-199708180-00027; Gilio F, 2003, J PHYSIOL-LONDON, V551, P563, DOI 10.1113/jphysiol.2003.044313; Goldsworthy M, 2002, CLIN NEURIPHYSIOL, V123, P2256; Hamada M, 2013, CEREB CORTEX, V23, P1593, DOI 10.1093/cercor/bhs147; Hinder MR, 2014, BRAIN STIMUL, V7, P365, DOI 10.1016/j.brs.2014.01.004; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Ishikawa S, 2007, CLIN NEUROPHYSIOL, V118, P1033, DOI 10.1016/j.clinph.2007.02.003; Katayama T, 2010, CLIN NEUROPHYSIOL, V121, P2097, DOI 10.1016/j.clinph.2010.05.014; Komssi S, 2004, HUM BRAIN MAPP, V21, P154, DOI 10.1002/hbm.10159; Komssi S, 2002, CLIN NEUROPHYSIOL, V113, P175, DOI 10.1016/S1388-2457(01)00721-0; Lefaucheur JP, 2014, CLIN NEUROPHYSIOL, V125, P2150, DOI 10.1016/j.clinph.2014.05.021; Lioumis P, 2009, HUM BRAIN MAPP, V30, P1387, DOI 10.1002/hbm.20608; Lopez-Alonso V, 2014, BRAIN STIMUL, V7, P372, DOI 10.1016/j.brs.2014.02.004; Nikouline V, 1999, CLIN NEUROPHYSIOL, V110, P1325, DOI 10.1016/S1388-2457(99)00070-X; Paus T, 2001, J NEUROPHYSIOL, V86, P1983, DOI 10.1152/jn.2001.86.4.1983; Perez MA, 2009, J PHYSIOL-LONDON, V587, P725, DOI 10.1113/jphysiol.2008.166926; Plewnia C, 2003, NEUROREPORT, V14, P609, DOI 10.1097/00001756-200303240-00017; Rocco MM, 2007, J NEUROSCI METH, V162, P139, DOI 10.1016/j.jneumeth.2007.01.002; Rogasch NC, 2013, BRAIN STIMUL, V6, P868, DOI 10.1016/j.brs.2013.04.004; Sekiguchi H, 2011, CLIN NEUROPHYSIOL, V122, P984, DOI 10.1016/j.clinph.2010.09.004; Sommer M, 2006, CLIN NEUROPHYSIOL, V117, P838, DOI 10.1016/j.clinph.2005.10.029; Stefan K, 2008, NEUROIMAGE, V40, P265, DOI 10.1016/j.neuroimage.2007.11.037; STEIGER JH, 1980, PSYCHOL BULL, V87, P245, DOI 10.1037/0033-2909.87.2.245; Suppa A, 2008, J PHYSIOL-LONDON, V586, P4489, DOI 10.1113/jphysiol.2008.156596; Talelli P, 2007, CLIN NEUROPHYSIOL, V118, P1815, DOI 10.1016/j.clinph.2007.05.062; Tiitinen H, 1999, CLIN NEUROPHYSIOL, V110, P982, DOI 10.1016/S1388-2457(99)00038-3; Torta DME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073263; Veniero D, 2009, CLIN NEUROPHYSIOL, V120, P1392, DOI 10.1016/j.clinph.2009.04.023; Vernet M, 2014, CLIN NEUROPHYSIOL, V125, P320, DOI 10.1016/j.clinph.2013.07.004; Vernet M, 2013, EUR J NEUROSCI, V37, P598, DOI 10.1111/ejn.12069; Young-Bernier M, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00182	41	23	23	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 11	2015	10	8							e0133893	10.1371/journal.pone.0133893	http://dx.doi.org/10.1371/journal.pone.0133893			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO7PP	26263505	Green Submitted, Green Published, gold			2023-01-03	WOS:000359353300013
J	Katsuda, Y; Niwano, Y; Nakashima, T; Mokudai, T; Nakamura, K; Oizumi, S; Kanno, T; Kanetaka, H; Egusa, H				Katsuda, Yusuke; Niwano, Yoshimi; Nakashima, Takuji; Mokudai, Takayuki; Nakamura, Keisuke; Oizumi, Satomi; Kanno, Taro; Kanetaka, Hiroyasu; Egusa, Hiroshi			Cytoprotective Effects of Grape Seed Extract on Human Gingival Fibroblasts in Relation to Its Antioxidant Potential	PLOS ONE			English	Article							POLYMERIC PROCYANIDIN FRACTIONS; RAPID COLORIMETRIC ASSAY; SCAVENGING ACTIVITY; SUPEROXIDE ANIONS; HYDROGEN-PEROXIDE; OXIDATIVE DAMAGE; HERBAL EXTRACTS; SINGLET OXYGEN; CELLS; MICE	Cytoprotective effects of short-term treatment with grape seed extract (GSE) upon human gingival fibroblasts (hGFs) were evaluated in relation to its antioxidant properties and compared with those of a water-soluble analog of vitamin E: trolox (Tx). GSE and Tx showed comparable antioxidant potential in vitro against di(phenyl)-(2,4,6-trinitrophenyl) iminoazanium (DPPH; a stable radical), hydroxyl radical ((OH)-O-center dot), singlet oxygen (O-1(2)), and hydrogen peroxide (H2O2). Pretreatment or concomitant treatment with GSE for 1 min protected hGFs from oxidative stressors, including H2O2, acid-electrolyzed water (AEW), and O-1(2), and attenuated the intracellular formation of reactive oxygen species induced by H2O2 and AEW. Tx also reduced the H2O2-and AEW-induced intracellular formation of reactive oxygen species, but showed no cytoprotective effects on hGFs exposed to H2O2, AEW, or O-1(2). These results suggest that the cytoprotective effects of GSE are likely exerted independently of its antioxidant potential.	[Katsuda, Yusuke; Niwano, Yoshimi; Mokudai, Takayuki; Nakamura, Keisuke; Oizumi, Satomi; Kanno, Taro; Kanetaka, Hiroyasu; Egusa, Hiroshi] Tohoku Univ, Grad Sch Dent, Sendai, Miyagi 980, Japan; [Nakashima, Takuji] Kitasato Univ, Kiasato Inst Life Sci, Minato Ku, Tokyo, Japan	Tohoku University; Kitasato University	Niwano, Y (corresponding author), Tohoku Univ, Grad Sch Dent, Sendai, Miyagi 980, Japan.	niwano@m.tohoku.ac.jp	Nakashima, Takuji/Q-4166-2019; Niwnao, Yoshimi/Z-3593-2019; Mokudai, Takayuki/M-1029-2018; MOKUDAI, TAKAYUKI/AAK-1541-2020; Nakashima, Takuji/AAK-1075-2021; Egusa, Hiroshi/AFT-9694-2022	Mokudai, Takayuki/0000-0003-4628-6908; MOKUDAI, TAKAYUKI/0000-0003-4628-6908; Nakashima, Takuji/0000-0001-6324-0472; Egusa, Hiroshi/0000-0002-0200-8132; Kanetaka, Hiroyasu/0000-0001-7744-3879	Ministry of Education, Culture, Sports, Science and Technology Japan [26460116]	Ministry of Education, Culture, Sports, Science and Technology Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This research was supported by the Ministry of Education, Culture, Sports, Science and Technology Japan, Grant-in-Aid for Scientific Research (C), 26460116, 2014. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1970, METHODS FOOD ANAL; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; Campos J, 2014, FOOD CHEM, V151, P175, DOI 10.1016/j.foodchem.2013.11.018; Cheah KY, 2013, DIGEST DIS SCI, V58, P970, DOI 10.1007/s10620-012-2464-1; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Gertzberg N, 2004, AM J PHYSIOL-LUNG C, V286, pL37, DOI 10.1152/ajplung.00116.2003; Graves D, 2008, J PERIODONTOL, V79, P1585, DOI 10.1902/jop.2008.080183; Herath TDK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058496; Hogan S, 2011, J AGR FOOD CHEM, V59, P3035, DOI 10.1021/jf1042773; Ishiyama K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037871; JIANG ZY, 1990, FEBS LETT, V268, P69, DOI 10.1016/0014-5793(90)80974-N; Kalaiselvi P, 2013, FOOD CHEM TOXICOL, V56, P110, DOI 10.1016/j.fct.2013.01.042; Kim YS, 2013, BIOL PHARM BULL, V36, P609, DOI 10.1248/bpb.b12-00990; Kim Y, 2013, FOOD CHEM, V137, P136, DOI 10.1016/j.foodchem.2012.10.006; Kurauchi M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113403; Mokudai T, 2015, J TOXICOL SCI, V40, P13, DOI 10.2131/jts.40.13; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nakamura K, 2011, J CLIN BIOCHEM NUTR, V49, P87, DOI 10.3164/jcbn.10-125; Niwano Y, 2007, BIOSCI BIOTECH BIOCH, V71, P1145, DOI 10.1271/bbb.60593; Nuttall SL, 1998, J CLIN PHARM THER, V23, P385, DOI 10.1046/j.1365-2710.1998.00180.x; Ohyama K, 2011, ANN NUTR METAB, V58, P250, DOI 10.1159/000330444; Padilla C, 2006, J PERIODONTAL RES, V41, P350, DOI 10.1111/j.1600-0765.2006.00882.x; Park HJ, 2009, ARCH PHARM RES, V32, P583, DOI 10.1007/s12272-009-1415-7; PRIEUR C, 1994, PHYTOCHEMISTRY, V36, P781, DOI 10.1016/S0031-9422(00)89817-9; PRYOR WA, 1986, ANNU REV PHYSIOL, V48, P657, DOI 10.1146/annurev.ph.48.030186.003301; Redmond RW, 2006, PHOTOCHEM PHOTOBIOL, V82, P1178, DOI 10.1562/2006-04-14-IR-874; RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9; Rzeppa S, 2012, MOL NUTR FOOD RES, V56, P653, DOI 10.1002/mnfr.201100471; Saito K, 2008, J SCI FOOD AGR, V88, P2707, DOI 10.1002/jsfa.3397; Saito K, 2008, PLANT FOOD HUM NUTR, V63, P65, DOI 10.1007/s11130-008-0071-2; Spranger I, 2008, FOOD CHEM, V108, P519, DOI 10.1016/j.foodchem.2007.11.004; Sun Y, 2010, J PERIODONTOL, V81, P1488, DOI 10.1902/jop.2010.100004; Tada M, 2010, J CLIN BIOCHEM NUTR, V46, P224, DOI 10.3164/jcbn.09-84; Terra X, 2009, J NUTR BIOCHEM, V20, P210, DOI 10.1016/j.jnutbio.2008.02.005; Velmurugan B, 2010, NEOPLASIA, V12, P95, DOI 10.1593/neo.91718; Vislocky LM, 2010, NUTR REV, V68, P656, DOI 10.1111/j.1753-4887.2010.00335.x; Wang H, 2013, MOL NUTR FOOD RES, V57, P2253, DOI 10.1002/mnfr.201300146; Wang YH, 2011, INT IMMUNOPHARMACOL, V11, P1620, DOI 10.1016/j.intimp.2011.05.024; WATTS RWE, 1965, J LAB CLIN MED, V66, P688; Wei C, 2015, INFLAMMATION, V38, P896, DOI 10.1007/s10753-014-0051-7; Yamaguchi F, 1999, J AGR FOOD CHEM, V47, P2544, DOI 10.1021/jf9806762	41	16	16	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 10	2015	10	8							e0134704	10.1371/journal.pone.0134704	http://dx.doi.org/10.1371/journal.pone.0134704			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO7PJ	26258747	gold, Green Submitted, Green Published			2023-01-03	WOS:000359352600021
J	Miura, M; Ito, K; Hayashi, M; Nakajima, M; Tanaka, T; Ogura, S				Miura, Mai; Ito, Kensuke; Hayashi, Maiko; Nakajima, Motowo; Tanaka, Tohru; Ogura, Shun-ichiro			The Effect of 5-Aminolevulinic Acid on Cytochrome P450-Mediated Prodrug Activation	PLOS ONE			English	Article							HUMAN LIVER-MICROSOMES; ABC TRANSPORTER ABCG2; IN-VITRO; BILE-SALTS; EXPRESSION; CANCER; CYCLOPHOSPHAMIDE; 5-FLUOROURACIL; THERAPY; ROLES	Of late, numerous prodrugs are widely used for therapy. The hemeprotein cytochrome P450 (CYP) catalyzes the activation of prodrugs to form active metabolites. Therefore, the activation of CYP function might allow the use of lower doses of prodrugs and decrease toxicity. We hypothesized that the addition of 5-aminolevulinic acid (ALA), a precursor in the porphyrin biosynthetic pathway, enhances the synthesis of heme, leading to the up-regulation of CYP activity. To test this hypothesis, we treated a human gastric cancer cell line with ALA and determined the effect on CYP-dependent prodrug activation. For this purpose, we focused on the anticancer prodrug tegafur, which is converted to its active metabolite 5-fluorouracil (5-FU) mainly by CYP2A6. We show here that ALA increased CYP2A6-dependent tegafur activation, suggesting that ALA elevated CYP activity and potentiated the activation of the prodrug.	[Miura, Mai; Ito, Kensuke; Hayashi, Maiko; Ogura, Shun-ichiro] Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; [Nakajima, Motowo; Tanaka, Tohru] SBI Pharmaceut CO LTD, Minato Ku, Tokyo 1066020, Japan	Tokyo Institute of Technology; SBI Pharmaceuticals	Ogura, S (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, 4259 B47 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.	sogura@bio.titech.ac.jp			Ministry of Education, Culture, Sports, Science and Technology [26430141]; SBI Pharma CO., LTD.	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); SBI Pharma CO., LTD.	The studies in the authors' laboratories were supported by the Grant-in-Aid for Scientific Research (C) (No. 26430141) from the Ministry of Education, Culture, Sports, Science and Technology. SBI Pharma CO., LTD., provided support in the form of salaries for authors MN and TT, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the author contributions section.	Bayeva M, 2013, CIRC RES, V113, P279, DOI 10.1161/CIRCRESAHA.113.301552; Chang TKH, 1997, CANCER RES, V57, P1946; GONZALEZ FJ, 1990, TRENDS GENET, V6, P182, DOI 10.1016/0168-9525(90)90174-5; Green RM, 2000, GENE, V241, P117, DOI 10.1016/S0378-1119(99)00460-6; Hagiya Y, 2013, PHOTODIAGN PHOTODYN, V10, P288, DOI 10.1016/j.pdpdt.2013.02.001; Hagiya Y, 2012, PHOTODIAGN PHOTODYN, V9, P204, DOI 10.1016/j.pdpdt.2011.12.004; Hagiya Yuichiro, 2008, J Exp Ther Oncol, V7, P153; Hagmann Wolfgang, 2010, Cancers (Basel), V3, P106, DOI 10.3390/cancers3010106; HENDRY GAF, 1980, J MED GENET, V17, P1, DOI 10.1136/jmg.17.1.1; Hirohashi T, 2000, J BIOL CHEM, V275, P2905, DOI 10.1074/jbc.275.4.2905; Hlavata I, 2012, MUTAGENESIS, V27, P187, DOI 10.1093/mutage/ger075; Ikeda K, 2000, CLIN CANCER RES, V6, P4409; Ishizuka M, 2011, INT IMMUNOPHARMACOL, V11, P358, DOI 10.1016/j.intimp.2010.11.029; Jounaidi Y, 2006, MOL CANCER THER, V5, P541, DOI 10.1158/1535-7163.MCT-05-0321; Komatsu T, 2000, DRUG METAB DISPOS, V28, P1457; Koskela S, 1999, BIOCHEM PHARMACOL, V57, P1407, DOI 10.1016/S0006-2952(99)00015-5; MORRISON GR, 1965, ANAL CHEM, V37, P1124, DOI 10.1021/ac60228a014; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; Ogura Shun-Ichiro, 2011, BMC Res Notes, V4, P66, DOI 10.1186/1756-0500-4-66; Pratt S, 2005, MOL CANCER THER, V4, P855, DOI 10.1158/1535-7163.MCT-04-0291; Rius M, 2003, HEPATOLOGY, V38, P374, DOI 10.1053/jhep.2003.50331; Robey RW, 2005, CANCER BIOL THER, V4, P187; Rodriguez-Antona C, 2006, ONCOGENE, V25, P1679, DOI 10.1038/sj.onc.1209377; SASSA S, 1988, SEMIN HEMATOL, V25, P312; Schwartz PS, 2003, CANCER GENE THER, V10, P571, DOI 10.1038/sj.cgt.7700601; Sugiyama Y, 2014, ONCOL REP, V31, P1282, DOI 10.3892/or.2013.2945; Tamura A, 2007, DRUG METAB PHARMACOK, V22, P428, DOI 10.2133/dmpk.22.428; Werck-Reichhart D., 2000, GENOME BIOL, V1, P1, DOI DOI 10.1186/GB-2000-1-6-REVIEWS3003; Zhou S, 2005, BLOOD, V105, P2571, DOI 10.1182/blood-2004-04-1566	29	16	20	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2015	10	7							e0131793	10.1371/journal.pone.0131793	http://dx.doi.org/10.1371/journal.pone.0131793			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RQ	26181717	Green Published, Green Submitted, gold			2023-01-03	WOS:000358198200011
J	Jaberzadeh, S; Bastani, A; Zoghi, M; Morgan, P; Fitzgerald, PB				Jaberzadeh, Shapour; Bastani, Andisheh; Zoghi, Maryam; Morgan, Prue; Fitzgerald, Paul B.			Anodal Transcranial Pulsed Current Stimulation: The Effects of Pulse Duration on Corticospinal Excitability	PLOS ONE			English	Article							MOTOR CORTICAL EXCITABILITY; MAGNETIC STIMULATION; ELECTRICAL-STIMULATION; TACS; PERCEPTION; MODULATION; SAFETY; CORTEX	The aim is to investigate the effects of pulse duration (PD) on the modulatory effects of transcranial pulsed current (tPCS) on corticospinal excitability (CSE). CSE of the dominant primary motor cortex (M1) of right first dorsal interosseous muscle was assessed by motor evoked potentials, before, immediately, 10, 20 and 30 minutes after application of five experimental conditions: 1) anodal transcranial direct current stimulation (a-tDCS), 2) a-tPCS with 125 ms pulse duartion (a-tPCS(PD = 125)), 3) a-tPCS with 250 ms pulse duration (a-tPCS(PD = 250)), 4) a-tPCS with 500 ms pulse duration (a-tPCS(PD = 500)) and 5) sham a-tPCS. The total charges were kept constant in all experimental conditions except sham condition. Post-hoc comparisons indicated that a-tPCS(PD = 500) produced larger CSE compared to a-tPCS(PD = 125) (P<0.0001), a-tPCS(PD = 250) (P = 0.009) and a-tDCS (P = 0.008). Also, there was no significant difference between a-tPCS(PD = 250) and a-tDCS on CSE changes (P>0.05). All conditions except a-tPCS(PD = 125) showed a significant difference to the sham group (P<0.006). All participants tolerated the applied currents. It could be concluded that a-tPCS with a PD of 500ms induces largest CSE changes, however further studies are required to identify optimal values.	[Jaberzadeh, Shapour; Bastani, Andisheh; Morgan, Prue] Monash Univ, Dept Physiotherapy, Sch Primary Hlth Care, Fac Med, Melbourne, Vic 3004, Australia; [Bastani, Andisheh; Zoghi, Maryam] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic 3050, Australia; [Fitzgerald, Paul B.] Monash Univ, Cent Clin Sch & Alfred, Monash Alfred Psychiat Res Ctr, Melbourne, Vic 3004, Australia	Monash University; Royal Melbourne Hospital; University of Melbourne; Monash University	Jaberzadeh, S (corresponding author), Monash Univ, Dept Physiotherapy, Sch Primary Hlth Care, Fac Med, Melbourne, Vic 3004, Australia.	shapour.jaberzadeh@monash.edu	Fitzgerald, Paul B/A-1225-2008; , Zoghi/AAF-9536-2019	Fitzgerald, Paul B/0000-0003-4217-8096; , Zoghi/0000-0002-1819-6895	Monash University; Postgraduate Publication Award scheme	Monash University(Monash University); Postgraduate Publication Award scheme	This work was supported by the Monash University, Faculty Grant, Strategic Grant Scheme (SJ, MZ, PM, PBF) and Postgraduate Publication Award scheme (AB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antal A, 2008, BRAIN STIMUL, V1, P97, DOI 10.1016/j.brs.2007.10.001; Bastani A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047582; Bergmann TO, 2009, J NEUROPHYSIOL, V102, P2303, DOI 10.1152/jn.00437.2009; Brunoni AR, 2011, INT J NEUROPSYCHOPH, V14, P1133, DOI 10.1017/S1461145710001690; Dundas JE, 2007, CLIN NEUROPHYSIOL, V118, P1166, DOI 10.1016/j.clinph.2007.01.010; Durand S, 2002, J PHYSIOL-LONDON, V540, P261, DOI 10.1113/jphysiol.2001.013364; George MS, 2010, NEUROPSYCHOPHARMACOL, V35, P301, DOI 10.1038/npp.2009.87; Gilmore K L, 1983, Aust J Physiother, V29, P3, DOI 10.1016/S0004-9514(14)60659-0; Groppa S, 2010, NEUROSCIENCE, V166, P1219, DOI 10.1016/j.neuroscience.2010.01.019; Hallett M, 1996, ANN NEUROL, V40, P344, DOI 10.1002/ana.410400303; Jaberzadeh S, 2014, CLIN NEUROPHYSIOL, V125, P344, DOI 10.1016/j.clinph.2013.08.025; Kanai R, 2010, CLIN NEUROPHYSIOL, V121, P1551, DOI 10.1016/j.clinph.2010.03.022; Kanai R, 2008, CURR BIOL, V18, P1839, DOI 10.1016/j.cub.2008.10.027; Keel JC, 2001, CLIN NEUROPHYSIOL, V112, P720, DOI 10.1016/S1388-2457(00)00518-6; Kendall F., 2010, MUSCLES TESTING FUNC, V5th ed; Lakhanpal Rohit R, 2003, Curr Opin Ophthalmol, V14, P122, DOI 10.1097/00055735-200306000-00002; Nitsche MA, 2003, SUPPL CLIN NEUROPHYS, V56, P255; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Noordzij M, 2010, NEPHROL DIAL TRANSPL, P732; Oh SJ, 2003, CLIN ELECTROMYOGRAPH, V3rd, P231, DOI 10.1046/j.1468-1331.2003.00654.x; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pahn U, 2008, BRAIN STIMUL, V1, P386, DOI 10.1016/j.brs.2008.04.003; Paulus W, 2011, NEUROPSYCHOL REHABIL, V21, P602, DOI 10.1080/09602011.2011.557292; Pell GS, 2011, PROG NEUROBIOL, V93, P59, DOI 10.1016/j.pneurobio.2010.10.003; Perotto A.O., 2005, ANATOMICAL GUIDE ELE, V4th; Robertson V, 2006, ELECTROTHERAPY EXPLA, V4th; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Schwartz M. S., 2003, BIOFEEDBACK PRACTITI, V3rd; Turi Z, 2013, RESTOR NEUROL NEUROS, V31, P275, DOI 10.3233/RNN-120297; Wassermann E., 2008, OXFORD HDB TRANSCRAN; Zaghi S, 2010, NEUROSCI LETT, V479, P211, DOI 10.1016/j.neulet.2010.05.060	32	18	19	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2015	10	7							e0131779	10.1371/journal.pone.0131779	http://dx.doi.org/10.1371/journal.pone.0131779			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RL	26177541	Green Submitted, gold, Green Published			2023-01-03	WOS:000358197600064
J	Kiss, HJ; Nemeth, J				Kiss, Huba J.; Nemeth, Janos			Isotonic Glycerol and Sodium Hyaluronate Containing Artificial Tear Decreases Conjunctivochalasis after One and Three Months: A Self-Controlled, Unmasked Study	PLOS ONE			English	Article							DRY EYE DISEASE; CONJUNCTIVAL FOLDS LIPCOF; OPHTHALMIC SOLUTION; EYEDROPS; EFFICACY; EPIDEMIOLOGY; 0.1-PERCENT; SUBCOMMITTEE; SEVERITY; SJOGREN	Dry eye complaints are ranked as the most frequent symptoms of patients visiting ophthalmologists. Conjunctivochalasis is a common dry eye disorder, which can cause an unstable tear film and ocular discomfort. The severe conjunctivochalasis characterized by high LId-Parallel COnjunctival Folds (LIPCOF) degree usually requires surgical intervention, where a conservative therapy would be highly desirable. Here we examined the efficacy of a preservative-free, inorganic salt-free unit-dose artificial tear, called Conheal containing isotonic glycerol and 0.015% sodium hyaluronate in a prospective, unmasked, self-controlled study involving 20 patients. The regular use of the glycerol/hyaluronate artificial tear in three months caused a significant improvement in the recorded parameters. Conjunctivochalasis decreased from a mean LIPCOF degree of 2.9 +/- 0.4 on both eyes to 1.4 +/- 0.6 on the right (median decrease of -2 points, 95% CI from -2.0 to -1.0), and to 1.4 +/- 0.7 on the left eye (median decrease of -1 points, 95% CI from -2.0 to -1.0) (p<0.001 for both sides). The tear film breakup time (TFBUT) lengthened from 4.8 +/- 1.9 seconds on both eyes to 5.9 +/- 2.3 seconds (mean increase of 1.1 seconds, 95% CI from 0.2 to 2.0) and 5.7 +/- 1.8 seconds (mean increase of 0.9 seconds, 95% CI from 0.3 to 1.5) on the right and left eyes, respectively (p(right eyes) = 0.020, p(left eyes) = 0.004). The corneal lissamine staining (Oxford Scheme grade) was reduced from 1.3 +/- 0.6 on the right and 1.4 +/- 0.6 on the left eye significantly (p<0.001) to 0.3 +/- 0.4 and 0.2 +/- 0.4 on the right and the left eyes. The Ocular Surface Disease Index (OSDI) questionnaire score indicating the subjective complaints of the patients also decreased from a mean value of 36.2 +/- 25.3 to 15.6 +/- 16.7 (p<0.001). In this study, the artificial tear, Conheal decreased the grade of the conjunctivochalasis significantly after one month of regular use already, from the LIPCOF degree 3, considered as indication of conjunctival surgery, to a LIPCOF degree 2 or lower requiring a conservative therapy. Our results raise the possibility that vision-related quality of life can be significantly improved by conservative therapies even in severe conjunctivochalasis.	[Kiss, Huba J.; Nemeth, Janos] Semmelweis Univ, Dept Ophthalmol, H-1085 Budapest, Hungary	Semmelweis University	Nemeth, J (corresponding author), Semmelweis Univ, Dept Ophthalmol, Maria Str 39, H-1085 Budapest, Hungary.	janos.nemeth@med.semmelweis-univ.hu		Nemeth, Janos/0000-0001-8575-4888	Foundation "For our eyesight" (Budapest, Hungary)	Foundation "For our eyesight" (Budapest, Hungary)	Work in the authors' laboratory was supported by the Foundation "For our eyesight" (Budapest, Hungary). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Sanchez MA, 2010, CORNEA, V29, P167, DOI 10.1097/ICO.0b013e3181b11648; Aragona P, 2013, EUR J OPHTHALMOL, V23, P368, DOI 10.5301/ejo.5000229; Baeyens V, 2012, J FR OPHTALMOL, V35, P412, DOI 10.1016/j.jfo.2011.07.017; Biro T, 2013, SKIN RES TECHNOL, V19, pe563; Bron AJ, 2003, CORNEA, V22, P640, DOI 10.1097/00003226-200310000-00008; Dausch D, 2006, KLIN MONATSBL AUGENH, V223, P974, DOI 10.1055/s-2006-927266; Eurostat, 2014, BAS FIG EU; Fodor E, 2010, CURR EYE RES, V35, P665, DOI 10.3109/02713681003770738; Gensheimer WG, 2012, J OCUL PHARMACOL TH, V28, P473, DOI 10.1089/jop.2011.0053; Hoh H, 2006, KLIN MONATSBL AUGENH, V223, P918, DOI 10.1055/s-2006-927103; Hoh H, 1995, Ophthalmologe, V92, P802; Hyon Joon Young, 2014, Korean J Ophthalmol, V28, P197, DOI 10.3341/kjo.2014.28.3.197; Johnson ME, 2006, GRAEF ARCH CLIN EXP, V244, P109, DOI 10.1007/s00417-005-0028-1; Johnson ME, 2008, OPTOMETRY VISION SCI, V85, P750, DOI 10.1097/OPX.0b013e318182476c; Kaercher T, 2009, CLIN OPHTHALMOL, V3, P33; Khaireddin R, 2010, KLIN MONATSBL AUGENH, V227, P128, DOI 10.1055/s-0028-1109686; Kiss HJ, 2013, OPHTHALMOLOGIA HUNGA, V150, P28; Lee S, 2004, KLIN MONATSBL AUGENH, V221, P825, DOI 10.1055/s-2004-813715; Lemp MA, 2007, OCUL SURF, V5, P75; Liu XW, 2012, CORNEA, V31, P1235, DOI 10.1097/ICO.0b013e31824988e5; Lopez-Garcia JS, 2014, ACTA OPHTHALMOL, V92, pE22, DOI 10.1111/aos.12167; Meller D, 1998, SURV OPHTHALMOL, V43, P225, DOI 10.1016/S0039-6257(98)00037-X; MENGHER LS, 1986, BRIT J OPHTHALMOL, V70, P442, DOI 10.1136/bjo.70.6.442; Murube J, 2005, OCUL SURF, V3, P7, DOI 10.1016/S1542-0124(12)70118-0; Na KS, 2012, INVEST OPHTH VIS SCI, V53, P5443, DOI 10.1167/iovs.11-9417; Nakasato S, 2012, CORNEA, V31, P514, DOI 10.1097/ICO.0b013e3181dc81d2; Nelson JD, 2006, DRY EYE DIS CLIN GUI, P43; Nemeth J, 2012, BRIT J OPHTHALMOL, V96, P1380, DOI 10.1136/bjophthalmol-2012-301580; Petricek I, 2006, OPHTHALMOLOGICA, V220, P229, DOI 10.1159/000093076; Rah MJ, 2011, OPTOMETRY, V82, P38, DOI 10.1016/j.optm.2010.08.003; Schaumberg DA, 2002, ADV EXP MED BIOL, V506, P989; Schiffman RM, 2000, ARCH OPHTHALMOL-CHIC, V118, P615, DOI 10.1001/archopht.118.5.615; Smith JA, 2007, OCUL SURF, V5, P93; Solomon A, 1998, J OCUL PHARMACOL TH, V14, P497, DOI 10.1089/jop.1998.14.497; Su CY, 2005, J FORMOS MED ASSOC, V104, P968; Szalai E, 2012, CORNEA, V31, P867, DOI 10.1097/ICO.0b013e3182532047; Troiano P, 2008, CORNEA, V27, P1126, DOI 10.1097/ICO.0b013e318180e55c; Vogel R, 2010, AM J OPHTHALMOL, V149, P594, DOI 10.1016/j.ajo.2009.09.023; Xu ML, 2013, J OCUL PHARMACOL TH, V29, P794, DOI 10.1089/jop.2013.0002; Yang HS, 2013, CORNEA, V32, P574, DOI 10.1097/ICO.0b013e318255eaaa; Zhang XR, 2013, CHINESE MED J-PEKING, V126, P3118, DOI 10.3760/cma.j.issn.0366-6999.20130899; Zhang Xing-ru, 2009, Zhonghua Yan Ke Za Zhi, V45, P135; Zhang XR, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-198	43	11	12	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2015	10	7							e0132656	10.1371/journal.pone.0132656	http://dx.doi.org/10.1371/journal.pone.0132656			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1QN	26172053	Green Published, Green Submitted, gold			2023-01-03	WOS:000358194900069
J	Liu, QH; Zhou, ZC; Wei, YC; Shen, DY; Feng, ZP; Hong, SP				Liu, Qinghua; Zhou, Zhichun; Wei, Yongcheng; Shen, Danyu; Feng, Zhongping; Hong, Shanping			Genome-Wide Identification of Differentially Expressed Genes Associated with the High Yielding of Oleoresin in Secondary Xylem of Masson Pine (Pinus massoniana Lamb) by Transcriptomic Analysis	PLOS ONE			English	Article							INDUCED TERPENE SYNTHASE; FUNCTIONAL-CHARACTERIZATION; CONIFER DEFENSE; CDNA ISOLATION; SITKA SPRUCE; RESIN YIELD; BIOSYNTHESIS; RESISTANCE; ENZYMES; INSECTS	Masson pine is an important timber and resource for oleoresin in South China. Increasing yield of oleoresin in stems can raise economic benefits and enhance the resistance to bark beetles. However, the genetic mechanisms for regulating the yield of oleoresin were still unknown. Here, high-throughput sequencing technology was used to investigate the transcriptome and compare the gene expression profiles of high and low oleoresin-yielding genotypes. A total of 40,690,540 reads were obtained and assembled into 137,499 transcripts from the secondary xylem tissues. We identified 84,842 candidate unigenes based on sequence annotation using various databases and 96 unigenes were candidates for terpenoid backbone biosynthesis in pine. By comparing the expression profiles of high and low oleoresin-yielding genotypes, 649 differentially expressed genes (DEGs) were identified. GO enrichment analysis of DEGs revealed that multiple pathways were related to high yield of oleoresin. Nine candidate genes were validated by QPCR analysis. Among them, the candidate genes encoding geranylgeranyl diphosphate synthase (GGPS) and (-)-alpha/beta-pinene synthase were up-regulated in the high oleoresin-yielding genotype, while tricyclene synthase revealed lower expression level, which was in good agreement with the GC/MS result. In addition, DEG encoding ABC transporters, pathogenesis-related proteins (PR5 and PR9), phosphomethylpyrimidine synthase, non-specific lipid-transfer protein-like protein and ethylene responsive transcription factors (ERFs) were also confirmed to be critical for the biosynthesis of oleoresin. The next-generation sequencing strategy used in this study has proven to be a powerful means for analyzing transcriptome variation related to the yield of oleoresin in masson pine. The candidate genes encoding GGPS, (-)-alpha/beta-pinene, tricyclene synthase, ABC transporters, non-specific lipid-transfer protein-like protein, phosphomethylpyrimidine synthase, ERFs and pathogen responses may play important roles in regulating the yield of oleoresin. These DEGs are worthy of special attention in future studies.	[Liu, Qinghua; Zhou, Zhichun; Wei, Yongcheng; Shen, Danyu] Chinese Acad Forestry, Res Inst Subtrop Forestry, Fuyang, Zhejiang, Peoples R China; [Liu, Qinghua; Zhou, Zhichun; Wei, Yongcheng] Zhejiang Prov Key Lab Tree Breeding, Fuyang, Zhejiang, Peoples R China; [Feng, Zhongping; Hong, Shanping] Laoshan Forest Farm Chunan Cty, Chunan, Zhejiang, Peoples R China	Chinese Academy of Forestry; Research Institute of Subtropical Forestry, CAF	Zhou, ZC (corresponding author), Chinese Acad Forestry, Res Inst Subtrop Forestry, Fuyang, Zhejiang, Peoples R China.	zczhou_risf@163.com			National Science & Technology Pillar Program of China [2012BAD01B02]; National Natural Science Foundation of China [31100491]; Major Science & Technology Project of New Agricultural Variety Cultivation of Zhejiang Province, China [2012C12908-12]	National Science & Technology Pillar Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major Science & Technology Project of New Agricultural Variety Cultivation of Zhejiang Province, China	This work was supported by funds from: 1) National Science & Technology Pillar Program of China (No. 2012BAD01B02, http://kjzc.jhgl.org/), ZZ. The funders had a role in decision to publish; 2) National Natural Science Foundation of China (31100491), QL. The funders had a role in study design; 3) Major Science & Technology Project of New Agricultural Variety Cultivation of Zhejiang Province, China (2012C12908-12), ZZ. The funders had a role in data collection and analysis, decision to publish.	Bohlmann J, 1998, P NATL ACAD SCI USA, V95, P4126, DOI 10.1073/pnas.95.8.4126; Bohlmann J, 2000, RECENT ADV PHYTOCHEM, V34, P109, DOI 10.1016/S0079-9920(00)80006-4; Bouvier F, 2005, PROG LIPID RES, V44, P357, DOI 10.1016/j.plipres.2005.09.003; Byun-McKay A, 2006, PLANT PHYSIOL, V140, P1009, DOI 10.1104/pp.105.071803; Coppen J. J. W., 1995, Non-Wood Forest Products; da Silva Rodrigues-Corr ^ea K.C., 2013, NATURAL PRODUCTS, P4037; Dafoe NJ, 2009, J PROTEOME RES, V8, P2341, DOI 10.1021/pr800968r; Davis EM, 2000, TOP CURR CHEM, V209, P53; Faldt J, 2003, PLANT MOL BIOL, V51, P119, DOI 10.1023/A:1020714403780; Gu Y, 2011, BIOMASS CHEM ENG, V45, P21; Guo HW, 2004, CURR OPIN PLANT BIOL, V7, P40, DOI 10.1016/j.pbi.2003.11.011; Haas BJ, 2013, NAT PROTOC, V8, P1494, DOI 10.1038/nprot.2013.084; Harvey BG, 2010, ENERG FUEL, V24, P267, DOI 10.1021/ef900799c; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Jasinski M, 2001, PLANT CELL, V13, P1095, DOI 10.1105/tpc.13.5.1095; Karanikas C, 2010, ANN FOREST SCI, V67, DOI 10.1051/forest/2009132; Keeling CI, 2006, NEW PHYTOL, V170, P657, DOI 10.1111/j.1469-8137.2006.01716.x; Kelkar VM, 2006, BIOMASS BIOENERG, V30, P316, DOI 10.1016/j.biombioe.2005.07.009; Lange BM, 2003, PLANT MOL BIOL, V51, P925, DOI 10.1023/A:1023005504702; Lee HJ, 2001, TETRAHEDRON, V57, P6155, DOI 10.1016/S0040-4020(01)00605-6; Li SiGuang, 2008, Journal of Zhejiang Forestry College, V25, P158; Liu, 2006, FORESTRY SCI TECHNOL, V31, P1; Liu QH, 2013, SILVAE GENET, V62, P38, DOI 10.1515/sg-2013-0005; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Martin D, 2005, RECENT ADV PHYTOCHEM, V39, P29; Martin DM, 2004, PLANT PHYSIOL, V135, P1908, DOI 10.1104/pp.104.042028; McKay SAB, 2003, PLANT PHYSIOL, V133, P368, DOI 10.1104/pp.103.022723; Miller B, 2005, PLANT PHYSIOL, V137, P369, DOI 10.1104/pp.104.050187; Nagy NE, 2000, AM J BOT, V87, P302, DOI 10.2307/2656626; Phillips MA, 2003, ARCH BIOCHEM BIOPHYS, V411, P267, DOI 10.1016/S0003-9861(02)00746-4; [秦小薇 QIN Xiaowei], 2006, [分析测试学报, Journal of Instrumental Analysis], V25, P6; Ralph SG, 2006, PLANT CELL ENVIRON, V29, P1545, DOI 10.1111/j.1365-3040.2006.01532.x; Roberds JH, 2003, CAN J FOREST RES, V33, P2469, DOI [10.1139/x03-186, 10.1139/X03-186]; ROBERTS WK, 1990, J GEN MICROBIOL, V136, P1771, DOI 10.1099/00221287-136-9-1771; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rodriguez-Garcia A, 2014, FOREST ECOL MANAG, V313, P47, DOI 10.1016/j.foreco.2013.10.038; Schmidt A, 2011, PLANT MOL BIOL, V77, P577, DOI 10.1007/s11103-011-9832-7; Steele CL, 1998, J BIOL CHEM, V273, P2078, DOI 10.1074/jbc.273.4.2078; Strom BL, 2002, FOREST ECOL MANAG, V158, P169, DOI 10.1016/S0378-1127(00)00710-6; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Tadesse W., 2001, Forest Genetics, V8, P271; Thabet I, 2012, MOL BIOL REP, V39, P3235, DOI 10.1007/s11033-011-1091-9; Trapp S, 2001, ANNU REV PLANT PHYS, V52, P689, DOI 10.1146/annurev.arplant.52.1.689; Uehara T, 2010, PLANT CELL PHYSIOL, V51, P1524, DOI 10.1093/pcp/pcq109; Wang Z. H., 2007, BIOMASS CHEM ENG, V41, P1; [翁海龙 Weng Hailong], 2010, [西北林学院学报, Journal of Northwest Forestry College], V25, P71; Westbrook JW, 2013, NEW PHYTOL, V199, P89, DOI 10.1111/nph.12240; Xu ZS, 2007, PLANT MOL BIOL, V65, P719, DOI 10.1007/s11103-007-9237-9; Zulak KG, 2010, J INTEGR PLANT BIOL, V52, P86, DOI 10.1111/j.1744-7909.2010.00910.x	49	25	30	5	56	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 13	2015	10	7							e0132624	10.1371/journal.pone.0132624	http://dx.doi.org/10.1371/journal.pone.0132624			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1PW	26167875	Green Published, gold, Green Submitted			2023-01-03	WOS:000358193100059
J	Wang, WL; Sheu, SY; Chen, YS; Kao, ST; Fu, YT; Kuo, TF; Chen, KY; Yao, CH				Wang, Wen-Ling; Sheu, Shi-Yuan; Chen, Yueh-Sheng; Kao, Shung-Te; Fu, Yuan-Tsung; Kuo, Tzong-Fu; Chen, Kuo-Yu; Yao, Chun-Hsu			Enhanced Bone Tissue Regeneration by Porous Gelatin Composites Loaded with the Chinese Herbal Decoction Danggui Buxue Tang	PLOS ONE			English	Article							TRICALCIUM PHOSPHATE; CYTOTOXICITY; FABRICATION; INDUCTION; SCAFFOLDS; MEDICINE	Danggui Buxue Tang (DBT) is a traditional Chinese herbal decoction containing Radix Astragali and Radix Angelicae sinensis. Pharmacological results indicate that DBT can stimulate bone cell proliferation and differentiation. The aim of the study was to investigate the efficacy of adding DBT to bone substitutes on bone regeneration following bone injury. DBT was incorporated into porous composites (GGT) made from genipin-crosslinked gelatin and beta-triclacium phosphates as bone substitutes (GGTDBT). The biological response of mouse calvarial bone to these composites was evaluated by in vivo imaging systems (IVIS), micro-computed tomography (micro-CT), and histology analysis. IVIS images revealed a stronger fluorescent signal in GGTDBT-treated defect than in GGT-treated defect at 8 weeks after implantation. Micro-CT analysis demonstrated that the level of repair from week 4 to 8 increased from 42.1% to 71.2% at the sites treated with GGTDBT, while that increased from 33.2% to 54.1% at GGT-treated sites. These findings suggest that the GGTDBT stimulates the innate regenerative capacity of bone, supporting their use in bone tissue regeneration.	[Wang, Wen-Ling; Sheu, Shi-Yuan; Chen, Yueh-Sheng; Kao, Shung-Te; Fu, Yuan-Tsung; Yao, Chun-Hsu] China Med Univ, Sch Chinese Med, Taichung, Taiwan; [Wang, Wen-Ling; Kao, Shung-Te] China Med Univ Hosp, Dept Chinese Internal Med, Taichung, Taiwan; [Sheu, Shi-Yuan] Chung Shan Med Univ, Sch Med, Taichung, Taiwan; [Sheu, Shi-Yuan] Chung Shan Med Univ Hosp, Dept Integrated Chinese & Western Med, Taichung, Taiwan; [Chen, Yueh-Sheng; Yao, Chun-Hsu] China Med Univ, Dept Biomed Imaging & Radiol Sci, Taichung, Taiwan; [Fu, Yuan-Tsung] Buddhist Tzu Chi Med Fdn, Taichung Tzu Chi Hosp, Dept Chinese Med, Taichung, Taiwan; [Kuo, Tzong-Fu] Natl Taiwan Univ, Sch Vet Med, Dept Vet Med, Taipei 10764, Taiwan; [Chen, Kuo-Yu] Natl Yunlin Univ Sci & Technol, Dept Chem & Mat Engn, Yunlin, Taiwan; [Yao, Chun-Hsu] Asia Univ, Dept Biomed Informat, Taichung, Taiwan	China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; China Medical University Taiwan; Buddhist Tzu Chi General Hospital; Taichung Tzu Chi Hospital; National Taiwan University; National Yunlin University Science & Technology; Asia University Taiwan	Chen, KY (corresponding author), Natl Yunlin Univ Sci & Technol, Dept Chem & Mat Engn, Yunlin, Taiwan.	chenkuo@yuntech.edu.tw; chyao@mail.cmu.edu.tw	Chen, Kuo-Yu/I-3646-2019	Chen, Kuo-Yu/0000-0002-1654-2715; KUO, TZONG-FU/0000-0002-6328-8967	National Science Council of the Republic of China, Taiwan [NSC98-2221-E-039-005-MY3]; China Medical University [CMU 101-AWARD-05, CMU101-S-01]	National Science Council of the Republic of China, Taiwan(Ministry of Science and Technology, Taiwan); China Medical University(China Medical University)	The authors are grateful to National Science Council of the Republic of China, Taiwan (contract No. NSC98-2221-E-039-005-MY3) and China Medical University (contract No. CMU 101-AWARD-05 and CMU101-S-01) for their kind financial support on the research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bigi A, 2004, BIOMATERIALS, V25, P2893, DOI 10.1016/j.biomaterials.2003.09.059; Calori GM, 2011, INJURY, V42, pS56, DOI 10.1016/j.injury.2011.06.011; Carrodeguas RG, 2011, ACTA BIOMATER, V7, P3536, DOI 10.1016/j.actbio.2011.06.019; Chen KY, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/283941; Chen KY, 2013, J BIOMED MATER RES A, V101, P954, DOI 10.1002/jbm.a.34397; Chen KY, 2009, BIOMATERIALS, V30, P1682, DOI 10.1016/j.biomaterials.2008.12.024; Choi RCY, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nen085; Dong GC, 2008, J BIOMED MATER RES A, V84A, P167, DOI 10.1002/jbm.a.31261; Gao Qiutao, 2007, Chin Med, V2, P12, DOI 10.1186/1749-8546-2-12; Hench LL, 2002, SCIENCE, V295, P1014, DOI 10.1126/science.1067404; HOLLINGER JO, 1986, CLIN ORTHOP RELAT R, P290; Katsumura T, 1998, BIOMATERIALS, V19, P1839, DOI 10.1016/S0142-9612(98)00076-3; Lin FH, 2003, BIOMATERIALS, V24, P2413, DOI 10.1016/S0142-9612(03)00031-0; LIN FH, 1993, J BIOMED ENG, V15, P481, DOI 10.1016/0141-5425(93)90063-5; Lin FH, 1998, BIOMATERIALS, V19, P905, DOI 10.1016/S0142-9612(97)00202-0; Liu BS, 2003, J BIOMED MATER RES A, V67A, P1163, DOI 10.1002/jbm.a.20017; Rezwan K, 2006, BIOMATERIALS, V27, P3413, DOI 10.1016/j.biomaterials.2006.01.039; Shue Li, 2012, Biomatter, V2, P271, DOI 10.4161/biom.22948; Takahashi Y, 2005, BIOMATERIALS, V26, P4856, DOI 10.1016/j.biomaterials.2005.01.012; Tsim KWK, 2004, ASIA PACIFIC BIOTECH, V8, P1316; Wang WL, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/853234; Weir MD, 2010, J BIOMED MATER RES A, V94A, P223, DOI 10.1002/jbm.a.32665; Wong RWK, 2006, J ORAL MAXIL SURG, V64, P828, DOI 10.1016/j.joms.2006.01.017; Yang Q, 2002, CLIN CHIM ACTA, V324, P89, DOI 10.1016/S0009-8981(02)00210-3; Yao CH, 2005, J BIOMED MATER RES B, V75B, P277, DOI 10.1002/jbm.b.30294; Yao CH, 2005, BIOMATERIALS, V26, P3065, DOI 10.1016/j.biomaterials.2004.09.011; Yao CH, 2004, J BIOMED MATER RES A, V69A, P709, DOI 10.1002/jbm.a.30045; Yao CH, 2002, AM J CHINESE MED, V30, P471, DOI 10.1142/S0192415X02000557	28	23	24	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2015	10	6							e0131999	10.1371/journal.pone.0131999	http://dx.doi.org/10.1371/journal.pone.0131999			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1BR	26126113	Green Published, gold, Green Submitted			2023-01-03	WOS:000358151300066
J	Shirai, Y; Fujita, Y; Hashimoto, R; Ohi, K; Yamamori, H; Yasuda, Y; Ishima, T; Suganuma, H; Ushida, Y; Takeda, M; Hashimoto, K				Shirai, Yumi; Fujita, Yuko; Hashimoto, Ryota; Ohi, Kazutaka; Yamamori, Hidenaga; Yasuda, Yuka; Ishima, Tamaki; Suganuma, Hiroyuki; Ushida, Yusuke; Takeda, Masatoshi; Hashimoto, Kenji			Dietary Intake of Sulforaphane-Rich Broccoli Sprout Extracts during Juvenile and Adolescence Can Prevent Phencyclidine-Induced Cognitive Deficits at Adulthood	PLOS ONE			English	Article							ASYMMETRIC SPINE SYNAPSES; PREFRONTAL CORTEX; OXIDATIVE STRESS; PARVALBUMIN INTERNEURONS; MISSING HERITABILITY; SCHIZOPHRENIA; PSYCHOSIS; MICE; DISORDERS; IMPACT	Oxidative stress and inflammation play a role in cognitive impairment, which is a core symptom of schizophrenia. Furthermore, a hallmark of the pathophysiology of this disease is the dysfunction of cortical inhibitory gamma-aminobutyric acid (GABA) neurons expressing parvalbumin (PV), which is also involved in cognitive impairment. Sulforaphane (SFN), an isothiocyanate derived from broccoli, is a potent activator of the transcription factor Nrf2, which plays a central role in the inducible expressions of many cytoprotective genes in response to oxidative stress. Keap1 is a cytoplasmic protein that is essential for the regulation of Nrf2 activity. Here, we found that pretreatment with SFN attenuated cognitive deficits, the increase in 8-oxo-dG-positive cells, and the decrease in PV-positive cells in the medial prefrontal cortex and hippocampus after repeated administration of phencyclidine (PCP). Furthermore, PCP-induced cognitive deficits were improved by the subsequent subchronic administration of SFN. Interestingly, the dietary intake of glucoraphanin (a glucosinolate precursor of SFN) during the juvenile and adolescence prevented the onset of PCP-induced cognitive deficits as well as the increase in 8-oxo-dG-positive cells and the decrease in PV-positive cells in the brain at adulthood. Moreover, the NRF2 gene and the KEAP1 gene had an epistatic effect on cognitive impairment (e.g., working memory and processing speed) in patients with schizophrenia. These findings suggest that SFN may have prophylactic and therapeutic effects on cognitive impairment in schizophrenia. Therefore, the dietary intake of SFN-rich broccoli sprouts during the juvenile and adolescence may prevent the onset of psychosis at adulthood.	[Shirai, Yumi; Fujita, Yuko; Ishima, Tamaki; Hashimoto, Kenji] Chiba Univ, Ctr Forens Mental Hlth, Div Clin Neurosci, Chiba, Japan; [Hashimoto, Ryota] Osaka Univ, United Grad Sch Child Dev, Mol Res Ctr Childrens Mental Dev, Osaka, Japan; [Hashimoto, Ryota; Ohi, Kazutaka; Yamamori, Hidenaga; Yasuda, Yuka; Takeda, Masatoshi] Osaka Univ, Grad Sch Med, Dept Psychiat, Osaka, Japan; [Suganuma, Hiroyuki; Ushida, Yusuke] Kagome Co Ltd, Div Res & Dev, Nasushiobara City, Tochigi, Japan	Chiba University; Osaka University; Osaka University; Kagome Co., Ltd.	Hashimoto, K (corresponding author), Chiba Univ, Ctr Forens Mental Hlth, Div Clin Neurosci, Chiba, Japan.	hashimoto@faculty.chiba-u.jp	Hashimoto, Ryota/P-8572-2014; Hashimoto, Ryota/AAE-3200-2019; Ohi, Kazutaka/J-7851-2019; Hashimoto, Kenji/I-5800-2015	Hashimoto, Ryota/0000-0002-5941-4238; Hashimoto, Ryota/0000-0002-5941-4238; Ohi, Kazutaka/0000-0001-9577-9640; Ushida, Yusuke/0000-0003-4117-929X; Suganuma, Hiroyuki/0000-0001-6596-9881; Hashimoto, Kenji/0000-0002-8892-0439	Ministry of Education, Culture, Sports, Science and Technology, Japan [24116006]; Ministry of Education, Science, Sports and Culture of Japan; Kagome Co. Ltd.	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Education, Science, Sports and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Kagome Co. Ltd.	This work was supported by a Grant-in-Aid for Scientific Research on Innovative Areas of the Ministry of Education, Culture, Sports, Science and Technology, Japan (to K. H., #24116006), and a Grant-in-Aid for Scientific Research on Innovative Areas (Comprehensive Brain Science Network) from the Ministry of Education, Science, Sports and Culture of Japan (to R. H. and K. H.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Kagome Co. Ltd. provided support in the form of salaries for authors HS and YS, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aas M, 2014, FRONT PSYCHIATRY, V4, DOI 10.3389/fpsyt.2013.00182; Benedict AL, 2012, J NEUROTRAUM, V29, P2576, DOI 10.1089/neu.2012.2474; Bennett RN, 2004, J AGR FOOD CHEM, V52, P5856, DOI 10.1021/jf040091+; Cabungcal JH, 2013, P NATL ACAD SCI USA, V110, P9130, DOI 10.1073/pnas.1300454110; Cabungcal JH, 2013, BIOL PSYCHIAT, V73, P574, DOI 10.1016/j.biopsych.2012.09.020; Carrion RE, 2011, AM J PSYCHIAT, V168, P806, DOI 10.1176/appi.ajp.2011.10081209; Chen HX, 2012, PSYCHOPHARMACOLOGY, V222, P37, DOI 10.1007/s00213-011-2619-3; COSGROVE J, 1991, J CLIN PSYCHOL, V47, P159, DOI 10.1002/1097-4679(199101)47:1<159::AID-JCLP2270470125>3.0.CO;2-O; Dinkova-Kostova AT, 2012, TRENDS MOL MED, V18, P337, DOI 10.1016/j.molmed.2012.04.003; Do KQ, 2010, J NUTRIGENET NUTRIGE, V3, P267, DOI 10.1159/000324366; Elsworth JD, 2011, INT J NEUROPSYCHOPH, V14, P1411, DOI 10.1017/S1461145711000939; Elsworth JD, 2011, NEUROPSYCHOPHARMACOL, V36, P2054, DOI 10.1038/npp.2011.96; Fahey JW, 2012, CANCER PREV RES, V5, P179, DOI 10.1158/1940-6207.CAPR-11-0572; Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367; Frommann I, 2011, SCHIZOPHRENIA BULL, V37, P861, DOI 10.1093/schbul/sbp155; Fujino H, 2014, PSYCHIAT CLIN NEUROS, V68, P534, DOI 10.1111/pcn.12165; Fusar-Poli P, 2012, ARCH GEN PSYCHIAT, V69, P562, DOI 10.1001/archgenpsychiatry.2011.1592; Girgis RR, 2014, BIOL PSYCHIAT, V75, P292, DOI 10.1016/j.biopsych.2013.12.002; Glantz LA, 2000, ARCH GEN PSYCHIAT, V57, P65, DOI 10.1001/archpsyc.57.1.65; Glausier JR, 2013, NEUROSCIENCE, V251, P90, DOI 10.1016/j.neuroscience.2012.04.044; Green Michael F, 2014, Schizophr Res Cogn, V1, pe1; Hajszan T, 2006, BIOL PSYCHIAT, V60, P639, DOI 10.1016/j.biopsych.2006.03.015; Hashimoto K, 2005, EUR J PHARMACOL, V519, P114, DOI 10.1016/j.ejphar.2005.07.002; Hashimoto K, 2008, BIOL PSYCHIAT, V63, P92, DOI 10.1016/j.biopsych.2007.04.034; Hashimoto K, 2007, NEUROPSYCHOPHARMACOL, V32, P514, DOI 10.1038/sj.npp.1301047; Hashimoto K, 2014, EXPERT OPIN THER TAR, V18, P1049, DOI 10.1517/14728222.2014.934225; Hashimoto R, 2007, MOL PSYCHIATR, V12, P1026, DOI 10.1038/sj.mp.4001982; Hashimoto R, 2006, HUM MOL GENET, V15, P3024, DOI 10.1093/hmg/ddl244; Hashimoto R, 2013, AM J PSYCHIAT, V170, P683, DOI 10.1176/appi.ajp.2013.12091228; Hashimoto R, 2010, AM J MED GENET B, V153B, P1459, DOI 10.1002/ajmg.b.31123; Jentsch JD, 1999, NEUROPSYCHOPHARMACOL, V20, P201, DOI 10.1016/S0893-133X(98)00060-8; Juge N, 2007, CELL MOL LIFE SCI, V64, P1105, DOI 10.1007/s00018-007-6484-5; Keefe Richard S E, 2012, Handb Exp Pharmacol, P11, DOI 10.1007/978-3-642-25758-2_2; Kensler TW, 2013, TOP CURR CHEM, V329, P163, DOI 10.1007/128_2012_339; Kolluri N, 2005, AM J PSYCHIAT, V162, P1200, DOI 10.1176/appi.ajp.162.6.1200; Kwak MK, 2010, TOXICOL APPL PHARM, V244, P66, DOI 10.1016/j.taap.2009.08.028; Lewis DA, 2012, TRENDS NEUROSCI, V35, P57, DOI 10.1016/j.tins.2011.10.004; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Marzec JM, 2007, FASEB J, V21, P2237, DOI 10.1096/fj.06-7759com; Matsuzawa D, 2011, ANTIOXID REDOX SIGN, V15, P2057, DOI 10.1089/ars.2010.3453; Milatovic D., 2010, CURR PROTOCOLS TOXIC, V12, P1, DOI [DOI 10.1002/0471140856.TX1216S43, DOI 10.1002/0471140856.tx1216s43]; Millan MJ, 2012, NAT REV DRUG DISCOV, V11, P141, DOI 10.1038/nrd3628; O'Connor RM, 2014, BIOL PSYCHIAT, V75, P4, DOI 10.1016/j.biopsych.2013.10.022; Ohi K, 2009, SCHIZOPHR RES, V109, P80, DOI 10.1016/j.schres.2009.01.019; Paus T, 2008, NAT REV NEUROSCI, V9, P947, DOI 10.1038/nrn2513; Potvin S, 2008, BIOL PSYCHIAT, V63, P801, DOI 10.1016/j.biopsych.2007.09.024; Rosoklija G, 2000, ARCH GEN PSYCHIAT, V57, P349, DOI 10.1001/archpsyc.57.4.349; Sawa A, 2014, NEURON, V83, P991, DOI 10.1016/j.neuron.2014.08.028; Shiina A, 2015, CLIN PSYCHOPHARM NEU, V13, P62, DOI 10.9758/cpn.2015.13.1.62; Shirai Yumi, 2012, Clin Psychopharmacol Neurosci, V10, P94, DOI 10.9758/cpn.2012.10.2.94; Singh K, 2014, P NATL ACAD SCI USA, V111, P15550, DOI 10.1073/pnas.1416940111; Solis M, 2014, NATURE, V508, pS12, DOI 10.1038/508S12a; Steullet P, 2016, SCHIZOPHR RES, V176, P41, DOI 10.1016/j.schres.2014.06.021; Suzuki T, 2013, TRENDS PHARMACOL SCI, V34, P340, DOI 10.1016/j.tips.2013.04.005; Tan HY, 2007, P NATL ACAD SCI USA, V104, P12536, DOI 10.1073/pnas.0610125104; Tortorella SM, 2015, ANTIOXID REDOX SIGN, V22, P1382, DOI 10.1089/ars.2014.6097; Wechsler D., 1997, MANUAL WECHSLER ADUL, V3rd ed.; West LG, 2004, J AGR FOOD CHEM, V52, P916, DOI 10.1021/jf0307189; Yang C, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyu121; Yao JK, 2011, ANTIOXID REDOX SIGN, V15, P2011, DOI 10.1089/ars.2010.3603; Zhang J, 2015, BIOMED SIGNAL PROCES, V18, P1, DOI 10.1016/j.bspc.2014.11.010; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399; Zuk O, 2014, P NATL ACAD SCI USA, V111, pE455, DOI 10.1073/pnas.1322563111	63	50	53	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2015	10	6							e0127244	10.1371/journal.pone.0127244	http://dx.doi.org/10.1371/journal.pone.0127244			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CL4OM	26107664	gold, Green Published, Green Submitted			2023-01-03	WOS:000356932500009
J	Li, Y; Pan, K; Liu, LZ; Li, YQ; Gu, MF; Zhang, H; Shen, WX; Xia, JC; Li, JJ				Li, Yin; Pan, Ke; Liu, Li-zhi; Li, Yong-qiang; Gu, Mo-fa; Zhang, Hua; Shen, Wei-xi; Xia, Jian-chuan; Li, Jian-jun			Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma	PLOS ONE			English	Article							HEPATOCELLULAR-CARCINOMA; PHASE-II; LOCALLY RECURRENT; THERAPY; CANCER; COMBINATION; TRIAL; LYMPHOCYTES; EVALUATE; RATES	In this study, we investigated the efficacy of sequential cytokine-induced killer cell (CIK) immunotherapy with gemcitabine plus cisplatin (GC) regimen chemotherapy in metastatic nasopharyngeal carcinoma (NPC) patients. Between September 2006 and April 2010, 222 NPC patients with distant metastasis after radiotherapy completion were retrospectively analyzed: 112 patients received 4-6 cycles of GC chemotherapy at 4-week intervals, followed by at least 4 cycles of CIK immunotherapy at 2-week intervals (GC+CIK group); the remaining 110 patients received 4-6 cycles of GC chemotherapy alone (GC group). The evaluation of long-term efficacy showed that the progression-free survival (PFS) rate was significantly higher in the GC+CIK group (log-rank test; p = 0.009), as was the overall survival (OS) rate (p = 0.006). In conclusion, sequential CIK treatment may be effective in enhancing the therapeutic efficacy of GC chemotherapy for metastatic NPC patients. This study provides a basis for alternative therapeutic strategies for metastatic NPC.	[Li, Yin; Pan, Ke; Liu, Li-zhi; Li, Yong-qiang; Gu, Mo-fa; Xia, Jian-chuan; Li, Jian-jun] Sun Yat Sen Univ Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China; [Li, Yin; Li, Jian-jun] Sun Yat Sen Univ Canc Ctr, Dept Endoscopy, Guangzhou 510060, Guangdong, Peoples R China; [Pan, Ke; Li, Yong-qiang; Xia, Jian-chuan] Sun Yat Sen Univ Canc Ctr, Dept Biotherapy, Guangzhou 510060, Guangdong, Peoples R China; [Liu, Li-zhi] Sun Yat Sen Univ Canc Ctr, Dept Imaging & Invent Radiol, Guangzhou 510060, Guangdong, Peoples R China; [Gu, Mo-fa] Sun Yat Sen Univ Canc Ctr, Radiat Dept, Guangzhou 510060, Guangdong, Peoples R China; [Zhang, Hua] Peoples Hosp Guangdong Prov, Ctr Canc, Guangzhou 510089, Guangdong, Peoples R China; [Shen, Wei-xi] Jinan Univ, Shenzhen Peoples Hosp, Inst Canc, Clin Med Coll 2, Shenzhen 518020, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; South China University of Technology; Jinan University	Xia, JC (corresponding author), Sun Yat Sen Univ Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China.	xiajch@mail.sysu.edu.cn; lijj@sysucc.org.cn			Health Industry Scientific Research Project [2009020022]; Science and Technology Plan Projects of Guangdong Province, P.R. China [2012B061700076, 2012A030400038]	Health Industry Scientific Research Project; Science and Technology Plan Projects of Guangdong Province, P.R. China	This work was supported by the Health Industry Scientific Research Project (NO: 2009020022) and Science and Technology Plan Projects of Guangdong Province, P.R. China (No: 2012B061700076 and 2012A030400038).	Chan ATC, 1998, CANCER-AM CANCER SOC, V82, P1003, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1003::AID-CNCR1>3.0.CO;2-F; Chang JTC, 2004, J FORMOS MED ASSOC, V103, P496; Chia WK, 2014, MOL THER, V22, P132, DOI 10.1038/mt.2013.242; Comoli P, 2005, J CLIN ONCOL, V23, P8942, DOI 10.1200/JCO.2005.02.6195; Comoli P, 2004, ANN ONCOL, V15, P113, DOI 10.1093/annonc/mdh027; Correale P, 2008, J IMMUNOTHER, V31, P132, DOI 10.1097/CJI.0b013e31815b69c8; FANDI A, 1994, SEMIN ONCOL, V21, P382; Gritzapis AD, 2002, CANCER IMMUNOL IMMUN, V51, P440, DOI 10.1007/s00262-002-0298-y; Gu MF, 2013, INT J CANCER, V132, P215, DOI 10.1002/ijc.27638; Leong SS, 2005, CANCER-AM CANCER SOC, V103, P569, DOI 10.1002/cncr.20804; Li JJ, 2012, J IMMUNOTHER, V35, P189, DOI 10.1097/CJI.0b013e318241d9de; Li RM, 2012, CANCER IMMUNOL IMMUN, V61, P2125, DOI 10.1007/s00262-012-1260-2; Liu L, 2012, CLIN CANCER RES, V18, P1751, DOI 10.1158/1078-0432.CCR-11-2442; Ma BBY, 2002, CANCER-AM CANCER SOC, V95, P2516, DOI 10.1002/cncr.10995; National Cancer Institute, 1999, CANC THER EV PROGR C; Ngan RKC, 2002, ANN ONCOL, V13, P1252, DOI 10.1093/annonc/mdf200; Pan K, 2013, ANN SURG ONCOL, V20, P4305, DOI 10.1245/s10434-013-3144-x; Poon D, 2005, CANCER-AM CANCER SOC, V103, P576, DOI 10.1002/cncr.20802; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; SchmidtWolf IGH, 1996, CELL IMMUNOL, V169, P85, DOI 10.1006/cimm.1996.0094; SCHMIDTWOLF IGH, 1991, J EXP MED, V174, P139, DOI 10.1084/jem.174.1.139; Shi LR, 2012, CANCER IMMUNOL IMMUN, V61, P2251, DOI 10.1007/s00262-012-1289-2; Shi M, 2004, WORLD J GASTROENTERO, V10, P1146; Su XS, 2010, CANCER BIOTHER RADIO, V25, P465, DOI 10.1089/cbr.2010.0762; Takayama T, 2000, LANCET, V356, P802, DOI 10.1016/S0140-6736(00)02654-4; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; WANG ZJ, 1989, INT J EPIDEMIOL, V18, P17, DOI 10.1093/ije/18.1.17; Weng DS, 2008, J IMMUNOTHER, V31, P63, DOI 10.1097/CJI.0b013e31815a121b; World Health Organization, 1991, INT CLASS TUM HIST T	29	14	17	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2015	10	6							e0130620	10.1371/journal.pone.0130620	http://dx.doi.org/10.1371/journal.pone.0130620			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL3FM	26098948	Green Published, Green Submitted, gold			2023-01-03	WOS:000356835800086
J	Lian, FM; Tian, JX; Chen, XY; Li, ZB; Piao, CL; Guo, JJ; Ma, LC; Zhao, LJ; Xia, CD; Wang, CZ; Yuan, CS; Tong, XL				Lian, Fengmei; Tian, Jiaxing; Chen, Xinyan; Li, Zhibin; Piao, Chunli; Guo, Junjie; Ma, Licheng; Zhao, Lijuan; Xia, Chengdong; Wang, Chong-Zhi; Yuan, Chun-Su; Tong, Xiaolin			The Efficacy and Safety of Chinese Herbal Medicine Jinlida as Add-On Medication in Type 2 Diabetes Patients Ineffectively Managed by Metformin Monotherapy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial	PLOS ONE			English	Article							GLYCEMIC CONTROL; IMPAIRED GLUCOSE; THERAPY; MELLITUS; ASSOCIATION; STATEMENT; PUERARIN; COLLEGE; EXTRACT; GINSENG	Background Metformin plays an important role in diabetes treatment. Studies have shown that the combined use of oral hypoglycemic medications is more effective than metformin monotherapy. In this double-blind, randomized, placebo-controlled, multicenter trial, we evaluated whether Jinlida, a Chinese herbal medicine, enhances the glycemic control of metformin in type 2 diabetes patients whose HbA1c was ineffectively controlled with metformin alone. Methods A total of 186 diabetes patients were enrolled in this double-Blind, randomized, placebo-controlled, multicenter trial. Subjects were randomly allocated to receive either Jinlida (9 g) or the placebo TID for 12 consecutive weeks. All subjects in both groups also continuously received their metformin without any dose change. During this 12-week period, the HbA1c, FPG, 2h PG, body weight, BMI were assessed. HOMA insulin resistance (HOMA-IR) and beta-cell function (HOMA-beta) were also evaluated. Results At week 12, compared to the HbA1c level from week 0, the level of the Jinlida group was reduced by 0.92 +/- 1.09% and that of the placebo group was reduced by 0.53 +/- 0.94%. The 95% CI was 0.69 - 1.14 for the Jinlida group vs. 0.34 - 0.72 for the placebo group. There was a very significant HbA1c reduction between the two groups after 12 weeks (p < 0.01). Both FG and 2h PG levels of the Jinlida group and placebo group were reduced from week 0. There were a very significant FG and 2h PG level reductions between the two groups after 12 weeks (both p < 0.01). The Jinlida group also showed improved beta-cell function with a HOMA-beta increase (p < 0.05). No statistical significance was observed in the body weight and BMI changes. No serious adverse events were reported. Conclusion Jinlida significantly enhanced the hypoglycemic action of metformin when the drug was used alone. This Chinese herbal medicine may have a clinical value as an add-on medication to metformin monotherapy.	[Lian, Fengmei; Tian, Jiaxing; Chen, Xinyan; Tong, Xiaolin] China Acad Chinese Med Sci, Guanganmen Hosp, Beijing, Peoples R China; [Li, Zhibin] Shijiazhuang Hosp Tradit Chinese Med, Shijiazhuang, Peoples R China; [Piao, Chunli] Changchun Univ Chinese Med, Affiliated Hosp, Changchun, Peoples R China; [Guo, Junjie] Shanxi Prov Hosp Tradit Chinese Med, Taiyuan, Peoples R China; [Ma, Licheng] Bethune Int Peace Hosp, Shijiazhuang, Peoples R China; [Zhao, Lijuan] Shanxi Univ Tradit Chinese Med, Affiliated Hosp, Taiyuan, Peoples R China; [Xia, Chengdong] China Acad Chinese Med Sci, Xiyuan Hosp, Beijing, Peoples R China; [Wang, Chong-Zhi; Yuan, Chun-Su] Univ Chicago, Tang Ctr Herbal Med Res, Chicago, IL 60637 USA	China Academy of Chinese Medical Sciences; Guang'anmen Hospital, CACMS; Changchun University of Chinese Medicine; China Academy of Chinese Medical Sciences; Xiyuan Hospital, CACMS; University of Chicago	Yuan, CS (corresponding author), Univ Chicago, Tang Ctr Herbal Med Res, Chicago, IL 60637 USA.	cyuan@dacc.uchicago.edu; xiaolintong66@sina.com	Chen, Xinyan/AAE-1152-2021; Wang, Chong-Zhi/B-8337-2014	Wang, Chong-Zhi/0000-0002-0950-2109				Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS14, DOI 10.2337/dc14-S014; Attele AS, 2002, DIABETES, V51, P1851, DOI 10.2337/diabetes.51.6.1851; Bolen S, 2007, ANN INTERN MED, V147, P386, DOI 10.7326/0003-4819-147-6-200709180-00178; Chinese Diabetes Society, 2014, CHIN J DIABETES MELL, V6, P447, DOI [10.3760/cma.j.issn.1000-6699.2014.10.020, DOI 10.3760/CMA.J.ISSN.1000-6699.2014.10.020]; DEFRONZO RA, 1995, NEW ENGL J MED, V333, P541, DOI 10.1056/NEJM199508313330902; DeFronzo RA, 2009, DIABETES CARE, V32, P1649, DOI 10.2337/dc08-1984; Fonseca V, 2000, JAMA-J AM MED ASSOC, V283, P1695, DOI 10.1001/jama.283.13.1695; Fouqueray P, 2013, DIABETES CARE, V36, P565, DOI 10.2337/dc12-0453; Gao YB, 2013, AM J CHINESE MED, V41, P21, DOI 10.1142/S0192415X1350002X; Guo M., 2013, J CLIN MED PRACT, V17, P35, DOI [10.7619/jcmp.201323010, DOI 10.7619/JCMP.201323010]; Inzucchi SE, 1998, NEW ENGL J MED, V338, P867, DOI 10.1056/NEJM199803263381303; Ji LN, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-602; Ji LN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056703; Kirpichnikov D, 2002, ANN INTERN MED, V137, P25, DOI 10.7326/0003-4819-137-1-200207020-00009; Li JB, 2013, EVAL ANAL DRUG USE H, V13, P591; Li ZP, 2014, J MOL ENDOCRINOL, V53, P71, DOI 10.1530/JME-13-0302; Lian FM, 2014, J CLIN ENDOCR METAB, V99, P648, DOI 10.1210/jc.2013-3276; Lu JM, 2012, CHIN J DIABETES, V4, P402, DOI [10.1111/j.2040-1124.2012.00209.x, DOI 10.1111/J.2040-1124.2012.00209.X]; Nauck MA, 2011, DIABETES CARE, V34, P2015, DOI 10.2337/dc11-0606; [庞洁 Pang Jie], 2014, [中国中医基础医学杂志, Chinese Journal of Basic Medicine in Traditional Chinese Medicine], V20, P605; Prasain JK, 2012, PHYTOMEDICINE, V20, P17, DOI 10.1016/j.phymed.2012.09.017; Rodbard HW, 2009, ENDOCR PRACT, V15, P540, DOI 10.4158/EP.15.6.540; Salpeter S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002967.pub2; Skyler JS, 2009, DIABETES CARE, V32, P187, DOI 10.2337/dc08-9026; So WY, 2011, J DIABETES, V3, P109, DOI 10.1111/j.1753-0407.2011.00115.x; Tong XL, 2013, DIABETES OBES METAB, V15, P448, DOI 10.1111/dom.12051; Tong XL, 2012, AM J CHINESE MED, V40, P877, DOI 10.1142/S0192415X12500656; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WHO, 1999, DIAGN CLASS DIAB M 1; World Health Organization, COUNTR REG DAT DIAB; Wu K, 2013, FOOD CHEM TOXICOL, V60, P341, DOI 10.1016/j.fct.2013.07.077; Xie JT, 2005, AM J CHINESE MED, V33, P397, DOI 10.1142/S0192415X05003004; Yang WY, 2010, NEW ENGL J MED, V362, P1090, DOI 10.1056/NEJMoa0908292; Zeitler P, 2012, NEW ENGL J MED, V366, P2247, DOI 10.1056/NEJMoa1109333; Zhang X., 2013, CHINESE J DIFFICULT, V12, P351; 郑莹, 2013, [中国中医基础医学杂志, Chinese Journal of Basic Medicine in Traditional Chinese Medicine], V19, P654	36	47	59	2	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2015	10	6							e0130550	10.1371/journal.pone.0130550	http://dx.doi.org/10.1371/journal.pone.0130550			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL3FM	26098833	Green Published, Green Submitted, gold			2023-01-03	WOS:000356835800082
J	Shao, YK; Mang, J; Li, PL; Wang, J; Deng, T; Xu, ZX				Shao, Yan-kun; Mang, Jing; Li, Pei-lan; Wang, Jie; Deng, Ting; Xu, Zhong-xin			Computer-Based Cognitive Programs for Improvement of Memory, Processing Speed and Executive Function during Age-Related Cognitive Decline: A Meta-Analysis	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; HEALTHY OLDER-ADULTS; TRAINING-PROGRAM; EXERCISE PROGRAM; PERFORMANCE; PLASTICITY; ASSOCIATION; IMPACT; INTERVENTIONS; IMPAIRMENT	Background Several studies have assessed the effects of computer-based cognitive programs (CCP) in the management of age-related cognitive decline, but the role of CCP remains controversial. Therefore, this systematic review evaluated the evidence on the efficacy of CCP for age-related cognitive decline in healthy older adults. Methods Six electronic databases (through October 2014) were searched. The risk of bias was assessed using the Cochrane Collaboration tool. The standardized mean difference (SMD) and 95% confidence intervals (CI) of a random-effects model were calculated. The heterogeneity was assessed using the Cochran Q statistic and quantified with the I2 index. Results Twelve studies were included in the current review and were considered as moderate to high methodological quality. The aggregated results indicate that CCP improves memory performance (SMD, 0.31; 95% CI 0.16 to 0.45; p < 0.0001) and processing speed (SMD, 0.50; 95% CI 0.14 to 0.87; p = 0.007) but not executive function (SMD, -0.12; 95% CI -0.33 to 0.09; p = 0.27). Furthermore, there were long-term gains in memory performance (SMD, 0.59; 95% CI 0.13 to 1.05; p = 0.01). Conclusion CCP may be a valid complementary and alternative therapy for age-related cognitive decline, especially for memory performance and processing speed. However, more studies with longer follow-ups are warranted to confirm the current findings.	[Shao, Yan-kun; Mang, Jing; Wang, Jie; Xu, Zhong-xin] Jilin Univ, Dept Neurol, China Japan Union Hosp, Changchun 130023, Peoples R China; [Li, Pei-lan; Deng, Ting] Capital Med Univ, Dept Emergency, Beijing Bo Ai Hosp, Beijing, Peoples R China; [Li, Pei-lan; Deng, Ting] Capital Med Univ, China Rehabil Res Ctr, Beijing, Peoples R China	Jilin University; Capital Medical University; Capital Medical University	Deng, T (corresponding author), Capital Med Univ, Dept Emergency, Beijing Bo Ai Hosp, Beijing, Peoples R China.	tingdengdr@163.com; zhongxinxudr@163.com		Mang, Jing/0000-0003-3154-9218				American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; Basak C, 2008, PSYCHOL AGING, V23, P765, DOI 10.1037/a0013494; Bozoki A, 2013, ARCH GERONTOL GERIAT, V57, P1, DOI 10.1016/j.archger.2013.02.009; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Buschkuehl M, 2008, PSYCHOL AGING, V23, P743, DOI 10.1037/a0014342; Cahn-Weiner DA, 2000, CLIN NEUROPSYCHOL, V14, P187, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT187; Coppin AK, 2006, AGE AGEING, V35, P619, DOI 10.1093/ageing/afl107; Edwards JD, 2005, AGING MENT HEALTH, V9, P262, DOI 10.1080/13607860412331336788; Edwards JD, 2002, GERONTOLOGY, V48, P329, DOI 10.1159/000065259; Gates N, 2010, CURR PSYCHIAT REP, V12, P20, DOI 10.1007/s11920-009-0085-y; Gilbert CD, 2001, NEURON, V31, P681, DOI 10.1016/S0896-6273(01)00424-X; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Jia FW, 2014, MED INFORM, V27, P2; Klusmann V, 2010, J GERONTOL A-BIOL, V65, P680, DOI 10.1093/gerona/glq053; Kueider AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040588; Lee Y, 2005, AGING CLIN EXP RES, V17, P20, DOI 10.1007/BF03337716; Levin HS, 2006, ARCH PHYS MED REHAB, V87, pS1, DOI 10.1016/j.apmr.2006.09.010; Li H, 2014, CURR ALZHEIMER RES, V11, P806, DOI 10.2174/156720501108140910123112; Lu WB, 2008, CHINESE J REHABILITA, V07, P88; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Mahncke HW, 2006, P NATL ACAD SCI USA, V103, P12523, DOI 10.1073/pnas.0605194103; Mesulam MM, 2000, ANN NY ACAD SCI, V924, P42; Miller KJ, 2013, AM J GERIAT PSYCHIAT, V21, P655, DOI 10.1016/j.jagp.2013.01.077; Nilsson LG, 2003, ACTA NEUROL SCAND, V107, P7, DOI 10.1034/j.1600-0404.107.s179.5.x; Nouchi R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029676; Owsley C, 2004, J AM GERIATR SOC, V52, P1901, DOI 10.1111/j.1532-5415.2004.52516.x; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Reijnders J, 2013, AGEING RES REV, V12, P263, DOI 10.1016/j.arr.2012.07.003; Royall DR, 2004, J AM GERIATR SOC, V52, P346, DOI 10.1111/j.1532-5415.2004.52104.x; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Smith GE, 2009, J AM GERIATR SOC, V57, P594, DOI 10.1111/j.1532-5415.2008.02167.x; Stern Y, 2011, AGING NEUROPSYCHOL C, V18, P653, DOI 10.1080/13825585.2011.613450; Uchida S, 2008, AGE, V30, P21, DOI 10.1007/s11357-007-9044-x; Zelinski EM, 2011, J AM GERIATR SOC, V59, P258, DOI 10.1111/j.1532-5415.2010.03277.x; Zhu L, 2011, CLIN J CEREBROVASC, V8, P508	36	24	25	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2015	10	6							e0130831	10.1371/journal.pone.0130831	http://dx.doi.org/10.1371/journal.pone.0130831			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CL3FM	26098943	Green Submitted, gold, Green Published			2023-01-03	WOS:000356835800108
J	Nguyen, HT; Nguyen, TD; van den Heuvel, ER; Haaijer-Ruskamp, FM; Taxis, K				Huong-Thao Nguyen; Tuan-Dung Nguyen; van den Heuvel, Edwin R.; Haaijer-Ruskamp, Flora M.; Taxis, Katja			Medication Errors in Vietnamese Hospitals: Prevalence, Potential Outcome and Associated Factors	PLOS ONE			English	Article							DRUG ADMINISTRATION ERRORS; PATIENT SAFETY; INTENSIVE-CARE; INTERVENTIONS; SEVERITY; INTERRUPTIONS; EXPERIENCE; PROGRAM; IMPACT; SCALE	Background Evidence from developed countries showed that medication errors are common and harmful. Little is known about medication errors in resource-restricted settings, including Vietnam. Objectives To determine the prevalence and potential clinical outcome of medication preparation and administration errors, and to identify factors associated with errors. Methods This was a prospective study conducted on six wards in two urban public hospitals in Vietnam. Data of preparation and administration errors of oral and intravenous medications was collected by direct observation, 12 hours per day on 7 consecutive days, on each ward. Multivariable logistic regression was applied to identify factors contributing to errors. Results In total, 2060 out of 5271 doses had at least one error. The error rate was 39.1%(95% confidence interval 37.8%-40.4%). Experts judged potential clinical outcomes as minor, moderate, and severe in 72 (1.4%), 1806 (34.2%) and 182 (3.5%) doses. Factors associated with errors were drug characteristics (administration route, complexity of preparation, drug class; all p values < 0.001), and administration time (drug round, p = 0.023; day of the week, p = 0.024). Several interactions between these factors were also significant. Nurse experience was not significant. Higher error rates were observed for intravenous medications involving complex preparation procedures and for anti-infective drugs. Slightly lower medication error rates were observed during afternoon rounds compared to other rounds. Conclusions Potentially clinically relevant errors occurred in more than a third of all medications in this large study conducted in a resource-restricted setting. Educational interventions, focusing on intravenous medications with complex preparation procedure, particularly antibiotics, are likely to improve patient safety.	[Huong-Thao Nguyen; Tuan-Dung Nguyen] Univ Med & Pharm Ho Chi Minh City, Sch Pharm, Dept Clin Pharm, Ho Chi Minh, Vietnam; [van den Heuvel, Edwin R.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands; [van den Heuvel, Edwin R.] Eindhoven Univ Technol, Dept Math & Comp Sci, NL-5600 MB Eindhoven, Netherlands; [Haaijer-Ruskamp, Flora M.] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharmacol, Groningen, Netherlands; [Huong-Thao Nguyen; Taxis, Katja] Univ Groningen, Dept Pharm, Unit Pharmacotherapy & Pharmaceut Care, Groningen, Netherlands	Hochiminh City University of Medicine & Pharmacy; University of Groningen; Eindhoven University of Technology; University of Groningen; University of Groningen	Taxis, K (corresponding author), Univ Groningen, Dept Pharm, Unit Pharmacotherapy & Pharmaceut Care, Groningen, Netherlands.	k.taxis@rug.nl	Taxis, Katja/ABE-2637-2021	Taxis, Katja/0000-0001-8539-2004	NUFFIC (the Netherlands Organisation for International Cooperation in Higher Education)	NUFFIC (the Netherlands Organisation for International Cooperation in Higher Education)	This study was supported by NUFFIC (the Netherlands Organisation for International Cooperation in Higher Education). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALLAN EL, 1990, AM J HOSP PHARM, V47, P555, DOI 10.1093/ajhp/47.3.555; American Society of Health-System Pharmacists, 2009, AHFS DRUG INFORM; Barber N, 2003, QUAL SAF HEALTH CARE, V12, pI29, DOI 10.1136/qhc.12.suppl_1.i29; Berdot S, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-60; Berdot S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068856; Chua SS, 2009, J CLIN PHARM THER, V34, P215, DOI 10.1111/j.1365-2710.2008.00997.x; Chua SS, 2010, EUR J PEDIATR, V169, P603, DOI 10.1007/s00431-009-1084-z; Dean B, 2001, AM J HEALTH-SYST PH, V58, P54, DOI 10.1093/ajhp/58.1.54; Dean BS, 1999, AM J HEALTH-SYST PH, V56, P57, DOI 10.1093/ajhp/56.1.57; Duckers M, 2009, MED CARE RES REV, V66, p90S, DOI 10.1177/1077558709345870; Flynn EA, 2002, AM J HEALTH-SYST PH, V59, P436, DOI 10.1093/ajhp/59.5.436; Freeman R, 2013, J NURS CARE QUAL, V28, P176, DOI 10.1097/NCQ.0b013e318275ac3e; Greengold NL, 2003, ARCH INTERN MED, V163, P2359, DOI 10.1001/archinte.163.19.2359; Nguyen HT, 2014, BMJ QUAL SAF, V23, P319, DOI 10.1136/bmjqs-2013-002357; Nguyen HT, 2014, NURS RES, V63, P68, DOI 10.1097/NNR.0000000000000010; Jha AK, 2010, QUAL SAF HEALTH CARE, V19, P42, DOI 10.1136/qshc.2008.029165; Keers RN, 2014, DRUG SAFETY, V37, P317, DOI 10.1007/s40264-014-0152-0; Keers RN, 2013, ANN PHARMACOTHER, V47, P237, DOI 10.1345/aph.1R147; Krahenbuhl-Melcher A, 2007, DRUG SAFETY, V30, P379; Lemoine Jennifer B, 2012, Nurs Womens Health, V16, P151, DOI 10.1111/j.1751-486X.2012.01721.x; Manias E, 2012, BRIT J CLIN PHARMACO, V74, P411, DOI 10.1111/j.1365-2125.2012.04220.x; McDowell SE, 2010, QUAL SAF HEALTH CARE, V19, P341, DOI 10.1136/qshc.2008.029785; Pierson S, 2007, QUAL SAF HEALTH CARE, V16, P297, DOI 10.1136/qshc.2007.022483; Prakash V, 2014, BMJ QUAL SAF, V23, P884, DOI 10.1136/bmjqs-2013-002484; Romero CM, 2013, J CRIT CARE, V28, P451, DOI 10.1016/j.jcrc.2012.11.011; Ross LM, 2000, ARCH DIS CHILD, V83, P492, DOI 10.1136/adc.83.6.492; Taxis K, 2004, EUR J CLIN PHARMACOL, V59, P815, DOI 10.1007/s00228-003-0689-9; Taxis K, 2003, BMJ-BRIT MED J, V326, P684, DOI 10.1136/bmj.326.7391.684; Tissot E, 2003, PHARM WORLD SCI, V25, P264, DOI 10.1023/B:PHAR.0000006519.44483.a0; Trissel L., 2009, HDB INJECTABLE DRUGS; Trossman Susan, 2010, Am Nurse, V42, P6; van den Bemt PMLA, 2002, CRIT CARE MED, V30, P846, DOI 10.1097/00003246-200204000-00022; Vietnam Ministry of Health, 2009, VIETN NAT DRUG FORM; Vietnam Ministry of Health, 2008, 072008TTBYT VIETN MI; Westbrook JI, 2011, BMJ QUAL SAF, V20, P1027, DOI 10.1136/bmjqs-2011-000089; Westbrook JI, 2010, ARCH INTERN MED, V170, P683, DOI 10.1001/archinternmed.2010.65; Williams T, 2014, AM J NURS, V114, P53, DOI 10.1097/01.NAJ.0000456433.07343.7f; Wilson RM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e832; Wirtz V, 2003, PHARM WORLD SCI, V25, P104, DOI 10.1023/A:1024009000113	39	14	15	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2015	10	9							e0138284	10.1371/journal.pone.0138284	http://dx.doi.org/10.1371/journal.pone.0138284			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS0ZE	26383873	gold, Green Published, Green Submitted			2023-01-03	WOS:000361790200086
J	Wainwright, CE; Kapur, N				Wainwright, Claire E.; Kapur, Nitin			Oxygen saturation targets in infants with bronchiolitis	LANCET			English	Editorial Material							COUGH		[Wainwright, Claire E.; Kapur, Nitin] Lady Cilento Childrens Hosp, Dept Resp & Sleep Med, Brisbane, Qld 4101, Australia		Wainwright, CE (corresponding author), Lady Cilento Childrens Hosp, Dept Resp & Sleep Med, Brisbane, Qld 4101, Australia.	claire.wainwright@health.qld.gov.au	Wainwright, Claire E/G-4218-2013; Kapur, Nitin/H-2003-2013	Wainwright, Claire E/0000-0001-8389-3809; Kapur, Nitin/0000-0002-8423-0596				Bass JL, 2004, PEDIATRICS, V114, P805, DOI 10.1542/peds.2004-0227; Bass JL, 2007, PEDIATRICS, V119, P611, DOI 10.1542/peds.2006-3002; Cunningham S, 2015, LANCET, V386, P1041, DOI 10.1016/S0140-6736(15)00163-4; Cunningham S, 2012, ARCH DIS CHILD, V97, P361, DOI 10.1136/adc.2010.205211; Hay AD, 2003, FAM PRACT, V20, P696, DOI 10.1093/fampra/cmg613; Hunt CE, 1999, J PEDIATR-US, V135, P580, DOI 10.1016/S0022-3476(99)70056-9; Lieberthal AS, 2006, PEDIATRICS, V118, P1774, DOI 10.1542/peds.2006-2223; Mason NP, 1999, EUR RESPIR J, V13, P508, DOI 10.1183/09031936.99.13350899; Network SIG, 2006, BRONCH CHILDR SIGN 9; Schuh S, 2014, JAMA-J AM MED ASSOC, V312, P712, DOI 10.1001/jama.2014.8637; Sundar Krishna M, 2010, Cough, V6, P2, DOI 10.1186/1745-9974-6-2; Unger S, 2008, PEDIATRICS, V121, P470, DOI 10.1542/peds.2007-1135; Walsh P, 2015, WEST J EMERG MED, V16, P85, DOI 10.5811/westjem.2015.1.24930	13	3	3	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 12	2015	386	9998					1016	1018		10.1016/S0140-6736(15)00155-5	http://dx.doi.org/10.1016/S0140-6736(15)00155-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CR2VQ	26382980	hybrid			2023-01-03	WOS:000361189200005
J	Dimick, JB; Miller, DC				Dimick, Justin B.; Miller, David C.			Hospital readmission after surgery: no place like home	LANCET			English	Editorial Material							MORTALITY; OUTCOMES		[Dimick, Justin B.; Miller, David C.] Univ Michigan, Ctr Healthcare Outcomes & Policy, Ann Arbor, MI 48109 USA; [Dimick, Justin B.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Miller, David C.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Dimick, JB (corresponding author), Univ Michigan, Ctr Healthcare Outcomes & Policy, Ann Arbor, MI 48109 USA.	jdimick@umich.edu						Brooke BS, 2015, LANCET; Chou SY, 2014, MED CARE, V52, P250, DOI 10.1097/MLR.0000000000000082; Dimick JB, 2015, JAMA-J AM MED ASSOC, V313, P512, DOI 10.1001/jama.2014.14179; Ferrer R, 2014, CRIT CARE MED, V42, P1749, DOI 10.1097/CCM.0000000000000330; Ghaferi AA, 2011, MED CARE, V49, P1076, DOI 10.1097/MLR.0b013e3182329b97; Ghaferi AA, 2009, NEW ENGL J MED, V361, P1368, DOI 10.1056/NEJMsa0903048; Newhouse JP, 1998, ANNU REV PUBL HEALTH, V19, P17, DOI 10.1146/annurev.publhealth.19.1.17	7	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 29	2015	386	9996					837	839		10.1016/S0140-6736(15)60462-7	http://dx.doi.org/10.1016/S0140-6736(15)60462-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CQ0MJ	26093916				2023-01-03	WOS:000360290000007
J	Zhao, Y; Zhang, MJ; Shi, CX; Zhang, Y; Cai, WP; Zhao, QX; Li, Y; Li, HQ; Liu, X; Chen, LM; Ma, Y; Zhang, FJ; Liu, ZF; Wu, ZY				Zhao, Yan; Zhang, Mingjie; Shi, Cynthia X.; Zhang, Yao; Cai, Weiping; Zhao, Qingxia; Li, Yong; Li, Huiqin; Liu, Xia; Chen, Limeng; Ma, Ye; Zhang, Fujie; Liu, Zhongfu; Wu, Zunyou			Renal Function in Chinese HIV-Positive Individuals following Initiation of Antiretroviral Therapy	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; INFECTED PATIENTS; RISK-FACTORS; PREVALENCE; COHORT; ASSOCIATION; TENOFOVIR; METAANALYSIS; NEPHROPATHY	Aim To identify the prevalence and predictors of abnormal renal function among HIV-positive Chinese patients prior to antiretroviral therapy (ART) initiation and to evaluate subsequent changes in renal function after ART exposure. Methods We conducted a nationwide cohort study of subjects who enrolled in the national Chinese ART program from January 1, 2012 to December 31, 2012. We estimated the glomerular filtration rate (eGFR) of subjects prior to and after initiating ART. Risk factors for abnormal renal function, as defined by eGFR < 60 ml/min/1.73m(2), at baseline and follow-up were assessed by logistic regression and Cox proportional hazards regression models, respectively. Results Among 41,862 subjects, at ART baseline, 3.3% had a baseline eGFR < 60 ml/min/1.73m(2) and 24.2% had eGFR = 60-90 ml/min/1.73m(2). Adjusted baseline risk factors for baseline eGFR < 60 ml/min/1.73m(2) were older age (Adjusted odds ratio [AOR] = 5.19, 95% confidence interval [CI]: 4.52-5.67), female (AOR = 1.68, 95% CI: 1.47-1.93), hemoglobin < 120g/L (AOR = 1.68, 95% CI: 1.47-1.93), blood glucose > 6.1 mmol/L (AOR = 1.46, 95% CI: 1.25-1.72), and hepatitis C co-infection (AOR = 1.36, 95% CI: 1.06-1.73). Among subjects with baseline eGFR > 90 ml/min/1.73m(2), the incidence of the eGFR falling to < 60 ml/min/1.73m(2) was 0.92/100 person-years after a median of 15.0 months of ART. Being on a tenofovir with lopinavir/ritonavir regimen (Adjusted hazard ratio [AHR] = 3.02, 95% CI: 1.96-4.66) and having an unsuppressed viral load (AHR = 2.70, 95% CI: 1.80-4.03) were independent predictors for eGFR < 60 ml/min/1.73m(2) after ART initiation as well as older age, female, and hemoglobin < 120 g/L. Conclusion A high proportion of HIV-positive subjects in China presented with abnormal renal function prior to ART initiation. But the incidence of the eGFR decrease after ART was low. Patient renal function should be regularly monitored by eGFR before initiating and during ART.	[Zhao, Yan; Zhang, Mingjie; Shi, Cynthia X.; Zhang, Yao; Liu, Xia; Ma, Ye; Zhang, Fujie; Liu, Zhongfu; Wu, Zunyou] Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China; [Cai, Weiping] Guangzhou 8th Hosp, Guangzhou, Guangdong, Peoples R China; [Zhao, Qingxia] Zhengzhou 6th Hosp, Zhengzhou, Henan, Peoples R China; [Li, Yong] Longtan Hosp, Guangxi, Peoples R China; [Li, Huiqin] Ctr AIDS Care, Kunming, Yunnan, Peoples R China; [Chen, Limeng] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China	Chinese Center for Disease Control & Prevention; National Center for AIDS/STD Control & Prevention, Chinese Center for Disease Control & Prevention; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital	Zhang, FJ (corresponding author), Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China.	zhang.fujie.t@gmail.com; zhongfuliu@163.com	Burdmann, Emmanuel/AAY-1966-2020; Burdmann, Emmanuel/B-7023-2009	Burdmann, Emmanuel/0000-0002-7644-8579	Chinese Government AIDS Program	Chinese Government AIDS Program	This study was supported by Chinese Government AIDS Program. The funding organizations had no role in the design of this study, in the analysis, or interpretation of data, or in the final decision to submit the manuscript for publication. The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the affiliated institutions.	Ando M, 2012, CLIN EXP NEPHROL, V16, P363, DOI 10.1007/s10157-012-0585-7; Bruggeman Leslie A, 2009, Curr Infect Dis Rep, V11, P479, DOI 10.1007/s11908-009-0069-4; Cailhol J, 2011, BMC NEPHROL, V12, DOI 10.1186/1471-2369-12-40; Cao Y, 2013, NEPHROLOGY, V18, P307, DOI 10.1111/nep.12031; Cooper RD, 2010, CLIN INFECT DIS, V51, P496, DOI 10.1086/655681; Dabrowska MM, 2012, CURR HIV RES, V10, P247, DOI 10.2174/157016212800618147; del Palacio M, 2012, CURR HIV RES, V10, P521, DOI 10.2174/157016212802429802; Fafin C, 2012, NEPHRON CLIN PRACT, V120, pC205, DOI 10.1159/000342377; Gupta SK, 2005, CLIN INFECT DIS, V40, P1559, DOI 10.1086/430257; Ibrahim F, 2012, AM J KIDNEY DIS, V60, P539, DOI 10.1053/j.ajkd.2012.03.006; Islam FM, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-234; Izzedine H, 2007, NEPHROL DIAL TRANSPL, V22, P2757, DOI 10.1093/ndt/gfm404; Kalayjian RC, 2012, AIDS, V26, P1907, DOI 10.1097/QAD.0b013e328357f5ed; Kalayjian RC, 2010, ADV CHRONIC KIDNEY D, V17, P59, DOI 10.1053/j.ackd.2009.08.013; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Longenecker CT, 2009, AIDS, V23, P1089, DOI 10.1097/QAD.0b013e32832a3f24; Lucas GM, 2004, AIDS, V18, P541, DOI 10.1097/00002030-200402200-00022; Lucas GM, 2008, J INFECT DIS, V197, P1548, DOI 10.1086/587994; Ma YC, 2006, J AM SOC NEPHROL, V17, P2937, DOI 10.1681/ASN.2006040368; Ministry of Health Working Group on Clinical AIDS Treatment, 2012, CHIN FREE ANT THER M; Monteagudo-Chu Maricelle O, 2012, J Pharm Pract, V25, P552; Naicker S, 2010, CLIN NEPHROL, V74, pS51; Orlando G, 2006, HIV MED, V7, P549, DOI 10.1111/j.1468-1293.2006.00420.x; Peters PJ, 2008, KIDNEY INT, V74, P925, DOI 10.1038/ki.2008.305; Rasch MG, 2012, SCAND J INFECT DIS, V44, P689, DOI 10.3109/00365548.2012.673730; Rocco MV, 2012, AM J KIDNEY DIS, V60, P857, DOI 10.1053/j.ajkd.2012.07.005; Ryom L, 2013, J INFECT DIS, V207, P1359, DOI 10.1093/infdis/jit043; Winston JA, 2010, ADV CHRONIC KIDNEY D, V17, P19, DOI 10.1053/j.ackd.2009.08.006; Zhang LX, 2012, LANCET, V379, P815, DOI 10.1016/S0140-6736(12)60033-6; Zuo L, 2005, AM J KIDNEY DIS, V45, P463, DOI 10.1053/j.ajkd.2004.11.012	30	9	10	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2015	10	8							e0135462	10.1371/journal.pone.0135462	http://dx.doi.org/10.1371/journal.pone.0135462			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ0PO	26317657	Green Submitted, Green Published, gold			2023-01-03	WOS:000360299100030
J	Dienes, L; Kiss, HJ; Perenyl, K; Szepessy, Z; Nagy, ZZ; Barsi, A; Acosta, MC; Gallar, J; Kovacs, I				Dienes, Lorant; Kiss, Huba J.; Perenyl, Kristof; Szepessy, Zsuzsanna; Nagy, Zoltan Z.; Barsi, Arpad; Carmen Acosta, M.; Gallar, Juana; Kovacs, Illes			The Effect of Tear Supplementation on Ocular Surface Sensations during the Interblink Interval in Patients with Dry Eye	PLOS ONE			English	Article							GELLABLE LUBRICANT EYE; HP-GUAR; CORNEAL SENSITIVITY; LIPID LAYER; COLD THERMORECEPTORS; FILM THICKNESS; PRECORNEAL; SYMPTOMS; CONJUNCTIVAL; STIMULATION	Purpose To investigate the characteristics of ocular surface sensations and corneal sensitivity during the interblink interval before and after tear supplementation in dry eye patients. Methods Twenty subjects (41.88 +/- 14.37 years) with dry eye symptoms were included in the dry eye group. Fourteen subjects (39.13 +/- 11.27 years) without any clinical signs and/or symptoms of dry eye were included in the control group. Tear film dynamics was assessed by non-invasive tear film breakup time (NI-BUT) in parallel with continuous recordings of ocular sensations during forced blinking. Corneal sensitivity to selective stimulation of corneal mechano-, cold and chemical receptors was assessed using a gas esthesiometer. All the measurements were made before and 5 min after saline and hydroxypropyl-guar (HP-guar) drops. Results In dry eye patients the intensity of irritation increased rapidly after the last blink during forced blinking, while in controls there was no alteration in the intensity during the first 10 sec followed by an exponential increase. Irritation scores were significantly higher in dry eye patients throughout the entire interblink interval compared to controls (p<0.004). NI-BUT significantly increased after HP-guar (p = 0.003) but not after saline drops (p = 0.14). In both groups, either after saline or HP-guar the shape of symptom intensity curves remained the same with significantly lower irritation scores (p<0.004), however after HP-guar the decrease was significantly more pronounced (p<0.004). Corneal sensitivity to selective mechanical, cold and chemical stimulation decreased significantly in both groups after HP-guar (p<0.05), but not after saline drops (p>0.05). Conclusion Ocular surface irritation responses due to tear film drying are considerably increased in dry eye patients compared to normal subjects. Although tear supplementation improves the protective tear film layer, and thus reduce unpleasant sensory responses, the rapid rise in discomfort is still maintained and might be responsible for the remaining complaints of dry eye patients despite the treatment.	[Dienes, Lorant; Kiss, Huba J.; Perenyl, Kristof; Szepessy, Zsuzsanna; Nagy, Zoltan Z.; Kovacs, Illes] Semmelweis Univ, Dept Ophthalmol, H-1085 Budapest, Hungary; [Barsi, Arpad] Budapest Univ Technol & Econ, Dept Photogrammetry & Geoinformat, Budapest, Hungary; [Carmen Acosta, M.; Gallar, Juana] Univ Miguel Hernandez, Inst Neurociencias, CSIC, Alacant, Spain	Semmelweis University; Budapest University of Technology & Economics; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN)	Kovacs, I (corresponding author), Semmelweis Univ, Dept Ophthalmol, H-1085 Budapest, Hungary.	kovacs.illes@med.semmelweis-univ.hu	Nagy, Zoltan Zsolt/T-6180-2017; Gallar, Juana/B-4563-2011; Barsi, Arpad/A-5030-2008; Acosta, M.Carmen/K-1313-2014	Gallar, Juana/0000-0002-3559-3649; Barsi, Arpad/0000-0002-0298-7502; Acosta, M. Carmen/0000-0002-1759-068X	Hungarian Scientific Research Fund OTKA [NN106649]; Ministerio de Economia y Competitividad, Spain [SAF2014-54518-C3-1-R]; Alcon Hungary Kft	Hungarian Scientific Research Fund OTKA(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); Ministerio de Economia y Competitividad, Spain; Alcon Hungary Kft	This work was supported by the Hungarian Scientific Research Fund OTKA NN106649 research grant (IK, LD) and SAF2014-54518-C3-1-R from Ministerio de Economia y Competitividad, Spain (JG, MCA). Publication fees of the manuscript were partially covered by the Spes Futuri Research Grant provided by Alcon Hungary Kft (LD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.	Acosta MC, 2004, INVEST OPHTH VIS SCI, V45, P2333, DOI 10.1167/iovs.03-1366; Acosta MC, 2001, J PHYSIOL-LONDON, V534, P511, DOI 10.1111/j.1469-7793.2001.t01-1-00511.x; Acosta MC, 2010, INVEST OPHTHALMOL VI; Argueso P, 2001, EXP EYE RES, V73, P281, DOI 10.1006/exer.2001.1045; Begley C, 2013, INVEST OPHTH VIS SCI, V54, P2645, DOI 10.1167/iovs.12-11299; Belmonte C, 1999, INVEST OPHTH VIS SCI, V40, P513; Belmonte C, 2004, EXP EYE RES, V78, P513, DOI 10.1016/j.exer.2003.09.023; Belmonte C, 2011, INVEST OPHTH VIS SCI, V52, P3888, DOI 10.1167/iovs.09-5119; BENEDETTO DA, 1984, ARCH OPHTHALMOL-CHIC, V102, P410; Benelli U, 2010, CONTACT LENS ANTERIO, V33, P61, DOI 10.1016/j.clae.2010.01.003; Blackie CA, 2009, CORNEA, V28, P789, DOI 10.1097/ICO.0b013e318191b870; Bourcier T, 2005, INVEST OPHTH VIS SCI, V46, P2341, DOI 10.1167/iovs.04-1426; Bron AJ, 2003, CORNEA, V22, P640, DOI 10.1097/00003226-200310000-00008; Christensen MT, 2010, INVEST OPHTH VIS SCI, V51; Christensen MT, 2004, CURR EYE RES, V28, P55, DOI 10.1076/ceyr.28.1.55.23495; Craig JP, 1997, OPTOMETRY VISION SCI, V74, P8, DOI 10.1097/00006324-199701000-00014; De Paiva CS, 2004, AM J OPHTHALMOL, V137, P109, DOI 10.1016/S0002-9394(03)00897-3; Foulks GN, 2007, SURV OPHTHALMOL, V52, P369, DOI 10.1016/j.survophthal.2007.04.009; Friedman NJ, 2010, CURR OPIN OPHTHALMOL, V21, P310, DOI 10.1097/ICU.0b013e32833a8c15; Gifford Paul, 2006, Cont Lens Anterior Eye, V29, P31, DOI 10.1016/j.clae.2005.12.003; Gomis A, 2009, OSTEOARTHR CARTILAGE, V17, P798, DOI 10.1016/j.joca.2008.11.013; Hartstein I, 2005, CURR MED RES OPIN, V21, P255, DOI 10.1185/030079905X26252; Jamison RN, 2002, PAIN, V99, P341, DOI 10.1016/S0304-3959(02)00178-1; King-Smith PE, 2008, OPTOMETRY VISION SCI, V85, P623, DOI 10.1097/OPX.0b013e318181ae60; King-Smith PE, 2000, INVEST OPHTH VIS SCI, V41, P3348; Miller KL, 2010, ARCH OPHTHALMOL-CHIC, V128, P94, DOI 10.1001/archophthalmol.2009.356; Montes-Mico R, 2004, INVEST OPHTH VIS SCI, V45, P1752, DOI 10.1167/iovs.03-0839; Murphy PJ, 1998, OPHTHAL PHYSL OPT, V18, P532, DOI 10.1016/S0275-5408(98)00021-0; Nichols JJ, 2005, INVEST OPHTH VIS SCI, V46, P2353, DOI 10.1167/iovs.05-0094; Ousler GW, 2007, CORNEA, V26, P949, DOI 10.1097/ICO.0b013e3180de1c38; Palakuru JR, 2007, INVEST OPHTH VIS SCI, V48, P3032, DOI 10.1167/iovs.06-1507; Parra A, 2014, PAIN, V155, P1481, DOI 10.1016/j.pain.2014.04.025; Parra A, 2010, NAT MED, V16, P1396, DOI 10.1038/nm.2264; Paugh JR, 2008, OPTOMETRY VISION SCI, V85, P873, DOI 10.1097/OPX.0b013e318185279d; Pflugfelder SC, 2007, OCUL SURF, V5, P163; PRYDAL JI, 1992, INVEST OPHTH VIS SCI, V33, P2006; Rolando M, 2009, J OCUL PHARMACOL TH, V25, P271, DOI 10.1089/jop.2008.0026; Sanchez MA, 2010, EYE, V24, P1331, DOI 10.1038/eye.2010.24; Schaumberg DA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076121; Schmidl D, 2015, CORNEA, V34, P421, DOI 10.1097/ICO.0000000000000358; SHARMA A, 1993, BIOPHYS CHEM, V47, P87, DOI 10.1016/0301-4622(93)80036-I; Sindt CW, 2013, CLIN OPHTHALMOL, V7, P1713, DOI [10.2147/OPTH.S35833, 10.2147/OPTH.S35833`]; Situ P, 2008, INVEST OPHTH VIS SCI, V49, P2971, DOI 10.1167/iovs.08-1734; Smith JA, 2007, OCUL SURF, V5, P93; SNIBSON GR, 1990, EYE, V4, P594, DOI 10.1038/eye.1990.83; Teson M, 2012, INVEST OPHTH VIS SCI, V53, P3154, DOI 10.1167/iovs.11-9304; Tomlinson A, 2009, OCUL SURF, V7, P186, DOI 10.1016/S1542-0124(12)70186-6; Varikooty J, 2009, INVEST OPHTH VIS SCI, V50, P1087, DOI 10.1167/iovs.08-1843; Vega JA, 1999, CORNEA, V18, P675, DOI 10.1097/00003226-199911000-00009; Versura P, 2008, CLIN OPHTHALMOL, V2, P629; Wang JH, 2006, INVEST OPHTH VIS SCI, V47, P3325, DOI 10.1167/iovs.06-0055	51	10	11	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2015	10	8							e0135629	10.1371/journal.pone.0135629	http://dx.doi.org/10.1371/journal.pone.0135629			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP5VA	26302222	Green Published, gold, Green Submitted			2023-01-03	WOS:000359951900023
J	Piguet, V; D'Incau, S; Besson, M; Desmeules, J; Cedraschi, C				Piguet, Valerie; D'Incau, Stephanie; Besson, Marie; Desmeules, Jules; Cedraschi, Christine			Prescribing Generic Medication in Chronic Musculoskeletal Pain Patients: An Issue of Representations, Trust, and Experience in a Swiss Cohort	PLOS ONE			English	Article							QUALITATIVE RESEARCH; HEALTH-CARE; DRUG SUBSTITUTION; SATURATION; MEDICINES; PHARMACY; POLICIES; VIEWS; NEED	Objective Parallel to an ever stronger advocacy for the use of generics, various sources of information report concerns regarding substitution. The literature indicates that information regarding substitution is not univocal. The aim of this qualitative study was to explore patients' representations regarding generics in patients suffering from non-specific disabling chronic musculoskeletal pain, as these patients are confronted with the issue of the prescription and/or substitution of original formulations with generics. Methods Qualitative methods were selected because the aim was to access the range of patients' representations and to consider their conceptions. Standardized face-to-face semi-structured interviews were used, and transcripts were submitted to content analysis. Results Patients' representations suggest that they might be confident in taking a generic medication: when he/she has an understanding of generics as resulting from a development process that has become part of the public domain; the generic medication is prescribed by the physician; each prescription is discussed, i.e., the patient is prescribed the generic version of a given medication and not a generic medication. Discussion Economic arguments are not sufficient to justify substitution, and may even raise issues calling upon cognitive dissonance. Even in non-life-threatening diseases, negative cues require attention and need be de-emphasized - in particular lower price as an indication of lower quality, and generic status as contradictory with advocating individualization of medication.	[Piguet, Valerie; Besson, Marie; Desmeules, Jules; Cedraschi, Christine] Univ Hosp Geneva, Ctr Multidisciplinary Pain, Div Clin Pharmacol & Toxicol, Geneva, Switzerland; [Piguet, Valerie; Besson, Marie; Desmeules, Jules; Cedraschi, Christine] Univ Geneva, Geneva, Switzerland; [D'Incau, Stephanie] Univ Hosp Geneva, Div Gen Internal Med, Geneva, Switzerland; [Cedraschi, Christine] Univ Hosp Geneva, Div Gen Med Rehabil, Geneva, Switzerland	University of Geneva; University of Geneva; University of Geneva; University of Geneva	Piguet, V (corresponding author), Univ Hosp Geneva, Ctr Multidisciplinary Pain, Div Clin Pharmacol & Toxicol, Geneva, Switzerland.	Valerie.Piguet@hcuge.ch	Besson, Marie/AAG-3253-2019					Al Ameri MN, 2011, TRANSPL INT, V24, P770, DOI 10.1111/j.1432-2277.2011.01268.x; Andersson K, 2005, PHARMACOEPIDEM DR S, V14, P341, DOI 10.1002/pds.1055; Babar ZUD, 2014, HEALTH POLICY, V117, P285, DOI 10.1016/j.healthpol.2014.06.004; Barbour RS, 2003, J EVAL CLIN PRACT, V9, P179, DOI 10.1046/j.1365-2753.2003.00371.x; Barbour RS, 2001, BMJ-BRIT MED J, V322, P1115, DOI 10.1136/bmj.322.7294.1115; Barry CA, 1999, QUAL HEALTH RES, V9, P26, DOI 10.1177/104973299129121677; Bowen GA, 2008, QUAL RES, V8, P137, DOI 10.1177/1468794107085301; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Daly J, 2007, J CLIN EPIDEMIOL, V60, P43, DOI 10.1016/j.jclinepi.2006.03.014; Daubresse M, 2013, MED CARE, V51, P870, DOI 10.1097/MLR.0b013e3182a95d86; Decollogny A, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-17; Dylst P, 2013, EXPERT REV PHARM OUT, V13, P59, DOI [10.1586/ERP.12.83, 10.1586/erp.12.83]; Ess SM, 2003, PHARMACOECONOMICS, V21, P89, DOI 10.2165/00019053-200321020-00002; Fairman KA, 2008, J MANAGE CARE PHARM, V14, P387, DOI 10.18553/jmcp.2008.14.4.387; Festinger L., 1957, COGNITIVE DISSONANCE; Gaskell G., 2000, QUALITATIVE RES TEXT, P38, DOI DOI 10.4135/9781849209731; Giacomini MK, 2000, JAMA-J AM MED ASSOC, V284, P357, DOI 10.1001/jama.284.3.357; Glaser B, 1996, DISCOVERY GROUNDED T; Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903; Hakonsen H, 2009, CURR MED RES OPIN, V25, P2515, DOI 10.1185/03007990903192223; Hassali Mohamed A A, 2009, Int J Pharm Pract, V17, P79; Heikkila Reeta, 2011, BMC Clin Pharmacol, V11, P20, DOI 10.1186/1472-6904-11-20; Himmel W, 2005, INT J CLIN PHARM TH, V43, P472; Kaplan WA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074399; Kjoenniksen I, 2006, PHARM WORLD SCI, V28, P284, DOI 10.1007/s11096-006-9043-5; KUZEL AJ, 1992, RES METH PR, V3, P31; LEVENTHAL H, 1992, COGNITIVE THER RES, V16, P143, DOI 10.1007/BF01173486; Leventhal H., 2003, SELF REGULATION HLTH, P138; Lincoln Y.S., 1985, NATURALISTIC INQUIRY; Lincoln Y.S., 2005, SAGE HDB QUALITATIVE; Lionberger R, 2013, CLIN PHARMACOL THER, V94, P438, DOI 10.1038/clpt.2013.104; Mays N, 1996, QUALITATIVE RES HLTH; Mody GM, 2012, BEST PRACT RES CL RH, V26, P237, DOI 10.1016/j.berh.2012.03.002; Morse JM, 2002, INT J QUAL METHODS, V1, P13, DOI DOI 10.1177/160940690200100202; Nelson AE, 2014, SEMIN ARTHRITIS RHEU, V43, P701, DOI 10.1016/j.semarthrit.2013.11.012; O'Reilly M, 2013, QUAL RES, V13, P190, DOI 10.1177/1468794112446106; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; Ritchie J., 1994, ANAL QUALITATIVE DAT, P173, DOI [DOI 10.4324/9780203413081_CHAPTER_9, 10.4324/9780203413081_chapter_9]; Sander JW, 2010, EXPERT REV NEUROTHER, V10, P1887, DOI 10.1586/ERN.10.163; Sarradon-Eck A, 2007, REV EPIDEMIOL SANTE, V55, P179, DOI 10.1016/j.respe.2007.01.026; Schwartz N, 1992, CONTEXT EFFECTS SOCI; Shah RR, 2012, BRIT J CLIN PHARMACO, V74, P698, DOI 10.1111/j.1365-2125.2012.04328.x; Shrank WH, 2007, J GEN INTERN MED, V22, P1298, DOI 10.1007/s11606-007-0284-3; Shrank WH, 2010, HEALTH AFFAIR, V29, P1383, DOI 10.1377/hlthaff.2009.0424; Shrank WH, 2009, HEALTH AFFAIR, V28, P546, DOI 10.1377/hlthaff.28.2.546; Shrank WH, 2009, MED CARE, V47, P319, DOI 10.1097/MLR.0b013e31818af850; Simoens Steven, 2008, Expert Rev Clin Pharmacol, V1, P497, DOI 10.1586/17512433.1.4.497; Stone J, 2010, FRONT SOC PSYCHOL, P313; Strauss A., 1990, BASICS GROUNDED THEO; Turk DC, 2011, LANCET, V377, P2226, DOI 10.1016/S0140-6736(11)60402-9; Waber RL, 2008, JAMA-J AM MED ASSOC, V299, P1016, DOI 10.1001/jama.299.9.1016; Wicklund R.A., 2013, PERSPECTIVES COGNITI; Yu Y, 2013, CLIN PHARMACOL THER, V94, P519, DOI 10.1038/clpt.2013.108	53	4	4	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2015	10	8							e0134661	10.1371/journal.pone.0134661	http://dx.doi.org/10.1371/journal.pone.0134661			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CO1UY	26237036	Green Submitted, Green Published, gold			2023-01-03	WOS:000358942400031
J	Boozary, AS; Manchin, J; Wicker, RF				Boozary, Andrew S.; Manchin, Joseph, III; Wicker, Roger F.			The Medicare Hospital Readmissions Reduction Program Time for Reform	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Boozary, Andrew S.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy &, Boston, MA 02115 USA; [Manchin, Joseph, III] US Senate D West Virginia, Washington, DC USA; [Wicker, Roger F.] US Senate R Mississippi, Washington, DC USA	Harvard University; Harvard T.H. Chan School of Public Health	Boozary, AS (corresponding author), Harvard Univ, Sch Publ Hlth, 677 Huntington Ave, Boston, MA 02115 USA.	asb242@mail.harvard.edu						Conway PH, 2013, JAMA-J AM MED ASSOC, V309, P2215, DOI 10.1001/jama.2013.4929; Fiscella K, 2014, JAMA-J AM MED ASSOC, V312, P2615, DOI 10.1001/jama.2014.15372; Glass D, 2012, REFINING HOSP READMI; Hershberger PJ, 2014, JAMA-J AM MED ASSOC, V312, P2613, DOI 10.1001/jama.2014.13304; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Jha AK, OUNCE EVIDENCE; Joynt KE, 2013, JAMA-J AM MED ASSOC, V309, P342, DOI 10.1001/jama.2012.94856; Rau J, MEDICARE FINES 2610; US Department of Health and Human Services, 2014, NEW HHS DAT SHOWS MA	9	65	65	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	2015	314	4					347	348		10.1001/jama.2015.6507	http://dx.doi.org/10.1001/jama.2015.6507			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CN6YY	26219049				2023-01-03	WOS:000358581700013
J	Gouleme, N; Gerard, CL; Bucci, MP				Gouleme, Nathalie; Gerard, Christophe-Loic; Bucci, Maria Pia			The Effect of Training on Postural Control in Dyslexic Children	PLOS ONE			English	Article							DEVELOPMENTAL DYSLEXIA; BALANCE; PERFORMANCE; PARAMETERS; PLATFORM; GAIT	The aim of this study was to explore whether a short postural training period could affect postural stability in dyslexic children. Postural performances were evaluated using Multitest Equilibre from Framiral. Posture was recorded in three different viewing conditions (eyes open fixating a target, eyes closed and eyes open with perturbed vision) and in two different postural conditions (on stable and unstable support). Two groups of dyslexic children participated in the study, i.e. G1:16 dyslexic participants (mean age 9.9 +/- 0.3 years) who performed short postural training and G2: 16 dyslexic participants of similar ages (mean age 9.1 +/- 0.3 years) who did not perform any short postural training. Findings showed that short postural training improved postural stability on unstable support surfaces with perturbed vision: indeed the surface, the mean velocity of CoP and the spectral power indices in both directions decreased significantly, and the cancelling time in the antero-posterior direction improved significantly. Such improvement could be due to brain plasticity, which allows better performance in sensory process and cerebellar integration.	[Gouleme, Nathalie; Bucci, Maria Pia] Paris Diderot Univ, UMR 1141, INSERM, Robert Debre Hosp, Paris, France; [Gerard, Christophe-Loic] Hop Robert Debre, Child & Adolescent Psychiat Dept, F-75019 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite	Gouleme, N (corresponding author), Paris Diderot Univ, UMR 1141, INSERM, Robert Debre Hosp, Paris, France.	gouleme.nathalie@gmail.com		Gouleme, Nathalie/0000-0002-0246-973X	Fondation Cotrel / Institut de France	Fondation Cotrel / Institut de France	The authors are grateful to the Fondation Cotrel / Institut de France for their financial support.	Abd El-Kafy EM, 2014, AM J PHYS MED REHAB, V93, P938, DOI 10.1097/PHM.0000000000000109; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; Angulo-Barroso RM, 2013, RES DEV DISABIL, V34, P3629, DOI 10.1016/j.ridd.2013.07.037; Barela JA, 2011, RES DEV DISABIL, V32, P1814, DOI 10.1016/j.ridd.2011.03.011; Barge L, 2007, EXPLORATION REEDUCAT, P8; Bernard-Demanze L, 2009, Curr Aging Sci, V2, P139; Brandt T, 2003, VERTIGO ITS MULTISEN, P503; Bucci MP, 2012, EXP BRAIN RES, V222, P21, DOI 10.1007/s00221-012-3192-7; Bucci M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057801; Burciu RG, 2013, J NEUROSCI, V33, P4594, DOI 10.1523/JNEUROSCI.3381-12.2013; Chevrie-Muller C, 1997, BATTERIE LANGUAGE OR; Chiari L, 2002, CLIN BIOMECH, V17, P666, DOI 10.1016/S0268-0033(02)00107-9; Eckert MA, 2003, BRAIN, V126, P482, DOI 10.1093/brain/awg026; Faigenbaum AD, 2013, J STRENGTH COND RES, V27, P323, DOI 10.1519/JSC.0b013e31827e135b; Fawcett A, 1999, REV ELECT INVEST PSI, V2, P35; GEURTS ACH, 1993, ARCH PHYS MED REHAB, V74, P1144; Ghulyan V, 2005, ACTA OTO-LARYNGOL, V125, P607, DOI 10.1080/00016480510026908; Gouleme N, 2015, CLIN NEUROPHYSIOL, V126, P1370, DOI 10.1016/j.clinph.2014.10.016; Ilg W, 2009, NEUROLOGY, V73, P1823, DOI 10.1212/WNL.0b013e3181c33adf; Ilg W, 2010, MOVEMENT DISORD, V25, P2239, DOI 10.1002/mds.23222; Ionescu E, 2006, INT J PEDIATR OTORHI, V70, P1457, DOI 10.1016/j.ijporl.2006.03.012; Katz-Leurer M, 2009, CLIN REHABIL, V23, P714, DOI 10.1177/0269215509335293; KohenRaz R, 1996, PERCEPT MOTOR SKILL, V82, P547, DOI 10.2466/pms.1996.82.2.547; Konczak J, 2005, BRAIN, V128, P1428, DOI 10.1093/brain/awh385; Lacour M, 2008, NEUROPHYSIOL CLIN, V38, P411, DOI 10.1016/j.neucli.2008.09.005; Legrand A, 2021, PLOS ONE, V7, P1; MAKI BE, 1990, J AM GERIATR SOC, V38, P1, DOI 10.1111/j.1532-5415.1990.tb01588.x; Miyai I, 2012, NEUROREHAB NEURAL RE, V26, P515, DOI 10.1177/1545968311425918; Moe-Nilssen R, 2003, EXP BRAIN RES, V150, P237, DOI 10.1007/s00221-003-1450-4; Naschner LN, 2008, PROGR BRAIN RES, V1979, P177; Nicolson RI, 2007, TRENDS NEUROSCI, V30, P135, DOI 10.1016/j.tins.2007.02.003; O'Hare Anne, 2002, Dyslexia, V8, P234, DOI 10.1002/dys.230; Paillard T, 2002, BRIT J SPORT MED, V36, P304, DOI 10.1136/bjsm.36.4.304; Perennou D, 2006, EFFICIENCE DEFICIENC, P65; Pozzo T, 2006, NEUROSCI LETT, V403, P211, DOI 10.1016/j.neulet.2006.03.049; Rae C, 1998, LANCET, V351, P1849, DOI 10.1016/S0140-6736(97)99001-2; Reynolds D, 2003, DYSLEXIA, V9, P48, DOI 10.1002/dys.235; Sehm B, 2014, NEUROBIOL AGING, V35, P232, DOI 10.1016/j.neurobiolaging.2013.06.021; Stoodley CJ, 2005, EXP BRAIN RES, V167, P370, DOI 10.1007/s00221-005-0042-x; Taubert M, 2010, J NEUROSCI, V30, P11670, DOI 10.1523/JNEUROSCI.2567-10.2010; Viana AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072719; Vieira S, 2009, NEUROSCI LETT, V462, P125, DOI 10.1016/j.neulet.2009.06.093; Woollacott MH, 1989, DEV POSTURE GAIT LIF, P77; YAP RL, 1994, J LEARN DISABIL, V27, P660, DOI 10.1177/002221949402701006; Zech A, 2014, EUR J APPL PHYSIOL, V114, P395, DOI 10.1007/s00421-013-2786-5	45	8	9	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2015	10	7							e0130196	10.1371/journal.pone.0130196	http://dx.doi.org/10.1371/journal.pone.0130196			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CN1FD	26162071	gold, Green Published, Green Submitted			2023-01-03	WOS:000358162300015
J	Zelasko-Leon, DC; Fuentes, CM; Messersmith, PB				Zelasko-Leon, Daria C.; Fuentes, Christina M.; Messersmith, Phillip B.			MUC1-Targeted Cancer Cell Photothermal Ablation Using Bioinspired Gold Nanorods	PLOS ONE			English	Article							BOVINE SERUM-ALBUMIN; IN-VIVO; PLASMA-PROTEINS; MUC1 MUCIN; NANOPARTICLES; POLYDOPAMINE; CARCINOMA; THERAPY; MUSSEL; BSA	Recent studies have highlighted the overexpression of mucin 1 (MUC1) in various epithelial carcinomas and its role in tumorigenesis. These mucins present a novel targeting opportunity for nanoparticle-mediated photothermal cancer treatments due to their unique antenna-like extracellular extension. In this study, MUC1 antibodies and albumin were immobilized onto the surface of gold nanorods using a "primer" of polydopamine (PD), a molecular mimic of catechol-and amine-rich mussel adhesive proteins. PD forms an adhesive platform for the deposition of albumin and MUC1 antibodies, achieving a surface that is stable, bioinert and biofunctional. Two-photon luminescence confocal and darkfield scattering imaging revealed targeting of MUC1-BSA-PD-NRs to MUC1(+) MCF-7 breast cancer and SCC-15 squamous cell carcinoma cells lines. Treated cells were exposed to a laser encompassing the near-infrared AuNR longitudinal surface plasmon and assessed for photothermal ablation. MUC1-BSA-PD-NRs substantially decreased cell viability in photoirradiated MCF-7 cell lines vs. MUC1-MDA-MB-231 breast cancer cells (p < 0.005). Agents exhibited no cytotoxicity in the absence of photothermal treatment. The facile nature of the coating method, combined with targeting and photoablation efficacy, are attractive features of these candidate cancer nanotherapeutics.	[Zelasko-Leon, Daria C.; Fuentes, Christina M.; Messersmith, Phillip B.] Northwestern Univ, Dept Biomed Engn, Chem Life Proc Inst, Evanston, IL 60208 USA; [Zelasko-Leon, Daria C.; Fuentes, Christina M.; Messersmith, Phillip B.] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA; [Messersmith, Phillip B.] Univ Calif Berkeley, Dept Mat Sci & Engn, Berkeley, CA 94720 USA	Northwestern University; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Zelasko-Leon, DC (corresponding author), Northwestern Univ, Dept Biomed Engn, Chem Life Proc Inst, Evanston, IL 60208 USA.	philm@berkeley.edu		Messersmith, Phillip/0000-0002-1197-333X	NCI CCSG [P30 CA060553]; MRSEC program at the Material Research Center [NSF DMR-1121262]; International Institute for Nanotechnology (IIN); Keck Foundation; State of Illinois; Northwestern University High Throughput Analysis Laboratory (HTAL); Keck Biophysics Facility; Northwestern University Flow Cytometry Facility; Cancer Center [NCI CA060553]; National Science Foundation [DGE-0824162]; Robert H. Lurie Comprehensive Cancer Center (RHLCC) of Northwestern University; McCormick Summer Research Award; NIH [R01 EB005772, R37 DE014193]; NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB005772] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE014193] Funding Source: NIH RePORTER	NCI CCSG; MRSEC program at the Material Research Center; International Institute for Nanotechnology (IIN); Keck Foundation(W.M. Keck Foundation); State of Illinois; Northwestern University High Throughput Analysis Laboratory (HTAL); Keck Biophysics Facility; Northwestern University Flow Cytometry Facility; Cancer Center; National Science Foundation(National Science Foundation (NSF)); Robert H. Lurie Comprehensive Cancer Center (RHLCC) of Northwestern University; McCormick Summer Research Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	Imaging work was performed at the Northwestern University Center for Advanced Molecular Imaging (CAMI), generously supported by NCI CCSG P30 CA060553 awarded to the Robert H. Lurie Comprehensive Cancer Center. Portions of this research were performed at the Keck-II and EPIC cores of the Northwestern University Atomic and Nanoscale Characterization Experimental (NUANCE) Center. The NUANCE Center is supported by the MRSEC program (NSF DMR-1121262) at the Material Research Center, the International Institute for Nanotechnology (IIN), the Keck Foundation, and the State of Illinois. Additional material characterization experiments were carrieed out with the support of the Northwestern University High Throughput Analysis Laboratory (HTAL) and Keck Biophysics Facility. This work was further supported by the Northwestern University Flow Cytometry Facility and a Cancer Center Support Grant (NCI CA060553). DCZL was supported by a National Science Foundation Graduate Research Fellowship (DGE-0824162; http://www.fastlane.nsf.gov/grfp) and a Malkin Scholar Award from the Robert H. Lurie Comprehensive Cancer Center (RHLCC) of Northwestern University (http://cancer.northwestern.edu/research/research_programs/funding/). CMF was supported by a McCormick Summer Research Award (http://www.mccormick.northwestern.edu/students/undergraduate/research-opportunities/). Additional support was provided by NIH grants R01 EB005772 and R37 DE014193 (PBM; http://report.nih.gov/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alkilany AM, 2012, ADV DRUG DELIVER REV, V64, P190, DOI 10.1016/j.addr.2011.03.005; Alkilany AM, 2009, SMALL, V5, P701, DOI 10.1002/smll.200801546; AMIJI M, 1992, J BIOMAT SCI-POLYM E, V3, P375, DOI 10.1163/156856292X00196; Apostolopoulos V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1505; Ball V, 2012, J COLLOID INTERF SCI, V386, P366, DOI 10.1016/j.jcis.2012.07.030; Black KCL, 2014, SMALL, V10, P169, DOI 10.1002/smll.201301283; Black KCL, 2013, NANOMEDICINE-UK, V8, P17, DOI [10.2217/NNM.12.82, 10.2217/nnm.12.82]; Brewer SH, 2005, LANGMUIR, V21, P9303, DOI 10.1021/la050588t; Carpin LB, 2011, BREAST CANCER RES TR, V125, P27, DOI 10.1007/s10549-010-0811-5; d'Ischia M, 2014, ACCOUNTS CHEM RES, V47, P3541, DOI 10.1021/ar500273y; Dalsin JL, 2005, MATER TODAY, V8, P38, DOI 10.1016/S1369-7021(05)71079-8; Danysh BP, 2012, THERANOSTICS, V2, P777, DOI 10.7150/thno.4494; Dickerson EB, 2008, CANCER LETT, V269, P57, DOI 10.1016/j.canlet.2008.04.026; Ding YH, 2014, LANGMUIR, V30, P12258, DOI 10.1021/la5026608; Dreyer DR, 2012, LANGMUIR, V28, P6428, DOI 10.1021/la204831b; El-Sayed IH, 2006, CANCER LETT, V239, P129, DOI 10.1016/j.canlet.2005.07.035; Feng J, 2014, RSC ADV, V4, P28683, DOI 10.1039/c4ra03122a; Fessler SP, 2009, BREAST CANCER RES TR, V118, P113, DOI 10.1007/s10549-009-0412-3; Finn OJ, 2008, J IMMUNOL, V181, P1589, DOI 10.4049/jimmunol.181.3.1589; Francis GL, 2010, CYTOTECHNOLOGY, V62, P1, DOI 10.1007/s10616-010-9263-3; Gelamo EL, 2002, BBA-PROTEIN STRUCT M, V1594, P84, DOI 10.1016/S0167-4838(01)00287-4; Gole A, 2005, CHEM MATER, V17, P1325, DOI 10.1021/cm048297d; Govorov AO, 2007, NANO TODAY, V2, P30, DOI 10.1016/S1748-0132(07)70017-8; Hong S, 2012, ADV FUNCT MATER, V22, P4711, DOI 10.1002/adfm.201201156; Horiguchi Y, 2008, LANGMUIR, V24, P12026, DOI 10.1021/la800811j; Housni A, 2008, J PHYS CHEM C, V112, P12282, DOI 10.1021/jp803890a; Huang XH, 2006, J AM CHEM SOC, V128, P2115, DOI 10.1021/ja057254a; Huang XH, 2007, NANO LETT, V7, P1591, DOI 10.1021/nl070472c; Kamps JAAM, 1997, P NATL ACAD SCI USA, V94, P11681, DOI 10.1073/pnas.94.21.11681; Kouchakzadeh Hasan, 2012, Human Antibodies, V21, P49, DOI 10.3233/HAB-2012-0261; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Lee BP, 2011, ANNU REV MATER RES, V41, P99, DOI 10.1146/annurev-matsci-062910-100429; Lee H, 2007, SCIENCE, V318, P426, DOI 10.1126/science.1147241; Lee H, 2009, ADV MATER, V21, P431, DOI 10.1002/adma.200801222; Lynge ME, 2011, NANOSCALE, V3, P4916, DOI 10.1039/c1nr10969c; Mamedova NN, 2001, NANO LETT, V1, P281, DOI 10.1021/nl015519n; Melancon MP, 2008, MOL CANCER THER, V7, P1730, DOI 10.1158/1535-7163.MCT-08-0016; Mitchell S, 2002, NEOPLASIA, V4, P9, DOI 10.1038/sj.neo.7900194; Mukai H, 2010, JPN J CLIN ONCOL, V40, P711, DOI 10.1093/jjco/hyq037; Mukhopadhyay P, 2011, BBA-REV CANCER, V1815, P224, DOI 10.1016/j.bbcan.2011.01.001; Nakanishi K, 2001, J BIOSCI BIOENG, V91, P233, DOI 10.1016/S1389-1723(01)80127-4; Nath N, 2004, SURF SCI, V570, P98, DOI 10.1016/j.susc.2004.06.182; Niidome T, 2006, J CONTROL RELEASE, V114, P343, DOI 10.1016/j.jconrel.2006.06.017; Nitta T, 2000, CANCER-AM CANCER SOC, V88, P245, DOI 10.1002/(SICI)1097-0142(20000115)88:2<245::AID-CNCR1>3.0.CO;2-T; Norde W, 2000, J BIOTECHNOL, V79, P259, DOI 10.1016/S0168-1656(00)00242-X; Ogawara K, 2004, J CONTROL RELEASE, V100, P451, DOI 10.1016/j.jconrel.2004.07.028; PACKHAM MA, 1969, J LAB CLIN MED, V73, P686; Pattani VP, 2015, J NANOPART RES, V17, DOI 10.1007/s11051-014-2822-3; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; Proks V, 2013, MACROMOL CHEM PHYS, V214, P499, DOI 10.1002/macp.201200505; Raina D, 2009, CANCER RES, V69, P5133, DOI 10.1158/0008-5472.CAN-09-0854; Ratner BD, 2002, J CONTROL RELEASE, V78, P211, DOI 10.1016/S0168-3659(01)00502-8; REED RG, 1986, J BIOL CHEM, V261, P5619; Sanavio B, 2007, BBA-PROTEINS PROTEOM, V1774, P781, DOI 10.1016/j.bbapap.2007.04.019; Sayari E, 2014, INT J PHARMACEUT, V473, P304, DOI 10.1016/j.ijpharm.2014.05.041; Sedo J, 2013, ADV MATER, V25, P653, DOI 10.1002/adma.201202343; Sileika TS, 2011, ACS APPL MATER INTER, V3, P4602, DOI 10.1021/am200978h; Singh AV, 2005, J MATER CHEM, V15, P5115, DOI 10.1039/b510398c; SLOCUM TL, 1991, ANAL BIOCHEM, V195, P14, DOI 10.1016/0003-2697(91)90287-4; Statz AR, 2009, BIOINTERPHASES, V4, pFA22, DOI 10.1116/1.3115103; Takahashi H, 2006, LANGMUIR, V22, P2, DOI 10.1021/la0520029; Technology NIoSa, 2012, NIST XRAY PHOTOELECT; Tenzer S, 2013, NAT NANOTECHNOL, V8, P772, DOI 10.1038/nnano.2013.181; Treuel L, 2010, CHEMPHYSCHEM, V11, P3093, DOI 10.1002/cphc.201000174; von Maltzahn G, 2011, NAT MATER, V10, P545, DOI [10.1038/nmat3049, 10.1038/NMAT3049]; VROMAN L, 1969, SURF SCI, V16, P438, DOI 10.1016/0039-6028(69)90037-5; WAITE JH, 1985, J MAR BIOL ASSOC UK, V65, P359, DOI 10.1017/S0025315400050487; Walsh MD, 1999, BREAST CANCER RES TR, V58, P255; Wang LM, 2013, J AM CHEM SOC, V135, P17359, DOI 10.1021/ja406924v; Weissleder R, 2001, NAT BIOTECHNOL, V19, P316, DOI 10.1038/86684; Whitney JR, 2013, SINGLE WALLED CARBON; Willets KA, 2007, ANNU REV PHYS CHEM, V58, P267, DOI 10.1146/annurev.physchem.58.032806.104607; Wiogo HTR, 2011, LANGMUIR, V27, P843, DOI 10.1021/la104278m; Wu P, 2012, ANAL CHEM, V84, P7692, DOI 10.1021/ac3015164; Zhao F, 2011, SMALL, V7, P1322, DOI 10.1002/smll.201100001; ZHOU NE, 1992, J BIOL CHEM, V267, P2664; Zhou WB, 2010, CHEM COMMUN, V46, P1479, DOI 10.1039/b915125g	77	24	24	1	80	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2015	10	7							e0128756	10.1371/journal.pone.0128756	http://dx.doi.org/10.1371/journal.pone.0128756			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1DQ	26147830	Green Published, Green Submitted, gold			2023-01-03	WOS:000358157600016
J	Workenhe, ST; Ketela, T; Moffat, J; Cuddington, BP; Mossman, KL				Workenhe, S. T.; Ketela, T.; Moffat, J.; Cuddington, B. P.; Mossman, K. L.			Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells	ONCOGENE			English	Article							HERPES-SIMPLEX-VIRUS; ANTITUMOR EFFICACY; THERAPEUTIC-EFFICACY; TOPOISOMERASE-I; SR PROTEINS; PHOSPHORYLATION; SPLICEOSOME; APOPTOSIS; GENES; HSV-1	Oncolytic human herpes simplex virus type 1 (HSV-1) shows promising treatment efficacy in late-stage clinical trials. The anticancer activity of oncolytic viruses relies on deregulated pathways in cancer cells, which make them permissive to oncolysis. To identify pathways that restrict HSV-1 KM100-mediated oncolysis, this study used a pooled genome-wide short hairpin RNA library and found that depletion of the splicing factor arginine-rich splicing factor 2 (SRSF2) leads to enhanced cytotoxicity of breast cancer cells by KM100. Serine/arginine-rich (SR) proteins are a family of RNA-binding phosphoproteins that control both constitutive and alternative pre-mRNA splicing. Further characterization showed that KM100 infection of HS578T cells under conditions of low SRSF2 leads to pronounced apoptosis without a corresponding increase in virus replication. As DNA topoisomerase I inhibitors can limit the phosphorylation of SRSF2, we combined a topoisomerase I inhibitor chemotherapeutic with KM100 and observed synergistic anticancer effect in vitro and prolonged survival of tumor-bearing mice in vivo.	[Workenhe, S. T.; Cuddington, B. P.; Mossman, K. L.] McMaster Univ, Inst Infect Dis Res, McMaster Immunol Res Ctr, Dept Pathol & Mol Med, 1280 Main St West,MDCL 5026, Hamilton, ON L8S 4K1, Canada; [Ketela, T.; Moffat, J.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada	McMaster University; University of Toronto	Workenhe, ST; Mossman, KL (corresponding author), McMaster Univ, Inst Infect Dis Res, McMaster Immunol Res Ctr, Dept Pathol & Mol Med, 1280 Main St West,MDCL 5026, Hamilton, ON L8S 4K1, Canada.	samuelworkenhe@gmail.com; mossk@mcmaster.ca	Moffat, Jason/AAC-1110-2020	Moffat, Jason/0000-0002-5663-8586	Cancer Research Society; Canadian Cancer Society Research Institute	Cancer Research Society; Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS))	These studies were supported by operating grants to KLM from the Cancer Research Society and the Canadian Cancer Society Research Institute.	Anczukow O, 2012, NAT STRUCT MOL BIOL, V19, P220, DOI 10.1038/nsmb.2207; Bolyard C, 2014, CLIN CANCER RES, V20, P6479, DOI 10.1158/1078-0432.CCR-14-0463; Bonnal S, 2012, NAT REV DRUG DISCOV, V11, P847, DOI 10.1038/nrd3823; Cheema TA, 2011, CLIN CANCER RES, V17, P7383, DOI 10.1158/1078-0432.CCR-11-1762; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Ciomei M, 2006, CLIN CANCER RES, V12, P2856, DOI 10.1158/1078-0432.CCR-05-1859; Diallo JS, 2010, MOL THER, V18, P1123, DOI 10.1038/mt.2010.67; Edmond V, 2013, CELL CYCLE, V12, P1267, DOI 10.4161/cc.24363; Edmond V, 2011, EMBO J, V30, P510, DOI 10.1038/emboj.2010.333; Hummel JL, 2005, MOL THER, V12, P1101, DOI 10.1016/j.ymthe.2005.07.533; Ilkow CS, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003836; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Ketela T, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-213; Kumler I, 2013, BREAST CANCER RES TR, V138, P347, DOI 10.1007/s10549-013-2476-3; Mahoney DJ, 2010, CYTOKINE GROWTH F R, V21, P161, DOI 10.1016/j.cytogfr.2010.02.013; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Moorman NJ, 2010, J VIROL, V84, P5260, DOI 10.1128/JVI.02733-09; Mossman KL, 1999, J VIROL, V73, P9726, DOI 10.1128/JVI.73.12.9726-9733.1999; Pilch B, 2001, CANCER RES, V61, P6876; Quidville V, 2013, CANCER RES, V73, P2247, DOI 10.1158/0008-5472.CAN-12-2501; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; Rovero S, 2000, J IMMUNOL, V165, P5133, DOI 10.4049/jimmunol.165.9.5133; Russell SJ, 2012, NAT BIOTECHNOL, V30, P658, DOI 10.1038/nbt.2287; Sobol PT, 2011, MOL THER, V19, P335, DOI 10.1038/mt.2010.264; Solier S, 2010, CANCER RES, V70, P8055, DOI 10.1158/0008-5472.CAN-10-2491; Soret J, 2003, CANCER RES, V63, P8203; Stickeler E, 1999, ONCOGENE, V18, P3574, DOI 10.1038/sj.onc.1202671; Tahara M, 2013, BIOCHEM BIOPH RES CO, V434, P753, DOI 10.1016/j.bbrc.2013.03.128; Twyffels L, 2011, FEBS J, V278, P3246, DOI 10.1111/j.1742-4658.2011.08274.x; Ueno M, 2002, EUR UROL, V42, P390, DOI 10.1016/S0302-2838(02)00321-4; Vanderbeeken MC, 2013, CURR BREAST CANCER R, V5, P31, DOI 10.1007/s12609-012-0098-0; Walsh D, 2004, GENE DEV, V18, P660, DOI 10.1101/gad.1185304; Walsh D, 2011, NAT REV MICROBIOL, V9, P860, DOI 10.1038/nrmicro2655; Workenhe ST, 2013, CANCER IMMUNOL RES, V1, P309, DOI 10.1158/2326-6066.CIR-13-0059-T; Workenhe ST, 2014, MOL THER, V22, P123, DOI 10.1038/mt.2013.238; Workenhe ST, 2009, MOL IMMUNOL, V46, P2955, DOI 10.1016/j.molimm.2009.06.015; Zhang J, 2013, CANCER DISCOV, V3, P1228, DOI 10.1158/2159-8290.CD-13-0253	38	21	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2465	2474		10.1038/onc.2015.303	http://dx.doi.org/10.1038/onc.2015.303			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26257065				2023-01-03	WOS:000376165500005
J	Pillay, J; Armstrong, MJ; Butalia, S; Donovan, LE; Sigal, RJ; Chordiya, P; Dhakal, S; Vandermeer, B; Hartling, L; Nuspl, M; Featherstone, R; Dryden, DM				Pillay, Jennifer; Armstrong, Marni J.; Butalia, Sonia; Donovan, Lois E.; Sigal, Ronald J.; Chordiya, Pritam; Dhakal, Sanjaya; Vandermeer, Ben; Hartling, Lisa; Nuspl, Megan; Featherstone, Robin; Dryden, Donna M.			Behavioral Programs for Type 1 Diabetes Mellitus A Systematic Review and Meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIAL; MOTIVATIONAL ENHANCEMENT THERAPY; PERSONAL TRAINER INTERVENTION; SELF-MANAGEMENT EDUCATION; IMPROVE REGIMEN ADHERENCE; POOR METABOLIC-CONTROL; QUALITY-OF-LIFE; GLYCEMIC CONTROL; MULTISYSTEMIC THERAPY; YOUNG-PEOPLE	Background: Whether behavioral approaches for self-management programs benefit individuals with type 1 diabetes mellitus is unclear. Purpose: To determine the effects of behavioral programs for patients with type 1 diabetes on behavioral, clinical, and health outcomes and to investigate factors that might moderate effect. Data Sources: 6 electronic databases (1993 to June 2015), trial registries and conference proceedings (2011 to 2014), and reference lists. Study Selection: 36 prospective, controlled studies involving participants of any age group that compared behavioral programs with usual care, active controls, or other programs. Data Extraction: One reviewer extracted and another verified data. Two reviewers assessed quality and strength of evidence (SOE). Data Synthesis: Moderate SOE showed reduction in glycated hemoglobin (HbA1c) at 6 months after the intervention compared with usual care (mean difference, -0.29 [95% CI, -0.45 to -0.13] percentage points) and compared with active controls (-0.44 [CI, -0.69 to -0.19] percentage points). At the end of the intervention and 12-month follow-up or longer, there were no statistically significant differences in HbA1c (low SOE) for comparisons with usual care or active control. Compared with usual care, generic quality of life at program completion did not differ (moderate SOE). Other outcomes had low or insufficient SOE. Adults appeared to benefit more for glycemic control at program completion (-0.28 [CI, -0.57 to 0.01] percentage points) than did youth (-0.12 [CI, -0.43 to 0.19] percentage points). Program intensity appeared not to influence effectiveness; some individual delivery appears beneficial. Limitations: All studies had medium or high risk of bias. There was scarce evidence for many outcomes. Conclusion: Behavioral programs for type 1 diabetes offer some benefit for glycemic control, at least at short-term followup, but improvement for other outcomes has not been shown. (PROSPERO registration number: CRD42014010515)	[Pillay, Jennifer; Chordiya, Pritam; Dhakal, Sanjaya; Vandermeer, Ben; Hartling, Lisa; Nuspl, Megan; Featherstone, Robin; Dryden, Donna M.] Univ Alberta, Alberta Res Ctr Hlth Evidence, Dept Pediat, Edmonton Clin Hlth Acad, Edmonton, AB T6G 1C9, Canada; Alberta Hlth Serv, Calgary, AB, Canada; [Armstrong, Marni J.; Butalia, Sonia; Donovan, Lois E.; Sigal, Ronald J.] Univ Calgary, Div Endocrinol & Metab, Richmond Rd Diagnost & Treatment Ctr, Calgary, AB T2T 5C7, Canada	University of Alberta; Alberta Health Services (AHS); University of Calgary; University of Calgary	Pillay, J (corresponding author), Univ Alberta, Alberta Res Ctr Hlth Evidence, Dept Pediat, Edmonton Clin Hlth Acad, 4th Floor,11405 87th Ave, Edmonton, AB T6G 1C9, Canada.	jpillay@ualberta.ca	Sigal, Ronald/AAU-6081-2020; Featherstone, Robin/J-5165-2014; Sigal, Ron/AAK-7627-2020	Featherstone, Robin/0000-0003-2517-2258; Butalia, Sonia/0000-0001-7865-9161	Agency for Healthcare Research and Quality	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Agency for Healthcare Research and Quality. (PROSPERD registration number: CRD42014010515)	Agency for Healthcare Research and Quality, 2014, AHRQ PUBL, V10; Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS14, DOI 10.2337/dc14-S014; Amsberg S, 2009, PATIENT EDUC COUNS, V77, P72, DOI 10.1016/j.pec.2009.01.015; Amsberg S, 2009, DIABETES RES CLIN PR, V84, P76, DOI 10.1016/j.diabres.2008.12.011; Anderson BJ, 1999, DIABETES CARE, V22, P713, DOI 10.2337/diacare.22.5.713; [Anonymous], 2008, DIABETES EDUCATOR, V34, P445, DOI 10.1177/0145721708316625; Ayling K, 2015, PSYCHOL HEALTH, V30, P85, DOI 10.1080/08870446.2014.953528; BOARDWAY RH, 1993, J PEDIATR PSYCHOL, V18, P29, DOI 10.1093/jpepsy/18.1.29; Chiang JL, 2014, DIABETES CARE, V37, P2034, DOI 10.2337/dc14-1140; Christie D, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18200; Cook S, 2002, DIABETES EDUCATOR, V28, P115, DOI 10.1177/014572170202800113; Couch Robert, 2008, Evid Rep Technol Assess (Full Rep), P1; Couper JJ, 1999, DIABETES CARE, V22, P1933, DOI 10.2337/diacare.22.12.1933; Court JM, 2009, PEDIATR DIABETES, V10, P185, DOI 10.1111/j.1399-5448.2009.00586.x; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ellis DA, 2005, J PEDIATR PSYCHOL, V30, P656, DOI 10.1093/jpepsy/jsi052; Ellis DA, 2005, DIABETES CARE, V28, P1604, DOI 10.2337/diacare.28.7.1604; Ellis DA, 2004, J CLIN PSYCHOL MED S, V11, P315, DOI 10.1023/B:JOCS.0000045351.98563.4d; Ellis DA, 2007, J CONSULT CLIN PSYCH, V75, P168, DOI 10.1037/0022-006X.75.1.168; Ellis DA, 2012, ANN BEHAV MED, V44, P207, DOI 10.1007/s12160-012-9378-1; Forlani G, 2006, J ENDOCRINOL INVEST, V29, P405, DOI 10.1007/BF03344123; Franklin VL, 2006, DIABETIC MED, V23, P1332, DOI 10.1111/j.1464-5491.2006.01989.x; Fullerton B, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009122.pub2; Funnell M, 2013, DIABETIC MED, V30, P765, DOI 10.1111/dme.12244; Griffin S, 1998, BMJ-BRIT MED J, V317, P390; Haas L, 2013, DIABETES CARE, V36, pS100, DOI [10.2337/dc13-S100, 10.2337/dc13-S004]; Hampson SE, 2000, DIABETES CARE, V23, P1416, DOI 10.2337/diacare.23.9.1416; Harris MA, 2015, DIABETES CARE, V38, P1427, DOI 10.2337/dc14-2469; Hermanns N, 2013, DIABETES RES CLIN PR, V102, P149, DOI 10.1016/j.diabres.2013.10.009; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Holmes CS, 2014, DIABETES CARE, V37, P1535, DOI 10.2337/dc13-1053; Hood KK, 2010, DIABETES CARE, V33, P1658, DOI 10.2337/dc09-2268; Husted GR, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-321; Ingerski LM, 2010, J ADOLESCENT HEALTH, V47, P191, DOI 10.1016/j.jadohealth.2010.01.012; International Diabetes Federation, 2011, POS STAT SELF MAN ED; IntHout J, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-25; Ip S, 2012, SYST REV, V1, DOI 10.1186/2046-4053-1-15; Ismail K, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14220; Ismail K, 2008, ANN INTERN MED, V149, P708, DOI 10.7326/0003-4819-149-10-200811180-00005; Jones H, 2013, CAN J DIABETES, V37, pS26, DOI 10.1016/j.jcjd.2013.01.015; Karlsen B, 2004, PATIENT EDUC COUNS, V53, P299, DOI 10.1016/j.pec.2003.10.008; Katz ML, 2014, PEDIATR DIABETES, V15, P142, DOI 10.1111/pedi.12065; Kichler JC, 2013, FAM SYST HEALTH, V31, P280, DOI 10.1037/a0033039; Knight KM, 2006, DIABETIC MED, V23, P485, DOI 10.1111/j.1464-5491.2005.01802.x; Laffel LMB, 2003, J PEDIATR-US, V142, P409, DOI 10.1067/mpd.2003.138; Lehmkuhl Heather D, 2010, J Diabetes Sci Technol, V4, P199; Lv JC, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001293; Malik K, 2013, HUMAN DEV REP 2013; Mannucci E, 2005, ACTA DIABETOL, V42, P1, DOI 10.1007/s00592-005-0167-1; Mayer-Davis EJ, 2015, DIABETIC MED, V32, P829, DOI 10.1111/dme.12641; MCNABB WL, 1994, DIABETES EDUCATOR, V20, P121, DOI 10.1177/014572179402000206; Moher D, 2000, J CLIN EPIDEMIOL, V53, P964, DOI 10.1016/S0895-4356(00)00188-8; Murphy HR, 2007, DIABETIC MED, V24, P1261, DOI 10.1111/j.1464-5491.2007.02229.x; Murphy HR, 2006, DIABETIC MED, V23, P935, DOI 10.1111/j.1464-5491.2006.01816.x; Murphy HR, 2012, DIABETIC MED, V29, pE249, DOI 10.1111/j.1464-5491.2012.03683.x; Nansel TR, 2007, DIABETES CARE, V30, P2471, DOI 10.2337/dc06-2621; Nansel TR, 2015, INT J BEHAV NUTR PHY, V12, DOI 10.1186/s12966-015-0214-4; Nansel TR, 2012, PEDIATRICS, V129, pE866, DOI 10.1542/peds.2011-2858; Nansel TR, 2009, DIABETES CARE, V32, P807, DOI 10.2337/dc08-1968; Nansel TR, 2009, PEDIATR DIABETES, V10, P105, DOI 10.1111/j.1399-5448.2008.00448.x; Nathan DM, 2014, DIABETES CARE, V37, P9, DOI 10.2337/dc13-2112; National Institute for Health and Clinical Excellence, 2010, MAN TYP 2 DIAB; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Norris SL, 2004, AM J MED, V117, P762, DOI 10.1016/j.amjmed.2004.05.024; Orchard TJ, 2015, JAMA-J AM MED ASSOC, V313, P45, DOI 10.1001/jama.2014.16107; Patel A, 2011, DIABETIC MED, V28, P470, DOI 10.1111/j.1464-5491.2010.03198.x; Perry TL, 1997, EUR J CLIN NUTR, V51, P757, DOI 10.1038/sj.ejcn.1600478; Peters A, 2011, DIABETES CARE, V34, P2477, DOI 10.2337/dc11-1723; Pettitt DJ, 2014, DIABETES CARE, V37, P402, DOI 10.2337/dc13-1838; Pillay J, 2015, BEHAV PROGRAMS DIABE; Pimouguet C, 2011, CAN MED ASSOC J, V183, pE115, DOI 10.1503/cmaj.091786; Revicki D, 2008, J CLIN EPIDEMIOL, V61, P102, DOI 10.1016/j.jclinepi.2007.03.012; Ridge K, 2012, PSYCHOSOM MED, V74, P319, DOI 10.1097/PSY.0b013e31824c181b; Schellenberg ES, 2013, ANN INTERN MED, V159, P543, DOI 10.7326/0003-4819-159-8-201310150-00007; Schilling Lynne S, 2006, J Pediatr Nurs, V21, P412, DOI 10.1016/j.pedn.2006.01.034; Serlachius AS, 2014, J HLTH PSYCHOL; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Sidik K, 2002, STAT MED, V21, P3153, DOI 10.1002/sim.1262; THOMASDOBERSEN DA, 1993, J AM DIET ASSOC, V93, P535, DOI 10.1016/0002-8223(93)91812-5; Tricco AC, 2012, LANCET, V379, P2252, DOI 10.1016/S0140-6736(12)60480-2; Urban AD, 2004, J CLIN OUTCOMES MANA, V11, P299; US Department of Health and Human Services CDER, 2008, GUID IND DIAB MELL D; Viklund G, 2007, DIABETIC MED, V24, P550, DOI 10.1111/j.1464-5491.2007.02114.x; Viner RM, 2003, DIABETIC MED, V20, P739, DOI 10.1046/j.1464-5491.2003.00995.x; Weinger K, 2011, ARCH INTERN MED, V171, P1990, DOI 10.1001/archinternmed.2011.502; Wells GA, 2015, NEWCASTLE OTTAWA SCA; Wysocki T, 2007, DIABETES CARE, V30, P555, DOI 10.2337/dc06-1613; Wysocki T, 2006, J PEDIATR PSYCHOL, V31, P928, DOI 10.1093/jpepsy/jsj098; Zoffmann V, 2006, PATIENT EDUC COUNS, V64, P78, DOI 10.1016/j.pec.2005.11.017	90	51	50	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	2015	163	11					836	+		10.7326/M15-1399	http://dx.doi.org/10.7326/M15-1399			24	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CX7FB	26414020				2023-01-03	WOS:000365866500007
J	Patnode, CD; Henderson, JT; Thompson, JH; Senger, CA; Fortmann, SP; Whitlock, EP				Patnode, Carrie D.; Henderson, Jillian T.; Thompson, Jamie H.; Senger, Caitlyn A.; Fortmann, Stephen P.; Whitlock, Evelyn P.			Behavioral Counseling and Pharmacotherapy Interventions for Tobacco Cessation in Adults, Including Pregnant Women: A Review of Reviews for the US Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Review							NICOTINE-REPLACEMENT THERAPY; RANDOMIZED CONTROLLED TRIAL; SMOKING-CESSATION; METHODOLOGICAL QUALITY; ELECTRONIC CIGARETTES; MEASUREMENT TOOL; METAANALYSIS; SMOKERS; VARENICLINE; PATCHES	Background: Tobacco use is the leading cause of preventable death in the United States. Purpose: To review the effectiveness and safety of pharmacotherapy and behavioral interventions for tobacco cessation. Data Sources: 5 databases and 8 organizational Web sites were searched through 1 August 2014 for systematic reviews, and PubMed was searched through 1 March 2015 for trials on electronic nicotine delivery systems. Study Selection: Two reviewers examined 114 articles to identify English-language reviews that reported health, cessation, or adverse outcomes. Data Extraction: One reviewer abstracted data from good-and fair-quality reviews, and a second checked for accuracy. Data Synthesis: 54 reviews were included. Behavioral interventions increased smoking cessation at 6 months or more (physician advice had a pooled risk ratio [RR] of 1.76 [95% CI, 1.58 to 1.96]). Nicotine replacement therapy (RR, 1.60 [CI, 1.53 to 1.68]), bupropion (RR, 1.62 [CI, 1.49 to 1.76]), and varenicline (RR, 2.27 [CI, 2.02 to 2.55]) were also effective for smoking cessation. Combined behavioral and pharmacotherapy interventions increased cessation by 82% compared with minimal intervention or usual care (RR, 1.82 [CI, 1.66 to 2.00]). None of the drugs were associated with major cardiovascular adverse events. Only 2 trials addressed efficacy of electronic cigarettes for smoking cessation and found no benefit. Among pregnant women, behavioral interventions benefited cessation and perinatal health; effects of nicotine replacement therapy were not significant. Limitation: Evidence published after each review's last search date was not included. Conclusion: Behavioral and pharmacotherapy interventions improve rates of smoking cessation among the general adult population, alone or in combination. Data on the effectiveness and safety of electronic nicotine delivery systems are limited.	[Patnode, Carrie D.; Henderson, Jillian T.; Thompson, Jamie H.; Senger, Caitlyn A.; Fortmann, Stephen P.; Whitlock, Evelyn P.] Kaiser Permanente Northwest, Ctr Hlth Res, Kaiser Permanente Res Affiliates Evidence Based P, Portland, OR 97232 USA	Kaiser Permanente	Patnode, CD (corresponding author), Kaiser Permanente Northwest, Ctr Hlth Res, Kaiser Permanente Res Affiliates Evidence Based P, Portland, OR 97232 USA.				Agency for Healthcare Research and Quality	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Agency for Healthcare Research and Quality.	Agaku IT, 2014, MMWR-MORBID MORTAL W, V63, P29; [Anonymous], 2014, SMOKING CESSATION IN; Banham L, 2010, ADDICTION, V105, P1176, DOI 10.1111/j.1360-0443.2010.02946.x; Barnes J, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001008.pub2; Benowitz Neal L, 2014, Ann Am Thorac Soc, V11, P231, DOI 10.1513/AnnalsATS.201312-433PS; Berlin Ivan, 2014, BMJ, V348, pg1622, DOI 10.1136/bmj.g1622; Bhatnagar A, 2014, CIRCULATION, V130, P1418, DOI 10.1161/CIR.0000000000000107; Bize R, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004705.pub4; Bodner Michael E., 2009, Physiotherapy Theory and Practice, V25, P369, DOI 10.1080/09593980903011887; Bondurant S, 2009, COMBATING TOBACCO MI; Brody JS, 2014, AM J RESP CRIT CARE, V189, P379, DOI 10.1164/rccm.201312-2263ED; Brown J, 2013, WORLDV EVID-BASED NU, V10, P150, DOI 10.1111/wvn.12000; Bullen C, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2008; Bullen C, 2013, LANCET, V382, P1629, DOI 10.1016/S0140-6736(13)61842-5; Cahill K, 2013, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD009329.pub2, 10.1002/14651858.CD006103.pub6]; Cahill K, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004492.pub4; Caponnetto P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066317; Carr AB, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005084.pub3; Carson KV, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009046.pub2; Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion, 2010, TOB SMOK CAUS DIS BI; Chamberlain Catherine, 2013, Cochrane Database Syst Rev, pCD001055, DOI 10.1002/14651858.CD001055.pub4; Chen YF, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16380; Cheng HM, 2012, AM J CHINESE MED, V40, P429, DOI 10.1142/S0192415X12500334; Civljak M, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007078.pub4; Coleman T, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010078; Coleman T, 2012, NEW ENGL J MED, V366, P808, DOI 10.1056/NEJMoa1109582; Cornell JE, 2014, ANN INTERN MED, V160, P267, DOI 10.7326/M13-2886; Di YM, 2014, DRUG ALCOHOL DEPEN, V142, P14, DOI 10.1016/j.drugalcdep.2014.07.002; Ebbert J, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004306.pub4; Filion KB, 2011, BJOG-INT J OBSTET GY, V118, P1422, DOI 10.1111/j.1471-0528.2011.03065.x; Fiore MC, 2000, JAMA-J AM MED ASSOC, V283, P3244; Fiore MC, 2008, CLIN PRACTICE GUIDEL; Fiore MC, 2008, AM J PREV MED, V35, P158, DOI 10.1016/j.amepre.2008.04.009; Free C, 2011, LANCET, V378, P49, DOI 10.1016/S0140-6736(11)60701-0; Gierisch J., 2010, COMP EFFECTIVENESS S; Hartmann-Boyce J, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001118.pub3; Hettema JE, 2010, J CONSULT CLIN PSYCH, V78, P868, DOI 10.1037/a0021498; Hitchman SC, 2014, ADDICTION, V109, P867, DOI 10.1111/add.12550; Huang YB, 2012, J PUBLIC HEALTH-HEID, V20, P355, DOI 10.1007/s10389-011-0476-5; Hughes JR, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000031.pub3, 10.1002/14651858.CD000031.pub4]; Hutton HE, 2011, NICOTINE TOB RES, V13, P227, DOI 10.1093/ntr/ntq252; Johnston V, 2013, NICOTINE TOB RES, V15, P1329, DOI 10.1093/ntr/ntt022; Kontopantelis E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069930; Lai DTC, 2010, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006936.pub2, 10.1002/14651858.CD006936.pub3]; Liu JJ, 2013, PREV MED, V57, P765, DOI 10.1016/j.ypmed.2013.09.014; Lumley J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001055.pub3; Maziak W, 2014, JAMA-J AM MED ASSOC, V311, P1922, DOI 10.1001/jama.2014.2995; McRobbie Hayden, 2014, Cochrane Database Syst Rev, pCD010216, DOI 10.1002/14651858.CD010216.pub2; Mills EJ, 2014, CIRCULATION, V129, P28, DOI 10.1161/CIRCULATIONAHA.113.003961; Mills EJ, 2012, ANN MED, V44, P588, DOI 10.3109/07853890.2012.705016; Mills Edward J, 2010, Tob Induc Dis, V8, P8, DOI 10.1186/1617-9625-8-8; Mottillo S, 2009, EUR HEART J, V30, P718, DOI 10.1093/eurheartj/ehn552; Myung SK, 2012, BJOG-INT J OBSTET GY, V119, P1029, DOI 10.1111/j.1471-0528.2012.03408.x; Myung SK, 2009, ARCH INTERN MED, V169, P929, DOI 10.1001/archinternmed.2009.109; National Center for Chronic Disease P, 2014, HLTH CONSMOK 50 YE; Nierkens V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073373; Oncken C, 2008, OBSTET GYNECOL, V112, P859, DOI 10.1097/AOG.0b013e318187e1ec; Patnode CD, 2015, BEHAV COUNSELING PHA; Prochaska JJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2856; Rice VH, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001188.pub4; Rodgers A, 2005, TOB CONTROL, V14, P255, DOI 10.1136/tc.2005.011577; ROSE G, 1992, J EPIDEMIOL COMMUN H, V46, P75, DOI 10.1136/jech.46.1.75; ROSE G, 1978, J EPIDEMIOL COMMUN H, V32, P275, DOI 10.1136/jech.32.4.275; Shahab L, 2009, ADDICTION, V104, P1792, DOI 10.1111/j.1360-0443.2009.02710.x; Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10; Shea BJ, 2009, J CLIN EPIDEMIOL, V62, P1013, DOI 10.1016/j.jclinepi.2008.10.009; Stead LF, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002850.pub2; Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub3; Stead LF, 2012, COCHRANE DB SYST REV, V12, DOI DOI 10.1002/14651858; Stead LF, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008286.pub2; Stead LF, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000165.pub4; Stotts AL, 2015, AM J PERINAT, V32, P351, DOI 10.1055/s-0034-1386635; Su A, 2014, MATERN CHILD HLTH J, V18, P714, DOI 10.1007/s10995-013-1298-6; Substance Abuse and Mental Health Services Administration, 2013, RES 2012 NAT SURV DR; Tahiri M, 2012, AM J MED, V125, P576, DOI 10.1016/j.amjmed.2011.09.028; Tran K, 2010, PHARM BASED STRATEGI; Tsoi DT, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007253.pub3; Tzelepis F, 2011, JNCI-J NATL CANCER I, V103, P922, DOI 10.1093/jnci/djr169; U. S. Preventive Services Task Force, 2011, PROC MAN; US Preventive Serv Task Force, 2009, ANN INTERN MED, V150, P551, DOI 10.7326/0003-4819-150-8-200904210-00009; Ussher MH, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002295.pub3; van der Meer RM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006102.pub2; Villanti AC, 2010, AM J PREV MED, V39, P564, DOI 10.1016/j.amepre.2010.08.009; White AR, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000009.pub4; White AR, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000009.pub3; Whittaker R, 2009, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006611.pub2, 10.1002/14651858.CD006611.pub3]; Wisborg K, 2000, OBSTET GYNECOL, V96, P967, DOI 10.1016/S0029-7844(00)01071-1; World Health Organization, 2013, WHO REC PREV MAN TOB; Zbikowski SM, 2012, MATURITAS, V71, P131, DOI 10.1016/j.maturitas.2011.11.019	89	116	119	1	32	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 20	2015	163	8					608	+		10.7326/M15-0171	http://dx.doi.org/10.7326/M15-0171			21	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CU7QV	26389650				2023-01-03	WOS:000363737400019
J	Ojha, D; Das, R; Sobia, P; Dwivedi, V; Ghosh, S; Samanta, A; Chattopadhyay, D				Ojha, Durbadal; Das, Rashmi; Sobia, Parveen; Dwivedi, Vedprakash; Ghosh, Soma; Samanta, Amalesh; Chattopadhyay, Debprasad			Pedilanthus tithymaloides Inhibits HSV Infection by Modulating NF-kappa B Signaling	PLOS ONE			English	Article							SIMPLEX-VIRUS TYPE-1; PROTEIN-KINASE; NUCLEAR TRANSLOCATION; ANTIVIRAL ACTIVITY; GENE-EXPRESSION; ACTIVATION; PATHWAYS; APOPTOSIS; ETHNOMEDICINE; FLAVONOIDS	Pedilanthus tithymaloides (PT), a widely used ethnomedicinal plant, has been employed to treat a number of skin conditions. To extend its utility and to fully exploit its medicinal potential, we have evaluated the in vitro antiviral activity of a methanolic extract of PT leaves and its isolated compounds against Herpes Simplex Virus type 2 (HSV-2). Bioactivity-guided studies revealed that the extract and one of its constituents, luteolin, had potent antiviral activity against wild-type and clinical isolates of HSV-2 (EC50 48.5-52.6 and 22.4-27.5 mu g/ml, respectively), with nearly complete inhibition at 86.5-101.8 and 40.2-49.6 mu g/ml, respectively. The inhibitory effect was significant (p<0.001) when the drug was added 2 h prior to infection, and was effective up to 4 h post-infection. As viral replication requires NF-kappa B activation, we examined whether the observed extract-induced inhibition of HSV-2 was related to NF-kappa B inhibition. Interestingly, we observed that treatment of HSV-2-infected cells with extract or luteolin suppressed NF-kappa B activation. Although NF-kappa B, JNK and MAPK activation was compromised during HSV replication, neither the extract nor luteolin affected HSV-2-induced JNK1/2 and MAPK activation. Moreover, the PT leaf extract and luteolin potently down-regulated the expression of tumor necrosis factor (TNF)-alpha, Interleukin (IL)-1 beta, IL-6, NO and iNOS and the production of gamma interferon (IFN-gamma), which are directly involved in controlling the NF-kappa B signaling pathway. Thus, our results indicate that both PT leaf extract and luteolin modulate the NF-kappa B signaling pathway, resulting in the inhibition of HSV-2 replication.	[Ojha, Durbadal; Das, Rashmi; Ghosh, Soma; Chattopadhyay, Debprasad] ID & BG Hosp, ICMR Virus Unit, Kolkata 700010, India; [Sobia, Parveen; Dwivedi, Vedprakash] Univ KwaZulu Natal, Dept Microbiol, Coll Cell Sci, ZA-4001 Durban, South Africa; [Ghosh, Soma; Samanta, Amalesh] Jadavpur Univ, Dept Pharmaceut Technol, Kolkata 700032, India	Indian Council of Medical Research (ICMR); ICMR - National Institute of Cholera & Enteric Diseases (NICED); ICMR - Virus Unit, Kolkata; University of Kwazulu Natal; Jadavpur University	Chattopadhyay, D (corresponding author), ID & BG Hosp, ICMR Virus Unit, Gen Block 4,57 Dr Suresh Chandra Banerjee Rd, Kolkata 700010, India.	debprasadc@gmail.com		Dwivedi, Ved Prakash/0000-0003-4321-2567; CHATTOPADHYAY, Dr DEBPRASAD/0000-0002-7999-329X	Science and Engineering Research Board, Department of Science and Technology, Govt. of India, New Delhi [SB/SO/HS-025/2013]	Science and Engineering Research Board, Department of Science and Technology, Govt. of India, New Delhi	The authors acknowledge financial support from the Science and Engineering Research Board, Department of Science and Technology, Govt. of India, New Delhi (SB/SO/HS-025/2013). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amici C, 2006, J BIOL CHEM, V281, P7110, DOI 10.1074/jbc.M512366200; Amici C, 2001, J BIOL CHEM, V276, P28759, DOI 10.1074/jbc.M103408200; Baba M, 2006, ANTIVIR RES, V71, P301, DOI 10.1016/j.antiviral.2006.01.002; Bag P, 2014, ANTIVIR RES, V105, P126, DOI 10.1016/j.antiviral.2014.02.007; Bag P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077937; Bag P, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-98; Behbahani M, 2013, ANTIVIR RES, V97, P376, DOI 10.1016/j.antiviral.2013.01.001; Bhattacharjee S, 2009, J ANTIMICROB CHEMOTH, V63, P317, DOI 10.1093/jac/dkn479; Bunyapraphatsara N, 2000, MED PLANTS INDIGENOU, P691; Chattopadhyay D, 2008, BIOTECHNOL ANN REV, V14, P297, DOI 10.1016/S1387-2656(08)00012-4; Chen XQ, 2011, ANTIVIR RES, V92, P341, DOI 10.1016/j.antiviral.2011.09.005; Chenoweth MJ, 2012, J IMMUNOL, V188, P4149, DOI 10.4049/jimmunol.1101883; Coen DM, 2003, NAT REV DRUG DISCOV, V2, P278, DOI 10.1038/nrd1065; Dai X, 2008, INT IMMUNOL, V20, P901, DOI 10.1093/intimm/dxn048; Dai XJ, 2006, J INVEST DERMATOL, V126, P1574, DOI 10.1038/sj.jid.5700294; Du T, 2013, P NATL ACAD SCI USA, V110, pE2621, DOI 10.1073/pnas.1309906110; Faith SA, 2006, ANTIVIR RES, V72, P242, DOI 10.1016/j.antiviral.2006.06.011; Ghosh S, 2013, MED CHEM RES, V22, P4347, DOI 10.1007/s00044-012-0449-4; Ghosh S, 2012, J ETHNOPHARMACOL, V142, P714, DOI 10.1016/j.jep.2012.05.048; Gregory D, 2004, J VIROL, V78, P13582, DOI 10.1128/JVI.78.24.13582-13590.2004; Hargett D, 2005, J VIROL, V79, P8348, DOI 10.1128/JVI.79.13.8348-8360.2005; Hirobe C, 1997, PHYTOCHEMISTRY, V46, P521, DOI 10.1016/S0031-9422(97)00127-1; Huang WJ, 2012, J IMMUNOL, V188, P6247, DOI 10.4049/jimmunol.1103706; Karaca G, 2004, VIROLOGY, V329, P142, DOI 10.1016/j.virol.2004.08.020; Khan MTH, 2005, ANTIVIR RES, V67, P107, DOI 10.1016/j.antiviral.2005.05.002; Krylova N. V., 2011, Antibiotiki i Khimioterapiya, V56, P7; Kumar G.P., 2010, ETHNOBOT LEAFL, V2010, P4; Kutluay SB, 2008, VIROLOGY, V373, P239, DOI 10.1016/j.virol.2007.11.028; Lee JK, 2009, BIOCHEM PHARMACOL, V77, P1391, DOI 10.1016/j.bcp.2009.01.009; Liu AL, 2008, PLANTA MED, V74, P847, DOI 10.1055/s-2008-1074558; Ludwig S, 2009, J ANTIMICROB CHEMOTH, V64, P1, DOI 10.1093/jac/dkp161; McLean TI, 1999, J VIROL, V73, P8415, DOI 10.1128/JVI.73.10.8415-8426.1999; Mehla R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027915; Mogensen TH, 2001, MICROBIOL MOL BIOL R, V65, P131, DOI 10.1128/MMBR.65.1.131-150.2001; Mukherjee H, 2013, MICROBIOL RES, V168, P238, DOI 10.1016/j.micres.2012.11.002; Patel A, 1998, VIROLOGY, V247, P212, DOI 10.1006/viro.1998.9243; Perkins D, 2002, J VIROL, V76, P1435, DOI 10.1128/JVI.76.3.1435-1449.2002; Roizman B, 2007, FIELDS VIROLOGY, V2, P2501, DOI DOI 10.1148/RADIOL.14144045; Shishodia S, 2005, BIOCHEM PHARMACOL, V70, P700, DOI 10.1016/j.bcp.2005.04.043; Smith CC, 2000, J VIROL, V74, P10417, DOI 10.1128/JVI.74.22.10417-10429.2000; Song SW, 2014, ANTIMICROB AGENTS CH, V58, P5068, DOI 10.1128/AAC.02427-14; Swiecki M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003728; VRIJSEN R, 1988, J GEN VIROL, V69, P1749, DOI 10.1099/0022-1317-69-7-1749; Wang QY, 2005, P NATL ACAD SCI USA, V102, P16055, DOI 10.1073/pnas.0505850102; Xu L, 2014, VIRUSES-BASEL, V6, P2778, DOI 10.3390/v6072778; Yedowitz JC, 2005, VIROLOGY, V342, P297, DOI 10.1016/j.virol.2005.07.036; Zachos G, 1999, J BIOL CHEM, V274, P5097, DOI 10.1074/jbc.274.8.5097	47	19	19	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2015	10	9							e0139338	10.1371/journal.pone.0139338	http://dx.doi.org/10.1371/journal.pone.0139338			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS1CR	26405764	Green Published, gold, Green Submitted			2023-01-03	WOS:000361800700207
J	Huang, X; He, Y; Dubuc, AM; Hashizume, R; Zhang, W; Reimand, J; Yang, HH; Wang, TFA; Stehbens, SJ; Younger, S; Barshow, S; Zhu, SJ; Cooper, MK; Peacock, J; Ramaswamy, V; Garzia, L; Wu, XC; Remke, M; Forester, CM; Kim, CC; Weiss, WA; James, CD; Shuman, MA; Bader, GD; Mueller, S; Taylor, MD; Jan, YN; Jan, LY				Huang, Xi; He, Ye; Dubuc, Adrian M.; Hashizume, Rintaro; Zhang, Wei; Reimand, Jueri; Yang, Huanghe; Wang, Tongfei A.; Stehbens, Samantha J.; Younger, Susan; Barshow, Suzanne; Zhu, Sijun; Cooper, Michael K.; Peacock, John; Ramaswamy, Vijay; Garzia, Livia; Wu, Xiaochong; Remke, Marc; Forester, Craig M.; Kim, Charles C.; Weiss, William A.; James, C. David; Shuman, Marc A.; Bader, Gary D.; Mueller, Sabine; Taylor, Michael D.; Jan, Yuh Nung; Jan, Lily Yeh			EAG2 potassium channel with evolutionarily conserved function as a brain tumor target	NATURE NEUROSCIENCE			English	Article							HEDGEHOG PATHWAY INHIBITOR; CANCER STEM-CELLS; ION CHANNELS; MEDULLOBLASTOMA; DROSOPHILA; VOLUME; EXPRESSION; GROWTH; MODEL; THIORIDAZINE	Over 20% of the drugs for treating human diseases target ion channels, but no cancer drug approved by the US Food and Drug Administration (FDA) is intended to target an ion channel. We found that the EAG2 (Ether-a-go-go 2) potassium channel has an evolutionarily conserved function for promoting brain tumor growth and metastasis, delineate downstream pathways, and uncover a mechanism for different potassium channels to functionally cooperate and regulate mitotic cell volume and tumor progression. EAG2 potassium channel was enriched at the trailing edge of migrating medulloblastoma (MB) cells to regulate local cell volume dynamics, thereby facilitating cell motility. We identified the FDA-approved antipsychotic drug thioridazine as an EAG2 channel blocker that reduces xenografted MB growth and metastasis, and present a case report of repurposing thioridazine for treating a human patient. Our findings illustrate the potential of targeting ion channels in cancer treatment.	[Huang, Xi; He, Ye; Zhang, Wei; Yang, Huanghe; Wang, Tongfei A.; Younger, Susan; Barshow, Suzanne; Zhu, Sijun; Jan, Yuh Nung; Jan, Lily Yeh] Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, San Francisco, CA 94143 USA; [Huang, Xi; He, Ye; Zhang, Wei; Yang, Huanghe; Wang, Tongfei A.; Younger, Susan; Barshow, Suzanne; Zhu, Sijun; Jan, Yuh Nung; Jan, Lily Yeh] Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biophys & Biochem, San Francisco, CA USA; [Dubuc, Adrian M.; Peacock, John; Ramaswamy, Vijay; Garzia, Livia; Wu, Xiaochong; Remke, Marc; Taylor, Michael D.] Hosp Sick Children, Dev & Stem Cell Program, Arthur & Sonia Labatt Brain Tumor Res Ctr, Toronto, ON M5G 1X8, Canada; [Hashizume, Rintaro; James, C. David] Northwestern Univ, Feinberg Sch Med, Dept Neurol Surg, Chicago, IL 60611 USA; [Reimand, Jueri; Bader, Gary D.] Univ Toronto, Donnelly Ctr, Toronto, ON, Canada; [Stehbens, Samantha J.] Univ Calif San Francisco, Dept Cell & Tissue Biol, San Francisco, CA 94143 USA; [Cooper, Michael K.] Vanderbilt Univ, Dept Neurol, Med Ctr, Nashville, TN 37235 USA; [Forester, Craig M.; Weiss, William A.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Kim, Charles C.] Univ Calif San Francisco, Dept Med, Dept Expt Med, San Francisco, CA USA; [Weiss, William A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Weiss, William A.; Shuman, Marc A.; Mueller, Sabine] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA; [Weiss, William A.; Mueller, Sabine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Shuman, Marc A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Northwestern University; Feinberg School of Medicine; University of Toronto; University of California System; University of California San Francisco; Vanderbilt University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Jan, LY (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, San Francisco, CA 94143 USA.	yuhnung.jan@ucsf.edu; lily.jan@ucsf.edu	Bader, Gary/C-1176-2009; Barshow, Suzanne/GVS-8898-2022; Stehbens, Samantha/AAH-4145-2019; Stehbens, Samantha/D-3512-2019; Huang, Xi/C-2409-2017; Reimand, Jüri/U-9264-2019; Forester, Craig/HCI-4174-2022; zhang, wei/H-7371-2014	Bader, Gary/0000-0003-0185-8861; Barshow, Suzanne/0000-0002-6744-1834; Stehbens, Samantha/0000-0002-8145-2708; Stehbens, Samantha/0000-0002-8145-2708; Huang, Xi/0000-0002-7177-7525; Reimand, Jüri/0000-0002-2299-2309; zhang, wei/0000-0002-1648-3364; Wang, Tongfei/0000-0002-6306-7371; Kim, Charles/0000-0001-6474-8227; Taylor, Michael/0000-0001-7009-3466; He, Ye/0000-0002-3936-4958; Yang, Huanghe/0000-0001-9521-9328; Jan, Lily/0000-0003-3938-8498; Remke, Marc/0000-0002-9404-9993; Weiss, William/0000-0003-2230-9132; Ramaswamy, Vijay/0000-0002-6557-895X	GEMS-CTSI postdoctoral award from the Howard Hughes Medical Institute; UCSF; Damon Runyon Cancer Research Foundation Fellowship; NIH [P41 GM103504, R37NS040929, R37MH065334, R01CA185039]; Pediatric Brain Tumor Foundation; Garron Family Chair in Childhood Cancer Research at The Hospital for Sick Children; University of Toronto; Canadian Institutes of Health Research; Terry Fox Research Institute;  [CA133091];  [CA148699];  [CA159859]; NATIONAL CANCER INSTITUTE [R01CA159859, T32CA128583, R01CA133091, R01CA148699, P30CA060553, R01CA185039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH065334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS040929] Funding Source: NIH RePORTER	GEMS-CTSI postdoctoral award from the Howard Hughes Medical Institute; UCSF; Damon Runyon Cancer Research Foundation Fellowship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pediatric Brain Tumor Foundation; Garron Family Chair in Childhood Cancer Research at The Hospital for Sick Children; University of Toronto(University of Toronto); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Terry Fox Research Institute; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Y. Song, W.-P. Ge, S.-B. Yang, H. Yang, C. Peters, B. Piggott, S. Morrissy, D. Shih, B.K.Shoichet and all of the members of the Jan laboratory for constructive suggestions. We thank C. Chiang for critical reading of the manuscript. This work was supported by the GEMS-CTSI postdoctoral award from the Howard Hughes Medical Institute and UCSF, and the Damon Runyon Cancer Research Foundation Fellowship to X.H. (Kandis Ann Ulrich-Carleton Fellow), NIH grant P41 GM103504 to G.D.B., the Pediatric Brain Tumor Foundation and R01 grants CA133091, CA148699 and CA159859 to W.A.W. and M.D.T., the Garron Family Chair in Childhood Cancer Research at The Hospital for Sick Children and The University of Toronto, operating funds from the Canadian Institutes of Health Research, the Terry Fox Research Institute, and the Pediatric Brain Tumor Foundation to M.D.T., NIH grants R37NS040929 to Y.N.J., and R37MH065334 and R01CA185039 to L.Y.J.Y.N.J. and L.Y.J. are Howard Hughes Medical Institute investigators.	Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Bhattacharjee A, 2003, J NEUROSCI, V23, P11681; Boucrot E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001477; Bowman SK, 2008, DEV CELL, V14, P535, DOI 10.1016/j.devcel.2008.03.004; Broughton SJ, 2004, CURR BIOL, V14, pR290, DOI 10.1016/j.cub.2004.03.037; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; Corno D, 2012, CANCER DISCOV, V2, P554, DOI 10.1158/2159-8290.CD-11-0199; Fraser SP, 2008, EMBO REP, V9, P512, DOI 10.1038/embor.2008.75; Garcia-Ferreiro RE, 2004, J GEN PHYSIOL, V124, P301, DOI 10.1085/jgp.200409041; Gonzalez C, 2013, NAT REV CANCER, V13, P172, DOI 10.1038/nrc3461; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Habela CW, 2007, CELL CYCLE, V6, P1613, DOI 10.4161/cc.6.13.4357; Hage TA, 2012, J NEUROSCI, V32, P2714, DOI 10.1523/JNEUROSCI.5088-11.2012; Hatton BA, 2008, CANCER RES, V68, P1768, DOI 10.1158/0008-5472.CAN-07-5092; Herzberg IM, 1998, J PHYSIOL-LONDON, V511, P3, DOI 10.1111/j.1469-7793.1998.003bi.x; Homem CCF, 2012, DEVELOPMENT, V139, P4297, DOI 10.1242/dev.080515; Huang X, 2014, J CELL BIOL, V206, P151, DOI 10.1083/jcb.201404136; Huang X, 2012, GENE DEV, V26, P1780, DOI 10.1101/gad.193789.112; Huang Xi, 2010, J Vis Exp, DOI 10.3791/2086; Jakab M, 2006, CONTRIB NEPHROL, V152, P161, DOI 10.1159/000096322; Janic A, 2010, SCIENCE, V330, P1824, DOI 10.1126/science.1195481; Kaczmarek Leonard K, 2013, ISRN Neurosci, V2013; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Lee Hae Young, 2009, J Vis Exp, DOI 10.3791/990; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336; Pardo LA, 2004, PHYSIOLOGY, V19, P285, DOI 10.1152/physiol.00011.2004; Preskorn S H, 2001, J Psychiatr Pract, V7, P209, DOI 10.1097/00131746-200105000-00007; Prevarskaya N, 2010, TRENDS MOL MED, V16, P107, DOI 10.1016/j.molmed.2010.01.005; Reimand J, 2011, NUCLEIC ACIDS RES, V39, pW307, DOI 10.1093/nar/gkr378; Richter C, 2011, NAT CELL BIOL, V13, P1029, DOI 10.1038/ncb2306; Romer J, 2005, CANCER RES, V65, P4975, DOI 10.1158/0008-5472.CAN-05-0481; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Rutkowski S, 2010, J CLIN ONCOL, V28, P4961, DOI 10.1200/JCO.2010.30.2299; Saini N, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/486169; Schneider SW, 2000, PFLUG ARCH EUR J PHY, V439, P297, DOI 10.1007/s004240050943; Schonherr R, 2005, J MEMBRANE BIOL, V205, P175, DOI 10.1007/s00232-005-0782-3; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Schwab A, 2006, J CELL PHYSIOL, V206, P86, DOI 10.1002/jcp.20434; SCHWAB A, 1995, PFLUG ARCH EUR J PHY, V430, P802, DOI 10.1007/BF00386179; Schwab A, 2008, PHYSIOLOGY, V23, P212, DOI 10.1152/physiol.00003.2008; Schwab A, 2012, PHYSIOL REV, V92, P1865, DOI 10.1152/physrev.00018.2011; SVENDSEN CN, 1988, PSYCHIAT RES, V23, P1, DOI 10.1016/0165-1781(88)90029-7; Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974; Vahasoyrinki M, 2006, J NEUROSCI, V26, P2652, DOI 10.1523/JNEUROSCI.3316-05.2006; VANDERHEEREN FAJ, 1977, EUR J CLIN PHARMACOL, V11, P135, DOI 10.1007/BF00562905; Wallace K, 2000, GENESIS, V26, P77, DOI 10.1002/(SICI)1526-968X(200001)26:1<77::AID-GENE10>3.0.CO;2-R; Wang Z, 2002, J BIOL CHEM, V277, P24022, DOI 10.1074/jbc.M201949200; Ward RJ, 2009, CANCER RES, V69, P4682, DOI 10.1158/0008-5472.CAN-09-0342; Willoughby LF, 2013, DIS MODEL MECH, V6, P521, DOI 10.1242/dmm.009985; Wu X, 2012, NATURE, V482, P529, DOI 10.1038/nature10825; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386; Zhu SJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046724	55	49	49	1	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	SEP	2015	18	9					1236	+		10.1038/nn.4088	http://dx.doi.org/10.1038/nn.4088			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CQ0NI	26258683	Green Accepted			2023-01-03	WOS:000360292600012
J	Zhu, CJ; Hua, F; Zhu, XL; Li, M; Wang, HX; Yu, XM; Li, Y				Zhu, Chuan-jiang; Hua, Fang; Zhu, Xiao-lu; Li, Meng; Wang, Hong-xu; Yu, Xiao-ming; Li, Yan			Stereoselective Regulation of P-gp Activity by Clausenamide Enantiomers in Caco-2, KB/KBv and Brain Microvessel Endothelial Cells	PLOS ONE			English	Article							TISSUE DISTRIBUTION; PROTEIN EXPRESSION; CYTOCHROME-P450 3A; GLYCOPROTEIN; RHODAMINE-123; METABOLISM; MONOLAYERS; SUBSTRATE; TRANSPORT; BINDING	The (-)- and (+)-clausenamide (CLA) enantiomers have different pharmacokinetic effects in animals, but their association with putative stereoselective regulation of P-glycoprotein (P-gp) remains unclear. Using three cells expressing P-gp-Caco-2, KBv and rat brain micro-vessel endothelial cells(RBMEC), this study investigated the association of CLA enantiomers with P-gp. The results showed that the rhodamine 123 (Rh123) accumulation, an indicator of P-gp activity, in Caco-2, KBv and RBMECs was increased by (-) CLA (1 or 5 mu mol/L) at 8.2%-28.5%, but reduced by (+) CLA at 11.7%-25.9%, showing stereoselectivity in their regulation of P-gp activity. Following co-treatment of these cells with each CLA enantiomer and verapamil as a P-gp inhibitor, the (+)-isomer clearly antagonized the inhibitory effects of verapamil on P-gp efflux, whereas the (-)-isomer had slightly synergistic or additive effects. When higher concentrations (5 or 10 mu mol/L) of CLA enantiomers were added, the stimulatory effects of the (+)-isomer were converted into inhibitory ones, leading to an enhanced intracellular uptake of Rh123 by 24.5%-58.2%; but (-)-isomer kept its inhibition to P-gp activity, causing 30.0%-63.0% increase in the Rh123 uptake. The biphasic effects of (+) CLA were confirmed by CLA uptake in the Caco-2 cells. (+) CLA at 1 mu mol/L had significantly lower intracellular uptake than (-) CLA with a ratio[(-)/(+)] of 2.593, which was decreased to 2.167 and 1.893 after CLA concentrations increased to 2.5 and 5 mu mol/L. Besides, in the non-induced KB cells, (+) CLA(5 mu mol/L) upregulated P-gp expression at 54.5% relative to vehicle control, and decreased Rh123 accumulation by 28.2%, while (-) CLA(5 mu mol/L) downregulated P-gp expression at 15.9% and increased Rh123 accumulation by 18.0%. These results suggested that (-) CLA could be a P-gp inhibitor and (+) CLA could be a modulator with concentration-dependent biphasic effects on P-gp activity, which may result in drug-drug interactions when combined with other P-gp substrate drugs.	[Zhu, Chuan-jiang; Hua, Fang; Zhu, Xiao-lu; Li, Meng; Wang, Hong-xu; Yu, Xiao-ming; Li, Yan] Chinese Acad Med Sci, Inst Mat Med, Beijing 100050, Peoples R China; [Zhu, Chuan-jiang; Hua, Fang; Zhu, Xiao-lu; Li, Meng; Wang, Hong-xu; Yu, Xiao-ming; Li, Yan] Peking Union Med Coll, Beijing 100021, Peoples R China; [Zhu, Chuan-jiang; Li, Yan] Beijing Key Lab Nonclin Drug Metab & PK PD Study, Beijing, Peoples R China; [Zhu, Chuan-jiang] Beijing Key Lab New Drug Mech & Pharmacol Evaluat, Beijing, Peoples R China; [Yu, Xiao-ming] Beijing Key Lab Act Subst Discovery & Druggabil E, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Materia Medica - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Zhu, CJ (corresponding author), Chinese Acad Med Sci, Inst Mat Med, Beijing 100050, Peoples R China.	zhucj@imm.ac.cn	meng, li/GVT-2063-2022; Zhu, Xiao/AAV-2637-2021		National Natural Science Foundation of China [30873117]; Major Scientific and Technological Special Project for "Significant New Drugs Creation" [2009ZX09501-018, 2009ZX09301-003-51, 2012ZX09301-002-001-002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major Scientific and Technological Special Project for "Significant New Drugs Creation"	This work was supported by the grants from the National Natural Science Foundation of China (30873117, http://www.nsfc.gov.cn/, CJZ), and the Major Scientific and Technological Special Project for "Significant New Drugs Creation" (http://www.most.gov.cn/; 2009ZX09501-018, CJZ, XMY; 2009ZX09301-003-51, CJZ, YL; 2012ZX09301-002-001-002, CJZ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bachmeier CJ, 2011, BIOPHARM DRUG DISPOS, V32, P233, DOI 10.1002/bdd.753; Chen Y, 2009, J PHARMACOL EXP THER, V330, P956, DOI 10.1124/jpet.109.154781; Duan Wenzhen, 1998, Yaoxue Xuebao, V33, P259; Duan WZ, 1998, ACTA PHARMACOL SIN, V19, P332; Fontaine M, 1996, LIFE SCI, V59, P1521, DOI 10.1016/0024-3205(96)00483-3; Glaeser H, 2011, HANDB EXP PHARMACOL, V201, P285, DOI 10.1007/978-3-642-14541-4_7; Hochman JH, 2000, J PHARMACOL EXP THER, V292, P310; Iwanaga K, 2011, BIOL PHARM BULL, V34, P1246, DOI 10.1248/bpb.34.1246; Karwatsky J, 2003, BIOCHEMISTRY-US, V42, P12163, DOI 10.1021/bi034149+; Kirby B, 2006, J CLIN PHARMACOL, V46, P1313, DOI 10.1177/0091270006292625; Kondratov RV, 2001, P NATL ACAD SCI USA, V98, P14078, DOI 10.1073/pnas.241314798; Litman T, 1997, BBA-MOL BASIS DIS, V1361, P169, DOI 10.1016/S0925-4439(97)00027-6; Liu Shaolin, 1998, Yaoxue Xuebao, V33, P254; Liu ShaoLin, 1999, Acta Pharmaceutica Sinica, V34, P325; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Meyer RP, 2007, CURR DRUG METAB, V8, P297, DOI 10.2174/138920007780655478; Qian ZY, 1999, CHIN J CELL BIOL, V21, P42; Rao EC, 1994, ACTA PHARMACOL SIN, V29, P502; Sachs-Barrable K, 2007, J PHARM PHARM SCI, V10, P319; Schuetz EG, 1996, MOL PHARMACOL, V49, P311; Shen SJ, 2007, CHIRALITY, V19, P485, DOI 10.1002/chir.20400; Swed A, 2009, MOL PHARMACEUT, V6, P1883, DOI 10.1021/mp900170y; Tang FX, 2004, J PHARM SCI-US, V93, P1185, DOI 10.1002/jps.20046; Tian Y, 2012, ACTA PHARM SIN B, V2, P168, DOI 10.1016/j.apsb.2012.02.005; WACHER VJ, 1995, MOL CARCINOGEN, V13, P129, DOI 10.1002/mc.2940130302; YANG M-H, 1987, Yaoxue Xuebao, V22, P33; YANG MH, 1987, ACTA CHIM SINICA, V45, P1170; Yumoto R, 1999, J PHARMACOL EXP THER, V289, P149; Zhang XH, 1994, ACTA PHARMACOL SINIC, V29, P246; Zhang Y, 2010, CANCER CHEMOTH PHARM, V66, P851, DOI 10.1007/s00280-009-1229-9; Zhu CJ, 2009, CHIRALITY, V21, P402, DOI 10.1002/chir.20623; Zhu CJ, 2013, EUR J PHARM SCI, V49, P761, DOI 10.1016/j.ejps.2013.04.033; Zhu CJ, 2003, CHIRALITY, V15, P668, DOI 10.1002/chir.10278; Zhu CJ, 2003, CHIRALITY, V15, P448, DOI 10.1002/chir.10228	34	6	6	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2015	10	8							e0135866	10.1371/journal.pone.0135866	http://dx.doi.org/10.1371/journal.pone.0135866			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP5MR	26295572	gold, Green Published, Green Submitted			2023-01-03	WOS:000359926900046
J	Giannasi, LC; Matsui, MY; Freitas, SRB; Caldas, BF; Grossmann, E; Amorim, JBO; dos Santos, ID; Oliveira, LVF; Oliveira, CS; Gomes, MF				Giannasi, Lilian Chrystiane; Matsui, Miriam Yumi; Batista Freitas, Sandra Regina; Caldas, Bruna F.; Grossmann, Eduardo; Amorim, Jose Benedito O.; dos Santos, Israel dos Reis; Franco Oliveira, Luis Vicente; Oliveira, Claudia Santos; Gomes, Monica Fernandes			Effects of Neuromuscular Electrical Stimulation on the Masticatory Muscles and Physiologic Sleep Variables in Adults with Cerebral Palsy: A Novel Therapeutic Approach	PLOS ONE			English	Article							QUALITY-OF-LIFE; CHILDREN; APNEA; DISORDERS; EPIDEMIOLOGY; INTERMITTENT; MASSETER; PATTERNS; HYPOXIA	Cerebral palsy (CP) is a term employed to define a group of non-progressive neuromotor disorders caused by damage to the immature or developing brain, with consequent limitations regarding movement and posture. CP may impair orapharygeal muscle tone, leading to a compromised chewing function and to sleep disorders (such as obstructive sleep apnea). Thirteen adults with CP underwent bilateral masseter and temporalis neuromuscular electrical stimulation (NMES) therapy. The effects on the masticatory muscles and sleep variables were evaluated using electromyography (EMG) and polysomnography (PSG), respectively, prior and after 2 months of NMES. EMG consisted of 3 tests in different positions: rest, mouth opening and maximum clenching effort (MCE). EMG values in the rest position were 100% higher than values recorded prior to therapy for all muscles analyzed (p < 0.05); mean mouth opening increased from 38.0 +/- 8.0 to 44.0 +/- 10.0 cm (p = 0.03). A significant difference in MCE was found only for the right masseter. PSG revealed an improved in the AHI from 7.2 +/- 7.0/h to 2.3 +/- 1.5/h (p < 0.05); total sleep time improved from 185 min to 250 min (p = 0.04) and minimun SaO2 improved from 83.6 +/- 3.0 to 86.4 +/- 4.0 (p = 0.04). NMES performed over a two-month period led to improvements in the electrical activity of the masticatory muscles at rest, mouth opening, isometric contraction and sleep variables, including the elimination of obstructive sleep apnea events in patients with CP.	[Giannasi, Lilian Chrystiane; Matsui, Miriam Yumi; Batista Freitas, Sandra Regina; Caldas, Bruna F.; Amorim, Jose Benedito O.; Gomes, Monica Fernandes] State Sao Paulo Univ Julio de Mesquita Filho, UNESP SJC, Biosci, Sao Jose Dos Campos, Brazil; [Giannasi, Lilian Chrystiane; dos Santos, Israel dos Reis; Franco Oliveira, Luis Vicente; Oliveira, Claudia Santos] Nove Julho Univ UNINOVE, Rehabil Sci Master & PhD Program, Sao Paulo, Brazil; [Grossmann, Eduardo] Univ Fed Rio Grande do Sul, Anat Lab, Porto Alegre, RS, Brazil	Universidade Nove de Julho; Universidade Federal do Rio Grande do Sul	Giannasi, LC (corresponding author), State Sao Paulo Univ Julio de Mesquita Filho, UNESP SJC, Biosci, Sao Jose Dos Campos, Brazil.	odontogiannasi@uol.com.br	Oliveira, Luis V F/K-8838-2013; Oliveira, Claudia/H-2328-2013; GIANNASI, LILIAN C/E-6875-2017	Oliveira, Luis V F/0000-0002-3852-9415; Oliveira, Claudia/0000-0001-8509-4576; Grossamann, Eduardo/0000-0001-7619-3249; Amorim, jose/0000-0002-8074-6528	Brazilian Coordination for the Improvement of Higher Education Personnel/Postdoctoral National Program (CAPES/PNPD) [02495/09-0]	Brazilian Coordination for the Improvement of Higher Education Personnel/Postdoctoral National Program (CAPES/PNPD)	This work was supported by Brazilian Coordination for the Improvement of Higher Education Personnel/Postdoctoral National Program (CAPES/PNPD)-grant number 02495/09-0. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abanto J, 2014, SPEC CARE DENT, V34, P56, DOI 10.1111/scd.12028; Arya BK, 2012, IEEE ENG MED BIO, P5726, DOI 10.1109/EMBC.2012.6347295; Bartlett DJ, 2014, DEV MED CHILD NEUROL, V56, P275, DOI 10.1111/dmcn.12317; Blair E, 2010, ORTHOP CLIN N AM, V41, P441, DOI 10.1016/j.ocl.2010.06.004; Colver A, 2014, LANCET, V383, P1240, DOI 10.1016/S0140-6736(13)61835-8; Cruccu G, 2001, J PHYSIOL-LONDON, V531, P559, DOI 10.1111/j.1469-7793.2001.0559i.x; Darian-Smith, 1973, HAND BOOK OF SENSORY; De Backer W, 2013, PANMINERVA MED, V55, P191; Deon LL, 2010, ORTHOP CLIN N AM, V41, P507, DOI 10.1016/j.ocl.2010.06.001; DuBrul EL, 1980, SICHERS ORAL ANATOMY; Elsayed RM, 2013, ANN INDIAN ACAD NEUR, V16, P62, DOI 10.4103/0972-2327.107708; Farahani R, 2008, PEDIATR PULM, V43, P20, DOI 10.1002/ppul.20729; Giannasi LC, 2014, ARCH ORAL BIOL, V59, P1352, DOI 10.1016/j.archoralbio.2014.08.011; Giannasi LC, 2014, J BODYW MOV THER, V18, P62, DOI 10.1016/j.jbmt.2013.05.009; Grossman E, 2013, DORES BUCOFACIAIS CO; Grossmann Eduardo, 2012, Rev. dor, V13, P271, DOI 10.1590/S1806-00132012000300013; Guimaraes KC, 2009, AM J RESP CRIT CARE, V179, P962, DOI 10.1164/rccm.200806-981OC; Hanamoto H, 2014, J ORAL REHABIL, V41, P588, DOI 10.1111/joor.12175; Harrington AT, 2012, INT J PEDIAT, V2012, DOI 10.1155/2012/504387; HORI T, 1974, JPN J PSYCHOL, V44, P289, DOI 10.4992/jjpsy.44.289; Hsiao KH, 2008, RES DEV DISABIL, V29, P133, DOI 10.1016/j.ridd.2007.01.003; Karabay I, 2012, DISABIL REHABIL, V34, P965, DOI 10.3109/09638288.2011.628741; Kato-Nishimura K, 2008, SLEEP MED, V9, P207, DOI 10.1016/j.sleep.2007.01.015; Kerr C, 2004, DEV MED CHILD NEUROL, V46, P205, DOI 10.1017/S0012162204000349; Koman LA, 2004, LANCET, V363, P1619, DOI 10.1016/S0140-6736(04)16207-7; Kontorinis G, 2013, INT J PEDIATR OTORHI, V77, P1647, DOI 10.1016/j.ijporl.2013.07.017; Kotze A, 2008, ANAEST INTENS CARE M, V9, P29, DOI 10.1016/j.mpaic.2007.10.008; Marret S, 2013, HAND CLINIC, V111, P169, DOI 10.1016/B978-0-444-52891-9.00016-6; McCarty SF, 2001, AM J PHYS MED REHAB, V80, P540, DOI 10.1097/00002060-200107000-00016; Montesanti L, 2006, MED REABIL, V25, P7; Moore KL, 1998, FUNDAMENTOS DE ANATO; Newman CJ, 2006, DEV MED CHILD NEUROL, V48, P564, DOI 10.1017/S0012162206001198; Odding E, 2006, DISABIL REHABIL, V28, P183, DOI 10.1080/09638280500158422; POINDEXTER AR, 1994, AM J MENT RETARD, V98, P776; Ries LGK, 2008, CRANIO, V26, P59; Sandella DE, 2011, SLEEP MED, V12, P252, DOI 10.1016/j.sleep.2010.07.019; Santos MTBR, 2010, SPEC CARE DENT, V30, P163, DOI 10.1111/j.1754-4505.2010.00143.x; SCOTT OM, 1985, J NEUROL NEUROSUR PS, V48, P774, DOI 10.1136/jnnp.48.8.774; Soderberg GL, 2000, PHYS THER, V80, P485, DOI 10.1093/ptj/80.5.485; Tufik S, 2010, SLEEP MED, V11, P441, DOI 10.1016/j.sleep.2009.10.005; Urschitz MS, 2004, PEDIATRICS, V114, P1041, DOI 10.1542/peds.2003-1145-L; Williams N, 2014, PHYSIOTHER THEOR PR, V30, P6, DOI 10.3109/09593985.2013.811567; Wright PA, 2012, ARCH DIS CHILD, V97, P364, DOI 10.1136/archdischild-2011-300437; Yoshida K, 1999, J PROSTHET DENT, V81, P196, DOI 10.1016/S0022-3913(99)70248-9; Zarowski Marcin, 2008, Roczniki Pomorskiej Akademii Medycznej w Szczecinie, V54, P59	46	8	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2015	10	8							e0128959	10.1371/journal.pone.0128959	http://dx.doi.org/10.1371/journal.pone.0128959			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO3MQ	26247208	Green Published, Green Submitted, gold			2023-01-03	WOS:000359062300002
J	El-Khoury, F; Cassou, B; Latouche, A; Aegerter, P; Charles, MA; Dargent-Molina, P				El-Khoury, Fabienne; Cassou, Bernard; Latouche, Aurelien; Aegerter, Philippe; Charles, Marie-Aline; Dargent-Molina, Patricia			Effectiveness of two year balance training programme on prevention of fall induced injuries in at risk women aged 75-85 living in community: Ossebo randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OLDER-PEOPLE; GROUP EXERCISE; HIP FRACTURE; PARTICIPATION; INTERVENTION; ASSOCIATION; DISABILITY; BARRIERS; ADULTS	OBJECTIVE To assess the effectiveness of a two year exercise programme of progressive balance retraining in reducing injurious falls among women aged 75-85 at increased risk of falls and injuries and living in the community. DESIGN Pragmatic multicentre, two arm, parallel group, randomised controlled trial. SETTING 20 study sites in 16 medium to large cities throughout France. PARTICIPANTS 706 women aged 75-85, living in their own home, and with diminished balance and gait capacities, randomly allocated to the experimental intervention group (exercise programme, n=352) or the control group (no intervention, n=354). INTERVENTION Weekly supervised group sessions of progressive balance training offered in community based premises for two years, supplemented by individually prescribed home exercises. OUTCOME MEASURES A geriatrician blinded to group assignment classified falls into one of three categories (no consequence, moderate, severe) based on physical damage and medical care. The primary outcome was the rate of injurious falls (moderate and severe). The two groups were compared for rates of injurious falls with a "shared frailty" model. Other outcomes included the rates of all falls, physical functional capacities (balance and motor function test results), fear of falling (FES-I), physical activity level, and perceived health related quality of life (SF-36). Analysis was by intention to treat. RESULTS There were 305 injurious falls in the intervention group and 397 in the control group (hazard ratio 0.81, 95% confidence interval 0.67 to 0.99). The difference in severe injuries (68 in intervention group v 87 in control group) was of the same order of magnitude (0.83, 0.60 to 1.16). At two years, women in the intervention group performed significantly better on all physical tests and had significantly better perception of their overall physical function than women in the control group. Among women who started the intervention (n=294), the median number of group sessions attended was 53 (interquartile range 16-71). Five injurious falls related to the intervention were recorded. CONCLUSION A two year progressive balance retraining programme combining weekly group and individual sessions was effective in reducing injurious falls and in improving measured and perceived physical function in women aged 75-85 at risk of falling.	[El-Khoury, Fabienne] Univ Paris Sud, UMR S1018, F-94807 Villejuif, France; [El-Khoury, Fabienne; Charles, Marie-Aline; Dargent-Molina, Patricia] Univ Paris 05, UMR S 1153, F-75014 Paris, France; [El-Khoury, Fabienne; Charles, Marie-Aline; Dargent-Molina, Patricia] INSERM, Ctr Rech Epidemiol & Stat Sorbonne Paris Cite, U1153, F-94807 Villejuif, France; [Cassou, Bernard; Aegerter, Philippe] Univ Versailles, UMR S 1168, UVSQ, Yvelines, France; [Cassou, Bernard; Aegerter, Philippe] INSERM, VIMA Vieillissement Maladies Chron, U1168, F-94807 Villejuif, France; [Cassou, Bernard] Hop Sainte Perine, AP HP, Ctr Gerontol, F-75016 Paris, France; [Latouche, Aurelien] Ctr Res Comp Sci & Telecommunicat Cedric, Conservatoire Natl Arts & Metiers Cnam, Paris, France; [Aegerter, Philippe] Hop Ambroise Pare, Unite Rech Clin, Dept Sante Publ, A1 AP HP, Boulogne Billancourt, France	UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Sainte-Perine - APHP; heSam Universite; Conservatoire National Arts & Metiers (CNAM); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	Dargent-Molina, P (corresponding author), INSERM, CRESS Equipe ORCHARD, Hop Paul Brousse batiment 15-16,16 Ave Paul Vaill, F-94807 Villejuif, France.	patricia.dargent@inserm.fr	Khoury, Fabienne/AAB-2123-2020; Dargent-Molina, Patricia/N-3887-2017; AEGERTER, Philippe/AAY-6003-2021; Charles, Marie Aline/S-1866-2019; Charles, Marie Aline/F-8567-2017	Khoury, Fabienne/0000-0002-6915-6850; Dargent-Molina, Patricia/0000-0001-8596-6899; AEGERTER, Philippe/0000-0002-9156-5028; Charles, Marie Aline/0000-0003-4025-4390; Charles, Marie Aline/0000-0003-4025-4390; Latouche, Aurelien/0000-0001-9218-0333	"Assistance Publique-Hopitaux de Paris" (AP-HP); French Ministry of Health (Programme Hospitalier de Recherche Clinique PHRC National) [2006: AOM06076, 2010: AOM10144]; French National Research Agency (ANR) [BLAN06-3_135165]; National Institute of Health Prevention and Education (INPES) [047/06-DAS]; Council of the Ile-de-France region [09003420]; hospital group "Ste Perine, Chardon-Lalache, Rossini" (Assistance Publique-Hopitaux de Paris (AP-HP))	"Assistance Publique-Hopitaux de Paris" (AP-HP); French Ministry of Health (Programme Hospitalier de Recherche Clinique PHRC National); French National Research Agency (ANR)(French National Research Agency (ANR)); National Institute of Health Prevention and Education (INPES); Council of the Ile-de-France region(Region Ile-de-France); hospital group "Ste Perine, Chardon-Lalache, Rossini" (Assistance Publique-Hopitaux de Paris (AP-HP))	This study was sponsored by "Assistance Publique-Hopitaux de Paris" (AP-HP). The project funded by grants from the French Ministry of Health (Programme Hospitalier de Recherche Clinique PHRC National, 2006: AOM06076, 2010: AOM10144), the French National Research Agency (ANR) (BLAN06-3_135165), the National Institute of Health Prevention and Education (INPES) (project No 047/06-DAS), and the Council of the Ile-de-France region (Partnership of Citizens and Institutions for Research and Innovation, PICRI, No 09003420). The funders had no role in study design, data collection, and analysis, the decision to publish or preparation of the manuscript. PD-M received a "Contrat d'Interface vers l'hopital" (interface Inserm-Hospitals) from the hospital group "Ste Perine, Chardon-Lalache, Rossini" (Assistance Publique-Hopitaux de Paris (AP-HP)) in June 2008.	Auster J, 2009, AUSTRALAS J AGEING, V28, P149, DOI 10.1111/j.1741-6612.2009.00362.x; Box-Steffensmeier JM, 2006, STAT MED, V25, P3518, DOI 10.1002/sim.2434; BUCHNER DM, 1993, J AM GERIATR SOC, V41, P297, DOI 10.1111/j.1532-5415.1993.tb06708.x; Bunn F, 2008, AGEING SOC, V28, P449, DOI 10.1017/S0144686X07006861; Campbell AJ, 1997, BMJ-BRIT MED J, V315, P1065, DOI 10.1136/bmj.315.7115.1065; Close JCT, 2013, BEST PRACT RES CL RH, V27, P821, DOI 10.1016/j.berh.2013.12.001; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; Dargent-Molina P, 2000, OSTEOPOROSIS INT, V11, P881, DOI 10.1007/s001980070048; Dargent- Molina P, 2008, GERONTOLOGIE SOC, V125, P65; Dargent-Molina P, 2013, GLOB HEALTH PROMOT, V20, P88, DOI 10.1177/1757975913483341; DargentMolina P, 1996, LANCET, V348, P145, DOI 10.1016/S0140-6736(96)01440-7; Day L, 2002, BRIT MED J, V325, P128, DOI 10.1136/bmj.325.7356.128; de Groot GCL, 2011, SCAND J OCCUP THER, V18, P153, DOI 10.3109/11038128.2010.487113; Dechartres A, 2011, ANN INTERN MED, V155, P39, DOI 10.7326/0003-4819-155-1-201107050-00006; Delbaere K, 2010, BRIT J SPORT MED, V44, P1029, DOI 10.1136/bjsm.2009.060350; Dickinson Angela, 2011, Br J Community Nurs, V16, P174; Donaldson MG, 2007, J GERONTOL A-BIOL, V62, P415, DOI 10.1093/gerona/62.4.415; Duchateau L, 2007, THE FRAILTY MODEL; El-Khoury F, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6234; Franco MR, 2015, J PHYSIOTHER, V61, P34, DOI 10.1016/j.jphys.2014.11.001; Freiberger E, 2013, CLIN INTERV AGING, V8, P1079, DOI 10.2147/CIA.S46218; Gill TM, 2013, AM J EPIDEMIOL, V178, P418, DOI 10.1093/aje/kws554; Gillespie Lesley D, 2012, Cochrane Database Syst Rev, pCD007146, DOI 10.1002/14651858.CD007146.pub3; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Gutierrez RG, 2013, GOOD NEW BAD OLD ANA; Howe TE, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004963.pub2; INSEE, 2005, INS REF PERS AG; Jones CJ, 2005, PHYS ACTIVITY INSTRU; Kannus P, 2005, LANCET, V366, P1885, DOI 10.1016/S0140-6736(05)67604-0; Lamb SE, 2005, J AM GERIATR SOC, V53, P1618, DOI 10.1111/j.1532-5415.2005.53455.x; Lee SH, 2002, J BONE MINER RES, V17, P817, DOI 10.1359/jbmr.2002.17.5.817; Leon C, 2014, COMPORTEMENTS SANTE; Leplege A, 1998, J CLIN EPIDEMIOL, V51, P1013, DOI 10.1016/S0895-4356(98)00093-6; Lord SR, 2003, J AM GERIATR SOC, V51, P1685, DOI 10.1046/j.1532-5415.2003.51551.x; LORD SR, 1995, J AM GERIATR SOC, V43, P1198, DOI 10.1111/j.1532-5415.1995.tb07394.x; McDonald AM, 2006, TRIALS, V7, DOI 10.1186/1745-6215-7-9; Nyman SR, 2012, AGE AGEING, V41, P16, DOI 10.1093/ageing/afr103; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Robertson MC, 2002, J AM GERIATR SOC, V50, P905, DOI 10.1046/j.1532-5415.2002.50218.x; Rose DJ, 2010, CLIN GERIATR MED, V26, P607, DOI 10.1016/j.cger.2010.07.003; Rubenstein LZ, 2006, AGE AGEING, V35, P37, DOI 10.1093/ageing/afl084; SCHLESSELMAN JJ, 1974, AM J EPIDEMIOL, V99, P381, DOI 10.1093/oxfordjournals.aje.a121625; Sherrington C, 2008, J AM GERIATR SOC, V56, P2234, DOI 10.1111/j.1532-5415.2008.02014.x; Skelton D, 2005, AGE AGEING, V34, P636, DOI 10.1093/ageing/afi174; Stevens Z, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-192; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Tinetti ME, 1997, NEW ENGL J MED, V337, P1279, DOI 10.1056/NEJM199710303371806; Treweek S, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-37; Yardley L, 2006, HEALTH EDUC RES, V21, P508, DOI 10.1093/her/cyh077; Yardley L, 2005, AGE AGEING, V34, P614, DOI 10.1093/ageing/afi196; Zwarenstein M, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2390	51	74	77	0	38	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 22	2015	351								h3830	10.1136/bmj.h3830	http://dx.doi.org/10.1136/bmj.h3830			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CN7WI	26201510	Green Published, hybrid			2023-01-03	WOS:000358644600001
J	D'Anna, C; Schmid, M; Bibbo, D; Bertollo, M; Comani, S; Conforto, S				D'Anna, Carmen; Schmid, Maurizio; Bibbo, Daniele; Bertollo, Maurizio; Comani, Silvia; Conforto, Silvia			The Effect of Continuous and Discretized Presentations of Concurrent Augmented Visual Biofeedback on Postural Control in Quiet Stance	PLOS ONE			English	Article							STANDING BALANCE; STROKE PATIENTS; HEALTHY-ADULTS; UPRIGHT STANCE; EXTERNAL-FOCUS; OLDER-ADULTS; FEEDBACK; SWAY; PRESSURE; YOUNG	The purpose of this study was to evaluate the effect of a continuous and a discretized Visual Biofeedback (VBF) on balance performance in upright stance. The coordinates of the Centre of Pressure (CoP), extracted from a force plate, were processed in real-time to implement the two VBFs, administered to two groups of 12 healthy participants. In the first group, a representation of the CoP was continuously shown, while in the second group, the discretized VBF was provided at an irregular frequency (that depended on the subject's performance) by displaying one out of a set of five different emoticons, each corresponding to a specific area covered by the current position of the CoP. In the first case, participants were asked to maintain a white spot within a given square area, whereas in the second case they were asked to keep the smiling emoticon on. Trials with no VBF were administered as control. The effect of the two VBFs on balance was studied through classical postural parameters and a subset of stabilogram diffusion coefficients. To quantify the amount of time spent in stable conditions, the percentage of time during which the CoP was inside the stability area was calculated. Both VBFs improved balance maintainance as compared to the absence of any VBF. As compared to the continuous VBF, in the discretized VBF a significant decrease of sway path, diffusion and Hurst coefficients was found. These results seem to indicate that a discretized VBF favours a more natural postural behaviour by promoting a natural intermittent postural control strategy.	[D'Anna, Carmen; Schmid, Maurizio; Bibbo, Daniele; Conforto, Silvia] Roma Tre Univ, Dept Engn, Rome, Italy; [Bertollo, Maurizio] Univ G DAnnunzio, Dept Basic & Appl Med Sci, Chieti, Italy; [Comani, Silvia] Univ G DAnnunzio, Dept Neurosci & Imaging, Chieti, Italy; [D'Anna, Carmen; Schmid, Maurizio; Bibbo, Daniele; Bertollo, Maurizio; Comani, Silvia; Conforto, Silvia] Univ G DAnnunzio, Behav Imaging & Neural Dynam Ctr BIND, Chieti, Italy	Roma Tre University; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara	D'Anna, C (corresponding author), Roma Tre Univ, Dept Engn, Rome, Italy.	carmen.danna@uniroma3.it	D'Anna, Carmen/AAE-1667-2019; Schmid, Maurizio/E-5140-2010; D'Anna, Carolina/P-3831-2019; Bertollo, Maurizio/K-5469-2013	D'Anna, Carmen/0000-0003-3271-3075; Schmid, Maurizio/0000-0003-3380-6994; Bertollo, Maurizio/0000-0002-0972-9178; COMANI, Silvia/0000-0001-8100-457X; Bibbo, Daniele/0000-0003-1341-5427				Asai Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006169; Balasubramaniam R, 2002, TRENDS COGN SCI, V6, P531, DOI 10.1016/S1364-6613(02)02021-1; Bechly KE, 2013, GAIT POSTURE, V37, P391, DOI 10.1016/j.gaitpost.2012.08.007; Bibbo D, 2012, PROC SPIE, V8295, DOI 10.1117/12.910605; Borg G, 2001, INT J SPORT PSYCHOL, V32, P110; Bottaro A, 2008, HUM MOVEMENT SCI, V27, P473, DOI 10.1016/j.humov.2007.11.005; Caudron S, 2014, NEUROPHYSIOL CLIN, V44, P77, DOI 10.1016/j.neucli.2013.10.134; Cawsey RP, 2009, GAIT POSTURE, V29, P280, DOI 10.1016/j.gaitpost.2008.09.007; Chiari L, 2000, GAIT POSTURE, V12, P225, DOI 10.1016/S0966-6362(00)00086-2; COLLINS JJ, 1995, EXP BRAIN RES, V103, P151, DOI 10.1007/BF00241972; Conforto S, 2001, GAIT POSTURE, V14, P28, DOI 10.1016/S0966-6362(01)00112-6; D'Anna C, 2014, 13 MED C MED BIOL EN, P1755; Dault MC, 2003, HUM MOVEMENT SCI, V22, P221, DOI 10.1016/S0167-9457(03)00034-4; Davis JR, 2010, GAIT POSTURE, V31, P465, DOI 10.1016/j.gaitpost.2010.02.002; DIENER HC, 1988, PROG BRAIN RES, V76, P253; Dozza M, 2005, ARCH PHYS MED REHAB, V86, P1401, DOI 10.1016/j.apmr.2004.12.036; Gawthrop P, 2011, BIOL CYBERN, V104, P31, DOI 10.1007/s00422-010-0416-4; Geiger RA, 2001, PHYS THER, V81, P995, DOI 10.1093/ptj/81.4.995; Goffredo M, 2006, MED ENG PHYS, V28, P719, DOI 10.1016/j.medengphy.2005.10.007; Goldie PA, 1996, CLIN BIOMECH, V11, P333, DOI 10.1016/0268-0033(96)00014-9; Hagger MS, 2001, J SPORT SCI, V19, P711, DOI 10.1080/02640410152475847; Halicka Z, 2014, GAIT POSTURE, V39, P410, DOI 10.1016/j.gaitpost.2013.08.005; Ikegami T, 2012, J NEUROSCI, V32, P653, DOI 10.1523/JNEUROSCI.4230-11.2012; Insperger T, 2006, IEEE T CONTR SYST T, V14, P974, DOI 10.1109/TCST.2006.876938; Kamen G, 1998, GERONTOLOGY, V44, P40, DOI 10.1159/000021981; Kapteyn T S, 1983, Agressologie, V24, P321; Kiemel T, 2002, BIOL CYBERN, V87, P262, DOI 10.1007/s00422-002-0333-2; Kiemel T, 2008, J NEUROPHYSIOL, V100, P3394, DOI 10.1152/jn.01272.2007; Laurens J, 2010, GAIT POSTURE, V31, P37, DOI 10.1016/j.gaitpost.2009.08.241; Loram ID, 2011, J PHYSIOL-LONDON, V589, P307, DOI 10.1113/jphysiol.2010.194712; Murnaghan CD, 2014, J NEUROPHYSIOL, V111, P1920, DOI 10.1152/jn.00853.2012; Nichols DS, 1997, PHYS THER, V77, P553, DOI 10.1093/ptj/77.5.553; Paillex R, 2005, GAIT POSTURE, V21, P403, DOI 10.1016/j.gaitpost.2004.04.011; Peterka RJ, 1998, IDENTIFYING CONTROL, P73; Pollock AS, 2000, CLIN REHABIL, V14, P402, DOI 10.1191/0269215500cr342oa; POULTON EC, 1966, PSYCHOL BULL, V66, P1, DOI 10.1037/h0023427; Rougier P, 2004, GAIT POSTURE, V19, P154, DOI 10.1016/S0966-6362(03)00056-0; Sackley C M, 1991, Int Disabil Stud, V13, P1; SALMONI AW, 1984, PSYCHOL BULL, V95, P355, DOI 10.1037/0033-2909.95.3.355; Sayenko DG, 2012, GAIT POSTURE, V35, P339, DOI 10.1016/j.gaitpost.2011.10.005; Freitas SMSF, 2012, GAIT POSTURE, V35, P83, DOI 10.1016/j.gaitpost.2011.08.011; Schmid M, 2004, HUM MOVEMENT SCI, V23, P105, DOI 10.1016/j.humov.2004.06.001; Schmid M, 2002, MED ENG PHYS, V24, P623, DOI 10.1016/S1350-4533(02)00046-2; Schmid Maurizio, 2005, J Neuroeng Rehabil, V2, P29, DOI 10.1186/1743-0003-2-29; Schmidt R. A., 1991, TUTORIALS MOTOR NEUR; Severini G, 2012, J ELECTROMYOGR KINES, V22, P878, DOI 10.1016/j.jelekin.2012.04.010; Shea CH, 1999, HUM MOVEMENT SCI, V18, P553, DOI 10.1016/S0167-9457(99)00031-7; SHUMWAYCOOK A, 1988, ARCH PHYS MED REHAB, V69, P395; Sullivan EV, 2009, NEUROBIOL AGING, V30, P793, DOI 10.1016/j.neurobiolaging.2007.08.021; Tanaka Hideyuki, 2002, J Hum Ergol (Tokyo), V31, P1; Torricelli D, 2008, COMPUT METH PROG BIO, V92, P66, DOI 10.1016/j.cmpb.2008.06.008; van der Kooij H, 2007, J NEUROPHYSIOL, V98, P730, DOI 10.1152/jn.00457.2006; Vannozzi G, 2010, J ELECTROMYOGR KINES, V20, P767, DOI 10.1016/j.jelekin.2010.02.007; Vuillerme N, 2007, EXP BRAIN RES, V179, P409, DOI 10.1007/s00221-006-0800-4; Wade MG, 1997, PHYS THER, V77, P619, DOI 10.1093/ptj/77.6.619; Walker C, 2000, PHYS THER, V80, P886, DOI 10.1093/ptj/80.9.886; Walther JB, 2001, SOC SCI COMPUT REV, V19, P324, DOI 10.1177/089443930101900307; Wulf G, 2001, PSYCHON B REV, V8, P648, DOI 10.3758/BF03196201; Wulf G, 2001, RES Q EXERCISE SPORT, V72, P335, DOI 10.1080/02701367.2001.10608970; Wulf G, 2001, Q J EXP PSYCHOL-A, V54, P1143, DOI 10.1080/02724980143000118; Wulf G., 2013, INT REV SPORT EXERCI, V6, P77; Wulf G., 2010, EFFORTLESS ATTENTION, P75, DOI [10.7551/MITPRESS/9780262013840.003.0004, DOI 10.7551/MITPRESS/9780262013840.003.0004]	62	9	9	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2015	10	7							e0132711	10.1371/journal.pone.0132711	http://dx.doi.org/10.1371/journal.pone.0132711			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CN6LZ	26196518	Green Published, gold, Green Submitted			2023-01-03	WOS:000358547600048
J	Chang, HY; Sung, YH; Wang, SM; Lung, HL; Chang, JH; Hsu, CH; Jim, WT; Lee, CH; Hung, HF				Chang, Hung-Yang; Sung, Yi-Hsiang; Wang, Shwu-Meei; Lung, Hou-Ling; Chang, Jui-Hsing; Hsu, Chyong-Hsin; Jim, Wai-Tim; Lee, Ching-Hsiao; Hung, Hsiao-Fang			Short- and Long-Term Outcomes in Very Low Birth Weight Infants with Admission Hypothermia	PLOS ONE			English	Article							BODY-TEMPERATURE; VLBW INFANTS; BORN; ENVIRONMENT; MORTALITY; DELIVERY; WRAP	Background Neonatal hypothermia remains a common problem and is related to elevated morbidities and mortality. However, the long-term neurodevelopmental effects of admission hypothermia are still unknown. This study attempted to determine the short-term and long-term consequences of admission hypothermia in VLBW preterm infants. Study Design This retrospective study measured the incidence and compared the outcomes of admission hypothermia in very low birth weight (VLBW) preterm infants in a tertiary-level neonatal intensive care unit. Infants were divided into the following groups: normothermia (36.5-37.5 degrees C), mild hypothermia (36.0-36.4 degrees C), moderate hypothermia (32.0-35.9 degrees C), and severe hypothermia (< 32 degrees C). We compared the distribution, demographic variables, short-term outcomes, and neurodevelopmental outcomes at 24 months of corrected age among groups. Results We studied 341 infants: 79 with normothermia, 100 with mild hypothermia, 162 with moderate hypothermia, and 0 with severe hypothermia. Patients in the moderate hypothermia group had significantly lower gestational ages (28.1 wk vs. 29.7 wk, P < .02) and smaller birth weight (1004 g vs. 1187 g, P < .001) compared to patients in the normothermia group. Compared to normothermic infants, moderately hypothermic infants had significantly higher incidences of 1-min Apgar score < 7 (63.6% vs. 31.6%, P < .001), respiratory distress syndrome (RDS) (58.0% vs. 39.2%, P = .006), and mortality (18.5% vs. 5.1%, P = .005). Moderate hypothermia did not affect neurodevelopmental outcomes at 2 years' corrected age. Mild hypothermia had no effect on short-term or long-term outcomes. Conclusions Admission hypothermia was common in VLBW infants and correlated inversely with birth weight and gestational age. Although moderate hypothermia was associated with higher RDS and mortality rates, it may play a limited role among multifactorial causes of neurodevelopmental impairment.	[Chang, Hung-Yang; Sung, Yi-Hsiang; Lung, Hou-Ling] MacKay Mem Hosp, Dept Pediat, Hsinchu Branch, Hsinchu, Taiwan; [Chang, Hung-Yang; Lee, Ching-Hsiao; Hung, Hsiao-Fang] Jen Teh Jr Coll Med Nursing & Management, Dept Med Technol, Miaoli, Taiwan; [Wang, Shwu-Meei; Chang, Jui-Hsing; Hsu, Chyong-Hsin; Jim, Wai-Tim] MacKay Childrens Hosp, Dept Pediat, Taipei, Taiwan	Mackay Memorial Hospital	Wang, SM (corresponding author), MacKay Childrens Hosp, Dept Pediat, Taipei, Taiwan.	smwang65@gmail.com						Aylott Marion, 2006, Paediatr Nurs, V18, P38; Bartels DB, 2005, ARCH DIS CHILD-FETAL, V90, pF53, DOI 10.1136/adc.2004.053892; BERTEROTTIERE D, 1990, J DEV PHYSIOL, V13, P303; Bhatt DR, 2007, J PERINATOL, V27, pS45, DOI 10.1038/sj.jp.7211842; Billimoria Z, 2013, J PERINAT MED, V41, P455, DOI 10.1515/jpm-2012-0259; Bissinger Robin L, 2010, Adv Neonatal Care, V10, P230, DOI 10.1097/ANC.0b013e3181f0ae63; Boo NY, 2013, J TROP PEDIATRICS, V59, P447, DOI 10.1093/tropej/fmt051; de Almeida MFB, 2014, J PEDIATR-US, V164, P271, DOI 10.1016/j.jpeds.2013.09.049; Bredemeyer S, 2005, J ADV NURS, V52, P482, DOI 10.1111/j.1365-2648.2005.03616.x; Chitty H, 2013, SEMIN FETAL NEONAT M, V18, P362, DOI 10.1016/j.siny.2013.08.002; Costeloe K, 2000, PEDIATRICS, V106, P659, DOI 10.1542/peds.106.4.659; DAGA AS, 1991, J TROP PEDIATRICS, V37, P53, DOI 10.1093/tropej/37.2.53; Fransson AL, 2005, ARCH DIS CHILD-FETAL, V90, pF500, DOI 10.1136/adc.2004.066589; GANDY GM, 1964, J CLIN INVEST, V43, P751, DOI 10.1172/JCI104959; HAMMARLUND K, 1982, ACTA PAEDIATR SCAND, V71, P191, DOI 10.1111/j.1651-2227.1982.tb09398.x; HERTING E, 1992, BIOL NEONATE, V61, P26; Kattwinkel J, 2010, CIRCULATION, V122, pS909, DOI 10.1161/CIRCULATIONAHA.110.971119; Laptook AR, 2007, PEDIATRICS, V119, pE643, DOI 10.1542/peds.2006-0943; MANN TP, 1957, LANCET, V1, P229; Mathur NB, 2005, J TROP PEDIATRICS, V51, P341, DOI 10.1093/tropej/fmi049; McCall EM, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004210.pub4; Miller SS, 2011, J PERINATOL, V31, pS49, DOI 10.1038/jp.2010.177; Mitchell Ann, 2002, Adv Neonatal Care, V2, P316, DOI 10.1053/adnc.2002.36831; Pinheiro JMB, 2014, PEDIATRICS, V133, pE218, DOI 10.1542/peds.2013-1293; POMERANC.JJ, 1974, PEDIATR RES, V8, P449; Reilly MC, 2015, J PEDIATR-US, V166, P262, DOI 10.1016/j.jpeds.2014.09.068; Russo A, 2014, PEDIATRICS, V133, pE1055, DOI 10.1542/peds.2013-2544; Smith J, 2013, NEONATAL NETW, V32, P235, DOI [10.1891/0730-0832.32.4.235, 10.1891/0730-0832.32.1.16]; Takayama JI, 2000, CLIN PEDIATR, V39, P503, DOI 10.1177/000992280003900901; van der Spek RDG, 2009, ACTA PAEDIATR, V98, P282, DOI 10.1111/j.1651-2227.2008.01063.x; World Health Organization, 1997, THERM PROT NEWB PRAC	31	49	56	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2015	10	7							e0131976	10.1371/journal.pone.0131976	http://dx.doi.org/10.1371/journal.pone.0131976			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN6LN	26193370	Green Published, gold, Green Submitted			2023-01-03	WOS:000358546400018
J	Wu, AP; Li, ZL; He, FF; Wang, YH; Dong, M				Wu, Ai-Ping; Li, Zi-Li; He, Fei-Fei; Wang, Yan-Hong; Dong, Ming			Screening Allelochemical-Resistant Species of the Alien Invasive Mikania micrantha for Restoration in South China	PLOS ONE			English	Article							MUSTARD BRASSICA-NIGRA; SEED-GERMINATION; BIOLOGICAL INVASIONS; LONICERA-MAACKII; ROOT EXTRACTS; GROWTH; PLANTS; RICE; LEAF; ESTABLISHMENT	To screen allelochemical-resistant species of the alien invasive weed Mikania micrantha, we studied the allelopathic inhibition effects of the leaf aqueous extract (LAE) of Mikania on seed germination and seedling growth of the 26 species native or naturalized in the invaded region in South China. Seed germination was more strongly negatively affected by LAE than seedling growth. Responses of seed germination and seed growth to LAE differed differently among the target species. LAE more strongly negatively affected seed germination, but less strongly negatively affected seedling growth, in non-legume species than in legume species. LAE more strongly negatively affected seed germination and seedling growth in native species than naturalized exotic species. Therefore, naturalized exotic non-legume seedlings are more suitable than seeds of native legume species for restoration of Mikania-invaded habitats.	[Wu, Ai-Ping; Li, Zi-Li] Hunan Agr Univ, Inst Ecol, Dept Ecol, Coll Biosci & Biotechnol, Changsha 410128, Hunan, Peoples R China; [He, Fei-Fei] Yunnan Univ, Sch Agr, Kunming 650091, Peoples R China; [Wang, Yan-Hong] Zhejiang Agr & Forestry Univ, Sch Forestry & Biotechnol, Hangzhou 311300, Zhejiang, Peoples R China; [Dong, Ming] Hangzhou Normal Univ, Coll Life & Environm Sci, Hangzhou 310036, Zhejiang, Peoples R China	Hunan Agricultural University; Yunnan University; Zhejiang A&F University; Hangzhou Normal University	Wu, AP (corresponding author), Hunan Agr Univ, Inst Ecol, Dept Ecol, Coll Biosci & Biotechnol, Changsha 410128, Hunan, Peoples R China.	wuaip8101@126.com; dongming@hznu.edu.cn	wang, yan/GSE-6489-2022; wang, yi/GVT-8516-2022; Wang, Yanbo/HFZ-8018-2022; Wu, Aiping/AAU-8710-2020		National Natural Science Foundation of China [31301725]; Zhejiang Provincial Natural Science Foundation of China [LQ12C03002]; State Key Laboratory of Vegetation and Environmental Change [LVEC-2012kf05]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Natural Science Foundation of China(Natural Science Foundation of Zhejiang Province); State Key Laboratory of Vegetation and Environmental Change	This research was financially supported by the National Natural Science Foundation of China (No. 31301725), Zhejiang Provincial Natural Science Foundation of China (No. LQ12C03002) and State Key Laboratory of Vegetation and Environmental Change (No. LVEC-2012kf05).	Ahn JK, 2000, AGRON J, V92, P1162, DOI 10.2134/agronj2000.9261162x; Alford ER, 2009, RESTOR ECOL, V17, P506, DOI 10.1111/j.1526-100X.2008.00405.x; Allaie RR, 2006, J AGRON CROP SCI, V192, P186, DOI 10.1111/j.1439-037X.2006.00205.x; Barnum Kimberly, 2013, International Journal of Plant Biology, V4, P8, DOI 10.4081/pb.2013.e2; Bauer JT, 2012, PLANT ECOL, V213, P1907, DOI 10.1007/s11258-012-0036-2; Bousquet-Melou A, 2005, CHEMOECOLOGY, V15, P193, DOI 10.1007/s00049-005-0311-y; Callaway RM, 2006, TRENDS ECOL EVOL, V21, P369, DOI 10.1016/j.tree.2006.04.008; Callaway RM, 2000, SCIENCE, V290, P521, DOI 10.1126/science.290.5491.521; Catford JA, 2012, GLOBAL CHANGE BIOL, V18, P44, DOI 10.1111/j.1365-2486.2011.02549.x; DemmigAdams B, 1996, PHYSIOL PLANTARUM, V98, P253, DOI 10.1034/j.1399-3054.1996.980206.x; Djurdjevic L, 2004, BIOCHEM SYST ECOL, V32, P533, DOI 10.1016/j.bse.2003.10.001; Dorning M, 2006, PLANT ECOL, V184, P287, DOI 10.1007/s11258-005-9073-4; Ebana K, 2001, AGRON J, V93, P12, DOI 10.2134/agronj2001.93112x; El-Darier SM, 2000, ANN APPL BIOL, V136, P273, DOI 10.1111/j.1744-7348.2000.tb00035.x; Emeterio LS, 2004, GRASS FORAGE SCI, V59, P107; Escudero A, 1999, J ECOL, V87, P290, DOI 10.1046/j.1365-2745.1999.00356.x; Fitter A, 2003, SCIENCE, V301, P1337, DOI 10.1126/science.1089291; FOWLER N, 1986, ANNU REV ECOL SYST, V17, P89, DOI 10.1146/annurev.es.17.110186.000513; Harrod RJ, 2001, NORTHWEST SCI, V75, P85; Hickman JE, 2010, P NATL ACAD SCI USA, V107, P10115, DOI 10.1073/pnas.0912279107; Hulme PE, 2009, SCIENCE, V324, P40, DOI 10.1126/science.1171111; Hunter ME, 2002, AM J BOT, V89, P1113, DOI 10.3732/ajb.89.7.1113; Inderjit, 2003, PLANTA, V217, P529, DOI 10.1007/s00425-003-1054-z; Inderjit, 2001, AGRON J, V93, P79; Ismail B. S., 2002, Weed Biology and Management, V2, P31, DOI 10.1046/j.1445-6664.2002.00045.x; Jefferson LV, 2003, J ARID ENVIRON, V55, P275, DOI 10.1016/S0140-1963(03)00028-4; Kaur R, 2012, BIOL FERT SOILS, V48, P481, DOI 10.1007/s00374-011-0645-2; Li JM, 2009, BIOL INVASIONS, V11, P687, DOI 10.1007/s10530-008-9283-5; Li WH, 2006, PLANT SOIL, V281, P309, DOI 10.1007/s11104-005-9641-3; Limpens E, 2003, CURR OPIN PLANT BIOL, V6, P343, DOI 10.1016/S1369-5266(03)00068-2; Lind EM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010429; Lorenzo P, 2013, SOIL BIOL BIOCHEM, V57, P156, DOI 10.1016/j.soilbio.2012.08.018; Mack MC, 1998, TRENDS ECOL EVOL, V13, P195, DOI 10.1016/S0169-5347(97)01286-X; Mao JA, 2006, SOIL BIOL BIOCHEM, V38, P201, DOI 10.1016/j.soilbio.2005.04.030; Myers JH, 2000, TRENDS ECOL EVOL, V15, P316, DOI 10.1016/S0169-5347(00)01914-5; Ni GY, 2007, ALLELOPATHY J, V19, P287; Ni GY, 2006, ALLELOPATHY J, V17, P247; Orr SP, 2005, PLANT ECOL, V181, P153, DOI 10.1007/s11258-005-5698-6; Parvez SS, 2004, PLANT GROWTH REGUL, V42, P245, DOI 10.1023/B:GROW.0000026493.95805.a5; Perry LG, 2005, RESTOR ECOL, V13, P725, DOI 10.1111/j.1526-100X.2005.00092.x; Saxena A, 1996, J ARID ENVIRON, V33, P255, DOI 10.1006/jare.1996.0061; Shao H, 2005, J CHEM ECOL, V31, P1657, DOI 10.1007/s10886-005-5805-0; Simons SB, 1999, SOUTHWEST NAT, V44, P256; Spehn EM, 2002, OIKOS, V98, P205, DOI 10.1034/j.1600-0706.2002.980203.x; Tawaha AM, 2003, J AGRON CROP SCI, V189, P298, DOI 10.1046/j.1439-037X.2003.00047.x; Turk M. A., 2003, Weed Biology and Management, V3, P37, DOI 10.1046/j.1445-6664.2003.00079.x; Turk MA, 2003, CROP PROT, V22, P673, DOI 10.1016/S0261-2194(02)00241-7; Tyrer SJ, 2007, RANGELAND ECOL MANAG, V60, P604, DOI 10.2111/06-147R2.1; Uddin MN, 2014, AM J BOT, V101, P479, DOI 10.3732/ajb.1400021; Vidotto F, 2013, CROP PROT, V54, P161, DOI 10.1016/j.cropro.2013.08.009; Vila M, 2011, ECOL LETT, V14, P702, DOI 10.1111/j.1461-0248.2011.01628.x; Vila M, 2010, FRONT ECOL ENVIRON, V8, P135, DOI 10.1890/080083; Vitousek PM, 1997, SCIENCE, V277, P494, DOI 10.1126/science.277.5325.494; Vivanco JM, 2004, ECOL LETT, V7, P285, DOI 10.1111/j.1461-0248.2004.00576.x; Wang BS, 2004, INVASION ECOLOGY MAN, P80; Wardle DA, 1998, BIOL REV, V73, P305, DOI 10.1017/S0006323198005192; Weiner J, 1997, OIKOS, V79, P85, DOI 10.2307/3546093; Wetzel RG, 1999, AQUAT BOT, V64, P111, DOI 10.1016/S0304-3770(99)00013-3; Wilcove DS, 1998, BIOSCIENCE, V48, P607, DOI 10.2307/1313420; Wu AP, 2009, TREES-STRUCT FUNCT, V23, P11, DOI 10.1007/s00468-008-0249-0; Wu AP, 2010, ALLELOPATHY J, V25, P503; Wu Z, 2013, BIOL INVASIONS, V15, P2755, DOI 10.1007/s10530-013-0490-3; Yu H, 2011, BIOL INVASIONS, V13, P747, DOI 10.1007/s10530-010-9865-x; Zalba SM, 2000, BIOL CONSERV, V93, P203, DOI 10.1016/S0006-3207(99)00146-9	64	8	9	2	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2015	10	7							e0132967	10.1371/journal.pone.0132967	http://dx.doi.org/10.1371/journal.pone.0132967			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RL	26177031	gold, Green Published, Green Submitted			2023-01-03	WOS:000358197600192
J	Benetos, A; Rossignol, P; Cherubini, A; Joly, L; Grodzicki, T; Rajkumar, C; Strandberg, TE; Petrovic, M				Benetos, Athanase; Rossignol, Patrick; Cherubini, Antonio; Joly, Laure; Grodzicki, Tomasz; Rajkumar, Chakravarthi; Strandberg, Timo E.; Petrovic, Mirko			Polypharmacy in the Aging Patient Management of Hypertension in Octogenarians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-PRACTICE GUIDELINES; ADVERSE DRUG-REACTIONS; HIGH BLOOD-PRESSURE; PULSE PRESSURE; OLDER PATIENTS; ELDERLY TRIAL; ARTERIAL STIFFNESS; AMERICAN SOCIETY; LIFE EXPECTANCY; MEDICATION USE	IMPORTANCE Hypertension treatment is beneficial for most hypertensive patients. The benefits for patients who are very old and frail, especially those taking numerous medications, are less certain. OBJECTIVE To provide recommendations for the evaluation and treatment of hypertension among patients aged 80 years and older. EVIDENCE ACQUISITION MEDLINE, PubMed Central, and the Cochrane Database of Systematic Reviews were searched from inception through April 2015, with an emphasis on 2010-2015. Manual cross-referencing of review articles and meta-analyses was also performed to identify randomized controlled trials (RCTs) examining antihypertensive use in octogenarians. The search strategy included the following Medical Subject Headings: hypertension or high blood pressure and trials and oldest old or very old or very elderly. FINDINGS Six post hoc analyses of the previously published Hypertension in the Very Elderly Trial (HYVET) met the inclusion criteria. In the only placebo-controlled RCT on hypertension management in patients older than 80 years (HYVET; N = 3845), the treatment was associated with lower total mortality and key cardiovascular end points but the effect on stroke (fatal and nonfatal), which was the primary outcome, failed to reach the significance level (P=.06). Post hoc analyses of HYVET suggested that active hypertension treatment in very elderly patients was beneficial by reducing blood pressure in individuals with white coat hypertension, showed moderate benefits of the active treatment for cognition, a possible effect for fractures prevention, and sustained differences in reductions of total mortality and cardiovascular mortality in those receiving active treatment. However, patients were community dwelling and less disabled than individuals of the same age in general. CONCLUSIONS AND RELEVANCE Hypertensive patients who are healthy, functionally independent, and aged 80 years and older should be treated according to current recommendations for people older than 65 years. There is insufficient evidence regarding the benefits of hypertension treatment for frail polymedicated octogenarians, for whom treatment should be individualized.	[Benetos, Athanase; Joly, Laure] Univ Lorraine, CHU Nancy, Dept Geriatr, Nancy, France; [Benetos, Athanase; Joly, Laure] Univ Lorraine, CHU Nancy, FHU CARTAGE, Nancy, France; [Rossignol, Patrick] Univ Lorraine, CHU Nancy, INSERM, Ctr Invest Clin Plurithemat 1433, Nancy, France; [Rossignol, Patrick] INI CRCT F CRIN Network, Nancy, France; [Cherubini, Antonio] IRCCS INRCA, Geriatria Accettaz Geriatr Urgenza, Ancona, Italy; [Grodzicki, Tomasz] Jagiellonian Univ, Dept Internal Med & Geriatr, Krakow, Poland; [Rajkumar, Chakravarthi] Brighton & Sussex Med Sch, Brighton, E Sussex, England; [Strandberg, Timo E.] Univ Helsinki, Cent Hosp, Dept Geriatr, Helsinki, Finland; [Strandberg, Timo E.] Univ Oulu, Inst Hlth Sci Geriatr, Oulu, Finland; [Petrovic, Mirko] Univ Ghent, Dept Geriatr, Ghent Univ Hosp, B-9000 Ghent, Belgium	CHU de Nancy; Universite de Lorraine; CHU de Nancy; Universite de Lorraine; CHU de Nancy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; IRCCS INRCA; Jagiellonian University; University of Brighton; University of Sussex; University of Helsinki; Helsinki University Central Hospital; University of Oulu; Ghent University; Ghent University Hospital	Benetos, A (corresponding author), Univ Lorraine, CHU Nancy, Dept Geriatr, Nancy, France.	a.benetos@chu-nancy.fr	Grodzicki, Tomasz/K-4451-2012; Cherubini, Antonio/AAL-4632-2020	Grodzicki, Tomasz/0000-0003-0159-4915; strandberg, timo/0000-0001-6299-925X; Joly, Laure/0000-0001-5389-6363; Cherubini, Antonio/0000-0003-0261-9897				Aguado A, 2009, BMC GERIATR, V8, P16; Alagiakrishnan K, 2003, J GERONTOL A-BIOL, V58, P362; Amati F, 2008, J APPL PHYSIOL, V105, P825, DOI 10.1152/japplphysiol.90384.2008; Aronow WS, 2011, J AM SOC HYPERTENS, V5, P259, DOI 10.1016/j.jash.2011.06.001; Askari M, 2004, AGING CLIN EXP RES, V16, P206, DOI 10.1007/BF03327385; Baitar A, 2013, J GERIATR ONCOL, V4, P32, DOI 10.1016/j.jgo.2012.08.001; Beckett N, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.d7541; Beckett NS, 2008, NEW ENGL J MED, V358, P1887, DOI 10.1056/NEJMoa0801369; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; Bejan-Angoulvant T, 2010, J HYPERTENS, V28, P1366, DOI 10.1097/HJH.0b013e328339f9c5; Benetos A, 2005, J HYPERTENS, V23, P1803, DOI 10.1097/01.hjh.0000179512.71018.40; Benetos A, 2015, JAMA INTERN MED, V175, P989, DOI 10.1001/jamainternmed.2014.8012; Benetos A, 2013, J AM MED DIR ASSOC, V14, P791, DOI 10.1016/j.jamda.2013.08.003; Benetos A, 2012, J AM COLL CARDIOL, V60, P1503, DOI 10.1016/j.jacc.2012.04.055; Benetos A, 2010, J HYPERTENS, V28, P41, DOI 10.1097/HJH.0b013e328332b879; Berrut G, 2013, J NUTR HEALTH AGING, V17, P688, DOI 10.1007/s12603-013-0039-2; Blacher J, 2014, FUND CLIN PHARMACOL, V28, P1, DOI 10.1111/fcp.12044; Bromfield SG, 2014, J CLIN HYPERTENS, V16, P270, DOI 10.1111/jch.12281; Bulpitt CJ, 2013, HYPERTENSION, V61, P89, DOI 10.1161/HYPERTENSIONAHA.112.191791; Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253; Cherubini A, 2011, ARCH INTERN MED, V171, P550, DOI 10.1001/archinternmed.2011.31; Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1; Dalleur O, SCREENING TOOLS ASSE; Ellis G, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006211.pub2; Emdin CA, 2015, JAMA-J AM MED ASSOC, V313, P603, DOI 10.1001/jama.2014.18574; Fick D, 2012, J AM GERIATR SOC, V60, P616, DOI 10.1111/j.1532-5415.2012.03923.x; Franco OH, 2005, HYPERTENSION, V46, P280, DOI 10.1161/01.HYP.0000173433.67426.9b; Franklin SS, 2001, CIRCULATION, V103, P1245; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Fried TR, 2014, J AM GERIATR SOC, V62, P2261, DOI 10.1111/jgs.13153; Fusco D, 2009, DRUG AGING, V26, P3, DOI 10.2165/11534620-000000000-00000; Gallagher P, 2008, INT J CLIN PHARM TH, V46, P72; Garfinkel D, 2010, ARCH INTERN MED, V170, P1648, DOI 10.1001/archinternmed.2010.355; Hajjar Emily R, 2007, Am J Geriatr Pharmacother, V5, P345, DOI 10.1016/j.amjopharm.2007.12.002; HANLON JT, 1992, J CLIN EPIDEMIOL, V45, P1045, DOI 10.1016/0895-4356(92)90144-C; Hiitola PK, 2007, J CLIN PHARM THER, V32, P253, DOI 10.1111/j.1365-2710.2007.00819.x; Hirdes JP, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-277; Hutchison LC., 2007, J PHARM PRACT, V20, P4, DOI [10.1177/0897190007304657, DOI 10.1177/0897190007304657]; James PA, 2014, JAMA-J AM MED ASSOC, V311, P1809, DOI 10.1001/jama.2013.284427; Kalyanasundaram A, 2011, NAT REV CARDIOL, V8, P592, DOI 10.1038/nrcardio.2011.128; Klotz U, 2009, DRUG METAB REV, V41, P67, DOI 10.1080/03602530902722679; Kostis JB, 2008, NEW ENGL J MED, V358, P1958, DOI 10.1056/NEJMe0801709; Lampela P, 2010, DRUG AGING, V27, P507, DOI 10.2165/11536650-000000000-00000; Launer LJ, 2000, NEUROBIOL AGING, V21, P49, DOI 10.1016/S0197-4580(00)00096-8; Lip GYH, 2015, JAMA-J AM MED ASSOC, V313, P1950, DOI 10.1001/jama.2015.4369; Lipsitz LA, 2013, JAMA-J AM MED ASSOC, V310, P1274, DOI 10.1001/jama.2013.277027; Lloyd-Jones DM, 2005, JAMA-J AM MED ASSOC, V294, P466, DOI 10.1001/jama.294.4.466; Mancia G, 2013, EUR HEART J, V34, P2159, DOI 10.1093/eurheartj/eht151; Mangoni AA, 2004, BRIT J CLIN PHARMACO, V57, P6, DOI 10.1046/j.1365-2125.2003.02007.x; Mannucci PM, 2014, INTERN EMERG MED, V9, P723, DOI 10.1007/s11739-014-1124-1; MATTILA K, 1988, BRIT MED J, V296, P887, DOI 10.1136/bmj.296.6626.887; Molander L, 2008, J AM GERIATR SOC, V56, P1853, DOI 10.1111/j.1532-5415.2008.01948.x; Moorhouse P, 2012, J AM GERIATR SOC, V60, P2326, DOI 10.1111/j.1532-5415.2012.04210.x; Muller M, 2014, HYPERTENSION, V63, P433, DOI 10.1161/HYPERTENSIONAHA.113.00911; National Institute for Health and Care Excellence, 2011, HYP CLIN MAN PRIM HY; National Institute on Aging National Institutes of Health and World Health Organisation, 2011, NIH PUBL, V11-7737; Naugler C T, 2000, Can J Clin Pharmacol, V7, P103; O'Mahony D, 2015, AGE AGEING, V44, P213, DOI 10.1093/ageing/afu145; Oates DJ, 2007, J AM GERIATR SOC, V55, P383, DOI 10.1111/j.1532-5415.2007.01069.x; Odden MC, 2012, ARCH INTERN MED, V172, P1162, DOI 10.1001/archinternmed.2012.2555; Onder G, 2014, J GERONTOL A-BIOL, V69, P430, DOI 10.1093/gerona/glt118; Onder G, 2011, CURR DRUG METAB, V12, P647, DOI 10.2174/138920011796504563; Organisation for Economic Co-operation and Development, HLTH GLANC 2009 OECD; Perry HM, 2000, JAMA-J AM MED ASSOC, V284, P465, DOI 10.1001/jama.284.4.465; Peters R, 2013, J HYPERTENS, V31, P1868, DOI 10.1097/HJH.0b013e3283622cc6; Peters R, 2010, AGE AGEING, V39, P609, DOI 10.1093/ageing/afq071; Peters R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011775; Petrovic M, 2012, DRUG AGING, V29, P453, DOI 10.2165/11631760-000000000-00000; Rastas S, 2006, J AM GERIATR SOC, V54, P912, DOI 10.1111/j.1532-5415.2006.00742.x; Romero-Ortuno R, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006645; Safar ME, 2003, CIRCULATION, V107, P2864, DOI 10.1161/01.CIR.0000069826.36125.B4; Sardar P, 2014, J AM GERIATR SOC, V62, P857, DOI 10.1111/jgs.12799; Scott IA, 2015, JAMA INTERN MED, V175, P827, DOI 10.1001/jamainternmed.2015.0324; Sinclair A, 2015, LANCET DIABETES ENDO, V3, P275, DOI 10.1016/S2213-8587(14)70176-7; Sinclair AJ, 2011, DIABETES METAB, V37, pS27, DOI 10.1016/S1262-3636(11)70962-4; Sparling PB, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h100; Strandberg TE, 2014, JAMA-J AM MED ASSOC, V312, P1136, DOI 10.1001/jama.2014.10924; Studenski S, 2011, JAMA-J AM MED ASSOC, V305, P50, DOI 10.1001/jama.2010.1923; Thoenes M, 2013, J HUM HYPERTENS, V27, P131, DOI 10.1038/jhh.2011.114; Thomas DR, 2007, CLIN NUTR, V26, P389, DOI 10.1016/j.clnu.2007.03.008; Van Den Noortgate N, 2009, ACTA CLIN BELG, V64, P7, DOI 10.1179/acb.2009.003; van der Cammen TJM, 2014, AGE AGEING, V43, P20, DOI 10.1093/ageing/aft166; Van Kan GA, 2008, J NUTR HEALTH AGING, V12, P29, DOI 10.1007/BF02982161; van Kan GA, 2010, CLIN GERIATR MED, V26, P275, DOI 10.1016/j.cger.2010.02.002; Van Pottelbergh G, 2010, AGE AGEING, V39, P542, DOI 10.1093/ageing/afq091; Warwick J, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0328-1; Weber MA, 2014, J HYPERTENS, V32, P3, DOI [10.1097/HJH.0000000000000065, 10.1111/jch.12237]	87	88	94	1	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	2015	314	2					170	180		10.1001/jama.2015.7517	http://dx.doi.org/10.1001/jama.2015.7517			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CM7JI	26172896				2023-01-03	WOS:000357867500017
J	Gazmuri, RJ; Whitehouse, K; Whittinghill, K; Baetiong, A; Radhakrishnan, J				Gazmuri, Raul J.; Whitehouse, Kasen; Whittinghill, Karla; Baetiong, Alvin; Radhakrishnan, Jeejabai			Vasopressin Infusion with Small-Volume Fluid Resuscitation during Hemorrhagic Shock Promotes Hemodynamic Stability and Survival in Swine	PLOS ONE			English	Article							ARGININE-VASOPRESSIN; ABDOMINAL-SURGERY; LIVER TRAUMA; IMPLEMENTATION; NOREPINEPHRINE; STRATEGIES; MILITARY; PRESSURE; FUTURE	Introduction Current management of hemorrhagic shock (HS) in the battlefield and civilian settings favors small-volume fluid resuscitation before controlling the source of bleeding. We investigated in a swine model of HS the effects of vasopressin infusion along with small-volume fluid resuscitation; with erythropoietin (EPO) and HS severity as additional factors. Methods HS was induced in 24 male domestic pigs (36 to 41 kg) by blood withdrawal (BW) through a right atrial cannula modeling spontaneous bleeding by a mono-exponential decay function. The initial 12 pigs received no fluids; the last 12 pigs received normal saline (NS) half the BW volume. Pigs were randomized 2:1 to receive intraosseously vasopressin (0.04 U/kg.min(-1)) or vehicle control from minute 7 to minute 210. Pigs assigned to vasopressin were further randomized 1:1 to receive EPO (1,200 U/kg) or vehicle control and 1:1 to have 65% or 75% BW of their blood volume. Shed blood was reinfused at 210 minutes and the pigs recovered from anesthesia. Results Survival at 72 hours was influenced by vasopressin and NS but not by EPO or % BW. Vasopressin with NS promoted the highest survival (8/8) followed by vasopressin without NS (3/8), NS without vasopressin (1/4), and neither treatment (0/4) with overall statistical significance (log-rank test, p = 0.009) and each subset different from vasopressin with NS by Holm-Sidak test. Vasopressin increased systemic vascular resistance whereas NS increased cardiac output. Conclusion Vasopressin infusion with small-volume fluid resuscitation during severe HS was highly effective enabling critical hemodynamic stabilization and improved 72 hour survival.	[Gazmuri, Raul J.; Whitehouse, Kasen; Whittinghill, Karla; Baetiong, Alvin; Radhakrishnan, Jeejabai] Rosalind Franklin Univ Med & Sci, Dept Med, N Chicago, IL 60064 USA; [Gazmuri, Raul J.; Whitehouse, Kasen; Whittinghill, Karla; Baetiong, Alvin; Radhakrishnan, Jeejabai] Rosalind Franklin Univ Med & Sci, Resuscitat Inst, N Chicago, IL USA; [Gazmuri, Raul J.] Rosalind Franklin Univ Med & Sci, Dept Physiol, N Chicago, IL USA; [Gazmuri, Raul J.] Captain James A Lovell Fed Hlth Care Ctr, Crit Care Med, N Chicago, IL USA	Rosalind Franklin University Medical & Science; Rosalind Franklin University Medical & Science; Rosalind Franklin University Medical & Science	Gazmuri, RJ (corresponding author), Rosalind Franklin Univ Med & Sci, Dept Med, N Chicago, IL 60064 USA.	raul.gazmuri@rosalindfranklin.edu		Gazmuri, Raul J./0000-0002-3848-7227	Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Materiel Command (USAMRMC) Fort Detrick, MD [W81XWH-11-2-0019]	Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Materiel Command (USAMRMC) Fort Detrick, MD	This research was supported by the Telemedicine and Advanced Technology Research Center (TATRC) at the U.S. Army Medical Research and Materiel Command (USAMRMC) Fort Detrick, MD under contract number: W81XWH-11-2-0019 to RJG.	Anand T, 2012, J SURG RES, V178, P321, DOI 10.1016/j.jss.2012.02.062; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Borovnik-Lesjak V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110908; Campion EM, 2013, J TRAUMA ACUTE CARE, V75, pS221, DOI 10.1097/TA.0b013e318299d59b; Davenport R, 2013, TRANSFUSION, V53, p23S, DOI 10.1111/trf.12032; den Ouden DT, 2005, NETH J MED, V63, P4; Dubick Michael A, 2011, US Army Med Dep J, P18; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Faybik P, 2010, RESUSCITATION, V81, P1584, DOI 10.1016/j.resuscitation.2010.05.024; Gazmuri RJ, 2001, CRIT CARE MED, V29, P673, DOI 10.1097/00003246-200103000-00042; Guzman JA, 2003, J APPL PHYSIOL, V95, P803, DOI 10.1152/japplphysiol.00017.2003; Hasser EM, 1997, CLIN EXP PHARMACOL P, V24, P102, DOI 10.1111/j.1440-1681.1997.tb01791.x; Hooper TJ, 2014, SHOCK, V41, P90, DOI 10.1097/SHK.0000000000000081; KELLEY KW, 1973, J ANIM SCI, V36, P927; Madigan MC, 2008, J TRAUMA, V64, P280, DOI 10.1097/TA.0b013e3181622bb6; Moore EE, 1996, AM J SURG, V172, P405, DOI 10.1016/S0002-9610(96)00216-4; Nunez TC, 2010, J TRAUMA, V68, P1498, DOI 10.1097/TA.0b013e3181d3cc25; PANG CCY, 1986, BRIT J PHARMACOL, V89, P389, DOI 10.1111/j.1476-5381.1986.tb10272.x; Radhakrishnan J, 2013, AM J TRANSL RES, V5, P316; Raedler C, 2004, ANESTH ANALG, V98, P1759, DOI 10.1213/01.ANE.0000117150.29361.5A; Rajani RR, 2009, AM SURGEON, V75, P1207; Russell JA, 2013, AM J RESP CRIT CARE, V188, P356, DOI 10.1164/rccm.201302-0355OC; SANDERS AB, 1994, ANN EMERG MED, V23, P56, DOI 10.1016/S0196-0644(94)70009-5; Shaw AD, 2012, ANN SURG, V255, P821, DOI 10.1097/SLA.0b013e31825074f5; Voelckel WG, 2003, CRIT CARE MED, V31, P1160, DOI 10.1097/01.CCM.0000060014.75282.69; Voelckel WG, 2010, J TRAUMA, V69, pS69, DOI 10.1097/TA.0b013e3181e44937; Volta CA, 2013, J INFLAMM-LOND, V10, DOI 10.1186/1476-9255-10-29; Yoo JH, 2007, J VET MED SCI, V69, P459, DOI 10.1292/jvms.69.459	28	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2015	10	6							e0130134	10.1371/journal.pone.0130134	http://dx.doi.org/10.1371/journal.pone.0130134			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL4OM	26107942	Green Submitted, Green Published, gold			2023-01-03	WOS:000356932500080
J	Basu, S; Phillips, RS; Bitton, A; Song, ZR; Landon, BE				Basu, Sanjay; Phillips, Russell S.; Bitton, Asaf; Song, Zirui; Landon, Bruce E.			Medicare Chronic Care Management Payments and Financial Returns to Primary Care Practices A Modeling Study	ANNALS OF INTERNAL MEDICINE			English	Article							HOSPITAL ADMISSIONS; GLOBAL PAYMENT; COMMUNITY CARE; HOME PILOT; PATIENT; HEALTH; COST; QUALITY; ORGANIZATIONS; IMPACT	Background: Physicians have traditionally been reimbursed for face-to-face visits. A new non-visit-based payment for chronic care management (CCM) of Medicare patients took effect in January 2015. Objective: To estimate financial implications of CCM payment for primary care practices. Design: Microsimulation model incorporating national data on primary care use, staffing, expenditures, and reimbursements. Data Sources: National Ambulatory Medical Care Survey and other published sources. Target Population: Medicare patients. Time Horizon: 10 years. Perspective: Practice-level. Intervention: Comparison of CCM delivery approaches by staff and physicians. Outcome Measures: Net revenue per full-time equivalent (FTE) physician; time spent delivering CCM services. Results of Base-Case Analysis: If nonphysician staff were to deliver CCM services, net revenue to practices would increase despite opportunity and staffing costs. Practices could expect approximately $332 per enrolled patient per year (95% CI, $234 to $429) if CCM services were delivered by registered nurses RNs), approximately $372 (CI, $276 to $468) if services were delivered by licensed practical nurses, and approximately $385 (CI, $286 to $485) if services were delivered by medical assistants. For a typical practice, this equates to more than $75 000 of net annual revenue per FTE physician and 12 hours of nursing service time per week if 50% of eligible patients enroll. At a minimum, 131 Medicare patients (CI, 115 to 140 patients) must enroll for practices to recoup the salary and overhead costs of hiring a full-time RN to provide CCM services. Results of Sensitivity Analysis: If physicians were to deliver all CCM services, approximately 25% of practices nationwide could expect net revenue losses due to opportunity costs of face-to-face visit time. Limitation: The CCM program may alter long-term primary care use, which is difficult to predict. Conclusion: Practices that rely on nonphysician team members to deliver CCM services will probably experience substantial net revenue gains but must enroll a sufficient number of eligible patients to recoup costs.	[Basu, Sanjay] Stanford Univ, Sch Med, Stanford, CA 94305 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Stanford University; Harvard University; Beth Israel Deaconess Medical Center; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital	Basu, S (corresponding author), Stanford Univ, Sch Med, Med Sch Off Build X322,1265 Welch Rd, Stanford, CA 94305 USA.				Center for Medicare & Medicaid Innovation	Center for Medicare & Medicaid Innovation	Dr. Bitton reports that he received personal fees from the Center for Medicare & Medicaid Innovation for serving as a part-time senior advisor to the Comprehensive Primary Care initiative at the Center for Medicare & Medicaid Innovation and that he participated in a technical expert panel convened by Mathematica Policy Research that advised the Assistant Secretary for Planning and Evaluation of Health and Human Services on the chronic care management fee. Dr. Landon reports personal fees from United Biosource and Research Triangle Institute outside the submitted work. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M14-2677.	American Academy of Family Physicians, 2014, FPM SER DIR OBS PRIM; [Anonymous], 2013, MED EXP PAN SURV; Basu S, 2015, MED CARE, V53, P125, DOI 10.1097/MLR.0000000000000278; Basu S, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001540; Bielaszka-DuVernay C, 2011, HEALTH AFFAIR, V30, P383, DOI 10.1377/hlthaff.2011.0169; Bureau of Labor Statistics, 2014, OCC OUTL HDB; Bureau of Labor Statistics, 2015, CONS PRIC IND; Caro JJ, 2012, MED DECIS MAKING, V32, P667, DOI 10.1177/0272989X12454577; Centers for Disease Control and Prevention, 2014, NAT AMB MED CAR SURV; Centers for Medicare & Medicaid Services, 2015, CHR CAR MAN SERV FAC; Centers for Medicare & Medicaid Services, 2014, POL PAYM CHANG MED P; Centers for Medicare & Medicaid Services, 2011, ANN WELLN VIS AWV IN; Centers for Medicare & Medicaid Services, 2014, MED MOV FORW 2014; Centers for Medicare & Medicaid Services (CMS). HHS, 2014, FED REGISTER, V79, P67547; Christensen EW, 2013, MIL MED, V178, P135, DOI 10.7205/MILMED-D-12-00220; Coleman K, 2010, ANN FAM MED, V8, P493, DOI 10.1370/afm.1190; Cuenca Arnold E, 2012, Fam Pract Manag, V19, P11; Design Cost Data, 2007, NHBC DAT; DeVries A, 2012, AM J MANAG CARE, V18, P534; Driscoll DL, 2013, ANN FAM MED, V11, pS41, DOI 10.1370/afm.1474; Epstein AM, 2014, HEALTH AFFAIR, V33, P95, DOI 10.1377/hlthaff.2013.1063; Ferguson JA, 1998, J GEN INTERN MED, V13, P123, DOI 10.1046/j.1525-1497.1998.00029.x; Fillmore H, 2014, POPUL HEALTH MANAG, V17, P141, DOI 10.1089/pop.2013.0055; Flottemesch TJ, 2012, AM J MANAG CARE, V18, P677; Friedberg MW, 2014, JAMA-J AM MED ASSOC, V311, P815, DOI 10.1001/jama.2014.353; Gilfillan RJ, 2010, AM J MANAG CARE, V16, P607; Grumbach K, 2013, JAMA INTERN MED, V173, P1913, DOI 10.1001/jamainternmed.2013.7652; Harbrecht MG, 2012, HEALTH AFFAIR, V31, P2010, DOI 10.1377/hlthaff.2012.0359; Hofert M, 2011, J STAT SOFTW, V39, P1; Husereau D, 2013, BJOG-INT J OBSTET GY, V120, P765, DOI 10.1111/1471-0528.12241; IBM, 2015, IBM KEN COMPANALYST; Landon BE, 2014, JAMA-J AM MED ASSOC, V312, P1633, DOI 10.1001/jama.2014.9529; Landon BE, 2012, NEW ENGL J MED, V366, P393, DOI 10.1056/NEJMp1112637; Lewis VA, 2013, HEALTH SERV RES, V48, P1840, DOI 10.1111/1475-6773.12102; Maeng DD, 2012, AM J MANAG CARE, V18, P149; Mathematica Policy Research, 2015, EV COMPR PRIM CAR IN; McWilliams JM, 2014, NEW ENGL J MED, V371, P1715, DOI 10.1056/NEJMsa1406552; Medical Group, 2015, DATADIVE; Medical Group Management Association, 2014, COST SURV SINGL SPEC; Milstein A, 2009, HEALTH AFFAIR, V28, P1317, DOI 10.1377/hlthaff.28.5.1317; Moore Kent J, 2015, Fam Pract Manag, V22, P7; Patel MS, 2013, AM J MANAG CARE, V19, P509; Phillips RL, 2011, J AMBUL CARE MANAG, V34, P67, DOI 10.1097/JAC.0b013e3181ffc342; Raskas RS, 2012, HEALTH AFFAIR, V31, P2002, DOI 10.1377/hlthaff.2012.0364; Reid RJ, 2013, ANN FAM MED, V11, pS19, DOI 10.1370/afm.1476; Roby DH, 2010, MED CARE RES REV, V67, P412, DOI 10.1177/1077558710368682; Rosenberg CN, 2012, HEALTH AFFAIR, V31, P2423, DOI 10.1377/hlthaff.2011.1002; Schillinger D, 2000, J GEN INTERN MED, V15, P329, DOI 10.1046/j.1525-1497.2000.07010.x; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; Song ZR, 2014, NEW ENGL J MED, V371, P1704, DOI 10.1056/NEJMsa1404026; Song ZR, 2012, NEW ENGL J MED, V366, P1560, DOI 10.1056/NEJMp1201261; Steiner BD, 2008, ANN FAM MED, V6, P361, DOI 10.1370/afm.866; Taha H. A., 2010, OPERATIONS RES INTRO; Takach M, 2011, HEALTH AFFAIR, V30, P1325, DOI 10.1377/hlthaff.2011.0170; U.S. Census Bureau, 2019, CURRENT POPULATION S	55	34	34	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 20	2015	163	8					580	+		10.7326/M14-2677	http://dx.doi.org/10.7326/M14-2677			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CU7QV	26389533				2023-01-03	WOS:000363737400016
J	Twomey, PS; Smith, BL; McDermott, C; Novitt-Moreno, A; McCarthy, W; Kachur, SP; Arguin, PM				Twomey, Patrick S.; Smith, Bryan L.; McDermott, Cathy; Novitt-Moreno, Anne; McCarthy, William; Kachur, S. Patrick; Arguin, Paul M.			Intravenous Artesunate for the Treatment of Severe and Complicated Malaria in the United States: Clinical Use Under an Investigational New Drug Protocol	ANNALS OF INTERNAL MEDICINE			English	Article							FALCIPARUM-MALARIA; PLASMODIUM-FALCIPARUM; QUINIDINE; RISK; ARTEMISININ; MANAGEMENT; RESISTANCE; THERAPY; DISEASE; ADULTS	Background: Quinidine gluconate, the only U.S. Food and Drug Administration-approved treatment for life-threatening malaria in the United States, has a problematic safety profile and is often unavailable in hospitals. Objective: To assess the safety and clinical benefit of intravenous artesunate as an alternative to quinidine. Design: Retrospective case series. Setting: U.S. hospitals. Patients: 102 patients aged 1 to 72 years (90% adults; 61% men) with severe and complicated malaria. Patients received 4 weight-based doses of intravenous artesunate (2.4 mg/kg) under a treatment protocol implemented by the Centers for Disease Control and Prevention between January 2007 and December 2010. At baseline, 35% had evidence of cerebral malaria, and 17% had severe hepatic impairment. Eligibility required the presence of microscopically confirmed malaria, need for intravenous treatment, and an impediment to quinidine. Measurements: Clinical and laboratory data from each patient's hospital records were abstracted retrospectively, including information from baseline through a maximum 7-day follow-up, and presented before a physician committee to evaluate safety and clinical benefit outcomes. Results: 7 patients died (mortality rate, 6.9%). The most frequent adverse events were anemia (65%) and elevated hepatic enzyme levels (49%). All deaths and most adverse events were attributed to the severity of malaria. Patients' symptoms generally improved or resolved within 3 days, and the median time to discharge from the intensive care unit was 4 days, even for patients with severe liver disease or cerebral malaria. More than 100 concomitant medications were used, with no documented drug-drug interactions. Limitation: Potential late-presenting safety issues might occur outside the 7-day follow-up. Conclusion: Artesunate was a safe and clinically beneficial alternative to quinidine.	[Twomey, Patrick S.] US Army Med Mat Dev Act, Ft Detrick, MD 21702 USA; Fast Track Drugs & Biol, North Potomac, MD USA; Ctr Dis Control & Prevent, Bethesda, MD USA	United States Department of Defense; United States Army; Centers for Disease Control & Prevention - USA	Twomey, PS (corresponding author), US Army Med Mat Dev Act, 1430 Vet Dr, Ft Detrick, MD 21702 USA.	patrick.s.twomey.mil@mail.mil	Kachur, Patrick/ABE-7220-2021		Office of the Surgeon General, Department of the U.S. Army	Office of the Surgeon General, Department of the U.S. Army	Office of the Surgeon General, Department of the U.S. Army.	Abanyie FA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-340; Abdallah TM, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-148; Abro AH, 2009, JCPSP-J COLL PHYSICI, V19, P363, DOI 06.2009/JCPSP.363366; Alves C, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-306; [Anonymous], TREATM GUID TREATM M; Askling HH, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-328; Bartoloni A, 2012, MEDITERR J HEMATOL I, V4, DOI 10.4084/MJHID.2012.026; Beales PF, 2000, T ROY SOC TROP MED H, V94, pS1; Briggs M, 2013, MMWR-MORBID MORTAL W, V62, P5; Bruneel F, 2003, AM J RESP CRIT CARE, V167, P684, DOI 10.1164/rccm.200206-631OC; Bruneel F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013236; Centers for Disease Control and Prevention, 2012, ART IS AV TREAT SEV; Centers for Disease Control and Prevention, 2013, GUID TREATM MAL US B; Centers for Disease Control and Prevention, 2015, MAL FACTS; Checkley AM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2116; Devlin JW, 2010, CRIT CARE MED, V38, pS231, DOI 10.1097/CCM.0b013e3181de125a; Dondorp AM, 2010, LANCET, V376, P1647, DOI 10.1016/S0140-6736(10)61924-1; Faiz MA, 2005, LANCET, V366, P717; Higgins SJ, 2011, EXPERT REV ANTI-INFE, V9, P803, DOI [10.1586/eri.11.96, 10.1586/ERI.11.96]; Ilett KF, 2002, BRIT J CLIN PHARMACO, V53, P23, DOI 10.1046/j.0306-5251.2001.01519.x; Kamath PS, 2007, HEPATOLOGY, V45, P797, DOI 10.1002/hep.21563; Kreeftmeijer-Vegter AR, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-102; Kremsner PG, 2012, J INFECT DIS, V205, P312, DOI 10.1093/infdis/jir724; Li QG, 2009, AM J TROP MED HYG, V81, P615, DOI 10.4269/ajtmh.2009.09-0150; Lon C, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-217; MESHNICK SR, 1994, T ROY SOC TROP MED H, V88, P31, DOI 10.1016/0035-9203(94)90468-5; Miller RS, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-255; Mishra SK, 2006, J POSTGRAD MED, V52, P281; Muhlberger N, 2003, CLIN INFECT DIS, V36, P990, DOI 10.1086/374224; Nadjm B, 2012, INFECT DIS CLIN N AM, V26, P243, DOI 10.1016/j.idc.2012.03.010; National Kidney Disease Education Program, 2013, HOM LAB EV GFR EST G; Phillips A, 2009, CLIN INFECT DIS, V48, P871, DOI 10.1086/597258; PHILLIPS RE, 1986, BRIT MED J, V292, P1319, DOI 10.1136/bmj.292.6531.1319; Santos LC, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-96; Shah S, 2009, JCPSP-J COLL PHYSICI, V19, P367, DOI 06.2009/JCPSP.367370; Takala-Harrison S, 2015, J INFECT DIS, V211, P670, DOI 10.1093/infdis/jiu491; Viskin S, 2013, J AM COLL CARDIOL, V62, P355, DOI 10.1016/j.jacc.2013.04.009; Viskin S, 2013, J AM COLL CARDIOL, V61, P2383, DOI 10.1016/j.jacc.2013.02.077; White NJ, 2008, SCIENCE, V320, P330, DOI 10.1126/science.1155165; White NJ, 1996, NEW ENGL J MED, V335, P800, DOI 10.1056/NEJM199609123351107; WHO, 2010, GUID TREATM MAL, V2nd; World Health Organization, 2013, WHO INF NOT DEL HAEM; Wroblewski HA, 2012, ANTIMICROB AGENTS CH, V56, P4495, DOI 10.1128/AAC.06396-11; Zamidei L, 2010, MINERVA ANESTESIOL, V76, P66	44	25	26	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 6	2015	163	7					498	+		10.7326/M15-0910	http://dx.doi.org/10.7326/M15-0910			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT0OQ	26301474	Green Accepted			2023-01-03	WOS:000362496400003
J	Kitterer, D; Latus, J; Pohlmann, C; Alscher, MD; Kimmel, M				Kitterer, Daniel; Latus, Joerg; Poehlmann, Christoph; Alscher, M. Dominik; Kimmel, Martin			Microbiological Surveillance of Peritoneal Dialysis Associated Peritonitis: Antimicrobial Susceptibility Profiles of a Referral Center in GERMANY over 32 Years	PLOS ONE			English	Article							CAPD PERITONITIS; INFECTIONS; EXPERIENCE; ORGANISMS; CEFAZOLIN; UPDATE; TRENDS	Objectives Peritonitis is one of the most important causes of treatment failure in peritoneal dialysis (PD) patients. This study describes changes in characteristics of causative organisms in PD-related peritonitis and antimicrobial susceptibility. Methods In this single center study we analyzed retrospective 487 susceptibility profiles of the peritoneal fluid cultures of 351 adult patients with peritonitis from 1979 to 2014 (divided into three time periods, P1-P3). Results Staphylococcus aureus decreased from P1 compared to P2 and P3 (P<0.05 and P<0.01, respectively). Methicillin-resistant S. aureus (MRSA) occurred only in P3. Methicillin-resistant Staphylococcus epidermidis (MRSE) increased in P3 over P1 and P2 (P<0.0001, respectively). In P2 and P3, vancomycin resistant enterococci were detected. The percentage of gram-negative organisms remained unchanged. Third generation cephalosporin resistant gram-negative rods (3GCR-GN) were found exclusively in P3. Cefazolin-susceptible gram-positive organisms decreased over the three decades (93% in P1, 75% in P2 and 58% in P3, P<0.01, P<0.05 and P<0.0001, respectively). Vancomycin susceptibility decreased and gentamicin susceptibility in gram-negatives was 94% in P1, 82% in P2 and 90% in P3. Ceftazidim susceptibility was 84% in P2 and 93% in P3. Conclusions Peritonitis caused by MSSA decreased, but peritonitis caused by MRSE increased. MRSA peritonitis is still rare. Peritonitis caused by 3GCR-GN is increasing. An initial antibiotic treatment protocol should be adopted for PD patients to provide continuous surveillance.	[Kitterer, Daniel; Latus, Joerg; Alscher, M. Dominik; Kimmel, Martin] Robert Bosch Krankenhaus, Dept Internal Med, Div Nephrol, Stuttgart, Germany; [Poehlmann, Christoph] Robert Bosch Krankenhaus, Dept Diagnost & Lab Med, Stuttgart, Germany	Bosch; Robert Bosch Krankenhaus; Bosch; Robert Bosch Krankenhaus	Kimmel, M (corresponding author), Robert Bosch Krankenhaus, Dept Internal Med, Div Nephrol, Stuttgart, Germany.	martin.kimmel@rbk.de	Kimmel, Martin/AAM-2514-2021					BAZZATO G, 1984, T AM SOC ART INT ORG, V30, P690; Bending M, 1996, J AM SOC NEPHROL, V7, P2403; Boeschoten EW, 2006, NEPHROL DIAL TRANSPL, V21, pii31; Boudville N, 2012, J AM SOC NEPHROL, V23, P1398, DOI 10.1681/ASN.2011121135; Chao CT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110315; Daly C, 2001, COCHRANE DB SYST REV; Friedman O, 2008, PERITON DIALYSIS INT, V28, P195; Grassmann A, 2005, NEPHROL DIAL TRANSPL, V20, P2587, DOI 10.1093/ndt/gfi159; HOLLEY JL, 1990, AM J KIDNEY DIS, V16, P142, DOI 10.1016/S0272-6386(12)80569-5; Institute CaLS, 2014, PERF STAND ANT SUSC; Jain AK, 2012, J AM SOC NEPHROL, V23, P533, DOI 10.1681/ASN.2011060607; Kavanagh D, 2004, NEPHROL DIAL TRANSPL, V19, P2584, DOI 10.1093/ndt/gfh386; KEANE WF, 1993, PERITON DIALYSIS INT, V13, P14; Kim DK, 2004, PERITON DIALYSIS INT, V24, P424; Leung CB, 2004, PERITON DIALYSIS INT, V24, P440; Li PKT, 2010, PERITON DIALYSIS INT, V30, P393, DOI 10.3747/pdi.2010.00049; Piraino B, 2011, PERITON DIALYSIS INT, V31, P614, DOI 10.3747/pdi.2011.00057; Strippoli GFM, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004679.PUB2; Szeto CC, 2007, CLIN J AM SOC NEPHRO, V2, P245, DOI 10.2215/CJN.03180906; Troidle Laura, 2006, Ann Clin Microbiol Antimicrob, V5, P6, DOI 10.1186/1476-0711-5-6; van Esch S, 2014, PERITON DIALYSIS INT, V34, P162, DOI 10.3747/pdi.2013.00275; Vlaar PJ, 2013, PERITON DIALYSIS INT, V33, P708, DOI 10.3747/pdi.2012.00155; WEBER J, 1989, PERITON DIALYSIS INT, V9, P191; Yip T, 2006, PERITON DIALYSIS INT, V26, P191	25	20	22	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2015	10	9							e0135969	10.1371/journal.pone.0135969	http://dx.doi.org/10.1371/journal.pone.0135969			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS1CR	26405797	Green Published, Green Submitted, gold			2023-01-03	WOS:000361800700007
J	Pritchard-Jones, K; Bergeron, C; de Camargo, B; van den Heuvel-Eibrink, MM; Acha, T; Godzinski, J; Oldenburger, F; Boccon-Gibod, L; Leuschner, I; Vujanic, G; Sandstedt, B; de Kraker, J; van Tinteren, H; Graf, N				Pritchard-Jones, Kathy; Bergeron, Christophe; de Camargo, Beatriz; van den Heuvel-Eibrink, Marry M.; Acha, Tomas; Godzinski, Jan; Oldenburger, Foppe; Boccon-Gibod, Liliane; Leuschner, Ivo; Vujanic, Gordan; Sandstedt, Bengt; de Kraker, Jan; van Tinteren, Harm; Graf, Norbert		SIOP Renal Tumours Study Grp	Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial	LANCET			English	Article							CHILDHOOD-CANCER; FAVORABLE-HISTOLOGY; PEDIATRIC-ONCOLOGY; INTERNATIONAL-SOCIETY; CARDIAC EVENTS; RENAL TUMORS; SURVIVORS; CHILDREN; CHEMOTHERAPY; EQUIVALENCE	Background Before this study started, the standard postoperative chemotherapy regimen for stage II-III Wilms' tumour pretreated with chemotherapy was to include doxorubicin. However, avoidance of doxorubicin-related cardiotoxicity effects is important to improve long-term outcomes for childhood cancers that have excellent prognosis. We aimed to assess whether doxorubicin can be omitted safely from chemotherapy for stage II-III, histological intermediate-risk Wilms' tumour when a newly defined high-risk blastemal subtype was excluded from randomisation. Methods For this international, multicentre, open-label, non-inferiority, phase 3, randomised SIOP WT 2001 trial, we recruited children aged 6 months to 18 years at the time of diagnosis of a primary renal tumour from 251 hospitals in 26 countries who had received 4 weeks of preoperative chemotherapy with vincristine and actinomycin D. Children with stage II-III intermediate-risk Wilms' tumours assessed after delayed nephrectomy were randomly assigned (1: 1) by a minimisation technique to receive vincristine 1.5 mg/m(2) at weeks 1-8, 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, and 27, plus actinomycin D 45 mu g/kg every 3 weeks from week 2, either with five doses of doxorubicin 50 mg/m(2) given every 6 weeks from week 2 (standard treatment) or without doxorubicin (experimental treatment). The primary endpoint was non-inferiority of event-free survival at 2 years, analysed by intention to treat and a margin of 10%. Assessment of safety and adverse events included systematic monitoring of hepatic toxicity and cardiotoxicity. This trial is registered with EudraCT, number 2007-004591-39, and is closed to new participants. Findings Between Nov 1, 2001, and Dec 16, 2009, we recruited 583 patients, 341 with stage II and 242 with stage III tumours, and randomly assigned 291 children to treatment including doxorubicin, and 292 children to treatment excluding doxorubicin. Median follow-up was 60.8 months (IQR 40.8-79.8). 2 year event-free survival was 92.6% (95% CI 89.6-95.7) for treatment including doxorubicin and 88.2% (84.5-92.1) for treatment excluding doxorubicin, a difference of 4.4% (95% CI 0.4-9.3) that did not exceed the predefined 10% margin. 5 year overall survival was 96.5% (94.3-98.8) for treatment including doxorubicin and 95.8% (93.3-98.4) for treatment excluding doxorubicin. Four children died from a treatment-related toxic effect; one (<1%) of 291 receiving treatment including doxorubicin died of sepsis, three (1%) of 292 receiving treatment excluding doxorubicin died of varicella, metabolic seizure, and sepsis during treatment for relapse. 17 patients (3%) had hepatic veno-occlusive disease. Cardiotoxic effects were reported in 15 (5%) of 291 children receiving treatment including doxorubicin. 12 children receiving treatment including doxorubicin, and ten children receiving treatment excluding doxorubicin, died, with the remaining deaths from tumour recurrence. Interpretation Doxorubicin does not need to be included in treatment of stage II-III intermediate risk Wilms' tumour when the histological response to preoperative chemotherapy is incorporated into the risk stratification. Copyright (C) Pritchard-Jones et al. Open Access article distributed under the terms of CC BY.	[Pritchard-Jones, Kathy] UCL, Inst Child Hlth, Canc Sect, London WC1H 1EH, England; [Bergeron, Christophe] Ctr Leon Berard, Dept Paediat Haematooncol, F-69373 Lyon, France; [de Camargo, Beatriz] Inst Nacl Canc, Res Ctr, Paediat Haematooncol Program, Rio De Janeiro, Brazil; [van den Heuvel-Eibrink, Marry M.] Princess Maxima Ctr Paediat Oncol, Utrecht, Netherlands; [Acha, Tomas] Hosp Maternoinfantil Carlos Haya, Unidad Oncol Pediat, Malaga, Spain; [Godzinski, Jan] Marciniak Hosp, Dept Paediat Surg, Wroclaw, Poland; [Oldenburger, Foppe] Univ Amsterdam, Acad Med Ctr, Dept Radiotherapy, NL-1105 AZ Amsterdam, Netherlands; [de Kraker, Jan] Univ Amsterdam, Acad Med Ctr, Dept Pediat Haematooncol, NL-1105 AZ Amsterdam, Netherlands; [Boccon-Gibod, Liliane] Univ Hop Armand Trousseau, Dept Paediat Pathol, Paris, France; [Leuschner, Ivo] Univ Hosp Schleswig Holstein, Dept Paediat Pathol, Kiel Paediat Tumour Registry, Kiel, Germany; [Vujanic, Gordan] Cardiff Univ, Inst Canc & Genet, Dept Paediat Pathol, Cardiff CF10 3AX, S Glam, Wales; [Sandstedt, Bengt] Karolinska Inst, Childhood Canc Res Unit, Stockholm, Sweden; [van Tinteren, Harm] Netherlands Canc Inst, Dept Biostat, Amsterdam, Netherlands; [Graf, Norbert] Univ Saarland, Dept Paediat Haematooncol, Homburg, Germany	University of London; University College London; UNICANCER; Centre Leon Berard; National Cancer Institute (Inca); University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Kiel; Schleswig Holstein University Hospital; Cardiff University; Karolinska Institutet; Netherlands Cancer Institute; Saarland University	Pritchard-Jones, K (corresponding author), UCL, Inst Child Hlth, Canc Sect, London WC1H 1EH, England.	k.pritchard-jones@ucl.ac.uk	ANSARI, Marc/V-3334-2017; Gregianin, Lauro/W-5658-2019; Vujanic, Gordan M./AAW-4712-2020; de Camargo, Beatriz/I-8414-2014; Almaraz, Ricardo López/X-2931-2019; Kuehne, Thomas/I-6143-2019; Llort, Anna/G-4066-2016; Graf, Norbert/H-1328-2011; Øra, Ingrid/J-2596-2013; Vujanic, Gordan M./AFS-3176-2022; Pritchard-Jones, Kathryn/F-4286-2014	Vujanic, Gordan M./0000-0003-0726-6939; de Camargo, Beatriz/0000-0002-5794-1042; Almaraz, Ricardo López/0000-0001-5521-9892; Kuehne, Thomas/0000-0002-7387-7028; Llort, Anna/0000-0001-9741-1655; Graf, Norbert/0000-0002-2248-323X; Øra, Ingrid/0000-0002-3931-4125; Vujanic, Gordan M./0000-0003-0726-6939; Pritchard-Jones, Kathryn/0000-0002-2384-9475; ansari, marc/0000-0002-9649-6498; Vaidya, Sucheta/0000-0003-2980-9316; Godzinski, Jan/0000-0001-9687-7146; van Tinteren, Harm/0000-0002-4626-8702; Zubizarreta, Pedro/0000-0001-8681-7502; DEFACHELLES, Anne-Sophie/0000-0002-4277-9871; Ljungman, Gustaf/0000-0002-4949-2494; Kearns, Pamela/0000-0003-2756-5813; Kager, Leo/0000-0003-4954-6488	Cancer Research UK [C1188/A8687]; UK National Cancer Research Network; Children's Cancer and Leukaemia Group (CCLG); Societe Francaise des Cancers de l'Enfant; Association Leon Berard Enfant Cancereux and Enfant et Sante; Gesellschaft fur Padiatrische Onkologie und Hamatologie; Deutsche Krebschilfe [50-2709-Gr2]; Grupo Cooperativo Brasileiro para o Tratamento do Tumor de Wilms; Sociedade Brasileira de Oncologia Pediatrica; Spanish Society of Pediatric Haematology and Oncology; Spanish Association Against Cancer; SIOP-NL; National Institute for Health Research Biomedical Research Centre Funding Scheme; Cancer Research UK [15958] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); UK National Cancer Research Network; Children's Cancer and Leukaemia Group (CCLG); Societe Francaise des Cancers de l'Enfant; Association Leon Berard Enfant Cancereux and Enfant et Sante; Gesellschaft fur Padiatrische Onkologie und Hamatologie; Deutsche Krebschilfe; Grupo Cooperativo Brasileiro para o Tratamento do Tumor de Wilms; Sociedade Brasileira de Oncologia Pediatrica; Spanish Society of Pediatric Haematology and Oncology; Spanish Association Against Cancer; SIOP-NL; National Institute for Health Research Biomedical Research Centre Funding Scheme(National Institute for Health Research (NIHR)); Cancer Research UK(Cancer Research UK)	The SIOP WT 2001 study was funded by Cancer Research UK (grant C1188/A8687), the UK National Cancer Research Network and Children's Cancer and Leukaemia Group (CCLG) (who supported the UK section), Societe Francaise des Cancers de l'Enfant and Association Leon Berard Enfant Cancereux and Enfant et Sante (who supported the French section), Gesellschaft fur Padiatrische Onkologie und Hamatologie and Deutsche Krebschilfe (grant 50-2709-Gr2, who supported the German section), Grupo Cooperativo Brasileiro para o Tratamento do Tumor de Wilms and Sociedade Brasileira de Oncologia Pediatrica (who supported the Brazilian section), the Spanish Society of Pediatric Haematology and Oncology and the Spanish Association Against Cancer (who supported the Spanish section) and SIOP-NL. K P-J is partly supported by the National Institute for Health Research Biomedical Research Centre Funding Scheme. We acknowledge the enormous efforts made by more than 1000 clinicians working at the 251 childhood cancer treatment centres in this study from 26 countries who enrolled and followed up patients in this study, and the patients and their families for their participation. The SIOP Renal Tumours Study Group and all authors thank the members of the independent data monitoring committee: Max Coppes (British Columbia Cancer Agency, Canada), Otilia Dalesio (Netherlands Cancer Institute, Amsterdam), and Dietmar Schmidt (Mannheim, Germany). We also acknowledge Lucy Wilkie and Aidan McManus for editorial assistance with journal style and formatting the final draft.	Armstrong GT, 2013, J CLIN ONCOL, V31, P3673, DOI 10.1200/JCO.2013.49.3205; Blanco JG, 2012, J CLIN ONCOL, V30, P1415, DOI 10.1200/JCO.2011.34.8987; Breslow NE, 2004, CANCER-AM CANCER SOC, V101, P1072, DOI 10.1002/cncr.20433; da Silva GT, 2009, BIOL BLOOD MARROW TR, V15, P120, DOI 10.1016/j.bbmt.2008.10.004; DANGIO GJ, 1989, CANCER-AM CANCER SOC, V64, P349, DOI 10.1002/1097-0142(19890715)64:2<349::AID-CNCR2820640202>3.0.CO;2-Q; de Kraker J, 2004, LANCET, V364, P1229, DOI 10.1016/S0140-6736(04)17139-0; Fernandez C, 2014, RENAL TUMORS CHILDHO, P77; Geenen MM, 2007, JAMA-J AM MED ASSOC, V297, P2705, DOI 10.1001/jama.297.24.2705; Graf N, 2012, EUR J CANCER, V48, P3240, DOI 10.1016/j.ejca.2012.06.007; Green DM, 2014, PEDIATR BLOOD CANCER, V61, P134, DOI 10.1002/pbc.24658; Green DM, 1998, J CLIN ONCOL, V16, P3744, DOI 10.1200/JCO.1998.16.12.3744; Green DM, 2004, J CLIN ONCOL, V22, P1366, DOI 10.1200/JCO.2004.08.008; Green DM, 2001, J CLIN ONCOL, V19, P1926, DOI 10.1200/JCO.2001.19.7.1926; Grundy PE, 2012, PEDIATR BLOOD CANCER, V59, P631, DOI 10.1002/pbc.24123; Grundy PE, 2005, J CLIN ONCOL, V23, P7312, DOI 10.1200/JCO.2005.01.2799; MACHIN D, 1988, BRIT MED J, V296, P1369, DOI 10.1136/bmj.296.6633.1369; Mertens AC, 2014, PSYCHO-ONCOLOGY, V23, P266, DOI 10.1002/pon.3414; Mitchell C, 2006, EUR J CANCER, V42, P2554, DOI 10.1016/j.ejca.2006.05.026; Pastore G, 2006, EUR J CANCER, V42, P2103, DOI 10.1016/j.ejca.2006.05.010; Pritchard-Jones K, 2012, ANN ONCOL, V23, P2457, DOI 10.1093/annonc/mds025; Reinhard H, 2004, KLIN PADIATR, V216, P132, DOI 10.1055/s-2004-822625; RODARY C, 1989, STAT MED, V8, P593, DOI 10.1002/sim.4780080508; TOURNADE MF, 1993, J CLIN ONCOL, V11, P1014, DOI 10.1200/JCO.1993.11.6.1014; Tournade MF, 2001, J CLIN ONCOL, V19, P488, DOI 10.1200/JCO.2001.19.2.488; UK Clinical Research Network Study Portfolio, SIOP NEPHR CLIN TRIA; Van Dalen E. C., 2006, COCHRANE DB SYST REV, V4; van Dalen EC, 2011, COCHRANE DB SYST REV, V19; van den Heuvel-Eibrink MM, 2015, EUR J CANCER, V51, P498, DOI 10.1016/j.ejca.2014.12.011; van der Pal HJ, 2012, J CLIN ONCOL, V30, P1429, DOI 10.1200/JCO.2010.33.4730; Verschuur AC, 2010, PEDIATR BLOOD CANCER, V55, P233, DOI 10.1002/pbc.22496; Vujanic GM, 2002, MED PEDIATR ONCOL, V38, P79, DOI 10.1002/mpo.1276.abs; Wegert J, 2015, CANCER CELL, V27, P298, DOI 10.1016/j.ccell.2015.01.002; Weirich A, 2001, ANN ONCOL, V12, P311, DOI 10.1023/A:1011167924230	33	112	120	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 19	2015	386	9999					1156	1164		10.1016/S0140-6736(14)62395-3	http://dx.doi.org/10.1016/S0140-6736(14)62395-3			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CR5GE	26164096	hybrid, Green Published, Green Accepted			2023-01-03	WOS:000361368000030
J	Dhanapal, AP; Ray, JD; Singh, SK; Hoyos-Villegas, V; Smith, JR; Purcell, LC; King, CA; Fritschi, FB				Dhanapal, Arun Prabhu; Ray, Jeffery D.; Singh, Shardendu K.; Hoyos-Villegas, Valerio; Smith, James R.; Purcell, Larry C.; King, C. Andy; Fritschi, Felix B.			Association Mapping of Total Carotenoids in Diverse Soybean Genotypes Based on Leaf Extracts and High-Throughput Canopy Spectral Reflectance Measurements	PLOS ONE			English	Article							ABSCISIC-ACID BIOSYNTHESIS; GENOME-WIDE ASSOCIATION; XANTHOPHYLL CYCLE; WAVELET DECOMPOSITION; POPULATION-STRUCTURE; OPTICAL-PROPERTIES; NITROGEN-CONTENT; BETA-CAROTENE; PHOTOSYSTEM-I; CHLOROPHYLL-B	Carotenoids are organic pigments that are produced predominantly by photosynthetic organisms and provide antioxidant activity to a wide variety of plants, animals, bacteria, and fungi. The carotenoid biosynthetic pathway is highly conserved in plants and occurs mostly in chromoplasts and chloroplasts. Leaf carotenoids play important photoprotective roles and targeted selection for leaf carotenoids may offer avenues to improve abiotic stress tolerance. A collection of 332 soybean [Glycine max (L.) Merr.] genotypes was grown in two years and total leaf carotenoid content was determined using three different methods. The first method was based on extraction and spectrophotometric determination of carotenoid content (eCaro) in leaf tissue, whereas the other two methods were derived from high-throughput canopy spectral reflectance measurements using wavelet transformed reflectance spectra (tCaro) and a spectral reflectance index (iCaro). An association mapping approach was employed using 31,253 single nucleotide polymorphisms (SNPs) to identify SNPs associated with total carotenoid content using a mixed linear model based on data from two growing seasons. A total of 28 SNPs showed a significant association with total carotenoid content in at least one of the three approaches. These 28 SNPs likely tagged 14 putative loci for carotenoid content. Six putative loci were identified using eCaro, five loci with tCaro, and nine loci with iCaro. Three of these putative loci were detected by all three carotenoid determination methods. All but four putative loci were located near a known carotenoid-related gene. These results showed that carotenoid markers can be identified in soybean using extract-based as well as by high-throughput canopy spectral reflectance-based approaches, demonstrating the utility of field-based canopy spectral reflectance phenotypes for association mapping.	[Dhanapal, Arun Prabhu; Fritschi, Felix B.] Univ Missouri, Div Plant Sci, Columbia, MO 65211 USA; [Ray, Jeffery D.; Smith, James R.] USDA ARS, Crop Genet Res Unit, Stoneville, MS 38776 USA; [Singh, Shardendu K.] USDA ARS, Crop Syst & Global Change Lab, Beltsville, MD USA; [Hoyos-Villegas, Valerio] Michigan State Univ, Dept Plant Soil & Microbial Sci, E Lansing, MI 48824 USA; [Purcell, Larry C.; King, C. Andy] Univ Arkansas, Dept Crop Soil & Environm Sci, Fayetteville, AR 72701 USA	University of Missouri System; University of Missouri Columbia; United States Department of Agriculture (USDA); United States Department of Agriculture (USDA); Michigan State University; University of Arkansas System; University of Arkansas Fayetteville	Fritschi, FB (corresponding author), Univ Missouri, Div Plant Sci, Columbia, MO 65211 USA.	fritschif@missouri.edu	Purcell, Larry/AAA-5986-2022; Dhanapal, Arun Prabhu/F-5030-2012; Hoyos-Villegas, Valerio/O-6138-2018	Dhanapal, Arun Prabhu/0000-0002-9686-7260; Hoyos-Villegas, Valerio/0000-0003-1080-9148	United States Department of Agriculture-Agriculture Research Service (USDA-ARS) [6066-21220-012-00D]; United Soybean Board project [9274, 1274]; ARS [ARS-0425092] Funding Source: Federal RePORTER	United States Department of Agriculture-Agriculture Research Service (USDA-ARS)(United States Department of Agriculture (USDA)USDA Agricultural Research Service); United Soybean Board project; ARS(United States Department of Agriculture (USDA)USDA Agricultural Research Service)	This work was supported by United States Department of Agriculture-Agriculture Research Service (USDA-ARS) project number 6066-21220-012-00D and United Soybean Board project numbers 9274 and 1274. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Aal EM, 2013, NUTRIENTS, V5, P1169, DOI 10.3390/nu5041169; Andrade-Sanchez P, 2014, FUNCT PLANT BIOL, V41, P68, DOI 10.1071/FP13126; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blackburn GA, 2007, INT J REMOTE SENS, V28, P2831, DOI 10.1080/01431160600928625; Bradbury PJ, 2007, BIOINFORMATICS, V23, P2633, DOI 10.1093/bioinformatics/btm308; Buckler E, 2009, EVOLUTION LINKAGE TA; Carter GA, 2001, AM J BOT, V88, P677, DOI 10.2307/2657068; Cazzaniga S, 2012, PLANT PHYSIOL, V159, P1745, DOI 10.1104/pp.112.201137; Cazzonelli CI, 2010, PLANT DEVELOPMENTAL BIOLOGY: BIOTECHNOLOGICAL PERSPECTIVES VOL 2, P117, DOI 10.1007/978-3-642-04670-4_7; Cazzonelli CI, 2011, FUNCT PLANT BIOL, V38, P833, DOI 10.1071/FP11192; CHAPPELLE EW, 1992, REMOTE SENS ENVIRON, V39, P239, DOI 10.1016/0034-4257(92)90089-3; Chen XY, 2011, J PLANT PHYSIOL, V168, P1828, DOI 10.1016/j.jplph.2011.05.019; Cunningham FX, 1998, ANNU REV PLANT PHYS, V49, P557, DOI 10.1146/annurev.arplant.49.1.557; Czyczylo-Mysza I, 2013, MOL BREEDING, V32, P189, DOI 10.1007/s11032-013-9862-8; Dall'Osto L, 2010, MOL PLANT, V3, P576, DOI 10.1093/mp/ssp117; Daughtry CST, 2000, REMOTE SENS ENVIRON, V74, P229, DOI 10.1016/S0034-4257(00)00113-9; Davison PA, 2002, NATURE, V418, P203, DOI 10.1038/nature00861; DellaPenna D, 2006, ANNU REV PLANT BIOL, V57, P711, DOI 10.1146/annurev.arplant.56.032604.144301; Demmig-Adams B, 2002, SCIENCE, V298, P2149, DOI 10.1126/science.1078002; DemmigAdams B, 1996, FASEB J, V10, P403, DOI 10.1096/fasebj.10.4.8647339; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; DemmigAdams B, 1996, TRENDS PLANT SCI, V1, P21, DOI 10.1016/S1360-1385(96)80019-7; Dhanapal AP, 2015, PLANT GENOME-US, V8, DOI 10.3835/plantgenome2014.11.0086; Dhanapal AP, 2015, THEOR APPL GENET, V128, P73, DOI 10.1007/s00122-014-2413-9; Dhanapal AP, 2013, 3 BIOTECH, V3, P481, DOI 10.1007/s13205-012-0109-x; Endelman JB, 2012, G3-GENES GENOM GENET, V2, P1405, DOI 10.1534/g3.112.004259; ESKINS K, 1981, PLANT PHYSIOL, V67, P759, DOI 10.1104/pp.67.4.759; Evanno G, 2005, MOL ECOL, V14, P2611, DOI 10.1111/j.1365-294X.2005.02553.x; FEHR WR, 1971, CROP SCI, V11, P929, DOI 10.2135/cropsci1971.0011183X001100060051x; Fernandez-Marin B, 2011, PLANTA, V234, P579, DOI 10.1007/s00425-011-1420-1; Fraser PD, 2004, PROG LIPID RES, V43, P228, DOI 10.1016/j.plipres.2003.10.002; GAUSMAN HW, 1984, ACS SYM SER, V257, P215; Giuliano G, 2014, CURR OPIN PLANT BIOL, V19, P111, DOI 10.1016/j.pbi.2014.05.006; Gomez-Roldan V, 2008, NATURE, V455, P189, DOI 10.1038/nature07271; Gotz T, 2002, PLANT MOL BIOL, V50, P129, DOI 10.1023/A:1016072218801; Grant D, 2010, NUCLEIC ACIDS RES, V38, pD843, DOI 10.1093/nar/gkp798; Guo J, 2012, ANN BOT-LONDON, V110, P777, DOI 10.1093/aob/mcs142; Hao DR, 2012, THEOR APPL GENET, V124, P447, DOI 10.1007/s00122-011-1719-0; Hirschberg J, 2001, CURR OPIN PLANT BIOL, V4, P210, DOI 10.1016/S1369-5266(00)00163-1; Holland JB, 2002, PL BRED RE, V22, P9; Howitt CA, 2006, PLANT CELL ENVIRON, V29, P435, DOI 10.1111/j.1365-3040.2005.01492.x; Hwang EY, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1; Iuchi S, 2001, PLANT J, V27, P325, DOI 10.1046/j.1365-313x.2001.01096.x; Jahns P, 2012, BBA-BIOENERGETICS, V1817, P182, DOI 10.1016/j.bbabio.2011.04.012; Johnson MP, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M702831200; Kannan B, 2014, SCI WORLD J, DOI 10.1155/2014/562327; Krinsky NI, 2004, CAROTENOIDS HLTH DIS, P576; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; Littell R.C., 1996, SAS SYSTEMS MIXED MO; Matthews PD, 2003, J EXP BOT, V54, P2215, DOI 10.1093/jxb/erg235; MIDDLETON EM, 1993, PLANT PHYSIOL, V103, P741, DOI 10.1104/pp.103.3.741; Murchie EH, 2002, PLANT PHYSIOL, V130, P1999, DOI 10.1104/pp.011098; Murchie EH, 1999, PLANT PHYSIOL, V119, P553, DOI 10.1104/pp.119.2.553; Musa A., 2012, International Journal of Biology, V4, P130; Myles S, 2009, PLANT CELL, V21, P2194, DOI 10.1105/tpc.109.068437; Nambara E, 2005, ANNU REV PLANT BIOL, V56, P165, DOI 10.1146/annurev.arplant.56.032604.144046; Penuelas J, 1998, TRENDS PLANT SCI, V3, P151, DOI 10.1016/S1360-1385(98)01213-8; Piepho HP, 2008, EUPHYTICA, V161, P209, DOI 10.1007/s10681-007-9449-8; Piepho HP, 2007, GENETICS, V177, P1881, DOI 10.1534/genetics.107.074229; Pogson B.J., 2005, PHOTOSYSTEM, P515; Pritchard JK, 2000, GENETICS, V155, P945; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Roelofsen HD, 2014, ECOL EVOL, V4, P706, DOI 10.1002/ece3.932; Ryu C, 2011, FIELD CROP RES, V122, P214, DOI 10.1016/j.fcr.2011.03.013; Sandmann G, 2001, TRENDS PLANT SCI, V6, P14, DOI 10.1016/S1360-1385(00)01817-3; Schwartz SH, 2001, J BIOL CHEM, V276, P25208, DOI 10.1074/jbc.M102146200; Sims DA, 2002, REMOTE SENS ENVIRON, V81, P337, DOI 10.1016/S0034-4257(02)00010-X; Singh SK, 2013, FIELD CROP RES, V149, P20, DOI 10.1016/j.fcr.2013.04.019; Song QJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054985; Spurgeon S.L., 1980, BIOCH ISOPRENOID COM, P1; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Telfer A, 2005, PHOTOCH PHOTOBIO SCI, V4, P950, DOI 10.1039/b507888c; Vigneau N, 2011, FIELD CROP RES, V122, P25, DOI 10.1016/j.fcr.2011.02.003; Wang LY, 2014, PLANT CELL REP, V33, P1441, DOI 10.1007/s00299-014-1627-2; Wang YL, 2004, BIOPHYS J, V86, P3097, DOI 10.1016/S0006-3495(04)74358-1; Wen ZX, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-809; White JW, 2012, FIELD CROP RES, V133, P101, DOI 10.1016/j.fcr.2012.04.003; Wongsen W., 2013, International Food Research Journal, V20, P1113; YAMAMOTO HY, 1962, ARCH BIOCHEM BIOPHYS, V97, P168, DOI 10.1016/0003-9861(62)90060-7; Yu JM, 2006, CURR OPIN BIOTECH, V17, P155, DOI 10.1016/j.copbio.2006.02.003; Zhang JP, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1441-4; Zhu CS, 2008, PLANT GENOME-US, V1, P5, DOI 10.3835/plantgenome2008.02.0089	82	14	14	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2015	10	9							e0137213	10.1371/journal.pone.0137213	http://dx.doi.org/10.1371/journal.pone.0137213			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR8KS	26368323	Green Published, gold, Green Submitted			2023-01-03	WOS:000361601100058
J	Georgianos, PI; Agarwal, R				Georgianos, Panagiotis I.; Agarwal, Rajiv			Relative Importance of Aortic Stiffness and Volume as Predictors of Treatment-Induced Improvement in Left Ventricular Mass Index in Dialysis	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; ARTERIAL STIFFNESS; HYPERTROPHY; HYPERTENSION; REDUCTION; IMPACT; REGRESSION; ATENOLOL	This study aimed to explore the relative contribution of aortic stiffness and volume in treatment- induced change of left ventricular mass in dialysis. Hypertension in Hemodialysis Patients Treated with Atenolol or Lisinopril trial compared the effect of lisinopril versus atenolol in reducing left ventricular mass index; 179 patients with echo measurements of aortic pulse wave velocity and left ventricular mass at baseline were included. In unadjusted analysis, overall reductions of 26.24 g/m(2) (95% CI: -49.20, -3.29) and 35.67 g/m(2) (95% CI: -63.70, -7.64) in left ventricular mass index were noted from baseline to 6 and 12 months respectively. Volume control emerged as an important determinant of regression of left ventricular mass index due to the following reasons: (i) additional control for change in ambulatory systolic blood pressure mitigated the reduction in left ventricular mass index in the statistical model above [6-month visit: -18.6 g/m(2) (95% CI: -43.7, 6.5); 12-month visit: -22.1 g/m(2) (95% CI: -52.2, 8.0)] (ii) regression of left ventricular hypertrophy was primarily due to reduction in left ventricular chamber and not wall thickness and (iii) adjustment for inferior vena cava diameter (as a proxy for volume) removed the effect of time on left ventricular mass index reduction [6-month visit: -6.6 g/m(2) (95% CI: (-41.6, 28.4); 12-month visit: 0.6 g/m(2) (95% CI: -39.5, 40.7)]. In contrast, aortic pulse wave velocity was neither a determinant of baseline left ventricular mass index nor predictor of its reduction. Among dialysis patients, ambulatory systolic pressure, a proxy for volume expansion, but not aortic stiffness is more important predictor of reduction in left ventricular mass index. Improving blood pressure control via adequate volume management appears as an effective strategy to improve left ventricular hypertrophy in dialysis.	[Agarwal, Rajiv] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA; Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	Agarwal, R (corresponding author), Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.	ragarwal@iu.edu	Georgianos, Panagiotis/H-7498-2019; Agarwal, Rajiv/H-3454-2019	Agarwal, Rajiv/0000-0001-8355-7100; Georgianos, Panagiotis/0000-0001-7065-2096	NIH [2R01-DK062030-10]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062030] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH 2R01-DK062030-10. The sponsors or funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal R, 2014, NEPHROL DIAL TRANSPL, V29, P672, DOI 10.1093/ndt/gft515; Agarwal R, 2011, AM J NEPHROL, V33, P373, DOI 10.1159/000326235; Agarwal R, 2011, CLIN J AM SOC NEPHRO, V6, P1066, DOI 10.2215/CJN.09321010; Agarwal Rajiv, J AM SOC NEPHROL; Bossola M, 2008, SEMIN DIALYSIS, V21, P422, DOI 10.1111/j.1525-139X.2008.00471.x; Chertow GM, 2010, NEW ENGL J MED, V363, P2287, DOI 10.1056/NEJMoa1001593; Devereux RB, 2004, CIRCULATION, V110, P1456, DOI 10.1161/01.CIR.0000141573.44737.5A; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; Drighil A, 2008, EUR J ECHOCARDIOGR, V9, P530, DOI 10.1093/ejechocard/jen125; Hashimoto J, 2008, J HYPERTENS, V26, P1017, DOI 10.1097/HJH.0b013e3282f62a9b; Hur E, 2013, AM J KIDNEY DIS, V61, P957, DOI 10.1053/j.ajkd.2012.12.017; Kayikcioglu M, 2009, NEPHROL DIAL TRANSPL, V24, P956, DOI 10.1093/ndt/gfn599; Laurent S, 2006, EUR HEART J, V27, P2588, DOI 10.1093/eurheartj/ehl254; Lehmann ED, 1997, LANCET S1, V350, pSI14; Levin A, 1999, AM J KIDNEY DIS, V34, P125, DOI 10.1016/S0272-6386(99)70118-6; LEVY D, 1991, J CARDIOVASC PHARM, V17, pS1, DOI 10.1097/00005344-199117002-00002; LIEBSON PR, 1995, CIRCULATION, V91, P698, DOI 10.1161/01.CIR.91.3.698; London G, 2011, KIDNEY INT SUPPL, V1, P10, DOI 10.1038/kisup.2011.5; London GM, 1996, KIDNEY INT, V50, P600, DOI 10.1038/ki.1996.355; Nitta K, 2004, HYPERTENS RES, V27, P47, DOI 10.1291/hypres.27.47; Palmieri V, 2008, AM J HYPERTENS, V21, P701, DOI 10.1038/ajh.2008.162; Parati G, 2014, J HYPERTENS, V32, P1359, DOI 10.1097/HJH.0000000000000221; Sinha AD, 2009, AM J KIDNEY DIS, V54, P788, DOI 10.1053/j.ajkd.2009.07.004; Zoccali C, 2004, KIDNEY INT, V65, P1492, DOI 10.1111/j.1523-1755.2004.00530.x; Zoccali C, 2001, J AM SOC NEPHROL, V12, P2768, DOI 10.1681/ASN.V12122768; Zoccali C, 2011, AM J NEPHROL, V33, P370, DOI 10.1159/000326239	26	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2015	10	9							e0135457	10.1371/journal.pone.0135457	http://dx.doi.org/10.1371/journal.pone.0135457			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ9WL	26356419	Green Published, gold, Green Submitted			2023-01-03	WOS:000360965800005
J	Aguera, ML; Martin-Malo, A; Alvarez-Lara, MA; Garcia-Montemayor, VE; Canton, P; Soriano, S; Aljama, P				Luisa Agueera, Maria; Martin-Malo, Alejandro; Antonia Alvarez-Lara, Maria; Eugenia Garcia-Montemayor, Victoria; Canton, Petra; Soriano, Sagrario; Aljama, Pedro			Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis	PLOS ONE			English	Article							ERYTHROPOIESIS-STIMULATING AGENTS; ANEMIA MANAGEMENT; MORTALITY; DISEASE; DRUGS; OUTCOMES	Aims The appropriate use of intravenous (IV) iron is essential to minimise the requirements for erythropoiesis-stimulating agents (ESAs). The clinical efficacy of generic IV iron compared to the original formulation is controversial. We evaluated the changes that were induced after switching from a generic IV iron to an original formulation in a stable, prevalent haemodialysis (HD) population. Methods A total of 342 patients were included, and the follow-up period was 56 weeks for each formulation. Anaemia parameters and doses of ESA and IV iron were prospectively recorded before and after the switch from generic to original IV iron. Results To maintain the same haemoglobin (Hb) levels after switching from the generic to the original formulation, the requirements for IV iron doses were reduced by 34.3% (from 52.8 +/- 33.9 to 34.7 +/- 31.8mg/week, p<0.001), and the ESA doses were also decreased by 12.5% (from 30.6 +/- 23.6 to 27 +/- 21 mu g/week, p<0.001). The erythropoietin resistance index declined from 8.4 +/- 7.7 to 7.4 +/- 6.7 IU/kg/week/g/dl after the switch from the generic to the original drug (p = 0.001). After the switch, the transferrin saturation ratio (TSAT) and serum ferritin levels rose by 6.8%(p<0.001) and 12.4%(p = 0.001), respectively. The mortality rate was similar for both periods. Conclusions The iron and ESA requirements are lower with the original IV iron compared to the generic drug. In addition, the uses of the original formulation results in higher ferritin and TSAT levels despite the lower dose of IV iron. Further studies are necessary to analyse the adverse effects of higher IV iron dosages.	[Luisa Agueera, Maria; Martin-Malo, Alejandro; Antonia Alvarez-Lara, Maria; Soriano, Sagrario; Aljama, Pedro] Hosp Univ Reina Sofia, Serv Nefrol, Cordoba, Spain; [Luisa Agueera, Maria; Martin-Malo, Alejandro; Antonia Alvarez-Lara, Maria; Soriano, Sagrario; Aljama, Pedro] Univ Cordoba, Inst Maimonides Invest Biomed Cordoba IMIBIC, Cordoba, Spain; [Luisa Agueera, Maria; Martin-Malo, Alejandro; Antonia Alvarez-Lara, Maria; Soriano, Sagrario; Aljama, Pedro] Inst Salud Carlos III, RedInRen, Madrid, Spain; [Eugenia Garcia-Montemayor, Victoria; Canton, Petra] SOCODI SL, Dialysis Unit, Cordoba, Spain	Hospital Universitario Reina Sofia - Cordoba; Universidad de Cordoba; Instituto de Salud Carlos III	Aguera, ML (corresponding author), Hosp Univ Reina Sofia, Serv Nefrol, Cordoba, Spain.	marisa.aguera@gmail.com		Aguera Morales, Maria Luisa/0000-0002-7736-908X	Fundacion Nefrologica, Hospital Universitario Reina Sofia, Cordoba, Spain	Fundacion Nefrologica, Hospital Universitario Reina Sofia, Cordoba, Spain	This study was supported by the Fundacion Nefrologica, Hospital Universitario Reina Sofia, Cordoba, Spain. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal R, 2015, KIDNEY INT, V88, P905, DOI 10.1038/ki.2015.163; Anemia Work Group, 2012, KIDNEY INT, V2, P279, DOI [DOI 10.1038/kisup.2012.37, DOI 10.1093/NDT/GFT033.13]; [Anonymous], 2013, EU CLIN TRIALS REGIS; Bailie GR, 2015, KIDNEY INT, V87, P162, DOI 10.1038/ki.2014.275; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Brissot P, 2012, BBA-GEN SUBJECTS, V1820, P403, DOI 10.1016/j.bbagen.2011.07.014; Brookhart MA, 2010, JAMA-J AM MED ASSOC, V303, P857, DOI 10.1001/jama.2010.206; Charytan DM, 2015, J AM SOC NEPHROL, V26, P1238, DOI 10.1681/ASN.2014090922; Connor JR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125272; Davit BM, 2009, ANN PHARMACOTHER, V43, P1583, DOI 10.1345/aph.1M141; Dunne S, 2013, BMC PHARMACOL TOXICO, V14, DOI 10.1186/2050-6511-14-1; Eduardo Toblli Jorge, 2012, Inflammation & Allergy Drug Targets, V11, P66; Feldman HI, 2004, J AM SOC NEPHROL, V15, P1623, DOI 10.1097/01.ASN.0000128009.69594.BE; Fishbane S, 2014, NEPHROL DIAL TRANSPL, V29, P255, DOI 10.1093/ndt/gft269; Freburger JK, 2012, AM J MED, V125, P906, DOI 10.1016/j.amjmed.2012.03.011; Fuller DS, 2013, AM J KIDNEY DIS, V62, P1213, DOI 10.1053/j.ajkd.2013.09.006; Gaweda AE, 2015, NEPHROL DIAL TRANSPL, V30, P187, DOI 10.1093/ndt/gfu104; Gaweda AE, 2014, J AM SOC NEPHROL, V25, P159, DOI 10.1681/ASN.2013010089; Harrison JJ, 2012, TRANSPLANTATION, V93, P657, DOI 10.1097/TP.0b013e3182445e9d; Ichii H, 2012, AM J NEPHROL, V36, P50, DOI 10.1159/000339285; Kalantar-Zadeh K, 2005, J AM SOC NEPHROL, V16, P3070, DOI 10.1681/ASN.2005040423; Kesselheim AS, 2008, JAMA-J AM MED ASSOC, V300, P2514, DOI 10.1001/jama.2008.758; Koulouridis I, 2013, AM J KIDNEY DIS, V61, P44, DOI 10.1053/j.ajkd.2012.07.014; Kshirsagar AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078930; Locatelli F, 2014, NEPHRON CLIN PRACT, V128, P323, DOI 10.1159/000366478; Locatelli F, 2013, NEPHROL DIAL TRANSPL, V28, P1346, DOI 10.1093/ndt/gft033; Lopez-Gomez JM, 2008, KIDNEY INT, V74, pS75, DOI 10.1038/ki.2008.523; Martin-Malo A, 2012, NEPHROL DIAL TRANSPL, V27, P2465, DOI 10.1093/ndt/gfr711; Miskulin DC, 2014, CLIN J AM SOC NEPHRO, V9, P1930, DOI 10.2215/CJN.03370414; Nishio A, 2013, BLOOD PURIFICAT, V36, P29, DOI 10.1159/000350583; Pai AB, 2011, BIOMETALS, V24, P603, DOI 10.1007/s10534-011-9409-6; Panichi V, 2011, NEPHROL DIAL TRANSPL, V26, P2641, DOI 10.1093/ndt/gfq802; Ramsey S., 2013, WHO GUIDELINE COUNTR; Rosati A, 2015, J NEPHROL, V28, P603, DOI 10.1007/s40620-014-0127-3; Rostoker G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115096; Rottembourg J, 2011, NEPHROL DIAL TRANSPL, V26, P3262, DOI 10.1093/ndt/gfr024; Schellekens H, 2011, REGUL TOXICOL PHARM, V59, P176, DOI 10.1016/j.yrtph.2010.09.021; Slotki I, 2015, J AM SOC NEPHROL, V26, P2612, DOI 10.1681/ASN.2015010052; Stauffer ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084943; Szczech LA, 2008, KIDNEY INT, V74, P791, DOI 10.1038/ki.2008.295; van der Meersch A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023611; Vaziri ND, 2013, AM J KIDNEY DIS, V61, P992, DOI 10.1053/j.ajkd.2012.10.027; Zhou J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043655; Zitt E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114144	44	25	26	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2015	10	8							e0135967	10.1371/journal.pone.0135967	http://dx.doi.org/10.1371/journal.pone.0135967			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ2MT	26322790	Green Published, Green Submitted, gold			2023-01-03	WOS:000360435500013
J	Gomes, ELFD; Carvalho, CRF; Peixoto-Souza, FS; Teixeira-Carvalho, EF; Mendonca, JFB; Stirbulov, R; Sampaio, LMM; Costa, D				Gomes, Evelim L. F. D.; Carvalho, Celso R. F.; Peixoto-Souza, Fabiana Sobral; Teixeira-Carvalho, Etiene Farah; Barreto Mendonca, Juliana Fernandes; Stirbulov, Roberto; Malosa Sampaio, Luciana Maria; Costa, Dirceu			Active Video Game Exercise Training Improves the Clinical Control of Asthma in Children: Randomized Controlled Trial	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; ENERGY-EXPENDITURE; INFLAMMATION; KINECT; CYCLE; TIME	Objective The aim of the present study was to determine whether aerobic exercise involving an active video game system improved asthma control, airway inflammation and exercise capacity in children with moderate to severe asthma. Design A randomized, controlled, single-blinded clinical trial was carried out. Thirty-six children with moderate to severe asthma were randomly allocated to either a video game group (VGG; N = 20) or a treadmill group (TG; n = 16). Both groups completed an eight-week supervised program with two weekly 40-minute sessions. Pre-training and post-training evaluations involved the Asthma Control Questionnaire, exhaled nitric oxide levels (FeNO), maximum exercise testing (Bruce protocol) and lung function. Results No differences between the VGG and TG were found at the baseline. Improvements occurred in both groups with regard to asthma control and exercise capacity. Moreover, a significant reduction in FeNO was found in the VGG (p < 0.05). Although the mean energy expenditure at rest and during exercise training was similar for both groups, the maximum energy expenditure was higher in the VGG. Conclusion The present findings strongly suggest that aerobic training promoted by an active video game had a positive impact on children with asthma in terms of clinical control, improvementin their exercise capacity and a reductionin pulmonary inflammation.	[Gomes, Evelim L. F. D.; Peixoto-Souza, Fabiana Sobral; Teixeira-Carvalho, Etiene Farah; Barreto Mendonca, Juliana Fernandes; Malosa Sampaio, Luciana Maria; Costa, Dirceu] Nove de Julho Univ, Postgrad Program Rehabil Sci, Sao Paulo, Brazil; [Carvalho, Celso R. F.] Univ Sao Paulo, Phys Therapy Dept, Sao Paulo, Brazil; [Stirbulov, Roberto] Santa Casa Sch Med Sci, Sao Paulo, Brazil	Universidade Nove de Julho; Universidade de Sao Paulo	Costa, D (corresponding author), Nove de Julho Univ, Postgrad Program Rehabil Sci, Sao Paulo, Brazil.	dcosta@uninove.br	COSTA, DIRCEU/W-8832-2019; Sampaio, Luciana Maria Malosa/H-9429-2016; COSTA, DIRCEU/GZL-8789-2022; de Freitas Dantas Gomes, Evelim Leal/B-5871-2014; de Carvalho, Etiene F Teixeira/G-7356-2018; Carvalho, Celso RF/B-7626-2012	COSTA, DIRCEU/0000-0002-0334-3899; Sampaio, Luciana Maria Malosa/0000-0002-0110-7710; de Freitas Dantas Gomes, Evelim Leal/0000-0002-0636-6041; de Carvalho, Etiene F Teixeira/0000-0002-5765-7228; Carvalho, Celso RF/0000-0003-3046-3412; Mendonca, Juliana/0000-0001-8989-7931				American Association of Cardiovascular & Pulmonary Rehabilitation, 1998, GUID PULM REH PROGR; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Baquet G, 2010, J STRENGTH COND RES, V24, P1381, DOI 10.1519/JSC.0b013e3181d1575a; Baranowski T, 2012, PEDIATRICS, V129, pE636, DOI 10.1542/peds.2011-2050; Barnes PJ, 2010, CHEST, V138, P682, DOI 10.1378/chest.09-2090; Berthoin S, 2006, EUR J APPL PHYSIOL, V98, P132, DOI 10.1007/s00421-006-0253-2; Biddiss E, 2010, ARCH PEDIAT ADOL MED, V164, P664, DOI 10.1001/archpediatrics.2010.104; Biddle SJH, 2004, J R SOC PROMO HEALTH, V124, P29, DOI 10.1177/146642400312400110; Bonsignore MR, 2008, MED SCI SPORT EXER, V40, P405, DOI [10.1249/MSS.0b013e31815d9670, 10.1249/mss.0b013e31815d9670]; Carson KV, 2013, COCHRANE DB SYST REV, V30, P9; Carson V, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-173; CLARK CJ, 1988, THORAX, V43, P745, DOI 10.1136/thx.43.10.745; Cohen J., 2013, STAT POWER ANAL BEHA; de Onis Mercedes, 2007, Bull World Health Organ, V85, P660; del Corral T, 2014, J CYST FIBROS, V13, P706, DOI 10.1016/j.jcf.2014.05.004; Disabella V, 1998, PHYSICIAN SPORTSMED, V26, P75, DOI 10.3810/psm.1998.06.1041; Dogra S, 2011, EUR RESPIR J, V37, P318, DOI 10.1183/09031936.00182209; Drenowatz C, 2011, EUR J APPL PHYSIOL, V111, P883, DOI 10.1007/s00421-010-1695-0; Fanelli A, 2007, MED SCI SPORT EXER, V39, P1474, DOI 10.1249/mss.0b013e3180d099ad; Gao Z, 2013, J SPORT HEALTH SCI, V2, P122, DOI 10.1016/j.jshs.2012.07.001; Giugliano Rodolfo, 2004, J. Pediatr. (Rio J.), V80, P129, DOI 10.1590/S0021-75572004000200010; Gleeson M, 2011, NAT REV IMMUNOL, V11, P607, DOI 10.1038/nri3041; GORAN MI, 1993, J APPL PHYSIOL, V75, P1776, DOI 10.1152/jappl.1993.75.4.1776; Graf DL, 2009, PEDIATRICS, V124, P534, DOI 10.1542/peds.2008-2851; Hallal PC, 2012, LANCET, V380, P247, DOI 10.1016/S0140-6736(12)60646-1; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Ko FWS, 2012, RESPIROLOGY, V17, P370, DOI 10.1111/j.1440-1843.2011.02105.x; Kuys SS, 2011, J PHYSIOTHER, V57, P35, DOI 10.1016/S1836-9553(11)70005-4; Lamb K.L., 1995, PEDIATR EXERC SCI, V7, P407, DOI 10.1123/pes.7.4.407; LeBlanc AG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065351; Leite Mylene, 2008, J. bras. pneumol., V34, P756, DOI 10.1590/S1806-37132008001000002; Maddison R, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-524; Mellecker RR, 2014, J SCI MED SPORT, V17, P288, DOI 10.1016/j.jsams.2013.05.008; Mendes FAR, 2010, CHEST, V138, P331, DOI 10.1378/chest.09-2389; Moreira A, 2008, EUR RESPIR J, V32, P1570, DOI 10.1183/09031936.00171707; O'Donovan C, 2012, PHYSIOTHERAPY, V98, P224, DOI 10.1016/j.physio.2012.05.010; Silva LOE, 2011, REV BRAS MED ESPORTE, V17, P393, DOI 10.1590/S1517-86922011000600004; Pakhale S, 2013, BMC PULM MED, V13, DOI 10.1186/1471-2466-13-38; Paw MJMCA, 2008, J SCI MED SPORT, V11, P163, DOI 10.1016/j.jsams.2007.06.001; Pedersen BK, 2007, J APPL PHYSIOL, V103, P1093, DOI 10.1152/japplphysiol.00080.2007; Peyer K, 2011, RES Q EXERCISE SPORT, V82, P685, DOI 10.1080/02701367.2011.10599805; Polgar P, 1971, PULMONARY TESTING CH, P100; Mendes FAR, 2011, MED SCI SPORT EXER, V43, P197, DOI 10.1249/MSS.0b013e3181ed0ea3; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Smallwood SR, 2012, ARCH PEDIAT ADOL MED, V166, P1005, DOI 10.1001/archpediatrics.2012.1271; van der Cammen-van Zijp MHM, 2010, EUR J APPL PHYSIOL, V108, P393, DOI 10.1007/s00421-009-1236-x; Villa F, 2011, ARCH DIS CHILD, V96, P554, DOI 10.1136/adc.2011.212431; Wanrooj VHM, 2013, BR J SPORTS MED	49	21	24	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2015	10	8							e0135433	10.1371/journal.pone.0135433	http://dx.doi.org/10.1371/journal.pone.0135433			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP5VA	26301706	gold, Green Published, Green Submitted			2023-01-03	WOS:000359951900017
J	Brewer, C				Brewer, Colin			PERSONAL VIEW Assisted dying: legal ambiguity lets down families as well as patients	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																		Brewer C, 2015, ILL SEE MYSELF OUT T	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 19	2015	351								h4453	10.1136/bmj.h4453	http://dx.doi.org/10.1136/bmj.h4453			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CP7PU	26289319				2023-01-03	WOS:000360081100007
J	Zhao, XF; Hu, HT; Li, JS; Shang, HC; Zheng, HZ; Niu, JF; Shi, XM; Wang, S				Zhao, Xiao-Feng; Hu, Han-Tong; Li, Jia-Shen; Shang, Hong-Cai; Zheng, Hai-Zhen; Niu, Jian-Fei; Shi, Xue-Ming; Wang, Shu			Is Acupuncture Effective for Hypertension? A Systematic Review and Meta-Analysis	PLOS ONE			English	Article							BLOOD-PRESSURE; BURDEN	Objective To determine the efficacy of acupuncture for hypertension. Method Seven electronic databases were searched on April 13, 2014 to include eligible randomized controlled trials (RCTs). Data were extracted and risk of bias was assessed. Subgroup analyses and meta-analysis were performed. Results 23 RCTs involving 1788 patients were included. Most trials had an unclear risk of bias regarding allocation concealment, blinding, incomplete outcome data and selective reporting. Compared with sham acupuncture plus medication, a meta-analysis of 2 trials revealed that acupuncture as an adjunct to medication was more effective on systolic (SBP) and diastolic (DBP) blood pressure change magnitude (n=170, SBP: mean difference (MD)= -7.47.95% confidence intervals (CI): -10.43 to -4.51, I-2 = 0%; DBP: -4.22,-6.26 to -2.18, 0%). A subgroup analysis of 4 trials also showed acupuncture combined with medication was superior to medication on efficacy rate (n=230, odds ratio (OR)=4.19, 95% CI: 1.65 to 10.67, I-2 =0%). By contrast, compared with medication, acupuncture alone showed no significant effect on SBP /DBP after intervention and efficacy rate in the subgroup analysis. (7 trials with 510 patients, SBP: MD=-0.56, 95% CI:-3.02 to 1.89, I-2 =60%; DBP: -1.01,-2.26 to 0.24, 23%; efficacy rate: 10 trials with 963 patients, OR=1.14, 95% CI: 0.70 to 1.85, I-2 =54%). Adverse events were inadequately reported in most RCTs. Conclusion Our review provided evidence of acupuncture as an adjunctive therapy to medication for treating hypertension, while the evidence for acupuncture alone lowing BP is insufficient. The safety of acupuncture is uncertain due to the inadequate reporting of it. However, the current evidence might not be sufficiently robust against methodological flaws and significant heterogeneity of the included RCTs. Larger high-quality trials are required.	[Zhao, Xiao-Feng; Hu, Han-Tong; Li, Jia-Shen; Zheng, Hai-Zhen; Niu, Jian-Fei] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Inst Acupuncture & Moxibust, Tianjin, Peoples R China; [Hu, Han-Tong; Li, Jia-Shen; Shang, Hong-Cai; Zheng, Hai-Zhen; Niu, Jian-Fei] Tianjin Univ Tradit Chinese Med, Tianjin, Peoples R China; [Shi, Xue-Ming; Wang, Shu] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Dept Acupuncture & Moxibust, Tianjin, Peoples R China; [Zhao, Xiao-Feng; Wang, Shu] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Key Lab Acupuncture Tianjin, Tianjin, Peoples R China	Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine	Zhao, XF (corresponding author), Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Inst Acupuncture & Moxibust, Tianjin, Peoples R China.	zhxf67@163.com	shang, hongcai/H-1257-2014; 胡, 汉通/GYJ-2069-2022; Zheng, Haizhen/GMW-7096-2022; Hu, Hantong/AAU-9912-2021	Hu, Hantong/0000-0001-8759-5083	National Basic Research Program of China (973 Program) [2012CB518505]; Inheritance Studio of famous veteran doctors of TCM of Xue-Ming Shi	National Basic Research Program of China (973 Program)(National Basic Research Program of China); Inheritance Studio of famous veteran doctors of TCM of Xue-Ming Shi	The current work was partially supported by the National Basic Research Program of China (973 Program, No. 2012CB518505) and the Inheritance Studio of famous veteran doctors of TCM of Xue-Ming Shi. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chen BG., 2006, SHANGHAI ZHENJIU ZAZ, V25, P15; Chen J, 2006, THESIS GUANGZHOU U T; Chen Jun, 2010, Zhongguo Zhen Jiu, V30, P896; Deeks J., 2011, COCHRANE HDB SYST RE, V5; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Feng Guoxiang, 2003, ZHONGGUO ZHEN JIU, V23, P193; Flachskampf FA, 2007, CIRCULATION, V115, P3121, DOI 10.1161/CIRCULATIONAHA.106.661140; Guo Yuhong, 2007, ACTA CHIN MED PHARM, V35, P51, DOI DOI 10.1016/J.IJOM.2012.01.007; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Hu HT, 2014, INT J CARDIOL, V177, P610, DOI 10.1016/j.ijcard.2014.09.121; Huang Fan, 2007, Zhongguo Zhen Jiu, V27, P403; Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3; Kim HM, 2012, J ALTERN COMPLEM MED, V18, P918, DOI 10.1089/acm.2011.0508; Kim LW, 2010, ALTERN THER HEALTH M, V16, P18; Kraft K, 1999, FORSCH KOMPLEMENTMED, V6, P74, DOI 10.1159/000021223; Lee H, 2009, AM J HYPERTENS, V22, P122, DOI 10.1038/ajh.2008.311; Lee XQ, 2008, LIAONING J TRADI CHI, V35, P919; Li DZ, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/279478; Liao Hui, 2006, ZHONGGUO ZHEN JIU, V26, P92; Liu T, 2007, EVID-BASED COMPL ALT, V4, P3, DOI 10.1093/ecam/nel061; Ma Chaoyang, 2011, NEW J TRADIT CHIN ME, V43, P89; Ma CY., 2002, GUIDING PRINCIPLE CL; Macklin EA, 2006, HYPERTENSION, V48, P838, DOI 10.1161/01.HYP.0000241090.28070.4c; Madsen MV, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3115; Pater C, 2005, CURR CONTR TRIALS C, V6, DOI 10.1186/1468-6708-6-6; Qu T, 2009, HUBEI J TRADI CHIN M, V31, P8; Shen ZK., 2007, SHAANXI ZHONGYI, V28, P1377; Tjen-A-Looi SC, 2013, AM J PHYSIOL-REG I, V304, pR321, DOI 10.1152/ajpregu.00451.2012; Vickers A, 1998, CONTROL CLIN TRIALS, V19, P159, DOI 10.1016/S0197-2456(97)00150-5; Wan Wen-jun, 2009, Zhongguo Zhen Jiu, V29, P349; Wang J, 2013, INT J CARDIOL, V169, P317, DOI 10.1016/j.ijcard.2013.09.001; Wei Y, 2006, J CLIN ACUPUNCTURE M, V22, P4; Wu QM, 2003, NEW J TRADIT CHIN ME, V35, P45; Yang Dian-Hui, 2010, Zhongguo Zhen Jiu, V30, P547; Yang Yue, 2010, ACTA CHIN MED PHARM, V38, P106; Yin C, 2007, NEUROL RES, V29, pS98, DOI 10.1179/016164107X172220; [张朝晖 Zhang Zhaohui], 2004, [中国针灸, Chinese Acupuncture and Moxibustion], V24, P539; Zhang ZR, 1954, J JIANGXI TRADI CHIN, V5, P53; [赵东杰 Zhao Dongjie], 2003, [中国针灸, Chinese Acupuncture and Moxibustion], V23, P165; Zhao R., 2011, CLIN J ACUPUNCT MOXI, V27, P46	40	55	58	0	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2015	10	7							e0127019	10.1371/journal.pone.0127019	http://dx.doi.org/10.1371/journal.pone.0127019			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN7NT	26207806	Green Published, gold, Green Submitted			2023-01-03	WOS:000358622000001
J	Wiangkham, T; Duda, J; Haque, S; Madi, M; Rushton, A				Wiangkham, Taweewat; Duda, Joan; Haque, Sayeed; Madi, Mohammad; Rushton, Alison			The Effectiveness of Conservative Management for Acute Whiplash Associated Disorder (WAD) II: A Systematic Review and Meta-Analysis of Randomised Controlled Trials	PLOS ONE			English	Review							2000-2010 TASK-FORCE; NECK PAIN; PROGNOSTIC-FACTORS; PHYSICAL-THERAPY; CLINICAL-TRIAL; INJURIES; QUALITY; INTERVENTION; RECOVERY; HEALTH	Objective To evaluate the effectiveness of conservative management (except drug therapy) for acute Whiplash Associated Disorder (WAD) II. Design Systematic review and meta-analysis of Randomised Controlled Trials (RCTs) using a predefined protocol. Two independent reviewers searched information sources, decided eligibility of studies, and assessed risk of bias (RoB) of included trials. Data were extracted by one reviewer and checked by the other. A third reviewer mediated any disagreements throughout. Qualitative trial and RoB data were summarised descriptively. Quantitative syntheses were conducted across trials for comparable interventions, outcome measures and assessment points. Meta-analyses compared effect sizes with random effects, using STATA version 12. Data Sources PEDro, Medline, Embase, AMED, CINAHL, PsycINFO, and Cochrane Library with manual searching in key journals, reference lists, British National Bibliography for Report Literature, Center for International Rehabilitation Research Information & Exchange, and National Technical Information Service were searched from inception to 15th April 2015. Active researchers in the field were contacted to determine relevant studies. Eligibility Criteria for Selecting Studies RCTs evaluating acute (<4 weeks) WADII, any conservative intervention, with outcome measures important to the International Classification of Function, Disability and Health. Results Fifteen RCTs all assessed as high RoB (n= 1676 participants) across 9 countries were included. Meta-analyses enabled 4 intervention comparisons: conservative versus standard/ control, active versus passive, behavioural versus standard/control, and early versus late. Conservative intervention was more effective for pain reduction at 6 months (95% CI: -20.14 to -3.38) and 1-3 years (-25.44 to -3.19), and improvement in cervical mobility in the horizontal plane at <3 months (0.43 to 5.60) compared with standard/control intervention. Active intervention was effective for pain alleviation at 6 months (-17.19 to -3.23) and 1-3 years (-26.39 to -10.08) compared with passive intervention. Behavioural intervention was more effective than standard/control intervention for pain reduction at 6 months (-15.37 to -1.55), and improvement in cervical movement in the coronal (0.93 to 4.38) and horizontal planes at 3-6 months (0.43 to 5.46). For early (< 4 days) versus late (>10 days) interventions, there were no statistically significant differences in all outcome measures between interventions at any time. Conclusions Conservative and active interventions may be useful for pain reduction in patients with acute WADII. Additionally, cervical horizontal mobility could be improved by conservative intervention. The employment of a behavioural intervention (e.g. act-as-usual, education and self-care including regularly exercise) could have benefits for pain reduction and improvement in cervical movement in the coronal and horizontal planes. The evidence was evaluated as low/very low level according to the Grading of Recommendations Assessment, Development and Evaluation system.	[Wiangkham, Taweewat; Duda, Joan; Madi, Mohammad; Rushton, Alison] Univ Birmingham, Sch Sport Exercise & Rehabil Sci, Birmingham B15 2TT, W Midlands, England; [Haque, Sayeed] Univ Birmingham, Sch Hlth & Populat Sci, Primary Care Clin Sci, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham	Wiangkham, T (corresponding author), Univ Birmingham, Sch Sport Exercise & Rehabil Sci, Birmingham B15 2TT, W Midlands, England.	txw214@bham.ac.uk	Wiangkham, Taweewat/I-9818-2019; Duda, Joan/ABA-5207-2020; Madi, Mohammad/AAE-6422-2021; Rushton, Alison/V-1260-2017; Haque, Mohammad S/B-9160-2018	Wiangkham, Taweewat/0000-0003-4115-704X; Madi, Mohammad/0000-0001-8521-286X; Rushton, Alison/0000-0001-8114-7669; Haque, (Mohammad) Sayeed/0000-0002-2467-8575				Abraha I, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2697; Aigner N, 2006, WIEN KLIN WOCHENSCHR, V118, P95, DOI 10.1007/s00508-006-0530-4; [Anonymous], 2001, HLTH SCI RES HDB QUA; BARNSLEY L, 1994, PAIN, V58, P283, DOI 10.1016/0304-3959(94)90123-6; Barnsley L, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5966; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Bonk AD, 2000, J MUSCULOSKELET PAIN, V8, P123, DOI 10.1300/J094v08n01_10; Borchgrevink GE, 1998, SPINE, V23, P25, DOI 10.1097/00007632-199801010-00006; Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12; Buitenhuis J, 2009, SPINE, V34, P262, DOI 10.1097/BRS.0b013e3181913d07; Buitenhuis J, 2011, SPINE, V36, pS238, DOI 10.1097/BRS.0b013e3182388400; Burton K, 2003, WHIPL C 2003 6 8 MAY; Carroll LJ, 2008, SPINE, V33, pS214, DOI 10.1097/BRS.0b013e318164462c; Cassidy JD, 2000, NEW ENGL J MED, V342, P1179, DOI 10.1056/NEJM200004203421606; Chappuis G, 2008, EUR SPINE J, V17, P1350, DOI 10.1007/s00586-008-0732-8; Conforti Maria, 2013, Muscles Ligaments Tendons J, V3, P106, DOI 10.11138/mltj/2013.3.2.106; Cote P, 2007, ARTHRIT RHEUM-ARTHR, V57, P861, DOI 10.1002/art.22775; de Koning CHP, 2008, EUR SPINE J, V17, P905, DOI 10.1007/s00586-008-0656-3; Dehner C, 2006, ARCH PHYS MED REHAB, V87, P1423, DOI 10.1016/j.apmr.2006.07.268; Dehner C, 2009, PATIENT SAF SURG, V3, DOI 10.1186/1754-9493-3-2; Eck JC, 2001, AM J MED, V110, P651, DOI 10.1016/S0002-9343(01)00680-5; Ferrari R, 2005, ACAD EMERG MED, V12, P699, DOI 10.1197/j.aem.2005.03.531; FOLEYNOLAN D, 1992, SCAND J REHABIL MED, V24, P51; Furlan AD, 2009, SPINE, V34, P1929, DOI 10.1097/BRS.0b013e3181b1c99f; Galasko CSB, 2002, BRIT COLUMBIA MED J, V44; Glasziou P, 2008, BMJ-BRIT MED J, V336, P1472, DOI 10.1136/bmj.39590.732037.47; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Holm LW, 2008, SPINE, V33, pS52, DOI 10.1097/BRS.0b013e3181643ece; Hopewell Sally, 2010, BMJ, V340, pc723, DOI 10.1136/bmj.c723; Jennum P, 2013, SPINE, V38, P449, DOI 10.1097/BRS.0b013e3182819203; Jull G, 2007, PAIN, V129, P28, DOI 10.1016/j.pain.2006.09.030; Jull G, 2013, PAIN, V154, P1798, DOI 10.1016/j.pain.2013.05.041; Jull GA, 2011, SPINE, V36, pS173, DOI 10.1097/BRS.0b013e31823883e6; Kamper SJ, 2008, PAIN, V138, P617, DOI 10.1016/j.pain.2008.02.019; Lau J, 2006, BMJ-BRIT MED J, V333, P597, DOI 10.1136/bmj.333.7568.597; Leth-Petersen S, 2009, J HEALTH ECON, V28, P996, DOI 10.1016/j.jhealeco.2009.06.013; MacDermid JC, 2009, J ORTHOP SPORT PHYS, V39, P400, DOI 10.2519/jospt.2009.2930; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Merrick Daniel, 2010, BMC Res Notes, V3, P190, DOI 10.1186/1756-0500-3-190; Michaleff ZA, 2014, LANCET, V384, P133, DOI 10.1016/S0140-6736(14)60457-8; Miettinen T, 2004, SPINE, V29, pE47, DOI 10.1097/01.BRS.0000106496.23202.60; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097e1000097, DOI 10.1371/JOURNAL.PMED.1000097]; Moher David, 2010, BMJ, V340, pc869, DOI [10.1016/j.jclinepi.2010.03.004, 10.1136/bmj.c869]; Mooney H, 2012, INSURANCE COMPANIES; Moore A, 2005, CLIN GUIDELINES PHYS; Myran R, 2011, SPINE, V36, pE862, DOI 10.1097/BRS.0b013e3181ff1dde; Nijs J, 2011, CLIN RHEUMATOL, V30, P927, DOI 10.1007/s10067-011-1712-7; Oostendorp RAB, 2013, J EVAL CLIN PRACT, V19, P1044, DOI 10.1111/jep.12025; Ottosson Carin, 2007, PLoS Clin Trials, V2, pe14, DOI 10.1371/journal.pctr.0020014; Picelli A, 2011, EUR J PHYS REHAB MED, V47, P561; RADANOV BP, 1995, MEDICINE, V74, P281, DOI 10.1097/00005792-199509000-00005; Rosenfeld M, 2003, SPINE, V28, P2491, DOI 10.1097/01.BRS.0000090822.96814.13; Rosenfeld M, 2006, SPINE, V31, P1799, DOI 10.1097/01.brs.0000225975.12978.6c; Rushton A, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000265; Schmid CH, 1998, STAT MED, V17, P1923, DOI 10.1002/(SICI)1097-0258(19980915)17:17<1923::AID-SIM874>3.0.CO;2-6; Schnabel M, 2004, EMERG MED J, V21, P306, DOI 10.1136/emj.2003.010165; Scholten-Peeters GGM, 2006, SPINE, V31, P723, DOI 10.1097/01.brs.0000206381.15224.0f; Scholten-Peeters GGM, 2003, PAIN, V104, P303, DOI 10.1016/S0304-3959(03)00050-2; Scholten-Peeters GGM, 2003, J MANIP PHYSIOL THER, V26, P412, DOI 10.1016/S0161-4754(03)00092-7; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI [10.1136/bmj.c332, 10.1186/1741-7015-8-18]; SPITZER WO, 1995, SPINE, V20, pS1; Sterling M, 2005, PAIN, V114, P141, DOI 10.1016/j.pain.2004.12.005; Sterling M, 2004, MANUAL THER, V9, P60, DOI 10.1016/j.math.2004.01.006; Sterling M, 2014, J PHYSIOTHER, V60, P5, DOI 10.1016/j.jphys.2013.12.004; Sterling M, 2011, SPINE, V36, pS322, DOI 10.1097/BRS.0b013e318238853f; Sterling M, 2010, CLIN J PAIN, V26, P573, DOI 10.1097/AJP.0b013e3181e5c25e; Stewart MJ, 2007, PAIN, V128, P59, DOI 10.1016/j.pain.2006.08.030; TRACsa, 2008, CLIN GUID BEST PRACT; Vassiliou T, 2006, PAIN, V124, P69, DOI 10.1016/j.pain.2006.03.017; Verhagen AP, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003338.pub3; Walker E, 2008, CLEV CLIN J MED, V75, P431, DOI 10.3949/ccjm.75.6.431; World Health Organization, 2001, ICF INT CLASFUNCT	75	33	33	2	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2015	10	7							e0133415	10.1371/journal.pone.0133415	http://dx.doi.org/10.1371/journal.pone.0133415			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN6LZ	26196127	Green Submitted, Green Published, gold			2023-01-03	WOS:000358547600095
J	Marban, E; Cingolani, E				Marban, Eduardo; Cingolani, Eugenio			Direct Reprogramming Bypassing Stem Cells for Therapeutics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							FIBROBLASTS		[Marban, Eduardo; Cingolani, Eugenio] Cedars Sinai Heart Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center	Marban, E (corresponding author), Cedars Sinai Heart Inst, 127 S San Vicente Blvd, Los Angeles, CA 90048 USA.	eduardo.marban@csmc.edu	Marban, Eduardo/GWC-8514-2022					Atkinson PJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102077; Clinicaltrials.gov, SAF TOL EFF CGF166 P; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Doudna JA, 2015, JAMA-J AM MED ASSOC, V313, P791, DOI 10.1001/jama.2015.287; Hu YF, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008681; Izumikawa M, 2005, NAT MED, V11, P271, DOI 10.1038/nm1193; Qian L, 2012, NATURE, V485, P593, DOI 10.1038/nature11044; Yamanaka S., NOBEL LECT WINDING R; Zhou Q, 2008, NATURE, V455, P627, DOI 10.1038/nature07314	9	7	7	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	2015	314	1					19	20		10.1001/jama.2015.4504	http://dx.doi.org/10.1001/jama.2015.4504			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CM1QR	26151260				2023-01-03	WOS:000357455900006
J	Balaoing, LR; Post, AD; Lin, AY; Tseng, H; Moake, JL; Grande-Allen, KJ				Balaoing, Liezl Rae; Post, Allison Davis; Lin, Adam Yuh; Tseng, Hubert; Moake, Joel L.; Grande-Allen, K. Jane			Laminin Peptide-Immobilized Hydrogels Modulate Valve Endothelial Cell Hemostatic Regulation	PLOS ONE			English	Article							ENGINEERED HEART-VALVES; PROGENITOR CELLS; SHEAR-STRESS; G-DOMAIN; EX-VIVO; BIOMATERIALS; ADHESION; IDENTIFICATION; CALCIFICATION; SYNDECAN-1	Valve endothelial cells (VEC) have unique phenotypic responses relative to other types of vascular endothelial cells and have highly sensitive hemostatic functions affected by changes in valve tissues. Furthermore, effects of environmental factors on VEC hemostatic function has not been characterized. This work used a poly(ethylene glycol) diacrylate (PEGDA) hydrogel platform to evaluate the effects of substrate stiffness and cell adhesive ligands on VEC phenotype and expression of hemostatic genes. Hydrogels of molecular weights (MWs) 3.4, 8, and 20 kDa were polymerized into platforms of different rigidities and thiol-modified cell adhesive peptides were covalently bound to acrylate groups on the hydrogel surfaces. The peptide RKRLQVQLSIRT (RKR) is a syndecan-1 binding ligand derived from laminin, a trimeric protein and a basement membrane matrix component. Conversely, RGDS is an integrin binding peptide found in many extracellular matrix (ECM) proteins including fibronectin, fibrinogen, and von Willebrand factor (VWF). VECs adhered to and formed a stable monolayer on all RKR-coated hydrogel-MW combinations. RGDS-coated platforms supported VEC adhesion and growth on RGDS-3.4 kDa and RGDS-8 kDa hydrogels. VECs cultured on the softer RKR-8 kDa and RKR-20 kDa hydrogel platforms had significantly higher gene expression for all anti-thrombotic (ADAMTS-13, tissue factor pathway inhibitor, and tissue plasminogen activator) and thrombotic (VWF, tissue factor, and P-selectin) proteins than VECs cultured on RGDS-coated hydrogels and tissue culture polystyrene controls. Stimulated VECs promoted greater platelet adhesion than non-stimulated VECs on their respective culture condition; yet stimulated VECs on RGDS-3.4 kDa gels were not as responsive to stimulation relative to the RKR-gel groups. Thus, the syndecan binding, laminin-derived peptide promoted stable VEC adhesion on the softer hydrogels and maintained VEC phenotype and natural hemostatic function. In conclusion, utilization of non-integrin adhesive peptide sequences derived from basement membrane ECM may recapitulate balanced VEC function and may benefit endothelialization of valve implants.	[Balaoing, Liezl Rae; Post, Allison Davis; Lin, Adam Yuh; Tseng, Hubert; Moake, Joel L.; Grande-Allen, K. Jane] Rice Univ, Dept Bioengn, Houston, TX 77005 USA	Rice University	Grande-Allen, KJ (corresponding author), Rice Univ, Dept Bioengn, Houston, TX 77005 USA.	grande@rice.edu	; Grande-Allen, Kathryn Jane/P-4042-2014	Lin, Adam/0000-0001-9359-882X; Grande-Allen, Kathryn Jane/0000-0003-1533-3767	American Heart Association; NIH [HL110063]; Mary R. Gibson Foundation; Mabel and Everett Hinkson Memorial Fund; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL110063] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mary R. Gibson Foundation; Mabel and Everett Hinkson Memorial Fund; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This research was funded by a predoctoral fellowship from the American Heart Association (to L.R.B.), NIH HL110063, the Mary R. Gibson Foundation, and the Mabel and Everett Hinkson Memorial Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen JB, 2010, STEM CELLS, V28, P318, DOI 10.1002/stem.275; Arya M, 2002, BLOOD, V99, P3971, DOI 10.1182/blood-2001-11-0060; Balaoing LR, 2014, ARTERIOSCL THROM VAS, V34, P72, DOI 10.1161/ATVBAHA.113.301936; Beauvais DLM, 2004, J CELL BIOL, V167, P171, DOI 10.1083/jcb.200404171; Butcher JT, 2007, PHILOS T R SOC B, V362, P1445, DOI 10.1098/rstb.2007.2127; Butcher JT, 2006, TISSUE ENG, V12, P905, DOI 10.1089/ten.2006.12.905; Butcher JT, 2006, ARTERIOSCL THROM VAS, V26, P69, DOI 10.1161/01.ATV.0000196624.70507.0d; Butcher JT, 2004, ARTERIOSCL THROM VAS, V24, P1429, DOI 10.1161/01.ATV.0000130462.50769.5a; Chalajour F, 2004, EXP CELL RES, V298, P455, DOI 10.1016/j.yexcr.2004.04.034; Chappell D, 2009, CIRC RES, V104, P1313, DOI 10.1161/CIRCRESAHA.108.187831; Cheung WY, 2008, J HEART VALVE DIS, V17, P674; Denis CV, 1999, CELL MOL LIFE SCI, V56, P977, DOI 10.1007/s000180050487; DENT JA, 1990, P NATL ACAD SCI USA, V87, P6306, DOI 10.1073/pnas.87.16.6306; Durbeej M, 2010, CELL TISSUE RES, V339, P259, DOI 10.1007/s00441-009-0838-2; Durst CA, 2011, ACTA BIOMATER, V7, P2467, DOI 10.1016/j.actbio.2011.02.018; Elbert DL, 2001, BIOMACROMOLECULES, V2, P430, DOI 10.1021/bm0056299; Engelmayr GC, 2006, BIOMATERIALS, V27, P6083, DOI 10.1016/j.biomaterials.2006.07.045; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Fang NT, 2007, CHINESE MED J-PEKING, V120, P696, DOI 10.1097/00029330-200704020-00016; Frendl CM, 2014, BIOMATERIALS, V35, P7714, DOI 10.1016/j.biomaterials.2014.05.075; Gwanmesia P, 2010, TISSUE ENG PART A, V49, P1, DOI 10.1089\ten.TEA.2010.0304; Hakuno D, 2009, J MOL MED, V87, P17, DOI 10.1007/s00109-008-0400-9; Halstenberg S, 2002, BIOMACROMOLECULES, V3, P710, DOI 10.1021/bm015629o; Hinton RB, 2006, CIRC RES, V98, P1431, DOI 10.1161/01.RES.0000224114.65109.4e; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; Hoyle CE, 2010, ANGEW CHEM INT EDIT, V49, P1540, DOI 10.1002/anie.200903924; Hozumi K, 2006, J BIOL CHEM, V281, P32929, DOI 10.1074/jbc.M605708200; Jian B, 2003, ANN THORAC SURG, V75, P457, DOI 10.1016/S0003-4975(02)04312-6; Latif N, 2005, J HEART VALVE DIS, V14, P218; Leask RL, 2003, MICROSC RES TECHNIQ, V60, P129, DOI 10.1002/jemt.10251; Lichtenberg A, 2006, BIOMATERIALS, V27, P4221, DOI 10.1016/j.biomaterials.2006.03.047; McGuigan AP, 2007, BIOMATERIALS, V28, P2547, DOI 10.1016/j.biomaterials.2007.01.039; Michiels C, 2003, J CELL PHYSIOL, V196, P430, DOI 10.1002/jcp.10333; Mohler ER, 2004, AM J CARDIOL, V94, P1396, DOI 10.1016/j.amjcard.2004.08.013; Moon JJ, 2008, CURR TOP MED CHEM, V8, P300; Morgan MR, 2007, NAT REV MOL CELL BIO, V8, P957, DOI 10.1038/nrm2289; Nemir S, 2010, BIOTECHNOL BIOENG, V105, P636, DOI 10.1002/bit.22574; Okazaki I, 2002, J BIOL CHEM, V277, P37070, DOI 10.1074/jbc.M201672200; Pearson JD, 1999, BEST PRACT RES CL HA, V12, P329, DOI 10.1053/beha.1999.0028; Ramaswamy S, 2010, BIOMATERIALS, V31, P1114, DOI 10.1016/j.biomaterials.2009.10.019; Rydholm AE, 2008, J BIOMED MATER RES A, V86A, P23, DOI 10.1002/jbm.a.31526; Sales VL, 2010, TISSUE ENG PT A, V16, P257, DOI [10.1089/ten.tea.2009.0424, 10.1089/ten.TEA.2009.0424]; Sewell-Loftin MK, 2011, J CARDIOVASC TRANSL, V4, P658, DOI 10.1007/s12265-011-9300-4; Sha JM, 2010, J HEART VALVE DIS, V19, P506; Thalla PK, 2014, BIOMACROMOLECULES, V15, P2512, DOI 10.1021/bm5003762; Tseng H, 2014, TISSUE ENG PT A, V20, P2634, DOI [10.1089/ten.tea.2013.0397, 10.1089/ten.TEA.2013.0397]; Turner N, 2012, SEMIN THROMB HEMOST, V38, P38, DOI 10.1055/s-0031-1300950; Turner NA, 2009, BLOOD, V114, P5102, DOI 10.1182/blood-2009-07-231597; Weymann A, 2013, CIRC J, V77, P207, DOI 10.1253/circj.CJ-12-0540; Xu XX, 2010, CYTOTECHNOLOGY, V62, P17, DOI 10.1007/s10616-010-9256-2; Yang JH, 2008, BIOCHEM BIOPH RES CO, V374, P512, DOI 10.1016/j.bbrc.2008.07.057; Young EWK, 2007, LAB CHIP, V7, P1759, DOI 10.1039/b712486d	52	19	19	0	48	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2015	10	6							e0130749	10.1371/journal.pone.0130749	http://dx.doi.org/10.1371/journal.pone.0130749			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL3FE	26090873	Green Published, gold			2023-01-03	WOS:000356835000149
J	Nakielski, P; Pawlowska, S; Pierini, F; Liwinska, W; Hejduk, P; Zembrzycki, K; Zabost, E; Kowalewski, TA				Nakielski, Pawel; Pawlowska, Sylwia; Pierini, Filippo; Liwinska, Wioletta; Hejduk, Patryk; Zembrzycki, Krzysztof; Zabost, Ewelina; Kowalewski, Tomasz A.			Hydrogel Nanofilaments via Core-Shell Electrospinning	PLOS ONE			English	Article							FLEXURAL RIGIDITY; NANOFIBERS; POLYMERIZATION; MICROTUBULES	Recent biomedical hydrogels applications require the development of nanostructures with controlled diameter and adjustable mechanical properties. Here we present a technique for the production of flexible nanofilaments to be used as drug carriers or in microfluidics, with deformability and elasticity resembling those of long DNA chains. The fabrication method is based on the core-shell electrospinning technique with core solution polymerisation post electrospinning. Produced from the nanofibers highly deformable hydrogel nanofilaments are characterised by their Brownian motion and bending dynamics. The evaluated mechanical properties are compared with AFM nanoindentation tests.	[Nakielski, Pawel; Pawlowska, Sylwia; Pierini, Filippo; Hejduk, Patryk; Zembrzycki, Krzysztof; Kowalewski, Tomasz A.] Polish Acad Sci, Inst Fundamental Technol Res, Dept Mech & Phys Fluids, Warsaw, Poland; [Liwinska, Wioletta; Zabost, Ewelina] Univ Warsaw, Fac Chem, Warsaw, Poland	Polish Academy of Sciences; Institute of Fundamental Technological Research of the Polish Academy of Sciences; University of Warsaw	Nakielski, P (corresponding author), Polish Acad Sci, Inst Fundamental Technol Res, Dept Mech & Phys Fluids, Warsaw, Poland.	pnakiel@ippt.pan.pl	Nakielski, Pawel/A-2077-2013; Pawłowska, Sylwia/HIK-1653-2022; Kowalewski, Tomasz Aleksander/F-2055-2011; Pierini, Filippo/B-5328-2019	Nakielski, Pawel/0000-0001-6194-701X; Kowalewski, Tomasz Aleksander/0000-0002-3664-9659; Pierini, Filippo/0000-0002-6526-4141; Zabost, Ewelina/0000-0003-4544-6033	National Science Centre Poland [2011/03/B/ST8/05481, 2012/05/D/ST5/03464]	National Science Centre Poland(National Science Centre, Poland)	This work was supported by 2011/03/B/ST8/05481, National Science Centre Poland (http:// www.ncn.gov.pl/?language = en) and 2012/05/D/ST5/03464, National Science Centre Poland (http://www.ncn.gov.pl/?language = en). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bhaduri B, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2887883; Brandl C, 2011, MACROMOL MATER ENG, V296, P858, DOI 10.1002/mame.201100031; Chen ML, 2010, CHEM MATER, V22, P4214, DOI 10.1021/cm100753r; Doi M., 1986, INT SERIES MONOGRAPH; Evingur GA, 2014, POLYM-PLAST TECHNOL, V53, P834, DOI 10.1080/03602559.2014.886049; Fathi M, 2013, RADIAT PHYS CHEM, V86, P145, DOI 10.1016/j.radphyschem.2013.02.005; Fu GD, 2008, MACROMOLECULES, V41, P6854, DOI 10.1021/ma800499h; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Graham JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094766; Hu M, 2010, BIOMATERIALS, V31, P863, DOI 10.1016/j.biomaterials.2009.10.002; Jia WJ, 2010, J MATER CHEM, V20, P8617, DOI 10.1039/c0jm01179g; Kikumoto M, 2006, BIOPHYS J, V90, P1687, DOI 10.1529/biophysj.104.055483; Koombhongse S, 2001, J POLYM SCI POL PHYS, V39, P2598, DOI 10.1002/polb.10015; Kowalczyk T, 2008, BIOMACROMOLECULES, V9, P2087, DOI 10.1021/bm800421s; MathWorks, 2014, MATLAB; Nakielski P, 2015, IPPT REPORTS; Nakielski P, 2015, J BIOMED MATER RES B, V103, P282, DOI 10.1002/jbm.b.33197; Oh JK, 2008, PROG POLYM SCI, V33, P448, DOI 10.1016/j.progpolymsci.2008.01.002; Ortega A, 2003, J CHEM PHYS, V119, P9914, DOI 10.1063/1.1615967; OTT A, 1993, PHYS REV E, V48, pR1642, DOI 10.1103/PhysRevE.48.R1642; Ottenbrite RM, 2010, BIOMEDICAL APPLICATIONS OF HYDROGELS HANDBOOK, P1, DOI 10.1007/978-1-4419-5919-5; Reddy CS, 2009, J MATER CHEM, V19, P7198, DOI 10.1039/b916185f; Sadlej K, 2010, INT J HEAT FLUID FL, V31, P996, DOI 10.1016/j.ijheatfluidflow.2010.02.021; Slowicka AM, 2012, J CHEM PHYS, V136, DOI 10.1063/1.3678852; Sun ZC, 2003, ADV MATER, V15, P1929, DOI 10.1002/adma.200305136; Tan EPS, 2006, COMPOS SCI TECHNOL, V66, P1102, DOI 10.1016/j.compscitech.2005.10.003; Wu Q, 2013, ANAL CHEM, V85, P5924, DOI 10.1021/ac4006974; Xue RP, 2014, SENSOR ACTUAT B-CHEM, V192, P697, DOI 10.1016/j.snb.2013.10.084; Yamakawa H., 1971, HARPERS CHEM SERIES; Yan H, 2005, LANGMUIR, V21, P7076, DOI 10.1021/la0512749; Yarin A. L., 2014, FUNDAMENTALS APPL MI; Zabost E, 2014, ELECTROCHEM COMMUN, V42, P50, DOI 10.1016/j.elecom.2014.02.011; Zheng F, 2011, TALANTA, V85, P1166, DOI 10.1016/j.talanta.2011.05.039	33	16	16	5	61	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2015	10	6							e0129816	10.1371/journal.pone.0129816	http://dx.doi.org/10.1371/journal.pone.0129816			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL3FE	26091487	gold, Green Published			2023-01-03	WOS:000356835000061
J	Kamal, AH; Maguire, JM; Meier, DE				Kamal, Arif H.; Maguire, Jennifer M.; Meier, Diane E.			Evolving the Palliative Care Workforce to Provide Responsive, Serious Illness Care	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HOSPICE		[Kamal, Arif H.] Duke Clin Res Inst, Durham, NC 27710 USA; Univ N Carolina, Sch Med, Chapel Hill, NC USA; Icahn Sch Med Mt Sinai, New York, NY 10029 USA	Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Icahn School of Medicine at Mount Sinai	Kamal, AH (corresponding author), Duke Clin Res Inst, 2400 Pratt St,Room 8043, Durham, NC 27710 USA.	arif.kamal@duke.edu	Maguire, Jane M.M./D-8427-2017	Maguire, Jane M.M./0000-0001-5722-8311				Accreditation Council for Graduate Medical Education, 2015, ACGME PUBL PROGR SEA; American Academy of Hospice and Palliative Medicine, NUMB CERT HOSP PALL; Center to Advance Palliative Care, 2014, NAT PALL CAR REG ANN; Feely MA, 2011, J PALLIAT MED, V14, P272, DOI 10.1089/jpm.2010.0455; Kamal A, 2014, J CLIN ONCOL S31, V32; Lupu D, 2010, J PAIN SYMPTOM MANAG, V40, P899, DOI 10.1016/j.jpainsymman.2010.07.004; National Hospice and Palliative Care Organization, 2014, NHPCOS FACTS FIG HOS; Quill TE, 2013, NEW ENGL J MED, V368, P1173, DOI 10.1056/NEJMp1215620; Wu S. Y., 2000, PROJECTION CHRONIC I	9	44	44	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 20	2015	163	8					637	+		10.7326/M15-0071	http://dx.doi.org/10.7326/M15-0071			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CU7QV	26258800				2023-01-03	WOS:000363737400022
J	Chi, PC; Bulage, P; Urdal, H; Sundby, J				Chi, Primus Che; Bulage, Patience; Urdal, Henrik; Sundby, Johanne			Barriers in the Delivery of Emergency Obstetric and Neonatal Care in Post-Conflict Africa: Qualitative Case Studies of Burundi and Northern Uganda	PLOS ONE			English	Article							MATERNAL MORTALITY; HEALTH-SERVICES; ARMED CONFLICT; AVAILABILITY; IMPACT; DISTRICT; ACCESS; WOMEN; KENYA; WAR	Objectives Maternal and neonatal mortality and morbidity rates are particularly grim in conflict, post-conflict and other crisis settings, a situation partly blamed on non-availability and/or poor quality of emergency obstetric and neonatal care (EmONC) services. The aim of this study was to explore the barriers to effective delivery of EmONC services in post-conflict Burundi and Northern Uganda, in order to provide policy makers and other relevant stakeholders context-relevant data on improving the delivery of these lifesaving services. Methods This was a qualitative comparative case study that used 42 face-to-face semi-structured in-depth interviews and 4 focus group discussions for data collection. Participants were 32 local health providers and 37 staff of NGOs working in the area of maternal health. Data was analysed using the framework approach. Results The availability, quality and distribution of EmONC services were major challenges across the sites. The barriers in the delivery of quality EmONC services were categorised into two major themes; human resources-related challenges, and systemic and institutional failures. While some of the barriers were similar, others were unique to specific sites. The common barriers included shortage of qualified staff; lack of essential installations, supplies and medications; increasing workload, burn-out and turnover; and poor data collection and monitoring systems. Barriers unique to Northern Uganda were demoralised personnel and lack of recognition; poor referral system; inefficient drug supply system; staff absenteeism in rural areas; and poor coordination among key personnel. In Burundi, weak curriculum; poor harmonisation and coordination of training; and inefficient allocation of resources were the unique challenges. To improve the situation across the sites, efforts are ongoing to improve the training and recruitment of more staff; harmonise and strengthen the curriculum and training; increase the number of EmONC facilities; and improve staff supervision, monitoring and support. Conclusions Post-conflict health systems face different challenges in the delivery of EmONC services and as such require context-specific interventions to improve the delivery of these services.	[Chi, Primus Che; Urdal, Henrik] PRIO, Oslo, Norway; [Chi, Primus Che; Sundby, Johanne] Univ Oslo, Inst Hlth Soc, Oslo, Norway; [Bulage, Patience] Int Org Migrat, Kampala, Uganda	Peace Research Institute Oslo (PRIO); University of Oslo; International Organization for Migration	Chi, PC (corresponding author), PRIO, POB 9229, Oslo, Norway.	prichi@prio.org		Chi, Primus Che/0000-0002-2727-2693	Folke Bernadotte Academy, Sweden; Institute of Health and Society, University of Oslo, Norway; EU 7th Framework Marie Curie ITN 'Training and Mobility Network for Economic Analysis of Conflict' TAMNEAC [263905]; Peace Research Institute Oslo (PRIO)	Folke Bernadotte Academy, Sweden; Institute of Health and Society, University of Oslo, Norway; EU 7th Framework Marie Curie ITN 'Training and Mobility Network for Economic Analysis of Conflict' TAMNEAC; Peace Research Institute Oslo (PRIO)	This fieldwork received funding from Folke Bernadotte Academy, Sweden, and the Institute of Health and Society, University of Oslo, Norway. The entire work has been supported by the EU 7th Framework Marie Curie ITN 'Training and Mobility Network for the Economic Analysis of Conflict' TAMNEAC (Grant agreement 263905) and the Peace Research Institute Oslo (PRIO). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ameh C, 2012, INT J GYNECOL OBSTET, V117, P283, DOI 10.1016/j.ijgo.2012.01.015; Ameh CA, 2011, MATERN CHILD HLTH J, V15, P4, DOI 10.1007/s10995-009-0545-3; [Anonymous], 2011, MIN IN SERV PACK MIS; Apuuli Kasaija Phillip, 2006, J INT CRIM JUSTICE, V4, P179; Apuuli KP, 2003, WAR NO UGANDA WORLDS; Averting Maternal Death and Disability, 2013, EM OBST NEWB CAR LIF; Bundervoet T, 2009, J HUM RESOUR, V44, P536; Cabinet of the President Republic of Burundi, 2010, REP BUR TROIS REC GE; Chi PC, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0449-8; Cho H, 2012, MONITORING MATERNAL; Chynoweth SK, 2008, REPROD HEALTH MATTER, V16, P93, DOI 10.1016/S0968-8080(08)31348-2; Devkota Bhimsen, 2010, Confl Health, V4, P20, DOI 10.1186/1752-1505-4-20; Echoka E, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-113; Fournier P, 2009, B WORLD HEALTH ORGAN, V87, P30, DOI 10.2471/BLT.07.047076; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Inter-agency Working Group on Reproductive Health in Crisis, 2010, INT FIELD MAN REPR H; Jamieson DJ, 2000, JAMA-J AM MED ASSOC, V283, P397, DOI 10.1001/jama.283.3.397; Kim YM, 2012, INT J GYNECOL OBSTET, V116, P192, DOI 10.1016/j.ijgo.2011.10.017; Kongnyuy EJ, 2009, BJOG-INT J OBSTET GY, V116, P41, DOI 10.1111/j.1471-0528.2009.02332.x; Krause S K, 2006, Glob Public Health, V1, P205, DOI 10.1080/17441690600679939; Kruk ME, 2010, B WORLD HEALTH ORGAN, V88, P527, DOI 10.2471/BLT.09.071068; Kyotalengerire A, 2014, NEW VISION NEWS 1115; Lam Jennifer O, 2012, Confl Health, V6, P2, DOI 10.1186/1752-1505-6-2; Lee RB, 2008, REPROD HEALTH MATTER, V16, P65, DOI 10.1016/S0968-8080(08)31346-9; Mbonye AK, 2007, INT J GYNECOL OBSTET, V98, P285, DOI 10.1016/j.ijgo.2007.05.019; Medecins Sans Frontieres, 2012, SAF DEL RED MAT MORT; Mezie-Okoye Margaret M, 2012, Afr J Reprod Health, V16, P171; Ministry of Health Republic of Uganda, 2005, HLTH MORT SURV INT D; Morof Diane F, 2014, Confl Health, V8, P8, DOI 10.1186/1752-1505-8-8; New Deal for Building Peaceful States, NEW DEAL ENG FRAG ST; O'Hare BAM, 2007, J ROY SOC MED, V100, P564, DOI 10.1258/jrsm.100.12.564; Ocowun C, 2010, GULU NEEDS 316 HLTH; Orinda V, 2005, INT J GYNECOL OBSTET, V91, P285, DOI 10.1016/j.ijgo.2005.07.023; Otunnu O, 2002, CAUSES CONSEQUENCES; Oyerinde K, 2011, INT J GYNECOL OBSTET, V114, P168, DOI 10.1016/j.ijgo.2011.05.006; Paxton A, 2006, INT J GYNECOL OBSTET, V93, P300, DOI 10.1016/j.ijgo.2006.01.030; Paxton A, 2005, INT J GYNECOL OBSTET, V88, P181, DOI 10.1016/j.ijgo.2004.11.026; Pearson L, 2005, INT J GYNECOL OBSTET, V88, P208, DOI 10.1016/j.ijgo.2004.09.027; Population Reference Bureau, 2014, 2014 WORLD POP SHEET; Reproductive Health Response in Conflict Consortium, 2004, EM OBST CAR CRIT NEE; Roberts B, 2008, REPROD HEALTH MATTER, V16, P57, DOI 10.1016/S0968-8080(08)31347-0; Tayler-Smith K, 2013, TROP MED INT HEALTH, V18, P993, DOI 10.1111/tmi.12121; Tayler-Smith K, 2013, TROP MED INT HEALTH, V18, P166, DOI 10.1111/tmi.12022; Turkmani S, 2013, MIDWIFERY, V29, P1166, DOI 10.1016/j.midw.2013.06.015; Uganda Medical & Dental Practitioners Council, REG; Uganda National Bureau of Statistics, 2010, UG NAT HOUS SURV 200; Uganda Nurses and Midwives Council, REG NURS MIDW HLTH W; UNFPA, 2012, WOM AR FABR REPR HLT; UNICEF, 2014, TRANSMONEE 2014 GUID; UNICEF WHO UN Population Fund, 1997, GUID MON AV US OBST; Urdal H, 2013, INT INTERACT, V39, P489, DOI 10.1080/03050629.2013.805133; Voors MJ, 2012, AM ECON REV, V102, P941, DOI 10.1257/aer.102.2.941; Wick L, 2012, REPROD HEALTH MATTER, V20, P7, DOI 10.1016/S0968-8080(12)40648-6; Women's Refugee Commission, 2009, REPR HLTH NO UG REP; World Bank, 2011, WORLD DEVELOPMENT REPORT 2011: CONFLICT, SECURITY AND DEVELOPMENT, P1, DOI 10.1596/978-0-8213-8439-8; World Bank, 2011, BUR NAT PERF BAS FIN; World Health Organization, 2009, HLTH WORKF INFR ESS; World Health Organization: Burundi, 2014, COUNTR COOP STRAT; World Health Organization: Uganda, 2014, COUNTR COOP STRAT; World Health Organization (WHO), 2005, TECHNICAL REPORT; Zotti ME, 2013, MATERN CHILD HLTH J, V17, P783, DOI 10.1007/s10995-012-1068-x; Zuniga I, 2013, PUBLIC HEALTH ACTION, V3, P276, DOI 10.5588/pha.13.0050	62	19	19	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2015	10	9							e0139120	10.1371/journal.pone.0139120	http://dx.doi.org/10.1371/journal.pone.0139120			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CS1CR	26405800	Green Submitted, Green Published, gold			2023-01-03	WOS:000361800700177
J	Hudson, MB; Smuder, AJ; Nelson, WB; Wiggs, MP; Shimkus, KL; Fluckey, JD; Szeto, HH; Powers, SK				Hudson, Matthew B.; Smuder, Ashley J.; Nelson, W. Bradley; Wiggs, Michael P.; Shimkus, Kevin L.; Fluckey, James D.; Szeto, Hazel H.; Powers, Scott K.			Partial Support Ventilation and Mitochondrial-Targeted Antioxidants Protect against Ventilator-Induced Decreases in Diaphragm Muscle Protein Synthesis	PLOS ONE			English	Article							PROLONGED MECHANICAL VENTILATION; CRITICALLY-ILL PATIENTS; OXIDATIVE STRESS; RAT DIAPHRAGM; MASS-SPECTROMETRY; KINASE-B; DYSFUNCTION; ATROPHY; WEAKNESS; ACTIVATION	Mechanical ventilation (MV) is a life-saving intervention in patients in respiratory failure. Unfortunately, prolonged MV results in the rapid development of diaphragm atrophy and weakness. MV-induced diaphragmatic weakness is significant because inspiratory muscle dysfunction is a risk factor for problematic weaning from MV. Therefore, developing a clinical intervention to prevent MV-induced diaphragm atrophy is important. In this regard, MV-induced diaphragmatic atrophy occurs due to both increased proteolysis and decreased protein synthesis. While efforts to impede MV-induced increased proteolysis in the diaphragm are well-documented, only one study has investigated methods of preserving diaphragmatic protein synthesis during prolonged MV. Therefore, we evaluated the efficacy of two therapeutic interventions that, conceptually, have the potential to sustain protein synthesis in the rat diaphragm during prolonged MV. Specifically, these experiments were designed to: 1) determine if partial-support MV will protect against the decrease in diaphragmatic protein synthesis that occurs during prolonged full-support MV; and 2) establish if treatment with a mitochondrial-targeted antioxidant will maintain diaphragm protein synthesis during full-support MV. Compared to spontaneously breathing animals, full support MV resulted in a significant decline in diaphragmatic protein synthesis during 12 hours of MV. In contrast, diaphragm protein synthesis rates were maintained during partial support MV at levels comparable to spontaneous breathing animals. Further, treatment of animals with a mitochondrial-targeted antioxidant prevented oxidative stress during full support MV and maintained diaphragm protein synthesis at the level of spontaneous breathing animals. We conclude that treatment with mitochondrial-targeted antioxidants or the use of partial-support MV are potential strategies to preserve diaphragm protein synthesis during prolonged MV.	[Hudson, Matthew B.] Temple Univ, Dept Kinesiol, Philadelphia, PA 19122 USA; [Smuder, Ashley J.; Wiggs, Michael P.; Powers, Scott K.] Univ Florida, Ctr Exercise Sci, Dept Appl Physiol & Kinesiol, Gainesville, FL 32611 USA; [Nelson, W. Bradley] Ohio Dominican Univ, Dept Nat Sci, Columbus, OH USA; [Shimkus, Kevin L.; Fluckey, James D.] Texas A&M Univ, Dept Hlth & Kinesiol, College Stn, TX USA; [Szeto, Hazel H.] Weill Cornell Med Coll, Dept Pharmacol, New York, NY USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; State University System of Florida; University of Florida; Ohio Dominican University; Texas A&M University System; Texas A&M University College Station; Cornell University	Hudson, MB (corresponding author), Temple Univ, Dept Kinesiol, Philadelphia, PA 19122 USA.	mbhudson@temple.edu	Nelson, Brad/P-8771-2016	Nelson, Brad/0000-0003-0793-2006	National Institute of Health [R01AR064189]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR064189] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This study was funded by the National Institute of Health (grant #R01AR064189) awarded to SKP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agten A, 2011, CRIT CARE MED, V39, P777, DOI 10.1097/CCM.0b013e318206cca9; Alirezaei M, 2001, J NEUROCHEM, V76, P1080, DOI 10.1046/j.1471-4159.2001.00105.x; Betters JL, 2004, AM J RESP CRIT CARE, V170, P1179, DOI 10.1164/rccm.200407-939OC; Bodine SC, 2006, MED SCI SPORT EXER, V38, P1950, DOI 10.1249/01.mss.0000233797.24035.35; Boles JM, 2007, EUR RESPIR J, V29, P1033, DOI 10.1183/09031936.00010206; Bruells CS, 2013, ANESTHESIOLOGY, V119, P652, DOI 10.1097/ALN.0b013e31829b3692; CALDER AG, 1992, RAPID COMMUN MASS SP, V6, P421, DOI 10.1002/rcm.1290060704; Eskandar N, 2007, CRIT CARE CLIN, V23, P263, DOI 10.1016/j.ccc.2006.12.002; Falk DJ, 2011, CHEST, V139, P816, DOI 10.1378/chest.09-2787; Futier E, 2008, CRIT CARE, V12, DOI 10.1186/cc7010; Gayan-Ramirez G, 2003, INTENS CARE MED, V29, P825, DOI 10.1007/s00134-003-1688-0; Hooijman PE, 2015, AM J RESP CRIT CARE, V191, P1126, DOI 10.1164/rccm.201412-2214OC; Hudson MB, 2014, AM J PHYSIOL-CELL PH, V307, pC314, DOI 10.1152/ajpcell.00395.2013; Hudson MB, 2014, AM J PHYSIOL-CELL PH, V306, pC551, DOI 10.1152/ajpcell.00266.2013; Hudson MB, 2012, CRIT CARE MED, V40, P1254, DOI 10.1097/CCM.0b013e31823c8cc9; Kavazis AN, 2009, FREE RADICAL BIO MED, V46, P842, DOI 10.1016/j.freeradbiomed.2009.01.002; Klawitter PF, 2004, J APPL PHYSIOL, V96, P89, DOI 10.1152/japplphysiol.00237.2003; Laghi F, 2003, AM J RESP CRIT CARE, V168, P10, DOI 10.1164/rccm.2206020; Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447; Maes K, 2007, AM J RESP CRIT CARE, V175, P1134, DOI 10.1164/rccm.200609-1342OC; McClung JM, 2007, J PHYSIOL-LONDON, V585, P203, DOI 10.1113/jphysiol.2007.141119; McClung JM, 2009, CRIT CARE MED, V37, P1373, DOI 10.1097/CCM.0b013e31819cef63; MORTOLA JP, 1983, J APPL PHYSIOL, V55, P250, DOI 10.1152/jappl.1983.55.1.250; Nelson WB, 2012, CRIT CARE MED, V40, P1857, DOI 10.1097/CCM.0b013e318246bb5d; Patel J, 2002, EUR J BIOCHEM, V269, P3076, DOI 10.1046/j.1432-1033.2002.02992.x; Patterson BW, 1997, METABOLISM, V46, P943, DOI 10.1016/S0026-0495(97)90084-6; Pham FH, 2000, CIRC RES, V86, P1252, DOI 10.1161/01.RES.86.12.1252; Picard M, 2012, AM J RESP CRIT CARE, V186, P1140, DOI 10.1164/rccm.201206-0982OC; Powers SK, 2013, AM J PHYSIOL-REG I, V305, pR464, DOI 10.1152/ajpregu.00231.2013; Powers SK, 2011, CRIT CARE MED, V39, P1749, DOI 10.1097/CCM.0b013e3182190b62; Powers SK, 2011, FREE RADICAL BIO MED, V51, P942, DOI 10.1016/j.freeradbiomed.2010.12.009; Rollier H, 1998, AM J RESP CRIT CARE, V157, P833, DOI 10.1164/ajrccm.157.3.9512103; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Shanely RA, 2004, AM J RESP CRIT CARE, V170, P994, DOI 10.1164/rccm.200304-575OC; Smuder AJ, 2014, ANESTHESIOLOGY, V121, P115, DOI 10.1097/ALN.0000000000000245; Smuder AJ, 2012, CRIT CARE MED, V40, P927, DOI 10.1097/CCM.0b013e3182374a84; Smuder AJ, 2012, J APPL PHYSIOL, V112, P501, DOI 10.1152/japplphysiol.01086.2011; Smuder AJ, 2010, FREE RADICAL BIO MED, V49, P1152, DOI 10.1016/j.freeradbiomed.2010.06.025; Supinski GS, 2013, CRIT CARE, V17, DOI 10.1186/cc12792; Szeto HH, 2011, J AM SOC NEPHROL, V22, P1041, DOI 10.1681/ASN.2010080808; Vassilakopoulos T, 2004, AM J RESP CRIT CARE, V169, P336, DOI 10.1164/rccm.200304-489CP; Vassilakopoulos T, 1996, Monaldi Arch Chest Dis, V51, P489; Whidden MA, 2010, J APPL PHYSIOL, V108, P1376, DOI 10.1152/japplphysiol.00098.2010; Whidden MA, 2009, J APPL PHYSIOL, V106, P385, DOI 10.1152/japplphysiol.91106.2008; Zhao KS, 2005, BIOCHEM PHARMACOL, V70, P1796, DOI 10.1016/j.bcp.2005.08.022; Zhao KS, 2004, J BIOL CHEM, V279, P34682, DOI 10.1074/jbc.M402999200	46	32	34	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2015	10	9							e0137693	10.1371/journal.pone.0137693	http://dx.doi.org/10.1371/journal.pone.0137693			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR0WB	26361212	Green Published, gold, Green Submitted			2023-01-03	WOS:000361043100072
J	Feudtner, C				Feudtner, Chris			Love at the End of the Beginning of Life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Feudtner, Chris] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Feudtner, Chris] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania	Feudtner, C (corresponding author), Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.	feudtner@email.chop.edu	Feudtner, Chris/AAI-1126-2019	Feudtner, Chris/0000-0002-5879-0434					0	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2015	314	10					1001	1002		10.1001/jama.2015.5944	http://dx.doi.org/10.1001/jama.2015.5944			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CQ8FA	26348747				2023-01-03	WOS:000360840700009
J	Boucher, JA; Abboud, J; Nougarou, F; Normand, MC; Descarreaux, M				Boucher, Jean-Alexandre; Abboud, Jacques; Nougarou, Francois; Normand, Martin C.; Descarreaux, Martin			The Effects of Vibration and Muscle Fatigue on Trunk Sensorimotor Control in Low Back Pain Patients	PLOS ONE			English	Article							POSITION SENSE; TENDON VIBRATION; SPINDLE ENDINGS; VISUAL ANALOG; MOVEMENT; CONTRACTION; AFFERENTS; INDIVIDUALS; RELIABILITY; PERFORMANCE	Introduction Changes in sensorimotor function and increased trunk muscle fatigability have been identified in patients with chronic low back pain (cLBP). This study assessed the control of trunk force production in conditions with and without local erector spinae muscle vibration and evaluated the influence of muscle fatigue on trunk sensorimotor control. Methods Twenty non-specific cLBP patients and 20 healthy participants were asked to perform submaximal isometric trunk extension torque with and without local vibration stimulation, before and after a trunk extensor muscle fatigue protocol. Constant error (CE), variable error (VE) as well as absolute error (AE) in peak torque were computed and compared across conditions. Trunk extensor muscle activation during isometric contractions and during the fatigue protocol was measured using surface electromyography (sEMG). Results Force reproduction accuracy of the trunk was significantly lower in the patient group (CE = 9.81 +/- 2.23 Nm; AE = 18.16 +/- 3.97 Nm) than in healthy participants (CE = 4.44 +/- 1.68 Nm; AE = 12.23 +/- 2.44 Nm). Local erector spinae vibration induced a significant reduction in CE (4.33 +/- 2.14 Nm) and AE (13.71 +/- 3.45 Nm) mean scores in the patient group. Healthy participants conversely showed a significant increase in CE (8.17 +/- 2.10 Nm) and AE (16.29 +/- 2.82 Nm) mean scores under vibration conditions. The fatigue protocol induced erector spinae muscle fatigue as illustrated by a significant decrease in sEMG median time-frequency slopes. Following the fatigue protocol, patients with cLBP showed significant decrease in sEMG root mean square activity at L4-5 level and responded in similar manner with and without vibration stimulation in regard to CE mean scores. Conclusions Patients with cLBP have a less accurate force reproduction sense than healthy participants. Local muscle vibration led to significant trunk neuromuscular control improvements in the cLBP patients before and after a muscle fatigue protocol. Muscle vibration stimulation during motor control exercises is likely to influence motor adaptation and could be considered in the treatment of cLBP. Further work is needed to clearly identify at what levels of the sensorimotor system these gains are achievable.	[Boucher, Jean-Alexandre] Univ Quebec Trois Rivieres, Dept Psychol, Trois Rivieres, PQ GA9 5H7, Canada; [Abboud, Jacques] Univ Quebec Trois Rivieres, Dept Anat, Trois Rivieres, PQ GA9 5H7, Canada; [Nougarou, Francois; Descarreaux, Martin] Univ Quebec Trois Rivieres, Dept Sci Act Phys, Trois Rivieres, PQ GA9 5H7, Canada; [Normand, Martin C.] Univ Quebec Trois Rivieres, Dept Chiroprat, Trois Rivieres, PQ GA9 5H7, Canada	University of Quebec; University of Quebec Trois Rivieres; University of Quebec; University of Quebec Trois Rivieres; University of Quebec; University of Quebec Trois Rivieres; University of Quebec; University of Quebec Trois Rivieres	Boucher, JA (corresponding author), Univ Quebec Trois Rivieres, Dept Psychol, Trois Rivieres, PQ GA9 5H7, Canada.	charljea@uqtr.ca		Descarreaux, Martin/0000-0002-3545-5860				Anonymous, 2008, Annales de Readaptation et de Medecine Physique, V51, P379, DOI 10.1016/j.annrmp.2008.03.006; BIERINGSORENSEN F, 1984, SPINE, V9, P106, DOI 10.1097/00007632-198403000-00002; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Bosco C, 1999, EUR J APPL PHYSIOL O, V79, P306, DOI 10.1007/s004210050512; Boucher JA, 2015, J MANIP PHYSIOL THER, V38, P35, DOI 10.1016/j.jmpt.2014.10.013; Boucher JA, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-89; Boucher JA, 2012, J MANIP PHYSIOL THER, V35, P662, DOI 10.1016/j.jmpt.2012.10.003; Brumagne S, 1999, SPINE, V24, P1328, DOI 10.1097/00007632-199907010-00010; Brumagne S, 2004, NEUROSCI LETT, V366, P63, DOI 10.1016/j.neulet.2004.05.013; Brumagne S, 2000, SPINE, V25, P989, DOI 10.1097/00007632-200004150-00015; Brumagne S, 2008, EUR SPINE J, V17, P1177, DOI 10.1007/s00586-008-0709-7; BURKE D, 1976, J PHYSIOL-LONDON, V261, P695, DOI 10.1113/jphysiol.1976.sp011581; BURKE D, 1976, J PHYSIOL-LONDON, V261, P673, DOI 10.1113/jphysiol.1976.sp011580; CARLSSON AM, 1983, PAIN, V16, P87, DOI 10.1016/0304-3959(83)90088-X; CORDO P, 1995, J NEUROPHYSIOL, V74, P1675, DOI 10.1152/jn.1995.74.4.1675; Demoulin C, 2006, JOINT BONE SPINE, V73, P43, DOI 10.1016/j.jbspin.2004.08.002; Dingwell JB, 2008, IEEE T BIO-MED ENG, V55, P2666, DOI 10.1109/TBME.2008.2001130; Enthoven P, 2003, J REHABIL MED, V35, P168, DOI 10.1080/16501970310013517; Flor H, 1997, NEUROSCI LETT, V224, P5, DOI 10.1016/S0304-3940(97)13441-3; Gandevia SC, 1998, ACTA PHYSIOL SCAND, V162, P275, DOI 10.1046/j.1365-201X.1998.0299f.x; Gill KP, 1998, SPINE, V23, P371, DOI 10.1097/00007632-199802010-00017; GOODWIN GM, 1972, BRAIN, V95, P705, DOI 10.1093/brain/95.4.705; Granata KP, 2008, ERGONOMICS, V51, P1258, DOI 10.1080/00140130802030722; Griffin L, 2001, J PHYSIOL-LONDON, V535, P929, DOI 10.1111/j.1469-7793.2001.00929.x; Hodges P, 2009, J BIOMECH, V42, P61, DOI 10.1016/j.jbiomech.2008.10.001; Hodges PW, 2011, J ELECTROMYOGR KINES, V21, P220, DOI 10.1016/j.jelekin.2011.01.002; Hollins M, 2003, J PAIN, V4, P381, DOI 10.1016/S1526-5900(03)00714-4; INGLIS JT, 1991, EXP BRAIN RES, V84, P631; Johanson E, 2011, EUR SPINE J, V20, P2152, DOI 10.1007/s00586-011-1825-3; KAKIGI R, 1992, J NEUROL NEUROSUR PS, V55, P282, DOI 10.1136/jnnp.55.4.282; Kori S.H., 1990, PAIN MANAG, V3, P35; Lariviere C, 2002, J ELECTROMYOGR KINES, V12, P91, DOI 10.1016/S1050-6411(02)00011-1; Lariviere C, 2011, MED SCI SPORT EXER, V43, P157, DOI 10.1249/MSS.0b013e3181e96388; MACEFIELD G, 1991, J PHYSIOL-LONDON, V440, P497, DOI 10.1113/jphysiol.1991.sp018721; Mannion AF, 1999, J ELECTROMYOGR KINES, V9, P363, DOI 10.1016/S1050-6411(99)00010-3; McCaffery M, 1999, PAIN CLIN MANUAL; Merletti R., 2004, ELECTROMYOGRAPHY; Mischi M, 2009, MED SCI SPORT EXER, V41, P645, DOI 10.1249/MSS.0b013e31818a8a69; Myers JB, 2006, MANUAL THER, V11, P197, DOI 10.1016/j.math.2006.04.002; Nakajima T, 2009, EXP BRAIN RES, V192, P211, DOI 10.1007/s00221-008-1571-x; Newcomer KL, 2000, SPINE, V25, P2488, DOI 10.1097/00007632-200010010-00011; PANJABI MM, 1992, J SPINAL DISORD, V5, P390, DOI 10.1097/00002517-199212000-00002; PARNIANPOUR M, 1988, SPINE, V13, P982, DOI 10.1097/00007632-198809000-00004; Passatore M, 2006, EUR J APPL PHYSIOL, V98, P423, DOI 10.1007/s00421-006-0312-8; ROLL JP, 1982, EXP BRAIN RES, V47, P177; Salvetti MD, 2013, REV LAT-AM ENFERM, V21, P12; Schmidt RA, 2005, MOTOR CONTROL LEARNI, P125; Schmidt RA, 2001, MOTOR LEARNING PERFO, P175; Scrimshaw SV, 2001, J MANIP PHYSIOL THER, V24, P501, DOI 10.1067/mmt.2001.118208; Sharma Leena, 1997, Current Opinion in Rheumatology, V9, P253, DOI 10.1097/00002281-199705000-00013; Sparto PJ, 1997, J SPINAL DISORD, V10, P145; Taimela S, 1999, SPINE, V24, P1322, DOI 10.1097/00007632-199907010-00009; van Dieen JH, 2003, J ELECTROMYOGR KINES, V13, P333, DOI 10.1016/S1050-6411(03)00041-5; VLAEYEN JWS, 1995, PAIN, V62, P363, DOI 10.1016/0304-3959(94)00279-N; VONKORFF M, 1994, SPINE, V19, pS2041; Willigenburg NW, 2013, HUM MOVEMENT SCI, V32, P228, DOI 10.1016/j.humov.2012.12.007	56	13	19	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2015	10	8							e0135838	10.1371/journal.pone.0135838	http://dx.doi.org/10.1371/journal.pone.0135838			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP7LO	26308725	Green Published, gold			2023-01-03	WOS:000360069400078
J	Tung-Thompson, G; Libera, DA; Koch, KL; de los Reyes, FL; Jaykus, LA				Tung-Thompson, Grace; Libera, Dominic A.; Koch, Kenneth L.; de los Reyes, Francis L., III; Jaykus, Lee-Ann			Aerosolization of a Human Norovirus Surrogate, Bacteriophage MS2, during Simulated Vomiting	PLOS ONE			English	Article							NORWALK VIRUS; AIRBORNE TRANSMISSION; ARTIFICIAL SALIVA; ENTERIC VIRUSES; UNITED-STATES; GASTROENTERITIS; CONTAMINATION; ENVIRONMENT; INFECTION; OUTBREAKS	Human noroviruses (NoV) are the leading cause of acute gastroenteritis worldwide. Epidemiological studies of outbreaks have suggested that vomiting facilitates transmission of human NoV, but there have been no laboratory-based studies characterizing the degree of NoV release during a vomiting event. The purpose of this work was to demonstrate that virus aerosolization occurs in a simulated vomiting event, and to estimate the amount of virus that is released in those aerosols. A simulated vomiting device was constructed at one-quarter scale of the human body following similitude principles. Simulated vomitus matrices at low (6.24 mPa*s) and high (177.5 mPa*s) viscosities were inoculated with low (10(8) PFU/mL) and high (10(10) PFU/mL) concentrations of bacteriophage MS2 and placed in the artificial "stomach" of the device, which was then subjected to scaled physiologically relevant pressures associated with vomiting. Bio aerosols were captured using an SKC Biosampler. In low viscosity artificial vomitus, there were notable differences between recovered aerosolized MS2 as a function of pressure (i.e., greater aerosolization with increased pressure), although this was not always statistically significant. This relationship disappeared when using high viscosity simulated vomitus. The amount of MS2 aerosolized as a percent of total virus "vomited" ranged from 7.2 x 10(-5) to 2.67 x 10(-2) (which corresponded to a range of 36 to 13,350 PFU total). To our knowledge, this is the first study to document and measure aerosolization of a NoV surrogate in a similitude-based physical model. This has implications for better understanding the transmission dynamics of human NoV and for risk modeling purposes, both of which can help in designing effective infection control measures.	[Tung-Thompson, Grace; Jaykus, Lee-Ann] N Carolina State Univ, Dept Food Bioproc & Nutr Sci, Raleigh, NC 27695 USA; [Libera, Dominic A.; de los Reyes, Francis L., III] N Carolina State Univ, Dept Civil Construct & Environm Engn, Raleigh, NC 27695 USA; [Koch, Kenneth L.] Wake Forest Univ, Bowman Gray Sch Med, Gastroenterol Sect, Winston Salem, NC 27157 USA	University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University; Wake Forest University; Wake Forest Baptist Medical Center	de los Reyes, FL (corresponding author), N Carolina State Univ, Dept Civil Construct & Environm Engn, Raleigh, NC 27695 USA.	fldelosr@ncsu.edu	de los Reyes, Francis/AAL-7909-2020; de los Reyes, Francis/E-6780-2011	de los Reyes, Francis/0000-0002-3593-0932; de los Reyes, Francis/0000-0002-3593-0932	USDA-CSREES National Integrated Food Safety Initiative (NIFSI) project [2011-51110-31020]; Agriculture and Food Research Initiative Competitive Grant from the USDA National Institute of Food and Agriculture [2011-68003-30395]	USDA-CSREES National Integrated Food Safety Initiative (NIFSI) project; Agriculture and Food Research Initiative Competitive Grant from the USDA National Institute of Food and Agriculture	This project was supported by the USDA-CSREES National Integrated Food Safety Initiative (NIFSI) project #2011-51110-31020 (http://www.nifa.usda.gov/nea/food/in_focus/safety_if_national.html). Partial support was also provided by Agriculture and Food Research Initiative Competitive Grant no. 2011-68003-30395 from the USDA National Institute of Food and Agriculture (http://www.nifa.usda.gov/funding/rfas/afri.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of this manuscript.	Atmar RL, 2008, EMERG INFECT DIS, V14, P1553, DOI 10.3201/eid1410.080117; Atmar RL, 2014, J INFECT DIS, V209, P1016, DOI 10.1093/infdis/jit620; Badman L, 2001, WATER MATTERS PROPOS, P43; Beggs CB, 2003, INDOOR BUILT ENVIRON, V12, P9, DOI 10.1177/1420326X03012001002; Beggs CB, 2000, INDOOR BUILT ENVIRON, V9, P241, DOI 10.1159/000057517; Bonifait L, 2015, CLIN INFECT DIS, V61, P299, DOI 10.1093/cid/civ321; CAUL EO, 1994, LANCET, V343, P1240, DOI 10.1016/S0140-6736(94)92146-6; Cheesbrough JS, 2000, EPIDEMIOL INFECT, V125, P93, DOI 10.1017/S095026889900432X; Dawson DJ, 2005, J APPL MICROBIOL, V98, P203, DOI 10.1111/j.1365-2672.2004.02439.x; Dijkstra PU, 1999, J ORAL REHABILITATIO; Eames I, 2009, J R SOC INTERFACE, V6, pS697, DOI 10.1098/rsif.2009.0407.focus; Fabian P, 2009, INDOOR AIR, V19, P433, DOI 10.1111/j.1600-0668.2009.00609.x; Fox R.W., 2004, INTRO FLUID MECH; Gallimore CI, 2008, J CLIN MICROBIOL, V46, P3112, DOI 10.1128/JCM.00400-08; Gralton J, 2011, J INFECTION, V62, P1, DOI 10.1016/j.jinf.2010.11.010; GREENBERG HB, 1979, LANCET, V1, P55; Hall AJ, 2013, EMERG INFECT DIS, V19, P1305, DOI 10.3201/eid1908.130482; Harris JP, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003060; Hogan CJ, 2005, J APPL MICROBIOL, V99, P1422, DOI 10.1111/j.1365-2672.2005.02720.x; Iqbal A, 2008, SURG ENDOSC, V22, P2571, DOI 10.1007/s00464-008-0080-0; Isakbaeva ET, 2005, EMERG INFECT DIS, V11, P154, DOI 10.3201/eid1101.040434; Koch KL, 2006, THERAPY DIGESTIVE DI, P1003; Kotwal G, 2014, CURR OPIN VIROL, V4, P37, DOI 10.1016/j.coviro.2013.12.003; Kuo Braden, 2006, GI MOTILITY ONLINE, DOI DOI 10.1038/GIMO6; Leith DE, 1986, INDOOR AIR, DOI [10.1002/cphy.cp030320.31, DOI 10.1002/CPHY.CP030320.31]; Lindsley WG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015100; Lopman B, 2012, CURR OPIN VIROL, V2, P96, DOI 10.1016/j.coviro.2011.11.005; MAILLARD JY, 1994, APPL ENVIRON MICROB, V60, P2205, DOI 10.1128/AEM.60.6.2205-2206.1994; Makison Booth Catherine, 2014, J Infect Prev, V15, P176, DOI 10.1177/1757177414545390; Marks PJ, 2000, EPIDEMIOL INFECT, V124, P481, DOI 10.1017/S0950268899003805; Nazaroff WW, 2011, INDOOR AIR, V21, P353, DOI 10.1111/j.1600-0668.2011.00735.x; Papineni R S, 1997, J Aerosol Med, V10, P105, DOI 10.1089/jam.1997.10.105; Sarkar A, 2009, FOOD HYDROCOLLOID, V23, P1270, DOI 10.1016/j.foodhyd.2008.09.008; Scallan E, 2011, EMERG INFECT DIS, V17, P7, DOI 10.3201/eid1701.P11101; Su XW, 2011, APPL ENVIRON MICROB, V77, P3982, DOI 10.1128/AEM.00193-11; Teunis PFM, 2008, J MED VIROL, V80, P1468, DOI 10.1002/jmv.21237; Todd ECD, 2008, J FOOD PROTECT, V71, P2582, DOI 10.4315/0362-028X-71.12.2582; Tseng CC, 2005, J AEROSOL SCI, V36, P593, DOI 10.1016/j.jaerosci.2004.12.004; Turgeon N, 2014, APPL ENVIRON MICROB, V80, P4242, DOI 10.1128/AEM.00767-14; Utrup LJ, 2004, EXP BIOL MED, V229, P345, DOI 10.1177/153537020422900409; Verreault D, 2008, MICROBIOL MOL BIOL R, V72, P413, DOI 10.1128/MMBR.00002-08; Zuo ZL, 2014, APPL ENVIRON MICROB, V80, P2796, DOI 10.1128/AEM.00056-14	42	33	33	3	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 19	2015	10	8							e0134277	10.1371/journal.pone.0134277	http://dx.doi.org/10.1371/journal.pone.0134277			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP6SN	26287612	Green Submitted, Green Published, gold			2023-01-03	WOS:000360018600018
J	Tumlin, JA; Galphin, CM; Tolwani, AJ; Chan, MR; Vijayan, A; Finkel, K; Szamosfalvi, B; Dev, D; DaSilva, JR; Astor, BC; Yevzlin, AS; Humes, HD				Tumlin, James A.; Galphin, Claude M.; Tolwani, Ashita J.; Chan, Micah R.; Vijayan, Anitha; Finkel, Kevin; Szamosfalvi, Balazs; Dev, Devasmita; DaSilva, J. Ricardo; Astor, Brad C.; Yevzlin, Alexander S.; Humes, H. David		SCD Investigator Grp	A Multi-Center, Randomized, Controlled, Pivotal Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device in Patients with Acute Kidney Injury	PLOS ONE			English	Article							ACUTE-RENAL-FAILURE; INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; DYSFUNCTION; PROGNOSIS; OUTCOMES; CELLS	Objective Acute kidney injury (AKI) is a highly morbid condition in critically ill patients that is associated with high mortality. Previous clinical studies have demonstrated the safety and efficacy of the Selective Cytopheretic Device (SCD) in the treatment of AKI requiring continuous renal replacement therapy in the intensive care unit (ICU). Design, Setting, Patients A randomized, controlled trial of 134 ICU patients with AKI, 69 received continuous renal replacement therapy (CRRT) alone and 65 received SCD therapy. Results No significant difference in 60-day mortality was observed between the treated (27/69; 39%) and control patients (21/59; 36%, with six patients lost to follow up) in the intention to treat (ITT) analysis. Of the 19 SCD subjects (CRRT+SCD) and 31 control subjects (CRRT alone) who maintained a post-filter ionized calcium (iCa) level in the protocol's recommended range (<= 0.4mmol/L) for greater or equal to 90% of the therapy time, 60-day mortality was 16%(3/19) in the SCD group compared to 41%(11/27) in the CRRT alone group (p = 0.11). Dialysis dependency showed a borderline statistically significant difference between the SCD treated versus control CRRT alone patients maintained for >= 90% of the treatment in the protocol's recommended (r) iCa target range of <= 0.4 mmol/ L with values of, 0% (0/16) and 25%(4/16), respectively (P = 0.10). When the riCa treated and control subgroups were compared for a composite index of 60 day mortality and dialysis dependency, the percentage of SCD treated subjects was 16% versus 58% in the control subjects (p<0.01). The incidence of serious adverse events did not differ between the treated (45/69; 65%) and control groups (40/65; 63%; p = 0.86). Conclusion SCD therapy may improve mortality and reduce dialysis dependency in a tightly controlled regional hypocalcaemic environment in the perfusion circuit.	[Tumlin, James A.; Galphin, Claude M.] Univ Tennessee, Dept Med, UT Coll Med, Chattanooga, TN 37403 USA; [Tolwani, Ashita J.] Univ Alabama Birmingham, UAB Sch Med, Dept Med, Birmingham, AL 35294 USA; [Chan, Micah R.; Astor, Brad C.; Yevzlin, Alexander S.] Univ Wisconsin, Dept Med, UW Med Fndtn, Madison, WI 53705 USA; [Vijayan, Anitha] Washington Univ, Sch Med, St Louis, MO 63110 USA; [Finkel, Kevin] Univ Texas Houston, UT Hlth Sci Ctr, Houston, TX 77030 USA; [Szamosfalvi, Balazs] Henry Ford Hosp, Henry Ford Hlth Syst, Detroit, MI 48202 USA; [Dev, Devasmita] Dallas VA Med Ctr, Dallas, TX 75216 USA; [DaSilva, J. Ricardo; Yevzlin, Alexander S.; Humes, H. David] CytoPherx Inc, Ann Arbor, MI 48108 USA; [Astor, Brad C.] Univ Wisconsin, Dept Populat Hlth Sci, Hlth Sci Learning Ctr, Madison, WI 53705 USA; [Humes, H. David] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Alabama System; University of Alabama Birmingham; University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL); University of Texas System; University of Texas Health Science Center Houston; Henry Ford Health System; Henry Ford Hospital; University of Wisconsin System; University of Wisconsin Madison; University of Michigan System; University of Michigan	Humes, HD (corresponding author), CytoPherx Inc, 401 W Morgan Rd, Ann Arbor, MI 48108 USA.	dhumes@cytopherx.com		Humes, David/0000-0002-4309-1614	CytoPherx, Inc.	CytoPherx, Inc.	The study was funded by CytoPherx, Inc. The funder provided support in the form of salaries and stock options for authors DaSilva JR, Yevzlin AS, and Humes HD. The specific roles of these authors are articulated in the 'author contributions' section. The funders had no role in the decision to publish or preparation of the manuscript, except for the financial support of some of the authors and provision of research materials. The study design was developed by the company, and the data was collected and analyzed by an independent clinical research organization and an independent statistical consultant. The data has been reviewed by a Data Safely Monitoring Board and by the FDA.	Ayub K, 2004, IMMUNOLOGY, V111, P8, DOI 10.1111/j.1365-2567.2004.01766.x; Bagshaw SM, 2005, CRIT CARE, V9, pR700, DOI 10.1186/cc3879; Ding F, 2011, ASAIO J, V57, P426, DOI 10.1097/MAT.0b013e31820a1494; Ding F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018584; Himmelfarb J, 2004, J AM SOC NEPHROL, V15, P2449, DOI 10.1097/01.ASN.0000138232.68452.3B; Jang HR, 2009, CLIN IMMUNOL, V130, P41, DOI 10.1016/j.clim.2008.08.016; Kaneider NC, 2006, FEBS J, V273, P4416, DOI 10.1111/j.1742-4658.2006.05441.x; Kinsey GR, 2008, NEPHRON EXP NEPHROL, V109, pE102, DOI 10.1159/000142934; Kinsey GR, 2014, CURR OPIN NEPHROL HY, V23, P9, DOI 10.1097/01.mnh.0000436695.29173.de; Liano F, 1998, KIDNEY INT, V53, pS16; Maroszynska I, 2000, Ann Transplant, V5, P5; Marshall JC, 2005, CRIT CARE MED, V33, pS502, DOI 10.1097/01.CCM.0000186266.34541.5F; McCarthy JT, 1996, MAYO CLIN PROC, V71, P117, DOI 10.4065/71.2.117; Metnitz PGH, 2002, CRIT CARE MED, V30, P2051, DOI 10.1097/00003246-200209000-00016; Molitoris BA, 2004, KIDNEY INT, V66, P496, DOI 10.1111/j.1523-1755.2004.761_5.x; Mutunga M, 2001, AM J RESP CRIT CARE, V163, P195, DOI 10.1164/ajrccm.163.1.9912036; Pino CJ, 2013, NEPHROL DIAL TRANSPL, V28, P296, DOI 10.1093/ndt/gfs503; Pino CJ, 2012, BLOOD PURIFICAT, V34, P117, DOI 10.1159/000341649; Sharfuddin AA, 2011, NAT REV NEPHROL, V7, P189, DOI 10.1038/nrneph.2011.16; Simmons EM, 2004, KIDNEY INT, V65, P1357, DOI 10.1111/j.1523-1755.2004.00512.x; Star RA, 1998, KIDNEY INT, V54, P1817, DOI 10.1046/j.1523-1755.1998.00210.x; Tumlin JA, 2013, SEMIN DIALYSIS, V26, P616, DOI 10.1111/sdi.12032; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813; Ward NS, 2008, CLIN CHEST MED, V29, P617, DOI 10.1016/j.ccm.2008.06.010; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806	25	28	31	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2015	10	8							e0132482	10.1371/journal.pone.0132482	http://dx.doi.org/10.1371/journal.pone.0132482			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO3MH	26244978	Green Submitted, Green Published, gold			2023-01-03	WOS:000359061400023
J	Hu, QY; Yang, CX; Wang, Q; Zeng, HY; Qin, WZ				Hu, Qiongyi; Yang, Chunxin; Wang, Qiang; Zeng, Haiying; Qin, Wanzhang			Demethylzeylasteral (T-96) Treatment Ameliorates Mice Lupus Nephritis Accompanied by Inhibiting Activation of NF-kappa B Pathway	PLOS ONE			English	Article							WILFORDII HOOK-F; DNA ANTIBODIES; RHEUMATOID-ARTHRITIS; NLRP3 INFLAMMASOME; RENAL MACROPHAGES; MURINE; DISEASE; MECHANISMS; TRIPTOLIDE; RESPONSES	Background Inflammation plays a vital role in the pathogenesis in lupus nephritis (LN), which is largely attributable to the activation of nuclear factor kappa B (NF-kappa B) signal pathway. NF-kappa B upregulates pro-inflammatory mediators, such as TNF-alpha, cyclo-oxygenase-2 (COX-2) and ICAM-1, and promotes macrophage infiltration into renal tissue, further inducing the progression of LN. Over the past 30 years, research has demonstrated that Tripterygium wilfordii Hook F (TWHF) possesses potent anti-inflammatory and immunosuppressive activities, and that demethylzeylasteral (T-96), an extract of TWHF, may be one of the responsible compounds. Here, we investigate the pharmacodynamic role and therapeutic mechanism by which T-96 suppresses inflammation and reduces renal pathology in the lupus-prone MRL/lpr mice. Methods Forty-eight MRL/lpr mice were equally randomly divided into 6 groups (1.2, 0.6 or 0.3 mg/10g T-96, 0.022 pills/10g kang lang chuang san (one of Traditional Chinese herb as positive control), 0.125 mg/10g prednisone and 0.1 ml/10g normal saline as the LN disease control group). Also, eight WT C57BL/6 mice were used as normal control. After treatment by gavage with 0.10 ml/10g/day volumes for 8 weeks, all mice were sacrificed and renal tissues were collected. The amount of 24 h proteinuria and the levels of anti-dsDNA antibody in serum were assessed respectively at weeks 0, 4 and 8. Inflammation, cytokines and NF-kappa B levels were assessed by histological examinations, immunohistochemical analyses and Western blot analyses. Results In comparison with untreated MRL/lpr mice, mice treated with 1.2 and 0.6 mg/10g of T-96 showed a significant improvement in 24 h proteinuria and the levels of anti-dsDNA antibody in serum. In addition, T-96 reduced the secretion of pro-inflammatory mediators such as TNF-alpha, COX-2 and ICAM-1, and the infiltration of macrophages in renal tissue. Moreover, T-96 significantly suppressed phosphorylations of cytoplasmic IKK and nuclear p65. Conclusion This study suggests that T-96 exhibits reno-protective effects in LN accompanied by inhibiting the activation of NF-kappa B, reducing the downstream pro-inflammatory mediators and thus restricting macrophage infiltration. Because of these potent properties, T-96 should be considered as a promising therapeutic drug for LN.	[Hu, Qiongyi; Wang, Qiang; Qin, Wanzhang] Fudan Univ, Zhongshan Hosp, Dept Dermatol, Shanghai 200032, Peoples R China; [Yang, Chunxin] Fudan Univ, Zhongshan Hosp, Dept Pharmaceut Chem, Shanghai 200032, Peoples R China; [Zeng, Haiying] Fudan Univ, Zhongshan Hosp, Dept Pathol, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University	Yang, CX (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Pharmaceut Chem, 180 Fenglin Rd, Shanghai 200032, Peoples R China.	yang.chunxin@zs-hospital.sh.cn; wang.qiang@zs-hospital.sh.cn	Hu, Anna/AAD-3585-2019					Abd-Elkareem MI, 2010, CLIN EXP NEPHROL, V14, P548, DOI 10.1007/s10157-010-0322-z; Berthier CC, 2012, J IMMUNOL, V189, P988, DOI 10.4049/jimmunol.1103031; Bethunaickan R, 2012, ARTHRITIS RHEUM-US, V64, P3399, DOI 10.1002/art.34553; Bethunaickan R, 2011, J IMMUNOL, V186, P4994, DOI 10.4049/jimmunol.1003010; Brinker AM, 2007, PHYTOCHEMISTRY, V68, P732, DOI 10.1016/j.phytochem.2006.11.029; Cai YX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062465; Davidson A, 2006, CURR OPIN RHEUMATOL, V18, P468; EHRENSTEIN MR, 1995, KIDNEY INT, V48, P705, DOI 10.1038/ki.1995.341; Ghosh S, 2012, IMMUNOL REV, V246, P5, DOI 10.1111/j.1600-065X.2012.01111.x; Goldbach-Mansky R, 2009, ANN INTERN MED, V151, P229, DOI 10.7326/0003-4819-151-4-200908180-00005; Han R, 2012, BRIT J CLIN PHARMACO, V74, P424, DOI 10.1111/j.1365-2125.2012.04221.x; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Ho LJ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-294; Holdsworth SR, 2007, SEMIN IMMUNOPATHOL, V29, P355, DOI 10.1007/s00281-007-0097-9; Isenberg DA, 2007, RHEUMATOLOGY, V46, P1052, DOI 10.1093/rheumatology/kem112; Ji W, 2010, CLIN RHEUMATOL, V29, P1067, DOI 10.1007/s10067-010-1497-0; Jiang T, 2014, KIDNEY INT, V85, P333, DOI 10.1038/ki.2013.343; Kalergis AM, 2009, IMMUNOLOGY, V128, pe306, DOI 10.1111/j.1365-2567.2008.02964.x; Kang HK, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2682; Lee SW, 2012, RHEUMATOLOGY, V51, P2131, DOI 10.1093/rheumatology/kes227; Liu HN, 2011, RHEUMATOL INT, V31, P1459, DOI 10.1007/s00296-010-1499-x; Liu YC, 2014, INT J BIOL SCI, V10, P520, DOI 10.7150/ijbs.8879; Manson JJ, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-6; Menke J, 2009, J AM SOC NEPHROL, V20, P2581, DOI 10.1681/ASN.2009050499; Mok CC, 2013, ARTHRITIS RHEUM-US, V65, P2154, DOI 10.1002/art.38006; Neumann I, 2005, NEPHROL DIAL TRANSPL, V20, P96, DOI 10.1093/ndt/gfh563; Okamoto A, 2008, J IMMUNOL, V181, P5264, DOI 10.4049/jimmunol.181.8.5264; OKAMURA M, 1993, ANN RHEUM DIS, V52, P14, DOI 10.1136/ard.52.1.14; Parameswaran N, 2010, CRIT REV EUKAR GENE, V20, P87, DOI 10.1615/CritRevEukarGeneExpr.v20.i2.10; Rahman A, 2008, NEW ENGL J MED, V358, P929, DOI 10.1056/NEJMra071297; RAZ E, 1989, J IMMUNOL, V142, P3076; Sahu R, 2014, ARTHRITIS RHEUMATOL, V66, P1596, DOI 10.1002/art.38410; Schiffer L, 2008, J IMMUNOL, V180, P1938, DOI 10.4049/jimmunol.180.3.1938; Shi X, 1989, MED LAB ANIMAL SCI; Tao XL, 2002, ARTHRITIS RHEUM, V46, P1735, DOI 10.1002/art.10411; Tao X, 2008, ARTHRITIS RHEUM-US, V58, P1774, DOI 10.1002/art.23513; Triantafyllopoulou A, 2010, P NATL ACAD SCI USA, V107, P3012, DOI 10.1073/pnas.0914902107; Tsai PY, 2011, FREE RADICAL BIO MED, V51, P744, DOI 10.1016/j.freeradbiomed.2011.05.016; Wong ET, 2009, CLIN SCI, V116, P451, DOI 10.1042/CS20080502; Xu WP, 2009, INT IMMUNOPHARMACOL, V9, P996, DOI 10.1016/j.intimp.2009.04.007; Yung S, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/317682; Zhang L, 2011, LUPUS, V20, P667, DOI 10.1177/0961203310393262; Zhang L, 2007, ARTHRITIS RHEUM-US, V56, P4132, DOI 10.1002/art.23054; Zhang L, 2015, LAB INVEST, V95, P65, DOI 10.1038/labinvest.2014.135; Zhao JJ, 2013, INT IMMUNOPHARMACOL, V17, P116, DOI 10.1016/j.intimp.2013.05.027; Zheng L, 2006, VIRCHOWS ARCH, V448, P172, DOI 10.1007/s00428-005-0061-9; Zheng L, 2008, J HISTOCHEM CYTOCHEM, V56, P517, DOI 10.1369/jhc.7A7368.2008; Zhou ZL, 2012, NAT PROD REP, V29, P457, DOI 10.1039/c2np00088a; Zhu JK, 2005, J CLIN INVEST, V115, P1869, DOI 10.1172/JCI23049	49	30	37	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2015	10	7							e0133724	10.1371/journal.pone.0133724	http://dx.doi.org/10.1371/journal.pone.0133724			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN7NT	26208003	Green Published, gold, Green Submitted			2023-01-03	WOS:000358622000123
J	Fekete, T				Fekete, Thomas			Clindamycin did not differ from trimethoprim-sulfamethoxazole for curing uncomplicated skin infections	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Temple Univ, Sch Med, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Fekete, T (corresponding author), Temple Univ, Sch Med, Philadelphia, PA 19122 USA.		Fekete, Thomas/AFI-5367-2022						0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 21	2015	163	2							JC9	10.7326/ACPJC-2015-163-2-009	http://dx.doi.org/10.7326/ACPJC-2015-163-2-009			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CN4NS	26192589				2023-01-03	WOS:000358407500009
J	Imamaki, H; Ishii, A; Yokoi, H; Kasahara, M; Kuwabara, T; Mori, KP; Kato, Y; Kuwahara, T; Satoh, M; Nakatani, K; Saito, Y; Tomosugi, N; Sugawara, A; Nakao, K; Mukoyama, M; Yanagita, M; Mori, K				Imamaki, Hirotaka; Ishii, Akira; Yokoi, Hideki; Kasahara, Masato; Kuwabara, Takashige; Mori, Keita P.; Kato, Yukiko; Kuwahara, Takashi; Satoh, Masugi; Nakatani, Kimihiko; Saito, Yoshihiko; Tomosugi, Naohisa; Sugawara, Akira; Nakao, Kazuwa; Mukoyama, Masashi; Yanagita, Motoko; Mori, Kiyoshi			Low Serum Neutrophil Gelatinase-associated Lipocalin Level as a Marker of Malnutrition in Maintenance Hemodialysis Patients	PLOS ONE			English	Article							ACUTE KIDNEY INJURY; ADULT CARDIAC-SURGERY; INSULIN-RESISTANCE; DIALYSIS PATIENTS; RENAL-FAILURE; REAL-TIME; IRON; NGAL; INFLAMMATION; RISK	Background Neutrophil gelatinase-associated lipocalin (NGAL or LCN2) is an iron-transporting factor which possesses various activities such as amelioration of kidney injury and host defense against pathogens. Its circulating concentrations are elevated in acute and chronic kidney diseases and show a positive correlation with poor renal outcome and mortality, but its clinical significance in maintenance hemodialysis (HD) patients remains elusive. Methods Serum NGAL levels were determined by enzyme-linked immunosorbent assay in outpatient, Japanese HD subjects. Their correlation to laboratory findings and morbidity (as development of severe infection or serum albumin reduction) was investigated using linear regression analysis and chi(2) test. Results Pre-dialysis serum NGAL levels in HD patients were elevated by 13-fold compared to healthy subjects (n=8, P<0.001). In a cross-sectional study of 139 cases, serum NGAL concentrations were determined independently by % creatinine generation rate (an indicator of muscle mass, standardized coefficient beta=0.40, P<0.001), peripheral blood neutrophil count (beta=0.38, P<0.001) and anion gap (which likely reflects dietary protein intake, beta=0.16, P<0.05). Iron administration to anemic HD patients caused marked elevation of peripheral blood hemoglobin, serum ferritin and iron-regulatory hormone hepcidin-25 levels, but NGAL levels were not affected. In a prospective study of 87 cases, increase in serum albumin levels a year later was positively associated to baseline NGAL levels by univariate analysis (r=0.36, P<0.01). Furthermore, within a year, patients with the lowest NGAL tertile showed significantly increased risk for marked decline in serum albumin levels (>= 0.4 g/dl; odds ratio 5.5, 95% confidence interval 1.5-20.3, P<0.05) and tendency of increased occurrence of severe infection requiring admission (odds ratio 3.1, not significant) compared to the middle and highest tertiles. Conclusion Low serum NGAL levels appear to be associated with current malnutrition and also its progressive worsening in maintenance HD patients.	[Imamaki, Hirotaka; Ishii, Akira; Yokoi, Hideki; Kuwabara, Takashige; Mori, Keita P.; Kato, Yukiko; Mukoyama, Masashi; Yanagita, Motoko] Kyoto Univ, Grad Sch Med, Dept Nephrol, Kyoto, Japan; [Kasahara, Masato] Kyoto Univ Hosp, Inst Adv Clin & Translat Sci, Kyoto 606, Japan; [Kuwahara, Takashi] Saiseikai Ibaraki Hosp, Dept Nephrol, Osaka, Japan; [Satoh, Masugi] Misugikai Satou Hosp, Osaka, Japan; [Nakatani, Kimihiko; Saito, Yoshihiko] Nara Med Univ, Dept Internal Med 1, Nara, Japan; [Tomosugi, Naohisa] Kanazawa Med Univ, Med Res Inst, Div Adv Med, Kanazawa, Ishikawa, Japan; [Sugawara, Akira] Osaka Red Cross Hosp, Dept Nephrol, Osaka, Japan; [Nakao, Kazuwa] Kyoto Univ, TK Project, Med Innovat Ctr, Grad Sch Med, Kyoto, Japan; [Kuwabara, Takashige; Mukoyama, Masashi] Kumamoto Univ, Grad Sch Med Sci, Dept Nephrol, Kumamoto, Japan; [Yanagita, Motoko; Mori, Kiyoshi] Kyoto Univ, TMK Project, Med Innovat Ctr, Grad Sch Med, Kyoto, Japan	Kyoto University; Kyoto University; Nara Medical University; Kanazawa Medical University; Osaka Red Cross Hospital; Kyoto University; Kumamoto University; Kyoto University	Mori, K (corresponding author), Kyoto Univ, TMK Project, Med Innovat Ctr, Grad Sch Med, Kyoto, Japan.	mori@tmk.med.kyoto-u.ac.jp	Yokoi, Hideki/R-1289-2016; Yokoi, Hideki/AAV-9038-2021; Mori, Kiyoshi/N-1267-2014; Yanagita, Motoko/AAJ-7731-2021	Yokoi, Hideki/0000-0001-8343-9737; Yokoi, Hideki/0000-0001-8343-9737; Mori, Kiyoshi/0000-0002-7285-8351; Kuwabara, Takashige/0000-0003-3507-4328; Yanagita, Motoko/0000-0002-0339-9008	JSPS KAKENHI [23390225, 26461224]; Ministry of Health, Labour and Welfare of Japan; Japan Kidney Foundation; Mitsubishi Tanabe Pharma Corporation	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Japan Kidney Foundation; Mitsubishi Tanabe Pharma Corporation(Mitsubishi Tanabe Pharma Corporation)	This work was supported in part by JSPS KAKENHI Grant Numbers 23390225 and 26461224 (KM and HI), Grant-in-Aid for Diabetic Nephropathy and Nephrosclerosis Research from the Ministry of Health, Labour and Welfare of Japan (KM), the Japan Kidney Foundation (KM), and research fund from Mitsubishi Tanabe Pharma Corporation (KM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bao GH, 2010, NAT CHEM BIOL, V6, P602, DOI [10.1038/nchembio.402, 10.1038/NCHEMBIO.402]; Barasch J, 2004, NATURE, V432, P811, DOI 10.1038/432811a; BERGSTROM J, 1995, J AM SOC NEPHROL, V6, P1329; Bolignano D, 2008, KIDNEY BLOOD PRESS R, V31, P255, DOI 10.1159/000143726; Bolignano D, 2010, CANCER LETT, V288, P10, DOI 10.1016/j.canlet.2009.05.027; Bolignano D, 2009, NEPHROL DIAL TRANSPL, V24, P3398, DOI 10.1093/ndt/gfp310; Bolignano D, 2009, CLIN J AM SOC NEPHRO, V4, P337, DOI 10.2215/CJN.03530708; BORAH MF, 1978, KIDNEY INT, V14, P491, DOI 10.1038/ki.1978.154; Bouillanne O, 2005, AM J CLIN NUTR, V82, P777, DOI 10.1093/ajcn/82.4.777; Chan YR, 2009, J IMMUNOL, V182, P4947, DOI 10.4049/jimmunol.0803282; CHANDRA RK, 1983, LANCET, V1, P688; Cowland JB, 2006, J IMMUNOL, V176, P5559, DOI 10.4049/jimmunol.176.9.5559; CRADDOCK PR, 1977, J CLIN INVEST, V59, P879, DOI 10.1172/JCI108710; DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205; Dent CL, 2007, CRIT CARE, V11, DOI 10.1186/cc6192; DRENICK EJ, 1971, AM J CLIN NUTR, V24, P859; Dumler F, 1999, ASAIO J, V45, P413, DOI 10.1097/00002480-199909000-00009; Fleischmann EH, 2001, ASAIO J, V47, P74, DOI 10.1097/00002480-200101000-00016; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; Fluckinger M, 2004, ANTIMICROB AGENTS CH, V48, P3367, DOI 10.1128/AAC.48.9.3367-3372.2004; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; Goldstein SL, 2006, CLIN J AM SOC NEPHRO, V1, P979, DOI 10.2215/CJN.02291205; Gupta A, 2010, BMC NEPHROL, V11, DOI 10.1186/1471-2369-11-16; Haase-Fielitz A, 2009, CRIT CARE MED, V37, P553, DOI 10.1097/CCM.0b013e318195846e; Hanai J, 2005, J BIOL CHEM, V280, P13641, DOI 10.1074/jbc.M413047200; HEYMSFIELD SB, 1983, AM J CLIN NUTR, V37, P478, DOI 10.1093/ajcn/37.3.478; Hingorani S, 2009, AM J KIDNEY DIS, V53, P569, DOI 10.1053/j.ajkd.2009.01.002; Horl WH, 2002, J AM SOC NEPHROL, V13, pS62; Iwama H, 2006, J AM COLL CARDIOL, V47, P1559, DOI 10.1016/j.jacc.2005.11.064; Jiang W, 2008, BLOOD CELL MOL DIS, V41, P169, DOI 10.1016/j.bcmd.2008.04.006; Johnson ACM, 2010, AM J PHYSIOL-RENAL, V299, pF426, DOI 10.1152/ajprenal.00248.2010; Kalantar-Zadeh K, 2004, SEMIN DIALYSIS, V17, P455, DOI 10.1111/j.0894-0959.2004.17606.x; Kalantar-Zadeh K, 2004, J AM SOC NEPHROL, V15, P442, DOI 10.1097/01.ASN.0000107564.60018.51; Kalantar-Zadeh K, 2003, KIDNEY INT, V63, P793, DOI 10.1046/j.1523-1755.2003.00803.x; Kanda J, 2015, CLIN EXP NEPHROL, V19, P99, DOI 10.1007/s10157-014-0952-7; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; Kuwabara T, 2009, KIDNEY INT, V75, P285, DOI 10.1038/ki.2008.499; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P549; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; Malyszko J, 2009, KIDNEY BLOOD PRESS R, V32, P464, DOI 10.1159/000274048; Mishra Jaya, 2005, Lancet, V365, P1231, DOI 10.1016/S0140-6736(05)74811-X; Mori K, 2007, KIDNEY INT, V71, P967, DOI 10.1038/sj.ki.5002165; Mori K, 2005, J CLIN INVEST, V115, P610, DOI 10.1172/JCI200523056; Nakanishi T, 2012, CLIN EXP NEPHROL, V16, P819, DOI 10.1007/s10157-012-0694-3; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Paragas N, 2011, NAT MED, V17, P216, DOI 10.1038/nm.2290; PAYNE RB, 1973, BMJ-BRIT MED J, V4, P643, DOI 10.1136/bmj.4.5893.643; Raj DSC, 2005, KIDNEY INT, V68, P2338, DOI 10.1111/j.1523-1755.2005.00695.x; Saiga H, 2008, J IMMUNOL, V181, P8521, DOI 10.4049/jimmunol.181.12.8521; SHINZATO T, 1994, NEPHRON, V67, P280, DOI 10.1159/000187980; Shinzato T, 1997, ARTIF ORGANS, V21, P864; Tomosugi N, 2006, BLOOD, V108, P1381, DOI 10.1182/blood-2005-10-4043; Wagener G, 2006, ANESTHESIOLOGY, V105, P485, DOI 10.1097/00000542-200609000-00011; Wang Y, 2007, CLIN CHEM, V53, P34, DOI 10.1373/clinchem.2006.075614; Wann JG, 2007, NEPHROL DIAL TRANSPL, V22, P2613, DOI 10.1093/ndt/gfm227; XU SY, 1995, SCAND J CLIN LAB INV, V55, P125, DOI 10.3109/00365519509089604; Yamada K, 2008, AM J CLIN NUTR, V87, P106, DOI 10.1093/ajcn/87.1.106; Yan QW, 2007, DIABETES, V56, P2533, DOI 10.2337/db07-0007; Yang J, 2002, MOL CELL, V10, P1045, DOI 10.1016/S1097-2765(02)00710-4; Zhang JH, 2008, MOL ENDOCRINOL, V22, P1416, DOI 10.1210/me.2007-0420; Zhang YY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096997	61	10	10	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2015	10	7							e0132539	10.1371/journal.pone.0132539	http://dx.doi.org/10.1371/journal.pone.0132539			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1FD	26161663	gold, Green Published, Green Submitted			2023-01-03	WOS:000358162300149
J	Szalavitz, M				Szalavitz, Maia			GENETICS No more addictive personality	NATURE			English	Editorial Material							ANTISOCIAL BEHAVIORAL SYNDROMES; NATIONAL EPIDEMIOLOGIC SURVEY; USE DISORDERS; ALCOHOL; DEPENDENCE											Fowler CD, 2014, NEUROPHARMACOLOGY, V76, P533, DOI 10.1016/j.neuropharm.2013.09.008; Giordano GN, 2014, ADDICTION, V109, P1119, DOI 10.1111/add.12537; Goldstein RB, 2007, DRUG ALCOHOL DEPEN, V90, P145, DOI 10.1016/j.drugalcdep.2007.02.023; Goldstein RB, 2007, ALCOHOL CLIN EXP RES, V31, P814, DOI 10.1111/j.1530-0277.2007.00364.x; Im HI, 2010, NAT NEUROSCI, V13, P1120, DOI 10.1038/nn.2615; Luczak SE, 2006, PSYCHOL BULL, V132, P607, DOI 10.1037/0033-2909.132.4.607	6	9	9	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 25	2015	522	7557					S48	S49		10.1038/522S48a	http://dx.doi.org/10.1038/522S48a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL2OC	26107094				2023-01-03	WOS:000356782900002
J	Okawa, S; Ansah, EK; Nanishi, K; Enuameh, Y; Shibanuma, A; Kikuchi, K; Yasuoka, J; Gyapong, M; Owusu-Agyei, S; Oduro, AR; Asare, GQ; Hodgson, A; Jimba, M				Okawa, Sumiyo; Ansah, Evelyn Korkor; Nanishi, Keiko; Enuameh, Yeetey; Shibanuma, Akira; Kikuchi, Kimiyo; Yasuoka, Junko; Gyapong, Margaret; Owusu-Agyei, Seth; Oduro, Abraham Rexford; Asare, Gloria Quansah; Hodgson, Abraham; Jimba, Masamine		Ghana EMBRACE Implementation Res P	High Incidence of Neonatal Danger Signs and Its Implications for Postnatal Care in Ghana: A Cross-Sectional Study	PLOS ONE			English	Article							FOR-GESTATIONAL-AGE; MULTILEVEL ANALYSIS; CHILD SURVIVAL; NORTHERN GHANA; MATERNAL-CARE; MORTALITY; HEALTH; DETERMINANTS; PROGRAM; SERVICES	Background Reducing neonatal mortality is a major public health priority in sub-Saharan Africa. Numerous studies have examined the determinants of neonatal mortality, but few have explored neonatal danger signs which potentially cause morbidity. This study assessed danger signs observed in neonates at birth, determined the correlations of multiple danger signs and complications between neonates and their mothers, and identified factors associated with neonatal danger signs. Methods A cross-sectional study was conducted in three sites across Ghana between July and September in 2013. Using two-stage random sampling, we recruited 1,500 pairs of neonates and their mothers who had given birth within the preceding two years. We collected data on their socio-demographic characteristics, utilization of maternal and neonatal health services, and experiences with neonatal danger signs and maternal complications. We calculated the correlations of multiple danger signs and complications between neonates and their mothers, and performed multiple logistic regression analysis to identify factors associated with neonatal danger signs. Results More than 25% of the neonates were born with danger signs. At-birth danger signs in neonates were correlated with maternal delivery complications (r = 0.20, p < 0.001), and neonatal complications within the first six weeks of life (r = 0.19, p < 0.001). However, only 29.1% of neonates with danger signs received postnatal care in the first two days, and 52.4% at two weeks of life. In addition to maternal complications during delivery, maternal age less than 20 years, maternal education level lower than secondary school, and fewer than four antenatal care visits significantly predicted neonatal danger signs. Conclusions Over a quarter of neonates are born with danger signs. Maternal factors can be used to predict neonatal health condition at birth. Management of maternal health and close medical attention to high-risk neonates are crucial to reduce neonatal morbidity in Ghana.	[Okawa, Sumiyo; Nanishi, Keiko; Shibanuma, Akira; Kikuchi, Kimiyo; Yasuoka, Junko; Jimba, Masamine] Univ Tokyo, Grad Sch Med, Dept Community & Global Hlth, Tokyo, Japan; [Ansah, Evelyn Korkor; Hodgson, Abraham] Ghana Hlth Serv, Div Res & Dev, Accra, Ghana; [Enuameh, Yeetey; Owusu-Agyei, Seth] Kintampo Hlth Res Ctr, Kintampo, Kintampo Hlth R, Ghana; [Gyapong, Margaret] Dodowa Hlth Res Ctr, Dodowa, Greater Accra, Ghana; [Oduro, Abraham Rexford] Navrongo Hlth Res Ctr, Navrongo, Upper East, Ghana; [Asare, Gloria Quansah] Ghana Hlth Serv, Accra, Ghana	University of Tokyo; Ghana Health Service; Kintampo Health Research Centre; Navrongo Health Research Center; Ghana Health Service	Jimba, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Community & Global Hlth, Tokyo, Japan.	mjimba@m.u-tokyo.ac.jp	Shibanuma, Akira/C-7652-2016; Yasuoka, Junko/GVT-8950-2022; Enuameh, Yeetey/AAO-7304-2020; Jimba, Masamine/AAF-5630-2020	Shibanuma, Akira/0000-0003-2058-1722; Enuameh, Yeetey/0000-0003-3772-7425; Gyapong, Margaret/0000-0002-4818-3497; Nanishi, Keiko/0000-0001-7067-8413; Owusu-Agyei, Seth/0000-0002-0807-1781; Ansah, Evelyn/0000-0003-0401-8606; ODURO, ABRAHAM/0000-0002-4191-7419	Japan International Cooperation Agency (JICA) Human Development Department; JICA Research Institute	Japan International Cooperation Agency (JICA) Human Development Department; JICA Research Institute	This paper was funded by the Japan International Cooperation Agency (JICA) Human Development Department, and JICA Research Institute (http://www.jica.go.jp/english/index.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2014, LANCET, V384, P1159, DOI [10.1016/S0140-6736(14)61707-4, DOI 10.1016/S0140-6736(14)61707-4]; Awoonor-Williams JK, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-S2-S3; Babalola S, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-43; Baiden F, 2006, TROP MED INT HEALTH, V11, P532, DOI 10.1111/j.1365-3156.2006.01582.x; Cox JE, 2008, J PEDIATR ADOL GYNEC, V21, P275, DOI 10.1016/j.jpag.2008.02.002; Debelew GT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107184; Engmann C, 2012, TROP MED INT HEALTH, V17, P272, DOI 10.1111/j.1365-3156.2011.02931.x; Ezeh OK, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-521; Ghana Health Service, 2008, GHAN NAT SAF MOTH SE; Ghana Statistical Service UNDP, 2013, 2010 POP HOUS CENS M; Katz J, 2013, LANCET, V382, P417, DOI 10.1016/S0140-6736(13)60993-9; Kayode GA, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-165; Kikuchi K, 2015, TRIALS, V16, DOI 10.1186/s13063-014-0539-3; Kozuki N, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-S3-S3; Kumar GA, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-357; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Manandhar S R, 2010, Kathmandu Univ Med J (KUMJ), V8, P62; Marchant T, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001292; Markovitz BP, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-79; Ministry of Health Ghana, 2014, GHAN  NAT NEWB HLTH; Mosley WH, 2003, B WORLD HEALTH ORGAN, V81, P140; Naariyong S, 2012, MATERN CHILD HLTH J, V16, P1709, DOI 10.1007/s10995-011-0880-z; Nyonator FK, 2005, HEALTH POLICY PLANN, V20, P25, DOI 10.1093/heapol/czi003; Singh K, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-941; Tuncalp O, 2014, MATERN CHILD HLTH J, V18, P1648, DOI 10.1007/s10995-013-1405-8; UNICEF, 2014, COMM CHILD SURV PROM, DOI [10.1186/1742-4755-11-82, DOI 10.1186/1742-4755-11-82]; Vogel JP, 2014, BJOG-INT J OBSTET GY, V121, P76, DOI 10.1111/1471-0528.12633; Welaga P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058924; Were M, 2007, ECON HUM BIOL, V5, P322, DOI 10.1016/j.ehb.2007.03.005; Worku AG, 2013, BMC INT HEALTH HUM R, V13, DOI 10.1186/1472-698X-13-20; World Health Organization, 2014, EV WOM EV CHILD POST	31	11	11	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2015	10	6							e0130712	10.1371/journal.pone.0130712	http://dx.doi.org/10.1371/journal.pone.0130712			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL3FE	26091424	gold, Green Published, Green Submitted			2023-01-03	WOS:000356835000145
J	Zheng, XY; Ding, H; Jiang, LN; Chen, SW; Zheng, JP; Qiu, M; Zhou, YX; Chen, Q; Guan, WJ				Zheng, Xue-yan; Ding, Hong; Jiang, Li-na; Chen, Shao-wei; Zheng, Jin-ping; Qiu, Min; Zhou, Ying-xue; Chen, Qing; Guan, Wei-jie			Association between Air Pollutants and Asthma Emergency Room Visits and Hospital Admissions in Time Series Studies: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							SHORT-TERM ASSOCIATIONS; DOCTORS HOUSE CALLS; PRIMARY-CARE VISITS; DEPARTMENT VISITS; CASE-CROSSOVER; PARTICULATE MATTER; RESPIRATORY CONDITIONS; OZONE EXPOSURE; FINE PARTICLES; MYOCARDIAL-INFARCTION	Background Air pollution constitutes a significant stimulus of asthma exacerbations; however, the impacts of exposure to major air pollutants on asthma-related hospital admissions and emergency room visits (ERVs) have not been fully determined. Objective We sought to quantify the associations between short-term exposure to air pollutants [ozone (O-3), carbon monoxide (CO), nitrogen dioxide (NO2), sulfur dioxide (SO2), and particulate matter <= 10 mu m (PM10) and PM2.5] and the asthma-related emergency room visits (ERV) and hospitalizations. Methods Systematic computerized searches without language limitation were performed. Pooled relative risks (RRs) and 95% confidence intervals (95% CIs) were estimated using the random-effect models. Sensitivity analyses and subgroup analyses were also performed. Results After screening of 246 studies, 87 were included in our analyses. Air pollutants were associated with significantly increased risks of asthma ERVs and hospitalizations [O-3: RR(95% CI), 1.009 (1.006, 1.011); I-2 = 87.8%, population-attributable fraction (PAF) (95% CI): 0.8 (0.6, 1.1); CO: RR(95% CI), 1.045 (1.029, 1.061); I-2 = 85.7%, PAF (95% CI): 4.3 (2.8, 5.7); NO2: RR(95% CI), 1.018 (1.014, 1.022); I-2 = 87.6%, PAF (95% CI): 1.8 (1.4, 2.2); SO2: RR (95% CI), 1.011 (1.007, 1.015); I-2 = 77.1%, PAF (95% CI): 1.1 (0.7, 1.5); PM10: RR(95% CI), 1.010 (1.008, 1.013); I-2 = 69.1%, PAF (95% CI): 1.1 (0.8, 1.3); PM2.5: RR(95% CI), 1.023 (1.015, 1.031); I-2 = 82.8%, PAF (95% CI): 2.3 (1.5, 3.1)]. Sensitivity analyses yielded compatible findings as compared with the overall analyses without publication bias. Stronger associations were found in hospitalized males, children and elderly patients in warm seasons with lag of 2 days or greater. Conclusion Short-term exposures to air pollutants account for increased risks of asthma-related ERVs and hospitalizations that constitute a considerable healthcare utilization and socioeconomic burden.	[Zheng, Xue-yan; Ding, Hong; Jiang, Li-na; Chen, Shao-wei; Qiu, Min; Chen, Qing] Southern Med Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, Guangzhou, Guangdong, Peoples R China; [Zheng, Jin-ping; Guan, Wei-jie] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Dis, State Key Lab Resp Dis,Natl Clin Res Ctr Resp Dis, Guangzhou, Guangdong, Peoples R China; [Zhou, Ying-xue] Southern Med Univ, Sch Publ Hlth & Trop Med, Dept Biostat, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China; Guangzhou Medical University; State Key Laboratory of Respiratory Disease; Southern Medical University - China	Chen, Q (corresponding author), Southern Med Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, Guangzhou, Guangdong, Peoples R China.	qch.2009@163.com; battery203@163.com	Guan, Wei-jie/K-8257-2019		School of Public Health and Tropical Medicine of Southern Medical University, China [GW201322]	School of Public Health and Tropical Medicine of Southern Medical University, China	This study was supported by a grant from School of Public Health and Tropical Medicine of Southern Medical University, China (Grant No. GW201322). This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.	Abe T, 2009, AM J EMERG MED, V27, P153, DOI 10.1016/j.ajem.2008.01.013; Amancio CT, 2012, REV ASSOC MED BRAS, V58, P302; American Thoracic Society, 1999, AM J RESP CRIT CARE, V153, P3; Andersen ZJ, 2008, OCCUP ENVIRON MED, V65, P458, DOI 10.1136/oem.2007.033290; Anderson HR, 1998, THORAX, V53, P842, DOI 10.1136/thx.53.10.842; Atkinson RW, 2014, THORAX, V69, P660, DOI 10.1136/thoraxjnl-2013-204492; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860, DOI 10.1164/ajrccm.164.10.2010138; Babin S, 2008, INT J ENVIRON HEAL R, V18, P209, DOI 10.1080/09603120701694091; Barnett AG, 2005, AM J RESP CRIT CARE, V171, P1272, DOI 10.1164/rccm.200411-1586OC; Bayram H, 2001, J ALLERGY CLIN IMMUN, V107, P287, DOI 10.1067/mai.2001.111141; Boutin-Forzano S, 2004, RESPIRATION, V71, P134, DOI 10.1159/000076673; Brugha RE, 2014, THORAX, V69, P654, DOI 10.1136/thoraxjnl-2013-204734; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Cadelis G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091136; Cai C, 2008, CLIN EXP ALLERGY, V38, P1680, DOI 10.1111/j.1365-2222.2008.03053.x; Cai J, 2014, ENVIRON POLLUT, V191, P139, DOI 10.1016/j.envpol.2014.04.028; Cassino C, 1999, AM J RESP CRIT CARE, V159, P1773, DOI 10.1164/ajrccm.159.6.9809042; CASTELLSAGUE J, 1995, THORAX, V50, P1051, DOI 10.1136/thx.50.10.1051; Chakraborty P, 2014, AEROBIOLOGIA, V30, P137, DOI 10.1007/s10453-013-9312-4; Chardon B, 2007, OCCUP ENVIRON MED, V64, P320, DOI 10.1136/oem.2005.026187; Cheng MH, 2014, J TOXICOL ENV HEAL A, V77, P1075, DOI 10.1080/15287394.2014.922387; Chew FT, 1999, ALLERGY, V54, P320, DOI 10.1034/j.1398-9995.1999.00012.x; Chimonas MAR, 2007, ENVIRON RES, V103, P397, DOI 10.1016/j.envres.2006.08.013; Cirera L, 2012, ALLERGOL IMMUNOPATH, V40, P231, DOI 10.1016/j.aller.2011.05.012; DELFINO RJ, 1994, ENVIRON RES, V67, P1, DOI 10.1006/enrs.1994.1061; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Evans KA, 2014, ENVIRON RES, V129, P11, DOI 10.1016/j.envres.2013.12.001; Fung K Y, 2005, Int J Environ Stud, V62, P677, DOI 10.1080/00207230500367879; Fusco D, 2001, EUR RESPIR J, V17, P1143, DOI 10.1183/09031936.01.00005501; Galan I, 2003, EUR RESPIR J, V22, P802, DOI 10.1183/09031936.03.00013003; Gasparrini A, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-1; Gleason JA, 2014, ENVIRON RES, V132, P421, DOI 10.1016/j.envres.2014.03.035; Goodman JE, 2009, CRIT REV TOXICOL, V39, P719, DOI 10.3109/10408440903283641; Gouveia N, 2000, OCCUP ENVIRON MED, V57, P477, DOI 10.1136/oem.57.7.477; Hajat S, 1999, THORAX, V54, P597, DOI 10.1136/thx.54.7.597; Halonen JI, 2008, THORAX, V63, P635, DOI 10.1136/thx.2007.091371; Hastie T.J., 1990, GEN ADDITIVE MODELS; HENDERSON RF, 1985, FUND APPL TOXICOL, V5, P451, DOI 10.1016/0272-0590(85)90092-2; Hernandez-Cadena L, 2000, SALUD PUBLICA MEXICO, V42, P288, DOI 10.1590/S0036-36342000000400003; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hoek G, 2008, ATMOS ENVIRON, V42, P7561, DOI 10.1016/j.atmosenv.2008.05.057; Howden-Chapman P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1411; Hua J, 2014, SCI TOTAL ENVIRON, V481, P433, DOI 10.1016/j.scitotenv.2014.02.070; Iskandar A, 2012, THORAX, V67, P252, DOI 10.1136/thoraxjnl-2011-200324; Ito K, 2007, J EXPO SCI ENV EPID, V17, pS45, DOI 10.1038/sj.jes.7500627; Jaffe DH, 2003, ENVIRON RES, V91, P21, DOI 10.1016/S0013-9351(02)00004-X; Jalaludin B, 2008, INT ARCH OCC ENV HEA, V81, P967, DOI 10.1007/s00420-007-0290-0; Jazbec Anamarija, 1999, Arhiv za Higijenu Rada i Toksikologiju, V50, P171; Kim SY, 2012, ENVIRON HEALTH PERSP, V120, P1094, DOI 10.1289/ehp.1104721; Ko FWS, 2007, CLIN EXP ALLERGY, V37, P1312, DOI 10.1111/j.1365-2222.2007.02791.x; Koenig JQ, 1999, J ALLERGY CLIN IMMUN, V104, P717, DOI 10.1016/S0091-6749(99)70280-0; Krmpotic D, 2011, INT ARCH ALLERGY IMM, V156, P62, DOI 10.1159/000322177; Laurent O, 2008, AM J EPIDEMIOL, V168, P58, DOI 10.1093/aje/kwn087; Lavigne E, 2012, CAN J PUBLIC HEALTH, V103, P4, DOI 10.1007/BF03404060; Lee JT, 2006, ARCH ENVIRON OCCUP H, V61, P123, DOI 10.3200/AEOH.61.3.123-130; Lee JT, 2002, EPIDEMIOLOGY, V13, P481, DOI 10.1097/00001648-200207000-00018; Lee SL, 2006, CLIN EXP ALLERGY, V36, P1138, DOI 10.1111/j.1365-2222.2006.02555.x; Levy JI, 2012, AM J EPIDEMIOL, V175, P1091, DOI 10.1093/aje/kwr457; Li N, 2015, TOXICOL LETT, V237, P55, DOI 10.1016/j.toxlet.2015.05.017; Li S, 2011, ENVIRON RES, V111, P1137, DOI 10.1016/j.envres.2011.06.002; Li Y, 2010, SCI TOTAL ENVIRON, V408, P1226, DOI 10.1016/j.scitotenv.2009.11.035; Lin M, 2004, AM J EPIDEMIOL, V159, P294, DOI 10.1093/aje/kwh043; Lin M, 2003, J EPIDEMIOL COMMUN H, V57, P50, DOI 10.1136/jech.57.1.50; Lin M, 2002, ENVIRON HEALTH PERSP, V110, P575, DOI 10.1289/ehp.02110575; Magas OK, 2007, ENVIRON SCI POLLUT R, V14, P19, DOI 10.1065/espr2006.08.333; Malig BJ, 2013, AM J EPIDEMIOL, V178, P58, DOI 10.1093/aje/kws451; Mar TF, 2010, INHAL TOXICOL, V22, P445, DOI 10.3109/08958370903575774; Mar TF, 2009, ANN ALLERG ASTHMA IM, V103, P474, DOI 10.1016/S1081-1206(10)60263-3; Mauderly JL, 2009, ENVIRON HEALTH PERSP, V117, P1, DOI 10.1289/ehp.11654; Medina S, 1997, ENVIRON RES, V75, P73, DOI 10.1006/enrs.1997.3773; Mehta A J, 2012, Swiss Med Wkly, V142, pw13681, DOI 10.4414/smw.2012.13681; Mikerov AN, 2014, TOXICOL LETT, V230, P333, DOI 10.1016/j.toxlet.2014.04.008; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]; Mohr LB, 2008, J ASTHMA, V45, P936, DOI 10.1080/02770900802404082; Morgan G, 1998, AM J PUBLIC HEALTH, V88, P1761, DOI 10.2105/AJPH.88.12.1761; Morgan G, 2010, EPIDEMIOLOGY, V21, P47, DOI 10.1097/EDE.0b013e3181c15d5a; Mustafic H, 2012, JAMA-J AM MED ASSOC, V307, P713, DOI 10.1001/jama.2012.126; Nawrot TS, 2011, LANCET, V377, P732, DOI 10.1016/S0140-6736(10)62296-9; Neidell M, 2010, ENVIRON SCI POLICY, V13, P97, DOI 10.1016/j.envsci.2009.12.006; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; Paulu C, 2008, J PUBLIC HEALTH MAN, V14, P581, DOI 10.1097/01.PHH.0000338371.53242.0e; Pereira G, 2010, MED J AUSTRALIA, V193, P511, DOI 10.5694/j.1326-5377.2010.tb04034.x; Petroeschevsky A, 2001, ARCH ENVIRON HEALTH, V56, P37, DOI 10.1080/00039890109604053; Pilotto LS, 2004, INT J EPIDEMIOL, V33, P208, DOI 10.1093/ije/dyh018; Pope CA, 2006, J AIR WASTE MANAGE, V56, P709, DOI 10.1080/10473289.2006.10464545; Raun LH, 2014, ENVIRON HEALTH-GLOB, V13, DOI 10.1186/1476-069X-13-58; Renzetti G, 2009, PEDIATRICS, V123, P1051, DOI 10.1542/peds.2008-1153; Romero-Placeres Manuel, 2004, Salud pública Méx, V46, P222; Sacks JD, 2014, ENVIRON HEALTH PERSP, V122, P506, DOI 10.1289/ehp.1306940; Samoli E, 2011, ENVIRON RES, V111, P418, DOI 10.1016/j.envres.2011.01.014; Santus P, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-95; Schouten JP, 1996, J EPIDEMIOL COMMUN H, V50, pS22, DOI 10.1136/jech.50.Suppl_1.s22; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; Silverman RA, 2010, J ALLERGY CLIN IMMUN, V125, P367, DOI 10.1016/j.jaci.2009.10.061; Slaughter JC, 2005, J EXPO ANAL ENV EPID, V15, P153, DOI 10.1038/sj.jea.7500382; Smargiassi A, 2009, ENVIRON HEALTH PERSP, V117, P653, DOI 10.1289/ehp.0800010; Son JY, 2013, EPIDEMIOLOGY, V24, P545, DOI 10.1097/EDE.0b013e3182953244; Stieb DM, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-25; Stieb DM, 1996, ENVIRON HEALTH PERSP, V104, P1354, DOI 10.2307/3432974; Strickland MJ, 2010, AM J RESP CRIT CARE, V182, P307, DOI 10.1164/rccm.200908-1201OC; Sunyer J, 1997, THORAX, V52, P760, DOI 10.1136/thx.52.9.760; Sunyer J, 2003, OCCUP ENVIRON MED, V60, DOI 10.1136/oem.60.8.e2; Szyszkowicz M, 2008, INT J OCCUP MED ENV, V21, P25, DOI 10.2478/v10001-008-0002-3; Tenias JM, 1998, OCCUP ENVIRON MED, V55, P541, DOI 10.1136/oem.55.8.541; Thompson AJ, 2001, ARCH ENVIRON HEALTH, V56, P234, DOI 10.1080/00039890109604447; Tsai SS, 2006, INHAL TOXICOL, V18, P549, DOI 10.1080/08958370600686176; WALTERS S, 1994, THORAX, V49, P133, DOI 10.1136/thx.49.2.133; Ward DJ, 2004, OCCUP ENVIRON MED, V61, DOI 10.1136/oem.2003.007088; Weinmayr G, 2010, ENVIRON HEALTH PERSP, V118, P449, DOI 10.1289/ehp.0900844; Wilson AM, 2005, ENVIRON RES, V97, P312, DOI 10.1016/j.envres.2004.07.010; Wong TW, 1999, OCCUP ENVIRON MED, V56, P679, DOI 10.1136/oem.56.10.679; Yamazaki S, 2013, ENVIRON HEALTH PREV, V18, P401, DOI 10.1007/s12199-013-0339-5; Yamazaki S, 2009, J EPIDEMIOL, V19, P143, DOI 10.2188/jea.JE20081025; Yang CY, 2007, J TOXICOL ENV HEAL A, V70, P111, DOI 10.1080/15287390600755059; Ye F, 2001, ENVIRON HEALTH PERSP, V109, P355, DOI 10.2307/3454894	115	166	173	2	55	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2015	10	9							e0138146	10.1371/journal.pone.0138146	http://dx.doi.org/10.1371/journal.pone.0138146			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS0ZE	26382947	Green Submitted, Green Published, gold			2023-01-03	WOS:000361790200062
J	John, G; Louis, C; Berner, A; Genne, D				John, Gregor; Louis, Celine; Berner, Amandine; Genne, Daniel			Tobacco Stained Fingers and Its Association with Death and Hospital Admission: A Retrospective Cohort Study	PLOS ONE			English	Article							SMOKING; ALCOHOL; READMISSION; MORTALITY; OUTCOMES; FRAILTY; PNEUMONIA; DRINKING; HISTORY; RISK	Background Among smokers, the presence of tobacco stains on fingers has recently been associated with a high prevalence of tobacco related conditions and alcohol abuse. Objective we aimed to explore tobacco stains as a marker of death and hospital readmission. Method Seventy-three smokers presenting tobacco-tar staining on their fingers and 70 control smokers were followed during a median of 5.5 years in a retrospective cohort study. We used the Kaplan-Meier survival analysis and the log-rank test to compare mortality and hospital readmission rates among smokers with and smokers without tobacco stains. Multivariable Cox models were used to adjust for confounding factors: age, gender, pack-year unit smoked, cancer, harmful alcohol use and diabetes. The number of hospital admissions was compared through a negative binomial regression and adjusted for the follow-up time, diabetes, and alcohol use. Results Forty-three patients with tobacco-stained fingers died compared to 26 control smokers (HR 1.6; 95% CI: 1.0 to 2.7; p 0.048). The association was not statistically significant after adjustment. Patients with tobacco-stained fingers needed a readmission earlier than smokers without stains (HR 2.1; 95% CI: 1.4 to 3.1; p<0.001), and more often (incidence rate ratio (IRR) 1.6; 95% CI: 1.1 to 2.1). Associations between stains and the first hospital readmission (HR 1.6; 95% CI: 1.0 to 2.5), and number of readmissions (IRR 1.5; 95% CI: 1.1 to 2.1) persisted after adjustment for confounding factors. Conclusions Compared to other smokers, those presenting tobacco-stained fingers have a high unadjusted mortality rate and need early and frequent hospital readmission even when controlling for confounders.	[John, Gregor; Louis, Celine; Berner, Amandine] Hop Neuchatelois, Dept Internal Med, CH-2300 La Chaux De Fonds, Switzerland; [John, Gregor] Univ Hosp Geneva, Dept Internal Med Geriatr & Rehabil, CH-1205 Geneva, Switzerland; [Genne, Daniel] Ctr Hosp Bienne, Dept Internal Med, CH-2501 Biel, Switzerland	University of Geneva	John, G (corresponding author), Hop Neuchatelois, Dept Internal Med, CH-2300 La Chaux De Fonds, Switzerland.	Gregor.John@h-ne.ch	Berner, Amandine/AHC-8435-2022; Genne, Daniel/O-2305-2014; John, Gregor/AAJ-6424-2021	John, Gregor/0000-0002-1548-7339				Abrams L, 2000, Nurs Stand, V14, P59; Abrams P, 2000, AM J MANAG CARE, V6, pS580; Bisson EF, 2015, FRONT SURG, V2, DOI 10.3389/fsurg.2015.00020; Burke RE, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-423; Calvillo-King L, 2013, J GEN INTERN MED, V28, P269, DOI 10.1007/s11606-012-2235-x; Dawson DA, 2000, DRUG ALCOHOL DEPEN, V59, P235, DOI 10.1016/S0376-8716(99)00130-1; El Solh AA, 2004, J AM GERIATR SOC, V52, P2010, DOI 10.1111/j.1532-5415.2004.52556.x; Evangelista LS, 2000, AM J CARDIOL, V86, P1339, DOI 10.1016/S0002-9149(00)01238-8; FRIEDMAN GD, 1991, DRUG ALCOHOL DEPEN, V27, P283, DOI 10.1016/0376-8716(91)90011-M; Guessous Idris, 2014, J Aging Res, V2014, P198603, DOI 10.1155/2014/198603; Hubbard RE, 2009, J NUTR HEALTH AGING, V13, P468, DOI 10.1007/s12603-009-0085-y; John G, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003304; Jorgensen CC, 2013, ACTA ANAESTH SCAND, V57, P631, DOI 10.1111/aas.12086; Jurschik P, 2012, ARCH GERONTOL GERIAT, V55, P625, DOI 10.1016/j.archger.2012.07.002; Kobayashi M, 2010, INT J PSYCHIAT MED, V40, P247, DOI 10.2190/PM.40.3.b; Kulaylat AN, 2015, COLORECTAL DIS; Lawder R, 2011, PUBLIC HEALTH, V125, P533, DOI 10.1016/j.puhe.2011.05.007; Leow JJ, 2014, CAN J UROL, V21, P7537; Long J. S, 2014, REGRESSION MODELS CA; Nelson JA, 2015, HERNIA, V19, P125, DOI 10.1007/s10029-014-1329-2; NIL R, 1984, PHARMACOL BIOCHEM BE, V20, P583, DOI 10.1016/0091-3057(84)90308-3; Prochaska JJ, 2014, AM J PUBLIC HEALTH, V104, P1557, DOI 10.2105/AJPH.2013.301403; Qiao Q, 2000, EUR HEART J, V21, P1621, DOI 10.1053/euhj.2000.2151; Rigotti NA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001837.pub2; Shen L, 2013, AM HEART J, V166, P1056, DOI 10.1016/j.ahj.2013.09.011; Sule S, 2011, CLIN CARDIOL, V34, P35, DOI 10.1002/clc.20872; The Criteria Committee of the New York Heart Association, 1994, NOM CRIT DAGN DIS HE; Wang CX, 2013, J GERONTOL A-BIOL, V68, P338, DOI 10.1093/gerona/gls166; WHO, 2010, INT STAT CLASS DIS R; Wood D, 1960, PROJECT WHEAT 1; World Health Organization (WHO), 2011, REP GLOB TOB EP; Yadav D, 2012, AM J GASTROENTEROL, V107, P1096, DOI 10.1038/ajg.2012.126	32	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2015	10	9							e0138211	10.1371/journal.pone.0138211	http://dx.doi.org/10.1371/journal.pone.0138211			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CR8NH	26375287	gold, Green Published, Green Submitted			2023-01-03	WOS:000361610200087
J	Clemens, KK; Shariff, S; Liu, KA; Hramiak, I; Mahon, JL; McArthur, E; Garg, AX				Clemens, Kristin K.; Shariff, Salimah; Liu, Kuan; Hramiak, Irene; Mahon, Jeffrey L.; McArthur, Eric; Garg, Amit X.			Trends in Antihyperglycemic Medication Prescriptions and Hypoglycemia in Older Adults: 2002-2013	PLOS ONE			English	Article							TYPE-2 DIABETES-MELLITUS; ROSIGLITAZONE; MONOTHERAPY; THERAPY; COMPLICATIONS; HYPERGLYCEMIA; PIOGLITAZONE; METFORMIN; ONTARIO; EVENTS	Background Over the last decade, several new antihyperglycemic medications have been introduced including those associated with a lower hypoglycemia risk. We aimed to investigate how these medications are being prescribed to older adults in our region. Methods We conducted population-based cross-sectional analyses of older adults (mean age 75 years) with treated diabetes in Ontario, Canada from 2002 until 2013, to examine the percentage prescribed insulin, sulphonylureas, alpha-glucosidase inhibitors, metformin, thiazolidinediones, meglitinides, and dipeptidyl peptidase-4 inhibitors. Over the study period, we also examined their hospital encounters for hypoglycemia (emergency room or inpatient encounter). Results The mean age of treated patients increased slightly over the study quarters and the proportion that were women declined. With the exception of chronic kidney disease, cancer, dementia, and neuropathy, the percentage with a comorbidity appeared to decline. The percentage of treated patients prescribed metformin, gliclazide and dipeptidyl peptidase-4 inhibitors increased as did combination therapy. Glyburide and thiazolidinedione prescriptions declined, and insulin use remained stable. In those with newly treated diabetes, the majority were prescribed metformin, with smaller percentages prescribed insulin and other oral agents. Although the absolute number of treated patients with a hypoglycemia encounter increased until mid-2006 and then decreased, the overall percentage with an encounter declined over the study period (0.8% with an event in the first quarter, 0.4% with an event in the last quarter). Conclusions Antihyperglycemic medications with safer profiles are being increasingly prescribed to older adults. In this setting there has been a decrease in the percentage of treated patients with a hospital encounter for hypoglycemia.	[Clemens, Kristin K.; Garg, Amit X.] Univ Western Ontario, Dept Med, London, ON, Canada; [Shariff, Salimah; Liu, Kuan; McArthur, Eric; Garg, Amit X.] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Hramiak, Irene; Mahon, Jeffrey L.] Univ Western Ontario, Dept Med, Div Endocrinol, London, ON, Canada; [Mahon, Jeffrey L.; Garg, Amit X.] Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada	Western University (University of Western Ontario); University of Toronto; Western University (University of Western Ontario); Western University (University of Western Ontario)	Clemens, KK (corresponding author), Univ Western Ontario, Dept Med, London, ON, Canada.	kclemens2008@meds.uwo.ca	Clemens, Kristin K/K-8898-2016; Garg, Amit X/G-3295-2011; Hramiak, Irene/G-3305-2011; Mahon, Jeff/G-3324-2011	Shariff, Salimah/0000-0002-1219-6763	Ontario Ministry of Health; Long-term Care (MOHLTC); Academic Medical Organization of Southwestern Ontario (AMOSO); Schulich School of Medicine and Dentistry (SSMD), Western University; Lawson Health Research Institute (LHRI); Adam Linton Chair in Kidney Health Analytics	Ontario Ministry of Health(Ministry of Health and Long-Term Care, Ontario); Long-term Care (MOHLTC)(Ministry of Health and Long-Term Care, Ontario); Academic Medical Organization of Southwestern Ontario (AMOSO); Schulich School of Medicine and Dentistry (SSMD), Western University; Lawson Health Research Institute (LHRI); Adam Linton Chair in Kidney Health Analytics	This project was conducted at the Institute for Clinical Evaluative Sciences (ICES) Western Site. ICES is funded by an annual grant from the Ontario Ministry of Health and Long-term Care (MOHLTC). Core funding for ICES Western is provided by the Academic Medical Organization of Southwestern Ontario (AMOSO), the Schulich School of Medicine and Dentistry (SSMD), Western University, and the Lawson Health Research Institute (LHRI). Dr. Amit Garg was supported by the Adam Linton Chair in Kidney Health Analytics. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The opinions, results, and conclusions are those of the authors, and no endorsement by ICES, AMOSO, SSMD, LHRI or the MOHLTC is intended or should be inferred. Parts of this material are based upon data and information compiled and provided by the Canadian Institute for Health Information (CIHI). However the analysis, conclusions, opinions and statements expressed herein are those of the authors and not necessarily CIHI.	Baviera M, 2011, DIABETES RES CLIN PR, V93, P123, DOI 10.1016/j.diabres.2011.05.004; Booth GL, 2005, DIABETES CARE, V28, P1045, DOI 10.2337/diacare.28.5.1045; Bronskill S, 2010, AGING ONTARIO ICES C; Cohen A, 2010, DIABETES CARE, V33, P823, DOI 10.2337/dc09-1834; Desai NR, 2012, AM J MED, V125, DOI 10.1016/j.amjmed.2011.07.033; Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9; Doucet J, 2011, CURR MED RES OPIN, V27, P863, DOI 10.1185/03007995.2011.554532; Filion KB, 2009, PHARMACOEPIDEM DR S, V18, P973, DOI 10.1002/pds.1802; Foster PD, 2013, DIABETIC MED, V30, P1209, DOI 10.1111/dme.12214; Garber AJ, 2002, DIABETES OBES METAB, V4, P201, DOI 10.1046/j.1463-1326.2002.00211.x; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Hampp C, 2014, DIABETES CARE, V37, P1367, DOI 10.2337/dc13-2289; Harper W, 2013, CANADIAN DIABETES AS; Hashim S, 2013, J POPUL THER CLIN PH, V20, pE238; Home PD, 2009, LANCET, V373, P2125, DOI 10.1016/S0140-6736(09)60953-3; Huang ES, 2013, JAMA INTERN MED, P251; Hux JE, 2002, DIABETES CARE, V25, P512, DOI 10.2337/diacare.25.3.512; Kahn SE, 2008, DIABETES CARE, V31, P845, DOI 10.2337/dc07-2270; Levy Adrian R, 2003, Can J Clin Pharmacol, V10, P67; Lincoff AM, 2007, JAMA-J AM MED ASSOC, V298, P1180, DOI 10.1001/jama.298.10.1180; Lipscombe LL, 2007, JAMA-J AM MED ASSOC, V298, P2634, DOI 10.1001/jama.298.22.2634; Lipska KJ, 2014, JAMA INTERN MED, V174, P1116, DOI 10.1001/jamainternmed.2014.1824; Meinelly G, 2013, CANADIAN DIABETES AS; Nissen SE, 2010, ARCH INTERN MED, V170, P1191, DOI 10.1001/archinternmed.2010.207; Patel A, 2008, NEW ENGL J MED, V358, P2560, DOI 10.1056/NEJMoa0802987; Rathmann W, 2007, DIABETES CARE, V30, P848, DOI 10.2337/dc06-2000; Rosenstock J, 2006, DIABETES OBES METAB, V8, P650, DOI 10.1111/j.1463-1326.2006.00659.x; Rosenstock J, 2013, DIABETES OBES METAB, V15, P906, DOI 10.1111/dom.12102; Rosenstock J, 2006, DIABETES OBES METAB, V8, P49, DOI 10.1111/j.1463-1326.2005.00541.x; Statistics Canada website, 2014, STAT CAN POP SEX AG; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; vanStaa T, 1997, J CLIN EPIDEMIOL, V50, P735, DOI 10.1016/S0895-4356(97)00024-3; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120]; Zaharan NL, 2014, IRISH J MED SCI, V183, P311, DOI 10.1007/s11845-013-1011-1	34	33	33	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2015	10	9							e0137596	10.1371/journal.pone.0137596	http://dx.doi.org/10.1371/journal.pone.0137596			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ5AJ	26335938	Green Submitted, Green Published, gold			2023-01-03	WOS:000360615400071
J	Chan, T; de Lusignan, S; Cooper, A; Elliott, M				Chan, Tom; de Lusignan, Simon; Cooper, Alun; Elliott, Mary			Improving Osteoporosis Management in Primary Care: An Audit of the Impact of a Community Based Fracture Liaison Nurse	PLOS ONE			English	Article							PRACTICE COMPUTER RECORDS; SECONDARY PREVENTION; POSTMENOPAUSAL WOMEN; FRAGILITY FRACTURES; SOCIAL DEPRIVATION; OLDER-PEOPLE; UK; FALLS; LESSONS; QUALITY	Background Osteoporosis and associated fragility fractures are a major health problem; they are more common in women over 50 years old. Fracture liaison nurses have been widely used in secondary care to promote the recognition of fragility fractures and to promote the use of bone-sparing medication to reduce the risk of recurrent facture. Objective Audit the impact of a primary care based fracture liaison nurse on the detection of fragility fractures in people with osteoporosis and their treatment with a bone-sparing medication. Method This audit took place in 12 GP practices using 'before and after' cross-sectional extractions of anonymised routine data. We report, for females 50-74 years and >= 75 years old, socioeconomic deprivation index, the prevalence of osteoporosis, recording of fragility fractures, dual-energy X-ray absorptiometry (DXA), smoking, and body-mass index (BMI) and use of appropriate bone-sparing medication. We used Altman's test of independent proportions to compare before and after data. Results Recording of the diagnosis of osteoporosis increased from 1.5% to 1.7% (p = 0.059); the rate of DXA scans fell (1.8% to 1.4%; p = 0.002); recording of fractures and fragility fractures more than doubled (0.8% to 2.0%; p<0.001 and 0.5% to 1.5%; p<0.001, respectively) with approximate doubling of the recording of smoking, and BMI (p<0.001 level). Fragility fracture recording rose from 8.8% to 15% in females aged 50 to 74, and from 0.8% to 2.3% in people aged >= 75years old (p<0.001). There appeared to be inequity in the service, people who were least deprived were more likely to receive DXA scans and the more deprived to be prescribed bone sparing agents. Conclusion A fracture liaison nurse in primary care has been associated with a period of improved management. Liaison nurses based in different parts of the health system should be tested in a prospective trial.	[Chan, Tom; de Lusignan, Simon] Univ Surrey, Dept Hlth Care Policy & Management, Clin Informat, Guildford GU2 5XH, Surrey, England; [Cooper, Alun; Elliott, Mary] Bridge Med Ctr, Crawley, W Sussex, England	University of Surrey	Chan, T (corresponding author), Univ Surrey, Dept Hlth Care Policy & Management, Clin Informat, Guildford GU2 5XH, Surrey, England.	t.chan@surrey.ac.uk	de Lusignan, Smion/S-7838-2019	de Lusignan, Smion/0000-0002-8553-2641	Crawley Practice Based Commissioning (PBC) group	Crawley Practice Based Commissioning (PBC) group	Crawley Practice Based Commissioning (PBC) group funded the audit.	Altman DG, 1990, PRACTICAL STAT MED R, P234; [Anonymous], 2007, SUMM M REP WHO SCI G; [Anonymous], IR MED J; Chakravarthy J, 2008, INT J CLIN PRACT, V62, P382, DOI 10.1111/j.1742-1241.2007.01662.x; Charalambous CP, 2009, ANN ROY COLL SURG, V91, P596, DOI 10.1308/003588409X432400; Compston J, 2009, MATURITAS, V62, P105, DOI 10.1016/j.maturitas.2008.11.022; Compston JE, 2006, LANCET, V368, P973, DOI 10.1016/S0140-6736(06)69394-X; Cooper A, 2002, BRIT J GEN PRACT, V52, P311; Court-Brown CM, 2011, OSTEOPOROSIS INT, V22, P1211, DOI 10.1007/s00198-010-1315-1; Crandall CJ, 2012, OSTEOPOROSIS INT, V23, P1503, DOI 10.1007/s00198-011-1736-5; De Laet C, 2005, OSTEOPOROSIS INT, V16, P1330, DOI 10.1007/s00198-005-1863-y; de Lusignan S, 2006, FAM PRACT, V23, P253, DOI 10.1093/fampra/cmi106; de Lusignan S, 2005, PUBLIC HEALTH, V119, P771, DOI 10.1016/j.puhe.2004.10.018; de Lusignan S, 2011, Yearb Med Inform, V6, P112; de Lusignan S, 2003, PUBLIC HEALTH, V117, P438, DOI 10.1016/S0033-3506(03)00129-X; de Lusignan Simon, 2006, Inform Prim Care, V14, P59; de Lusignan S, 2007, INT J MED INFORM, V76, P261, DOI 10.1016/j.ijmedinf.2005.11.003; de Lusignan Simon, 2004, Inform Prim Care, V12, P147; de Lusignan Simon, 2005, Inform Prim Care, V13, P65; de Lusignan Simon, 2011, Inform Prim Care, V19, P127; de Lusignan S, 2011, FAM PRACT, V28, P638, DOI 10.1093/fampra/cmr036; de Lusignan S, 2008, J AMBUL CARE MANAG, V31, P201, DOI 10.1097/01.JAC.0000324664.88131.d2; de Lusignan Simon, 2006, Inform Prim Care, V14, P153; Department for Communities and Local Government, 2011, ENGL IND DEPR 2010; Department of Health, 2004, QUAL OUTC FRAM GUID; Department of Health, 2003, INV GEN PRACT NEW GE; Flicker L, 2005, J AM GERIATR SOC, V53, P1881, DOI 10.1111/j.1532-5415.2005.00468.x; Goldhahn J, 2010, BONE, V46, P267, DOI 10.1016/j.bone.2009.10.004; Gormley KJ, 2011, INT J OLDER PEOPLE N, V6, P307, DOI 10.1111/j.1748-3743.2011.00303.x; Gray Sarah, 2012, Menopause Int, V18, P30, DOI 10.1258/mi.2012.012002; Harvey M, 2002, BRIT J GEN PRACT, V52, P496; Iki Masayuki, 2005, Clin Calcium, V15, P156; Ip TP, 2010, OSTEOPOROSIS INT, V21, pS605, DOI 10.1007/s00198-010-1398-8; Kanis JA, 2008, OSTEOPOROSIS INT, V19, P1395, DOI 10.1007/s00198-008-0712-1; Larsson S, 2007, INJURY, V38, P1225, DOI 10.1016/j.injury.2007.09.004; Mercer SW, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4152; Michalakidis G, 2010, STUD HEALTH TECHNOL, V160, P724, DOI 10.3233/978-1-60750-588-4-724; Murray J, 2010, FAM PRACT, V27, P430, DOI 10.1093/fampra/cmq030; National Institute for Health and Care Excellence (NICE) Centre for Clinical Practice, 2013, NICE CLIN GUID; National Institute for Health and Clinical Excellence (NICE), 2008, COST REP TECHN APPR; National Osteoporosis Society (NOS), OST DIR ENH SERV DES; National Research Authority, NAT RES ETH SERV NRE; Neyens JC, 2011, J AM MED DIR ASSOC, V12, P410, DOI 10.1016/j.jamda.2010.07.018; NICE, 2008, AL ET RIS RAL STRONT; NOS (National Osteoporosis Society), 2013, VIT D BON HLTH PRACT; Office for National Statistics, 2003, CENS 2001 S; Oliver D, 2009, ARCH GERONTOL GERIAT, V49, pS7, DOI 10.1016/S0167-4943(09)70005-6; Pearson D, 2004, OSTEOPOROSIS INT, V15, P132, DOI 10.1007/s00198-003-1499-8; Prasad N, 2006, ANN ROY COLL SURG, V88, P470, DOI 10.1308/003588406X116891; Schade CP, 2006, J AM MED INFORM ASSN, V13, P470, DOI 10.1197/jamia.M2041; van Vlymen J, 2005, STUD HEALTH TECHNOL, V116, P1010	51	8	8	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2015	10	8							e0132146	10.1371/journal.pone.0132146	http://dx.doi.org/10.1371/journal.pone.0132146			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CP8KZ	26313924	Green Published, Green Submitted, gold			2023-01-03	WOS:000360144000004
J	Caro-Vega, Y; del Rio, C; Lima, VD; Lopez-Cervantes, M; Crabtree-Ramirez, B; Bautista-Arredondo, S; Colchero, MA; Sierra-Madero, J				Caro-Vega, Yanink; del Rio, Carlos; Lima, Viviane Dias; Lopez-Cervantes, Malaquias; Crabtree-Ramirez, Brenda; Bautista-Arredondo, Sergio; Colchero, M. Arantxa; Sierra-Madero, Juan			Estimating the Impact of Earlier ART Initiation and Increased Testing Coverage on HIV Transmission among Men Who Have Sex with Men in Mexico using a Mathematical Model	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; PREVENTION; ACCESS; HAART; PREVALENCE; VIRUS	Objective To estimate the impact of late ART initiation on HIV transmission among men who have sex with men (MSM) in Mexico. Methods An HIV transmission model was built to estimate the number of infections transmitted by HIV-infected men who have sex with men (MSM-HIV+) MSM-HIV+ in the short and long term. Sexual risk behavior data were estimated from a nationwide study of MSM. CD4(+) counts at ART initiation from a representative national cohort were used to estimate time since infection. Number of MSM-HIV+ on treatment and suppressed were estimated from surveillance and government reports. Status quo scenario (SQ), and scenarios of early ART initiation and increased HIV testing were modeled. Results We estimated 14239 new HIV infections per year from MSM-HIV+ in Mexico. In SQ, MSM take an average 7.4 years since infection to initiate treatment with a median CD4(+) count of 148 cells/mm(3)(25th-75th percentiles 52-266). In SQ, 68% of MSM-HIV+ are not aware of their HIV status and transmit 78% of new infections. Increasing the CD4(+) count at ART initiation to 350 cells/mm(3) shortened the time since infection to 2.8 years. Increasing HIV testing to cover 80% of undiagnosed MSM resulted in a reduction of 70% in new infections in 20 years. Initiating ART at 500 cells/mm(3) and increasing HIV testing the reduction would be of 75% in 20 years. Conclusion A substantial number of new HIV infections in Mexico are transmitted by undiagnosed and untreated MSM-HIV+. An aggressive increase in HIV testing coverage and initiating ART at a CD4 count of 500 scells/mm(3) in this population would significantly benefit individuals and decrease the number of new HIV infections in Mexico.	[Caro-Vega, Yanink; Lopez-Cervantes, Malaquias] Univ Nacl Autonoma Mexico, Fac Med, Mexico City 04510, DF, Mexico; [Caro-Vega, Yanink; Crabtree-Ramirez, Brenda; Sierra-Madero, Juan] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infect Dis, Mexico City, DF, Mexico; [del Rio, Carlos] Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA USA; [del Rio, Carlos] Emory Ctr AIDS Res, Atlanta, GA USA; [Lima, Viviane Dias] Univ British Columbia, Div Aids, Dept Med, Fac Med, Vancouver, BC, Canada; [Bautista-Arredondo, Sergio; Colchero, M. Arantxa] Natl Inst Publ Hlth, Div Hlth Econ & Hlth Syst Innovat, Cuernavaca, Morelos, Mexico	Universidad Nacional Autonoma de Mexico; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Emory University; Rollins School Public Health; Emory University; University of British Columbia; Instituto Nacional de Salud Publica	Sierra-Madero, J (corresponding author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infect Dis, Mexico City, DF, Mexico.	jsmadero@yahoo.com	Sierra Madero, Juan/AAW-8825-2021; Bautista-Arredondo, Sergio/N-7305-2016; del Rio, Carlos/B-3763-2012	Bautista-Arredondo, Sergio/0000-0001-8910-3011; del Rio, Carlos/0000-0002-0153-3517; Crabtree-Ramirez, Brenda/0000-0002-2587-1123	National Council on Science and Technology (CONACyT) of Mexico; NIH/FIC (AIDS International Training and Research Program of Emory University) [D43 TW01042]; Emory Center for AIDS Research [NIH/NIAID P30 AI050409]; US National Institute on Drug Abuse [R03DA033851]; Canadian Institutes of Health Research [MOP-125948]; Michael Institute for Health Research; Canadian Institutes of Health Research; Glaxosmithkline; GSK/ViiV; Stendhal; Janssen; MSD; Pfizer; BMS; GSK; Gilead; FOGARTY INTERNATIONAL CENTER [D43TW001042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI050409, U01AI069923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R03DA033851] Funding Source: NIH RePORTER	National Council on Science and Technology (CONACyT) of Mexico(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); NIH/FIC (AIDS International Training and Research Program of Emory University); Emory Center for AIDS Research; US National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Michael Institute for Health Research; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Glaxosmithkline(GlaxoSmithKline); GSK/ViiV; Stendhal; Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); MSD; Pfizer(Pfizer); BMS(Bristol-Myers Squibb); GSK(GlaxoSmithKline); Gilead(Gilead Sciences); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	YCV has been funded by a scholarship from the National Council on Science and Technology (CONACyT) of Mexico and the NIH/FIC (AIDS International Training and Research Program of Emory University; Grant No. D43 TW01042). CDR has received support from the Emory Center for AIDS Research (NIH/NIAID P30 AI050409). VDL is funded by a grant from the US National Institute on Drug Abuse (R03DA033851), by a grant from the Canadian Institutes of Health Research (MOP-125948) and by a Scholar Award from the Michael Institute for Health Research and a New Investigator award from the Canadian Institutes of Health Research. VDL has received limited unrestricted funding, paid to her institution, from Glaxosmithkline. JSM has received speaker and consulting fees from GSK/ViiV, Stendhal, Janssen, and MSD. Research support from Pfizer, BMS, MSD, GSK, Gilead. BCR is speaker for BMS and Stendhal. All others have no funding or other conflicts of interest to disclose. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andronis L, 2009, SENSITIVITY ANAL EC, V13; Attia S, 2009, AIDS, V23, P1397, DOI 10.1097/QAD.0b013e32832b7dca; Bautista-Arredondo S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072616; Carrizosa CM, 2010, AIDS PATIENT CARE ST, V24, P333, DOI 10.1089/apc.2009.0138; CENSIDA, 2011, B GRUP INF SECT VIH; CENSIDA, 2012, SEC SAL EI VIH SIDA; CENSIDA, 2012, INF NAC AV LUCH CONT; CENSIDA, 2011, B SALVAR; CENSIDA, 2013, VIG EP CAS VIH SIDA; Centers for Disease Control and Prevention, 1994, ZID PREV HIV TRANSM; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Cori A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084511; Crabtree-Ramirez B, 2012, SALUD PUBLICA MEXICO, V54, P506, DOI 10.1590/S0036-36342012000500007; Crabtree-Ramirez B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020272; Crabtree-Ramirez B, 2010, AIDS RES HUM RETROV, V26, P373, DOI 10.1089/aid.2009.0077; Cuadra-Hernandez SM, 2012, SALUD COLECT, V8, P191, DOI 10.1590/S1851-82652012000200007; Das M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011068; Dieffenbach CW, 2009, JAMA-J AM MED ASSOC, V301, P2380, DOI 10.1001/jama.2009.828; Eyawo O, 2013, CAN J PUBLIC HEALTH, V104, pE418, DOI 10.17269/c; Fang CT, 2004, J INFECT DIS, V190, P879, DOI 10.1086/422601; Granich R, 2010, CURR OPIN HIV AIDS, V5, P298, DOI 10.1097/COH.0b013e32833a6c32; Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9; Huang X, 1999, J ACQ IMMUN DEF SYND, V62, P441; Infante C, 2006, SALUD PUBLICA MEXICO, V48, P141, DOI 10.1590/S0036-36342006000200007; Infante C, 2009, CULT HEALTH SEX, V11, P125, DOI 10.1080/13691050802431314; Jia ZW, 2013, LANCET, V382, P1195, DOI 10.1016/S0140-6736(12)61898-4; Johnson LF, 2012, J R SOC INTERFACE, V9, P1544, DOI 10.1098/rsif.2011.0826; Johnston KM, 2010, AIDS, V24, P1929, DOI 10.1097/QAD.0b013e32833af85d; Kahn JG, 2011, CURR HIV RES, V9, P405, DOI 10.2174/157016211798038542; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Lima VD, 2008, J INFECT DIS, V198, P59, DOI 10.1086/588673; Ma ZM, 2009, J VIROL, V83, P3288, DOI 10.1128/JVI.02423-08; Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1; Gutierrez JP, 2012, TROP MED INT HEALTH, V17, P353, DOI 10.1111/j.1365-3156.2011.02934.x; Pilcher CD, 2007, AIDS, V21, P1723, DOI 10.1097/QAD.0b013e3281532c82; Sanchez R, 2013, REALIZARAN PRIMER DI; UNAIDS, 2011, EP FACT SHEET HIV AI; UNAIDS, 2000, WOM HIV AIDS	38	9	10	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2015	10	8							e0136534	10.1371/journal.pone.0136534	http://dx.doi.org/10.1371/journal.pone.0136534			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CP5VA	26302044	Green Submitted, Green Published, gold			2023-01-03	WOS:000359951900073
J	Al-Asmari, AK; Albalawi, SM; Athar, MT; Khan, AQ; Al-Shahrani, H; Islam, M				Al-Asmari, Abdulrahman Khazim; Albalawi, Sulaiman Mansour; Athar, Md Tanwir; Khan, Abdul Quaiyoom; Al-Shahrani, Hamoud; Islam, Mozaffarul			Moringa oleifera as an Anti-Cancer Agent against Breast and Colorectal Cancer Cell Lines	PLOS ONE			English	Article							MOLECULAR-MECHANISMS; SAUDI-ARABIA; D-ALLOSE; EUGENOL; APOPTOSIS; CURCUMIN; HEALTH; PHYTOCHEMICALS; ISOTHIOCYANATE	In this study we investigated the anti-cancer effect of Moringa oleifera leaves, bark and seed extracts. When tested against MDA-MB-231 and HCT-8 cancer cell lines, the extracts of leaves and bark showed remarkable anti-cancer properties while surprisingly, seed extracts exhibited hardly any such properties. Cell survival was significantly low in both cells lines when treated with leaves and bark extracts. Furthermore, a striking reduction (about 70-90%) in colony formation as well as cell motility was observed upon treatment with leaves and bark. Additionally, apoptosis assay performed on these treated breast and colorectal cancer lines showed a remarkable increase in the number of apoptotic cells; with a 7 fold increase in MD-MB-231 to an increase of several fold in colorectal cancer cell lines. However, no significant apoptotic cells were detected upon seeds extract treatment. Moreover, the cell cycle distribution showed a G2/M enrichment (about 2-3 fold) indicating that these extracts effectively arrest the cell progression at the G2/M phase. The GC-MS analyses of these extracts revealed numerous known anti-cancer compounds, namely eugenol, isopropyl isothiocynate, D-allose, and hexadeconoic acid ethyl ester, all of which possess long chain hydrocarbons, sugar moiety and an aromatic ring. This suggests that the anticancer properties of Moringa oleifera could be attributed to the bioactive compounds present in the extracts from this plant. This is a novel study because no report has yet been cited on the effectiveness of Moringa extracts obtained in the locally grown environment as an anti-cancer agent against breast and colorectal cancers. Our study is the first of its kind to evaluate the anti-malignant properties of Moringa not only in leaves but also in bark. These findings suggest that both the leaf and bark extracts of Moringa collected from the Saudi Arabian region possess anti-cancer activity that can be used to develop new drugs for treatment of breast and colorectal cancers.	[Al-Asmari, Abdulrahman Khazim; Albalawi, Sulaiman Mansour; Athar, Md Tanwir; Khan, Abdul Quaiyoom; Al-Shahrani, Hamoud; Islam, Mozaffarul] Prince Sultan Mil Med City, Res Ctr, Riyadh 11159, Saudi Arabia	Prince Sultan Military Medical City	Al-Asmari, AK (corresponding author), Prince Sultan Mil Med City, Res Ctr, Riyadh 11159, Saudi Arabia.	abdulrahman.alasmari@gmail.com			Prince Sultan Military Medical City	Prince Sultan Military Medical City	Funding: This work was funded by Prince Sultan Military Medical City. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ACS, 2013, BREAST CANC FACTS FI, P1; Aggarwal BB, 2007, ADV EXP MED BIOL, V595, P1; Aja P, 2014, ADV LIFE SCI TECHNOL, V24, P73; Al-Sharif I, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-600; Alaklabi A, 2014, SAUDI J BIOL SCI; Alghamdi IG, 2013, BREAST CANCER-TARGET, V5, P103, DOI 10.2147/BCTT.S50750; American Cancer Society (ACS), 2014, COL CANC FACTS FIG, P1; Berkovich L, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-212; Bhuvaneswari V., 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P627, DOI 10.2174/156801105774574667; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Craig W, 1999, CAN J DIET PRACT RES, V60, P78; Craig WJ, 1997, J AM DIET ASSOC, V97, pS199, DOI 10.1016/S0002-8223(97)00765-7; Emmanuel S.A., 2014, AM J ETHNOMED, V1, P346; Ferreira Paulo Michel Pinheiro, 2014, PHARM THERAPEUTICS; FOLKMAN J, 1982, ANN NY ACAD SCI, V401, P212, DOI 10.1111/j.1749-6632.1982.tb25720.x; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Garg AK, 2005, ANTIOXID REDOX SIGN, V7, P1630, DOI 10.1089/ars.2005.7.1630; Gaurisankar Sa, 2010, Al Ameen Journal of Medical Sciences, V3, P21; Ghosh R, 2005, J BIOL CHEM, V280, P5812, DOI 10.1074/jbc.M411429200; Ghosh R, 2009, J STEROID BIOCHEM, V113, P25, DOI 10.1016/j.jsbmb.2008.11.002; Harada H, 2002, ANTICANCER RES, V22, P2587; Islam M, 2000, EXP EYE RES, V70, P261, DOI 10.1006/exer.1999.0783; Islam M, 2013, ORAL ONCOL, V49, P778, DOI 10.1016/j.oraloncology.2013.04.003; Islam M, 2009, MOL CANCER RES, V7, P1771, DOI 10.1158/1541-7786.MCR-08-0512; Jung IL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095492; Kalkunte S, 2006, J EXP THER ONCOL, V5, P287; Kaur G, 2010, MOL CARCINOGEN, V49, P290, DOI 10.1002/mc.20601; Kong KW, 2010, MOLECULES, V15, P959, DOI 10.3390/molecules15020959; Lacroix M, 2006, ENDOCR-RELAT CANCER, V13, P293, DOI 10.1677/erc.1.01172; Leone A, 2015, INT J MOL SCI, V16, P12791, DOI 10.3390/ijms160612791; MANIGAUHA, 2010, DRUG INVENTION TODAY, V2; Manikandan P, 2011, INVEST NEW DRUG, V29, P110, DOI 10.1007/s10637-009-9345-2; Manikandan P, 2010, LIFE SCI, V86, P936, DOI 10.1016/j.lfs.2010.04.010; Mann J, 2002, NAT REV CANCER, V2, P143, DOI 10.1038/nrc723; Matsuda H, 2007, EUR J PHARMACOL, V561, P172, DOI 10.1016/j.ejphar.2006.12.040; Mbikay M., 2012, FRONT PHARMACOL, P3; Mosli MH, 2012, ASIAN PAC J CANCER P, V13, P3809, DOI 10.7314/APJCP.2012.13.8.3809; Olson ME, 2002, SYST BOT, V27, P55; Pal D, 2010, J DERMATOL SCI, V59, P31, DOI 10.1016/j.jdermsci.2010.04.013; Park BS, 2005, APOPTOSIS, V10, P193, DOI 10.1007/s10495-005-6074-7; Pisano M, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-8; Rao AVR, 2000, J AM COLL NUTR, V19, P563, DOI 10.1080/07315724.2000.10718953; Razis AFA, 2014, ASIAN PAC J CANCER P, V15, P8571, DOI 10.7314/APJCP.2014.15.20.8571; Shanmugam MK, 2015, MOLECULES, V20, P2728, DOI 10.3390/molecules20022728; Shehzad A, 2013, BIOFACTORS, V39, P27, DOI 10.1002/biof.1065; Shin SH, 2007, J KOR ASSOC ORAL MAX, V32, P20; Shishodia S, 2013, BIOFACTORS, V39, P37, DOI 10.1002/biof.1041; Sui L, 2005, INT J ONCOL, V27, P907; Tiloke C, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-226; Trejo-Solis C, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/705121; Vermeulen SJ, 1998, CANCER GENET CYTOGEN, V107, P76, DOI 10.1016/S0165-4608(98)00081-8; Yamaguchi F, 2008, INT J ONCOL, V32, P377; Yoo CB, 2005, CANCER LETT, V225, P41, DOI 10.1016/j.canlet.2004.11.018; Yuan Peng, 2008, Chinese Journal of Natural Medicines, V6, P325, DOI 10.3724/SP.J.1009.2008.00325; 김규천, 2006, Anatomy and Cell Biology, V39, P245	55	143	150	0	53	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 19	2015	10	8							e0135814	10.1371/journal.pone.0135814	http://dx.doi.org/10.1371/journal.pone.0135814			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP6SN	26288313	Green Published, Green Submitted, gold			2023-01-03	WOS:000360018600073
J	Harper, CC; Rocca, CH; Thompson, KM; Morfesis, J; Goodman, S; Darney, PD; Westhoff, CL; Speidel, JJ				Harper, Cynthia C.; Rocca, Corinne H.; Thompson, Kirsten M.; Morfesis, Johanna; Goodman, Suzan; Darney, Philip D.; Westhoff, Carolyn L.; Speidel, J. Joseph			Reductions in pregnancy rates in the USA with long-acting reversible contraception: a cluster randomised trial	LANCET			English	Article							UNITED-STATES; INTRAUTERINE CONTRACEPTION; UNINTENDED PREGNANCIES; NATIONAL-SURVEY; KNOWLEDGE; IMMEDIATE; PROVISION; INSERTION; ABORTION; HEALTH	Background Unintended pregnancy remains a serious public health challenge in the USA. We assessed the effects of an intervention to increase patients' access to long-acting reversible contraceptives (LARCs) on pregnancy rates. Methods We did a cluster randomised trial in 40 reproductive health clinics across the USA in 2011-13. 20 clinics were randomly assigned to receive evidence-based training on providing counselling and insertion of intrauterine devices (IUDs) or progestin implants and 20 to provide standard care. Usual costs for contraception were maintained at all sites. We recruited women aged 18-25 years attending family planning or abortion care visits and not desiring pregnancy in the next 12 months. The primary outcome was selection of an IUD or implant at the clinic visit and secondary outcome was pregnancy within 12 months. We used generalised estimating equations for clustered data to measure the intervention effect on contraceptive selection, and used survival analysis to assess pregnancy rates. Findings Of 1500 women enrolled, more at intervention than control sites reported receiving counselling on IUDs or implants (565 [71%] of 797 vs 271 [39%] of 693, odds ratio 3.8, 95% CI 2.8-5.2) and more selected LARCs during the clinic visit (224 [28%] vs 117 [17%], 1.9, 1.3-2.8). The pregnancy rate was lower in intervention group than in the control group after family planning visits (7.9 vs 15.4 per 100 person-years), but not after abortion visits (26.5 vs 22.3 per 100 person-years). We found a significant intervention effect on pregnancy rates in women attending family planning visits (hazard ratio 0.54, 95% CI 0.34-0.85). Interpretation The pregnancy rate can be reduced by provision of counselling on long-term reversible contraception and access to devices during family planning counselling visits.	[Harper, Cynthia C.; Rocca, Corinne H.; Thompson, Kirsten M.; Goodman, Suzan; Darney, Philip D.; Speidel, J. Joseph] Univ Calif San Francisco, Sch Med, Dept Obstet Gynecol & Reprod Sci, Bixby Ctr Global Reprod Hlth, San Francisco, CA 94143 USA; [Morfesis, Johanna; Westhoff, Carolyn L.] Planned Parenthood Federat Amer, New York, NY USA; [Westhoff, Carolyn L.] Columbia Univ Coll Phys & Surg, Dept Obstet & Gynecol, New York, NY 10032 USA	University of California System; University of California San Francisco; Columbia University	Harper, CC (corresponding author), Univ Calif San Francisco, Sch Med, Dept Obstet Gynecol & Reprod Sci, Bixby Ctr Global Reprod Hlth, 3333 Calif St,Suite 335,UCSF Box 0744, San Francisco, CA 94143 USA.	cynthia.harper@ucsf.edu		Thompson, Kirsten/0000-0002-1552-7257	William and Flora Hewlett Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024131] Funding Source: NIH RePORTER	William and Flora Hewlett Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	William and Flora Hewlett Foundation.	AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; [Anonymous], 2011, CLIN PREV SERV WOM C; [Anonymous], 2011, CONTRACEPTIVE TECHNO; Arrowsmith ME, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008896.pub2; Barnet B, 2009, ANN FAM MED, V7, P436, DOI 10.1370/afm.1014; Bednarek PH, 2011, NEW ENGL J MED, V364, P2208, DOI 10.1056/NEJMoa1011600; Ferreira ALCG, 2009, EUR J CONTRACEP REPR, V14, P1, DOI 10.1080/13625180802549970; Centers for Disease Control and Prevention, 2014, NAT SURV FAM GROWTH; Centers for Disease Control and Prevention, 2013, UN PREGN PREV; Cleland K, 2011, NEW ENGL J MED, V364, DOI 10.1056/NEJMp1104373; Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, 2012, OBSTET GYNECOL, V120, P983, DOI DOI 10.1097/AOG.0B013E3182723B7D; Finer LB, 2014, AM J PUBLIC HEALTH, V104, pS43, DOI 10.2105/AJPH.2013.301416; Finer LB, 2012, FERTIL STERIL, V98, P893, DOI 10.1016/j.fertnstert.2012.06.027; Goodman S, 2008, CONTRACEPTION, V78, P143, DOI 10.1016/j.contraception.2008.03.003; Harper CC, 2013, PREV MED, V57, P883, DOI 10.1016/j.ypmed.2013.10.005; Harper CC, 2012, FAM MED, V44, P637; Hayes RJ, 2009, INTERD STAT, P3; Institute of Medicine, 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Johnson Kay, 2006, Morbidity and Mortality Weekly Report, V55, P1; Kavanaugh ML, 2011, WOMEN HEALTH ISS, V21, pS26, DOI 10.1016/j.whi.2011.01.009; Kost K, 2008, CONTRACEPTION, V77, P10, DOI 10.1016/j.contraception.2007.09.013; Langston AM, 2014, CONTRACEPTION, V89, P103, DOI 10.1016/j.contraception.2013.10.014; Lewis C, 2013, CONTRACEPTION, V88, P226, DOI 10.1016/j.contraception.2013.06.004; Lopez LM, 2013, COCHRANE DB SYST REV, V4; Mazurek Gerald H., 2010, Morbidity and Mortality Weekly Report, V59, P1; Ott MA, 2014, PEDIATRICS, V134, pE1244, DOI 10.1542/peds.2014-2299; Peipert JF, 2012, OBSTET GYNECOL, V120, P1291, DOI [10.1097/AOG.0b013e318273eb56, http://10.1097/AOG.0b013e318273eb56]; Raine TR, 2011, OBSTET GYNECOL, V117, P363, DOI 10.1097/AOG.0b013e31820563d3; Rocca CH, 2012, PERSPECT SEX REPRO H, V44, P150, DOI 10.1363/4415012; Stanwood NL, 2006, OBSTET GYNECOL, V108, P1417, DOI 10.1097/01.AOG.0000245447.56585.a0; Steiner MJ, 2007, AM J OBSTET GYNECOL, V197, P118, DOI 10.1016/j.ajog.2007.03.049; Thompson KMJ, 2011, CONTRACEPTION, V83, P41, DOI 10.1016/j.contraception.2010.06.008; Thomson A, 2009, STAT MED, V28, P1739, DOI 10.1002/sim.3582; United Nations Department of Economic and Social Affairs Population Division, WORLD CONTR US 2011; US. Department of Health and Human Services Office of Disease Prevention and Health Promotion, 2020, HLTH PEOPL 2020; Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855	36	138	138	0	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 8	2015	386	9993					562	568		10.1016/S0140-6736(14)62460-0	http://dx.doi.org/10.1016/S0140-6736(14)62460-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CO8PG	26091743				2023-01-03	WOS:000359431900030
J	Pinnock, H; Taylor, SJC				Pinnock, Hilary; Taylor, Stephanie J. C.			CASE REVIEW Self management for a man with asthma	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							QUALITY-OF-LIFE; INTRANASAL CORTICOSTEROIDS; ALLERGIC RHINITIS; INTERVENTIONS; COMMUNITY; OUTCOMES; IMPACT		[Pinnock, Hilary] Univ Edinburgh, Asthma UK Ctr Appl Res, Usher Inst Populat Hlth Sci & Informat, Edinburgh EH8 9AG, Midlothian, Scotland; [Taylor, Stephanie J. C.] Queen Mary Univ, Asthma UK Ctr Appl Res, Ctr Primary Care & Publ Hlth, Barts & London Sch Med & Dent, London, England	University of Edinburgh; University of London; Queen Mary University London	Pinnock, H (corresponding author), Univ Edinburgh, Asthma UK Ctr Appl Res, Usher Inst Populat Hlth Sci & Informat, Edinburgh EH8 9AG, Midlothian, Scotland.	hilary.pinnock@ed.ac.uk	TAYLOR, STEPHANIE/GYV-4768-2022	Taylor, Stephanie/0000-0001-7454-6354	National Institute for Health Research [11/1014/04] Funding Source: researchfish; Asthma UK [AUK-AC-2012-01, 07/047] Funding Source: researchfish; Chief Scientist Office [PCRCA/08/01] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK; Chief Scientist Office		Adams N P, 2005, COCHRANE DB SYST REV, V1; Adams NP, 1999, COCHRANE DB SYST REV, V4; Adams NP, 2008, COCHRANE DB SYST REV, V4; [Anonymous], 2014, THORAX, V69, P1; Asthma UK, ACT PLANS; Barbanel D, 2003, THORAX, V58, P851, DOI 10.1136/thorax.58.10.851; Bousquet J, 2008, ARIA ALLERGIC RHINIT; Gibson PG, 2004, THORAX, V59, P94, DOI 10.1136/thorax.2003.011858; GIBSON PG, 2003, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001117; Global Initiative for Asthma, 2014, GLOB STRAT ASTH MAN; Honkoop PJ, 2013, EUR RESPIR J, V41, P53, DOI 10.1183/09031936.00205911; Huckvale K, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-144; Kielmann T, 2010, PATIENT EDUC COUNS, V79, P55, DOI 10.1016/j.pec.2009.07.015; Lohia S, 2013, ALLERGY, V68, P569, DOI 10.1111/all.12124; Marcano Belisario Jose S, 2013, Cochrane Database Syst Rev, pCD010013, DOI 10.1002/14651858.CD010013.pub2; Morrison D, 2014, J MED INTERNET RES, V16, DOI 10.2196/jmir.2814; Moudgil H, 2000, THORAX, V55, P177, DOI 10.1136/thorax.55.3.177; National Heart Lung and Blood Institute, 2007, 3 NAEPP; Nokela M, 2010, RESPIRATION, V79, P388, DOI 10.1159/000235548; Nunes V., 2009, MED ADHERENCE INVOLV; Partridge M, IMPERIAL COLL ELECT; Pinnock H, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0361-0; Pinnock H, 2015, CURR OPIN PULM MED, V21, P95, DOI 10.1097/MCP.0000000000000127; Powell H, 2002, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD004107; Press VG, 2012, J GEN INTERN MED, V27, P1001, DOI 10.1007/s11606-012-2058-9; Royal College of Physicians, 2014, CONF ENQ REP; Ryan D, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1756; Tapp S, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003000.pub2; Taylor SJC, 2014, HLTH SERV DELIV RES, V2, P54, DOI DOI 10.3310/HSDR02530; Thoonen BPA, 2003, THORAX, V58, P30, DOI 10.1136/thorax.58.1.30; Weiner JM, 1998, BMJ-BRIT MED J, V317, P1624, DOI 10.1136/bmj.317.7173.1624; Wiener-Ogilvie S, 2008, BMC FAM PRACT, V9, DOI 10.1186/1471-2296-9-32; Wiener-Ogilvie Sharon, 2007, Prim Care Respir J, V16, P369; Wolf FM, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000326	34	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	2015	351								h3970	10.1136/bmj.h3970	http://dx.doi.org/10.1136/bmj.h3970			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CN8HZ	26208652				2023-01-03	WOS:000358682400001
J	Morimoto-Kobayashi, Y; Ohara, K; Takahashi, C; Kitao, S; Wang, GY; Taniguchi, Y; Katayama, M; Nagai, K				Morimoto-Kobayashi, Yumie; Ohara, Kazuaki; Takahashi, Chika; Kitao, Sayoko; Wang, Guanying; Taniguchi, Yoshimasa; Katayama, Mikio; Nagai, Katsuya			Matured Hop Bittering Components Induce Thermogenesis in Brown Adipose Tissue via Sympathetic Nerve Activity	PLOS ONE			English	Article							DIET-INDUCED OBESITY; FAT; ISOHUMULONES; BEER; ANTIOBESITY; ALPHA; ACIDS; XANTHOHUMOL; RESISTANCE; PRODUCTS	Obesity is the principal symptom of metabolic syndrome, which refers to a group of risk factors that increase the likelihood of atherosclerosis. In recent decades there has been a sharp rise in the incidence of obesity throughout the developed world. Iso-alpha-acids, the bitter compounds derived from hops in beer, have been shown to prevent diet-induced obesity by increasing lipid oxidation in the liver and inhibition of lipid absorption from the intestine. Whereas the sharp bitterness induced by effective dose of iso-alpha-acids precludes their acceptance as a nutrient, matured hop bittering components (MHB) appear to be more agreeable. Therefore, we tested MHB for an effect on ameliorating diet-induced body fat accumulation in rodents. MHB ingestion had a beneficial effect but, compared to iso-alpha-acids and despite containing structurally similar compounds, acted via different mechanisms to reduce body fat accumulation. MHB supplementation significantly reduced body weight gain, epididymal white adipose tissue weight, and plasma non-esterified free fatty acid levels in diet-induced obese mice. We also found that uncoupling protein 1 (UCP1) expression in brown adipose tissue (BAT) was significantly increased in MHB-fed mice at both the mRNA and protein levels. In addition, MHB administration in rats induced the beta-adrenergic signaling cascade, which is related to cAMP accumulation in BAT, suggesting that MHB could modulate sympathetic nerve activity innervating BAT (BAT-SNA). Indeed, single oral administration of MHB elevated BAT-SNA in rats, and this elevation was dissipated by subdiaphragmatic vagotomy. Single oral administration of MHB maintained BAT temperature at a significantly higher level than in control rats. Taken together, these findings indicate that MHB ameliorates diet-induced body fat accumulation, at least partly, by enhancing thermogenesis in BAT via BAT-SNA activation. Our data suggests that MHB is a useful tool for developing functional foods or beverages to counteract the accumulation of body fat.	[Morimoto-Kobayashi, Yumie; Ohara, Kazuaki; Takahashi, Chika; Kitao, Sayoko; Wang, Guanying; Taniguchi, Yoshimasa; Katayama, Mikio] KIRIN Co Ltd, Res Labs Hlth Sci & Food Technol, Yokohama, Kanagawa, Japan; [Nagai, Katsuya] ANBAS Corp, Osaka, Japan		Morimoto-Kobayashi, Y (corresponding author), KIRIN Co Ltd, Res Labs Hlth Sci & Food Technol, Yokohama, Kanagawa, Japan.	Yumie_Kobayashi@kirin.co.jp		Taniguchi, Yoshimasa/0000-0003-4588-4877	Kirin Company, Ltd.; ANBAS Corporation	Kirin Company, Ltd.; ANBAS Corporation	Kirin Company, Ltd. and ANBAS Corporation provided support in the form of salaries for authors YMK, KO, CT, SK, GW, YT, MK and KN, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Almaguer C, 2012, BREW SCI, V65, P118; Azzu V, 2010, TRENDS BIOCHEM SCI, V35, P298, DOI 10.1016/j.tibs.2009.11.001; Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160; Bordicchia M, 2012, J CLIN INVEST, V122, P1022, DOI 10.1172/JCI59701; Boss Olivier, 2012, Front Endocrinol (Lausanne), V3, P14, DOI 10.3389/fendo.2012.00014; Bullen JW, 2007, AM J PHYSIOL-ENDOC M, V292, pE1079, DOI 10.1152/ajpendo.00245.2006; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Chen HY, 2013, PPAR RES, V2013, DOI 10.1155/2013/476049; Fisher FM, 2012, GENE DEV, V26, P271, DOI 10.1101/gad.177857.111; FOLCH J, 1957, J BIOL CHEM, V226, P497; Hemmeryckx B, 2011, OBESITY, V19, P659, DOI 10.1038/oby.2010.266; Inokuma K, 2006, AM J PHYSIOL-ENDOC M, V290, pE1014, DOI 10.1152/ajpendo.00105.2005; Janssen S, 2013, TRENDS ENDOCRIN MET, V24, P92, DOI 10.1016/j.tem.2012.11.006; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kajimura S, 2010, CELL METAB, V11, P257, DOI 10.1016/j.cmet.2010.03.005; Kim SY, 2013, CHEM-BIOL INTERACT, V203, P565, DOI 10.1016/j.cbi.2013.03.012; Lee YH, 2014, BBA-MOL BASIS DIS, V1842, P358, DOI 10.1016/j.bbadis.2013.05.011; Li B, 2000, NAT MED, V6, P1115, DOI 10.1038/80450; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Mathieu P, 2006, VASC HEALTH RISK MAN, V2, P285, DOI 10.2147/vhrm.2006.2.3.285; Milligan S, 2002, REPRODUCTION, V123, P235, DOI 10.1530/rep.0.1230235; Miura Y, 2005, BRIT J NUTR, V93, P559, DOI 10.1079/BJN20041384; Nozawa H, 2005, MOL NUTR FOOD RES, V49, P772, DOI 10.1002/mnfr.200500027; Ono E, 2011, BIOCHEM BIOPH RES CO, V410, P677, DOI 10.1016/j.bbrc.2011.06.055; ONO M, 1987, Journal of the American Society of Brewing Chemists, V45, P61; Puigserver P, 2005, INT J OBESITY, V29, pS5, DOI 10.1038/sj.ijo.0802905; Saito M, 2014, ENDOCR J, V61, P409, DOI 10.1507/endocrj.EJ13-0527; Saito M, 2013, DIABETES METAB J, V37, P22, DOI 10.4093/dmj.2013.37.1.22; Saito M, 2009, DIABETES, V58, P1526, DOI 10.2337/db09-0530; Schoonjans K, 1996, J LIPID RES, V37, P907; Shen J, 2005, NEUROSCI LETT, V383, P188, DOI 10.1016/j.neulet.2005.04.010; Shen J, 2009, NEUROSCI LETT, V461, P30, DOI 10.1016/j.neulet.2009.05.067; Shimamura M, 2001, BIOCHEM BIOPH RES CO, V289, P220, DOI 10.1006/bbrc.2001.5934; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Stevens JF, 2004, PHYTOCHEMISTRY, V65, P1317, DOI 10.1016/j.phytochem.2004.04.025; Taniguchi Y, 2015, BIOSCI BIOT IN PRESS; Taniguchi Y, 2014, J NAT PROD, V77, P1252, DOI 10.1021/np4008427; Taniguchi Y, 2013, J AGR FOOD CHEM, V61, P3121, DOI 10.1021/jf3047187; Yajima H, 2005, INT J OBESITY, V29, P991, DOI 10.1038/sj.ijo.0802965; Yajima H, 2004, J BIOL CHEM, V279, P33456, DOI 10.1074/jbc.M403456200; Zanoli P, 2008, J ETHNOPHARMACOL, V116, P383, DOI 10.1016/j.jep.2008.01.011	42	21	21	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2015	10	6							e0131042	10.1371/journal.pone.0131042	http://dx.doi.org/10.1371/journal.pone.0131042			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL3FM	26098641	Green Published, gold, Green Submitted			2023-01-03	WOS:000356835800135
J	Knowles, CH; Horrocks, EJ; Bremner, SA; Stevens, N; Norton, C; O'Connell, PR; Eldridge, S				Knowles, Charles H.; Horrocks, Emma J.; Bremner, Stephen A.; Stevens, Natasha; Norton, Christine; O'Connell, P. Ronan; Eldridge, Sandra		CONFIDeNT Study Grp	Percutaneous tibial nerve stimulation versus sham electrical stimulation for the treatment of faecal incontinence in adults (CONFIDeNT): a double-blind, multicentre, pragmatic, parallel-group, randomised controlled trial	LANCET			English	Article							QUALITY-OF-LIFE; PLACEBO-RESPONSES	Background Percutaneous tibial nerve stimulation (PTNS) is a new ambulatory therapy for faecal incontinence. Data from case series suggest it has beneficial outcomes in 50-80% patients; however its effectiveness against sham electrical stimulation has not been investigated. We therefore aimed to assess the short-term efficacy of PTNS against sham electrical stimulation in adults with faecal incontinence. Methods We did a double-blind, multicentre, pragmatic, parallel-group, randomised controlled trial (CONtrol of Faecal Incontinence using Distal NeuromodulaTion [CONFIDeNT]) in 17 specialist hospital units in the UK that had the skills to manage patients with faecal incontinence. Eligible participants aged 18 years or older with substantial faecal incontinence for whom conservative treatments (such as dietary changes and pelvic floor exercises) had not worked, were randomly assigned (1: 1) to receive either PTNS (via the Urgent PC neuromodulation system) or sham stimulation (via a transcutaneous electrical nerve stimulation machine to the lateral forefoot) once per week for 12 weeks. Randomisation was done with permuted block sizes of two, four, and six, and was stratified by sex and then by centre for women. Patients and outcome assessors were both masked to treatment allocation for the 14-week duration of the trial (but investigators giving the treatment were not masked). The primary outcome was a clinical response to treatment, which we defined as a 50% or greater reduction in episodes of faecal incontinence per week. We assessed this outcome after 12 treatment sessions, using data from patients' bowel diaries. Analysis was by intention to treat, and missing data were multiply imputed. This trial is registered with the ISRCTN registry, number 88559475, and is closed to new participants. Findings Between Jan 23, 2012, and Oct 31, 2013, we randomly assigned 227 eligible patients (of 373 screened) to receive either PTNS (n=115) or sham stimulation (n=112). 12 patients withdrew from the trial: seven from the PTNS group and five from the sham group (mainly because they could not commit to receiving treatment every week). Two patients (one in each group) withdrew because of an adverse event that was unrelated to treatment (exacerbation of fibromyalgia and rectal bleeding). 39 (38%) of 103 patients with full data from bowel diaries in the PTNS group had a 50% or greater reduction in the number of episodes of faecal incontinence per week compared with 32 (31%) of 102 patients in the sham group (adjusted odds ratio 1.28, 95% CI 0.72-2.28; p=0.396). No serious adverse events related to treatment were reported in the trial. Seven mild, related adverse events were reported in each treatment group, mainly pain at the needle site (four in PTNS, three in sham). Interpretation PTNS given for 12 weeks did not confer significant clinical benefit over sham electrical stimulation in the treatment of adults with faecal incontinence. Further studies are warranted to determine its efficacy in the long term, and in patient subgroups (ie, those with urgency).	[Knowles, Charles H.; Horrocks, Emma J.] Univ London, Blizard Inst, Natl Ctr Bowel Res & Surg Innovat, London, England; [Bremner, Stephen A.; Stevens, Natasha; Eldridge, Sandra] Univ London, Blizard Inst, Pragmat Clin Trials Unit, London, England; [Norton, Christine] Kings Coll London, Florence Nightingale Fac Nursing & Midwifery, London WC2R 2LS, England; [O'Connell, P. Ronan] Univ Coll Dublin, Sch Med & Med Sci, Dublin 2, Ireland	University of London; University of London; University of London; King's College London; University College Dublin	Knowles, CH (corresponding author), Natl Ctr Bowel Res & Surg Innovat, London E1 2AT, England.	c.h.knowles@qmul.ac.uk	O'Connell, Patrick Ronan/H-6583-2019; Bremner, Stephen/R-4038-2016	O'Connell, Patrick Ronan/0000-0002-1846-5629; Bremner, Stephen/0000-0003-0790-7070; Eldridge, Sandra/0000-0001-5638-2317	Pragmatic Clinical Trials Unit (PCTU); Barts; London School of Medicine and Dentistry; UK NIHR Health Technology Assessment (HTA) programme [HTA 09/104/16]; National Institute for Health Research [NF-SI-0514-10066, 09/104/16] Funding Source: researchfish	Pragmatic Clinical Trials Unit (PCTU); Barts; London School of Medicine and Dentistry; UK NIHR Health Technology Assessment (HTA) programme; National Institute for Health Research(National Institute for Health Research (NIHR))	National Institute for Health Research.; The trial was under the auspices of the Chief Investigator and the Pragmatic Clinical Trials Unit (PCTU), Barts and The London School of Medicine and Dentistry (sponsor: Queen Mary University of London). It was funded by the UK NIHR Health Technology Assessment (HTA) programme (HTA 09/104/16). The views and opinions expressed in this report are those of the authors and are not necessarily those of the HTA programme, NIHR, the UK National Health Service, or the UK Department of Health. We would like to acknowledge the following people in relation to the CONFIDeNT study: Deborah Gilbert (Patient and Public Involvement representative), Norman Williams (clinical adviser), Sandy Smith, Mike Waring, Lara Edwards, Anitha Manivannan, Glenn Poon, Syed Arafath, and Polly Jordan (the Data Management and Quality Assurance team), and Elaine Denny and Daniel Altmann (the Data and Safety Monitoring committee).	Asari SA, 2014, COLORECTAL DIS, V16, pO393, DOI DOI 10.1111/CODI.12680; Brown SR, 2013, COCHRANE DB SYST REV, V7; Carpenter JR, 2011, J STAT SOFTW, V45, P1; Cotterill N, 2011, DIS COLON RECTUM, V54, P1235, DOI 10.1097/DCR.0b013e3182272128; Enck P, 2012, EUR J GASTROEN HEPAT, V24, P1, DOI 10.1097/MEG.0b013e32834bb951; EYPASCH E, 1995, BRIT J SURG, V82, P216, DOI 10.1002/bjs.1800820229; George AT, 2013, BRIT J SURG, V100, P330, DOI 10.1002/bjs.9000; Graf W, 2011, LANCET, V377, P997, DOI 10.1016/S0140-6736(10)62297-0; Horrocks EJ, 2014, BRIT J SURG, V101, P457, DOI 10.1002/bjs.9391; Hotouras A, 2012, COLORECTAL DIS, V14, P1101, DOI 10.1111/j.1463-1318.2011.02906.x; Hotouras A, 2014, SURG TODAY, V44, P2124, DOI 10.1007/s00595-014-0898-0; Kahan BC, 2013, STAT MED, V32, P1136, DOI 10.1002/sim.5667; Leroi AM, 2012, AM J GASTROENTEROL, V107, P1888, DOI 10.1038/ajg.2012.330; MATZEL KE, 1995, LANCET, V346, P1124, DOI 10.1016/S0140-6736(95)91799-3; Musial F, 2007, WORLD J GASTROENTERO, V13, P3425, DOI 10.3748/wjg.v13.i25.3425; National Institute for Health and Care Excellence, 2007, FAEC INC MAN FAEC IN; National Institute for Health and Care Excellence, 2011, NICE INT PROC GUID I; NELSON R, 1995, JAMA-J AM MED ASSOC, V274, P559, DOI 10.1001/jama.274.7.559; Pacheco-Lopez G, 2006, BRAIN BEHAV IMMUN, V20, P430, DOI 10.1016/j.bbi.2006.05.003; Peters KM, 2010, J UROLOGY, V183, P1438, DOI 10.1016/j.juro.2009.12.036; Rockwood TH, 2000, DIS COLON RECTUM, V43, P9, DOI 10.1007/BF02237236; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; Thin NN, 2015, BRIT J SURG, V102, P349, DOI 10.1002/bjs.9695; Vaizey CJ, 2014, COLORECTAL DIS, V16, P156, DOI 10.1111/codi.12566; Vaizey CJ, 1999, GUT, V44, P77, DOI 10.1136/gut.44.1.77; Wexner SD, 2010, ANN SURG, V251, P441, DOI 10.1097/SLA.0b013e3181cf8ed0; Whitehead WE, 2009, GASTROENTEROLOGY, V137, P512, DOI 10.1053/j.gastro.2009.04.054; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	28	83	90	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 24	2015	386	10004					1640	1648		10.1016/S0140-6736(15)60314-2	http://dx.doi.org/10.1016/S0140-6736(15)60314-2			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CU0HS	26293315				2023-01-03	WOS:000363197500031
J	Gould, J				Gould, J.			Cannabis: 4 big questions	NATURE			English	Article																			0	1	1	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 24	2015	525	7570					S18	S18		10.1038/525S18a	http://dx.doi.org/10.1038/525S18a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR8KI	26398735	Bronze			2023-01-03	WOS:000361599900062
J	Koo, T; Song, C; Kim, JS; Kim, K; Chie, EK; Kang, SB; Lee, KW; Kim, JH; Jeong, SY; Kim, TY				Koo, Taeryool; Song, Changhoon; Kim, Jae-Sung; Kim, Kyubo; Chie, Eui Kyu; Kang, Sung-Bum; Lee, Keun-Wook; Kim, Jee Hyun; Jeong, Seung-Yong; Kim, Tae-You			Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy	PLOS ONE			English	Article							PREOPERATIVE CHEMORADIOTHERAPY; CURATIVE RESECTION; COLORECTAL-CANCER; PROGNOSTIC-FACTOR; TUMOR RESPONSE; CHEMORADIATION; TRIAL; RADIOCHEMOTHERAPY; OXALIPLATIN; RETRIEVAL	Purpose To evaluate the prognostic impact of the lymph node ratio (LNR) in ypStage III rectal cancer patients who were treated with neoadjuvant chemoradiotherapy (NCRT). Materials and Methods We retrospectively reviewed the data of 638 consecutive patients who underwent NCRT followed by total mesorectal excision, and postoperative adjuvant chemotherapy for rectal cancer from 2004 to 2011. Of these, 125 patients were positive for lymph node (LN) metastasis and were analyzed in this study. Results The median numbers of examined and metastatic LNs were 17 and 2, respectively, and the median LNR was 0.143 (range, 0.02-1). Median follow-up time was 55 months. In multivariate analyses, LNR was an independent prognostic factor for overall survival (OS) (hazard ratio [HR] 2.17, p = 0.041), disease-free survival (DFS) (HR 2.28, p = 0.005), and distant metastasis-free survival (DMFS) (HR 2.30, p = 0.010). When ypN1 patients were divided into low (low LNR ypN1 group) and high LNR (high LNR ypN1 group) according to a cut-off value of 0.152, the high LNR ypN1 group had poorer OS (p = 0.043) and DFS (p = 0.056) compared with the low LNR ypN1 group. And there were no differences between the high LNR ypN1 group and the ypN2 group in terms of the OS (p = 0.703) and DFS (p = 0.831). Conclusions For ypN-positive rectal cancer patients, the LNR was a more effective prognostic marker than the ypN stage, circumferential resection margin, or tumor regression grade after NCRT, and could be used to discern the high-risk group among ypN1 patients.	[Koo, Taeryool; Kim, Kyubo; Chie, Eui Kyu] Seoul Natl Univ, Dept Radiat Oncol, Coll Med, Seoul, South Korea; [Song, Changhoon; Kim, Jae-Sung] Seoul Natl Univ, Bundang Hosp, Dept Radiat Oncol, Songnam, South Korea; [Kang, Sung-Bum] Seoul Natl Univ, Bundang Hosp, Dept Surg, Songnam, South Korea; [Lee, Keun-Wook; Kim, Jee Hyun] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Songnam, South Korea; [Jeong, Seung-Yong] Seoul Natl Univ, Coll Med, Dept Surg, Seoul, South Korea; [Kim, Tae-You] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Kim, JS (corresponding author), Seoul Natl Univ, Bundang Hosp, Dept Radiat Oncol, Songnam, South Korea.	jskim@snubh.org	Kim, Kyubo/R-8061-2019	Kim, Jae-Sung/0000-0001-5348-9178; Song, Changhoon/0000-0002-0714-8775; Chie, Eui Kyu/0000-0003-2027-7472				Aschele C, 2011, J CLIN ONCOL, V29, P2773, DOI 10.1200/JCO.2010.34.4911; Bhatti I, 2010, WORLD J SURG, V34, P768, DOI 10.1007/s00268-009-0336-4; Chang GJ, 2007, J NATL CANCER I, V99, P433, DOI 10.1093/jnci/djk092; Chang GJ, 2009, CANCER, V115, P5432, DOI 10.1002/cncr.24622; de la Fuente SG, 2009, J GASTROINTEST SURG, V13, P269, DOI 10.1007/s11605-008-0717-2; Fokas E, 2014, J CLIN ONCOL, V32, P1554, DOI 10.1200/JCO.2013.54.3769; Frederique P, 2008, ANN SURG, V248, P1067, DOI 10.1097/SLA.0b013e31818842ec; Glynne-Jones R, 2006, ANN ONCOL, V17, P1239, DOI 10.1093/annonc/mdl173; Hong YS, 2014, LANCET ONCOL, V15, P1245, DOI 10.1016/S1470-2045(14)70377-8; Jang NY, 2011, DIS COLON RECTUM, V54, P245, DOI 10.1007/DCR.0b013e3181fcee68; Kang J, 2011, J SURG ONCOL, V104, P53, DOI 10.1002/jso.21913; Kim H, 2014, CANCER RES TREAT, V46, P148, DOI 10.4143/crt.2014.46.2.148; Kim TH, 2010, INT J RADIAT ONCOL, V77, P1158, DOI 10.1016/j.ijrobp.2009.06.019; Kim YS, 2009, INT J RADIAT ONCOL, V74, P796, DOI 10.1016/j.ijrobp.2008.08.065; Klos CL, 2011, DIS COLON RECTUM, V54, P171, DOI 10.1007/DCR.0b013e3181fd677d; Laska E, 2012, STAT MED, V31, P3178, DOI 10.1002/sim.5384; Lee JH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-576; Lee SD, 2012, EJSO-EUR J SURG ONC, V38, P478, DOI 10.1016/j.ejso.2012.03.002; Lim SB, 2012, J SURG ONCOL, V106, P667, DOI 10.1002/jso.23198; Madbouly KM, 2014, AM J SURG, V207, P824, DOI 10.1016/j.amjsurg.2013.07.022; Moug SJ, 2009, BRIT J CANCER, V100, P1530, DOI 10.1038/sj.bjc.6605049; Nadoshan JJ, 2013, ASIAN PAC J CANCER P, V14, P3769, DOI 10.7314/APJCP.2013.14.6.3769; Nagtegaal ID, 2008, J CLIN ONCOL, V26, P303, DOI 10.1200/JCO.2007.12.7027; Rosenberg R, 2010, ANN SURG, V251, P1070, DOI 10.1097/SLA.0b013e3181d7789d; Rosenberg R, 2008, ANN SURG, V248, P968, DOI 10.1097/SLA.0b013e318190eddc; Sun Z, 2009, ANN ONCOL, V20, P897, DOI 10.1093/annonc/mdn707; Tong LL, 2011, ANN SURG ONCOL, V18, P2453, DOI 10.1245/s10434-011-1687-2; Wichmann MW, 2002, ARCH SURG-CHICAGO, V137, P206, DOI 10.1001/archsurg.137.2.206; Wu SG, 2014, CANC RES TREAT	29	10	11	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2015	10	9							e0138728	10.1371/journal.pone.0138728	http://dx.doi.org/10.1371/journal.pone.0138728			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS0ZE	26381522	Green Submitted, Green Published, gold			2023-01-03	WOS:000361790200154
J	Roura, M; Bisoffi, F; Navaza, B; Pool, R				Roura, Maria; Bisoffi, Federico; Navaza, Barbara; Pool, Robert			"Carrying Ibuprofen in the Bag": Priority Health Concerns of Latin American Migrants in Spain- A Participatory Qualitative Study	PLOS ONE			English	Article							CORONARY-HEART-DISEASE; PROSPECTIVE COHORT; SWEDISH MEN; IMMIGRANTS; STRESS; EUROPE; RISK; DETERMINANTS; SERVICE; MORTALITY	Background An estimated 2.7 million Latin Americans reside in Europe, mostly in Spain. Part of a broader project aimed at developing a research agenda on the health status and determinants of this population, this qualitative study engaged Latin American migrants in the identification of research priorities. Methods We conducted 30 group discussions between November 2012-March 2013 with 84 participants purposively selected for maximum diversity in Madrid and Barcelona (Spain). We facilitated sequences of task-oriented visual activities to explore their views on priority health concerns. We tape-recorded and transcribed discussions and developed a coding frame based on socio-ecological frameworks, which we applied to all the data using NVIVO-10. A final round of eight group discussions allowed us to triangulate and enrich interpretations by including participants' insights. Findings The cumulative toll of daily stresses was the major health concern perceived by a population that conceptualised ill-health as a constellation of symptoms rather than as specific diseases. Work-related factors, legislative frameworks regulating citizenship entitlements and feeling ethnically discriminated were major sources of psycho-social strain. Except for sexually transmitted infections, participants rarely referred to communicable diseases as a concern. The perception that clinicians systematically prescribed painkillers discouraged health seeking and fostered self-medication. Participants felt that the medicalised, chemicalised, sexually liberal and accelerated culture of the host society damaged their own, and the local populations' health. Conclusion Health systems bear a disproportionate responsibility in addressing health problems rooted in other sectors. Occupational and migration policies should be recognised explicitly as health policies. The mismatch between researchers' emphasis on communicable infections and the health concerns of Latin American migrants highlights the need for greater interaction between different forms of knowledge. In this process, the biomedical culture of reliance on pharmacological solutions should not remain unquestioned.	[Roura, Maria; Bisoffi, Federico; Navaza, Barbara] Univ Barcelona, ISGlobal, Barcelona Ctr Int Hlth Res CRESIB, Hosp Clin, Barcelona, Spain; [Pool, Robert] Univ Amsterdam, Ctr Social Sci & Global Hlth, Amsterdam, Netherlands	ISGlobal; CRESIB; University of Barcelona; Hospital Clinic de Barcelona; University of Amsterdam	Roura, M (corresponding author), Univ Barcelona, ISGlobal, Barcelona Ctr Int Hlth Res CRESIB, Hosp Clin, Barcelona, Spain.	maria.roura@isglobal.org	Roura, Maria/K-6668-2014	Roura, Maria/0000-0001-9556-1940	European Commission [FP7-GA-261495]; Spanish Ministry of Economy and Competitiveness (MINECO) under the Ramon y Cajal Fellowship program [RYC-2011-08428]	European Commission(European CommissionEuropean Commission Joint Research Centre); Spanish Ministry of Economy and Competitiveness (MINECO) under the Ramon y Cajal Fellowship program	This research was undertaken as part of the COHEMI project supported by the European Commission 7th Framework Program, Grant Agreement no FP7-GA-261495, (http://ec.europa.eu/research/health/public-health/public-health-and-health-systems/projects/cohemi_en.html). MR is financed by the Spanish Ministry of Economy and Competitiveness (MINECO) under the Ramon y Cajal Fellowship program (RYC-2011-08428),(http://www.idi.mineco.gob.es/portal/site/MICINN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahonen EQ, 2010, AM J IND MED, V53, P405, DOI 10.1002/ajim.20710; Aragona M, 2012, ETHNIC HEALTH, V17, P477, DOI 10.1080/13557858.2012.661406; Arango Joaquin., 2013, PROMOTING INTEGRATIO; BARTLEY M, 1994, J EPIDEMIOL COMMUN H, V48, P333, DOI 10.1136/jech.48.4.333; Bazeley P., 2013, QUALITATIVE DATA ANA; Bonney R, 2014, SCIENCE, V343, P1436, DOI 10.1126/science.1251554; Bosma H, 1998, AM J PUBLIC HEALTH, V88, P68, DOI 10.2105/AJPH.88.1.68; Boulanger RF, 2013, LANCET INFECT DIS, V13, P540, DOI 10.1016/S1473-3099(13)70042-2; Brigidi S., 2009, MIGRACIONES Y SALUD, P300; Brunner E, 1997, BMJ-BRIT MED J, V314, P1472, DOI 10.1136/bmj.314.7092.1472; Brunner E, 2011, SOCIAL DETERMINANTS; Campanya Tanquem els CIE, 2015, CAMP PEL TANC DELS C; Casino G, 2012, LANCET, V379, P1777, DOI 10.1016/S0140-6736(12)60745-4; Castaneda H., 2010, NAPA B, V34, P6, DOI DOI 10.1111/J.1556-4797.2010.01049.X; Ceberio M., 2012, INTERIOR PROHIBE RED; Conrad P, 2005, J HEALTH SOC BEHAV, V46, P3, DOI 10.1177/002214650504600102; Coyne JC, 2009, AM HEART J, V157, DOI 10.1016/j.ahj.2009.03.004; Cruz Ines, 2010, BMC Public Health, V10, P255, DOI 10.1186/1471-2458-10-255; Davies A.A., 2006, MIGRATION SOCIAL DET; EFE, 2015, PAIS; Espinosa P., 2013, ULISES VIVEN ANDALUC; Factor R, 2011, SOC SCI MED, V73, P1292, DOI 10.1016/j.socscimed.2011.07.027; Ferrie JE, 2001, BMJ-BRIT MED J, V322, P647, DOI 10.1136/bmj.322.7287.647; Frank J., 2013, J EPIDEMIOL COMMUNIT, V67, P469; Ganann R, 2013, J IMMIGR MINOR HEALT, V15, P341, DOI 10.1007/s10903-012-9622-6; Garcia-Ramirez M, 2009, INT J MIGR HEALTH SO, V5, P2, DOI 10.1108/17479894200900001; GILL PS, 2007, HLTH CARE NEEDS ASSE, P227; Glasziou P, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4247; Good B., 1985, CULTURE DEPRESSION; Graham GG, 2013, INFLAMMOPHARMACOLOGY, V21, P201, DOI 10.1007/s10787-013-0172-x; Guta A, 2014, SOC SCI MED, V123, P250, DOI 10.1016/j.socscimed.2014.07.028; Guta A, 2013, CRIT PUBLIC HEALTH, V23, P432, DOI 10.1080/09581596.2012.761675; Gutthann SP, 1997, EPIDEMIOLOGY, V8, P18, DOI 10.1097/00001648-199701000-00003; Horowitz CR, 2009, CIRCULATION, V119, P2633, DOI 10.1161/CIRCULATIONAHA.107.729863; Ingleby D, 2010, HLTH SYSTEMS CAN ADD; International Centre for Migration Policy Development, 2012, CLAND DAT IRR MIGR S; Johannes Siegrist, 2002, RES OCCUPATIONAL STR, V2, P261; KARASEK R, 1981, AM J PUBLIC HEALTH, V71, P694, DOI 10.2105/AJPH.71.7.694; Kivimaki M, 2002, BRIT MED J, V325, P857, DOI 10.1136/bmj.325.7369.857; Kleinman A, 2006, PLOS MED, V3, P1673, DOI 10.1371/journal.pmed.0030294; Knutsson A, 1999, OCCUP ENVIRON MED, V56, P46, DOI 10.1136/oem.56.1.46; Kristenson M, 2004, SOC SCI MED, V58, P1511, DOI 10.1016/S0277-9536(03)00353-8; Kristenson M, 1997, BRIT MED J, V314, P629, DOI 10.1136/bmj.314.7081.629; Kunst A. E., 2011, Migration and health in the European Union, P101; Lam JR, 2013, JAMA-J AM MED ASSOC, V310, P2435, DOI 10.1001/jama.2013.280490; Legido-Quigley H, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2363; Lindert J, 2009, SOC SCI MED, V69, P246, DOI 10.1016/j.socscimed.2009.04.032; Lo MCM, 2008, SOCIOL HEALTH ILL, V30, P741, DOI 10.1111/j.1467-9566.2008.01091.x; Marmot M, 2012, LANCET, V380, P1011, DOI 10.1016/S0140-6736(12)61228-8; McDonald JT, 2004, SOC SCI MED, V59, P1613, DOI 10.1016/j.socscimed.2004.02.004; Ministerio de Interior, 2013, LUCH INM IRR BAL 201; Mladovsky P, 2012, HEALTH POLICY, V105, P1, DOI 10.1016/j.healthpol.2012.01.007; MOYNIHAN R, 2013, BMJ-BRIT MED J, V347, DOI DOI 10.1136/BMJ.F7141; Napier AD, 2014, LANCET, V384, P1607, DOI 10.1016/S0140-6736(14)61603-2; Nyberg ST, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067323; Patino C, 2010, PSYCHOPATHOLOGY, V43, P17, DOI 10.1159/000255959; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; POPE C, 1995, BRIT MED J, V311, P42, DOI 10.1136/bmj.311.6996.42; QSR International, NVIVO 10 WIND; Rechel B, 2013, LANCET, V381, P1235, DOI 10.1016/S0140-6736(12)62086-8; Requena-Mendez A, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003540; Roberts E, 2015, ANN RHEUMATIC DIS; Ronda E, 2013, J IMMIGR MINOR HEALT, V15, P164, DOI 10.1007/s10903-012-9664-9; Perez ER, 2012, ETHNIC HEALTH, V17, P563, DOI 10.1080/13557858.2012.730606; Roura M, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1799-x; Villarroel N, 2012, HEALTH PLACE, V18, P1282, DOI 10.1016/j.healthplace.2012.09.009; Viruell-Fuentes EA, 2007, SOC SCI MED, V65, P1524, DOI 10.1016/j.socscimed.2007.05.010; Whitehead M, 1991, GEOL FORENINGAN STOC; Williams CM, 2014, LANCET, V384, P1586, DOI 10.1016/S0140-6736(14)60805-9; World Health Organization, 2005, HLTH ALL POL FRAM WH	70	11	11	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2015	10	8							e0136315	10.1371/journal.pone.0136315	http://dx.doi.org/10.1371/journal.pone.0136315			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ0PO	26317781	Green Submitted, Green Published, gold			2023-01-03	WOS:000360299100071
J	Contzen, N; De Pasquale, S; Mosler, HJ				Contzen, Nadja; De Pasquale, Sandra; Mosler, Hans-Joachim			Over-Reporting in Handwashing Self-Reports: Potential Explanatory Factors and Alternative Measurements	PLOS ONE			English	Article							SOCIAL DESIRABILITY SCALE; HAND-HYGIENE; STRUCTURED OBSERVATIONS; INDIVIDUAL-DIFFERENCES; COGNITIVE-DISSONANCE; SENSITIVE QUESTIONS; BURKINA-FASO; BEHAVIOR; VALIDITY; MEMORY	Handwashing interventions are a priority in development and emergency aid programs. Evaluation of these interventions is essential to assess the effectiveness of programs; however, measuring handwashing is quite difficult. Although observations are considered valid, they are time-consuming and cost-ineffective; self-reports are highly efficient but considered invalid because desirable behaviour tends to be over-reported. Socially desirable responding has been claimed to be the main cause of inflated self-reports, but its underlying factors and mechanisms are understudied. The present study investigated socially desirable responding and additional potential explanatory factors for over-reported handwashing to identify indications for measures which mitigate over-reporting. Additionally, a script-based covert recall, an alternative interview question intended to mitigate recall errors and socially desirable responding, was developed and tested. Cross-sectional data collection was conducted in the Borena Zone, Ethiopia, through 2.5-hour observations and 1-hour interviews with the primary caregivers in households. A total sample of N = 554 was surveyed. Data were analysed with correlation and multiple regression analyses and dependent t-tests. Over-reporting of handwashing was associated with factors assumed to be involved in (1) socially desirable responding, (2) encoding and recall of information, and (3) dissonance processes. The latter two factor groups explained over-reported handwashing beyond socially desirable responding. The alternative interview question-script-based covert recall-reduced over-reporting compared to conventional self-reports. Although the difficulties involved in measuring handwashing by self-reports and observations are widely known, the present study is the first to investigate the factors which explain over-reporting of handwashing. This research contributes to the limited evidence base on a highly important subject: how to evaluate handwashing interventions efficiently and accurately.	[Contzen, Nadja; Mosler, Hans-Joachim] Eawag Swiss Fed Inst Aquat Sci & Technol, Dept Environm Social Sci, Environm & Hlth Psychol, Dubendorf, Switzerland; [De Pasquale, Sandra] Univ Zurich, Dept Psychol, Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; Swiss Federal Institute of Aquatic Science & Technology (EAWAG); University of Zurich	Contzen, N (corresponding author), Eawag Swiss Fed Inst Aquat Sci & Technol, Dept Environm Social Sci, Environm & Hlth Psychol, Dubendorf, Switzerland.	nadja.contzen@eawag.ch		Contzen, Nadja/0000-0001-5875-5578				Aiello AE, 2008, AM J PUBLIC HEALTH, V98, P1372, DOI 10.2105/AJPH.2007.124610; AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Aquilino WS, 2000, SUBST USE MISUSE, V35, P845, DOI 10.3109/10826080009148424; Biran A, 2008, TROP MED INT HEALTH, V13, P278, DOI 10.1111/j.1365-3156.2007.02001.x; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Boyce JM, 2011, INFECT CONT HOSP EP, V32, P1016, DOI 10.1086/662015; Bradburn NM, 2000, SCIENCE OF SELF-REPORT, P49; Brener ND, 2003, J ADOLESCENT HEALTH, V33, P436, DOI 10.1016/S1054-139X(03)00052-1; BURTON S, 1991, PUBLIC OPIN QUART, V55, P50, DOI 10.1086/269241; Cairncross S, 2010, INT J EPIDEMIOL, V39, P193, DOI 10.1093/ije/dyq035; Cialdini R.B., 2006, SOC INFLUENCE, V1, P3, DOI [10.1080/15534510500181459, DOI 10.1080/15534510500181459]; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen J., 2002, APPL MULTIPLE REGRES, V3rd, DOI 10.4324/9780203774441; Contzen N, 2015, AM J INFECT CONTROL, V43, P826, DOI 10.1016/j.ajic.2015.04.186; Contzen N, 2013, J PUBLIC HEALTH-HEID, V21, P559, DOI 10.1007/s10389-013-0577-4; Cousens S, 1996, SOC SCI MED, V43, P1299, DOI 10.1016/0277-9536(95)00380-0; Crisp RJ, 2006, PERS SOC PSYCHOL B, V32, P1204, DOI 10.1177/0146167206289409; CROWNE DP, 1960, J CONSULT PSYCHOL, V24, P349, DOI 10.1037/h0047358; CURTIS V, 1993, B WORLD HEALTH ORGAN, V71, P23; Davidson KW, 2003, ANN BEHAV MED, V26, P161, DOI 10.1207/S15324796ABM2603_01; DeMaio T., 1984, SURVEYING SUBJECTIVE, P257, DOI 10.2458/v7i2.20321; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Festinger L., 1962, THEORY COGNITIVE DIS; Fishbein M., 2010, PREDICTING AND CHANG; Fotuhi O, 2013, TOB CONTROL, V22, P52, DOI 10.1136/tobaccocontrol-2011-050139; Gittelsohn J, 1997, HUM ORGAN, V56, P182, DOI 10.17730/humo.56.2.c7x0532q2u86m207; Global WASH Cluster, 2009, HYG PROM EM WASH CLU; Gollwitzer PM, 2006, ADV EXP SOC PSYCHOL, V38, P69, DOI 10.1016/S0065-2601(06)38002-1; Gould DJ, 2007, J HOSP INFECT, V66, P109, DOI 10.1016/j.jhin.2007.02.009; Halder AK, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-545; Heeb JL, 2005, ADDICT BEHAV, V30, P403, DOI 10.1016/j.addbeh.2004.04.022; Hershfield AF, 1993, SOCIAL RES DEV COUNT, P241; Hoffmeyer-Zlotnik J.H.P, 2003, DEV APPL STAT; Iyer P., 2005, HANDWASHING HDB GUID; King MF, 2000, PSYCHOL MARKET, V17, P79, DOI 10.1002/(SICI)1520-6793(200002)17:2<79::AID-MAR2>3.0.CO;2-0; KRISTIANSEN CM, 1984, PUBLIC HEALTH REP, V99, P384; LOFTUS EF, 1992, APPL COGNITIVE PSYCH, V6, P93, DOI 10.1002/acp.2350060202; Luby SP, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001052; ManunEbo M, 1997, TROP MED INT HEALTH, V2, P1015, DOI 10.1046/j.1365-3156.1997.d01-180.x; McAteer J, 2008, J HOSP INFECT, V68, P222, DOI 10.1016/j.jhin.2007.12.009; Mcdowell I., 2006, MEASURING HLTH GUIDE, V3, P37, DOI [DOI 10.1093/ACPROF:OSO/9780195165678.001.0001, 10.1093/acprof:oso/9780195165678.001.0001]; MENON G, 1993, J CONSUM RES, V20, P431, DOI 10.1086/209359; Moshfegh AJ, 2008, AM J CLIN NUTR, V88, P324; Naher AF, 2012, QUAL QUANT, V46, P1601, DOI 10.1007/s11135-011-9469-2; Organization WH, 2009, WHO GUID HAND HYG HL; Pessoa-Silva CL, 2007, PEDIATRICS, V120, pE382, DOI 10.1542/peds.2006-3712; Ram P., 2010, PRACTICAL GUIDANCE M; Ram P, 2013, PRACTICAL GUIDANCE M; REYNOLDS WM, 1982, J CLIN PSYCHOL, V38, P119, DOI 10.1002/1097-4679(198201)38:1<119::AID-JCLP2270380118>3.0.CO;2-I; Schwarz N, 2001, AM J EVAL, V22, P127, DOI 10.1177/109821400102200202; STANTON BF, 1987, B WORLD HEALTH ORGAN, V65, P217; Stevenson RJ, 2009, AM J INFECT CONTROL, V37, P557, DOI 10.1016/j.ajic.2009.01.003; TAGLIACOZZO R, 1979, ADDICT BEHAV, V4, P393, DOI 10.1016/0306-4603(79)90010-8; Tourangeau R, 2007, PSYCHOL BULL, V133, P859, DOI 10.1037/0033-2909.133.5.859; Turner J.C., 1987, REDISCOVERING SOCIAL; United Nations Children's Fund, 2008, WAT SAN HYG HYG PROM; Unsworth N, 2007, PSYCHOL REV, V114, P104, DOI 10.1037/0033-295X.114.1.104; Verardi S, 2010, J CROSS CULT PSYCHOL, V41, P19, DOI 10.1177/0022022109348918; Vu A, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-162; Watson JT, 2007, EMERG INFECT DIS, V13, P1, DOI 10.3201/eid1301.060779; Weisberg HF, 2005, TOTAL SURVEY ERROER; Wisner B., 2002, ENV HLTH EMERGENCIES	62	64	64	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2015	10	8							e0136445	10.1371/journal.pone.0136445	http://dx.doi.org/10.1371/journal.pone.0136445			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CP5VA	26301781	Green Submitted, Green Published, gold			2023-01-03	WOS:000359951900070
J	Cosmo, C; Baptista, AF; de Araujo, AN; do Rosario, RS; Miranda, JGV; Montoya, P; de Sena, EP				Cosmo, Camila; Baptista, Abrahao Fontes; de Araujo, Arao Nogueira; do Rosario, Raphael Silva; Vivas Miranda, Jose Garcia; Montoya, Pedro; de Sena, Eduardo Ponde			A Randomized, Double-Blind, Sham-Controlled Trial of Transcranial Direct Current Stimulation in Attention-Deficit/Hyperactivity Disorder	PLOS ONE			English	Article							HUMAN MOTOR CORTEX; MINI-MENTAL-STATE; PREFRONTAL CORTEX; DC-STIMULATION; EXECUTIVE FUNCTIONS; BRAIN-STIMULATION; WORKING-MEMORY; TDCS; DEPRESSION; ADHD	Background Current standardized treatments for cognitive impairment in attention-deficit/hyperactivity disorder remain limited and their efficacy restricted. Transcranial direct current stimulation (tDCS) is a promising tool for enhancing cognitive performance in several neuropsychiatric disorders. Nevertheless, the effects of tDCS in reducing cognitive impairment in patients with attention-deficit/hyperactivity disorder (ADHD) have not yet been investigated. Methods A parallel, randomized, double-blind, sham-controlled trial was conducted to examine the efficacy of tDCS on the modulation of inhibitory control in adults with ADHD. Thirty patients were randomly allocated to each group and performed a go/no-go task before and after a single session of either anodal stimulation (1 mA) over the left dorsolateral prefrontal cortex or sham stimulation. Results A nonparametric two-sample Wilcoxon rank-sum (Mann-Whitney) test revealed no significant differences between the two groups of individuals with ADHD (tDCS vs. sham) in regard to behavioral performance in the go/no go tasks. Furthermore, the effect sizes of group differences after treatment for the primary outcome measures-correct responses, impulsivity and omission errors-were small. No adverse events resulting from stimulation were reported. Conclusion According to these findings, there is no evidence in support of the use of anodal stimulation over the left dorsolateral prefrontal cortex as an approach for improving inhibitory control in ADHD patients. To the best of our knowledge, this is the first clinical study to assess the cognitive effects of tDCS in individuals with ADHD. Further research is needed to assess the clinical efficacy of tDCS in this population.	[Cosmo, Camila; de Araujo, Arao Nogueira; de Sena, Eduardo Ponde] Univ Fed Bahia, Interact Proc Organs & Syst, Postgrad Program, Salvador, BA, Brazil; [Cosmo, Camila] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Spaulding Neuromodulat Ctr, Boston, MA USA; [Cosmo, Camila] Bahia State Hlth Dept SESAB, Salvador, BA, Brazil; [Cosmo, Camila; Baptista, Abrahao Fontes] Univ Fed Bahia, Funct Electrostimulat Lab, Biomorphol Dept, Salvador, BA, Brazil; [Baptista, Abrahao Fontes] Univ Fed Bahia, Sch Med, Postgrad Program Med & Human Hlth, Salvador, BA, Brazil; [do Rosario, Raphael Silva; Vivas Miranda, Jose Garcia] Univ Fed Bahia, Inst Phys, Salvador, BA, Brazil; [Montoya, Pedro] Univ Balearic Isl, Res Inst Hlth Sci IUNICS IdisPa, Palma De Mallorca, Spain	Universidade Federal da Bahia; Harvard University; Harvard Medical School; Spaulding Rehabilitation Hospital; Universidade Federal da Bahia; Universidade Federal da Bahia; Universidade Federal da Bahia; Institut Investigacio Sanitaria Illes Balears (IdISBa); Universitat de les Illes Balears	Cosmo, C (corresponding author), Univ Fed Bahia, Interact Proc Organs & Syst, Postgrad Program, Salvador, BA, Brazil.	ccosmo@ufba.br	Baptista, Abrahão F/N-8036-2018; Miranda, Jose/HCI-6099-2022; Montoya, Pedro/A-4666-2009; de Sena, Eduardo Pondé/D-2481-2010	Baptista, Abrahão F/0000-0001-7870-3820; Montoya, Pedro/0000-0001-8652-948X; de Sena, Eduardo Pondé/0000-0002-6166-8093; de Araujo, Arao/0000-0001-5861-6818	CAPES/Brazil	CAPES/Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	The authors received no specific funding for this trial. CC and PM received scholarship from CAPES/Brazil.	Accornero N, 2014, J NEUROPHYSIOL, V112, P1367, DOI 10.1152/jn.00088.2014; Agarwal Rashi, 2012, Innov Clin Neurosci, V9, P10; Ambrus GG, 2012, BRAIN STIMUL, V5, P499, DOI 10.1016/j.brs.2011.12.001; Antshel KM, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-72; Arnsten AFT, 2005, BIOL PSYCHIAT, V57, P1377, DOI 10.1016/j.biopsych.2004.08.019; Berman SM, 2009, MOL PSYCHIATR, V14, P123, DOI 10.1038/mp.2008.90; BERTOLUCCI PHF, 1994, ARQ NEURO-PSIQUIAT, V52, P1, DOI 10.1590/S0004-282X1994000100001; Boggio PS, 2007, J AFFECT DISORDERS, V101, P91, DOI 10.1016/j.jad.2006.10.026; Boggio PS, 2006, J NEUROL SCI, V249, P31, DOI 10.1016/j.jns.2006.05.062; Brunoni AR, 2012, BRAIN STIMUL, V5, P175, DOI 10.1016/j.brs.2011.03.002; Brunoni AR, 2011, INT J NEUROPSYCHOPH, V14, P1133, DOI 10.1017/S1461145710001690; Carlson RV, 2004, BRIT J CLIN PHARMACO, V57, P695, DOI 10.1111/j.1365-2125.2004.02103.x; Cubillo A, 2011, PSYCHIAT RES-NEUROIM, V193, P17, DOI 10.1016/j.pscychresns.2010.12.014; Demirtas-Tatlidede A, 2013, NEUROPHARMACOLOGY, V64, P566, DOI 10.1016/j.neuropharm.2012.06.020; Dickstein SG, 2006, J CHILD PSYCHOL PSYC, V47, P1051, DOI 10.1111/j.1469-7610.2006.01671.x; Ditye T, 2012, EXP BRAIN RES, V219, P363, DOI 10.1007/s00221-012-3098-4; Dockery CA, 2009, J NEUROSCI, V29, P7271, DOI 10.1523/JNEUROSCI.0065-09.2009; Doyle AE, 2006, J CLIN PSYCHIAT, V67, P21; Durston S, 2011, BIOL PSYCHIAT, V69, P1178, DOI 10.1016/j.biopsych.2010.07.037; Fecteau S, 2007, J NEUROSCI, V27, P12500, DOI 10.1523/JNEUROSCI.3283-07.2007; Fecteau S, 2007, J NEUROSCI, V27, P6212, DOI 10.1523/JNEUROSCI.0314-07.2007; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fritz CO, 2012, J EXP PSYCHOL GEN, V141, P2, DOI 10.1037/a0024338; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Hsu TY, 2011, NEUROIMAGE, V56, P2249, DOI 10.1016/j.neuroimage.2011.03.059; Iyer MB, 2005, NEUROLOGY, V64, P872, DOI 10.1212/01.WNL.0000152986.07469.E9; Jacobson L, 2012, CLIN NEUROPHYSIOL, V123, P979, DOI 10.1016/j.clinph.2011.09.016; Kang EK, 2009, RESTOR NEUROL NEUROS, V27, P645, DOI 10.3233/RNN-2009-0514; Keeser D, 2011, J NEUROSCI, V31, P15284, DOI 10.1523/JNEUROSCI.0542-11.2011; Kessler RC, 2005, PSYCHOL MED, V35, P245, DOI 10.1017/S0033291704002892; Lang N, 2005, EUR J NEUROSCI, V22, P495, DOI 10.1111/j.1460-9568.2005.04233.x; Lange KW, 2010, ADHD-ATTEND DEFICIT, V2, P241, DOI 10.1007/s12402-010-0045-8; Lapenta OM, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00256; Lauro LJR, 2014, CORTEX, V58, P99, DOI 10.1016/j.cortex.2014.05.003; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; Loo CK, 2012, BRIT J PSYCHIAT, V200, P52, DOI 10.1192/bjp.bp.111.097634; Loo CK, 2010, INT J NEUROPSYCHOPH, V13, P61, DOI 10.1017/S1461145709990411; Lundervold AJ, 2011, BEHAV BRAIN FUNCT, V7, DOI 10.1186/1744-9081-7-27; Martin DM, 2014, EXP BRAIN RES, V232, P3345, DOI 10.1007/s00221-014-4022-x; McGough JJ, 2015, BRAIN STIMUL, V8, P299, DOI 10.1016/j.brs.2014.11.013; Neuling Toralf, 2012, Front Psychiatry, V3, P83; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2003, CLIN NEUROPHYSIOL, V114, P600, DOI 10.1016/S1388-2457(02)00412-1; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Noetscher GM, 2014, IEEE T BIO-MED ENG, V61, P2488, DOI 10.1109/TBME.2014.2322774; O'Connell NE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047514; Oliveira JF, 2013, NEUROSCI LETT, V537, P60, DOI 10.1016/j.neulet.2013.01.023; Polania R, 2012, HUM BRAIN MAPP, V33, P2499, DOI 10.1002/hbm.21380; Ranby KW, 2012, J CLIN CHILD ADOLESC, V41, P261, DOI 10.1080/15374416.2012.654465; Rubia K, 2014, REV NEUROLOGIA, V58, pS3, DOI 10.33588/rn.58S01.2013570; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Turi Z, 2015, CORTEX, V63, P145, DOI 10.1016/j.cortex.2014.08.026; Wirth M, 2011, NEUROPSYCHOLOGIA, V49, P3989, DOI 10.1016/j.neuropsychologia.2011.10.015; Wolkenstein L, 2013, BIOL PSYCHIAT, V73, P646, DOI 10.1016/j.biopsych.2012.10.010	54	49	54	1	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2015	10	8							e0135371	10.1371/journal.pone.0135371	http://dx.doi.org/10.1371/journal.pone.0135371			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO9JT	26267861	Green Published, Green Submitted, gold			2023-01-03	WOS:000359492300108
J	Bayer, R; Galea, S				Bayer, Ronald; Galea, Sandro			Public Health in the Precision-Medicine Era	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Bayer, Ronald] Columbia Univ, Ctr Hist & Eth Publ Hlth, Mailman Sch Publ Hlth, New York, NY 10027 USA; [Galea, Sandro] Boston Univ, Off Dean, Sch Publ Hlth, Boston, MA 02215 USA	Columbia University; Boston University	Bayer, R (corresponding author), Columbia Univ, Ctr Hist & Eth Publ Hlth, Mailman Sch Publ Hlth, New York, NY 10027 USA.		Galea, Sandro/GLR-6066-2022	Galea, Sandro/0000-0002-7534-0945				[Anonymous], 2013, MMWR SURVEILL SUM S3, V62, P184; Bassett MT, 2015, NEW ENGL J MED, V372, P1085, DOI 10.1056/NEJMp1500529; Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Collins FS, 2015, JAMA-J AM MED ASSOC, V313, P131, DOI 10.1001/jama.2014.16736; Porter Eduardo, 2015, NY TIMES	5	139	146	0	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 6	2015	373	6					499	501		10.1056/NEJMp1506241	http://dx.doi.org/10.1056/NEJMp1506241			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CO2LM	26244305				2023-01-03	WOS:000358987700003
J	Anderson, C				Anderson, Claire			Changing the way pharmacy only drugs are supplied would be unwise	BMJ-BRITISH MEDICAL JOURNAL			English	Letter									Royal Pharmaceut Soc, London E1W 1AW, England		Anderson, C (corresponding author), Royal Pharmaceut Soc, London E1W 1AW, England.	claire.anderson@nottingham.ac.uk		Anderson, Claire/0000-0002-5406-2296				Rutter P, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3415; Stevenson FA, 2008, SOCIOL HEALTH ILL, V30, P913, DOI 10.1111/j.1467-9566.2008.01108.x; Van Eikenhorst L, 2014, INT J PHARM PRAC S1, P27; Watson MC, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006261; Watson MC, 2015, BMJ	5	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 23	2015	351								h3951	10.1136/bmj.h3951	http://dx.doi.org/10.1136/bmj.h3951			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CN7WL	26205650				2023-01-03	WOS:000358645000011
J	Sheahan, TD; Copits, BA; Golden, JP; Gereau, RW				Sheahan, Tayler D.; Copits, Bryan A.; Golden, Judith P.; Gereau, Robert W.			Voluntary Exercise Training: Analysis of Mice in Uninjured, Inflammatory, and Nerve-Injured Pain States	PLOS ONE			English	Article							PERIPHERAL NEUROPATHIC PAIN; STRESS-INDUCED ANALGESIA; QUALITY-OF-LIFE; PHYSICAL-EXERCISE; HSP72 EXPRESSION; BETA-ENDORPHIN; MUSCLE ATROPHY; RATS; INTENSITY; SKIN	Both clinical and animal studies suggest that exercise may be an effective way to manage inflammatory and neuropathic pain conditions. However, existing animal studies commonly use forced exercise paradigms that incorporate varying degrees of stress, which itself can elicit analgesia, and thus may complicate the interpretation of the effects of exercise on pain. We investigated the analgesic potential of voluntary wheel running in the formalin model of acute inflammatory pain and the spared nerve injury model of neuropathic pain in mice. In uninjured, adult C57BL/6J mice, 1 to 4 weeks of exercise training did not alter nociceptive thresholds, lumbar dorsal root ganglia neuronal excitability, or hindpaw intraepidermal innervation. Further, exercise training failed to attenuate formalin-induced spontaneous pain. Lastly, 2 weeks of exercise training was ineffective in reversing spared nerve injury-induced mechanical hypersensitivity or in improving muscle wasting or hindpaw denervation. These findings indicate that in contrast to rodent forced exercise paradigms, short durations of voluntary wheel running do not improve pain-like symptoms in mouse models of acute inflammation and peripheral nerve injury.	[Sheahan, Tayler D.; Copits, Bryan A.; Golden, Judith P.; Gereau, Robert W.] Washington Univ, Pain Ctr, St Louis, MO 63130 USA; [Sheahan, Tayler D.; Copits, Bryan A.; Golden, Judith P.; Gereau, Robert W.] Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; [Sheahan, Tayler D.; Gereau, Robert W.] Washington Univ, Sch Med, Washington Univ Program Neurosci, St Louis, MO USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Gereau, RW (corresponding author), Washington Univ, Pain Ctr, St Louis, MO 63130 USA.	gereaur@wustl.edu		Golden, Judith/0000-0002-5168-8525; Sheahan, Tayler/0000-0002-5015-0600	National Institutes of Neurological Disorders and Stroke [R01 NS48602]; Washington University in St. Louis W.M. Keck Fellowship in Molecular Medicine; National Institutes of General Medical Sciences [TR32 GM108539]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM108539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048602] Funding Source: NIH RePORTER	National Institutes of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Washington University in St. Louis W.M. Keck Fellowship in Molecular Medicine; National Institutes of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	RWG was supported by National Institutes of Neurological Disorders and Stroke R01 NS48602 (nih.gov). BAC was supported by Washington University in St. Louis W.M. Keck Fellowship in Molecular Medicine (http://www.wmkeck.org) and National Institutes of General Medical Sciences TR32 GM108539 (nih.gov). The funders had no role in study design, data collection and analysis, decision to publish, or in preparation of the manuscript.	Almeida C, 2015, PAIN, V156, P504, DOI 10.1097/01.j.pain.0000460339.23976.12; Armada-da-Silva PAS, 2013, INT REV NEUROBIOL, V109, P125, DOI 10.1016/B978-0-12-420045-6.00006-7; Baldo G, 2013, J INHERIT METAB DIS, V36, P499, DOI 10.1007/s10545-012-9530-x; Belter JG, 2004, J APPL PHYSIOL, V96, P1270, DOI 10.1152/japplphysiol.00838.2003; Bement MKH, 2005, ARCH PHYS MED REHAB, V86, P1736, DOI 10.1016/j.apmr.2005.03.029; BENRATH J, 1995, NEUROSCI LETT, V200, P17, DOI 10.1016/0304-3940(95)12062-9; Binder E, 2004, BEHAV BRAIN RES, V155, P197, DOI 10.1016/j.bbr.2004.04.017; Bobinski F, 2011, NEUROSCIENCE, V194, P337, DOI 10.1016/j.neuroscience.2011.07.075; Boeltz T, 2013, J NEUROPHYSIOL, V109, P2645, DOI 10.1152/jn.00946.2012; Bonaldo P, 2013, DIS MODEL MECH, V6, P25, DOI 10.1242/dmm.010389; Boucher TJ, 2000, SCIENCE, V290, P124, DOI 10.1126/science.290.5489.124; Brenner DS, 2015, JOVE-J VIS EXP, DOI 10.3791/52640; Brenner DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039765; Butler RK, 2009, PROG NEUROBIOL, V88, P184, DOI 10.1016/j.pneurobio.2009.04.003; CAGGIULA AR, 1995, PSYCHOPHARMACOLOGY, V122, P301, DOI 10.1007/BF02246552; CARMODY J, 1987, NEUROSCI LETT, V74, P358, DOI 10.1016/0304-3940(87)90324-7; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chen YW, 2013, ANESTH ANALG, V116, P482, DOI 10.1213/ANE.0b013e318274e4a0; Chiang HY, 1998, EXP NEUROL, V154, P137, DOI 10.1006/exnr.1998.6896; Cobianchi S, 2010, NEUROSCIENCE, V168, P273, DOI 10.1016/j.neuroscience.2010.03.035; Cobianchi S, 2013, EXP NEUROL, V240, P157, DOI 10.1016/j.expneurol.2012.11.023; Courneya KS, 2013, JNCI-J NATL CANCER I, V105, P1821, DOI 10.1093/jnci/djt297; Daenen L, 2015, CLIN J PAIN, V31, P108, DOI 10.1097/AJP.0000000000000099; Decosterd I, 2000, PAIN, V87, P149, DOI 10.1016/S0304-3959(00)00276-1; Decosterd I, 2002, PAIN, V96, P269, DOI 10.1016/S0304-3959(01)00456-0; Detloff MR, 2014, EXP NEUROL, V255, P38, DOI 10.1016/j.expneurol.2014.02.013; Dixit S, 2014, QUAL LIFE RES, V23, P1629, DOI 10.1007/s11136-013-0602-7; Djouhri L, 2006, J NEUROSCI, V26, P1281, DOI 10.1523/JNEUROSCI.3388-05.2006; Dobson JL, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00102; Draxler P, 2014, J NEUROSCI, V34, P12015, DOI 10.1523/JNEUROSCI.2157-14.2014; Dubreucq S, 2011, HIPPOCAMPUS, V21, P239, DOI 10.1002/hipo.20778; Duman CH, 2008, BRAIN RES, V1199, P148, DOI 10.1016/j.brainres.2007.12.047; Duraku LS, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-61; Gereau RW, 2014, J PAIN, V15, P1203, DOI 10.1016/j.jpain.2014.09.004; Geva N, 2013, PAIN, V154, P2317, DOI 10.1016/j.pain.2013.06.031; Grace PM, 2014, J PAIN, V15, P121, DOI 10.1016/j.jpain.2013.10.001; Groover AL, 2013, PAIN, V154, P2658, DOI 10.1016/j.pain.2013.07.052; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hawkley LC, 2012, HORM BEHAV, V62, P314, DOI 10.1016/j.yhbeh.2012.05.011; HOFFMANN P, 1990, REGUL PEPTIDES, V28, P233, DOI 10.1016/0167-0115(90)90021-N; Hurkmans E, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006853.pub2; Ilha J, 2008, NEUROREHAB NEURAL RE, V22, P355, DOI 10.1177/1545968307313502; Inst Med, 2011, RELIEVING PAIN IN AMERICA: A BLUEPRINT FOR TRANSFORMING PREVENTION, CARE, EDUCATION, AND RESEARCH, P1; Ke Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016643; Klusakova I, 2009, ANN ANAT, V191, P248, DOI 10.1016/j.aanat.2009.02.007; Koltyn KF, 2000, SPORTS MED, V29, P85, DOI 10.2165/00007256-200029020-00002; Korb A, 2010, NEUROCHEM RES, V35, P380, DOI 10.1007/s11064-009-0066-x; Kuphal KE, 2007, J PAIN, V8, P989, DOI 10.1016/j.jpain.2007.08.001; Lame IE, 2005, EUR J PAIN, V9, P15, DOI 10.1016/j.ejpain.2004.02.006; Leasure JL, 2008, NEUROSCIENCE, V156, P456, DOI 10.1016/j.neuroscience.2008.07.041; Li YB, 1997, EXP NEUROL, V147, P452, DOI 10.1006/exnr.1997.6624; Mathes WF, 2006, PHARMACOL BIOCHEM BE, V83, P578, DOI 10.1016/j.pbb.2006.03.020; Michaelis M, 2000, J NEUROSCI, V20, P2742; Moraska A, 2000, AM J PHYSIOL-REG I, V279, pR1321, DOI 10.1152/ajpregu.2000.279.4.R1321; Noble EG, 1999, J APPL PHYSIOL, V86, P1696, DOI 10.1152/jappl.1999.86.5.1696; Ploughman M, 2007, BRAIN RES, V1150, P207, DOI 10.1016/j.brainres.2007.02.065; Ren Ke, 1999, ILAR J, V40, P111; Rubinstein M, 1996, P NATL ACAD SCI USA, V93, P3995, DOI 10.1073/pnas.93.9.3995; Salam JN, 2009, BEHAV BRAIN RES, V197, P31, DOI 10.1016/j.bbr.2008.07.036; Sciolino NR, 2012, NEUROSCI BIOBEHAV R, V36, P1965, DOI 10.1016/j.neubiorev.2012.06.005; Sharma NK, 2010, PHYS THER, V90, P714, DOI 10.2522/ptj.20090168; Shen J, 2013, PAIN MED, V14, P516, DOI 10.1111/pme.12057; SHYU BC, 1982, LIFE SCI, V30, P833; Sluka KA, 2013, J APPL PHYSIOL, V114, P725, DOI 10.1152/japplphysiol.01317.2012; Stagg NJ, 2011, ANESTHESIOLOGY, V114, P940, DOI 10.1097/ALN.0b013e318210f880; TAKAHASHI K, 1993, J INVEST DERMATOL, V101, P646, DOI 10.1111/1523-1747.ep12371670; Tesarz J, 2012, PAIN, V153, P1253, DOI 10.1016/j.pain.2012.03.005; Urban R, 2011, PAIN, V152, P990, DOI 10.1016/j.pain.2010.12.003; van der Heijden MMP, 2013, DIABETOLOGIA, V56, P1210, DOI 10.1007/s00125-013-2871-7; Wright A, 2001, CLIN J PAIN, V17, P33, DOI 10.1097/00002508-200103000-00006; Xu QH, 2011, CURR OPIN ANESTHESIO, V24, P400, DOI 10.1097/ACO.0b013e32834871df; Zhao L, 2012, NEURAL REGEN RES, V7, P2507, DOI 10.3969/j.issn.1673-5374.2012.32.004	72	26	28	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2015	10	7							e0133191	10.1371/journal.pone.0133191	http://dx.doi.org/10.1371/journal.pone.0133191			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN6LZ	26196858	Green Published, Green Submitted, gold			2023-01-03	WOS:000358547600070
J	Tistad, M; von Koch, L				Tistad, Malin; von Koch, Lena			Usual Clinical Practice for Early Supported Discharge after Stroke with Continued Rehabilitation at Home: An Observational Comparative Study	PLOS ONE			English	Article							SERVICES; METAANALYSIS; CONSENSUS; LIFE; CARE	Introduction Based on randomised controlled trials, evidence exists that early supported discharge (ESD) from the hospital with continued rehabilitation at home has beneficial effects after stroke; however, the effects of ESD service in regular clinical practice have not been investigated. The purpose of the current study was to compare ESD service with conventional rehabilitation in terms of patient outcomes, caregiver burden at 3 and 12 months and the use and costs of healthcare during the first year after stroke. Material and Methods This study was a subgroup analysis of a longitudinal observational study of patients who received care in the stroke unit at Karolinska University Hospital in Sweden. Patients who met the inclusion criteria for ESD in previous experimental studies were included. The patients were referred to available rehabilitation services at discharge, and comparisons between those who received ESD service (the ESD group, n = 40) and those who received conventional rehabilitation (the NoESD group, n = 110) were performed with regard to independence in activities of daily living (ADL), the frequency of social activities, life satisfaction, and caregiver burden and the use and costs of healthcare during the first year after stroke. Results At 3 and 12 months, no differences were observed with regard to patient outcomes; however, ESD was associated with a lower caregiver burden (p = 0.01) at 12 months. The initial length of stay (LOS) at the hospital was 8 days for the ESD group and 15 days for the NoESD group (p = 0.02). The median number of outpatient rehabilitation contacts was 20.5 for the ESD group (81% constituting ESD service) and 3 for the NoESD group (p<0.001). There was no difference between the groups with regard to overall healthcare costs. Conclusions ESD service in usual clinical practice renders similar health benefits as conventional rehabilitation but a different pattern of resource use and with released capacity in acute stroke care.	[Tistad, Malin; von Koch, Lena] Care Sci & Soc Karolinska Inst, Dept Neurobiol, Div Occupat Therapy, Huddinge, Sweden; [Tistad, Malin] Dalarna Univ, Sch Educ Hlth & Social Studies, Falun, Sweden; [von Koch, Lena] Karolinska Univ Hosp, Karolinska Inst, Div Neurol, Dept Clin Neurosci, Huddinge, Sweden	Karolinska Institutet; Dalarna University; Karolinska Institutet; Karolinska University Hospital	Tistad, M (corresponding author), Care Sci & Soc Karolinska Inst, Dept Neurobiol, Div Occupat Therapy, Huddinge, Sweden.	malin.tistad@ki.se	von Koch, Lena/P-2310-2018	von Koch, Lena/0000-0002-8560-3016	Stockholm County Council [20060700]; Karolinska Institutet (ALF) [20060700]; Swedish Research Council (Vetenskapsradet) [2007-3087]; Swedish Brain Foundation (Hjarnfonden); Swedish Stroke Association (STROKE-Riksforbundet)	Stockholm County Council(Stockholm County Council); Karolinska Institutet (ALF)(Karolinska Institutet); Swedish Research Council (Vetenskapsradet)(Swedish Research Council); Swedish Brain Foundation (Hjarnfonden); Swedish Stroke Association (STROKE-Riksforbundet)	The study was funded by the regional agreement between the Stockholm County Council and Karolinska Institutet (ALF) (grant number 20060700), the Swedish Research Council (Vetenskapsradet) (grant number 2007-3087) http://www.vr.se/ the Swedish Brain Foundation (Hjarnfonden) http://www.hjarnfonden.se/startsida_1 the Swedish Stroke Association (STROKE-Riksforbundet) http://www.strokeforbundet.se/show.asp. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ASPLUND K, 1985, STROKE, V16, P885; Brusco NK, 2014, ARCH PHYS MED REHAB, V95, P94, DOI 10.1016/j.apmr.2013.03.017; Chouliara N, 2014, CLIN REHABIL, V28, P370, DOI 10.1177/0269215513502212; Cobley CS, 2013, CLIN REHABIL, V27, P750, DOI 10.1177/0269215512474030; Craig LE, 2014, INT J STROKE, V9, P88, DOI 10.1111/ijs.12041; Dow Briony, 2004, Aust Health Rev, V28, P260; Elmstahl S, 1996, ARCH PHYS MED REHAB, V77, P177, DOI 10.1016/S0003-9993(96)90164-1; Fearon P, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000443.pub3; Fisher RJ, 2011, STROKE, V42, P1392, DOI 10.1161/STROKEAHA.110.606285; Fjaertoft H, 2004, CLIN REHABIL, V18, P580, DOI 10.1191/0269215504cr773oa; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Grol RPTM, 2007, MILBANK Q, V85, P93, DOI 10.1111/j.1468-0009.2007.00478.x; Hackett ML, 2002, STROKE, V33, P643, DOI 10.1161/str.33.2.643; Haussen DC, 2011, NAT REV NEUROL, V7, P482, DOI 10.1038/nrneurol.2011.128; Intercollegiate Stroke Working Party, 2012, NAT CLIN GUID STROK, V4th ed; Langhorne P, 2005, LANCET, V365, P501; Langhorne P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000197.pub3; MAHONEY F I, 1965, Md State Med J, V14, P61; Mas MA, 2012, INT J STROKE, V11, P1747; Riksstroke, 2014, ARSR 2013 SWED STROK; Scottish Intercollegiate Guideline Network, 2010, MAN PAT STROK 591 RE; Seenan P, 2007, STROKE, V38, P1886, DOI 10.1161/STROKEAHA.106.480871; Socialstyrelsen, 2009, NAT RIKTL STROK 2009; SONN U, 1991, SCAND J REHABIL MED, V23, P193; Susanne P, 2012, J NEUROL SCI, V321, P29, DOI 10.1016/j.jns.2012.07.024; The Swedish Association of Local Authorities and Regions, 2018, PERS VARD SVER; Tistad M., 2012, THESIS KAROLINSKA I; Tistad M, 2012, J NEUROL SCI, V313, P160, DOI 10.1016/j.jns.2011.08.038; Tummers Johanneke F M M, 2012, Int J Integr Care, V12, pe193; VIITANEN M, 1988, SCAND J REHABIL MED, V20, P17; Von Koch L, 1998, DISABIL REHABIL, V20, P367, DOI 10.3109/09638289809166095; von Koch L, 2000, CLIN REHABIL, V14, P574, DOI 10.1191/0269215500cr364oa; Wade D T, 1985, Int Rehabil Med, V7, P176; Wottrich AW, 2007, PHYS THER, V87, P778, DOI 10.2522/ptj.20060152	34	10	10	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2015	10	7							e0133536	10.1371/journal.pone.0133536	http://dx.doi.org/10.1371/journal.pone.0133536			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RV	26186211	Green Published, Green Submitted, gold			2023-01-03	WOS:000358198700154
J	Cleuren, ACA; Blankevoort, VT; van Diepen, JA; Verhoef, D; Voshol, PJ; Reitsma, PH; van Vlijmen, BJM				Cleuren, Audrey C. A.; Blankevoort, Vicky T.; van Diepen, Janna A.; Verhoef, Daniel; Voshol, Peter J.; Reitsma, Pieter H.; van Vlijmen, Bart J. M.			Changes in Dietary Fat Content Rapidly Alters the Mouse Plasma Coagulation Profile without Affecting Relative Transcript Levels of Coagulation Factors	PLOS ONE			English	Article							ORAL-CONTRACEPTIVE USE; WEIGHT-LOSS; OBESE MICE; THROMBIN GENERATION; VENOUS THROMBOSIS; ENDOTHELIAL-CELLS; GENE-EXPRESSION; FACTOR-VIII; RISK; ADAPTATION	Background Obesity is associated with a hypercoagulable state and increased risk for thrombotic cardiovascular events. Objective Establish the onset and reversibility of the hypercoagulable state during the development and regression of nutritionally-induced obesity in mice, and its relation to transcriptional changes and clearance rates of coagulation factors as well as its relation to changes in metabolic and inflammatory parameters. Methods Male C57BL/6J mice were fed a low fat (10% kcal as fat; LFD) or high fat diet (45% kcal as fat; HFD) for 2, 4, 8 or 16 weeks. To study the effects of weight loss, mice were fed the HFD for 16 weeks and switched to the LFD for 1, 2 or 4 weeks. For each time point analyses of plasma and hepatic mRNA levels of coagulation factors were performed after overnight fasting, as well as measurements of circulating metabolic and inflammatory parameters. Furthermore, in vivo clearance rates of human factor (F) VII, FVIII and FIX proteins were determined after 2 weeks of HFD-feeding. Results HFD feeding gradually increased the body and liver weight, which was accompanied by a significant increase in plasma glucose levels from 8 weeks onwards, while insulin levels were affected after 16 weeks. Besides a transient rise in cytokine levels at 2 weeks after starting the HFD, no significant effect on inflammation markers was present. Increased plasma levels of fibrinogen, FII, FVII, FVIII, FIX, FXI and FXII were observed in mice on a HFD for 2 weeks, which in general persisted throughout the 16 weeks of HFD-feeding. Interestingly, with the exception of FXI the effects on plasma coagulation levels were not paralleled by changes in relative transcript levels in the liver, nor by decreased clearance rates. Switching from HFD to LFD reversed the HFD-induced procoagulant shift in plasma, again not coinciding with transcriptional modulation. Conclusions Changes in dietary fat content rapidly alter the mouse plasma coagulation profile, thereby preceding plasma metabolic changes, which cannot be explained by changes in relative expression of coagulation factors or decreased clearance rates.	[Cleuren, Audrey C. A.; Blankevoort, Vicky T.; Verhoef, Daniel; Reitsma, Pieter H.; van Vlijmen, Bart J. M.] Leiden Univ, Med Ctr, Einthoven Lab Expt Vasc Med, Dept Thrombosis & Hemostasis, Leiden, Netherlands; [van Diepen, Janna A.; Voshol, Peter J.] Leiden Univ, Med Ctr, Einthoven Lab Expt Vasc Med, Dept Endocrinol, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van Vlijmen, BJM (corresponding author), Leiden Univ, Med Ctr, Einthoven Lab Expt Vasc Med, Dept Thrombosis & Hemostasis, Leiden, Netherlands.	b.j.m.van_vlijmen@lumc.nl	van Diepen, Janna/E-9485-2010; Cleuren, Audrey/AAV-3684-2021	van Diepen, Janna/0000-0001-9091-1075; Cleuren, Audrey/0000-0003-1384-4651	Leducq Foundation (Paris, France); Netherlands Heart Foundation [2006B045]	Leducq Foundation (Paris, France)(Leducq Foundation); Netherlands Heart Foundation(Netherlands Heart Foundation)	This study was supported by the Leducq Foundation (Paris, France; LINAT project) and grant 2006B045 from the Netherlands Heart Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdollahi M, 2003, THROMB HAEMOSTASIS, V89, P493, DOI 10.1055/s-0037-1613379; Ay L, 2010, J THROMB HAEMOST, V8, P759, DOI 10.1111/j.1538-7836.2010.03766.x; Cleuren ACA, 2010, J THROMB HAEMOST, V8, P1838, DOI 10.1111/j.1538-7836.2010.03930.x; Cleuren ACA, 2009, THROMB HAEMOSTASIS, V102, P993, DOI 10.1160/TH09-03-0169; Do GM, 2011, MOL NUTR FOOD RES, V55, pS173, DOI 10.1002/mnfr.201100064; Everett LA, 2014, BLOOD, V123, P3697, DOI 10.1182/blood-2014-02-554501; Fahs SA, 2014, BLOOD, V123, P3706, DOI 10.1182/blood-2014-02-555151; FOLSOM AR, 1993, ARTERIOSCLER THROMB, V13, P162, DOI 10.1161/01.ATV.13.2.162; Godsland IF, 2005, J CLIN ENDOCR METAB, V90, P190, DOI 10.1210/jc.2004-1292; HAUS E, 1990, CHRONOBIOL INT, V7, P203, DOI 10.3109/07420529009056976; Kaji N, 2013, J VET MED SCI, V75, P1245, DOI 10.1292/jvms.13-0029; Mertens I, 2002, Obes Rev, V3, P85, DOI 10.1046/j.1467-789X.2002.00056.x; Muller M, 2003, NAT REV GENET, V4, P315, DOI 10.1038/nrg1047; Nagai N, 2008, THROMB RES, V122, P549, DOI 10.1016/j.thromres.2007.12.017; Oishi K, 2006, J THROMB HAEMOST, V4, P1774, DOI 10.1111/j.1538-7836.2006.02032.x; Pomp ER, 2007, BRIT J HAEMATOL, V139, P289, DOI 10.1111/j.1365-2141.2007.06780.x; Radonjic M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006646; Rosito GA, 2004, THROMB HAEMOSTASIS, V91, P683, DOI 10.1160/TH03-01-0014; Samad F, 1999, THROMB HAEMOSTASIS, V82, P742, DOI 10.1055/s-0037-1615906; Sanchez C, 2012, ARTERIOSCL THROM VAS, V32, P2394, DOI 10.1161/ATVBAHA.112.250332; Sola E, 2009, THROMB RES, V123, P697, DOI 10.1016/j.thromres.2008.07.017	21	11	12	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2015	10	7							e0131859	10.1371/journal.pone.0131859	http://dx.doi.org/10.1371/journal.pone.0131859			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RL	26176620	Green Submitted, Green Published, gold			2023-01-03	WOS:000358197600067
J	Singh, S; Pandey, S; Bhatt, AN; Chaudhary, R; Bhuria, V; Kalra, N; Soni, R; Roy, BG; Saluja, D; Dwarakanath, BS				Singh, Saurabh; Pandey, Sanjay; Bhatt, Anant Narayan; Chaudhary, Richa; Bhuria, Vikas; Kalra, Namita; Soni, Ravi; Roy, Bal Gangadhar; Saluja, Daman; Dwarakanath, Bilikere S.			Chronic Dietary Administration of the Glycolytic Inhibitor 2-Deoxy-D-Glucose (2-DG) Inhibits the Growth of Implanted Ehrlich's Ascites Tumor in Mice	PLOS ONE			English	Article							REGULATORY T-CELLS; CALORIE RESTRICTION; CARBOHYDRATE RESTRICTION; CANCER RADIOTHERAPY; GLUCOSE-METABOLISM; MAMMARY CARCINOMAS; OXIDATIVE STRESS; PROSTATE-CANCER; PROLIFERATION; 2-DEOXYGLUCOSE	Background Dietary energy restriction (DER) has been well established as a potent anticancer strategy. Non-adoption of restricted diet for an extended period has limited its practical implementation in humans with a compelling need to develop agents that mimic effects similar to DER, without reduction in actual dietary intake. Glycolytic inhibitor, 2-deoxy-D-glucose (2-DG), has recently been shown to possess potential as an energy restriction mimetic agent (ERMA). In the present study we evaluated the effect of dietary 2-DG administration on a mouse tumor model, with a focus on several potential mechanisms that may account for the inhibition of tumorigenesis. Methodology/Principal Findings Swiss albino strain 'A' mice were administered with 0.2% and 0.4% w/v 2-DG in drinking water for 3 months prior to tumor implantation (Ehrlich's ascites carcinoma; EAC) and continued till the termination of the study with no adverse effects on general physiology and animal growth. Dietary 2-DG significantly reduced the tumor incidence, delayed the onset, and compromised the tumor growth along with enhanced survival. We observed reduced blood glucose and serum insulin levels along with decreased proliferating cell nuclear antigen (PCNA) and bromodeoxyuridine positive (BrdU(+)) tumor cells in 2-DG fed mice. Also, reduced levels of certain key players of metabolic pathways such as phosphatidylinositol 3-kinase (PI3K), phosphorylated-Akt and hypoxia inducible factor-1 alpha (HIF-1 alpha) were also noted in tumors of 2-DG fed mice. Further, decrease in CD4(+)/CD8(+) ratio and T-regulatory cells observed in 2-DG fed mice suggested enhanced antitumor immunity and T cell effector function. Conclusion/Significance These results strongly suggest that dietary 2-DG administration in mice, at doses easily achievable in humans, suitably modulates several pleotrophic factors mimicking DER and inhibits tumorigenesis, emphasizing the use of ERMAs as a promising cancer preventive strategy.	[Singh, Saurabh; Pandey, Sanjay; Bhatt, Anant Narayan; Bhuria, Vikas; Kalra, Namita; Soni, Ravi; Roy, Bal Gangadhar; Dwarakanath, Bilikere S.] Inst Nucl Med & Allied Sci, Div Radiat Biosci, Delhi, India; [Singh, Saurabh; Pandey, Sanjay; Chaudhary, Richa; Saluja, Daman] Univ Delhi, Med Biotechnol Lab, Dr BR Ambedkar Ctr Biomed Res, Delhi 110007, India	Defence Research & Development Organisation (DRDO); Institute of Nuclear Medicine & Allied Sciences (INMAS); University of Delhi	Dwarakanath, BS (corresponding author), Inst Nucl Med & Allied Sci, Div Radiat Biosci, Brig SK Mazumdar Rd, Delhi, India.	dwarakanathdrbs@gmail.com	Pandey, Sanjay/AAQ-4396-2020; Singh, Saurabh/AAG-1129-2021	Dwarakanath, Bilikere S./0000-0001-6988-2601; Pandey, Sanjay/0000-0003-2948-1816	Defence Research and Development Organisation (DRDO), Government of India [INM 301, 311/1.4, INM-301, INM-311]; University Grants Commission	Defence Research and Development Organisation (DRDO), Government of India(Defence Research & Development Organisation (DRDO)); University Grants Commission(University Grants Commission, India)	This work was supported by grants (INM 301 and 311/1.4) funded by Defence Research and Development Organisation (DRDO), Government of India. SS received fellowship from University Grants Commission. This work was supported by grants INM-301 and INM-311 from Defence Research and Development Organization (DRDO), Government of India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abecassis I, 2003, EXP CELL RES, V291, P363, DOI 10.1016/j.yexcr.2003.08.006; Barger JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002264; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BLECHER M, 1961, ANAL BIOCHEM, V2, P30, DOI 10.1016/0003-2697(61)90036-7; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Caso J, 2013, PROSTATE, V73, P449, DOI 10.1002/pros.22586; Castellino RC, 2007, NAT CLIN PRACT NEURO, V3, P682, DOI 10.1038/ncpneuro0661; Chen JC, 1998, J GERONTOL A-BIOL, V53, pB330, DOI 10.1093/gerona/53A.5.B330; Chen ML, 2005, P NATL ACAD SCI USA, V102, P419, DOI 10.1073/pnas.0408197102; De Lorenzo MS, 2011, CARCINOGENESIS, V32, P1381, DOI 10.1093/carcin/bgr107; Dunn SE, 1997, CANCER RES, V57, P4667; Dwarakanath BS, 2009, FUTURE ONCOL, V5, P581, DOI [10.2217/fon.09.44, 10.2217/FON.09.44]; Dwarakanath BS, 2005, BIOMEDICINE, V24, P36; Dwarakanath BS, 1999, INT NUCL INFORM SYST, V31; Farooque A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108131; Farooque A, 2009, J CANCER RES THER, V5, P32, DOI 10.4103/0973-1482.55138; Fernandes G, 1997, J CLIN IMMUNOL, V17, P85, DOI 10.1023/A:1027344730553; Goldstein D S, 1992, Clin Auton Res, V2, P359, DOI 10.1007/BF01831392; Gupta S, 2009, J CANCER RES THER, V5, P16, DOI 10.4103/0973-1482.55135; Hadley EC, 2001, J GERONTOL A-BIOL, V56, P5, DOI 10.1093/gerona/56.suppl_1.5; Heilbronn LK, 2003, AM J CLIN NUTR, V78, P361, DOI 10.1093/ajcn/78.3.361; Hyun DH, 2006, P NATL ACAD SCI USA, V103, P19908, DOI 10.1073/pnas.0608008103; Ingram DK, 2006, AGING CELL, V5, P97, DOI 10.1111/j.1474-9726.2006.00202.x; JHA B, 1992, INT J RADIAT BIOL, V62, P409, DOI 10.1080/09553009214552291; Jiang WQ, 2008, CANCER RES, V68, P5492, DOI 10.1158/0008-5472.CAN-07-6721; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KALANT N, 1988, MECH AGEING DEV, V46, P89, DOI 10.1016/0047-6374(88)90117-0; Kaleoglu O., 1977, TIP FAKULTESI MECMUA, V40, P978; KLEIN S, 1992, AM J PHYSIOL, V262, pE631, DOI 10.1152/ajpendo.1992.262.5.E631; Kurtoglu M, 2007, MOL CANCER THER, V6, P3049, DOI 10.1158/1535-7163.MCT-07-0310; Lakka SS, 2005, BRAIN PATHOL, V15, P327; Lane MA, 1998, J ANTI-AGING MED, V1, P327, DOI [10.1089/rej.1.1998.1.327, DOI 10.1089/REJ.1.1998.1.327]; Lin JN, 2010, J AGR FOOD CHEM, V58, P1584, DOI 10.1021/jf9035782; Lin X, 2003, CANCER RES, V63, P3413; Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6; Marshall NA, 2004, BLOOD, V103, P1755, DOI 10.1182/blood-2003-07-2594; Mohanti BK, 1996, INT J RADIAT ONCOL, V35, P103, DOI 10.1016/S0360-3016(96)85017-6; Mukherjee P, 2004, CLIN CANCER RES, V10, P5622, DOI 10.1158/1078-0432.CCR-04-0308; ROSS MH, 1971, J NATL CANCER I, V47, P1095; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Segrelles C, 2007, CANCER RES, V67, P10879, DOI 10.1158/0008-5472.CAN-07-2564; Singh DH, 2005, STRAHLENTHER ONKOL, V181, P507, DOI 10.1007/s00066-005-1320-z; Soare A, 2011, AGING-US, V3, P374, DOI 10.18632/aging.100280; Spitz DR, 2000, ANN NY ACAD SCI, V899, P349, DOI 10.1111/j.1749-6632.2000.tb06199.x; Stein M, 2010, PROSTATE, V70, P1388, DOI 10.1002/pros.21172; STEINBACH G, 1994, CANCER RES, V54, P1194; Taniguchi CM, 2006, P NATL ACAD SCI USA, V103, P12093, DOI 10.1073/pnas.0604628103; Thompson HJ, 2004, CANCER RES, V64, P1541, DOI 10.1158/0008-5472.CAN-03-3108; Varady KA, 2008, FASEB J, V22, P2090, DOI 10.1096/fj.07-098178; Venkataramanaa Neelam K, 2013, Asian J Neurosurg, V8, P9, DOI 10.4103/1793-5482.110274; Venkatraman Jaya T., 1994, Aging Immunology and Infectious Disease, V5, P13; Wan RQ, 2004, AM J PHYSIOL-HEART C, V287, pH1186, DOI 10.1152/ajpheart.00932.2003; Wang LN, 2014, J INTEGR MED-JIM, V12, P20, DOI 10.1016/S2095-4964(14)60003-0; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Weindruch R, 1996, TOXICOL PATHOL, V24, P742, DOI 10.1177/019262339602400618; Wilker E, 2005, MOL CARCINOGEN, V44, P137, DOI 10.1002/mc.20132; Woodward GE., 1952, J FRANKLIN I, V254, P259, DOI DOI 10.1016/0016-0032(52)90482-1; Workman P, 1998, BRIT J CANCER, V77, P1; Yang XJ, 2010, CLIN CANCER RES, V16, P2833, DOI 10.1158/1078-0432.CCR-10-0059; Zhu ZJ, 2005, CANCER RES, V65, P7023, DOI 10.1158/0008-5472.CAN-05-0453; Zhu Zongjian, 2011, J Carcinog, V10, P17	62	17	18	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2015	10	7							e0132089	10.1371/journal.pone.0132089	http://dx.doi.org/10.1371/journal.pone.0132089			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1CS	26135741	Green Published, gold, Green Submitted			2023-01-03	WOS:000358154400100
J	Ubel, PA				Ubel, Peter A.			Medical Facts versus Value Judgments - Toward Preference-Sensitive Guidelines	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CANCER		[Ubel, Peter A.] Duke Univ, Sch Med, Fuqua Sch Business, Durham, NC 27708 USA; [Ubel, Peter A.] Duke Univ, Sanford Sch Publ Policy, Durham, NC USA	Duke University; Duke University	Ubel, PA (corresponding author), Duke Univ, Sch Med, Fuqua Sch Business, Durham, NC 27708 USA.							Bartelink H, 2007, J CLIN ONCOL, V25, P3259, DOI 10.1200/JCO.2007.11.4991; HAMMOND KR, 1976, SCIENCE, V194, P389, DOI 10.1126/science.194.4263.389; National Comprehensive Cancer Network, 2014, NCCN GUID PAT PROST; National Comprehensive Cancer Network, 2015, NCCN CLIN PRACT GUID; Thompson I, 2007, J UROLOGY, V177, P2106, DOI 10.1016/j.juro.2007.03.003	5	32	32	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 25	2015	372	26					2475	2477		10.1056/NEJMp1504245	http://dx.doi.org/10.1056/NEJMp1504245			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CL2QD	26107051				2023-01-03	WOS:000356788200003
J	Brenk-Franz, K; Strauss, B; Tiesler, F; Fleischhauer, C; Ciechanowski, P; Schneider, N; Gensichen, J				Brenk-Franz, Katja; Strauss, Bernhard; Tiesler, Fabian; Fleischhauer, Christian; Ciechanowski, Paul; Schneider, Nico; Gensichen, Jochen			The Influence of Adult Attachment on Patient Self-Management in Primary Care The Need for a Personalized Approach and Patient-Centred Care	PLOS ONE			English	Article							ILLNESS RATING-SCALE; CHRONIC DISEASE; HEALTH-CARE; PATTERNS; STYLES; MODEL	Objective Self-management strategies are essential elements of evidence-based treatment in patients with chronic conditions in primary care. Our objective was to analyse different self-management skills and behaviours and their association to adult attachment in primary care patients with multiple chronic conditions. Methods In the apricare study (Adult Attachment in Primary Care) we used a prospective longitudinal design to examine the association between adult attachment and self-management in primary care patients with multimorbidity. The attachment dimensions avoidance and anxiety were measured using the ECR-RD. Self-management skills were measured by the FERUS (motivation to change, coping, self-efficacy, hope, social support) and self-management-behaviour by the DSMQ (glucose management, dietary control, physical activity, health-care use). Clinical diagnosis and severity of disease were assessed by the patients' GPs. Multivariate analyses (GLM) were used to assess the relationship between the dimensions of adult attachment and patient self-management. Results 219 patients in primary care with multiple chronic conditions (type II diabetes, hypertension and at least one other chronic condition) between the ages of 50 and 85 were included in the study. The attachment dimension anxiety was positively associated with motivation to change and negatively associated with coping, self-efficacy and hope, dietary control and physical activity. Avoidance was negatively associated with coping, self-efficacy, social support and health care use. Conclusion The two attachment dimensions anxiety and avoidance are associated with different components of self-management. A personalized, attachment-based view on patients with chronic diseases could be the key to effective, individual self-management approaches in primary care.	[Brenk-Franz, Katja; Tiesler, Fabian; Fleischhauer, Christian; Schneider, Nico; Gensichen, Jochen] Univ Hosp, Inst Gen Practice & Family Med, Jena, Germany; [Brenk-Franz, Katja; Strauss, Bernhard] Univ Hosp, Inst Psychosocial Med & Psychotherapy, Jena, Germany; [Ciechanowski, Paul] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; University of Washington; University of Washington Seattle	Brenk-Franz, K (corresponding author), Univ Hosp, Inst Gen Practice & Family Med, Jena, Germany.	katja.brenk-franz@med.uni-jena.de			German Research Foundation (DFG) [FZ GE 2073/5-1]	German Research Foundation (DFG)(German Research Foundation (DFG))	Financial support (about 100.000 Euro) was provided by the German Research Foundation, (http://www.dfg.de/en/index.jsp) DFG: FZ GE 2073/5-1.	BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Bandura A., 1997, PSYCHOL REV, V12, P8; BARTHOLOMEW K, 1991, J PERS SOC PSYCHOL, V61, P226, DOI 10.1037/0022-3514.61.2.226; Berman WH, 1994, ATTACHEMENT ADULTS T; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; BOWLBY J, 1977, BRIT J PSYCHIAT, V130, P201, DOI 10.1192/bjp.130.3.201; Bowlby J., 1988, SECURE BASE CLIN APP; Campbell L, 2005, J PERS SOC PSYCHOL, V88, P510, DOI 10.1037/0022-3514.88.3.510; Ciechanowski P, 1999, PSYCHOSOM MED, V61, P110, DOI 10.1097/00006842-199901000-00145; Ciechanowski PS, 2002, PSYCHOSOM MED, V64, P660, DOI 10.1097/01.PSY.0000021948.90613.76; Ciechanowski PS, 2002, DIABETES CARE, V25, P731, DOI 10.2337/diacare.25.4.731; Consedine NS, 2013, J BEHAV HLTH, V2, P308; Ehrenthal Johannes C, 2009, Psychother Psychosom Med Psychol, V59, P215, DOI 10.1055/s-2008-1067425; Fraley RC, 2000, J PERS SOC PSYCHOL, V78, P350, DOI 10.1037/0022-3514.78.2.350; Gensichen Jochen, 2006, Z Arztl Fortbild Qualitatssich, V100, P365; Gilks W, 1996, MARKOV CHAIN MONTE C, DOI 10.2307/2965438; Henderson SJ, 2009, ATTACHMENT SECURITY; Hudon C, 2007, J CLIN EPIDEMIOL, V60, P212, DOI 10.1016/j.jclinepi.2005.12.021; Jack M., 2007, FERUS QUESTIONNAIRE; Ju┬ckel KH., 1998, MESSUNG SOZIODEMOGRA, P7; Kanfer FH., 2006, SELBSTMANAGEMENT THE; Konig CJ, 2006, LEHRBUCH PERSONALPSY; Maunder RG, 2001, PSYCHOSOM MED, V63, P556, DOI 10.1097/00006842-200107000-00006; MIKULINCER M, 1991, J PERS SOC PSYCHOL, V61, P321, DOI 10.1037/0022-3514.61.2.321; Mikulincer M, 2003, MOTIV EMOTION, V27, P77, DOI 10.1023/A:1024515519160; Mikulincer M., 2007, ATTACHMENT ADULTHOOD; MILLER MD, 1992, PSYCHIAT RES, V41, P237, DOI 10.1016/0165-1781(92)90005-N; OLSON CL, 1976, PSYCHOL BULL, V83, P579, DOI 10.1037/0033-2909.83.4.579; Rholes W.S., 1998, ATTACHMENT THEORY CL, P166; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Rubin DB, 1996, J AM STAT ASSOC, V91, P473, DOI 10.1080/01621459.1996.10476908; Schafer I, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-145; Schafer J.L., 1997, ANAL INCOMPLETE MULT; Schmidt S, 2002, J PSYCHOSOM RES, V53, P763, DOI 10.1016/S0022-3999(02)00335-5; Schmitt A, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-138; Schwarzer R, 2002, HLTH PSYCHOL A Z; Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64	37	26	27	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2015	10	9							e0136723	10.1371/journal.pone.0136723	http://dx.doi.org/10.1371/journal.pone.0136723			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CS0ZE	26381140	gold, Green Published, Green Submitted			2023-01-03	WOS:000361790200011
J	Sun, HZ; Ge, WJ; Gao, X; Wang, SS; Jiang, SJ; Hu, Y; Yu, M; Hu, SS				Sun, Haizhu; Ge, Wenjie; Gao, Xin; Wang, Shaoshan; Jiang, Shijian; Hu, Ying; Yu, Miao; Hu, Shaoshan			Apoptosis-Promoting Effects of Hematoporphyrin Monomethyl Ether-Sonodynamic Therapy (HMME-SDT) on Endometrial Cancer	PLOS ONE			English	Article							ENDOPLASMIC-RETICULUM; OXIDATIVE STRESS; CELL-DEATH; ULTRASOUND; CALCIUM; MITOCHONDRIA; INDUCTION	Objective The aim of the present study was to examine the apoptosis-promoting effects and mechanisms of hematoporphyrin monomethyl ether (HMME)-sonodynamic therapy (SDT) on endometrial cancer cells in vitro. Methods Endometrial cancer cell samples were divided into four groups: 1) untreated control group, 2) HMME group, 3) pure ultrasound group, and 4) HMME combined with ultrasound, i.e. SDT group. CCK-8 method was utilized to assess the inhibiting effect of SDT on the proliferation of endometrial cancer cells. Optical microscope and field emission transmission electron microscopy were used to characterize the morphology changes of the cancer cells induced by the treatments. Apoptosis rate, reactive oxygen species (ROS) and mitochondrial membrane potential (MMP) were examined by flow cytometer. Fluorescence intensity measured by laser scanning confocal microscopy was used to explore the variation of intracellular calcium ion (Ca2+) concentration. Apoptosis-related proteins involved in both intrinsic and extrinsic apoptosis signallings were analyzed by western blot. Results SDT can effectively induce the apoptosis of endometrial cancer cells. Compared with ultrasound which is known as an effective anti-tumor method, SDT leads to a significant improvement on suppression of cell viability and induction of apoptosis, together with more remarkable modifications on the morphology and substructure in both ultrasound sensitive and resistant endometrial cancer cells. Further studies reveals that SDT promotes ROS production, induces loss of MMP and increases intracellular Ca2+ concentration more efficiently than HMME or ultrasound alone. SDT groups also show a rather high expression of apoptosis- promoting proteins, including Bax, Fas and Fas-L, and a significant low expression of apoptosis- suspending proteins including Bcl-2 and Survivin. Meanwhile, both cleaved caspse-3 and caspase-8 are dramatically enhanced in SDT groups. Multiple pathways has been proposed in the process, including the intrinsic activation by excessive ROS and overloaded Ca2+, silencing survivin gene, and the extrinsic pathway mediated by the death receptor. Conclusion Given its considerable effectivity in both ultrasound sensitive and resistant cells, SDT may therefore be a promising therapeutic method for treating endometrial cancers.	[Sun, Haizhu; Gao, Xin; Hu, Shaoshan] Harbin Med Univ, Affiliated Hosp 2, Dept Neurosurg, Harbin 150001, Peoples R China; [Wang, Shaoshan; Yu, Miao] Harbin Inst Technol, Sch Chem Engn & Technol, State Key Lab Urban Water Resource & Environm, Harbin 150001, Peoples R China; [Sun, Haizhu] Harbin Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Harbin 150001, Peoples R China; [Ge, Wenjie; Jiang, Shijian; Hu, Ying] Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150001, Peoples R China	Harbin Medical University; Harbin Institute of Technology; Harbin Medical University; Harbin Institute of Technology	Hu, Y (corresponding author), Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150001, Peoples R China.	shaoshanhu@126.com; huying@hit.edu.cn; miaoyu_che@hit.edu.cn	Hu, Ying/ABG-2935-2021	Hu, Ying/0000-0003-2469-5604; Yu, Miao/0000-0001-8820-9594	National Natural Science Foundation of China [30872650]; Program for New Century Excellent Talents in University of China [NCET-09-0131]; Recruitment Program of Global Young Experts, China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University of China(Program for New Century Excellent Talents in University (NCET)); Recruitment Program of Global Young Experts, China	This work was financially supported by the National Natural Science Foundation of China (Grant No. 30872650); Program for New Century Excellent Talents in University of China (Grant No. NCET-09-0131); MY acknowledges financial support from the Recruitment Program of Global Young Experts, China.	Amant F, 2005, LANCET, V366, P491, DOI 10.1016/S0140-6736(05)67063-8; Ando H, 2006, CANCER LETT, V242, P37, DOI 10.1016/j.canlet.2005.10.032; Ashush H, 2000, CANCER RES, V60, P1014; Breckenridge DG, 2004, CURR OPIN CELL BIOL, V16, P647, DOI 10.1016/j.ceb.2004.09.009; Chen HJ, 2014, DRUG DISCOV TODAY, V19, P502, DOI 10.1016/j.drudis.2014.01.010; Dellinger TH, 2009, EXPERT REV ANTICANC, V9, P905, DOI [10.1586/era.09.54, 10.1586/ERA.09.54]; Ding XM, 2004, CANCER LETT, V216, P43, DOI 10.1016/j.canlet.2004.07.005; Furusawa Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029012; Guan HT, 2006, WORLD J GASTROENTERO, V12, P2901, DOI 10.3748/wjg.v12.i18.2901; Hammadi M, 2013, FASEB J, V27, P1600, DOI 10.1096/fj.12-218875; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Kumar B, 2012, BIOCHEM BIOPH RES CO, V417, P903, DOI 10.1016/j.bbrc.2011.12.072; Lei TC, 2012, PHOTODIAGN PHOTODYN, V9, P232, DOI 10.1016/j.pdpdt.2012.01.003; Li YC, 2009, NEUROCHEM RES, V34, P418, DOI 10.1007/s11064-008-9799-1; Masgras I, 2012, J BIOL CHEM, V287, P9845, DOI 10.1074/jbc.M111.250357; Rosenthal I, 2004, ULTRASON SONOCHEM, V11, P349, DOI 10.1016/j.ultsonch.2004.03.004; Sun SY, 2004, JNCI-J NATL CANCER I, V96, P662, DOI 10.1093/jnci/djh123; Tang W, 2010, ULTRASONICS, V50, P567, DOI 10.1016/j.ultras.2009.12.001; Tang W, 2009, ULTRASONICS, V49, P786, DOI 10.1016/j.ultras.2009.06.002; Tarkowski R, 2003, INT J GYNECOLOGICAL, V13, P72; Vyssokikh MY, 2002, MOL BIOL REP, V29, P93, DOI 10.1023/A:1020383108620; Wang B, 2013, FREE RADICAL BIO MED, V65, P882, DOI 10.1016/j.freeradbiomed.2013.08.173; Wang HY, 2010, BIOMATERIALS, V31, P413, DOI 10.1016/j.biomaterials.2009.09.066; Wood AKW, 2015, ULTRASOUND MED BIOL, V41, P905, DOI 10.1016/j.ultrasmedbio.2014.11.019; YUMITA N, 1989, JPN J CANCER RES, V80, P219, DOI 10.1111/j.1349-7006.1989.tb02295.x; Zhang L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/696107; Zhivotovsky B, 2011, CELL CALCIUM, V50, P211, DOI 10.1016/j.ceca.2011.03.003; Zhou YJ, 2009, TOXICOL IN VITRO, V23, P288, DOI 10.1016/j.tiv.2008.12.009	28	20	22	0	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2015	10	9							e0137980	10.1371/journal.pone.0137980	http://dx.doi.org/10.1371/journal.pone.0137980			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR8KS	26367393	gold, Green Submitted, Green Published			2023-01-03	WOS:000361601100194
J	Bucciardini, R; Fragola, V; Abegaz, T; Lucattini, S; Halifom, A; Tadesse, E; Berhe, M; Pugliese, K; Binelli, A; De Castro, P; Terlizzi, R; Fucili, L; Di Gregorio, M; Mirra, M; Olivieri, E; Teklu, T; Zegeye, T; Haile, A; Vella, S; Abraham, L				Bucciardini, Raffaella; Fragola, Vincenzo; Abegaz, Teshome; Lucattini, Stefano; Halifom, Atakilt; Tadesse, Eskedar; Berhe, Micheal; Pugliese, Katherina; Binelli, Andrea; De Castro, Paola; Terlizzi, Roberta; Fucili, Luca; Di Gregorio, Massimiliano; Mirra, Marco; Olivieri, Erika; Teklu, Tsigemariam; Zegeye, Teame; Haile, Amanuel; Vella, Stefano; Abraham, Loko		CASA-project Health Facilities	Retention in Care of Adult HIV Patients Initiating Antiretroviral Therapy in Tigray, Ethiopia: A Prospective Observational Cohort Study	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; COMMUNITY-HEALTH WORKERS; TREATMENT PROGRAM; CLINICAL-OUTCOMES; ADHERENCE SUPPORT; DELIVERY; SURVIVAL; GENDER; IMPACT; INCOME	Introduction Although Ethiopia has been scaling up the antiretroviral therapy (ART) services, low retention in care of patients remains one of the main obstacles to treatment success. We report data on retention in care and its associated determinants in Tigray, Ethiopia. Methods We used data from the CASA project, a prospective observational and multi-site study of a cohort of HIV-infected patients who initiated ART for the first time in Tigray. Four participating health facilities (HFs) located in the South of Tigray were considered for this study. Patients were followed for one year after ART initiation. The main outcome measure was represented by the current retention in care, defined as the proportion of patients who were alive and receiving ART at the same HF one year after ART initiation. Patients who started ART between January 1, 2013 and December 31, 2013 were included in this analysis. Patients were followed for one year after ART initiation. The determinants of retention were analysed using univariate and multivariate Cox Proportional Hazards model with robust sandwich estimates to account for within HF correlation. Results The four participating HFs in Tigray were able to retain overall 85.1% of their patients after one year from starting ART. Loss to follow-up (5.5%) and transfers to other HF (6.6) were the main determinant of attrition. A multivariate analysis shows that the factors significantly associated with retention were the type of HF, gender and active TB. Alamata health center was the HF with the highest attrition rate (HR 2.99, 95% CI: 2.77-3.23). Active TB (HR 1.72, 95% CI: 1.23-2.41) and gender (HR 1.64, 95% CI: 1.10-2.56) were also significantly associated with attrition. Conclusions Although Ethiopia has significantly improved access to the ART program, achieving and maintaining a satisfactory long-term retention rate is a future goal. This is difficult because of different retention rates among HFs. Moreover specific interventions should be directed to people of different sex to improve retention in care in male population.	[Bucciardini, Raffaella; Fragola, Vincenzo; Lucattini, Stefano; Pugliese, Katherina; Binelli, Andrea; De Castro, Paola; Terlizzi, Roberta; Fucili, Luca; Di Gregorio, Massimiliano; Mirra, Marco; Olivieri, Erika; Vella, Stefano] Ist Super Sanita, I-00161 Rome, Italy; [Abegaz, Teshome; Tadesse, Eskedar; Berhe, Micheal; Haile, Amanuel; Abraham, Loko] Mekelle Univ, Coll Hlth Sci, Mekelle, Ethiopia; [Halifom, Atakilt; Teklu, Tsigemariam; Zegeye, Teame; CASA-project Health Facilities] Tigray Reg Hlth Bur, Mekelle, Ethiopia	Istituto Superiore di Sanita (ISS); Mekelle University	Bucciardini, R (corresponding author), Ist Super Sanita, Viale Regina Elena 299, I-00161 Rome, Italy.	raffaella.bucciardini@iss.it	Vella, Stefano/GZM-0519-2022; VELLA, STEFANO/ABI-3368-2020; VELLA, STEFANO/V-8440-2019; De Castro, Paola/D-6218-2011	VELLA, STEFANO/0000-0003-2347-5984; De Castro, Paola/0000-0001-8717-9418	Italian Ministry of Health-Department of Prevention and Innovation, Rome, Italy	Italian Ministry of Health-Department of Prevention and Innovation, Rome, Italy	This work was supported by the Italian Ministry of Health-Department of Prevention and Innovation, Rome, Italy. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2014, FEDERAL DEMOCRATIC R; [Anonymous], 2013, MMWR MORB MORTAL WKL; Arem H, 2011, AIDS PATIENT CARE ST, V25, P719, DOI 10.1089/apc.2010.0349; Assefa Yibeltal, 2008, Ethiop Med J, V46, P401; Assefa Y, 2014, GLOBALIZATION HEALTH, V10, DOI 10.1186/1744-8603-10-43; Assefa Y, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-45; Assefa Y, 2012, J HEALTH SERV RES PO, V17, P24, DOI 10.1258/jhsrp.2011.010135; Assefa Y, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-81; Assefa Y, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000056; Barnighausen T, 2011, LANCET INFECT DIS, V11, P942, DOI 10.1016/S1473-3099(11)70181-5; Callaghan M, 2010, HUM RESOUR HEALTH, V8, DOI 10.1186/1478-4491-8-8; Central Statistical Agency of Ethiopia, 2011, ETH DEM HLTH SURV; Cornell M, 2009, TROP MED INT HEALTH, V14, P722, DOI 10.1111/j.1365-3156.2009.02290.x; Etienne M, 2010, TROP MED INT HEALTH, V15, P76, DOI 10.1111/j.1365-3156.2010.02513.x; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Fatti G, 2012, JAIDS-J ACQ IMM DEF, V61, pE50, DOI 10.1097/QAI.0b013e31826a6aee; Federal HIV/AIDS Prevention and Control Office, 2009, ETH MULT HIV AIDS RE; Federal HIV/ AIDS Prevention and Control Office, 2013, MON EV REP 2011 2012; Federal Ministry of Health of Ethiopia, 2010, GUID IMPL HIV AIDS C; Fox MP, 2010, TROP MED INT HEALTH, V15, P1, DOI 10.1111/j.1365-3156.2010.02508.x; Geng Elvin H, 2010, Curr HIV/AIDS Rep, V7, P234, DOI 10.1007/s11904-010-0061-5; Hart JE, 2010, JAIDS-J ACQ IMM DEF, V54, P167, DOI 10.1097/QAI.0b013e3181d9a330; Massaquoi M, 2009, T ROY SOC TROP MED H, V103, P594, DOI 10.1016/j.trstmh.2009.02.012; Melaku Z, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1776-4; Ministry of Health (MOH), 2004, ACC ACC HIV AIDS TRE; Muula AS, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-63; Mwai GW, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.1.18586; Organization WH, 2012, RET HIV PROGR DEF CH; Rich ML, 2012, JAIDS-J ACQ IMM DEF, V59, pE35, DOI 10.1097/QAI.0b013e31824476c4; Schneider H, 2010, AIDS CARE, V22, P60, DOI 10.1080/09540120903483042; Selke HM, 2010, JAIDS-J ACQ IMM DEF, V55, P483, DOI 10.1097/QAI.0b013e3181eb5edb; Tassie JM, 2010, JAIDS-J ACQ IMM DEF, V54, P437, DOI 10.1097/QAI.0b013e3181d73e1b; UNAIDS, 2010, GETT ZER 2011 2015 S; WHO, 2015, COUNTR STAT GLOB HLT; World Health Organisation, 2007, TASK SHIFT RAT RED T; World Health Organization, 2013, CONS GUID ANT DRUGS; World Health Organization, 2011, UN ACC SCAL PRIOR HI; Wouters E, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-194; Wright J, 2004, TROP MED INT HEALTH, V9, P559, DOI 10.1111/j.1365-3156.2004.01230.x; Wubshet Mamo, 2012, ISRN AIDS, V2012, P721720, DOI 10.5402/2012/721720	40	17	17	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2015	10	9							e0136117	10.1371/journal.pone.0136117	http://dx.doi.org/10.1371/journal.pone.0136117			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ6BA	26340271	Green Published, Green Submitted, gold			2023-01-03	WOS:000360688200005
J	Yang, XW; Yang, S; Chai, HY; Yang, ZG; Lee, RJ; Liao, WW; Teng, LS				Yang, Xuewei; Yang, Shuang; Chai, Hongyu; Yang, Zhaogang; Lee, Robert J.; Liao, Weiwei; Teng, Lesheng			A Novel Isoquinoline Derivative Anticancer Agent and Its Targeted Delivery to Tumor Cells Using Transferrin-Conjugated Liposomes	PLOS ONE			English	Article							METHYLENE-GAMMA-BUTYROLACTONES; ALLYLIC-ALKYLATION; LIGAND	We have screened 11 isoquinoline derivatives and alpha-methylene-gamma-butyrolactones using the 3-(4,5-dimethylthi-azol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity assay in HeLa and HEK-293T cells. Compound 2 was identified as potential anticancer agent. To further improve its therapeutic potential, this agent was incorporated into transferrin (Tf)-conjugated liposomes (LPs) for targeted delivery to tumor cells. We have demonstrated Tf-LP-Compound 2 have superior antitumor activity compared to non-targeted controls and the free drug. These data show Tf-LP-Compound 2 to be a promising agent that warrants further evaluation.	[Yang, Xuewei; Yang, Shuang; Chai, Hongyu; Lee, Robert J.; Teng, Lesheng] Jilin Univ, Coll Life Sci, Changchun 130023, Peoples R China; [Yang, Zhaogang; Lee, Robert J.] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA; [Liao, Weiwei] Jilin Univ, Dept Organ Chem, Coll Chem, Changchun 130023, Peoples R China	Jilin University; University System of Ohio; Ohio State University; Jilin University	Liao, WW (corresponding author), Jilin Univ, Dept Organ Chem, Coll Chem, Changchun 130023, Peoples R China.	wliao@jlu.edu.cn; tenglesheng@jlu.edu.cn		Teng, Lesheng/0000-0003-1623-5384				Ahamad MS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110003; Allen TM, 1998, DRUGS, V56, P747, DOI 10.2165/00003495-199856050-00001; Anabousi S, 2006, EUR J PHARM SCI, V29, P367, DOI 10.1016/j.ejps.2006.07.004; Bentley KW, 2006, NAT PROD REP, V23, P444, DOI 10.1039/b509523a; Chiu SJ, 2006, J CONTROL RELEASE, V112, P199, DOI 10.1016/j.jconrel.2006.02.011; Daniels TR, 2006, CLIN IMMUNOL, V121, P159, DOI 10.1016/j.clim.2006.06.006; Farooq S, 2014, EUR J MED CHEM, V84, P545, DOI 10.1016/j.ejmech.2014.07.069; Fonseca C, 2005, EUR J PHARM BIOPHARM, V59, P359, DOI 10.1016/j.ejpb.2004.08.012; Hatakeyama H, 2004, INT J PHARMACEUT, V281, P25, DOI 10.1016/j.ijpharm.2004.05.025; Hossen MN, 2010, J CONTROL RELEASE, V147, P261, DOI 10.1016/j.jconrel.2010.07.100; Ishida O, 2001, PHARMACEUT RES, V18, P1042, DOI 10.1023/A:1010960900254; Janecka A, 2012, DRUG DISCOV TODAY, V17, P561, DOI 10.1016/j.drudis.2012.01.013; Kitson RRA, 2009, ANGEW CHEM INT EDIT, V48, P9426, DOI 10.1002/anie.200903108; Kobayashi T, 2007, INT J PHARMACEUT, V329, P94, DOI 10.1016/j.ijpharm.2006.08.039; Li HY, 2002, MED RES REV, V22, P225, DOI 10.1002/med.10008; Li XM, 2009, INT J PHARMACEUT, V373, P116, DOI 10.1016/j.ijpharm.2009.01.023; Martin A, 2005, INT J TUBERC LUNG D, V9, P901; Moodley S, 2014, J MICROBIOL METH, V104, P72, DOI 10.1016/j.mimet.2014.06.014; Noble GT, 2014, TRENDS BIOTECHNOL, V32, P32, DOI 10.1016/j.tibtech.2013.09.007; Panwar P, 2010, INT J NANOMED, V5, P101; Prathapan A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096220; Qin TY, 2013, ORG BIOMOL CHEM, V11, P984, DOI 10.1039/c2ob27269e; Sakaguchi N, 2008, BIOCONJUGATE CHEM, V19, P1588, DOI 10.1021/bc800126s; Wang XM, 2014, CURR PHARM BIOTECHNO, V15, P839, DOI 10.2174/1389201015666141031105234; Xie J, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/710502; Xu SL, 2011, INT J PHARMACEUT, V404, P205, DOI 10.1016/j.ijpharm.2010.10.053; Yan Y, 2014, TETRAHEDRON LETT, V55, P479, DOI 10.1016/j.tetlet.2013.11.067; Yang ZG, 2014, NANOSCALE, V6, P9742, DOI 10.1039/c4nr01510j; Yang ZG, 2009, BBA-MOL CELL RES, V1793, P1868, DOI 10.1016/j.bbamcr.2009.10.007; Zhou CG, 2014, CURR PHARM BIOTECHNO, V15, P829, DOI 10.2174/1389201015666141020155620	30	49	50	0	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2015	10	8							e0136649	10.1371/journal.pone.0136649	http://dx.doi.org/10.1371/journal.pone.0136649			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP7LO	26309138	Green Published, gold, Green Submitted			2023-01-03	WOS:000360069400147
J	Hyacinth, HI; Adams, RJ; Greenberg, CS; Voeks, JH; Hill, A; Hibbert, JM; Gee, BE				Hyacinth, Hyacinth I.; Adams, Robert J.; Greenberg, Charles S.; Voeks, Jenifer H.; Hill, Allyson; Hibbert, Jacqueline M.; Gee, Beatrice E.			Effect of Chronic Blood Transfusion on Biomarkers of Coagulation Activation and Thrombin Generation in Sickle Cell Patients at Risk for Stroke	PLOS ONE			English	Article							VON-WILLEBRAND-FACTOR; DISEASE; CHILDREN; ANEMIA; HYPERCOAGULABILITY; HEMOGLOBIN; PREVENTION; VELOCITY	Hypercoagulability in sickle cell disease (SCD) is associated with multiple SCD phenotypes, association with stroke risk has not been well described. We hypothesized that serum levels of biomarkers of coagulation activation correlate with high transcranial Doppler ultrasound velocity and decreases with blood transfusion therapy in SCD patients. Stored serum samples from subjects in the Stroke Prevention in Sickle Cell Anemia (STOP) trial were analyzed using ELISA and protein multiplexing techniques. 40 subjects from each treatment arm (Standard Care [SC] and Transfusion [Tx]) at three time points-baseline, study exit and one year post-trial and 10 each of age matched children with SCD but normal TCD (SNTCD) and with normal hemoglobin (HbAA) were analyzed. At baseline, median vWF, TAT and D-dimer levels were significantly higher among STOP subjects than either HbAA or SNTCD. At study exit, median hemoglobin level was significantly higher while median TCD velocity was significantly lower in Tx compared to SC subjects. Median vWF (409.6 vs. 542.9 mu g/ml), TAT (24.8 vs. 40.0 ng/ml) and D-dimer (9.2 vs. 19.1 mu g/ml) levels were also significantly lower in the Tx compared to the SC group at study exit. Blood levels of biomarkers coagulation activation/thrombin generation correlated positively with TCD velocity and negatively with number of blood transfusions. Biomarkers of coagulation activation/thrombin generation were significantly elevated in children with SCD, at high risk for stroke. Reduction in levels of these biomarkers correlated with reduction in stroke risk (lower TCD velocity), indicating a possible role for hypercoagulation in SCD associated stroke.	[Hyacinth, Hyacinth I.] Emory Univ, Sch Med, Dept Pediat Hematol Oncol, Atlanta, GA 30322 USA; [Hyacinth, Hyacinth I.; Adams, Robert J.; Voeks, Jenifer H.] Med Univ S Carolina, Dept Neurol, Stroke Ctr, Charleston, SC 29425 USA; [Greenberg, Charles S.] Med Univ S Carolina, Dept Hematol, Charleston, SC 29425 USA; [Hill, Allyson] Coll Charleston, Dept Biol, Charleston, SC 29424 USA; [Hibbert, Jacqueline M.] Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA; [Gee, Beatrice E.] Morehouse Sch Med, Dept Pediat, Atlanta, GA 30310 USA; [Gee, Beatrice E.] Morehouse Sch Med, Cardiovasc Res Inst, Atlanta, GA 30310 USA; [Gee, Beatrice E.] Childrens Healthcare Atlanta, Atlanta, GA USA	Emory University; Medical University of South Carolina; Medical University of South Carolina; College of Charleston; Morehouse School of Medicine; Morehouse School of Medicine; Morehouse School of Medicine; Children's Healthcare of Atlanta (CHOA)	Hyacinth, HI (corresponding author), Emory Univ, Sch Med, Dept Pediat Hematol Oncol, Atlanta, GA 30322 USA.	hhyacinth@emory.edu	Adams, Robert/GPW-8528-2022; Hyacinth, Hyacinth/U-5722-2017; Hibbert, Jacqueline/W-2282-2019	Hyacinth, Hyacinth/0000-0002-1991-7463; 	National Centre for Advancing Translational Sciences (NCATS) of National Institutes of Health [UL1TR000454]; National Institute on Minority Health and Health Disparities (NIMHD) from National Centre for Research Resources (NCRR) [8 U54 MD007588-04]; NIMHD [S21 MD000101-05]; Children's Healthcare of Atlanta Friends Pilot Project Award [00051285]; MUSC/Department of Defense Cooperative Agreement (SE VIEW) [W81XWH-10-2-0057]; National Heart, Lung, and Blood Institute [U10 HL 52193, U10 HL 52016]; NIH/NHLBI [R21HL092358]; NIH/NCRR [5P20RR0111044]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025008, U54RR026137] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL092358, U10HL052193, U01HL052193, U10HL052016] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [U54MD007588, S21MD000101] Funding Source: NIH RePORTER	National Centre for Advancing Translational Sciences (NCATS) of National Institutes of Health; National Institute on Minority Health and Health Disparities (NIMHD) from National Centre for Research Resources (NCRR); NIMHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); Children's Healthcare of Atlanta Friends Pilot Project Award; MUSC/Department of Defense Cooperative Agreement (SE VIEW); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	The authors are grateful to Ellen Debenham, RN, Judy Luden, Corinne Hilbert and the staff of Dr. Kindy's lab (all at MUSC) and Jane Chu from the Protein Profiling Core at MSM, for their logistical support in retrieving the samples and equipment setup. This project was supported in part by grants from The National Centre for Advancing Translational Sciences (NCATS) of the National Institutes of Health, under Award Number UL1TR000454, the National Institute on Minority Health and Health Disparities (NIMHD) Grant Number 8 U54 MD007588-04 (Formerly Grant Number U54 RR026137) from the National Centre for Research Resources (NCRR), NIMHD Grant Number S21 MD000101-05, Children's Healthcare of Atlanta Friends Pilot Project Award, Emory/Pediatrics Pilot project, grant number 00051285, the MUSC/Department of Defense Cooperative Agreement (SE VIEW) number: W81XWH-10-2-0057, the Cooperative Agreements with the National Heart, Lung, and Blood Institute (U10 HL 52193 and U10 HL 52016), and also in part by NIH/NHLBI grant number R21HL092358 and NIH/NCRR grant number 5P20RR0111044, pilot. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the Department of Defense or other sources of funding. The funding agencies have no responsibility in the preparation of this manuscript or interpretation of the results.	ADAMS R, 1992, NEW ENGL J MED, V326, P605, DOI 10.1056/NEJM199202273260905; Adams RJ, 2005, NEW ENGL J MED, V353, P2769; Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102; Asare K, 2010, CYTOKINE, V49, P39, DOI 10.1016/j.cyto.2009.10.002; Ataga KI, 2007, HAEMATOLOGICA, V93, P20, DOI 10.3324/haematol.11763; Ataga KI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029786; Ataga KI, 2009, HAEMATOL-HEMATOL J, V94, P1481, DOI 10.3324/haematol.2009.013672; Ataga KI, 2003, AM J MED, V115, P721, DOI 10.1016/j.amjmed.2003.07.011; Blann A, 1999, BLOOD COAGUL FIBRIN, V10, P277, DOI 10.1097/00001721-199907000-00009; Centers for Disease Control and Prevention, 2012, CHILDR SICKL CELL DI, V2012; Colombatti R, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0078801, DOI 10.1371/J0URNAL.P0NE.0078801]; Danesh J, 2001, CIRCULATION, V103, P2323; Deane CR, 2010, HAEMATOL-HEMATOL J, V95, P1287, DOI 10.3324/haematol.2010.022624; Dobson SR, 2002, BLOOD, V99, P3144, DOI 10.1182/blood.V99.9.3144; Gebreyohanns M, 2004, CNS SPECTRUMS, V9, P445; Hassell KL, 2010, AM J PREV MED, V38, pS512, DOI 10.1016/j.amepre.2009.12.022; Hulbert ML, 2006, J PEDIATR-US, V149, P710, DOI 10.1016/j.jpeds.2006.06.037; Hulbert ML, 2011, BLOOD, V117, P772, DOI 10.1182/blood-2010-01-261123; Hyacinth HI, 2014, AM J HEMATOL, V89, P47, DOI 10.1002/ajh.23586; Hyacinth HI, 2012, CYTOKINE, V60, P302, DOI 10.1016/j.cyto.2012.05.017; Jordan LC, 2012, BRIT J HAEMATOL, V157, P14, DOI 10.1111/j.1365-2141.2011.09005.x; Kato Gregory J, 2009, Am J Hematol, V84, P618, DOI 10.1002/ajh.21475; Lezcano NE, 2006, STROKE, V37, P1424, DOI 10.1161/01.STR.0000221173.97108.01; MERKEL KHH, 1978, STROKE, V9, P45, DOI 10.1161/01.STR.9.1.45; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; PROHOVNIK I, 1989, NEUROLOGY, V39, P344, DOI 10.1212/WNL.39.3.344; Prohovnik I, 2009, J CEREBR BLOOD F MET, V29, P803, DOI 10.1038/jcbfm.2009.6; Setty BNY, 2001, BLOOD, V98, P3228, DOI 10.1182/blood.V98.12.3228; Smith LA, 2006, PEDIATRICS, V117, P1763, DOI 10.1542/peds.2005-1611; Thorlacius-Ussing O, THROMBO RES, V81, P253; van Beers EJ, 2009, HAEMATOL-HEMATOL J, V94, P1513, DOI 10.3324/haematol.2009.008938; Ware RE, 2012, BLOOD, V119, P3925, DOI 10.1182/blood-2011-11-392340; Weatherall DJ, 2008, CURR MOL MED, V8, P592, DOI 10.2174/156652408786241375; Whelihan MF, 2013, J THROMB HAEMOST, V11, P2187, DOI 10.1111/jth.12423; Whelihan MF, 2012, BLOOD, V120, P3837, DOI 10.1182/blood-2012-05-427856; Woodhams B, 2001, BLOOD COAGUL FIBRIN, V12, P229, DOI 10.1097/00001721-200106000-00002; Zhou Z, 2009, THROMB HAEMOSTASIS, V101, P1070, DOI 10.1160/TH08-10-0677; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	38	16	16	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 25	2015	10	8							e0134193	10.1371/journal.pone.0134193	http://dx.doi.org/10.1371/journal.pone.0134193			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP6KK	26305570	Green Submitted, gold, Green Published			2023-01-03	WOS:000359995500006
J	Oliver, D				Oliver, David			ACUTE PERSPECTIVE David Oliver: Who is to blame for older people's readmission?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												davidoliver372@googlemail.com						[Anonymous], 2013, NURSING TIMES; Battye F, 2012, RES REPORT OLD PEOPL; Conroy S, 2012, AGE AGEING, V41, P702, DOI 10.1093/ageing/afs154; Cowling TE, 2014, J ROY SOC MED, V107, P432, DOI 10.1177/0141076814542669; Feinmann J., 2014, DAILY MAIL; Healthwatch England, 2015, SAF HOM WHAT HAPP PE; Macready N., 2012, LINK LENGTH HOSP STA; National Institute for Health Research: Service Delivery and Organisation Programme, 2012, UND IMPR TRANS OLD P; NHS Benchmarking Network, 2014, NAT AUD INT CAR SUMM; NHS Confederation Foundation Trust Network, 2011, BRIEF IMP NONP AC RE; Royal Voluntary Service, 2013, AV UNH RET RAD RED R	11	7	7	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 7	2015	351								h4244	10.1136/bmj.h4244	http://dx.doi.org/10.1136/bmj.h4244			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CO8AV	26253123	Bronze			2023-01-03	WOS:000359387800004
J	Wu, SX; Xia, B; Han, F; Xie, RF; Song, T; Lu, LX; Yu, W; Deng, XW; He, QC; Zhao, C; Xie, CH				Wu, Shixiu; Xia, Bing; Han, Fei; Xie, Ruifei; Song, Tao; Lu, Lixia; Yu, Wei; Deng, Xiaowu; He, Qiancheng; Zhao, Cong; Xie, Conghua			Prognostic Nomogram for Patients with Nasopharyngeal Carcinoma after Intensity-Modulated Radiotherapy	PLOS ONE			English	Article							PRIMARY TUMOR VOLUME; RADIATION-THERAPY; CHEMOTHERAPY; CANCER; EXPERIENCE; TRIAL; STAGE; METAANALYSIS; PREDICTIONS; CONCURRENT	This study was aimed to define possible predictors of overall survival in nasopharyngeal carcinoma (NPC). Patients were treated with intensity-modulated radiation therapy (IMRT), to establish an effective prognostic nomogram that could provide individualized predictions of treatment outcome in this setting. We reviewed the records of 533 patients with non-metastatic NPC who underwent IMRT with or without concurrent chemotherapy at the Department of Radiation Oncology of Sun Yat-Sen University from 2002 to 2009; none of these patients received induction or adjuvant chemotherapy. These data sets were used to construct a nomogram based on Cox regression. Nomogram performance was determined via a concordance index (C-index) and a calibration curve which was compared with the TNM staging system for NPC. The results were validated in an external cohort of 442 patients from the Department of Radiation Oncology of Wenzhou Medical College who were treated during the same period. Results showed that the greatest influence on survival were primary gross tumor volume, age, tumor stage and nodal stage (2002 Union for International Cancer Control [UICC] staging system), which were selected into the nomogram. The C-index of the nomogram for predicting survival was 0.748 (95% CI, 0.704-0.785), which was statistically higher than that of TNM staging system (0.684, P<0.001). The calibration curve exhibited agreement between nomogram-predicted and the actual observed probabilities for overall survival. In the validation cohort, the nomogram discrimination was superior to the TNM staging system (C-index: 0.768 vs 0.721; P = 0.026). In conclusion, the nomogram proposed in this study resulted in more-accurate prognostic prediction for patients with NPC after IMRT and compared favorably to the TNM staging system; this individualized information will aid in patient counseling and may be used for de-escalation trials in the future.	[Wu, Shixiu; Xie, Conghua] Wuhan Univ, Zhongnan Hosp, Dept Radiat & Med Oncol, Wuhan 430072, Hubei, Peoples R China; [Wu, Shixiu; Xie, Conghua] Wuhan Univ, Hubei Canc Clin Study Ctr, Wuhan 430072, Hubei, Peoples R China; [Wu, Shixiu; Xia, Bing; Xie, Ruifei] Hangzhou Canc Hosp, Dept Radiat Oncol, Hangzhou, Zhejiang, Peoples R China; [Han, Fei; Lu, Lixia; Deng, Xiaowu; Zhao, Cong] State Key Lab Oncol Southern China, Guangzhou, Guangdong, Peoples R China; [Han, Fei; Lu, Lixia; Deng, Xiaowu; Zhao, Cong] Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, Guangzhou 510275, Guangdong, Peoples R China; [Han, Fei; Lu, Lixia; Deng, Xiaowu; Zhao, Cong] Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China; [Song, Tao; Yu, Wei; He, Qiancheng] Wenzhou Med Coll Canc Ctr, Dept Radiat Oncol, Wenzhou, Zhejiang, Peoples R China	Wuhan University; Wuhan University; State Key Lab Oncology South China; Sun Yat Sen University	Xie, CH (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Radiat & Med Oncol, Wuhan 430072, Hubei, Peoples R China.	xiechonghuast@yeah.net	Han, Fei/AAD-7348-2021	Han, Fei/0000-0002-1598-9048; Deng, Xiaowu/0000-0003-2923-1251				Abu-Rustum NR, 2010, GYNECOL ONCOL, V116, P399, DOI 10.1016/j.ygyno.2009.11.027; Ali S, 2013, JAMA OTOLARYNGOL, V139, P698, DOI 10.1001/jamaoto.2013.3347; Baujat B, 2006, INT J RADIAT ONCOL, V64, P47, DOI 10.1016/j.ijrobp.2005.06.037; Chen CB, 2011, JPN J CLIN ONCOL, V41, P537, DOI 10.1093/jjco/hyq242; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Greiner M, 2000, PREV VET MED, V45, P23, DOI 10.1016/S0167-5877(00)00115-X; Guo R, 2012, RADIOTHER ONCOL, V104, P294, DOI 10.1016/j.radonc.2012.09.001; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Iasonos A, 2008, J CLIN ONCOL, V26, P1364, DOI 10.1200/JCO.2007.12.9791; JOHNSON CR, 1995, INT J RADIAT ONCOL, V33, P281, DOI 10.1016/0360-3016(95)00119-J; Kam MKM, 2007, J CLIN ONCOL, V25, P4873, DOI 10.1200/JCO.2007.11.5501; Kam MKM, 2004, INT J RADIAT ONCOL, V60, P1440, DOI 10.1016/j.ijrobp.2004.05.022; Kwong DLW, 2004, J CLIN ONCOL, V22, P2643, DOI 10.1200/JCO.2004.05.173; Langendijk JA, 2004, J CLIN ONCOL, V22, P4604, DOI 10.1200/JCO.2004.10.074; Lee AWM, 2005, J CLIN ONCOL, V23, P6966, DOI 10.1200/JCO.2004.00.7542; Lee CC, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-20; Lee N, 2002, INT J RADIAT ONCOL, V53, P12, DOI 10.1016/S0360-3016(02)02724-4; Lee N, 2009, J CLIN ONCOL, V27, P3684, DOI 10.1200/JCO.2008.19.9109; Liang W, 2015, J CLIN ONCOLOGY; Lin SJ, 2009, INT J RADIAT ONCOL, V75, P1071, DOI 10.1016/j.ijrobp.2008.12.015; Ma J, 2001, J CLIN ONCOL, V19, P1350, DOI 10.1200/JCO.2001.19.5.1350; Marks JE, 1998, CANCER, V83, P582, DOI 10.1002/(SICI)1097-0142(19980801)83:3<582::AID-CNCR29>3.0.CO;2-R; Montero PH, 2014, CANCER-AM CANCER SOC, V120, P214, DOI 10.1002/cncr.28407; Ng WT, 2011, INT J RADIAT ONCOL, V79, P420, DOI 10.1016/j.ijrobp.2009.11.024; Polterauer S, 2012, BRIT J CANCER, V107, P918, DOI 10.1038/bjc.2012.340; Pow EHN, 2006, INT J RADIAT ONCOL, V66, P981, DOI 10.1016/j.ijrobp.2006.06.013; Tham IWK, 2009, INT J RADIAT ONCOL, V75, P1481, DOI 10.1016/j.ijrobp.2009.01.018; Velazquez ER, 2014, RADIOTHER ONCOL, V113, P324, DOI 10.1016/j.radonc.2014.09.005; Wang Y, 2013, CANCER EPIDEMIOL, V37, P793, DOI 10.1016/j.canep.2013.08.008; Wu SX, 2006, INT J RADIAT ONCOL, V66, pS40, DOI 10.1016/j.ijrobp.2005.12.041; Wu Z, 2013, HEAD NECK-J SCI SPEC, V35, P689, DOI 10.1002/hed.23010; Xiao WW, 2011, CANCER-AM CANCER SOC, V117, P1874, DOI 10.1002/cncr.25754; Xu ZJ, 2013, CHIN J CANCER, V32, P453, DOI 10.5732/cjc.013.10118; Yip TTC, 2014, ORAL ONCOL, V50, P527, DOI 10.1016/j.oraloncology.2013.12.011	34	16	16	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2015	10	8							e0134491	10.1371/journal.pone.0134491	http://dx.doi.org/10.1371/journal.pone.0134491			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO3MQ	26248338	gold, Green Published, Green Submitted			2023-01-03	WOS:000359062300041
J	Kang, HR; Lee, YA; Kim, YH; Lee, DG; Kim, BJ; Kim, KJ; Kim, BG; Oh, MG; Han, CK; Lee, S; Ryu, BY				Kang, Hye-Ryun; Lee, Yong-An; Kim, Yong-Hee; Lee, Dong Gu; Kim, Bang-Jin; Kim, Ki-Jung; Kim, Byung-Gak; Oh, Myeong-Geun; Han, Chan Kyu; Lee, Sanghyun; Ryu, Buom-Yong			Petasites japonicus Stimulates the Proliferation of Mouse Spermatogonial Stem Cells	PLOS ONE			English	Article							JAPANESE HERBAL MEDICINE; FUNCTIONAL-CHARACTERISTICS; SELF-RENEWAL; EXTRACTS	Oriental natural plants have been used as medical herbs for the treatment of various diseases for over 2,000 years. In this study, we evaluated the effect of several natural plants on the preservation of male fertility by assessing the ability of plant extracts to stimulate spermatogonial stem cell (SSC) proliferation by using a serum-free culture method. In vitro assays showed that Petasites japonicus extracts, especially the butanol fraction, have a significant effect on germ cells proliferation including SSCs. The activity of SSCs cultured in the presence of the Petasites japonicus butanol fraction was confirmed by normal colony formation and spermatogenesis following germ cell transplantation of the treated SSCs. Our findings could lead to the discovery of novel factors that activate SSCs and could be useful for the development of technologies for the prevention of male infertility.	[Kang, Hye-Ryun; Lee, Yong-An; Kim, Yong-Hee; Kim, Bang-Jin; Kim, Ki-Jung; Oh, Myeong-Geun; Ryu, Buom-Yong] Chung Ang Univ, Dept Anim Sci & Technol, Ansong, South Korea; [Lee, Dong Gu; Lee, Sanghyun] Chung Ang Univ, Dept Integrat Plant Sci, Ansong, South Korea; [Kim, Byung-Gak] Michigan State Univ, Dept Obstet Gynecol & Reprod Biol, Van Andel Inst, Grand Rapids, MI USA; [Han, Chan Kyu] Korea Food Res Inst, Songnam, South Korea	Chung Ang University; Chung Ang University; Michigan State University; Van Andel Institute; Korea Food Research Institute (KFRI)	Ryu, BY (corresponding author), Chung Ang Univ, Dept Anim Sci & Technol, Ansong, South Korea.	byryu@cau.ac.kr		Lee, Yong-An/0000-0001-7253-2397	Korea Food Research Institute, Republic of Korea [ER142023887]; Excellent Student Scholarship (CAU) from Chung-Ang University, Republic of Korea	Korea Food Research Institute, Republic of Korea; Excellent Student Scholarship (CAU) from Chung-Ang University, Republic of Korea	This work was supported by the fund of Korea Food Research Institute (ER142023887), Republic of Korea. HRK YAL YHK DGL BJK KJK BGK MGO CKH SL BYR received the funding above for this work. MGO was supported by the Excellent Student Scholarship 2015 (CAU2015) from Chung-Ang University, Republic of Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aponte PM, 2005, APMIS, V113, P727, DOI 10.1111/j.1600-0463.2005.apm_302.x; Bickford PC, 2006, STEM CELLS DEV, V15, P118, DOI 10.1089/scd.2006.15.118; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11303, DOI 10.1073/pnas.91.24.11303; Buaas FW, 2004, NAT GENET, V36, P647, DOI 10.1038/ng1366; Chignell CF, 2007, PHOTOCHEM PHOTOBIOL, V83, P938, DOI 10.1111/j.1751-1097.2007.00086.x; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Cui HS, 2005, J AGR FOOD CHEM, V53, P8526, DOI 10.1021/jf051595q; de Kretser DM, 1998, HUM REPROD, V13, P1; Debrunner B, 1998, Pharm Acta Helv, V72, P359, DOI 10.1016/S0031-6865(97)00027-7; Deters AM, 2012, J ETHNOPHARMACOL, V142, P438, DOI 10.1016/j.jep.2012.05.014; Engel N, 2011, J ETHNOPHARMACOL, V137, P1003, DOI 10.1016/j.jep.2011.07.023; Grabowska-Joachimiak A, 2011, CYTOGENET GENOME RES, V132, P203, DOI 10.1159/000321584; Hisha H, 1997, BLOOD, V90, P1022, DOI 10.1182/blood.V90.3.1022.1022_1022_1030; Hisha H, 2002, STEM CELLS, V20, P311, DOI 10.1634/stemcells.20-4-311; Holehouse EL, 1998, BBA-LIPID LIPID MET, V1390, P52, DOI 10.1016/S0005-2760(97)00176-8; Kubota H, 2003, P NATL ACAD SCI USA, V100, P6487, DOI 10.1073/pnas.0631767100; Kubota H, 2004, P NATL ACAD SCI USA, V101, P16489, DOI 10.1073/pnas.0407063101; Lee DY, 2009, J ETHNOPHARMACOL, V123, P149, DOI 10.1016/j.jep.2009.02.009; Lee JS, 2011, J ETHNOPHARMACOL, V133, P551, DOI 10.1016/j.jep.2010.10.038; Naughton CK, 2006, BIOL REPROD, V74, P314, DOI 10.1095/biolreprod.105.047365; Nembo EN, 2014, J ETHNOPHARMACOL, V156, P73, DOI 10.1016/j.jep.2014.07.046; Ng TB, 2003, COMP BIOCHEM PHYS C, V136, P109, DOI 10.1016/S1532-0456(03)00170-4; Oatley JM, 2007, J BIOL CHEM, V282, P25842, DOI 10.1074/jbc.M703474200; Oatley JM, 2006, METHOD ENZYMOL, V419, P259, DOI 10.1016/S0076-6879(06)19011-4; Ogawa T, 1997, INT J DEV BIOL, V41, P111; Paul C, 2013, NAT REV UROL, V10, P227, DOI 10.1038/nrurol.2013.18; Pryor WA, 2006, AM J PHYSIOL-REG I, V291, pR491, DOI 10.1152/ajpregu.00614.2005; Ryu BY, 2006, STEM CELLS, V24, P1505, DOI 10.1634/stemcells.2005-0580; Ryu BY, 2004, DEV BIOL, V274, P158, DOI 10.1016/j.ydbio.2004.07.004; Schmidt S, 2013, J ETHNOPHARMACOL, V150, P85, DOI 10.1016/j.jep.2013.08.013; Shinohara T, 2000, P NATL ACAD SCI USA, V97, P8346, DOI 10.1073/pnas.97.15.8346; Turner TT, 2008, J ANDROL, V29, P488, DOI 10.2164/jandrol.108.005132; vanPelt AMM, 1996, BIOL REPROD, V55, P439, DOI 10.1095/biolreprod55.2.439; Wang SN, 2013, FOOD CHEM, V141, P2075, DOI 10.1016/j.foodchem.2013.04.116; Yeap SK, 2007, J ETHNOPHARMACOL, V114, P406, DOI 10.1016/j.jep.2007.08.020	36	4	4	3	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2015	10	7							e0133077	10.1371/journal.pone.0133077	http://dx.doi.org/10.1371/journal.pone.0133077			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN7NT	26207817	Green Submitted, gold, Green Published			2023-01-03	WOS:000358622000061
J	Fisher, P; Ernst, E				Fisher, Peter; Ernst, Edzard			Should doctors recommend homeopathy?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PLACEBO-CONTROLLED TRIALS; METAANALYSIS		[Fisher, Peter] Royal London Hosp Integrated Med, Res, London WC1N 3HR, England; [Ernst, Edzard] Univ Exeter, Exeter EX4 4QJ, Devon, England	University of Exeter	Fisher, P (corresponding author), Royal London Hosp Integrated Med, Res, London WC1N 3HR, England.	peter.fisher@uclh.nhs.uk; E.Ernst@exeter.ac.uk						Australian National Health and Medical Research Council, 2015, STAT HOM; Bergemann SM, 2011, HOMEOPATHY HEALTHCAR, P127; Campbell A., 2008, HOMEOPATHY PERSPECTI; Chikramane PS, 2012, LANGMUIR, V28, P15864, DOI 10.1021/la303477s; Ernst E, 2005, TRENDS PHARMACOL SCI, V26, P547, DOI 10.1016/j.tips.2005.09.003; Ernst E, 2002, BRIT J CLIN PHARMACO, V54, P577, DOI 10.1046/j.1365-2125.2002.01699.x; Ernst E., 2014, HOMEOPATHY PROOF CON; Grimaldi-Bensouda L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089990; Haidvogl Max, 2007, BMC Complement Altern Med, V7, P7, DOI 10.1186/1472-6882-7-7; Jacobs J, 2003, PEDIATR INFECT DIS J, V22, P229, DOI 10.1097/00006454-200303000-00005; Kelley JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094207; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; Linde K, 2005, LANCET, V366, P2081, DOI 10.1016/S0140-6736(05)67878-6; Mathie RT, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-142; Riley D, 2001, J ALTERN COMPLEM MED, V7, P149, DOI 10.1089/107555301750164226; Rossignol M, 2012, PHARMACOEPIDEM DR S, V21, P1093, DOI 10.1002/pds.3316; Schmidt K, 2003, VACCINE, V21, P1044, DOI 10.1016/S0264-410X(02)00628-X; Schneider B, 2005, ARZNEIMITTELFORSCH, V55, P23; Shang AJ, 2005, LANCET, V366, P726, DOI 10.1016/S0140-6736(05)67177-2; Spence DS, 2005, J ALTERN COMPLEM MED, V11, P793, DOI 10.1089/acm.2005.11.793; Swayne J., 2000, INT DICT HOMEOPATHY; Taylor MA, 2000, BMJ-BRIT MED J, V321, P471, DOI 10.1136/bmj.321.7259.471; Trichard M, 2004, DIS MANAG HEALTH OUT, V12, P419, DOI 10.2165/00115677-200412060-00009; Walach H, 2000, CEPHALALGIA, V20, P835, DOI 10.1046/j.1468-2982.2000.00129.x; Wiesenauer M, 1996, FORSCH KOMPLEMENTMED, V3, P230; Witt C, 2005, COMPLEMENT THER MED, V13, P79, DOI 10.1016/j.ctim.2005.03.005; Witt CM, 2007, COMPLEMENT THER MED, V15, P128, DOI 10.1016/j.ctim.2007.01.011	27	6	6	0	30	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 15	2015	351								h3735	10.1136/bmj.h3735	http://dx.doi.org/10.1136/bmj.h3735			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CN3CU	26173948				2023-01-03	WOS:000358302300002
J	Casetti, R; De Simone, G; Sacchi, A; Rinaldi, A; Viola, D; Agrati, C; Bordoni, V; Cimini, E; Tumino, N; Besi, F; Martini, F				Casetti, Rita; De Simone, Gabriele; Sacchi, Alessandra; Rinaldi, Alessandra; Viola, Domenico; Agrati, Chiara; Bordoni, Veronica; Cimini, Eleonora; Tumino, Nicola; Besi, Francesca; Martini, Federico			V gamma V delta 2 T-Cell Polyfunctionality Is Differently Modulated in HAART-Treated HIV Patients according to CD4 T-Cell Count	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; MYCOBACTERIAL ANTIGENS; INFECTED PERSONS; REPLICATION; LYMPHOCYTE; RESPONSES; ASSOCIATION; SUPPRESSION; REPERTOIRE	Alteration of gamma delta T-cell distribution and function in peripheral blood is among the earliest defects during HIV-infection. We asked whether the polyfunctional response could also be affected, and how this impairment could be associated to CD4 T-cell count. To this aim, we performed a cross-sectional study on HIV-infected individuals. In order to evaluate the poly-functional- V gamma 9V delta 2 T-cell response after phosphoantigen-stimulation, we assessed the cytokine/chemokine production and cytotoxicity by flow-cytometry in HAART-treated-HIV+ persons and healthy-donors. During HIV-infection V gamma 9V delta 2-polyfunctional response quality is affected, since several V gamma 9V delta 2 T-cell subsets resulted significantly lower in HIV+ patients in respect to healthy donors. Interestingly, we found a weak positive correlation between V gamma 9V delta 2 T-cell-response and CD4 T-cell counts. By dividing the HIV+ patients according to CD4 T-cell count, we found that Low-CD4 patients expressed a lower number of two V gamma 9V delta 2 T-cell subsets expressing MIP-1 beta in different combinations with other molecules (CD107a/IFN gamma.) in respect to High-CD4 individuals. Our results show that the V gamma 9V delta 2 T-cell- response quality in Low-CD4 patients is specifically affected, suggesting a direct link between innate V gamma 9V delta 2 T-cells and CD4 T-cell count. These findings suggest that V gamma 9V delta 2 T-cell quality may be indirectly influenced by HAART therapy and could be included in a new therapeutical strategy which would perform an important role in fighting HIV infection.	[Casetti, Rita; De Simone, Gabriele; Sacchi, Alessandra; Rinaldi, Alessandra; Viola, Domenico; Agrati, Chiara; Bordoni, Veronica; Cimini, Eleonora; Tumino, Nicola; Besi, Francesca; Martini, Federico] IRCCS, Lazzaro Spallanzani Natl Inst Infect Dis, Cellular Immunol Lab, Rome, Italy	IRCCS Lazzaro Spallanzani	Casetti, R (corresponding author), IRCCS, Lazzaro Spallanzani Natl Inst Infect Dis, Cellular Immunol Lab, Rome, Italy.	rita.casetti@inmi.it	Tumino, Nicola/Y-4761-2019; Besi, Francesca/AAH-9352-2019; bordoni, veronica/K-8614-2016; Sacchi, Alessandra/K-7782-2016; Cimini, Eleonora/K-8878-2016; Casetti, Rita/K-8631-2016; Agrati, Chiara/K-8806-2016	Tumino, Nicola/0000-0003-3773-8829; Besi, Francesca/0000-0002-9401-300X; bordoni, veronica/0000-0002-1747-2245; Sacchi, Alessandra/0000-0003-4964-386X; Cimini, Eleonora/0000-0002-2659-0868; Casetti, Rita/0000-0002-7574-8780; Agrati, Chiara/0000-0002-5252-0927	Italian Ministry of Health "Ricerca Corrente" fund	Italian Ministry of Health "Ricerca Corrente" fund	Funding provided by Italian Ministry of Health "Ricerca Corrente" fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agerberth B, 2000, BLOOD, V96, P3086, DOI 10.1182/blood.V96.9.3086.h8003086_3086_3093; Agrati C, 2011, AIDS REV, V13, P3; AUTRAN B, 1989, CLIN EXP IMMUNOL, V75, P206; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5; Bordon J, 2004, J INFECT DIS, V189, P1482, DOI 10.1086/382961; Casetti R, 2014, INT J IMMUNOPATH PH, V27, P291, DOI 10.1177/039463201402700218; Garcia VE, 1997, J IMMUNOL, V159, P1328; Gong GM, 2009, BLOOD, V113, P837, DOI 10.1182/blood-2008-06-162792; Hebbeler AM, 2008, CLIN IMMUNOL, V128, P349, DOI 10.1016/j.clim.2008.04.008; Kosub DA, 2008, J VIROL, V82, P1155, DOI 10.1128/JVI.01275-07; Li HS, 2008, CLIN INFECT DIS, V46, P1466, DOI 10.1086/587107; Lopez M, 2008, EUR J IMMUNOL, V38, P1548, DOI 10.1002/eji.200738054; Martini F, 2000, IMMUNOLOGY, V100, P481, DOI 10.1046/j.1365-2567.2000.00068.x; Migueles SA, 2009, J VIROL, V83, P11876, DOI 10.1128/JVI.01153-09; Poccia F, 1999, J INFECT DIS, V180, P858, DOI 10.1086/314925; Poccia F, 1996, J IMMUNOL, V157, P449; Poccia F, 2009, AIDS, V23, P555, DOI 10.1097/QAD.0b013e3283244619; Qin G, 2009, J INFECT DIS, V200, P858, DOI 10.1086/605413; Rehr M, 2008, J VIROL, V82, P3391, DOI 10.1128/JVI.02383-07; Restrepo C, 2013, J MED VIROL, V85, P200, DOI 10.1002/jmv.23447; Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015; Ryan-Payseur B, 2012, J IMMUNOL, V189, P1285, DOI 10.4049/jimmunol.1200641; Sciammas R, 1999, MICROBES INFECT, V1, P203, DOI 10.1016/S1286-4579(99)80035-5; Wallace M, 1997, MOL MED, V3, P60, DOI 10.1007/BF03401668	25	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2015	10	7							e0132291	10.1371/journal.pone.0132291	http://dx.doi.org/10.1371/journal.pone.0132291			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1FD	26161861	gold, Green Submitted, Green Published			2023-01-03	WOS:000358162300115
J	Kolhe, NV; Staples, D; Reilly, T; Merrison, D; Mcintyre, CW; Fluck, RJ; Selby, NM; Taal, MW				Kolhe, Nitin V.; Staples, David; Reilly, Timothy; Merrison, Daniel; Mcintyre, Christopher W.; Fluck, Richard J.; Selby, Nicholas M.; Taal, Maarten W.			Impact of Compliance with a Care Bundle on Acute Kidney Injury Outcomes: A Prospective Observational Study	PLOS ONE			English	Article							ACUTE-RENAL-FAILURE; ELECTRONIC ALERT; SEVERE SEPSIS; MORTALITY; IMPLEMENTATION; INTERVENTION; MANAGEMENT	Background A recent report has highlighted suboptimal standards of care for acute kidney injury (AKI) patients in England. The objective of this study was to ascertain if improvement in basic standard of care by implementing a care bundle (CB) with interruptive alert improved outcomes in patients with AKI. Methods An AKI CB linked to electronic recognition of AKI, coupled with an interruptive alert, was introduced to improve basic care delivered to patients with AKI. Outcomes were compared in patients who had the CB completed within 24 hours (early CB group) versus those who didn't have the CB completed or had it completed after 24 hours. Results In the 11-month period, 2297 patients had 2500 AKI episodes, with 1209 and 1291 episodes occurring before and after implementation of the AKI CB with interruptive alert, respectively. The CB was completed within 24 hours in 306 (12.2%) of AKI episodes. Inhospital case-fatality was significantly lower in the early CB group (18% versus 23.1%, p 0.046). Progression to higher AKI stages was lower in the early CB group (3.9% vs. 8.1%, p 0.01). In multivariate analysis, patients in the early CB group had lower odds of death at discharge (0.641; 95% CI 0.46, 0.891), 30 days (0.707; 95% CI 0.527, 0.950), 60 days (0.704; 95% CI 0.526, 0.941) and after a median of 134 days (0.771; 95% CI 0.62, 0.958). Conclusions Compliance with AKI CB was associated with a decrease in case-fatality and reduced progression to higher AKI stage. Further interventions are required to improve utilization of the CB.	[Kolhe, Nitin V.; Mcintyre, Christopher W.; Fluck, Richard J.; Selby, Nicholas M.; Taal, Maarten W.] Royal Derby Hosp, Dept Renal Med, Derby DE22 3NE, England; [Staples, David] Royal Derby Hosp, Dept Acute Med, Derby DE22 3NE, England; [Reilly, Timothy; Merrison, Daniel] Dept Informat Management & Technol, Derby DE22 3NE, England; [Mcintyre, Christopher W.; Selby, Nicholas M.; Taal, Maarten W.] Univ Nottingham, Div Med Sci & Grad Entry Med, Derby DE22 3NE, England	University of Nottingham; University of Nottingham; University of Nottingham	Kolhe, NV (corresponding author), Royal Derby Hosp, Dept Renal Med, Uttoxeter Rd, Derby DE22 3NE, England.	nitin.kolhe@nhs.net	Selby, Nicholas/T-6759-2019; McIntyre, Christopher W/O-8927-2014	Kolhe, Nitin/0000-0003-2528-4436; Selby, Nicholas/0000-0003-0351-8326; Taal, Maarten/0000-0002-9065-212X				Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413; Cho A, 2012, AM J KIDNEY DIS, V60, P74, DOI 10.1053/j.ajkd.2012.02.331; Colpaert K, 2007, ACTA CLIN BELG, V62, P322, DOI 10.1179/acb.2007.073; Colpaert K, 2012, CRIT CARE MED, V40, P1164, DOI 10.1097/CCM.0b013e3182387a6b; Endre ZH, 2010, KIDNEY INT, V77, P1020, DOI 10.1038/ki.2010.25; Furuya EY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015452; Gao F, 2005, CRIT CARE, V9, pR764, DOI 10.1186/cc3909; Handler SM, 2014, NEPHROL DIAL TRANSPL, V29, P1802, DOI 10.1093/ndt/gfu211; Hsu CY, 2007, KIDNEY INT, V72, P208, DOI 10.1038/sj.ki.5002297; Kawamoto K, 2005, BMJ-BRIT MED J, V330, P765, DOI 10.1136/bmj.38398.500764.8F; Kellum JA, 2001, CRIT CARE MED, V29, P1526, DOI 10.1097/00003246-200108000-00005; McCoy AB, 2012, J AM MED INFORM ASSN, V19, P346, DOI 10.1136/amiajnl-2011-000185; Nguyen HB, 2007, CRIT CARE MED, V35, P1105, DOI 10.1097/01.CCM.0000259463.33848.3D; Porter CJ, 2014, NEPHROL DIAL TRANSPL, V29, P1888, DOI 10.1093/ndt/gfu082; Ronco C, 2000, LANCET, V356, P26, DOI 10.1016/S0140-6736(00)02430-2; Selby NM, 2012, CLIN J AM SOC NEPHRO, V7, P533, DOI 10.2215/CJN.08970911; Stewart JAD, 2009, BRIT J HOSP MED, V70, P372, DOI 10.12968/hmed.2009.70.7.43116; Thomas M, 2011, NEPHROL DIAL TRANSPL, V26, P2161, DOI 10.1093/ndt/gfq710; Uchino S, 2004, CRIT CARE MED, V32, P1669, DOI 10.1097/01.CCM.0000132892.51063.2F; Van Hoecke S, 2008, METHOD INFORM MED, V47, P364, DOI 10.3414/ME0480; Waikar SS, 2006, J AM SOC NEPHROL, V17, P1143, DOI 10.1681/ASN.2005091017; Wallace K, 2014, CLIN MED, V14, P22, DOI 10.7861/clinmedicine.14-1-22; Xu G, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004388; Xue JL, 2006, J AM SOC NEPHROL, V17, P1135, DOI 10.1681/ASN.2005060668; Zambon M, 2008, J CRIT CARE, V23, P455, DOI 10.1016/j.jcrc.2007.08.003	25	80	84	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2015	10	7							e0132279	10.1371/journal.pone.0132279	http://dx.doi.org/10.1371/journal.pone.0132279			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1FD	26161979	gold, Green Published, Green Submitted			2023-01-03	WOS:000358162300110
J	Kim, JE; Park, SH; Kwak, MH; Go, J; Koh, EK; Song, SH; Sung, JE; Lee, HS; Hong, JT; Hwang, DY				Kim, Ji Eun; Park, So Hae; Kwak, Moon Hwa; Go, Jun; Koh, Eun Kyoung; Song, Sung Hwa; Sung, Ji Eun; Lee, Hee Seob; Hong, Jin Tae; Hwang, Dae Youn			Characterization of Changes in Global Genes Expression in the Distal Colon of Loperamide-Induced Constipation SD Rats in Response to the Laxative Effects of Liriope platyphylla	PLOS ONE			English	Article							GELATINASE-ASSOCIATED LIPOCALIN; FIBROBLAST-GROWTH-FACTOR; AQUEOUS EXTRACTS; INHIBITION; HYPERMETHYLATION; IDENTIFICATION; MODULATION; KALLIKREIN; SECRETION; OXIDATION	To characterize the changes in global gene expression in the distal colon of constipated SD rats in response to the laxative effects of aqueous extracts of Liriope platyphylla (AEtLP), including isoflavone, saponin, oligosaccharide, succinic acid and hydroxyproline, the total RNA extracted from the distal colon of AEtLP-treated constipation rats was hybridized to oligonucleotide microarrays. The AEtLP treated rats showed an increase in the number of stools, mucosa thickness, flat luminal surface thickness, mucin secretion, and crypt number. Overall, compared to the controls, 581 genes were up-regulated and 216 genes were down-regulated by the constipation induced by loperamide in the constipated rats. After the AEtLP treatment, 67 genes were up-regulated and 421 genes were down-regulated. Among the transcripts up-regulated by constipation, 89 were significantly down-regulated and 22 were recovered to the normal levels by the AEtLP treatment. The major genes in the down-regulated categories included Slc9a5, klk10, Fgf15, and Alpi, whereas the major genes in the recovered categories were Cyp2b2, Ace, G6pc, and Setbp1. On the other hand, after the AEtLP treatment, ten of these genes down-regulated by constipation were up-regulated significantly and five were recovered to the normal levels. The major genes in the up-regulated categories included Serpina3n, Lcn2 and Slc5a8, whereas the major genes in the recovered categories were Tmem45a, Rerg and Rgc32. These results indicate that several gene functional groups and individual genes as constipation biomarkers respond to an AEtLP treatment in constipated model rats.	[Kim, Ji Eun; Kwak, Moon Hwa; Go, Jun; Koh, Eun Kyoung; Song, Sung Hwa; Sung, Ji Eun; Hwang, Dae Youn] Pusan Natl Univ, Life & Ind Convergence Res Inst, Coll Nat Resources & Life Sci, Dept Biomat Sci, Miryang 627706, South Korea; [Park, So Hae; Lee, Hee Seob] Pusan Natl Univ, Coll Human Ecol, Dept Food Sci & Nutr, Busan 609735, South Korea; [Hong, Jin Tae] Chungbuk Natl Univ, Coll Pharm, Chungju 361763, South Korea; [Hong, Jin Tae] Chungbuk Natl Univ, Med Res Ctr, Chungju 361763, South Korea	Pusan National University; Pusan National University; Chungbuk National University; Chungbuk National University	Hong, JT (corresponding author), Chungbuk Natl Univ, Coll Pharm, Chungju 361763, South Korea.	jinthong@chungbuk.ac.kr; dyhwang@pusan.ac.kr			National Research Foundation of Korea (NRF) grant - Korea government (MSIP) [MRC-2008-0062275]; Regional Innovation System (RIS) of the Ministry of Knowledge Economy in Korea	National Research Foundation of Korea (NRF) grant - Korea government (MSIP); Regional Innovation System (RIS) of the Ministry of Knowledge Economy in Korea	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. MRC-2008-0062275). Also, this research was supported by a grant from the Regional Innovation System (RIS) of the Ministry of Knowledge Economy in Korea.	Altabas K, 2003, COLLEGIUM ANTROPOL, V27, P197; Beltran-Ramirez O, 2012, TOXICOL PATHOL, V40, P466, DOI 10.1177/0192623311431947; Bharucha AE, 2007, BEST PRACT RES CL GA, V21, P709, DOI 10.1016/j.bpg.2007.07.001; Bolignano D, 2009, REJUV RES, V12, P7, DOI 10.1089/rej.2008.0803; Borgono CA, 2004, NAT REV CANCER, V4, P876, DOI 10.1038/nrc1474; Bousserouel S, 2011, PATHOL INT, V61, P80, DOI 10.1111/j.1440-1827.2010.02621.x; Byrnes JJ, 2009, INFLAMM RES, V58, P819, DOI 10.1007/s00011-009-0053-3; Chassaing B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044328; Choi SB, 2004, LIFE SCI, V75, P2653, DOI 10.1016/j.lfs.2004.04.039; Choi SI, 2012, MOL MED REP, V6, P1160, DOI 10.3892/mmr.2012.1024; Colman RW, 1997, P ASSOC AM PHYSICIAN, V109, P10; DIGNASS AU, 1994, GASTROENTEROLOGY, V106, P1254, DOI 10.1016/0016-5085(94)90017-5; Emmanuel AV, 2009, NEUROGASTROENT MOTIL, V21, P41, DOI 10.1111/j.1365-2982.2009.01403.x; Erasto P, 2005, AFR J BIOTECHNOL, V4, P1458; Flower DR, 1996, BIOCHEM J, V318, P1; Goo JS, 2013, MOL NEUROBIOL, V48, P232, DOI 10.1007/s12035-013-8453-3; Goyal J, 1998, CANCER RES, V58, P4782; Gronborg M, 2004, J PROTEOME RES, V3, P1042, DOI 10.1021/pr0499085; Hoogerwerf WA, 1996, AM J PHYSIOL, V270, P29; Hou XiangYu, 2013, Journal of China Medical University, V42, P348; Houchen CW, 1999, AM J PHYSIOL-GASTR L, V276, pG249, DOI 10.1152/ajpgi.1999.276.1.G249; Hur J, 2009, EUR J PHARMACOL, V620, P9, DOI 10.1016/j.ejphar.2009.08.016; Imamura T, 2014, BIOL PHARM BULL, V37, P1081, DOI 10.1248/bpb.b14-00265; Imig JD, 2004, HYPERTENSION, V43, P533, DOI 10.1161/01.HYP.0000118054.86193.ce; Izzo AA, 2009, DRUGS, V69, P1777, DOI 10.2165/11317010-000000000-00000; Jeong S, 2008, J ETHNOPHARMACOL, V119, P245, DOI 10.1016/j.jep.2008.06.037; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kakino M, 2010, BIOSCI BIOTECH BIOCH, V74, P1550, DOI 10.1271/bbb.100122; Kim JE, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-333; Kim Ji Eun, 2010, Laboratory Animal Research, V26, P377; Kim JE, 2011, BIOMOL THER, V19, P348, DOI 10.4062/biomolther.2011.19.3.348; 김형진, 2010, Laboratory Animal Research, V26, P7; Kim SD, 2001, J KOREAN SOC FOOD SC, V30, P20; Kim SW, 2002, BIOSCI BIOTECH BIOCH, V66, P2751, DOI 10.1271/bbb.66.2751; Kim WR, 2000, GASTROENTEROLOGY, V119, P1631, DOI 10.1053/gast.2000.20197; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; Koga H, 2008, SURGERY, V144, P259, DOI 10.1016/j.surg.2008.03.043; Kwak MH, 2013, J ETHNOPHARMACOL, V148, P880, DOI 10.1016/j.jep.2013.05.036; Lazartigues E, 2007, CURR PHARM DESIGN, V13, P1231, DOI 10.2174/138161207780618911; Lee C, 2014, LIFE SCI, V95, P29, DOI 10.1016/j.lfs.2013.11.005; Lee HY, 2012, FOOD CHEM TOXICOL, V50, P895, DOI 10.1016/j.fct.2011.12.001; Lee YC, 2005, J ETHNOPHARMACOL, V101, P144, DOI 10.1016/j.jep.2005.04.030; Leung FW, 2007, DIGEST DIS SCI, V52, P313, DOI 10.1007/s10620-006-9298-7; Linz D, 2012, HYPERTENSION, V60, P1560, DOI 10.1161/HYPERTENSIONAHA.112.201590; Martin P, 2010, ACTA PHARMACOL SIN, V31, P51, DOI 10.1038/aps.2009.187; McCallum IJD, 2009, BMJ-BRIT MED J, V338, P831; Meda A, 2005, FOOD CHEM, V91, P571, DOI 10.1016/j.foodchem.2004.10.006; Mishra J, 2003, J AM SOC NEPHROL, V14, P2534, DOI 10.1097/01.ASN.0000088027.54400.C6; Mori K, 2005, J CLIN INVEST, V115, P610, DOI 10.1172/JCI200523056; Morita R, 2011, ARCH TOXICOL, V85, P1475, DOI 10.1007/s00204-011-0696-z; Nebert DW, 2000, PHARMACOLOGY, V61, P124, DOI 10.1159/000028393; Neri F, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/896162; Niwa T, 2009, CURR DRUG METAB, V10, P700, DOI 10.2174/138920009789895525; Nyam DCNK, 1997, DIS COLON RECTUM, V40, P273, DOI 10.1007/BF02050415; Ostvik AE, 2013, CLIN EXP IMMUNOL, V173, P502, DOI 10.1111/cei.12136; Parker Lynn P., 2009, Cancer Genomics & Proteomics, V6, P189; PODOLSKY DK, 1993, AM J PHYSIOL, V264, pG179, DOI 10.1152/ajpgi.1993.264.2.G179; Poniatowski B, 2009, KIDNEY BLOOD PRESS R, V32, P77, DOI 10.1159/000208989; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; Raffatellu M, 2009, CELL HOST MICROBE, V5, P476, DOI 10.1016/j.chom.2009.03.011; Roman-Gomez J, 2004, LEUKEMIA, V18, P362, DOI 10.1038/sj.leu.2403223; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Schwartz N, 2007, ANN NY ACAD SCI, V1109, P265, DOI 10.1196/annals.1398.032; Shankaran H, 2007, PLOS COMPUT BIOL, V3, P986, DOI 10.1371/journal.pcbi.0030101; Sidiropoulos M, 2005, TUMOR BIOL, V26, P324, DOI 10.1159/000089290; Singleton VL, 1999, METHOD ENZYMOL, V299, P152; Sui Haixia, 2010, Wei Sheng Yan Jiu, V39, P693; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; Walia R, 2009, CURR OPIN PEDIATR, V21, P661, DOI 10.1097/MOP.0b013e32832ff241; Wintola OA, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-95; Xu H, 2005, AM J PHYSIOL-GASTR L, V289, pG36, DOI 10.1152/ajpgi.00552.2004; Yang ZH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003348; Ye Xu-ying, 2008, Zhongguo Zhong Xi Yi Jie He Za Zhi, V28, P824; Yu HR, 2000, HYPERTENSION, V35, P135, DOI 10.1161/01.HYP.35.1.135; ZEITLIN IJ, 1973, GUT, V14, P133, DOI 10.1136/gut.14.2.133; Zhang JH, 2013, AM J PHYSIOL-GASTR L, V304, pG940, DOI 10.1152/ajpgi.00398.2012; Zhang R, 2004, ANAL BIOCHEM, V280, P286	77	10	10	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2015	10	7							e0129664	10.1371/journal.pone.0129664	http://dx.doi.org/10.1371/journal.pone.0129664			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1EC	26151867	Green Submitted, Green Published, gold			2023-01-03	WOS:000358158900005
J	Zheng, GH; Lan, XL; Li, MY; Ling, K; Lin, H; Chen, LD; Tao, J; Li, JZ; Zheng, X; Chen, B; Fang, QY				Zheng, Guohua; Lan, Xiulu; Li, Moyi; Ling, Kun; Lin, Hui; Chen, Lidian; Tao, Jing; Li, Junzhe; Zheng, Xin; Chen, Bai; Fang, Qianying			Effectiveness of Tai Chi on Physical and Psychological Health of College Students: Results of a Randomized Controlled Trial	PLOS ONE			English	Article							QUALITY-OF-LIFE; MENTAL-HEALTH; RISK-FACTORS; CARDIOVASCULAR-DISEASE; UNIVERSITY-STUDENTS; SELF-ESTEEM; EXERCISE; BADUANJIN; ADULTS; BEHAVIORS	Objective To investigate the effectiveness and safety of Tai Chi Chuan (TCC) on physical and psychological health of college students. Methods Two hundred six college students were recruited and randomly allocated to a control group or a TCC exercise group in an equal ratio. Participants in the control group were instructed to maintain their original activity level and those in the TCC exercise group received 12 weeks of TCC exercise training based on their original activity level. Physical and psychological outcomes were evaluated at baseline, 13 weeks and 25 weeks. Intention-to-treat analysis was performed for the above outcomes. Results Compared with the control group, the TCC exercise group showed significant improvements at the end of the 12-week intervention period for flexibility (length of Sit and Reach (cm): TCC group 14.09 +/- 7.40 versus control 12.88 +/- 6.57, P = 0.039 adjusted for its baseline measures using a general linear model) and balance ability (open eyes perimeter: TCC group 235.6(191 similar to 314) versus control 261(216 similar to 300); closed eyes perimeter: TCC group 370.5 (284 similar to 454) versus control 367 (293 similar to 483); P = 0.0414, 0.008, respectively, adjusted for corresponding baseline measures using a general linear model). No significant changes in other physical and mental outcomes were found between the two groups. No adverse events were reported during the study period. Conclusion TCC exercise was beneficial in college students for improving flexibility and balance capability to some extent, compared with usual exercise.	[Zheng, Guohua; Lan, Xiulu; Li, Moyi; Tao, Jing; Li, Junzhe; Zheng, Xin; Chen, Bai; Fang, Qianying] Fujian Univ Tradit Chinese Med, Coll Rehabil Med, Fuzhou 350122, Peoples R China; [Ling, Kun; Lin, Hui] Fujian Univ Tradit Chinese Med, Dept Phys Educ, Fuzhou 350122, Peoples R China; [Chen, Lidian] Fujian Univ Tradit Chinese Med, Fuzhou 350122, Peoples R China	Fujian University of Traditional Chinese Medicine; Fujian University of Traditional Chinese Medicine; Fujian University of Traditional Chinese Medicine	Chen, LD (corresponding author), Fujian Univ Tradit Chinese Med, Fuzhou 350122, Peoples R China.	lidianchen87@163.com		Chen, Lidian/0000-0002-6454-7932; Tao, Jing/0000-0001-9751-5294	Special Scientific Research Fund of Public Welfare Profession of China from Ministry of finance of the People's Republic of China [201307004]	Special Scientific Research Fund of Public Welfare Profession of China from Ministry of finance of the People's Republic of China	This project was supported by 'the Special Scientific Research Fund of Public Welfare Profession of China (Grant No. 201307004)' from Ministry of finance of the People's Republic of China. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American College Health Association, 2009, J Am Coll Health, V57, P477, DOI 10.3200/JACH.57.5.477-488; Bagnato S, 2009, NEUROL SCI, V30, P107, DOI 10.1007/s10072-009-0031-0; Barnes AS, 2013, TEX HEART I J, V40, P293; Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008; Brevard PB, 1996, J AM DIET ASSOC, V96, P35, DOI 10.1016/S0002-8223(96)00011-9; BROOKS JH, 1995, J COLL STUDENT DEV, V36, P347; Caldwell K, 2011, J ALTERN COMPLEM MED, V17, P931, DOI 10.1089/acm.2010.0645; Cheng FK, 2015, J BODYW MOV THER, V19, P138, DOI 10.1016/j.jbmt.2014.11.001; Converse AK, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00013; Cook LJ, 2007, J PSYCHOSOC NURS, V45, P40, DOI 10.3928/02793695-20070401-09; Eisenberg D, 2013, J NERV MENT DIS, V201, P60, DOI 10.1097/NMD.0b013e31827ab077; Fang JQ, 2000, QUALITY LIFE MEASURE, P228; Folsom AR, 1996, AM J EPIDEMIOL, V144, P235, DOI 10.1093/oxfordjournals.aje.a008918; Gore FM, 2011, LANCET, V377, P2093, DOI 10.1016/S0140-6736(11)60512-6; Haase A, 2004, PREV MED, V39, P182, DOI 10.1016/j.ypmed.2004.01.028; [胡建平 Hu Jianping], 2012, [中华物理医学与康复杂志, Chinese Journal of Physical Medicine and Rehabilitation], V34, P34; Hunt J, 2010, J ADOLESCENT HEALTH, V46, P3, DOI 10.1016/j.jadohealth.2009.08.008; Jahnke Roger, 2010, Am J Health Promot, V24, pe1, DOI 10.4278/ajhp.081013-LIT-248; Ji YF., 1993, CHINESE MENTAL HLTH, V7, P251; Kitzrow M., 2003, J STUDENT AFFAIRS RE, V41, P167, DOI 10.2202/1949-6605.1310; KOH TC, 1982, AM J CHINESE MED, V10, P14, DOI 10.1142/S0192415X8200004X; Kwan MY, 2012, AM J PREV MED, V42, P14, DOI 10.1016/j.amepre.2011.08.026; Lan C, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/502131; Lee LYK, 2007, J CLIN NURS, V16, P1580, DOI 10.1111/j.1365-2702.2007.02061.x; Li FZ, 2001, STRUCT EQU MODELING, V8, P53, DOI 10.1207/S15328007SEM0801_4; Liu JY, 1975, TAMKANG, V13, P217; Luepker RV, 1996, JAMA-J AM MED ASSOC, V276, P241; Matthews CE, 2008, AM J EPIDEMIOL, V167, P875, DOI 10.1093/aje/kwm390; Mikolajczyk RT, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-215; Mustian KM, 2004, SUPPORT CARE CANCER, V12, P871, DOI 10.1007/s00520-004-0682-6; Norman JE, 2003, INT J OBESITY, V27, P369, DOI 10.1038/sj.ijo.0802243; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Penedo FJ, 2005, CURR OPIN PSYCHIATR, V18, P189, DOI 10.1097/00001504-200503000-00013; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Seo DC, 2012, INT J BEHAV MED, V19, P316, DOI 10.1007/s12529-011-9167-4; Tong Y, 2009, CHINESE NATL STANDAR; Tosevski DL, 2010, CURR OPIN PSYCHIATR, V23, P48, DOI 10.1097/YCO.0b013e328333d625; Valois RF, 2004, J SCHOOL HEALTH, V74, P59, DOI 10.1111/j.1746-1561.2004.tb04201.x; Verhagen AP, 2004, FAM PRACT, V21, P107, DOI 10.1093/fampra/cmh122; Wang CC, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-23; [王盛 Wang Sheng], 2011, [中国康复医学杂志, Chinese Journal of Rehabilitation Medicine], V26, P1035; Wang XD, 1993, CHIN MENT HLTH J S, P31; Wang Y, 2004, AM J CHINESE MED, V32, P453, DOI 10.1142/S0192415X04002107; Xiong XJ, 2015, MATURITAS, V80, P370, DOI 10.1016/j.maturitas.2015.01.002; Yang Ting-zhong, 2003, Zhonghua Liu Xing Bing Xue Za Zhi, V24, P760; Yeh GY, 2009, J CARDIOPULM REHABIL, V29, P152, DOI 10.1097/HCR.0b013e3181a33379; ZHANG JX, 1995, PSYCHOLOGIA, V38, P174; Zheng GH, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-129; Zheng GH, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-422; Zhu B., 1995, J TIANJIN I PHYS ED, V1, P35, DOI DOI 10.13297/j.cnki.issn1005-0000.1995.01.007	50	17	17	4	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2015	10	7							e0132605	10.1371/journal.pone.0132605	http://dx.doi.org/10.1371/journal.pone.0132605			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CN1DQ	26147842	Green Published, gold, Green Submitted			2023-01-03	WOS:000358157600304
J	Jacquez, P; Avila, G; Boone, K; Altiyev, A; Puschhof, J; Sauter, R; Arigi, E; Ruiz, B; Peng, XL; Almeida, I; Sherman, M; Xiao, C; Sun, JJ				Jacquez, Pedro; Avila, Gustavo; Boone, Kyle; Altiyev, Agamyrat; Puschhof, Jens; Sauter, Roland; Arigi, Emma; Ruiz, Blanca; Peng, Xiuli; Almeida, Igor; Sherman, Michael; Xiao, Chuan; Sun, Jianjun			The Disulfide Bond Cys255-Cys279 in the Immunoglobulin-Like Domain of Anthrax Toxin Receptor 2 Is Required for Membrane Insertion of Anthrax Protective Antigen Pore	PLOS ONE			English	Article							CAPILLARY MORPHOGENESIS PROTEIN-2; DIPHTHERIA-TOXIN; CRYSTAL-STRUCTURE; CHOLERA-TOXIN; MEDIATED REDUCTION; MAMMALIAN-CELLS; LIPID NANODISCS; LETHAL-FACTOR; PH THRESHOLD; HIV-1 ENTRY	Anthrax toxin receptors act as molecular clamps or switches that control anthrax toxin entry, pH-dependent pore formation, and translocation of enzymatic moieties across the endosomal membranes. We previously reported that reduction of the disulfide bonds in the immunoglobulin-like (Ig) domain of the anthrax toxin receptor 2 (ANTXR2) inhibited the function of the protective antigen (PA) pore. In the present study, the disulfide linkage in the Ig domain was identified as Cys255-Cys279 and Cys230-Cys315. Specific disulfide bond deletion mutants were achieved by replacing Cys residues with Ala residues. Deletion of the disulfide bond C255-C279, but not C230-C315, inhibited the PA pore-induced release of the fluorescence dyes from the liposomes, suggesting that C255-C279 is essential for PA pore function. Furthermore, we found that deletion of C255-C279 did not affect PA prepore-to-pore conversion, but inhibited PA pore membrane insertion by trapping the PA membrane-inserting loops in proteinaceous hydrophobic pockets. Fluorescence spectra of Trp59, a residue adjacent to the PA-binding motif in vonWillebrand factor A (VWA) domain of ANTXR2, showed that deletion of C255-C279 resulted in a significant conformational change on the receptor ectodomain. The disulfide deletion-induced conformational change on the VWA domain was further confirmed by single-particle 3D reconstruction of the negatively stained PA-receptor heptameric complexes. Together, the biochemical and structural data obtained in this study provides a mechanistic insight into the role of the receptor disulfide bond C255-C279 in anthrax toxin action. Manipulation of the redox states of the receptor, specifically targeting to C255-C279, may become a novel strategy to treat anthrax.	[Jacquez, Pedro; Puschhof, Jens; Sauter, Roland; Arigi, Emma; Ruiz, Blanca; Almeida, Igor; Sun, Jianjun] Univ Texas El Paso, Dept Biol Sci, El Paso, TX 79968 USA; [Jacquez, Pedro; Puschhof, Jens; Sauter, Roland; Arigi, Emma; Ruiz, Blanca; Almeida, Igor; Sun, Jianjun] Univ Texas El Paso, Border Biomed Res Ctr, El Paso, TX 79968 USA; [Avila, Gustavo; Xiao, Chuan] Univ Texas El Paso, Dept Chem, El Paso, TX 79968 USA; [Boone, Kyle; Altiyev, Agamyrat] Univ Texas El Paso, Bioinformat Program, El Paso, TX 79968 USA; [Sherman, Michael] Univ Texas Med Branch, Sealy Ctr Struct Biol & Mol Biophys, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; [Peng, Xiuli] Huazhong Agr Univ, China Natl Key Lab Agr Microbiol, Wuhan 430070, Peoples R China	University of Texas System; University of Texas El Paso; University of Texas System; University of Texas El Paso; University of Texas System; University of Texas El Paso; University of Texas System; University of Texas El Paso; University of Texas System; University of Texas Medical Branch Galveston; Huazhong Agricultural University	Xiao, C (corresponding author), Univ Texas El Paso, Dept Chem, 500 West Univ Ave, El Paso, TX 79968 USA.	cxiao@utep.edu; jsun@utep.edu	Almeida, Igor C./AAF-9409-2019; Xiao, Chuan/B-2130-2010	Almeida, Igor C./0000-0002-2443-8213; Xiao, Chuan/0000-0001-6599-8762; Ruiz-Medina, Blanca E./0000-0003-1947-4014; Boone, Kyle/0000-0001-6383-6479	National Institute of General Medical Sciences [SC1GM095475]; UTEP new faculty startup fund; National Center for Research Resources [5G12RR008124]; National Institute on Minority Health and Health Disparities [G12MD007592]; NSF [DUE-0926721]; DAAD RISE program; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [SC1GM095475] Funding Source: NIH RePORTER; Division Of Undergraduate Education [1153832] Funding Source: National Science Foundation	National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); UTEP new faculty startup fund; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NSF(National Science Foundation (NSF)); DAAD RISE program; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Division Of Undergraduate Education(National Science Foundation (NSF)NSF- Directorate for Education & Human Resources (EHR))	This study is supported by a grant from National Institute of General Medical Sciences SC1GM095475 (to J. Sun), UTEP new faculty startup fund (to J. Sun) and UTEP new faculty startup fund (to C. Xiao), the grants from National Center for Research Resources (5G12RR008124), and the National Institute on Minority Health and Health Disparities (G12MD007592). The negatively stained EM images were taken using a JEOL 3200FS electron microscope acquired by NSF MRI 0923437. AA was supported by a NSF grant DUE-0926721 (to Ming-Ying Leung, UTEP bioinformatics). JP and RS were supported by DAAD RISE program.	Abrami L, 2006, J CELL BIOL, V172, P309, DOI 10.1083/jcb.200507067; Abrami L, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000792; Abromaitis S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000357; Akkaladevi N, 2013, PROTEIN SCI, V22, P492, DOI 10.1002/pro.2231; Auwerx J, 2009, INT J BIOCHEM CELL B, V41, P1269, DOI 10.1016/j.biocel.2008.10.031; Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Collier RJ, 2003, ANNU REV CELL DEV BI, V19, P45, DOI 10.1146/annurev.cellbio.19.111301.140655; Conant CG, 2007, CELL MICROBIOL, V9, P222, DOI 10.1111/j.1462-5822.2006.00783.x; De Leon J, 2012, J BIOL CHEM, V287, P44184, DOI 10.1074/jbc.M112.420869; Dennis MK, 2014, BIOCHEMISTRY-US, V53, P2166, DOI 10.1021/bi5000756; Deuquet J, 2011, EMBO MOL MED, V3, P208, DOI 10.1002/emmm.201100124; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; FALNES PO, 1995, J BIOL CHEM, V270, P20787, DOI 10.1074/jbc.270.35.20787; Grigorieff N, 2007, J STRUCT BIOL, V157, P117, DOI 10.1016/j.jsb.2006.05.004; Hogg PJ, 2003, TRENDS BIOCHEM SCI, V28, P210, DOI 10.1016/S0968-0004(03)00057-4; Jacquez P, 2014, PROTEIN EXPRES PURIF, V95, P149, DOI 10.1016/j.pep.2013.12.010; Katayama H, 2010, P NATL ACAD SCI USA, V107, P3453, DOI 10.1073/pnas.1000100107; Katayama H, 2008, NAT STRUCT MOL BIOL, V15, P754, DOI 10.1038/nsmb.1442; Kintzer AF, 2009, J MOL BIOL, V392, P614, DOI 10.1016/j.jmb.2009.07.037; Lacy DB, 2004, P NATL ACAD SCI USA, V101, P6367, DOI 10.1073/pnas.0401506101; Lacy DB, 2002, CURR TOP MICROBIOL, V271, P61; Lacy DB, 2004, P NATL ACAD SCI USA, V101, P13147, DOI 10.1073/pnas.0405405101; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; Lin AEJ, 2010, PROTOPLASMA, V244, P75, DOI 10.1007/s00709-010-0164-2; Liu SL, 2009, P NATL ACAD SCI USA, V106, P12424, DOI 10.1073/pnas.0905409106; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Majoul I, 1997, FEBS LETT, V401, P104, DOI 10.1016/S0014-5793(96)01447-0; Matthias LJ, 2003, ANTIOXID REDOX SIGN, V5, P133, DOI 10.1089/152308603321223621; Matthias LJ, 2002, NAT IMMUNOL, V3, P727, DOI 10.1038/ni815; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Mogridge J, 2002, P NATL ACAD SCI USA, V99, P7045, DOI 10.1073/pnas.052160199; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Mullangi V, 2014, BIOCHEMISTRY-US, V53, P6084, DOI 10.1021/bi500718g; Naik S, 2013, BIOCHEMISTRY-US, V52, P6335, DOI 10.1021/bi400705n; Orlandi PA, 1997, J BIOL CHEM, V272, P4591; PAPINI E, 1993, J BIOL CHEM, V268, P1567; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Pilpa RM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002354; Rainey GJA, 2005, P NATL ACAD SCI USA, V102, P13278, DOI 10.1073/pnas.0505865102; Rajapaksha M, 2009, PROTEIN SCI, V18, P17, DOI 10.1002/pro.26; Ratts R, 2003, J CELL BIOL, V160, P1139, DOI 10.1083/jcb.200210028; Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5; Ryser HJP, 2005, DRUG DISCOV TODAY, V10, P1085, DOI 10.1016/S1359-6446(05)03550-6; RYSER HJP, 1991, J BIOL CHEM, V266, P18439; Santelli E, 2004, NATURE, V430, P905, DOI 10.1038/nature02763; Scobie HM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000329; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Sun J, 2008, P NATL ACAD SCI USA, V105, P4346, DOI 10.1073/pnas.0800701105; Sun JJ, 2007, J BIOL CHEM, V282, P1059, DOI 10.1074/jbc.M609869200; Sun JJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010553; Tang G, 2007, J STRUCT BIOL, V157, P38, DOI 10.1016/j.jsb.2006.05.009; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; Tsai M, 2002, J CELL BIOL, V159, P207, DOI 10.1083/jcb.200207120; Wigelsworth DJ, 2004, J BIOL CHEM, V279, P23349, DOI 10.1074/jbc.M401292200; Williams AS, 2009, PROTEIN SCI, V18, P2277, DOI 10.1002/pro.238; Wolfe JT, 2005, J BIOL CHEM, V280, P39417, DOI 10.1074/jbc.M509049200; Yang Z, 2012, J STRUCT BIOL, V179, P269, DOI 10.1016/j.jsb.2011.09.006; Young JAT, 2007, ANNU REV BIOCHEM, V76, P243, DOI 10.1146/annurev.biochem.75.103004.142728	60	5	5	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2015	10	6							e0130832	10.1371/journal.pone.0130832	http://dx.doi.org/10.1371/journal.pone.0130832			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL4OM	26107617	gold, Green Published, Green Submitted			2023-01-03	WOS:000356932500127
J	Mayer, KH; Beyrer, C				Mayer, Kenneth H.; Beyrer, Chris			Antiretroviral chemoprophylaxis: PROUD and pragmatism	LANCET			English	Editorial Material							PREEXPOSURE PROPHYLAXIS; HIV-INFECTION; PREVENTION; TRANSMISSION; WOMEN		[Mayer, Kenneth H.] Fenway Hlth, Fenway Inst, Boston, MA 02215 USA; [Mayer, Kenneth H.] Harvard Univ, Dept Med, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA; [Beyrer, Chris] Johns Hopkins Univ, Dept Epidemiol, Ctr Hlth & Human Rights, Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Beyrer, Chris] Int AIDS Soc, Geneva, Switzerland	Fenway Health; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Mayer, KH (corresponding author), Fenway Hlth, Fenway Inst, Boston, MA 02215 USA.	khmayer@gmail.com						ABDOOL KQ, 2010, SCIENCE, V329, P1168, DOI DOI 10.1126/SCIENCE.1193748; AIDS Vaccine Advocacy Coalition, AVAC REP 2013 RES RE; Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; McCormack S, 2015, LANCET; Molina JMCC., 2015, C RETR OPP INF 2015; Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; UNAIDS, AIDS INF; van de Vijver DAMC, 2013, AIDS, V27, P2943, DOI 10.1097/01.aids.0000433237.63560.20; Walensky RP, 2012, CLIN INFECT DIS, V54, P1504, DOI 10.1093/cid/cis225	15	3	3	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 2	2016	387	10013					6	7		10.1016/S0140-6736(15)00153-1	http://dx.doi.org/10.1016/S0140-6736(15)00153-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CZ9ZU	26364262	hybrid			2023-01-03	WOS:000367457300006
J	Coelho, C; Foti, A; Hartmann, T; Santos-Silva, T; Leimkuhler, S; Romao, MJ				Coelho, Catarina; Foti, Alessandro; Hartmann, Tobias; Santos-Silva, Teresa; Leimkuehler, Silke; Romao, Maria Joao			Structural insights into xenobiotic and inhibitor binding to human aldehyde oxidase	NATURE CHEMICAL BIOLOGY			English	Article							MOLYBDENUM HYDROXYLASES; XANTHINE OXIDOREDUCTASE; CRYSTAL-STRUCTURE; IN-VITRO; LIVER; OXIDATION; FLAVOENZYMES; METABOLISM; EXPRESSION; MECHANISM	Aldehyde oxidase (AOX) is a xanthine oxidase (XO)-related enzyme with emerging importance due to its role in the metabolism of drugs and xenobiotics. We report the first crystal structures of human AOX1, substrate free (2.6-angstrom resolution) and in complex with the substrate phthalazine and the inhibitor thioridazine (2.7-angstrom resolution). Analysis of the protein active site combined with steady-state kinetic studies highlight the unique features, including binding and substrate orientation at the active site, that characterize human AOX1 as an important drug-metabolizing enzyme. Structural analysis of the complex with the noncompetitive inhibitor thioridazine revealed a new, unexpected and fully occupied inhibitor-binding site that is structurally conserved among mammalian AOXs and XO. The new structural insights into the catalytic and inhibition mechanisms of human AOX that we now report will be of great value for the rational analysis of clinical drug interactions involving inhibition of AOX1 and for the prediction and design of AOX-stable putative drugs.	[Coelho, Catarina; Santos-Silva, Teresa; Romao, Maria Joao] Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, Res Unit Appl Mol Biosci Rede Quim & Tecnol UCIBI, Caparica, Portugal; [Foti, Alessandro; Hartmann, Tobias; Leimkuehler, Silke] Univ Potsdam, Inst Biochem & Biol, Dept Mol Enzymol, Potsdam, Germany	Universidade Nova de Lisboa; University of Potsdam	Coelho, C (corresponding author), Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, Res Unit Appl Mol Biosci Rede Quim & Tecnol UCIBI, Caparica, Portugal.	mjr@fct.unl.pt	Santos-Silva, Teresa/D-2050-2013; Coelho, Catarina M C/D-2073-2013; UCIBIO, U Cienc Biom Apl/F-7948-2017; Santos-Silva, Teresa/AAE-1795-2019; Romao, Maria J/A-4115-2013	Santos-Silva, Teresa/0000-0003-3060-8378; Coelho, Catarina M C/0000-0003-1852-5406; UCIBIO, U Cienc Biom Apl/0000-0002-3004-0543; Santos-Silva, Teresa/0000-0003-3060-8378; Romao, Maria J/0000-0002-3004-0543; Leimkuhler, Silke/0000-0003-3238-2122	Fundacao para a Ciencia e Tecnologia (FCT-MEC) [UID/Multi/04378/2013, EXCL/QEQ-COM/0394/2012, PTDC/BIA-PRO/118377/2010, SFRH/BPD/84581/2012, DAAD-441.00]; Deutsche Forschungsgemeinschaft Grant [Le1171/8-1]; European Community [283570]	Fundacao para a Ciencia e Tecnologia (FCT-MEC); Deutsche Forschungsgemeinschaft Grant(German Research Foundation (DFG)); European Community(European Commission)	This work was financially supported by the Fundacao para a Ciencia e Tecnologia (FCT-MEC) through projects UID/Multi/04378/2013, EXCL/QEQ-COM/0394/2012, PTDC/BIA-PRO/118377/2010 (M.J.R., T.S.-S., C.C.), SFRH/BPD/84581/2012 (C.C.) and DAAD-441.00 (M.J.R., T.S.-S., S.L.) and by Deutsche Forschungsgemeinschaft Grant Le1171/8-1 (S.L.). We thank the I02 staff of the Diamond Light Source (DLS, Didcot, United Kingdom) and X06DA-PXIII staff from the Swiss Light Source (SLS, Paul Scherrer Institut, Villigen, Switzerland) for assistance during data collection. We also thank the staff from beamlines ID14-1, ID29-1 and ID23-1 from the European Synchrotron Radiation Facility (ESRF, Grenoble, France). The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under BioStruct-X (grant agreement no. 283570). We thank R. Hille (University of California, Riverside) for providing bXO for the inhibition experiments and A. Palma (Universidade Nova de Lisboa, Portugal) for critical reading of the manuscript.	Amaral L, 2012, INT J ANTIMICROB AG, V39, P376, DOI 10.1016/j.ijantimicag.2012.01.012; Baral PK, 2014, STRUCTURE, V22, P291, DOI 10.1016/j.str.2013.11.009; Barr JT, 2011, DRUG METAB DISPOS, V39, P2381, DOI 10.1124/dmd.111.041806; Basu LR, 2005, MICROBIOL RES, V160, P95, DOI 10.1016/j.micres.2004.10.002; Beedham C, 1998, BIOM HLTH R, V25, P39; Beedham C, 1997, PHARM WORLD SCI, V19, P255, DOI 10.1023/A:1008668913093; Christensen J.B., 2014, US patent, Patent No. [8,623,864, 8623864]; Christensen JB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057493; Coelho C, 2012, J BIOL CHEM, V287, P40690, DOI 10.1074/jbc.M112.390419; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; Fu CX, 2013, DRUG METAB DISPOS, V41, P1797, DOI 10.1124/dmd.113.053082; Garattini E, 2008, CELL MOL LIFE SCI, V65, P1019, DOI 10.1007/s00018-007-7398-y; Garattini E, 2003, BIOCHEM J, V372, P15, DOI 10.1042/BJ20030121; Garattini E, 2012, EXPERT OPIN DRUG MET, V8, P487, DOI 10.1517/17425255.2012.663352; Garattini E, 2011, DRUG METAB REV, V43, P374, DOI 10.3109/03602532.2011.560606; Garattini Enrico, 2009, Human Genomics, V4, P119; Hartmann T, 2012, DRUG METAB DISPOS, V40, P856, DOI 10.1124/dmd.111.043828; Hille R, 2014, CHEM REV, V114, P3963, DOI 10.1021/cr400443z; Ishikita H, 2012, J AM CHEM SOC, V134, P999, DOI 10.1021/ja207173p; Jones RM, 1999, INORG CHEM, V38, P4963, DOI 10.1021/ic990154j; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Kitamura S, 2006, DRUG METAB PHARMACOK, V21, P83, DOI 10.2133/dmpk.21.83; Leslie AGW, 2007, NATO SCI SER II-MATH, V245, P41, DOI 10.1007/978-1-4020-6316-9_4; Mahro M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082285; Mahro M, 2011, DRUG METAB DISPOS, V39, P1939, DOI 10.1124/dmd.111.040873; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Obach RS, 2005, J CLIN PSYCHOPHARM, V25, P605, DOI 10.1097/01.jcp.0000186740.22395.50; Obach RS, 2004, J CLIN PHARMACOL, V44, P7, DOI 10.1177/0091270003260336; Okamoto K, 2004, P NATL ACAD SCI USA, V101, P7931, DOI 10.1073/pnas.0400973101; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; Pryde DC, 2010, J MED CHEM, V53, P8441, DOI 10.1021/jm100888d; Rashidi MR, 1997, DRUG METAB DISPOS, V25, P805; Romao MJ, 2009, DALTON T, P4053, DOI 10.1039/b821108f; Schlauderer F, 2013, ANGEW CHEM INT EDIT, V52, P10384, DOI 10.1002/anie.201304290; Schwarzenbacher R, 2004, ACTA CRYSTALLOGR D, V60, P1229, DOI 10.1107/S0907444904010145; Temple CA, 2000, ARCH BIOCHEM BIOPHYS, V383, P281, DOI 10.1006/abbi.2000.2089; Terao M, 2006, J BIOL CHEM, V281, P19748, DOI 10.1074/jbc.M600850200; WAHL RC, 1982, J BIOL CHEM, V257, P1354; Wang A, 2015, J BIOL CHEM, V290, P5092, DOI 10.1074/jbc.M114.627661; Wilder Paul T, 2010, Int J High Throughput Screen, V2010, P109	43	65	67	0	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	OCT	2015	11	10					779	+		10.1038/NCHEMBIO.1895	http://dx.doi.org/10.1038/NCHEMBIO.1895			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CR7NG	26322824				2023-01-03	WOS:000361536500010
J	Lee, HJ; Park, IA; Song, IH; Kim, SB; Jung, KH; Ahn, JH; Ahn, SH; Kim, HH; Gong, G				Lee, Hee Jin; Park, In Ah; Song, In Hye; Kim, Sung-Bae; Jung, Kyung Hae; Ahn, Jin-Hee; Ahn, Sei-Hyun; Kim, Hak Hee; Gong, Gyungyub			Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers	PLOS ONE			English	Article							SURGICAL ADJUVANT BREAST; PREOPERATIVE CHEMOTHERAPY; PROGNOSTIC-SIGNIFICANCE; TUMOR RESPONSE; SURVIVAL; CLASSIFICATION; DISEASE; CARCINOMA; DOXORUBICIN; DOCETAXEL	Purpose Several methods are used to assess the pathologic response of breast cancer after neoadjuvant chemotherapy (NAC) to predict clinical outcome. However, the clinical utility of these systems for each molecular subtype of breast cancer is unclear. Therefore, we applied six pathologic response assessment systems to specific subtypes of breast cancer and compared the results. Patients and Methods Five hundred and eighty eight breast cancer patients treated with anthracycline with/without taxane-based NAC were retrospectively analyzed, and the ypTNM stage, residual cancer burden (RCB), residual disease in breast and nodes (RDBN), tumor response ratio, Sataloff's classification, and Miller-Payne grading system were evaluated. The results obtained for each assessment system were analyzed in terms of patient survival. Results In triple-negative tumors, all systems were significantly associated with disease-free survival and Kaplan-Meier survival curves for disease-free survival were clearly separated by all assessment methods. For HR+/HER2-tumors, systems assessing the residual tumor (ypTNM stage, RCB, and RDBN) had prognostic significance. However, for HER2+ tumors, the association between patient survival and the pathologic response assessment results varied according to the system used, and none resulted in distinct Kaplan-Meier curves. Conclusion Most of the currently available pathologic assessment systems used after anthracycline with/without taxane-based NAC effectively classified triple-negative breast cancers into groups showing different prognoses. The pathologic assessment systems evaluating residual tumors only also had prognostic significance in HR+/HER2-tumors. However, new assessment methods are required to effectively evaluate the pathologic response of HR +/HER2+ and HR-/HER2+ tumors to anthracycline with/without taxane-based NAC.	[Lee, Hee Jin; Park, In Ah; Song, In Hye; Gong, Gyungyub] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea; [Kim, Sung-Bae; Jung, Kyung Hae; Ahn, Jin-Hee] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea; [Ahn, Sei-Hyun] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul, South Korea; [Kim, Hak Hee] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, Seoul, South Korea	University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center	Gong, G (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea.	gygong@amc.seoul.kr			Asan Institute for Life Sciences, Seoul, Korea [2015-0169]	Asan Institute for Life Sciences, Seoul, Korea	Funding: This study was supported by a grant (2015-0169) from the Asan Institute for Life Sciences, Seoul, Korea.	Bear HD, 2003, J CLIN ONCOL, V21, P4165, DOI 10.1200/JCO.2003.12.005; Bhargava R, 2009, INT J CLIN EXP PATHO, V2, P444; Blanche P, 2013, STAT MED, V32, P5381, DOI 10.1002/sim.5958; Blanche P, 2013, BIOMETRICAL J, V55, P687, DOI 10.1002/bimj.201200045; Chollet P, 2008, CANCER J, V14, P128, DOI 10.1097/PPO.0b013e31816bdea2; Corben AD, 2013, ARCH PATHOL LAB MED, V137, P1074, DOI 10.5858/arpa.2012-0290-OA; Edge S.B., 2010, AJCC CANC STAGING MA, V649; Fisher B, 1997, J CLIN ONCOL, V15, P2483, DOI 10.1200/JCO.1997.15.7.2483; Fisher B, 1998, J CLIN ONCOL, V16, P2672, DOI 10.1200/JCO.1998.16.8.2672; Fisher ER, 2002, CANCER-AM CANCER SOC, V95, P681, DOI 10.1002/cncr.10741; Kaufmann M, 2006, J CLIN ONCOL, V24, P1940, DOI 10.1200/JCO.2005.02.6187; Lakhani SR, 2012, WHO CLASSIFICATION T; Lee HJ, 2015, ANN SURG ONCOL, V22, P392, DOI 10.1245/s10434-014-4054-2; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; Miller M, 2014, ANN SURG ONCOL, V21, P3317, DOI 10.1245/s10434-014-3922-0; Ogston KN, 2003, BREAST, V12, P320, DOI 10.1016/S0960-9776(03)00106-1; Onitilo AA, 2009, CLIN MED RES, V7, P4, DOI 10.3121/cmr.2009.825; Penault-Llorca F, 2008, HUM PATHOL, V39, P1221, DOI 10.1016/j.humpath.2007.11.019; Provenzano E, 2013, CLIN ONCOL-UK, V25, P80, DOI 10.1016/j.clon.2012.10.008; SATALOFF DM, 1995, J AM COLL SURGEONS, V180, P297; Shien T, 2009, BREAST CANCER RES TR, V113, P307, DOI 10.1007/s10549-008-9935-2; Spitale A, 2009, ANN ONCOL, V20, P628, DOI 10.1093/annonc/mdn675; Symmans WF, 2007, J CLIN ONCOL, V25, P4414, DOI 10.1200/JCO.2007.10.6823; Untch M, 2010, J CLIN ONCOL, V28, P2024, DOI 10.1200/JCO.2009.23.8451; von Minckwitz G, 2012, J CLIN ONCOL, V30, P1796, DOI 10.1200/JCO.2011.38.8595; Wolff AC, 2014, ARCH PATHOL LAB MED, V138, P241, DOI 10.5858/arpa.2013-0953-SA; Zhang GC, 2013, CURR ONCOL, V20, pE180, DOI 10.3747/co.20.1294	27	15	15	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2015	10	9							e0137885	10.1371/journal.pone.0137885	http://dx.doi.org/10.1371/journal.pone.0137885			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS0ZW	26394326	gold, Green Published, Green Submitted			2023-01-03	WOS:000361792100022
J	Green, DM				Green, Daniel M.			Doxorubicin in stage II-III, intermediate-risk Wilms' tumour	LANCET			English	Editorial Material							CHILDHOOD-CANCER; RENAL TUMORS; SURVIVORS; COHORT		St Jude Childrens Res Hosp, Dept Epidemiol & Canc Control, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Green, DM (corresponding author), St Jude Childrens Res Hosp, Dept Epidemiol & Canc Control, 332 N Lauderdale St, Memphis, TN 38105 USA.	daniel.green@stjude.org						BECKWITH JB, 1986, J UROLOGY, V136, P320, DOI 10.1016/S0022-5347(17)44854-3; BRISTOW MR, 1978, ANN INTERN MED, V88, P168, DOI 10.7326/0003-4819-88-2-168; DANGIO GJ, 1989, CANCER-AM CANCER SOC, V64, P349, DOI 10.1002/1097-0142(19890715)64:2<349::AID-CNCR2820640202>3.0.CO;2-Q; Green DM, 2014, LANCET ONCOL, V15, P1215, DOI 10.1016/S1470-2045(14)70408-5; Green DM, 2004, J CLIN ONCOL, V22, P1366, DOI 10.1200/JCO.2004.08.008; Hudson MM, 2007, J CLIN ONCOL, V25, P3635, DOI 10.1200/JCO.2006.09.7451; Lipshultz SE, 2013, NAT REV CLIN ONCOL, V10, P697, DOI 10.1038/nrclinonc.2013.195; Perlman EJ, 2005, PEDIATR DEVEL PATHOL, V8, P320, DOI 10.1007/s10024-005-1156-7; Pritchard-Jones K, 2015, LANCET; TOURNADE MF, 1993, J CLIN ONCOL, V11, P1014, DOI 10.1200/JCO.1993.11.6.1014; van Dalen EC, 2006, EUR J CANCER, V42, P3191, DOI 10.1016/j.ejca.2006.08.005; Vujanic GM, 2009, CANCER-AM CANCER SOC, V115, P1977, DOI 10.1002/cncr.24214	12	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 19	2015	386	9999					1118	1119		10.1016/S0140-6736(15)60686-9	http://dx.doi.org/10.1016/S0140-6736(15)60686-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CR5GE	26164099				2023-01-03	WOS:000361368000011
J	Daelmans, B; Black, MM; Lombardi, J; Lucas, J; Richter, L; Silver, K; Britto, P; Yoshikawa, H; Perez-Escamilla, R; MacMillan, H; Dua, T; Bouhouch, RR; Bhutta, ZA; Darmstadt, GL; Rao, N				Daelmans, Bernadette; Black, Maureen M.; Lombardi, Joan; Lucas, Jane; Richter, Linda; Silver, Karlee; Britto, Pia; Yoshikawa, Hirokazu; Perez-Escamilla, Rafael; MacMillan, Harriet; Dua, Tarun; Bouhouch, Raschida R.; Bhutta, Zulfiqar A.; Darmstadt, Gary L.; Rao, Nirmala			Effective interventions and strategies for improving early child development	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							COMMUNITY-HEALTH WORKERS; NUTRITION INTERVENTIONS; STIMULATION; OUTCOMES; INCOME; PREVENTION; COUNTRIES; PROGRAMS; PAKISTAN; GROWTH		[Daelmans, Bernadette; Bouhouch, Raschida R.] WHO, Dept Maternal Newborn Child & Adolescent Hlth, Policy Planning & Programmes, CH-1211 Geneva 27, Switzerland; [Black, Maureen M.] Univ Maryland, Sch Med, Dept Pediat, Pediat, Baltimore, MD 21201 USA; [Lombardi, Joan] Bernard van Leer Fdn, The Hague, Netherlands; [Richter, Linda] DST NRF Ctr Excellence Human Dev, Durban, South Africa; [Richter, Linda] Human Sci Res Council, Durban, South Africa; [Silver, Karlee] Grand Challenges Canada, Toronto, ON, Canada; [Britto, Pia] United Nations Childrens Fund, Early Child Dev, New York, NY USA; [Yoshikawa, Hirokazu] NYU Steinhardt, Dept Appl Physiol, Globalizat & Educ, New York, NY USA; [Perez-Escamilla, Rafael] Yale Univ, Sch Publ Hlth, Dept Chron Dis Epidemiol, Epidemiol & Publ Hlth, New Haven, CT USA; [MacMillan, Harriet] McMaster Univ, Dept Psychiat & Behav Neurosci, Psychiat & Behav Neurosci, Hamilton, ON, Canada; [MacMillan, Harriet] McMaster Univ, Dept Pediat, Hamilton, ON, Canada; [Dua, Tarun] WHO, Dept Mental Hlth & Substance Abuse, CH-1211 Geneva 27, Switzerland; [Bhutta, Zulfiqar A.] Hosp Sick Children, Ctr Global Child Hlth, Toronto, ON M5G 1X8, Canada; [Bhutta, Zulfiqar A.] Aga Khan Univ, Ctr Excellence Women & Child Hlth, Karachi, Pakistan; [Darmstadt, Gary L.] Stanford Univ, Sch Med, Dept Pediat, Maternal & Child Hlth, Stanford, CA 94305 USA; [Darmstadt, Gary L.] Stanford Univ, Sch Med, Dept Pediat, Neonatal & Dev Pediat, Stanford, CA 94305 USA; [Rao, Nirmala] Univ Hong Kong, Fac Educ, Early Childhood Dev & Educ, Hong Kong, Hong Kong, Peoples R China	World Health Organization; University System of Maryland; University of Maryland Baltimore; Human Sciences Research Council-South Africa; UNICEF; Yale University; McMaster University; McMaster University; World Health Organization; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Aga Khan University; Stanford University; Stanford University; University of Hong Kong	Daelmans, B (corresponding author), WHO, Dept Maternal Newborn Child & Adolescent Hlth, Policy Planning & Programmes, CH-1211 Geneva 27, Switzerland.	daelmansb@who.int	MacMillan, Harriet/B-4530-2016; Darmstadt, Gary/AAU-7488-2020	MacMillan, Harriet/0000-0002-1223-706X; Darmstadt, Gary/0000-0002-7522-5824; Black, Maureen/0000-0002-6427-4639				Black MM, 2014, ANN NY ACAD SCI, V1308, P1, DOI 10.1111/nyas.12351; BOWLBY J, 1951, Bull World Health Organ, V3, P355; Britto P.R., 2013, HDB EARLY CHILDHOOD; Britto PR, 2014, ANN NY ACAD SCI, V1308, P245, DOI 10.1111/nyas.12365; Denboba AD, 2014, STEPPING EARLY CHILD; Ertem I, 2012, DEV DIFFICULTIES EAR; Fernald LCH, 2008, LANCET, V371, P828, DOI 10.1016/S0140-6736(08)60382-7; Garcia M, 2012, DIR DEV, P1, DOI 10.1596/978-0-8213-8897-6; Gertler P, 2014, SCIENCE, V344, P998, DOI 10.1126/science.1251178; Grantham-McGregor S, 2007, LANCET, V369, P60, DOI 10.1016/S0140-6736(07)60032-4; Grantham-McGregor SM, 2014, ANN NY ACAD SCI, V1308, P11, DOI 10.1111/nyas.12284; GRANTHAMMCGREGOR SM, 1991, LANCET, V338, P1, DOI 10.1016/0140-6736(91)90001-6; Heckman J, 2015, 4 BIG BENEFITS INVES; Irwin L, 2007, EARLY CHILD DEV POWE; Jayaratne K, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-172; Jin X, 2007, J DEV BEHAV PEDIATR, V28, P123; Kent AL, 2012, PEDIATRICS, V129, P124, DOI 10.1542/peds.2011-1578; Khan NZ, 2013, CHILD CARE HLTH DEV, V39, P643, DOI 10.1111/j.1365-2214.2012.01393.x; Mikton C, 2009, B WORLD HEALTH ORGAN, V87, P353, DOI 10.2471/BLT.08.057075; Pallas SW, 2013, AM J PUBLIC HEALTH, V103, pE74, DOI 10.2105/AJPH.2012.301102; Rahman A, 2008, LANCET, V372, P902, DOI 10.1016/S0140-6736(08)61400-2; Richards E, 2013, SOC SCI MED, V95, P24, DOI 10.1016/j.socscimed.2012.06.015; Sandler IN, 2011, ANNU REV PSYCHOL, V62, P299, DOI 10.1146/annurev.psych.121208.131619; Shonkoff J. P., 2000, NEURONS NEIGHBORHOOD; Shonkoff JP, 2013, HDB EARLY CHILDHOOD, P24; UN, 2014, ROAD DIGN 2030 END P; UN Sustainable Development Solutions Network, 2015, KEY EL SUCC ADD AB A; Wachs TD, 2013, HDB EARLY CHILDHOOD, P85, DOI DOI 10.1093/ACPROF:OSO/9780199922994.003.0005; Walker SP, 2011, LANCET, V378, P1325, DOI 10.1016/S0140-6736(11)60555-2; WHO, 2013, M REPORT NURTURING H; WHO, 2014, GLOB HLTH OBS; WHO Unicef, 2012, CAR CHILD DEV; World Health Organization, 2008, MAT MENT HLTH CHILD; Yousafzai AK, 2014, LANCET, V384, P1282, DOI 10.1016/S0140-6736(14)60455-4; Yousafzai AK, 2014, ARCH DIS CHILD, V99, P840, DOI 10.1136/archdischild-2012-302066	35	26	26	3	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 14	2015	351								h4029					4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CR9LW	26371213	Bronze			2023-01-03	WOS:000361678200001
J	Nishizawa, M; Matsuda, M; Hattori, J; Shiino, T; Matano, T; Heneine, W; Johnson, JA; Sugiura, W				Nishizawa, Masako; Matsuda, Masakazu; Hattori, Junko; Shiino, Teiichiro; Matano, Tetsuro; Heneine, Walid; Johnson, Jeffrey A.; Sugiura, Wataru			Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy	PLOS ONE			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; SINGLE-DOSE NEVIRAPINE; TREATMENT-NAIVE; VIROLOGICAL FAILURE; INFECTED PATIENTS; TYPE-1 POL; VARIANTS; MUTATIONS; TRANSMISSION; PCR	Background Drug-resistant HIV are more prevalent and persist longer than previously demonstrated by bulk sequencing due to the ability to detect low-frequency variants. To clarify a clinical benefit to monitoring minority-level drug resistance populations as a guide to select active drugs for salvage therapy, we retrospectively analyzed the dynamics of low-frequency drug-resistant population in antiretroviral (ARV)-exposed drug resistant individuals. Materials and Methods Six HIV-infected individuals treated with ARV for more than five years were analyzed. These individuals had difficulty in controlling viremia, and treatment regimens were switched multiple times guided by standard drug resistance testing using bulk sequencing. To detect minority variant populations with drug resistance, we used a highly sensitive allele-specific PCR (AS-PCR) with detection thresholds of 0.3-2%. According to ARV used in these individuals, we focused on the following seven reverse transcriptase inhibitor-resistant mutations: M41L, K65R, K70R, K103N, Y181C, M184V, and T215F/Y. Results of AS-PCR were compared with bulk sequencing data for concordance and presence of additional mutations. To clarify the genetic relationship between low-frequency and high-frequency populations, AS-PCR amplicon sequences were compared with bulk sequences in phylogenetic analysis. Results The use of AS-PCR enabled detection of the drug-resistant mutations, M41L, K103N, Y181C, M184V and T215Y, present as low-frequency populations in five of the six individuals. These drug resistant variants persisted for several years without ARV pressure. Phylogenetic analysis indicated that pre-existing K103N and T215I variants had close genetic relationships with high-frequency K103N and T215I observed during treatment. Discussion and Conclusion Our results demonstrate the long-term persistence of drug-resistant viruses in the absence of drug pressure. The rapid virologic failures with pre-existing mutant viruses detectable by AS-PCR highlight the clinical importance of low-frequency drug-resistant viruses. Thus, our results highlight the usefulness of AS-PCR and support its expanded evaluation in ART clinical management.	[Nishizawa, Masako; Matano, Tetsuro; Sugiura, Wataru] Natl Inst Infect Dis, AIDS Res Ctr, Tokyo, Japan; [Matsuda, Masakazu; Hattori, Junko; Sugiura, Wataru] Natl Hosp Org, Clin Res Ctr, Nagoya Med Ctr, Nagoya, Aichi, Japan; [Shiino, Teiichiro] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Tokyo, Japan; [Heneine, Walid; Johnson, Jeffrey A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA; [Sugiura, Wataru] Nagoya Univ, Grad Sch Med, Dept AIDS Res, Nagoya, Aichi 4648601, Japan	National Institute of Infectious Diseases (NIID); Nagoya Medical Center; National Institute of Infectious Diseases (NIID); Centers for Disease Control & Prevention - USA; Nagoya University	Sugiura, W (corresponding author), Natl Inst Infect Dis, AIDS Res Ctr, Tokyo, Japan.	taru1600@me.com			Ministry of Health, Labour, and Welfare of Japan [H25-AIDS-004]	Ministry of Health, Labour, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan)	This work was supported by a Grant-in-Aid for AIDS research from the Ministry of Health, Labour, and Welfare of Japan (H25-AIDS-004) http://www.mhlw.go.jp/ to WS.	Albrecht D, 2002, J CLIN VIROL, V24, P93, DOI 10.1016/S1386-6532(01)00231-1; Avidor B, 2013, J CLIN MICROBIOL, V51, P880, DOI 10.1128/JCM.02652-12; Boltz VF, 2010, J VIROL METHODS, V164, P122, DOI 10.1016/j.jviromet.2009.11.025; Borroto-Esoda K, 2007, AIDS RES HUM RETROV, V23, P988, DOI 10.1089/aid.2006.0310; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Delobel P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021655; Dudley DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036494; Edelstein RE, 1998, J CLIN MICROBIOL, V36, P569, DOI 10.1128/JCM.36.2.569-572.1998; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Flys T, 2005, J INFECT DIS, V192, P24, DOI 10.1086/430742; Gianella S, 2011, J VIROL, V85, P8359, DOI 10.1128/JVI.02582-10; Goodman DD, 2011, AIDS, V25, P325, DOI 10.1097/QAD.0b013e3283427dcb; Gunthard HF, 1998, AIDS RES HUM RETROV, V14, P869, DOI 10.1089/aid.1998.14.869; Halfon P, 2003, AIDS, V17, P1351, DOI 10.1097/00002030-200306130-00009; Halvas EK, 2010, J INFECT DIS, V201, P672, DOI 10.1086/650542; Hattori J, 2010, ANTIVIR RES, V88, P72, DOI 10.1016/j.antiviral.2010.07.008; Johnson JA, 2005, J INFECT DIS, V192, P16, DOI 10.1086/430741; Johnson JA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000638; Johnson JA, 2008, PLOS MED, V5, P1112, DOI 10.1371/journal.pmed.0050158; Katlama C, 2012, EXPERT OPIN INV DRUG, V21, P523, DOI 10.1517/13543784.2012.661713; Kuritzkes DR, 2008, J INFECT DIS, V197, P867, DOI 10.1086/528802; Lataillade M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010952; LEITNER T, 1993, BIOTECHNIQUES, V15, P120; Li JZ, 2011, JAMA-J AM MED ASSOC, V305, P1327, DOI 10.1001/jama.2011.375; MacLeod IJ, 2010, J CLIN VIROL, V48, P162, DOI 10.1016/j.jcv.2010.03.017; Martinez-Picado J, 2008, VIRUS RES, V134, P104, DOI 10.1016/j.virusres.2007.12.021; Messiaen P, 2012, VIROLOGY, V426, P7, DOI 10.1016/j.virol.2012.01.002; Metzner KJ, 2007, AIDS, V21, P703, DOI 10.1097/QAD.0b013e3280121ac6; Metzner KJ, 2013, J INFECT DIS, V208, P1102, DOI 10.1093/infdis/jit310; Metzner KJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021734; Metzner KJ, 2011, J CLIN VIROL, V50, P156, DOI 10.1016/j.jcv.2010.10.001; Metzner KJ, 2010, J INFECT DIS, V201, P1063, DOI 10.1086/651136; Metzner KJ, 2009, CLIN INFECT DIS, V48, P239, DOI 10.1086/595703; Mohamed S, 2014, AIDS; Nei M., 2000, MOL EVOLUTION PHYLOG; Nishizawa M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083150; Palmer S, 2006, P NATL ACAD SCI USA, V103, P7094, DOI 10.1073/pnas.0602033103; Panel on Antiretroviral Guidelines for Adults and Adolescents, 2014, GUIDELINES FOR THE U; Paredes R, 2007, J VIROL METHODS, V146, P136, DOI 10.1016/j.jviromet.2007.06.012; Peuchant O, 2008, AIDS, V22, P1417, DOI 10.1097/QAD.0b013e3283034953; Sax PE, 2005, CLIN INFECT DIS, V41, P1316, DOI 10.1086/496984; Simen BB, 2009, J INFECT DIS, V199, P693, DOI 10.1086/596736; Stekler JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028952; Stelzl E, 2011, J VIROL METHODS, V178, P94, DOI 10.1016/j.jviromet.2011.08.020; Sterne JAC, 2005, LANCET, V366, P378, DOI 10.1016/S0140-6736(05)67022-5; Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]; Vandenhende MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086771; Wainberg MA, 2011, J ANTIMICROB CHEMOTH, V66, P2346, DOI 10.1093/jac/dkr291	48	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2015	10	9							e0135941	10.1371/journal.pone.0135941	http://dx.doi.org/10.1371/journal.pone.0135941			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR0WB	26360259	Green Published, gold, Green Submitted			2023-01-03	WOS:000361043100006
J	Tsoneva, D; Stritzker, J; Bedenk, K; Zhang, Q; Frentzen, A; Cappello, J; Fischer, U; Szalay, AA				Tsoneva, Desislava; Stritzker, Jochen; Bedenk, Kristina; Zhang, Qian; Frentzen, Alexa; Cappello, Joseph; Fischer, Utz; Szalay, Aladar A.			Drug-Encoded Biomarkers for Monitoring Biological Therapies	PLOS ONE			English	Article							ONCOLYTIC VACCINIA VIRUS; IN-VIVO; CANCER; GLUCURONIDASE; LUCIFERASE; INSERTION; BACTERIA; TUMORS; AGENT	Blood tests are necessary, easy-to-perform and low-cost alternatives for monitoring of oncolytic virotherapy and other biological therapies in translational research. Here we assessed three candidate proteins with the potential to be used as biomarkers in biological fluids: two glucuronidases from E. coli (GusA) and Staphylococcus sp. RLH1 (GusPlus), and the luciferase from Gaussia princeps (GLuc). The three genes encoding these proteins were inserted individually into vaccinia virus GLV-1h68 genome under the control of an identical promoter. The three resulting recombinant viruses were used to infect tumor cells in cultures and human tumor xenografts in nude mice. In contrast to the actively secreted GLuc, the cytoplasmic glucuronidases GusA and GusPlus were released into the supernatants only as a result of virus-mediated oncolysis. GusPlus resulted in the most sensitive detection of enzyme activity under controlled assay conditions in samples containing as little as 1 pg/ml of GusPlus, followed by GusA (25 pg/ml) and GLuc (>= 375 pg/ml). Unexpectedly, even though GusA had a lower specific activity compared to GusPlus, the substrate conversion in the serum of tumor-bearing mice injected with the GusA-encoding virus strains was substantially higher than that of GusPlus. This was attributed to a 3.2 fold and 16.2 fold longer half-life of GusA in the blood stream compared to GusPlus and GLuc respectively, thus a more sensitive monitor of virus replication than the other two enzymes. Due to the good correlation between enzymatic activity of expressed marker gene and virus titer, we conclude that the amount of the biomarker protein in the body fluid semiquantitatively represents the amount of virus in the infected tumors which was confirmed by low light imaging. We found GusA to be the most reliable biomarker for monitoring oncolytic virotherapy among the three tested markers.	[Tsoneva, Desislava; Bedenk, Kristina; Fischer, Utz; Szalay, Aladar A.] Univ Wurzburg, Dept Biochem, Bioctr, D-97070 Wurzburg, Germany; [Stritzker, Jochen; Zhang, Qian; Frentzen, Alexa; Cappello, Joseph] Genelux Corp, San Diego Sci Ctr, San Diego, CA 92109 USA; [Stritzker, Jochen] Univ Wurzburg, Bioctr, D-97070 Wurzburg, Germany; [Fischer, Utz; Szalay, Aladar A.] Univ Calif San Diego, Dept Radiat Oncol, Moores Canc Ctr, San Diego, CA 92103 USA	University of Wurzburg; University of Wurzburg; University of California System; University of California San Diego	Stritzker, J (corresponding author), Genelux Corp, San Diego Sci Ctr, San Diego, CA 92109 USA.	js@genelux.com; szalay@biozentrum.uni-wuerzburg.de	Fischer, Utz/A-4090-2016; Fischer, Utz/AAT-8422-2020	Fischer, Utz/0000-0002-1465-6591; Fischer, Utz/0000-0002-1465-6591	Genelux Corporation; University of Wurzburg; German Research Foundation (DFG)	Genelux Corporation; University of Wurzburg; German Research Foundation (DFG)(German Research Foundation (DFG))	The work was supported by Genelux Corporation and a Service Grant awarded to the University of Wurzburg, graduate stipends from the University of Wurzburg. The publication costs were co-funded by the German Research Foundation (DFG) and the University of wurzburg in the funding program Open Access Publishing. The funder provided support in the form of salaries for authors (JS, QZ, AF, JC, UF, AAS), but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Arul L, 2008, BIOINFORMATION, V2, P339, DOI 10.6026/97320630002339; Broothaerts W, 2005, NATURE, V433, P629, DOI 10.1038/nature03309; Browne AW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019530; Chen NH, 2009, MOL MED, V15, P144, DOI 10.2119/molmed.2009.00014; Chen NG, 2010, FUTURE VIROL, V5, P763, DOI 10.2217/FVL.10.58; Coupar BEH, 2000, J GEN VIROL, V81, P431, DOI 10.1099/0022-1317-81-2-431; FALKNER FG, 1990, J VIROL, V64, P3108, DOI 10.1128/JVI.64.6.3108-3111.1990; Haddad D, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-36; Heo J, 2013, NAT MED, V19, P329, DOI 10.1038/nm.3089; Hess M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-172; Jefferson RA, 2002, MICROBIAL BETA GLUCU; Kirn DH, 2009, NAT REV CANCER, V9, P64, DOI 10.1038/nrc2545; Mansfield D, 2013, VALIDATION BIOMARKER; Phuong LK, 2003, CANCER RES, V63, P2462; Ruiz-Hernandez E, 2014, POLYM CHEM-UK, V5, P1674, DOI [10.1039/c3py01097j, 10.1039/C3PY01097J]; Stritzker J, 2013, P NATL ACAD SCI USA, V110, P3316, DOI 10.1073/pnas.1216916110; Tannous BA, 2009, NAT PROTOC, V4, P582, DOI 10.1038/nprot.2009.28; Wurdinger T, 2008, NAT METHODS, V5, P171, DOI [10.1038/nmeth.1177, 10.1038/NMETH.1177]; Yu YA, 2004, NAT BIOTECHNOL, V22, P313, DOI 10.1038/nbt937; Zenser TV, 1999, DRUG METAB DISPOS, V27, P1064; Zhang Q, 2007, CANCER RES, V67, P10038, DOI 10.1158/0008-5472.CAN-07-0146	21	4	4	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2015	10	9							e0137573	10.1371/journal.pone.0137573	http://dx.doi.org/10.1371/journal.pone.0137573			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ8YQ	26348361	gold, Green Submitted, Green Published			2023-01-03	WOS:000360897600055
J	Xu, YD; Deng, XL; Han, Y; Zhou, LX; He, WQ; Chen, SB; Nong, LB; Huang, H; Zhang, Y; Yu, TO; Li, YM; Liu, XQ				Xu, Yuanda; Deng, Xilong; Han, Yun; Zhou, Lixin; He, Weiqun; Chen, Sibei; Nong, Lingbo; Huang, Huang; Zhang, Yan; Yu, Tieou; Li, Yimin; Liu, Xiaoqing			A Multicenter Retrospective Review of Prone Position Ventilation (PPV) in Treatment of Severe Human H7N9 Avian Flu	PLOS ONE			English	Article								Background Patients with H7N9 avian flu concurrent with severe acute respiratory distress syndrome (ARDS) usually have a poor clinical outcome. Prone position ventilation (PPV) has been shown to improve the prognosis of patients with severe ARDS. This study explored the effects of PPV on the respiratory and circulatory mechanics of H7N9-infected patients with severe ARDS. Methods Individuals admitted to four hospitals designated for H7N9 patients in Guangdong province were treated with PPV, and their clinical data were recorded before and after receiving PPV. Results Six of 20 critically ill patients in the ICU received PPV. After treatment with 35 PPV sessions, the oxygenation index (OI) values of the six patients when measured post-PPV and post-supine position ventilation (SPV) were significantly higher than those measured pre-PPV (P < 0.05). The six patients showed no significant differences in their values for respiratory rate (RR), peak inspiratory pressure (PIP), tidal volume (TV) or arterial partial pressure of carbon dioxide (PaCO2) when compared pre-PPV, post-PPV, and post-SPV. Additionally, there were no significant differences in the mean values for arterial pressure (MAP), cardiac index (CI), central venous pressure (CVP), heart rate (HR), lactic acid (LAC) levels or the doses of norepinephrine (NE) administered when compared pre-PPV, post-PPV, and post-SPV. Conclusion PPV provided improved oxygenation that was sustained after returning to a supine position, and resulted in decreased carbon dioxide retention. PPV can thus serve as an alternative lung protective ventilation strategy for use in patients with H7N9 avian flu concurrent with severe ARDS.	[Xu, Yuanda; He, Weiqun; Chen, Sibei; Nong, Lingbo; Li, Yimin; Liu, Xiaoqing] Guangzhou Med Univ, Dept Crit Care Med, State Key Lab Resp Dis, Affiliated Hosp 1, Guangzhou 510120, Guangdong, Peoples R China; [Deng, Xilong; Huang, Huang] Guangzhou Eighth Peoples Hosp, Dept Crit Care Med, Guangzhou 510060, Guangdong, Peoples R China; [Han, Yun; Zhang, Yan] Guangdong Hosp Tradit Chinese Med, Dept Crit Care Med, Fangcun Branch, Guangzhou 510360, Guangdong, Peoples R China; [Zhou, Lixin; Yu, Tieou] Foshan First Peoples Hosp, Dept Crit Care Med, Foshan 528000, Peoples R China	Guangzhou Medical University; State Key Laboratory of Respiratory Disease; Guangzhou University of Chinese Medicine	Li, YM (corresponding author), Guangzhou Med Univ, Dept Crit Care Med, State Key Lab Resp Dis, Affiliated Hosp 1, Guangzhou 510120, Guangdong, Peoples R China.	dryiminli@vip.163.com; lxq1118@126.com	Zhou, Li/GSE-4531-2022					[Anonymous], CHINESE J CLIN RATIO; Charron C, 2011, CRIT CARE, V15, DOI 10.1186/cc10324; Chiumello D, 2006, CRIT CARE, V10, DOI 10.1186/cc4933; Diaz JV, 2010, CRIT CARE MED, V38, P1644, DOI 10.1097/CCM.0b013e3181e795ee; Gao HN, 2013, NEW ENGL J MED, V368, P2277, DOI 10.1056/NEJMoa1305584; Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103; Hay AJ, 2013, LANCET, V381, P2230, DOI 10.1016/S0140-6736(13)61209-X; Hering R, 2001, ANESTH ANALG, V92, P1226, DOI 10.1097/00000539-200105000-00027; Lam TTY, 2015, NATURE, V522, P102, DOI 10.1038/nature14348; Liu L, 2005, CHINESE J ANESTHESIO, V9, P20; Mure M, 2000, J APPL PHYSIOL, V88, P1076, DOI 10.1152/jappl.2000.88.3.1076; National Health and Family Planning Commission of the People's Republic of China, 2014, INFECT DIS INFORM, V01, P1; Pelosi P, 1998, AM J RESP CRIT CARE, V157, P387, DOI 10.1164/ajrccm.157.2.97-04023; PIEHL MA, 1976, CRIT CARE MED, V4, P13, DOI 10.1097/00003246-197601000-00003; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; The Chinese Medical Association Society of critical care medicine, 2007, CHINESE J INTERNAL M, V5, P430; van Riel D, 2013, AM J PATHOL, V183, P1137, DOI 10.1016/j.ajpath.2013.06.011; Zhan HQ, 2014, CAPITAL MED, V12, P52	18	9	10	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2015	10	8							e0136520	10.1371/journal.pone.0136520	http://dx.doi.org/10.1371/journal.pone.0136520			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ0PO	26317621	Green Published, Green Submitted, gold			2023-01-03	WOS:000360299100094
J	D'Silva, J				D'Silva, Jeetha			India's problem with toxic alcohol	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												j.dsilva@gmail.com						[Anonymous], 2015, HINDU; [Anonymous], 2015, HINDUSTAN TIMES 0605; Basu I, 2015, HUFFINGTON POST; Pal S., 2015, DNA; Press Trust of India, 2015, DNA; Press Trust of India, 2015, HINDUSTAN TIMES 0429; World Health Organization, 2014, METH POIS OUTBR	7	6	6	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 25	2015	351									10.1136/bmj.h4536	http://dx.doi.org/10.1136/bmj.h4536			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CQ2NG	26306757				2023-01-03	WOS:000360437200003
J	Aberese-Ako, M; Agyepong, IA; Gerrits, T; Van Dijk, H				Aberese-Ako, Matilda; Agyepong, Irene Akua; Gerrits, Trudie; Van Dijk, Han			'I Used to Fight with Them but Now I Have Stopped!': Conflict and Doctor-Nurse-Anaesthetists' Motivation in Maternal and Neonatal Care Provision in a Specialist Referral Hospital	PLOS ONE			English	Article							HEALTH WORKER MOTIVATION; PUBLIC-SECTOR; TRUST; SATISFACTION; PERFORMANCE; MANAGEMENT; CONSEQUENCES	Background and Objectives This paper analyses why and how conflicts occur and their influence on doctors and nurse-anaesthetists' motivation in the provision of maternal and neonatal health care in a specialist hospital. Methodology The study used ethnographic methods including participant observation, conversation and in-depth interviews over eleven months in a specialist referral hospital in Ghana. Qualitative analysis software Nvivo 8 was used for coding and analysis of data. Main themes identified in the analysis form the basis for interpreting and reporting study findings. Ethics Statement Ethical clearance was obtained from the Ghana Health Service Ethics Review board (approval number GHS-ERC: 06/01/12) and from the University of Wageningen. Written consent was obtained from interview participants, while verbal consent was obtained for conversations. To protect the identity of the hospital and research participants pseudonyms are used in the article and the part of Ghana in which the study was conducted is not mentioned. Results Individual characteristics, interpersonal and organisational factors contributed to conflicts. Unequal power relations and distrust relations among doctors and nurse-anaesthetists affected how they responded to conflicts. Responses to conflicts including forcing, avoiding, accommodating and compromising contributed to persistent conflicts, which frustrated and demotivated doctors and nurse-anaesthetists. Demotivated workers exhibited poor attitudes in collaborating with co-workers in the provision of maternal and neonatal care, which sometimes led to poor health worker response to client care, consequently compromising the hospital's goal of providing quality health care to clients. Conclusion To improve health care delivery in health facilities in Ghana, health managers and supervisors need to identify conflicts as an important phenomenon that should be addressed whenever they occur. Effective mechanisms including training managers and health workers on conflict management should be put in place. Additionally promoting communication and interaction among health workers can foster team spirit. Also resolving conflicts using the collaborating response may help to create a conducive work environment that will promote healthy work relations, which can facilitate the delivery of quality maternal and neonatal health care. However, such an approach requires that unequal power relations, which is a root cause of the conflicts is addressed.	[Aberese-Ako, Matilda; Van Dijk, Han] Wageningen Univ, Sociol Dev & Change SDC Grp, NL-6700 AP Wageningen, Netherlands; [Aberese-Ako, Matilda; Agyepong, Irene Akua] Ghana Hlth Serv, Accra, Ghana; [Agyepong, Irene Akua] Univ Ghana, Sch Publ Hlth, Legon, Ghana; [Gerrits, Trudie] Univ Amsterdam, Amsterdam Sch Social Sci Res, Amsterdam, Netherlands	Wageningen University & Research; Ghana Health Service; University of Ghana; University of Amsterdam	Aberese-Ako, M (corresponding author), Wageningen Univ, Sociol Dev & Change SDC Grp, NL-6700 AP Wageningen, Netherlands.	matilda.aberese-ako@wur.nl	van Dijk, Han/L-6710-2016	van Dijk, Han/0000-0002-4406-4909; Agyepong, Irene Akua/0000-0002-0193-5882	Netherlands Organization for Scientific Research (NWO/WOTRO) [WOTRO-IP W 07.45.102.00]	Netherlands Organization for Scientific Research (NWO/WOTRO)(Netherlands Organization for Scientific Research (NWO))	This work was funded by the Netherlands Organization for Scientific Research (NWO/WOTRO) on the project "Accelerating progress towards attainment of MDG 4 and 5 in Ghana through basic health systems function strengthening," grant number [WOTRO-IP W 07.45.102.00]. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agyepong I A, 2001, Qual Manag Health Care, V9, P1; Agyepong IA, 2004, INT J HEALTH PLAN M, V19, P319, DOI 10.1002/hpm.770; Almost J, 2006, J ADV NURS, V53, P444, DOI 10.1111/j.1365-2648.2006.03738.x; Almost J, 2010, J NURS MANAGE, V18, P981, DOI 10.1111/j.1365-2834.2010.01154.x; Ansong-Tornui Janet, 2007, Ghana Med J, V41, P125; Bazin JE, 2014, ANN FR ANESTH, V33, P335, DOI 10.1016/j.annfar.2014.04.006; Bercovitch J, 1983, ASIAN J PUBLIC ADM, V5, P104; Board E, 1994, ANAESTHETISTS DISCUO; Bonenberger M, 2014, HUM RESOUR HEALTH, V12, DOI 10.1186/1478-4491-12-43; Booij LHDJ, 2007, CURR OPIN ANESTHESIO, V20, P152, DOI 10.1097/ACO.0b013e32809f9506; Bosu Wk, 2007, Ghana Med J, V41, P118; Bousari M. P., 2009, Research Journal of Biological Sciences, V4, P236; Brinkert R, 2010, J NURS MANAGE, V18, P145, DOI 10.1111/j.1365-2834.2010.01061.x; Capitulo KL, 2009, NURSE LEAD, V7, P38, DOI 10.1016/j.mnl.2009.01.009; Cinar F, 2012, PROCD SOC BEHV, V58, P197, DOI 10.1016/j.sbspro.2012.09.993; Coe R, 2008, J ADV NURS, V61, P609, DOI 10.1111/j.1365-2648.2007.04544.x; Coombs Maureen, 2003, Intensive Crit Care Nurs, V19, P125, DOI 10.1016/S0964-3397(03)00040-5; DAHL RA, 1957, BEHAV SCI, V2, P201, DOI 10.1002/bs.3830020303; De Dreu CKW, 2003, J APPL PSYCHOL, V88, P741, DOI 10.1037/0021-9010.88.4.741; Dieleman M, 2006, HUMAN RESOURCES HLTH, V4, P1; Dieleman Marjolein, 2003, Hum Resour Health, V1, P10, DOI 10.1186/1478-4491-1-10; DISCOMBE G, 1954, BRIT MED J, V1, P326, DOI 10.1136/bmj.1.4857.326; Emerson M.R., 2005, WRITING ETHNOGRAPHIC, P353; Encyclopedia Wikipedia, 2014, UT MYOM; Ferres N., 2004, J MANAGE PSYCHOL, V19, P608, DOI [10.1108/02683940410551516, DOI 10.1108/02683940410551516]; Fox A., 1974, CONTRACT WORK POWER; Franco LM, 2004, SOC SCI MED, V58, P343, DOI 10.1016/S0277-9536(03)00203-X; Franco LM, 2002, SOC SCI MED, V54, P1255, DOI 10.1016/S0277-9536(01)00094-6; Gilson L, 2003, SOC SCI MED, V56, P1453, DOI 10.1016/S0277-9536(02)00142-9; Gilson L, 2005, SOC SCI MED, V61, P1418, DOI 10.1016/j.socscimed.2004.11.062; Gilson Lucy, 2006, J Health Organ Manag, V20, P359, DOI 10.1108/14777260610701768; Guerra ST, 2011, REV LAT-AM ENFERM, V19, P362, DOI 10.1590/S0104-11692011000200019; Jack H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057940; Jehn KA, 2006, INT J CONFL MANAGE, V17, P96, DOI 10.1108/10444060610736594; Johns JL, 1996, J ADV NURS, V24, P76, DOI 10.1046/j.1365-2648.1996.16310.x; Katiliute E, 2007, BALT J MANAG, V2, P213, DOI DOI 10.1108/17465260710751008; Katz JD, 2007, J CLIN ANESTH, V19, P152, DOI 10.1016/j.jclinane.2006.07.007; Laschinger HKS, 2000, J NURS ADMIN, V30, P413, DOI 10.1097/00005110-200009000-00008; Lipsky M., 1980, STREET LEVEL BUREAUC, DOI DOI 10.1007/s13178-012-0092-3; Mansour JB, 2005, MANAGERS WHO LEAD HD; Mathauer Inke, 2006, Hum Resour Health, V4, P24, DOI 10.1186/1478-4491-4-24; Mintzberg H., 1983, POWER ORG, DOI DOI 10.1177/017084068400500419; Mohammed A, 2012, INT FEDERATION GYNEC; National Development Planning Commission Government of Ghana United Nations Development Programme (UNDP) Ghana, 2010, 2008 GHAN MILL DEV G; Pavlakis A, 2011, INT NURS REV, V58, P242, DOI 10.1111/j.1466-7657.2011.00880.x; PONDY LR, 1967, ADMIN SCI QUART, V12, P296, DOI 10.2307/2391553; Purohit B, 2014, HUM RESOUR HEALTH, V12, DOI 10.1186/1478-4491-12-12; Rosenstein AH, 2011, AM J OBSTET GYNECOL, V204, P187, DOI 10.1016/j.ajog.2010.10.899; Rowe AK, 2005, LANCET, V366, P1026, DOI 10.1016/S0140-6736(05)67028-6; Slack T., 2006, UNDERSTANDING SPORT; Thom DH, 2004, HEALTH AFFAIR, V23, P124, DOI 10.1377/hlthaff.23.4.124; Van der Geest S, 1998, SOC SCI MED, V47, P1373, DOI 10.1016/S0277-9536(98)00179-8; Vivar Cristina Garcia, 2006, J Nurs Manag, V14, P201; Whetten DA, 1996, EFFECTIVE CONFLICT M; ZAND DE, 1972, ADMIN SCI QUART, V17, P229, DOI 10.2307/2393957	55	24	24	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 18	2015	10	8							e0135129	10.1371/journal.pone.0135129	http://dx.doi.org/10.1371/journal.pone.0135129			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CP1VY	26285108	Green Published, gold, Green Submitted			2023-01-03	WOS:000359666100022
J	Kruse, M; Wildner, R; Barnes, G; Martin, M; Mueller, U; Lo-Coco, F; Pathak, A				Kruse, Morgan; Wildner, Rebecca; Barnes, Gisoo; Martin, Monique; Mueller, Udo; Lo-Coco, Francesco; Pathak, Ashutosh			Budgetary Impact of Treating Acute Promyelocytic Leukemia Patients with First-Line Arsenic Trioxide and Retinoic Acid from an Italian Payer Perspective	PLOS ONE			English	Article							CONSOLIDATION THERAPY; CHEMOTHERAPY; REMISSION; RISK; INTERGROUP; INDUCTION; SURVIVAL; ADULTS; TRIAL	The objective of this study was to estimate the net cost of arsenic trioxide (ATO) added to all-trans retinoic acid (ATRA) compared to ATRA plus chemotherapy when used in first-line acute promyelocytic leukemia (APL) treatment for low to intermediate risk patients from the perspective of the overall Italian healthcare systemA Markov model was developed with 3 health states: stable disease, disease event and death. Each month, patients could move from stable to disease event or die from either state. After a disease event, patients discontinued initial treatment and switched to the other regimen as second-line therapy. Treatment regimens, efficacy and adverse events were derived from published sources and expert opinion; unit costs were collected from standard Italian sources. Clinical outcomes and costs for pre-ATO and post-ATO scenarios were combined with population and product utilization information to calculate the total budgetary impact using a 3-year time horizon; one-way sensitivity analyses were conducted. Three-year cumulative pharmacy costs for ATO+ATRA were (sic)46,700 per-patient versus (sic)6,500 for ATRA+chemotherapy; however, medical costs for ATO+ATRA were (sic)12,300 per-patient versus (sic)30,200 for ATRA+chemotherapy. The total budgetary impact was estimated to be an additional (sic)127,300, (sic)312,500 and (sic)477,800 in the first, second and third years, respectively. The model was most sensitive to changes in the cost of the ATO+ATRA regimen during the consolidation phase. Budgetary impact models are valuable to payers making formulary decisions regarding the access and affordability of new medicines. The cost of treatment analysis showed that pharmacy costs for ATO+ATRA were higher than for ATRA+chemotherapy, while all other evaluated costs were lower for ATO+ATRA treated patients. The average budgetary impact was (sic)305,900 per year overall, representing a 3.5% increase. Further research is needed to determine the cost-effectiveness of ATO+ATRA compared to the current first-line standard of care in APL.	[Kruse, Morgan; Wildner, Rebecca] Optum, Cambridge, MA USA; [Barnes, Gisoo; Pathak, Ashutosh] Teva Pharmaceut, Frazer, PA USA; [Martin, Monique] MapiGroup, Uxbridge, Middx, England; [Mueller, Udo] Teva Pharmaceut, Ulm, Germany; [Lo-Coco, Francesco] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy	Optum; University of Rome Tor Vergata	Lo-Coco, F (corresponding author), Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy.	francesco.lo.coco@uniroma2.it			Teva Pharmaceuticals; Optum; MapiGroup	Teva Pharmaceuticals(Teva Pharmaceutical Industries); Optum; MapiGroup	The study was funded by Teva Pharmaceuticals. Co-authors GB, AP and UM are employed by Teva Pharmaceuticals. Teva Pharmaceuticals provided support in the form of salaries for authors GB, AP and UM but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. Optum and MapiGroup provided support in the form of salaries for authors MK, RW and MM, but did not have an additional direct role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Ades L, 2010, BLOOD, V115, P1690, DOI 10.1182/blood-2009-07-233387; AIRTUM ITCAN, 2014, AIRTUM ITCAN CANC IT; [Anonymous], 2014, DEMOGRAPHIC BALANCE; [Anonymous], 2013, NOM TAR ASS SPEC AMB; [Anonymous], 2014, EL FARM FAS H PRINC; Asou N, 2007, BLOOD, V110, P59, DOI 10.1182/blood-2006-08-043992; Au WY, 2003, ANN ONCOL, V14, P752, DOI 10.1093/annonc/mdg208; Avvisati G, 2011, BLOOD, V117, P4716, DOI 10.1182/blood-2010-08-302950; Capri S, 2001, DRUG INF J, V35, P189, DOI 10.1177/009286150103500122; Efficace F, 2014, J CLIN ONCOL, V32, P3406, DOI 10.1200/JCO.2014.55.3453; Estey E, 2006, BLOOD, V107, P3469, DOI 10.1182/blood-2005-10-4006; Ghavamzadeh A, 2011, J CLIN ONCOL, V29, P2753, DOI 10.1200/JCO.2010.32.2107; Iland HJ, 2012, BLOOD, V120, P1570, DOI 10.1182/blood-2012-02-410746; Lengfelder E, 2015, LEUKEMIA, V29, P1084, DOI 10.1038/leu.2015.12; Lengfelder E, 2012, ACUTE PROMYELOCYTIC; Lo-Coco F, 2013, NEW ENGL J MED, V369, P111, DOI 10.1056/NEJMoa1300874; Lo-Coco F, 2010, BLOOD, V116, P3171, DOI 10.1182/blood-2010-03-276196; Marchetti M, 2004, CLIN THER, V26, P1546, DOI 10.1016/j.clinthera.2004.09.014; Mathews V, 2006, BLOOD, V107, P2627, DOI 10.1182/blood-2005-08-3532; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Powell BL, 2010, BLOOD, V116, P3751, DOI 10.1182/blood-2010-02-269621; Prontuario farmaceuticoh [ Internet], 2014, PRONT FARM; Raffoux E, 2003, J CLIN ONCOL, V21, P2326, DOI 10.1200/JCO.2003.01.149; Sanz MA, 2000, BLOOD, V96, P1247; Sanz MA, 2010, BLOOD, V115, P5137, DOI 10.1182/blood-2010-01-266007; Sanz MA, 2009, BLOOD, V113, P1875, DOI 10.1182/blood-2008-04-150250; Shen ZX, 2004, P NATL ACAD SCI USA, V101, P5328, DOI 10.1073/pnas.0400053101; Shigeno K, 2005, INT J HEMATOL, V82, P224, DOI 10.1532/IJH97.05044; Soignet SL, 2001, J CLIN ONCOL, V19, P3852, DOI 10.1200/JCO.2001.19.18.3852; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Sullivan SD, 2014, VALUE HEALTH, V17, P5, DOI 10.1016/j.jval.2013.08.2291; Tallman Martin S, 2008, Hematology Am Soc Hematol Educ Program, P391, DOI 10.1182/asheducation-2008.1.391; Tallman MS, 2002, BLOOD, V100, P4298, DOI 10.1182/blood-2002-02-0632; Watts JM, 2014, BLOOD REV, V28, P205, DOI 10.1016/j.blre.2014.07.001	34	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2015	10	8							e0134587	10.1371/journal.pone.0134587	http://dx.doi.org/10.1371/journal.pone.0134587			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO9JT	26267454	Green Published, gold, Green Submitted			2023-01-03	WOS:000359492300050
J	Guedes, CES; Lima, JGB; Helfer, E; Veras, PST; Viallat, A				Guedes, Carlos E. S.; Lima, Jose G. B.; Helfer, Emmanuele; Veras, Patricia S. T.; Viallat, Annie			Encapsulation of Living Leishmania Promastigotes in Artificial Lipid Vacuoles	PLOS ONE			English	Article							PHAGOCYTOSIS; DIFFERENTIATION; MACROPHAGES; PHAGOSOMES; PROTEIN	After phagocytosis by mammalian macrophages, promastigote forms of Leishmania parasites settle inside intracellular parasitophorous vacuoles (PVs) in which they transform into amastigote forms and replicate. Here, using a variant of the 'inverted emulsion' method, we succeeded in encapsulating living L. amazonensis parasites in giant artificial liposomes that serve as model PVs. We were able to control the size of liposomes, the pH and the composition of their internal volume, and the number of internalized parasites per liposome. L. amazonensis promastigotes encapsulated in liposomes filled with RPMI-Dextran solution at pH 7.5 or 6.5 survived up to 96 h at 24 degrees C. At 37 degrees C and pH 5.5, parasites survived 48h. This method paves the way to identifying certain effectors secreted by the parasite and to unraveling specific mechanisms of fusion between the PV and intracellular vesicles of the host cell. This method will also facilitate the study of the temporal evolution of biophysical properties of the PV during its maturation.	[Guedes, Carlos E. S.; Lima, Jose G. B.; Veras, Patricia S. T.] Fiocruz MS, Ctr Pesquisas Goncalo Moniz, Lab Patol & Biointervencao, Salvador, BA, Brazil; [Helfer, Emmanuele; Viallat, Annie] Aix Marseille Univ, CNRS, CINaM UMR 7325, F-13288 Marseille, France	Fundacao Oswaldo Cruz; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Aix-Marseille Universite	Veras, PST (corresponding author), Fiocruz MS, Ctr Pesquisas Goncalo Moniz, Lab Patol & Biointervencao, Rua Waldemar Falcao 121, Salvador, BA, Brazil.	pveras@bahia.fiocruz.br; viallat@cinam.univ-mrs.fr	Veras, Patricia S T Sampaio Tavares/I-9632-2014	Veras, Patricia S T Sampaio Tavares/0000-0001-8308-9263; Helfer, Emmanuele/0000-0001-8123-0964	program Coordenacao de Aperfeicoamento do Pessoal de Nivel Superior (CAPES) Comite Francais d'Evaluation de la Cooperation Universitaire et Scientifique avec le Bresil (COFECUB) [Sv 726/11]; CAPES	program Coordenacao de Aperfeicoamento do Pessoal de Nivel Superior (CAPES) Comite Francais d'Evaluation de la Cooperation Universitaire et Scientifique avec le Bresil (COFECUB); CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This work was supported by the program Coordenacao de Aperfeicoamento do Pessoal de Nivel Superior (CAPES) Comite Francais d'Evaluation de la Cooperation Universitaire et Scientifique avec le Bresil (COFECUB) Sv 726/11 and by CAPES.	Abkarian M, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.041906; Abkarian M, 2011, SOFT MATTER, V7, P15; ANGELOVA MI, 1992, PROG COLL POL SCI S, V89, P127; Antoine JC, 1998, TRENDS MICROBIOL, V6, P392, DOI 10.1016/S0966-842X(98)01324-9; Besteiro S, 2007, INT J PARASITOL, V37, P1063, DOI 10.1016/j.ijpara.2007.03.008; Burchmore RJS, 2001, INT J PARASITOL, V31, P1311, DOI 10.1016/S0020-7519(01)00259-4; CHAKRABORTY P, 1994, METHOD CELL BIOL, V45, P261; Dermine JF, 2000, CELL MICROBIOL, V2, P115, DOI 10.1046/j.1462-5822.2000.00037.x; Descoteaux A, 1999, BBA-MOL BASIS DIS, V1455, P341, DOI 10.1016/S0925-4439(99)00065-4; KIERSZENBAUM F, 1974, J IMMUNOL, V112, P1839; Landfear SM, 2011, EUKARYOT CELL, V10, P483, DOI 10.1128/EC.00287-10; MDaA Descoteaux, 1999, ADV CELL MOL BIOL M, V6, P380; NICHOLS BA, 1981, LAB INVEST, V44, P324; Pautot S, 2003, LANGMUIR, V19, P10; Pincet F, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.218101; Richmond DL, 2011, P NATL ACAD SCI USA, V108, P9431, DOI 10.1073/pnas.1016410108; Roux A, 2002, P NATL ACAD SCI USA, V99, P5394, DOI 10.1073/pnas.082107299; Shevchuk Olga, 2013, Methods Mol Biol, V983, P419, DOI 10.1007/978-1-62703-302-2_23; Tsigankov P, 2014, MOL CELL PROTEOMICS, V13, P1787, DOI 10.1074/mcp.M114.037705; Vinet Adrien F., 2009, V531, P329, DOI 10.1007/978-1-59745-396-7_20; Yanagisawa M, 2011, J AM CHEM SOC, V133, P11774, DOI 10.1021/ja2040859	21	0	0	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2015	10	8							e0134925	10.1371/journal.pone.0134925	http://dx.doi.org/10.1371/journal.pone.0134925			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO1VB	26241746	Green Submitted, Green Published, gold			2023-01-03	WOS:000358942700082
J	Chuzel, T; Sanchez, V; Vandamme, M; Martin, S; Flety, O; Pager, A; Chabanel, C; Magnier, L; Foskolos, M; Petit, O; Rokbi, B; Chereul, E				Chuzel, Thomas; Sanchez, Violette; Vandamme, Marc; Martin, Stephane; Flety, Odile; Pager, Aurelie; Chabanel, Christophe; Magnier, Luc; Foskolos, Marie; Petit, Oceane; Rokbi, Bachra; Chereul, Emmanuel			Impact of Anesthesia Protocols on In Vivo Bioluminescent Bacteria Imaging Results	PLOS ONE			English	Article							INFECTIONS; MICE; HEMODYNAMICS; LUCIFERASE; MODELS	Infectious murine models greatly benefit from optical imaging using bioluminescent bacteria to non-invasively and repeatedly follow in vivo bacterial infection. In this context, one of the most critical parameters is the bioluminescence sensitivity to reliably detect the smallest number of bacteria. Another critical point is the anesthetic approaches that have been demonstrated to impact the bioluminescence flux emission in studies with luciferase-transfected tumor cells. However, this impact has never been assessed on bacteria bioluminescent models. To this end, we investigated the effects of four anesthesia protocols on the bioluminescence flux in a central venous catheter murine model (SKH1-hrhr mice) infected by a bioluminescent S. aureus Xen36 strain. Bioluminescence imaging was performed on mice anesthetized by either ketamine/xylazine (with or without oxygen supplementation), or isoflurane carried with air or oxygen. Total flux emission was determined in vivo daily for 3 days and ex vivo at the end of the study together with a CFU counting of the biofilm in the catheter. Bioluminescence flux differences appear between the different anesthetic protocols. Using a ketamine/xylazine anesthesia (with air), bacteria detection was impossible since the bioluminescence signal remains in the background signal. Mice anesthetized with isoflurane and oxygen led to a signal significantly higher to the background all along the kinetics. The use of isoflurane in air presents a bioluminescence signal similar to the use of ketamine/xylazine with oxygen. These data highlight the importance of oxygen to improve bioluminescence flux by bacteria with isoflurane as well as with ketamine/xylazine anesthetics. As a conclusion, we recommend the use of isoflurane anesthetic with oxygen to increase the bioluminescence sensitivity in this kind of study.	[Chuzel, Thomas; Vandamme, Marc; Martin, Stephane; Pager, Aurelie; Magnier, Luc; Foskolos, Marie; Petit, Oceane; Chereul, Emmanuel] Voxcan, Marcy Letoile, France; [Sanchez, Violette; Flety, Odile; Chabanel, Christophe; Rokbi, Bachra] Sanofi Pasteur, Marcy Letoile, France		Chereul, E (corresponding author), Voxcan, Marcy Letoile, France.	emmanuel.chereul@voxcan.fr			VOXCAN; SANOFI PASTEUR	VOXCAN; SANOFI PASTEUR	The authors received no specific funding for this work. VOXCAN provided support in the form of salaries for authors TC, MV, SM, AP, LM, MF, OP, and EC, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. SANOFI PASTEUR provided support in the form of salaries for authors VS, OF, CC, and BR, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Andreu N, 2011, FEMS MICROBIOL REV, V35, P360, DOI 10.1111/j.1574-6976.2010.00252.x; Chauhan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037281; Cui KM, 2008, LUMINESCENCE, V23, P292, DOI 10.1002/bio.1032; Ebert T, 2011, HUM VACCINES, V7, P630, DOI 10.4161/hv.7.6.15407; Fish R, 2011, ANESTHESIA ANALGESIA; Francis KP, 2000, INFECT IMMUN, V68, P3594, DOI 10.1128/IAI.68.6.3594-3600.2000; Francis KP, 2001, INFECT IMMUN, V69, P3350, DOI 10.1128/IAI.69.5.3350-3358.2001; Franks NP, 1998, BIOPHYS J, V75, P2205, DOI 10.1016/S0006-3495(98)77664-7; Guo Y, 2013, ANTIMICROB AGENTS CH, V57, P855, DOI 10.1128/AAC.01003-12; Hildebrandt IJ, 2008, ILAR J NATL RES COUN, P49; Janssen BJA, 2004, AM J PHYSIOL-HEART C, V287, pH1618, DOI 10.1152/ajpheart.01192.2003; Kadurugamuwa Jagath L., 2008, V431, P225; Keyaerts M, 2012, PLOS ONE, V7, P374, DOI 10.1371/journal.pone.0030061; Kuklin NA, 2003, ANTIMICROB AGENTS CH, V47, P2740, DOI 10.1128/AAC.47.9.2740-2748.2003; Lerondel S., 2013, CURRENT MOL IMAGING, V2, P18, DOI [10.2174/2211555211302010004, DOI 10.2174/2211555211302010004]; Lorenz U, 2008, MICROBES INFECT, V10, P217, DOI 10.1016/j.micinf.2007.11.006; Semprini S, 2012, J AM ASSOC LAB ANIM, V51, P820; Winson MK, 1998, FEMS MICROBIOL LETT, V163, P193, DOI 10.1111/j.1574-6968.1998.tb13045.x; Zuurbier CJ, 2002, AM J PHYSIOL-HEART C, V282, pH2099, DOI 10.1152/ajpheart.01002.2001	19	4	4	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2015	10	7							e0134048	10.1371/journal.pone.0134048	http://dx.doi.org/10.1371/journal.pone.0134048			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN7NT	26208168	gold, Green Submitted, Green Published			2023-01-03	WOS:000358622000195
J	Irfan, N; Brooks, A; Mithoowani, S; Celetti, SJ; Main, C; Mertz, D				Irfan, Neal; Brooks, Annie; Mithoowani, Siraj; Celetti, Steve J.; Main, Cheryl; Mertz, Dominik			A Controlled Quasi-Experimental Study of an Educational Intervention to Reduce the Unnecessary Use of Antimicrobials For Asymptomatic Bacteriuria	PLOS ONE			English	Article							URINARY-TRACT-INFECTION; DISEASES-SOCIETY; INAPPROPRIATE TREATMENT; HOSPITALIZED-PATIENTS; AMERICA GUIDELINES; PREVENTION; WOMEN; OVERTREATMENT; ANTIBIOTICS; DIAGNOSIS	Background Asymptomatic bacteriuria (ABU) should only be treated in cases of pregnancy or in-patients undergoing urologic procedures; however, unnecessary treatment of ABU is common in clinical practice. Objective To identify risk factors for unnecessary treatment and to assess the impact of an educational intervention focused on these risk factors on treatment of ABU. Design Quasi-experimental study with a control group. Setting Two tertiary teaching adult care hospitals. Participants Consecutive patients with positive urine cultures between January 30th and April 17th, 2012 (baseline) and January 30th and April 30th, 2013 (intervention). Intervention In January 2013, a multifaceted educational intervention based on risk factors identified during the baseline period was provided to medical residents (monthly) on one clinical teaching unit (CTU) at one hospital site, with the CTU of the other hospital serving as the control. Results During the baseline period, 160/341 (46.9%) positive urine cultures were obtained from asymptomatic patients at the two hospitals, and 94/160 (58.8%) were inappropriately treated with antibiotics. Risk factors for inappropriate use included: female gender (OR 2.1, 95% CI 1.1-4.3), absence of a catheter (OR 2.5, 1.2-5), bacteriuria versus candiduria (OR 10.6, 3.8-29.4), pyuria (OR 2.0, 1.1-3.8), and positive nitrites (OR 2.2, 1.1-4.5). In 2013, only 2/24 (8%) of ABU patients were inappropriately treated on the intervention CTU as compared to 14/29 (52%) on the control CTU (OR 0.10; 95% CI 0.02-0.49). A reduction was also observed as compared to baseline on the intervention CTU (OR 0.1, 0.02-0.7) with no significant change noted on the control CTU (OR 0.47, 0.13-1.7). Conclusions A multifaceted educational intervention geared towards medical residents with a focus on identified risk factors for inappropriate management of ABU was effective in reducing unnecessary antibiotic use.	[Irfan, Neal; Brooks, Annie; Main, Cheryl; Mertz, Dominik] Hamilton Hlth Sci, Hamilton, ON, Canada; [Brooks, Annie; Mithoowani, Siraj; Mertz, Dominik] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Celetti, Steve J.] Univ Waterloo, Fac Pharm, Kitchener, ON, Canada; [Main, Cheryl; Mertz, Dominik] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada; [Mertz, Dominik] McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Mertz, Dominik] Michael G DeGroote Inst Infect Dis Res IIDR, Hamilton, ON, Canada	McMaster University; McMaster University; University of Waterloo; McMaster University; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba	Mertz, D (corresponding author), Hamilton Hlth Sci, Hamilton, ON, Canada.	mertzd@mcmaster.ca						Cai T, 2012, CLIN INFECT DIS, V55, P771, DOI 10.1093/cid/cis534; Chowdhury F, 2012, J COMMUNITY HOSP INT, V2, DOI 10.3402/jchimp.v2i2.17814; CLASSEN DC, 1991, AM J INFECT CONTROL, V19, P136, DOI 10.1016/0196-6553(91)90019-9; Cope M, 2009, CLIN INFECT DIS, V48, P1182, DOI 10.1086/597403; Dalen Dawn M, 2005, Can J Infect Dis Med Microbiol, V16, P166; Dellit TH, 2007, CLIN INFECT DIS, V44, P159, DOI 10.1086/510393; Gandhi T, 2009, INFECT CONT HOSP EP, V30, P193, DOI 10.1086/593951; GARIBALDI RA, 1974, NEW ENGL J MED, V291, P215, DOI 10.1056/NEJM197408012910501; Gupta K, 2011, CLIN INFECT DIS, V52, pE103, DOI [10.1093/cid/ciq257, 10.1093/cid/cir102]; Hartley S, 2013, INFECT CONT HOSP EP, V34, P1204, DOI 10.1086/673449; HARTSTEIN AI, 1981, INFECT CONT HOSP EP, V2, P380, DOI 10.1017/S0195941700055533; Hecker MT, 2003, ARCH INTERN MED, V163, P972, DOI 10.1001/archinte.163.8.972; Hooton TM, 2010, CLIN INFECT DIS, V50, P625, DOI 10.1086/650482; Kelley D, 2014, INFECT CONT HOSP EP, V35, P193, DOI 10.1086/674848; Khawcharoenporn T, 2011, AM J EMERG MED, V29, P828, DOI 10.1016/j.ajem.2011.04.007; KUNIN CM, 1966, NEW ENGL J MED, V274, P1155, DOI 10.1056/NEJM196605262742101; Leis JA, 2014, CLIN INFECT DIS, V58, P980, DOI 10.1093/cid/ciu010; Leis JA, 2013, INFECT CONT HOSP EP, V34, P1113, DOI 10.1086/673151; Lin E, 2012, ARCH INTERN MED, V172, P33, DOI 10.1001/archinternmed.2011.565; Mody L, 2014, JAMA-J AM MED ASSOC, V311, P844, DOI 10.1001/jama.2014.303; Nicolle LE, 2005, CLIN INFECT DIS, V40, P643, DOI 10.1086/427507; RUBIN RH, 1992, CLIN INFECT DIS, V15, pS216, DOI 10.1093/clind/15.Supplement_1.S216; Silver SA, 2009, CAN J INFECT DIS MED, V20, P107, DOI 10.1155/2009/702545; Srigley JA, 2013, AM J INFECT CONTROL, V41, P1116, DOI 10.1016/j.ajic.2013.04.017; Trautner BW, 2014, AM J INFECT CONTROL, V42, P653, DOI 10.1016/j.ajic.2014.02.003; Tsan L, 2010, AM J INFECT CONTROL, V38, P461, DOI 10.1016/j.ajic.2009.12.009; WARREN JW, 1987, J INFECT DIS, V155, P1151, DOI 10.1093/infdis/155.6.1151; WARREN JW, 1982, J INFECT DIS, V146, P719, DOI 10.1093/infdis/146.6.719; Zabarsky TF, 2008, AM J INFECT CONTROL, V36, P476, DOI 10.1016/j.ajic.2007.11.007	29	24	24	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2015	10	7							e0132071	10.1371/journal.pone.0132071	http://dx.doi.org/10.1371/journal.pone.0132071			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RQ	26182348	gold, Green Submitted, Green Published			2023-01-03	WOS:000358198200015
J	Cattaneo, L; Cicconi, R; Mignogna, G; Giorgi, A; Mattei, M; Graziani, G; Ferracane, R; Grosso, A; Aducci, P; Schinina, ME; Marra, M				Cattaneo, Lucia; Cicconi, Rosella; Mignogna, Giuseppina; Giorgi, Alessandra; Mattei, Maurizio; Graziani, Giulia; Ferracane, Rosalia; Grosso, Alessandro; Aducci, Patrizia; Schinina, M. Eugenia; Marra, Mauro			Anti-Proliferative Effect of Rosmarinus officinalis L. Extract on Human Melanoma A375 Cells	PLOS ONE			English	Article							ENDOPLASMIC-RETICULUM STRESS; PROTEIN DISULFIDE-ISOMERASE; TANDEM MASS-SPECTROMETRY; SALVIA-OFFICINALIS; ROSEMARY EXTRACT; CARNOSIC ACID; CYCLE ARREST; ANTIOXIDANT PROPERTIES; MYELOID-LEUKEMIA; BRONCHIAL CELLS	Rosemary (Rosmarinus officinalis L.) has been used since ancient times in traditional medicine, while nowadays various rosemary formulations are increasingly exploited by alternative medicine to cure or prevent a wide range of health disorders. Rosemary's bioproperties have prompted scientific investigation, which allowed us to ascertain antioxidant, anti-inflammatory, cytostatic, and cytotoxic activities of crude extracts or of pure components. Although there is a growing body of experimental work, information about rosemary's anticancer properties, such as chemoprotective or anti-proliferative effects on cancer cells, is very poor, especially concerning the mechanism of action. Melanoma is a skin tumor whose diffusion is rapidly increasing in the world and whose malignancy is reinforced by its high resistance to cytotoxic agents; hence the availability of new cytotoxic drugs would be very helpful to improve melanoma prognosis. Here we report on the effect of a rosemary hydroalcoholic extract on the viability of the human melanoma A375 cell line. Main components of rosemary extract were identified by liquid chromatography coupled to tandem mass spectrometry (LC/ESI-MS/MS) and the effect of the crude extract or of pure components on the proliferation of cancer cells was tested by MTT and Trypan blue assays. The effect on cell cycle was investigated by using flow cytometry, and the alteration of the cellular redox state was evaluated by intracellular ROS levels and protein carbonylation analysis. Furthermore, in order to get information about the molecular mechanisms of cytotoxicity, a comparative proteomic investigation was performed.	[Cattaneo, Lucia; Grosso, Alessandro; Aducci, Patrizia; Marra, Mauro] Univ Roma Tor Vergata, Dept Biol, I-00173 Rome, Italy; [Cicconi, Rosella; Mattei, Maurizio] Univ Roma Tor Vergata, Ctr Serv Interdipartimentale, Staz Tecnol Anim, Rome, Italy; [Mignogna, Giuseppina; Giorgi, Alessandra; Schinina, M. Eugenia] Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; [Graziani, Giulia; Ferracane, Rosalia] Univ Naples Federico II, Dept Agr & Food Sci, Naples, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; Sapienza University Rome; University of Naples Federico II	Marra, M (corresponding author), Univ Roma Tor Vergata, Dept Biol, I-00173 Rome, Italy.	marra@uniroma2.it	Mattei, Maurizio/AAC-1303-2019; Graziani, Giulia/AAN-4828-2020	Mattei, Maurizio/0000-0002-0814-8873; Graziani, Giulia/0000-0003-3070-5389; Mignogna, Giuseppina/0000-0001-9238-132X; Ferracane, Rosalia/0000-0002-1323-7715	Italian grant from MIUR [PRIN 2010HEBBB8_002]; Sapienza University grant [C26A124WCR]	Italian grant from MIUR; Sapienza University grant	This work has been partly supported by an Italian grant from MIUR (to MES; grant number PRIN 2010HEBBB8_002) and by a Sapienza University grant (to MES; grant number C26A124WCR).	Al-Sereiti M. R., 1999, Indian Journal of Experimental Biology, V37, P124; Atallah Ehab, 2005, Curr Treat Options Oncol, V6, P185; Bai HH, 2014, SCANNING, V36, P622, DOI 10.1002/sca.21170; Bai NS, 2010, J AGR FOOD CHEM, V58, P5363, DOI 10.1021/jf100332w; Bakirel T, 2008, J ETHNOPHARMACOL, V116, P64, DOI 10.1016/j.jep.2007.10.039; Benham AM, 2012, ANTIOXID REDOX SIGN, V16, P781, DOI 10.1089/ars.2011.4439; Bozin B, 2007, J AGR FOOD CHEM, V55, P7879, DOI 10.1021/jf0715323; Chang IS, 2007, BLOOD, V110, P994, DOI 10.1182/blood-2007-03-078303; Cheung S, 2007, ONCOL REP, V17, P1525; Chiu CC, 2011, CLIN CANCER RES, V17, P4629, DOI 10.1158/1078-0432.CCR-10-2107; Cho NH, 2006, J PROTEOME RES, V5, P643, DOI 10.1021/pr050460x; Choi EJ, 2013, ONCOL LETT, V6, P1784, DOI 10.3892/ol.2013.1601; D'Alessio C, 1999, J BIOL CHEM, V274, P25899, DOI 10.1074/jbc.274.36.25899; Das S, 2012, EXP BIOL MED, V237, P1433, DOI 10.1258/ebm.2012.012148; Dias PC, 2000, J ETHNOPHARMACOL, V69, P57, DOI 10.1016/S0378-8741(99)00133-6; Ding HY, 2010, FOOD CHEM, V123, P254, DOI 10.1016/j.foodchem.2010.04.025; Drenth JPH, 2005, TRENDS MOL MED, V11, P37, DOI 10.1016/j.molmed.2004.11.004; George VC, 2013, ASIAN PAC J CANCER P, V14, P631, DOI 10.7314/APJCP.2013.14.2.631; Gonzalez-Trujano ME, 2007, J ETHNOPHARMACOL, V111, P476, DOI 10.1016/j.jep.2006.12.011; Gutierrez R, 2010, PHYTOTHER RES, V24, P595, DOI 10.1002/ptr.2997; Han W, 2013, J CLIN INVEST, V123, P2103, DOI 10.1172/JCI61820; Herrero M, 2010, J CHROMATOGR A, V1217, P2512, DOI 10.1016/j.chroma.2009.11.032; Higa A, 2014, MOL CELL BIOL, V34, P1839, DOI 10.1128/MCB.01484-13; Hu CE, 2014, BIOCHEM BIOPH RES CO, V448, P437, DOI 10.1016/j.bbrc.2014.04.124; HUANG MT, 1994, CANCER RES, V54, P701; Huang SC, 2005, BIOCHEM PHARMACOL, V69, P221, DOI 10.1016/j.bcp.2004.09.019; Johnson JJ, 2011, CANCER LETT, V305, P1, DOI 10.1016/j.canlet.2011.02.005; Johnson JJ, 2008, PHARM RES-DORDR, V25, P2125, DOI 10.1007/s11095-008-9552-0; Kontogianni VG, 2013, FOOD CHEM, V136, P120, DOI 10.1016/j.foodchem.2012.07.091; Liao Y, 2014, PLOS ONE, V19; Lin Y, 2008, CURR CANCER DRUG TAR, V8, P634, DOI 10.2174/156800908786241050; Lovat PE, 2008, CANCER RES, V68, P5363, DOI 10.1158/0008-5472.CAN-08-0035; Marugame T, 2010, JPN J CLIN ONCOL, V40, P710, DOI 10.1093/jjco/hyq107; Menoret A, 2014, MOL CARCINOGEN, V53, pE11, DOI 10.1002/mc.21986; Molinaro RJ, 2006, NUCLEIC ACIDS RES, V34, P6684, DOI 10.1093/nar/gkl968; Moran AE, 2005, CANCER RES, V65, P1097; OFFORD EA, 1995, CARCINOGENESIS, V16, P2057, DOI 10.1093/carcin/16.9.2057; Offord EA, 1997, CANCER LETT, V114, P275, DOI 10.1016/S0304-3835(97)04680-6; Pappin Darryl J C, 2003, Methods Mol Biol, V211, P211; Park SJ, 2009, BONE, V45, P994, DOI 10.1016/j.bone.2009.07.018; Qu J, 2001, J CHROMATOGR A, V919, P437, DOI 10.1016/S0021-9673(01)00849-4; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Russo A, 2009, NAT PROD COMMUN, V4, P1707; Senorans FJ, 2000, J CHROMATOGR A, V870, P491, DOI 10.1016/S0021-9673(99)00941-3; Shabtay A, 2008, ONCOLOGY-BASEL, V75, P203, DOI 10.1159/000163849; Sharabani H, 2006, INT J CANCER, V118, P3012, DOI 10.1002/ijc.21736; Singletary K, 1996, CANCER LETT, V104, P43, DOI 10.1016/0304-3835(96)04227-9; Singletary KW, 1997, PLANT FOOD HUM NUTR, V50, P47, DOI 10.1007/BF02436042; Sotelo-Felix JI, 2002, J ETHNOPHARMACOL, V81, P145, DOI 10.1016/S0378-8741(02)00090-9; Steiner M, 2001, NUTR CANCER, V41, P135, DOI 10.1207/S15327914NC41-1&amp;2_19; Sun W, 2001, Curr Treat Options Oncol, V2, P193, DOI 10.1007/s11864-001-0033-5; Tawbi Hussein A, 2010, Clin Adv Hematol Oncol, V8, P259; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; Ullah MF, 2013, CELL BIOCHEM BIOPHYS, V67, P431, DOI 10.1007/s12013-011-9303-4; Urich-Merzenich G, 2009, PHYTOMEDICINE, V16, P495, DOI 10.1016/j.phymed.2009.04.001; Visanji JM, 2006, CANCER LETT, V237, P130, DOI 10.1016/j.canlet.2005.05.045; Wang F, 2014, DRUG RES; Wei Feng-Xiang, 2008, Zhong Yao Cai, V31, P877; Xavier CPR, 2009, NUTR CANCER, V61, P564, DOI 10.1080/01635580802710733; Xu SL, 2014, DRUG DISCOV TODAY, V19, P222, DOI 10.1016/j.drudis.2013.10.017; Yamamoto J, 2005, NUTRITION, V21, P580, DOI 10.1016/j.nut.2004.09.016; Yang B, 2013, CARBOHYD POLYM, V92, P1308, DOI 10.1016/j.carbpol.2012.10.012; Yesil-Celiktas O, 2010, PLANT FOOD HUM NUTR, V65, P158, DOI 10.1007/s11130-010-0166-4; YU SG, 1995, J NUTR, V125, P2763; Zhang JY, 2014, INT IMMUNOPHARMACOL, V21, P94, DOI 10.1016/j.intimp.2014.04.011; Zhavoronkov A, 2012, J MOL MED, V90, P1361, DOI 10.1007/s00109-012-0962-4	66	51	56	3	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2015	10	7							e0132439	10.1371/journal.pone.0132439	http://dx.doi.org/10.1371/journal.pone.0132439			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RL	26176704	Green Published, gold, Green Submitted			2023-01-03	WOS:000358197600113
J	Wei, YQ; Wang, DG; Yang, H; Cao, H				Wei, You-quan; Wang, Dian-gang; Yang, Hao; Cao, Heng			Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome	PLOS ONE			English	Article							CLOPIDOGREL RESPONSIVENESS; PLATELET-AGGREGATION; INTERVENTION; POLYMORPHISM; INHIBITION; REACTIVITY; GENOTYPE; OUTCOMES; DISEASE; RISK	Background The cytochrome P450 (CYP450) 2C19 681 genotypes affect the antiplatelet activity of clopidogrel. We investigated the correlation of CYP 2C19 681G > A mutation with clopidogrel resistance (CR). Additionally, we studied the effect of CR on clinical prognosis of patients with acute coronary syndrome (ACS). Methods One hundred ten ACS patients undergoing percutaneous coronary intervention, who were followed-up for 1 year, were included in the study. The patients were co-administered aspirin 100 mg/d and clopidogrel 75mg/d following a loading dose of 300 mg. CR was assessed on the basis of polymorphism observed in the CYP2C19 subgroup. Results Patients in GG genotype group exhibited greater inhibition of platelet aggregation than patients in GA and AA genotype groups (16.2 +/- 10.1%; 10.2 +/- 9.9%; 8.0 +/- 5.9%, respectively, p < 0.01). CYP2C19 681GG genotype group was associated with lower CR than CYP2C19 681A allele (GA + AA) group (9/59 vs. (12+ 5)/51; p = 0.009). Over a follow-up of 12 months, the incidence of recurrent angina, acute myocardial infarction, and intra-stent thrombosis in CYP2C19 681 GG carriers was significantly lower than that in CYP2C19 681A allele (GA + AA) group (2/59 vs. 8/51, 1/59 vs. 6/51, 0 vs. 4/51, respectively, p < 0.05). Conclusion CYP 2C19*2 is associated with reduced clopidogrel antiplatelet activity and might be an important marker for poor prognosis of ACS.	[Wei, You-quan; Yang, Hao; Cao, Heng] Wannan Med Coll, Affiliated Hosp 1, Dept Cardiol, Wuhu, Peoples R China; [Wang, Dian-gang] Second Peoples Hosp Huangchuan Cty, Dept Cardiol, Xinyang, Peoples R China	Wannan Medical College	Cao, H (corresponding author), Wannan Med Coll, Affiliated Hosp 1, Dept Cardiol, Wuhu, Peoples R China.	ablationer@aliyun.com			Natural Science Research of Anhui Province College, Anhui, China, HC [kj2011A263]	Natural Science Research of Anhui Province College, Anhui, China, HC	This work was supported by grants from the Key Project of Natural Science Research of Anhui Province College (kj2011A263), Anhui, China, HC.	Bhatt DL, 2012, EUR HEART J, V33, P2143, DOI 10.1093/eurheartj/ehs059; Collet JP, 2009, LANCET, V373, P309, DOI 10.1016/S0140-6736(08)61845-0; Guengerich FP, 2006, AAPS J, V8, pE101, DOI 10.1208/aapsj080112; Gurbel PA, 2005, J AM COLL CARDIOL, V45, P1392, DOI 10.1016/j.jacc.2005.01.030; Hulot JS, 2006, BLOOD, V108, P2244, DOI 10.1182/blood-2006-04-013052; Hulot JS, 2010, J AM COLL CARDIOL, V56, P134, DOI 10.1016/j.jacc.2009.12.071; Jaremo P, 2002, J INTERN MED, V252, P233, DOI 10.1046/j.1365-2796.2002.01027.x; Kazui M, 2010, DRUG METAB DISPOS, V38, P92, DOI 10.1124/dmd.109.029132; Muller I, 2003, THROMB HAEMOSTASIS, V89, P783, DOI 10.1055/s-0037-1613462; Nelson David R., 2009, Human Genomics, V4, P59; Price MJ, 2012, J AM COLL CARDIOL, V59, P1928, DOI 10.1016/j.jacc.2011.11.068; Price MJ, 2011, CIRCULATION, V124, P1132, DOI 10.1161/CIRCULATIONAHA.111.029165; Rothenbacher D, 2013, BMC CARDIOVASC DISOR, V13, DOI 10.1186/1471-2261-13-61; Serebruany VL, 2005, J AM COLL CARDIOL, V45, P246, DOI 10.1016/j.jacc.2004.09.067; Shuldiner AR, 2009, JAMA-J AM MED ASSOC, V302, P849, DOI 10.1001/jama.2009.1232; Simon T, 2009, NEW ENGL J MED, V360, P363, DOI 10.1056/NEJMoa0808227; Smith SMG, 2007, J AM COLL CARDIOL, V49, p375A; Speed WC, 2009, PHARMACOGENOMICS J, V9, P283, DOI 10.1038/tpj.2009.10; Trenk D, 2008, J AM COLL CARDIOL, V51, P1925, DOI 10.1016/j.jacc.2007.12.056	19	22	22	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2015	10	7							e0132561	10.1371/journal.pone.0132561	http://dx.doi.org/10.1371/journal.pone.0132561			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1DQ	26147597	Green Published, gold, Green Submitted			2023-01-03	WOS:000358157600301
J	Baez-Saldana, R; Villafuerte-Garcia, A; Cruz-Hervert, P; Delgado-Sanchez, G; Ferreyra-Reyes, L; Ferreira-Guerrero, E; Mongua-Rodriguez, N; Montero-Campos, R; Melchor-Romero, A; Garcia-Garcia, L				Baez-Saldana, Renata; Villafuerte-Garcia, Adriana; Cruz-Hervert, Pablo; Delgado-Sanchez, Guadalupe; Ferreyra-Reyes, Leticia; Ferreira-Guerrero, Elizabeth; Mongua-Rodriguez, Norma; Montero-Campos, Rogelio; Melchor-Romero, Ada; Garcia-Garcia, Lourdes			Association between Highly Active Antiretroviral Therapy and Type of Infectious Respiratory Disease and All-Cause In-Hospital Mortality in Patients with HIV/AIDS: A Case Series	PLOS ONE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; MIDDLE-INCOME COUNTRIES; BACTERIAL PNEUMONIA; HIV-INFECTION; ERA; OUTCOMES; ADULTS; AIDS; EPIDEMIOLOGY; PREVENTION	Background Respiratory manifestations of HIV disease differ globally due to differences in current availability of effective highly active antiretroviral therapy (HAART) programs and epidemiology of infectious diseases. Objective To describe the association between HAART and discharge diagnosis and all-cause in-hospital mortality among hospitalized patients with infectious respiratory disease and HIV/AIDS. Material and Methods We retrospectively reviewed the records of patients hospitalized at a specialty hospital for respiratory diseases in Mexico City between January 1st, 2010 and December 31st, 2011. We included patients whose discharge diagnosis included HIV or AIDS and at least one infectious respiratory diagnosis. The information source was the clinical chart. We analyzed the association between HAART for 180 days or more and type of respiratory disease using polytomous logistic regression and all-cause hospital mortality by multiple logistic regressions. Results We studied 308 patients, of whom 206 (66.9%) had been diagnosed with HIV infection before admission to the hospital. The CD4+ lymphocyte median count was 68 cells/mm(3) [interquartile range (IQR): 30-150]. Seventy-five (24.4%) cases had received HAART for more than 180 days. Pneumocystis jirovecii pneumonia (PJP) (n = 142), tuberculosis (n = 63), and bacterial community-acquired pneumonia (n = 60) were the most frequent discharge diagnoses. Receiving HAART for more than 180 days was associated with a lower probability of PJP [Adjusted odd ratio (aOR): 0.245, 95% Confidence Interval (CI): 0.08-0.8, p = 0.02], adjusted for sociodemographic and clinical covariates. HAART was independently associated with reduced odds (aOR 0.214, 95% CI 0.06-0.75) of all-cause in-hospital mortality, adjusting for HIV diagnosis previous to hospitalization, age, access to social security, low socioeconomic level, CD4 cell count, viral load, and discharge diagnoses. Conclusions HAART for 180 days or more was associated with 79% decrease in all-cause in-hospital mortality and lower frequency of PJP as discharge diagnosis. The prevalence of poorly controlled HIV was high, regardless of whether HIV was diagnosed before or during admission. HIV diagnosis and treatment resources should be improved, and strengthening of HAART program needs to be promoted.	[Baez-Saldana, Renata; Villafuerte-Garcia, Adriana; Cruz-Hervert, Pablo; Delgado-Sanchez, Guadalupe; Ferreyra-Reyes, Leticia; Ferreira-Guerrero, Elizabeth; Mongua-Rodriguez, Norma; Montero-Campos, Rogelio; Melchor-Romero, Ada; Garcia-Garcia, Lourdes] Inst Nacl Salud Publ, Ctr Invest Enfermedades Infecciosas, Cuernavaca, Morelos, Mexico; [Baez-Saldana, Renata] Inst Nacl Enfermedades Resp, Serv Clin Neumol Oncol, Mexico City, DF, Mexico; [Baez-Saldana, Renata; Mongua-Rodriguez, Norma] Univ Nacl Autonoma Mexico, Fac Med, Div Posgrad, Mexico City 04510, DF, Mexico; [Cruz-Hervert, Pablo] Univ Nacl Autonoma Mexico, Fac Odontol, Div Posgrad, Mexico City 04510, DF, Mexico	Instituto Nacional de Salud Publica; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Garcia-Garcia, L (corresponding author), Inst Nacl Salud Publ, Ctr Invest Enfermedades Infecciosas, Cuernavaca, Morelos, Mexico.	garcigarml@gmail.com	García, Maria de Lourdes/I-2724-2019; Cruz-Hervert, Luis Pablo/AEI-4595-2022	García, Maria de Lourdes/0000-0001-5262-1157; Cruz-Hervert, Luis Pablo/0000-0002-6094-958X	National Council of Science and Technology (CONACyT)	National Council of Science and Technology (CONACyT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	AVG received a scholarship from the National Council of Science and Technology (CONACyT).	Adebamowo CA, 2014, JAIDS-J ACQ IMM DEF, V67, pS17, DOI 10.1097/QAI.0000000000000255; Baez SR, 2013, NEUMOL CIR TORAX S1, V72, P6; Bartlett J, 2004, DEP HLTH HUMAN SERVI, P13; Bower M, 2003, AIDS, V17, P371, DOI 10.1097/00002030-200302140-00011; Corbett EL, 2002, CLIN INFECT DIS, V34, P1251, DOI 10.1086/339540; Crabtree-Ramirez B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020272; Crothers K, 2006, CHEST, V130, P1326, DOI 10.1378/chest.130.5.1326; Crothers K, 2011, AM J RESP CRIT CARE, V183, P388, DOI 10.1164/rccm.201006-0836OC; Fink VI, 2011, JAIDS-J ACQ IMM DEF, V56, P467, DOI 10.1097/QAI.0b013e31820bb1c3; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; Hassani AS, 2015, JAIDS-J ACQ IMM DEF, V68, pS257, DOI 10.1097/QAI.0000000000000486; Hull MW, 2008, CHEST, V134, P1287, DOI 10.1378/chest.08-0364; Iglesias Chiesa M, 2011, 30 ANOS VIH SIDA PER, P61; Jiang HB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083078; Kaplan Jonathan E., 2009, Morbidity and Mortality Weekly Report, V58, P1; Kohli R, 2006, CLIN INFECT DIS, V43, P90, DOI 10.1086/504871; Lawn SD, 2006, CLIN INFECT DIS, V43, P770, DOI 10.1086/507095; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; Madeddu G, 2008, INFECTION, V36, P231, DOI 10.1007/s15010-007-7162-0; Madeddu G, 2010, CURR OPIN PULM MED, V16, P201, DOI 10.1097/MCP.0b013e3283375825; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0; Morris A, 2004, EMERG INFECT DIS, V10, P1713, DOI 10.3201/eid1010.030985; Palella FJ, 2003, ANN INTERN MED, V138, P620, DOI 10.7326/0003-4819-138-8-200304150-00007; Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16; Secretaria de Salud, GUIA MAN ANT PERS CO; Shiels MS, 2011, J NATL CANCER I, V103, P753, DOI 10.1093/jnci/djr076; Shorr AF, 2004, CHEST, V125, P260, DOI 10.1378/chest.125.1.260; Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782; Sullivan JH, 2000, AM J RESP CRIT CARE, V162, P64, DOI 10.1164/ajrccm.162.1.9904101; Tuboi SH, 2009, JAIDS-J ACQ IMM DEF, V51, P615, DOI 10.1097/QAI.0b013e3181a44f0a; Weidle PJ, 2002, LANCET, V360, P34, DOI 10.1016/S0140-6736(02)09330-3; WHO UNAIDS UNICEF, 2007, UN ACC SCAL PRIOR HI; World Health Organization, 2007, GUID PROV IN HIV TES; World Health Organization, INT STAT CLASS DIS R	35	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2015	10	9							e0138115	10.1371/journal.pone.0138115	http://dx.doi.org/10.1371/journal.pone.0138115			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS0RH	26379281	gold, Green Submitted, Green Published			2023-01-03	WOS:000361769400054
J	Chisti, MJ; Salam, MA; Smith, JH; Ahmed, T; Pietroni, MAC; Shahunja, KM; Shahid, ASMSB; Faruque, ASG; Ashraf, H; Bardhan, PK; Sharifuzzaman; Graham, SM; Duke, T				Chisti, Mohammod J.; Salam, Mohammed A.; Smith, Jonathan H.; Ahmed, Tahmeed; Pietroni, Mark A. C.; Shahunja, K. M.; Shahid, Abu S. M. S. B.; Faruque, Abu S. G.; Ashraf, Hasan; Bardhan, Pradip K.; Sharifuzzaman; Graham, Stephen M.; Duke, Trevor			Bubble continuous positive airway pressure for children with severe pneumonia and hypoxaemia in Bangladesh: an open, randomised controlled trial	LANCET			English	Article							CHILDHOOD PNEUMONIA; OXYGEN-THERAPY; CHLORAMPHENICOL; MANAGEMENT; INFANTS; CPAP	Background In developing countries, mortality in children with very severe pneumonia is high, even with the provision of appropriate antibiotics, standard oxygen therapy, and other supportive care. We assessed whether oxygen therapy delivered by bubble continuous positive airway pressure (CPAP) improved outcomes compared with standard low-flow and high-flow oxygen therapies. Methods This open, randomised, controlled trial took place in Dhaka Hospital of the International Centre for Diarrhoeal Disease Research, Bangladesh. We randomly assigned children younger than 5 years with severe pneumonia and hypoxaemia to receive oxygen therapy by either bubble CPAP (5 L/min starting at a CPAP level of 5 cm H2O), standard low-flow nasal cannula (2 L/min), or high-flow nasal cannula (2 L/kg per min up to the maximum of 12 L/min). Randomisation was done with use of the permuted block methods (block size of 15 patients) and Fisher and Yates tables of random permutations. The primary outcome was treatment failure (ie, clinical failure, intubation and mechanical ventilation, death, or termination of hospital stay against medical advice) after more than 1 h of treatment. Primary and safety analyses were by intention to treat. We did two interim analyses and stopped the trial after the second interim analysis on Aug 3, 2013, as directed by the data safety and monitoring board. This trial is registered at ClinicalTrials.gov, number NCT01396759. Findings Between Aug 4, 2011, and July 17, 2013, 225 eligible children were recruited. We randomly allocated 79 (35%) children to receive oxygen therapy by bubble CPAP, 67 (30%) to low-flow oxygen therapy, and 79 (35%) to high-flow oxygen therapy. Treatment failed for 31 (14%) children, of whom five (6%) had received bubble CPAP, 16 (24%) had received low-flow oxygen therapy, and ten (13%) had received high-flow oxygen therapy. Significantly fewer children in the bubble CPAP group had treatment failure than in the low-flow oxygen therapy group (relative risk [RR] 0.27, 99.7% CI 0.07-0.99; p=0.0026). No difference in treatment failure was noted between patients in the bubble CPAP and those in the high-flow oxygen therapy group (RR 0.50, 99.7% 0.11-2.29; p=0.175). 23 (10%) children died. Three (4%) children died in the bubble CPAP group, ten (15%) children died in the low-flow oxygen therapy group, and ten (13%) children died in the high-flow oxygen therapy group. Children who received oxygen by bubble CPAP had significantly lower rates of death than the children who received oxygen by low-flow oxygen therapy (RR 0.25, 95% CI 0.07-0.89; p=0.022). Interpretation Oxygen therapy delivered by bubble CPAP improved outcomes in Bangladeshi children with very severe pneumonia and hypoxaemia compared with standard low-flow oxygen therapy. Use of bubble CPAP oxygen therapy could have a large effect in hospitals in developing countries where the only respiratory support for severe childhood pneumonia and hypoxaemia is low-flow oxygen therapy. The trial was stopped early because of higher mortality in the low-flow oxygen group than in the bubble CPAP group, and we acknowledge that the early cessation of the trial reduces the certainty of the findings. Further research is needed to test the feasibility of scaling up bubble CPAP in district hospitals and to improve bubble CPAP delivery technology.	[Chisti, Mohammod J.; Salam, Mohammed A.; Ahmed, Tahmeed; Shahunja, K. M.; Shahid, Abu S. M. S. B.; Faruque, Abu S. G.; Ashraf, Hasan; Bardhan, Pradip K.; Sharifuzzaman] Int Ctr Diarrhoeal Dis Res Bangladesh Icddr B, Dhaka, Bangladesh; [Chisti, Mohammod J.; Graham, Stephen M.; Duke, Trevor] Univ Melbourne, Ctr Int Child Hlth, Dept Paediat, Murdoch Childrens Res Inst, Melbourne, Vic 3052, Australia; [Chisti, Mohammod J.; Graham, Stephen M.; Duke, Trevor] Royal Childrens Hosp, Intens Care Unit, Melbourne, Vic 3052, Australia; [Smith, Jonathan H.] UCL Inst Child Hlth, Portex Unit Paediat Anaesthesia, London, England; [Pietroni, Mark A. C.] Publ Hlth South Gloucestershire, South Gloucestershire, England; [Graham, Stephen M.] Int Union TB & Lung Dis, Paris, France	International Centre for Diarrhoeal Disease Research (ICDDR); Murdoch Children's Research Institute; University of Melbourne; Royal Children's Hospital Melbourne; University of London; University College London	Duke, T (corresponding author), Univ Melbourne, Ctr Int Child Hlth, Dept Paediat, Murdoch Childrens Res Inst, Melbourne, Vic 3052, Australia.	trevor.duke@rch.org.au	Smith, Jonathan/S-9476-2019; Shahunja, K M/AAR-6229-2020; Chisti, Mohammod J/A-7216-2018	Shahunja, K M/0000-0002-9345-206X; Smith, Jonathan/0000-0002-0295-6773; Graham, Stephen/0000-0003-3525-2294	International Centre for Diarrhoeal Disease Research, Bangladesh; Centre for International Child Health, University of Melbourne; Centre for International Child Health, through a Knowledge Hubs for Health grant from Australian Agency for International Development (AusAID) [Gr 00837]; University of Melbourne; government of Australia; government of Bangladesh; government of Canada; government of Sweden; government of UK	International Centre for Diarrhoeal Disease Research, Bangladesh; Centre for International Child Health, University of Melbourne; Centre for International Child Health, through a Knowledge Hubs for Health grant from Australian Agency for International Development (AusAID); University of Melbourne(University of Melbourne); government of Australia; government of Bangladesh; government of Canada(CGIAR); government of Sweden; government of UK	International Centre for Diarrhoeal Disease Research, Bangladesh, and Centre for International Child Health, University of Melbourne.; This research was partly funded by the Centre for International Child Health, through a Knowledge Hubs for Health grant from Australian Agency for International Development (AusAID; grant number Gr 00837). MJC received a PhD scholarship from University of Melbourne to complete this study. We thank Colin Robertson for support as a member of MJC's PhD Advisory Panel and staff at the Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute for statistical advice. We thank the physicians, clinical fellows, nurses, and members of nutrition team for their contribution during patient enrolment and data collection. We thank the parents of children involved in this study for their generous participation. We thank the governments of Australia, Bangladesh, Canada, Sweden, and the UK for providing core or unrestricted support to the International Centre for Diarrhoeal Disease Research, Bangladesh.	Ahmed T, 2001, LANCET, V353, P1912; BAHL R, 1995, ANN TROP PAEDIATR, V15, P173, DOI 10.1080/02724936.1995.11747768; Banajeh SM, 1997, ANN TROP PAEDIATR, V17, P321, DOI 10.1080/02724936.1997.11747905; Cambonie G, 2008, INTENS CARE MED, V34, P1865, DOI 10.1007/s00134-008-1201-x; Chisti MJ, 2012, TROP MED INT HEALTH, V17, P106, DOI 10.1111/j.1365-3156.2011.02890.x; De Paoli AG, 2003, ARCH DIS CHILD-FETAL, V88, P168; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Duke T, 2002, LANCET, V359, P474, DOI 10.1016/S0140-6736(02)07677-8; Duke T, 2001, INT J TUBERC LUNG D, V5, P511; Duke T, 2008, LANCET, V372, P1328, DOI 10.1016/S0140-6736(08)61164-2; Duke T, 2014, PAEDIATR INT CHILD H, V34, P3, DOI 10.1179/2046905513Y.0000000102; Fisher RA., 1974, STAT TABLES BIOL AGR; Frey B, 2001, EUR J PEDIATR, V160, P556, DOI 10.1007/s004310100798; Graham SM, 2008, B WORLD HEALTH ORGAN, V86, P349, DOI 10.2471/BLT.07.048512; Keenan W, 2013, J PEDIATR-US, V162, P892, DOI 10.1016/j.jpeds.2012.11.075; Lampland AL, 2009, J PEDIATR-US, V154, P177, DOI 10.1016/j.jpeds.2008.07.021; Martin S, 2014, ARCH DIS CHILD-FETAL, V99, pF495, DOI 10.1136/archdischild-2013-305519; McKiernan C, 2010, J PEDIATR-US, V156, P634, DOI 10.1016/j.jpeds.2009.10.039; MISHRA S, 1993, J TROP PEDIATRICS, V39, P288, DOI 10.1093/tropej/39.5.288; Pocock SJ, 1983, CLIN TRIALS PRACTICA, P66; Schibler A, 2011, INTENS CARE MED, V37, P847, DOI 10.1007/s00134-011-2177-5; Sehgal V, 1997, Indian Pediatr, V34, P213; SHANN F, 1985, LANCET, V2, P684; Smyth A, 1997, ARCH DIS CHILD, V77, P227, DOI 10.1136/adc.77.3.227; Spentzas Thomas, 2009, J Intensive Care Med, V24, P323, DOI 10.1177/0885066609340622; Subhi R, 2009, LANCET INFECT DIS, V9, P219, DOI 10.1016/S1473-3099(09)70071-4; ten Brink F, 2013, PEDIATR CRIT CARE ME, V14, pE326, DOI 10.1097/PCC.0b013e31828a894d; Tiewsoh K, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-15; Van den Heuvel M, 2011, ANN TROP PAEDIATR, V31, P59, DOI 10.1179/1465328110Y.0000000001; Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6; Wild M, 2001, BRIT J ANAESTH, V3, P92; Wilson PT, 2013, J PEDIATR-US, V162, P988, DOI 10.1016/j.jpeds.2012.10.022; World Health Organization, 2013, HOSP CAR CHILDR GUID	33	149	158	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 12	2015	386	9998					1057	1065		10.1016/S0140-6736(15)60249-5	http://dx.doi.org/10.1016/S0140-6736(15)60249-5			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CR2VQ	26296950				2023-01-03	WOS:000361189200025
J	Mwangi, MN; Roth, JM; Smit, MR; Trijsburg, L; Mwangi, AM; Demir, AY; Wielders, JPM; Mens, PF; Verweij, JJ; Cox, SE; Prentice, AM; Brouwer, ID; Savelkoul, HFJ; Andang'o, PEA; Verhoef, H				Mwangi, Martin N.; Roth, Johanna M.; Smit, Menno R.; Trijsburg, Laura; Mwangi, Alice M.; Demir, Ayse Y.; Wielders, Jos P. M.; Mens, Petra F.; Verweij, Jaco J.; Cox, Sharon E.; Prentice, Andrew M.; Brouwer, Inge D.; Savelkoul, Huub F. J.; Andang'o, Pauline E. A.; Verhoef, Hans			Effect of Daily Antenatal Iron Supplementation on Plasmodium Infection in Kenyan Women A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIRTH-WEIGHT; MALARIA; PREGNANCY; GESTATION; ANEMIA; MEDICATION; MORTALITY; GROWTH; RISK	IMPORTANCE Anemia affects most pregnant African women and is predominantly due to iron deficiency, but antenatal iron supplementation has uncertain health benefits and can increase the malaria burden. OBJECTIVE To measure the effect of antenatal iron supplementation on maternal Plasmodium infection risk, maternal iron status, and neonatal outcomes. DESIGN, SETTING, AND PARTICIPANTS Randomized placebo-controlled trial conducted October 2011 through April 2013 in a malaria endemic area among 470 rural Kenyan women aged 15 to 45 years with singleton pregnancies, gestational age of 13 to 23 weeks, and hemoglobin concentration of 9 g/dL or greater. All women received 5.7 mg iron/day through flour fortification during intervention, and usual intermittent preventive treatment against malaria was given. INTERVENTIONS Supervised daily supplementation with 60 mg of elemental iron (as ferrous fumarate, n = 237 women) or placebo (n = 233) from randomization until 1 month postpartum. MAIN OUTCOMES AND MEASURES Primary outcome was maternal Plasmodium infection at birth. Predefined secondary outcomes were birth weight and gestational age at delivery, intrauterine growth, and maternal and infant iron status at 1 month after birth. RESULTS Among the 470 participating women, 40 women (22 iron, 18 placebo) were lost to follow-up or excluded at birth; 12 mothers were lost to follow-up postpartum (5 iron, 7 placebo). At baseline, 190 of 318 women (59.7%) were iron-deficient. In intention-to-treat analysis, comparison of women who received iron vs placebo, respectively, yielded the following results at birth: Plasmodium infection risk: 50.9% vs 52.1% (crude difference, -1.2%, 95% CI, -11.8% to 9.5%; P = .83); birth weight: 3202 g vs 3053 g (crude difference, 150 g, 95% CI, 56 to 244; P = .002); birth-weight-for-gestational-age z score: 0.52 vs 0.31 (crude difference, 0.21, 95% CI, -0.11 to 0.52; P = .20); and at 1 month after birth: maternal hemoglobin concentration: 12.89 g/dL vs 11.99 g/dL (crude difference, 0.90 g/dL, 95% CI, 0.61 to 1.19; P < .001); geometric mean maternal plasma ferritin concentration: 32.1 mu g/L vs 14.4 mu g/L (crude difference, 123.4%, 95% CI, 85.5% to 169.1%; P < .001); geometric mean neonatal plasma ferritin concentration: 163.0 mu g/L vs 138.7 mu g/L (crude difference, 17.5%, 95% CI, 2.4% to 34.8%; P = .02). Serious adverse events were reported for 9 and 12 women who received iron and placebo, respectively. There was no evidence that intervention effects on Plasmodium infection risk were modified by intermittent preventive treatment use. CONCLUSIONS AND RELEVANCE Among rural Kenyan women with singleton pregnancies, administration of daily iron supplementation, compared with administration of placebo, resulted in no significant differences in overall maternal Plasmodium infection risk. Iron supplementation led to increased birth weight.	[Mwangi, Martin N.; Roth, Johanna M.; Smit, Menno R.; Trijsburg, Laura; Savelkoul, Huub F. J.; Verhoef, Hans] Wageningen Univ, Cell Biol & Immunol Grp, NL-6700 AH Wageningen, Netherlands; [Mwangi, Martin N.; Andang'o, Pauline E. A.] Maseno Univ, Sch Publ Hlth & Community Dev, Maseno, Kenya; [Roth, Johanna M.; Mens, Petra F.] Royal Trop Inst, KIT Biomed Res, NL-1105 AZ Amsterdam, Netherlands; [Mwangi, Alice M.] Univ Nairobi, Appl Nutr Programme, Nairobi, Kenya; [Demir, Ayse Y.; Wielders, Jos P. M.] Meander Med Ctr, Clin Chem Lab, Amersfoort, Netherlands; [Verweij, Jaco J.] St Elizabeth Hosp, Lab Med Microbiol & Immunol, Tilburg, Netherlands; [Cox, Sharon E.; Prentice, Andrew M.; Verhoef, Hans] London Sch Hyg & Trop Med, MRC Int Nutr Programme, London, England; [Cox, Sharon E.; Prentice, Andrew M.; Verhoef, Hans] MRC, MRC Int Nutr Programme, Keneba, Gambia; [Brouwer, Inge D.] Wageningen Univ, Div Human Nutr, NL-6700 AH Wageningen, Netherlands	Wageningen University & Research; Maseno University; University of Nairobi; Meander Medisch Centrum; Elisabeth-TweeSteden Ziekenhuis (ETZ); University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; Wageningen University & Research	Mwangi, MN (corresponding author), Wageningen Univ, Cell Biol & Immunol Grp, POB 338, NL-6700 AH Wageningen, Netherlands.	mart.mwangi@gmail.com	Cox, Sharon E/ABA-7986-2020; Smit, Menno R./J-7153-2019; Mwangi, Martin/Q-5821-2017; Prentice, Andrew/AAG-1961-2019; Demir, Ayse Yasemin/GPF-7965-2022; Verhoef, Hans/AGD-5388-2022; Savelkoul, Huub FJ/F-6026-2012; Brouwer, Inge D/K-8455-2013; Verhoef, Hans/L-3024-2015	Cox, Sharon E/0000-0002-9908-2936; Smit, Menno R./0000-0003-3405-6638; Verhoef, Hans/0000-0002-9346-9689; Verweij, Jaco J./0000-0001-8553-931X; Brouwer, Inge/0000-0002-2554-7227; Mwangi, Martin/0000-0002-8358-4448	INSTAPA project - European Union [211484]; Medical Research Council [MC_U123292701, MC_U123292699] Funding Source: researchfish; MRC [MC_U123292699, MC_U123292701] Funding Source: UKRI	INSTAPA project - European Union; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the INSTAPA project, which received funding from the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement 211484. Fortitech and Swiss Precision Diagnostics donated fortification premix and urine pregnancy tests, respectively. Laboratory and Allied, Nairobi, prepared supplemental capsules (without financial compensation).	[Anonymous], 1958, IR DEF AN REP STUD G; [Anonymous], 2008, KEN NAT TECHN GUID M; Beaton GH, 2000, AM J CLIN NUTR, V72, p265S, DOI 10.1093/ajcn/72.1.265S; BULMER JN, 1993, HISTOPATHOLOGY, V22, P211, DOI 10.1111/j.1365-2559.1993.tb00110.x; Clark MA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5446; Cogswell ME, 2003, AM J CLIN NUTR, V78, P773, DOI 10.1093/ajcn/78.4.773; Cottrell G, 2006, ACTA TROP, V98, P255, DOI 10.1016/j.actatropica.2006.05.009; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; De Benois B., 2008, WORLDWIDE PREVALENCE; Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X; GALLOWAY R, 1994, SOC SCI MED, V39, P381, DOI 10.1016/0277-9536(94)90135-X; Haider BA, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3443; Kayentao K, 2013, JAMA-J AM MED ASSOC, V309, P594, DOI 10.1001/jama.2012.216231; Kenya National Bureau of Statistics and ICF Macro, 2010, KEN DEM HLTH SURV 20; Mason J., 2001, MICRONUTRIENT REPORT; McCarthy M, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1841; MENENDEZ C, 1994, T ROY SOC TROP MED H, V88, P590, DOI 10.1016/0035-9203(94)90176-7; Mikolajczyk RT, 2011, LANCET, V377, P1855, DOI 10.1016/S0140-6736(11)60364-4; Ministry of Public Health and Sanitation M.o.M.S., 2010, GUID DET REG PROC GE; Moody A, 2002, CLIN MICROBIOL REV, V15, P66, DOI 10.1128/CMR.15.1.66-78.2002; OLIVIERI NF, 1991, ARCH DIS CHILD, V66, P1399, DOI 10.1136/adc.66.12.1399; Oppenheimer SJ, 2001, J NUTR, V131, p616S, DOI 10.1093/jn/131.2.616S; Othoro C, 2006, CLIN VACCINE IMMUNOL, V13, P568, DOI 10.1128/CVI.13.5.568-574.2006; Pena-Rosas JP, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004736.pub4; Pena-Rosas JP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004736.pub3; Prentice AM, 2012, ADV NUTR, V3, P583, DOI 10.3945/an.111.001230; Preziosi P, 1997, AM J CLIN NUTR, V66, P1178, DOI 10.1093/ajcn/66.5.1178; Price C., 2009, 20090049 NCEE US DEP; Sangare L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087743; Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2; Scholl TO, 2011, NUTR REV, V69, pS23, DOI 10.1111/j.1753-4887.2011.00429.x; United Nations Children's Fund and World Health Organization, 2004, LOW BIRTHW COUNTR RE; US Institute of Medicine, 2001, DIET REF INT VIT A V; Veenemans J, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001125; Vucic V, 2013, NUTR REV, V71, P386, DOI 10.1111/nure.12037; World Health Organization, GUID DAIL IR FOL AC; Zeng LX, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2001	37	49	49	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2015	314	10					1009	1020		10.1001/jama.2015.9496	http://dx.doi.org/10.1001/jama.2015.9496			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CQ8FA	26348751	Green Accepted, Bronze			2023-01-03	WOS:000360840700013
J	Hayat, T; Saeed, Y; Alsaedi, A; Asad, S				Hayat, T.; Saeed, Yusra; Alsaedi, A.; Asad, Sadia			Effects of Convective Heat and Mass Transfer in Flow of Powell-Eyring Fluid Past an Exponentially Stretching Sheet	PLOS ONE			English	Article							BOUNDARY-LAYER-FLOW; POROUS-MEDIUM; MIXED CONVECTION; MAXWELL FLUID; SURFACE; PLATE; EQUATIONS; NANOFLUID; SLIP	The aim here is to investigate the effects of convective heat and mass transfer in the flow of Eyring-Powell fluid past an inclined exponential stretching surface. Mathematical formulation and analysis have been performed in the presence of Soret, Dufour and thermal radiation effects. The governing partial differential equations corresponding to the momentum, energy and concentration are reduced to a set of non-linear ordinary differential equations. Resulting nonlinear system is computed for the series solutions. Interval of convergence is determined. Physical interpretation is seen for the embedded parameters of interest. Skin friction coefficient, local Nusselt number and local Sherwood number are numerically computed and examined.	[Hayat, T.; Saeed, Yusra; Asad, Sadia] Quaid I Azam Univ 45320, Dept Math, Islamabad 44000, Pakistan; [Hayat, T.; Alsaedi, A.] King Abdulaziz Univ, Nonlinear Anal & Appl Math NAAM Res Grp, Dept Math, Fac Sci, Jeddah 21589, Saudi Arabia	Quaid I Azam University; King Abdulaziz University	Asad, S (corresponding author), Quaid I Azam Univ 45320, Dept Math, Islamabad 44000, Pakistan.	asadsadia@ymail.com	Alsaedi, Ahmed/A-2094-2013; Hayat, Tasawar/A-3853-2013; Hayat, Tasawar/Y-2524-2019	Alsaedi, Ahmed/0000-0003-3452-8922; 				Abbasbandy S, 2013, QUAEST MATH, V36, P93, DOI 10.2989/16073606.2013.780336; Alsaedi A, 2012, COMMUN NONLINEAR SCI, V17, P4210, DOI 10.1016/j.cnsns.2012.03.008; Auranzaib Shafie S., 2013, J FRANKLIN I, V351, P1268; Awais M, 2014, COMPUT FLUIDS, V91, P21, DOI 10.1016/j.compfluid.2013.12.002; Aziz A, 2009, COMMUN NONLINEAR SCI, V14, P1064, DOI 10.1016/j.cnsns.2008.05.003; CRANE LJ, 1970, Z ANGEW MATH PHYS, V21, P645, DOI 10.1007/BF01587695; Das K, 2011, INT J HEAT MASS TRAN, V54, P3505, DOI 10.1016/j.ijheatmasstransfer.2011.03.035; Das K, 2014, J EGYPTIAN MATH 0627; Hamad MAA, 2012, INT J HEAT MASS TRAN, V55, P1355, DOI 10.1016/j.ijheatmasstransfer.2011.08.043; Hayat T, 2014, CHINESE PHYS B, V23, DOI 10.1088/1674-1056/23/8/084701; Hayat T, 2012, NUCL ENG DES, V252, P242, DOI 10.1016/j.nucengdes.2012.07.012; Hayat T, 2010, COMMUN NONLINEAR SCI, V15, P2375, DOI 10.1016/j.cnsns.2009.09.013; Hayat T, 2010, COMMUN NONLINEAR SCI, V15, P1183, DOI 10.1016/j.cnsns.2009.05.062; Hayat T, 2014, APPL MATH MECH, V35, P1; Joneidi AA, 2010, J TAIWAN INST CHEM E, V41, P35, DOI 10.1016/j.jtice.2009.05.008; Kandasamy R, 2011, NUCL ENG DES, V21, P55; KHANI F, 2012, J KING SAUD UNIV SCI, V24, P123, DOI DOI 10.1016/j.jksus.2010.09.002; Liao SJ, 2010, COMMUN NONLINEAR SCI, V15, P2003, DOI 10.1016/j.cnsns.2009.09.002; Makinde OD, 2011, INT J THERM SCI, V50, P1326, DOI 10.1016/j.ijthermalsci.2011.02.019; Pal D, 2013, APPL MATH COMPUT, V219, P7556, DOI 10.1016/j.amc.2012.10.119; Patil PM, 2014, INT J HEAT MASS TRAN, V70, P313, DOI 10.1016/j.ijheatmasstransfer.2013.11.021; Ramesh GK, 2014, AIN SHAMS ENG J, V5, P991, DOI 10.1016/j.asej.2014.04.003; Rashad AM, 2013, COMPUT FLUIDS, V86, P380, DOI 10.1016/j.compfluid.2013.07.030; Rashidi MM, 2014, AIN SHAMS ENG J, V5, P901, DOI 10.1016/j.asej.2014.02.007; Rostami B, 2014, ABSTR APPL ANAL, DOI 10.1155/2014/496254; Shehzad SA, 2012, INT J HEAT MASS TRAN, V55, P3971, DOI 10.1016/j.ijheatmasstransfer.2012.03.027; Sheikholeslami M, 2014, J COMPUT THEOR NANOS, V11, P486, DOI 10.1166/jctn.2014.3384; Turkyilmazoglu M, 2013, APPL MATH MODEL, V37, P7539, DOI 10.1016/j.apm.2013.02.014; Turkyilmazoglu M, 2011, INT J THERM SCI, V50, P2264, DOI 10.1016/j.ijthermalsci.2011.05.014; Turkyilmazoglu M, 2014, J HEAT TRANS-T ASME, V136, DOI 10.1115/1.4027772	30	15	15	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2015	10	9							e0133831	10.1371/journal.pone.0133831	http://dx.doi.org/10.1371/journal.pone.0133831			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ2NK	26327398	gold, Green Submitted, Green Published			2023-01-03	WOS:000360437700008
J	Bacelo, AC; Ramalho, A; Brasil, PE; Cople-Rodrigues, CD; Georg, I; Paiva, E; Argolo, SVL; Rolla, VC				Bacelo, Adriana Costa; Ramalho, Andrea; Brasil, Pedro Emmanuel; Cople-Rodrigues, Claudia dos Santos; Georg, Ingebourg; Paiva, Eliane; Leandro Argolo, Sheila Vasques; Rolla, Valeria Cavalcante			Nutritional Supplementation Is a Necessary Complement to Dietary Counseling among Tuberculosis and Tuberculosis-HIV Patients	PLOS ONE			English	Article							RISK-FACTOR LEVELS; PULMONARY; DEFICIENCY; INFECTION; EFFICACY; SELENIUM; SUPPORT; HEALTH; ALPHA; INDEX	The Brazilian Ministry of Health and the World Health Organization recommend dietary counseling for patients with malnutrition during tuberculosis treatment. Patients under tuberculosis therapy (infected and not infected with HIV) were followed-up to evaluate the effectiveness of dietary counseling. Objective: describe the nutritional status of patients with tuberculosis. Methods: an observational follow-up study over a 180-day period of tuberculosis therapy in adults was conducted. Subjects were assessed for body composition (using BMI, TSF and MUAC parameters), serum biomarkers and offered dietary counseling. The data obtained at each visit (D15, D30, D60, D90, D120, D150, and D180) were analyzed, showing trajectories over time and central tendencies each time. Results: at baseline, the mean age was 41.1 (+/- 13.4) years; they were predominantly male, with income lower than a local minimum wage and at least six years of schooling. Patients showed predominantly pulmonary tuberculosis. At baseline, all patients suffered from malnutrition. The overall energy malnutrition prevalence was of 70.6%. Anemia at baseline was observed in both groups (63.2%), however, it was significantly more pronounced in the HIV+. At the end, energy malnutrition was reduced to 57.1% (42.9% of HIV- and 71.4% of the HIV+). Micronutrients malnutrition was evident in 71.4% of the HIV-patients and 85.7% of HIV+ patients at the end of tuberculosis therapy. Using BMI (<= 18.5 kg/m(2)cutoff) as an index of malnutrition, it was detected in 23.9% of the HIV- and 27.3% of the HIV+ patients at baseline, with no evident improvement over time; using TSF (<= 11.4mm as cutoff) or MUAC (<= 28.5cm as cutoff), malnutrition was detected in 70.1% and 85.3% of all patients, respectively. Nevertheless, combining all biomarkers, at the end of follow-up, all patients suffered from malnutrition. Conclusion: Although with a limited number of patients, the evidence does not support that dietary counseling is effective to recover from malnutrition in our population.	[Rolla, Valeria Cavalcante] Fiocruz MS, Natl Inst Infect Dis Evandro Chagas, Clin Res Lab Mycobacteria, BR-21045900 Rio De Janeiro, RJ, Brazil; [Bacelo, Adriana Costa] Fiocruz MS, Natl Inst Infect Dis Evandro Chagas, Nutr Serv, BR-21045900 Rio De Janeiro, RJ, Brazil; [Ramalho, Andrea] Univ Fed Rio de Janeiro, Josue de Castro Inst, Rio de Janeiro, RJ, Brazil; [Brasil, Pedro Emmanuel] Fiocruz MS, Natl Inst Infect Dis Evandro Chagas, Clin Reasearch Lab Chagas Dis, BR-21045900 Rio De Janeiro, RJ, Brazil; [Cople-Rodrigues, Claudia dos Santos] Univ Estado Rio De Janeiro, Inst Nutr, Rio De Janeiro, RJ, Brazil; [Georg, Ingebourg] Fiocruz MS, Natl Inst Infect Dis Evandro Chagas, Immunodiagnost Sect, Diagnost Activ Coordinating, BR-21045900 Rio De Janeiro, RJ, Brazil; [Paiva, Eliane] UNISUAM, Dept Nutr, Rio De Janeiro, RJ, Brazil; [Leandro Argolo, Sheila Vasques] Sergio Franco Lab, Caxias, RJ, Brazil	Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz; Universidade do Estado do Rio de Janeiro; Fundacao Oswaldo Cruz; Centro Universitario Augusto Motta (UNISUAM)	Bacelo, AC (corresponding author), Fiocruz MS, Natl Inst Infect Dis Evandro Chagas, Nutr Serv, BR-21045900 Rio De Janeiro, RJ, Brazil.	adriana.bacelo@ini.fiocruz.br	Brasil, Pedro E A A/B-4357-2008; Bacelo, Adriana/G-4336-2015; Rolla, Valeria Cavalcanti/AAI-6078-2021	Brasil, Pedro E A A/0000-0002-6700-2268; Rolla, Valeria Cavalcanti/0000-0002-0841-1408				Al Moamary MS, 2014, ANN THORAC MED, V9, P3, DOI 10.4103/1817-1737.124408; Amin T, 2012, INDIAN HORTIC J, V2, P94; [Anonymous], 2013, STATE OF FOOD AND AG; Armijos RX, 2010, SALUD PUBLICA MEXICO, V52, P185, DOI 10.1590/s0036-36342010000300001; Baeten JM, 2006, J NUTR, V136, P1624, DOI 10.1093/jn/136.6.1624; Baruzzi R G, 2001, Cad Saude Publica, V17, P407, DOI 10.1590/S0102-311X2001000200015; Braveman P, 2011, ANNU REV PUBL HEALTH, V32, P381, DOI 10.1146/annurev-publhealth-031210-101218; Cantalice JP, 2009, J BRAS PNEUMOL, V35, P992, DOI 10.1590/S1806-37132009001000008; Cardoso MC de AF, 2010, SISTEMA ESTOMATOGNAT; Chakraborty R, 2011, RURAL REMOTE HEALTH, V11; Freedman DS, 2013, AM J CLIN NUTR, V98, P1417, DOI 10.3945/ajcn.113.065961; Freedman DS, 2013, BRIT J NUTR, V109, P338, DOI 10.1017/S0007114512000979; Gaikwad SS., 2013, J MED NUTR NUTRACEUT, V2, P99, DOI [10.4103/2278-019X.114721, DOI 10.4103/2278-019X.114721]; Ghone RA, 2013, J CLIN DIAGN RES, V7, P2146, DOI 10.7860/JCDR/2013/6019.3454; Govender A, 2009, INT J ENVIRON AN CH, V89, P367, DOI 10.1080/03067310802627221; Guo CH, 2013, NUTRIENTS, V5, P594, DOI 10.3390/nu5020594; Gupta S, 2011, TROP MED INT HEALTH, V16, P74, DOI 10.1111/j.1365-3156.2010.02676.x; Hsu JW, 2005, MACRONUTRIENTS AND H, P10; Instituto Brasileiro de Geografia e Estatistica, 2010, PESQ ORC FAM 2008 20, P130; Instituto Brasileiro de Geografia e Estatistica, 2010, COORDENACAO DE TRABA; Islam QS, 2013, PUBLIC HEALTH ACTION, V3, P136, DOI 10.5588/pha.13.0005; Kawai K, 2014, EPIDEMIOL INFECT, V142, P1505, DOI 10.1017/S0950268813002495; King DK, 2010, DIABETES CARE, V33, P751, DOI 10.2337/dc09-1746; Klautau Giselle Burlamaqui, 2005, Braz J Infect Dis, V9, P464, DOI 10.1590/S1413-86702005000600004; Lohmann TG, 1988, ANTHROPOMETRIC STAND; Makanjuola T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087166; Maras JE, 2004, J AM DIET ASSOC, V104, P567, DOI 10.1016/j.jada.2004.01.004; Maret W, 2011, BIOMETALS, V24, P411, DOI 10.1007/s10534-010-9406-1; Martins N, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4248; Mehdi Y, 2013, MOLECULES, V18, P3292, DOI 10.3390/molecules18033292; Ministerio da Saude do Brasil, 2014, GUIA ALIMENTAR PARA; Ministerio da Saude do Brasil, 2004, VIGILANCIA ALIMENTAR; Ministerio da Saude do Brasil, 2011, MANUAL DE RECOMENDAC; Ministerio da Saude do Brasil, 2008, RECOMENDACOES PARA T; Ministerio da Saude do Brasil Programa Nacional de Doencas Sexualmente Transmissiveis/AIDS (Brazil), 2006, PROGRAMA NACIONAL DE; Motswagole BS, 2013, ANN NUTR METAB, V62, P323, DOI 10.1159/000346966; NICUS NIC, 2007, TUB TB NUTR TUB TB N, P8; Piva SGN, 2013, J BRAS PNEUMOL, V39, P476, DOI 10.1590/S1806-37132013000400012; Oliveira Claudia Maria Costa de, 2010, Braz. J. Nephrol., V32, P57; Orellana Jesem D. Y., 2006, J. Pediatr. (Rio J.), V82, P383, DOI [10.1590/S0021-75572006000600013, 10.2223/JPED.1528]; Ramalho Rejane Andréa, 2002, Rev Panam Salud Publica, V12, P117, DOI 10.1590/S1020-49892002000800007; Saleem Khan, 2012, Sarhad Journal of Agriculture, V28, P303; Schwenk A, 2004, AM J CLIN NUTR, V79, P1006; Sinclair D, 2011, COCHRANE LIB    1109, P11; Swaminathan S, 2008, CLIN INFECT DIS, V46, P946, DOI 10.1086/528860; Thiam S, 2007, JAMA-J AM MED ASSOC, V297, P380, DOI 10.1001/jama.297.4.380; Thomas C, 2011, INT J LAB HEMATOL, V33, P187, DOI 10.1111/j.1751-553X.2010.01265.x; Villamor E, 2006, EUR J CLIN NUTR, V60, P163, DOI 10.1038/sj.ejcn.1602281; Visser ME, 2011, AM J CLIN NUTR, V93, P93, DOI 10.3945/ajcn.110.001784; Wessels I, 2013, J NUTR BIOCHEM, V24, P289, DOI 10.1016/j.jnutbio.2012.06.007; World Health Organization, 2013, GUIDELINE NUTRITIONA	51	13	14	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2015	10	8							e0134785	10.1371/journal.pone.0134785	http://dx.doi.org/10.1371/journal.pone.0134785			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CP8KZ	26313258	Green Published, Green Submitted, gold			2023-01-03	WOS:000360144000010
J	Baras, AS; Gandhi, N; Munari, E; Faraj, S; Shultz, L; Marchionni, L; Schoenberg, M; Hahn, N; Hoque, M; Berman, D; Bivalacqua, TJ; Netto, G				Baras, Alexander S.; Gandhi, Nilay; Munari, Enrico; Faraj, Sheila; Shultz, Luciana; Marchionni, Luigi; Schoenberg, Mark; Hahn, Noah; Hoque, Mohammad; Berman, David; Bivalacqua, Trinity J.; Netto, George			Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma	PLOS ONE			English	Article							BLADDER-CANCER; GENE-EXPRESSION; PREDICTING RESPONSE; RADICAL CYSTECTOMY; COMBINATION; SUBTYPES	Background The 5-year cancer specific survival (CSS) for patients with muscle invasive urothelial carcinoma of the bladder (MIBC) treated with cystectomy alone is approximately 50%. Platinum based neoadjuvant chemotherapy (NAC) plus cystectomy results in a marginal 5-10% increase in 5-year CSS in MIBC. Interestingly, responders to NAC (<ypT2) have a 5-year CSS of 90% which is in stark contrast to the 30-40% CSS for those whose MIBC is resistance to NAC. While the implementation of NAC for MIBC is increasing, it is still not widely utilized due to concerns related to delay of cystectomy, potential side-effects, and inability to predict effectiveness. Recently suggested molecular signatures of chemoresponsiveness, which could prove useful in this setting, would be of considerable utility but are yet to be translated into clinical practice. Methods mRNA expression data from a prior report on a NAC-treated MIBC cohort were re-analyzed in conjunction with the antibody database of the Human Protein Atlas (HPA) to identify candidate protein based biomarkers detectable by immunohistochemistry (IHC). These candidate biomarkers were subsequently tested in tissue microarrays derived from an independent cohort of NAC naive MIBC biopsy specimens from whom the patients were treated with neoadjuvant gemcitabine cisplatin NAC and subsequent cystectomy. The clinical parameters that have been previously associated with NAC response were also examined in our cohort. Results Our analyses of the available mRNA gene expression data in a discovery cohort (n = 33) and the HPA resulted in 8 candidate protein biomarkers. The combination of GDPD3 and SPRED1 resulted in a multivariate classification tree that was significantly associated with NAC response status (Goodman-Kruskal gamma = 0.85 p<0.0001) in our independent NAC treated MIBC cohort. This model was independent of the clinical factors of age and clinical tumor stage, which have been previously associated with NAC response by our group. The combination of both these protein biomarkers detected by IHC in biopsy specimens along with the relevant clinical parameters resulted in a prediction model able to significantly stratify the likelihood of NAC resistance in our cohort (n = 37) into two well separated halves: low-26% n = 19 and high-89% n = 18, Fisher's exact p = 0.0002). Conclusion We illustrate the feasibility of translating a gene expression signature of NAC response from a discovery cohort into immunohistochemical markers readily applicable to MIBC biopsy specimens in our independent cohort. The results from this study are being characterized in additional validation cohorts. Additionally, we anticipate that emerging somatic mutations in MIBC will also be important for NAC response prediction. The relationship of the findings in this study to the current understanding of variant histologic subtypes of MIBC along with the evolving molecular subtypes of MIBC as it relates to NAC response remains to be fully characterized.	[Baras, Alexander S.; Munari, Enrico; Faraj, Sheila; Shultz, Luciana; Netto, George] Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Baras, Alexander S.; Gandhi, Nilay; Bivalacqua, Trinity J.; Netto, George] Johns Hopkins Sch Med, Dept Urol, Baltimore, MD USA; [Marchionni, Luigi; Hahn, Noah; Bivalacqua, Trinity J.; Netto, George] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD USA; [Schoenberg, Mark] Albert Einstein Coll Med, Dept Urol, Bronx, NY 10467 USA; [Hoque, Mohammad] Johns Hopkins Sch Med, Dept Otolaryngol, Baltimore, MD USA; [Berman, David] Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Yeshiva University; Albert Einstein College of Medicine; Johns Hopkins University; Johns Hopkins Medicine; Queens University - Canada	Baras, AS (corresponding author), Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD 21205 USA.	baras@jhmi.edu; gnetto1@jhmi.edu	Marchionni, Luigi/S-6774-2017; Faraj, Sheila F/I-9725-2016; berman, david/HIR-4177-2022; Munari, Enrico/J-7516-2016	Marchionni, Luigi/0000-0002-7336-8071; Munari, Enrico/0000-0002-3867-6685; Netto, George/0000-0003-3915-9134; Hoque, Mohammad Obaidul/0000-0001-6701-9978; berman, david/0000-0001-5985-3698	Flight Attendant Medical Research Institute; James Buchanan Brady Urological Institute	Flight Attendant Medical Research Institute; James Buchanan Brady Urological Institute	This work was supported by funding provided by the Flight Attendant Medical Research Institute and The James Buchanan Brady Urological Institute.	Advanced Bladder Cancer Overview Collaboration, 2005, COCHRANE DB SYST REV, V18; Amin MB, 2009, MODERN PATHOL, V22, pS96, DOI 10.1038/modpathol.2009.26; Apolo AB, 2014, UROL ONCOL-SEMIN ORI, V32, P637, DOI 10.1016/j.urolonc.2013.12.012; Chang SS, 2003, J UROLOGY, V170, P1085, DOI 10.1097/01.ju.0000086828.26001.ca; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Friedman J., 1998, ANN STAT; Gandhi NM, 2015, UROL ONCOL; George B, 2007, J CLIN ONCOL, V25, P5352, DOI 10.1200/JCO.2006.10.4125; Groenendijk FH, 2015, EUR UROL; Grossman HB, 2003, NEW ENGL J MED, V349, P859, DOI 10.1056/NEJMoa022148; Kato Y, 2011, EXP THER MED, V2, P47, DOI 10.3892/etm.2010.166; KAUFMAN DS, 1993, NEW ENGL J MED, V329, P1377, DOI 10.1056/NEJM199311043291903; Lindgren D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038863; Lindgren D, 2010, CANCER RES, V70, P3463, DOI 10.1158/0008-5472.CAN-09-4213; McConkey DJ, 2010, UROL ONCOL-SEMIN ORI, V28, P429, DOI 10.1016/j.urolonc.2010.04.008; Riester M, 2012, CLIN CANCER RES, V18, P1323, DOI 10.1158/1078-0432.CCR-11-2271; Ross JS, 2013, MOD PATHOL; Sanchez-Ortiz RF, 2003, J UROLOGY, V169, P110, DOI 10.1016/S0022-5347(05)64047-5; Sjodahl G, 2013, AM J PATHOL, V183, P681, DOI 10.1016/j.ajpath.2013.05.013; Sjodahl G, 2012, CLIN CANCER RES, V18, P3377, DOI 10.1158/1078-0432.CCR-12-0077-T; Smith SC, 2011, LANCET ONCOL, V12, P137, DOI 10.1016/S1470-2045(10)70296-5; Stein JP, 2001, J CLIN ONCOL, V19, P666, DOI 10.1200/JCO.2001.19.3.666; Takata R, 2005, CLIN CANCER RES, V11, P2625, DOI 10.1158/1078-0432.CCR-04-1988; Takata R, 2010, AKTUEL UROL, V41, pS41, DOI 10.1055/s-0029-1224655; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Van Allen EM, 2014, CANCER DISCOV, V4, P1140, DOI 10.1158/2159-8290.CD-14-0623; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Williams PD, 2009, CANCER RES, V69, P8302, DOI 10.1158/0008-5472.CAN-09-0798; Zaid HB, 2014, UROLOGY, V83, P75, DOI 10.1016/j.urology.2013.07.072	29	39	40	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2015	10	7							e0131245	10.1371/journal.pone.0131245	http://dx.doi.org/10.1371/journal.pone.0131245			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO0JY	26230923	gold, Green Published, Green Submitted			2023-01-03	WOS:000358838400008
J	Lewinson, RT; Wiley, JP; Humble, RN; Worobets, JT; Stefanyshyn, DJ				Lewinson, Ryan T.; Wiley, J. Preston; Humble, R. Neil; Worobets, Jay T.; Stefanyshyn, Darren J.			Altering Knee Abduction Angular Impulse Using Wedged Insoles for Treatment of Patellofemoral Pain in Runners: A Six-Week Randomized Controlled Trial	PLOS ONE			English	Article							VISUAL ANALOG SCALE; JOINT COORDINATE SYSTEM; FOOT-ORTHOSES; ADDUCTION MOMENT; OSTEOARTHRITIS; KINEMATICS; INJURIES; KINETICS; ORTHOTICS; SEVERITY	Objective Determine if a change in internal knee abduction angular impulse (KAAI) is related to pain reduction for runners with patellofemoral pain (PFP) by comparing lateral and medial wedge insole interventions, and increased KAAI and decreased KAAI groups. Design Randomized controlled clinical trial (ClinicalTrials. gov ID# NCT01332110). Setting Biomechanics laboratory and community. Patients Thirty-six runners with physician-diagnosed PFP enrolled in the trial, and 27 were analyzed. Interventions Runners with PFP were randomly assigned to either an experimental 3 mm lateral wedge or control 6 mm medial wedge group. Participants completed a biomechanical gait analysis to quantify KAAIs with their assigned insole, and then used their assigned insole for six-weeks during their regular runs. Usual pain during running was measured at baseline and at six-week follow-up using a visual analog scale. Statistical tests were performed to identify differences between wedge types, differences between biomechanical response types (i.e. increase or decrease KAAI), as well as predictors of pain reduction. Main Outcome Measures Percent change in KAAI relative to neutral, and % change in pain over six weeks. Results Clinically meaningful reductions in pain (>33%) were measured for both footwear groups; however, no significant differences between footwear groups were found (p = 0.697). When participants were regrouped based on KAAI change (i.e., increase or decrease), again, no significant differences in pain reduction were noted (p = 0.146). Interestingly, when evaluating absolute change in KAAI, a significant relationship between absolute% change in KAAI and % pain reduction was observed (R-2 = 0.21; p = 0.030), after adjusting for baseline pain levels. Conclusion The greater the absolute % change in KAAI during running, the greater the % reduction in pain over six weeks, regardless of wedge type, and whether KAAIs increased or decreased. Lateral and medial wedge insoles were similar in effectiveness for treatment of PFP.	[Lewinson, Ryan T.; Wiley, J. Preston; Worobets, Jay T.; Stefanyshyn, Darren J.] Univ Calgary, Fac Kinesiol, Human Performance Lab, Calgary, AB, Canada; [Lewinson, Ryan T.; Stefanyshyn, Darren J.] Univ Calgary, Schulich Sch Engn, Biomed Engn Program, Calgary, AB, Canada; [Lewinson, Ryan T.; Wiley, J. Preston; Humble, R. Neil] Univ Calgary, Cumming Sch Med, Calgary, AB, Canada; [Wiley, J. Preston] Univ Calgary, Fac Kinesiol, Sport Med Ctr, Calgary, AB, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary	Lewinson, RT (corresponding author), Univ Calgary, Fac Kinesiol, Human Performance Lab, Calgary, AB, Canada.	lewinson@ucalgary.ca		Stefanyshyn, Darren/0000-0001-7180-360X	Canadian Institutes of Health Research; Natural Sciences & Engineering Research Council of Canada CREATE program; Alberta Innovates [201300001] Funding Source: researchfish	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Natural Sciences & Engineering Research Council of Canada CREATE program(Natural Sciences and Engineering Research Council of Canada (NSERC)); Alberta Innovates	This study was funded by graduate student awards for RTL from the Canadian Institutes of Health Research (http://www.cihr-irsc.gc.ca/e/193.html) and the Natural Sciences & Engineering Research Council of Canada CREATE program (http://www.nserc-crsng.gc.ca/index_eng.asp). The funding agencies played no role in study design or analysis.	Barton CJ, 2010, SPORTS MED, V40, P377, DOI 10.2165/11530780-000000000-00000; Barton CJ, 2009, GAIT POSTURE, V30, P405, DOI 10.1016/j.gaitpost.2009.07.109; Bennell KL, 2011, ANN RHEUM DIS, V70, P1770, DOI 10.1136/ard.2010.147082; Boldt AR, 2013, J APPL BIOMECH, V29, P68, DOI 10.1123/jab.29.1.68; Brechter JH, 2002, MED SCI SPORT EXER, V34, P1582, DOI 10.1249/01.MSS.0000035990.28354.c6; Chapman GJ, OSTEOARTHRI IN PRESS; Clauser C. E., 1969, WEIGHT VOLUME CTR MA, P1; Clement D B, 1981, Phys Sportsmed, V9, P47, DOI 10.1080/00913847.1981.11711077; COLE GK, 1993, J BIOMECH ENG-T ASME, V115, P344, DOI 10.1115/1.2895496; Collins N, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1735; Dempster WT., 1955, 55159 WADC WRIGHT PA; ENG JJ, 1993, PHYS THER, V73, P62, DOI 10.1093/ptj/73.2.62; Fisher DS, 2007, J ORTHOP RES, V25, P540, DOI 10.1002/jor.20157; Fukuchi C, 2012, FOOTWEAR SCI, V4, P207, DOI 10.1080/19424280.2012.683044; Fulkerson JP, 2002, AM J SPORT MED, V30, P447, DOI 10.1177/03635465020300032501; GROOD ES, 1983, J BIOMECH ENG-T ASME, V105, P136, DOI 10.1115/1.3138397; Herzog W, 2003, ARTHRIT RHEUM-ARTHR, V49, P239, DOI 10.1002/art.11004; Hinman RS, 2008, ARTHRIT RHEUM-ARTHR, V59, P408, DOI 10.1002/art.23326; Jensen MP, 2003, J PAIN, V4, P407, DOI 10.1016/S1526-5900(03)00716-8; Kelly AM, 2001, EMERG MED J, V18, P205, DOI 10.1136/emj.18.3.205; Lenhart RL, 2014, MED SCI SPORT EXER, V46, P557, DOI 10.1249/MSS.0b013e3182a78c3a; Lewinson RT, 2013, CLIN J SPORT MED, V23, P392, DOI 10.1097/JSM.0b013e31828b0848; Lewinson RT, 2013, P I MECH ENG H, V227, P811, DOI 10.1177/0954411913483431; Lewinson RT, 2013, CLIN J SPORT MED, V23, P208, DOI 10.1097/JSM.0b013e31826b7c83; Lun VMY, 2005, CLIN J SPORT MED, V15, P233; MacLean CL, 2008, CLIN J SPORT MED, V18, P338, DOI 10.1097/MJT.0b013e31815fa75a; MATHESON GO, 1989, MED SCI SPORT EXER, V21, P379; Mundermann A, 2003, CLIN BIOMECH, V18, P254, DOI 10.1016/S0268-0033(02)00186-9; Mundermann A, 2003, MED SCI SPORT EXER, V35, P1710, DOI 10.1249/01.MSS.0000089352.47259.CA; Nigg BM, 2003, MED SCI SPORT EXER, V35, P314, DOI 10.1249/01.MSS.0000048828.02268.79; Nimon G, 1998, J PEDIATR ORTHOPED, V18, P118, DOI 10.1097/00004694-199801000-00021; Park SK, 2011, CLIN BIOMECH, V26, P392, DOI 10.1016/j.clinbiomech.2010.11.015; Radzimski AO, 2012, KNEE, V19, P163, DOI 10.1016/j.knee.2011.05.013; Reeves ND, 2011, NAT REV RHEUMATOL, V7, P113, DOI 10.1038/nrrheum.2010.212; Robertson GE., 2004, RES METHODS BIOMECHA; Sawatsky A, 2012, CLIN BIOMECH, V27, P595, DOI 10.1016/j.clinbiomech.2011.12.011; Schmalz T, 2006, CLIN BIOMECH, V21, P631, DOI 10.1016/j.clinbiomech.2006.02.004; Sharma L, 1998, ARTHRITIS RHEUM, V41, P1233, DOI 10.1002/1529-0131(199807)41:7<1233::AID-ART14>3.0.CO;2-L; Stefanyshyn DJ, 2006, AM J SPORT MED, V34, P1844, DOI 10.1177/0363546506288753; Taunton JE, 2002, BRIT J SPORT MED, V36, P95, DOI 10.1136/bjsm.36.2.95; Thomee R, 1997, PHYS THER, V77, P1690, DOI 10.1093/ptj/77.12.1690; Utting MR, 2005, KNEE, V12, P362, DOI 10.1016/j.knee.2004.12.006; van Gent RN, 2007, BRIT J SPORT MED, V41, P469, DOI 10.1136/bjsm.2006.033548; van Linschoten R, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4074; Winter D.A., 2009, BIOMECHANICS MOTOR C, V4, P176	45	7	7	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2015	10	7							e0134461	10.1371/journal.pone.0134461	http://dx.doi.org/10.1371/journal.pone.0134461			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO0JY	26230399	Green Published, Green Submitted, gold			2023-01-03	WOS:000358838400123
J	Ostermann, JK; Reinhold, T; Witt, CM				Ostermann, Julia K.; Reinhold, Thomas; Witt, Claudia M.			Can Additional Homeopathic Treatment Save Costs? A Retrospective Cost-Analysis Based on 44500 Insured Persons	PLOS ONE			English	Article							COHORT	Objectives The aim of this study was to compare the health care costs for patients using additional homeopathic treatment (homeopathy group) with the costs for those receiving usual care (control group). Methods Cost data provided by a large German statutory health insurance company were retrospectively analysed from the societal perspective (primary outcome) and from the statutory health insurance perspective. Patients in both groups were matched using a propensity score matching procedure based on socio-demographic variables as well as costs, number of hospital stays and sick leave days in the previous 12 months. Total cumulative costs over 18 months were compared between the groups with an analysis of covariance (adjusted for baseline costs) across diagnoses and for six specific diagnoses (depression, migraine, allergic rhinitis, asthma, atopic dermatitis, and headache). Results Data from 44,550 patients (67.3% females) were available for analysis. From the societal perspective, total costs after 18 months were higher in the homeopathy group (adj. mean: EUR 7,207.72 [95% CI 7,001.14-7,414.29]) than in the control group (EUR 5,857.56 [5,650.98-6,064.13]; p<0.0001) with the largest differences between groups for productivity loss (homeopathy EUR 3,698.00 [3,586.48-3,809.53] vs. control EUR 3,092.84 [2,981.31-3,204.37]) and outpatient care costs (homeopathy EUR 1,088.25 [1,073.90-1,102.59] vs. control EUR 867.87 [853.52-882.21]). Group differences decreased over time. For all diagnoses, costs were higher in the homeopathy group than in the control group, although this difference was not always statistically significant. Conclusion Compared with usual care, additional homeopathic treatment was associated with significantly higher costs. These analyses did not confirm previously observed cost savings resulting from the use of homeopathy in the health care system.	[Ostermann, Julia K.; Reinhold, Thomas; Witt, Claudia M.] Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, D-10117 Berlin, Germany; [Witt, Claudia M.] Univ Zurich, Inst Complementary & Integrat Med, Zurich, Switzerland; [Witt, Claudia M.] Univ Zurich Hosp, CH-8091 Zurich, Switzerland; [Witt, Claudia M.] Univ Maryland, Sch Med, Ctr Integrat Med, Baltimore, MD 21201 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Zurich; University of Zurich; University Zurich Hospital; University System of Maryland; University of Maryland Baltimore	Ostermann, JK (corresponding author), Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, D-10117 Berlin, Germany.	julia.ostermann@charite.de	Witt, Claudia M./AAX-2370-2021	Witt, Claudia M./0000-0002-5440-7805; Reinhold, Thomas/0000-0001-5169-7029; Ostermann, Julia/0000-0002-0180-8752	statutory health insurance company Techniker Krankenkasse	statutory health insurance company Techniker Krankenkasse	This is an investigator initiated trial that is co-sponsored by the statutory health insurance company Techniker Krankenkasse. The co-sponsor provided data, but was not involved in the main data analysis, data interpretation, writing, or decision to submit the manuscript. All authors had full access to the data and are responsible for the veracity and completeness of the data reported. All authors had full access to the data in the study and take final responsibility to submit for publication.	AVERILL RF, 1992, HEALTH SERV RES, V27, P587; AVINA RL, 1978, WESTERN J MED, V128, P366; Baars EW, 2014, BMJ OPEN, V4, DOI DOI 10.1136/BMJ0PEN-2014-005332; DZVh&Auml;, 2012, SEL KLASS HOM BET KR; Ernst E, 2002, BRIT J CLIN PHARMACO, V54, P577, DOI 10.1046/j.1365-2125.2002.01699.x; Gesundheitsberichterstattung des Bundes, 2015, ARZT ARZT ZUS WEIT; Institut f&uuml;r Demoskopie, 2014, HOM ARZN 2014 BEK VE; Jain Asha, 2003, Homeopathy, V92, P71, DOI 10.1016/S1475-4916(03)00004-3; Kliems H, 2011, J ALTERN COMPLEM MED, V17, P265, DOI 10.1089/acm.2010.0158; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; MADDOX J, 1988, NATURE, V334, P287, DOI 10.1038/334287a0; Marian F, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-52; Moebus S, 2002, FEDERAL HLTH REPORT; R.C. Team Vienna Austria R.F. f.S. Computing, 2021, R LANG ENV STAT COMP; Reinhold T, 2010, J PUBLIC HEALTH-HEID, V18, P327, DOI 10.1007/s10389-010-0315-0; Roll S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054973; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Smith K, 2012, BIOETHICS, V26, P398, DOI 10.1111/j.1467-8519.2010.01876.x; Statistisches Bundesamt, 2014, JAHR ARB; Studer HP, 2011, FORSCH KOMPLEMENTMED, V18, P315, DOI 10.1159/000334797; Viksveen P, 2014, EUR J HEALTH ECON, V15, P157, DOI 10.1007/s10198-013-0462-7; Witt C, 2005, COMPLEMENT THER MED, V13, P79, DOI 10.1016/j.ctim.2005.03.005; Witt CM, 2009, DERMATOLOGY, V219, P329, DOI 10.1159/000248854; Witt CM, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2158-5-115	24	14	14	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2015	10	7							e0134657	10.1371/journal.pone.0134657	http://dx.doi.org/10.1371/journal.pone.0134657			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO0JY	26230412	Green Accepted, gold, Green Published, Green Submitted			2023-01-03	WOS:000358838400145
J	Rossi, L; Stevens, D; Pierga, JY; Lerebours, F; Reyal, F; Robain, M; Asselain, B; Rouzier, R				Rossi, Lea; Stevens, Denise; Pierga, Jean-Yves; Lerebours, Florence; Reyal, Fabien; Robain, Mathieu; Asselain, Bernard; Rouzier, Roman			Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population	PLOS ONE			English	Article							OLDER WOMEN; EPIDEMIOLOGY; MORTALITY; THERAPY	Background The impact of adjuvant chemotherapy on breast cancer prognosis has been demonstrated in randomized trials, but its impact is unknown in real-world populations. The aim of this study was to evaluate the effect of adjuvant chemotherapy on the survival of breast cancer patients in an unselected population. Methods This prospective cohort study included 32,502 women treated at the Institut Curie between 1981 and 2008 for a first invasive breast cancer without metastasis. The patients were matched based on their propensity score to receive adjuvant chemotherapy. Results The matching generated a subsample of 9,180 patients with an overlapping propensity score. In the group without chemotherapy, the overall survival (OS) rates at 5 and 10 years of follow-up were 87.6% (95% CI [86.7-88.6]) and 75.0% (95% CI [73.6-76.5]), respectively, versus 92.1% (95% CI [91.3-92.9]) and 81.9% (95% CI [80.6-83.2]), respectively, in the chemotherapy group. Distant disease-free survival (DDFS) was significantly improved in the five first years (absolute benefit of 3.5%). In a multivariate analysis, adjuvant chemotherapy was associated with better OS (HR = 0.75, 95% CI [0.69-0.83], p<0.0001) and DDFS (HR = 0.82, 95% CI [0.75-0.90], p<0.0001). Conclusion Adjuvant chemotherapy significantly improves OS and DDFS rates in an unselected population, in accordance with previous results reported by randomized trials.	[Rossi, Lea; Stevens, Denise; Pierga, Jean-Yves; Lerebours, Florence; Reyal, Fabien; Robain, Mathieu; Asselain, Bernard; Rouzier, Roman] Inst Curie, Paris, France; [Rossi, Lea; Rouzier, Roman] Univ Versailles St Quentin, Risk & Safety Clin Med Women & Perinatal Hlth, Equipe Accueil 7285, Montigny Le Bretonneux, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Saclay	Rouzier, R (corresponding author), Inst Curie, Paris, France.	roman.rouzier@curie.fr	Rouzier, Roman/G-2953-2018	Rouzier, Roman/0000-0002-8167-6808	Fondation Curie; Fonds d'etude et de recherche du corps medical (FERCM)	Fondation Curie; Fonds d'etude et de recherche du corps medical (FERCM)	This work was supported by Fondation Curie and Fonds d'etude et de recherche du corps medical (FERCM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Abe O, 1998, LANCET, V352, P930; Albain K, 2012, LANCET, V379, P432, DOI 10.1016/S0140-6736(11)61625-5; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Ban KA, 2014, SURG ONCOL CLIN N AM, V23, P409, DOI 10.1016/j.soc.2014.03.011; Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518; Bosco JLF, 2010, J CLIN EPIDEMIOL, V63, P64, DOI 10.1016/j.jclinepi.2009.03.001; Brookhart M Alan, 2007, Int J Biostat, V3, P14; DRAKE C, 1995, INT J EPIDEMIOL, V24, P183, DOI 10.1093/ije/24.1.183; Elkin EB, 2006, J CLIN ONCOL, V24, P2757, DOI 10.1200/JCO.2005.03.6053; Glynn RJ, 2006, BASIC CLIN PHARMACOL, V98, P253, DOI 10.1111/j.1742-7843.2006.pto_293.x; Hassan MSU, 2010, ONCOL REP, V24, P1121, DOI 10.3892/or_00000963; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; Hery C, 2008, ANN ONCOL, V19, P1009, DOI 10.1093/annonc/mdm593; Kemeny MM, 2003, J CLIN ONCOL, V21, P2268, DOI 10.1200/JCO.2003.09.124; Kwan ML, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2261; Olszewski AJ, 2013, BREAST CANCER RES TR, V138, P215, DOI 10.1007/s10549-013-2423-3; Poole CJ, 2006, NEW ENGL J MED, V355, P1851, DOI 10.1056/NEJMoa052084; Schneider M, 2011, J AM GERIATR SOC, V59, P637, DOI 10.1111/j.1532-5415.2011.03351.x; Sorensen HT, 2006, HEPATOLOGY, V44, P1075, DOI 10.1002/hep.21404; Webb PM, 2004, BREAST, V13, P7, DOI 10.1016/S0960-9776(03)00129-2; Youlden DR, 2012, CANCER EPIDEMIOL, V36, P237, DOI 10.1016/j.canep.2012.02.007	22	34	35	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2015	10	7							e0132853	10.1371/journal.pone.0132853	http://dx.doi.org/10.1371/journal.pone.0132853			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN7DN	26214853	Green Submitted, Green Published, gold			2023-01-03	WOS:000358594300012
J	Liu, RC; Leung, RKK; Chen, TM; Zhang, XX; Chen, FM; Chen, SL; Zhao, J				Liu, Ruchun; Leung, Ross Ka-kit; Chen, Tianmu; Zhang, Xixing; Chen, Faming; Chen, Shuilian; Zhao, Jin			The Effectiveness of Age-Specific Isolation Policies on Epidemics of Influenza A (H1N1) in a Large City in Central South China	PLOS ONE			English	Article							PANDEMIC INFLUENZA; MODELS; TRANSMISSIBILITY; STRATEGIES; INSIGHTS; FUTURE	During the early stage of a pandemic, isolation is the most effective means of controlling transmission. However, the effectiveness of age-specific isolation policies is not clear; especially little information is available concerning their effectiveness in China. Epidemiological and serological survey data in the city of Changsha were employed to estimate key model parameters. The average infectious period (date of recovery - date of symptom onset) of influenza A (H1N1) was 5.2 days. Of all infected persons, 45.93% were asymptomatic. The basic reproduction number of the influenza A (H1N1) pandemic was 1.82. Based on the natural history of influenza A (H1N1), we built an extended susceptible-exposed-infectious/asymptomatic-removed model, taking age groups: 0-5, 6-14, 15-24, 25-59, and >= 60 years into consideration for isolation. Without interventions, the total attack rates (TARs) in each age group were 42.73%, 41.95%, 20.51%, 45.03%, and 37.49%, respectively. Although the isolation of 25-59 years-old persons was the most effective, the TAR of individuals of aged 0-5 and 6-14 could not be reduced. Paradoxically, isolating individuals >= 60 year olds was not predicted to be an effective way of reducing the TAR in this group but isolating the age-group 25-59 did, which implies inter-age-group transmission from the latter to the former is significant. Isolating multiple age groups increased effectiveness. The most effective combined isolation target groups were of 6-14 + 25-59 year olds, 6-14 + 15-24 + 25-59 year olds, and 0-5 + 6-14 + 25-59 + >= 60 year olds. The last of these isolation schemas reduced the TAR of the total population from 39.64% to 0.006%, which was exceptionally close to the effectiveness of isolating all five age groups (TAR = 0.004%).	[Liu, Ruchun; Leung, Ross Ka-kit; Chen, Tianmu; Zhang, Xixing; Chen, Faming; Chen, Shuilian; Zhao, Jin] Changsha Ctr Dis Control & Prevent, Off Dis Control & Emergency Response, Changsha, Hunan, Peoples R China; [Leung, Ross Ka-kit] Chinese Univ Hong Kong, Stanley Ho Ctr Emerging Infect Dis, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong	Chen, TM (corresponding author), Changsha Ctr Dis Control & Prevent, Off Dis Control & Emergency Response, Changsha, Hunan, Peoples R China.	13698665@qq.com			Scientific Research Program of Health Department of Hunan Province [B2012-138]; Scientific Research Program of Changsha Science and Technology Bureau [K1205028-31]	Scientific Research Program of Health Department of Hunan Province; Scientific Research Program of Changsha Science and Technology Bureau	This work was partially supported by the Scientific Research Program of Health Department of Hunan Province (B2012-138, url: http://www.21hospital.com/) and by the Scientific Research Program of Changsha Science and Technology Bureau (K1205028-31, url: http://www.cssti.cn/html/cskjw/index.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arino J, 2006, J R SOC INTERFACE, V3, P453, DOI 10.1098/rsif.2006.0112; Belser JA, 2009, EMERG INFECT DIS, V15, P859, DOI 10.3201/eid1506.090072; Chen SC, 2008, EPIDEMIOL INFECT, V136, P1035, DOI 10.1017/S0950268807009284; Chen TM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095006; CHEN TM, 2011, ZHONGHUA LIU XING BI, V32, P723; Coburn BJ, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-30; Cruz-Pacheco G, 2009, EUROSURVEILLANCE, V14, P1; DIEKMANN O, 1990, J MATH BIOL, V28, P365; Germann TC, 2006, P NATL ACAD SCI USA, V103, P5935, DOI 10.1073/pnas.0601266103; Lee VJ, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-76; Liu DongHui, 2010, Chinese Preventive Medicine, V11, P109; Longini IM, 2004, AM J EPIDEMIOL, V159, P623, DOI 10.1093/aje/kwh092; Longini IM, 2005, SCIENCE, V309, P1083, DOI 10.1126/science.1115717; Mikolajczyk R, 2009, DTSCH ARZTEBL INT, V106, P777, DOI 10.3238/arztebl.2009.0777; National Health and Family Planning Commission of the People's Republic of China, 2011, DIAGN TREATM GUID IN; National Health and Family Planning Commission of the People's Republic of China, 2010, INFL SURV PROGR CHIN; National Health and Family Planning Commission of the People's Republic of China, 2009, DIAGN TREATM PROGR I; National Health and Family Planning Commission of the People's Republic of China, 2012, GUID DISP INFL LIK I; Russell CJ, 2005, CELL, V123, P368, DOI 10.1016/j.cell.2005.10.019; Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979; Tracht SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009018; van den Driessche P, 2002, MATH BIOSCI, V180, P29, DOI 10.1016/S0025-5564(02)00108-6; WHO, 2009, SIT UPD PAND H1N1 20; WHO, PAND H1N1 2009 UPD 1; Wu JT, 2011, EXP BIOL MED, V236, P955, DOI 10.1258/ebm.2010.010271; Yang Y, 2009, SCIENCE, V326, P729, DOI 10.1126/science.1177373; Zhang SG, 2010, INFLUENZA OTHER RESP, V4, P27, DOI 10.1111/j.1750-2659.2009.00117.x	27	17	17	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2015	10	7							e0132588	10.1371/journal.pone.0132588	http://dx.doi.org/10.1371/journal.pone.0132588			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1FD	26161740	gold, Green Published, Green Submitted			2023-01-03	WOS:000358162300156
J	Ban, L; Fleming, KM; Doyle, P; Smeeth, L; Hubbard, RB; Fiaschi, L; Tata, LJ				Ban, Lu; Fleming, Kate M.; Doyle, Pat; Smeeth, Liam; Hubbard, Richard B.; Fiaschi, Linda; Tata, Laila J.			Congenital Anomalies in Children of Mothers Taking Antiepileptic Drugs with and without Periconceptional High Dose Folic Acid Use: A Population-Based Cohort Study	PLOS ONE			English	Article							NEURAL-TUBE DEFECTS; IN-UTERO EXPOSURE; FETAL MALFORMATIONS; PREGNANCY OUTCOMES; UK-EPILEPSY; WOMEN; RISK; ANTAGONISTS; VALPROATE; INFANTS	Background Antenatal antiepileptic drug (AED) use has been found to be associated with increased major congenital anomaly (CA) risks. However whether such AED-associated risks were different according to periconceptional high dose (5mg daily) folic acid supplementation is still unclear. Methods We included 258,591 singleton live-born children ofmothers aged 15-44 years in 1990-2013 from The Health Improvement Network, a large UK primary care database. We identified all major CAs according to the European Surveillance of Congenital Anomalies classification. Absolute risks and adjusted odds ratios (aOR) were calculated comparing children of mothers prescribed AEDs to those without such prescriptions, stratified by folic acid prescriptions around the time of conception (one month before conception to two months post-conception). Results CA risk was 476/10,000 in children of mothers with first trimester AEDs compared with 269/10,000 in those without AEDs equating to an aOR of 1.82, 95% confidence interval 1.30-2.56. The highest system-specific risks were for heart anomalies (198/10,000 and 79/10,000 respectively, aOR 2.49,1.47-4.21). Sodium valproate and lamotrigine were both associated with increased risks of any CA (aOR 2.63,1.46-4.74 and aOR 2.01,1.12-3.59 respectively) and system-specific risks. Stratification by folic acid supplementation did not show marked reductions in AED-associated risks (e.g. for CAs overall aOR 1.75, 1.01-3.03 in the high dose folic acid group and 1.94, 95% CI 1.21-3.13 in the low dose or no folic acid group); however, the majority of mothers taking AEDs only initiated high dose folic acid from the second month of pregnancy. Conclusions Children of mothers with AEDs in the first trimester of pregnancy have a 2-fold increased risk of major CA compared to those unexposed. We found no evidence that prescribed high dose folic acid supplementation reduced such AED-associated risks. Although statistical power was limited, prescribing of folic acid too late for it to be effective during the organogenic period or selective prescribing to those with more severe morbidity may explain these findings.	[Ban, Lu; Fleming, Kate M.; Hubbard, Richard B.; Fiaschi, Linda; Tata, Laila J.] Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG7 2RD, England; [Doyle, Pat; Smeeth, Liam] London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London WC1, England	University of Nottingham; University of London; London School of Hygiene & Tropical Medicine	Tata, LJ (corresponding author), Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG7 2RD, England.	laila.tata@nottingham.ac.uk	Fleming, Kate M/A-6475-2010; Fiaschi, Linda/AAB-4905-2022; Tata, Laila/J-5227-2012; Smeeth, Liam/X-5862-2018	Fleming, Kate M/0000-0002-6572-5016; Fiaschi, Linda/0000-0002-3780-5895; Tata, Laila/0000-0002-6404-8658; Ban, Lu/0000-0001-9388-9141; Smeeth, Liam/0000-0002-9168-6022	Wellcome Trust [86101/Z/08/Z]; Medical Research Council [MR/K006584/1] Funding Source: researchfish; National Institute for Health Research [NF-SI-0510-10090] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	This work was funded by a grant from Wellcome Trust, http://www.wellcome.ac.uk/ (PI: LJT; grant number: 86101/Z/08/Z). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali M, 2012, INVESTIGATING USE ME; [Anonymous], 1991, Lancet, V338, P131, DOI 10.1016/0140-6736(91)90133-A; Ban L, 2015, BJOG-INT J OBSTET GY, V122, P1833, DOI 10.1111/1471-0528.13102; BINOCAR, 2012, CONG AN STAT 2010 EN; Bukowski R, 2011, JAMA-J AM MED ASSOC, V306, P2459, DOI 10.1001/jama.2011.1823; Cassina M, 2013, REPROD TOXICOL, V39, P50, DOI 10.1016/j.reprotox.2013.04.002; Chen YH, 2009, ARCH NEUROL-CHICAGO, V66, P979, DOI 10.1001/archneurol.2009.142; Confidential Enquiry into Maternal and Child Health ( CEMACH), 2009, PER MORT 2007 UK; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; Department of Health, 2011, AB STAT ENGL WAL 201; Diav-Citrin O, 2008, CNS DRUGS, V22, P325, DOI 10.2165/00023210-200822040-00004; EUR-Lex, 2012, CHART FUND RIGHTS EU; European Surveillance of Congenital Anomalies, 2015, EUROCAT PREV TABL; Grosse SD, 2007, BIRTH DEFECTS RES A, V79, P737, DOI 10.1002/bdra.20394; Harden CL, 2009, NEUROLOGY, V73, P133, DOI 10.1212/WNL.0b013e3181a6b312; Hernandez-Diaz S, 2012, NEUROLOGY, V78, P1692, DOI 10.1212/WNL.0b013e3182574f39; Hernandez-Diaz S, 2001, AM J EPIDEMIOL, V153, P961, DOI 10.1093/aje/153.10.961; Hernandez-Diaz S, 2000, NEW ENGL J MED, V343, P1608, DOI 10.1056/NEJM200011303432204; Holmes LB, 2001, NEW ENGL J MED, V344, P1132, DOI 10.1056/NEJM200104123441504; Jentink J, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6581; Jentink J, 2010, PHARMACOEPIDEM DR S, V19, P803, DOI 10.1002/pds.1975; Jentink J, 2010, NEW ENGL J MED, V362, P2185, DOI 10.1056/NEJMoa0907328; Joint Formulary Committee, 2012, BRITISH NATIONAL FOR; Kaaja E, 2003, NEUROLOGY, V60, P575, DOI 10.1212/01.WNL.0000044157.28073.DC; Kulaga S, 2011, SEIZURE-EUR J EPILEP, V20, P667, DOI 10.1016/j.seizure.2011.06.012; LEPPIK IE, 1990, POSTGRAD MED, V88, P253, DOI 10.1080/00325481.1990.11716375; Lewis JD, 2007, PHARMACOEPIDEM DR S, V16, P393, DOI 10.1002/pds.1335; Linnebank M, 2011, ANN NEUROL, V69, P352, DOI 10.1002/ana.22229; Man SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052339; Mawhinney E, 2012, SEIZURE-EUR J EPILEP, V21, P215, DOI 10.1016/j.seizure.2012.01.005; Mawhinney E, 2013, NEUROLOGY, V80, P400, DOI 10.1212/WNL.0b013e31827f0874; Meador K, 2008, EPILEPSY RES, V81, P1, DOI 10.1016/j.eplepsyres.2008.04.022; Molgaard-Nielsen D, 2011, JAMA-J AM MED ASSOC, V305, P1996, DOI 10.1001/jama.2011.624; Morrow J, 2006, J NEUROL NEUROSUR PS, V77, P193, DOI 10.1136/jnnp.2005.074203; Morrow JI, 2009, J NEUROL NEUROSUR PS, V80, P506, DOI 10.1136/jnnp.2008.156109; NICE, 2011, CG62 ANT CAR NICE GU; NICE, CG137 EP FULL GUID; Prajapati B, OPTOMETRY TODAY 0716; QueisserLuft A, 1996, AM J MED GENET, V63, P268, DOI 10.1002/(SICI)1096-8628(19960503)63:1<268::AID-AJMG45>3.0.CO;2-J; Say Lale, 2006, Reprod Health, V3, P1, DOI 10.1186/1742-4755-3-1; Sokal R, 2013, BIRTH DEFECTS RES A, V97, P546, DOI 10.1002/bdra.23150; Thomas SV, 2008, PEDIATR CARDIOL, V29, P604, DOI 10.1007/s00246-007-9161-4; Tomson T, 2011, LANCET NEUROL, V10, P609, DOI 10.1016/S1474-4422(11)70107-7; Vajda FJE, 2006, EUR J NEUROL, V13, P645, DOI 10.1111/j.1468-1331.2006.01359.x; Vajda FJ, 2013, NEUROLOGY, V81, P999, DOI 10.1212/WNL.0b013e3182a43e81; van Gelder MMHJ, 2010, HUM REPROD UPDATE, V16, P378, DOI 10.1093/humupd/dmp052; Wallace H, 1998, LANCET, V352, P1970, DOI 10.1016/S0140-6736(98)04512-7; World Health Organization(WHO), BMI CLASS	48	28	30	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2015	10	7							e0131130	10.1371/journal.pone.0131130	http://dx.doi.org/10.1371/journal.pone.0131130			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1DQ	26147467	Green Submitted, Green Accepted, Green Published, gold			2023-01-03	WOS:000358157600065
J	Xu, JL; Jin, B; Ren, ZH; Lou, YQ; Zhou, ZR; Yang, QZ; Han, BH				Xu, J. L.; Jin, B.; Ren, Z. H.; Lou, Y. Q.; Zhou, Z. R.; Yang, Q. Z.; Han, B. H.			Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis	PLOS ONE			English	Article							GROWTH-FACTOR RECEPTOR; RANDOMIZED PHASE-II; 1ST-LINE TREATMENT; 2ND-LINE TREATMENT; OPEN-LABEL; COMBINATION; TRIAL; GEMCITABINE; MULTICENTER; CARBOPLATIN	Background Whether a combination of chemotherapy and erlotinib is beneficial for advanced non-small cell lung cancer (NSCLC) remains controversial. This study aimed to summarize the currently available evidence and compare the efficacy and safety of chemotherapy plus erlotinib versus chemotherapy alone for treating advanced NSCLC. Methods EMBASE, PubMed, and the Cochrane Central Register of Controlled Trials were searched for relevant studies. Our protocol was registered in PROSPERO (CRD42014015015). Results Nine randomized controlled trials with a total of 3599 patients were included. Compared to chemotherapy alone, chemotherapy plus erlotinib was superior in PFS (HR = 0.76 [95% CI 0.62, 0.92], P = 0.006), and no statistically significant difference was observed in OS (HR = 0.94 [95% CI 0.86, 1.03], P = 0.16). Intercalated erlotinib plus chemotherapy demonstrated improvements in PFS (HR = 0.67 [95% CI 0.50, 0.91], P = 0.009) and OS (HR = 0.82 [95% CI 0.69, 0.98], P = 0.03). Continuous erlotinib plus chemotherapy treatment failed to demonstrate improvements in PFS (HR = 0.91 [95% CI 0.80, 1.04], P = 0.16) and OS (HR = 0.98 [95% CI 0.89, 1.09], P = 0.75). The association of chemotherapy plus erlotinib with improvement in PFS was significant in never smoking patients (HR = 0.46 [95% CI 0.37, 0.56], P < 0.00001) but not in smoking patients (HR = 0.70 [95% CI 0.49, 1.00], P = 0.05). Among patients with EGFR mutant tumors, chemotherapy plus erlotinib demonstrated significant improvements in PFS (HR = 0.31 [95% CI 0.17, 0.58], P = 0.0002) and OS (HR = 0.52 [95% CI 0.30, 0.88], P = 0.01). Among patients with EGFR wild-type tumors, no statistically significant difference was observed with respect to PFS (HR = 0.87 [95% CI 0.70, 1.08], P = 0.21) and OS (HR = 0.78 [95% CI 0.59, 1.01], P = 0.06). Conclusion Combination of chemotherapy and erlotinib is a viable treatment option for patients with NSCLC, especially for patients who never smoked and patients with EGFR mutation-positive disease. In addition, intercalated administration is an effective combinatorial strategy.	[Xu, J. L.; Jin, B.; Lou, Y. Q.; Han, B. H.] Shanghai Jiao Tong Univ, Dept Pulm, Shanghai Chest Hosp, Shanghai 200030, Peoples R China; [Jin, B.] Shanghai Jiao Tong Univ, Ninth Peoples Hosp Shanghai, Shanghai 200030, Peoples R China; [Zhou, Z. R.] Fudan Univ, Dept Oncol, Shanghai Canc Ctr, Shanghai Med Coll, Shanghai 200433, Peoples R China; [Yang, Q. Z.] Women & Child Care Heyuan, Dept Gynecol, Guangzhou, Guangdong, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Fudan University	Han, BH (corresponding author), Shanghai Jiao Tong Univ, Dept Pulm, Shanghai Chest Hosp, Shanghai 200030, Peoples R China.	xkyyhan@gmail.com			Key projects of Biomedicine Department, Science and Technology Commission of Shanghai Municipality [11411951200]	Key projects of Biomedicine Department, Science and Technology Commission of Shanghai Municipality	The study was supported by Key projects of Biomedicine Department, Science and Technology Commission of Shanghai Municipality (Project No11411951200). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aerts JG, 2013, ANN ONCOL, V24, P2860, DOI 10.1093/annonc/mdt341; Ahn MJ, 2010, J THORAC ONCOL, V5, P1185, DOI 10.1097/JTO.0b013e3181e2f624; Auliac JB, 2014, LUNG CANCER, V85, P415, DOI 10.1016/j.lungcan.2014.07.006; Boutsikou E, 2013, ONCOTARGETS THER, V6, P125, DOI 10.2147/OTT.S42245; Cataldo VD, 2011, NEW ENGL J MED, V364, P947, DOI 10.1056/NEJMct0807960; Dittrich C, 2014, EUR J CANCER, V50, P1571, DOI 10.1016/j.ejca.2014.03.007; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Feld R, 2006, J THORAC ONCOL, V1, P367, DOI 10.1097/01243894-200605000-00018; Gatzemeier U, 2007, J CLIN ONCOL, V25, P1545, DOI 10.1200/JCO.2005.05.1474; Herbst RS, 2005, J CLIN ONCOL, V23, P5892, DOI 10.1200/JCO.2005.02.840; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Lee DH, 2013, EUR J CANCER, V49, P3111, DOI 10.1016/j.ejca.2013.06.035; Li T, 2013, J CLIN ONCOL, P31; Li TH, 2007, CLIN CANCER RES, V13, P3413, DOI 10.1158/1078-0432.CCR-06-2923; Michael M, 2014, ASIA PAC J CLIN ONCO; Minami S, 2013, LUNG CANCER, V82, P271, DOI 10.1016/j.lungcan.2013.07.022; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Mok TSK, 2009, J CLIN ONCOL, V27, P5080, DOI 10.1200/JCO.2008.21.5541; Qi WX, 2012, ASIAN PAC J CANCER P, V13, P5177, DOI 10.7314/APJCP.2012.13.10.5177; Reck M, 2014, ANN ONCOL, V25, P27, DOI 10.1093/annonc/mdu199; Rossi A, 2014, LANCET ONCOL, V15, P1254, DOI 10.1016/S1470-2045(14)70402-4; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Stinchcombe TE, 2013, J THORAC ONCOL, V8, P443, DOI 10.1097/JTO.0b013e3182835577; Stinchcombe TE, 2011, J THORAC ONCOL, V6, P1569, DOI 10.1097/JTO.0b013e3182210430; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Wu YL, 2013, LANCET ONCOL, V14, P777, DOI 10.1016/S1470-2045(13)70254-7; Xu J, 2014, PROSPERO; Zhang WS, 2014, DRUG DES DEV THER, V8, P735, DOI 10.2147/DDDT.S60672; Zheng YL, 2013, LANCET ONCOL, V14, pE438, DOI 10.1016/S1470-2045(13)70412-1; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X; Zhou JG, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0471-0; Zwitter M, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/185646	33	10	12	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2015	10	7							e0131278	10.1371/journal.pone.0131278	http://dx.doi.org/10.1371/journal.pone.0131278			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1DQ	26147288	gold, Green Published, Green Submitted			2023-01-03	WOS:000358157600081
J	Wilky, BA; Kim, C; McCarty, G; Montgomery, EA; Kammers, K; DeVine, LR; Cole, RN; Raman, V; Loeb, DM				Wilky, B. A.; Kim, C.; McCarty, G.; Montgomery, E. A.; Kammers, K.; DeVine, L. R.; Cole, R. N.; Raman, V.; Loeb, D. M.			RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma	ONCOGENE			English	Article							CELL-GROWTH; PROTEIN; TRANSLATION; TUMOR; RESISTANCE; STRATEGY; SURVIVAL; FUSION	RNA helicase DDX3 has oncogenic activity in breast and lung cancers and is required for translation of complex mRNA transcripts, including those encoding key cell-cycle regulatory proteins. We sought to determine the expression and function of DDX3 in sarcoma cells, and to investigate the antitumor activity of a novel small molecule DDX3 inhibitor, RK-33. Utilizing various sarcoma cell lines, xenografts and human tissue microarrays, we measured DDX3 expression at the mRNA and protein levels, and evaluated cytotoxicity of RK-33 in sarcoma cell lines. To study the role of DDX3 in Ewing sarcoma, we generated stable DDX3-knockdown Ewing sarcoma cell lines using DDX3-specific small hairpin RNA (shRNA), and assessed oncogenic activity. DDX3-knockdown and RK-33-treated Ewing sarcoma cells were compared with wild-type cells using an isobaric mass-tag quantitative proteomics approach to identify target proteins impacted by DDX3 inhibition. Overall, we found high expression of DDX3 in numerous human sarcoma subtypes compared with non-malignant mesenchymal cells, and knockdown of DDX3 by RNA interference inhibited oncogenic activity in Ewing sarcoma cells. Treatment with RK-33 was preferentially cytotoxic to sarcoma cells, including chemotherapy-resistant Ewing sarcoma stem cells, while sparing non-malignant cells. Sensitivity to RK-33 correlated with DDX3 protein expression. Growth of human Ewing sarcoma xenografts expressing high DDX3 was inhibited by RK-33 treatment in mice, without overt toxicity. DDX3 inhibition altered the Ewing sarcoma cellular proteome, especially proteins involved in DNA replication, mRNA translation and proteasome function. These data support further investigation of the role of DDX3 in sarcomas, advancement of RK-33 to Ewing sarcoma clinical trials and development of RNA helicase inhibition as a novel anti-neoplastic strategy.	[Wilky, B. A.; Kim, C.; McCarty, G.; Raman, V.; Loeb, D. M.] Johns Hopkins Univ, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; [Montgomery, E. A.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA; [Kammers, K.] Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [DeVine, L. R.; Cole, R. N.] Johns Hopkins Univ, Dept Biol Chem, Baltimore, MD USA; [Raman, V.] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University	Wilky, BA (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, 1120 NW 14th St,Suite 610E, Miami, FL 33136 USA.	b.wilky@med.miami.edu		Wilky, Breelyn/0000-0001-5080-497X	NIH [R01 CA138212, T32 CA009071-31, P30 CA006973, HHSN268201000032C]; Alex's Lemonade Stand Foundation, LLC; Conquer Cancer Foundation/ASCO Young Investigator Award - WWWW Foundation, Inc. (QuadW); Giant Food Children's Cancer Research Fund; Heather Brooke Foundation; German Research Foundation [KA 3884/1-1]; Flight Attendant Medical Research Institute (FAMRI); Alpha Omega Alpha Postgraduate Award; NATIONAL CANCER INSTITUTE [R01CA138212, P30CA006973, T32CA009071] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alex's Lemonade Stand Foundation, LLC; Conquer Cancer Foundation/ASCO Young Investigator Award - WWWW Foundation, Inc. (QuadW); Giant Food Children's Cancer Research Fund; Heather Brooke Foundation; German Research Foundation(German Research Foundation (DFG)); Flight Attendant Medical Research Institute (FAMRI); Alpha Omega Alpha Postgraduate Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors wish to thank Jeffrey Toretsky (Georgetown University), Jonathan Powell (JHU), Lee Helman (NIH), Chand Khanna (Pediatric Oncology Branch NCI) and Nita Ahuja (JHU) for providing cell lines and xenografts. They also credit Richard Jones, MD, Milada Vala and Gabriel Ghaiur, MD, PhD (JHU) for assistance with hematopoietic stem cells experiments; Hao Zhang, PhD (JHU) for assistance with flow cytometry; and Enrico Capobianco at the Center for Computational Analysis at the University of Miami for assistance with STRING networking. This work was supported by grants from the NIH (R01 CA138212 (DL),T32 CA009071-31 (BW), P30 CA006973 and HHSN268201000032C) (RC); a 2013 Reach Award from Alex's Lemonade Stand Foundation, LLC (DL); a Conquer Cancer Foundation/ASCO 2012 Young Investigator Award sponsored by WWWW Foundation, Inc. (QuadW) (BW); additional funding provided from the Giant Food Children's Cancer Research Fund (DL), the Heather Brooke Foundation (DL), German Research Foundation (KA 3884/1-1) (KK), Flight Attendant Medical Research Institute (FAMRI) (VR), and a 2012 Alpha Omega Alpha Postgraduate Award (BW).	Abdelhaleem M, 2004, BBA-REV CANCER, V1704, P37, DOI 10.1016/j.bbcan.2004.05.001; Awad O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013943; Bol GM, 2012, CANC RES CHICAGO IL; Bol GM, 2015, EMBO MOL MED, V7, P648, DOI 10.15252/emmm.201404368; Bol GM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063548; Botlagunta M, 2008, ONCOGENE, V27, P3912, DOI 10.1038/onc.2008.33; Chang PC, 2006, ONCOGENE, V25, P1991, DOI 10.1038/sj.onc.1209239; Erkizan HV, 2009, NAT MED, V15, P750, DOI 10.1038/nm.1983; Fukumura J, 2003, J BIOCHEM, V134, P71, DOI 10.1093/jb/mvg126; Garbelli A, 2011, CURR MED CHEM, V18, P3015, DOI 10.2174/092986711796391688; Geissler R, 2012, NUCLEIC ACIDS RES, V40, P4998, DOI 10.1093/nar/gks070; Gonzalez-Nieto D, 2012, BLOOD, V119, P5144, DOI 10.1182/blood-2011-07-368506; HAZELTON BJ, 1987, CANCER RES, V47, P4501; Herbrich SM, 2013, J PROTEOME RES, V12, P594, DOI 10.1021/pr300624g; Italiano A, 2012, GENE CHROMOSOME CANC, V51, P207, DOI 10.1002/gcc.20945; Italiano A, 2011, CANCER-AM CANCER SOC, V117, P1049, DOI 10.1002/cncr.25538; Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760; Kirsch DG, 2007, NAT MED, V13, P992, DOI 10.1038/nm1602; Kondaskar A, 2011, ACS MED CHEM LETT, V2, P252, DOI 10.1021/ml100281b; Lai MC, 2008, MOL BIOL CELL, V19, P3847, DOI 10.1091/mbc.E07-12-1264; Lai MC, 2010, MOL CELL BIOL, V30, P5444, DOI 10.1128/MCB.00560-10; Lee CS, 2008, NUCLEIC ACIDS RES, V36, P4708, DOI 10.1093/nar/gkn454; Miao XY, 2013, INT J CLIN EXP PATHO, V6, P179; NYGREN P, 1991, INT J CANCER, V48, P598, DOI 10.1002/ijc.2910480419; Pierce A, 2008, MOL CELL PROTEOMICS, V7, P853, DOI 10.1074/mcp.M700251-MCP200; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200; Shih JW, 2008, ONCOGENE, V27, P700, DOI 10.1038/sj.onc.1210687; Sison EAR, 2013, BRIT J HAEMATOL, V160, P785, DOI 10.1111/bjh.12205; Smyth GK., 2004, STAT APPL GENET MOL, V3, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Soto-Rifo R, 2012, EMBO J, V31, P3745, DOI 10.1038/emboj.2012.220; Specht K, 2014, GENE CHROMOSOME CANC, V53, P622, DOI 10.1002/gcc.22172; Sun M, 2008, CELL DEATH DIFFER, V15, P1887, DOI 10.1038/cdd.2008.124; Sun MN, 2013, BBA-MOL CELL RES, V1833, P1489, DOI 10.1016/j.bbamcr.2013.02.026; Sun MN, 2011, BBA-MOL CELL RES, V1813, P438, DOI 10.1016/j.bbamcr.2011.01.003; Toretsky JA, 2006, CANCER RES, V66, P5574, DOI 10.1158/0008-5472.CAN-05-3293; Velikodvorskaya T, 2010, CANCER RES, V70, P663; Wang YX, 2011, PROTEOMICS, V11, P2019, DOI 10.1002/pmic.201000722; Wu DW, 2014, ONCOGENE, V33, P1515, DOI 10.1038/onc.2013.107	39	39	40	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2574	2583		10.1038/onc.2015.336	http://dx.doi.org/10.1038/onc.2015.336			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26364611				2023-01-03	WOS:000376165700004
J	Vodonos, A; Friger, M; Katra, I; Krasnov, H; Zahger, D; Schwartz, J; Novack, V				Vodonos, Alina; Friger, Michael; Katra, Itzhak; Krasnov, Helena; Zahger, Doron; Schwartz, Joel; Novack, Victor			Individual Effect Modifiers of Dust Exposure Effect on Cardiovascular Morbidity	PLOS ONE			English	Article							PARTICULATE AIR-POLLUTION; CASE-CROSSOVER DESIGN; SAHARAN DUST; HOSPITAL ADMISSIONS; MEASUREMENT ERROR; DESERT DUST; DISEASE; MORTALITY; RISK; ASSOCIATION	Background High concentrations of particulate matter (PM) air pollution have been associated with death and hospital admissions due to cardiovascular morbidity. However, it is not clear a) whether high levels of non-anthropogenic PM from dust storms constitute a health risk; and b) whether these health risks are exacerbated in a particular demographic. Methods This study comprised all patients above 18 years old admitted to Soroka University Medical Center (1000 bed tertiary hospital, Be'er-Sheva, Israel, 2001-2010) with a primary diagnosis of acute coronary syndrome (ACS). Data on meteorological parameters and PM10 (particulate matter < 10 mu m in aerodiameter) were obtained from monitoring stations in the city of Be'er-Sheva. Data were analyzed using a case crossover analysis to examine the effect of dust exposure on hospitalization due to ACS and the interaction with co-morbidities and demographic factors. Results There were 16,734 hospitalizations due to ACS during the study period. The estimated odds of hospitalization due to ACS was significantly associated with PM10 during non dust storm days at the same day of the exposure (lag0); OR = 1.014 (95% CI 1.001-1.027) for a 10 mu g/m(3) increase, while a delayed response (lag1) was found during the dust storm days; OR = 1.007 (95% CI 1.002-1.012). The effect size for the dust exposure association was larger for older (above the age of 65), female or Bedouin patients. Conclusions Exposure to non-anthropogenic PM is associated with cardiovascular morbidity. Health risk associated dust exposure is gender and age specific with older women and Bedouin patients being the most vulnerable groups.	[Vodonos, Alina; Friger, Michael] Ben Gurion Univ Negev, Dept Publ Hlth, IL-84105 Beer Sheva, Israel; [Vodonos, Alina; Novack, Victor] Soroka Univ, Med Ctr, Clin Res Ctr, Beer Sheva, Israel; [Katra, Itzhak; Krasnov, Helena] Ben Gurion Univ Negev, Dept Geog & Environm Dev, IL-84105 Beer Sheva, Israel; [Zahger, Doron] Soroka Univ, Med Ctr, Dept Cardiol, Intens Cardiac Care Unit, Beer Sheva, Israel; [Schwartz, Joel] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA	Ben Gurion University; Ben Gurion University; Soroka Medical Center; Ben Gurion University; Ben Gurion University; Soroka Medical Center; Harvard University; Harvard T.H. Chan School of Public Health	Novack, V (corresponding author), Soroka Univ, Med Ctr, Clin Res Ctr, Beer Sheva, Israel.	victorno@clalit.org.il	KATRA, ITZHAK/F-1547-2012		Israeli Environment and Health Fund (EHF) [RGA 1004]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER	Israeli Environment and Health Fund (EHF); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by the Israeli Environment and Health Fund (EHF) Grant # RGA 1004. IK received the funding (http://www.ehf.org.il/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alessandrini ER, 2013, OCCUP ENVIRON MED, V70, P432, DOI 10.1136/oemed-2012-101182; Alpert P, 2004, INT J CLIMATOL, V24, P1013, DOI 10.1002/joc.1037; Bateson TF, 1999, EPIDEMIOLOGY, V10, P539, DOI 10.1097/00001648-199909000-00013; Bateson TF, 2004, EPIDEMIOLOGY, V15, P143, DOI 10.1097/01.ede.0000112210.68754.fa; Brook RD, 2004, CIRCULATION, V109, P2655, DOI 10.1161/01.CIR.0000128587.30041.C8; BURNETT RT, 1995, AM J EPIDEMIOL, V142, P15, DOI 10.1093/oxfordjournals.aje.a117540; Cadelis G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091136; Chen LH, 2005, ENVIRON HEALTH PERSP, V113, P1723, DOI 10.1289/ehp.8190; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Ganor E, 2010, J GEOPHYS RES-ATMOS, V115, DOI 10.1029/2009JD012638; Ganor E, 2010, J GEOPHYS RES-ATMOS, V115, DOI 10.1029/2009JD012500; Goldberg MS, 2001, ENVIRON HEALTH PERSP, V109, P487, DOI 10.2307/3454658; Jimenez E, 2010, SCIENCE OF THE TOTAL; KANNEL WB, 1976, ANN INTERN MED, V85, P447, DOI 10.7326/0003-4819-85-4-447; Krasnov H, 2015, BUILD ENVIRON, V87, P169, DOI 10.1016/j.buildenv.2015.01.035; Krasnov H, 2014, J AIR WASTE MANAGE, V64, P89, DOI 10.1080/10962247.2013.841599; Kwan M.-P., 2004, SPAT INTEGR SOC SCI, V27, P721; Lepeule J, 2012, ENVIRON HEALTH PERSP, V120, P965, DOI 10.1289/ehp.1104660; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Lumley T, 2000, ENVIRONMETRICS, V11, P689, DOI 10.1002/1099-095X(200011/12)11:6<689::AID-ENV439>3.0.CO;2-N; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; Middleton N, 2008, ENV HLTH, V22, P7; Novack V, 2007, ETHNIC DIS, V17, P441; Perez L, 2008, EPIDEMIOLOGY, V19, P800, DOI 10.1097/EDE.0b013e31818131cf; Peters A, 2001, CIRCULATION, V103, P2810; Pope CA, 2006, J AIR WASTE MANAGE, V56, P709, DOI 10.1080/10473289.2006.10464545; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Reyes M, 2014, INT J ENVIRON HEAL R, V24, P63, DOI 10.1080/09603123.2013.782604; Sajani SZ, 2011, OCCUP ENVIRON MED, V68, P446, DOI 10.1136/oem.2010.058156; Samoli E, 2011, SCI TOTAL ENVIRON, V409, P2049, DOI 10.1016/j.scitotenv.2011.02.031; Sandstrom T, 2008, EPIDEMIOLOGY, V19, P808, DOI 10.1097/EDE.0b013e31818809e0; Schwartz J, 1997, EPIDEMIOLOGY, V8, P371, DOI 10.1097/00001648-199707000-00004; Shao YP, 2011, AEOLIAN RES, V2, P181, DOI 10.1016/j.aeolia.2011.02.001; Sunyer J, 2000, AM J EPIDEMIOL, V151, P50, DOI 10.1093/oxfordjournals.aje.a010121; Suwa T, 2002, J AM COLL CARDIOL, V39, P935, DOI 10.1016/S0735-1097(02)01715-1; THOMAS D, 1993, ANNU REV PUBL HEALTH, V14, P69, DOI 10.1146/annurev.pu.14.050193.000441; Vodonos A, 2014, AIR QUAL ATMOS HLTH, V7, P433, DOI 10.1007/s11869-014-0253-z; WHO (World Health Organization), 2006, INDIAN J MED RES; Yitshak-Sade M, 2015, EUR RESPIR J, V45, P652, DOI 10.1183/09031936.00078614; Zanobetti A, 2000, ENVIRON HEALTH PERSP, V108, P841, DOI 10.2307/3434991; Zanobetti A, 2005, ENVIRON HEALTH PERSP, V113, P978, DOI 10.1289/ehp.7550; Zanobetti A, 2000, J OCCUP ENVIRON MED, V42, P469, DOI 10.1097/00043764-200005000-00002; Zeger SL, 2000, ENVIRON HEALTH PERSP, V108, P419, DOI 10.2307/3454382	43	42	42	4	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2015	10	9							e0137714	10.1371/journal.pone.0137714	http://dx.doi.org/10.1371/journal.pone.0137714			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS0ZE	26381397	Green Published, Green Submitted, gold			2023-01-03	WOS:000361790200033
J	van Mol, MMC; Kompanje, EJO; Benoit, DD; Bakker, J; Nijkamp, MD				van Mol, Margo M. C.; Kompanje, Erwin J. O.; Benoit, Dominique D.; Bakker, Jan; Nijkamp, Marjan D.			The Prevalence of Compassion Fatigue and Burnout among Healthcare Professionals in Intensive Care Units: A Systematic Review	PLOS ONE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; SECONDARY TRAUMATIC STRESS; JOB-SATISFACTION; NURSES WORKING; EMOTIONAL INTELLIGENCE; MORAL DISTRESS; SELF-CARE; PHYSICIANS; INTERVENTION; OUTCOMES	Background Working in the stressful environment of the Intensive Care Unit (ICU) is an emotionally charged challenge that might affect the emotional stability of medical staff. The quality of care for ICU patients and their relatives might be threatened through long-term absenteeism or a brain and skill drain if the healthcare professionals leave their jobs prematurely in order to preserve their own health. Purpose The purpose of this review is to evaluate the literature related to emotional distress among healthcare professionals in the ICU, with an emphasis on the prevalence of burnout and compassion fatigue and the available preventive strategies. Methods A systematic literature review was conducted, using Embase, Medline OvidSP, Cinahl, Web-of-science, PsychINFO, PubMed publisher, Cochrane and Google Scholar for articles published between 1992 and June, 2014. Studies reporting the prevalence of burnout, compassion fatigue, secondary traumatic stress and vicarious trauma in ICU healthcare professionals were included, as well as related intervention studies. Results Forty of the 1623 identified publications, which included 14,770 respondents, met the selection criteria. Two studies reported the prevalence of compassion fatigue as 7.3% and 40%; five studies described the prevalence of secondary traumatic stress ranging from 0% to 38.5%. The reported prevalence of burnout in the ICU varied from 0% to 70.1%. A wide range of intervention strategies emerged from the recent literature search, such as different intensivist work schedules, educational programs on coping with emotional distress, improving communication skills, and relaxation methods. Conclusions The true prevalence of burnout, compassion fatigue, secondary traumatic stress and vicarious trauma in ICU healthcare professionals remains open for discussion. A thorough exploration of emotional distress in relation to communication skills, ethical rounds, and mindfulness might provide an appropriate starting point for the development of further preventive strategies.	[van Mol, Margo M. C.; Kompanje, Erwin J. O.; Bakker, Jan] Erasmus MC Univ Med Ctr, Dept Intens Care Adults, Rotterdam, Netherlands; [Benoit, Dominique D.] Ghent Univ Hosp, Med Unit, Dept Intens Care, Ghent, Belgium; [Nijkamp, Marjan D.] Open Univ Netherlands, Fac Psychol & Educ Sci, Heerlen, Netherlands	Erasmus University Rotterdam; Erasmus MC; Ghent University; Ghent University Hospital; Open University Netherlands	van Mol, MMC (corresponding author), Erasmus MC Univ Med Ctr, Dept Intens Care Adults, Rotterdam, Netherlands.	m.vanmol@erasmusmc.nl	Bakker, Jan/A-4011-2009	Bakker, Jan/0000-0003-2236-7391; van Mol, M/0000-0002-0213-6054; Seedat, Soraya/0000-0002-5118-786X; Nijkamp, Marjan/0000-0001-7335-9653				Ali NA, 2011, AM J RESP CRIT CARE, V184, P803, DOI 10.1164/rccm.201103-0555OC; Awa WL, 2010, PATIENT EDUC COUNS, V78, P184, DOI 10.1016/j.pec.2009.04.008; Aycock N, 2009, CLIN J ONCOL NURS, V13, P183, DOI 10.1188/09.CJON.183-191; Bakker AB, 2005, J ADV NURS, V51, P276, DOI 10.1111/j.1365-2648.2005.03494.x; Barbosa FT, 2012, SAO PAULO MED J, V130, P282, DOI 10.1590/S1516-31802012000500003; Beck CT, 2011, ARCH PSYCHIAT NURS, V25, P1, DOI 10.1016/j.apnu.2010.05.005; Bellieni CV, 2012, J MATERN-FETAL NEO M, V25, P2130, DOI 10.3109/14767058.2012.666590; Bockerman P, 2008, SOC SCI MED, V67, P520, DOI 10.1016/j.socscimed.2008.04.008; Caine Randy M, 2003, Crit Care Nurse, V23, P59; Cho SH, 2009, J CLIN NURS, V18, P1729, DOI 10.1111/j.1365-2702.2008.02721.x; Coetzee SK, 2010, NURS HEALTH SCI, V12, P235, DOI 10.1111/j.1442-2018.2010.00526.x; Crickmore R, 1987, Intensive Care Nurs, V3, P19, DOI 10.1016/0266-612X(87)90006-X; Curtis JR, 2014, INTENS CARE MED, V40, P606, DOI 10.1007/s00134-013-3201-8; Curtis JR, 2012, CONTEMP CLIN TRIALS, V33, P1245, DOI 10.1016/j.cct.2012.06.010; Czaja AS, 2012, J PEDIATR NURS, V27, P357, DOI 10.1016/j.pedn.2011.04.024; Davies William Richard, 2008, Holist Nurs Pract, V22, P32, DOI 10.1097/01.HNP.0000306326.56955.14; De Villers MJ, 2013, NURS ETHICS, V20, P589, DOI 10.1177/0969733012452882; Donchin Yoel, 2002, Curr Opin Crit Care, V8, P316, DOI 10.1097/00075198-200208000-00008; Eagle S, 2012, J PALLIAT MED, V15, P1178, DOI 10.1089/jpm.2012.0231; Elkonin D, 2011, HEALTH SA GESONDHEID, V16, DOI 10.4102/hsag.v16i1.436; Embriaco N, 2007, CURR OPIN CRIT CARE, V13, P482, DOI 10.1097/MCC.0b013e3282efd28a; Embriaco N, 2007, AM J RESP CRIT CARE, V175, P686, DOI 10.1164/rccm.200608-1184OC; Epp Kirstin, 2012, Dynamics, V23, P25; Fallowfield L, 2003, BRIT J CANCER, V89, P1445, DOI 10.1038/sj.bjc.6601309; Figley C. R., 1995, COPING SECONDARY TRA, DOI [10.4324/9780203777381, DOI 10.4324/9780203777381]; Figley C. R., 2013, TRAUMA AND ITS WAKE; Fink A., 2010, CONDUCTING RES LIT R; Freudenberger H, 1980, BURNOUT COST HIGH AC; Garland A, 2012, AM J RESP CRIT CARE, V185, P738, DOI 10.1164/rccm.201109-1734OC; Goetz K, 2012, INT NURS REV, V59, P88, DOI 10.1111/j.1466-7657.2011.00921.x; Grzeskowiak M, 2011, E J MED, V17, P59; Guntupalli KK, 2014, INDIAN J CRIT CARE M, V18, P139, DOI 10.4103/0972-5229.128703; Guntupalli KK, 1996, INTENS CARE MED, V22, P625, DOI 10.1007/BF01709737; Hays MA, 2006, DIMENS CRIT CARE NUR, V25, P185, DOI 10.1097/00003465-200607000-00016; Jenkins B, 2012, CRIT CARE NURS Q, V35, P388, DOI 10.1097/CNQ.0b013e318268fe09; Jenkins SR, 2002, J TRAUMA STRESS, V15, P423, DOI 10.1023/A:1020193526843; Joinson C, 1992, Nursing, V22, P118; Karanikola MNK, 2012, DIMENS CRIT CARE NUR, V31, P94, DOI 10.1097/DCC.0b013e3182445fd2; Kaschka WP, 2011, DTSCH ARZTEBL INT, V108, P781, DOI 10.3238/arztebl.2011.0781; Kearney MK, 2009, JAMA-J AM MED ASSOC, V301, P1155, DOI 10.1001/jama.2009.352; Kerasiotis Bernadina, 2004, Int J Emerg Ment Health, V6, P121; Klopper HC, 2012, J NURS MANAGE, V20, P685, DOI 10.1111/j.1365-2834.2011.01350.x; Kompanje EJO, 2013, CURR OPIN CRIT CARE, V19, P630, DOI 10.1097/MCC.0000000000000026; Lan HK, 2014, AUST J ADV NURS, V31, P22; Lederer W, 2008, ANAESTH INTENS CARE, V36, P208, DOI 10.1177/0310057X0803600211; Leiter M.P., 2014, BURNOUT WORK PSYCHOL; Liberati, 2009, PLOS MED, V6; Liu K, 2012, J CLIN NURS, V21, P1476, DOI 10.1111/j.1365-2702.2011.03991.x; Liu YE, 2015, J NURS MANAGE, V23, P487, DOI 10.1111/jonm.12161; Loiselle Carmen G, 2012, Intensive Crit Care Nurs, V28, P32, DOI 10.1016/j.iccn.2011.11.006; Iglesias MEL, 2013, DIMENS CRIT CARE NUR, V32, P130, DOI 10.1097/DCC.0b013e31828647fc; Marcial L, 2013, DIMENS CRIT CARE NUR, V32, P18, DOI 10.1097/DCC.0b013e31826bc687; Mason VM, 2014, DIMENS CRIT CARE NUR, V33, P215, DOI 10.1097/DCC.0000000000000056; Meadors P, 2008, J PEDIATR HEALTH CAR, V22, P24, DOI 10.1016/j.pedhc.2007.01.006; Meadors P, 2009, OMEGA-J DEATH DYING, V60, P103, DOI 10.2190/OM.60.2.a; Mealer ML, 2007, AM J RESP CRIT CARE, V175, P693, DOI 10.1164/rccm.200606-735OC; Mehrabi Tayebe, 2012, Iran J Nurs Midwifery Res, V17, P421; Merlani P, 2011, AM J RESP CRIT CARE, V184, P1140, DOI 10.1164/rccm.201101-0068OC; Murphy, 1995, ORG RISK FACTORS JOB, P259, DOI [10.1037/10173-016, DOI 10.1037/10173-016]; Myhren H, 2013, CRIT CARE RES PRACT, V2013, DOI 10.1155/2013/786176; National Center for Post Traumatic Stress Disorder, 2014, HLTH SA GESONDHEID; Nimmo A., 2013, AUSTRALASIAN J DISAS, V1, P37; Nooryan K, 2011, INT J COLLAB RES INT, V3, P704; Nooryan K, 2012, INT J GEN MED, V5, P5, DOI 10.2147/IJGM.S25850; OALVAN ME, 2012, ARCH ARGENT PEDIATR, V110, P466, DOI DOI 10.1590/S0325-00752012000600003; Poncet MC, 2007, AM J RESP CRIT CARE, V175, P698, DOI 10.1164/rccm.200606-806OC; Quenot JP, 2012, INTENS CARE MED, V38, P55, DOI 10.1007/s00134-011-2413-z; Raftopoulos V, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-457; Raggio B, 2007, MINERVA ANESTESIOL, V73, P195; Rochefort CM, 2010, J ADV NURS, V66, P2213, DOI 10.1111/j.1365-2648.2010.05376.x; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; Sabo Brenda, 2011, Online J Issues Nurs, V16, P1, DOI 10.3912/OJIN.Vol16No01Man01; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; Saini R., 2011, J MENTAL HLTH HUM BE, V16, P43; Schaufeli W, 2013, PSYCHOL LABOR HLTH; SCHAUFELI WB, 1995, PSYCHOL REP, V76, P1083, DOI 10.2466/pr0.1995.76.3c.1083; Shehabi Yahya, 2008, Crit Care Resusc, V10, P312; Sluiter JK, 2005, INTENS CARE MED, V31, P1409, DOI 10.1007/s00134-005-2769-z; Smart D, 2014, NURS HEALTH SCI, V16, P3, DOI 10.1111/nhs.12068; Stamm B. H., 2002, TREATING COMPASSION, P107, DOI DOI 10.4324/9780203890318; Stamm B.H., 2010, CONCISE PROQOL MANUA, V2nd ed.; Su TP, 2007, J PSYCHIATR RES, V41, P119, DOI 10.1016/j.jpsychires.2005.12.006; Teixeira C, 2014, J MED ETHICS, V40, P97, DOI 10.1136/medethics-2012-100619; Teixeira C, 2013, BMC ANESTHESIOL, V13, DOI 10.1186/1471-2253-13-38; Todaro-Franceschi V., 2019, COMPASSION FATIGUE B, V2nd; Todaro-Franceschi V, 2013, DIMENS CRIT CARE NUR, V32, P184, DOI 10.1097/DCC.0b013e31829980af; Verdon M, 2008, INTENS CARE MED, V34, P152, DOI 10.1007/s00134-007-0907-5; West CP, 2014, JAMA INTERN MED, V174, P527, DOI 10.1001/jamainternmed.2013.14387; West CP, 2014, JAMA INT MED; Whitebird RR, 2013, J PALLIAT MED, V16, P1534, DOI 10.1089/jpm.2013.0202; Yoder EA, 2010, APPL NURS RES, V23, P191, DOI 10.1016/j.apnr.2008.09.003; Young JL, 2011, CRIT CARE NURS Q, V34, P227, DOI 10.1097/CNQ.0b013e31821c67d5; Zhang XC, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004813	93	288	291	10	151	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2015	10	8							e0136955	10.1371/journal.pone.0136955	http://dx.doi.org/10.1371/journal.pone.0136955			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CQ2MT	26322644	gold, Green Published			2023-01-03	WOS:000360435500054
J	Kaplovitch, E; Gomes, T; Camacho, X; Dhalla, IA; Mamdani, MM; Juurlink, DN				Kaplovitch, Eric; Gomes, Tara; Camacho, Ximena; Dhalla, Irfan A.; Mamdani, Muhammad M.; Juurlink, David N.			Sex Differences in Dose Escalation and Overdose Death during Chronic Opioid Therapy: A Population-Based Cohort Study	PLOS ONE			English	Article							CHRONIC NONCANCER PAIN; UNITED-STATES; PRESCRIPTION OPIOIDS; NONMALIGNANT PAIN; TRENDS; GENDER; RISK; METAANALYSIS; ANALGESICS; MORTALITY	Background The use of opioids for noncancer pain is widespread, and more than 16,000 die of opioid-related causes in the United States annually. The patients at greatest risk of death are those receiving high doses of opioids. Whether sex influences the risk of dose escalation or opioid-related mortality is unknown. Methods and Findings We conducted a cohort study using healthcare records of 32,499 individuals aged 15 to 64 who commenced chronic opioid therapy for noncancer pain between April 1, 1997 and December 31, 2010 in Ontario, Canada. Patients were followed from their first opioid prescription until discontinuation of therapy, death from any cause or the end of the study period. Among patients receiving chronic opioid therapy, 589 (1.8%) escalated to high dose therapy and n = 59 (0.2%) died of opioid-related causes while on treatment. After multivariable adjustment, men were more likely than women to escalate to high-dose opioid therapy ( adjusted hazard ratio 1.44; 95% confidence interval 1.21 to 1.70) and twice as likely to die of opioid-related causes (adjusted hazard ratio 2.04; 95% confidence interval 1.18 to 3.53). These associations were maintained in a secondary analysis of 285,520 individuals receiving any opioid regardless of the duration of therapy. Conclusions Men are at higher risk than women for escalation to high-dose opioid therapy and death from opioid-related causes. Both outcomes were more common than anticipated.	[Kaplovitch, Eric; Dhalla, Irfan A.; Juurlink, David N.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Gomes, Tara; Camacho, Ximena; Dhalla, Irfan A.; Mamdani, Muhammad M.; Juurlink, David N.] Inst Clin Evaluat Sci, Chron Dis & Pharmacotherapy Res Program, Toronto, ON, Canada; [Gomes, Tara; Mamdani, Muhammad M.] Univ Toronto, Dept Pharm, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto	Juurlink, DN (corresponding author), Univ Toronto, Dept Med, Toronto, ON, Canada.	david.juurlink@ices.on.ca		Gomes, Tara/0000-0002-1468-1965	Ontario Ministry of Health and Long-Term Care (MOHLTC) Drug Innovation Fund; Institute for Clinical Evaluative Sciences (ICES) - Ontario MOHLTC	Ontario Ministry of Health and Long-Term Care (MOHLTC) Drug Innovation Fund; Institute for Clinical Evaluative Sciences (ICES) - Ontario MOHLTC	This study was supported by a grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC) Drug Innovation Fund and the Institute for Clinical Evaluative Sciences (ICES), a non-profit research institute sponsored by the Ontario MOHLTC. The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], US MED US REV 2011; Back SE, 2010, ADDICT BEHAV, V35, P1001, DOI 10.1016/j.addbeh.2010.06.018; Back SE, 2009, CLIN J PAIN, V25, P477, DOI 10.1097/AJP.0b013e31819c2c2f; Boudreau D, 2009, PHARMACOEPIDEM DR S, V18, P1166, DOI 10.1002/pds.1833; Campbell CI, 2010, AM J PUBLIC HEALTH, V100, P2541, DOI 10.2105/AJPH.2009.180646; Caudill-Slosberg MA, 2004, PAIN, V109, P514, DOI 10.1016/j.pain.2004.03.006; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chou R, 2009, J PAIN, V10, P147, DOI 10.1016/j.jpain.2008.10.007; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Dhalla IA, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5142; Dhalla IA, 2009, CAN MED ASSOC J, V181, P891, DOI 10.1503/cmaj.090784; Fillingim RB, 2009, J PAIN, V10, P447, DOI 10.1016/j.jpain.2008.12.001; Furlan AD, 2006, CAN MED ASSOC J, V174, P1589, DOI 10.1503/cmaj.051528; Gomes T, 2013, JAMA INTERN MED, V173, P196, DOI 10.1001/2013.jamainternmed.733; Gomes Tara, 2011, Open Med, V5, pe13; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Green CR, 2003, J PAIN, V4, P29, DOI 10.1054/jpai.2003.5; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Hall S, 2006, J CLIN EPIDEMIOL, V59, P67, DOI 10.1016/j.jclinepi.2005.05.001; Han Huijun, 2013, J Opioid Manag, V9, P129, DOI 10.5055/jom.2012.0154; Hux JE, 2002, DIABETES CARE, V25, P512, DOI 10.2337/diacare.25.3.512; Jamison RN, 2010, J PAIN, V11, P312, DOI 10.1016/j.jpain.2009.07.016; Joynt M, 2013, J GEN INTERN MED; Kissin I, 2013, J PAIN RES, V6, P513, DOI [10.2147/JPR.S47182, 10.2147/JPR.S47162]; Levy Adrian R, 2003, Can J Clin Pharmacol, V10, P67; Mamdani M, 2005, BMJ-BRIT MED J, V330, P960, DOI 10.1136/bmj.330.7497.960; National Opioid Use Guideline Group (NOUGG), 2010, CAN GUID SAF EFF US; Nelson LS, 2012, JAMA-J AM MED ASSOC, V308, P457, DOI 10.1001/jama.2012.8165; Noble M, 2008, J PAIN SYMPTOM MANAG, V35, P214, DOI 10.1016/j.jpainsymman.2007.03.015; Paulozzi Leonard J., 2012, Morbidity and Mortality Weekly Report, V61, P493; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Pletcher MJ, 2008, JAMA-J AM MED ASSOC, V299, P70, DOI 10.1001/jama.2007.64; PORTENOY RK, 1986, PAIN, V25, P171, DOI 10.1016/0304-3959(86)90091-6; Sadowski CA, 2009, J POPUL THER CLIN PH, V16, pE322; Spiller H, 2009, J ADDICT DIS, V28, P130, DOI 10.1080/10550880902772431; Sullivan MD, 2008, PAIN, V138, P440, DOI 10.1016/j.pain.2008.04.027; Von Korff M, 2011, ANN INTERN MED, V155, P325, DOI 10.7326/0003-4819-155-5-201109060-00011; Warner Margaret, 2011, NCHS Data Brief, P1; Wisniewski AM, 2008, J ADDICT DIS, V27, P1, DOI 10.1300/J069v27n01_01; YOLA M, 1994, J CLIN EPIDEMIOL, V47, P731, DOI 10.1016/0895-4356(94)90170-8	40	98	99	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2015	10	8							e0134550	10.1371/journal.pone.0134550	http://dx.doi.org/10.1371/journal.pone.0134550			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CP5KH	26291716	Green Published, gold			2023-01-03	WOS:000359919900008
J	Li, GC; Wang, JZ; Hu, WG; Zhang, Z				Li, Guichao; Wang, Jiazhou; Hu, Weigang; Zhang, Zhen			Radiation-Induced Liver Injury in Three-Dimensional Conformal Radiation Therapy (3D-CRT) for Postoperative or Locoregional Recurrent Gastric Cancer: Risk Factors and Dose Limitations	PLOS ONE			English	Article							COMPLICATION PROBABILITY MODEL; HEPATOCELLULAR-CARCINOMA; PARALLEL-ARCHITECTURE; NORMAL-TISSUES; DISEASE; RADIOTHERAPY; IRRADIATION; TOLERANCE; PREDICTION	Purpose This study examined the status of radiation-induced liver injury in adjuvant or palliative gastric cancer radiation therapy (RT), identified risk factors of radiation-induced liver injury in gastric cancer RT, analysed the dose-volume effects of liver injury, and developed a liver dose limitation reference for gastric cancer RT. Methods and Materials Data for 56 post-operative gastric cancer patients and 6 locoregional recurrent gastric cancer patients treated with three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) from Sep 2007 to Sep 2009 were analysed. Forty patients (65%) were administered concurrent chemotherapy. Pre- and post-radiation chemotherapy were given to 61 patients and 43 patients, respectively. The radiation dose was 45-50.4 Gy in 25-28 fractions. Clinical parameters, including gender, age, hepatic B virus status, concurrent chemotherapy, and the total number of chemotherapy cycles, were included in the analysis. Univariate analyses with a non-parametric rank test (Mann-Whitney test) and logistic regression test and a multivariate analysis using a logistic regression test were completed. We also analysed the correlation between RT and the changes in serum chemistry parameters [including total bilirubin, (TB), direct bilirubin (D-TB), alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and serum albumin (ALB)] after RT. Results The Child-Pugh grade progressed from grade A to grade B after radiotherapy in 10 patients. A total of 16 cases of classic radiation-induced liver disease (RILD) were observed, and 2 patients had both Child-Pugh grade progression and classic RILD. No cases of non-classic radiation liver injury occurred in the study population. Among the tested clinical parameters, the total number of chemotherapy cycles correlated with liver function injury. V35 and ALP levels were significant predictive factors for radiation liver injury. Conclusions In 3D-CRT for gastric cancer patients, radiation-induced liver injury may occur and affect the overall treatment plan. The total number of chemotherapy cycles correlated with liver function injury, and V35 and ALP are significant predictive factors for radiation-induced liver injury. Our dose limitation reference for liver protection is feasible.	[Zhang, Zhen] Fudan Univ, Dept Radiat Oncol, Shanghai Canc Ctr, Shanghai 200433, Peoples R China; Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai 200433, Peoples R China	Fudan University; Fudan University	Zhang, Z (corresponding author), Fudan Univ, Dept Radiat Oncol, Shanghai Canc Ctr, Shanghai 200433, Peoples R China.	zhenzhang6@163.com						Bockbrader M, 2009, EXPERT REV ANTICANC, V9, P637, DOI 10.1586/ERA.09.16; Cheng JCH, 2005, INT J RADIAT ONCOL, V62, P1150, DOI 10.1016/j.ijrobp.2004.12.031; Cheng JCH, 2002, INT J RADIAT ONCOL, V54, P156, DOI 10.1016/S0360-3016(02)02915-2; Cunningham D, 2008, NEW ENGL J MED, V358, P36, DOI 10.1056/NEJMoa073149; Dawson LA, 2005, SEMIN RADIAT ONCOL, V15, P279, DOI 10.1016/j.semradonc.2005.04.005; Dawson LA, 2001, INT J RADIAT ONCOL, V51, P1410, DOI 10.1016/S0360-3016(01)02653-0; Dawson LA, 2001, SEMIN RADIAT ONCOL, V11, P240, DOI 10.1053/srao.2001.23485; Dawson LA, 2002, INT J RADIAT ONCOL, V53, P810, DOI 10.1016/S0360-3016(02)02846-8; JACKSON A, 1993, MED PHYS, V20, P613, DOI 10.1118/1.597056; Kang Y., 2006, ASCO, V24, DOI [10.1200/jco.2006.24.18_suppl.lba4018, DOI 10.1200/JCO.2006.24.18_SUPPL.LBA4018]; Kim TH, 2007, INT J RADIAT ONCOL, V67, P225, DOI 10.1016/j.ijrobp.2006.08.015; Koizumi W, 2008, LANCET ONCOL, V9, P215, DOI 10.1016/S1470-2045(08)70035-4; Liang SX, 2006, INT J RADIAT ONCOL, V65, P426, DOI 10.1016/j.ijrobp.2005.12.031; Macdonald JS, 2001, NEW ENGL J MED, V345, P725, DOI 10.1056/NEJMoa010187; Ohara K, 1997, INT J RADIAT ONCOL, V38, P367, DOI 10.1016/S0360-3016(96)00587-1; Pan CC, 2010, INT J RADIAT ONCOL, V76, pS94, DOI 10.1016/j.ijrobp.2009.06.092; Tai A, 2009, INT J RADIAT ONCOL, V74, P283, DOI 10.1016/j.ijrobp.2008.11.029; Xu ZY, 2006, INT J RADIAT ONCOL, V65, P189, DOI 10.1016/j.ijrobp.2005.11.034; Yorke ED, 2001, SEMIN RADIAT ONCOL, V11, P197, DOI 10.1053/srao.2001.23478; YORKE ED, 1993, RADIOTHER ONCOL, V26, P226, DOI 10.1016/0167-8140(93)90264-9; Zhu J, 2006, JPN J CLIN ONCOL, V36, P783, DOI 10.1093/jjco/hyl117	21	12	15	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2015	10	8							e0136288	10.1371/journal.pone.0136288	http://dx.doi.org/10.1371/journal.pone.0136288			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP5KH	26291715	gold, Green Submitted, Green Published			2023-01-03	WOS:000359919900074
J	van Lelyveld, SFL; Drylewicz, J; Krikke, M; Veel, EM; Otto, SA; Richter, C; Soetekouw, R; Prins, JM; Brinkman, K; Mulder, JW; Kroon, F; Middel, A; Symons, J; Wensing, AMJ; Nijhuis, M; Borghans, JAM; Tesselaar, K; Hoepelman, AIM				van Lelyveld, Steven F. L.; Drylewicz, Julia; Krikke, Maaike; Veel, Ellen M.; Otto, Sigrid A.; Richter, Clemens; Soetekouw, Robin; Prins, Jan M.; Brinkman, Kees; Mulder, Jan Willem; Kroon, Frank; Middel, Ananja; Symons, Jori; Wensing, Annemarie M. J.; Nijhuis, Monique; Borghans, Jose A. M.; Tesselaar, Kiki; Hoepelman, Andy I. M.		MIRS Study Grp	Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; HIV-INFECTED INDIVIDUALS; T-CELL RECOVERY; IMMUNE ACTIVATION; VIROLOGICAL SUPPRESSION; VIRAL SUPPRESSION; ADDING MARAVIROC; CCR5 EXPRESSION; APOPTOSIS; INCREASES	Objective The immunomodulatory effects of the CCR5-antagonist maraviroc might be beneficial in patients with a suboptimal immunological response, but results of different cART (combination antiretroviral therapy) intensification studies are conflicting. Therefore, we performed a 48-week placebo-controlled trial to determine the effect of maraviroc intensification on CD4(+) T-cell counts and immune activation in these patients. Design Double-blind, placebo-controlled, randomized trial. Methods Major inclusion criteria were 1. CD4(+) T-cell count <350 cells/mu L while at least two years on cART or CD4(+) T-cell count <200 cells/mu L while at least one year on cART, and 2. viral suppression for at least the previous 6 months. HIV-infected patients were randomized to add maraviroc (41 patients) or placebo (44 patients) to their cART regimen for 48 weeks. Changes in CD4(+) T-cell counts (primary endpoint) and other immunological parameters were modeled using linear mixed effects models. Results No significant differences for the modelled increase in CD4(+) T-cell count (placebo 15.3 CD4(+) T cells/mu L (95% confidence interval (CI) [1.0, 29.5] versus maraviroc arm 22.9 CD4(+) T cells/mu L (95% CI [7.4, 38.5] p = 0.51) or alterations in the expression of markers for T-cell activation, proliferation and microbial translocation were found between the arms. However, maraviroc intensification did increase the percentage of CCR5 expressing CD4(+) and CD8(+) T-cells, and the plasma levels of the CCR5 ligand MIP-1 beta. In contrast, the percentage of ex-vivo apoptotic CD8(+) and CD4(+) T-cells decreased in the maraviroc arm. Conclusions Maraviroc intensification of cART did not increase CD4(+) T-cell restoration or decrease immune activation as compared to placebo. However, ex-vivo T-cell apoptosis was decreased in the maraviroc arm.	[van Lelyveld, Steven F. L.; Krikke, Maaike; Middel, Ananja; Hoepelman, Andy I. M.] Univ Med Ctr Utrecht, Dept Internal Med & Infect Dis, Utrecht, Netherlands; [Drylewicz, Julia; Veel, Ellen M.; Otto, Sigrid A.; Borghans, Jose A. M.; Tesselaar, Kiki] Univ Med Ctr Utrecht, Dept Immunol, Utrecht, Netherlands; [Richter, Clemens] Rijnstate Hosp, Dept Internal Med, Arnhem, Netherlands; [van Lelyveld, Steven F. L.; Soetekouw, Robin] Spaarne Gasthuis, Dept Internal Med & Gastroenterol, Haarlem, Netherlands; [Prins, Jan M.] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Div Infect Dis,Ctr Infect & Immun, NL-1105 AZ Amsterdam, Netherlands; [Brinkman, Kees] Onze Lieve Vrouw Hosp, Dept Internal Med, Amsterdam, Netherlands; [Mulder, Jan Willem] Slotervaart Hosp, Dept Internal Med, Amsterdam, Netherlands; [Kroon, Frank] Leiden Univ, Med Ctr, Dept Infect Dis, Leiden, Netherlands; [Symons, Jori; Wensing, Annemarie M. J.; Nijhuis, Monique] Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Rijnstate Hospital; Spaarne Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Onze Lieve Vrouwe Gasthuis Hospital; Slotervaart Hospital; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Utrecht University; Utrecht University Medical Center	Tesselaar, K (corresponding author), Univ Med Ctr Utrecht, Dept Immunol, Utrecht, Netherlands.	k.tesselaar@umcutrecht.nl	Prins, Jan M./AAF-4945-2020; Drylewicz, Julia/I-4703-2019	Drylewicz, Julia/0000-0002-9434-8459; Tesselaar, Kiki/0000-0002-9847-0814; Symons, Jori/0000-0001-6560-1577; Prins, Jan/0000-0002-5415-8933; Symons, Joir/0000-0003-0252-3887	Pfizer Inc. USA; VIDI grant from the Netherlands Organisation for Scientific Research (NWO) [917.96.350]; Aids Fonds Netherlands [2007040]	Pfizer Inc. USA(Pfizer); VIDI grant from the Netherlands Organisation for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Aids Fonds Netherlands	This work was supported by a grant from Pfizer Inc. USA, a VIDI grant from the Netherlands Organisation for Scientific Research (NWO, grant 917.96.350) and a grant from the Aids Fonds Netherlands (grant 2007040). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahuja SK, 2008, NAT MED, V14, P413, DOI 10.1038/nm1741; Algeciras-Schimnich A, 2002, AIDS, V16, P1467, DOI 10.1097/00002030-200207260-00003; Arberas H, 2013, J ANTIMICROB CHEMOTH, V68, P577, DOI 10.1093/jac/dks432; Baker JV, 2008, JAIDS-J ACQ IMM DEF, V48, P541, DOI 10.1097/QAI.0b013e31817bebb3; Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; Bloemers BLP, 2011, J IMMUNOL, V186, P4500, DOI 10.4049/jimmunol.1001700; Camargo JF, 2009, J IMMUNOL, V182, P171, DOI 10.4049/jimmunol.182.1.171; Cooper DA, 2010, J INFECT DIS, V201, P803, DOI 10.1086/650697; Cuzin L, 2012, J ACQUIR IMMUNE DEFI; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dronda F, 2002, CLIN INFECT DIS, V35, P1005, DOI 10.1086/342695; Florence E, 2003, HIV Med, V4, P255, DOI 10.1046/j.1468-1293.2003.00156.x; Grabar S, 2000, ANN INTERN MED, V133, P401, DOI 10.7326/0003-4819-133-6-200009190-00007; Gulick RM, 2008, NEW ENGL J MED, V359, P1429, DOI 10.1056/NEJMoa0803152; Gutierrez C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027864; Hazenberg MD, 2000, BLOOD, V95, P249, DOI 10.1182/blood.V95.1.249.001k40_249_255; Hunt PW, 2013, BLOOD, V121, P4635, DOI 10.1182/blood-2012-06-436345; Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786; Kelley CF, 2009, CLIN INFECT DIS, V48, P787, DOI 10.1086/597093; Kohler S, 2009, BLOOD, V113, P769, DOI 10.1182/blood-2008-02-139154; Kraaijeveld AO, 2007, CIRCULATION, V116, P1931, DOI 10.1161/CIRCULATIONAHA.107.706986; Lin YL, 2008, AIDS, V22, P430, DOI 10.1097/QAD.0b013e3282f46a6f; Moore DM, 2005, JAIDS-J ACQ IMM DEF, V40, P288, DOI 10.1097/01.qai.0000182847.38098.d1; Murooka TT, 2006, J BIOL CHEM, V281, P25184, DOI 10.1074/jbc.M603912200; Pett SL, 2010, AIDS RES HUM RETROV, V26, P653, DOI 10.1089/aid.2009.0278; Portales P, 2012, IMMUNOLOGY, V137, P89, DOI 10.1111/j.1365-2567.2012.03609.x; Pozo-Balado MM, 2014, J INFECT DIS; Psomas C, 2013, BLOOD, V122, P2282, DOI 10.1182/blood-2013-06-507012; Reshef R, 2012, NEW ENGL J MED, V367, P135, DOI 10.1056/NEJMoa1201248; Rusconi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080157; Stepanyuk O, 2009, AIDS, V23, P1911, DOI 10.1097/QAD.0b013e32832f3c65; Symons J, 2012, CLIN MICROBIOL INFEC, V18, P606, DOI 10.1111/j.1469-0691.2011.03631.x; Tan RM, 2008, JAIDS-J ACQ IMM DEF, V47, P553, DOI 10.1097/QAI.0b013e31816856c5; Tilling R, 2002, AIDS, V16, P589, DOI 10.1097/00002030-200203080-00010; van Lelyveld SFL, 2012, AIDS, V26, P465, DOI 10.1097/QAD.0b013e32834f32f8; Vandekerckhove LPR, 2011, LANCET INFECT DIS, V11, P394, DOI 10.1016/S1473-3099(10)70319-4; Westrop SJ, 2012, MOL MED, V18, P1240, DOI 10.2119/molmed.2012.00206; Wilkin TJ, 2012, J INFECT DIS, V206, P534, DOI 10.1093/infdis/jis376; Wilkin TJ, 2010, HIV CLIN TRIALS, V11, P351, DOI 10.1310/hct1106-351; Zaunders JJ, 2003, J INFECT DIS, V187, P1735, DOI 10.1086/375030	40	21	21	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2015	10	7							e0132430	10.1371/journal.pone.0132430	http://dx.doi.org/10.1371/journal.pone.0132430			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN7NT	26208341	Green Published, gold			2023-01-03	WOS:000358622000027
J	Samanta, AK; Jayaram, C; Jayapal, N; Sondhi, N; Kolte, AP; Senani, S; Sridhar, M; Dhali, A				Samanta, Ashis Kumar; Jayaram, C.; Jayapal, N.; Sondhi, N.; Kolte, A. P.; Senani, S.; Sridhar, M.; Dhali, A.			Assessment of Fecal Microflora Changes in Pigs Supplemented with Herbal Residue and Prebiotic	PLOS ONE			English	Article							FRAGMENT-LENGTH-POLYMORPHISMS; INTESTINAL MICROFLORA; MICROBIAL DIVERSITY; T-RFLP; 16S; BACTERIUM; ACID; IDENTIFICATION; COMMUNITIES; PERFORMANCE	Antibiotic usage in animals as a growth promoter is considered as public health issue due to its negative impact on consumer health and environment. The present study aimed to evaluate effectiveness of herbal residue (ginger, Zingiber officinale, dried rhizome powder) and prebiotic (inulin) as an alternative to antibiotics by comparing fecal microflora composition using terminal restriction fragment length polymorphism. The grower pigs were offered feed containing antibiotic (tetracycline), ginger and inulin separately and un-supplemented group served as control. The study revealed significant changes in the microbial abundance based on operational taxonomic units (OTUs) among the groups. Presumptive identification of organisms was established based on the fragment length of OTUs generated with three restriction enzymes (MspI, Sau3AI and BsuRI). The abundance of OTUs representing Bacteroides intestinalis, Eubacterium oxidoreducens, Selonomonas sp., Methylobacterium sp. and Denitrobacter sp. was found significantly greater in inulin supplemented pigs. Similarly, the abundance of OTUs representing Bacteroides intestinalis, Selonomonas sp., and Phascolarcobacterium faecium was found significantly greater in ginger supplemented pigs. In contrast, the abundance of OTUs representing pathogenic microorganisms Atopostipes suicloacalis and Bartonella quintana str. Toulouse was significantly reduced in ginger and inulin supplemented pigs. The OTUs were found to be clustered under two major phylotypes; ginger-inulin and control-tetracycline. Additionally, the abundance of OTUs was similar in ginger and inulin supplemented pigs. The results suggest the potential of ginger and prebioticsto replace antibiotics in the diet of grower pig.	[Samanta, Ashis Kumar; Jayaram, C.; Jayapal, N.; Sondhi, N.; Senani, S.] Natl Inst Anim Nutr & Physiol, Feed Addit & Nutraceut Lab, Bangalore 560030, Karnataka, India; [Kolte, A. P.; Dhali, A.] Natl Inst Anim Nutr & Physiol, Omics Lab, Bangalore 560030, Karnataka, India; [Sridhar, M.] Natl Inst Anim Nutr & Physiol, Fermentat Technol Lab, Bangalore 560030, Karnataka, India	Indian Council of Agricultural Research (ICAR); ICAR - National Institute of Animal Nutrition & Physiology; Indian Council of Agricultural Research (ICAR); ICAR - National Institute of Animal Nutrition & Physiology; Indian Council of Agricultural Research (ICAR); ICAR - National Institute of Animal Nutrition & Physiology	Samanta, AK (corresponding author), Natl Inst Anim Nutr & Physiol, Feed Addit & Nutraceut Lab, Hosur Rd, Bangalore 560030, Karnataka, India.	drashiskumarsamanta@gmail.com	Samanta, Ashis Kumar/AAE-6920-2019; Senani, Swaraj/ABD-8567-2020; Chikkerur, Jayaram/ABI-5147-2020	Samanta, Ashis Kumar/0000-0003-1646-294X; Chikkerur, Jayaram/0000-0001-8575-7632	Department of Biotechnology, Ministry of Science and Technology, Government of India [BT/PR13932/AAQ/01/435/2010]	Department of Biotechnology, Ministry of Science and Technology, Government of India(Department of Biotechnology (DBT) IndiaMinistry of Science and Technology, Government of India)	The grant was received by AKS from the Department of Biotechnology, Ministry of Science and Technology, Government of India (www.dbtindia.nic.in) Grant No. BT/PR13932/AAQ/01/435/2010.	Al Jassim RAM, 2003, LETT APPL MICROBIOL, V37, P213, DOI 10.1046/j.1472-765X.2003.01380.x; Apajalahti J, 2005, J APPL POULTRY RES, V14, P444, DOI 10.1093/japr/14.2.444; BRAY J. ROGER, 1957, ECOL MONOGR, V27, P325, DOI 10.2307/1942268; Casewell M, 2003, J ANTIMICROB CHEMOTH, V52, P159, DOI 10.1093/jac/dkg313; Castanon JIR, 2007, POULTRY SCI, V86, P2466, DOI 10.3382/ps.2007-00249; Clarke K.R., 2001, CHANGE MARINE COMMUN; CLARKE KR, 1993, AUST J ECOL, V18, P117, DOI 10.1111/j.1442-9993.1993.tb00438.x; Costa E, 2009, J MICROBIOL METH, V78, P175, DOI 10.1016/j.mimet.2009.05.011; Costa LB, 2013, S AFR J ANIM SCI, V43, P181, DOI 10.4314/sajas.v43i2.9; de Lange CFM, 2010, LIVEST SCI, V134, P124, DOI 10.1016/j.livsci.2010.06.117; Dicksved J, 2007, APPL ENVIRON MICROB, V73, P2284, DOI 10.1128/AEM.02223-06; Duncan SH, 1998, FEMS MICROBIOL LETT, V164, P283, DOI 10.1111/j.1574-6968.1998.tb13099.x; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Economic and Social Committee of the European Union, 1998, OP RES ANT THREAT PU; Engebretson JJ, 2003, APPL ENVIRON MICROB, V69, P4823, DOI 10.1128/AEM.69.8.4823-4829.2003; Fukuda S, 2006, J APPL MICROBIOL, V100, P787, DOI 10.1111/j.1365-2672.2006.02864.x; Gaggia F, 2010, INT J FOOD MICROBIOL, V141, pS15, DOI 10.1016/j.ijfoodmicro.2010.02.031; Genersch E, 2005, APPL ENVIRON MICROB, V71, P7551, DOI 10.1128/AEM.71.11.7551-7555.2005; Hong PY, 2014, APPL ENVIRON MICROB, V80, P2084, DOI 10.1128/AEM.03176-13; Konstantinov SR, 2004, APPL ENVIRON MICROB, V70, P3821, DOI 10.1128/AEM.70.7.3821-3830.2004; KRUSKAL JB, 1964, PSYCHOMETRIKA, V29, P1, DOI 10.1007/BF02289565; Kverka M, 2011, CLIN EXP IMMUNOL, V163, P250, DOI 10.1111/j.1365-2249.2010.04286.x; Lane DJ., 1991, NUCL ACID TECHNIQUES, P115; Li JR, 2003, APPL ENVIRON MICROB, V69, P901, DOI 10.1128/AEM.69.2.901-908.2003; Li PF, 2012, ASIAN AUSTRAL J ANIM, V25, P1617, DOI 10.5713/ajas.2012.12292; Liu WT, 1997, APPL ENVIRON MICROB, V63, P4516, DOI 10.1128/AEM.63.11.4516-4522.1997; Loh G, 2006, J NUTR, V136, P1198, DOI 10.1093/jn/136.5.1198; Lynch MB, 2007, ANIMAL, V1, P1112, DOI 10.1017/S1751731107000407; Marsh TL, 1999, CURR OPIN MICROBIOL, V2, P323, DOI 10.1016/S1369-5274(99)80056-3; MOORE LVH, 1987, INT J SYST BACTERIOL, V37, P271, DOI 10.1099/00207713-37-3-271; MUDARRIS M, 1994, INT J SYST BACTERIOL, V44, P447, DOI 10.1099/00207713-44-3-447; MUYZER G, 1995, ARCH MICROBIOL, V164, P165, DOI 10.1007/BF02529967; O'Mahony R, 2005, WORLD J GASTROENTERO, V11, P7499, DOI 10.3748/wjg.v11.i47.7499; Ohl ME, 2000, CLIN INFECT DIS, V31, P131, DOI 10.1086/313890; Oli MW, 1998, DIGEST DIS SCI, V43, P138, DOI 10.1023/A:1018892524790; Patterson JK, 2010, J NUTR, V140, P2158, DOI 10.3945/jn.110.130302; Pedersen R, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-30; Prive F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069076; Samanta AK, 2011, CURR SCI INDIA, V101, P43; Samanta AK, 2012, J MICROBIOL, V50, P218, DOI 10.1007/s12275-012-1362-8; Schutte UME, 2008, APPL MICROBIOL BIOT, V80, P365, DOI 10.1007/s00253-008-1565-4; SHEPARD RN, 1962, PSYCHOMETRIKA, V27, P125, DOI 10.1007/BF02289630; Shyu C, 2007, MICROB ECOL, V53, P562, DOI 10.1007/s00248-006-9106-0; Spear GT, 2010, AIDS RES HUM RETROV, V26, P193, DOI 10.1089/aid.2009.0166; Sun YZ, 2011, J APPL MICROBIOL, V110, P1093, DOI 10.1111/j.1365-2672.2011.04967.x; Suryanarayana M.V.A.N., 2013, J AGR SUSTAIN, V3, P183; Thies JE, 2007, SOIL SCI SOC AM J, V71, P579, DOI 10.2136/sssaj2006.0318; Torok VA, 2008, APPL ENVIRON MICROB, V74, P783, DOI 10.1128/AEM.01384-07; Ueno N, 2011, INFLAMM BOWEL DIS, V17, P2235, DOI 10.1002/ibd.21597; Van Loo J, 2007, J NUTR, V137, p2594S, DOI 10.1093/jn/137.11.2594S; Varley PF, 2010, J SCI FOOD AGR, V90, P2447, DOI 10.1002/jsfa.4105; Watanabe Y, 2012, APPL ENVIRON MICROB, V78, P511, DOI 10.1128/AEM.06035-11; WINTER J, 1989, APPL ENVIRON MICROB, V55, P1203, DOI 10.1128/AEM.55.5.1203-1208.1989; World Health Organization, 1997, MED IMP US ANT FOOD; Yan L, 2012, LIVEST SCI, V145, P189, DOI 10.1016/j.livsci.2012.02.001	55	11	14	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2015	10	7							e0132961	10.1371/journal.pone.0132961	http://dx.doi.org/10.1371/journal.pone.0132961			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RL	26176779	Green Published, gold, Green Submitted			2023-01-03	WOS:000358197600189
J	Chau, PH; Leung, AYM; Li, HLH; Sea, M; Chan, R; Woo, J				Chau, P. H.; Leung, Angela Y. M.; Li, Holly L. H.; Sea, Mandy; Chan, Ruth; Woo, Jean			Development and Validation of Chinese Health Literacy Scale for Low Salt Consumption - Hong Kong Population (CHLSalt-HK)	PLOS ONE			English	Article							REDUCE SALT; KNOWLEDGE	Globally, sodium intake far exceeds the level recommended by the World Health Organization. Assessing health literacy related to salt consumption among older adults could guide the development of interventions that target their knowledge gaps, misconceptions, or poor dietary practices. This study aimed to develop and validate the Chinese Health Literacy Scale for Low Salt Consumption - Hong Kong population (CHLSalt-HK). Based on previous studies on salt intake and nutrition label reading in other countries, we developed similar questions that were appropriate for the Chinese population in Hong Kong. The questions covered the following eight broad areas: functional literacy (term recognition and nutrition label reading), knowledge of the salt content of foods, knowledge of the diseases related to high salt intake, knowledge of international standards, myths about salt intake, attitudes toward salt intake, salty food consumption practices, and nutrition label reading practices. Eight professionals, including doctors, nurses, and dietitians, provided feedback on the scale. The psychometric properties of the scale were assessed based on data collected from a convenience sample of 603 Chinese elderly adults recruited from Elderly Health Centres in Hong Kong. The 49-item CHLSalt-HK had a possible score range of 0 to 98, with a higher score indicating higher health literacy related to salt intake. The CHLSalt-HK had acceptable content validity; the item-level Content Validity Index ranged from 0.857 to 1.000, and the scale-level Content Validity Index was 0.994. Additionally, it had good internal consistency (Cronbach's alpha of 0.799) and good test-retest reliability (intraclass correlation coefficient of 0.846). The mean CHLSalt-HK score among those who were aware of the public education slogan about nutrition labels and sodium intake was higher by 3.928 points (95% confidence interval: 1.742 to 6.115) than that among those who were not aware of the slogan, which supports adequate discriminant validity. The validated CHLSalt-HK had acceptable content validity, acceptable construct validity, good internal consistency, good test-retest reliability, and adequate discriminant validity. The scale could be completed in 10-15 minutes and is easy to administer compared with the collection of biomarkers or food diaries. Further research should investigate its concurrent validity and predictive validity. The development of this scale supports the first step in salt intake reduction among older Chinese adults in Hong Kong by enabling the assessment of their health literacy related to salt consumption in health screenings or health assessments, and it can be used to evaluate salt reduction interventions.	[Chau, P. H.; Leung, Angela Y. M.] Univ Hong Kong, Sch Nursing, Hong Kong, Hong Kong, Peoples R China; [Li, Holly L. H.] Dept Hlth, Elderly Hlth Serv, Hong Kong, Hong Kong, Peoples R China; [Sea, Mandy] Chinese Univ Hong Kong, Ctr Nutr Studies, Hong Kong, Hong Kong, Peoples R China; [Chan, Ruth; Woo, Jean] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Chau, PH (corresponding author), Univ Hong Kong, Sch Nursing, Hong Kong, Hong Kong, Peoples R China.	phchau@graduate.hku.hk	Chan, Ruth/K-4995-2014; Woo, Jean/K-2625-2014; Leung, Angela Yee Man/X-4415-2019; Chau, Pui Hing/A-2290-2010	Woo, Jean/0000-0001-7593-3081; Leung, Angela Yee Man/0000-0002-9836-1925; Chan, Ruth/0000-0002-5725-4066; Chau, Pui Hing/0000-0003-0287-8020				Berkman ND, 2011, ANN INTERN MED, V155, P97, DOI 10.7326/0003-4819-155-2-201107190-00005; Brown IJ, 2009, INT J EPIDEMIOL, V38, P791, DOI 10.1093/ije/dyp139; Centers for Disease Control and Prevention, 2014, HLTH LITERACY; Chau PH, 2011, CEREBROVASC DIS, V31, P138, DOI 10.1159/000321734; Claro RM, 2012, REV PANAM SALUD PUBL, V32, P265, DOI 10.1590/S1020-49892012001000004; Cohen J., 2013, STAT POWER ANAL BEHA; Cutilli CC, 2011, ORTHOP NURS, V30, P281, DOI 10.1097/NOR.0b013e3182247c8f; Department of Health of HKSAR Department of Community Medicine of The University of Hong Kong, 2005, REPORT POPULATION HL; Freedman DA, 2009, AM J PREV MED, V36, P446, DOI 10.1016/j.amepre.2009.02.001; Frisch AL, 2012, HEALTH PROMOT INT, V27, P117, DOI 10.1093/heapro/dar043; He F. J., 2013, BMJ, V346; He FJ, 2010, PROG CARDIOVASC DIS, V52, P363, DOI 10.1016/j.pcad.2009.12.006; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Janus ED, 1997, HONG KONG CARDIOVASC; Jay M, 2009, PREV MED, V48, P25, DOI 10.1016/j.ypmed.2008.10.011; Ji C, 2012, REV PANAM SALUD PUBL, V32, P307, DOI 10.1590/S1020-49892012001000010; Kim MK, 2012, J FOOD SCI, V77, pS307, DOI 10.1111/j.1750-3841.2012.02843.x; Leung AYM, 2013, J HEALTH COMMUN, V18, P205, DOI 10.1080/10810730.2013.829138; Liu ZM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104018; Moshfegh Alanna J., 2012, Morbidity and Mortality Weekly Report, V61, P92; Ngan MHR, 1996, RES REPORT; Nunnally J. C., 1978, PSYCHOMETRIC THEORY, V2nd; Okuda N, 2014, J HYPERTENS, V32, P2385, DOI 10.1097/HJH.0000000000000341; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; Polit DF, 2006, RES NURS HEALTH, V29, P489, DOI 10.1002/nur.20147; Sarmugam R, 2014, PUBLIC HEALTH NUTR, V17, P1061, DOI 10.1017/S1368980013000517; Tavakol M, 2011, INT J MED EDUC, V2, P1, DOI 10.5116/ijme.4d27.32ff; Temple NJ, 2014, NUTRITION, V30, P257, DOI 10.1016/j.nut.2013.06.012; Webster J, 2014, NUTRIENTS, V6, P3274, DOI 10.3390/nu6083274; Woo J, 1998, J EPIDEMIOL COMMUN H, V52, P631, DOI 10.1136/jech.52.10.631	30	18	21	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2015	10	7							e0132303	10.1371/journal.pone.0132303	http://dx.doi.org/10.1371/journal.pone.0132303			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CN1DQ	26148008	Green Submitted, Green Published, gold			2023-01-03	WOS:000358157600236
J	Castro-Avila, AC; Seron, P; Fan, E; Gaete, M; Mickan, S				Castro-Avila, Ana Cristina; Seron, Pamela; Fan, Eddy; Gaete, Monica; Mickan, Sharon			Effect of Early Rehabilitation during Intensive Care Unit Stay on Functional Status: Systematic Review and Meta-Analysis	PLOS ONE			English	Review							MECHANICALLY VENTILATED PATIENTS; ELECTRICAL MUSCLE STIMULATION; CRITICALLY-ILL PATIENTS; QUALITY-OF-LIFE; CRITICAL ILLNESS; PHYSICAL-THERAPY; ACQUIRED WEAKNESS; CONTROLLED-TRIAL; CLINICAL-TRIALS; ICU SURVIVORS	Background and Aim Critically ill survivors may have functional impairments even five years after hospital discharge. To date there are four systematic reviews suggesting a beneficial impact for mobilisation in mechanically ventilated and intensive care unit (ICU) patients, however there is limited information about the influence of timing, frequency and duration of sessions. Earlier mobilisation during ICU stay may lead to greater benefits. This study aims to determine the effect of early rehabilitation for functional status in ICU/high-dependency unit (HDU) patients. Design Systematic review and meta-analysis. MEDLINE, EMBASE, CINALH, PEDro, Cochrane Library, AMED, ISI web of science, Scielo, LILACS and several clinical trial registries were searched for randomised and non-randomised clinical trials of rehabilitation compared to usual care in adult patients admitted to an ICU/HDU. Results were screened by two independent reviewers. Primary outcome was functional status. Secondary outcomes were walking ability, muscle strength, quality of life, and healthcare utilisation. Data extraction and methodological quality assessment using the PEDro scale was performed by primary reviewer and checked by two other reviewers. The authors of relevant studies were contacted to obtain missing data. Results 5733 records were screened. Seven articles were included in the narrative synthesis and six in the meta-analysis. Early rehabilitation had no significant effect on functional status, muscle strength, quality of life, or healthcare utilisation. However, early rehabilitation led to significantly more patients walking without assistance at hospital discharge (risk ratio 1.42; 95% CI 1.17-1.72). There was a non-significant effect favouring intervention for walking distance and incidence of ICU-acquired weakness. Conclusions Early rehabilitation during ICU stay was not associated with improvements in functional status, muscle strength, quality of life or healthcare utilisation outcomes, although it seems to improve walking ability compared to usual care. Results from ongoing studies may provide more data on the potential benefits of early rehabilitation in critically ill patients.	[Castro-Avila, Ana Cristina] Clin Alemana Univ Desarrollo, Fac Med, Carrera Kinesiol, Santiago, Chile; [Seron, Pamela; Gaete, Monica] Univ La Frontera, Fac Med, Dept Internal Med, Temuco, Chile; [Fan, Eddy] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada; [Mickan, Sharon] Univ Oxford, Dept Primary Care Hlth Sci, Oxford, England	Universidad del Desarrollo; Universidad de La Frontera; University of Toronto; University of Oxford	Castro-Avila, AC (corresponding author), Clin Alemana Univ Desarrollo, Fac Med, Carrera Kinesiol, Santiago, Chile.	anacastro@udd.cl	Seron, Pamela/AAN-3304-2021; Castro-Ávila, Ana/ABI-2587-2020; Mickan, Sharon/AAZ-6262-2021	Seron, Pamela/0000-0003-0190-8988; Castro-Ávila, Ana/0000-0003-4475-4325; Mickan, Sharon/0000-0002-5690-1997				Abba K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008122.pub2; Adler Joseph, 2012, Cardiopulm Phys Ther J, V23, P5; Ali NA, 2008, AM J RESP CRIT CARE, V178, P261, DOI 10.1164/rccm.200712-1829OC; Amidei Christina, 2012, Intensive Crit Care Nurs, V28, P73, DOI 10.1016/j.iccn.2011.12.006; Bailey Polly P, 2009, Crit Care Med, V37, pS429, DOI 10.1097/CCM.0b013e3181b6e227; Bohannon RW, 2001, AM J PHYS MED REHAB, V80, P13, DOI 10.1097/00002060-200101000-00004; Brummel NE, 2014, INTENS CARE MED, V40, P370, DOI 10.1007/s00134-013-3136-0; Burtin C, 2009, CRIT CARE MED, V37, P2499, DOI 10.1097/CCM.0b013e3181a38937; Calvo-Ayala E, 2013, CHEST, V144, P1469, DOI 10.1378/chest.13-0779; Cuthbertson BH, 2010, CRIT CARE, V14, DOI 10.1186/cc8848; De Jonghe B, 2007, CRIT CARE MED, V35, P2007, DOI 10.1097/01.ccm.0000281450.01881.d8; Denehy L, 2008, OPEN CRIT CARE MED J, V1, P39; Denehy L, 2013, CRIT CARE, V17, DOI 10.1186/cc12835; Dowdy DW, 2005, INTENS CARE MED, V31, P611, DOI 10.1007/s00134-005-2592-6; Elliott D, 2011, AUST CRIT CARE, V24, P155, DOI 10.1016/j.aucc.2011.05.002; Fan E, 2012, RESP CARE, V57, P933, DOI 10.4187/respcare.01634; Fan E, 2010, INTENS CARE MED, V36, P1038, DOI 10.1007/s00134-010-1796-6; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Gosselink R, 2008, INTENS CARE MED, V34, P1188, DOI 10.1007/s00134-008-1026-7; Gosselink R, 1996, AM J RESP CRIT CARE, V153, P976, DOI 10.1164/ajrccm.153.3.8630582; Hanekom SD, 2012, CRIT CARE, V16, DOI 10.1186/cc11894; Hermans G, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006832.pub2; Hermans G, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006832.pub3; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Kayambu G, 2013, CRIT CARE MED, V41, P1543, DOI 10.1097/CCM.0b013e31827ca637; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Leditschke I Anne, 2012, Cardiopulm Phys Ther J, V23, P26; Lefebvre C, 2011, COCHRANE COLLABORATI; Li ZQ, 2013, ARCH PHYS MED REHAB, V94, P551, DOI 10.1016/j.apmr.2012.10.023; Maffiuletti NA, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-137; Manriquez JJ, 2008, J CLIN EPIDEMIOL, V61, P407, DOI 10.1016/j.jclinepi.2007.06.009; Nava S, 1998, ARCH PHYS MED REHAB, V79, P849, DOI 10.1016/S0003-9993(98)90369-0; NICE, 2009, REH CRIT ILLN, V83; Nordon-Craft A, 2012, PHYS THER, V92, P1494, DOI 10.2522/ptj.20110117; Parker A, 2013, CRIT CARE, V17, DOI 10.1186/cc12884; Parry SM, 2013, CRIT CARE MED, V41, P2406, DOI 10.1097/CCM.0b013e3182923642; Routsi C, 2010, CRIT CARE, V14, DOI 10.1186/cc8987; Saxena MK, 2012, ANAEST INTENS CARE M, V13, P145; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schweickert WD, 2011, CHEST, V140, P1612, DOI 10.1378/chest.10-2829; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Scottish Intercollegiate Guidelines Network (SIGN), 2012, SEARCH FILT; Skinner EH, 2008, PHYSIOTHERAPY, V94, P220, DOI 10.1016/j.physio.2007.11.004; Stevens RD, 2007, INTENS CARE MED, V33, P1876, DOI 10.1007/s00134-007-0772-2; Stiller K, 2013, CHEST, V144, P825, DOI 10.1378/chest.12-2930; Timmerman RA, 2007, DIMENS CRIT CARE NUR, V26, P175, DOI 10.1097/01.DCC.0000286816.40570.da; Van der Schaaf M, 2000, DISABIL REHABIL, V22, P808; Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0	51	100	110	0	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2015	10	7							e0130722	10.1371/journal.pone.0130722	http://dx.doi.org/10.1371/journal.pone.0130722			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1CG	26132803	Green Published, Green Submitted, gold			2023-01-03	WOS:000358153000078
J	Smith, JE; Rockett, M; Creanor, SS; Squire, R; Hayward, C; Ewings, P; Barton, A; Pritchard, C; Eyre, V; Cocking, L; Benger, J				Smith, Jason E.; Rockett, Mark; Creanor, Siobhan S.; Squire, Rosalyn; Hayward, Chris; Ewings, Paul; Barton, Andy; Pritchard, Colin; Eyre, Victoria; Cocking, Laura; Benger, Jonathan		PASTIES Res Team	PAin SoluTions In the Emergency Setting (PASTIES)-patient controlled analgesia versus routine care in emergency department patients with pain from traumatic injuries: randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE POSTOPERATIVE PAIN; MANAGEMENT; GUIDELINES; VARIABLES; EFFICACY; SAFETY	OBJECTIVE To determine whether patient controlled analgesia (PCA) is better than routine care in patients presenting to emergency departments with moderate to severe pain from traumatic injuries. DESIGN Pragmatic, multicentre, parallel group, randomised controlled trial. SETTING Five English hospitals. PARTICIPANTS 200 adults (71% (n=142) male), aged 18 to 75 years, who presented to the emergency department requiring intravenous opioid analgesia for the treatment of moderate to severe pain from traumatic injuries and were expected to be admitted to hospital for at least 12 hours. INTERVENTIONS PCA (n=99) or nurse titrated analgesia (treatment as usual; n=101). MAIN OUTCOME MEASURES The primary outcome was total pain experienced over the 12 hour study period, derived by standardised area under the curve (scaled from 0 to 100) of each participant's hourly pain scores, captured using a visual analogue scale. Pre-specified secondary outcomes included total morphine use, percentage of study period in moderate/severe pain, percentage of study period asleep, length of hospital stay, and satisfaction with pain management. RESULTS 200 participants were included in the primary analyses. Mean total pain experienced was 47.2 (SD 21.9) for the treatment as usual group and 44.0 (24.0) for the PCA group. Adjusted analyses indicated slightly (but not statistically significantly) lower total pain experienced in the PCA group than in the routine care group (mean difference 2.7, 95% confidence interval-2.4 to 7.8). Participants allocated to PCA used more morphine in total than did participants in the treatment as usual group (mean 44.3 (23.2) v 27.2 (18.2) mg; mean difference 17.0, 11.3 to 22.7). PCA participants spent, on average, less time in moderate/severe pain (36.2% (31.0) v 44.1% (31.6)), but the difference was not statistically significant. A higher proportion of PCA participants reported being perfectly or very satisfied compared with the treatment as usual group (86% (78/91) v 76% (74/98)), but this was also not statistically significant. CONCLUSIONS PCA provided no statistically significant reduction in pain compared with routine care for emergency department patients with traumatic injuries.	[Smith, Jason E.; Rockett, Mark; Squire, Rosalyn] Derriford Hosp, Plymouth PL6 8DH, Devon, England; [Smith, Jason E.] Med Directorate, Acad Dept Mil Emergency Med, Royal Ctr Def Med Res & Academia, Birmingham, W Midlands, England; [Smith, Jason E.; Rockett, Mark] Plymouth Univ Peninsula, Ctr Clin Trials & Populat Studies, Sch Med, Plymouth, Devon, England; [Smith, Jason E.; Rockett, Mark] Plymouth Univ Peninsula, Ctr Clin Trials & Populat Studies, Sch Dent, Plymouth, Devon, England; [Creanor, Siobhan S.] Plymouth Univ Peninsula, Ctr Biostat Bioinformat & Biomarkers, Sch Med, Plymouth, Devon, England; [Creanor, Siobhan S.] Plymouth Univ Peninsula, Ctr Biostat Bioinformat & Biomarkers, Sch Dent, Plymouth, Devon, England; [Hayward, Chris; Eyre, Victoria; Cocking, Laura] Plymouth Univ Peninsula, Peninsula Clin Trials Unit, Sch Med, Plymouth, Devon, England; [Hayward, Chris; Eyre, Victoria; Cocking, Laura] Plymouth Univ Peninsula, Peninsula Clin Trials Unit, Sch Dent, Plymouth, Devon, England; [Ewings, Paul; Barton, Andy; Pritchard, Colin] NIHR Res Design Serv South West, Bristol, Avon, England; [Benger, Jonathan] Univ W England, Fac Hlth & Appl Sci, Bristol BS16 1QY, Avon, England	Derriford Hospital; Royal Centre for Defence Medicine; University of West England	Smith, JE (corresponding author), Derriford Hosp, Plymouth PL6 8DH, Devon, England.	jasonesmith@nhs.net	Skene, Imogen/D-6153-2018; Coats, Timothy/AAW-1254-2021; Rockett, Mark/A-9465-2012; Creanor, Siobhan/A-9985-2018; Smith, Jason Edward/H-9380-2013	Skene, Imogen/0000-0001-5215-2899; Coats, Timothy/0000-0003-2736-2784; Rockett, Mark/0000-0001-8907-4396; Creanor, Siobhan/0000-0002-7373-8263; Smith, Jason Edward/0000-0002-6143-0421; barton, andy/0000-0003-2245-1446; Hayward, Christopher/0000-0002-2666-5073; Cocking, Laura/0000-0002-1371-6978	National Institute for Health Research (NIHR) [PB-PG-0909-20048]; National Institute for Health Research [PB-PG-0909-20048] Funding Source: researchfish	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	This research was funded by the National Institute for Health Research (NIHR)'s research for patient benefit programme, grant reference number PB-PG-0909-20048. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.	Ab Rahman NHN, 2012, EUR J EMERG MED, V19, P241, DOI 10.1097/MEJ.0b013e32834bfc17; [Anonymous], 1979, Pain, V6, P249; Arendts G, 2006, J PAIN, V7, P682, DOI 10.1016/j.jpain.2006.03.003; Birnbaum A, 2012, ACAD EMERG MED, V19, DOI 10.1111/j.1553-2712.2012.01322.x; Camu F, 1998, ANESTH ANALG, V87, P890, DOI 10.1097/00000539-199810000-00027; Care Quality Commission, 2012, ACC EM 2012; CHOINIERE M, 1992, ANAESTHESIA, V47, P467, DOI 10.1111/j.1365-2044.1992.tb02266.x; College of Emergency Medicine, 2014, CLIN STAND EM DEP; Dolin SJ, 2002, BRIT J ANAESTH, V89, P409, DOI 10.1093/bja/aef207; Evans E, 2005, EMERG MED J, V22, P25, DOI 10.1136/emj.2002.004614; Hudcova J, 2006, COCHRANE DB SYST REV, DOI 10.1002/146518583.CD003348.pub2; Lvovschi V, 2008, AM J EMERG MED, V26, P676, DOI 10.1016/j.ajem.2007.10.025; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; Moher David, 2010, BMJ, V340, pc869, DOI [10.1016/j.jclinepi.2010.03.004, 10.1136/bmj.c869]; OWEN H, 1989, ANAESTHESIA, V44, P11, DOI 10.1111/j.1365-2044.1989.tb11088.x; OWEN H, 1989, ANAESTHESIA, V44, P7, DOI 10.1111/j.1365-2044.1989.tb11087.x; Plummer JL, 1997, ANESTH ANALG, V84, P794, DOI 10.1097/00000539-199704000-00018; Rahman NHNA, 2012, J EMERG MED, V43, P951, DOI 10.1016/j.jemermed.2012.02.069; Rees DC, 2003, BRIT J HAEMATOL, V120, P744, DOI 10.1046/j.1365-2141.2003.04193.x; Smith JE, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002577; Todd KH, 2007, J PAIN, V8, P460, DOI 10.1016/j.jpain.2006.12.005; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x; WHITE PF, 1988, JAMA-J AM MED ASSOC, V259, P243, DOI 10.1001/jama.259.2.243	24	20	20	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 21	2015	350								h2988	10.1136/bmj.h2988	http://dx.doi.org/10.1136/bmj.h2988			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	DO3WK	26094763	Green Published, hybrid			2023-01-03	WOS:000377712900001
J	Zhang, W; Cho, SY; Xiang, G; Min, KJ; Yu, Q; Jin, JO				Zhang, Wei; Cho, Si-Young; Xiang, Gao; Min, Kyung-Jin; Yu, Qing; Jin, Jun-O			Ginseng Berry Extract Promotes Maturation of Mouse Dendritic Cells	PLOS ONE			English	Article							IMMUNE-RESPONSES; T-CELLS; LIPOPOLYSACCHARIDES; POLYSACCHARIDES; ANTIGEN; VACCINE; RG1	Ginseng extract has been shown to possess certain anti-virus, anti-tumor and immune-activating effects. However, the immunostimulatory effect of ginseng berry extract (GB) has been less well characterized. In this study, we investigated the effect of GB on the activation of mouse dendritic cells (DCs) in vitro and in vivo. GB treatment induced up-regulation of co-stimulatory molecules in bone marrow-derived DCs (BMDCs). Interestingly, GB induced a higher degree of co-stimulatory molecule up-regulation than ginseng root extract (GR) at the same concentrations. Moreover, in vivo administration of GB promoted up-regulation of CD86, MHC class I and MHC class II and production of IL-6, IL-12 and TNF-alpha in spleen DCs. GB also promoted the generation of Th1 and Tc1 cells. Furthermore, Toll like receptor 4 (TLR4) and myeloid differentiation primary response 88 (MyD88) signaling pathway were essential for DC activation induced by GB. In addition, GB strongly prompted the proliferation of ovalbumin (OVA)-specific CD4 and CD8 T cells. Finally, GB induced DC activation in tumor-bearing mice and the combination of OVA and GB treatment inhibited B16-OVA tumor cell growth in C57BL/6 mice. These results demonstrate that GB is a novel tumor therapeutic vaccine adjuvant by promoting DC and T cell activation.	[Zhang, Wei; Jin, Jun-O] Fudan Univ, Shanghai Med Coll, Shanghai Publ Hlth Clin Ctr, Shanghai 200433, Peoples R China; [Cho, Si-Young] AmorePacific Corp, R&D Unit, Yongin, Gyeonggi Do, South Korea; [Xiang, Gao] Nanjing Univ, Model Anim Res Ctr, Nanjing 210008, Jiangsu, Peoples R China; [Min, Kyung-Jin] Inha Univ, Dept Biol Sci, Inchon, South Korea; [Yu, Qing] Forsyth Inst, Dept Immunol & Infect Dis, Cambridge, MA USA	Fudan University; Nanjing University; Inha University; Harvard University; Forsyth Institute	Jin, JO (corresponding author), Fudan Univ, Shanghai Med Coll, Shanghai Publ Hlth Clin Ctr, Shanghai 200433, Peoples R China.	Junojin1@gmail.com	yu, qing/HGC-4611-2022; Min, Kyung-Jin/AAG-5774-2020; Jin, Jun-O/G-2998-2014	Min, Kyung-Jin/0000-0001-5829-6842; Jin, Jun-O/0000-0003-4216-8111	Research fund for International Young Scientists from National Natural Science Foundation of China [81450110090]; AmorePacific Corporation	Research fund for International Young Scientists from National Natural Science Foundation of China; AmorePacific Corporation	This study was supported by Research fund for International Young Scientists from National Natural Science Foundation of China (81450110090). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. AmorePacific Corporation provided support in the form of salary for author Si-Young Cho and research materials, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of this author are articulated in the 'author contributions' section.	Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592; Blumenthal M., 2001, ADV NURSE PRACTITION, V9, P33; Byeon SE, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/732860; Calzas C, 2013, INFECT IMMUN, V81, P3106, DOI 10.1128/IAI.00113-13; Chen LW, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-48; Cho KS, 2013, ASIAN J ANDROL, V15, P503, DOI 10.1038/aja.2013.49; Choi YD, 2013, INT J IMPOT RES, V25, P45, DOI 10.1038/ijir.2012.45; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Dey L, 2003, PHYTOMEDICINE, V10, P600, DOI 10.1078/094471103322331908; Dubensky TW, 2010, SEMIN IMMUNOL, V22, P155, DOI 10.1016/j.smim.2010.04.007; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Inagawa H, 2011, ANTICANCER RES, V31, P2431; Jin JO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099396; Jin JO, 2009, BLOOD, V113, P5839, DOI 10.1182/blood-2008-10-184796; Kim CK, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/490301; KIMURA M, 1981, J PHARMACOBIO-DYNAM, V4, P410, DOI 10.1248/bpb1978.4.410; Lee JS, 2014, INT J MOL MED, V34, P183, DOI 10.3892/ijmm.2014.1750; Lin CY, 2013, MAR DRUGS, V11, P1336, DOI 10.3390/md11041336; MURAKAMI M, 1994, J EXP MED, V180, P111, DOI 10.1084/jem.180.1.111; Ochi A, 2012, J EXP MED, V209, P1671, DOI 10.1084/jem.20111706; Oketani K, 2001, EUR J PHARMACOL, V427, P159, DOI 10.1016/S0014-2999(01)01234-1; Park EY, 2012, J GINSENG RES, V36, P153, DOI 10.5142/jgr.2012.36.2.153; Pooley JL, 2001, J IMMUNOL, V166, P5327, DOI 10.4049/jimmunol.166.9.5327; Ramberg JE, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-54; Shortman K, 2010, IMMUNOL REV, V234, P18, DOI 10.1111/j.0105-2896.2009.00870.x; Su F, 2012, VACCINE, V30, P4106, DOI 10.1016/j.vaccine.2012.03.052; Tran TL, 2014, BIOORGAN MED CHEM, V22, P499, DOI 10.1016/j.bmc.2013.11.002; Villadangos JA, 2007, NAT REV IMMUNOL, V7, P543, DOI 10.1038/nri2103; Wang Y, 2014, INT IMMUNOPHARMACOL, V23, P77, DOI 10.1016/j.intimp.2014.07.028; Wang ZZ, 2013, INT J BIOL MACROMOL, V53, P93, DOI 10.1016/j.ijbiomac.2012.11.009; Zhai LJ, 2011, VACCINE, V29, P5007, DOI 10.1016/j.vaccine.2011.04.097; Zhang GY, 2013, INT J BIOL MACROMOL, V53, P1, DOI 10.1016/j.ijbiomac.2012.10.031; Zhang W, 2014, MAR DRUGS, V12, P4148, DOI 10.3390/md12074148; Zhao BS, 2014, MOLECULES, V19, P16925, DOI 10.3390/molecules191016925; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806	36	23	25	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2015	10	6							e0130926	10.1371/journal.pone.0130926	http://dx.doi.org/10.1371/journal.pone.0130926			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL3FE	26090808	Green Submitted, Green Published, gold			2023-01-03	WOS:000356835000160
J	Slusher, TM; Olusanya, BO; Vreman, HJ; Brearley, AM; Vaucher, YE; Lund, TC; Wong, RJ; Emokpae, AA; Stevenson, DK				Slusher, Tina M.; Olusanya, Bolajoko O.; Vreman, Hendrik J.; Brearley, Ann M.; Vaucher, Yvonne E.; Lund, Troy C.; Wong, Ronald J.; Emokpae, Abieyuwa A.; Stevenson, David K.			A Randomized Trial of Phototherapy with Filtered Sunlight in African Neonates	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; HYPERBILIRUBINEMIA; JAUNDICE; KERNICTERUS; IMPAIRMENT; MANAGEMENT; ETIOLOGY; OUTCOMES	BACKGROUND Sequelae of severe neonatal hyperbilirubinemia constitute a substantial disease burden in areas where effective conventional phototherapy is unavailable. We previously found that the use of filtered sunlight for the purpose of phototherapy is a safe and efficacious method for reducing total bilirubin. However, its relative safety and efficacy as compared with conventional phototherapy are unknown. METHODS We conducted a randomized, controlled noninferiority trial in which filtered sunlight was compared with conventional phototherapy for the treatment of hyperbilirubinemia in term and late-preterm neonates in a large, urban Nigerian maternity hospital. The primary end point was efficacy, which was defined as a rate of increase in total serum bilirubin of less than 0.2 mg per deciliter per hour for infants up to 72 hours of age or a decrease in total serum bilirubin for infants older than 72 hours of age who received at least 5 hours of phototherapy; we pre-specified a noninferiority margin of 10% for the difference in efficacy rates between groups. The need for an exchange transfusion was a secondary end point. We also assessed safety, which was defined as the absence of the need to withdraw therapy because of hyperthermia, hypothermia, dehydration, or sunburn. RESULTS We enrolled 447 infants and randomly assigned 224 to filtered sunlight and 223 to conventional phototherapy. Filtered sunlight was efficacious on 93% of treatment days that could be evaluated, as compared with 90% for conventional phototherapy, and had a higher mean level of irradiance (40 vs. 17 mu W per square centimeter per nanometer, P<0.001). Temperatures higher than 38.0 degrees C occurred in 5% of the infants receiving filtered sunlight and in 1% of those receiving conventional phototherapy (P<0.001), but no infant met the criteria for withdrawal from the study for reasons of safety or required an exchange transfusion. CONCLUSIONS Filtered sunlight was noninferior to conventional phototherapy for the treatment of neonatal hyperbilirubinemia and did not result in any study withdrawals for reasons of safety.	[Slusher, Tina M.; Lund, Troy C.] Univ Minnesota, Dept Pediat, Minneapolis, MN 55414 USA; [Brearley, Ann M.] Univ Minnesota, Clin & Translat Sci Inst, Biostat Design & Anal Ctr, Minneapolis, MN 55414 USA; [Slusher, Tina M.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA; [Olusanya, Bolajoko O.] Ctr Hlth Start Initiat, Lagos, Nigeria; [Emokpae, Abieyuwa A.] Massey St Childrens Hosp, Lagos, Nigeria; [Vreman, Hendrik J.; Wong, Ronald J.; Stevenson, David K.] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA; [Vaucher, Yvonne E.] Univ Calif San Diego, San Diego, CA 92103 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Hennepin County Medical Center; Stanford University; University of California System; University of California San Diego	Slusher, TM (corresponding author), Univ Minnesota, Dept Pediat, Ctr Global Pediat, 717 Delaware St SE,3rd Fl, Minneapolis, MN 55414 USA.	tslusher@umn.edu	Olusanya, Bolajoko O./F-4504-2012	Olusanya, Bolajoko O./0000-0002-3826-0583	Thrasher Research Fund, Salt Lake City; National Center for Advancing Translational Sciences of the National Institutes of Health; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000114] Funding Source: NIH RePORTER	Thrasher Research Fund, Salt Lake City; National Center for Advancing Translational Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Funded by the Thrasher Research Fund, Salt Lake City, and the National Center for Advancing Translational Sciences of the National Institutes of Health; Clinical Trials.gov number, NCT01434810.	BEUTLER E, 1979, BRIT J HAEMATOL, V43, P465, DOI 10.1111/j.1365-2141.1979.tb03774.x; Bhutani VK, 2013, PEDIATR RES, V74, P86, DOI 10.1038/pr.2013.208; Bhutani VK, 2011, PEDIATRICS, V128, pE1046, DOI 10.1542/peds.2011-1494; Burke BL, 2009, PEDIATRICS, V123, P524, DOI 10.1542/peds.2007-2915; Carlin JB, 2008, LANCET, V371, P135, DOI 10.1016/S0140-6736(08)60106-3; Cline BK, 2013, J TROP PEDIATRICS, V59, P321, DOI 10.1093/tropej/fmt027; CREMER RJ, 1958, LANCET, V1, P1094; Gladstone M, 2010, ANN TROP PAEDIATR, V30, P181, DOI 10.1179/146532810X12786388978481; Hansen TWR, 1997, ACTA PAEDIATR, V86, P843; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Harrison S, 2013, J TROP PEDIATRICS, V59, P403, DOI 10.1093/tropej/fmt042; JAHRIG K, 1982, ACTA PAEDIATR SCAND, V71, P293, DOI 10.1111/j.1651-2227.1982.tb09417.x; Johnson L, 2009, J PERINATOL, V29, pS25, DOI 10.1038/jp.2008.211; Kuzniewicz MW, 2014, PEDIATRICS, V134, P504, DOI 10.1542/peds.2014-0987; Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; Maisels MJ, 2008, NEW ENGL J MED, V358, P920, DOI 10.1056/NEJMct0708376; Maisels MJ, 2004, PEDIATRICS, V114, P297; Maulik PK, 2007, PEDIATRICS, V120, pS1, DOI 10.1542/peds.2007-0043B; McDonagh A F, 2001, J Perinatol, V21 Suppl 1, pS7, DOI 10.1038/sj.jp.7210625; Mwaniki MK, 2012, LANCET, V379, P445, DOI 10.1016/S0140-6736(11)61577-8; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; Okperi BO, 2013, INT J MED BIOMED RES, V2, P226; Olusanya BO, 2015, SEMIN FETAL NEONAT M, V20, P58, DOI 10.1016/j.siny.2014.12.009; Olusanya BO, 2014, ACTA PAEDIATR, V103, P1102, DOI 10.1111/apa.12735; Olusanya BO, 2014, ARCH DIS CHILD, V99, P1117, DOI 10.1136/archdischild-2013-305506; Olusanya BO, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-180; Owa JA, 2011, INDIAN J PEDIATR, V78, P996, DOI 10.1007/s12098-011-0382-4; Pejaver Ranjan Kumar, 2000, Indian Journal of Pediatrics, V67, P883, DOI 10.1007/BF02723951; Petrova Anna, 2006, BMC Pediatr, V6, P6, DOI 10.1186/1471-2431-6-6; Salih FM, 2001, PHOTODERMATOL PHOTO, V17, P272, DOI 10.1034/j.1600-0781.2001.170605.x; Satrom K, 2014, J TROP PEDIATRICS, V60, P264, DOI [10.1093/tropej/fmt110, 10.1093/t]; Scrafford CG, 2013, TROP MED INT HEALTH, V18, P1317, DOI 10.1111/tmi.12189; Slusher T, 2012, TXB GOBAL CHILD HLTH; Slusher TM, 2014, PEDIATRICS, V133, pE1568, DOI 10.1542/peds.2013-3500; Slusher TM, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-446; Strauss KA, 2006, EUR J PEDIATR, V165, P306, DOI 10.1007/s00431-005-0055-2; Tomashek KM, 2006, PAEDIATR PERINAT EP, V20, P24, DOI 10.1111/j.1365-3016.2006.00690.x; Vreman HJ, 2013, J TROP PEDIATRICS, V59, P496, DOI 10.1093/tropej/fmt062	38	45	45	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 17	2015	373	12					1115	1124		10.1056/NEJMoa1501074	http://dx.doi.org/10.1056/NEJMoa1501074			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CR7UG	26376136				2023-01-03	WOS:000361556400007
J	Sanford, T; McCulloch, CE; Callcut, RA; Carroll, PR; Breyer, BN				Sanford, Thomas; McCulloch, Charles E.; Callcut, Rachael A.; Carroll, Peter R.; Breyer, Benjamin N.			Bicycle Trauma Injuries and Hospital Admissions in the United States, 1998-2013	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Sanford, Thomas; Carroll, Peter R.; Breyer, Benjamin N.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94110 USA; [McCulloch, Charles E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94110 USA; [Callcut, Rachael A.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94110 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Breyer, BN (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Urol, 1001 Potrero Ave, San Francisco, CA 94110 USA.	bbreyer@urology.ucsf.edu	Callcut, Rachael/ABE-1484-2021	Sanford, Thomas/0000-0002-7123-9807	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K12DK083021] Funding Source: NIH RePORTER; NCATS NIH HHS [8KL2TR000143-09, KL2 TR000143] Funding Source: Medline; NIDDK NIH HHS [K12 DK083021, K12DK083021] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Division of Hazard and Injury Data Systems United States consumer product safety commission, NAT EL INJ SURV SYST; Edmonson B, US BICYCLE MARKET TR; Lopez DS, 2012, J TRAUMA ACUTE CARE, V73, P1602, DOI 10.1097/TA.0b013e318265fc04; Pucher J, 2011, TRANSPORT RES A-POL, V45, P451, DOI 10.1016/j.tra.2011.03.001; Rivara FP, 2015, INJURY PREV, V21, P47, DOI 10.1136/injprev-00002-0038rep; USA Cycling and the USA Cycling Development Foundation, 2013, 2013 ANN REP	6	38	38	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	2015	314	9					947	949		10.1001/jama.2015.8295	http://dx.doi.org/10.1001/jama.2015.8295			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CQ1WX	26325564	Green Published, Bronze, Green Accepted			2023-01-03	WOS:000360392100022
J	Nagaya, T; Sato, K; Harada, T; Nakamura, Y; Choyke, PL; Kobayashi, H				Nagaya, Tadanobu; Sato, Kazuhide; Harada, Toshiko; Nakamura, Yuko; Choyke, Peter L.; Kobayashi, Hisataka			Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen	PLOS ONE			English	Article							GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; ENHANCED PERMEABILITY; PHOTODYNAMIC THERAPY; TUMOR-MODEL; EXPRESSION; EFFICACY; SUBTYPES; CETUXIMAB; COCKTAIL	Aim Triple-negative breast cancer (TNBC) is considered one of the most aggressive subtypes of breast cancer. Near infrared photoimmunotherapy (NIR-PIT) is a cancer treatment that employs an antibody-photosensitizer conjugate (APC) followed by exposure of NIR light for activating selective cytotoxicity on targeted cancer cells and may have application to TNBC. In order to minimize the dose of APC while maximizing the therapeutic effects, dosing of the APC and NIR light need to be optimized. In this study, we investigate in vitro and in vivo efficacy of cetuximab (cet)-IR700 NIR-PIT on two breast cancer models MDAMB231 (TNBC, EGFR moderate) and MDAMB468 (TNBC, EGFR high) cell lines, and demonstrate a method to optimize the dosing APC and NIR light. Method After validating in vitro cell-specific cytotoxicity, NIR-PIT therapeutic effects were investigated in mouse models using cell lines derived from TNBC tumors. Tumor-bearing mice were separated into 4 groups for the following treatments: (1) no treatment (control); (2) 300 mu g of cet-IR700 i.v., (APC i.v. only); (3) NIR light exposure only, NIR light was administered at 50 J/cm(2) on day 1 and 100 J/cm(2) on day 2 (NIR light only); (4) 300 mu g of cet-IR700 i.v., NIR light was administered at 50 J/cm(2) on day 1 after injection and 100 J/cm(2) of light on day 2 after injection (one shot NIR-PIT). To compare different treatment regimens with a fixed dose of APC, we added the following treatments (5) 100 mu g of cet-IR700 i.v., NIR light administered at 50 J/cm(2) on day 1 and 50 mu g of cet-IR700 i.v. immediately after NIR-PIT, then NIR light was administered at 100 J/cm(2) on day 2, which were performed two times every week ("two split" NIR-PIT) and (6) 100 mu g of cet-IR700 i.v., NIR light was administered at 50 J/cm(2) on day 1 and 100 J/cm(2) on day 2, which were performed three times per week ("three split" NIR-PIT). Result Both specific binding and NIR-PIT effects were greater with MDAMB468 than MDAMB231 cells in vitro. Tumor accumulation of cet-IR700 in MDAMB468 tumors was significantly higher (p < 0.05) than in MDAMB231 tumors in vivo. Tumor growth and survival of MDAMB231 tumor bearing mice was significantly lower in the NIR-PIT treatment group (p < 0.05). In MDAMB468 bearing mice, tumor growth and survival was significantly improved in the NIR-PIT treatment groups in all treatment regimens (one shot NIR-PIT; p < 0.05, "two split" NIR-PIT; p < 0.01, "three split" NIR-PIT; p < 0.001) compared with control groups. Conclusion NIR-PIT for TNBC was effective regardless of expression of EGFR, however, greater cell killing was shown with higher EGFR expression tumor in vitro. In all treatment regimens, NIR-PIT suppressed tumor growth, resulting in significantly prolonged survival that further improved by splitting the APC dose and using repeated light exposures.	[Nagaya, Tadanobu; Sato, Kazuhide; Harada, Toshiko; Nakamura, Yuko; Choyke, Peter L.; Kobayashi, Hisataka] NCI, Mol Imaging Program, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kobayashi, H (corresponding author), NCI, Mol Imaging Program, Ctr Canc Res, Bethesda, MD 20892 USA.	kobayash@mail.nih.gov		Sato, Kazuhide/0000-0003-3025-088X	National Cancer Institute [ZIA BC 011513]; NATIONAL CANCER INSTITUTE [ZIABC011513] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	HK received funding from the National Cancer Institute, ZIA BC 011513, https://ccrod.cancer.gov/confluence/display/CCRARSINFO/Z+Numbers+-+2013+Completed+Projects. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barrett T, 2007, CLIN CANCER RES, V13, P6639, DOI 10.1158/1078-0432.CCR-07-1119; Baselga J, 2013, J CLIN ONCOL, V31, P2586, DOI 10.1200/JCO.2012.46.2408; Bertucci F, 2012, CURR MOL MED, V12, P96, DOI 10.2174/156652412798376134; Chen B, 2006, CLIN CANCER RES, V12, P917, DOI 10.1158/1078-0432.CCR-05-1673; Engebraaten O, 2013, AM J PATHOL, V183, P1064, DOI 10.1016/j.ajpath.2013.05.033; Finn RS, 2009, J CLIN ONCOL, V27, P3908, DOI 10.1200/JCO.2008.18.1925; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gelmon K, 2012, ANN ONCOL, V23, P2223, DOI 10.1093/annonc/mds067; Gil M, 2011, BRIT J CANCER, V105, P1512, DOI 10.1038/bjc.2011.429; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Hoffman RM, 1999, INVEST NEW DRUG, V17, P343, DOI 10.1023/A:1006326203858; Kaufmann M, 2011, CANCER-AM CANCER SOC, V117, P1575, DOI 10.1002/cncr.25660; Kobayashi H, 2014, THERANOSTICS, V4, P81, DOI 10.7150/thno.7193; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; MEW D, 1983, J IMMUNOL, V130, P1473; Mitsunaga M, 2012, BIOCONJUGATE CHEM, V23, P604, DOI 10.1021/bc200648m; Mitsunaga M, 2011, NAT MED, V17, P1685, DOI 10.1038/nm.2554; Modi S, 2006, CLIN BREAST CANCER, V7, P270, DOI 10.3816/CBC.2006.n.040; Momiyama M, 2013, J CELL BIOCHEM, V114, P428, DOI 10.1002/jcb.24381; Momiyama M, 2012, ANTICANCER RES, V32, P4327; Nakajima T, 2013, THERANOSTICS, V3, P357, DOI 10.7150/thno.5908; Nechushtan H, 2014, BREAST, V23, P435, DOI 10.1016/j.breast.2014.03.003; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Reichert JM, 2005, NAT BIOTECHNOL, V23, P1073, DOI 10.1038/nbt0905-1073; Sano K, 2014, MOL CANCER THER, V13, P426, DOI 10.1158/1535-7163.MCT-13-0633; Sano K, 2013, ACS NANO, V7, P717, DOI 10.1021/nn305011p; Sato K, 2015, THERANOSTICS, V5, P698, DOI 10.7150/thno.11559; Sato K, 2015, MOL CANCER THER, V14, P141, DOI 10.1158/1535-7163.MCT-14-0658; Sato K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113276; Sato K, 2014, MOL ONCOL, V8, P620, DOI 10.1016/j.molonc.2014.01.006; Snyder JW, 2003, CANCER RES, V63, P8126; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309	33	60	68	1	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2015	10	8							e0136829	10.1371/journal.pone.0136829	http://dx.doi.org/10.1371/journal.pone.0136829			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP8KZ	26313651	Green Published, gold, Green Submitted			2023-01-03	WOS:000360144000098
J	Pal, SK; Lin, YI; Yuh, B; DeWalt, K; Kazarian, A; Vogelzang, N; Nelson, RA				Pal, Sumanta Kumar; Lin, Yulan Ingrid; Yuh, Bertram; DeWalt, Kara; Kazarian, Austin; Vogelzang, Nicholas; Nelson, Rebecca A.			Conditional Survival in de novo Metastatic Urothelial Carcinoma	PLOS ONE			English	Article							TRANSITIONAL-CELL CARCINOMA; PHASE-II TRIAL; 1ST-LINE TREATMENT; GEMCITABINE; THERAPY; CISPLATIN; CANCER; CHEMOTHERAPY; COMBINATION; CARBOPLATIN	Background Second-line therapy is frequently utilized for metastatic urothelial carcinoma, but there are limited data to guide this approach. While an assessment of overall survival based on registry data may not capture the impact of second-and third-line therapies on clinical outcome, this may be reflected in relative conditional survival (RCS). Methods Patients with stage IV urothelial carcinoma diagnosed from 1990-2010 were identified from the Surveillance, Epidemiology and End Results (SEER) dataset. The association of clinicopathologic variables with disease specific survival (DSS) was explored through univariate and multivariate analyses. DSS in subgroups divided by time period (1990-2000 v 2001-2010) was compared using the Kaplan-Meier method and log-rank test. One-year RCS at annual landmarks up to 5 years was compared in subgroups divided by time period. Results Of 261,987 patients diagnosed with urothelial carcinoma from 1990-2010, 3,110 patients met criteria for the current analysis. Characteristics of patients diagnosed between 1990 and 2000 (n = 810) and 2001 to 2010 (n = 2,300) were similar and there was no significant difference in DSS between the two groups. On multivariate analysis, older age (age >= 80) was associated with shorter DSS (HR 1.79, 95% CI 1.48-2.15), but no association was found between time period of diagnosis and outcome. One-year RCS improved substantially through successive annual landmarks up to 5 years, but no differences were seen in subgroups divided by time of diagnosis. Conclusions No difference in RCS was observed amongst patients with stage IV urothelial carcinoma diagnosed from 1990-2000 and 2001-2010. A lack of difference in RCS (more so than cumulative DSS) may reflect a lack of progress in salvage therapies for the disease.	[Pal, Sumanta Kumar; Lin, Yulan Ingrid; DeWalt, Kara; Kazarian, Austin] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA USA; [Yuh, Bertram] City Hope Comprehens Canc Ctr, Dept Surg, Div Urol, Duarte, CA USA; [Vogelzang, Nicholas] US Oncol Res, Ctr Comprehens Canc, Las Vegas, NV USA; [Nelson, Rebecca A.] City Hope Comprehens Canc Ctr, Dept Informat Sci, Div Biostat, Duarte, CA USA	City of Hope; City of Hope; US Oncology Network; City of Hope	Pal, SK (corresponding author), City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA USA.	spal@coh.org			NIH [K12 2K12CA001727-16A1]; NATIONAL CANCER INSTITUTE [K12CA001727] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH K12 2K12CA001727-16A1 (to S.K.P.) (www.nih.gov). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abida W, 2015, HEMATOL ONCOL CLIN N, V29, P319, DOI 10.1016/j.hoc.2014.10.005; Bajorin DF, 1999, J CLIN ONCOL, V17, P3173, DOI 10.1200/JCO.1999.17.10.3173; Bamias A, 2006, CANCER, V106, P297, DOI 10.1002/cncr.21604; Bellmunt J, 2009, J CLIN ONCOL, V27, P4454, DOI 10.1200/JCO.2008.20.5534; Corazziari I, 2004, EUR J CANCER, V40, P2307, DOI 10.1016/j.ejca.2004.07.002; Dreicer R, 2008, CANCER-AM CANCER SOC, V112, P2671, DOI 10.1002/cncr.23503; Fechner G, 2006, INT J CLIN PRACT, V60, P27, DOI 10.1111/j.1368-5031.2005.00663.x; Galsky MD, 2013, CANCER-AM CANCER SOC, V119, P3012, DOI 10.1002/cncr.28146; Galsky MD, 2011, LANCET ONCOL, V12, P211, DOI 10.1016/S1470-2045(10)70275-8; Galsky MD, 2013, J CLIN ONCOL, V31; Gitlitz BJ, 2003, CANCER-AM CANCER SOC, V98, P1863, DOI 10.1002/cncr.11726; Gondo T, 2011, INT J CLIN ONCOL, V16, P345, DOI 10.1007/s10147-011-0188-4; Grivas P, 2012, J CLIN ONCOL, V30; Hahn NM, 2011, J CLIN ONCOL, V29, P1525, DOI 10.1200/JCO.2010.31.6067; Harshman LC, 2012, LANCET ONCOL, V13, P927, DOI 10.1016/S1470-2045(12)70285-1; Linardou H, 2004, UROLOGY, V64, P479, DOI 10.1016/j.urology.2004.04.024; OSTROW S, 1980, CANCER, V46, P1715, DOI 10.1002/1097-0142(19801015)46:8<1715::AID-CNCR2820460802>3.0.CO;2-H; Pal SK, 2013, J NATL COMPR CANC NE, V11, P793, DOI 10.6004/jnccn.2013.0101; Ploussard G, 2014, EUR UROL, V66, P361, DOI 10.1016/j.eururo.2013.09.050; Pond GR, 2014, BJU INT, V113, pE137, DOI 10.1111/bju.12564; Rossof AH, CANC TREAT REP, V63, P1605; Rossof AH, CANC TREAT REP, V63, P557; Sonpavde G, 2010, LANCET ONCOL, V11, P861, DOI 10.1016/S1470-2045(10)70086-3; Srinivas S, 2009, CHEMOTHERAPY, V55, P321, DOI 10.1159/000230695; Sun M, 2012, EUR J CANCER, V48, P1503, DOI 10.1016/j.ejca.2011.11.024; Surveillance E, SEER STAT DAT MORT A; Sweeney CJ, 2006, J CLIN ONCOL, V24, P3451, DOI 10.1200/JCO.2005.03.6699; YAGODA A, 1976, CANCER TREAT REP, V60, P917	28	9	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2015	10	8							e0136622	10.1371/journal.pone.0136622	http://dx.doi.org/10.1371/journal.pone.0136622			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP7LO	26308952	gold, Green Published, Green Submitted			2023-01-03	WOS:000360069400145
J	Shiba, N; Matsuse, H; Takano, Y; Yoshimitsu, K; Omoto, M; Hashida, R; Tagawa, Y; Inada, T; Yamada, S; Ohshima, H				Shiba, Naoto; Matsuse, Hiroo; Takano, Yoshio; Yoshimitsu, Kazuhiro; Omoto, Masayuki; Hashida, Ryuki; Tagawa, Yoshihiko; Inada, Tomohisa; Yamada, Shin; Ohshima, Hiroshi			Electrically Stimulated Antagonist Muscle Contraction Increased Muscle Mass and Bone Mineral Density of One Astronaut - Initial Verification on the International Space Station	PLOS ONE			English	Article							EXERCISE; VOLUNTARY; STRENGTH; HYPERTROPHY; SPACEFLIGHT; RESPONSES; VOLUME	Background Musculoskeletal atrophy is one of the major problems of extended periods of exposure to weightlessness such as on the International Space Station (ISS). We developed the Hybrid Training System (HTS) to maintain an astronaut's musculoskeletal system using an electrically stimulated antagonist to resist the volitional contraction of the agonist instead of gravity. The present study assessed the system's orbital operation capability and utility, as well as its preventative effect on an astronaut's musculoskeletal atrophy. Methods HTS was attached to the non-dominant arm of an astronaut staying on the ISS, and his dominant arm without HTS was established as the control (CTR). 10 sets of 10 reciprocal elbow curls were one training session, and 12 total sessions of training (3 times per week for 4 weeks) were performed. Pre and post flight ground based evaluations were performed by Biodex (muscle performance), MRI (muscle volume), and DXA (BMD, lean [muscle] mass, fat mass). Pre and post training inflight evaluations were performed by a hand held dynamometer (muscle force) and a measuring tape (upper arm circumference). Results The experiment was completed on schedule, and HTS functioned well without problems. Isokinetic elbow extension torque (Nm) changed -19.4% in HTS, and -21.7% in CTR. Isokinetic elbow flexion torque changed -23.7% in HTS, and there was no change in CTR. Total Work (Joule) of elbow extension changed -8.3% in HTS, and +0.3% in CTR. For elbow flexion it changed -23.3% in HTS and -32.6% in CTR. Average Power (Watts) of elbow extension changed +22.1% in HTS and -8.0% in CTR. For elbow flexion it changed -6.5% in HTS and -4.8% in CTR. Triceps muscle volume according to MRI changed +11.7% and that of biceps was +2.1% using HTS, however -0.1% and -0.4% respectively for CTR. BMD changed +4.6% in the HTS arm and -1.2% for CTR. Lean (muscle) mass of the arm changed only +10.6% in HTS. Fat mass changed -12.6% in HTS and -6.4% in CTR. Conclusions These results showed the orbital operation capability and utility, and the preventive effect of HTS for an astronaut's musculoskeletal atrophy. The initial flight data together with the ground data obtained so far will be utilized in the future planning of human space exploration.	[Shiba, Naoto; Yoshimitsu, Kazuhiro; Omoto, Masayuki; Hashida, Ryuki] Kurume Univ, Sch Med, Dept Orthoped, Kurume, Fukuoka 830, Japan; [Shiba, Naoto; Matsuse, Hiroo; Omoto, Masayuki; Hashida, Ryuki] Kurume Univ, Sch Med, Div Rehabil, Kurume, Fukuoka 830, Japan; [Takano, Yoshio] Fukuoka Int Univ Hlth & Welf, Div Phys Therapy, Okawa City, Fukuoka 8318501, Japan; [Tagawa, Yoshihiko; Inada, Tomohisa] Kyushu Inst Technol, Dept Mech & Control Engn, Kitakyushu, Fukuoka 804, Japan; [Yamada, Shin; Ohshima, Hiroshi] Japan Aerosp Explorat Agcy, Space Environm Utilizat Ctr, Tsukuba, Ibaraki, Japan	Kurume University; Kurume University; International University of Health & Welfare; Kyushu Institute of Technology; Japan Aerospace Exploration Agency (JAXA)	Shiba, N (corresponding author), Kurume Univ, Sch Med, Dept Orthoped, Kurume, Fukuoka 830, Japan.	nshiba@med.kurume-u.ac.jp			International Announcement of Utilization at ISS; Grant of ISS Research of Japan Space Forum	International Announcement of Utilization at ISS; Grant of ISS Research of Japan Space Forum	This study was supported by the International Announcement of Utilization at ISS 2009 and Grant of ISS Research of Japan Space Forum.	Akima H, 2000, MED SCI SPORT EXER, V32, P1743, DOI 10.1097/00005768-200010000-00013; BALOGUN JA, 1993, ARCH PHYS MED REHAB, V74, P910; Belavy DL, 2013, J APPL PHYSIOL, V115, P586, DOI 10.1152/japplphysiol.00376.2013; Bennie SD, 2002, EUR J APPL PHYSIOL, V88, P13, DOI 10.1007/s00421-002-0711-4; Cavanagh Peter R, 2005, Gravit Space Biol Bull, V18, P39; Conley MS, 1997, EUR J APPL PHYSIOL, V75, P443, DOI 10.1007/s004210050186; Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034; Gopalakrishnan R, 2010, AVIAT SPACE ENVIR MD, V81, P91, DOI 10.3357/ASEM.2583.2010; HAINAUT K, 1992, SPORTS MED, V14, P100, DOI 10.2165/00007256-199214020-00003; Iwasaki T, 2006, TOHOKU J EXP MED, V209, P33, DOI 10.1620/tjem.209.33; Kawaguchi T, 2011, APPL PHYSIOL NUTR ME, V36, P276, DOI [10.1139/h10-108, 10.1139/H10-108]; Kawaguchi T, 2011, J GASTROENTEROL, V46, P746, DOI 10.1007/s00535-011-0378-x; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LeBlanc A, 2000, J APPL PHYSIOL, V89, P2158, DOI 10.1152/jappl.2000.89.6.2158; LEBLANC A, 1995, AVIAT SPACE ENVIR MD, V66, P1151; LeBlanc A, 2013, OSTEOPOROSIS INT, V24, P2105, DOI 10.1007/s00198-012-2243-z; LeBlanc A., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P157; LeBlanc A. D., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P33; Matsugaki Toru, 2010, Kurume Medical Journal, V57, P101; Matsuse H, 2013, J REHABIL RES DEV, V50, P545, DOI 10.1682/JRRD.2012.04.0067; Orwoll ES, 2013, J BONE MINER RES, V28, P1243, DOI 10.1002/jbmr.1948; Ploutz-Snyder LL, 2015, HRP47072 HUM HLTH CO; Seger JY, 2000, ACTA PHYSIOL SCAND, V169, P63; Smith SM, 2012, J BONE MINER RES, V27, P1896, DOI 10.1002/jbmr.1647; Stein RB, 1999, J BIOMECH, V32, P347, DOI 10.1016/S0021-9290(98)00187-0; Tesch PA, 2005, EUR J APPL PHYSIOL, V93, P463, DOI 10.1007/s00421-004-1236-9; Thornton W.E., 1977, BIOMEDICAL RESULTS S, P191; Trappe S, 2009, J APPL PHYSIOL, V106, P1159, DOI 10.1152/japplphysiol.91578.2008; Weir JP, 2005, J STRENGTH COND RES, V19, P231, DOI 10.1519/15184.1; Welle S, 1996, J GERONTOL A-BIOL, V51, pM270, DOI 10.1093/gerona/51A.6.M270; Yanagi T, 2003, ARCH PHYS MED REHAB, V84, P843, DOI 10.1016/S0003-9993(02)04948-1; Yoshimitsu K, 2010, TOHOKU J EXP MED, V220, P83, DOI 10.1620/tjem.220.83; Zwart SR, 2005, INT SPORTMED J, V6, P199	33	11	13	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2015	10	8							e0134736	10.1371/journal.pone.0134736	http://dx.doi.org/10.1371/journal.pone.0134736			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP5MR	26296204	Green Published, Green Submitted, gold			2023-01-03	WOS:000359926900015
J	Davis, J; Finlay, I				Davis, Jacky; Finlay, Ilora			HEAD TO HEAD Would judicial consent for assisted dying protect vulnerable people?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PREVALENCE		[Davis, Jacky] Whittington Hosp, London, England; [Finlay, Ilora] Cardiff Univ, Palliat Med, Cardiff CF10 3AX, S Glam, Wales; [Finlay, Ilora] Natl Council Palliat Care, London, England; [Finlay, Ilora] BMA, London, England	University of London; University College London; Cardiff University	Davis, J (corresponding author), Whittington Hosp, London, England.							[Anonymous], 2014, MEDECONNECT HEALTHCA; [Anonymous], 2015, GUARDIAN; Association for Palliative Medicine, 2015, ASS PALL MED GREAT B; Battin MP, 2007, J MED ETHICS, V33, P591, DOI 10.1136/jme.2007.022335; Canadian Medical Association, 2014, CMA POL EUTH ASS DEA; Dierickx S, 2015, JAMA INTERN MED, V175, P1703, DOI 10.1001/jamainternmed.2015.3982; Dignitas, 2015, ACC SUIC MEMB DIGN Y; Dignity in Dying, 2014, FREED INF REQ; Finlay IG, 2011, J MED ETHICS, V37, P171, DOI 10.1136/jme.2010.037044; Ganzini L, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1682; George RJD, 2005, BMJ-BRIT MED J, V331, P684, DOI 10.1136/bmj.331.7518.684; Jackson A Oregon Hospice Association, 2006, REALITY ASSISTED DYI; Lerner BH, 2015, JAMA INTERN MED, V175, P1640, DOI 10.1001/jamainternmed.2015.4086; Medix, 2014, EUTH PHYS ASS SUIC; Populus, 2015, DIGN DYING POLL; Raymont V, 2004, LANCET, V364, P1421, DOI 10.1016/S0140-6736(04)17224-3; Seale C, 2009, PALLIATIVE MED, V23, P198, DOI 10.1177/0269216308102042; Whitcomb D., 2015, REUTERS	18	5	5	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 19	2015	351								h4437	10.1136/bmj.h4437	http://dx.doi.org/10.1136/bmj.h4437			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CP7PU	26294757				2023-01-03	WOS:000360081100006
J	Kwon, E; Cho, JH; Jang, HM; Kim, YS; Kang, SW; Yang, CW; Kim, NH; Kim, HJ; Park, JM; Lee, JE; Jung, HY; Choi, JY; Park, SH; Kim, CD; Kim, YL				Kwon, Eugene; Cho, Jang-Hee; Jang, Hye Min; Kim, Yon Su; Kang, Shin-Wook; Yang, Chul Woo; Kim, Nam-Ho; Kim, Hyun-Ji; Park, Jeung-Min; Lee, Ji-Eun; Jung, Hee-Yeon; Choi, Ji-Young; Park, Sun-Hee; Kim, Chan-Duck; Kim, Yong-Lim		Clinical Res Ctr End Stage Renal D	Differential Effect of Viral Hepatitis Infection on Mortality among Korean Maintenance Dialysis Patients: A Prospective Multicenter Cohort Study	PLOS ONE			English	Article							C VIRUS-INFECTION; CHRONIC-RENAL-FAILURE; HEMODIALYSIS-PATIENTS; B-VIRUS; PERITONEAL-DIALYSIS; HCV INFECTION; KIDNEY-TRANSPLANTATION; POSITIVE PATIENTS; CAPD PATIENTS; LAMIVUDINE	The role of infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) in terms of survival among dialysis patients remains incompletely understood. In the present multicenter prospective cohort study, we investigated the prevalences of HBV and HCV infection among 3,321 patients receiving maintenance dialysis in Korea, and assessed the impacts of these infections on survival. All included patients underwent hepatitis B antigen (HBsAg) and HCV antibody (Ab) testing, which revealed that 236 patients (7.1%) were HBsAg-positive, and 123 patients (3.7%) were HCV Ab-positive. HBsAg-positive and HCV Ab-positive patients were matched to hepatitis virus-negative patients using a propensity score at a ratio of 1: 2. The prevalences of HBV and HCV infection did not significantly differ according to dialysis modality. Linear-by-linear association analysis revealed that hepatitis B prevalence significantly increased with increasing dialysis vintage (p = 0.001), and hepatitis C prevalence tended to be higher with increasing dialysis vintage (p = 0.074). We compared the survival of HBsAg-positive and HCV Ab-positive patients to that of hepatitis virus-negative patients. After propensity score matching, cumulative survival did not differ between HBsAg-positive and HBsAg-negative patients (p = 0.37), while HCV Ab-positive patients showed significantly lower survival than HCV Ab-negative patients (p = 0.03). The main conclusions of the present study are that HBV infection prevalence increased with longer dialysis vintage, and that both HBV and HCV infections were most prevalent among patients with the longest dialysis vintage. Additionally, HCV infection among maintenance dialysis patients is associated with an increased risk of mortality.	[Kwon, Eugene; Cho, Jang-Hee; Kim, Hyun-Ji; Park, Jeung-Min; Lee, Ji-Eun; Jung, Hee-Yeon; Choi, Ji-Young; Park, Sun-Hee; Kim, Chan-Duck; Kim, Yong-Lim] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; [Jang, Hye Min] Kyungpook Natl Univ, Dept Stat, Daegu, South Korea; [Kim, Yon Su] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea; [Kang, Shin-Wook] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Yang, Chul Woo] Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul, South Korea; [Kim, Nam-Ho] Chonnam Natl Univ, Sch Med, Dept Internal Med, Gwangju, South Korea; [Kwon, Eugene; Cho, Jang-Hee; Jang, Hye Min; Kim, Yon Su; Kang, Shin-Wook; Yang, Chul Woo; Kim, Nam-Ho; Kim, Hyun-Ji; Park, Jeung-Min; Lee, Ji-Eun; Jung, Hee-Yeon; Choi, Ji-Young; Park, Sun-Hee; Kim, Chan-Duck; Kim, Yong-Lim] Clin Res Ctr End Stage Renal Dis, Daegu, South Korea; [Kim, Yong-Lim] Kyungpook Natl Univ, Dept Biomed Sci, KNU Biomed Convergence Program BK21Plus, Daegu, South Korea	Kyungpook National University; Kyungpook National University; Seoul National University (SNU); Yonsei University; Yonsei University Health System; Catholic University of Korea; Chonnam National University; Kyungpook National University	Kim, YL (corresponding author), Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea.	ylkim@knu.ac.kr	Cho, Jang-hee/ABD-3534-2020	Cho, Jang-hee/0000-0002-7031-5214; Jung, Hee-Yeon/0000-0003-0232-7202	Biomedical Research Institute grant, Kyungpook National University Hospital [15-28]	Biomedical Research Institute grant, Kyungpook National University Hospital	This work was supported by the Biomedical Research Institute grant, Kyungpook National University Hospital (2015). The assigned project number is 15-28. E. Kwon received the funding.	Ben-Ari Z, 2000, AM J GASTROENTEROL, V95, P3579, DOI 10.1111/j.1572-0241.2000.03296.x; Boyacioglu S, 2002, TRANSPL P, V34, P2131, DOI 10.1016/S0041-1345(02)02879-8; Custer B, 2004, J CLIN GASTROENTEROL, V38, pS158, DOI 10.1097/00004836-200411003-00008; Di Napoli A, 2006, AM J KIDNEY DIS, V48, P629, DOI 10.1053/j.ajkd.2006.07.004; Edey M, 2010, NEPHROLOGY, V15, P137, DOI 10.1111/j.1440-1797.2009.01268.x; Espinosa M, 2002, CLIN NEPHROL, V58, P143; Espinosa M, 2001, NEPHROL DIAL TRANSPL, V16, P1669, DOI 10.1093/ndt/16.8.1669; Fabrizi F, 2007, J VIRAL HEPATITIS, V14, P697, DOI 10.1111/1365-2893.2007.00868.x; Fabrizi F, 2007, INT J ARTIF ORGANS, V30, P6, DOI 10.1177/039139880703000103; Fabrizi F, 2003, INT J ARTIF ORGANS, V26, P1048, DOI 10.1177/039139880302601202; Fabrizi F, 2010, NAT REV NEPHROL, V6, P395, DOI 10.1038/nrneph.2010.37; Fontaine H, 2000, TRANSPLANTATION, V69, P2090, DOI 10.1097/00007890-200005270-00020; Gordon CE, 2008, AM J KIDNEY DIS, V52, P811, DOI 10.1053/j.ajkd.2008.08.005; HARNETT JD, 1988, AM J KIDNEY DIS, V11, P210, DOI 10.1016/S0272-6386(88)80151-3; Hung KY, 1997, BLOOD PURIFICAT, V15, P195, DOI 10.1159/000170332; Hwang EW, 2011, N AM J MED SCI BOSTO, V4; JHA R, 1993, J NEPHROL, V6, P98; Johnson DW, 2009, NEPHROL DIAL TRANSPL, V24, P1598, DOI 10.1093/ndt/gfn684; JOSSELSON J, 1987, AM J KIDNEY DIS, V9, P456, DOI 10.1016/S0272-6386(87)80071-9; Kalantar-Zadeh K, 2005, AM J KIDNEY DIS, V46, P290, DOI 10.1053/j.ajkd.2005.05.006; Kalantar-Zadeh K, 2005, NEPHROL DIAL TRANSPL, V20, P1662, DOI 10.1093/ndt/gfh895; Kalantar-Zadeh K, 2007, J AM SOC NEPHROL, V18, P1584, DOI 10.1681/ASN.2006070736; Khan N, 2004, J CLIN VIROL, V30, P175, DOI 10.1016/j.jcv.2003.10.004; Lapinski TW, 2005, WORLD J GASTROENTERO, V11, P400, DOI 10.3748/wjg.v11.i3.400; Lim Young Suk, 2009, Korean J Hepatol, V15 Suppl 6, pS25, DOI 10.3350/kjhep.2009.15.S6.S25; McMurray RW, 1997, SEMIN ARTHRITIS RHEU, V26, P689, DOI 10.1016/S0049-0172(97)80005-4; Meyers CM, 2003, AM J KIDNEY DIS, V42, P631, DOI 10.1016/S0272-6386(03)00828-X; Nakayama E, 2000, J AM SOC NEPHROL, V11, P1896, DOI 10.1681/ASN.V11101896; NETO MC, 1995, NEPHROL DIAL TRANSPL, V10, P240; Nocente R, 2003, HEPATO-GASTROENTEROL, V50, P1149; Ohsawa M, 2011, J EPIDEMIOL, V21, P491, DOI 10.2188/jea.JE20100187; Ow MMG, 2014, NEW ZEAL MED J, V127, P34; Pawlak K, 2004, CYTOKINE, V28, P197, DOI 10.1016/j.cyto.2004.07.007; Pereira BJG, 1998, KIDNEY INT, V53, P1374, DOI 10.1046/j.1523-1755.1998.00883.x; Pereira BJG, 1997, KIDNEY INT, V51, P981, DOI 10.1038/ki.1997.139; Perz JF, 2006, J HEPATOL, V45, P529, DOI 10.1016/j.jhep.2006.05.013; Puttinger H, 2002, SEMIN NEPHROL, V22, P351, DOI 10.1053/snep.2002.33676; Santoro D, 2009, RENAL FAILURE, V31, P6, DOI 10.1080/08860220802546289; Sayiner AA, 1999, NEPHROL DIAL TRANSPL, V14, P256, DOI 10.1093/ndt/14.1.256; Schmilovitz-Weiss H, 2003, J CLIN GASTROENTEROL, V37, P64, DOI 10.1097/00004836-200307000-00016; Stehman-Breen CO, 1998, AM J KIDNEY DIS, V32, P629, DOI 10.1016/S0272-6386(98)70027-7; Strader DB, 2004, HEPATOLOGY, V39, P1147, DOI 10.1002/hep.20119; Sulowicz Wladyslaw, 2007, Hemodial Int, V11, P286, DOI 10.1111/j.1542-4758.2007.00181.x; Sun JH, 2009, RENAL FAILURE, V31, P610, DOI 10.1080/08860220903003446; Thanachartwet V, 2007, NEPHROLOGY, V12, P399, DOI 10.1111/j.1440-1797.2007.00815.x; Wang CY, 2010, RENAL FAILURE, V32, P1255, DOI 10.3109/0886022X.2010.517354; Wang SM, 2008, PERITON DIALYSIS INT, V28, P183; Weclawiak H, 2010, HEPAT RES TREAT, V2010	48	14	15	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 11	2015	10	8							e0135476	10.1371/journal.pone.0135476	http://dx.doi.org/10.1371/journal.pone.0135476			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO7PP	26263373	Green Published, gold, Green Submitted			2023-01-03	WOS:000359353300084
J	Dukers-Muijrers, NHTM; Theunissen, KATM; Wolffs, PT; Kok, G; Hoebe, CJPA				Dukers-Muijrers, Nicole H. T. M.; Theunissen, Kevin A. T. M.; Wolffs, Petra T.; Kok, Gerjo; Hoebe, Christian J. P. A.			Acceptance of Home-Based Chlamydia Genital and Anorectal Testing Using Short Message Service (SMS) in Previously Tested Young People and Their Social and Sexual Networks	PLOS ONE			English	Article							TAKEN VAGINAL SWABS; OF-THE-LITERATURE; NEISSERIA-GONORRHOEAE; TRANSMITTED-DISEASES; UROGENITAL CHLAMYDIA; SCREENING-PROGRAM; TRACHOMATIS; WOMEN; ACCEPTABILITY; RISK	Background Control strategies for Chlamydia trachomatis (CT) are most effective when targeting people at highest risk. We assessed test acceptance of home-collection test kits offered by short messaging services (SMS) texts, in high-risk young people, i.e. those who had previously tested CT positive (positive indices), or negative reporting more than 3 sex partners (negative indices), and their sexual and social networks. Methods Young (16 to 25 years old) heterosexuals who previously tested positive (n=536) or negative (n=536) in our STI clinic received, 3 to 20 months after their initial screening, an SMS inviting them to re-test. They were offered a free home-collection test kit including a genital (men and women) and anorectal (women only) test, and a test kit to pass on to a friend or sex partner (peer). SMS reminders were sent in case of non-response. We assessed proportions of tests requested and returned, peers tested, and positivity. Associations with the individual's initial screening result and other factors were explored using logistic regression. Results Of 1072 people invited to retest, 34.4% (n=369) requested a test. Of these, 55.8% (n=206) retested. Overall, retest participation was higher in positive (22%) than in negative indices (16%) (p<0.001); it was also higher in women and in those aged >22 years. Positivity was 13% and 7% in positive and negative indices, respectively. One in 3 retesters also had a peer tested. Of tested peers (n=87), 84% were friends, 31% were first-time testers, and 7% tested positive. Conclusion Acceptance of a relatively low-cost strategy for genital and anorectal testing, i.e. using SMS and home-collection test kits, was highest in individuals who previously tested CT positive suggesting that implementation for this group may be considered. By further including a peer-led testing component, undetected CT positives can be identified in the social networks surrounding a high-risk individual.	[Dukers-Muijrers, Nicole H. T. M.; Theunissen, Kevin A. T. M.; Hoebe, Christian J. P. A.] South Limburg Publ Hlth Serv, Dept Sexual Hlth Infect Dis & Environm Hlth, Geleen, Netherlands; [Dukers-Muijrers, Nicole H. T. M.; Wolffs, Petra T.; Hoebe, Christian J. P. A.] MUMC, Sch Publ Hlth & Primary Care CAPHRI, Dept Med Microbiol, Maastricht, Netherlands; [Kok, Gerjo] Maastricht Univ, Dept Work & Social Psychol, Maastricht, Netherlands	Maastricht University; Maastricht University	Dukers-Muijrers, NHTM (corresponding author), South Limburg Publ Hlth Serv, Dept Sexual Hlth Infect Dis & Environm Hlth, Geleen, Netherlands.	nicole.dukers@ggdzl.nl	Dukers-Muijrers, Nicole/M-7178-2014	Hoebe, Christian/0000-0003-1815-0974; Dukers-Muijrers, Nicole/0000-0003-4896-758X; Wolffs, Petra/0000-0002-5326-3985				Balfe M, 2010, SOCIOL HEALTH ILL, V32, P1041, DOI 10.1111/j.1467-9566.2010.01281.x; Bilardi JE, 2010, SEX TRANSM DIS, V37, P563, DOI 10.1097/OLQ.0b013e3181d707f1; Blake DR, 2003, ARCH PEDIAT ADOL MED, V157, P523, DOI 10.1001/archpedi.157.6.523; Burton J, 2014, SEX TRANSM INFECT, V90, P11, DOI 10.1136/sextrans-2013-051228; Busse P, 2010, COMMUN RES, V37, P239, DOI 10.1177/0093650209356393; Centers for Disease Control and Prevention, SUMM REV LIT PROG PR; Cunningham SD, 2009, PERSPECT SEX REPRO H, V41, P225, DOI 10.1363/4122509; Desai M, 2015, SEX TRANSM INFECT, V91, P314, DOI 10.1136/sextrans-2014-051930; Dokkum NFB, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-176; Doshi JS, 2008, INT J STD AIDS, V19, P507, DOI 10.1258/ijsa.2008.008056; Downing SG, 2013, SEX TRANSM INFECT, V89, P16, DOI 10.1136/sextrans-2011-050454; Dukers-Muijrers NHTM, 2013, SEX TRANSM INFECT, V89, P25, DOI 10.1136/sextrans-2011-050467; European Centre for Disease Prevention and Control, 2014, CHLAM CONTR EUR LIT; Farley TA, 2003, PREV MED, V36, P502, DOI 10.1016/S0091-7435(02)00058-0; Gaydos CA, 2013, INT J STD AIDS, V24, P736, DOI 10.1177/0956462413483252; Gotz HM, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-239; Gotz HM, 2005, SEX TRANSM DIS, V32, P557, DOI 10.1097/01.olq.0000175416.15905.db; Gotz HM, 2014, SEX TRANSM INFECT, V90, P195, DOI 10.1136/sextrans-2013-051254; Guy R, 2013, SEX TRANSM INFECT, V89, P11, DOI 10.1136/sextrans-2011-050370; Guy R, 2012, SEX TRANSM DIS, V39, P136, DOI 10.1097/OLQ.0b013e31823ed4ec; Guy R, 2011, SEX HEALTH, V8, P242, DOI 10.1071/SH10086; Hoebe CJPA, 2006, SEX TRANSM DIS, V33, P491, DOI 10.1097/01.olq.0000204619.87066.28; Hosenfeld CB, 2009, SEX TRANSM DIS, V36, P478, DOI 10.1097/OLQ.0b013e3181a2a933; Jamil MS, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-189; Kegg S, 2004, COMMUNICATION, V15; Kotchick BA, 2001, CLIN PSYCHOL REV, V21, P493, DOI 10.1016/S0272-7358(99)00070-7; Loaring J, 2013, J FAM PLAN REPROD H, V39, P21, DOI 10.1136/jfprhc-2011-100151; Lunny C, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-7; Masek BJ, 2009, J CLIN MICROBIOL, V47, P1663, DOI 10.1128/JCM.02387-08; Newby KV, 2012, BRIT J HEALTH PSYCH, V17, P144, DOI 10.1111/j.2044-8287.2011.02027.x; Odesanmi TY, 2013, SEX HEALTH, V10, P559, DOI 10.1071/SH13029; Ostergaard L, 2003, SEX TRANSM INFECT, V79, P358, DOI 10.1136/sti.79.5.358; Pavlin NL, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-221; Peters RPH, 2014, SEX TRANSM DIS, V41, P564, DOI 10.1097/OLQ.0000000000000175; Rose SB, 2010, AUST NZ J PUBL HEAL, V34, P517, DOI 10.1111/j.1753-6405.2010.00600.x; Senior K, 2012, LANCET INFECT DIS, V12, P517, DOI 10.1016/S1473-3099(12)70161-5; Smith KS, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-223; Theunissen KATM, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-996; Torrone E, 2014, MMWR-MORBID MORTAL W, V63, P834; Trebach JD, 2015, SEX TRANSM DIS, V42, P233, DOI 10.1097/OLQ.0000000000000248; van der Helm JJ, 2009, SEX TRANSM DIS, V36, P493, DOI 10.1097/OLQ.0b013e3181a44b8c; van Liere GAFS, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-274; Youm Y, 2002, SEX TRANSM DIS, V29, P689, DOI 10.1097/00007435-200211000-00012	43	11	11	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2015	10	7							e0133575	10.1371/journal.pone.0133575	http://dx.doi.org/10.1371/journal.pone.0133575			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CO0JY	26230085	Green Published, Green Submitted, gold			2023-01-03	WOS:000358838400043
J	Castelli, A; Daidone, S; Jacobs, R; Kasteridis, P; Street, AD				Castelli, Adriana; Daidone, Silvio; Jacobs, Rowena; Kasteridis, Panagiotis; Street, Andrew David			The Determinants of Costs and Length of Stay for Hip Fracture Patients	PLOS ONE			English	Article							MORTALITY; RISK; OUTCOMES; MODELS; TRENDS; CARE	Background and Purpose An ageing population at greater risk of proximal femoral fracture places an additional clinical and financial burden on hospital and community medical services. We analyse the variation in i) length of stay (LoS) in hospital and ii) costs across the acute care pathway for hip fracture from emergency admission, to hospital stay and follow-up outpatient appointments. Patients and Methods We analyse patient-level data from England for 2009/10 for around 60,000 hip fracture cases in 152 hospitals using a random effects generalized linear multi-level model where the dependent variable is given by the patient's cost or length of stay (LoS). We control for socio-economic characteristics, type of fracture and intervention, co-morbidities, discharge destination of patients, and quality indicators. We also control for provider and social care characteristics. Results Older patients and those from more deprived areas have higher costs and LoS, as do those with specific co-morbidities or that develop pressure ulcers, and those transferred between hospitals or readmitted within 28 days. Costs are also higher for those having a computed tomography (CT) scan or cemented arthroscopy. Costs and LoS are lower for those admitted via a 24h emergency department, receiving surgery on the same day of admission, and discharged to their own homes. Interpretation Patient and treatment characteristics are more important as determinants of cost and LoS than provider or social care factors. A better understanding of the impact of these characteristics can support providers to develop treatment strategies and pathways to better manage this patient population.	[Castelli, Adriana; Jacobs, Rowena; Kasteridis, Panagiotis; Street, Andrew David] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England; [Daidone, Silvio] UN, FAO, I-00153 Rome, Italy	University of York - UK; Food & Agriculture Organization of the United Nations (FAO)	Castelli, A (corresponding author), Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England.	adriana.castelli@york.ac.uk	Daidone, Silvio/ABC-5526-2021; Daidone, Silvio/AAJ-4490-2021	Daidone, Silvio/0000-0002-1789-5635; 	Policy Research Programme in the English Department of Health from the Economics of Social and Health Care Research Unit (ESHCRU) [103/0001]	Policy Research Programme in the English Department of Health from the Economics of Social and Health Care Research Unit (ESHCRU)	The work was funded by the Policy Research Programme in the English Department of Health from the Economics of Social and Health Care Research Unit (ESHCRU) (Ref 103/0001). The funders have approved the manuscript for submission but had no role in the design or conduct of the study. The views expressed are those of the authors and not necessarily those of the funders.	Abrahamsen B, 2009, OSTEOPOROSIS INT, V20, P1633, DOI 10.1007/s00198-009-0920-3; Austin PC, 2002, HLTH SERV OUTCOME RE, V3, P107; Blough DK, 1999, J HEALTH ECON, V18, P153, DOI 10.1016/S0167-6296(98)00032-0; Brauer CA, 2009, JAMA-J AM MED ASSOC, V302, P1573, DOI 10.1001/jama.2009.1462; Department of Health, 2008, NHS COST MAN 2009 10; Department of Health, 2009 10 2010 11 PCT; Draper B, 1998, INT J GERIATR PSYCH, V13, P1, DOI 10.1002/(SICI)1099-1166(199801)13:1<1::AID-GPS716>3.0.CO;2-V; Duan N, 1983, J BUS ECON STAT, V1, P115, DOI DOI 10.2307/1391852; Eastwood EA, 1999, ARCH PHYS MED REHAB, V80, P1457, DOI 10.1016/S0003-9993(99)90258-7; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Frakt AB, 2011, MILBANK Q, V89, P90, DOI 10.1111/j.1468-0009.2011.00621.x; Garcia AE, 2012, J ORTHOP TRAUMA, V26, P620, DOI 10.1097/BOT.0b013e3182695416; Gehlbach SH, 2007, OSTEOPOROSIS INT, V18, P585, DOI 10.1007/s00198-006-0281-0; Holt G, 2009, INJURY, V40, P722, DOI 10.1016/j.injury.2008.11.004; Laudicella M, 2010, SOC SCI MED, V71, P1872, DOI 10.1016/j.socscimed.2010.06.049; Leslie WD, 2009, JAMA-J AM MED ASSOC, V302, P883, DOI 10.1001/jama.2009.1231; Manning WG, 2001, J HEALTH ECON, V20, P461, DOI 10.1016/S0167-6296(01)00086-8; Manning WG, 2005, J HEALTH ECON, V24, P465, DOI 10.1016/j.jhealeco.2004.09.011; Marsh D, 2007, CARE PATIENTS FRAGIL; Moran JL, 2012, BMC MED RES METHODOL, V12, P1; National Clinical Guideline Centre, 2011, MAN HIP FRACT AD, P664; Nikkel LE, 2012, J BONE JOINT SURG AM, V94A, P9, DOI [10.2106/JBJS.J.01077, 10.2106/JBJS.K.01214]; Panula J, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-105; Richmond J, 2003, J ORTHOP TRAUMA, V17, P53, DOI 10.1097/00005131-200301000-00008; Rosen AB, 1999, AM HEART J, V138, P69, DOI 10.1016/S0002-8703(99)70249-8; Titler M, 2007, NURS OUTLOOK, V55, P5, DOI 10.1016/j.outlook.2006.06.006; White SM, 2011, INJURY, V42, P1230, DOI 10.1016/j.injury.2010.11.010	27	43	43	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2015	10	7							e0133545	10.1371/journal.pone.0133545	http://dx.doi.org/10.1371/journal.pone.0133545			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CN7NJ	26204450	Green Submitted, Green Published, gold			2023-01-03	WOS:000358621000032
J	Holbrook, A				Holbrook, Anne			Use of long-acting, vs short-acting, opioids for chronic pain was linked to unintentional overdose	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									McMaster Univ, Hamilton, ON, Canada	McMaster University	Holbrook, A (corresponding author), McMaster Univ, Hamilton, ON, Canada.							Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559; Dhalla IA, 2009, CAN MED ASSOC J, V181, P891, DOI 10.1503/cmaj.090784	3	0	0	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 21	2015	163	2							JC11	10.7326/ACPJC-2015-163-2-011	http://dx.doi.org/10.7326/ACPJC-2015-163-2-011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CN4NS	26192579				2023-01-03	WOS:000358407500011
J	van Poppel, PCM; Breedveld, P; Abbink, EJ; Roelofs, H; van Heerde, W; Smits, P; Lin, WZ; Tan, AH; Russel, FG; Donders, R; Tack, CJ; Rongen, GA				van Poppel, Pleun C. M.; Breedveld, Pauline; Abbink, Evertine J.; Roelofs, Hennie; van Heerde, Waander; Smits, Paul; Lin, Wenzhi; Tan, Aaitje H.; Russel, Frans G.; Donders, Rogier; Tack, Cees J.; Rongen, Gerard A.			Salvia Miltiorrhiza Root Water-Extract (Danshen) Has No Beneficial Effect on Cardiovascular Risk Factors. A Randomized Double-Blind Cross-Over Trial	PLOS ONE			English	Article							ENDOTHELIAL DYSFUNCTION; ESSENTIAL-HYPERTENSION; BOILED COFFEE; NITRIC-OXIDE; DISEASE; CHOLESTEROL; PLASMA; THERAPY; PRODUCTS; QUALITY	Purpose Danshen is the dried root extract of the plant Salvia Miltiorrhiza and it is used as traditional Chinese medicinal herbal product to prevent and treat atherosclerosis. However, its efficacy has not been thoroughly investigated. This study evaluates the effect of Danshen on hyperlipidemia and hypertension, two well known risk factors for the development of atherosclerosis. Methods This was a randomized, placebo-controlled, double-blind crossover study performed at a tertiary referral center. Participants were recruited by newspaper advertisement and randomized to treatment with Danshen (water-extract of the Salvia Miltiorrhiza root) or placebo for 4 consecutive weeks. There was a wash out period of 4 weeks. Of the 20 analysed participants, 11 received placebo first. Inclusion criteria were: age 40-70 years, hyperlipidemia and hypertension. At the end of each treatment period, plasma lipids were determined (primary outcome), 24 hours ambulant blood pressure measurement (ABPM) was performed, and vasodilator endothelial function was assessed in the forearm. Results LDL cholesterol levels were 3.82 +/- 0.14 mmol/l after Danshen and 3.52 +/- 0.16 mmol/l after placebo treatment (mean +/- SE; p<0.05 for treatment effect corrected for baseline). Danshen treatment had no effect on blood pressure (ABPM 138/84 after Danshen and 136/87 after placebo treatment). These results were further substantiated by the observation that Danshen had neither an effect on endothelial function nor on markers of inflammation, oxidative stress, glucose metabolism, hemostasis and blood viscosity. Conclusion Four weeks of treatment with Danshen (water-extract) slightly increased LDL-cholesterol without affecting a wide variety of other risk markers. These observations do not support the use of Danshen to prevent or treat atherosclerosis.	[van Poppel, Pleun C. M.; Tack, Cees J.; Rongen, Gerard A.] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, NL-6525 ED Nijmegen, Netherlands; [Abbink, Evertine J.] Radboud Univ Nijmegen, Med Ctr, Clin Res Ctr Nijmegen, NL-6525 ED Nijmegen, Netherlands; [Roelofs, Hennie] Radboud Univ Nijmegen, Med Ctr, Dept Gastroenterol, NL-6525 ED Nijmegen, Netherlands; [van Heerde, Waander] Radboud Univ Nijmegen, Med Ctr, Dept Clin Chem, NL-6525 ED Nijmegen, Netherlands; [Breedveld, Pauline; Smits, Paul; Russel, Frans G.; Rongen, Gerard A.] Radboud Univ Nijmegen, Med Ctr, Dept Pharmacol & Toxicol, NL-6525 ED Nijmegen, Netherlands; [Donders, Rogier] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, NL-6525 ED Nijmegen, Netherlands; [Lin, Wenzhi] Med Ctr Balans, The Hague, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Rongen, GA (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, NL-6525 ED Nijmegen, Netherlands.	gerard.rongen@radboudumc.nl	Rongen, Gerard A/C-1578-2018; van Heerde, Waander/L-4357-2015; Smits, P.A.B.M./E-2889-2015; Russel, Frans G.M./B-3184-2014; Rongen, Gerard/AAJ-9694-2021; Donders, A.R.T./L-4277-2015; Tack, Cees J/A-2368-2014	van Heerde, Waander/0000-0001-7101-8775; Russel, Frans G.M./0000-0002-7959-2314; Donders, A.R.T./0000-0002-0484-1419; 	Cinmar Pharma BV, 's Hertogenbosch, the Netherlands; Department of Pharmacology-Toxicology, Radboud university medical centre, Nijmegen, the Netherlands; Dutch Association of Acupuncture Medicine (NAAV, Amsterdam, the Netherlands)	Cinmar Pharma BV, 's Hertogenbosch, the Netherlands; Department of Pharmacology-Toxicology, Radboud university medical centre, Nijmegen, the Netherlands; Dutch Association of Acupuncture Medicine (NAAV, Amsterdam, the Netherlands)	This study was financed by Cinmar Pharma BV, 's Hertogenbosch, the Netherlands, Department of Pharmacology-Toxicology, Radboud university medical centre, Nijmegen, the Netherlands, and the Dutch Association of Acupuncture Medicine (NAAV, Amsterdam, the Netherlands). Cinmar Pharma had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. AHT is a representative of NAAV and was involved in preparation of the manuscript. He nor NAAV have any financial interest in Danshen.	AHOLA I, 1991, J INTERN MED, V230, P293, DOI 10.1111/j.1365-2796.1991.tb00447.x; Al Suwaidi J, 2000, CIRCULATION, V101, P948, DOI 10.1161/01.CIR.101.9.948; Baigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5; BAK AAA, 1989, NEW ENGL J MED, V321, P1432, DOI 10.1056/NEJM198911233212103; BENJAMIN N, 1995, HYPERTENSION, V25, P918, DOI 10.1161/01.HYP.25.5.918; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Cheng TO, 2007, INT J CARDIOL, V121, P9, DOI 10.1016/j.ijcard.2007.01.004; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gluckman TJ, 2004, ARCH INTERN MED, V164, P1490, DOI 10.1001/archinte.164.14.1490; Halcox JPJ, 2002, CIRCULATION, V106, P653, DOI 10.1161/01.CIR.0000025404.78001.D8; Joyner MJ, 1985, J APPL PHYSIOL, V83, P1785; KANNEL WB, 1976, AM J CARDIOL, V38, P46, DOI 10.1016/0002-9149(76)90061-8; Klingbeil AU, 2003, AM J HYPERTENS, V16, P123, DOI 10.1016/S0895-7061(02)03154-0; LENDERS J, 1991, CLIN SCI, V80, P413, DOI 10.1042/cs0800413; Li YG, 2009, J CHROMATOGR A, V1216, P1941, DOI 10.1016/j.chroma.2008.12.032; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; O'Keefe JH, 2009, MAYO CLIN PROC, V84, P741, DOI 10.1016/S0025-6196(11)60525-9; On YK, 2002, HYPERTENS RES, V25, P365, DOI 10.1291/hypres.25.365; Pitt B, 1996, CARDIOVASC DRUG THER, V10, P469, DOI 10.1007/BF00051113; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Senn S., 2002, CROSS OVER TRIALS CL, V5; Sieveking DP, 2005, INT J CARDIOL, V105, P40, DOI 10.1016/j.ijcard.2004.10.052; Tachjian A, 2010, J AM COLL CARDIOL, V55, P515, DOI 10.1016/j.jacc.2009.07.074; Tan Y, 2011, CLIN SCI, V120, P297, DOI 10.1042/CS20100441; TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801; van Geffen M, 2011, HEMATOLOGY, V16, P327, DOI 10.1179/102453311X13085644680348; van Tits LJH, 2001, FREE RADICAL BIO MED, V30, P1122, DOI 10.1016/S0891-5849(01)00519-6; WEUSTENVANDERWOUW MPME, 1994, J LIPID RES, V35, P721; WHO, 2014, TOP 10 CAUS DEATH WO; Widlansky ME, 2003, J AM COLL CARDIOL, V42, P1149, DOI 10.1016/S0735-1097(03)00994-X; Williamson EM, 2013, J ETHNOPHARMACOL, V149, P453, DOI 10.1016/j.jep.2013.06.050; Wu B, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004295.pub3; Wu TX, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004465.pub2; Yu SC, 2009, J ALTERN COMPLEM MED, V15, P557, DOI 10.1089/acm.2008.0436; Yu XY, 2007, XENOBIOTICA, V37, P375, DOI 10.1080/00498250701230559; Zanchetti A, 2004, BLOOD PRESSURE, V13, P17, DOI 10.1080/08038020410016548; Zhou LM, 2006, J PHARMACEUT BIOMED, V41, P744, DOI 10.1016/j.jpba.2005.12.032; Zhou LM, 2005, J CLIN PHARMACOL, V45, P1345, DOI 10.1177/0091270005282630	39	10	10	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2015	10	7							e0128695	10.1371/journal.pone.0128695	http://dx.doi.org/10.1371/journal.pone.0128695			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN6LN	26192328	Green Submitted, Green Published, gold			2023-01-03	WOS:000358546400002
J	Woo, JH; Shimoni, Y; Yang, WS; Subramaniam, P; Iyer, A; Nicoletti, P; Martinez, MR; Lopez, G; Mattioli, M; Realubit, R; Karan, C; Stockwell, BR; Bansal, M; Califano, A				Woo, Jung Hoon; Shimoni, Yishai; Yang, Wan Seok; Subramaniam, Prem; Iyer, Archana; Nicoletti, Paola; Martinez, Maria Rodriguez; Lopez, Gonzalo; Mattioli, Michela; Realubit, Ronald; Karan, Charles; Stockwell, Brent R.; Bansal, Mukesh; Califano, Andrea			Elucidating Compound Mechanism of Action by Network Perturbation Analysis	CELL			English	Article							DNA-DAMAGE; TARGET; IDENTIFICATION; PROTEIN; PREDICTION; MODE; INHIBITOR; INDUCTION; DATABASE; BIOLOGY	Genome-wide identification of the mechanism of action (MoA) of small-molecule compounds characterizing their targets, effectors, and activity modulators represents a highly relevant yet elusive goal, with critical implications for assessment of compound efficacy and toxicity. Current approaches are labor intensive and mostly limited to elucidating high-affinity binding target proteins. We introduce a regulatory network-based approach that elucidates genome-wide MoA proteins based on the assessment of the global dysregulation of their molecular interactions following compound perturbation. Analysis of cellular perturbation profiles identified established MoA proteins for 70% of the tested compounds and elucidated novel proteins that were experimentally validated. Finally, unknown-MoA compound analysis revealed altretamine, an anticancer drug, as an inhibitor of glutathione peroxidase 4 lipid repair activity, which was experimentally confirmed, thus revealing unexpected similarity to the activity of sulfasalazine. This suggests that regulatory network analysis can provide valuable mechanistic insight into the elucidation of small-molecule MoA and compound similarity.	[Woo, Jung Hoon; Califano, Andrea] Columbia Univ, DBMI, New York, NY 10032 USA; [Shimoni, Yishai; Subramaniam, Prem; Iyer, Archana; Nicoletti, Paola; Martinez, Maria Rodriguez; Lopez, Gonzalo; Stockwell, Brent R.; Bansal, Mukesh; Califano, Andrea] Columbia Univ, Dept Syst Biol, New York, NY 10032 USA; [Shimoni, Yishai; Subramaniam, Prem; Iyer, Archana; Nicoletti, Paola; Martinez, Maria Rodriguez; Lopez, Gonzalo; Bansal, Mukesh; Califano, Andrea] Columbia Univ, Ctr Computat Biol & Bioinformat C2B2, New York, NY 10032 USA; [Yang, Wan Seok; Stockwell, Brent R.] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; [Mattioli, Michela] Fdn Ist Italiano Tecnol IIT, Ctr Genom Sci IIT SEMM, I-20139 Milan, Italy; [Realubit, Ronald; Karan, Charles] Columbia Univ, Columbia Genome Ctr, High Throughput Screening Facil, New York, NY 10032 USA; [Stockwell, Brent R.] Columbia Univ, Dept Chem, New York, NY 10027 USA; [Stockwell, Brent R.] Columbia Univ, Howard Hughes Med Inst, New York, NY 10027 USA; [Califano, Andrea] Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; [Califano, Andrea] Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; [Califano, Andrea] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Istituto Italiano di Tecnologia - IIT; Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute; Columbia University; Columbia University; Columbia University	Bansal, M (corresponding author), Columbia Univ, Dept Syst Biol, New York, NY 10032 USA.	mb3113@cumc.columbia.edu; califano@cumc.columbia.edu	Stockwell, Brent R/AAE-7200-2019; Lopez, Gonzalo/AAG-1169-2019; Martinez, Maria Rodriguez/M-4624-2019; Mattioli, Michela/K-3951-2013	Stockwell, Brent R/0000-0002-3532-3868; Lopez, Gonzalo/0000-0002-5092-1284; Martinez, Maria Rodriguez/0000-0003-3766-4233; Mattioli, Michela/0000-0002-1692-9178; Califano, Andrea/0000-0003-4742-3679	CTD2 [5U01CA168426]; LINCS [1U01CA164184-02, 3U01HL111566-02]; MAGNet [5U54CA121852-08]; NIH [5R01CA097061, R01CA161061]; New York Stem Cell Science [C026715]; Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE [R01CA161061, R01CA097061, U01CA168426, U01CA164184, U54CA121852] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL111566] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD012351] Funding Source: NIH RePORTER	CTD2; LINCS; MAGNet; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); New York Stem Cell Science; Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Katia Basso for providing the U-2932 cell line for experimental validation, Wei Keat Lim for GEP normalization, and Beatrice Salvatori for helpful feedback on the manuscript. This work is supported in part by the CTD2 (5U01CA168426), LINCS (1U01CA164184-02 and 3U01HL111566-02), and MAGNet (5U54CA121852-08) grants to A.C. B.R.S. is supported by the NIH (5R01CA097061, R01CA161061) and New York Stem Cell Science (C026715) and is an Early Career Scientist of the Howard Hughes Medical Institute.	Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Bansal M, 2006, BIOINFORMATICS, V22, P815, DOI 10.1093/bioinformatics/btl003; Bansal M, 2014, NAT BIOTECHNOL, V32, P1213, DOI 10.1038/nbt.3052; Basilico C, 2013, CLIN CANCER RES, V19, P2381, DOI 10.1158/1078-0432.CCR-12-3459; Basso K, 2010, BLOOD, V115, P975, DOI 10.1182/blood-2009-06-227017; Basu A, 2013, CELL, V154, P1151, DOI 10.1016/j.cell.2013.08.003; Brigelius-Flohe R, 2013, BBA-GEN SUBJECTS, V1830, P3289, DOI 10.1016/j.bbagen.2012.11.020; BROWN MB, 1975, BIOMETRICS, V31, P987, DOI 10.2307/2529826; Califano A, 2012, NAT GENET, V44, P841, DOI 10.1038/ng.2355; Choi J, 2009, NUCLEIC ACIDS RES, V37, P5993, DOI 10.1093/nar/gkp660; di Bernardo D, 2005, NAT BIOTECHNOL, V23, P377, DOI 10.1038/nbt1075; Dixon SJ, 2014, ELIFE, V3, DOI 10.7554/eLife.02523; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Floratos A, 2010, BIOINFORMATICS, V26, P1779, DOI 10.1093/bioinformatics/btq282; Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094; Ganter B, 2005, J BIOTECHNOL, V119, P219, DOI 10.1016/j.jbiotec.2005.03.022; Gardner TS, 2003, SCIENCE, V301, P102, DOI 10.1126/science.1081900; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gilbert LA, 2010, CELL, V143, P355, DOI 10.1016/j.cell.2010.09.043; Goldwasser F, 1996, ONCOL RES, V8, P317; Gunther S, 2008, NUCLEIC ACIDS RES, V36, pD919, DOI 10.1093/nar/gkm862; Gupta M, 2012, BLOOD, V119, P2844, DOI 10.1182/blood-2011-10-388538; Hansen NT, 2009, CLIN PHARMACOL THER, V86, P183, DOI 10.1038/clpt.2009.42; Hirota T, 2012, SCIENCE, V337, P1094, DOI 10.1126/science.1223710; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Iorio F, 2010, P NATL ACAD SCI USA, V107, P14621, DOI 10.1073/pnas.1000138107; Ito T, 2010, SCIENCE, V327, P1345, DOI 10.1126/science.1177319; Jang CY, 2012, BIOCHEM BIOPH RES CO, V429, P57, DOI 10.1016/j.bbrc.2012.10.093; KULLBACK S, 1951, ANN MATH STAT, V22, P79, DOI 10.1214/aoms/1177729694; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lefebvre C, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.31; Li J, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000450; Lomenick B, 2009, P NATL ACAD SCI USA, V106, P21984, DOI 10.1073/pnas.0910040106; Mani KM, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.2; Miller MA, 2002, NAT REV DRUG DISCOV, V1, P220, DOI 10.1038/nrd745; Pang BX, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2921; Romito A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009029; Scannell JW, 2012, NAT REV DRUG DISCOV, V11, P191, DOI 10.1038/nrd3681; Shao SJ, 2006, J BIOL CHEM, V281, P28943, DOI 10.1074/jbc.M600235200; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Silverman B.W, 1986, DENSITY ESTIMATION S; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thoma CR, 2009, NAT CELL BIOL, V11, P994, DOI 10.1038/ncb1912; THOMAS JP, 1990, BIOCHIM BIOPHYS ACTA, V1045, P252, DOI 10.1016/0005-2760(90)90128-K; Wehling M, 2009, NAT REV DRUG DISCOV, V8, P541, DOI 10.1038/nrd2898; Werning G, 2008, CANCER CELL, V13, P311, DOI 10.1016/j.ccr.2008.02.009; Wolpaw AJ, 2011, P NATL ACAD SCI USA, V108, pE771, DOI 10.1073/pnas.1106149108; Yamanishi Y, 2008, BIOINFORMATICS, V24, pI232, DOI 10.1093/bioinformatics/btn162; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Zhang QC, 2012, NATURE, V490, P556, DOI 10.1038/nature11503; Zhang S, 2012, NAT MED, V18, P1639, DOI 10.1038/nm.2919	54	181	192	2	54	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 16	2015	162	2					441	451		10.1016/j.cell.2015.05.056	http://dx.doi.org/10.1016/j.cell.2015.05.056			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	CN0EU	26186195	Green Accepted, Bronze			2023-01-03	WOS:000358087700022
J	Caudrillier, A; Mallavia, B; Rouse, L; Marschner, S; Looney, MR				Caudrillier, Axelle; Mallavia, Benat; Rouse, Lindsay; Marschner, Susanne; Looney, Mark R.			Transfusion of Human Platelets Treated with Mirasol Pathogen Reduction Technology Does Not Induce Acute Lung Injury in Mice	PLOS ONE			English	Article							MOUSE MODEL; LIGHT; INACTIVATION	Pathogen reduction technology (PRT) has been developed in an effort to make the blood supply safer, but there is controversy as to whether it may induce structural or functional changes to platelets that could lead to acute lung injury after transfusion. In this study, we used a commercial PRT system to treat human platelets that were then transfused into immunodeficient mice, and the development of acute lung injury was determined. P-selectin expression was higher in the Mirasol PRT-treated platelets compared to control platelets on storage day 5, but not storage day 1. Transfusion of control vs. Mirasol PRT-treated platelets (day 5 of storage, 109 platelets per mouse) into NOD/SCID mice did not result in lung injury, however transfusion of storage day 5 platelets treated with thrombin receptor-activating peptide increased both extravascular lung water and lung vascular permeability. Transfusion of day 1 platelets did not produce lung injury in any group, and LPS priming 24 hours before transfusion had no effect on lung injury. In a model of transfusion-related acute lung injury, NOD/SCID mice were susceptible to acute lung injury when challenged with H-2Kd monoclonal antibody vs. isotype control antibody. Using lung intravital microscopy, we did not detect a difference in the dynamic retention of platelets in the lung circulation in control vs. Mirasol PRT-treated groups. In conclusion, Mirasol PRT produced an increase in P-selectin expression that is storage-dependent, but transfusion of human platelets treated with Mirasol PRT into immunodeficient mice did not result in greater platelet retention in the lungs or the development of acute lung injury.	[Caudrillier, Axelle; Mallavia, Benat; Looney, Mark R.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Rouse, Lindsay; Marschner, Susanne] Terumo BCT Inc, Lakewood, CO USA; [Looney, Mark R.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Looney, MR (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.	mark.looney@ucsf.edu		Hartson, Lindsay/0000-0002-3131-3507	Terumo BCT, Inc.	Terumo BCT, Inc.	This study was funded by Terumo BCT, Inc. Lindsay Rouse and Susanne Marschner are employees of Terumo BCT, Inc. Terumo BCT, Inc. provided support in the form of salaries for authors LR and SM but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Caudrillier A, 2012, J CLIN INVEST, V122, P2661, DOI 10.1172/JCI61303; Chi X, 2014, TRANSFUSION, V54, P74, DOI 10.1111/trf.12242; Chi X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044829; Cookson P, 2012, TRANSFUSION, V52, P983, DOI 10.1111/j.1537-2995.2011.03388.x; Dwyre DM, 2011, VOX SANG, V100, P92, DOI 10.1111/j.1423-0410.2010.01426.x; Fung YL, 2010, BLOOD, V116, P3073, DOI 10.1182/blood-2010-05-284570; Gelderman MP, 2011, TRANSFUSION, V51, P2343, DOI 10.1111/j.1537-2995.2011.03135.x; Goodrich RP, 2006, TRANSFUS APHER SCI, V35, P5, DOI 10.1016/j.transci.2006.01.007; Looney MR, 2006, J CLIN INVEST, V116, P1615, DOI 10.1172/JCI27238; Looney MR, 2011, NAT METHODS, V8, P91, DOI 10.1038/NMETH.1543; Looney MR, 2009, J CLIN INVEST, V119, P3450, DOI 10.1172/JCI38432; Ortiz-Munoz G, 2014, BLOOD, V124, P2625, DOI 10.1182/blood-2014-03-562876; Schlenke P, 2014, TRANSFUS MED HEMOTH, V41, P309, DOI 10.1159/000365646; SHULTZ LD, 1995, J IMMUNOL, V154, P180; Snyder E, 2005, TRANSFUSION, V45, P1864, DOI 10.1111/j.1537-2995.2005.00639.x; Spinella PC, 2008, CRIT CARE MED, V36, pS340, DOI 10.1097/CCM.0b013e31817e2ef9; Zarbock A, 2006, J CLIN INVEST, V116, P3211, DOI 10.1172/JCI29499	17	7	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2015	10	7							e0133022	10.1371/journal.pone.0133022	http://dx.doi.org/10.1371/journal.pone.0133022			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RL	26176623	gold, Green Submitted, Green Published			2023-01-03	WOS:000358197600202
J	Radhakrishnan, P				Radhakrishnan, Priti			Commentary: Making middle income countries pay full price for drugs is a big mistake	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												priti@i-mak.org						Amin T, 2014, AL JAZEERA AM   1121; [Anonymous], 2015, AIDSINFO DATABASE; [Anonymous], 2009, IND REJ ARV PAT APPL; Glassman A., 2013, NEW DATA SAME STORY; Global Fund To Fight AIDS, 2014, EL LIST 2014; Ludwig M, 2014, TRUTHOUT         OCT; Medecins Sans Frontieres Access Campaign, 2013, PROP SHAK UP DRUG PR; Medecins Sans Frontieres Access Campaign, 2013, UNT WEB ANT PRIC RED; MSF Access Campaign, 2014, UNT WEB ANT PRIC RED; Pierson B, 2015, REUTERS; Provost C, 2014, GUARDIAN; Schwartlander B., 2012, WHAT WILL IT TAKE TU; Walker J, 2015, WALL STREET J; WHO, WTO TRIPS AGR; WHO, 2014, INCR ACC HIV TREATM; World Bank, MIDDL INC COUNTR; World Intellectual Property Organization, ADV FLEX TRIPS AGR	17	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	2015	351								h3757	10.1136/bmj.h3757	http://dx.doi.org/10.1136/bmj.h3757			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CM8MY	26163479				2023-01-03	WOS:000357956900004
J	Bila, DCA; Boullosa, LT; Vubil, AS; Mabunda, NJ; Abreu, CM; Ismael, N; Jani, IV; Tanuri, A				Adolfo Bila, Dulce Celina; Boullosa, Lidia Teodoro; Vubil, Adolfo Salvador; Mabunda, Nedio Jonas; Abreu, Celina Monteiro; Ismael, Nalia; Jani, Ilesh Vinodrai; Tanuri, Amilcar			Trends in Prevalence of HIV-1 Drug Resistance in a Public Clinic in Maputo, Mozambique	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE INHIBITORS; NAIVE PATIENTS; SUBTYPE-C; HIV-1-INFECTED PATIENTS; VIROLOGICAL FAILURE; K65R RESISTANCE; HEALTH APPROACH; 1ST YEAR; MUTATIONS	Background An observational study was conducted in Maputo, Mozambique, to investigate trends in prevalence of HIV drug resistance (HIVDR) in antiretroviral (ART) naive subjects initiating highly active antiretroviral treatment (HAART). Methodology/Principal Findings To evaluate the pattern of drug resistance mutations (DRMs) found in adults on ART failing first- line HAART [patients with detectable viral load (VL)]. Untreated subjects [Group 1 (G1;n= 99)] and 274 treated subjects with variable length of exposure to ARV's [6- 12 months, Group 2 (G2;n= 93); 12- 24 months, Group 3 (G3;n= 81); >24 months (G4;n= 100)] were enrolled. Virological and immunological failure (VF and IF) were measured based on viral load (VL) and T lymphocyte CD4+ cells (TCD4+) count and genotypic resistance was also performed. Major subtype found was C (untreated: n= 66, 97,06%;treated: n= 36, 91.7%). Maximum virological suppression was observed in G3, and significant differences intragroup were observed between VF and IF in G4 (p= 0.022). Intergroup differences were observed between G3 and G4 for VF (p= 0.023) and IF between G2 and G4 (p= 0.0018). Viral suppression (<50 copies/ml) ranged from 84.9% to 90.1%, and concordant VL and DRM ranged from 25% to 57%. WHO cut- off for determining VF as given by 2010 guidelines (>5000 copies/ml) identified 50% of subjects carrying DRM compared to 100% when lower VL cut- off was used (<50 copies/ml). Length of exposure to ARVs was directly proportional to the complexity of DRM patterns. In Mozambique, VL suppression was achieved in 76% of individuals after 24 months on HAART. This is in agreement with WHO target for HIVDR prevention target (70%). Conclusions We demonstrated that the best way to determine therapeutic failure is VL compared to CD4 counts. The rationalized use of VL testing is needed to ensure timely detection of treatment failures preventing the occurrence of TDR and new infections.	[Adolfo Bila, Dulce Celina; Vubil, Adolfo Salvador; Mabunda, Nedio Jonas; Ismael, Nalia; Jani, Ilesh Vinodrai] Natl Inst Hlth Mozambique, Maputo, Mozambique; [Adolfo Bila, Dulce Celina; Boullosa, Lidia Teodoro; Abreu, Celina Monteiro; Tanuri, Amilcar] Univ Fed Rio de Janeiro, Dept Genet, Mol Virol Lab, Rio De Janeiro, Brazil; [Adolfo Bila, Dulce Celina] Univ Fed Rio de Janeiro, Dept Inst Biophys Carlos Chagas Filho, Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Tanuri, A (corresponding author), Univ Fed Rio de Janeiro, Dept Genet, Mol Virol Lab, Rio De Janeiro, Brazil.	atanuri@biologia.ufrj.br	Abreu, Celina Monteiro/AAT-7447-2020; Tanuri, Amilcar/AAM-8601-2021	Jani, Ilesh/0000-0002-6880-6655	CAPES/Ministry of Education, Brazil	CAPES/Ministry of Education, Brazil(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	Dulce Bila is a PhD student at the Laboratorio de Virologia Molecular, Universidade Federal do Rio de Janeiro, Brazil, and receives a fellowship from CAPES/Ministry of Education, Brazil. We are grateful to the study participants and work done by the health care providers and administrative staff at Centro de Saude do Alto Mae. We would like to acknowledge the work done by laboratory staff at reference laboratory and Mussagy Mahomed at surveillance department at national health institute in Mozambique at Laboratorio de AIDS in FIOCRUZ Brazil.	Abreu CM, 2008, ARCH VIROL, V153, P2013, DOI 10.1007/s00705-008-0215-6; [Anonymous], 2015, MEGA SOFTWARE; [Anonymous], 2015, HIV REC AN; Auld AF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018453; Autran B, 1999, IMMUNOL LETT, V66, P207, DOI 10.1016/S0165-2478(98)00159-X; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; Bennett DE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004724; Borroto-Esoda K, 2007, AIDS RES HUM RETROV, V23, P988, DOI 10.1089/aid.2006.0310; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Brenner B, 2003, AIDS, V17, pF1, DOI 10.1097/00002030-200301030-00001; Brenner BG, 2006, AIDS, V20, pF9, DOI 10.1097/01.aids.0000232228.88511.0b; Chunduri H, 2011, VIROLOGY, V414, P34, DOI 10.1016/j.virol.2011.03.007; Comite Nacional de Assistencia Medica e Colaboradores, GUIA TRAT ANT INF OP; Ferradini L, 2006, LANCET, V367, P1335, DOI 10.1016/S0140-6736(06)68580-2; Fourati S, 2013, J ANTIMICROB CHEMOTH, V68, P2199, DOI 10.1093/jac/dkt200; Gaardbo JC, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/670957; Gilks CF, 2006, LANCET, V368, P505, DOI 10.1016/S0140-6736(06)69158-7; Granados JMS, 2003, PEDIATR INFECT DIS J, V22, P863, DOI 10.1097/01.inf.0000091282.70253.5f; Hosseinipour MC, 2009, AIDS, V23, P1127, DOI 10.1097/QAD.0b013e32832ac34e; Jordan MR, 2008, ANTIVIR THER, V13, P15; Kuritzkes DR, 2004, AIDS PATIENT CARE ST, V18, P259, DOI 10.1089/108729104323076007; Marconi VC, 2008, CLIN INFECT DIS, V46, P1589, DOI 10.1086/587109; Miiro G, 2009, TROP MED INT HEALTH, V14, P556, DOI 10.1111/j.1365-3156.2009.02259.x; Mouroux M, 2001, ANTIVIR THER, V6, P179; National Institute of Health NI of S (Mozambique) and C for DC (US), 2009, NAT SURV PREV BEH RI; Orrell C, 2009, ANTIVIR THER, V14, P523; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Rhee SY, 2003, NUCLEIC ACIDS RES, V31, P298, DOI 10.1093/nar/gkg100; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; Shafer RW, 2008, AIDS REV, V10, P67; Shafer RW, 2008, ANTIVIR THER, V13, P59; Soares MA, 2003, AIDS, V17, P11, DOI 10.1097/00002030-200301030-00004; Stanford University, 2015, DRUG RES AN; Sunpath H, 2012, AIDS, V26, P1679, DOI 10.1097/QAD.0b013e328356886d; Tiba Fabrice, 2012, Open AIDS J, V6, P16, DOI 10.2174/1874613601206010016; Turner D, 2009, J MED VIROL, V81, P1509, DOI 10.1002/jmv.21567; Wallis CL, 2010, JAIDS-J ACQ IMM DEF, V53, P480, DOI 10.1097/QAI.0b013e3181bc478b; WHO, 2010, ANT THER HIV INF AD	38	7	7	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2015	10	7							e0130580	10.1371/journal.pone.0130580	http://dx.doi.org/10.1371/journal.pone.0130580			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1EC	26151752	Green Submitted, gold, Green Published			2023-01-03	WOS:000358158900013
J	Liu, XQ; Hu, ZQ; Zhou, B; Li, X; Tao, R				Liu, Xiqiang; Hu, Zhiqiu; Zhou, Bin; Li, Xiang; Tao, Ran			Chinese Herbal Preparation Xuebijing Potently Inhibits Inflammasome Activation in Hepatocytes and Ameliorates Mouse Liver Ischemia-Reperfusion Injury	PLOS ONE			English	Article							HEPATIC ISCHEMIA/REPERFUSION INJURY; ACUTE LUNG INJURY; HYDROXYSAFFLOR YELLOW; NETWORK PHARMACOLOGY; CARBON-TETRACHLORIDE; OXIDATIVE STRESS; UP-REGULATION; MICE; PROTECTS; INJECTION	The Chinese herb preparation Xuebijing injection (XBJ) has been widely used in the management of various septic disorders or inflammation-related conditions, however the molecular mechanism of its anti-inflammatory effect remains largely elusive. In the current study, we found that XBJ treatment potently ameliorated mouse hepatic ischemia-reperfusion (IR) injury, manifested as decreased liver function tests (LDH, ALT, AST), improved inflammation and less hepatocyte apoptosis. Notably, XBJ markedly inhibited inflammasome activation and IL-1 production in mouse livers subjected to IRI, even in the absence of Kupffer cells, suggesting Kupffer cells are not necessary for hepatic inflammasome activation upon Redox-induced sterile inflammation. This finding led us to investigate the role of XBJ on hepatocyte apoptosis and inflammasome activation using an in vitro hydrogen peroxide (H2O2)-triggered hepatocyte injury model. Our data clearly demonstrated that XBJ potently inhibited apoptosis, as well as caspase-1 cleavage and IL-1 beta production in a time-and dose-dependent manner in isolated hepatocytes, suggesting that in addition to its known modulatory effect on NF-kappa B-dependent inflammatory gene expression, it also has a direct impact on hepatocyte inflammasome activation. The current study not only deepens our understanding of how XBJ ameliorates inflammation and apoptosis, but also has immediate practical significance in many clinical situations such as partial hepatectomy, liver transplantation, etc.	[Liu, Xiqiang; Tao, Ran] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Surg, Shanghai 200030, Peoples R China; [Hu, Zhiqiu] Fudan Univ, Minhang Hosp, Dept Surg, Shanghai 200433, Peoples R China; [Zhou, Bin] Zhejiang Prov Peoples Hosp ZJPPH, Dept Cardiothorac Surg, Hangzhou, Zhejiang, Peoples R China; [Li, Xiang] Zhejiang Med Coll, Fac Basic Med, Dept Pharmacol, Hangzhou, Zhejiang, Peoples R China; [Tao, Ran] Zhejiang Prov Peoples Hosp ZJPPH, Dept Hepatobiliary Pancreat Surg, Hangzhou, Zhejiang, Peoples R China	Shanghai Jiao Tong University; Fudan University; Zhejiang Provincial People's Hospital; Zhejiang Provincial People's Hospital	Tao, R (corresponding author), Zhejiang Prov Peoples Hosp ZJPPH, Dept Hepatobiliary Pancreat Surg, 14th Floor,Bldg 1,158 Shangtang Rd, Hangzhou, Zhejiang, Peoples R China.	taohdac9@hotmail.com			National Nature and Science Foundation (NSF) [81001324, 81373163]; "Oriental Scholar" Endowed Professorship grant from the Municipal Scientific Committee of Shanghai; "SMG-Rising Star" grant from Shanghai Jiaotong University; interim start funding from ZJPPH	National Nature and Science Foundation (NSF); "Oriental Scholar" Endowed Professorship grant from the Municipal Scientific Committee of Shanghai; "SMG-Rising Star" grant from Shanghai Jiaotong University; interim start funding from ZJPPH	This work was supported by National Nature and Science Foundation (NSF) grant (81001324, 81373163 to RT), "Oriental Scholar" Endowed Professorship grant from the Municipal Scientific Committee of Shanghai (to RT), "SMG-Rising Star" grant from Shanghai Jiaotong University (to RT) and an interim start funding from ZJPPH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bamboat ZM, 2010, HEPATOLOGY, V51, P621, DOI 10.1002/hep.23365; Barone S, 2005, AM J PHYSIOL-CELL PH, V289, pC826, DOI 10.1152/ajpcell.00629.2004; Cardinal J, 2009, HEPATOLOGY, V50, P565, DOI 10.1002/hep.23021; Chen L, 2013, NEUROCHEM RES, V38, P2268, DOI 10.1007/s11064-013-1135-8; Deng J., 2013, COCHRANE DB SYST REV, V7; Dong H, 2013, PHARM BIOL; Gong Bei-lei, 2010, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V22, P543; Han B, 2013, EUR J PHARMACOL, V714, P83, DOI 10.1016/j.ejphar.2013.06.011; Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118; Hopkins AL, 2007, NAT BIOTECHNOL, V25, P1110, DOI 10.1038/nbt1007-1110; Huang H, 2011, PHYTOCHEM ANALYSIS, V22, P330, DOI 10.1002/pca.1284; Ji HF, 2013, HEPATOLOGY, V57, P1225, DOI 10.1002/hep.25802; Jiang M, 2013, J ETHNOPHARMACOL, V147, P426, DOI 10.1016/j.jep.2013.03.032; Jiang SJ, 2014, INT J CLIN EXP PATHO, V7, P2595; Kamo N, 2013, HEPATOLOGY, V58, P351, DOI 10.1002/hep.26320; Kato A, 2002, AM J PATHOL, V161, P1797, DOI 10.1016/S0002-9440(10)64456-2; Kim HJ, 2013, J PHARMACOL EXP THER, V346, P465, DOI 10.1124/jpet.113.205732; Li CC, 2012, EUR J PHARM SCI, V46, P397, DOI 10.1016/j.ejps.2012.03.003; Li DG, 2014, INT J MOL SCI, V15, P10541, DOI 10.3390/ijms150610541; Li J, 2013, NEUROSCI LETT, V535, P51, DOI 10.1016/j.neulet.2012.12.056; Liu Ming-wei, 2014, BMC Complement Altern Med, V14, P498, DOI 10.1186/1472-6882-14-498; Liu MW, 2014, INT J MOL MED, V34, P1492, DOI 10.3892/ijmm.2014.1943; Liu Q, 2014, PHARM BIOL, V52, P1085, DOI 10.3109/13880209.2013.877491; Liu SX, 2012, INT J CARDIOL, V160, P95, DOI 10.1016/j.ijcard.2011.03.033; Liu YL, 2014, INT IMMUNOPHARMACOL, V23, P649, DOI 10.1016/j.intimp.2014.10.018; Llacuna L, 2010, HEPATOLOGY, V52, P1371, DOI 10.1002/hep.23833; Llacuna L, 2009, AM J PATHOL, V174, P1776, DOI 10.2353/ajpath.2009.080857; Lutz A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115603; Ogura Y, 2006, CELL, V126, P659, DOI 10.1016/j.cell.2006.08.002; Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892; Qi F, 2011, J TRADIT CHIN MED, V31, P46, DOI 10.1016/S0254-6272(11)60011-3; Qi ZF, 2014, TRANSL STROKE RES, V5, P501, DOI 10.1007/s12975-014-0346-x; Sakai N, 2012, HEPATOLOGY, V56, P1468, DOI 10.1002/hep.25768; Sakai N, 2012, HEPATOLOGY, V55, P888, DOI 10.1002/hep.24756; Serafin A, 2004, HEPATOLOGY, V39, P688, DOI 10.1002/hep.20089; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sun JP, 2010, EXP LUNG RES, V36, P211, DOI 10.3109/01902140903312123; Takehara T, 1999, GASTROENTEROLOGY, V117, P661, DOI 10.1016/S0016-5085(99)70460-9; Taniai H, 2004, HEPATOLOGY, V39, P1544, DOI 10.1002/hep.20217; Tsutsui H, 2014, INT J MOL SCI, V15, P7711, DOI 10.3390/ijms15057711; Ueki S, 2011, HEPATOLOGY, V54, P216, DOI 10.1002/hep.24360; Wang CY, 2013, PHYTOMEDICINE, V20, P592, DOI 10.1016/j.phymed.2013.02.001; Wang CY, 2013, TOXICOL APPL PHARM, V272, P895, DOI 10.1016/j.taap.2013.07.021; Wang YY, 2014, NANOSCALE RES LETT, V9, P1, DOI 10.1186/1556-276X-9-251; Wang YX, 2014, EXP THER MED, V8, P1593, DOI 10.3892/etm.2014.1949; Wei LL, 2014, INFLAMM RES, V63, P485, DOI 10.1007/s00011-014-0720-x; Wree A, 2013, HEPATOLOGY; Wu L., 2013, DATABASE, V2013; Wu Y, 2012, BIOL PHARM BULL, V35, P515, DOI 10.1248/bpb.35.515; Yin QQ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/310194; Yu HC, 2011, HEPATOLOGY, V54, P979, DOI 10.1002/hep.24469; Yu W, 2008, NAT GENET, V40, P124, DOI 10.1038/ng0208-124; Zhang YB, 2011, EUR J PHARMACOL, V660, P438, DOI 10.1016/j.ejphar.2011.04.015; Zhang ZH, 2014, BRAIN RES, V1563, P72, DOI 10.1016/j.brainres.2014.03.036; Zhu P, 2011, HUM GENE THER, V22, P853, DOI 10.1089/hum.2010.145	55	13	14	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2015	10	7							e0131436	10.1371/journal.pone.0131436	http://dx.doi.org/10.1371/journal.pone.0131436			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1CG	26132490	gold, Green Submitted, Green Published			2023-01-03	WOS:000358153000117
J	Dong, D; Thomas, N; Thierry, B; Vreugde, S; Prestidge, CA; Wormald, PJ				Dong, Dong; Thomas, Nicky; Thierry, Benjamin; Vreugde, Sarah; Prestidge, Clive A.; Wormald, Peter-John			Distribution and Inhibition of Liposomes on Staphylococcus aureus and Pseudomonas aeruginosa Biofilm	PLOS ONE			English	Article							IN-VITRO ACTIVITY; CHRONIC RHINOSINUSITIS; BACTERIAL BIOFILMS; SURFACE-PROPERTIES; NANOPARTICLES; ACCUMULATION; PENETRATION; FORMULATION; INFECTIONS; MECHANISMS	Background Staphylococcus aureus and Pseudomonas aeruginosa are major pathogens in chronic rhinosinusitis (CRS) and their biofilms have been associated with poorer postsurgical outcomes. This study investigated the distribution and anti-biofilm effect of cationic (+) and anionic (-) phospholipid liposomes with different sizes (unilamellar and multilamellar vesicle, ULV and MLV respectively) on S. aureus and P. aeruginosa biofilms. Method Specific biofilm models for S. aureus ATCC 25923 and P. aeruginosa ATCC 15692 were established. Liposomal distribution was determined by observing SYTO9 stained biofilm exposed to DiI labeled liposomes using confocal scanning laser microscopy, followed by quantitative image analysis. The anti-biofilm efficacy study was carried out by using the alamarBlue assay to test the relative viability of biofilm treated with various liposomes for 24 hours and five minutes. Results The smaller ULVs penetrated better than larger MLVs in both S. aureus and P. aeruginosa biofilm. Except that + ULV and -ULV displayed similar distribution in S. aureus biofilm, the cationic liposomes adhered better than their anionic counterparts. Biofilm growth was inhibited at 24-hour and five-minute exposure time, although the decrease of viability for P. aeruginosa biofilm after liposomal treatment did not reach statistical significance. Conclusion The distribution and anti-biofilm effects of cationic and anionic liposomes of different sizes differed in S. aureus and P. aeruginosa biofilms. Reducing the liposome size and formulating liposomes as positively charged enhanced the penetration and inhibition of S. aureus and P. aeruginosa biofilms.	[Dong, Dong; Vreugde, Sarah; Wormald, Peter-John] Queen Elizabeth Hosp, Dept Surg Otorhinolaryngol Head & Neck Surg, Adelaide, SA, Australia; [Dong, Dong; Vreugde, Sarah; Wormald, Peter-John] Univ Adelaide, Adelaide, SA, Australia; [Thomas, Nicky; Thierry, Benjamin; Prestidge, Clive A.] Univ S Australia, Ian Wark Res Inst, Mawson Lakes, Australia; [Dong, Dong] Zhengzhou Univ, Affiliated Hosp 1, Rhinol Dept, Zhengzhou 450052, Peoples R China	University of Adelaide; University of South Australia; Zhengzhou University	Wormald, PJ (corresponding author), Queen Elizabeth Hosp, Dept Surg Otorhinolaryngol Head & Neck Surg, Adelaide, SA, Australia.	peterj.wormald@adelaide.edu.au	Thierry, benjamin/B-2785-2009; Dong, Dong/AAI-1403-2020; Thomas, Nicky/D-1708-2016	Thierry, benjamin/0000-0002-6757-2842; Thomas, Nicky/0000-0001-8920-1391; Prestidge, Clive/0000-0001-5401-7535; Vreugde, Sarah/0000-0003-4719-9785	National Health and Medical Research Council of Australia (NHMRC) [GNT1047576]	National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia)	This study was supported by a grant from The National Health and Medical Research Council of Australia (NHMRC: GNT1047576) [http://www.nhmrc.gov.au/]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the	Ahmed K, 2002, J LIPOSOME RES, V12, P285, DOI 10.1081/LPR-120016195; Allison DG, 2003, BIOFOULING, V19, P139, DOI 10.1038/nrmicro2415; Andar AU, 2014, PHARM RES-DORDR, V31, P401, DOI 10.1007/s11095-013-1171-8; BANGHAM AD, 1965, J MOL BIOL, V13, P253, DOI 10.1016/S0022-2836(65)80094-8; Bendouah Z, 2006, OTOLARYNG HEAD NECK, V134, P991, DOI 10.1016/j.otohns.2006.03.001; Bjarnsholt T, 2013, TRENDS MICROBIOL, V21, P466, DOI 10.1016/j.tim.2013.06.002; Boase S, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-210; Cottenye N, 2013, BIOFOULING, V29, P817, DOI 10.1080/08927014.2013.807505; Desbois AP, 2010, APPL MICROBIOL BIOT, V85, P1629, DOI 10.1007/s00253-009-2355-3; Dong D, 2014, LARYNGOSCOPE, V124, P1071, DOI 10.1002/lary.24424; Flemming HC, 2007, J BACTERIOL, V189, P7945, DOI 10.1128/JB.00858-07; Foreman A, 2012, CURR ALLERGY ASTHM R, V12, P127, DOI 10.1007/s11882-012-0246-7; Foreman A, 2011, LARYNGOSCOPE, V121, P1085, DOI 10.1002/lary.21438; Forier K, 2014, J CONTROL RELEASE, V195, P21, DOI 10.1016/j.jconrel.2014.07.061; Forier K, 2014, J CONTROL RELEASE, V190, P607, DOI 10.1016/j.jconrel.2014.03.055; FRESTA M, 1995, J PHARM SCI, V84, P895, DOI 10.1002/jps.2600840721; Fresta M, 1996, ANTIMICROB AGENTS CH, V40, P2865, DOI 10.1128/AAC.40.12.2865; Furneri PM, 2000, ANTIMICROB AGENTS CH, V44, P2458, DOI 10.1128/AAC.44.9.2458-2464.2000; Grant SS, 2013, VIRULENCE, V4, P273, DOI 10.4161/viru.23987; Gross M, 2001, INFECT IMMUN, V69, P3423, DOI 10.1128/IAI.69.5.3423-3426.2001; Ha KR, 2008, LARYNGOSCOPE, V118, P535, DOI 10.1097/MLG.0b013e31815bf2e3; Hajipour MJ, 2012, TRENDS BIOTECHNOL, V30, P499, DOI 10.1016/j.tibtech.2012.06.004; Hamblin KA, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00079; Hinna A, 2016, J LIPOSOME RES, V26, P11, DOI 10.3109/08982104.2015.1022556; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; Jardeleza C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092117; Lai SK, 2011, BIOMATERIALS, V32, P6285, DOI 10.1016/j.biomaterials.2011.05.008; Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002; Li H, 2012, EUR ARCH OTO-RHINO-L, V269, P155, DOI 10.1007/s00405-011-1683-y; Meers P, 2008, J ANTIMICROB CHEMOTH, V61, P859, DOI 10.1093/jac/dkn059; Merritt Judith H, 2005, Curr Protoc Microbiol, VChapter 1, DOI 10.1002/9780471729259.mc01b01s00; Montagna MT, 2014, J MED MICROBIOL, V63, P1638, DOI 10.1099/jmm.0.075507-0; Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/NMAT2442, 10.1038/nmat2442]; Obonyo M, 2012, MOL PHARMACEUT, V9, P2677, DOI 10.1021/mp300243w; Parmentier J, 2012, INT J PHARMACEUT, V437, P253, DOI 10.1016/j.ijpharm.2012.08.018; Peeters E, 2008, J MICROBIOL METH, V72, P157, DOI 10.1016/j.mimet.2007.11.010; Peschel A, 1999, J BIOL CHEM, V274, P8405, DOI 10.1074/jbc.274.13.8405; Powell LC, 2014, AM J RESP CELL MOL, V50, P483, DOI 10.1165/rcmb.2013-0287OC; Rehman ZU, 2013, APPL ENVIRON MICROB, V79, P3264, DOI 10.1128/AEM.00460-13; Rogers SA, 2010, ANTIMICROB AGENTS CH, V54, P2112, DOI 10.1128/AAC.01418-09; Sandt C, 2007, J ANTIMICROB CHEMOTH, V60, P1281, DOI 10.1093/jac/dkm382; Singhal D, 2011, LARYNGOSCOPE, V121, P1578, DOI 10.1002/lary.21805; Soenen SJ, 2011, NANO TODAY, V6, P446, DOI 10.1016/j.nantod.2011.08.001; SONOHARA R, 1995, BIOPHYS CHEM, V55, P273, DOI 10.1016/0301-4622(95)00004-H; Sudagidan M, 2010, MIKROBIYOL BUL, V44, P93; Xu XM, 2011, INT J PHARMACEUT, V419, P52, DOI 10.1016/j.ijpharm.2011.07.012	47	50	53	4	39	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2015	10	6							e0131806	10.1371/journal.pone.0131806	http://dx.doi.org/10.1371/journal.pone.0131806			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1BR	26125555	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000358151300055
J	Jeter, PE; Moonaz, SH; Bittner, AK; Dagnelie, G				Jeter, Pamela E.; Moonaz, Steffany Haaz; Bittner, Ava K.; Dagnelie, Gislin			Ashtanga-Based Yoga Therapy Increases the Sensory Contribution to Postural Stability in Visually-Impaired Persons at Risk for Falls as Measured by the Wii Balance Board: A Pilot Randomized Controlled Trial	PLOS ONE			English	Article							TAI-CHI; OLDER-ADULTS; PRESSURE MEASURES; FUNCTIONAL REACH; INJURIOUS FALLS; VISION; SWAY; STABILIZATION; PERFORMANCE; FORCE	Objective Persons with visual impairment (VI) are at greater risk for falls due to irreparable damage to visual sensory input contributing to balance. Targeted training may significantly improve postural stability by strengthening the remaining sensory systems. Here, we evaluate the Ashtanga-based Yoga Therapy (AYT) program as a multi-sensory behavioral intervention to develop postural stability in VI. Design A randomized, waitlist-controlled, single-blind clinical trial Methods The trial was conducted between October 2012 and December 2013. Twenty-one legally blind participants were randomized to an 8-week AYT program (n = 11, mean (SD) age = 55 (17)) or waitlist control (n= 10, mean (SD) age = 55(10)). AYT subjects convened for one group session at a local yoga studio with an instructor and two individual home-based practice sessions per week for a total of 8 weeks. Subjects completed outcome measures at baseline and post-8 weeks of AYT. The primary outcome, absolute Center of Pressure (COP), was derived from the Wii Balance Board (WBB), a standalone posturography device, in 4 sensory conditions: firm surface, eyes open (EO); firm surface, eyes closed (EC); foam surface, EO; and foam surface, EC. Stabilization Indices (SI) were computed from COP measures to determine the relative visual (SIfirm, SIfoam), somatosensory (SIEO, SIEC) and vestibular (SIV, i.e., Foam(EC) vs. Firm(EO)) contributions to balance. This study was not powered to detect between group differences, so significance of pre-post changes was assessed by paired samples t-tests within each group. Results Groups were equivalent at baseline (all p > 0.05). In the AYT group, absolute COP significantly increased in the Foam(EO)(t(8) = -3.66, p = 0.01) and Foam(EC) (t(8) = -3.90, p = 0.01) conditions. Relative somatosensory SIEO (t(8) = -2.42, p = 0.04) and SIEC (t(8) = -3.96, p = 0.01), and vestibular SIV (t(8) = -2.47, p = 0.04) contributions to balance increased significantly. As expected, no significant changes from EO to EC conditions were found indicating an absence of visual dependency in VI. No significant pre-post changes were observed in the control group (all p > 0.05). Conclusions These preliminary results establish the potential for AYT training to develop the remaining somatosensory and vestibular responses used to optimize postural stability in a VI population.	[Jeter, Pamela E.; Dagnelie, Gislin] Johns Hopkins Univ, Wilmer Eye Inst, Dept Ophthalmol, Lions Vision Res Ctr, Baltimore, MD 21218 USA; [Jeter, Pamela E.; Moonaz, Steffany Haaz] Maryland Univ Integrat Hlth, Dept Integrat Hlth Sci, Laurel, MD USA; [Bittner, Ava K.] Nova SE Univ, Coll Optometry, Ft Lauderdale, FL 33314 USA	Johns Hopkins University; Johns Hopkins Medicine; Nova Southeastern University	Jeter, PE (corresponding author), Johns Hopkins Univ, Wilmer Eye Inst, Dept Ophthalmol, Lions Vision Res Ctr, Baltimore, MD 21218 USA.	pamela.jeter@gmail.com	Northcote, Matthew/B-8209-2019; Moonaz, Steffany Haaz/Z-4467-2019; Northcote, Matthew/L-1135-2019; Bittner, Ava/AAK-8778-2021	Bittner, Ava/0000-0002-9498-2230; Jeter, Pamela/0000-0001-9697-9767	Louise L. Sloan Research Grant Award; Lions Vision Research Foundation; Wilmer Eye Institute; Johns Hopkins University; National Eye Institute [R01EY021220-S1]; NATIONAL EYE INSTITUTE [R01EY021220] Funding Source: NIH RePORTER	Louise L. Sloan Research Grant Award; Lions Vision Research Foundation; Wilmer Eye Institute(Johns Hopkins University); Johns Hopkins University(Johns Hopkins University); National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	PEJ has obtained two grants: Louise L. Sloan Research Grant Award, Lions Vision Research Foundation, Wilmer Eye Institute, Johns Hopkins University ($2,000) and National Eye Institute, Diversity Supplement (Administrative Supplement #R01EY021220-S1, pays salary only). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asslander L, 2014, J NEUROPHYSIOL, V111, P1852, DOI 10.1152/jn.00669.2013; Bartlett HL, 2014, GAIT POSTURE, V39, P224, DOI 10.1016/j.gaitpost.2013.07.010; BLACK FO, 1982, AM J OTOLARYNG, V3, P309, DOI 10.1016/S0196-0709(82)80002-1; Brownstone A, 2001, INT J YOGA THERAP, V11, P11; Chen EW, 2012, AGE AGEING, V41, P254, DOI 10.1093/ageing/afr146; Chiacchiero M, 2012, TOP GERIATR REHABIL, V28, P182, DOI 10.1097/TGR.0b013e318257d1ed; Chiacchiero M, 2010, TOP GERIATR REHABIL, V26, P148, DOI 10.1097/TGR.0b013e3181e854bc; Clark RA, 2010, GAIT POSTURE, V31, P307, DOI 10.1016/j.gaitpost.2009.11.012; COOGLER CE, 1992, POSTURE AND GAIT, CONTROL MECHANISMS 1992, VOL 1 AND 2, pB239; Cornilleau-Peres V, 2005, GAIT POSTURE, V22, P96, DOI 10.1016/j.gaitpost.2004.07.009; Coulter H. D., 2001, ANATOMY HATHA YOGA M; CSUKA M, 1985, AM J MED, V78, P77, DOI 10.1016/0002-9343(85)90465-6; Dagnelie G, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12934; Davids K, 1999, J MOTOR BEHAV, V31, P358, DOI 10.1080/00222899909601000; Di Girolamo S, 1999, J VESTIBUL RES-EQUIL, V9, P445; DUNCAN PW, 1990, J GERONTOL, V45, pM192, DOI 10.1093/geronj/45.6.M192; ELLIOTT DB, 1995, OPHTHAL PHYSL OPT, V15, P553, DOI 10.1016/0275-5408(95)00025-9; Era P, 2006, GERONTOLOGY, V52, P204, DOI 10.1159/000093652; Esculier JF, 2012, J REHABIL MED, V44, P144, DOI 10.2340/16501977-0922; FELSON DT, 1989, J AM GERIATR SOC, V37, P495, DOI 10.1111/j.1532-5415.1989.tb05678.x; Ferguson CJ, 2009, PROF PSYCHOL-RES PR, V40, P532, DOI 10.1037/a0015808; Fiori F, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00734; Freeman EE, 2007, INVEST OPHTH VIS SCI, V48, P4445, DOI 10.1167/iovs.07-0326; Gauchard GC, 1999, NEUROSCI LETT, V273, P81, DOI 10.1016/S0304-3940(99)00615-1; Goldstein JE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1028, DOI 10.1001/archophthalmol.2012.1197; Gyllensten AL, 2010, ARCH PHYS MED REHAB, V91, P215, DOI 10.1016/j.apmr.2009.10.009; Harbourne RT, 2009, PHYS THER, V89, P284, DOI 10.2522/ptj.20080130.ar; Hart CEF, 2008, J STRENGTH COND RES, V22, P1659, DOI 10.1519/JSC.0b013e31818200dd; Harwood RH, 2001, AGE AGEING, V30, P13, DOI 10.1093/ageing/30.suppl_4.13; Hewett ZL, 2011, J EXERC SCI FIT, V9, P87, DOI 10.1016/S1728-869X(12)60003-3; Hong YL, 2007, SPORT BIOMECH, V6, P453, DOI 10.1080/14763140701491674; HORAK FB, 1990, EXP BRAIN RES, V82, P167; Horak FB, 1997, GAIT POSTURE, V6, P76, DOI 10.1016/S0966-6362(97)00018-0; HU MH, 1994, J GERONTOL, V49, pM52, DOI 10.1093/geronj/49.2.M52; Hughes MA, 1996, ARCH PHYS MED REHAB, V77, P567, DOI 10.1016/S0003-9993(96)90296-8; Jeter P, 2014, J ALTERN COMPLEM MED, V20, pA57, DOI [10.1089/acm.2014.5149, DOI 10.1089/ACM.2014.5149]; Jeter P.E., 2012, ALTERNATIVE MED STUD, V2, P5, DOI [10.4081/ams.2012.e5, DOI 10.4081/AMS.2012.E5]; Jeter PE, 2015, GAIT POSTURE, V41, P482, DOI 10.1016/j.gaitpost.2014.11.012; Jeter PE, 2014, J ALTERN COMPLEM MED, V20, P221, DOI 10.1089/acm.2013.0378; Jeter PE, 2012, ALTERN MED STUDIIES, V2; Jones CJ, 2002, J ACTIVE AGING, P24; Jonsson E, 2003, J REHABIL MED, V35, P26, DOI 10.1080/16501970306099; Kiemel T, 2011, J NEUROSCI, V31, P15144, DOI 10.1523/JNEUROSCI.1013-11.2011; Klein BEK, 1998, OPHTHALMOLOGY, V105, P160, DOI 10.1016/S0161-6420(98)91911-X; Kotecha A, 2012, INVEST OPHTH VIS SCI, V53, P7795, DOI 10.1167/iovs.12-10866; Le TT, 2008, GAIT POSTURE, V27, P493, DOI 10.1016/j.gaitpost.2007.06.003; Li FZ, 2012, NEW ENGL J MED, V366, P511, DOI 10.1056/NEJMoa1107911; LORD SR, 1991, J GERONTOL, V46, pM69, DOI 10.1093/geronj/46.3.M69; Lord SR, 2006, AGE AGEING, V35, P2; MAKI BE, 1994, J GERONTOL, V49, pM72, DOI 10.1093/geronj/49.2.M72; Massion Jean, 1994, Current Opinion in Neurobiology, V4, P877, DOI 10.1016/0959-4388(94)90137-6; Mohanty S, 2014, BRIT J VISUAL IMPA, V32, P124, DOI 10.1177/0264619614522132; NIH N, 2013, YOGA FOR HLTH; Odom J, 2011, INSIGHT RES PRACTICE, V4, P92; Owsley C, 2011, VISION RES, V51, P1610, DOI 10.1016/j.visres.2010.10.020; Pajala S, 2008, J GERONTOL A-BIOL, V63, P171, DOI 10.1093/gerona/63.2.171; Palmieri RM, 2002, J SPORT REHABIL, V11, P51, DOI 10.1123/jsr.11.1.51; PATLA A, 1990, Physiotherapy Canada, V42, P89; PAULUS W, 1987, J NEUROL NEUROSUR PS, V50, P1542, DOI 10.1136/jnnp.50.11.1542; PAULUS WM, 1984, BRAIN, V107, P1143, DOI 10.1093/brain/107.4.1143; PETERKA RJ, 1995, EXP BRAIN RES, V105, P101; Peterka RJ, 2002, J NEUROPHYSIOL, P88; Piirtola M, 2006, GERONTOLOGY, V52, P1, DOI 10.1159/000089820; Radvay X, 2007, J VESTIBUL RES-EQUIL, V17, P183; Rogers ME, 2001, J OCCUP REHABIL, V11, P291, DOI 10.1023/A:1013300725964; Rose DJ, 2010, FALLPROOF; Ross A, 2010, J ALTERN COMPLEM MED, V16, P3, DOI 10.1089/acm.2009.0044; Salavati M, 2009, GAIT POSTURE, V29, P460, DOI 10.1016/j.gaitpost.2008.11.016; Schmid AA, 2010, LOWER EXTREMITY 0813, P1; Schmid AA, 2010, ARCH PHYS MED REHAB, V91, P576, DOI 10.1016/j.apmr.2009.12.018; Schwesig R, 2011, EUR J OPHTHALMOL, V21, P303, DOI 10.5301/EJO.2010.5504; Shabana N, 2005, CLIN EXP OPHTHALMOL, V33, P264, DOI 10.1111/j.1442-9071.2005.01003.x; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; Simmons RW, 2005, INT J NEUROSCI, V115, P87, DOI 10.1080/00207450490512678; Tsang WW, 2004, ARCH PHYS MED REHAB, V85, P129, DOI 10.1016/j.apmr.2003.02.002; TURANO K, 1993, INVEST OPHTH VIS SCI, V34, P3004; Tuzun S, 2010, EUR J PHYS REHAB MED, V46, P69; Vellas BJ, 1997, J AM GERIATR SOC, V45, P735, DOI 10.1111/j.1532-5415.1997.tb01479.x; Vuillerme N, 2001, NEUROSCI LETT, V311, P73, DOI 10.1016/S0304-3940(01)02147-4; Wang MY, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-8; Wayne PM, 2014, J ALTERN COMPLEM MED, V20, pA25; Winter D. A, 1995, GAIT POSTURE, V3, P193; Wolf SL, 1997, PHYS THER, V77, P371, DOI 10.1093/ptj/77.4.371; Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644; Yim-Chiplis PK, 2000, BIOL RES NURS, V1; Young W, 2011, GAIT POSTURE, V33, P303, DOI 10.1016/j.gaitpost.2010.10.089	86	25	26	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2015	10	6							e0129646	10.1371/journal.pone.0129646	http://dx.doi.org/10.1371/journal.pone.0129646			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CL4OM	26107256	Green Submitted, Green Published, gold			2023-01-03	WOS:000356932500064
J	Cerrato, CP; Pirisinu, M; Vlachos, EN; Langel, U				Cerrato, Carmine Pasquale; Pirisinu, Marco; Vlachos, Efstathios Nikolaos; Langel, Ulo			Novel cell-penetrating peptide targeting mitochondria	FASEB JOURNAL			English	Article						mitochondrial targeting; ROS reduction; mitochondrial membrane potential; antioxidant activity	HUMAN IMMUNODEFICIENCY VIRUS; ANTIOXIDANTS; PROTEIN; SUPEROXIDE; ANALOGS; GLUTATHIONE; PREDICTION; MEMBRANES; DELIVERY; BILAYERS	Cell-penetrating peptides (CPPs) are short, nontoxic peptides with cationic and/or amphipathic properties able to cross the cellular membrane. CPPs are used for the delivery of awide variety of cargoes, such as proteins, oligonucleotides, and therapeuticmolecules. The aim of the present study was to synthesize unusually small novel CPPs targeting mitochondria based on the Szeto-Schiller peptide (SS-31) to influence intramitochondrial processes and to improve the biologic effects. All the peptides used were synthesized manually using 9-fluorenylmethyloxycarbonyl chemistry. In the first part of the study, HeLa 705, U87, and bEnd. 3 cells were used as in vitro delivery model. Cells were incubated for 24 h at 37 degrees C and 5% CO2 with different concentrations of our peptides. Cell proliferation assay was performed to evaluate cell viability. Biologic effects such as mitochondrial membrane potential and antioxidant activity were evaluated. H2O2 was used as positive control. Uptake studies were performed using peptides conjugated with 5(6)-carboxyfluorescein (FAM). Fluorescent microscopy was used to determine presence and localization of peptides into the cells. Isolated mitochondria from pretreated cells and mitochondria treated after isolation were used to confirmthe targeting ability of the peptide. Uptake of FAM alone was used as negative control. Microscopy studies confirmed the ability of peptides to penetrate cell. Localization analysis showed increase in uptake by35% compared with SS-31. Mitochondrial CPP 1 (mtCPP-1) had no effect on mitochondrial membrane potential and prevented reactive oxygen species formation in bEnd. 3 cells by 2-fold compared with SS-31. No cytotoxicity was observed even at high concentration (100 mu M). These data suggest that mtCPP-1 is a mitochondrial CPP and protect mitochondria from oxidative damage due to its own antioxidant activities.	[Cerrato, Carmine Pasquale; Pirisinu, Marco; Vlachos, Efstathios Nikolaos; Langel, Ulo] Stockholm Univ, Dept Neurochem, SE-10691 Stockholm, Sweden; [Pirisinu, Marco] Univ Sassari, Dept Clin & Expt Med, I-07100 Sassari, Italy	Stockholm University; University of Sassari	Cerrato, CP (corresponding author), Stockholm Univ, Dept Neurochem, Svante Arrhenius Vag 16B, SE-10691 Stockholm, Sweden.	carmine@neurochem.su.se	Cerrato, Carmine Pasquale/Y-5180-2019; Pirisinu, Marco/AAR-5399-2021; Langel, Ulo/K-9773-2018	Cerrato, Carmine Pasquale/0000-0001-7769-6905; Pirisinu, Marco/0000-0002-7834-4386; Langel, Ulo/0000-0001-6107-0844				Cartier R, 2002, GENE THER, V9, P157, DOI 10.1038/sj.gt.3301635; Chen H, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S4-S14; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Dai Dao-Fu, 2014, Longev Healthspan, V3, P6, DOI 10.1186/2046-2395-3-6; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Doughan AK, 2007, ANTIOXID REDOX SIGN, V9, P1825, DOI 10.1089/ars.2007.1693; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Gauuan PJF, 2002, BIOORGAN MED CHEM, V10, P3013, DOI 10.1016/S0968-0896(02)00153-0; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Horobin RW, 2007, J CONTROL RELEASE, V121, P125, DOI 10.1016/j.jconrel.2007.05.040; Kaminaga Y, 2003, FEBS LETT, V555, P311, DOI 10.1016/S0014-5793(03)01265-1; Mahon KP, 2007, CHEM BIOL, V14, P923, DOI 10.1016/j.chembiol.2007.07.011; Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110; PICHORNER H, 1995, ARCH BIOCHEM BIOPHYS, V323, P429, DOI 10.1006/abbi.1995.0064; Rosania GR, 2003, CURR TOP MED CHEM, V3, P659, DOI 10.2174/1568026033452410; Ross MF, 2004, BIOCHEM SOC T, V32, P1072, DOI 10.1042/BST0321072; Ross MF, 2004, BIOCHEM J, V383, P457, DOI 10.1042/BJ20041095; Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536; Roy A, 2008, MOL PHARMACOL, V74, P1292, DOI 10.1124/mol.108.050161; Schiller PW, 2000, EUR J MED CHEM, V35, P895, DOI 10.1016/S0223-5234(00)01171-5; Soomets Ursel, 2005, V298, P241; Steinhubl SR, 2008, AM J CARDIOL, V101, p14D, DOI 10.1016/j.amjcard.2008.02.003; Szeto HH, 2006, AAPS J, V8, pE521, DOI 10.1208/aapsj080362; Szeto HH, 2006, AAPS J, V8, pE277, DOI 10.1007/BF02854898; Terrone D, 2003, BIOCHEMISTRY-US, V42, P13787, DOI 10.1021/bi035293y; Tieu K, 2003, IUBMB LIFE, V55, P329, DOI 10.1080/1521654032000114320; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Zhao KS, 2004, J BIOL CHEM, V279, P34682, DOI 10.1074/jbc.M402999200	29	72	72	2	84	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2015	29	11					4589	4599		10.1096/fj.14-269225	http://dx.doi.org/10.1096/fj.14-269225			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CV8EZ	26195590				2023-01-03	WOS:000364514700018
J	Williams, M; To, A; Bozhilov, K; Talbot, P				Williams, Monique; To, An; Bozhilov, Krassimir; Talbot, Prue			Strategies to Reduce Tin and Other Metals in Electronic Cigarette Aerosol	PLOS ONE			English	Article							IN-VITRO; NICOTINE; SMOKE	Background Metals are present in electronic cigarette (EC) fluid and aerosol and may present health risks to users. Objective The objective of this study was to measure the amounts of tin, copper, zinc, silver, nickel and chromium in the aerosol from four brands of EC and to identify the sources of these metals by examining the elemental composition of the atomizer components. Methods Four brands of popular EC were dissected and the cartomizers were examined microscopically. Elemental composition of cartomizer components was determined using integrated energy dispersive X-ray microanalysis, and the concentrations of the tin, copper, zinc silver, nickel, and chromium in the aerosol were determined for each brand using inductively coupled plasma optical emission spectroscopy. Results All filaments were made of nickel and chromium. Thick wires were copper coated with either tin or silver. Wires were joined to each other by tin solder, brazing, or by brass clamps. High concentrations of tin were detected in the aerosol when tin solder joints were friable. Tin coating on copper wires also contributed to tin in the aerosol. Conclusions Tin concentrations in EC aerosols varied both within and between brands. Tin in aerosol was reduced by coating the thick wire with silver rather than tin, placing stable tin solder joints outside the atomizing chamber, joining wires with brass clamps or by brazing rather than soldering wires. These data demonstrate the feasibility of removing tin and other unwanted metals from EC aerosol by altering designs and using materials of suitable quality.	[Williams, Monique; To, An; Talbot, Prue] Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA; [Bozhilov, Krassimir] Univ Calif Riverside, Cent Facil Adv Microscopy & Microanal, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Talbot, P (corresponding author), Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA.	talbot@ucr.edu	Talbot, Prue/AAY-3896-2021	To, An/0000-0003-3170-2999	National Institutes of Health; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA036493] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Funding: The work was supported by National Institutes of Health. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bahl V, 2012, REPROD TOXICOL, V34, P529, DOI 10.1016/j.reprotox.2012.08.001; Behar RZ, 2014, TOXICOL IN VITRO, V28, P198, DOI 10.1016/j.tiv.2013.10.006; Behar RZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117222; Brown CC, 2014, ARCH DIS CHILDHOOD-E, V99, P13, DOI 10.1136/archdischild-2013-304675; Callahan-Lyon P, 2014, TOB CONTROL, V23, P36, DOI 10.1136/tobaccocontrol-2013-051470; Chen IL, 2013, NICOTINE TOB RES, V15, P615, DOI 10.1093/ntr/nts145; Davis B, 2015, NICOTINE TOB RES, V17, P134, DOI 10.1093/ntr/ntu080; Flouris AD, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c311; Goniewicz ML, 2014, TOB CONTROL, V23, P133, DOI 10.1136/tobaccocontrol-2012-050859; Grana R, 2014, CIRCULATION, V129, P1972, DOI 10.1161/CIRCULATIONAHA.114.007667; Hua M, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2324; Hua M, 2013, TOB CONTROL, V22, P103, DOI 10.1136/tobaccocontrol-2011-050226; King BA, 2013, NICOTINE TOB RES, V15, P1623, DOI 10.1093/ntr/ntt013; Knoll M, 1998, REPROD TOXICOL, V12, P57, DOI 10.1016/S0890-6238(97)00100-7; KNOLL M, 1995, BIOL REPROD, V53, P29, DOI 10.1095/biolreprod53.1.29; Lee N-C, 2009, MAT ADV PACKAGING, P181, DOI DOI 10.1007/978-0-387-78219-5_5; Mansour SA, 2014, PRACTICAL FOOD SAFETY: CONTEMPORARY ISSUES AND FUTURE DIRECTIONS, P213; McCauley L, 2012, CHEST, V141, P1110, DOI 10.1378/chest.11-1334; Thota D, 2014, J EMERG MED, V47, P15, DOI 10.1016/j.jemermed.2013.09.034; Trehy ML, 2011, J LIQ CHROMATOGR R T, V34, P1442, DOI 10.1080/10826076.2011.572213; Trtchounian A, 2011, TOB CONTROL, V20, P47, DOI 10.1136/tc.2010.037259; Trtchounian A, 2010, NICOTINE TOB RES, V12, P905, DOI 10.1093/ntr/ntq114; Williams M, 2015, NICOTINE TOB RES, V17, P201, DOI 10.1093/ntr/ntu118; Williams M, 2011, NICOTINE TOB RES, V13, P1276, DOI 10.1093/ntr/ntr164; Williams M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057987; Zhu SH, 2014, TOB CONTROL, V23, P3, DOI 10.1136/tobaccocontrol-2014-051670	26	43	46	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2015	10	9							e0138933	10.1371/journal.pone.0138933	http://dx.doi.org/10.1371/journal.pone.0138933			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS1CR	26406602	Green Published, Green Submitted, gold			2023-01-03	WOS:000361800700121
J	Wang, GF; Liu, GF; Zhang, RH; Ji, RJ; Gao, BQ; Wang, YL; Pan, YS; Li, ZX; Wang, YJ				Wang, Guifen; Liu, Gaifen; Zhang, Runhua; Ji, Ruijun; Gao, Baoqin; Wang, Yilong; Pan, Yuesong; Li, Zixiao; Wang, Yongjun			Evaluation of Off-Hour Emergency Care in Acute Ischemic Stroke: Results from the China National Stroke Registry	PLOS ONE			English	Article							CASE-FATALITY; PERFORMANCE-MEASURES; WEEKDAY ADMISSION; WEEKEND; MORTALITY; QUALITY; ASSOCIATION; COHORT; TIME	Background and Purpose The quality of after-hour emergency care of patients with acute ischemic stroke is debatable. We therefore, sought to analyze the performance measures, quality of care and clinical outcomes in these patients admitted during off-hours. Methods Our study included 4493 patients from a selected cohort of patients admitted to the hospitals with ischemic stroke in the China National Stroke Registry (CNSR) from September 2007 to August 2008. On-hour presentation was defined as arrival at the emergency department from the scene between 8AM and 5PM from Monday through Friday. Off-hours included the remainder of the on-hours and statutory holidays. The association between off-hour presentation and outcome was analyzed using multivariate logistic-regression models. Results Off-hour presentation was identified in 2672 (59.5%) patients with ischemic stroke. Comparison of patients admitted during off-hours with those admitted during on-hours revealed an unadjusted odds ratio of in-hospital mortality of 1.38 (95% confidence interval, 1.04-1.85), which declined to 1.34 (95% confidence interval, 0.93-1.93) after adjusting for patient characteristics (especially, pre-hospital delay). No difference in 30-day mortality, total death or dependence at three, six and 12 months between two groups was observed. No association between off-hour admission and quality of care was found. Conclusions In the CNSR database, compared with on-hour patients, off-hour patients with acute ischemic stroke admitted to the emergency departments from scene manifested a higher incidence of in-hospital mortality. However, the difference in incidence and quality of care between the groups disappeared after adjusting for pre-hospital delay and other variables.	[Wang, Guifen; Gao, Baoqin] Capital Med Univ, Beijing Tiantan Hosp, Dept Pediat, Beijing, Peoples R China; [Liu, Gaifen; Zhang, Runhua; Ji, Ruijun; Wang, Yilong; Pan, Yuesong; Li, Zixiao; Wang, Yongjun] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China; [Wang, Guifen; Liu, Gaifen; Zhang, Runhua; Ji, Ruijun; Gao, Baoqin; Wang, Yilong; Pan, Yuesong; Li, Zixiao; Wang, Yongjun] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China; [Wang, Guifen; Liu, Gaifen; Zhang, Runhua; Ji, Ruijun; Gao, Baoqin; Wang, Yilong; Pan, Yuesong; Li, Zixiao; Wang, Yongjun] Beijing Inst Brain Disorders, Ctr Stroke, Beijing, Peoples R China; [Wang, Guifen; Liu, Gaifen; Zhang, Runhua; Ji, Ruijun; Gao, Baoqin; Wang, Yilong; Pan, Yuesong; Li, Zixiao; Wang, Yongjun] Beijing Key Lab Translat Med Cerebrovasc Dis, Beijing, Peoples R China	Capital Medical University; Capital Medical University	Wang, YJ (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China.	yongjunwang1962@gmail.com	Pan, Yuesong/AAI-6303-2020	Pan, Yuesong/0000-0003-3082-6789	Ministry of Science and Technology; Ministry of Health of the People's Republic of China: National Science and Technology Major Project of China [2008ZX09312-008]; State Key Development Program of Basic Research of China [2009CB521905]; National 11th & 12th Five-year S & T Major Project [2006BAI01A11, 2011BAI08B01, 2011BAI08B02]; Beijing Biobank of Cerebral Vascular Disease [D131100005313003]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Ministry of Health of the People's Republic of China: National Science and Technology Major Project of China; State Key Development Program of Basic Research of China(State Key Development Program for Basic Research of China); National 11th & 12th Five-year S & T Major Project; Beijing Biobank of Cerebral Vascular Disease	This study was funded by the Ministry of Science and Technology and the Ministry of Health of the People's Republic of China: National Science and Technology Major Project of China (2008ZX09312-008) and State Key Development Program of Basic Research of China (2009CB521905). The grant numbers are the National 11th & 12th Five-year S & T Major Project (2006BAI01A11, 2011BAI08B01, 2011BAI08B02) and Beijing Biobank of Cerebral Vascular Disease (D131100005313003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albright KC, 2009, CEREBROVASC DIS, V27, P107, DOI 10.1159/000177916; [Anonymous], 1989, STROKE, V20, P1407; Bejot Y, 2013, EUR J NEUROL, V20, P1177, DOI 10.1111/ene.12154; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Cloud G, 2013, CLIN MED, V13, P444, DOI 10.7861/clinmedicine.13-5-444; Concha OP, 2014, BMJ QUAL SAF, V23, P215, DOI 10.1136/bmjqs-2013-002218; Fang JM, 2010, NEUROLOGY, V75, P1589, DOI 10.1212/WNL.0b013e3181fb84bc; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; He Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092763; Hoh BL, 2010, STROKE, V41, P2323, DOI 10.1161/STROKEAHA.110.591081; Janszky I, 2007, STROKE, V38, pE94, DOI 10.1161/STROKEAHA.107.491449; Jauss M, 2009, EUR J NEUROL, V16, P1165, DOI 10.1111/j.1468-1331.2009.02656.x; Kazley AS, 2010, ARCH NEUROL-CHICAGO, V67, P39, DOI 10.1001/archneurol.2009.286; Kim C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105799; Kostis WJ, 2007, NEW ENGL J MED, V356, P1099, DOI 10.1056/NEJMoa063355; Kristiansen NS, 2014, STROKE, V45, P3663, DOI 10.1161/STROKEAHA.114.005535; Manfredini R, 2007, STROKE, V38, pE112, DOI 10.1161/STROKEAHA.107.489898; Martinez-Martinez MM, 2012, EUR J NEUROL, V19, P1140, DOI 10.1111/j.1468-1331.2012.03692.x; McKinney JS, 2011, STROKE, V42, P2403, DOI 10.1161/STROKEAHA.110.612317; Minister of Health, 1989, ACTS HOSP CLASS; Minister of Health, 2010, SINGL DIS QUAL MAN M, P142; Ogbu UC, 2011, J NEUROL NEUROSUR PS, V82, P8, DOI 10.1136/jnnp.2009.202176; Palmer WL, 2012, ARCH NEUROL-CHICAGO, V69, P1296, DOI 10.1001/archneurol.2012.1030; Reeves MJ, 2010, STROKE, V41, P1573, DOI 10.1161/STROKEAHA.109.577171; Reeves MJ, 2009, STROKE, V40, P569, DOI 10.1161/STROKEAHA.108.519355; Saposnik G, 2007, STROKE, V38, P1211, DOI 10.1161/01.STR.0000259622.78616.ea; Sorita A, 2014, EUR J INTERN MED, V25, P394, DOI 10.1016/j.ejim.2014.03.012; Streifler JY, 2012, EUR J NEUROL, V19, P643, DOI 10.1111/j.1468-1331.2011.03603.x; Wang PL, 2012, CHINESE MED J-PEKING, V125, P2449, DOI 10.3760/cma.j.issn.0366-6999.2012.14.010; Wang YL, 2011, STROKE, V42, P1658, DOI 10.1161/STROKEAHA.110.604249; Wang YJ, 2011, INT J STROKE, V6, P355, DOI 10.1111/j.1747-4949.2011.00584.x	31	3	3	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2015	10	9							e0138046	10.1371/journal.pone.0138046	http://dx.doi.org/10.1371/journal.pone.0138046			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CS0RH	26379280	Green Submitted, Green Published, gold			2023-01-03	WOS:000361769400047
J	Brenneman, EC; Kuntz, AB; Wiebenga, EG; Maly, MR				Brenneman, Elora C.; Kuntz, Alexander B.; Wiebenga, Emily G.; Maly, Monica R.			A Yoga Strengthening Program Designed to Minimize the Knee Adduction Moment for Women with Knee Osteoarthritis: A Proof-Of-Principle Cohort Study	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; PHYSICAL FUNCTION; OARSI RECOMMENDATIONS; CARTILAGE LOSS; OUTCOME SCORE; IYENGAR YOGA; BASE-LINE; EXERCISE; HIP; MANAGEMENT	People with knee osteoarthritis may benefit from exercise prescriptions that minimize knee loads in the frontal plane. The primary objective of this study was to determine whether a novel 12-week strengthening program designed to minimize exposure to the knee adduction moment (KAM) could improve symptoms and knee strength in women with symptomatic knee osteoarthritis. A secondary objective was to determine whether the program could improve mobility and fitness, and decrease peak KAM during gait. The tertiary objective was to evaluate the biomechanical characteristics of this yoga program. In particular, we compared the peak KAM during gait with that during yoga postures at baseline. We also compared lower limb normalized mean electromyography (EMG) amplitudes during yoga postures between baseline and follow-up. Primary measures included self-reported pain and physical function (Knee injury and Osteoarthritis Outcome Score) and knee strength (extensor and flexor torques). Secondary measures included mobility (six-minute walk, 30-second chair stand, stair climbing), fitness (submaximal cycle ergometer test), and clinical gait analysis using motion capture synchronized with electromyography and force measurement. Also, KAM and normalized mean EMG amplitudes were collected during yoga postures. Forty-five women over age 50 with symptomatic knee osteoarthritis, consistent with the American College of Rheumatology criteria, enrolled in our 12-week (3 sessions per week) program. Data from 38 were analyzed (six drop-outs; one lost to co-intervention). Participants experienced reduced pain (mean improvement 10.1-20.1 normalized to 100; p < 0.001), increased knee extensor strength (mean improvement 0.01 Nm/kg; p = 0.004), and increased flexor strength (mean improvement 0.01 Nm/kg; p = 0.001) at follow-up compared to baseline. Participants improved mobility on the six-minute walk (mean improvement 37.7 m; p < 0.001) and 30-second chair stand (mean improvement 1.3; p = 0.006) at follow-up compared to baseline. Fitness and peak KAM during gait were unchanged between baseline and follow-up. Average KAM during the yoga postures were lower than that of normal gait. Normalized mean EMG amplitudes during yoga postures were up to 31.0% of maximum but did not change between baseline and follow-up. In this cohort study, the yoga-based strengthening postures that elicit low KAMs improved knee symptoms and strength in women with knee OA following a 12 week program (3 sessions per week). The program also improved mobility, but did not improve fitness or reduce peak KAM during gait. The KAM during the yoga postures were lower than that of normal gait. Overall, the proposed program may be useful in improving pain, strength, and mobility in women with knee osteoarthritis. Clinical efficacy needs to be assessed using a randomized controlled trial design.	[Brenneman, Elora C.; Wiebenga, Emily G.; Maly, Monica R.] McMaster Univ, Sch Rehabil Sci, Hamilton, ON, Canada; [Kuntz, Alexander B.; Maly, Monica R.] McMaster Univ, Dept Kinesiol, Hamilton, ON, Canada	McMaster University; McMaster University	Maly, MR (corresponding author), McMaster Univ, Sch Rehabil Sci, Hamilton, ON, Canada.	mmaly@mcmaster.ca			Labarge Optimal Aging Initiative-Opportunities Fund; Natural Sciences and Engineering Research Council of Canada [353715]; Canadian Foundation of Innovation; Ontario Ministry of Research and Innovation [27501]	Labarge Optimal Aging Initiative-Opportunities Fund; Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Canadian Foundation of Innovation(Canada Foundation for Innovation); Ontario Ministry of Research and Innovation(Ministry of Research and Innovation, Ontario)	This study was funded by Labarge Optimal Aging Initiative-Opportunities Fund (MRM) (http://optimalaging.mcmaster.ca/opportunities_fund.html), Natural Sciences and Engineering Research Council of Canada-Discovery (#353715; MRM) (http://www.nserc-crsng.gc.ca/Professors-Professeurs/GrantsSubs/DGIGP-PSIGP_eng.asp) and Canadian Foundation of Innovation and Ontario Ministry of Research and Innovation-Leaders Opportunities Fund (#27501; MRM) (http://roads.mcmaster.ca/funding/initiatives/cfi-lof). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ades PA, 1996, ANN INTERN MED, V124, P568, DOI 10.7326/0003-4819-124-6-199603150-00005; Ageberg E, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-232; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Alviar MJ, 2011, J REHABIL MED, V43, P374, DOI 10.2340/16501977-0801; Andriacchi TP, 2013, ARTHRITIS RHEUM-US, V65, P310, DOI 10.1002/art.37724; Andriacchi TP, 2009, J BONE JOINT SURG AM, V91A, P95, DOI 10.2106/JBJS.H.01408; Andriacchi TP, 2004, ANN BIOMED ENG, V32, P447, DOI 10.1023/B:ABME.0000017541.82498.37; [Anonymous], 2014, WAIT TIMES PRIORITY, P1; Australian Institute of Health and Welfare, 2014, HIP KNEE ARTHR, P1; Beekley MD, 2004, RES Q EXERCISE SPORT, V75, P337, DOI 10.1080/02701367.2004.10609165; Bennell KL, 2010, OSTEOARTHR CARTILAGE, V18, P621, DOI 10.1016/j.joca.2010.01.010; Bennell KL, 2008, RHEUM DIS CLIN N AM, V34, P731, DOI 10.1016/j.rdc.2008.05.005; Bennell KL, 2015, CURR OPIN RHEUMATOL, V27, P304, DOI 10.1097/BOR.0000000000000160; Bennell KL, 2013, RHEUM DIS CLIN N AM, V39, P145, DOI 10.1016/j.rdc.2012.11.003; Bennell KL, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-276; Bennell KL, 2011, ANN RHEUM DIS, V70, P1770, DOI 10.1136/ard.2010.147082; Bombardier C, 2011, ARTHRITIS ALLIANCE C, V606, P1; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Bukowski EL, 2006, INT Q COMMUNITY HEAL, V26, P287, DOI 10.2190/IQ.26.3.f; Chang A, 2005, ARTHRITIS RHEUM-US, V52, P3515, DOI 10.1002/art.21406; Chang A, 2007, ANN RHEUM DIS, V66, P1271, DOI 10.1136/ard.2006.062927; Chehab EF, 2014, OSTEOARTHR CARTILAGE, V22, P1833, DOI 10.1016/j.joca.2014.08.009; Cheung C, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-160; COLE GK, 1993, J BIOMECH ENG-T ASME, V115, P344, DOI 10.1115/1.2895496; Collins NJ, 2011, ARTHRIT CARE RES, V63, pS208, DOI 10.1002/acr.20632; Creaby MW, 2010, OSTEOARTHR CARTILAGE, V18, P1380, DOI 10.1016/j.joca.2010.08.013; Dobson F, 2012, OSTEOARTHR CARTILAGE, V20, P1548, DOI 10.1016/j.joca.2012.08.015; Foroughi N, 2011, CLIN BIOMECH, V26, P167, DOI 10.1016/j.clinbiomech.2010.08.011; Franciozi CES, 2013, OSTEOARTHR CARTILAGE, V21, P965, DOI 10.1016/j.joca.2013.04.007; Fransen M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004376.pub3; Fransen M, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004376.pub2; Fransen M, 2009, J RHEUMATOL, V36, P1109, DOI 10.3899/jrheum.090058; Horisberger M, 2013, CLIN BIOMECH, V28, P536, DOI 10.1016/j.clinbiomech.2013.04.009; Hunt MA, 2008, OSTEOARTHR CARTILAGE, V16, P591, DOI 10.1016/j.joca.2007.10.017; Kean CO, 2010, ARCH PHYS MED REHAB, V91, P1447, DOI 10.1016/j.apmr.2010.06.002; Keenan GS, 2011, GAIT POSTURE, V33, P350, DOI 10.1016/j.gaitpost.2010.09.019; Kelley GA, 2001, AM J PHYS MED REHAB, V80, P65, DOI 10.1097/00002060-200101000-00017; Kennedy DM, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-3; Kolasinski SL, 2005, J ALTERN COMPLEM MED, V11, P689, DOI 10.1089/acm.2005.11.689; KOOS, 2012, KOOS SCOR 2012; Kurtz S, 2007, J BONE JOINT SURG AM, V89A, P780, DOI 10.2106/JBJS.F.00222; Lange AK, 2008, ARTHRIT RHEUM-ARTHR, V59, P1488, DOI 10.1002/art.24118; Larose J, 2013, APPL PHYSIOL NUTR ME, V38, P886, DOI 10.1139/apnm-2012-0487; Lim BW, 2008, ARTHRIT RHEUM-ARTHR, V59, P943, DOI 10.1002/art.23823; Longpre HS, CLIN BIOMECH; Longpre HS, 2015, THESIS MCMASTER U; Messier SP, 2000, J AM GERIATR SOC, V48, P131, DOI 10.1111/j.1532-5415.2000.tb03903.x; Messier SP, 2013, JAMA-J AM MED ASSOC, V310, P1263, DOI 10.1001/jama.2013.277669; Messier SP, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-208; Miyazaki T, 2002, ANN RHEUM DIS, V61, P617, DOI 10.1136/ard.61.7.617; Moisio KC, 2003, J BIOMECH, V36, P599, DOI 10.1016/S0021-9290(02)00433-5; Monticone M, 2013, AM J PHYS MED REHAB, V92, P864, DOI 10.1097/PHM.0b013e31829f19d8; Mundermann A, 2008, J BIOMECH, V41, P165, DOI 10.1016/j.jbiomech.2007.07.001; Mundermann A, 2004, ARTHRITIS RHEUM-US, V50, P1172, DOI 10.1002/art.20132; Robbins SM, 2011, ARTHRIT CARE RES, V63, P991, DOI 10.1002/acr.20476; Roddy E, 2005, ANN RHEUM DIS, V64, P544, DOI 10.1136/ard.2004.028746; Roos EM, 2005, ARTHRITIS RHEUM-US, V52, P3507, DOI 10.1002/art.21415; Runhaar J, 2015, OSTEOARTHRITIS CARTI; Rutherford DJ, 2008, OSTEOARTHR CARTILAGE, V16, P883, DOI 10.1016/j.joca.2007.11.012; RUUSKANEN JM, 1995, AGE AGEING, V24, P292, DOI 10.1093/ageing/24.4.292; SCHIPPLEIN OD, 1991, J ORTHOPAED RES, V9, P113, DOI 10.1002/jor.1100090114; Sled EA, 2010, PHYS THER, V90, P895, DOI 10.2522/ptj.20090294; The NJR Editorial Board, 2013, 10 NJR ED BOARD, P1; Thorstensson CA, 2007, OSTEOARTHR CARTILAGE, V15, P1163, DOI 10.1016/j.joca.2007.03.012; van Baar ME, 2001, ANN RHEUM DIS, V60, P1123, DOI 10.1136/ard.60.12.1123; Wang MY, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-8; Winter D. A, 2009, BIOMECHANICS MOTOR C; Wluka A, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1962; Zhang W, 2008, OSTEOARTHR CARTILAGE, V16, P137, DOI 10.1016/j.joca.2007.12.013; Zhang W, 2007, OSTEOARTHR CARTILAGE, V15, P981, DOI 10.1016/j.joca.2007.06.014; Zhao D, 2007, J ORTHOP RES, V25, P789, DOI 10.1002/jor.20379	71	15	17	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2015	10	9							e0136854	10.1371/journal.pone.0136854	http://dx.doi.org/10.1371/journal.pone.0136854			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR8KS	26367862	Green Published, Green Submitted, gold			2023-01-03	WOS:000361601100028
J	Eberhardt, WEE; Stuschke, M				Eberhardt, Wilfried E. E.; Stuschke, Martin			Multimodal treatment of non-small-cell lung cancer	LANCET			English	Editorial Material							PHASE-III; CONCURRENT CHEMORADIATION; INDUCTION CHEMOTHERAPY; TRIAL; SURGERY; CHEMORADIOTHERAPY; RESECTION; SURVIVAL; THERAPY; CRT		[Eberhardt, Wilfried E. E.] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol,Ruhrlandklin, D-45122 Essen, Germany; [Stuschke, Martin] Univ Hosp Essen, West German Tumour Ctr, Dept Radiat Oncol, Essen, Germany	University of Duisburg Essen; University of Duisburg Essen	Eberhardt, WEE (corresponding author), Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol,Ruhrlandklin, D-45122 Essen, Germany.	wilfried.eberhardt@uni-duisburg-essen.de		Eberhardt, Wilfried Ernst Erich/0000-0003-4284-3586				Albain KS, 2009, LANCET, V374, P379, DOI 10.1016/S0140-6736(09)60737-6; Auperin A, 2010, J CLIN ONCOL, V28, P2181, DOI 10.1200/JCO.2009.26.2543; Bradley J, 2013, J THORAC ONCOL, V8, pS3; Brunelli A, 2009, EUR RESPIR J, V34, P17, DOI 10.1183/09031936.00184308; Cerfolio RJ, 2009, EUR J CARDIO-THORAC, V35, P718, DOI 10.1016/j.ejcts.2008.12.029; Curran WJ, 2011, J NATL CANCER I, V103, P1452, DOI 10.1093/jnci/djr325; Douillard JY, 2008, INT J RADIAT ONCOL, V72, P695, DOI 10.1016/j.ijrobp.2008.01.044; Eberhardt WEE, 2015, ANN ONCOL, V26, P1573, DOI 10.1093/annonc/mdv187; Eberhardt WEE, 2014, J CLIN ONCOL S, V32, p5s; Eberhardt WEE, 2013, LUNG CANCER, V82, P83, DOI 10.1016/j.lungcan.2013.06.007; Pless M, 2015, LANCET; Stuschke M, 2014, INT J RADIAT ONCOL, V90, pS146, DOI 10.1016/j.ijrobp.2014.05.617	12	14	15	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 12	2015	386	9998					1018	1020		10.1016/S0140-6736(15)61083-2	http://dx.doi.org/10.1016/S0140-6736(15)61083-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CR2VQ	26275734				2023-01-03	WOS:000361189200006
J	Kao, LT; Lee, HC; Lin, HC; Tsai, MC; Chung, SD				Kao, Li-Ting; Lee, Hsin-Chien; Lin, Herng-Ching; Tsai, Ming-Chieh; Chung, Shiu-Dong			Healthcare Service Utilization by Patients with Obstructive Sleep Apnea: A Population-Based Study	PLOS ONE			English	Article							QUALITY-OF-LIFE; INTERMITTENT HYPOXIA; ECONOMIC-IMPACT; ASSOCIATION; DIAGNOSIS; ACTIVATION; RESOURCES; MORBIDITY; PATHWAYS; OBESITY	Objective Although obstructive sleep apnea (OSA) is not a life-threatening disease, very few studies have compared differences in healthcare service utilization between patients with and those without OSA in an Asian population according to different age groups. This study attempted to investigate differences in healthcare service utilization between patients with and those without OSA in different age groups in Taiwan. Methods Sampled subjects and data on their health service utilization were retrieved from the Taiwan Longitudinal Health Insurance Database 2005. We included 568 patients with OSA and 2840 subjects without OSA. Each subject was followed for a 1-year period to evaluate their healthcare resource utilization. Wilcoxon-Mann-Whitney tests were performed to compare differences in healthcare utilization between patients with and those without OSA during the 1-year follow-up period. Results As to all healthcare service utilization, patients with OSA had significantly more outpatient visits (30.3 vs. 18.6), outpatient costs (US$1231.2 vs. US$764.8), inpatient days (1.8 vs. 1.2), inpatient costs (US$563.6 vs. US$276.7), and total costs (US$1794.8 vs. US$1041.5) than comparison subjects during the 1-year follow-up period. Moreover, patients with OSA aged 40 similar to 49 and 50 similar to 59 years respectively incurred 2.11- and 2.02-fold higher total costs compared to patients without OSA. However, patients with OSA aged over 70 years did not have higher total costs compared to those without OSA. Conclusions This study found that patients with OSA had greater healthcare service utilization than those without OSA. Additionally, patients with OSA in the 40 similar to 49- and 50 similar to 59-year age groups had about 2-fold higher total costs of healthcare services than those without OSA.	[Kao, Li-Ting] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; [Kao, Li-Ting; Lee, Hsin-Chien; Lin, Herng-Ching; Chung, Shiu-Dong] Taipei Med Univ Hosp, Sleep Res Ctr, Taipei, Taiwan; [Lee, Hsin-Chien] Taipei Med Univ, Sch Med, Dept Psychiat, Taipei, Taiwan; [Tsai, Ming-Chieh] Cathay Gen Hosp, Dept Internal Med, Taipei, Taiwan; [Chung, Shiu-Dong] Fu Jen Catholic Univ, Sch Med, Hsingchuang, Taiwan; [Chung, Shiu-Dong] Far Eastern Mem Hosp, Dept Surg, New Taipei City, Taiwan	National Defense Medical Center; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Cathay General Hospital; Fu Jen Catholic University; Far Eastern Memorial Hospital	Chung, SD (corresponding author), Taipei Med Univ Hosp, Sleep Res Ctr, Taipei, Taiwan.	chungshiudong@gmail.com	Kao, Li-Ting/W-9287-2018	Kao, Li-Ting/0000-0003-0692-7408				Addison-Brown KJ, 2014, J SLEEP RES, V23, P69, DOI 10.1111/jsr.12086; Albarrak M, 2005, SLEEP, V28, P1306, DOI 10.1093/sleep/28.10.1306; AlGhanim N, 2008, LUNG, V186, P7, DOI 10.1007/s00408-007-9055-5; Bahammam A, 1999, SLEEP, V22, P740, DOI 10.1093/sleep/22.6.740; Baldwin CM, 2001, SLEEP, V24, P96, DOI 10.1093/sleep/24.1.96; Banno K, 2006, SLEEP, V29, P1307, DOI 10.1093/sleep/29.10.1307; Banno K, 2009, SLEEP, V32, P247, DOI 10.1093/sleep/32.2.247; Berg G, 2001, CHEST, V120, P377, DOI 10.1378/chest.120.2.377; Chen YC, 2011, SCIENTOMETRICS, V86, P365, DOI 10.1007/s11192-010-0289-2; Diaz K, 2014, ANN THORAC MED, V9, P92, DOI 10.4103/1817-1737.128854; Dong JY, 2013, ATHEROSCLEROSIS, V229, P489, DOI 10.1016/j.atherosclerosis.2013.04.026; Greenberg-Dotan S, 2007, SLEEP, V30, P1173, DOI 10.1093/sleep/30.9.1173; Jelic S, 2008, TRENDS CARDIOVAS MED, V18, P253, DOI 10.1016/j.tcm.2008.11.008; Jennum P, 2011, THORAX, V66, P560, DOI 10.1136/thx.2010.143958; Jennum P, 2014, EUR RESPIR J, V43, P134, DOI 10.1183/09031936.00169212; Jurado-Gamez B, 2014, ARCH BRONCONEUMOL; Kapur V, 1999, SLEEP, V22, P749, DOI 10.1093/sleep/22.6.749; Kryger MH, 1996, SLEEP, V19, pS111, DOI 10.1093/sleep/19.suppl_9.S111; Lam Jamie C M, 2009, Expert Rev Respir Med, V3, P177, DOI 10.1586/ers.09.10; Lee RWW, 2010, SLEEP, V33, P1075, DOI 10.1093/sleep/33.8.1075; Mannarino MR, 2012, EUR J INTERN MED, V23, P586, DOI 10.1016/j.ejim.2012.05.013; Otake K, 2002, THORAX, V57, P417, DOI 10.1136/thorax.57.5.417; Peppard PE, 2006, ARCH INTERN MED, V166, P1709, DOI 10.1001/archinte.166.16.1709; Reuveni H, 2008, EUR RESPIR J, V31, P273, DOI 10.1183/09031936.00097907; Ronald J, 1999, SLEEP, V22, P225, DOI 10.1093/sleep/22.2.225; Ronald J, 1998, Sleep Res Online, V1, P71; Ronksley PE, 2009, THORAX, V64, P834, DOI 10.1136/thx.2009.115105; Ryan S, 2005, CIRCULATION, V112, P2660, DOI 10.1161/CIRCULATIONAHA.105.556746; Ryan Silke, 2008, Archives of Physiology and Biochemistry, V114, P261, DOI [10.1080/13813450802307337, 10.1080/13813450802307337 ]; Sharafkhaneh A, 2005, SLEEP, V28, P1405, DOI 10.1093/sleep/28.11.1405; Smith R, 2002, CHEST, V121, P164, DOI 10.1378/chest.121.1.164; Tarasiuk A, 2005, CHEST, V128, P1310, DOI 10.1378/chest.128.3.1310; Tarasiuk A, 2008, J AM GERIATR SOC, V56, P247, DOI 10.1111/j.1532-5415.2007.01544.x; Tarasiuk A, 2013, CURR OPIN PULM MED, V19, P639, DOI 10.1097/MCP.0b013e3283659e1e; Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Ziegler Michael G, 2011, Drug Discov Today Dis Models, V8, P155	37	27	28	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2015	10	9							e0137459	10.1371/journal.pone.0137459	http://dx.doi.org/10.1371/journal.pone.0137459			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ6BA	26339792	Green Published, Green Submitted, gold			2023-01-03	WOS:000360688200061
J	Burton, A; Osborn, D; Atkins, L; Michie, S; Gray, B; Stevenson, F; Gilbert, H; Walters, K				Burton, Alexandra; Osborn, David; Atkins, Lou; Michie, Susan; Gray, Ben; Stevenson, Fiona; Gilbert, Hazel; Walters, Kate			Lowering Cardiovascular Disease Risk for People with Severe Mental Illnesses in Primary Care: A Focus Group Study	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; INTERVENTION; BARRIERS; MOTIVATION; ADULTS	Background People with severe mental illnesses die early from cardiovascular disease. Evidence is lacking regarding effective primary care based interventions to tackle this problem. Aim To identify current procedures for, barriers to, and facilitators of the delivery of primary care based interventions for lowering cardiovascular risk for people with severe mental illnesses. Method 75 GPs, practice nurses, service users, community mental health staff and carers in UK GP practice or community mental health settings were interviewed in 14 focus groups which were audio-recorded, transcribed and analysed using Framework Analysis. Results Five barriers to delivering primary care based interventions for lowering cardiovascular risk in people with severe mental illnesses were identified by the groups: negative perceptions of people with severe mental illnesses amongst some health professionals, difficulties accessing GP and community-based services, difficulties in managing a healthy lifestyle, not attending appointments, and a lack of awareness of increased cardiovascular risk in people with severe mental illnesses by some health professionals. Identified facilitators included involving supportive others, improving patient engagement with services, continuity of care, providing positive feedback in consultations and goal setting. Conclusion We identified a range of factors which can be incorporated in to the design, delivery and evaluation of services to reduce cardiovascular risk for people with severe mental illnesses in primary care. The next step is determining the clinical and cost effectiveness of primary care based interventions for lowering cardiovascular risk in people with severe mental illnesses, and evaluating the most important components of such interventions.	[Burton, Alexandra; Osborn, David] UCL, Fac Brain Sci, Div Psychiat, Epidemiol & Appl Clin Res Dept, London, England; [Atkins, Lou; Michie, Susan] UCL, Ctr Behav Change, Dept Clin Educ & Hlth Psychol, Div Psychol & Language Sci,Fac Brain Sci, London, England; [Gray, Ben] McPin Fdn, London, England; [Stevenson, Fiona; Gilbert, Hazel; Walters, Kate] UCL, Inst Epidemiol & Hlth Care, Fac Populat Hlth Sci, Dept Primary Care & Populat Hlth, London, England	University of London; University College London; University of London; University College London; University of London; University College London	Burton, A (corresponding author), UCL, Fac Brain Sci, Div Psychiat, Epidemiol & Appl Clin Res Dept, London, England.	a.burton@ucl.ac.uk; d.osborn@ucl.ac.uk	Stevenson, Fiona/AAJ-2727-2021; Atkins, Louise/C-7740-2011; Gray, Ben/R-6326-2017; Gray, Ben/AAG-6312-2020; Osborn PhD FRCPsych, David/B-8165-2009	Stevenson, Fiona/0000-0003-2139-2309; Gray, Ben/0000-0001-7647-9474; Osborn PhD FRCPsych, David/0000-0003-2519-1539; Walters, Kate/0000-0003-2173-2430; Gilbert, Hazel/0000-0002-1254-6874	National Institute for Health Research (NIHR) under its Programme Grants for Applied Research (PGfAR) scheme [RP-PG-0609-10156]; National Institute for Health Research [RP-PG-0609-10156] Funding Source: researchfish	National Institute for Health Research (NIHR) under its Programme Grants for Applied Research (PGfAR) scheme; National Institute for Health Research(National Institute for Health Research (NIHR))	This paper summarises independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research (PGfAR) scheme (Grant Reference Number RP-PG-0609-10156). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The findings from this work have been used to develop an intervention and training programme for lowering CVD risk in people with SMI in primary care. The clinical and cost effectiveness of the intervention is being tested in a clinical trial: ISRCTN13762819.	Bassilios B, 2014, AUSTRALAS PSYCHIATRY, V22, P71, DOI 10.1177/1039856213510575; Bonfioli E, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-78; Disability Rights Commission, 2006, EQ TREATM CLOS GAP F; Gierisch JM, 2014, J CLIN PSYCHIAT, V75, pE424, DOI 10.4088/JCP.13r08558; Gray B, 2013, J MENT HEALTH TRAIN, V8, P141, DOI 10.1108/JMHTEP-03-2013-0008; Greaves CJ, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-119; Hardy S, 2012, MENT HLTH FAM MED, V9, P33; Hardy S, 2014, INT J SOC PSYCHIATR, V60, P236, DOI 10.1177/0020764013483721; Hardy S, 2013, J MENT HEALTH, V22, P42, DOI 10.3109/09638237.2012.759194; Heffner JL, 2011, BIPOLAR DISORD, V13, P439, DOI 10.1111/j.1399-5618.2011.00943.x; Klingaman EA, 2014, PSYCHIATR REHABIL J, V37, P270, DOI 10.1037/prj0000084; Maayan L, 2010, NEUROPSYCHOPHARMACOL, V35, P1520, DOI 10.1038/npp.2010.21; McCabe Marita P, 2008, Psychol Health Med, V13, P303, DOI 10.1080/13548500701473952; McDevitt J, 2006, J NURS SCHOLARSHIP, V38, P50, DOI 10.1111/j.1547-5069.2006.00077.x; National Institute of Health and Care Excellence, 2014, PSYCH SCHIZ AD TREAT; Osborn DPJ, 2007, ARCH GEN PSYCHIAT, V64, P242, DOI 10.1001/archpsyc.64.2.242; Osborn DPJ, 2011, SCHIZOPHR RES, V129, P104, DOI 10.1016/j.schres.2011.04.003; Osborn DPJ, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-61; Pearson ES, 2012, PATIENT EDUC COUNS, V87, P32, DOI 10.1016/j.pec.2011.07.018; Pitman AL, 2011, PSYCHIAT SERV, V62, P1338, DOI 10.1176/ps.62.11.pss6211_1338; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; QSR International, 1999, NVIVO QUAL DAT AN SO; Rethink Mental Illness, 2013, STOP LETH DISCR; Ritchie J, 1993, ANAL QUALITATIVE DAT, P173, DOI DOI 10.1016/J.JPSYCHORES.2008.12.001; Roberts SH, 2011, J ADV NURS, V67, P690, DOI 10.1111/j.1365-2648.2010.05546.x; Royal College of Psychiatrists, 2018, WHOL PERS CAR RHET R; Schizophrenia Commission, 2012, AB ILLN REP SCHIZ CO; Tetlie T, 2009, J PSYCHOSOC NURS MEN, V47, P32, DOI 10.3928/02793695-20090201-14; Tsoi DT, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007253.pub2; Vancampfort D, 2013, PSYCHIAT RES, V210, P812, DOI 10.1016/j.psychres.2013.10.004; Wright CA, 2006, BMC PSYCHIATRY, V6, DOI 10.1186/1471-244X-6-16	31	17	17	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2015	10	8							e0136603	10.1371/journal.pone.0136603	http://dx.doi.org/10.1371/journal.pone.0136603			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CQ0PO	26317516	gold, Green Published, Green Submitted			2023-01-03	WOS:000360299100109
J	Uchiyama, H; Zhao, QL; Hassan, MA; Andocs, G; Nojima, N; Takeda, K; Ishikawa, K; Hori, M; Kondo, T				Uchiyama, Hidefumi; Zhao, Qing-Li; Hassan, Mariame Ali; Andocs, Gabor; Nojima, Nobuyuki; Takeda, Keigo; Ishikawa, Kenji; Hori, Masaru; Kondo, Takashi			EPR-Spin Trapping and Flow Cytometric Studies of Free Radicals Generated Using Cold Atmospheric Argon Plasma and X-Ray Irradiation in Aqueous Solutions and Intracellular Milieu	PLOS ONE			English	Article							NONVOLATILE SOLUTES; NONTHERMAL PLASMA; NITRIC-OXIDE; ULTRASOUND; CELLS; RESONANCE; HYDROGEN; SONOCHEMISTRY; PYROLYSIS; APOPTOSIS	Electron paramagnetic resonance (EPR)-spin trapping and flow cytometry were used to identify free radicals generated using argon-cold atmospheric plasma (Ar-CAP) in aqueous solutions and intracellularly in comparison with those generated by X-irradiation. Ar-CAP was generated using a high-voltage power supply unit with low-frequency excitation. The characteristics of Ar-CAP were estimated by vacuum UV absorption and emission spectra measurements. Hydroxyl (center dot OH) radicals and hydrogen (H) atoms in aqueous solutions were identified with the spin traps 5,5-dimethyl-1-pyrroline N-oxide (DMPO), 3,3,5,5-tetramethyl-1-pyrroline-N-oxide (M4PO), and phenyl N-t-butylnitrone (PBN). The occurrence of Ar-CAP-induced pyrolysis was evaluated using the spin trap 3,5-dibromo-4-nitrosobenzene sulfonate (DBNBS) in aqueous solutions of DNA constituents, sodium acetate, and L-alanine. Human lymphoma U937 cells were used to study intracellular oxidative stress using five fluorescent probes with different affinities to a number of reactive species. The analysis and quantification of EPR spectra revealed the formation of enormous amounts of center dot OH radicals using ArCAP compared with that by X-irradiation. Very small amounts of H atoms were detected whereas nitric oxide was not found. The formation of center dot OH radicals depended on the type of rare gas used and the yield correlated inversely with ionization energy in the order of krypton > argon = neon > helium. No pyrolysis radicals were detected in aqueous solutions exposed to Ar-CAP. Intracellularly, center dot OH, H2O2, which is the recombination product of center dot OH, and OCl- were the most likely formed reactive oxygen species after exposure to Ar-CAP. Intracellularly, there was no practical evidence for the formation of NO whereas very small amounts of superoxides were formed. Despite the superiority of Ar-CAP in forming center dot OH radicals, the exposure to X-rays proved more lethal. The mechanism of free radical formation in aqueous solutions and an intracellular milieu is discussed.	[Uchiyama, Hidefumi; Andocs, Gabor; Nojima, Nobuyuki] Tateyama Machine Co Ltd, Toyama 9301305, Japan; [Zhao, Qing-Li; Hassan, Mariame Ali; Kondo, Takashi] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Radiol Sci, Toyama 9300194, Japan; [Takeda, Keigo; Ishikawa, Kenji; Hori, Masaru] Nagoya Univ, Plasma Nanotechnol Res Ctr, Nagoya, Aichi 4648601, Japan	University of Toyama; Nagoya University	Kondo, T (corresponding author), Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Radiol Sci, Toyama 9300194, Japan.	kondot@med.u-toyama.ac.jp	Ishikawa, Kenji/I-6758-2014; Kamachi, Toshiaki/C-4230-2015	Ishikawa, Kenji/0000-0002-8288-6620; Kamachi, Toshiaki/0000-0002-9720-0265	Ministry of Education, Culture, Sports, Science, and Technology of Japan [25108503]; Tateyama Machine Co., Ltd	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Tateyama Machine Co., Ltd	This work was supported by a Grant-in-Aid for Scientific Research on Innovative Areas, Grant No. 25108503 from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, and a Grant-in-Aid for Practical and Commercial Application of Advanced Technology (TONIO), Toyama Prefecture. The funders had no role in study design, data collection, analysis, decision, and preparation of the manuscript or publishing. Tateyama Machine Co., Ltd provided support in the form of salaries for authors (HU, GA and NN), but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the "author contributions" section.	Ahn HJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086173; Ahn HJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028154; Alkawareek MY, 2014, INT J ANTIMICROB AG, V43, P154, DOI 10.1016/j.ijantimicag.2013.08.022; Arndt S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079325; Bekeschus S, 2014, FREE RADICAL RES, V48, P542, DOI 10.3109/10715762.2014.892937; Brun P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033245; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; Bundscherer L, 2013, IMMUNOBIOLOGY, V218, P1248, DOI 10.1016/j.imbio.2013.04.015; CARMICHAEL AJ, 1984, RADIAT RES, V100, P222, DOI 10.2307/3576343; Chang JW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092198; DARLEYUSMAR V, 1995, FEBS LETT, V369, P131, DOI 10.1016/0014-5793(95)00764-Z; Duske K, 2012, J CLIN PERIODONTOL, V39, P400, DOI 10.1111/j.1600-051X.2012.01853.x; Hoffmann C, 2013, MED GAS RES, V3, DOI 10.1186/2045-9912-3-21; Honda H, 2004, ULTRASOUND MED BIOL, V30, P683, DOI 10.1016/j.ultrasmedbio.2004.02.008; Idlibi AN, 2013, BIOFOULING, V29, P369, DOI 10.1080/08927014.2013.775255; Ikawa S, 2010, PLASMA PROCESS POLYM, V7, P33, DOI 10.1002/ppap.200900090; Ikuse K, 2014, P 8 INT C REACT PLAS; Kalghatgi S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016270; Kalghatgi SU, 2007, IEEE T PLASMA SCI, V35, P1559, DOI 10.1109/TPS.2007.905953; Kang SU, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.33; KONDO T, 1989, RADIAT RES, V118, P211, DOI 10.2307/3577438; KONDO T, 1988, INT J RADIAT BIOL, V53, P331, DOI 10.1080/09553008814550681; KONDO T, 1989, FREE RADICAL BIO MED, V7, P259, DOI 10.1016/0891-5849(89)90133-0; KONDO T, 1993, FREE RADICAL RES COM, V19, pS193, DOI 10.3109/10715769309056s193; Lackmann JW, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0591; Li P, 2014, APOPTOSIS, V19, P1043, DOI 10.1007/s10495-014-0984-1; Lu H, 2014, J APPL MICROBIOL, V116, P784, DOI 10.1111/jam.12426; Mai-Prochnow A, 2014, INT J ANTIMICROB AG, V43, P508, DOI 10.1016/j.ijantimicag.2014.01.025; Maisch T, 2012, J IND MICROBIOL BIOT, V39, P1367, DOI 10.1007/s10295-012-1137-6; Mastanaiah N, 2013, PLASMA PROCESS POLYM, V10, P1120, DOI 10.1002/ppap.201300108; PUMMER H, 1983, PHYS REV A, V28, P795, DOI 10.1103/PhysRevA.28.795; Reszka KJ, 2006, NITRIC OXIDE-BIOL CH, V15, P133, DOI 10.1016/j.niox.2006.03.004; RIESZ P, 1990, ULTRASONICS, V28, P295, DOI 10.1016/0041-624X(90)90035-M; RIESZ P, 1992, FREE RADICAL BIO MED, V13, P247, DOI 10.1016/0891-5849(92)90021-8; Setsukinai K, 2003, J BIOL CHEM, V278, P3170, DOI 10.1074/jbc.M209264200; Steinbeck MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082143; Takeda K, 2013, J PHYS D APPL PHYS, V46, DOI 10.1088/0022-3727/46/46/464006; Utsumi F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081576; Walk RM, 2013, J PEDIATR SURG, V48, P67, DOI 10.1016/j.jpedsurg.2012.10.020; Wang MA, 2014, TISSUE ENG PT A, V20, P1060, DOI [10.1089/ten.tea.2013.0235, 10.1089/ten.TEA.2013.0235]; Wang M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073741; Zhao SS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073665	42	54	54	2	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2015	10	8							e0136956	10.1371/journal.pone.0136956	http://dx.doi.org/10.1371/journal.pone.0136956			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CQ0PO	26318000	Green Published, Green Submitted, gold			2023-01-03	WOS:000360299100185
J	Andersen, L; Berg, KM; Saindon, BZ; Massaro, JM; Raymond, TT; Berg, RA; Nadkarni, VM; Donnino, MW				Andersen, Larsw.; Berg, Katherine M.; Saindon, Brian Z.; Massaro, Joseph M.; Raymond, Tia T.; Berg, Robert A.; Nadkarni, Vinay M.; Donnino, Michael W.		Amer Heart Assoc Get	Time to Epinephrine and Survival After Pediatric In-Hospital Cardiac Arrest	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EUROPEAN-RESUSCITATION-COUNCIL; AMERICAN-HEART-ASSOCIATION; EMERGENCY CARDIOVASCULAR CARE; STANDARD-DOSE EPINEPHRINE; CARDIOPULMONARY-RESUSCITATION; LIFE-SUPPORT; GUIDELINES-RESUSCITATION; PREHOSPITAL EPINEPHRINE; STROKE-FOUNDATION; NATIONAL REGISTRY	IMPORTANCE Delay in administration of the first epinephrine dose is associated with decreased survival among adults after in-hospital, nonshockable cardiac arrest. Whether this association is true in the pediatric in-hospital cardiac arrest population remains unknown. OBJECTIVE To determine whether time to first epinephrine dose is associated with outcomes in pediatric in-hospital cardiac arrest. DESIGN, SETTING. AND PARTICIPANTS We performed an analysis of data from the Get With the Guidelines-Resuscitation registry. We included US pediatric patients (age <18 years) with an in-hospital cardiac arrest and an initial nonshockable rhythm who received at least 1 dose of epinephrine. A total of 1558 patients (median age, 9 months [interquartile range [IQR], 13 days-5 years]) were included in the final cohort. EXPOSURE Time to epinephrine, defined as time in minutes from recognition of loss of pulse to the first dose of epinephrine. MAIN OUTCOMES AND MEASURES The primary outcome was survival to hospital discharge. Secondary outcomes included return of spontaneous circulation (ROSC), survival at 24 hours, and neurological outcome. A favorable neurological outcome was defined as a score of 1 to 2 on the Pediatric Cerebral Performance Category scale. RESULTS Among the 1558 patients, 487 (31.3%) survived to hospital discharge. The median time to first epinephrine dose was 1 minute (IQR, 0-4; range, 0-20; mean [SD], 2.6 [3.4] minutes). Longer time to epinephrine administration was associated with lower risk of survival to discharge in multivariable analysis (multivariable-adjusted risk ratio [RR] per minute delay, 0.95 [95% CI, 0.93-0.98]). Longer time to epinephrine administration was also associated with decreased risk of ROSC (multivariable-adjusted RR per minute delay, 0.97 [95% CI, 0.96-0.99]), decreased risk of survival at 24 hours (multivariable-adjusted RR per minute delay, 0.97 [95% CI, 0.95-0.99]), and decreased risk of survival with favorable neurological outcome (multivariable-adjusted RR per minute delay, 0.95 [95% CI, 0.91-0.99]). Patients with time to epinephrine administration of longer than 5 minutes (233/1558) compared with those with time to epinephrine of 5 minutes or less (1325/1558) had lower risk of in-hospital survival to discharge (21.0%[49/233] vs 33.1%[438/1325]; multivariable-adjusted RR, 0.75 [95% CI, 0.60-0.93]; P = .01). CONCLUSIONS AND RELEVANCE Among children with in-hospital cardiac arrest with an initial nonshockable rhythm who received epinephrine, delay in administration of epinephrine was associated with decreased chance of survival to hospital discharge, ROSC, 24-hour survival, and survival to hospital discharge with a favorable neurological outcome.	[Andersen, Larsw.; Saindon, Brian Z.; Donnino, Michael W.] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA; [Andersen, Larsw.] Aarhus Univ Hosp, Dept Anesthesiol, DK-8000 Aarhus, Denmark; [Berg, Katherine M.; Donnino, Michael W.] Beth Israel Deaconess Med Ctr, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02215 USA; [Massaro, Joseph M.] Harvard Clin Res Inst, Boston, MA USA; [Massaro, Joseph M.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Raymond, Tia T.] Med City Childrens Hosp, Dept Pediat, Div Cardiac Crit Care, Dallas, TX USA; [Berg, Robert A.; Nadkarni, Vinay M.] Univ Penn, Childrens Hosp Philadelphia, Dept Anesthesiol Crit Care & Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA	Harvard University; Beth Israel Deaconess Medical Center; Aarhus University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Boston University; Medical City Dallas Hospital; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Donnino, MW (corresponding author), Beth Israel Deaconess Med Ctr, One Deaconess Rd,W-CC 2, Boston, MA 02215 USA.	mdonnino@bidmc.harvard.edu	Raymond, Tia Tortoriello/ABA-7422-2021	Raymond, Tia Tortoriello/0000-0001-9454-8410; Andersen, Lars Wiuff/0000-0001-5752-8082; Sutton, Robert/0000-0002-2771-8931; Bembea, Melania/0000-0003-4984-520X	National Heart, Lung, and Blood Institute (NHLBI) [1K02HL107447-01A1]; American Heart Association (AHA) [14GRNT2001002, 13CRP16930000]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K02HL107447] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS075363] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Heart Association (AHA)(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Dr Donnino is supported by the National Heart, Lung, and Blood Institute (NHLBI) (1K02HL107447-01A1) and American Heart Association (AHA) (14GRNT2001002). Dr K. Berg is supported by the AHA (13CRP16930000).	Berg MD, 2008, PEDIATR CLIN N AM, V55, P589, DOI 10.1016/j.pcl.2008.02.005; Biarent D, 2010, RESUSCITATION, V81, P1364, DOI 10.1016/j.resuscitation.2010.08.012; Callaway CW, 2012, JAMA-J AM MED ASSOC, V307, P1198, DOI 10.1001/jama.2012.313; Carpenter TC, 1997, PEDIATRICS, V99, P403, DOI 10.1542/peds.99.3.403; Chan PS, 2008, NEW ENGL J MED, V358, P9, DOI 10.1056/NEJMoa0706467; Cummins RO, 1997, CIRCULATION, V95, P2213, DOI 10.1161/01.CIR.95.8.2213; DIECKMANN RA, 1995, PEDIATRICS, V95, P901; Donnino MW, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3028; Donoghue AJ, 2006, PEDIATRICS, V118, P995, DOI 10.1542/peds.2006-0453; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Girotra S, 2013, CIRC-CARDIOVASC QUAL, V6, P42, DOI 10.1161/CIRCOUTCOMES.112.967968; Goto Y, 2013, CRIT CARE, V17, DOI 10.1186/cc12872; Hagihara A, 2012, JAMA-J AM MED ASSOC, V307, P1161, DOI 10.1001/jama.2012.294; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Jacobs IG, 2011, RESUSCITATION, V82, P1138, DOI 10.1016/j.resuscitation.2011.06.029; Kleinman ME, 2010, CIRCULATION, V122, pS876, DOI 10.1161/CIRCULATIONAHA.110.971101; Kleinman ME, 2010, CIRCULATION, V122, P8466, DOI [10.1161/CIRCULATIONAHA.110.971093, 10.1542/peds.2010-2972A]; Kumar G, 2013, NEW ENGL J MED, V368, P680, DOI 10.1056/NEJMc1215155; Matos RI, 2013, CIRCULATION, V127, P442, DOI 10.1161/CIRCULATIONAHA.112.125625; Meaney PA, 2006, PEDIATRICS, V118, P2424, DOI 10.1542/peds.2006-1724; Nadkarni VM, 2006, JAMA-J AM MED ASSOC, V295, P50, DOI 10.1001/jama.295.1.50; Nakahara S, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6829; NIEMANN JT, 1985, ANN EMERG MED, V14, P521, DOI 10.1016/S0196-0644(85)80774-5; Olasveengen TM, 2009, JAMA-J AM MED ASSOC, V302, P2222, DOI 10.1001/jama.2009.1729; Olasveengen TM, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7268; Ornato JP, 2012, RESUSCITATION, V83, P63, DOI 10.1016/j.resuscitation.2011.09.009; Ortmann L, 2011, CIRCULATION, V124, P2329, DOI 10.1161/CIRCULATIONAHA.110.013466; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Peberdy MA, 2008, JAMA-J AM MED ASSOC, V299, P785, DOI 10.1001/jama.299.7.785; Peng TJ, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0867-z; Perondi MBM, 2004, NEW ENGL J MED, V350, P1722, DOI 10.1056/NEJMoa032440; Reynolds JC, 2007, RESUSCITATION, V74, P13, DOI 10.1016/j.resuscitation.2006.10.032; SANDERS AB, 1984, CRIT CARE MED, V12, P871, DOI 10.1097/00003246-198410000-00007; Tibballs J, 2006, RESUSCITATION, V71, P310, DOI 10.1016/j.resuscitation.2006.05.009; Topjian AA, 2008, PEDIATRICS, V122, P1086, DOI 10.1542/peds.2007-3313; Weiner GM, 2012, CLIN PERINATOL, V39, P843, DOI 10.1016/j.clp.2012.09.005; Zou GY, 2013, STAT METHODS MED RES, V22, P661, DOI 10.1177/0962280211427759; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	39	124	125	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2015	314	8					802	810		10.1001/jama.2015.9678	http://dx.doi.org/10.1001/jama.2015.9678			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CP6SA	26305650	Bronze, Green Accepted			2023-01-03	WOS:000360017200020
J	Lu, JH; Ma, D				Lu, Jianhua; Ma, Dan			Repellent and Contact Toxicity of Alpinia officinarum Rhizome Extract against Lasioderma serricorne Adults	PLOS ONE			English	Article							TRIBOLIUM-CASTANEUM HERBST; SITOPHILUS-ZEAMAIS MOTSCHULSKY; STORED-PRODUCT INSECTS; ESSENTIAL OILS; FUMIGANT TOXICITY; BOTANICAL INSECTICIDES; PHOSPHINE RESISTANCE; PACKAGING MATERIALS; STORAGE INSECTS; GRANARY WEEVIL	The repellent and contact toxicities of Alpinia officinarum rhizome extract on Lasioderma serricorne adults, and its ability to protect stored wheat flour from L. serricorne adults infestation were investigated. The A. officinarum extract exhibited strong repellent and contact toxicities against L. serricorne adults. The toxicities enhanced significantly with the increasing treatment time and treatment dose. The mean percentage repellency value reached 91.3% at class V at the dose of 0.20 mu L/cm(2) after 48 h of exposure. The corrected mortality reached over 80.0% at the dose of 0.16 mu L/cm(2) after 48 h of exposure. The A. officinarum extract could significantly reduce L. serricorne infestation level against stored wheat flour. Particularly, the insect infestation was nil in wheat flour packaged with kraft paper bags coated with the A. officinarum extract at the dose of above 0.05 mu L/cm(2). The naturally occurring A. officinarum extract could be useful for integrated management of L. serricorne.	[Lu, Jianhua; Ma, Dan] Henan Univ Technol, Sch Food Sci & Technol, Zhengzhou 450001, Henan, Peoples R China	Henan University of Technology	Lu, JH (corresponding author), Henan Univ Technol, Sch Food Sci & Technol, Lianhua St, Zhengzhou 450001, Henan, Peoples R China.	jianhlv@163.com			National Research Plan for the High-tech R & D Program during the Twelfth Five-year Plan Period (National 863 plan) [2012AA101705-2]; Plan of Nature Science Fundamental Research in Henan University of Technology [11JCYJ01]; Key Technologies R & D Program of the Education Department of Henan Province [12A210003]; Basic and Cutting-edge Technology Research Projects of Henan Province	National Research Plan for the High-tech R & D Program during the Twelfth Five-year Plan Period (National 863 plan); Plan of Nature Science Fundamental Research in Henan University of Technology; Key Technologies R & D Program of the Education Department of Henan Province; Basic and Cutting-edge Technology Research Projects of Henan Province	This research was supported by the National Research Plan for the High-tech R & D Program during the Twelfth Five-year Plan Period (National 863 plan, No. 2012AA101705-2), Plan of Nature Science Fundamental Research in Henan University of Technology (No. 11JCYJ01), Key Technologies R & D Program of the Education Department of Henan Province (No. 12A210003) and the Basic and Cutting-edge Technology Research Projects of Henan Province (No. 2015).	Abdelghany AY, 2010, J STORED PROD RES, V46, P93, DOI 10.1016/j.jspr.2009.11.001; Allahvaisi S, 2010, NOT BOT HORTI AGROBO, V38, P21; [Anonymous], 1925, J ECON ENTOMOL; BARRER PM, 1980, J STORED PROD RES, V16, P1, DOI 10.1016/0022-474X(80)90028-4; BELL CH, 1995, J STORED PROD RES, V31, P199, DOI 10.1016/0022-474X(95)00012-V; BLOSZYK E, 1990, J APPL ENTOMOL, V110, P96, DOI 10.1111/j.1439-0418.1990.tb00100.x; BUTLER JH, 1996, METHYL BROMIDE ISSUE, V1, P27; Cosimi S, 2009, J STORED PROD RES, V45, P125, DOI 10.1016/j.jspr.2008.10.002; Daglish GJ, 1998, STORED PRODUCT PROTE, P584; Fan GJ, 2007, BIOORG MED CHEM LETT, V17, P6720, DOI 10.1016/j.bmcl.2007.10.054; Fardisi M, 2013, J STORED PROD RES, V52, P93, DOI 10.1016/j.jspr.2012.12.006; Germinara GS, 2012, J FOOD PROTECT, V75, P366, DOI 10.4315/0362-028X.JFP-11-142; Highland H.A., 1984, P311; Highland HA, 1991, ECOLOGY MANAGEMENT F, P345; Hill J.M., 1981, RECENT ADV FOOD SCI, V1, P473; Hou XW, 2004, J STORED PROD RES, V40, P47, DOI 10.1016/S0022-474X(02)00063-2; Isman MB, 2006, ANNU REV ENTOMOL, V51, P45, DOI 10.1146/annurev.ento.51.110104.151146; Isman MB, 2008, PEST MANAG SCI, V64, P8, DOI 10.1002/ps.1470; Jovanovic Z, 2007, IND CROP PROD, V26, P100, DOI 10.1016/j.indcrop.2007.01.010; JULIANA G, 1983, J ECON ENTOMOL, V76, P154; Kim SI, 2003, J STORED PROD RES, V39, P11, DOI 10.1016/S0022-474X(02)00013-9; Kljajic P, 2006, J STORED PROD RES, V42, P149, DOI 10.1016/j.jspr.2005.01.002; Lee BH, 2004, J STORED PROD RES, V40, P553, DOI 10.1016/j.jspr.2003.09.001; Lee BH, 2001, CROP PROT, V20, P317, DOI 10.1016/S0261-2194(00)00158-7; Lee SE, 2003, LIFE SCI, V73, P167, DOI 10.1016/S0024-3205(03)00259-5; Lee SE, 2001, PEST MANAG SCI, V57, P548, DOI 10.1002/ps.322; Liu ZL, 2007, J STORED PROD RES, V43, P290, DOI 10.1016/j.jspr.2006.06.010; Liu ZL, 1999, J STORED PROD RES, V35, P317, DOI 10.1016/S0022-474X(99)00015-6; MBTOC, 1998, METHYL BROMIDE TECHN, P374; Mikhaiel AA, 2011, J STORED PROD RES, V47, P357, DOI 10.1016/j.jspr.2011.06.002; Mowery SV, 2002, J ECON ENTOMOL, V95, P1333, DOI 10.1603/0022-0493-95.6.1333; Mullen M. A., 2000, International Food Hygiene, V11, P13; MULLEN MA, 1994, J STORED PROD RES, V30, P95, DOI 10.1016/0022-474X(94)90278-X; Papadopoulou SC, 2004, J PEST SCI, V77, P183, DOI 10.1007/s10340-004-0052-7; Paul UV, 2009, J STORED PROD RES, V45, P97, DOI 10.1016/j.jspr.2008.09.006; Radwan R. N., 1997, U. S. Patent, Patent No. [5,688,509, 5688509]; RAJENDRAN S, 1994, INT J PEST MANAGE, V40, P207, DOI 10.1080/09670879409371883; Shaaya E, 1997, J STORED PROD RES, V33, P7, DOI 10.1016/S0022-474X(96)00032-X; Tapondjou AL, 2005, J STORED PROD RES, V41, P91, DOI 10.1016/j.jspr.2004.01.004; Wang J, 2006, J STORED PROD RES, V42, P339, DOI 10.1016/j.jspr.2005.06.001; White N.D.G., 1995, INTREGATED PEST MANA; Wong KKY, 2005, J AGR FOOD CHEM, V53, P4633, DOI 10.1021/jf050096m; YANG RZ, 1988, ECON BOT, V42, P376, DOI 10.1007/BF02860162; ZETTLER JL, 1994, J ECON ENTOMOL, V87, P546, DOI 10.1093/jee/87.3.546; Zhang BB, 2010, FITOTERAPIA, V81, P948, DOI 10.1016/j.fitote.2010.06.015	45	9	10	2	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2015	10	8							e0135631	10.1371/journal.pone.0135631	http://dx.doi.org/10.1371/journal.pone.0135631			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CP5KH	26292097	Green Published, gold, Green Submitted			2023-01-03	WOS:000359919900022
J	Yu, N; Zhang, Z; Chen, P; Zhong, YM; Cai, XX; Hu, H; Yang, Y; Zhang, J; Li, KJ; Ge, J; Yu, KM; Liu, X; Zhuang, J				Yu, Na; Zhang, Zhang; Chen, Pei; Zhong, Yimin; Cai, Xiaoxiao; Hu, Huan; Yang, Ying; Zhang, Jing; Li, Kaijing; Ge, Jian; Yu, Keming; Liu, Xing; Zhuang, Jing			Tetramethylpyrazine (TMP), an Active Ingredient of Chinese Herb Medicine Chuanxiong, Attenuates the Degeneration of Trabecular Meshwork through SDF-1/CXCR4 Axis	PLOS ONE			English	Article							RECEPTOR CXCR4 EXPRESSION; NERVOUS-SYSTEM; CULTURED HUMAN; CELLS; GLAUCOMA; MIGRATION; MATRIX; NEOVASCULARIZATION; CHEMOKINES; INHIBITION	Background A traditional Chinese medicine, Tetramethylpyrazine (TMP), has been prescribed as a complementary treatment for glaucoma to improve patient prognosis. However, the pharmacological mechanism of action of TMP is poorly understood. In previous studies, we demonstrated that TMP exerts potent inhibitory effects on neovascularization, suppresses the tumorigenic behavior of glioma cells, and protects neural cells by regulating CXCR4 expression. Here, we further investigated whether the SDF-1/CXCR4 pathway is also involved in the TMP-mediated activity in trabecular meshwork cells. Methodology/Principal Findings CXCR4 expression was examined by quantitative real-time PCR in trabecular and iris specimens from 54 primary open-angle glaucoma (POAG) patients who required surgery and 19 non-glaucomatous donors. Our data revealed markedly elevated CXCR4 expression in the trabecular meshwork of POAG patients compared with that of controls. Consistently, CXCR4 expression was much higher in glaucomatous trabecular meshwork cells than in normal trabecular meshwork cells. Using RT-PCR and western blot assays, we determined that glaucoma-related cytokines and dexamethasone (DEX) also significantly up-regulated CXCR4 expression in primary human trabecular meshwork (PHTM) cells. Moreover, the TGF-beta 1-mediated induction of CXCR4 expression in PHTM cells was markedly down-regulated by TMP compared with control treatment (PBS) and the CXCR4 antagonist AMD3100. In addition, TMP could counteract the TGF-beta 1-induced effects on stress fiber accumulation and expansion of PHTM cells. TMP markedly suppressed the migration of PHTM cells stimulated by TGF-beta 1 in transwell and scratch wound assays. TMP also suppressed the extracellular matrix (ECM) accumulation induced by TGF-beta 2. Conclusions Our findings demonstrate that CXCR4 might be involved in the pathogenetic changes in the trabecular meshwork of patients with POAG. Additionally, TMP might exert its beneficial effects in POAG patients by down-regulating CXCR4 expression.	[Yu, Na; Zhang, Zhang; Chen, Pei; Zhong, Yimin; Cai, Xiaoxiao; Hu, Huan; Yang, Ying; Zhang, Jing; Li, Kaijing; Ge, Jian; Yu, Keming; Liu, Xing; Zhuang, Jing] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University	Yu, KM (corresponding author), Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.	yukeming@mail.sysu.edu.cn; liuxing@mail.sysu.edu.cn; zhuangj@mail.sysu.edu.cn	Cai, Xiaoxiao/C-4868-2018	Cai, Xiaoxiao/0000-0002-5654-7414	National Natural Science Foundation [81370987]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC))	All the studies were funded by the grants from the National Natural Science Foundation (Project: 81370987) [KMY].	Acott TS, 2008, EXP EYE RES, V86, P543, DOI 10.1016/j.exer.2008.01.013; Sanchez-Alcaniz JA, 2011, NEURON, V69, P77, DOI 10.1016/j.neuron.2010.12.006; Banisadr G, 2002, EUR J NEUROSCI, V16, P1661, DOI 10.1046/j.1460-9568.2002.02237.x; Baudouin Christophe, 2012, Trans Am Ophthalmol Soc, V110, P40; Bertran E, 2013, HEPATOLOGY, V58, P2032, DOI 10.1002/hep.26597; Cai XX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088176; Chen M, 2011, INVEST OPHTH VIS SCI, V52, P7027, DOI 10.1167/iovs.11-7524; Chen Z, 2013, CANCER LETT, V336, P281, DOI 10.1016/j.canlet.2013.03.015; Chu CY, 2007, ONCOGENE, V26, P2491, DOI 10.1038/sj.onc.1210040; De Groef L, 2013, INVEST OPHTH VIS SCI, V54, P7756, DOI 10.1167/iovs.13-13088; Denoyer A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037873; Foster Paul J, 2002, Semin Ophthalmol, V17, P50; Fu YS, 2008, NEURO-ONCOLOGY, V10, P139, DOI 10.1215/15228517-2007-051; Fuchshofer R, 2012, CELL TISSUE RES, V347, P279, DOI 10.1007/s00441-011-1274-7; Guyon A, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00065; Kitagawa K, 2001, JPN J OPHTHALMOL, V45, P227, DOI 10.1016/S0021-5155(01)00320-3; Kucia M, 2004, J MOL HISTOL, V35, P233; Kwon YH, 2009, NEW ENGL J MED, V360, P1113, DOI 10.1056/NEJMra0804630; Lee E, 2010, INVEST OPHTH VIS SCI, V51, P3666, DOI 10.1167/iovs.09-3802; Liang XL, 2012, INVEST OPHTH VIS SCI, V53, P2157, DOI 10.1167/iovs.11-9315; Liu M, 2004, CHIN J CLIN REHAB, V8, P1299; Liu Y, 1998, HUBEI J TRADITIONAL, V20, P54; Luo X, 2013, J LIAONING U TCM, P1673; Man D, 2011, CLIN J CHINESE MED, V14, P1674; Nguyen TD, 1998, J BIOL CHEM, V273, P6341, DOI 10.1074/jbc.273.11.6341; Pang PKT, 1996, PLANTA MED, V62, P431, DOI 10.1055/s-2006-957933; Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7; Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844; Robertson JV, 2010, INVEST OPHTH VIS SCI, V51, P308, DOI 10.1167/iovs.09-3380; Rostene W, 2011, J NEUROCHEM, V118, P680, DOI 10.1111/j.1471-4159.2011.07371.x; Scala S, 2007, CANCER IMMUNOL IMMUN, V56, P1589, DOI 10.1007/s00262-007-0303-6; Shifera AS, 2010, EXP EYE RES, V91, P42, DOI 10.1016/j.exer.2010.04.001; SOMMER A, 1989, AM J OPHTHALMOL, V107, P186, DOI 10.1016/0002-9394(89)90221-3; Son BR, 2006, STEM CELLS, V24, P1254, DOI 10.1634/stemcells.2005-0271; Strasser GA, 2010, BLOOD, V115, P5102, DOI 10.1182/blood-2009-07-230284; Stumm RK, 2002, J NEUROSCI, V22, P5865; Takai Y, 2012, INVEST OPHTH VIS SCI, V53, P241, DOI 10.1167/iovs.11-8434; Tamm ER, 1996, EXP EYE RES, V62, P389, DOI 10.1006/exer.1996.0044; Tang Ze-yao, 2011, Zhongguo Yaolixue Yu Dulixue Zazhi, V25, P114, DOI 10.3867/j.issn.1000-3002.2011.01.023; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Tektas OY, 2009, EXP EYE RES, V88, P769, DOI 10.1016/j.exer.2008.11.025; Xia CL, 2009, J XIAN JIAOTONG U ME, V30, P423; Yang JN, 2005, ACTA PHARMACOL SIN, V26, P887, DOI 10.1111/j.1745-7254.2005.00141.x; Yang ZK, 2008, NEUROCHEM INT, V52, P1176, DOI 10.1016/j.neuint.2007.12.008; You JM, 2010, CHIN MED, V28, P2666; Yu KM, 2007, BIOCHEM BIOPH RES CO, V358, P990, DOI 10.1016/j.bbrc.2007.05.004; Yu KM, 2012, ONCOL REP, V28, P955, DOI 10.3892/or.2012.1866; Zhang HQ, 2011, J NEUROSCI, V31, P15894, DOI 10.1523/JNEUROSCI.3943-11.2011	48	13	16	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2015	10	8							e0133055	10.1371/journal.pone.0133055	http://dx.doi.org/10.1371/journal.pone.0133055			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO9KD	26275042	Green Published, Green Submitted, gold			2023-01-03	WOS:000359493600008
J	Zhou, XL; Li, L; Jiang, C; Xu, B; Wang, HL; Xiong, D; Sheng, LP; Yang, QS; Jiang, S; Xu, P; Chen, ZQ; Zhao, Y				Zhou, Xian-Long; Li, Lei; Jiang, Cheng; Xu, Bing; Wang, Huang-Lei; Xiong, Dan; Sheng, Li-Pin; Yang, Qi-Sheng; Jiang, Shan; Xu, Peng; Chen, Zhi-Qiao; Zhao, Yan			Up-Down Hand Position Switch May Delay the Fatigue of Non-Dominant Hand Position Rescuers and Improve Chest Compression Quality during Cardiopulmonary Resuscitation: A Randomized Crossover Manikin Study	PLOS ONE			English	Article							HEART-ASSOCIATION GUIDELINES; CPR; DOMINANT; RATIO	Previous studies have shown improved external chest compression (ECC) quality and delayed rescuer fatigue when the dominant hand (DH) was in contact with the sternum. However, many rescuers prefer placing the non-dominant hand (NH) in contact with the sternum during ECC. We aimed to investigate the effects of up-down hand position switch on the quality of ECC and the fatigue of rescuers during cardiopulmonary resuscitation (CPR). After completion of a review of the standard adult basic life support (BLS) course, every candidate performed 10 cycles of single adult CPR twice on an adult manikin with either a constant hand position (CH) or a switched hand position (SH) in random order at 7-day intervals. The rescuers' general characteristics, hand positions, physiological signs, fatigue appearance and ECC qualities were recorded. Our results showed no significant differences in chest compression quality for the DH position rescuers between the CH and SH sessions (p>0.05, resp.). And also no significant differences were found for Borg score (p = 0.437) or cycle number (p = 0.127) of fatigue appearance after chest compressions between the two sessions. However, for NH position rescuers, the appearance of fatigue was delayed (p = 0.046), with a lower Borg score in the SH session (12.67 +/- 2.03) compared to the CH session (13.33 +/- 1.95) (p = 0.011). Moreover, the compression depth was significantly greater in the SH session (39.3 +/- 7.2 mm) compared to the CH session (36.3 +/- 8.1 mm) (p = 0.015). Our data suggest that the up-down hand position switch during CPR may delay the fatigue of non-dominant hand position rescuers and improve the quality of chest compressions.	[Zhou, Xian-Long; Li, Lei; Jiang, Cheng; Xu, Bing; Wang, Huang-Lei; Xiong, Dan; Sheng, Li-Pin; Yang, Qi-Sheng; Jiang, Shan; Xu, Peng; Chen, Zhi-Qiao; Zhao, Yan] Wuhan Univ, Zhongnan Hosp, Emergency Ctr, Wuhan 430071, Hubei, Peoples R China	Wuhan University	Zhao, Y (corresponding author), Wuhan Univ, Zhongnan Hosp, Emergency Ctr, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.	doctoryanzhao@163.com		Zhou, Xianlong/0000-0002-6163-5320	Emergency Diagnostic & Therapeutic Center of Central China (Wuhan, Hubei, China)	Emergency Diagnostic & Therapeutic Center of Central China (Wuhan, Hubei, China)	This study was financially supported by the Emergency Diagnostic & Therapeutic Center of Central China (Wuhan, Hubei, China).	Abella BS, 2005, CIRCULATION, V111, P428, DOI 10.1161/01.CIR.0000153811.84257.59; Berg RA, 2010, CIRCULATION, V122, pS685, DOI 10.1161/CIRCULATIONAHA.110.970939; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Chung TN, 2012, J EMERG MED, V43, P1049, DOI 10.1016/j.jemermed.2012.01.021; Edelson DP, 2012, RESUSCITATION, V83, P874, DOI 10.1016/j.resuscitation.2012.03.005; Field JM, 2010, CIRCULATION, V122, pS640, DOI 10.1161/CIRCULATIONAHA.110.970889; Foo NP, 2010, RESUSCITATION, V81, P579, DOI 10.1016/j.resuscitation.2010.02.006; Haque IU, 2008, RESUSCITATION, V79, P82, DOI 10.1016/j.resuscitation.2008.04.026; Hong MY, 2014, AM J EMERG MED; Jiang C, 2015, J EMERG MED, V48, P436, DOI 10.1016/j.jemermed.2014.12.034; Kern KB, 2005, RESUSCITATION, V64, P261, DOI 10.1016/j.resuscitation.2004.08.009; Kovic I, 2013, J EMERG MED, V45, P570, DOI 10.1016/j.jemermed.2013.04.021; Kundra P, 2000, BRIT J ANAESTH, V84, P491, DOI 10.1093/oxfordjournals.bja.a013475; Monsieurs KG, 2012, RESUSCITATION, V83, P1319, DOI 10.1016/j.resuscitation.2012.07.015; Nikandish R, 2008, RESUSCITATION, V76, P256, DOI 10.1016/j.resuscitation.2007.07.032; NOBLE BJ, 1983, MED SCI SPORT EXER, V15, P523; Odegaard S, 2007, RESUSCITATION, V74, P127, DOI 10.1016/j.resuscitation.2006.12.006; R Core Team, 2014, R A LANGUAGE AND ENV; Trojan DA, 1997, NEUROREHABILITATION, V8, P93, DOI 10.3233/NRE-1997-8204; Vaillancourt C, 2011, RESUSCITATION, V82, P51, DOI 10.1016/j.resuscitation.2010.09.003; Yang Z, 2013, CRITICAL CARE MED, V41, pA116	23	4	4	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2015	10	8							e0133483	10.1371/journal.pone.0133483	http://dx.doi.org/10.1371/journal.pone.0133483			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CO9JT	26267353	Green Published, Green Submitted, gold			2023-01-03	WOS:000359492300016
J	Jemielita, T; Gerton, GL; Neidell, M; Chillrud, S; Yan, BZ; Stute, M; Howarth, M; Saberi, P; Fausti, N; Penning, TM; Roy, J; Propert, KJ; Panettieri, RA				Jemielita, Thomas; Gerton, George L.; Neidell, Matthew; Chillrud, Steven; Yan, Beizhan; Stute, Martin; Howarth, Marilyn; Saberi, Pounw; Fausti, Nicholas; Penning, Trevor M.; Roy, Jason; Propert, Kathleen J.; Panettieri, Reynold A., Jr.			Unconventional Gas and Oil Drilling Is Associated with Increased Hospital Utilization Rates	PLOS ONE			English	Article							SHALE GAS; OPERATIONS; EXTRACTION	Over the past ten years, unconventional gas and oil drilling (UGOD) has markedly expanded in the United States. Despite substantial increases in well drilling, the health consequences of UGOD toxicant exposure remain unclear. This study examines an association between wells and healthcare use by zip code from 2007 to 2011 in Pennsylvania. Inpatient discharge databases from the Pennsylvania Healthcare Cost Containment Council were correlated with active wells by zip code in three counties in Pennsylvania. For overall inpatient prevalence rates and 25 specific medical categories, the association of inpatient prevalence rates with number of wells per zip code and, separately, with wells per km(2) (separated into quantiles and defined as well density) were estimated using fixed-effects Poisson models. To account for multiple comparisons, a Bonferroni correction with associations of p<0.00096 was considered statistically significant. Cardiology inpatient prevalence rates were significantly associated with number of wells per zip code (p<0.00096) and wells per km(2) (p<0.00096) while neurology inpatient prevalence rates were significantly associated with wells per km(2) (p<0.00096). Furthermore, evidence also supported an association between well density and inpatient prevalence rates for the medical categories of dermatology, neurology, oncology, and urology. These data suggest that UGOD wells, which dramatically increased in the past decade, were associated with increased inpatient prevalence rates within specific medical categories in Pennsylvania. Further studies are necessary to address healthcare costs of UGOD and determine whether specific toxicants or combinations are associated with organ-specific responses.	[Jemielita, Thomas; Roy, Jason; Propert, Kathleen J.] Univ Penn, Perelman Sch Med, Dept Biostat, Philadelphia, PA 19104 USA; [Gerton, George L.; Howarth, Marilyn; Saberi, Pounw; Fausti, Nicholas; Penning, Trevor M.; Panettieri, Reynold A., Jr.] Univ Penn, Ctr Excellence Environm Toxicol, Airways Biol Initiat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Neidell, Matthew] Columbia Univ, Mailman Sch Publ Hlth, Dept Hlth Policy & Management, New York, NY USA; [Chillrud, Steven; Yan, Beizhan] Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Columbia University; Columbia University	Panettieri, RA (corresponding author), Univ Penn, Ctr Excellence Environm Toxicol, Airways Biol Initiat, Perelman Sch Med, Philadelphia, PA 19104 USA.	rap@mail.med.upenn.edu	panettieri, reynold/AAG-9485-2019	Penning, Trevor/0000-0002-3937-1066	National Institute of Environmental Health Sciences [P30-ES013508, P30-ES009089]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL114471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089, P30ES013508] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was funded by grants from the National Institute of Environmental Health Sciences (www.niehs.nih.gov): P30-ES013508 (GLG MH PS NF TMP JR KJP RAP) and P30-ES009089 (GLG MN SC BY MS MH PS NF TMP JR KJP RAP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adgate JL, 2014, ENVIRON SCI TECHNOL, V48, P8307, DOI 10.1021/es404621d; Bernstein AB, 2003, DHHS PUBLICATION, V2004-1031; Colborn T, 2011, HUM ECOL RISK ASSESS, V17, P1039, DOI 10.1080/10807039.2011.605662; Earthworks, EARTHW HYDR FRACT 10, V101; EIA, 2014, ANN EN OUTL 2014; EPA, 2014, PROC HYDR FRACT; Gross SA, 2013, J AIR WASTE MANAGE, V63, P424, DOI 10.1080/10962247.2012.759166; IER, 2012, US LEADS WORLD NAT G; Jackson RB, 2013, P NATL ACAD SCI USA, V110, P11250, DOI 10.1073/pnas.1221635110; Lampe DJ, 2015, J ENVIRON SCI HEAL A, V50, P434, DOI 10.1080/10934529.2015.992653; Lanki T., 2015, ENV HLTH PERSPECT; Macy PG, 2014, ENV HLTH, V13, P82, DOI [10.1186/1476-069X-13-82, DOI 10.1186/1476-069X-13-82]; McKenzie LM, 2014, ENVIRON HEALTH PERSP, V122, P412, DOI 10.1289/ehp.1306722; McKenzie LM, 2012, SCI TOTAL ENVIRON, V424, P79, DOI 10.1016/j.scitotenv.2012.02.018; PA Department of Environmental Protection, 2013, 2013 OIL GAS ANN REP; PA Department of Environmental Protection, 2013, MARC SHAK DEV; Penning TM, 2014, ENVIRON HEALTH PERSP, V122, P1155, DOI 10.1289/ehp.1408207; Rabinowitz PM, 2014, ENV HLTH PERSPECT; Schnoor JL, 2012, ENVIRON SCI TECHNOL, V46, P4686, DOI 10.1021/es3011767; US Government, 2010, 2010 CENS DAT; Warner NR, 2013, ENVIRON SCI TECHNOL, V47, P11849, DOI 10.1021/es402165b; Wooldridge JM, 1999, J ECONOMETRICS, V90, P77, DOI 10.1016/S0304-4076(98)00033-5	22	61	63	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2015	10	7							e0131093	10.1371/journal.pone.0131093	http://dx.doi.org/10.1371/journal.pone.0131093			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1RL	26176544	Green Submitted, Green Published, gold			2023-01-03	WOS:000358197600036
J	Wang, XM; Kindzierski, W; Kaul, P				Wang, Xiaoming; Kindzierski, Warren; Kaul, Padma			Air Pollution and Acute Myocardial Infarction Hospital Admission in Alberta, Canada: A Three-Step Procedure Case-Crossover Study	PLOS ONE			English	Article							POTENTIALLY SENSITIVE GROUPS; PARTICULATE MATTER; EMERGENCY ADMISSIONS; REFERENT SELECTION; FINE PARTICLES; MINAP DATABASE; TIME-SERIES; EXPOSURE; RISK; MORTALITY	Adverse associations between air pollution and myocardial infarction (MI) are widely reported in medical literature. However, inconsistency and sensitivity of the findings are still big concerns. An exploratory investigation was undertaken to examine associations between air pollutants and risk of acute MI (AMI) hospitalization in Alberta, Canada. A time stratified case-crossover design was used to assess the transient effect of five air pollutants (carbon monoxide (CO), nitrogen dioxide (NO2), nitric oxide (NO), ozone (O-3) and particulate matter with an aerodynamic diameter <= 2.5 (PM2.5)) on the risk of AMI hospitalization over the period 1999-2009. Subgroups were predefined to see if any susceptible group of individuals existed. A three-step procedure, including univariate analysis, multivariate analysis, and bootstrap model averaging, was used. The multivariate analysis was used in an effort to address adjustment uncertainty; whereas the bootstrap technique was used as a way to account for regression model uncertainty. There were 25,894 AMI hospital admissions during the 11-year period. Estimating health effects that are properly adjusted for all possible confounding factors and accounting for model uncertainty are important for making interpretations of air pollution-health effect associations. The most robust findings included: (1) only 1-day lag NO2 concentrations (6-, 12- or 24-hour average), but not those of CO, NO, O-3 or PM2.5, were associated with an elevated risk of AMI hospitalization; (2) evidence was suggested for an effect of elevated risk of hospitalization for NSTEMI (Non-ST Segment Elevation Myocardial Infarction), but not for STEMI (ST segment elevation myocardial infarction); and (3) susceptible subgroups included elders (age >= 65) and elders with hypertension. As this was only an exploratory study there is a need to replicate these findings with other methodologies and datasets.	[Wang, Xiaoming; Kindzierski, Warren] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada; [Kaul, Padma] Univ Alberta, Dept Med, Canadian Vigour Ctr, Edmonton, AB, Canada	University of Alberta; University of Alberta	Kindzierski, W (corresponding author), Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada.	warrenk@ualberta.ca		Kaul, Padma/0000-0003-2239-3944	Alberta Public Health Information Network Project	Alberta Public Health Information Network Project	This study was funded by the Alberta Public Health Information Network Project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bard D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100307; Barnett AG, 2006, ENVIRON HEALTH PERSP, V114, P1018, DOI 10.1289/ehp.8674; Bateson TF, 2004, EPIDEMIOLOGY, V15, P143, DOI 10.1097/01.ede.0000112210.68754.fa; Berglind N, 2010, INT J ENV RES PUB HE, V7, P1486, DOI 10.3390/ijerph7041486; Bhaskaran K, 2009, HEART, V95, P1746, DOI 10.1136/hrt.2009.175018; Bhaskaran K, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5531; Cadum E, 2009, EPIDEMIOL PREV, V33, P113; Cheng MF, 2009, J TOXICOL ENV HEAL A, V72, P1135, DOI 10.1080/15287390903091756; Clyde M, 2000, ENVIRONMETRICS, V11, P745, DOI 10.1002/1099-095X(200011/12)11:6<745::AID-ENV431>3.0.CO;2-N; D'Ippoliti D, 2003, EPIDEMIOLOGY, V14, P528, DOI 10.1097/01.ede.0000082046.22919.72; Dominici F, 2004, J AM STAT ASSOC, V99, P938, DOI 10.1198/016214504000000656; Dominici F, 2008, EPIDEMIOLOGY, V19, P558, DOI 10.1097/EDE.0b013e31817307dc; Dominici F, 2014, SCIENCE, V344, P257, DOI 10.1126/science.1247348; Environment Canada, 2013, NAT AIR POLL SURV NA; Gardner B, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/1743-8977-11-1; Hastie T., 2009, ELEMENTS STAT LEARNI, V2, P1; Hodas N, 2013, J EXPO SCI ENV EPID, V23, P573, DOI 10.1038/jes.2013.24; Hsieh YL, 2010, J TOXICOL ENV HEAL A, V73, P757, DOI 10.1080/15287391003684789; Janes H, 2005, STAT MED, V24, P285, DOI 10.1002/sim.1889; Janes H, 2005, EPIDEMIOLOGY, V16, P717, DOI 10.1097/01.ede.0000181315.18836.9d; Kioumourtzoglou MA, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-68; Koop G, 2010, ENVIRON MODELL SOFTW, V25, P873, DOI 10.1016/j.envsoft.2010.01.010; Levinsson A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099043; Levy D, 2001, EPIDEMIOLOGY, V12, P186, DOI 10.1097/00001648-200103000-00010; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; Milojevic A, 2014, HEART, V100, P1093, DOI 10.1136/heartjnl-2013-304963; Mustafic H, 2012, JAMA-J AM MED ASSOC, V307, P713, DOI 10.1001/jama.2012.126; National Oceanic and Atmospheric Administration (NOAA), 2013, LAND BAS STAT DAT; Nuvolone D, 2011, AM J EPIDEMIOL, V174, P63, DOI 10.1093/aje/kwr046; Peel JL, 2007, AM J EPIDEMIOL, V165, P625, DOI 10.1093/aje/kwk051; Peters A, 2001, CIRCULATION, V103, P2810; Poloniecki JD, 1997, OCCUP ENVIRON MED, V54, P535, DOI 10.1136/oem.54.8.535; Rich DQ, 2013, ENVIRON SCI TECHNOL, V47, P9414, DOI 10.1021/es4027248; Rich DQ, 2010, ENVIRON HEALTH PERSP, V118, P1229, DOI 10.1289/ehp.0901624; Rosenthal FS, 2013, J EXPO SCI ENV EPID, V23, P281, DOI 10.1038/jes.2012.121; Ruidavets JB, 2005, CIRCULATION, V111, P563, DOI 10.1161/01.CIR.0000154546.32135.6E; Schwartz Joel, 1991, Public Health Reviews, V19, P39; Simmons JP, 2011, PSYCHOL SCI, V22, P1359, DOI 10.1177/0956797611417632; Stylianou M, 2009, ENVIRON POLLUT, V157, P2216, DOI 10.1016/j.envpol.2009.04.011; Sullivan J, 2005, EPIDEMIOLOGY, V16, P41, DOI 10.1097/01.ede.0000147116.34813.56; Tsai SS, 2012, J TOXICOL ENV HEAL A, V75, P242, DOI 10.1080/15287394.2012.641202; Turin TC, 2012, NEUROEPIDEMIOLOGY, V38, P84, DOI 10.1159/000335654; von Klot S, 2011, PROG CARDIOVASC DIS, V53, P361, DOI 10.1016/j.pcad.2011.01.002; Wichmann J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062059; Wichmann J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053684; Wichmann J, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-19; Zanobetti A, 2000, ENVIRON HEALTH PERSP, V108, P841, DOI 10.2307/3434991; Zanobetti A, 2005, ENVIRON HEALTH PERSP, V113, P978, DOI 10.1289/ehp.7550; Zanobetti A, 2006, J EPIDEMIOL COMMUN H, V60, P890, DOI 10.1136/jech.2005.039834	49	42	42	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 13	2015	10	7							e0132769	10.1371/journal.pone.0132769	http://dx.doi.org/10.1371/journal.pone.0132769			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1PW	26167938	Green Published, gold, Green Submitted			2023-01-03	WOS:000358193100078
J	Trecki, J; Gerona, RR; Schwartz, MD				Trecki, Jordan; Gerona, Roy R.; Schwartz, Michael D.			Synthetic Cannabinoid-Related Illnesses and Deaths	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							STATES		[Trecki, Jordan] Drug Enforcement Adm, Off Div Control, Drug & Chem Evaluat Sect, Springfield, VA 22152 USA; [Gerona, Roy R.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Schwartz, Michael D.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA	University of California System; University of California San Francisco; Centers for Disease Control & Prevention - USA	Trecki, J (corresponding author), Drug Enforcement Adm, Off Div Control, Drug & Chem Evaluat Sect, Springfield, VA 22152 USA.							[Anonymous], 2015, MMWR MORB MORTAL WKL, V64, P618; Bonar EE, 2014, DRUG ALCOHOL DEPEN, V143, P268, DOI 10.1016/j.drugalcdep.2014.07.009; Centers for Disease Control (CDC), 2013, MMWR MORB MORTAL WKL, V62, P93; Schwartz MD, 2015, J EMERG MED, V48, P573, DOI 10.1016/j.jemermed.2014.12.038; van Amsterdam J, 2015, J PSYCHOPHARMACOL, V29, P254, DOI 10.1177/0269881114565142	5	198	200	2	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 9	2015	373	2					103	107		10.1056/NEJMp1505328	http://dx.doi.org/10.1056/NEJMp1505328			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CM3QP	26154784				2023-01-03	WOS:000357598600002
J	Lau, C; Yu, R; Woo, J				Lau, Caren; Yu, Ruby; Woo, Jean			Effects of a 12-Week Hatha Yoga Intervention on Metabolic Risk and Quality of Life in Hong Kong Chinese Adults with and without Metabolic Syndrome	PLOS ONE			English	Article							CARDIOVASCULAR-DISEASE RISK; RANDOMIZED CONTROLLED-TRIAL; RESISTANCE-RELATED INDEXES; PHYSICAL-ACTIVITY; CHRONIC STRESS; HEALTH; EXERCISE; BENEFITS; HYPERTENSION; PREVALENCE	Objective To determine the efficacy of a 12-week Hatha yoga intervention to improve metabolic risk profiles and health-related quality of life (HRQoL) in Chinese adults with and without metabolic syndrome (MetS). Methods We conducted a controlled trial within an university-affiliated hospital. 173 Chinese men and women aged 18 or above were assigned to either the yoga intervention group (n = 87) or the control group (n = 86). Primary outcomes included 12-week change in metabolic risk factors and MetS z score. Secondary outcome was HRQoL (Medical Outcomes Short Form Survey at 12 weeks). Results The mean age of participants was 52.0 (SD 7.4, range 31-71) years. Analysis involving the entire study population revealed that the yoga group achieved greater decline in waist circumference (p<0.001), fasting glucose (p<0.01), triglycerides (p<0.05), and MetS z score (p<0.01). Yoga training also improved general health perceptions (p<0.01), physical component score (p<0.01), and social functioning (p<0.01) domains score of HRQoL. However, no significant differences between groups were observed in the mean change of systolic/diastolic blood pressures or high-density lipid protein cholesterol (all p>0.05). There were no significant differences in the intervention effects on waist circumference and MetS z score between the MetS subgroups (both p>0.05). Conclusion A 12-week Hatha yoga intervention improves metabolic risk profiles and HRQoL in Chinese adults with and without MetS.	[Lau, Caren; Yu, Ruby; Woo, Jean] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong	Yu, R (corresponding author), Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China.	rubyyu@cuhk.edu.hk	Woo, Jean/K-2625-2014; Yu, Ruby/N-5006-2015	Woo, Jean/0000-0001-7593-3081; 				Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009; Bernardi L, 1998, LANCET, V351, P1308, DOI 10.1016/S0140-6736(97)10341-5; Chen KM, 2008, J CLIN NURS, V17, P2634, DOI 10.1111/j.1365-2702.2008.02338.x; Cohen Beth E., 2008, Metabolic Syndrome and Related Disorders, V6, P223, DOI 10.1089/met.2008.0016; Cowen VS, 2005, J BODYW MOV THER, V9, P211, DOI 10.1016/j.jbmt.2004.08.001; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Crow R., 1999, HEALTH TECHNOL ASSES, V3, P1, DOI [DOI 10.3310/HTA3030, DOI 10.3310/hta3030]; Ding Ding, 2014, BMC Res Notes, V7, P172, DOI 10.1186/1756-0500-7-172; Feuerstein Georg, 2003, DEEPER DIMENSION YOG; Gordon LA, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-21; Grundy SM, 2008, ARTERIOSCL THROM VAS, V28, P629, DOI 10.1161/ATVBAHA.107.151092; Hagins Marshall, 2007, BMC Complement Altern Med, V7, P40, DOI 10.1186/1472-6882-7-40; Hedner T, 2005, BLOOD PRESSURE, V14, P131, DOI 10.1080/08037051510034310; Hegde SV, 2011, DIABETES CARE, V34, P2208, DOI 10.2337/dc10-2430; Hughes JW, 2013, PSYCHOSOM MED, V75, P721, DOI 10.1097/PSY.0b013e3182a3e4e5; Hunter SD, 2013, J ALTERN COMPLEM MED, V19, P930, DOI 10.1089/acm.2012.0709; Innes KE, 2007, ALTERN THER HEALTH M, V13, P44; Innes KE, 2007, EVID-BASED COMPL ALT, V4, P469, DOI 10.1093/ecam/nel103; Innes KE, 2007, ALTERN THER HEALTH M, V13, P46; Johnson JL, 2007, AM J CARDIOL, V100, P1759, DOI 10.1016/j.amjcard.2007.07.027; Khatri Deepali, 2007, Diabetes Res Clin Pract, V78, pe9, DOI 10.1016/j.diabres.2007.05.002; Kristal AR, 2005, ALTERN THER HEALTH M, V11, P28; Lakka TA, 2007, APPL PHYSIOL NUTR ME, V32, P76, DOI [10.1139/H06-113, 10.1139/h06-113]; Lam CL, 1999, HONG KONG PRACTITION, V21, P460; Lam CLK, 1998, J CLIN EPIDEMIOL, V51, P1139, DOI 10.1016/S0895-4356(98)00105-X; Lee JA, 2012, MENOPAUSE, V19, P296, DOI 10.1097/gme.0b013e31822d59a2; Lim S, 2011, DIABETES CARE, V34, P1323, DOI 10.2337/dc10-2109; Littman AJ, 2012, SUPPORT CARE CANCER, V20, P267, DOI 10.1007/s00520-010-1066-8; Malathi A., 2000, Indian Journal of Physiology and Pharmacology, V44, P202; McIver S, 2009, COMPLEMENT THER MED, V17, P196, DOI 10.1016/j.ctim.2009.05.002; Moadel AB, 2007, J CLIN ONCOL, V25, P4387, DOI 10.1200/JCO.2006.06.6027; Parati G, 2007, J HYPERTENS, V25, P57, DOI 10.1097/HJH.0b013e328012bf0f; Pickering Thomas G., 2005, Hypertension (Baltimore), V45, P142; Pullen PR, 2010, MED SCI SPORT EXER, V42, P651, DOI 10.1249/MSS.0b013e3181bf24c4; RAGLAND DR, 1992, EPIDEMIOLOGY, V3, P434, DOI 10.1097/00001648-199209000-00009; Ross A, 2013, COMPLEMENT THER MED, V21, P313, DOI 10.1016/j.ctim.2013.04.001; Saquib N, 2013, BMC PUBLIC HLTH, V13; Scholze J, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-529; Seeman TE, 1996, ANN EPIDEMIOL, V6, P442, DOI 10.1016/S1047-2797(96)00095-6; Sullivan PW, 2007, OBESITY, V15, P511, DOI 10.1038/oby.2007.580; Ware J.E., 1993, SF 36 HLTH SURVEY MA; West J, 2004, ANN BEHAV MED, V28, P114, DOI 10.1207/s15324796abm2802_6; Wijndaele K, 2009, EUR J CLIN NUTR, V63, P421, DOI 10.1038/sj.ejcn.1602944; Wolff M, 2013, BMC CARDIOVASC DISOR, V13, DOI 10.1186/1471-2261-13-111	44	21	22	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2015	10	6							e0130731	10.1371/journal.pone.0130731	http://dx.doi.org/10.1371/journal.pone.0130731			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CL4OY	26111165	Green Published, Green Submitted, gold			2023-01-03	WOS:000356933800079
J	Chang, CH; Chen, SJ; Liu, CY				Chang, Chun-Hung; Chen, Shaw-Ji; Liu, Chieh-Yu			Fracture Risk and Adjuvant Therapies in Young Breast Cancer Patients: A Population-Based Study	PLOS ONE			English	Article							BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; AROMATASE INHIBITORS; TAMOXIFEN; ANASTROZOLE; TRIAL	Background Breast cancer survivors have an increased risk of bone fracture. But the risk among young patients with adjuvant therapies remains unknown. This population-based study is aimed to assess the incidence and risk of fracture among young (age of 20 to 39 years) breast cancer patients who received adjuvant therapies. Methods From January 2001 to December 2007, 5,146 newly diagnosed breast cancer patients were enrolled from the National Health Insurance Research Database (NHIRD) in Taiwan. Patients were observed for a maximum of 6 years to determine the incidence of newly onset fracture. Kaplan Meier and Cox regression analyses were used to evaluate the risk of fracture in young breast cancer patients who received adjuvant treatments. Results Of the total 5,146 young (age of 20 to 39 years) breast cancer patients, the Cox multivariate proportional hazards analysis showed that AIs, radiotherapy, and monoclonal antibodies were significantly associated with a high risk of fracture. Moreover, patients who received AIs for more than 180 days had a high hazard ratio (HR) of 1.77 (95% CI = 0.68-4.57), and patients who received more than four radiotherapy visits had a high HR of 2.54 (95% CI = 1.07-6.06). Under the site-specific analysis, young breast cancer patients who received AIs had the highest risk of hip fracture (HR = 8.520, 95% CI = 1.711-42.432, p < 0.04), whereas patients who received radiotherapy had the highest risk of vertebral fracture (HR = 5.512, 95% CI = 1.847-16.451, p < 0.01). Conclusion Young breast cancer patients who are receiving AIs, radiotherapy or monoclonal antibody need to be more careful for preventing fracture events. Breast cancer treatment plans are suggested to incorporate fracture prevention interventions.	[Chang, Chun-Hung] China Med Univ Hosp, Taichung, Taiwan; [Chang, Chun-Hung] China Med Univ, Inst Clin Med, Taichung, Taiwan; [Chen, Shaw-Ji] Mackay Mem Hosp, Dept Psychiat, Taitung Branch, Taitung, Taiwan; [Chen, Shaw-Ji] Tzu Chi Univ, Inst Med Sci, Hualien, Taiwan; [Liu, Chieh-Yu] Natl Taipei Univ Nursing & Hlth Sci, Inst Nursing Midwifery, Biostat Consulting Lab, Taipei, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Mackay Memorial Hospital; Tzu Chi University; National Taipei University of Nursing & Health Science (NTUNHS)	Liu, CY (corresponding author), Natl Taipei Univ Nursing & Hlth Sci, Inst Nursing Midwifery, Biostat Consulting Lab, Taipei, Taiwan.	b89401068@ntu.edu.tw	Liu, Chieh-Yu/AAR-9654-2021; Chang, Chun-Hung/AAT-1641-2021; Liu, Chieh-Yu/J-3789-2019	Liu, Chieh-Yu/0000-0003-3283-028X; 				Ademuyiwa FO, 2015, CANCER-AM CANCER SOC, V121, P1469, DOI 10.1002/cncr.29178; Anders CK, 2009, SEMIN ONCOL, V36, P237, DOI 10.1053/j.seminoncol.2009.03.001; Benson JR, 2009, LANCET, V373, P1463, DOI 10.1016/S0140-6736(09)60316-0; Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518; Bleyer A, 2006, NIH PUBLICATION, V06-5767, DOI [10.1634/theoncologist.11-6-590, DOI 10.1634/THEONCOLOGIST.11-6-590]; Buchholz TA, 2009, NEW ENGL J MED, V360, P63, DOI 10.1056/NEJMct0803525; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chen Z, 2005, ARCH INTERN MED, V165, P552, DOI 10.1001/archinte.165.5.552; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210; Coleman RE, 2007, LANCET ONCOL, V8, P119, DOI 10.1016/S1470-2045(07)70003-7; Coombes RC, 2007, LANCET, V369, P559, DOI 10.1016/S0140-6736(07)60200-1; Court-Brown CM, 2006, INJURY, V37, P691, DOI 10.1016/j.injury.2006.04.130; Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8; DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203; Eastell R, 2008, J CLIN ONCOL, V26, P1051, DOI 10.1200/JCO.2007.11.0726; Eastell R, 2006, J BONE MINER RES, V21, P1215, DOI 10.1359/JBMR.060508; Geisler J, 2005, J STEROID BIOCHEM, V95, P75, DOI 10.1016/j.jsbmb.2005.04.015; Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Jakesz R, 2005, LANCET, V366, P455, DOI 10.1016/S0140-6736(05)67059-6; Kanis JA, 1999, BRIT J CANCER, V79, P1179, DOI 10.1038/sj.bjc.6690188; KRISTENSEN B, 1994, J CLIN ONCOL, V12, P992, DOI 10.1200/JCO.1994.12.5.992; Kristensen B, 1996, BREAST CANCER RES TR, V39, P321, DOI 10.1007/BF01806160; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; Neuner JM, 2011, OSTEOPOROSIS INT, V22, P2847, DOI 10.1007/s00198-010-1493-x; Newcomb PA, 2001, AM J EPIDEMIOL, V153, P1071, DOI 10.1093/aje/153.11.1071; Powles T, 1996, J CLIN ONCOL, V14, P78, DOI 10.1200/JCO.1996.14.1.78; Simpson ER, 2002, RECENT PROG HORM RES, V57, P317, DOI 10.1210/rp.57.1.317; Tsa CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075109; Vestergaard P, 2008, CALCIFIED TISSUE INT, V82, P334, DOI 10.1007/s00223-008-9132-7; Warner E, 2011, NEW ENGL J MED, V365, P1025, DOI 10.1056/NEJMcp1101540; Xu L, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0128-z	33	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2015	10	6							e0130725	10.1371/journal.pone.0130725	http://dx.doi.org/10.1371/journal.pone.0130725			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL4OM	26107848	Green Published, gold, Green Submitted			2023-01-03	WOS:000356932500120
J	Chu, HJ; Lee, CW; Yeh, SJ; Tsai, LK; Tang, SC; Jeng, JS				Chu, Hai-Jui; Lee, Chung-Wei; Yeh, Shin-Joe; Tsai, Li-Kai; Tang, Sung-Chun; Jeng, Jiann-Shing			Cerebral Lipiodol Embolism in Hepatocellular Carcinoma Patients Treated with Transarterial Embolization/Chemoembolization	PLOS ONE			English	Article							TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; LIPID EMBOLIZATION; PULMONARY; COMPLICATION; LYMPHOGRAPHY; LYMPHOMA	Background and Purpose Liver cancer is the third leading cause of cancer mortality worldwide. The aim of this study was to investigate the frequency and characteristics of cerebral lipiodol embolism (CLE) in patients with hepatocellular carcinoma (HCC) receiving transarterial embolization/chemoembolization (TAE/TACE). Methods We reviewed all HCC patients who received TAE/TACE during the period of 2007 and 2013 at a university medical center. The frequency of CLE per procedure and the clinical manifestations of CLE, including the review of previous reported cases (n = 24), were analyzed. Results During the study period, a total of 7855 TAE/TACE procedures were conducted on 3277 patients. There were 8 patients (mean age 59 +/- 11 years; 5 males and 3 females) who developed CLE. The frequency of TAE/TACE-related CLE was 1.02 (95% CI, 0.44-2.01) per 1000 procedures. Acute disturbance of consciousness and respiratory distress after TAE/TACE were the most common presentations of CLE. All patients had disseminated infarcts involving both the anterior and posterior cerebral circulations. For 3 patients with shunting between the tumor feeding artery and the pulmonary vein, a specific imaging pattern of coexisting scattered hyperdense spots was found. Furthermore, combined with our 8 cases, the total of 32 cases indicated that old age and female sex were the two risk factors for poor outcome after CLE. Conclusions CLE is a rare but potentially serious complication in HCC patients receiving TAE/TACE. The clinical characteristics of CLE summarized in our study would help facilitate the ability of clinicians to provide timely diagnosis and management.	[Chu, Hai-Jui; Yeh, Shin-Joe; Tsai, Li-Kai; Tang, Sung-Chun; Jeng, Jiann-Shing] Natl Taiwan Univ Hosp, Stroke Ctr, Taipei, Taiwan; [Chu, Hai-Jui; Yeh, Shin-Joe; Tsai, Li-Kai; Tang, Sung-Chun; Jeng, Jiann-Shing] Natl Taiwan Univ Hosp, Dept Neurol, Taipei, Taiwan; [Lee, Chung-Wei] Natl Taiwan Univ Hosp, Dept Med Imaging & Radiol, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Tang, SC (corresponding author), Natl Taiwan Univ Hosp, Stroke Ctr, Taipei, Taiwan.	tangneuro@gmail.com	yeh, shin-joe/HGV-0244-2022; Tsai, Li-Kai/HJA-2534-2022	Yeh, Shin-Joe/0000-0003-1511-6295; JENG, JIANN-SHING/0000-0002-1456-3686; LEE, CHUNG-WEI/0000-0002-3573-2506; Tsai, Li-Kai/0000-0001-8420-6951; Tang, Sung-Chun/0000-0003-3731-5973				Bansaghi Z, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-122; Barthel HR, 2005, J GASTROEN HEPATOL, V20, P1464, DOI 10.1111/j.1440-1746.2005.03848.x; Chang YC, 2010, CHINESE J INTERVENTI, V7; Choi CS, 2008, WORLD J GASTROENTERO, V14, P4834, DOI 10.3748/wjg.14.4834; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Ishikawa T, 2013, HEPATOL RES, V43, P1251, DOI 10.1111/hepr.12074; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jia ZZ, 2012, WORLD J GASTROENTERO, V18, P4069, DOI 10.3748/wjg.v18.i30.4069; Karapanayiotides T, 2009, J NEUROL, V256, P1171, DOI 10.1007/s00415-009-5066-x; Kim JT, 2009, J NEUROIMAGING, V19, P394, DOI 10.1111/j.1552-6569.2009.00380.x; Kritzinger J, 2013, CLIN RADIOL, V68, P1, DOI 10.1016/j.crad.2012.06.112; KUSUMOTO S, 1991, CLIN RADIOL, V44, P279, DOI 10.1016/S0009-9260(05)80199-0; Lee CS, 2010, J COMPUT ASSIST TOMO, V34, P105, DOI 10.1097/RCT.0b013e3181b382f8; Lencioni R, 2012, SEMIN ONCOL, V39, P503, DOI 10.1053/j.seminoncol.2012.05.004; Li Z, 2011, CHINESE MED J-PEKING, V124, P4355, DOI 10.3760/cma.j.issn.0366-6999.2011.24.040; Llovet JM, 1999, SEMIN LIVER DIS, V19, P329, DOI 10.1055/s-2007-1007122; Matsumoto K, 2007, CARDIOVASC INTER RAD, V30, P512, DOI 10.1007/s00270-006-0092-x; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Sakamoto I, 1998, RADIOGRAPHICS, V18, P605, DOI 10.1148/radiographics.18.3.9599386; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Takao H, 2005, J COMPUT ASSIST TOMO, V29, P680, DOI 10.1097/01.rct.0000165906.83160.7d; Wan CC, 2015, LIVER INT, V35, P673, DOI 10.1111/liv.12511; Winterer JT, 1999, RADIOLOGY, V210, P381, DOI 10.1148/radiology.210.2.r99fe09381; Wu JJ, 2009, WORLD J GASTROENTERO, V15, P633, DOI 10.3748/wjg.15.633; Wu JJ, 2009, CHINESE MED J-PEKING, V122, P878, DOI 10.3760/cma.j.issn.0366-6999.2009.07.022; Wu L, 2010, WORLD J GASTROENTERO, V16, P398, DOI 10.3748/wjg.v16.i3.398; Yoo KM, 2004, NEUROLOGY, V63, P181, DOI 10.1212/01.WNL.0000132645.23611.2D; Zach V, 2012, J STROKE CEREBROVASC, V21, P217, DOI 10.1016/j.jstrokecerebrovasdis.2010.08.001	29	5	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2015	10	6							e0129367	10.1371/journal.pone.0129367	http://dx.doi.org/10.1371/journal.pone.0129367			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL4OM	26107693	gold, Green Published, Green Submitted			2023-01-03	WOS:000356932500049
J	Ribeiro, SC; Figueiredo, AE; Barretti, P; Pecoits, R; de Moraes, TP				Ribeiro, Silvia Carreira; Figueiredo, Ana Elizabeth; Barretti, Pasqual; Pecoits-Filho, Roberto; de Moraes, Thyago Proenca		Ctr Contributed BRAZPD II Stud	Low Serum Potassium Levels Increase the Infectious-Caused Mortality in Peritoneal Dialysis Patients: A Propensity-Matched Score Study	PLOS ONE			English	Article							HYPOKALEMIA; RISK	Background and Objectives Hypokalemia has been consistently associated with high mortality rate in peritoneal dialysis. However, studies investigating if hypokalemia is acting as a surrogate marker of comorbidities or has a direct effect in the risk for mortality have not been studied. Thus, the aim of this study was to analyze the effect of hypokalemia on overall and cause-specific mortality. Design, Setting, Participants and Measurements This is an analysis of BRAZPD II, a nationwide prospective cohort study. All patients on PD for longer than 90 days with measured serum potassium levels were used to verify the association of hypokalemia with overall and cause-specific mortality using a propensity match score to reduce selection bias. In addition, competing risks were also taken into account for the analysis of cause-specific mortality. Results There was a U-shaped relationship between time-averaged serum potassium and all-cause mortality of PD patients. Cardiovascular disease was the main cause of death in the normokalemic group with 133 events (41.8%) followed by PD-non related infections, n=105 (33.0%). Hypokalemia was associated with a 49% increased risk for CV mortality after adjustments for covariates and the presence of competing risks (SHR 1.49; CI95% 1.01-2.21). In contrast, in the group of patients with K < 3.5mEq/L, PD-non related infections were the main cause of death with 43 events (44.3%) followed by cardiovascular disease (n=36; 37.1%). For PD-non related infections the SHR was 2.19 (CI95% 1.52-3.14) while for peritonitis was SHR 1.09 (CI95% 0.47-2.49). Conclusions Hypokalemia had a significant impact on overall, cardiovascular and infectious mortality even after adjustments for competing risks. The causative nature of this association suggested by our study raises the need for intervention studies looking at the effect of potassium supplementation on clinical outcomes of PD patients.	[Ribeiro, Silvia Carreira; Pecoits-Filho, Roberto; de Moraes, Thyago Proenca] Pontificia Univ Catolica Parana PUCPR, Sch Med, Curitiba, Parana, Brazil; [Figueiredo, Ana Elizabeth] Pontificia Univ Catolica Rio Grande Sul PUCRS, Grad Program Med & Hlth Sci, Porto Alegre, RS, Brazil; [Barretti, Pasqual] UNESP, Sch Med, Botucatu, SP, Brazil	Pontificia Universidade Catolica do Parana; Pontificia Universidade Catolica Do Rio Grande Do Sul; Universidade Estadual Paulista	de Moraes, TP (corresponding author), Pontificia Univ Catolica Parana PUCPR, Sch Med, Curitiba, Parana, Brazil.	thyago.moraes@pucpr.br	Barretti, Pasqual/AAK-7934-2021; de Moraes, Thyago Proenca/M-9400-2014; Barretti, Pasqual/K-4156-2012; Pecoits-Filho, Roberto/K-7986-2013; Figueiredo, Ana/GWU-6748-2022; Figueiredo, Ana Elizabeth/C-2137-2013	Barretti, Pasqual/0000-0003-4979-4836; de Moraes, Thyago Proenca/0000-0002-2983-3968; Barretti, Pasqual/0000-0003-4979-4836; Pecoits-Filho, Roberto/0000-0002-0255-6710; Figueiredo, Ana Elizabeth/0000-0002-8555-8649	Baxter Healthcare	Baxter Healthcare	This study was funded by Baxter Healthcare. The sponsor had no participation in the study design, data analysis or preparation of the manuscript.	Ahmed A, 2007, EUR HEART J, V28, P1334, DOI 10.1093/eurheartj/ehm091; Chuang YW, 2009, NEPHROL DIAL TRANSPL, V24, P1603, DOI 10.1093/ndt/gfn709; Dahabreh IJ, 2012, EUR HEART J, V33, P1893, DOI 10.1093/eurheartj/ehs114; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; FITZOVICH DE, 1991, J AM COLL CARDIOL, V18, P1105, DOI 10.1016/0735-1097(91)90774-4; Ho Daniel E., 2011, J STAT SOFTW, V42, P1, DOI DOI 10.18637/JSS.V042.I08; Jung Ji Yong, 2009, Electrolyte Blood Press, V7, P73, DOI 10.5049/EBP.2009.7.2.73; Khan AN, 1996, PERITON DIALYSIS INT, V16, P652; Kwan BCH, 2012, NAT REV NEPHROL, V8, P501, DOI 10.1038/nrneph.2012.159; Li PKT, 2010, PERITON DIALYSIS INT, V30, P393, DOI 10.3747/pdi.2010.00049; Ming KW, 2000, BIOMETRICS, V56, P118, DOI 10.1111/j.0006-341X.2000.00118.x; Szeto CC, 2005, AM J KIDNEY DIS, V46, P128, DOI 10.1053/j.ajkd.2005.03.015; Torlen K, 2012, CLIN J AM SOC NEPHRO, V7, P1272, DOI 10.2215/CJN.00960112; TPd Moraes, 2014, PERITONEAL DIALYSIS; Tziviskou Effie, 2003, International Urology and Nephrology, V35, P429, DOI 10.1023/B:UROL.0000022867.93739.03; Verduijn M, 2011, NEPHROL DIAL TRANSPL, V26, P56, DOI 10.1093/ndt/gfq661; Xu QD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086750	17	28	32	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2015	10	6							e0127453	10.1371/journal.pone.0127453	http://dx.doi.org/10.1371/journal.pone.0127453			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CL3FE	26091005	gold, Green Published, Green Submitted			2023-01-03	WOS:000356835000010
J	Eisenstein, M				Eisenstein, Michael			Showdown at the cannabis corral	NATURE			English	Editorial Material							CONTROLLED-TRIAL; MARIJUANA USE											Abrams DI, 2007, NEUROLOGY, V68, P515, DOI 10.1212/01.wnl.0000253187.66183.9c; Bechtold J., 2015, PSYCHOL ADDICT BEHAV; Hasin DS, 2015, LANCET PSYCHIAT, V2, P601, DOI 10.1016/S2215-0366(15)00217-5; Hazekamp A, 2013, EUR J CLIN PHARMACOL, V69, P1575, DOI 10.1007/s00228-013-1503-y; Meier MH, 2012, P NATL ACAD SCI USA, V109, pE2657, DOI 10.1073/pnas.1206820109; Naftali T, 2013, CLIN GASTROENTEROL H, V11, P1276, DOI 10.1016/j.cgh.2013.04.034; Press CA, 2015, EPILEPSY BEHAV, V45, P49, DOI 10.1016/j.yebeh.2015.02.043; Volkow ND, 2014, NEW ENGL J MED, V370, P2219, DOI 10.1056/NEJMra1402309; Ware MA, 2010, CAN MED ASSOC J, V182, DOI [DOI 10.1503/cmaj.091414, 10.1503/cmaj.091414]; Whiting PF, 2015, JAMA-J AM MED ASSOC, V313, P2456, DOI 10.1001/jama.2015.6358	10	12	12	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 24	2015	525	7570					S15	S17		10.1038/525S15a	http://dx.doi.org/10.1038/525S15a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CR8KI	26443869	Bronze			2023-01-03	WOS:000361599900007
J	Jain, S; Self, WH; Wunderink, RG; Fakhran, S; Balk, R; Bramley, AM; Reed, C; Grijalva, CG; Anderson, EJ; Courtney, DM; Chappell, JD; Qi, C; Hart, EM; Carroll, F; Trabue, C; Donnelly, HK; Williams, DJ; Zhu, Y; Arnold, SR; Ampofo, K; Waterer, GW; Levine, M; Lindstrom, S; Winchell, JM; Katz, JM; Erdman, D; Schneider, E; Hicks, LA; McCullers, JA; Pavia, AT; Edwards, KM; Finelli, L				Jain, S.; Self, W. H.; Wunderink, R. G.; Fakhran, S.; Balk, R.; Bramley, A. M.; Reed, C.; Grijalva, C. G.; Anderson, E. J.; Courtney, D. M.; Chappell, J. D.; Qi, C.; Hart, E. M.; Carroll, F.; Trabue, C.; Donnelly, H. K.; Williams, D. J.; Zhu, Y.; Arnold, S. R.; Ampofo, K.; Waterer, G. W.; Levine, M.; Lindstrom, S.; Winchell, J. M.; Katz, J. M.; Erdman, D.; Schneider, E.; Hicks, L. A.; McCullers, J. A.; Pavia, A. T.; Edwards, K. M.; Finelli, L.		CDC EPIC Study Team	Community-Acquired Pneumonia Requiring Hospitalization among US Adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE-CHAIN-REACTION; PNEUMOCOCCAL CONJUGATE VACCINE; IMMUNIZATION PRACTICES ACIP; ACUTE RESPIRATORY-INFECTION; MYCOPLASMA-PNEUMONIAE; CHLAMYDIA-PNEUMONIAE; ADVISORY-COMMITTEE; REACTION ASSAYS; DIAGNOSIS; VIRUSES	BACKGROUND Community-acquired pneumonia is a leading infectious cause of hospitalization and death among U.S. adults. Incidence estimates of pneumonia confirmed radio-graphically and with the use of current laboratory diagnostic tests are needed. METHODS We conducted active population-based surveillance for community-acquired pneumonia requiring hospitalization among adults 18 years of age or older in five hospitals in Chicago and Nashville. Patients with recent hospitalization or severe immunosuppression were excluded. Blood, urine, and respiratory specimens were systematically collected for culture, serologic testing, antigen detection, and molecular diagnostic testing. Study radiologists independently reviewed chest radiographs. We calculated population-based incidence rates of community-acquired pneumonia requiring hospitalization according to age and pathogen. RESULTS From January 2010 through June 2012, we enrolled 2488 of 3634 eligible adults (68%). Among 2320 adults with radiographic evidence of pneumonia (93%), the median age of the patients was 57 years (interquartile range, 46 to 71); 498 patients (21%) required intensive care, and 52 (2%) died. Among 2259 patients who had radiographic evidence of pneumonia and specimens available for both bacterial and viral testing, a pathogen was detected in 853 (38%): one or more viruses in 530 (23%), bacteria in 247 (11%), bacterial and viral pathogens in 59 (3%), and a fungal or mycobacterial pathogen in 17 (1%). The most common pathogens were human rhinovirus (in 9% of patients), influenza virus (in 6%), and Streptococcus pneumoniae (in 5%). The annual incidence of pneumonia was 24.8 cases (95% confidence interval, 23.5 to 26.1) per 10,000 adults, with the highest rates among adults 65 to 79 years of age (63.0 cases per 10,000 adults) and those 80 years of age or older (164.3 cases per 10,000 adults). For each pathogen, the incidence increased with age. CONCLUSIONS The incidence of community-acquired pneumonia requiring hospitalization was highest among the oldest adults. Despite current diagnostic tests, no pathogen was detected in the majority of patients. Respiratory viruses were detected more frequently than bacteria.	[Jain, S.; Bramley, A. M.; Reed, C.; Levine, M.; Lindstrom, S.; Winchell, J. M.; Katz, J. M.; Erdman, D.; Schneider, E.; Hicks, L. A.; Finelli, L.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; [Self, W. H.; Grijalva, C. G.; Chappell, J. D.; Carroll, F.; Williams, D. J.; Zhu, Y.; Edwards, K. M.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Trabue, C.] Univ Tennessee, Hlth Sci Ctr, St Thomas Hlth, Nashville, TN USA; [Arnold, S. R.; McCullers, J. A.] Le Bonheur Childrens Hosp, Memphis, TN USA; [Arnold, S. R.; McCullers, J. A.] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; [McCullers, J. A.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA; [Wunderink, R. G.; Anderson, E. J.; Courtney, D. M.; Qi, C.; Hart, E. M.; Donnelly, H. K.; Waterer, G. W.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Fakhran, S.] John H Stroger Jr Hosp Cook Cty, Chicago, IL USA; [Balk, R.] Rush Univ, Med Ctr, Chicago, IL 60612 USA; [Ampofo, K.; Pavia, A. T.] Univ Utah, Hlth Sci Ctr, Salt Lake City, UT USA; [Waterer, G. W.] Univ Western Australia, Perth, WA 6009, Australia	Centers for Disease Control & Prevention - USA; Vanderbilt University; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; Northwestern University; Feinberg School of Medicine; John H Stroger Junior Hospital Cook County; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rush University; Utah System of Higher Education; University of Utah; University of Western Australia	Jain, S (corresponding author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-32, Atlanta, GA 30333 USA.	bwc8@cdc.gov	Arnold, Sandra R/O-4712-2014; Finelli, Lyn/AAK-2360-2020; Waterer, Grant/AAG-2385-2021; Levine, Min/ABB-4350-2021	Arnold, Sandra R/0000-0001-6130-8154; Mizgerd, Joseph/0000-0002-4042-3169; Wunderink, Richard/0000-0002-8527-4195; Grijalva, Carlos/0000-0002-2329-7797; Self, Wesley/0000-0002-9300-3045	Influenza Division of the National Center for Immunizations and Respiratory Diseases; NATIONAL CENTER FOR IMMUNICATION AND RESPIRATORY DISEASES [U18IP000303, U18IP000301, U18IP000299, U18IP000302] Funding Source: NIH RePORTER; National Center for Immunization and Respiratory Diseases (NCIRD) [U18IP000488, U18IP000490, U18IP000491, U18IP000489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI104779] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K23GM110469] Funding Source: NIH RePORTER	Influenza Division of the National Center for Immunizations and Respiratory Diseases; NATIONAL CENTER FOR IMMUNICATION AND RESPIRATORY DISEASES(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Center for Immunization and Respiratory Diseases (NCIRD)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Funded by the Influenza Division of the National Center for Immunizations and Respiratory Diseases.	[Anonymous], 2014, MMWR MORB MORTAL WKL, V63, P822; [Anonymous], 2012, VINT 2012 POSTC EST; [Anonymous], 2012, VACCINES; Bartlett JG, 2011, CLIN INFECT DIS, V52, pS296, DOI 10.1093/cid/cir045; Bartlett RC, 1974, MED MICROBIOLOGY QUA, P24; Blaschke AJ, 2012, DIAGN MICR INFEC DIS, V74, P349, DOI 10.1016/j.diagmicrobio.2012.08.013; Caliendo AM, 2013, CLIN INFECT DIS, V57, pS139, DOI 10.1093/cid/cit578; Caliendo AM, 2011, CLIN INFECT DIS, V52, pS326, DOI 10.1093/cid/cir047; Carvalho MDS, 2007, J CLIN MICROBIOL, V45, P2460, DOI 10.1128/JCM.02498-06; Centers for Disease Control and Prevention, FLUVIEW WEEKL INFL S; Charles PGP, 2008, CLIN INFECT DIS, V46, P1513, DOI 10.1086/586749; Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353; Dare RK, 2007, J INFECT DIS, V196, P1321, DOI 10.1086/521308; Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951; Feikin DR, 2013, CLIN VACCINE IMMUNOL, V20, P113, DOI 10.1128/CVI.00325-12; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Fry AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017780; Griffin MR, 2013, NEW ENGL J MED, V369, P155, DOI 10.1056/NEJMoa1209165; Grijalva CG, 2007, LANCET, V369, P1179, DOI 10.1016/S0140-6736(07)60564-9; Health United States, 2012, HLTH US 2012 SPEC FE, P297; Jain S, 2015, NEW ENGL J MED, V372, P835, DOI 10.1056/NEJMoa1405870; Jennings LC, 2008, THORAX, V63, P42, DOI 10.1136/thx.2006.075077; Johansson N, 2010, CLIN INFECT DIS, V50, P202, DOI 10.1086/648678; Johnstone J, 2008, CHEST, V134, P1141, DOI 10.1378/chest.08-0888; Karhu J, 2014, CLIN INFECT DIS, V59, P62, DOI 10.1093/cid/ciu237; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KENDAL AP, 1983, J CLIN MICROBIOL, V18, P930, DOI 10.1128/JCM.18.4.930-934.1983; Kumar S, 2007, CLIN INFECT DIS, V44, P568, DOI 10.1086/511076; Lanspa MJ, 2015, J HOSP MED, V10, P90, DOI 10.1002/jhm.2280; Lexau CA, 2005, JAMA-J AM MED ASSOC, V294, P2043, DOI 10.1001/jama.294.16.2043; Lieberman D, 2010, CHEST, V138, P811, DOI 10.1378/chest.09-2717; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; Marston BJ, 1997, ARCH INTERN MED, V157, P1709, DOI 10.1001/archinte.157.15.1709; MONTO AS, 1981, J CLIN MICROBIOL, V13, P54, DOI 10.1128/JCM.13.1.54-57.1981; Murdoch DR, 2003, CLIN INFECT DIS, V36, P64, DOI 10.1086/345529; Murdoch DR, 2001, J CLIN MICROBIOL, V39, P3495, DOI 10.1128/JCM.39.10.3495-3498.2001; Musher DM, 2014, NEW ENGL J MED, V371, P1619, DOI 10.1056/NEJMra1312885; Nelson JC, 2008, VACCINE, V26, P4947, DOI 10.1016/j.vaccine.2008.07.016; Nilsson AC, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-93; Nir-Paz R, 2006, CLIN MICROBIOL INFEC, V12, P685, DOI 10.1111/j.1469-0691.2006.01469.x; Pavia AT, 2011, CLIN INFECT DIS, V52, pS284, DOI 10.1093/cid/cir043; Pfuntner A., 2006, COSTS HOSP STAYS US; Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593; POLLOCK HM, 1983, J CLIN MICROBIOL, V17, P255, DOI 10.1128/JCM.17.2.255-259.1983; Ruuskanen O, 2014, CLIN INFECT DIS, V59, P71, DOI 10.1093/cid/ciu242; Sawatwong P, 2012, CLIN INFECT DIS, V54, P445, DOI 10.1093/cid/cir710; Templeton KE, 2005, CLIN INFECT DIS, V41, P345, DOI 10.1086/431588; Thurman KA, 2011, DIAGN MICR INFEC DIS, V70, P1, DOI 10.1016/j.diagmicrobio.2010.11.014; Walsh EE, 2008, ARCH INTERN MED, V168, P2489, DOI 10.1001/archinte.168.22.2489; Watt JP, 2010, EPIDEMIOL INFECT, V138, P1146, DOI 10.1017/S0950268809991464; Weinberg GA, 2013, J CLIN VIROL, V57, P254, DOI 10.1016/j.jcv.2013.03.016; Werno AM, 2008, CLIN INFECT DIS, V46, P926, DOI 10.1086/528798; WHO Global Influenza Surveillance Network, 2011, MAN LAB DIAGN VIR SU, P43; [No title captured]	54	1072	1126	6	122	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 30	2015	373	5					415	427		10.1056/NEJMoa1500245	http://dx.doi.org/10.1056/NEJMoa1500245			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CN8BO	26172429	Green Accepted			2023-01-03	WOS:000358662200005
J	Mitchell, SL				Mitchell, Susan L.			Advanced Dementia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NURSING-HOME RESIDENTS; LONG-TERM-CARE; OF-LIFE CARE; FEEDING OPTIONS; HOSPICE CARE; END; SURVIVAL; PNEUMONIA; IMPACT; DEATH	An 89-year-old male nursing home resident with a 10-year history of Alzheimer's disease presents with a temperature of 38.3 degrees C, a productive cough, and a respiratory rate of 28 breaths per minute. Nurses report that for the past 6 months he has been coughing at breakfast and having trouble swallowing. He has profound memory deficits, no longer recognizes his daughter (who is his health care proxy), is bed-bound, is able to mumble a couple of words, and is unable to perform any activities of daily living. The nurse asks whether he should be hospitalized. How should this patient be evaluated and treated?	[Mitchell, Susan L.] Beth Israel Deaconess Med Ctr, Dept Med, Hebrew SeniorLife Inst Aging Res, Boston, MA 02215 USA; [Mitchell, Susan L.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Hebrew SeniorLife; Harvard University; Harvard Medical School	Mitchell, SL (corresponding author), Hebrew SeniorLife Inst Aging Res, 1200 Ctr St, Boston, MA 02131 USA.	smitchell@hsl.harvard.edu			NIA NIH HHS [K24 AG033640] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K24AG033640] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 2013, FEED TUB PEOPL ALZH; [Anonymous], HOSPICE J; Arrighi HM, 2010, ALZ DIS ASSOC DIS, V24, P90, DOI 10.1097/WAD.0b013e31819fe7d1; BUCHANAN A, 1986, MILBANK Q, V64, P17, DOI 10.2307/3349960; Cegelka A, 2014, J AM GERIATR SOC, V62, P1590, DOI 10.1111/jgs.12924; Chen JH, 2006, J AM GERIATR SOC, V54, P290, DOI 10.1111/j.1532-5415.2005.00524.x; D'Agata E, 2008, ARCH INTERN MED, V168, P357, DOI 10.1001/archinternmed.2007.104; D'Agata E, 2013, J AM GERIATR SOC, V61, P62, DOI 10.1111/jgs.12070; Fischberg D, 2013, J PAIN SYMPTOM MANAG, V45, P595, DOI 10.1016/j.jpainsymman.2012.12.002; Gill TM, 2010, NEW ENGL J MED, V362, P1173, DOI 10.1056/NEJMoa0909087; Givens JL, 2012, J AM GERIATR SOC, V60, P905, DOI 10.1111/j.1532-5415.2012.03919.x; Givens JL, 2010, ARCH INTERN MED, V170, P1102, DOI 10.1001/archinternmed.2010.181; Givens JL, 2009, J AM GERIATR SOC, V57, P1149, DOI 10.1111/j.1532-5415.2009.02304.x; Gozalo P, 2011, NEW ENGL J MED, V365, P1212, DOI 10.1056/NEJMsa1100347; Hanson LC, 2011, J AM GERIATR SOC, V59, P2009, DOI 10.1111/j.1532-5415.2011.03629.x; Hanson LC, 2011, J AM GERIATR SOC, V59, P463, DOI 10.1111/j.1532-5415.2011.03320.x; Hebert LE, 2013, NEUROLOGY, V80, P1778, DOI 10.1212/WNL.0b013e31828726f5; Hendriks SA, 2014, J PAIN SYMPTOM MANAG, V47, P710, DOI 10.1016/j.jpainsymman.2013.05.015; Holmes HM, 2008, J AM GERIATR SOC, V56, P1306, DOI 10.1111/j.1532-5415.2008.01741.x; Huskamp HA, 2012, MED CARE RES REV, V69, P3, DOI 10.1177/1077558711418518; Jayes RL, 2012, J PAIN SYMPTOM MANAG, V44, P750, DOI 10.1016/j.jpainsymman.2012.08.004; Kiely DK, 2010, J AM GERIATR SOC, V58, P2284, DOI 10.1111/j.1532-5415.2010.03185.x; Loeb M, 2001, INFECT CONT HOSP EP, V22, P120, DOI 10.1086/501875; Loeb M, 2006, JAMA-J AM MED ASSOC, V295, P2503, DOI 10.1001/jama.295.21.2503; Miller SC, 2001, AM J MED, V111, P38, DOI 10.1016/S0002-9343(01)00747-1; Miller SC, 2002, J AM GERIATR SOC, V50, P507, DOI 10.1046/j.1532-5415.2002.50118.x; Mitchell SL, 1997, ARCH INTERN MED, V157, P327, DOI 10.1001/archinte.157.3.327; Mitchell SL, 2005, J AM GERIATR SOC, V53, P299, DOI 10.1111/j.1532-5415.2005.53118.x; Mitchell SL, 2014, JAMA INTERN MED, V174, P1660, DOI 10.1001/jamainternmed.2014.3918; Mitchell SL, 2010, JAMA-J AM MED ASSOC, V304, P1929, DOI 10.1001/jama.2010.1572; Mitchell SL, 2009, NEW ENGL J MED, V361, P1529, DOI 10.1056/NEJMoa0902234; Morrison RS, 2000, JAMA-J AM MED ASSOC, V284, P47, DOI 10.1001/jama.284.1.47; National Hospice and Palliative Care Organization, 2014, NHPCOS FACTS FIG HOS; REISBERG B, 1982, AM J PSYCHIAT, V139, P1136; Sampson EL, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007209.pub2; Schneider LS, 2005, JAMA-J AM MED ASSOC, V294, P1934, DOI 10.1001/jama.294.15.1934; Shega JW, 2008, J PAIN SYMPTOM MANAG, V35, P499, DOI 10.1016/j.jpainsymman.2007.06.011; Sink KM, 2005, JAMA-J AM MED ASSOC, V293, P596, DOI 10.1001/jama.293.5.596; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; Teno JM, 2012, J AM GERIATR SOC, V60, P1918, DOI 10.1111/j.1532-5415.2012.04148.x; Teno JM, 2012, ARCH INTERN MED, V172, P697, DOI 10.1001/archinternmed.2012.1200; Tjia J, 2014, JAMA INTERN MED, V174, P1763, DOI 10.1001/jamainternmed.2014.4103; Todd S, 2013, INT J GERIATR PSYCH, V28, P1109, DOI 10.1002/gps.3946; Unroe KT, 2013, J AM GERIATR SOC, V61, P1212, DOI 10.1111/jgs.12318; Volicer L, 2001, ALZ DIS ASSOC DIS, V15, P194, DOI 10.1097/00002093-200110000-00005; Warden Victoria, 2003, J Am Med Dir Assoc, V4, P9, DOI 10.1097/00130535-200301000-00002; Weuve Jennifer, 2014, Alzheimers Dement, V10, pe40, DOI 10.1016/j.jalz.2014.01.004; 2011, NATL VITAL STAT REP, V86, P1	48	102	113	1	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 25	2015	372	26					2533	2540		10.1056/NEJMcp1412652	http://dx.doi.org/10.1056/NEJMcp1412652			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	CL2QD	26398084	Green Accepted			2023-01-03	WOS:000356788200009
